<SEC-DOCUMENT>0001564590-21-008124.txt : 20210224
<SEC-HEADER>0001564590-21-008124.hdr.sgml : 20210224
<ACCEPTANCE-DATETIME>20210224163108
ACCESSION NUMBER:		0001564590-21-008124
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		118
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210224
DATE AS OF CHANGE:		20210224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptive Biotechnologies Corp
		CENTRAL INDEX KEY:			0001478320
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				270907024
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38957
		FILM NUMBER:		21673798

	BUSINESS ADDRESS:	
		STREET 1:		1551 EASTLAKE AVENUE EAST SUITE 200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		206-659-0067

	MAIL ADDRESS:	
		STREET 1:		1551 EASTLAKE AVENUE EAST SUITE 200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptive TCR Corp
		DATE OF NAME CHANGE:	20091209
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>adpt-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T03:56:24.2740419+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b31e096b02284e6886ec6a280547abc3 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:adpt="http://www.adaptivebiotech.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
adpt-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001478320_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001478320_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001478320_20200101_20201231">0001478320</ix:nonNumeric>
			<ix:nonNumeric id="F_000009" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001478320_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000472" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000473" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000474" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000483" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000484" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000485" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000487" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000488" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000489" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000491" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000492" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000493" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000701" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000703" name="adpt:LeaseExpirationMonthAndYear" contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831">2032-10</ix:nonNumeric>
			<ix:nonNumeric id="F_000710" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001478320_20190801_20190831">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000718" name="adpt:LeaseExpirationMonthAndYear" contextRef="C_0001478320_20191001_20191031">2029-10</ix:nonNumeric>
			<ix:nonNumeric id="F_000723" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001478320_20180401_20180430">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000733" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001478320_20200101_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000724" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" contextRef="C_0001478320_20180401_20180430">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000795" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001478320_srtTitleOfIndividualAxis_adptNonEmployeeDirectorsMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000892" name="adpt:MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000259" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0001478320_20200101_20201231">us-gaap:AccountingStandardsUpdate201602Member</ix:nonNumeric>
			<ix:nonNumeric id="F_000738" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001478320_20201231">P11Y3M29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000845" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20200101_20201231">P5Y3M7D</ix:nonNumeric>
			<ix:nonNumeric id="F_000846" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20190101_20191231">P5Y3M7D</ix:nonNumeric>
			<ix:nonNumeric id="F_000847" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20180101_20181231">P6Y29D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000851" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001478320_20200101_20201231" decimals="3">0.004</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000852" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001478320_20190101_20191231" decimals="3">0.014</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000853" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001478320_20180101_20181231" decimals="3">0.026</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000857" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001478320_20200101_20201231" decimals="3">0.705</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000858" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001478320_20190101_20191231" decimals="3">0.643</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000859" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001478320_20180101_20181231" decimals="3">0.650</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000841" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20200101_20201231" decimals="2">17.68</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000842" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20190101_20191231" decimals="2">7.80</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000843" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20200101_20201231" decimals="2">55.23</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000844" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20190101_20191231" decimals="2">47.81</ix:nonFraction>
			<ix:nonNumeric id="F_000848" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000849" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20190101_20191231">P6Y29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000850" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20180101_20181231">P10Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000854" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001478320_20200101_20201231" decimals="3">0.017</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000855" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001478320_20190101_20191231" decimals="3">0.025</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000856" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001478320_20180101_20181231" decimals="3">0.030</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000860" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001478320_20200101_20201231" decimals="3">0.733</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000861" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001478320_20190101_20191231" decimals="3">0.729</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000862" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001478320_20180101_20181231" decimals="3">0.692</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001478320_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001478320_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:PreferredStockValue" contextRef="C_0001478320_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:PreferredStockValue" contextRef="C_0001478320_20191231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="adpt-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001478320_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_20210219">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRestatementAxis_srtRevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRestatementAxis_srtRevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptCustomerCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncAndRocheGroupMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncAndRocheGroupMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerEquipmentAndSoftwareMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adpt:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adpt:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adpt:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_adptPerformance_Obligation">
				<xbrli:measure>adpt:Performance_Obligation</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_adptSegment">
				<xbrli:measure>adpt:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentSupportRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentSupportRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentSupportRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueRegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueRegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueRegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151201_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-12-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20190201_20190228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-01</xbrli:startDate>
					<xbrli:endDate>2019-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:DevelopmentMilestonesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptCommercialMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:CommercialMilestonesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerSoftwareMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerSoftwareMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptBuildToSuitAssetCostMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:BuildToSuitAssetCostMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtRangeAxis_srtMinimumMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtRangeAxis_srtMaximumMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20201230_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-30</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtMajorCustomersAxis_adptSpecificPatientsMember_srtProductOrServiceAxis_adptMedicareRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:MedicareRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:SpecificPatientsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_srtStatementGeographicalAxis_stprWA_20190831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-08-01</xbrli:startDate>
					<xbrli:endDate>2019-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20190831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20190801_20190831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-08-01</xbrli:startDate>
					<xbrli:endDate>2019-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20191001_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20180401_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMinimumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_adptLease">
				<xbrli:measure>adpt:Lease</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190629_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-29</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_adptVote">
				<xbrli:measure>adpt:Vote</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_adptCommonStockOptionsAndRestrictedStockUnitsGrantedMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockOptionsAndRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190701_20190701">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20140101_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adpt:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-01-01</xbrli:startDate>
					<xbrli:endDate>2014-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPlanNameAxis_adptSequentaTwoThousandAndEightStockPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:SequentaTwoThousandAndEightStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtTitleOfIndividualAxis_adptNonEmployeeDirectorsMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adpt:NonEmployeeDirectorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMinimumMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMinimumMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_srtRangeAxis_srtMaximumMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_adptOption">
				<xbrli:measure>adpt:Option</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MicrosoftCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-12-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapStatementClassOfStockAxis_adptSeriesFOneConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adpt:SeriesFOneConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MicrosoftCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptUnvestedRestrictedStockUnitsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptUnvestedRestrictedStockUnitsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptConvertiblePreferredStockWarrantsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:ConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptConvertiblePreferredStockWarrantsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:ConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="line-height:2pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549</p>
<p style="text-align:center;margin-bottom:6pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001478320_20200101_20201231">10-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:6pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:DocumentAnnualReport" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001478320_20200101_20201231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001478320_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000031" name="dei:DocumentTransitionReport" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:95%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from _____to _____</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number: <ix:nonNumeric id="F_000021" name="dei:EntityFileNumber" contextRef="C_0001478320_20200101_20201231">001-38957</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001478320_20200101_20201231">ADAPTIVE BIOTECHNOLOGIES CORPORATION</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:1.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1.5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:stateprovnameen">Washington</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001478320_20200101_20201231">27-0907024</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressAddressLine1" contextRef="C_0001478320_20200101_20201231">1551 Eastlake Avenue East</ix:nonNumeric>, <ix:nonNumeric id="F_000024" name="dei:EntityAddressAddressLine2" contextRef="C_0001478320_20200101_20201231">Suite 200</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressCityOrTown" contextRef="C_0001478320_20200101_20201231">Seattle</ix:nonNumeric>,<ix:nonNumeric id="F_000026" name="dei:EntityAddressStateOrProvince" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:stateprovnameen"> Washington</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityAddressPostalZipCode" contextRef="C_0001478320_20200101_20201231">98102</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric id="F_000028" name="dei:CityAreaCode" contextRef="C_0001478320_20200101_20201231">(206)</ix:nonNumeric> <ix:nonNumeric id="F_000029" name="dei:LocalPhoneNumber" contextRef="C_0001478320_20200101_20201231">659-0067</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:2.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:2.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:14.35pt;">
<td valign="top" style="width:35%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000015" name="dei:Security12bTitle" contextRef="C_0001478320_20200101_20201231">Common stock, par value $0.0001 per share</ix:nonNumeric></span></p></td>
<td valign="top" style="width:2.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001478320_20200101_20201231">ADPT</ix:nonNumeric></p></td>
<td valign="top" style="width:2.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:35%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SecurityExchangeName" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:exchnameen">The NASDAQ Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <span style="font-weight:bold;">None </span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000011" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001478320_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000008" name="dei:EntityVoluntaryFilers" contextRef="C_0001478320_20200101_20201231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000018" name="dei:EntityCurrentReportingStatus" contextRef="C_0001478320_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000020" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001478320_20200101_20201231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1.5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1.5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.5pt;">
<td valign="top" style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityFilerCategory" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:entityfilercategoryen">Large&#160;accelerated&#160;filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="top" style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntitySmallBusiness" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000033" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span><span style="font-size:10pt;">&#160;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000019" name="dei:EntityShellCompany" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Global Select Market on June 30, 2020 (the last business day of the Registrant&#8217;s most recently completed second fiscal quarter), was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000012" name="dei:EntityPublicFloat" contextRef="C_0001478320_20200630" decimals="0" format="ixt:numdotdecimal">3,590,000,000</ix:nonFraction>. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 19, 2021, the Registrant had <ix:nonFraction unitRef="U_xbrlishares" id="F_000017" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001478320_20210219" decimals="INF" format="ixt:numdotdecimal">139,219,503</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000034" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001478320_20200101_20201231">The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2021.</ix:nonNumeric></p>
<p style="line-height:2pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:underline;">PART I</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:underline;">PART&#160;II</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:underline;">Selected Financial Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_AND_SUPPLEME"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:underline;">PART&#160;III</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:underline;">PART&#160;IV</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">SIGNATURES</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. Some of the statements in the &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections and elsewhere in this Annual Report on Form 10-K contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements expressed or implied in this Annual Report on Form 10-K include, but are not limited to, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of our significant investments in our continued research and development of new products and services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of developing, commercializing and achieving commercial market acceptance of clonoSEQ, T-Detect, immunoSEQ, our TCR-Antigen Map, T cell receptor (&#8220;TCR&#8221;)-based cellular therapies, neutralizing antibody products or processes, such as TruAB, and additional products and services beyond our current portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential for our identified research priorities to advance our proprietary immune medicine platform or our future products and services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success, cost and timing of our research development activities, preclinical and clinical studies and, in certain instances, clinical trials and clinical validations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential benefits of collaborations, our ability to enter into collaborations or arrangements, and our ability to attract collaborators with development, manufacturing, regulatory and commercialization expertise&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability and willingness of our collaborators to continue development, manufacturing, distribution and commercialization activities relating to our jointly developed products and services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop products and services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain and maintain regulatory approval of our products and services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability, and that of our collaborators, to commercialize our products and services, including products related to COVID-19, such as T-Detect COVID and neutralizing antibodies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain equipment and materials (including reagents or other materials that may also require additional internal validation) from our suppliers, and in some cases single suppliers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to generate revenue and obtain funding for our operations, including funding necessary to complete further development of our current and future products and services, and if successful, commercialization&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in combination with others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the rate and degree of market acceptance of our products and services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential adverse effect on our business, operations and plans or timelines (including those plans and timelines related to expansion initiatives and clinical development) resulting from a health epidemic or pandemic, including the recent COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our financial performance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the pricing and reimbursement of our products and services following approval where required&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding our ability to obtain and maintain intellectual property protection for our immune medicine platform, products, services and related technologies and the direction of such protection&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory developments in the United States (&#8220;U.S.&#8221;) and foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of competing products or services that are or may become available&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments relating to our competitors and our industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract and retain key scientific or management personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of laws and regulations&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, you should refer to the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the&#160;forward-looking&#160;statements. As a result of these factors, we cannot assure you that the&#160;forward-looking&#160;statements in this Annual Report on Form 10-K will prove to be accurate. Furthermore, if the&#160;forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these&#160;forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The&#160;forward-looking&#160;statements herein represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these&#160;forward-looking&#160;statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these&#160;forward-looking&#160;statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this Annual Report on Form 10-K, unless the context requires otherwise, all references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Adaptive&#8221; and the &#8220;Company&#8221; refer to Adaptive Biotechnologies Corporation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use these insights to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have three commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Since our inception in 2009, we have characterized over 58 billion immune receptors, established partnerships and commercial relationships with 175 biopharmaceutical companies and launched three product lines. Our goal is to understand the adaptive immune system and translate it into new products with unprecedented scale, precision and speed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immune medicine platform is the foundation for our expanding suite of products and services. The cornerstone of our platform and core immunosequencing product, immunoSEQ, serves as our underlying research and development engine and generates revenue from academic and biopharmaceutical customers. Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the Food and Drug Administration (&#8220;FDA&#8221;) for the detection and monitoring of minimal residual disease (&#8220;MRD&#8221;) in patients with multiple myeloma (&#8220;MM&#8221;), B cell acute lymphoblastic leukemia (&#8220;ALL&#8221;) and chronic lymphocytic leukemia (&#8220;CLL&#8221;) and is also available as a CLIA-validated laboratory developed test (&#8220;LDT&#8221;) for patients with other lymphoid cancers. Leveraging our collaboration with Microsoft Corporation (&#8220;Microsoft&#8221;), we are creating a map of the interaction between the immune system and disease (&#8220;TCR-Antigen Map&#8221;). We are using this map to develop research solutions by disease called immunoSEQ T-MAP and a diagnostic product for many diseases from a single blood test called T-Detect. T-Detect was formerly known as immunoSEQ Dx. T-Detect COVID, for which we have applied for Emergency Use Authorization (&#8220;EUA&#8221;), confirms past SARS-CoV-2 infection, the virus that causes COVID-19, and is also the first indication for the T-Detect product line. We are finalizing clinical validation of T-Detect for Lyme disease and continue to pursue signals for other disease states in parallel. Our therapeutic product candidates, being developed under our collaboration agreement with Genentech, Inc. (&#8220;Genentech&#8221;), leverage our platform to identify specific receptors on immune cells to develop into cellular therapies in oncology. We believe this approach has the potential to be applicable to patients across a wide range of cancers. We also extended our platform to identify highly potent neutralizing antibodies against SARS-CoV-2 and we believe this differentiated approach may be leveraged across multiple disease states.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immune medicine is one of the largest global addressable markets in healthcare. We estimate the potential market opportunity for our portfolio to be $54.7&#160;billion, including $1.0&#160;billion for research products, $22.3&#160;billion for clinical diagnostics and $31.4&#160;billion for cellular therapy in oncology. We use multiple sources and assumptions to estimate the total addressable market for immune medicine. While we believe them to be reasonable, these sources and assumptions may be incorrect or subject to change due to any number of factors. In particular, the indications we choose to commercialize for T-Detect may vary depending on ongoing signal validation and market considerations. In addition, our drug discovery initiatives are still in the early stages of development and the market opportunity excludes neutralizing antibodies, which may make our assumptions and estimates more uncertain. Despite the novelty of this area, we believe we are uniquely positioned to develop and commercialize a pipeline of immune-driven diagnostic and therapeutic products across multiple disease states by leveraging the cumulative learning from our immune medicine platform. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite operating with challenges presented by the global COVID-19 pandemic, we were able to achieve and progress towards many key milestones in 2020 in each business area: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We&#160;extended our collaboration with Microsoft to decode the population-wide T-cell immune response to COVID-19. We believe that quantifying virus-specific T cells may provide important research and diagnostic advantages because T cells appear earlier than antibodies and persist longer. Together, we implemented the ImmuneCODE Program to quantitatively assess the T-cell immune response to the virus in over 5,000 individuals from around the world and we have made this data publicly available. As a result of this work, we have broadened our product portfolio in our life sciences research and clinical diagnostic business areas. In addition, we also leveraged these samples to contribute to our research and development efforts to identify potent neutralizing antibodies against the virus, which extended our drug discovery capabilities. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">In clinical diagnostics, we now have two products on the market &#8211; clonoSEQ and T-Detect. For clonoSEQ, we grew our test volume by 49% to 15,186 tests delivered. We increased the all-time number of unique patients tested by </span><span style="color:#000000;">more than </span><span style="color:#000000;">50% to over 15,000 patients by the end of 2020. We also achieved an expansion of our FDA label to include CLL from both bone marrow and blood and have filed </span><span style="color:#000000;">to expand our existing label for ALL in bone marrow to include blood</span><span style="color:#000000;">. For T-Detect, we launched the first indication, T-Detect COVID, to confirm past SARS-CoV-2 infection. Our data demonstrates that our T-cell based test outperforms antibody serology to confirm past infection. We will be completing our ImmuneSENSE Lyme clinical validation study and are preparing for commercialization in 2021, and we announced another clinical signal for Crohn&#8217;s Disease. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In life sciences research, we launched the upgraded immunoSEQ RUO kit, which has been selected by 35 core labs and user groups at premier institutions and by two global clinical research organizations (&#8220;CROs&#8221;), Q2 Solutions LLC (&#8220;Q2 Solutions&#8221;) and Laboratory Corporation of America Holdings (&#8220;Labcorp&#8221;), to offer gold standard immunosequencing to their research clientele. In the third quarter, leveraging our work with Microsoft, we launched a new product extension called immunoSEQ T-MAP COVID to accurately and reproducibly measure the T-cell immune response to vaccines and track the persistence of that response over time, and we are in late-stage discussions with several companies developing next-generation vaccines. This is the first application of the immunoSEQ T-MAP product extension whereby we will be offering access to the mapped sequence data generated by our platform. In the fourth quarter of 2020, we entered into our first multi-year immunoSEQ T-MAP cancer collaboration with AstraZeneca plc (&#8220;AZ&#8221;) to generate data from antigen-specific T-cell immune responses across AZ&#8217;s oncology drug portfolio. T-MAP data may inform early disease intervention to help improve patient outcomes, with the potential for additional opportunities to develop companion diagnostic or novel therapeutics with AZ. We also signed two additional collaborations with Genentech and GlaxoSmithKline plc to use the research application of our MRD product to support clinical development and potential regulatory approval or label extensions of novel blood cancer therapies. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In drug discovery, Genentech is planning to file an investigational new drug (&#8220;IND&#8221;) submission in the first half of 2021 for our first shared cellular therapy product and we are in late-stage characterization of our next cancer-specific immune receptor that could be selected by Genentech for the potential development of a second shared cellular therapy product. We are scaling our research and development efforts and plan to generate proof of concept data for the personalized approach and are on track to open our dedicated prototype lab in South San Francisco in early 2021. For our neutralizing antibody efforts, we identified several highly potent neutralizing antibodies against SARS-CoV-2 and are in active partnering discussions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Key financial highlights for 2020 include full year revenue up 16% to $98.4 million, cash, cash equivalents and marketable securities of $806.8 million and clinical sequencing volumes up 50% to 15,216 tests, which now includes both clonoSEQ and T-Detect tests.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In addition, we expect to complete construction and move into our new corporate headquarters in Seattle, Washington in the second half of 2021. This approximately 100,000 square foot facility is designed to enable us to quadruple our volume over time and allow for continued scaling and growth.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Immune Medicine Platform </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adaptive immune system is comprised of specialized cells, called T&#160;cells and B&#160;cells, which hold the instructions for diagnosing and treating most diseases. These instructions enable these cells to identify, bind and destroy pathogens or human cells presenting foreign signals of disease (&#8220;antigens&#8221;) using receptors on their cell surface. Unlike all other genes in the human genome, the genetic sequences of TCRs and B cell receptors (&#8220;BCRs&#8221;) rearrange over time creating massive genetic diversity. The resulting diversity of the adaptive immune repertoire, which consists of over 100&#160;million different genes in a healthy adult compared to approximately 30,000 genes in the static human genome, gives the immune system the ability to detect and respond to millions of different antigens associated with human disease. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immune medicine platform combines a suite of proprietary chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. It extracts and interprets insights from the adaptive immune system with the scale, precision and speed required to enable the design of clinical products tailored to the specific genetics of each patient&#8217;s immune system.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000001.jpg" title="" alt="" style="width:316px;height:316px;" /><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immune medicine platform performs the following key functions related to immune receptors: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Sequence.</span><span style="color:#000000;"> immunoSEQ sequences single chains of &#8220;Y-shaped&#8221; TCRs or BCRs using next generation sequencing (&#8220;NGS&#8221;), enabling us to understand the quantity and diversity of T and B cells in a biological sample. This provides deep insights into individual and collective immune responses at a scale that is thousands of times greater than was previously possible. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Map.</span><span style="color:#000000;"> MIRA (Multiplexed Identification of T cell Receptor Antigen Specificity) maps millions of TCRs to thousands of clinically relevant antigens. Combined with immunoSEQ, MIRA elucidates what potential diseases a patient&#8217;s immune system has been exposed to or is actively fighting. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Pair.</span><span style="color:#000000;"> pairSEQ builds on immunoSEQ by using a combinatorial strategy to accurately pair both chains of Y-shaped immune cell receptors at high-throughput, which is challenging to do at scale using other methods because the two chains of the Y-shaped receptors are located on different chromosomes. The ability to accurately pair both chains of the receptors in a sample enables us to reconstruct receptors for therapeutic purposes. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Characterize.</span><span style="color:#000000;"> TruTCR characterizes binding, cytotoxicity and safety properties of antigen-specific, paired TCRs to identify a subset that is therapeutic-grade, enabling the discovery and development of optimal clinical candidates to be engineered into TCR-mediated cellular therapies. </span><span style="Background-color:#FFFFFF;color:#000000;">TruAB is our high-throughput antibody discovery process that enables the selection of potent, naturally occurring, full length antibodies for therapeutic or prophylactic development.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The massive amount of data generated by our immune medicine platform is stored in our dynamic clinical immunomics database of over 58&#160;billion immune receptors. We believe the application of machine learning, supported by our collaboration with Microsoft, has the potential to exponentially accelerate our ability to derive novel insights from this database and use them to inform our robust product development efforts. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current coronavirus pandemic is highlighting the critical importance of understanding the immune response to disease broadly, making our technology more relevant than ever. We are focused on translating the genetic language of the adaptive immune system into clinical products to diagnose and treat disease, and we are committed to leveraging our immune medicine platform to support the efforts to combat the COVID-19 pandemic. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By elucidating immune receptor data specific to SARS-CoV-2, we developed multiple products. In our research business, for the first time, we offered a product that not only sequences, but also maps the immune response to the virus. This product, called immunoSEQ T-MAP COVID, provides a better way for vaccine developers and researchers to include the T-cell response in their studies. We are pleased to see top-tier vaccine developers recognizing the power of this product. Leveraging the same data, we launched a clinical diagnostic called T-Detect COVID to confirm past infection. In addition, we created an antibody discovery platform to find highly potent neutralizing antibodies against COVID-19 that is applicable not only to the current pandemic, but also in the unfortunate event of future pandemics and other diseases states. Importantly, we believe we can leverage what we accomplished for COVID-19 using disease-specific immune receptor data across other disease states going forward.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000002.jpg" title="" alt="" style="width:656px;height:315px;" /><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe COVID-19 brought the role of the immune system to the forefront of society and has created the opportunity for us to be positioned as the &#8220;go to&#8221; company to rapidly and reproducibly assess the T-cell response to any pathogen, including future pandemics.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Current Products and Pipeline </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current portfolio includes commercial products and services in life sciences research and clinical diagnostics, and we are developing products and services in both clinical diagnostics and drug discovery. Our commercial research products, immunoSEQ and immunoSEQ T-MAP, primarily serve as our underlying research and development engine to develop and validate our clinical pipeline. We plan to continue to invest in our immune medicine platform to develop additional clinical products, which we prioritize based on clinical actionability, unmet medical need and commercial viability. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Life Sciences Research </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immunoSEQ research service and kits are used to answer translational research questions and discover new prognostic and diagnostic signals. Our technology has been used for research purposes by over 2,400 academic researchers and 175 biopharmaceutical companies and incorporated into over 650 clinical trials since our inception in 2009. We have completed development of a next generation, sample-type agnostic research use only (&#8220;RUO&#8221;) kit that has been selected by 35 academic core labs and user groups in the United States and we continue to expand these collaborations. Additionally, we announced our first distribution agreement with two CROs, Q2 Solutions and Labcorp, and we are in discussions with several others. By enabling academic core labs and CROs as centers of excellence with our gold standard immunoSEQ RUO kit, we expect to set the foundation for long term growth going forward. Importantly, immunoSEQ is analytically validated so that all research data generated using immunoSEQ can be used for clinical validation of potential diagnostic applications. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We launched immunoSEQ T-MAP COVID in August 2020 for vaccine developers and researchers to accurately and reproducibly measure the T-cell immune response to vaccines and track the persistence of that response over time. A key objective with T-MAP COVID is to answer many outstanding questions about durability of COVID-19 vaccines, especially in light of new variants of the virus. Our T-MAP product offers significant advantages over other technologies to detect and monitor T cells at scale using a small amount of blood without the need for live cells that require special sample handling.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have sequenced a subset of patient samples (pre- and post-vaccination) from clinical trials sponsored by several top-tier vaccine developers, including AZ, University of Oxford, Bill and Melinda Gates Foundation and several prestigious academic labs who are studying the impact of COVID-19 vaccines on patients receiving other immune-mediated therapies. Using our immunoSEQ T-MAP COVID product, we can identify and track expanded T cells induced by a vaccine, which can be distinguished from a natural infection, in order to monitor vaccine efficacy. In vaccinated subjects who test positive for the virus utilizing the two-step multiplex polymerase chain reaction (&#8220;PCR&#8221;) amplification process, immunoSEQ T-MAP COVID can specifically track vaccine-induced T cells and correlate response with improved patient outcomes. In addition, we are also in late-stage discussions with several companies developing next-generation vaccines.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fourth quarter of 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our first</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> multi-year</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> immunoSEQ T-MAP </span><span style="color:#000000;">c</span><span style="color:#000000;">ancer </span><span style="color:#000000;">collaboration with AZ</span><span style="color:#000000;"> to</span><span style="color:#000000;"> generate data from</span><span style="color:#000000;"> antigen-specific T-cell immune response</span><span style="color:#000000;">s</span><span style="color:#000000;"> across AZ</span><span style="color:#000000;">&#8217;s oncology drug portfolio</span><span style="color:#000000;">.</span><span style="color:#000000;"> T-MAP data may</span><span style="color:#000000;"> inform early disease intervention to help improve patient outcomes</span><span style="color:#000000;">, with the potential for additional partnership opportunities to develop companion </span><span style="color:#000000;">diagnostics or novel therapeutics with AZ</span><span style="color:#000000;">. The partnership</span><span style="color:#000000;"> also</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> allows for data sharing between </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AZ</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benefit</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our independent efforts. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect this</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will help expedite our ability to map the large antigenic space in cancer.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Diagnostics </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clonoSEQ diagnostic test detects and monitors the remaining number of cancer cells that are present in a patient&#8217;s body during and after treatment, known as MRD. In September 2018, clonoSEQ was granted marketing authorization from the FDA, under the <span style="font-style:italic;">de novo</span> process, for patients with MM and ALL to monitor their MRD from bone marrow samples. In August 2020, the clonoSEQ label was expanded to include patients with CLL from bone marrow and blood samples. clonoSEQ is also available for use in other lymphoid cancers as an LDT. In January 2019, clonoSEQ received Medicare coverage aligned with the FDA label and National Comprehensive Cancer Network (&#8220;NCCN&#8221;) guidelines for longitudinal monitoring in MM and ALL. Throughout 2019 and 2020, we secured additional payor coverage for clonoSEQ aligned with our FDA label with Medicare, national private payors and large regional plans for a total of over 225&#160;million covered lives for ALL and MM and over 110 million covered lives for CLL. clonoSEQ testing has been ordered by clinicians for over 15,000 unique patients and used by more than 40 biopharmaceutical companies in over 190 clinical trials.&#160;We continue to deepen our commercial investments to expand clinical adoption of clonoSEQ and have increased the size of our specialized sales and customer support organization and supporting infrastructure in the United States, and we have successfully transferred the technology to seven labs in other parts of the world. We also signed a co-promotion agreement with Labcorp to leverage their growing oncology salesforce to expand our commercial reach and further deepen our market penetration. We believe clonoSEQ has broad applicability across all lymphoid malignancies. We recently submitted a 510(k) premarket notification for ALL from blood samples in February 2021 and are actively advancing validation studies in certain non-Hodgkin&#8217;s lymphoma (&#8220;NHL&#8221;) sub-types. We are also awaiting results from a clinical study using clonoSEQ to assess MRD in blood for multiple myeloma. Importantly, we have also implemented collaborations with Labcorp and Phlebotek Solutions Corporation (&#8220;Phlebotek&#8221;) to ease access to blood sample collection for patients. We believe these solutions may facilitate more frequent monitoring and benefit patients longer term as they enable a convenient and safe alternative to inpatient visits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leveraging Microsoft&#8217;s machine learning capabilities to create the TCR-Antigen Map, we are developing a diagnostic product, T-Detect, that may enable early or accurate detection of many diseases from a single blood test. Initially, we are validating detection of a set of discrete diseases for which there is a significant unmet medical need for better diagnostic testing and early intervention, and where antigen specificity is well-known. These include infectious diseases, autoimmune disorders and certain prevalent cancer types. In December 2020, we launched an early access program for T-Detect COVID as the first indication of T-Detect, which came a year earlier than originally planned. The formal launch of T-Detect COVID, which includes a virtual provider to authorize the prescription, occurred in February 2021. Leveraging the infrastructure built to support this initial indication, we are on track to launch T-Detect Lyme in our CLIA lab towards the end of 2021. Additionally, we have early clinical signals in gastrointestinal disorders such as Celiac disease and Crohn&#8217;s disease, and we have built a robust research and development pipeline to rapidly identify signals across many disease states simultaneously. Our immune medicine platform enables parallel development because it can work with retrospective sample sets and uses machine learning and computational statistics to continuously improve our detection and accuracy which is applied to all of the diagnostic algorithms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For T-Detect, we launched the first indication, T-Detect COVID, to confirm past SARS-CoV-2 infection, which represents a stepping-stone to the long-term vision of T-Detect where a single blood sample can provide information about what diseases a person&#8217;s immune system has seen or is currently fighting. In two real-world studies with convalescent patients, including our own IRB-sponsored study called ImmuneRACE, our T-cell based test shows higher sensitivity than multiple antibody serology tests to confirm past infection. Additionally, data demonstrates that the T-cell response is more persistent than the antibody response to the virus, persisting to at least five months following initial infection and that the performance of T-Detect COVID is equivalent to or better than antibody testing at all timepoints evaluated. The test was launched in December 2020, primarily targeting groups and individuals for whom knowledge of past COVID-19 infection or exposure is valuable, including self-pay consumers, employers and concierge medicine physician groups. Our market research shows that there are many people who were unable to access testing in spring of 2020 or had unexpected results from antibody or PCR testing, and are still curious or skeptical about a previous infection. This is particularly true for individuals who were asymptomatic or had mild symptoms, in whom antibody testing may be less reliable.&#160;Additionally, our research indicates high interest among consumers in understanding immunity to COVID-19. Therefore, we are offering the ability to contribute to on-market research to quantitatively assess the duration of immunity as defined by the persistence of SARS-CoV-2 specific T cells. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T-Detect Lyme is the second indication planned for the T-Detect product line, with an anticipated market launch towards the end of 2021 as a CLIA-service offering</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> leveraging the infrastructure built for T-Detect COVID. An interim analysis of the ImmuneSense Lyme study comparing our T-cell based diagnostic to current standard of care testing will support the CLIA launch. We have enrolled 91% of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the subjects</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> needed for the interim analysis. We intend to continue full enrollment of the 990 subject study, of which approximately 420 will have either a clinical diagnosis or clinical suspicion based on a physician's assessment of Lyme disease. The remaining subjects will include negative controls from both endemic and non-endemic regions and potential cross-reactive diseases. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are approximately 3.4 million Lyme diagnostic tests performed annually. Initially, we are focused on generating data that supports market entry for early and more accurate diagnosis of Lyme disease for patients with non-descript symptoms that are suspected to be caused by Lyme.&#160;This population is over 600,000 patients in the US each year. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In terms of other T-Detect indications in the pipeline, we recently confirmed our third clinical signal in Crohn&#8217;s disease. Crohn&#8217;s is a gastrointestinal disorder that is often confused with other conditions with similar symptom presentation and there is a significant unmet need for a highly specific and sensitive non-invasive test.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leveraging acceleration from our T-Detect COVID efforts, we are now able to assess an increasing number of diseases in parallel across the five stages of our research and development pipeline. We begin the process with diseases that meet key market attractiveness criteria such as high unmet medical need, understanding of the antigenic space, and our access to samples with metadata. We then seek early clinical signals in prioritized disease states and continue to refine our modeling for those that appear promising. For each signal, we generate data in several ways: run na&#239;ve blood to map receptors to antigens, collaborate on studies with control groups, and leverage a database of unlabeled samples. Once a signal is confirmed in additional independent cohorts and the product profile is deemed attractive, we proceed with a full commercial validation and generation of a locked-down algorithm to take into clinical validation and regulatory submission.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are many economic advantages of T-Detect both in the research and development stage and as a commercial product. For the research and development pipeline, we leverage the same capital expenditures and workflow for signal generation across all diseases allowing us to study multiple diseases in parallel without requiring substantial workflow adjustments or significant new capital expenditures for specific new disease states. Once commercialized, again, we use the same blood sample and the same underlying chemistry for all diseases with a small incremental investment in software for each individual disease, enabling a long-term high margin profile. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Drug Discovery </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug discovery efforts to date are focused on identifying therapeutic-grade TCRs and antibody-secreting BCRs to enable our partners to engineer, manufacture and commercialize therapeutic candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our TruTCR process characterizes TCRs against shared antigens for use in the development of therapeutics. In December&#160;2018, we entered into an exclusive collaboration with Genentech to&#160;leverage this capability for the development of cellular therapies in oncology. We are pursuing two product development pathways for novel T&#160;cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Shared Products.</span><span style="color:#000000;"> The shared products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among patients (&#8220;Shared Products&#8221;). Genentech is planning its first IND submission for the first shared product targeting a selected shared cancer antigen in the first half of 2021. We continue to screen and characterize TCRs against clinically relevant targets in solid tumors and we are in late-stage characterization of several promising TCRs that could be considered by Genentech for the development of a second Shared Product.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Personalized Product.</span><span style="color:#000000;"> The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#8220;Personalized Product&#8221;). In the second half of 2020, we started screening blood from cancer patients to identify TCRs specific to a patient&#8217;s tumor mutations and our goal is to generate proof of concept data by early 2021. To support our near-term and long-term objectives for our private product, we plan to open our dedicated prototype lab in South San Francisco in 2021, which will have capacity to perform first-in-human clinical trials. We believe this investment positions us to potentially pursue additional opportunities outside of this collaboration, including cellular therapy in other disease states and cancer vaccines.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our TruAB process, similar to our TruTCR process, leverages our high-throughput capabilities to screen millions of BCRs to identify unique antibodies from the blood of COVID-19 patients. In several months, we used blood from over 300 patients to identify hundreds of thousands of antibodies, of which we synthesized and characterized over 3,300 antibodies that bind to various parts of the SARS-CoV-2 virus. Our lead TruAB candidates that neutralize live virus at very low concentrations, which means that a very small amount of each of these antibodies is able to block the virus from infecting cells. Importantly, our drug discovery approach is differentiated from other groups because of the scale and throughput of our TruAB approach that allows us to identify a much broader set of naturally-occurring, fully human antibody candidates to select the best ones for clinical development. The first potential clinical application of our antibodies is to treat patients who are actively fighting or have recently recovered from COVID-19.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Clinical Portfolio and Pipeline</span></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000003.jpg" title="" alt="" style="width:679px;height:334px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Competitive Strengths </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We aim to harness the inherent biology of the adaptive immune system to develop clinical products and services that improve human health by leveraging our core competitive strengths. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our immune medicine platform is uniquely capable of supporting clinical products.</span><span style="color:#000000;"> We have developed a platform that is capable of reading and translating the massive genetic diversity of the adaptive immune system and its selective response to disease. Specifically, our platform</span><span style="font-style:italic;color:#000000;"> sequences</span><span style="color:#000000;"> immune receptors and</span><span style="font-style:italic;color:#000000;"> maps</span><span style="color:#000000;"> them to antigens for diagnostic applications,</span><span style="font-style:italic;color:#000000;"> pairs</span><span style="color:#000000;"> receptor chains and</span><span style="font-style:italic;color:#000000;"> characterizes</span><span style="color:#000000;"> antigen-specific, paired receptors to identify optimal clinical targets for therapeutic use. We are the only company that can perform all of these functions&#8212;and we do so at an unprecedented scale to develop novel clinical diagnostic and therapeutic products.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our clinical immunomics database provides a robust product development engine.</span><span style="color:#000000;"> Using the adaptive immune system as our source-code, we are building a dynamic clinical immunomics database of over 58&#160;billion immune receptors, now being annotated with antigens using machine learning, that drives our ability to rapidly discover and develop potential diagnostic and therapeutic applications. Our aim is to translate the natural capabilities of the immune system into the clinic by capturing the millions of diverse unique receptors present in a patient&#8217;s blood. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Clinical applicability spans diagnostic and therapeutic product potential.</span><span style="color:#000000;"> Our ability to accumulate, synthesize and process billions of immunomic datapoints to generate multiple clinical diagnostic and therapeutic applications across disease areas provides optionality to our commercial pipeline. Each of our products also has broad applicability, enabling robust product lifecycle extensions. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Regulatory and reimbursement expertise will help inform future clinical product development.</span><span style="color:#000000;"> Having successfully obtained FDA marketing authorization and coverage for clonoSEQ from Medicare and several national private payors, we believe we have developed valuable core capabilities that will facilitate future product development through to regulatory approval and reimbursement. We believe this capability will inform future development of other clinical products, including early detection tests. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Transformational collaborations with industry leaders validate our platform.</span><span style="color:#000000;"> Our collaborations with industry-defining leaders such as Genentech and Microsoft validate our unique approach to advancing the promise of immune medicine. We will continue to seek opportunities to optimize our ever-growing clinical immunomics database to drive product development and commercial success and facilitate efficient use of capital. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Strong intellectual property protects our immune medicine platform and its applications.</span><span style="color:#000000;"> As of December 31, 2020, we had filed 451 patent applications, 386 of which had issued as of that date, covering improvements in sequencing methods and new ways to leverage adaptive immune receptors for life sciences research, clinical diagnostic and drug discovery applications. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our focus is to leverage our immune medicine platform and competitive strengths to develop transformative clinical solutions accessible to patients around the world. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Powering the age of immune medicine.</span><span style="color:#000000;"> We facilitate the development of the immune medicine field by providing a platform to encourage generation of immunomics data to facilitate a deeper understanding of, and biological discovery from, the adaptive immune system. We leverage the unique capability of our platform to translate the genetics of a patient&#8217;s immune system with the scale, precision and speed required to enable the development of Personalized Products, including clinical diagnostic tests for disease monitoring and early detection, as well as immune-based therapeutics. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Rapidly identify and advance new products, leveraging foundational technology.</span><span style="color:#000000;"> Integrate proven chemistry into our clinical products in development, avoiding the need to re-engineer new products for every clinical application. We do this by serially identifying new applications of T-Detect for early detection of disease using retrospective datasets without requiring live cells from large cohorts of patients, and by characterizing TCRs for therapeutic use. As our platform expands into new indications across cancer, autoimmune conditions and infectious diseases, we believe we will benefit from economies of scale and drive margin improvement over time. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Entrench our products and services in clinical drug development with biopharmaceutical collaborators.</span><span style="color:#000000;"> Position our platform as the gold standard for the validation of potential immune-driven clinical discoveries in late-stage clinical trials. Since inception, our products and services have been used by 175 biopharmaceutical companies and incorporated into over 650 clinical trials, and clonoSEQ has proven to be the MRD test of choice for select registrational trials. To deepen our established position as a partner of choice, we provide end-to-end support, including hypothesis-driven trial design, extensive data analyses, parallel regulatory support, compliant data transfers and novel target screening. These synergistic relationships advance the development and adoption of our own clinical products and also inform drug development for our partners. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Drive the commercial adoption of distributed, reimbursed and regulated clinical products.</span><span style="color:#000000;"> Expand distribution and drive usage of our products and services, including the possibility of developing clinical </span><span style="font-style:italic;color:#000000;">in vitro</span><span style="color:#000000;"> diagnostic (&#8220;IVD&#8221;) kits. Leverage the commercial infrastructure built for clonoSEQ to submit clinical data for regulatory clearance of our products and services, expand current payor coverage and provide robust billing and patient access infrastructure for multiple clinical applications. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Maintain an entrepreneurial, scientifically rigorous, data-driven and inclusive corporate culture.</span><span style="color:#000000;"> Fuel the promise and potential that our platform offers to help patients better manage their disease by translating insights from our world-class team, which includes 124 people with medical or doctoral degrees with expertise in biology, chemistry, bioinformatics, software, drug discovery, development and commercialization, into clinical products and services. We plan to continue to expand our team to advance the promise of immune medicine.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A Primer: The Adaptive Immune System </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over millions of years, the adaptive immune system has evolved an elegant solution to keeping people healthy. It recognizes and responds to most antigens, whether they come from outside the body, such as a virus, or inside the body, such as mutations that drive cancer. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The innate and adaptive immune systems both play a role in human immunity, but only the adaptive immune system provides a specific response to signals of disease, or antigens. These disease specific antigens are primarily fragments of proteins that are recognized as foreign, such as proteins from a virus. However, antigens can be recognized as foreign even if they are not from a pathogen. In cancer cells, antigens are generated from neoantigens, which are derived from mutations specific only to the cancer, or tumor associated antigens (&#8220;TAAs&#8221;), which are from aberrantly expressed normal proteins. For autoimmune disorders, the immune system mistakenly recognizes normal protein fragments as foreign antigens and attacks otherwise healthy tissue. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Adaptive Immune Response </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The key cells of the adaptive immune system that enable our bodies to mount responses against antigens are called T&#160;cells and B&#160;cells. T&#160;cells can destroy target cells directly, and B&#160;cells secrete antibodies, activating other parts of the immune system to destroy targets. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each T and B&#160;cell has a unique Y-shaped receptor, which can recognize one or a small number of the millions of antigens to which our bodies are continuously exposed. When an adaptive immune response is initiated against a particular disease, the T&#160;cells and B&#160;cells encoding the disease-specific targeting receptors rapidly multiply through clonal expansion, allowing for a powerful immune response. Some of these expanded cells directly attack the disease, and others form long-term memory to allow rapid recognition of the same antigens in the future and protect against reinfection. Unlike all other genes in the human genome, the genetic sequences of TCRs and BCRs rearrange over time through a complex biological process resulting in massive diversity. The diversity of these receptors is made possible by a unique reshuffling of their genetic code known as V(D)J recombination (V&#61;Variable, D&#61;Diversity, J&#61;Joining). This recombination process only occurs in T&#160;cells and B&#160;cells, and it results in each cell clone having a unique receptor-associated deoxyribonucleic acid (&#8220;DNA&#8221;) sequence. This unique DNA sequence acts like a barcode that can be used to identify and track an individual receptor over time, as shown in the figure below: </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000004.jpg" title="" alt="" style="width:665px;height:259px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adaptive immune response requires millions of these unique receptors to be widely distributed and present in the blood at all times in order to have the ability to rapidly respond to many different diseases simultaneously. Even after a specific TCR binds to an antigen and clonally expands, the frequency of these expanded T-cell clones containing the TCR remains relatively low in relation to the estimated trillions of other T cells that are circulating. We have demonstrated this by sequencing thousands of healthy individuals for control cohorts for our research and development efforts. We now know that disease-specific TCRs that are clonally expanded in a patient&#8217;s blood are present, on average, at less than 1 cell out of 100,000 cells. Despite their relatively low abundance, disease-specific TCRs can mount a systemic, persistent response to most perturbations because of the highly specialized properties of the immune response summarized in the table below: </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000005.jpg" title="" alt="" style="width:683px;height:304px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to fully leverage these inherent properties of the immune system to develop clinical products, this enormous diversity and scale must be taken into consideration to be able to reliably and repeatedly measure the relative frequency of each disease-specific T&#160;cell in the blood. For example, cancer-specific TCRs circulating in the blood of a cancer patient are only present at 1 out of 100,000 cells. Auto-reactive T&#160;cells specific to any given autoimmune disorder circulating in the blood are only present at 1 out of 1,000,000 cells. Accordingly, the ability to detect disease-specific T&#160;cells requires a technology that can quantitatively probe a minimum of hundreds of thousands to millions of blood cells from each sample. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Immune Medicine Platform </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We built a platform that can reveal and translate these properties of the adaptive immune system with the scale, precision and speed required to enable the development of Personalized Products, including disease monitoring, clinical diagnostic tests for early detection and immune-based therapeutics. Our immune medicine platform combines a suite of proprietary chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system and transform the diagnosis and treatment of disease. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The massive amount of data generated by our immune medicine platform is stored in our dynamic clinical immunomics database of over 58&#160;billion immune receptors. We believe the application of machine learning with Microsoft has the potential to exponentially accelerate the growth of novel insights from this database, which we expect will further inform our product development efforts, as demonstrated by the growing number of clinical signals we are generating. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sequence with immunoSEQ </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">immunoSEQ sequences single chains of Y-shaped TCRs and BCRs using NGS. NGS generally describes several modern sequencing technologies that enable more efficient DNA and ribonucleic acid (&#8220;RNA&#8221;) sequencing than prior technologies. The key innovation in the development of immunoSEQ, pioneered by Dr.&#160;Harlan Robins and a team of leading immunologists at the Fred Hutchinson Cancer Research Center (&#8220;Fred Hutch&#8221;), was a novel approach utilizing PCR, hybridization and sequencing of rearranged TCRs to determine the sequences in millions of rearranged TCR genes, as shown in the figure below. We apply a similar approach for BCR sequencing. All of the data generated by immunoSEQ is uploaded to our clinical immunomics database and accessed through our proprietary cloud-based visualization and analytic tool called the immunoSEQ Analyzer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000006.jpg" title="" alt="" style="width:704px;height:426px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of the biggest challenges of any multiplex PCR technique is controlling for PCR amplification bias, which is critical for accuracy. We solved for this problem by creating a synthetic immune repertoire that mimics rearranged immune receptor loci for all V and J genes. By identifying specific primers that are either under or over amplified, titrating the primer concentrations and computationally adjusting residual bias, we optimize quantitation. The accuracy and reproducibility of our bias control methodology was demonstrated in our lab and independently in a multi-center, lab-to-lab concordance study using our immunoSEQ RUO kit. The ability to generate an unbiased TCR or BCR sequencing read-out is paramount for any clinical product and will be required for the utility and reliability of clinical kits. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">immunoSEQ enables us to observe the majority of receptors involved in a real human immune response, providing deep insights into a complex biological system that was previously challenging to understand. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Map with MIRA </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary MIRA technology enables the identification of TCRs specific to thousands of antigens simultaneously. The MIRA technology leverages a multiplexed, combinatorial approach to mapping TCRs to antigens in four steps: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Identify and query antigens of interest which can include neoantigens, tumor-associated, viral, infectious, autoimmune or other antigens. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Pool the antigens of interest and incubate them with immune cells from multiple donors whereby antigen specificities are determined based on the antigen pool design. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Sort T cells by marker of interest. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Match T cell clones to specific antigens based on the presence of specific sequences in designated pools. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combined with immunoSEQ, MIRA elucidates what diseases a patient&#8217;s immune system has been exposed to or is actively fighting at a scale that is one thousand times more sensitive than standard immunological techniques such as ELISPOT, or enzyme-linked immunospot. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pair with pairSEQ </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary pairSEQ technology builds on immunosequencing by using a combinatorial strategy to accurately pair the two chains of Y-shaped immune cell receptors at higher throughput than can be achieved with single cell sequencing. Pairing is difficult because the two chains of the Y-shaped receptor are located on different chromosomes, which get separated when DNA is extracted from a cell for sequencing. By pairing TCRs or BCRs, we rapidly detect thousands of complete chain sequences to develop new TCR-mediated cellular therapies or to develop differentiated antibodies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Characterize with TruTCR </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TruTCR characterizes binding, cytotoxicity and safety properties of antigen-specific, paired TCRs to identify a select subset that are therapeutic-grade, enabling the development of optimal clinical candidates to be engineered into TCR-mediated cellular therapies. Our comprehensive TCR characterization process utilizes advanced cellular immunology to measure TCRs against a variety of metrics to determine the optimal clinical candidates. Antigen-specific, paired TCRs undergo evaluation for avidity, cytokine release, cytotoxicity and safety. Those TCRs that pass the first safety filter are then evaluated for TCR reactivity against T&#160;cell lines and primary cells. To date, we have identified and characterized to different stages more than 4,000 unique antigen-specific TCRs against 600 different clinically relevant targets, constituting our pipeline of possible clinical candidates. TCR characterization using TruTCR is summarized in the figure below: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000007.jpg" title="" alt="" style="width:720px;height:214px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In collaboration with Genentech, we plan to apply a similar process to screen, identify and characterize in real-time what we believe are the most promising patient-specific TCRs targeting the patient&#8217;s specific cancer antigens, advancing the next generation of cellular therapy in oncology. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Discover with TruAB</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TruAB enables the discovery and characterization of BCRs for use as therapeutic antibodies. Our key differentiator is the ability to tap into the massive diversity of the B-cell repertoire to identify naturally-occurring, fully human antibodies at unprecedented scale. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, we deployed our platform to identify neutralizing antibodies to the SARS-CoV-2 virus that causes COVID-19. We processed blood from more than 300 recovered and symptomatic COVID-19 patients. We then applied our high-throughput BCR pairing technology and paired more than 490,000 antibody heavy and light chains. We evaluated these BCR sequences <span style="font-style:italic;">in silico</span> and selected more than 3,300 likely attractive antibody candidates for downstream functional characterization, including affinity binding and live virus neutralization.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000008.jpg" title="" alt="" style="width:720px;height:264px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of November 12, 2020, Amgen, Inc. declined its option to negotiate an agreement to develop, manufacture and commercialize our neutralizing antibodies against the SARS-CoV-2 virus.<span style="font-weight:bold;"> </span>We are evaluating several options to further advance our lead candidate(s).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond COVID-19, we believe these efforts represent a differentiated platform extension that will position us to pursue additional potential antibody discovery opportunities in a variety of disease states, including in autoimmunity where there is an unmet need.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Immunomics Database </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a large, dynamic clinical immunomics database, which currently contains over 58&#160;billion immune receptors. We use our proprietary software and core competency in computational biology to structure and store immune receptor data and to create tools for rapid analysis and easy visualization. All immunosequencing data is processed and uploaded to a secure cloud-based database. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The record of diseases a person has encountered, both past and present, is recorded in their TCR repertoire. This comprehensive disease information is contained in the immunosequencing data that we generate from each sample, which we believe will be revealed over time by our TCR-Antigen Map. We plan to map, both directly and through machine learning, an estimated 10<sup style="font-size:85%;line-height:120%;vertical-align:top">15</sup> TCRs to thousands of clinically relevant antigens, which we believe will allow us to annotate this immunosequencing data with information about disease states, increasing the value of the data over time. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We leverage our database to fuel our pipeline of immune medicine products. With over 58 billion immune receptors, our platform enables us to work with retrospective samples which serve as training sets to which our Microsoft collaborators apply machine learning and computational statistics to improve the accuracy of certain of our clinical products and services. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Products and Services </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current portfolio includes commercial products and services in life sciences research and clinical diagnostics, and we are developing products and services in both clinical diagnostics and drug discovery. Our commercial research product, immunoSEQ, primarily serves as our underlying research and development engine to develop and validate our clinical pipeline. Our first commercial diagnostic product, clonoSEQ, is our FDA-cleared test to monitor MRD in patients with select blood cancers. In the fourth quarter of 2020, we initiated the launch of our second commercial diagnostic product, T-Detect COVID, for the confirmation of past COVID-19 infection. Our commercial research and clinical products leverage the sequencing and mapping capabilities of our immune medicine platform and the revenue generated by these products largely contributes to sequencing revenues. Our pipeline of clinical diagnostics for the early and accurate detection of many diseases will be commercialized under the expanding T-Detect product line and will continue to grow our sequencing revenues over time. Our drug discovery efforts to date are focused on identifying therapeutic-grade TCRs (TruTCR) and antibody-secreting BCRs (TruAB) to enable our partners to engineer, manufacture and commercialize therapeutic candidates. With Genentech, we are advancing our pipeline of both shared and private TCR-mediated cellular therapies for cancer patients. We also extended our platform to identify highly potent neutralizing antibodies against SARS-CoV-2 and this differentiated approach can be leveraged across other disease states. Our drug discovery pipeline leverages the sequencing, mapping, pairing and characterization components of our platform and generates most of our development revenue. We plan to continue to invest in our platform to develop additional clinical applications, which we prioritize based on rigorous data requirements for clinically actionability, unmet medical need and commercial viability. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Life Sciences Research </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">immunoSEQ for Research Use Only </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immunoSEQ technology, which we offer to customers as a service and a kit, is the core of our immune medicine platform. immunoSEQ utilizes multiplex, bias-controlled PCR to accurately and quantitatively sequence millions of immune receptors at high-throughput directly from DNA. We believe immunoSEQ is positioned to become the global standard for immunosequencing due to the quality and reliability of our data and the analytics and data visualization tools that are easily accessible to customers in the immunoSEQ Analyzer, whether sequenced as a service or a kit. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, immunoSEQ has been used for research purposes by over 2,400 academic researchers and 175 biopharmaceutical companies and incorporated into over 650 clinical trials to answer translational research questions relating to the adaptive immune system, monitor response to therapies and discover new prognostic and diagnostic signals. These research questions are answered by using the data generated by immunoSEQ and uploaded to the immunoSEQ Analyzer to study different properties and dynamics of all of the sequences in an immune repertoire, such as frequency or abundance, and by tracking specific sequences over time in clinical trials. Graphical representations of the Analyzer output are shown in the figure below: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000009.jpg" title="" alt="" style="width:720px;height:160px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">immunoSEQ provides a growing revenue stream. However, we also use immunoSEQ as the foundational technology for our clinical diagnostic and therapeutic products. To fuel innovation, we also provide immunoSEQ to select research and development collaborators who gain access to immunoSEQ and significant computational and analytical support, co-share and co-publish the data with us, and contribute to the validation of potential clinical diagnostic discoveries. For example, we work closely with our collaborators to conduct translational research to explore the use of immunosequencing to predict responders to novel immunotherapies such as checkpoint inhibitors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immunoSEQ Analyzer is housed on a secure cloud-based database and is the visualization gateway to our clinical immunomics database that currently has billions of TCR and BCR sequences which are often annotated and accompanied by samples with associated metadata. We offer computational services to assist our customers in realizing the power of their data and to compare their data to other publicly available datasets in our clinical immunomics database. We contribute some of our own research and development sequences into the publicly available datasets and customers are offered the option to make their data public using one of our tools on our immunoSEQ Analyzer, called immuneACCESS, through which researchers can expedite and streamline the peer-review process by sharing their data with reviewers prior to manuscript submission. The ongoing analysis of immune receptor data from an expanding database tagged with clinical metadata, when possible, has led to over </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">550</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">peer-reviewed publications referencing immunoSEQ and potential clinical signals to explore. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recently launched an improved version of immunoSEQ to our research customers. We incorporated chemistry improvements into a new RUO kit, which was completed in the fourth quarter of 2019 and launched in 2020. We expect this service and kit offering to become the technology upon which we clinically validate the early detection diagnostics we are developing using our TCR-Antigen Map. The kit improvements will further enhance the quantitation of the data and allow for any sample type to be used, including stored cancer tumor tissue sections, which is more readily available globally amongst researchers in the field of cancer immunotherapy. The RUO kit has been selected by 35 academic core labs and user groups in the United States and we continue to expand these collaborations. Additionally, we announced distribution agreements with two CROs, Q2 Solutions and Labcorp, and we are in discussions with several others. By enabling academic core labs and CROs as centers of excellence with our gold standard immunoSEQ RUO kit, we expect to set the foundation for long term growth going forward.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">immunoSEQ T-MAP </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we identified some key opportunities to expand our research product offering to include mapping data generating by our platform. Sequences mapped to clinically relevant antigens has many benefits beyond just repertoire sequencing dynamics and we plan to offer immunoSEQ T-MAP across many disease states in the future. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We launched our first immunoSEQ T-MAP product extension in August 2020 for COVID-19 vaccine developers and researchers to accurately and reproducibly measure the T-cell immune response to vaccines and track the persistence of that response over time. Our immunoSEQ T-MAP product offers significant advantages over other technologies to detect and monitor T cells at scale using a small amount of blood without the need for live cells that require special sample handling.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have sequenced a subset of patient samples (pre- and post-vaccination) from clinical trials sponsored by several top-tier vaccine developers, including AZ, University of Oxford, Bill and Melinda Gates Foundation and several prestigious academic labs who are studying the impact of COVID-19 vaccines on patients receiving other immune-mediated therapies. Using our immunoSEQ T-MAP COVID product, we can identify and track expanded T cells induced by a vaccine, which can be distinguished from a natural infection, in order to monitor vaccine efficacy. In vaccinated subjects who test positive for the virus utilizing the two-step multiplex PCR amplification process, immunoSEQ T-MAP COVID can specifically track vaccine-induced T cells and correlate response with improved patient outcomes. In addition, we are also in late-stage discussions with several companies developing next-generation vaccines.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2020, we entered into our first multi-year immunoSEQ T-MAP cancer collaboration with AZ to generate data from antigen-specific T-cell immune responses across AZ&#8217;s oncology drug portfolio. T-MAP data may inform early disease intervention to help improve patient outcomes, with the potential for additional opportunities to develop companion diagnostics or novel therapeutics with AZ. The partnership also allows for data sharing between us and AZ that benefits our independent efforts. We expect this will help expedite our ability to map the large antigenic space in cancer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Diagnostics </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We aim to be a global leader in immune-driven diagnostics for early detection, prognosis and monitoring of disease. To achieve this long-term goal, we are focused on leveraging the sequencing and mapping functions of our immune medicine platform to develop diagnostic tests that meet regulatory standards, are widely reimbursed and are accessible to patients all around the world. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Monitoring MRD with clonoSEQ </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our first diagnostic product, clonoSEQ, is an FDA-authorized NGS test for the detection and monitoring of MRD in bone marrow or blood samples in patients with select lymphoid malignancies in which the malignant cell is derived from a T cell or a B cell. MRD refers to the presence and number of these malignant T&#160;or B cells that may remain in a patient&#8217;s body during and following treatment. Because our technology quantifies the frequency of every T&#160;cell or B&#160;cell in a sample, we can monitor MRD accurately at a sensitivity of 1 out of 1,000,000 cells, given sufficient sample input. By taking a baseline measurement prior to starting therapy and then tracking the number of cells at several time points following therapy initiation, hematologists can improve their ability to assess treatment response, predict long-term patient outcomes, monitor disease burden over time and detect potential relapse. clonoSEQ is FDA-authorized for patients with MM and ALL from bone marrow samples and for patients with CLL from bone marrow and blood samples. clonoSEQ is also currently available as an LDT for use across lymphoid malignancies and sample types, including those which have not been authorized by the FDA.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NCCN Guidelines recommend using a validated test to measure MRD to define the burden of disease and assess response to therapy in MM and ALL after each treatment stage. NGS MRD testing has been added to these guidelines and we plan to seek expansion of the recommendations to include additional time points in each disease state and to incorporate clonoSEQ specific data. To that end, in 2020, NCCN published favorable updates to their myeloma guidelines and pediatric ALL guidelines to include more specifics related to how and when to measure MRD, the importance of using a sensitive and validated test, and a reference to the necessity of collecting a baseline sample at diagnosis.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MRD monitoring is becoming increasingly important in the hematologic oncology field because highly effective new therapies are extending survival. This has created a need for more sensitive tools to monitor the disease status of patients over longer periods of time and has introduced the potential for MRD to be included as a surrogate or primary endpoint in registrational clinical trials. We believe we are uniquely positioned to benefit from these industry dynamics with both our clinical and biopharmaceutical customers. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the clinic, clonoSEQ testing has been ordered by clinicians at centers all around the country, including all 30 NCCN centers, for over 15,000 unique patients. We believe increased adoption of clonoSEQ will now be possible due to the extensive coverage policies granted in 2019 and 2020 by Medicare to assess MRD at multiple time points throughout therapy in MM, ALL and CLL, and several national private payors and large regional payors, together representing over 225&#160;million total covered lives in ALL and MM and over 110 million covered lives in CLL. We are in active discussions with other large private national and regional payors. To further develop the mounting real world evidence demonstrating the actionability of MRD monitoring, we launched a clinical registry in 2020. This prospective, multicenter, observational study will include approximately 500 adult patients with lymphoid malignancies in the United States.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among biopharmaceutical companies, we believe clonoSEQ will remain the preferred commercial test for MRD monitoring in their registrational trials. To that end, clonoSEQ is now being used by more than 40 biopharmaceutical companies in over 190 clinical trials. To continue demonstrating clinical utility across disease settings and lines of therapy, clonoSEQ is also being used in 79 ongoing prospective investigator-led clinical trials, and our MRD data have been included in over 92 peer-reviewed publications. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe clonoSEQ has broad applicability across all lymphoid malignancies. Specifically, we recently submitted a 510(k) premarket notification for ALL from blood samples in February 2021 and are actively validating the test for patients with non-Hodgkin&#8217;s lymphoma (&#8220;NHL&#8221;) disease types. Importantly, we have also implemented collaborations with Labcorp and Phlebotek to ease access to blood sample collection for patients. We believe these solutions may facilitate more frequent monitoring and benefit patients longer term as they enable a convenient and safe alternative to inpatient visits.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to deepen our commercial investments to expand clinical adoption of clonoSEQ and have increased the size of our specialized sales and customer support organization and supporting infrastructure. We have also added a new team of demand generation representatives who are hematology specialists and are working closely with our key account managers in accounts that are onboarded.&#160;We are also building another team focused on Integrated Delivery Networks.&#160;Outside of the United States, we have successfully transferred the technology to seven labs across France, Germany, Italy, UK, Spain, Australia and Japan which provide local testing options, primarily in support of collaborative group and investigator-sponsored studies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The Technology </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clonoSEQ is our FDA-authorized, NGS MRD technology that is designed to sequence all rearranged receptor sequences in a tumor in parallel to ensure accurate, sensitive and robust MRD monitoring. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the steps for FDA-authorized usage is as follows: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">gDNA is extracted from bone marrow. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Extracted DNA quality is assessed, and rearranged immune receptors are amplified using a multiplex PCR. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Reaction-specific index barcode sequences for sample identification are added to the amplified receptor sequences by PCR. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">Sequencing libraries are prepared from barcoded amplified DNA which are then sequenced by synthesis using NGS. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Raw sequence data are uploaded from the sequencing instrument to our analysis pipeline. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Sequence data is analyzed in a multi-step process, where a sample&#8217;s sequence data is first identified using the sample index sequences and the data is then processed using a proprietary algorithm with in-line controls to remove amplification bias. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Following completion of these data processing steps, a report is issued. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Adaptive Assist: Patient support program </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Assist is our patient support program to facilitate access to clonoSEQ testing services for patients who could benefit from the clinical insights provided by NGS MRD testing. Patients can call to discuss their individual circumstances with one of our dedicated patient support representatives in order to better understand their coverage prior to clonoSEQ testing and to navigate the insurance process, including appeals for denied claims. We also offer financial assistance for qualified uninsured and under-insured patients who cannot afford their patient financial responsibility for clonoSEQ. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Validation in FDA Filing for MM, ALL and CLL </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clonoSEQ test has been shown to help better predict patient outcomes and add insight to the evaluation of disease response to therapy because we have clinically validated clonoSEQ&#8217;s ability to detect MRD at a sensitivity greater than the current clinical standard for all lymphoid malignancies. clonoSEQ has demonstrated sensitivity of 1 out of 1,000,000 cells (10<sup style="font-size:85%;line-height:120%;vertical-align:top">-6</sup>), given sufficient sample input, which is a deeper resolution than the current accepted standard of 1 out of 100,000 cells (10<sup style="font-size:85%;line-height:120%;vertical-align:top">-5</sup>), 1 out of 10,000 cells (10<sup style="font-size:85%;line-height:120%;vertical-align:top">-4</sup>) or 1 out of 10,000 cells (10<sup style="font-size:85%;line-height:120%;vertical-align:top">-4</sup>) for MM,ALL and CLL, respectively. Based on these results, as further illustrated below, we believe clinical standards for MRD sensitivity may be increased to 10<sup style="font-size:85%;line-height:120%;vertical-align:top">-6</sup> to better predict patient outcomes. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical validation in MM was demonstrated in two studies. The first study, a 720 patient, randomized phase III trial conducted at the Dana Farber Cancer Institute (DFCI 10-106), evaluated the ability to predict progression-free survival (&#8220;PFS&#8221;) and disease-free survival in patients who achieved complete response (&#8220;CR&#8221;) and the ability to predict PFS in all evaluable patients. This study demonstrates that MRD negativity for patients in CR significantly predicts PFS. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The second study, a 706 patient, randomized phase III trial sponsored by Janssen Biotech, Inc. (&#8220;ALCYONE&#8221;), evaluated Darzalex in patients with newly diagnosed MM who were transplant ineligible and served as the basis of the approval of Darzalex in combination with Bortezomib, Melphalan and Prednisone (&#8220;VMP&#8221;) in this patient population. This study provides evidence that our clonoSEQ diagnostic test is predictive of PFS, regardless of treatment received. Patients who were MRD negative at less than or equal to 10<sup style="font-size:85%;line-height:120%;vertical-align:top">-5</sup> had longer PFS and the group with persistent MRD negativity had the longest PFS overall. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patients who were MRD negative by the clonoSEQ Assay had longer PFS </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">compared to MRD positive patients regardless of treatment. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000010.jpg" title="" alt="" style="width:546px;height:329px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical validation in ALL was demonstrated in two Children&#8217;s Oncology Group studies, AALL0232 (high risk) and AALL0331 (standard risk) by evaluating the ability of clonoSEQ to predict event-free survival (&#8220;EFS&#8221;) at a primary cutoff of 10<sup style="font-size:85%;line-height:120%;vertical-align:top">-4</sup> and across a continuous MRD measure. Results demonstrate that patients with the lowest levels of MRD have better outcomes than patients with higher disease burden regardless of risk stratification. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patients with lower levels of MRD (less than 1/100,000 cells), using the increased </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">sensitivity of clonoSEQ, have a higher probability of EFS. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000011.jpg" title="" alt="" style="width:378px;height:332px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical validation in CLL was demonstrated in two studies. The first, a 337 patient randomized phase III registrational study in previously untreated CLL patients sponsored by Roche (CLL14), evaluated the ability of clonoSEQ to predict PFS at a primary cutoff of 10<sup style="font-size:85%;line-height:120%;vertical-align:top">-5 </sup>and across continuous<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>MRD measures from blood. The study demonstrates that MRD negative patients had significantly better PFS, independent of treatment regimen.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The second was a prospective, phase 2 clinical trial in previously untreated CLL patients in which MRD was assessed from both blood and bone marrow. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MRD negativity at multiple cutoffs (10</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">-4</sup></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 10</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">-5</sup></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and 10</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">-6</sup></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) was significantly associated with better PFS. MRD was also prognostic of PFS when disease burden was assessed as a continuous measure (no MRD threshold).</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> This study demonstrates that MRD is predictive of better PFS and can be assessed from either bone marrow or blood.</span></p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CLL Patients with lower levels of MRD in blood have a higher probability of EFS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000012.jpg" title="" alt="" style="width:382px;height:318px;" /></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Strategy to Achieve Market Leadership</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We aim to drive adoption and achieve market leadership for MRD monitoring with clonoSEQ for all lymphoid malignancies. To do so, we are executing upon the following strategic initiatives: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Expand reimbursement with public and private payors.</span><span style="color:#000000;"> We are working with new payors to develop appropriate coverage policies, generate healthcare economic information and provide robust billing and patient access infrastructure. As of December 31, 2020, we secured Medicare and private payor coverage for clonoSEQ for over 225&#160;million covered lives for MM and ALL and over 110 million covered lives for CLL. We continue to seek broader coverage in line with our planned FDA label expansions and we continue to invest in health economic research and real-world evidence generation to demonstrate the actionability of MRD monitoring. We launched a watch registry in 2020 as a prospective, multicenter, observational study of approximately 500 adult patients with lymphoid malignancies in the United States to support these efforts.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Entrench clonoSEQ in biopharmaceutical clinical trials.</span><span style="color:#000000;"> As the industry pursues the inclusion of MRD as a potential surrogate or primary endpoint in clinical trials for lymphoid malignancies, having a standardized and highly accurate and sensitive method for MRD testing to guide clinical decisions in late-stage trials, including registrational trials, is valuable. Our goal is to position clonoSEQ for use by our biopharmaceutical collaborators as the MRD test of choice for these clinical trials. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Validate clonoSEQ in additional indications for use.</span><span style="color:#000000;"> With the end goal of clonoSEQ becoming a universal MRD test for all lymphoid malignancies, we have developed a robust lifecycle development plan to generate sufficient clinical evidence to support the extension of the FDA label across lymphoid malignancies. We are already cleared in ALL and MM from bone marrow and CLL from bone marrow and blood. At the same time, we are increasing marketing support for clonoSEQ usage as a CLIA-validated lab-developed testing service, where samples for any lymphoid cancer indication and a range of sample types (including blood) are acceptable, and payer coverage is already in place for blood-based testing in ALL and myeloma. Going forward, we will continue to evaluate the optimal commercial path (FDA or CLIA) for each additional indication.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Validate clonoSEQ in blood to offer a minimally invasive alternative.</span><span style="color:#000000;"> Testing with blood is less invasive for patients and less expensive as compared to MRD testing from bone marrow samples, and it may only be possible because of the deep sensitivity of our clonoSEQ diagnostic test. Therefore, blood-based MRD testing may enable more frequent monitoring of patients over longer periods of time. We have already received FDA clearance for clonoSEQ from blood samples for patients with CLL, we recently submitted for FDA clearance for ALL from blood samples, and we will continue to expand testing with blood to other indications over time.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Invest in commercial initiatives to increase awareness and usage.</span><span style="color:#000000;"> We are expanding our sales organization to target key customer segments, including academic centers, integrated health networks and community clinicians, in a tiered manner based on patient volume. In 2019 and 2020, we focused on Tier 1 and Tier 2 accounts, which we estimate to be the sites of care for approximately two-thirds of the patients that comprise the potential market. With increasing adoption and our recent CLL label expansion, we are beginning to drive uptake in Tier 3 community accounts. We will continue to increase the size of our specialized sales organization and supporting infrastructure, including building out our teams focused on community oncology centers and integrated delivery networks.&#160;We also launched a variety of patient educational initiatives and peer to peer programming to spread awareness about the impact of MRD status to inform clinical decision-making.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Evaluate a decentralized testing solution.</span><span style="color:#000000;"> We continue to explore options to service the MRD opportunity in institutions and markets where local testing is needed or required. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Expand internationally.</span><span style="color:#000000;"> We have expanded our technology transfer program to select centers to conduct investigational studies that further demonstrate the value of clonoSEQ and are essential for reimbursement submissions. We have already completed successful technology transfers in France, Germany, Italy, UK, Spain, Australia and Japan. In 2019, we obtained a Conformit&#233; Europ&#233;ene (&#8220;CE&#8221;) mark for our clonoSEQ reagents, which is intended to support our reimbursement efforts in Europe. We expect these market development activities to enhance our commercialization efforts and accelerate international market acceptance over the next three to five years. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Early or Accurate Detection with T-Detect </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By learning to read the antigen specificity of a patient&#8217;s immune system, we are developing the T-Detect test for early or accurate detection across a broad range of diseases, including infectious diseases, autoimmune disorders, and certain prevalent cancer types. We believe the adaptive immune system presents an ideal model for diagnostic tools for early or accurate detection of disease. In many cases, treatment is typically most effective early in the course of a disease, when there is a minimal amount of disease-specific antigen present. TCRs recognize this very small amount of antigen before it is detectable by conventional methods and then they expand exponentially. Given this large response in proportion to the amount of antigen present, we believe we will be able to see this signal of disease much sooner than is possible with other methods of early disease detection. Additionally, in some disease states, knowledge of prior infection from certain pathogens, e.g., COVID-19 and Lyme, may inform the basis of clinical decision-making or ongoing patient care. Finally, the ability to rapidly and accurately identify the cause of non-descript symptoms may increase efficiency and compress the timeline between symptom and diagnosis, thus reducing the diagnostic odyssey that patients often endure in the current diagnostic paradigm.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are leveraging our existing immunoSEQ technology to develop T-Detect for the early or accurate detection of many diseases simultaneously. This is possible because our platform works with retrospective sample sets and uses machine learning and computational statistics to continuously improve accuracy without requiring large cohorts of prospective patients. We began by developing T-Detect for the early detection of specific disease states that meet the following criteria: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinically relevant antigens are known and understood. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">High unmet medical need for diagnosis. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Potential to improve patient outcomes with early intervention. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Availability of sample sets with patient outcomes. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using these data, we aim to simulate the natural diagnostic capability of the immune system into the clinic where we will use the map for the early or accurate detection of many diseases.&#160;The potential economic model for T-Detect of becoming "one test with many results" is very compelling. When multiple tests are ordered at the same time, the marginal cost for each additional test result is negligible.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through iterative data generation efforts, we continue to improve the accuracy of the TCR signatures of each disease by running blood samples from healthy donors, collaborating on retrospective studies with control groups in select disease states, and leveraging our database for additional sequences to include in the TCR signatures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We see the evolution of T-Detect in three phases over time:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase I: Launch T-Detect disease by disease with a more accurate test versus current standard of care.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase II: Introduce T-Detect panel(s) for the differentiated diagnosis of disease when the symptoms are shared among several diseases. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase III: Enable T-Detect for population immunomics, where anything we map, we will be able to diagnose from a single blood sample.&#160;</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Proof of Concept </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For proof of concept of the ability of our technology to detect infectious disease exposure in patients, our researchers profiled the T&#160;cell repertoire of more than 660 subjects with known cytomegalovirus (&#8220;CMV&#8221;) status and identified a set of TCRs across that population that are specific for CMV. This set of CMV-specific TCRs was then tested as a method for CMV diagnosis in a new cohort of 120 people. Using this TCR set, we were able to confirm CMV infection in up to 93% of blood samples evaluated. These data represent a significant step forward for the potential use of TCR sequences to detect exposure to pathogens or other diseases with distinct T&#160;cell profiles. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By combining the power of our clinical immunomics database with a machine learning technique known as pseudo-labeling, we are rapidly scaling the identification and validation of antigen-specific TCRs for diagnostic applications. For example, we have already iteratively scaled the identification of additional CMV-specific TCRs to improve the diagnostic accuracy in our proof of concept study to 98% with a minimal false positive rate. We believe this approach has the potential to significantly reduce the time and number of individuals, and ultimately the cost, required to accurately validate our clinical diagnostics across different diseases. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">First Commercial Indication: T-Detect COVID </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, we and Microsoft committed to decode the population-wide T cell immune response to COVID-19. We believe that quantifying virus-specific T cells may provide important diagnostic advantages because T cells appear earlier than antibodies and persist longer. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Timing and Persistence of T-cell Response<sup style="font-size:85%;line-height:120%;vertical-align:top">1,2,3,4,5,6,7</sup></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000013.jpg" title="" alt="" style="width:720px;height:306px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. Gallais et al., Peng et al., Snyder et al., Subbarao et al., Channappanavar et al., and Zuo et al.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Zuo J, Dowell A, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection. bioRxiv. 2020 Nov 2&#59;2020.11.01.362319.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Gallais F, Velay A, Wendling M-J, Nazon C, Partisani M, Sibilia J, et al. Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion. medRxiv. 2020 Jun 22&#59;2020.06.21.20132449.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020&#59;21(11):1336&#8211;45.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. Snyder TM, Gittelman RM, Klinger M, May DH, Osborne EJ, Taniguchi R, et al. Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels. MedRxiv. 2020 Aug 4. 2020.07.31.20165647.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6. Subbarao K, Mahanty S. Respiratory virus infections: Understanding COVID-19. Immunity. 2020&#59;52(6):905&#8211;9.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014&#59;59(1&#8211;3):118&#8211;28.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Together, we implemented the immuneCODE Program to quantitatively assess the T-cell immune response to the virus in over </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,000 individuals </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">around the world and we have made this data publicly available. To date, we have mapped hundreds of thousands of TCRs to all of the immunogenic parts of the SARS-CoV-2 virus, inclusive of but not limited to the spike protein. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T-Detect COVID confirms past SARS-CoV-2 infection, which represents a stepping-stone to the long-term vision of T-Detect where a blood sample can provide information about what diseases a person&#8217;s immune system has seen or is currently fighting. In two real-world studies with convalescent patients, including our own IRB-sponsored study called ImmuneRACE, our T-cell based test demonstrated higher sensitivity than multiple antibody serology tests to confirm past infection. Additionally, data demonstrates that the T-cell response is more persistent than the antibody response to the virus, persisting to at least five months following initial infection, and performance of T-Detect COVID is equivalent to or better than antibody testing at all timepoints evaluated. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T-Detect COVID was launched in December 2020, primarily targeting groups and individuals for whom knowledge of past COVID-19 infection or exposure is valuable, including self-pay consumers, employers and concierge medicine physician groups. Our market research shows that there are many people who were unable to access testing in spring of 2020 or had unexpected results from antibody or PCR testing, and are still curious or skeptical about a previous infection. This is particularly true for individuals who were asymptomatic or had mild symptoms, in whom antibody testing may be less reliable. Additionally, our research indicates high interest among consumers in understanding immunity to COVID-19. Therefore, we are offering the ability to contribute to on-market research to quantitatively assess the duration of immunity as defined by the persistence of SARS-CoV-2 specific T cells.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial and operational infrastructure needed to deliver T-Detect COVID will be critical as we move T-Detect forward in additional indications. These efforts will set the base of our near-term commercial focus in infectious diseases including COVID-19 and Lyme disease and a medium-term expansion into autoimmune disorders.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Validation in FDA EUA filing for Detection of Recent or Past SARS-CoV-2 Infection</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our T-Detect COVID test is a novel T-cell based assay that has demonstrated high percent positive and percent negative agreement (PPA and NPA) to identify or exclude prior SARS-CoV-2 infection in PCR-confirmed SARS-CoV-2 cases and lack of cross-reactivity to several viral and/or respiratory pathogens.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PPA was demonstrated in two studies 1) a primary PPA study evaluating residual blood samples (N&#61;205) from subjects diagnosed with SARS-CoV-2 infection based on the EUA Abbott RealTime SARS-CoV-2 RT-PCR test from a single US reference lab (Discovery Life Sciences, New York)&#59; and 2) a secondary PPA study using both retrospectively and prospectively collected samples from multiple cohorts (N&#61;77&#59; ImmuneRACE and ImmuneSense&#8482; COVID-19) and identified as positive based on a variety of EUA testing methods performed by a number of different labs. T-Detect COVID demonstrated high PPA particularly in the timeframe of &#8805;15 days since diagnosis (97.1%) as well as &#8805;15 days since symptom onset (94.5%) (Table 1).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table 1. Positive Percent Agreement (PPA) of T-Detect COVID Assay with SARS-CoV-2 RT-PCR according to days since symptom onset or days since diagnosis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:487.5pt;;">
<tr>
<td style="width:114pt;"></td>
<td style="width:67.9pt;"></td>
<td style="width:148.5pt;"></td>
<td style="width:157.1pt;"></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Days&#160;Since&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Diagnosis<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RT-PCR+ Samples (N)</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">T-Detect Positive (N)</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">T-Detect PPA&#160;(95% CI)</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0-7 days&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.4 (53.7 - 85.4)</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-14 days&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.9&#160;(92.7 - 99.3)&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8805;15 days&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97.1&#160;(92.7 - 99.2)</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All&#160;(range 0-91 days)</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A&#160;</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Days&#160;Since&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symptom&#160;Onset<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0-7 days&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53.8&#160;(25.1 - 80.8)</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-14 days&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.8 (40.0 - 97.2)</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8805;15 days&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94.5&#160;(84.9&#160;-&#160;98.9)</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All&#160;(range 0-106 days)</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NPA was demonstrated in two studies: 1) a primary NPA including 124 retrospective frozen clinical remnant blood samples collected prior to December 2019 and thus presumed negative for SARS-CoV-2 infection&#59; and 2) a secondary NPA study using blood samples from subjects enrolled prospectively (ImmuneSense COVID-19) from Oct-Nov 2020 who presented with SARS-CoV-2 symptoms but tested negative for SARS-CoV-2 using RT-PCR EUA, BioFire RP V2.1, and EUA antibody tests. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T-Detect COVID demonstrated NPA of approximately 100% in individuals who had compatible symptoms of infection but were either presumed or confirmed negative for SARS-CoV-2 by PCR and antibody testing (Table 2).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table 2. Negative Percent Agreement (NPA) of T-Detect COVID Assay with pre-pandemic samples sourced retrospectively (DLS) and prospectively enrolled subjects (ImmuneSense COVID-19) negative for SARS-CoV-2 by EUA RT-PCR and antibody testing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:91.41%;">
<tr>
<td style="width:24.37%;"></td>
<td style="width:17.02%;"></td>
<td style="width:25.19%;"></td>
<td style="width:24.63%;"></td>
<td style="width:0.19%;"></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cohort&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Samples&#160;(N)</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">T-Detect Negative Results&#160;(N)</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NPA&#160;(95% CI)&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DLS&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100 (95.8&#160;&#8211;&#160;100)&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmuneSense&#160;COVID-19&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.7 (93.1&#160;&#8211; 99.97)&#160;</p></td>
<td valign="middle" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Second Indication in Late-Stage Development: T-Detect Lyme</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2019, we established proof of concept in acute Lyme disease from two independent, retrospective cohorts of over 200 patients. In both of these studies, we compared to standard of care, two-tiered serology testing. Results demonstrate a doubling of sensitivity of our test compared to standard two-tiered serology in acute patients. We have also seen that our test can confirm an ongoing infection in patients who were treated with standard 2-3 weeks of doxycylcine but still have lingering symptoms. The signal in Lyme further demonstrates that machine learning can be leveraged to develop diagnostic signals, even without the large cohorts of prospective patient data often required for diagnostics development. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For T-Detect Lyme, we launched the ImmuneSENSE Lyme study with the goal to enroll 990 participants. Even though Lyme visits and diagnoses were down in 2020 due to COVID-19, by the end of 2020, we enrolled 91% of the subjects needed for the interim analysis. We intend to continue full enrollment of the 990 subject study, of which approximately 420 will have either a clinical diagnosis or clinical suspicion based on a physician's assessment of Lyme disease. The remaining subjects will include negative controls from both endemic and non-endemic regions and potential cross-reactive diseases. We expect to launch as a CLIA-service offering at the end of 2021, leveraging the infrastructure built for T-Detect COVID.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">T-Detect Pipeline</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To achieve our goal of developing a diagnostic test for early detection across a broad range of diseases, we are pursuing the following strategic plan: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Apply machine learning to high-throughput mapping to generate the TCR-Antigen Map. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Demonstrate clinical signals for early detection using mapped TCRs in select indications. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Launch one TCR sequencing technology, T-Detect, for initial indications. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Broaden utility to a wide range of diseases without requiring large prospective trials.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the past year, we have optimized our five-stage research and development funnel and expanded our lab capacity to expedite our ability to move many diseases through the funnel in parallel. We start by prioritizing diseases that meet key market attractiveness criteria such as high unmet medical need, understanding of the antigenic space, and our access to samples with metadata. Once an early signal is identified, we refine our modeling with additional case control studies and by leveraging our clinical immunomics dataset. Once we confirm a signal, we proceed with a full commercial validation and generation of a locked-down algorithm to take into clinical validation and regulatory submission. We have about four to five diseases under study in each of the earlier stages of the research and development funnel and continue to invest heavily in the speed and robustness of this funnel with people and data analytic capabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:3.33%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">T-Detect R</span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">esearch and </span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">D</span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">evelopment</span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> Funnel</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000014.jpg" title="" alt="" style="width:668px;height:311px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, we announced the confirmation of our third clinical signal in Crohn&#8217;s disease. Crohn&#8217;s is a gastrointestinal disorder that is often confused with other conditions with similar symptom presentation and there is a significant unmet need for a highly specific and sensitive non-invasive test. Data will be shared in a scientific forum next year. Other indications such as celiac, ovarian cancer and other autoimmune disorders continue under development within our research and development funnel and we will update you on future progress as they advance.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are many economic advantages of T-Detect both in the research and development stage and as a commercial product. For the research and development pipeline, we use the same capex and workflow for signal generation across all diseases allowing us to study multiple disease in parallel. Once commercialized, again, we use the same blood sample and the same underlying chemistry for all diseases with a small incremental investment in software for each individual disease, enabling a long-term high margin profile. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Drug Discovery </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our aim is to develop immune-mediated therapies in oncology and other disease areas by using the full functionality of our immune medicine platform, including TruTCR and TruAB for TCR and antibody characterization, respectively. We are currently working to leverage our immune receptor discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our own end-to-end capabilities for the further development of our own portfolio of therapeutic candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000015.jpg" title="" alt="" style="width:664px;height:343px;" /><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">TCR Discovery for Cellular Therapy using TruTCR </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed a high-throughput TCR screening process that allows for the discovery of antigen-specific TCRs that occur in low frequencies in healthy individuals. We believe this provides a set of naturally-occurring TCRs with a more favorable safety profile in comparison to engineered TCRs. We then further characterize these naturally-occurring TCRs for binding avidity and cytotoxic potency. To date, we have identified and characterized to different stages more than 4,000 unique antigen-specific, paired TCRs against 600 different clinically relevant targets, constituting our pipeline of possible clinical candidates. We complete a data package for each characterized TCR that we believe meets the thresholds for therapeutic evaluation. These thresholds are divided into a series of seven key steps covering antigen specificity, functional avidity, cytolysis and safety assessment. A package is considered complete when the TCR meets the rigorous criteria for all seven steps and the data are compiled to support an IND package. As a proof of concept, we compared our fully characterized TCR against WT-1, a TAA often overexpressed in various cancers, to a benchmark WT-1 TCR. A gold standard for testing TCR efficacy is killing of cells that naturally express the target antigen at low levels. Using a cancer cell line that is known to express low levels of WT-1, our candidate WT-1 TCR was over four times more effective at killing cancer cells than the benchmark TCR. The complete data package for our lead WT-1 TCR candidate demonstrates improved avidity, cytolysis and a promising safety profile. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our high-throughput screening technologies enable us to discover TCRs against any type of antigen which opens up the potential to develop novel TCR-mediated cellular therapies for any type of cancer. As compared to cellular therapies that target T&#160;cell surface antigens that are not specific to cancer, we believe our approach to TCR cellular therapies may mitigate the risk of off-target side effects. Therefore, we believe our approach may be applicable to the vast majority of solid tumors, even those where the tissue of origin is vital to survival such as lung or renal. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, Genentech selected our platform to develop, manufacture and commercialize novel neoantigen directed T&#160;cell therapies for the treatment of a broad range of cancers. Our ultimate goal is to harness the vast majority of therapeutically relevant, patient-specific TCRs against neoantigens and advance the next generation of cellular therapies in oncology. We believe our TCR discovery capabilities may also facilitate the development of cellular therapies in disease areas beyond cancer, which we can commercialize outside of the Genentech collaboration. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to cellular therapy applications, we believe our TCR screening capabilities can guide the design and development of next generation vaccines by characterizing the immunogenicity of hundreds of antigens at a time. Our platform can also be used to then monitor early signs of antigen-specific immune response in patients treated with novel vaccines. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Strategic Collaboration with Genentech </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through our worldwide collaboration and license agreement with Genentech, we plan to develop, manufacture and commercialize novel neoantigen directed T&#160;cell therapies for the treatment of a broad range of cancers to advance the next generation of cellular therapies in oncology. We are pursuing two product development pathways for novel T&#160;cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Shared Products.</span><span style="color:#000000;"> The Shared Products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among patients. Genentech is planning its first IND submission for the first shared product targeting a selected shared cancer antigen in the first half of 2021. We continue to screen and characterize TCRs against clinically relevant targets in solid tumors and we are in late-stage characterization of several promising TCRs that could be considered by Genentech for the development of a second Shared Product.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Personalized Product.</span><span style="color:#000000;"> The Personalized Product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient. In the second half of 2020, we started screening blood from cancer patients to identify TCRs specific to a patient&#8217;s tumor mutations and our goal is to generate proof of concept data in early 2021. To support our near-term and long-term objectives for our private product, we plan to open our dedicated prototype lab in South San Francisco in 2021, which will have capacity to perform first-in-human clinical trials. We believe this investment positions us to potentially pursue additional opportunities outside of this collaboration, including cellular therapy in other disease states and cancer vaccines.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000016.jpg" title="" alt="" style="width:720px;height:294px;" /></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, we received a $300.0&#160;million initial upfront payment in February 2019, and we may be eligible to receive approximately $1.8&#160;billion in aggregate milestone payments upon achievement of specified development, regulatory and commercial milestones. Additionally, we may receive royalties on sales of products commercialized under that agreement. Genentech will be responsible for clinical, regulatory and commercialization efforts. We will be responsible for the screening and identification of TCRs that can most effectively recognize and directly target specific cancer antigens, including neoantigens. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In parallel, we plan to evaluate an investment in additional facilities that would allow us to scale our end-to-end screening of patient-specific TCRs for potential future late-stage clinical trials and commercialization of the Personalized Product. We believe this investment would position us to potentially pursue additional opportunities outside of this collaboration, including developing and commercializing vaccines and cellular therapies in other disease states. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Developing neutralizing antibodies using TruAB</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our TruAB process, similar to our TruTCR process, leverages our high-throughput capabilities to screen millions of BCRs to identify unique antibodies from human blood. Our first proof of concept is for patients who are actively fighting or have recently recovered from COVID-19. In just several months, we collected blood from over 300 patients and hundreds of thousands of antibodies, of which we synthesized and characterized over 3,300 antibodies to various parts of the SARS-CoV-2 virus. To date, we identified several candidates that neutralize live virus at very low concentrations, which means that a very small amount of each of these antibodies is able to block the virus from infecting cells. <span style="color:#000000;">Using our TruAB antibody discovery approach, we identified several lead antibody candidates that strongly bind to different parts of the virus. Our growing portfolio of novel antibodies includes candidates that don&#8217;t bind the classic RBD region and instead bind to S1, Trimer or S2.&#160;We believe we are one of the only groups that has identified S2-specific antibodies that neutralize the virus. This could have important advantages in a cocktail strategy that targets different mechanisms of action to inhibit the virus and potentially virus variants.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000017.jpg" title="" alt="" style="width:704px;height:442px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Importantly, our drug discovery approach is differentiated from other groups because of the scale and throughput of our TruAB approach that allows us to identify a much broader set of naturally-occurring, fully human antibody candidates to select the best ones for clinical development. Beyond COVID-19, we are exploring applications of TruAB discovery in other diseases, including autoimmunity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our People and Culture </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our employees, internally referred to as &#8220;Adapters,&#8221; are passionate about immune medicine, empowered by scientific discipline and fueled by our foresight and curiosity about the adaptive immune system.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 622 full-time employees of which 124 hold medical or doctoral degrees. None of our employees are subject to a collective bargaining agreement and we have not experienced any work stoppages. We believe relations with our employees are good.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our talented employees drive our mission and share core values that both stem from and define our culture, which plays an invaluable role in our execution at all levels in our organization. Our core values are used in candidate screening and in employee evaluations to help reinforce their importance in our organization:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Make it happen.</span><span style="color:#000000;"> Individual ownership and accountability keep us moving forward</span><span style="font-style:italic;color:#000000;">.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Innovate fearlessly.</span><span style="color:#000000;"> Push against boundaries and think boldly to achieve world-changing results</span><span style="font-style:italic;color:#000000;">.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Debate openly.</span><span style="color:#000000;"> Value discussions inspired by different points of view</span><span style="font-style:italic;color:#000000;">.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Work together.</span><span style="color:#000000;"> Demonstrate you care about the success of others. The same goes for our partners and customers&#8212;together we can achieve more</span><span style="font-style:italic;color:#000000;">.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Follow True North.</span><span style="color:#000000;"> Show up with integrity and do the right thing</span><span style="font-style:italic;color:#000000;">.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Have fun.</span><span style="color:#000000;"> Fun makes everything better</span><span style="font-style:italic;color:#000000;">.</span><span style="color:#000000;"> </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our employees are highly engaged, and we were recognized consecutively in 2018, 2019 and 2020 by the Puget Sound Business Journal as one of Washington State&#8217;s Best Places to Work. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Diversity and Inclusion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We pride ourselves on inclusive team building, product design and gender diversity at all levels of management. We are committed to creating and maintaining a culture of belonging. In 2020, we expanded and implemented several diversity and inclusion initiatives. We launched multiple employee resource groups, including Women&#64;Adaptive, Adaptive PRIDE, Black Adapter Network and Working Life and Wellness. We developed diversity sourcing programs and implemented hiring manager diversity training. We also established an Equity Advisory Council of senior leaders focused on specific objectives looking at clinical studies, commercial engagement, recruiting, and retention through a diversity and inclusion lens. We integrated hidden bias training into our Leader of People Program. Most recently, we launched a STEM minority mentoring program with a local university.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Compensation and Benefits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to provide compensation and benefits that are competitive to market and create incentives to attract and retain employees. Our compensation package includes market-competitive base pay, performance-based short-term incentives, health care, retirement benefits, paid time off and family leave. In addition, we offer employees the benefit of equity ownership in the Company through stock option and restricted stock unit awards. We also provide access to a variety of health and wellness resources.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Development &#38; Training</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We prioritize employee development and training and have established programs to support a culture of employee development. Specifically, in 2020, we offered multiple learning solutions, including our Leader Orientation Program, our Leader of People Program, and our L-re:combinator Program. Our Leader Orientation Program is an eight-week blended learning program that features self-paced online learning and live virtual training, designed to train new line to mid-level leaders about our culture, HR policies, communication, motivation, and more. Our Leader of People Program is a three-part, 15-week program designed to train leaders on change management, interviewing and hiring the best, having difficult discussions and creating alignment. Our L-re:combinator Program is a peer-to-peer learning group that provides mid-level managers with education, support, and collaboration opportunities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, over 100 Adapters attended leadership development programs and consumed over 2,000 hours of training.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COVID-19 Preparedness</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the emergence of the COVID-19 pandemic, management formed a cross-functional COVID-19 preparedness committee to regularly monitor the progress of the disease, stay apprised of expert external guidance, discuss and implement preparedness plans as needed and provide clear communication to all Adapters. We implemented measures to reduce the risk of exposure of&#160;COVID-19 to the employees who continue to work on site, including the implementation of work-from-home policies for certain employees, as well as the implementation of shifts and zones to physically distance employees who remain on site and extra sanitation measures. For those employees working remotely, we provided additional equipment to support their ergonomic and technology needs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strategic Collaborations and Other Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Genentech Agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2018, we entered into the Genentech Agreement to develop, manufacture and commercialize novel neoantigen directed T&#160;cell therapies for the treatment of a broad range of cancers. Pursuant to the Genentech Agreement, we are responsible for the screening and identification of TCRs that can most effectively recognize and directly target specific neoantigens, while Genentech is responsible for clinical, regulatory and commercialization efforts. During the term of the Genentech Agreement, we have agreed to certain defined exclusivity obligations or restrictions with respect to the development and commercialization of certain cell therapies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we received a $300.0&#160;million upfront payment from Genentech. We also may be eligible to receive approximately $1.8&#160;billion over time, including payments of up to $75.0&#160;million upon the achievement of specified regulatory milestones, up to $300.0&#160;million upon the achievement of specified development milestones, and up to $1.4&#160;billion upon the achievement of specified commercial milestones. Genentech will also pay us tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of the Shared Products and the Personalized Product arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. For the year ended December 31, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019, the Genentech Agreement accounted for approximately</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 53.7</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.3% of our revenue</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Genentech Agreement will continue until the expiration of all royalty payments, but may be terminated by mutual agreement, upon an uncured material breach by either party, upon insolvency of either party, or by Genentech for convenience upon prior written notice. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Microsoft Agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2017, we entered into a strategic collaboration agreement with Microsoft (&#8220;Microsoft Agreement&#8221;) to map TCR sequences to the antigens they bind with the goal of developing diagnostic tests for early detection of many diseases from a single blood test. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Microsoft Agreement, Microsoft applies machine learning and computational statistics to our clinical immunomics data in order to produce predictive models that allow us to map TCR sequences to the antigens they bind. Under the Microsoft Agreement, we retain all rights to these predictive models and the data underlying our TCR-Antigen Map, including the right to commercialize clinical products using our TCR-Antigen Map. We and Microsoft have granted each other certain licenses to one another&#8217;s intellectual property rights and have agreed to certain defined exclusivity obligations with respect to collaborations and projects that are substantially similar to the Microsoft Agreement. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the Microsoft Agreement, we have agreed to exclusively use Microsoft&#8217;s Azure cloud services at standard volume pricing with a minimum Azure consumption requirement. We have also agreed to host each diagnostic product developed as a direct result of the Microsoft Agreement on Azure throughout the term of the Microsoft Agreement and for a period of five years thereafter. In addition, we&#160;have agreed to exclusively use Microsoft&#8217;s immunomics artificial intelligence services for TCR-antigen mapping in connection with all of our technology, products and services developed as a direct result of our collaboration with Microsoft throughout the term of the Microsoft Agreement. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Microsoft Agreement has a seven-year term and may be terminated by mutual agreement or by either party upon an uncured material breach. Concurrently with entry into the Microsoft Agreement, Microsoft purchased shares of our Series F-1 convertible preferred stock which were converted into common stock upon the closing of our initial public offering in July 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Processing and Manufacturing </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We process both clinical and research use samples in our laboratory in Seattle, Washington. Our Seattle laboratory is CLIA-certified, CAP-accredited and ISO 13485-certified. After we intake samples sent to us from healthcare providers or research and biopharmaceutical customers, we extract DNA from the sample if required, amplify it and otherwise prepare it for our sequencing and data analysis. Throughout our processes, we apply a rigorous quality management system, which is designed to comply with the Quality System Regulation (&#8220;QSR&#8221;) and the requirements of CLIA, CAP and other applicable state licensing and accreditation requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to process samples submitted to us using immunoSEQ or clonoSEQ, we utilize a combination of proprietary primer mixes and commercial materials, including a multiplex PCR master mix, enzymes, high throughput multi-cycle sequencing reagents and other materials, which we obtain and assemble as needed from various third-party vendors on customary terms. A number of our processing steps utilize automated equipment to help ensure consistency and efficiency. Sequencing is performed using the Illumina NextSeq System, which we have appropriately qualified for the intended uses of our products and services. We also work with a third-party vendor to manufacture our immunoSEQ RUO kit using our proprietary primer mix and other materials. We also use Illumina to develop IVD kits and provide related support for clonoSEQ and T-Detect, pursuant to a September 2019 development and supply agreement with a six-year term and payments to Illumina based on Illumina achieving milestones and revenue share payments ranging from a low to mid-single digit percentage of future net sales, subject to customary reductions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our TCR-Antigen Map and drug discovery initiatives, we conduct our current operations at our laboratories in Seattle, Washington and South San Francisco, California. These laboratories have cell sorting, tissue culture and other processing equipment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use a limited number of suppliers, or in some cases single suppliers, for our laboratory equipment and materials. We manage this concentration risk by targeting </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or building to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">levels of surplus stock that, we believe, would allow us to locate alternative suppliers if needed. However, if one of our suppliers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers and may face delays in processing samples or developing and commercializing our products and services. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in 2020, we have faced delays in the form of longer lead times for equipment that is subject to increased demand due to public health measures taken to combat the COVID-19 pandemic, such as freezers. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, we have purchased the Illumina NextSeq System, and Illumina also supplies us with reagents that have been designed for use solely with this sequencer. While we acquire these reagents from Illumina on customary terms, if we had to replace the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reagents</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we use we may also need to acquire and qualify a replacement sequencer, validate the reagents and potentially revalidate aspects of our existing assays. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Distribution </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We processed our first immunoSEQ samples in 2011 and issued our first clonoSEQ report in 2013. Since then, we have focused on expanding our customer base. We sell our products and services primarily through our own internal sales force. Our sales and marketing efforts are targeted at department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors and research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. We seek to increase awareness of our products and services among our target customers through direct sales calls, trade shows, seminars, academic conferences, web presence and other forms of internet marketing. Our drug discovery efforts are focused on large biopharmaceutical companies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into relationships with distributors to leverage an improved RUO immunoSEQ kit that can be used with various sample types, which we expect to enable global distribution of our research product. We plan to utilize a third-party global distributor but may not be able to engage a distributor in a timely manner or on commercially reasonable terms.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an extensive global portfolio of intellectual property rights to protect our immune medicine platform, the products and services that draw on it and our reputation in the industry. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we owned or controlled 451 active patents and patent applications whose claims are intended to cover what we do, what we plan to do and what others might do to compete with us. From our earliest patent filings in 2009, our portfolio has been tailored to reflect our efforts to harness the adaptive immune system for research, diagnostic and therapeutic applications. Our patent claims extend to not only adaptive immune receptor molecules, but also to uniquely powerful techniques for sequencing immune cell receptors, determining clonality and immune competency, diagnosing disease, predicting responses to immunotherapy and identifying new drug candidates. Our patent protection generally expires in years ranging from 2029 to 2040. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Critical know-how we develop is protected by a trade secrecy program to ensure against inappropriate disclosure or use. Encompassed in our know-how is our proprietary database of coding sequences, antigen reactivities and safety profiles for immune receptors, which is vast and growing. Even with collaborators, access to our immune medicine platform technology is limited and tightly controlled through contracts and careful communication. We own our immune medicine platform, including improvements we or collaborators make to it, and retain rights in data resulting from its use. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also pursue trademark registration for our product and service names and promotional slogans in our existing and projected markets. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual Property Portfolio by the Numbers </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, our intellectual property portfolio consisted of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">451 patent applications filed worldwide directly or in conjunction with a co-owner or licensor since 2009&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">65 pending patent applications&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">386 issued patents across our immune medicine platform&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">24 patent families directed to methods and tools useful in our immune medicine platform for non-target specific immunosequencing and research, including immunoSEQ&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">17 patent families directed to methods and tools useful in diagnosis, prognosis and disease monitoring, including clonoSEQ, T-Detect and the TCR-Antigen Map&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">12</span><span style="color:#000000;"> </span><span style="color:#000000;">patent families directed to methods and tools useful in drug discovery, including TruTCR, MIRA and pairSEQ&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">1 patent family directed to therapeutic antibodies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">1 patent family directed to gene sequencing technology&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">28 trademarks registered and pending registration worldwide. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent Portfolio </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed an expansive patent portfolio in commercially important markets with claims to critical aspects of our technology, beginning with our first patent applications exclusively licensed from Fred Hutch in 2009. Our ongoing patent strategy is to generate a return on our patenting investments, which values substantive quality over volume to build a defensible moat around technology we use as well as what others might develop to design around our position. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We prioritize pursuing patent claims with a reasonable likelihood of being granted. Where patentability for a particular invention is questionable, we often choose to protect it as a trade secret instead. In some instances, however, we may seek to push the patentability envelope when the state of the applicable patent laws are in flux, such as patent eligibility for naturally occurring molecules, including TCRs, in the United States. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Methods of Measuring Adaptive Immunity </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2009, a U.S. provisional patent application was filed to pursue protection for immunosequencing by our co-founder, Dr.&#160;Harlan Robins. The invention broadly relates to methods for assessing the adaptive immune system status of individuals. Rearranged V and J&#160;segment genes of TCRs or BCRs are targeted as biomarkers for assessing the status of the immune system at one or more points in time. Granted claims extend to the use of particular sets of amplification primers, while pending claims are being pursued to capture additional assessment techniques. Licensed exclusively to us by Fred Hutch, the application has since spawned more than 31 additional patent applications, many of which have been granted as of December&#160;31, 2020, including U.S. Patent No.&#160;9,809,813. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Optimizing Nucleic Acid Amplification Reactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amplification of nucleic acids can result in over- or under-representation of the amplified molecules, misrepresenting the number present in the source material, such as a blood sample. Dr.&#160;Robins invented a method to correct for such bias, thereby improving the precision of PCR-based quantification of TCR and BCR coding sequences in a sample. The claimed approach utilizes synthetic templates, reflecting nucleic acid sequences for rearranged V and J receptor segments in the sampled cells. More than twenty-eight related patent applications have since been filed, many of which have been granted as of December&#160;31, 2020, including U.S. Patent Nos. 9,371,558 and 10,214,770.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Diagnosing and Monitoring Disease </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our acquisition (&#8220;Sequenta Acquisition&#8221;) of Sequenta, Inc (&#8220;Sequenta&#8221;) in 2015, we purchased Sequenta&#8217;s extensive patent portfolio. The portfolio includes 124 patent applications which disclose and claim methods to identify and quantify T&#160;cell-based immune responses to antigen exposure using NGS. TCR and BCR DNA, RNA or cell-free DNA from samples, including blood and bone marrow, are used to detect, prognose and monitor disease, including autoimmune disease, infection and cancer. More than one hundred twelve patents have been granted in the portfolio as of December&#160;31, 2020, including U.S. Patent Nos. 8,628,927 and 8,236,503. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our diagnostic methods also apply to the detection of MRD (the target of our B cell-based clonoSEQ diagnostic test for assessing how disease burden changes in response to treatment or during remission) and T-Detect (our T cell-based diagnostic tests). Multiple patents have been granted from additional applications relating to diagnostic methods and diagnostically significant TCRs filed by us, including U.S.&#160;Patent No.&#160;9,824,179. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">TCR-Antigen Map </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our Microsoft collaboration, we are developing a diagnostic product to detect cancer and other diseases at their earliest stage by learning the signals and responses of the activated immune receptors in a patient&#8217;s blood. Pre-collaboration, we filed 10&#160;related patent applications for methods to produce antigen-exposed enriched T&#160;cell populations and identify their antigen specificities by comparison to a pre-exposure population of cells or by use of an algorithm. We have filed additional patent applications relating to algorithmic-based methods to characterize antigen specificities and will continue to do so as our work proceeds with Microsoft. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">MIRA</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We developed and are pursuing patent protection for bioinformatic-based methods to determine the antigen specificity of TCRs by exposing T&#160;cells to a panel of multiple antigens. Antigen exposure can be performed by incubation or presentation&#59; for example, it can be performed via recombinant expression in another cell. These methods may also be used to pair the two TCR chains as well as to identify high avidity TCRs. Several patents have been granted as of December&#160;31, 2020, including U.S. Patent No.&#160;10,066,265. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">pairSEQ </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In nature, TCRs and BCRs exist as a heterodimer of paired chains, each of which is encoded on a different chromosome. Immunosequencing reveals the nucleotide structure of each individual chain, but not which chains match as cognate pairs. We developed and are pursuing patent protection for multiple bioinformatic-based approaches to pairing the two chains of TCRs and BCRs, including one deployed in our pairSEQ technique. Our methods also allow for identification of receptor chain pairs which are specific to particular antigen targets. Over fifty related patent applications have been filed, nearly half of which have matured into granted patents as of December&#160;31, 2020, including U.S. Patent No.&#160;10,077,478. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Assessing Responsiveness to Immunotherapy </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leveraging our immunosequencing technologies, we developed methods for predicting responses to immunotherapy, vaccines and infection. To those ends, rearranged TCR or BCR sequences are quantified and their levels or frequencies compared at different points in time. More than 20 related patent applications have been filed, most of which have been granted as of December&#160;31, 2020, including U.S. Patent No.&#160;10,221,461. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Therapeutic Antibodies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We developed a therapeutic antibody discovery process called TruAB from which neutralizing antibodies to SARS-CoV-2 have been produced. A patent application to these antibodies was filed in 2020 and is pending.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In-Licensed and Acquired Intellectual Property Rights </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have developed the majority of our immune medicine platform, products and services, we occasionally license or acquire third-party owned inventions to bolster the strength of our patent estate and ensure freedom to operate. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Early work by Dr.&#160;Robins with Fred Hutch led to discoveries around immunosequencing methods and tools covered by 128 patents and patent applications in the United States and abroad which we exclusively licensed. Our rights are for all fields of use worldwide and are sublicensable. To the extent any licensed granted patent rights extend to products or services sold by us, we pay Fred Hutch a royalty rate of 0.75% of net sales on licensed products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through our Sequenta Acquisition, we also obtained an exclusive paid-up license, with rights to sublicense, to patents filed in the United States, Europe, Australia and China owned by iRepertoire, Inc. The license is for worldwide use in diagnosis, prognosis, treatment and monitoring of any proliferative disorder for which rearranged nucleic acids capable of encoding an immune receptor, whether productive or unproductive, or functional or nonfunctional, of a cell, excluding tumor infiltrating lymphocytes, of the proliferative disorder can be used as markers for the disorder, including, but not limited to, lymphoid and myeloid proliferative disorders, such as ALL, CLL, acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin&#8217;s and non-Hodgkin&#8217;s lymphomas, plasma cell neoplasms, such as MM, monoclonal gammopathy of undetermined significance, monoclonal B&#160;cell lymphocytosis and myelodysplastic syndromes. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the patent estate acquired from Sequenta, we also acquired ownership of immunosequencing-related patent portfolios from Imdaptive, Inc. and ImmunID S.A.S. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Trademarks </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own various trademarks, applications and unregistered trademarks in the United States and other commercially important markets, including our company name, product and service names and other trade or service marks. Our trademark portfolio is designed to protect the brands for our products and services, both current and in the pipeline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Trade Secrecy Program </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a trade secrecy program to prevent disclosure of our trade secrets to others, except under stringent conditions of confidentiality when disclosure is critical to our business. Our trade secrets include the composition of certain reagents, assay protocols and immunosequencing-related data, such as immune receptor sequences. We protect trade secrets and&#160;know-how&#160;by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements provide that all confidential information developed or made known during the course of an individual or entities&#8217; relationship with us must be kept confidential during and after the relationship. These agreements also provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Accordingly, we may not be able to meaningfully protect our trade secrets. For more information regarding the risks related to our intellectual property, see &#8220;<span style="font-style:italic;">Risk Factors&#8212;Risks Related to Our Intellectual Property</span>.&#8221; </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries, including the fields of life sciences research, clinical diagnostics and drug discovery, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. Given the breadth and promise of immune medicine, we face substantial competition from many different sources, including life sciences tools, diagnostics, pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions across various components of our platform and product and service offerings. Due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition to increase. However, we believe our scale, precision and speed, and the resulting clinical applicability, distinguish us from our competitors. In life sciences research, immunoSEQ faces competition from a number of companies. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In clinical diagnostics, clonoSEQ faces competition primarily from institutions performing flow cytometry in-house, particularly outside of the United States. We may also face competition from companies developing early cancer detection testing products for indications that do not currently compete with clonoSEQ.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In drug discovery, clinical trials in the field of immune medicine are being pursued by a number of industry and academic players. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval and compliance, and sales and distribution than we do. Mergers and acquisitions involving life sciences research, clinical diagnostics or drug discovery companies in the immune medicine space may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize research or diagnostic products or services that are more accurate, more convenient to use or more cost-effective than our products or services. Competitor therapeutic products could also prove safer, more effective, more convenient to administer or more cost-effective than any therapeutic products we may develop with our collaborators. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the relevant market. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Life Sciences Research Use Only Technologies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our core research product, immunoSEQ, is a RUO tool in the United States that provides data to third parties such as biopharmaceutical companies that are themselves engaged in the research and development of potential diagnostic and therapeutic products and services for which they may later pursue investigation and clearance, authorization or approval from regulatory authorities, such as the FDA. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RUO products belong to a separate regulatory classification under a long-standing FDA regulation. From an FDA perspective, products that are intended for research use only and are labeled as RUO are not regulated by the FDA as</span><span style="font-style:italic;"> in vitro</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> diagnostic devices and are therefore not subject to the regulatory requirements discussed below for clinical diagnostic products. Thus, RUO products may be used or distributed for research use without first obtaining FDA clearance, authorization or approval. The products must bear the statement: &#8220;For Research Use Only. Not for Use in Diagnostic Procedures.&#8221; RUO products cannot make any claims related to safety, effectiveness or diagnostic utility, and they cannot be intended for human clinical diagnostic use. Accordingly, a product labeled RUO but intended or promoted for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and subject to FDA enforcement action. The FDA will consider the totality of the circumstances surrounding distribution and use of an RUO product, including how the product is marketed and to whom, when determining its intended use. If the FDA disagrees with a company&#8217;s RUO status for its product, the company may be subject to FDA enforcement activities, including, without limitation, requiring the company to seek clearance, authorization or approval for the products. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Diagnostics in the United States</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our first diagnostic product, clonoSEQ, was granted marketing authorization by the FDA for the detection and monitoring of MRD in bone marrow samples in patients with MM and ALL under the <span style="font-style:italic;">de novo</span> process, which classified clonoSEQ and future DNA-based tests to measure MRD in hematological malignancies as Class II devices, as explained further below. In August 2020, we received our third FDA clearance for clonoSEQ, following a 510(k) submission, for CLL in bone marrow as well as blood samples.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, medical devices are subject to extensive regulation by the FDA under the FDCA and its implementing regulations, and other federal and state statutes and regulations. The FDA regulates the design, development, preclinical, analytical and clinical testing, manufacture, safety, effectiveness, clearance, authorization or approval, record-keeping, packaging, labeling, storage, adverse event reporting, advertising, promotion, marketing, sales, distribution and import and export of medical devices. IVDs are a type of medical device and include reagents and instruments used in the diagnosis or detection of diseases, conditions or infections, including, without limitation, the presence of certain chemicals, genetic information or other biomarkers. Predictive, prognostic and screening tests can also be IVDs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a medical device is placed on the market, numerous regulatory requirements apply.&#160;These include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with the FDA&#8217;s QSR, which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">labeling regulations, which prohibit the promotion of products for uncleared, or unapproved uses, or &#8220;off-label&#8221; uses, and impose other restrictions on labeling&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obligations to investigate and report to the FDA adverse events, including deaths, or serious injuries that may have been or were caused by a medical device and malfunctions in the device that would likely cause or contribute to a death or serious injury if it were to recur.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions, including but not limited to, warning letters&#59; fines, injunctions, and civil penalties&#59; recall or seizure of the device&#59; operating restrictions, partial suspension or total shutdown of production&#59; refusal to grant 510(k) clearance or premarket approvals (&#8220;PMAs&#8221;) of new devices&#59; withdrawal of clearance or approval&#59; and civil or criminal prosecution.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Position in the European Union </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, IVDs can be placed on the market by obtaining a &#8220;CE mark,&#8221; which demonstrates conformity with the<span style="font-style:italic;"> In vitro</span> Diagnostic Medical Device Directive (&#8220;IVDD&#8221;). The requirements under the Directive include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Essential Requirements</span><span style="color:#000000;">. The IVDD specifies &#8220;essential requirements&#8221; that all medical devices must meet to demonstrate the product is safe and effective under normal conditions of use. The requirements are similar to those adopted by the FDA relating to quality systems and product labeling. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Conformity Assessment</span><span style="color:#000000;">. The requirements to obtain a CE mark are risk-based, and follow a similar classification system as in the United States. However, unlike the United States, which requires virtually all devices to undergo some level of premarket review by the FDA, the IVDD currently allows manufacturers to bring many devices to market using a process in which the manufacturer self-certifies that the device conforms to the applicable essential requirements. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Vigilance</span><span style="color:#000000;">. The IVDD specifies requirements for post market reporting similar to those adopted by the FDA. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;26, 2017, the EU released a new regulatory framework, the<span style="font-style:italic;"> In vitro</span> Diagnostic Medical Device Regulation (&#8220;IVDR&#8221;), which will replace the IVDD. Our products in the EU will have to comply with the IVDR requirements after May&#160;26, 2022, subject to the applicable transitional provisions before full compliance is required. The IVDR is considerably stricter in regulatory oversight than the IVDD and will require more IVD devices to be reviewed by a notified body before being placed on the market. Until that time, our products must continue to meet the requirements of IVDD for commercialization in the EU.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Federal and State Regulation of Laboratories </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given that aspects of our business at certain facilities involve acting as a clinical laboratory, we are required to hold certain federal and state licenses, certifications and permits to conduct our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As to federal certifications, CLIA establishes rigorous quality standards for all laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of, or assessment of health. As a clinical laboratory, we must obtain a CLIA certificate based on the complexity of testing performed at the laboratory, such as a Certificate of Compliance for high-complexity testing. CLIA also mandates compliance with various operational, personnel, facilities administration, quality and proficiency requirements, intended to ensure that their clinical laboratory testing services are accurate, reliable and timely. CLIA compliance and certification is also a prerequisite to be eligible to bill for services provided to government payors and for many private payors. Furthermore, we are subject to survey and inspection every two years to assess compliance with program standards, and may be subject to additional unannounced inspections. Laboratories performing high-complexity testing are required to meet more stringent requirements than laboratories performing less complex tests. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to CLIA requirements, we elect to participate in the accreditation program of the CAP. The U.S. Centers for Medicare &#38; Medicaid Services (&#8220;CMS&#8221;), the agency that oversees CLIA, has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of CMS inspections for accredited laboratories. Therefore, because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. Select states, including Washington, have laboratory regulations that have been deemed by the federal government to be at least as stringent as CLIA, and thus laboratories licensed under those state regimes are exempt from CLIA and the state Department of Health is permitted to issue a CLIA number, along with a state Medical Test Site license, rather than a certificate being issued by CMS. Our laboratory holds the required Washington license. State laws may require that laboratory personnel meet certain qualifications, specify certain quality control procedures, facility requirements or prescribe record maintenance requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several states additionally require the licensure of out-of-state laboratories that accept specimens from those states. For example, New York requires a laboratory to hold a permit which is issued after an on-site inspection and approval of each LDT offered by a laboratory, and has various, more stringent requirements than CLIA and CAP, including those for personnel qualifications, proficiency testing, physical facility and equipment and quality control standards. Our laboratory holds the required licenses for Maryland, Rhode Island, Pennsylvania, New York and California. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, other states may require out-of-state laboratories to obtain licensure in order to accept specimens from the state. If we identify any other state with such requirements, or if we are contacted by any other state advising us of such requirements, we intend to follow instructions from the state regulators as to how we should comply with such requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a clinical laboratory is found to be out of compliance with CLIA certification, CAP accreditation or a state license or permit, the applicable regulatory agency may, among other things, suspend, restrict or revoke the certification, accreditation, license or permit to operate the clinical laboratory, assess civil monetary penalties and impose specific corrective action plans, among other sanctions. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laboratory Developed Tests in the United States</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.56%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has historically exercised enforcement discretion to not regulate most LDTs. As such, LDTs have not been subject to FDA&#8217;s marketing clearance and approval processes, or post-marketing controls, for medical devices. LDTs are generally considered to be tests that are designed, developed, validated and used within a single laboratory. Laboratories certified as &#8220;high complexity&#8221; under CLIA may develop, manufacture, validate and run LDTs. clonoSEQ is available as an LDT for use in assessing MRD for other lymphoid malignancies, including CLL and NHL, at our Seattle, Washington laboratory.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In that respect, Congress introduced legislation to establish a framework for FDA to oversee marketing of </span><span style="font-style:italic;">in vitro</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical tests (&#8220;IVCTs&#8221;), such as test kits and LDTs (the Verifying Accurate Leading-edge IVCT Development Act, or &#8220;VALID Act&#8221;). Under the VALID Act, FDA would oversee IVCTs, requiring pre-market review for high-risk IVCTs which expose patients to serious or irreversible harm and novel IVCTs. As currently drafted, existing LDTs at the time of VALID Act passage would be grandfathered as approved. For new low risk IVCTs, developers would submit a representative IVCT to FDA for review and issuance of a technology certification for the specific IVCT reviewed and later developed test within the scope of the certification. It is not certain whether or in what form the VALID Act bill will pass Congress, but passage could increase the stringency of regulatory review required for our LDT products. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the VALID Act does not pass, FDA may decide to exercise enforcement discretion for LDTs, especially if it perceives a LDT as posing a risk to patients. Therefore, the regulatory path for marketing of LDTs is subject to uncertainty given the FDA&#8217;s latitude in interpreting and applying its laws and policies. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of November 2020, the U.S. Department of Health and Human Services instructed the FDA to review voluntary EUA submissions of LDTs for COVID-19 in order to extend certain statutory immunities to liability for those laboratories under the federal Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;). Failure to obtain an EUA for a COVID-19 LDT can impair such immunity and could make payor reimbursement for COVID-19 LDTs under the Family First Coronavirus Act unavailable. We are seeking an EUA for our T-Detect COVID test and could be at risk of product liability or lack of payor reimbursement if the EUA is not granted.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Federal and State Privacy, Security and Breach Notification Laws </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many state and federal laws govern the processing of personally identifiable information or individually identifiable health information. At the federal level, under the administrative simplification provisions of the <span style="Background-color:#FFFFFF;color:#000000;">Health Insurance Portability and Accountability Act of 1996</span> (&#8220;HIPAA&#8221;) and <span style="Background-color:#FFFFFF;color:#000000;">the Health Information Technology for Economic and Clinical Health Act of 2009</span> (&#8220;HITECH&#8221;), the U<span style="Background-color:#FFFFFF;color:#000000;">.S. Department of Health and Human Services</span> (&#8220;HHS&#8221;) issued regulations that establish standards for protecting the privacy and security of &#8220;protected health information&#8221; used or disclosed by certain healthcare providers and other &#8220;covered entities&#8221; and their &#8220;business associates.&#8221; Three principal data protection-related regulations with which we are required to comply have been issued in final form under HIPAA and HITECH: privacy regulations, security regulations and security breach notification regulations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The privacy regulations govern the use and disclosure of &#8220;protected&#8221; health information by covered healthcare providers, as well as health insurance plans. They also set forth certain rights that an individual has with respect to his or her protected health information maintained by a covered health care provider, including the right to access or amend certain records containing protected health information or to request restrictions on the use or disclosure of protected health information. The security regulations establish requirements for safeguarding the confidentiality, integrity and availability of protected health information that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify HHS and each affected individual of a breach of unsecured protected health information as well as the media if the breach involves more than 500 individuals. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA violations are subject to civil and criminal penalties. Additionally, to the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;5(a) of the Federal Trade Commission Act (&#8220;FTCA&#8221;) has also been used to regulate data privacy and security at the federal level. According to the <span style="Background-color:#FFFFFF;color:#000000;">U.S. Federal Trade Commission</span> (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure or using or disclosing personal information in violation of a company&#8217;s privacy notice may constitute unfair or deceptive acts or practices in or affecting commerce in violation of the FTCA. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Although we have and maintain a system for compliance with privacy laws and regulations, failure to comply with them could expose us to potential FTC enforcement action and fines.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain state laws govern the privacy and security of health information, some of which are more stringent than HIPAA (including providing for patient enforcement of these state laws) and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. In addition, there are state breach notification laws in every state. Failure to comply with these laws, where applicable, can result in the imposition of significant civil or criminal penalties and private litigation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;" id="page31"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General Data Protection Regulation in the EU </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The General Data Protection Regulation (&#8220;GDPR&#8221;) is a legal framework that sets requirements for the collection and processing of personal information of individuals within the European Economic Area (&#8220;EEA&#8221;). The GDPR sets out the principles for data management and the rights of the individual, while also imposing very significant fines that can be revenue-based. It applies to U.S. companies that process personal information of persons in the EEA in connection with the offer of products or services to those persons, or the monitoring of such persons&#8217; behavior. It may also apply when a U.S. company processes personal information in the context of the activities of an entity established in the EEA. The GDPR became enforceable on May&#160;25, 2018. The regulation applies to the human resources record of employees and even the Internet Protocol addresses of people using online services. The GDPR builds upon data rights that the EU had previously advocated, such as the right of an individual to be forgotten and the right to data portability. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Federal, State and Foreign Fraud and Abuse Laws </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there are various fraud and abuse laws with which we must comply and we are subject to regulation by various federal, state and local authorities, including CMS, other divisions of HHS, such as the <span style="Background-color:#FFFFFF;color:#000000;">Office of Inspector General</span> (&#8220;OIG&#8221;), the <span style="Background-color:#FFFFFF;color:#000000;">U.S. Department of Justice</span> (&#8220;DOJ&#8221;) and individual U.S. Attorney offices within the DOJ, and state and local governments. We also may be subject to foreign fraud and abuse laws. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the Anti-Kickback Statute (&#8220;AKS&#8221;) prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for patient referrals for, or purchasing, leasing, ordering or arranging for the purchase, lease or order of, any healthcare item or service reimbursable under a governmental payor program. Courts have stated that a financial arrangement may violate the AKS if any one purpose of the arrangement is to encourage patient referrals or other federal healthcare program business, regardless of whether there are other legitimate purposes for the arrangement. The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including gifts, discounts, meals, travel, credit arrangements, payments of cash, consulting fees, waivers of co-payments, ownership interests and providing anything at less than its fair market value. Recognizing that the AKS is broad and may technically prohibit many innocuous or beneficial arrangements within the healthcare industry, the OIG issued a series of regulatory &#8220;safe harbors.&#8221; These safe harbor regulations set forth certain provisions, which, if met, will assure healthcare providers and other parties that they will not be prosecuted under the AKS. The failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the AKS will be pursued. In those instances, arrangements will be evaluated on a case-by-case basis to determine whether enforcement will be pursued. Penalties for AKS violations are severe and can include imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs. The regulations establishing safe harbor protection are subject to change and could affect future operations. Many states also have anti-kickback statutes, some of which may apply to items or services reimbursed by any third-party payor, including commercial insurers as well as patient self-pay. A violation of the AKS may be grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The civil monetary penalties statute is another potential statute under which a clinical laboratory may be subject to enforcement. Among other things, the civil monetary penalties statute imposes fines against any person who is determined to have presented, or caused to be presented, claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent. The civil monetary penalties statute also prohibits a person from offering or providing remuneration to any Medicare or Medicaid beneficiary that is likely to influence the individual to order or receive its items or services from a particular provider or supplier. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exclusion statute requires the exclusion of entities and individuals who have been convicted of federal-program related crimes or healthcare felony fraud or controlled substance charges. The statute also permits the exclusion of those that have been convicted of any form of fraud, the AKS, for obstructing an investigation or audit, certain controlled substance offenses, those whose healthcare license has been revoked or suspended and those who have filed claims for excessive charges or unnecessary services. If we were to be excluded, our products and services would be ineligible for reimbursement from any federal programs, including Medicare and Medicaid, and no other entity participating in those programs would be permitted to enter into contracts with us. In order to preserve access to beneficial healthcare items and services, the government may elect to exclude officers and key employees of manufacturers, rather than excluding the organization. Such enforcement actions would prohibit us from engaging those individuals, which could adversely affect operations and result in significant reputational harm. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congress has also enacted statutes that impose criminal liability for healthcare fraud and abuse. The Health Care Fraud Statute prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs such as the Medicare and Medicaid programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefit programs, items or services-public or private. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal governmental payor program. The</span><span style="font-style:italic;"> qui tam</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has defrauded the federal government by submitting a false claim to the federal government and permit such individuals to share in any amounts paid by the entity to the government in fines or settlement.</span><span style="font-style:italic;"> Qui tam</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> complaints are filed under seal, and the cases may progress for a number of years before a complaint is unsealed and a healthcare provider or supplier becomes aware of its existence. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties ranging from $11,463 to $22,927 for each false claim. The False Claims Act is the federal government&#8217;s primary civil tool in healthcare fraud cases. False Claims Act liability is not limited to direct providers of health items or services. The government has asserted liability under the False Claims Act against manufacturers and other third parties who caused another party to file a false claim. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, various states have enacted false claim laws analogous to the federal False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely a governmental payor program. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;25, 2018, the Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act of 2018 (&#8220;SUPPORT Act&#8221;) was enacted. The SUPPORT Act included the Eliminating Kickbacks in Recovery Act of 2018 (&#8220;EKRA&#8221;), which establishes an all-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories and clinical treatment facilities. EKRA includes a number of statutory exceptions, and directs agencies to develop further exceptions. Current exceptions in some cases reference and in others differ from the AKS safe harbors. Significantly, the prohibitions apply with respect to the soliciting or receipt of remuneration for&#160;any&#160;referrals to recovery homes, clinical treatment facilities, or clinical laboratories, whether or not related to treating substance use disorders. Further, the prohibitions cover the payment or offer of remuneration to induce a referral to, or in exchange for, an individual using the services of, such providers. This new law creates additional risk that relationships with referral sources could be problematic. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For anti-corruption legislation, the <span style="Background-color:#FFFFFF;color:#000000;">U.S. Foreign Corrupt Practices Act (&#8220;</span>FCPA&#8221;) is the most widely enforced law. It is the first to introduce corporate liability, responsibility for third parties and extraterritoriality for corruption offences, meaning companies and persons can be held criminally and civilly responsible for corruption offences committed abroad. It was enacted for the purpose of making it unlawful for certain classes of persons and entities to make payments to foreign government officials to assist in obtaining or retaining business. With the enactment of certain amendments in 1998, the anti-bribery provisions of the FCPA now also apply to foreign firms and persons who cause, directly or through agents, an act in furtherance of such a corrupt payment to take place within the territory of the United States. The FCPA also requires companies whose securities are listed in the United States to meet its accounting provisions, which were designed to operate in tandem with the anti-bribery provisions, require corporations covered by the provisions to (a)&#160;make and keep books and records that accurately and fairly reflect the transactions of the corporation and (b)&#160;devise and maintain an adequate system of internal accounting controls. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, various countries have adopted anti-bribery laws providing for severe consequences, in the form of criminal penalties or significant fines, for individuals or companies committing a bribery offence. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation. For instance, in the United Kingdom, under the Bribery Act 2010, which came into effect in July&#160;2011, a bribery offense occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the Bribery Act 2010. Under this regime, an individual found in breach of the Bribery Act 2010 faces imprisonment of up to 10 years. In addition, the individual can be subject to an unlimited fine, if found to have committed an offense, as can commercial organizations that are found to have failed to prevent bribery. Most recently, France has passed an anti-bribery and compliance law (&#8220;Sapin II&#8221;), and the new French anti-corruption agency (&#8220;AFA&#8221;) has been established. The Sapin II law makes it compulsory for companies within the scope of the law to implement internal procedures to fight corruption. One of the items that must be prepared is a corruption risk map, as well as an anti-corruption code of conduct. These documents are subject to investigation by the AFA and failure to comply with the requirements can lead to a fine of up to &#8364;1.0&#160;million for a company and &#8364;200,000 for executives. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, we are not subject to the jurisdictional requirements of the UK Bribery Act or Sapin II as we do not have offices in either country and do not employ a requisite amount of employees in these countries. If we were to have future growth in the European market, these laws could potentially apply to us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Physician Referral Prohibitions</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Physician Self-Referral Law (&#8220;Stark Law&#8221;) prohibits physicians from referring patients to entities with which the physician or an immediate family member has a financial relationship, such as ownership, investment or compensation, for designed health services (&#8220;DHS&#8221;) payable by Medicare and Medicaid, unless the financial arrangement meets an applicable exception. DHS includes clinical laboratory tests. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties and possible exclusion from federal health care programs.&#160;In addition to the Stark Law, many states have their own self-referral bans, which may extend to all self-referrals, regardless of the payor. See &#8220;<span style="font-style:italic;">Risk Factors&#8212;Risks Relating to Government Regulation&#8212;We are subject to various laws and regulations, such as healthcare fraud and</span> <span style="font-style:italic;">abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business</span>.&#8221;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Corporate Practice of Medicine in the United States </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous states have enacted laws prohibiting business corporations, such as us, from practicing medicine and employing or engaging physicians to practice medicine, generally referred to as the prohibition against the corporate practice of medicine. These laws are designed to prevent interference in the medical decision-making process by anyone who is not a licensed physician. For example, California&#8217;s Medical Board has indicated that determining what diagnostic tests are appropriate for a particular condition and taking responsibility for the ultimate overall care of the patient, including providing treatment options available to the patient, would constitute the unlicensed practice of medicine if performed by an unlicensed person. Violation of these corporate practice of medicine laws may result in civil or criminal fines, as well as sanctions imposed against us or the professional through licensure proceedings. Typically such laws are only applicable to entities that have a physical presence in the state. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Regulatory Requirements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our laboratory is subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemical, biological agents and compounds, blood and bone marrow samples and other human tissue. Typically, we use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our partners in the development of therapeutic agents are responsible for developing and manufacturing those products. In so doing, they are subject to FDA and Medicare regulatory requirements related to, among other things, manufacture, promotion, price reporting and fraud and abuse laws. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our laboratories are subject to extensive requirements related to workplace safety established by the U.S. Occupational Safety and Health Administration. These include requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Healthcare Reform </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, a number of recent legislative and regulatory changes at the federal and state levels have sought to reduce healthcare costs and improve the quality of healthcare. For example, in March&#160;2010, the <span style="Background-color:#FFFFFF;color:#000000;">Affordable Care Act (&#8220;</span>ACA&#8221;) became law. This law substantially changed the way healthcare is financed by both commercial and government payors, and it has significantly impacted our industry. Since 2016 there have been efforts to repeal all or part of the ACA. For example, the <span style="Background-color:#FFFFFF;color:#000000;">Tax Cuts and Jobs Act (&#8220;</span>TCJA&#8221;), among other things, removes penalties for not complying with the ACA&#8217;s individual mandate to carry health insurance. The U.S. Congress may take further action regarding the ACA, including, but not limited to, repeal or replacement. Additionally, all or a portion of the ACA and related subsequent legislation may be modified, repealed or otherwise invalidated through judicial challenge, which could result in lower numbers of insured individuals, or reduced coverage for insured individuals, and which could adversely affect our business. However, it remains to be seen whether or when new legislation modifying the ACA will be enacted, what any such the new legislation might provide and what impact it might have on the size and coverage of the insured population or on efforts to contain or lower the cost of healthcare. We cannot predict the implications, if any, of such legislation on our and our collaborators&#8217; businesses and financial conditions. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial payors to reduce costs while trying to expand individual healthcare benefits. If enacted, some such proposals could expand or contract the insured population, increasing or decreasing demand for our products and services. On the other hand, some proposals could impose additional limitations on the prices we will be able to charge for our tests or on the coverage of or the amounts of reimbursement available for our tests from payors, including commercial payors and government payors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal physician payment transparency requirements (&#8220;Physician Payments Sunshine Act&#8221;) and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, with certain exceptions, to annually report to HHS information related to certain payments or other transfers of value made or distributed to physicians, defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The SUPPORT Act, under a provision entitled &#8220;Fighting the Opioid Epidemic with Sunshine,&#8221; extends the Physician Payments Sunshine Act to payments and transfers of value to physician assistants, nurse practitioners and other mid-level healthcare providers, with reporting requirements going into effect in 2022 for payments and transfers of value made to these practitioners in 2021.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also state &#8220;sunshine&#8221; laws that require manufacturers to provide reports to state governments on pricing and marketing information.&#160;Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales and marketing activities, and such laws may also prohibit or limit certain other sales and marketing practices.&#160;These laws may adversely affect our sales, marketing, and other activities by imposing administrative and compliance burdens on us.&#160;Although we have a system for tracking and reporting &#8220;sunshine&#8221; law required information, if we fail to do so as required, we could be subject to government enforcement action and potential penalties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and Reimbursement Generally</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement and billing requirements of applicable laws and payors for diagnostic services are highly complex.&#160;Laboratories must bill various payors, such as private third-party payors, including managed care organizations (&#8220;MCO&#8221;), and state and federal health care programs, such as Medicare and Medicaid, and each may have different billing requirements.&#160;Depending on the reimbursement arrangement and applicable law, the party that reimburses us for our services may be a third party who provides coverage to the patient, such as an insurance company or MCO&#59; a state or federal healthcare program&#59; or the patient. Additionally, the audit requirements we must meet to ensure compliance with applicable laws and regulations, as well as our internal compliance policies and procedures, add further complexity to the billing process.&#160;As such, we are at risk of being paid less or no part of our price for our products for reasons including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">variability in coverage and information requirements among various payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patient financial assistance programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">missing, incomplete or inaccurate billing information provided by ordering physicians&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">billings to payors with whom we do not have contracts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes with payors as to which party is responsible for payment&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes with payors as to the appropriate level of reimbursement.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may not be free to determine the price charged for our products. Certain countries, including a number of member states of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products. Additionally, some countries require approval of the maximum sale price of a product before it can be marketed, and this price may be reviewed during the product lifecycle, or mandatory discounts or profit caps may be applied. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. We may therefore be constrained in our pricing strategies in markets outside of the United States.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="page35">For additional information on coverage and reimbursement in the United States, see &#8220;<span style="font-style:italic;">Risk Factors&#8212;Risks Relating to Government Regulation&#8212;Future Medicare payment</span> <span style="font-style:italic;">rates are uncertain</span>.&#8221; </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Compliance Program </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our compliance program is intended to prevent and detect violations of law or our policies. It was developed in view of both adopting the principles of the AdvaMed Code of Ethics and addressing the HHS OIG&#8217;s elements of a compliance program. We have designed our compliance program to fit the size, resources, market position and other unique aspects of our company. Our code of conduct is our statement of ethical and compliance principles that guide our daily operations. In addition, we have developed policies and procedures, and corresponding education and training, to effectively communicate our standards to employees as it relates to job functions and legal obligations under applicable state and federal healthcare program requirements, as well as those outside the United States. We regularly perform live and process monitoring activities on a risk-based approach, and audit capabilities are built into our transparency procedures. We maintain a hotline available via multiple channels to report any known or suspected compliance violations, and we have a strict non-retaliation policy for all claims brought forward in good faith. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in the State of Washington on September&#160;8, 2009 under the name Adaptive TCR Corporation. On December&#160;21, 2011, we changed our name to Adaptive Biotechnologies Corporation. In January&#160;2015, we acquired Sequenta, Inc. (&#8220;Sequenta&#8221;), a San&#160;Francisco, California-based company that was also developing an NGS test for MRD (&#8220;Sequenta Acquisition&#8221;). Our principal executive offices are located at 1551 Eastlake Avenue East, Suite 200, Seattle, Washington 98102, and our telephone number is (206) 659-0067.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a website at www.adaptivebiotech.com. The contents of our website are not incorporated in, or otherwise to be regarded as part of, this Annual Report on Form 10-K. We make available, free of charge on our website, access to our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as soon as reasonably practicable after we file or furnish them electronically with the Securities and Exchange Commission (&#8220;SEC&#8221;). Investors and others should note that we announce material financial information to our investors using our investor relations website (http://investors.adaptivebiotech.com), SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on social media channels.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our Company involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K, including our financial statements and related notes and the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section, before investing in our Company. Any of the risk factors we describe below could adversely affect our business, financial condition, results of operations, prospects or the trading price of our securities. The risks described below are not the only ones we face and additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business, financial condition, operating results, prospects and the trading price of our securities. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, the risks described below relate to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effects of health epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant laboratory operations, manufacturing facilities, concentrations of clinical trial sites or other business operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our significant net losses since inception, expected net losses in the future and need for significant investments in products and services&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to leverage our immune medicine platform to discover, develop, commercialize and obtain regulatory clearance, authorization and approval for our products and services, particularly in light of the novelty of immune medicine and our methods&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to develop our TCR-Antigen Map and yield insights from it that are commercially viable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our collaboration with Genentech and ability to develop and commercialize cellular therapeutics, including our ability to achieve milestones and realize the intended benefits of the collaboration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to leverage our immune medicine platform to discover, develop and commercialize additional products and services, including those related to COVID-19, may not be successful&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our laboratory operations, including errors or defects in our products or services and our reliance on a limited number of suppliers, and in some cases single suppliers, for our equipment and materials, some of which include reagents or other materials that may also require additional internal validation prior to use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our limited experience with the development and commercialization of cellular therapeutics&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">market acceptance of our products and services, and our limited sales and marketing experience&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expected reliance on collaborators for development and clinical testing of therapeutic product candidates, which may fail at any time due to a number of possible unforeseen events&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to increase our capacity, manage the evolution of our products and services, stay current in our rapidly changing industry, expand our workforce and otherwise manage our growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the loss of any member of our senior management team, or of the support of key opinion leaders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extensive regulation of our industry, including reimbursement coverage decisions&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the validity of our patents, protection of our trade secrets and related intellectual property matters.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Our Business </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception. For the years ended December&#160;31, 2020, 2019 and 2018, we incurred net losses of $146.2 million, $68.6 million and $46.4&#160;million, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $511.6 million. We have funded our operations to date principally from the sale of convertible preferred stock and common stock, including the sale of common stock in our initial public offering, and, to a lesser extent, sequencing and development revenue. We have devoted most of our financial resources to the research and development of products and services under our immune medicine platform. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue to invest in the development of products and services utilizing our immune medicine platform to support the validation of additional clinical diagnostic and therapeutic products and services. We will need to generate significant additional revenue to achieve and sustain profitability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to make significant investments in our continued research and development of new products and services, which may not be successful. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are seeking to leverage our immune medicine platform to develop a pipeline of future disease-specific research, diagnostic and therapeutic products and services. For example, we are developing our TCR-Antigen Map with a view toward advancing the development of T-Detect, a diagnostic test that may enable early and accurate detection of multiple diseases, including acute Lyme and celiac disease, from a single blood test. In addition, we are developing certain therapeutic product candidates under our collaboration agreement with Genentech by leveraging our platform to identify TCRs that can be engineered into personalized cellular immunotherapies. We expect to incur significant expenses to advance these development efforts, but they may not be successful. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing new products and services is a speculative and risky endeavor. Products or services that initially show promise may fail to achieve the desired results or may not achieve acceptable levels of analytical accuracy or clinical utility. We may need to alter our products in development and repeat clinical studies before we identify a potentially successful product or service. Product development is expensive, may take years to complete and can have uncertain outcomes. Failure can occur at any stage of the development. If, after development, a product or service appears successful, we or our collaborators may, depending on the nature of the product or service, still need to obtain FDA and other regulatory clearances, authorizations or approvals before we can market it. The FDA&#8217;s clearance, authorization or approval pathways are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA may not clear, authorize or approve any future product or service we develop. Even if we develop a product or service that receives regulatory clearance, authorization or approval, we or our collaborators would need to commit substantial resources to commercialize, sell and market it before it could be profitable, and the product or service may never be commercially successful. Additionally, development of any product or service may be disrupted or made less viable by the development of competing products or services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New potential products and services may fail at any stage of development or commercialization and if we determine that any of our current or future products or services are unlikely to succeed, we may abandon them without any return on our investment. If we are unsuccessful in developing additional products or services, our potential for growth may be impaired. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not successful in leveraging our immune medicine platform to discover, develop and commercialize additional products and services, our ability to expand our business and achieve our strategic objectives would be impaired. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key element of our strategy is to leverage our immune medicine platform to discover, develop and potentially commercialize additional products and services beyond our current portfolio to diagnose and treat various disease states. In particular, for clonoSEQ we are attempting to generate sufficient clinical evidence to support the utility of MRD in additional lymphoid cancers beyond ALL, MM and CLL, while also demonstrating the clinical utility of blood as a <span style="text-decoration:line-through;">s</span>ample type for all lymphoid cancers. If we are unable to generate compelling evidence supporting clonoSEQ use in other indications or sample types, our platform may face a broader obstacle to using our immunosequencing data for commercially viable products and services.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying new products and services requires substantial technical, financial and human resources, whether or not any products or services are ultimately developed or commercialized. We may pursue what we believe is a promising opportunity to leverage our platform only to discover that certain of our risk or resource allocation decisions were incorrect or insufficient, or that individual products, services or our science in general has technology or biology risks that were previously unknown or underappreciated. Our strategy of pursuing the value of our immune medicine platform over a long time horizon and across a broad array of human diseases may not be effective. In the event material decisions in any of these areas turn out to be incorrect or sub-optimal, we may experience a material adverse impact on our business and ability to fund our operations and we may never realize what we believe is the potential of our immune medicine platform. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our efforts to develop our TCR-Antigen Map may not be successful, and it may not yield the insights we expect at all or on a timetable that allows us to develop or commercialize any new diagnostic products. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are leveraging our collaboration with Microsoft to develop our TCR-Antigen Map. Together we are using immunosequencing, proprietary computational modeling and machine learning to map TCR sequences to the antigens they bind. However, we may not be successful in developing a comprehensive TCR-Antigen Map for any number of reasons. Our collaboration with Microsoft is in the early stages, and our computations and algorithmic-based methods are largely untested and may not allow us to accurately pair TCR sequences to a meaningful number of antigens. As a result, it may require significantly more time and resources for us to determine how to use machine learning to accelerate our mapping process, which could adversely impact our ability to develop or commercialize new diagnostic products or services. In addition, even with the aid of machine learning, we expect the TCR-Antigen Map to take us several years to develop. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TCR-Antigen Map we are developing may not yield clinically actionable insights on a timetable that is commercially viable, or at all. Our goal is to leverage the TCR-Antigen Map in connection with the development of T-Detect to enable early or accurate detection across a broad range of diseases. We have confirmed clinical signals for SARS-CoV-2, acute Lyme disease, and Crohn&#8217;s disease, but are still validating early detection testing for other disease states. If our computational modeling and machine learning efforts do not accelerate the pace at which we can validate association of TCR sequences to the antigens they bind, the timetable for our business model may not be commercially viable. Even if we can accelerate this timeline, our products and services derived from our novel technologies may have product or service level errors. If we are unable to make meaningful progress in our TCR-Antigen Map and successfully use it to develop and commercialize new diagnostic products or services, our business and results of operations will suffer. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are exposed to risks associated with our agreement with Genentech, and we may not realize the advantages we expect from it. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (&#8220;Genentech Agreement&#8221;), with the goal of accelerating the development and commercialization of novel cancer-specific antigen and neoantigen directed T cell therapies for the treatment of a broad range of tumor types. Under the terms of the Genentech Agreement, we received $300.0&#160;million in an initial upfront payment in February 2019 and may be eligible to receive approximately $1.8&#160;billion in additional payments over time upon achievement of specified development, regulatory and commercial milestones. In addition, Genentech will pay us royalties on sales of products commercialized under the agreement. We may not be successful in achieving these milestones, and products developed under the Genentech Agreement may not be commercialized in the timeframe we expect, achieve significant sales, or be commercialized at all. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to numerous risks associated with the Genentech Agreement, including sharing a measure of control over the operations of our research and development portions of the collaboration with Genentech and Genentech having sole control over the commercialization of any products developed via the collaboration. The Genentech Agreement also prevents us from, among other things, developing or commercializing TCR-based cellular therapies outside the scope of the collaboration in the field of oncology on our own or with any third party. Our collaboration involves risks that are different from the risks involved in independently conducting operations, including that Genentech may: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">have or develop economic or business interests that are inconsistent with ours&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">take actions contrary to our instructions, requests, policies or objectives&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">take actions that reduce our return on investment for this collaboration&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fail to distinguish itself from biosimilar competition&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">take actions that harm our reputation or restrict our ability to run our business. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech&#8217;s degree of control over collaboration development and commercialization efforts may impact the amounts we receive under the Genentech Agreement. For example, Genentech may decide not to pursue commercialization of product candidates at all, or it may agree to pay royalties to third parties or adopt a pricing model that reduces the amount of royalties we might otherwise expect. It is also possible that effective cell therapies will not be developed under the Genentech Agreement or, if developed, approved by the FDA or comparable regulatory authorities outside of the United States. Genentech may also terminate the Genentech Agreement at its convenience, at any time and without cause. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to perform our product research, development and commercialization related obligations under the Genentech Agreement, including performing TCR screening activities for product candidates being developed and commercialized under that agreement. For example, in the event a product is commercialized under the Genentech Agreement, as the volume of product sales grows, we will likely need to continue to increase our workflow capacity for sample intake, customer service and general process improvements, and expand our internal quality assurance program to support TCR screening on a larger scale within expected turnaround times. We will likely need additional certified laboratory scientists and other scientific and technical personnel for the Personalized Product to identify and target therapeutically relevant, patient-specific neoantigens. We will likely also need to acquire additional laboratory space and equipment, which can take several months or more to procure, set up and validate. These process enhancements and increases in scale, expansion of personnel, laboratory space and equipment may not be successfully implemented, and we may not have adequate space in our existing laboratory facilities to accommodate the required expansion. If we cannot satisfy our obligations, Genentech is entitled to trigger a technology transfer of our TCR screening process (specific to the Personalized Product) or terminate the Genentech Agreement. In addition, due to our significant obligations under the Genentech Agreement, we may face challenges in keeping existing customers, collaborators and suppliers and obtaining new customers, including any biopharmaceutical customers that are actual or potential competitors with Genentech. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we support the commercialization of one or more products under the Genentech Agreement, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business, both under the Genentech Agreement and otherwise. As a result, our relationship with Genentech may not result in the realization of its anticipated benefits. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have limited experience with the development and commercialization of cellular therapeutics, and future TCR-based cellular therapies may never be successfully developed and commercialized as part of our Genentech collaboration. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience with the development of cellular therapeutics, and no experience with the commercialization, marketing and distribution of cellular therapeutics. Our therapeutic product candidates are at an early stage of discovery and development under our Genentech collaboration, and we are continuing to develop our TruTCR process being used under that collaboration to develop TCR-based cellular therapies for the treatment of cancer. Under our Genentech collaboration, Genentech has invested significant financial resources to develop future TCR-based cellular therapies, including conducting preclinical studies and other&#160;early&#160;research and development&#160;activities, and providing general and administrative support for these operations.&#160;Our future success is dependent on our and Genentech&#8217;s ability to successfully develop therapeutic product candidates, and Genentech&#8217;s ability, where applicable, to obtain regulatory and marketing approval for, and then successfully commercialize, cellular therapeutics. We and Genentech have not yet developed and commercialized any cellular therapeutics, and we may not be able to do so. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We currently use, and in the future expect to increase our use of, collaborators for several aspects of our operations, and if we cannot maintain current and enter new relationships with collaborators, our business will suffer. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited resources to conduct our life sciences research, clinical diagnostics and drug discovery operations and have not yet fully established infrastructure for sales, marketing or distribution in connection with our products and services. Accordingly, we have entered into collaboration agreements under which our collaborators have provided, and may in the future provide, funding and other resources for developing and potentially commercializing our products and services. In particular, we have entered into the Genentech Agreement, with the goal of accelerating the development and commercialization of T&#160;cell therapies for the treatment of a broad range of tumor types, and a strategic collaboration agreement with Microsoft (&#8220;Microsoft Agreement&#8221;), which provides us with access to Microsoft&#8217;s research and machine learning technologies that we are using to develop our TCR-Antigen Map. These collaborations may result in our incurring significant expenses in pursuit of potential products and services, and we may not be successful in identifying, developing or commercializing any potential products or services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success depends in part on our ability to maintain these relationships and to establish new relationships. Many factors may impact the success of such collaborations, including our ability to perform our obligations, our collaborators&#8217; satisfaction with our products and services, our collaborators&#8217; performance of their obligations to us, our collaborators&#8217; internal priorities, resource allocation decisions and competitive opportunities, the ability to obtain regulatory approvals, disagreements with collaborators, the costs required of either party to the collaboration and related financing needs, and operating, legal and other risks in any relevant jurisdiction. In addition to reducing our revenue or delaying the development of our future products and services, the loss of one or more of these relationships may reduce our exposure to research, data, clinical trials or computing technologies that facilitate the collection and incorporation of new information into our clinical immunomics database. All of the risks relating to product and service development, regulatory clearance, authorization or approval and commercialization described herein apply to us derivatively through the activities of our collaborators. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We engage in conversations with companies regarding potential collaborations on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, and any products and services developed as part of the collaboration may not produce successful outcomes. Speculation in the industry about our existing or potential collaborations can be a catalyst for adverse speculation about us, or our products or services, which can adversely affect our reputation and our business. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant additional research and development and, in certain instances, clinical trials or validation will be required before we can potentially seek regulatory clearance, authorization or approval for, or commercialize any of our products or services in development. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a pipeline of immune-driven diagnostics and therapeutics, including T-Detect (formerly immunoSEQ Dx) and cellular therapies in oncology, but significant additional research and development activities and clinical trials or validations could be required before we and our collaborators will have a chance to achieve additional commercially viable products. Our research and development efforts remain subject to all of the risks associated with the development of new products and services based on immune-driven diagnostics and immune-mediated therapies. Development of the underlying technology may be affected by unanticipated technical or other problems, among other research and development issues, and the possible insufficiency of funds needed to complete development of these products and services. Safety, regulatory and efficacy issues, clinical hurdles or other challenges may result in delays and cause us to incur additional expenses that would increase our losses. If we and our collaborators cannot complete, or if we experience significant delays in developing, our clinical diagnostics or cellular therapies, particularly after incurring significant expenditures, our business may fail and investors may lose the entirety of their investment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining regulatory clearances, authorizations or approvals for the commercial sale of any new products or services, we must demonstrate that our products and services are both safe and effective for use in each target disease indication. Clinical studies may be necessary to demonstrate that a product or service is safe and effective. Clinical testing or validation is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time. For therapeutics, the results of preclinical studies and early clinical trials of products and services in development may not be predictive of the results of later-stage clinical trials, and initial success in clinical trials may not be indicative of results obtained when clinical trials are completed. There is typically an extremely high rate of failure as therapeutic products in development proceed through clinical trials. Products in later stages of clinical trials or validation also may fail to show the desired safety and efficacy profile despite having progressed through non-clinical studies and initial clinical trials or validations. Any delays in the development of our products and services may harm our business, financial condition and prospects significantly. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Errors or defects in our products or services could harm our reputation, decrease market acceptance of our products or services or expose us to product liability claims. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are creating new products and services, many of which are initially based on largely untested technologies. As all of our products and services progress, we or others may determine that we made product or service level scientific or technological mistakes or omissions. The testing processes utilize a number of complex and sophisticated biochemical, informatics, optical and mechanical processes, many of which are highly sensitive to external factors and variation between testing runs. Refinements to our processes may initially result in unanticipated issues that reduce the efficiency or increase variability. In particular, sequencing, which is a key component of these processes, could be inefficient with higher than expected variability thereby increasing total sequencing costs and reducing the number of samples we can process in a given time period, which may negatively impact customer turnaround time. Therefore, inefficient or variable processes can cause variability in our operating results and damage our reputation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our laboratory operations could result in any number of errors or defects. Our quality assurance system or product development processes may fail to prevent us from inadvertent problems with samples, sample quality, lab processes including sequencing, software, data upload or analysis, raw materials, reagent manufacturing, assay quality or design, or other components or processes. In addition, our assays may have quality or design errors, and we may have inadequate procedures or instrumentation to process samples, assemble our proprietary primer mixes and commercial materials, upload and analyze data, or otherwise conduct our laboratory operations. If we provide products or services with undiscovered errors to our customers, our clinical diagnostics may falsely indicate a patient has a disease or fail to detect disease in a patient who requires treatment. We believe our customers are likely to be particularly sensitive to product and service defects, errors and delays, including if our products and services fail to indicate the presence of residual disease with high accuracy from clinical specimens or if we fail to list or inaccurately indicate the presence or absence of disease in our test report. In drug discovery, such errors may interfere with our collaborators&#8217; clinical studies or result in adverse safety or efficacy profiles for their products in development. This may harm our customers&#8217; businesses and may cause us to incur significant costs, divert the attention of key personnel, encourage regulatory enforcement action against us, create a significant customer relations problem for us and cause our reputation to suffer. We may also be subject to warranty and liability claims for damages related to errors or defects in our products or services. Any of these developments could harm our business and operating results. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our current and future products and services may never achieve significant commercial market acceptance. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends on the market&#8217;s confidence that we can provide immune-driven research, diagnostic and therapeutic products and services that improve clinical outcomes, lower healthcare costs and enable better biopharmaceutical development. Failure of our products and services, or those jointly developed with our collaborators, to perform as expected could significantly impair our operating results and our reputation. We believe patients, clinicians, academic institutions and biopharmaceutical companies are likely to be particularly sensitive to defects, errors, inaccuracies, delays and toxicities in or associated with our products and services. Furthermore, inadequate performance of these products or services may result in lower confidence in our immune medicine platform in general. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our collaborators may not succeed in achieving significant commercial market acceptance for our current or future products and services due to a number of factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to demonstrate the clinical utility of our immune medicine platform and related products and services and their potential advantages over existing life sciences research, clinical diagnostic and drug discovery technologies to academic institutions, biopharmaceutical companies and the medical community&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability, and that of our collaborators, to secure and maintain FDA and other regulatory clearance, authorization or approval for our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the agreement by third-party payors to reimburse our diagnostics, the scope and extent of which will affect patients&#8217; willingness or ability to pay for our diagnostics, even in markets that we expect to be primarily self-pay, and will likely heavily influence physicians&#8217; decisions to recommend our tests&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the rate of adoption of our immune medicine platform and related products and services by academic institutions, clinicians, key opinion leaders, advocacy groups and biopharmaceutical companies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of our investments in product innovation and commercial growth. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our customers and collaborators may decide to decrease or discontinue their use of our products and services due to changes in their research and development plans, failures in their clinical trials, financial constraints, the regulatory environment, negative publicity about our products and services, competing products or the reimbursement landscape, all of which are circumstances outside of our control. We may not be successful in addressing these or other factors that might affect the market acceptance of our products, services and technologies. Failure to achieve widespread market acceptance of our immune medicine platform and related products and services would materially harm our business, financial condition and results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely on a limited number of suppliers or, in many cases, single suppliers, for laboratory equipment and materials and may not be able to find replacements or immediately transition to alternative suppliers. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on a limited number of suppliers, or in many cases single suppliers, to provide certain sequencers and equipment that we use in our laboratory operations, as well as reagents and other laboratory materials for our products and services. An interruption in our laboratory operations, kit distribution or technology transfer could occur if we encounter delays, quality issues or other difficulties in securing these sequencers, equipment, reagents or other materials, and if we cannot then obtain an acceptable substitute. In addition, we would likely be required to incur significant costs and devote significant efforts to find new suppliers, acquire and qualify new equipment, validate new reagents and revalidate aspects of our existing assays, which may cause delays in our processing of samples or development and commercialization of products and services. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. Internal changes in processes or compositions of our reagents or other materials may also require validation efforts by us and supply of new materials from our suppliers which could impact timing of production and levels of inventory while such changes are being implemented. Further, as a result of the COVID-19 pandemic, the overall demand for supplies and equipment used in vaccine development and distribution or other public health or disease prevention initiatives, such as Hamilton tips and freezers, may continue to increase lead times for purchased supplies and equipment, thus potentially lowering our production capacity. Combined with lowered production capacity, any significantly increased demand for new products or services such as T-Detect may affect our ability to fulfill orders, resulting in a material adverse effect on volume or revenue.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, we have purchased and rely on the Illumina </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NextSeq</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> System. Illumina supplies us with reagents that have been designed for use solely with this sequencer and Illumina is the sole provider of maintenance and repair services for the Illumina </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NextSeq</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> System. We also license our laboratory information management software from Illumina and receive services from Illumina related to that software. We believe there are only a few other equipment manufacturers that are currently capable of supplying the equipment necessary for our laboratory operations, including sequencers and various associated reagents.&#160;The use of sequencers manufactured by a company other than Illumina would require us to alter our laboratory operations. Transitioning to and qualifying a new sequencer would be time-consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate the reagents of our immunoSEQ kits, immunoSEQ </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">services, T-</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Detect</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clonoSEQ diagnostic testing services, and could require us to obtain additional clearance, authorization, approval, accreditation, or licensure for the changes. We may not be able to secure and implement alternative sequencers, associated reagents and other materials without experiencing interruptions in our workflow. In the case of an alternative supplier to Illumina, any replacement sequencers and various associated reagents may not be available or may not meet our quality control and performance requirements for our laboratory operations. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment and reagents we require for our products and services, our business, financial condition, results of operations and reputation could be adversely affected. In addition, Illumina is not obligated to meet all of our requirements for reagent supply.&#160;In the event Illumina ceases or slows its production of, or is otherwise unwilling or unable to continue to supply the sequencer reagents necessary for and currently used in our business at or near current pricing, we may be required to purchase different reagents from Illumina or to purchase from a different reagent vendor under terms and conditions which could be less favorable to us. Any disruption in Illumina&#8217;s operations or the suppliers of our reagents</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, materials or other equipment</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> could impact our supply chain and laboratory operations of our immune medicine platform and our ability to conduct our business and generate revenue. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have limited experience in marketing and selling products and services, and if we are unable to expand our direct sales and marketing force or partner with collaborators in certain product areas and markets to adequately address our customers&#8217; needs, our business may be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience in marketing and selling our research and diagnostic products and services and no experience marketing and selling therapeutic products and services. Accordingly, we or our collaborators may not be able to market and sell our current or future products and services effectively enough to support our planned growth. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and diagnostic sales and marketing efforts are targeted at a large and diverse market with highly specialized segments, including department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors and research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. As a result, we believe it is necessary for our sales representatives to have relevant, specialized market experience. Our internal sales organization is currently small, and competition for experienced sales and marketing personnel is intense. We may not be able to attract and retain personnel or be able to build or adequately train an efficient and effective sales organization, which could negatively impact sales and market acceptance of our clinical diagnostics and limit our revenue growth and potential profitability. We have engaged distributors for our improved immunoSEQ RUO kit in Japan and the United States. We may not be able to engage a distribution partner in other countries on favorable terms, or at all. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We established a collaboration with Genentech for the research, development, marketing, promotion, distribution and sale of TCR-based cellular therapies for the treatment of cancer. Under the Genentech Agreement, Genentech has the sole right and authority to commercialize products developed under that agreement. It will be Genentech&#8217;s responsibility to locate, qualify and engage distribution partners, clinicians and local hospitals with industry experience and knowledge to effectively market and sell products developed under that agreement. Genentech may not be able to engage distribution partners, clinicians or hospitals on favorable terms, or at all. If Genentech&#8217;s sales and marketing efforts with respect to products developed under the Genentech Agreement are not successful, we may not achieve significant market acceptance for our drug discovery services and platform, which would materially and adversely impact our business operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we or our collaborators experience any of a number of possible unforeseen events in connection with clinical trials, our or their ability to conduct further clinical trials of, obtain regulatory clearance, authorization or approval of or commercialize future products and services or improvements to current products and services, could be delayed or prevented. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our or their ability to conduct further clinical trials or obtain regulatory clearance, authorization or approval of or commercialize future products and services or improvements to current products and services, including: </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Evolving Regulatory Requirements and Policies </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the area of &#8220;precision medicine&#8221; or &#8220;personalized medicine&#8221; and its regulation may be subject to ongoing changes in terms of regulatory requirements and governmental policies, in ways we cannot predict&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Trial Design </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities or ethical review boards, including IRBs, may not authorize commencement of a clinical trial or conduct a clinical trial at a prospective trial site&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">there may be delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or other regulatory authorities may disagree with a clinical trial design or a sponsor&#8217;s interpretation of data and may change the requirements for product clearance, authorization or approval even after they have reviewed and commented on the clinical trial design&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differences in trial design between early stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or other regulatory authorities may disagree about whether study endpoints are clinically meaningful&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number of patients, or amount of data, required for clinical trials, or improvements to current products, may be larger than anticipated, patient enrollment in these clinical trials may be slower than anticipated or patients may drop out of clinical trials at a higher rate than anticipated&#59; </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Testing </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes may be made to product candidates after commencing clinical trials, which may require that previously completed stages of clinical testing be repeated or delay later stages of testing, for example, we, or our collaborators, may pursue one or more different product development pathways for our T cell immunotherapies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trials may fail to satisfy the applicable regulatory requirements of the FDA or other regulatory authorities responsible for oversight of the conduct of clinical trials in other countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulators may elect to impose a clinical hold, or governing IRBs, data safety monitoring board or ethics committees may elect to suspend or terminate our clinical research or trials for various reasons, including non-compliance with regulatory requirements or a finding that the participants are being exposed to unacceptable risks to their health or the privacy of their health information being disclosed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of clinical trials of future products and services, or improvements to current products and services, may be greater than we anticipate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not have sufficient capacity in our laboratories, including the additional capacity we expect to come online as the result of the anticipated expansion of our corporate headquarters, to perform testing as requested or volumes requested or with the requested turnaround times necessary for clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the supply or quality of materials or data necessary to conduct clinical trials of future products and services, or improvements to current products and services, may be insufficient or inadequate&#59; </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Trial Outcomes </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the outcome of our collaborators&#8217; preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product candidates may be associated with negative or inconclusive results in clinical trials, and we or our collaborators may decide to deprioritize or abandon these product candidates, or regulatory authorities may require us to abandon them or impose onerous changes or requirements, which could lead to deprioritization or abandonment&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product candidates may have undesirable side effects which could lead to serious adverse events, or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us, our collaborators or their investigators, IRBs or ethics committees to suspend or terminate the trial of that product candidate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trials may suggest or demonstrate that products or services are not as efficacious or safe as other similar diagnostics or therapies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">preclinical and clinical data are often susceptible to varying interpretations and analyses, and our products and services in development may fail to obtain regulatory clearance, authorization or approval, even if they perform satisfactorily in preclinical studies and clinical trials. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays of this nature could also allow competitors to bring products to market before we or our collaborators do, potentially impairing our ability to successfully commercialize our products and services in development and harming our business and results of operations. Any delays in the development of our products and services or those jointly developed with our collaborators may significantly harm our business, financial condition and prospects. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory clearance, authorization or approval of products and services in development. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to develop and expand our workforce, commercial infrastructure and laboratory operations to support anticipated growth in demand for our products and services. We may encounter difficulties in managing this and in meeting fluctuations in this demand. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to expand our workforce, commercial infrastructure and laboratory operations to support anticipated growth in demand for our products and services. If we are unable to support fluctuations in the demand for our products and services, including ensuring that we have adequate capacity to meet increased demand as well as other customer requirements (such as turnaround time and service level), our business could suffer. As of December&#160;31, 2020, we had 622 full-time employees and we expect to increase the number of employees, including potential contingent employees as needed to address demand fluctuations, and the scope of our operations as we continue to develop our clinical diagnostic products and services. As we and our collaborators commercialize additional products and services, we will need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher service costs, declining service quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and services and could damage our reputation and the prospects for our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To manage our anticipated expansion, we must continue to implement and improve our managerial, operational and financial systems, continue to expand our facilities (including our corporate headquarters in Seattle, Washington and cellular lab in South San Francisco, California) and continue to recruit and train additional qualified personnel. Also, our management and operations teams may need to divert a disproportionate amount of their attention away from their&#160;day-to-day&#160;activities and devote a substantial amount of time to managing these development and improvement activities. Due to our limited resources and early stage of growth, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, operational mistakes, slower development of our products and services, missed or delayed milestone achievement, significant cost overruns, loss of business opportunities, loss of employees, inability to execute on hiring plans and reduced productivity among remaining employees. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, and our ability to develop and commercialize our products and services and compete effectively, will depend, in part, on our ability to effectively manage our future development and expansion. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business could be adversely affected by the effects of health epidemics, including the recent COVID&#8209;19 pandemic, in regions where we or third parties on which we rely have significant laboratory operations, manufacturing facilities, concentrations of clinical trial sites or other business operations. The COVID-19 pandemic could materially affect our operations, including at our headquarters in Seattle and at our offices in South San Francisco, each subject to COVID-19 related government restrictions, as well as the business or operations of our manufacturers, contract research organizations or other third parties with whom we conduct business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be adversely affected by global pandemics or health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and such pandemics or epidemics could cause significant disruption in the operations of third-party manufacturers, suppliers, general contractors and sub-contractors related to capital projects and CROs upon whom we rely. For example, in December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the United States and several European countries, and the World Health Organization has declared the outbreak a &#8220;pandemic.&#8221; In response to the pandemic, the U.S. government has imposed travel restrictions on travel between the United States, Europe and certain other countries. Further, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response. Most of our facilities and employees are based in Seattle, Washington at our corporate headquarters, where the state government has imposed &#8220;stay at home&#8221; restrictions designed to slow the spread of COVID-19, which have disrupted our normal operations. Similarly, San Mateo County, California had a &#8220;shelter-in-place&#8221; order with restrictions that have disrupted our normal operations in our South San Francisco office. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our laboratory operations, we intend to rely on the measures implemented </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the first half of 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to reduce the risk of exposure of COVID-19 to the employees who continue to work on site as part of government-defined essential services, including the implementation of work-from-home policies for certain employees, as well as the implementation of teams and zones to physically distance employees who remain on site. These policies may be modified as employees become vaccinated, causing additional operational disruption. We work with a variety of materials and samples from COVID-19 patients that could be hazardous to human health. We intend to continue to adhere to the safety measures implemented to reduce the risk of exposure to our on-site staff. In the event of COVID-19 exposure to our employees, it is possible that all or a portion of our operations could be materially disrupted.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effects of the stay at home orders or similar government orders and our work-from-home and teams and zones measures may negatively impact productivity, disrupt our business and delay our clinical programs and corporate expansion initiatives, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations regarding our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarantines, stay at home orders and similar government orders, or the perception that such orders, shutdowns or other restrictions on business operations could occur, whether related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing or supplier facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In addition, public health measures undertaken to combat the COVID-19 pandemic or vaccine development and distribution efforts may increase demand for equipment, such as freezers, or supplies, such as Hamilton tips, which we use in the ordinary course of our business. This increased demand has resulted in longer lead times for equipment purchases and may result in internal conservation of supplies, which may slow production. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global pandemic of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, clinical trials, corporate expansion plans and other initiatives, or the impacts to healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The COVID-19 pandemic could adversely impact portions of our business that rely on research and development activities or clinical trials and delay or disrupt our pipeline, which may adversely impact revenue.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which the COVID-19 pandemic may impact our business with respect to research and development and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, vaccine distribution, variants of the virus, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.&#160;As the COVID-19 pandemic continues to spread around the globe, we will likely experience disruptions that could severely impact our business with respect to research and development and clinical trials, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays or difficulties in enrolling patients or maintaining scheduled study visits in our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">diversion of healthcare resources away from the conduct of clinical trials related to our non-COVID-19 related products and services, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">limitations in employee resources that would otherwise be focused on the conduct of our business with respect to research and development or clinical trials, including due to illness of our employees or their families, an increase in childcare responsibilities for certain employees, the desire of our employees to avoid close contact or contact with large groups of people or as a result of the governmental imposition of stay at home orders or similar working restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays in clinical sites receiving the supplies and materials needed to conduct clinical trials&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">interruption in global shipping that may affect the transport of clinical trial materials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in local regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or discontinuing clinical trials altogether&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, regulatory milestones represent a substantial part of our business strategy and are a key component of development revenue.&#160;The disruptions set forth above may materially affect our ability to achieve regulatory milestones, resulting in delays in our clinical pipeline and a material adverse effect on revenues.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our efforts to discover and develop products and services related to COVID-19 may not be successful from either a platform extension or commercialization perspective.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are attempting to leverage our immune medicine platform to discover and develop potential antibody therapies and diagnostics for COVID-19. In December 2020, we launched an early access program for T-Detect COVID to confirm past SARS-CoV-2 infection, and we also developed a therapeutic antibody discovery process called TruAB from which neutralizing antibodies to SARS-CoV-2 have been produced. Our efforts in this area are early and continue to evolve and mature continuously as we augment our databases and pool of knowledge. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we believe quantifying virus-specific T cells may provide important research and diagnostic advantages because T cells appear earlier than antibodies and persist longer, the data upon which such belief is based is limited and our analyses are preliminary. As we continue to collect and analyze additional data, we may find that our initial hypotheses are not applicable to new variants of the SARS-CoV-2 virus or are not supported by a larger data set or further analysis. If our beliefs regarding the effectiveness of T-Detect COVID are incorrect, that could have a material adverse effect on the market for T-Detect COVID, our revenue, reputation, financial condition, and our stock price would be adversely impacted. Failure to obtain an EUA for a COVID-19 LDT can impair immunity under the PREP Act and could also make payor reimbursement for COVID-19 LDTs under the Family First Coronavirus Act unavailable.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our efforts to further develop and commercialize T-Detect COVID and neutralizing antibodies for COVID-19 involve a high degree of risk, and our efforts may fail for many reasons, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure of our products to be effective against new variants of COVID-19&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">lack of new patients infected by COVID-19 that require neutralizing antibody treatment due to increased availability of vaccines&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure of T-Detect COVID or TruAB to perform as expected, including defects and errors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure to obtain a suitable partner for neutralizing antibody therapeutics&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">lack of validation data, particularly as new variants of COVID-19 arise&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure to demonstrate the analytical accuracy or clinical utility of existing antibody therapies and diagnostic tests&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure to obtain the necessary regulatory approvals or clearances&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">commercial disruption caused by the development of competing products or services. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there can be no assurances as to the commercial success of either T-Detect COVID or other neutralizing antibody or diagnostic tests. Our investments in the discovery and development of products and services related to COVID-19 may not be accretive to our future financial results and if we determine that any product or service is unlikely to succeed, we may abandon them without any return on our investment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial condition and operating results have varied in the past and will continue to fluctuate from quarter-to-quarter and year-to-year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Annual Report on Form 10-K: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of upfront payments from our collaborators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability and that of our collaborators to develop and successfully commercialize our products and services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to achieve collaboration-based milestones on currently contemplated timelines, or at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">availability and extent of reimbursement by governmental and private payors for our products and services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability of our clinical sales teams to convert physicians from using incumbent products in the market to clonoSEQ and new diagnostic products and services we may develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to drive repeat usage of the clonoSEQ diagnostic test by physicians and get reimbursed for that repeat usage by commercial and government payors for monitoring of MRD&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the outcomes of research initiatives, clinical trials or other product development or approval processes conducted by us or our collaborators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of demand for our products and services, which may vary significantly or be unknown for our newest products and services, such as T-Detect or immunoSEQ T-MAP COVID&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our relationships, and any associated exclusivity terms, with collaborators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to manage our growth&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our contractual or other obligations to provide resources to fund our products and services and to provide resources to our collaborations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or failures in advancement of future products in clinical trials by us or our collaborators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">risks associated with the future international expansion of our business, including the potential to conduct clinical trials and commercialize our products and services in multiple international locations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability and that of our collaborators to consistently manufacture our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our dependence on, and the need to attract and retain, key management and other personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain, protect and enforce our intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain additional capital that may be necessary to expand our business&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to accurately report our financial results in a timely manner&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions such as power outages, strikes, acts of terrorism or natural disasters&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to use our net operating loss (&#8220;NOL&#8221;) carryforwards to offset future taxable income. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While as a general matter we intend to periodically report on the status of our development initiatives, including anticipated next steps, we may not provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosure of any such milestones related to any of our products and services that are managed by our collaborators. Any disclosure by us or our collaborators of data that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may decline as a result of unexpected clinical trial results in one or more of our products and services, including adverse safety events reported for any of our products or services. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have estimated the sizes of the markets for our current and future products and services, and these markets may be smaller than we estimate. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our estimates of the annual addressable markets for our current products and services and those under development are based on a number of internal and third-party estimates, including, without limitation, the number of patients who have developed one or more of a broad range of cancers, the number of individuals who are at a higher risk for developing one or more of a broad range of cancers, the number of individuals who have developed or are at a higher risk of developing certain autoimmune disorders, the number of individuals with certain infectious diseases we or our collaborators are able to treat through our products and services, <span style="Background-color:#FFFFFF;">the proportion of patients in each market whose needs can be addressed by our or our collaborators&#8217; products and services, </span>the number of potential tests utilized per treatment course per patient and the assumed prices at which we can sell our current and future products and services for markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual addressable market for our current or future products and services may prove to be incorrect. If the actual number of patients who would benefit from our products or services, the price at which we can sell future products and services or the annual addressable market for our products or services is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully commercialize our products and services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries, including the fields of life sciences research, clinical diagnostics and drug discovery are intense and highly competitive. These fields are characterized by rapidly advancing technologies and a strong emphasis on intellectual property. Given the breadth and promise of immune medicine, we face substantial competition from many different sources, including life sciences tools, diagnostics, pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions across various components of our platform and product and service offerings. Due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition to increase. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, in life sciences research, immunoSEQ faces competition from a number of companies, including Thermo Fisher Scientific Inc. and 10X Genomics, Inc., among others. In clinical diagnostics, our clonoSEQ MRD test faces competition from both conventional and next-generation flow cytometry performed either in-house by our target customers or by reference labs, as well as from labs and institutions advancing research-use-only MRD technologies for clinical applications. In drug discovery, clinical trials of immune medicines are being undertaken by a number of industry and academic players.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may have or obtain the knowledge necessary to generate and characterize similar data to our known data for the purpose of identifying and developing products or services that could compete with any of our products or services. Further, immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval and compliance, and sales and distribution than we do. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could be adversely affected if we do not develop our life sciences research, clinical diagnostic and drug discovery products and services, obtain required regulatory and other clearances, authorizations or approvals, obtain or enforce patents covering our discoveries and launch our products and services before our competitors. Moreover, our competitors may succeed in developing immunosequencing-based life sciences research, clinical diagnostics and drug discoveries that circumvent our technologies, products or services. Our competitors may succeed in developing and commercializing research or diagnostic products or services that are more accurate, more convenient to use or more cost-effective than our products or services or therapeutic products that prove to be safer, more effective, more convenient to administer or more cost-effective than any therapeutic products we may develop with our collaborators or that would render our technologies, products and services less competitive or obsolete. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known. For additional information regarding our competition, see the &#8220;<span style="font-style:italic;">Business&#8212;Competition</span>&#8221; section of this Annual Report on Form 10-K. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The life sciences industry is subject to rapid change, which could make our immune medicine platform and related products and services that we develop obsolete. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product and service introductions and enhancements and evolving industry standards, all of which could make our current and future products and services obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to life sciences research and the diagnosis and treatment of cancer, other diseases and autoimmune disorders. There have also been advances in technologies used to computationally analyze very large amounts of biologic information. If we do not update our products and services to reflect new scientific knowledge about immunosequencing, immunology, computational biology, software development, new disease diagnostics and therapies or the diseases we seek to treat, our products and services could become obsolete and sales of our current products and services and any future products and services we develop based on our immune medicine platform could decline or fail to grow as expected. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The loss of any member of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and salespeople could adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends on the skills, experience and performance of key members of our senior management team, including Chad Robins, our chief executive officer and co-founder, Dr.&#160;Harlan Robins, our chief scientific officer and co-founder, and Julie Rubinstein, our president. The individual and collective efforts of these employees will be important as we continue to develop products and services based on our immune medicine platform. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. Our executive officers have signed employment agreements with us, but their service is at-will and may end at any point in time. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development initiatives and laboratory operations depend on our ability to attract and retain highly skilled scientists, technicians and software engineers. We may not be able to attract or retain qualified scientists, technicians or software engineers in the future due to the competition for qualified personnel among life sciences and technology businesses, particularly near our headquarters located in Seattle, Washington and our laboratory facilities located in South San Francisco, California. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting, training and retention difficulties can limit our ability to support our research and development and commercialization efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory and commercialization strategy. Our consultants and advisors may provide services to other organizations and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current consultants or advisors might impede the achievement of our research, development, regulatory and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part-time workers. We may not be able to retain the services of such personnel which might result in delays in the operation of our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we lose the support of key thought leaders, it may be difficult to establish products and services enabled by our immune medicine platform as industry standards, which may limit our revenue growth and ability to achieve profitability. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established relationships with leading oncology, hematology, immunology, autoimmunity or inflammatory disease, transplantation and solid tumor thought leaders at premier academic and research institutions. If these key thought leaders determine that our immune medicine platform or our current or future products or services are not clinically effective, determine that alternative technologies are more effective or elect to use internally developed services, we could encounter significant difficulty validating our products or services, driving adoption or establishing our immune medicine platform as an industry standard, which would limit our revenue growth and our ability to achieve profitability. In addition, negative publications or reviews by clinicians, industry groups or other important stakeholders may negatively impact our revenue growth and ability to achieve profitability. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on our information technology systems and any failure of these systems could harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend on information technology and telecommunications systems, including third-party cloud computing infrastructure, operating systems and artificial intelligence platforms, for significant elements of our operations, including our laboratory information management system, clinical immunomics database, immunoSEQ Analyzer, TCR-Antigen Map, laboratory workflow tools, customer and collaborator reporting and related functions. We also depend on our proprietary workflow software to&#160;support new product and service launches and regulatory&#160;compliance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use complex software processes and pipelines to manage samples and evaluate sequencing result data. These are subject to initial design or ongoing modifications which may result in unanticipated issues that could cause variability in patient results, leading to service disruptions or errors, resulting in liability. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. In addition to these business systems, we have installed, and intend to extend, the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, test validation, sample tracking, quality control, customer service support, billing and reimbursement, research and development activities, scientific and medical curation and general administrative activities. In addition, our third-party billing and collections provider depends upon technology and telecommunications systems provided by outside vendors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts (such as ransomware) and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of these systems or those used by our collaborators or subcontractors could prevent us from conducting our comprehensive immunosequencing analysis, clinical diagnostics and drug discovery, preparing and providing reports to researchers, clinicians and our collaborators, billing payors, handling physician inquiries, conducting research and development activities and managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we and our collaborators currently market our products and services outside of the United States and may market future products and services outside of the United States, if cleared, authorized or approved, our business is subject to risks associated with doing business outside of the United States, including an increase in our expenses and diversion of our management&#8217;s attention from the development of future products and services. Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">multiple, conflicting and changing laws and regulations such as privacy, security and data use regulations, tax laws, export and import restrictions, economic sanctions and embargoes, employment laws, anticorruption laws, regulatory requirements, reimbursement or payor regimes and other governmental approvals, permits and licenses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure by us, our collaborators or our distributors to obtain regulatory clearance, authorization or approval for the use of our products and services in various countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additional potentially relevant third-party patent rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in staffing and managing foreign operations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in negotiating favorable reimbursement negotiations with governmental authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">logistics and regulations associated with shipping samples, including infrastructure conditions and transportation delays&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limits in our ability to penetrate international markets if we are not able to conduct our immunosequencing or clinical diagnostic services locally&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and services and exposure to foreign currency exchange rate fluctuations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the FCPA, its books and records provisions, or its anti-bribery provisions, or laws similar to the FCPA in other jurisdictions in which we may now or in the future operate, such as the United Kingdom&#8217;s Bribery Act of 2010&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">anti-bribery requirements of several member states in the European Union (&#8220;EU&#8221;) and other countries, such as the&#160;United Kingdom&#8217;s Bribery Act of 2010, that are constantly changing and require disclosure of information to which U.S. legal privilege may not extend. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may never obtain approval in the EU or in any other foreign country for any of our products or services and, even if we do, we or our collaborators may never be able to commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to eventually market any of our current or future products and services in any particular foreign jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding quality, safety, performance and efficacy. In addition, clinical trials or clinical investigations conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory clearance, authorization or approval in one country does not guarantee regulatory clearance, authorization or approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seeking foreign regulatory clearance, authorization or approval could result in difficulties and costs for us and our collaborators and require additional preclinical studies, clinical trials or clinical investigations which could be costly and time-consuming. Regulatory requirements and ethical approval obligations can vary widely from country to country and could delay or prevent the introduction of our products and services in those countries. The foreign regulatory clearance, authorization or approval process involves all of the risks and uncertainties associated with FDA clearance, authorization or approval. We currently sell our RUO kits outside of the United States and have completed a technology transfer process for research use to sites in France, Germany, Italy, the United Kingdom, Spain, and Australia, but have no experience in obtaining regulatory clearance, authorization or approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required regulatory clearances, authorizations or approvals in international markets, or if those approvals are delayed, our target market will be reduced and our ability to realize the full market potential of our products and services will be unrealized. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our laboratory facilities become damaged or inoperable or we are required to vacate our existing facilities, our ability to conduct our laboratory processes and analysis and pursue our research and development efforts may be jeopardized. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate laboratory facilities located in Seattle, Washington and South San Francisco, California, and are currently expanding our corporate headquarters in Seattle, Washington to enable us to expand our laboratory capacity and research and development footprint. Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure or terrorism, which may render it difficult or impossible for us to operate our immune medicine platform for some period of time. The inability to perform our laboratory processes or to reduce the backlog of sequences that could develop if our facilities are inoperable, for even a short period of time, or to replace or repair inventory such as reagents or customer samples may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our facilities and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace, and we may not be able to execute on our anticipated expansion, which may increase the backlog of sequences if our laboratory space is not expanded to meet our expected increased throughput. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify new facilities or license or transfer our proprietary technologies to a third party, particularly in light of licensure and accreditation requirements. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct our laboratory processes, we may be unable to negotiate commercially reasonable terms. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may need to raise additional capital to fund our existing operations, develop additional products and services, commercialize new products and services or expand our operations. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flow from operations, will be sufficient to meet our anticipated cash requirements over at least the next 12&#160;months. If our available cash and investment balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, including because of lower demand for our products and services as a result of risks described herein, we may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">increase our sales and marketing efforts to drive market adoption of our life sciences research, clinical diagnostics and therapeutics&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fund development efforts for our current and future products and services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expand our products and services into other disease indications and clinical applications&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acquire, license or invest in technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acquire or invest in complementary businesses or assets&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">finance capital expenditures, such as our corporate headquarters expansion, and general and administrative expenses. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our present and future funding requirements will depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to achieve revenue growth&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our rate of progress in establishing payor coverage and reimbursement arrangements with domestic and international commercial third-party payors and government payors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of our immunoSEQ research services and kits, and reimbursement for our clonoSEQ diagnostic test, our T-Detect early detection test and cellular therapies developed under the Genentech Agreement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our rate of progress in, and cost of research and development activities associated with, products and services in research and early development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effect of competing technological, product and market developments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs related to international expansion&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential cost of and delays in product development as a result of any regulatory oversight applicable to our products and services. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders could result. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products and services or grant licenses on terms that are not favorable to us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to use our NOL carryforwards and certain other tax attributes may be limited.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses since our inception and we may never achieve or sustain profitability. Generally, losses incurred will carry forward until such losses expire (for losses generated prior to January&#160;1, 2018) or are used to offset future taxable income, if any. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;), if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change in its equity ownership by certain shareholders over a three-year period, the corporation&#8217;s ability to use its pre-ownership change NOL carryforwards and other pre-ownership change tax attributes, such as research tax credits, to offset its post-ownership change income or taxes may be limited. Under the TCJA, which significantly reformed U.S. tax law, federal NOLs incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of annual taxable income. It is uncertain if and to what extent various states will conform to the TCJA. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. <span style="color:#231F20;">We have completed a Section 382 analysis for changes in ownership through December 31, 2018 and an analysis is ongoing for ownership changes through December 31, 2020. Based on these analyses, we do not expect to have any permanent limitations on the utilization of our federal NOLs.</span> We may experience ownership changes in the future as a result of shifts in our stock ownership, which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change NOL carryforwards to offset such taxable income will be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we attain profitability, we may be unable to use a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the TCJA reduced the corporate tax rate from a top marginal tax rate of 35% to a flat rate of 21%, limited the tax deduction for net business interest expense to 30% of adjusted taxable income, eliminated NOL carrybacks and modified or repealed many business deductions and credits, including reducing the business tax credit for certain clinical testing expenses incurred in the testing of&#160;certain drugs for rare diseases or conditions generally referred to as &#8220;orphan drugs.&#8221; The U.S. Department of the Treasury and the U.S. Internal Revenue Service (&#8220;IRS&#8221;) have already issued and are expected to continue to provide guidance on the implementation of the TCJA. We continue to examine the impact this tax reform legislation may have on our business and the operations of our collaborators. However, the effect of the TCJA on our business and the operations of our collaborators, whether adverse or favorable, is uncertain and may not become evident for some period of time. We urge investors to consult with their legal and tax advisors regarding the implications of the TCJA on an investment in our Company. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be adversely affected by violations of the FCPA and other worldwide anti-bribery laws. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we expand geographically, commercialize our products and services, and attempt to obtain required clearances, authorizations or approvals required to offer products and services for sale, we or our collaborators may be deemed to do business outside the United States, including because international customers may be able to order our products and services. As a result, we or our collaborators would be subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, our collaborators or any third-party distributors could be deemed to be our agents and we could be held responsible for their actions, including violations of the FCPA. Other U.S. companies in the life sciences industry have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with non-U.S. government officials. We may also become subject to similar anti-bribery laws in the jurisdictions in which we may operate, including the United Kingdom&#8217;s Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. These laws are complex and far-reaching in nature, and we may be required in the future to alter one or more of our practices to be in compliance with these laws. Accordingly, our expansion internationally will demand a high degree of vigilance, and any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, prospects, financial condition or results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could negatively affect our operating results, dilute our shareholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may pursue acquisitions of businesses and assets. We also may pursue joint ventures or investments that leverage our immune medicine platform and industry experience to expand our offerings or distribution. We have no experience forming joint ventures and limited experience investing in or acquiring other companies. We may not be able to find suitable joint ventures, investment or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate the acquired company successfully into our existing business, and we could assume unknown or contingent liabilities, including regulatory violations such as the FCPA or similar laws. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our financial condition, results of operations and cash flows. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a material negative effect on our results of operations and financial condition. We may not realize the anticipated benefits of any acquisition, technology license, collaboration or joint venture. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To finance any acquisitions or joint ventures, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our shareholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition or results of operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our results of operations could be adversely affected by general conditions in the global economy and financial markets. A severe or prolonged economic downturn, as result of a global pandemic or otherwise, could result in a variety of risks to our business, including weakened demand for our products and services and our ability to raise additional capital when needed on favorable terms, if at all. A weak or declining economy could strain our collaborators, possibly resulting in supply disruption, or cause delays in their payments to us. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, research and development programs, and business operations, as well as environmental damage resulting in costly&#160;cleanup&#160;and liabilities under applicable laws and regulations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. While our property insurance policy provides limited coverage in the event of contamination from hazardous and biological products and the resulting cleanup costs, we do not currently have any additional insurance coverage for legal liability for claims arising from the handling, storage or disposal of hazardous materials. Accordingly, in the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketing, sale and use of our products and services could lead to the filing of product or professional liability claims were someone to allege that our products or services identified inaccurate, incomplete or untimely information regarding the sequence or antigen specificities of TCRs, BCRs or antigens analyzed or the clonality characterized, or MRD or malignancy detected, or that our products or services otherwise failed to perform as designed or intended. We could also be potentially exposed to claims relating to therapeutic failures of products commercialized under our collaborations, such as a cellular therapy marketed by Genentech that is manufactured based on TCR-related sequences and data we provide. We may also be subject to liability for errors in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. Regardless of merit or eventual outcome, product liability and professional liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for any products, services or clinical solutions that we have developed or may develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">loss of revenue&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to patients or their families&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant time and costs to defend related litigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical trial participants&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to commercialize any products, services or clinical solutions that we have developed or may develop&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injury to our reputation and significant negative media attention. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause current collaborators to terminate existing agreements or potential collaborators to seek other companies, any of which could impact our results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or our collaborators may be adversely affected by natural or man-made disasters or other business interruptions, such as cybersecurity attacks, and our business continuity and disaster recovery plans, or those of our collaborators, may not adequately protect us from the effects of a serious disaster. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Natural and man-made disasters and other events beyond our control could severely disrupt our operations, or those of our collaborators, and have a material adverse impact on our business, results of operations, financial condition and prospects. If a natural disaster, power outage, cybersecurity attack or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our laboratory facilities or those of our collaborators, limited our or our collaborators&#8217; ability to access or use our respective digital information systems or that otherwise disrupted our respective operations, it may be difficult or, in certain cases, impossible for us or our collaborators to continue our respective businesses for a substantial period of time. The disaster recovery and business continuity plans we and our collaborators currently have in place are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. Our cybersecurity liability insurance may not cover any or all damages, depending on the severity and extent, we or our collaborators could sustain based on any breach of our respective computer security protocols or other cybersecurity attack. We may incur substantial expenses as a result of the limited nature of our respective disaster recovery and business continuity plans, which could have a material adverse impact on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Government Regulation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We conduct our business in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition and harm our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The life sciences industry is highly regulated, and the regulatory environment in which we and our collaborators operate may change significantly and adversely to us in the future. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation, federal and state laws relating to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laboratory testing, including CLIA and state laboratory licensing laws&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the development, testing, use, distribution, promotion and advertising of research services, kits, clinical diagnostics and cellular therapies, including certain LDTs, which are regulated by the FDA under the FDCA and the FTC&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">test ordering, documentation of tests ordered, billing practices and claims payment under CMS and the HHS OIG enforcing those laws and regulations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cellular therapies, medical device and</span><span style="font-style:italic;color:#000000;"> in vitro</span><span style="color:#000000;"> diagnostic clearance, marketing authorization or approval&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laboratory anti-mark-up laws&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the handling and disposal of medical and hazardous waste&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fraud and abuse laws such as the False Claims Act, the AKS, EKRA, and the Stark Law&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Occupational Safety and Health Administration rules and regulations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA and other federal and state medical data privacy and security laws&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Genetic Information Nondiscrimination Act (&#8220;GINA&#8221;) and similar state laws&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">coverage and restrictions on coverage and reimbursement for research services, kits, clinical diagnostics and cellular therapies and Medicare, Medicaid, other governmental payors and private insurers reimbursement levels. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, the laws, regulations and policies governing the marketing of RUO products, LDTs and clinical diagnostic tests and services are extremely complex and are subject to interpretation by the courts and governmental agencies. Our failure to comply could lead to civil or criminal penalties, exclusion from participation in state and federal health care programs, or prohibitions or restrictions on our laboratories&#8217; ability to provide or receive payment for our services.&#160;We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law.&#160;Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The insurance coverage and reimbursement status of newly approved products and services, in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future products and services could limit our ability, and that of our collaborators, to fully commercialize our products and services and decrease our ability to generate revenue. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford the clinical diagnostic tests and cellular therapeutics that we and our collaborators currently or plan to develop and sell. In addition, because our clinical diagnostics and therapeutic products and services represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our products and services, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of our products and services will depend substantially, both domestically and internationally, on the extent to which the costs of our products and services are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize some of our products or services. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment in any of our products or services. If we adopt a self-pay strategy with respect to any products or services, we may experience similar difficulties in the establishment or maintenance of sufficiently high pricing. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our products and services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly cleared, authorized or approved products and services. In the United States, many significant decisions about reimbursement for new diagnostics and medicines are typically made by CMS, an agency within the HHS. CMS decides whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products and services such as ours. Additionally, reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement, or have been approved under restricted conditions, in certain European countries. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, the reimbursement process and timelines vary significantly. Certain countries, including a number of member states of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products, or medicinal products, as they are commonly referred to in the EU, with limited participation from the marketing authorization or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conformit&#233;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europ&#233;ene</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (&#8220;CE&#8221;) mark holders, or may take decisions that are unfavorable to the authorization or CE mark holder where they have participated in the process. We cannot be sure that such prices and reimbursement decisions will be acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products and services in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a lesser extent, medical devices, provided under their state-run healthcare systems. These international price control efforts have impacted all regions of the world, but have been most prominent in the EU. Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of that product or service in that particular country. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized or approved devices and medicines and, as a result, they may not cover or provide adequate payment for our clinical diagnostics or the cellular therapies to be sold by us or our collaborators. For example, the U.S. government recently introduced the Lower Drug Costs Now Act of 2019 to reduce the cost of drugs. This blueprint contains certain measures that HHS is already working to implement. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological program pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other countries and bulk purchasing. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to experience pricing pressures on our clinical diagnostics and cellular therapies sold by us and our collaborators due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business could be harmed by the loss, suspension or other restriction on a license, certification or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal law requires virtually all clinical laboratories to comply with CLIA, which generally involves becoming certified by the federal and state government for the testing that will be performed and complying with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate and reliable. CLIA certification is also a prerequisite to be eligible to bill state and federal healthcare programs, as well as many private third-party payors, for laboratory research and clinical diagnostic testing services. As a condition of our CLIA certification, our Seattle, Washington laboratory is subject to survey and inspection every other year, additional random inspections and surprise inspections based on complaints received by state or federal regulators. The biennial survey and inspection is conducted by CMS, a CMS agent or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization, such as CAP. Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business, as well as the imposition of significant civil, administrative or criminal sanctions against the lab, its owners and other individuals. In addition, we are subject to regulation under certain state laws and regulations governing laboratory licensure. Some states, including Washington, have enacted laboratory licensure and compliance laws that are more stringent than CLIA. Changes in state licensure laws that affect our ability to offer and provide research and diagnostic products and services across state or foreign country lines could materially and adversely affect our business.&#160;In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any sanction imposed under CLIA, its implementing regulations or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in law relating to health insurance coverage and payment may adversely affect our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. clinical diagnostic and biopharmaceutical industries. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and medical devices, including laboratory kits, and promoted a new Medicare Part&#160;D coverage gap discount program. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the provisions of the ACA have been subject to judicial and Congressional challenges. It is also unclear how regulatory provisions and sub-regulatory guidance, both of which fluctuate continually, may affect interpretation and implementation of the ACA and its practical effects on our business. In addition, changes in the number of patients that can look to third-party payment to help afford our products and services may affect the demand for these products and services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase downward pressure on drug and device pricing. Such reforms could have an adverse effect on anticipated revenues from our products and services, including those that we jointly develop with our collaborators, and may affect our overall financial condition and ability to develop or obtain regulatory clearance, authorization or approval for our products and services. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and clear, authorize or approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory and policy changes. In addition, government funding of agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and devices to be reviewed and cleared, authorized or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged&#160;government shutdown&#160;occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We must maintain compliance with FDA requirements for our products and services and failure to maintain compliance with FDA requirements may prevent or delay the marketing of our products and services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after we have obtained marketing authorization, as we have for clonoSEQ, we must comply with the scope of that clearance, authorization or approval. Failure to comply with those limitations or the additional, extensive and ongoing post-marketing obligations imposed by the FDA or other regulatory requirements of other regulatory agencies could result in unanticipated compliance expenditures, a range of administrative enforcement actions, injunctions and criminal prosecution. FDA post-market obligations include, among other things, compliance with the FDA QSR, establishing registration and device listings, labeling requirements, reporting of certain adverse events and malfunctions, and reporting of certain recalls. In addition, circumstances may arise that cause us to recall equipment used in connection with our products and services. Such recalls could have an adverse effect on our ability to provide those products and services, which in turn would adversely affect our financial condition. Our collaborators will also be required to maintain FDA clearance, authorization or approval for the products and services that we jointly develop. Any failure by us or our collaborators to maintain such clearance, authorization or approval could impair or cause a delay in our ability to profit from these collaborations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Products and services offered RUO may be subject to regulatory scrutiny. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our products are currently labeled and sold for RUO and not for the diagnosis or treatment of disease. Because such products are not intended for diagnostic use, and the products do not include clinical or diagnostic claims or provide directions for use as diagnostic products, they are not subject to the same level of regulation by the FDA as medical devices. In particular, while the FDA regulations require that RUO products be appropriately labeled, &#8220;For Research Use Only,&#8221; the regulations do not subject such products to the FDA&#8217;s pre- and post-market controls for medical devices. Pursuant to FDA guidance on RUO products, a company may not make clinical or diagnostic claims about an RUO product or provide clinical directions or clinical support services to customers of RUO products. A product labeled RUO but deemed by the FDA to be intended for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the FDCA and subject to FDA enforcement action. The FDA considers the totality of the circumstances surrounding distribution and use of a product labeled as RUO, including how the product is marketed and to whom, when determining its intended use. If the FDA were to disagree with our RUO classification or modify its approach to regulating products labeled for RUO, we could experience reduced revenue or increased compliance and other costs, which could adversely affect our business, prospects, results of operations and financial condition. In the event that the FDA requires marketing authorization of our RUO products in the future, the FDA may not ultimately grant any clearance, authorization or approval requested by us in a timely manner, or at all. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future changes in FDA enforcement discretion for LDTs could subject our operations to much more significant regulatory requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to offering the cleared version of clonoSEQ as a test for MRD in certain blood cancers, we also currently offer an LDT version of this test. Further, we offer our T-Detect COVID test as an LDT. The FDA has a policy of enforcement discretion with respect to LDTs whereby the FDA does not actively enforce its medical device regulatory requirements for such tests. However, in October 2014, the FDA issued two draft guidance documents stating that the FDA intended to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the existing classification of medical devices. Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give Congressional authorizing committees the opportunity to develop a legislative solution, it is unclear if Congress or the FDA will modify the current approach to the regulation of LDTs in a way that would subject our current or future services marketed as LDTs to the enforcement of FDA regulatory requirements. The FDA Commissioner and the Director of the Center for Devices and Radiological Health (&#8220;CDRH&#8221;) have expressed significant concerns regarding disparities between some LDTs and<span style="font-style:italic;"> in vitro</span> diagnostics that have been reviewed, cleared, authorized or approved by the FDA. If the FDA were to determine that T-Detect COVID and NGS MRD tests offered as LDTs are not within the policy for LDTs for any reason, including new rules, policies or guidance, or due to changes in statute, our tests may become subject to extensive FDA requirements or our business may otherwise be adversely affected. If the FDA were to disagree with our LDT status or modify its approach to regulating LDTs, we could experience reduced revenue or increased costs, which could adversely affect our business, prospects, results of operations and financial condition. If required, the regulatory marketing authorization process required to bring our current or future LDTs into compliance may involve, among other things, successfully completing additional clinical validations and submitting to and obtaining clearance from the FDA for a premarket clearance (510(k)) submission or authorization for a<span style="font-style:italic;"> de novo</span> or approval of a PMA. Furthermore, recently introduced legislation, if passed, such as the VALID Act, could create new or different regulatory and compliance burdens on us and could have a negative effect on our ability to develop new products, which could have a material effect on our business. In the event that the FDA requires marketing authorization of our LDTs in the future, the FDA may not ultimately grant any clearance, authorization or approval requested by us in a timely manner, or at all. In addition, if the FDA inspects our laboratory in relation to the marketing of our FDA-cleared clonoSEQ test, any enforcement action the FDA takes might not be limited to the FDA-cleared clonoSEQ test and could encompass our LDT testing service. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">For each product and service we are developing that requires FDA premarket review, the FDA may not grant clearance, authorization or premarket approval and failure to obtain necessary approvals for our future products and services would adversely affect our ability to grow our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we begin to manufacture, label and market additional clinical diagnostic products for commercial diagnostic use in the United States, we may be required to obtain either clearance, marketing authorization or approval from the FDA, unless an exemption applies or the FDA exercises its enforcement discretion and refrains from enforcing its requirements. For example, the FDA currently has a policy of refraining from enforcing its medical device requirements with respect to LDTs, which the FDA considers to be a type of<span style="font-style:italic;"> in vitro</span> diagnostic test that is designed, manufactured and used within a single properly licensed laboratory. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining PMA is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. Conversely, in the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally marketed &#8220;predicate&#8221; device in order for the product to be cleared for marketing. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics or if it has different technological characteristics as the predicate device, the proposed device must be as safe and effective as, and not raise different questions of safety or effectiveness than, the predicate device. Clinical data is sometimes required to support substantial equivalence. For lower-risk devices that would otherwise automatically be placed into Class&#160;III, which require a PMA because no predicate device is available and the devices do not fall within an existing 510(k)-exempt classification, an applicant may submit a</span><span style="font-style:italic;"> de novo</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> request to down classify the device into Class&#160;II or Class&#160;I, which would not require a PMA. In the</span><span style="font-style:italic;"> de novo</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> process, the FDA must determine that general and special controls are sufficient to provide reasonable assurance of the safety and effectiveness of a device, which is low to moderate risk and has no predicate. In other words, the applicant must justify the &#8220;down-classification&#8221; to Class&#160;I or II for a new product type that would otherwise automatically be placed into Class&#160;III, but is lower risk. Clinical data may be required. For laboratory tests for which FDA clearance, authorization or approval is required, the FDA may also require data to support analytical and clinical validity. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 510(k),<span style="font-style:italic;"> de novo</span> and PMA processes can be expensive and lengthy and require the payment of significant fees, unless an exemption applies. The FDA&#8217;s 510(k) clearance pathway usually takes from three to nine months from submission, but it can take longer for a novel type of product. The FDA&#8217;s<span style="font-style:italic;"> de novo</span> classification pathway usually takes from six to 12 months, but for many applicants can take up to 18 months or more. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory clearances, authorizations or approvals would have a material adverse effect on our business, financial condition and prospects. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA can delay, limit or deny clearance, authorization or approval of a device for many reasons, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to demonstrate to the satisfaction of the FDA that the products are safe or effective for their intended uses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the disagreement of the FDA with the design, conduct or implementation of the clinical trials or the analysis or interpretation of data from preclinical studies, analytical studies or clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">serious and unexpected adverse device effects experienced by participants in clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the data from preclinical studies, analytical studies and clinical trials may be insufficient to support clearance, authorization or approval, where required&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to demonstrate that the clinical and other benefits of the device outweigh the risks&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an advisory committee, if convened by the FDA, may recommend against approval of a PMA or other application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee makes a favorable recommendation, the FDA may still not approve the product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA may identify deficiencies in our marketing application&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA may identify deficiencies in our or our collaborators&#8217; manufacturing processes, facilities or analytical methods&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential for policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering clinical data or regulatory filings insufficient for clearance, authorization or approval&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or foreign regulatory authorities may audit clinical trial data and conclude that the data is not sufficiently reliable to support a PMA. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are numerous FDA personnel assigned to review different aspects of marketing submissions, which can present uncertainties based on their ability to exercise judgment and discretion during the review process. During the course of review, the FDA may request or require additional data and information, and the development and provision of these data and information may be time-consuming and expensive. The process of obtaining regulatory clearances, authorizations or approvals to market a medical device can be costly and time-consuming, and we may not be able to obtain these clearances, authorizations or approvals on a timely basis, or at all for our products in development. If we are unable to obtain clearance, authorization or approval for any products for which we plan to seek clearance, authorization or approval, our business may be harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Modifications to our products with FDA clearance may require new FDA clearances, authorizations or approvals, or may require us to cease marketing or recall the modified clinical diagnostic products or future clinical products until clearances are obtained. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any modification to a 510(k)-cleared device that significantly affects its safety or effectiveness, or that constitutes a major change in its intended use, could require a new 510(k) clearance, a new<span style="font-style:italic;"> de novo</span> authorization or approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether new clearances, authorizations or approvals are necessary. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For any product approved pursuant to a PMA, we would be required to seek supplemental approval for many types of modifications to the approved product. The FDA requires manufacturers in the first instance to determine whether a PMA supplement or other regulatory filing is needed or whether the change may be reported via the PMA Annual Report, but may disagree with a company&#8217;s assessment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA disagrees with our determination, which it may not review until we submit an annual report or the FDA conducts an inspection or other inquiry, and requires us to seek new clearances, authorizations or approvals for modifications to our previously cleared, authorized or approved clinical diagnostic products for which we have concluded new clearances, authorizations or approvals are unnecessary, we may be required to cease marketing or distribution of these clinical diagnostic products or to recall the modified products until we obtain clearance, authorization or approval. We may also be subject to enforcement action, including, among other things, significant regulatory fines or penalties. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and collaborators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, consultants and those of our collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent improper marketing, fraud, misconduct, kickbacks, bribery, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct. In addition, our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such investigations or actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, which could have a significant impact on our business. We currently have a compliance program in accordance with the elements of an effective program outlined by the OIG, which could help mitigate damages, but cannot prevent all misconduct. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, suffer adverse publicity and reputational harm, and have the attention of management diverted in defending ourselves against any of these claims or investigations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If third-party payors, including private payors and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our clinical diagnostic products, our commercial success will be negatively affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue depends in part on achieving broad coverage and reimbursement for our diagnostic tests from payors, including both private and government payors. Certain large private payors have issued policies that decline to cover testing methods that they regard as experimental or investigational. Other payors may issue similar non-coverage policies. If payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the price of our diagnostic tests, we may need to seek payment from the patient where this is not precluded by law or contract, which may adversely affect demand for our tests. Coverage determinations by a payor may depend on a number of factors, including, but not limited to, a payor&#8217;s determination that a certain diagnostic test is appropriate, medically necessary or cost-effective. If we are unable to provide payors with sufficient evidence of the clinical utility and validity of our diagnostic tests, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. To the extent that more competitors enter our markets, the availability of coverage and the reimbursement rate for our tests and new diagnostic products may decrease as we encounter pricing pressure from our competitors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each payor makes its own decision regarding coverage of our tests and the applicable payment rates, and payors may not provide adequate coverage or reimbursement for our current or future products. Although we may contract with certain payors, working with payors through contract or otherwise to assure reimbursement is time-consuming and costly and outcomes are uncertain. In addition, the determinations by a payor whether to cover our clinical diagnostic product and the amount it will reimburse for them are often made on an indication-by-indication basis. In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the test, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection. Through our Adaptive Assist patient support program, we provide clonoSEQ diagnostic tests for reduced rates or without charge to eligible low-income patients that may result in payors requiring us to provide evidence of eligibility of such patients to pay reduced out-of-pocket amounts. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our claims for reimbursement from payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming, expensive and may not result in payment. Payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the payors believe the funds were paid in error or determine that our clonoSEQ diagnostic tests or other clinical diagnostic products were medically unnecessary. In addition, similar to federal payors, state and federal laws permit commercial payors to seek civil and criminal penalties against a manufacturer if they feel they have been defrauded. If a payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial payors for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was too much. In these situations, the payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We do not have a mechanism to dispute these retroactive adjustments and we cannot predict when, or how often, a payor might engage in these reviews. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future Medicare payment rates are uncertain.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, CMS revised the National Coverage Determination (&#8220;NCD&#8221;) for molecular diagnostic laboratory testing services utilizing a NGS methodology, which includes our clinical diagnostic products, for Medicare beneficiaries with advanced cancer. CMS revised the NCD to extend specific coverage for germline (inherited) testing. CMS stated that it is continuing to make other technical, clarifying and conforming changes in the NCD manual and they are also clarifying the existing policy related to diagnostic tests for Somatic (Acquired) Cancer. If CMS were to make material revisions to policy, this could potentially impact the scope of clonoSEQ coverage. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Medicare Part B, payment for most diagnostic laboratory tests is made under the Clinical Laboratory Fee Schedule (&#8220;CLFS&#8221;), which assigns payment amounts to tests based on billing codes. Under the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), certain laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or Medicare&#8217;s Physician Fee Schedule are required to report to CMS every three years, or annually for &#8220;advanced diagnostic laboratory tests,&#8221; commercial payor payment rates and volumes for tests they perform and that are assigned specific billing codes. PAMA has special provisions relating to &#8220;advanced diagnostic laboratory tests,&#8221; as defined by the statute, and these provisions affect the rate-setting at the time of launch and the periodicity of rate reporting and revision. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. If, in the future, clonoSEQ or any of our tests are assigned a specific code we would be required to report commercial payor payment data on those tests. Payments for tests billed under miscellaneous codes are determined by the MACs, which also have discretion to change those payment rates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMS uses the data reported by laboratories to calculate a payment rate for each CLFS test, other than those coded with miscellaneous codes and certain others, based on the volume-weighted median of the private payor rates. These rates apply for three years, except that payment rates for advanced diagnostic laboratory tests apply for one year. If we offer tests with specific codes, this apparatus would apply. Under these circumstances, Medicare&#8217;s payment rates would be determined by the rates we and other laboratories, if any, with tests that share the specific codes we use, obtain from commercial payors. In that case, if we are unable to obtain and maintain adequate reimbursement rates from commercial payors, this may adversely affect our Medicare rates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some circumstances, our tests may be furnished to hospital inpatients and paid by Medicare under different rules. For example, when a specimen is obtained from a patient who is at the time classified by Medicare as a hospital inpatient, Medicare would not make a separate payment for the test and we would have to look to the hospital for payment. We do not know how often this will occur or whether hospitals will resist paying us for our tests. In this situation, Medicare coverage would be determined by the MAC for the jurisdiction where the hospital is located, which may not cover our tests. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our RUO, clinical diagnostic and therapeutic products or services, and those jointly developed with our collaborators, may in the future be subject to product or service recalls. A recall of products or services, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our or our collaborators&#8217; products or services, could have a significant adverse impact on us. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has the authority to require the recall of commercialized products or services that are subject to FDA regulation. Manufacturers may, under their own initiative, recall a product or service if any deficiency is found. The FDA requires that certain corrections and removals, including recalls intended to reduce a health risk, be reported to the FDA within ten working days of initiating such correction or removal. For reportable corrections and removals, companies are required to make additional periodic submissions to the FDA after initiating the recall, and often engage with the FDA on their recall strategy prior to initiating the recall. A government-mandated or voluntary recall by us, one of our distributors or our collaborators could occur as a result of an unacceptable health risk, component failures, failures in laboratory processes, malfunctions, manufacturing errors, design or labeling defects, or other deficiencies and issues. Recalls of any of our commercialized products or services or those jointly developed with our collaborators would divert managerial and financial resources and adversely affect our reputation, results of operations and financial condition. We may also be subject to liability claims, be required to bear other costs or take other actions that may negatively impact our future sales and our ability to generate profits. Companies are also required to maintain certain records of corrections and removals, even if these do not require reporting to the FDA. We or our collaborators may initiate voluntary recalls involving our commercialized products or services in the future that we determine do not require FDA notification. If the FDA disagrees with our determinations, they may require us to report those actions as recalls. A future recall announcement by us or our collaborators could harm our reputation with customers and negatively affect our results of operations and financial condition. In addition, the FDA or other agency could take enforcement action for failing to report the recalls when they were conducted. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators initiate a recall, including a correction or removal, for one of our commercialized products or services, issue a safety alert, or undertake a field action or recall to reduce a health risk, this could lead to increased scrutiny by the FDA, other governmental and regulatory enforcement bodies, and our or our collaborators&#8217; customers regarding the quality and safety of our products and services, and to negative publicity, including FDA alerts, press releases, or administrative or judicial actions. Furthermore, the submission of these reports could be used against us by competitors and cause customers to delay purchase decisions or cancel orders, which would harm our reputation. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any additional commercialized products and services or any future products and services that obtain regulatory clearance, authorization, approval, accreditation or licensure will remain subject to regulatory scrutiny and our failure to maintain our regulatory clearances, authorizations, approvals, accreditations or licensures could adversely affect our reputation, business and results of operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we or our collaborators obtain regulatory clearance, authorization, approval, accreditation or licensure in a jurisdiction for our products and services, the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our products and services, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance of our or our collaborators&#8217; manufacturing and distribution. Advertising for certain devices and labeling, including promotional labeling, for all devices must comply with FDA requirements. In addition, device advertising and promotion may also be subject to other federal and state laws. For example, the FDA shares jurisdiction over the regulation of device advertising with the FTC. Advertising for devices characterized as restricted by the FDA is subject to specified FDA requirements, while advertising for non-restricted devices is regulated by the FTC. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators fail to comply with applicable regulatory requirements following clearance, authorization, approval, accreditation or licensure of any of our products and services, a regulatory agency may: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">initiate an inspection of our or our collaborators&#8217; facilities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issue an untitled or warning letter asserting that we or our collaborators are in violation of law&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek an injunction or impose civil or criminal penalties or monetary fines&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspend or withdraw regulatory clearance, authorization or approval, or revoke a license or accreditation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspend any ongoing clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay or refuse clearance, authorization or approval of a pending regulatory submission or supplement submitted by us or our collaborators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impose restrictions on our or our collaborators&#8217; cleared, authorized, approved, accredited or licensed products or services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seize or recall the product or service&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">partially suspend or entirely shut down our or our collaborators&#8217; manufacturing or laboratory operations&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issue advisories or other field actions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impose operating restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refuse to allow us or our collaborators to enter into supply contracts, including government contracts&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refer matters to the DOJ or other enforcement or regulatory bodies. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our and our collaborators&#8217; ability to commercialize any cleared, authorized or approved products and services and generate revenues. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If any of our diagnostic products or services cause or contribute to a death or serious injury, or malfunction in certain ways, we will be required to report such death, serious injury or malfunction under applicable medical device reporting regulations, and such events can result in voluntary corrective actions or agency enforcement actions. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or one of our similar devices were to recur. If such a death, serious injury or malfunction were to occur, and we or our collaborators are unable to demonstrate that the adverse events were caused by factors other than our or our collaborator&#8217;s products and services, regulatory authorities could order us to cease further development of, or deny clearance, authorization or approval of, any of our or our collaborators&#8217; products and services for any or all targeted indications. Even if we and our collaborators are able to demonstrate that any serious adverse events are not related to our products and services, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial of any product in development, the commercial prospects of such product in development may be harmed and our ability to generate product revenues may be delayed or eliminated. Any of these occurrences may harm our and our collaborators&#8217; ability to identify and develop future products and services, and may significantly harm our business, financial condition, result of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to various laws and regulations, such as healthcare fraud and abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians, hospitals and third-party payors often play a primary role in the recommendation and prescription of any currently marketed products and services for which we may obtain clearance, authorization or approval. Our current and future arrangements with healthcare providers, physicians, hospitals and third-party payors, and our sales, marketing and educational activities related to our products and services, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations at the federal and state level that may constrain our business or financial arrangements, and the relationships through which we market, sell and distribute our products and services. In addition, our operations are also subject to various federal and state fraud and abuse, physician payment transparency, and privacy and security laws, including, without limitation: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The AKS, which prohibits, among other things, persons and entities, including clinical laboratories, from knowingly and willfully soliciting, receiving, offering or paying remuneration, whether directly or indirectly, overtly or covertly, in case or in kind, to induce or reward or in return for either the referral of an individual or the purchase, lease, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program such as Medicare or Medicaid. The AKS has been interpreted broadly to apply to, among other things, arrangements between clinical laboratories and prescribers and purchasers of our tests. The term &#8220;remuneration&#8221; expressly includes kickbacks, bribes or rebates and has been broadly interpreted to include anything of value, including gifts, discounts, waivers of payment, ownership interests and any goods or services provided at less than their fair market value. We are also subject to the Beneficiary Inducement Statute set forth in the civil monetary penalty provisions of the AKS. There are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, these exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct</span><span style="font-style:italic;color:#000000;"> per se</span><span style="color:#000000;"> illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of the facts and circumstances to determine whether one purpose of the remuneration in the arrangement was to induce referrals or generate business that is payable by a federal healthcare program. A violation of the AKS may be grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the False Claims Act. Moreover, certain AKS safe harbors currently protecting rebates paid by device manufacturers to third parties and other arrangements between device manufacturers and third parties may later be modified or repealed pursuant to a pending regulatory proposal, which could require us to revisit or modify our business practices. Our practices may not meet all of the criteria for safe harbor protection from AKS liability in all cases. A person or entity does not need to have actual knowledge of the AKS or specific intent to violate any AKS provisions to have committed a violation. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Section&#160;8122 of the SUPPORT Act, EKRA, which establishes an all-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories and clinical treatment facilities. EKRA includes a number of statutory exceptions, and directs agencies to develop further exceptions. Current EKRA exceptions in some cases reference, and in others differ from, the AKS safe harbors. Significantly, the EKRA prohibitions apply to the soliciting or receipt of remuneration for any referrals to recovery homes, clinical treatment facilities or clinical laboratories, whether or not related to the treatment of substance use disorders. Further, the EKRA prohibitions cover the payment or offer of remuneration to induce a referral to, or in exchange for, an individual using the services of such providers. EKRA creates additional risk that relationships with referral sources could be problematic. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment to, or approval by, the federal government that are false, fictitious or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. The False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. In addition, AKS violations implicate the False Claims Act. Conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">The Criminal Health Care Fraud Statute, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the AKS, a person or entity does not need to have actual knowledge or specific intent to violate </span><span style="color:#000000;">the Criminal Health Care Fraud Statute</span><span style="color:#000000;">. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The Stark Law, which is directed at &#8220;self-referral,&#8221; prohibits, with certain exceptions, referrals for certain DHS, including laboratory services, that are covered by Medicare and Medicaid by physicians who personally, or through a family member, have an investment or ownership interest in, or a compensation arrangement with, an entity performing the tests. The prohibition also extends to payment for any testing referred in violation of the Stark Law. Because the Stark Law is a strict liability statute, proof of specific intent to violate the law is not a required element of a violation. Any person who engages in a scheme to circumvent the Stark Law&#8217;s referral prohibition may be fined up to $100,000 for each such arrangement or scheme. In addition, any person who presents or causes to be presented a claim to Medicare or Medicaid in violation of the Stark Law is subject to civil monetary penalties of up to $15,000 per bill submission, an assessment of up to three times the amount claimed and possible exclusion from participation in federal governmental payor programs, and those claims are considered false claims for which the parties to the arrangement may be liable under the False Claims Act. Bills submitted in violation of the Stark Law may not be paid by Medicare or Medicaid, and any person collecting any amounts with respect to any such prohibited bill is obligated to refund such amounts. Many states have comparable laws that are not limited to Medicare and Medicaid referrals. The Stark Law also places an annual cap, currently at $429 for 2021, on the amount of non-monetary compensation, which consists of meal spend and educational items, that a company can spend on a physician in the aggregate. This annual cap requires careful tracking and coordination and if it is exceeded, as long as the amount exceeded is less than 50% of the total annual cap and is recouped from the physician within 180 calendar days or before the end of the calendar year, it is not a violation. This &#8220;return&#8221; option may only be used once every three years with respect to the same referring physician. We occasionally enter into financial relationships, usually compensation relationships, such as a consulting arrangement, with physicians who refer patients for testing. If these arrangements do not meet the Stark Law&#8217;s requirements, any claims submitted to Medicare or Medicaid could violate the law and put both the physician referral source and us at risk. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The administrative simplification provisions of HIPAA, as amended and supplemented by HITECH, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of protected health information (&#8220;PHI&#8221;) held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and their respective business associates. Among other things, HITECH made certain aspects of HIPAA&#8217;s rules, notably the &#8220;HIPAA Security Rule,&#8221; directly applicable to business associates, independent contractors or agents of covered entities that create, receive, maintain or transmit PHI in connection with providing a function on behalf of, or a service to, a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA regulation and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. The HHS Office for Civil Rights (&#8220;OCR&#8221;) has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. The OCR has recently increased both its efforts to audit HIPAA compliance and its level of enforcement, with one recent penalty exceeding $16&#160;million. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">GINA, which restricts employers and health insurance companies from requiring or using the results of genetic tests in specific contexts and does not provide a private right of action. A number of states have also adopted laws regarding genetic tests, some aligned with GINA and some with broader applicability, including granting broader rights to individuals. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The Physician Payments Sunshine Act created under the ACA, and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, with certain exceptions, to annually report to HHS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The Physician Payments Sunshine Act has been extended to payments and transfers of value to physician assistants, nurse practitioners and other mid-level healthcare providers, with reporting requirements going into effect in 2022 for payments and transfers of value made to these practitioners in 2021. In addition, certain state and local laws may impose additional transparency and healthcare compliance requirements on medical device manufacturers, as well as certain restrictions or limits on interactions with healthcare professionals. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">The FTCA, which the FTC interprets to require taking appropriate steps to secure consumers&#8217; personal information and considers the failures to do so to constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a) of the FTCA. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards, and the FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is consistent with what is required by the HIPAA Security Rule. Some states, most notably Massachusetts and Nevada, also have adopted laws requiring the implementation of security measures to protect personal information, and all 50 states and the District of Columbia, Puerto Rico and Guam, have adopted breach notification laws. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Analogous state laws and regulations, such as state anti-kickback, self-referral and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and in some cases even in self-pay scenarios. In addition, some state laws require life sciences companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to impose transparency requirements or restrictions on marketing activities. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Various state, federal and foreign laws and regulations govern our ability to communicate, prospect, advertise and market our products and services through email, phone, text messages, facsimile and online methods. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the exceptions and safe harbors available under them, it is possible that certain of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of the ongoing interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that business arrangements with third parties comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert management&#8217;s attention from our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private<span style="font-style:italic;"> qui tam</span> actions brought by individual whistleblowers in the name of the government and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our collection, use and disclosure of personal information, including health and employee information, is subject to state, federal and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The privacy and security of personal information stored, maintained, received or transmitted, including electronically, is a major issue in the United States and abroad. While we strive to comply with all applicable privacy and security laws and regulations, including, in our case, our own posted privacy policies, legal standards for privacy, including but not limited to &#8220;unfairness&#8221; and &#8220;deception,&#8221; as enforced by the FTC and state attorneys general, these laws and regulations continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause us to lose customers, which could have a material adverse effect on our business. Recently, there has been an increase in public awareness of privacy issues in the wake of revelations about the data-collection activities of various government agencies and in the number of private privacy-related lawsuits filed against companies (including a new private right of action under the CCPA as described below). Concerns about our practices with regard to the collection, use, retention, disclosure or security of personal information or other privacy-related matters, even if unfounded and even if we are in compliance with applicable laws, could damage our reputation and harm our business. Additionally, we receive personal information, including PHI from third parties, and if such third parties breach their representations to us regarding their compliance with applicable privacy and security laws, we could be exposed to proceedings or actions by government agencies or others. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous foreign, federal and state laws and regulations govern the collection, dissemination, use and confidentiality of personal information, including genetic, biometric and health information, including state privacy, data security and breach notification laws, federal and state consumer protection and employment laws, HIPAA, GINA, the GDPR and other foreign data protection laws. These laws and regulations are increasing in complexity and number, may change frequently and sometimes conflict. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The HIPAA privacy, security and breach notification regulations, including the expanded requirements under HITECH, establish comprehensive federal standards with respect to the uses and disclosures of PHI by health plans, healthcare providers, including laboratories, and healthcare clearinghouses, in addition to setting standards to protect the confidentiality, integrity and security of PHI. The regulations establish a complex regulatory framework on a variety of subjects, including: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the circumstances under which uses and disclosures of PHI are permitted or required without a specific authorization by the patient&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a patient&#8217;s rights to access, amend and receive an accounting of certain disclosures of PHI&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">requirements to notify individuals if there is a breach of their unsecured PHI&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the contents of notices that must be provided to patients regarding our privacy practices for PHI&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">administrative, technical and physical safeguards required of entities that use or receive PHI&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the safeguarding of PHI. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penalties for violations of these laws vary. For instance, penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include civil monetary penalties of up to $58,490 per violation, which cap has been increased to account for inflation, not to exceed approximately $1.75&#160;million per calendar year, for each provision of HIPAA that is violated and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and imprisonment. However, a single breach can result in findings of violations of multiple provisions, leading to possible penalties in excess of $1.75&#160;million for violations in a calendar year. Any person who knowingly obtains or discloses PHI in violation of HIPAA may face a criminal penalty of up to $50,000 and up to one year of imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm. In addition, responding to government investigations regarding alleged violations of these and other laws and regulations, even if they ultimately result in no findings of violations or no penalties imposed, can consume our resources and impact our business and, if public, harm our reputation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer networks are vulnerable to breach and unauthorized persons may in the future be able to exploit weaknesses in the security systems of our computer networks and gain access to PHI. Additionally, we share PHI with third-party contractors, and while they are contractually obligated under business associate agreements to safeguard and maintain the confidentiality of PHI, their indemnification of us would not insulate us from reputational harm. Unauthorized persons may be able to gain access to PHI stored in such third-party contractors&#8217; computer networks. Any wrongful use or disclosure of PHI by us or our third-party contractors, including disclosure due to data theft or unauthorized access to our or our third-party contractors&#8217; computer networks, could subject us to fines or penalties that could adversely affect our business and results of operations. Although HIPAA and the regulations promulgated thereunder do not provide for a private right of action, we could incur damages under state laws to private parties for the wrongful use or disclosure of confidential health information or other private personal information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, various states, such as California, New York and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personal information. These laws and regulations are not necessarily preempted by HIPAA, but they afford greater protection to individuals than HIPAA. Where state laws are more protective, we and our collaborators must comply with the stricter provisions where they apply. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our customers and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy, security and data use issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our immune medicine platform and related products and services could intensify. Changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as PHI, along with increased customer demand for enhanced data security infrastructure, could greatly increase the cost of providing our products and services, decrease demand for our products and services, reduce our revenue and subject us to additional liabilities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the interpretation and application of consumer, health-related and data protection laws, especially with respect to genetic samples and data, in the United States, the EU and elsewhere, are often uncertain, contradictory and in flux. We may eventually operate in a number of countries outside of the United States whose laws may in some cases be more stringent than the requirements in the United States. For example, the EU has specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States. In addition, some countries have stricter consumer notice or consent requirements relating to personal data collection, use or sharing, have more stringent requirements relating to organizations&#8217; privacy programs and provide stronger individual rights. Moreover, international privacy and data security regulations may become more complex and result in greater penalties. For instance, as of May&#160;25, 2018, the GDPR, has replaced the EU Data Protection Directive with respect to the collection and use of personal data of data subjects in the EU and the EEA. The GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to obtain consent or other legal bases from individuals to process their personal data, provide robust disclosures to individuals, accommodate a set of individual data rights, provide data security breach notifications within 72 hours after discovering the breach, limit retention of personal information and apply enhanced protections to health data and other special categories of personal data. The GDPR also applies to pseudonymized data, which is defined as &#8220;the processing of personal data in such a way that the data can no longer be attributed to a specific data subject without the use of additional information,&#8221; and imposes additional obligations when we contract with third-party processors in connection with the processing of any personal data. The GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data, could cause our costs to increase and could harm our financial condition. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20&#160;million or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. To comply with the new data protection rules imposed by the GDPR, we may be required to put in place additional mechanisms ensuring compliance, which may result in other substantial expenditures. This may be onerous and adversely affect our business, financial condition, results of operations and the profitability of our platform of products and services. Failure to comply with the GDPR and other countries&#8217; privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payors, and have an adverse effect on our business and financial condition. Currently, the GDPR is only applicable to us as a processor, but as we continue to expand into the European market, the GDPR will have direct applicability to us as a controller. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.74%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR also imposes strict rules on the transfer of personal data out of the EU to the United States. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. In addition, these rules are consistently under scrutiny. In July 2020, the CJEU invalidated the EU-US Privacy Shield, effective immediately, one of the methods for transfers of personal data into the US. The court found that under US surveillance laws, the US government has access to personal data that does not provide Europeans with privacy protections equivalent with the level of protection required under EU law. The Standard Contractual Clauses, which are currently being revised by the European Commission, are still valid but given the court's findings on US surveillance laws, a future case might deem transfers to the United States based on Standard Contractual Clauses invalid because they fail to meet that "essentially equivalent to that guaranteed within the EU" standard.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the GDPR, we continue to expand our business into several jurisdictions that have data privacy laws or begin to develop new data privacy laws. Organizations operating in Canada and covered by the Personal Information Protection and Electronic Documents Act (&#8220;PIPEDA&#8221;), or equivalent Canadian provincial laws, must obtain an individual&#8217;s consent when they collect, use or disclose that individual&#8217;s personal information. Individuals have the right to access and challenge the accuracy of their personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal information for another purpose, it must again obtain that individual&#8217;s consent. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data privacy and security issues. If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private<span style="font-style:italic;"> qui tam</span> actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corrective action plan or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Security breaches, loss of data and other disruptions could compromise confidential, personal and sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of our business, we and our collaborators collect and store sensitive data, including PHI, personal information, credit card and other financial information, intellectual property and proprietary business information owned or controlled by ourselves or our customers, third-party payors, our collaborators, government entities, insurance companies and other parties. We manage and maintain our applications and data through a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage components of our data centers. We also transmit sensitive data, including patient data, telephonically, through our website and pursuant to arrangements with multiple third-party vendors and their subcontractors. These applications and data encompass a wide variety of critical business information, including research and development information, patient data, commercial information and financial information. We face a number of risks related to protecting this critical information, including loss-of-access risk, unauthorized access, use, disclosure or modification, and the risk of our inability to adequately monitor, audit and modify our respective control over our critical information. This risk extends to the data we entrust to the third-party vendors and subcontractors that help us manage this sensitive data or otherwise process it on our behalf. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive and proprietary data from unauthorized access, use or disclosure, no security measures can be perfect and our respective information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, liability under federal or state laws that protect the privacy of personal information, such as HIPAA or HITECH, and regulatory penalties. Notice of breaches may be required to be provided to affected individuals, the Secretary of HHS or other federal, state and foreign regulators, the media or state attorneys general. Such a notice could harm our reputation and ability to compete. Although we have implemented security measures and formal, dedicated enterprise security programs to prevent unauthorized access to patient and other personal data, such data is currently accessible through multiple channels and we may experience one or more data breaches. Unauthorized access, loss or dissemination could also disrupt our operations and damage our reputation, which could adversely affect our results of operations and financial condition. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">No TCR-based cellular therapies have been approved in this new potential category of medicines and may never be approved as a result of efforts by others or us. TCR-based cellular therapy drug discovery has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of immune medicines. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a potential new category of medicines, no TCR-based cellular therapies have been approved to date by the FDA or other regulatory agency. Successful discovery and development of TCR-based cellular therapies by us and our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our and their control. We and our collaborators have made and will continue to make a series of business decisions and take calculated risks to advance our development efforts and pipeline of immune-driven therapeutic product candidates, including those related to TCR-based cellular therapies, delivery technology and manufacturing processes, which may be shown to be incorrect based on further work by us, our collaborators or others. Our cellular therapeutics product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic, experience clinical holds or fail to reach the market for many reasons, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">discovery efforts identifying potential TCR-based cellular therapies may not be successful&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">nonclinical or preclinical study results may show potential TCR-based cellular therapies to be less effective than desired or to have harmful or problematic side effects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trials may fail to meet one or more endpoints, or results may show the TCR-based cellular therapies to be less effective than expected or to have unacceptable side effects or toxicities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse effects relating to any one of our therapeutic product candidates or adverse effects relating to our TruTCR process may lead to delays in or termination of one or more of our products or services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability of our translational models to reduce risk or predict outcomes in humans, given that each component of our therapeutic product candidates may have a dependent or independent effect on safety, tolerability and efficacy, and that such effects may, among other things, be species-dependent&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing failures or insufficient supply of current good manufacturing practices (&#8220;cGMP&#8221;) materials for future clinical trials, or higher than expected cost, could delay or set back clinical trials or make TCR-based cellular therapies commercially unattractive&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our collaborators&#8217; improvements in the manufacturing processes for this new class of potential immune medicines may not be sufficient to satisfy the clinical or commercial demand of our jointly developed TCR-based cellular therapies or regulatory requirements for clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes that we or our collaborators make to optimize manufacturing, testing or formulating of cGMP materials could impact the safety, tolerability and efficacy of our therapeutic products in development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pricing or reimbursement issues or other factors that delay clinical trials or make any TCR-based cellular therapies uneconomical or noncompetitive with other immunotherapies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to timely advance our or our collaborators&#8217; therapeutic products or receive the necessary regulatory clearances, authorizations or approvals or a delay in receiving such clearances, authorizations or approvals due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, Biologics License Application or the equivalent application, discussions with the FDA or the European Medicines Agency, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the proprietary rights of others and their competing products and services that may prevent our TCR-based cellular therapies from being commercialized or threaten future commercialization activities. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Intellectual Property </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in obtaining or maintaining sufficient intellectual property protection for our products, services and technologies and uses thereof, and the scope of the intellectual property protection obtained may not be sufficiently broad. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other companies engaged in the life sciences industry, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or license from third parties, particularly patents, in the United States and other countries with respect to our products, services and technologies. We rely on patent protection in addition to trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or enable us to gain or maintain any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate barriers to competition, our competitive position could be adversely affected, as could our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply for or in-license patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing patents is costly, time-consuming and complex, and we may fail to apply for patents on important products, services and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications or to maintain the rights to patents licensed from third parties. Consequently, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we own or have rights to 451 active patents and patent applications filed in the United States, Europe and elsewhere. Of these, there are 65 pending patent applications and 386 granted patents. Our pending patent applications may not result in issued patents in a timely fashion or at all. Even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is also possible that others will design around our current or future patented technologies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our patents, licensed patents or patent applications may be challenged in the future, and we may not be successful in defending any such challenges. For example, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), or become involved in opposition, derivation, reexamination,</span><span style="font-style:italic;"> inter </span><span style="font-style:italic;">partes</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> review, post-grant review or interference proceedings challenging our patent rights. Any successful third-party challenge to our patents could result in patent claims being narrowed, or patents being invalidated or held unenforceable, in whole or in part, which could lead to increased competition to our business. Conversely, we may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products or services. The patent positions of biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Inconsistent policies regarding the eligibility for patent protection and the breadth of patentable claims in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods and compositions of matter useful in relation to immunosequencing. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of companies engaged in the development and commercialization of clinical diagnostic tests, like our clonoSEQ diagnostic test, are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the eligibility and scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related technology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular immune receptors and cancer) may not be patentable. Precisely what constitutes a law of nature is uncertain, and it is possible that certain aspects of our clinical diagnostics would be considered natural laws. The evolving case law in the United States may adversely affect our ability to obtain patents or defend patents we have obtained or have licensed and may facilitate third-party challenges to any owned or licensed patents. The laws of some foreign countries do not protect intellectual property rights to the same extent or for the same subject matter as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on our products and services in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products and services. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, a third party that files a patent application before us could be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either file any patent application related to our products or services or invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may also submit prior art to the USPTO during patent prosecution to attack the validity of a patent and it is also possible in the United States and other countries for third parties to challenge granted patents through Patent Office proceedings such as, in the United States, post-grant review,<span style="font-style:italic;"> inter partes</span> review and derivation proceedings. In the United States, a lower evidentiary standard is imposed in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim. As such, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents could have a material adverse effect on our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent U.S. Supreme Court rulings have also narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including with respect to naturally occurring biological molecules such as the immune cell receptors which are a focus of our immune medicine platform. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issued patents covering our products and services could be found invalid or unenforceable if challenged. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the United States and abroad, in opposition, derivation, reexamination,<span style="font-style:italic;"> inter partes</span> review, post-grant review or interference. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our products or technologies, the defendant could counterclaim that the patent covering our product is invalid or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. In addition, the United States now awards patent priority to the first party to file a patent application, and others may submit patent claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. A successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, which could have a material adverse impact on our business. Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products and services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be aware of all third-party intellectual property rights potentially relating to our immune medicine platform, products and services. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management&#8217;s attention and resources. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely on licenses from third parties in relation to certain products and services and if we lose these licenses then we may be subjected to future litigation. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to license agreements that grant us rights to use certain intellectual property, including patents and patent applications, typically in certain specified fields of use. Some of those licensed rights could provide us with freedom to operate for aspects of our products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether, and the extent to which, our products, services, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our right to sublicense patent and other rights to third parties under collaborative development relationships&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the priority of invention of patented technology. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize any affected products or services, which could have a material adverse effect on our business, financial conditions, results of operations and prospects. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs to us and distract our management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys&#8217; fees, costs and expenses and royalties or be enjoined from selling our products or services, which could adversely affect our ability to offer products or services, our ability to continue operations and our financial condition. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, collaborators, academic institutions, life sciences research partners and, when needed, our advisers as well as other third parties. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems. Besides the possibility that these security measures could be breached, such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may also not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain former employees have obtained employment with companies or academic institutions that could be considered competitive with us. This competition may be limited by contractual provisions which may or may not be enforceable by us in certain jurisdictions. In addition, we may not be aware of such competitive employment arrangements until after our trade secrets have been disclosed to potentially competitive companies. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ, and expect to employ in the future, individuals who were previously employed at universities or other companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect and enforce our trademarks. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet registered certain of our trademarks in all of our potential markets, although we have registered Adaptive Biotechnologies, clonoSEQ, immunoSEQ, pairSEQ and TruTCR in the United States, the EU and a number of other countries and are seeking to register additional trademarks, including our new corporate logos, T-Detect and TruAB for our antibody development program. As we apply to register our unregistered trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In certain countries outside of the United States, trademark registration is required to enforce trademark rights. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Ownership disputes may arise, for example, from conflicting obligations of employees, consultants or others who are involved in developing our future products and services. Our co-founder, Dr.&#160;Harlan Robins, had dual employment with Fred Hutch and us until June of 2019, and accordingly has had obligations to assign his rights to inventions to either Fred Hutch or us depending on how and where the inventions were conceived, reduced to practice, developed or created. Disputes may arise in the future between Fred Hutch and us regarding ownership of intellectual property generated by Dr.&#160;Robins&#8217; work. Fred Hutch may claim to have ownership rights to our intellectual property. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation may be necessary to defend against these and other claims by a third party challenging inventorship of our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product or services. Alternatively, we may need to obtain one or more additional licenses from the third party which will be time-consuming and expensive and could result in substantial costs and diversion of resources and could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our development and commercialization efforts of our products and services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the life sciences, clinical diagnostics and drug discovery industries, including patent infringement lawsuits, declaratory judgment litigation and adversarial proceedings before the USPTO, including interferences, derivation proceedings,<span style="font-style:italic;"> ex parte</span> reexaminations, post-grant review and<span style="font-style:italic;"> inter partes</span> review, as well as corresponding proceedings in foreign courts and foreign patent offices. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently involved in appeals from Opposition Proceedings at the European Patent Office related to three of our patents: EP2364368, EP2387627, and EP3059337. We may, in the future, become involved with litigation or actions at the USPTO or foreign patent offices with various third parties. We expect that the number of such claims may increase as our industry expands, more patents are issued, the number of products or services increases and the level of competition in our industry increases. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management&#8217;s time and attention from the development of our business, requiring the payment of monetary damages (including treble damages, attorneys&#8217; fees, costs and expenses) or royalty payments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we move into new markets and expand our products or services offerings, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are employing their proprietary technology without authorization. Given that clinical diagnostics and drug discovery fields are intense and highly competitive areas, there may be third-party intellectual property rights that others believe could relate to our immune medicine platform, products and services. We have been approached on four occasions with an offer from a third-party patent owner or licensee to license rights to us under patents relating to immune medicine. We have been contacted by Invivoscribe, Inc. regarding U.S. Pat. No.&#160;7,785,783 on March&#160;24, 2012&#59; by Keygene NV regarding U.S. Pat. No.&#160;9,453,256 on October&#160;10, 2016&#59; by MorphoSys AG regarding EP Patent 2243030 and U.S. Pat. No.&#160;9,404,929 on October&#160;10, 2018&#59; and by DName-iT NV regarding EP Patent 2201143 and U.S. Pat. No.&#160;8,318,434 in December 2018. In each instance, we have declined to pursue licenses to the patents and the matters have not been pursued further. One or more of these or other third-party patent owners or licensees may pursue or threaten to pursue litigation against us to enforce one or more patents. It would be costly and time-consuming to defend such claims. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future products, technologies and services may infringe. We cannot be certain that we have identified or addressed all potentially significant third-party patents in advance of an infringement claim being made against us. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our products or services infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorneys&#8217; fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our products or services could materially affect our business and our ability to gain market acceptance for our products or services. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our products and services for an adequate amount of time. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products and services are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new products and services, patents protecting such products and services might expire before or shortly after such products and services are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market price of our common stock is volatile and is likely to continue to fluctuate substantially. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a new public company and the market price of our common stock has been and is likely to continue to be highly volatile and may fluctuate substantially due to many factors, many of which are beyond our control. These factors include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the commencement or termination of our collaborations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of achievement of specified milestones in the development of our products and services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">introductions of new or expanded products or services or new pricing policies by us or by our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the status of our regulatory clearances, authorizations, approvals or applications, or those jointly developed with our collaborators&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">where required, the results of clinical trials of our future products and services, those jointly developed with our collaborators or those of our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of competitive products or technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements by us or our competitors of significant acquisitions, collaborators or divestitures&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in governmental regulations and regulatory or legal developments in the United States and other countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments or disputes concerning patent applications, issued patents or other proprietary rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the recruitment or departure of key personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the structure of healthcare payment systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">market conditions in the life sciences, clinical diagnostics or drug discovery industry&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic, industry and market conditions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of our securities, including sales by our directors, officers or significant shareholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">speculation about our business in the media or the investment community&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other factors, including factors unrelated to our operating performance or the operating performance of our competitors. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. If the market for stock in our industry or the stock market in general experiences uneven investor confidence, the market price of our common stock could decline for reasons unrelated to our business, operating results or financial condition. The market price of our common stock might also decline in reaction to events that affect other companies within, or outside, our industry even if these events do not directly affect us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in their stock price. This type of litigation, if instituted against us, could result in substantial costs to us and divert our management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not control these analysts. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable evaluations of our company or our stock, the price of our stock could decline. If one or more of these analysts cease coverage of our company or fail to publish reports covering our company regularly, our stock may lose visibility in the market, which in turn could cause our stock price to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, industry group or the general or financial press, our stock price may decline. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Substantial future sales or perceived potential sales of our common stock or other equity securities in the public market could cause the price of our common stock to decline significantly. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of substantial amounts of our common stock or other equity securities in the public market, particularly by our directors, executive officers and significant shareholders, including upon the expiration of any lock-up periods entered into in connection with offerings of our common stock or other equity securities, or the perception that these sales could occur, could materially and adversely affect the price of our common stock and impair our ability to raise capital through the sale of equity securities. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared. </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-right:0.37%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;), we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we were an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, our auditors were not required to formally attest to the effectiveness of our internal control over financial reporting. As of the end of our fiscal year ended December 31, 2020, we qualified as a &#8220;large accelerated filer&#8221; as defined in the Exchange Act and, as a result, ceased to qualify as an emerging growth company. Accordingly, commencing with our Annual Report on Form 10-K for the year ended December 31, 2020, we are required to have our auditors formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. Our compliance with Section 404 necessitates that we incur substantial accounting expense and expend significant management efforts. We will continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also required to maintain disclosure controls and procedures. Disclosure controls and procedures means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. We do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. We believe a control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions in our charter documents and Washington law could make an acquisition of our company more difficult and limit attempts by our shareholders to replace or remove our current management. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated articles of incorporation (&#8220;Articles of Incorporation&#8221;) and our amended and restated bylaws (&#8220;Bylaws&#8221;), as well as Washington law, contain provisions that may have the effect of deterring takeovers or delaying or preventing a change in control of us or changes in our management that a shareholder might deem to be in his or her best interest. Our Articles of Incorporation and Bylaws contain provisions that: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without shareholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">create a classified board of directors whose members serve staggered three-year terms, with one class being elected each year by our shareholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">specify that special meetings of our shareholders can be called only by our board of directors, the Chairperson of our board of directors, our chief executive officer or our president&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that a director may only be removed from the board of directors for cause and then only by the affirmative vote of our shareholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even if less than a quorum&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">specify that only our board of directors may change the size of our board of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including proposed nominations of persons for election to our board of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">specify that no shareholder is permitted to cumulate votes at any election of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expressly authorize our board of directors to modify, alter or repeal our Bylaws&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require supermajority votes of the holders of our common stock to amend specified provisions of our Articles of Incorporation and Bylaws. </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management or our board of directors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in the State of Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act (&#8220;WBCA&#8221;), which prohibits certain business combinations between us and certain significant shareholders unless specified conditions are met. These provisions may also have the effect of delaying or preventing a change in control of our company. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any provision of our Articles of Incorporation or Bylaws or Washington law that has the effect of delaying or deterring a change in control could limit the opportunity for our shareholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Articles of Incorporation provide that the state courts located in King County, Washington and, to the extent enforceable, the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Articles of Incorporation provide that, unless we consent in writing to the selection of an alternative forum, the state courts located in King County, Washington (or, if the state courts located within King County, Washington do not have jurisdiction, the federal district court for the Western District of Washington) shall be the sole and exclusive forum for commencing and maintaining any proceeding (1)&#160;asserting a claim based on a violation of a duty under the laws of the State of Washington by any of our current or former directors, officers or shareholders in such capacity, (2)&#160;commenced or maintained in the right of our corporation, (3)&#160;asserting a claim arising pursuant to any provision of the WBCA, our Articles of Incorporation or our Bylaws (as either may be amended from time to time) or (4)&#160;asserting a claim concerning our internal affairs that is not included in clauses (1)&#160;through (3)&#160;above, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Articles of Incorporation provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), subject to applicable law. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our shareholders will not be deemed to have waived our compliance with these laws, rules and regulations. These exclusive-forum provisions may limit a shareholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a court were to find these exclusive-forum provisions in our Articles of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations. For example, the Court of Chancery of the State of Delaware recently determined that a provision stating that U.S. federal district courts are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act is not enforceable under Delaware law. It is unclear whether the Delaware Supreme Court will review and ultimately overturn this decision, and whether Washington courts would reach a similar conclusion under Washington law. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Articles of Incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Washington law. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as permitted by Section&#160;23B.08.510 through Section&#160;23B.08.570 of the WBCA, our Articles of Incorporation and our indemnification agreements that we have entered into with our directors and officers provide that: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Washington law. Washington law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The rights conferred in our Articles of Incorporation are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not retroactively amend our Articles of Incorporation provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business, and do not anticipate paying any cash dividends on our common stock for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item 1B. Unresolved Staff Comments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable<span style="color:#000000;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current corporate headquarters is located in Seattle, Washington, where we lease approximately 65,500 square feet of laboratory and office space. This lease expires October 2032, subject to two options to extend the lease for five years. In 2019, we entered into an additional lease in Seattle, Washington to rent approximately 100,000 square feet, which we plan to occupy in 2021 when construction is complete. The lease expires in August 2033, subject to our option to twice extend the lease for five years. Additionally, we lease approximately 14,750 square feet in a separate Seattle, Washington location, pursuant to a lease expiring in October 2029, subject to our ability to exercise an early termination right in 2022.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also lease approximately 33,300 square feet of laboratory and office space in South San Francisco, California, pursuant to an amended lease that expires March 2026, subject to our option to extend the lease for five years, and approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025, subject to our ability to exercise an early termination right in 2023.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may add new facilities or expand existing facilities as we add employees and scale our operations, and we believe suitable additional or substitute space will be available as needed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable<span style="font-weight:bold;color:#000000;">.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Market information for common stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock began trading on The Nasdaq Global Select Market under the symbol &#8220;ADPT&#8221; on June 27, 2019. Prior to that date, there was no public trading market for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Holders of record</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;February 19, 2021, there were approximately&#160;117&#160;holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Dividend policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to retain all available funds and any future earnings to fund the growth and development of our business. We do not intend to pay cash dividends to our shareholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. Our future ability to pay cash dividends on our common stock may also be limited by the terms of any future debt securities, preferred stock or credit facility.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Stock performance graph</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph below compares the cumulative total shareholder return on our common stock with the cumulative total return on the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph assumes $100 was invested at the market close on June 27, 2019, which was our initial trading day, in our common stock. Data for the NASDAQ Composite Index and the NASDAQ Biotechnology Index assume reinvestment of dividends. Our offering price of our common stock in our initial public offering, which had a closing stock price of $40.30 on June 27, 2019, was $20.00 per share. The stock price performance below is based upon historical data and is not necessarily indicative of, nor intended to forecast, future performance of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0.93%;text-indent:0%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0vsdaj33nnl000018.jpg" title="" alt="" style="width:548px;height:278px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This graph shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing of Adaptive Biotechnologies Corporation under the Securities Act or the Exchange Act.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_SELECTED_FINANCIAL_DATA">Item 6. Selected Financial Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. We early adopted the SEC&#8217;s final rule issued on January 11, 2021 related to amendments to modernize, simplify and enhance certain financial disclosure requirements in Regulation S-K.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes and the other financial information appearing elsewhere in this Annual Report on Form 10-K, as well as the other financial information we file with the SEC from time to time. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties relating to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">This section generally discusses 2020 and 2019 items and year-to-year comparisons between 2020 and 2019. Discussions of 2018 items and year-to-year comparisons between 2019 and 2018 may be found in Part II, Item 7 under the caption "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune conditions and infectious diseases.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our immune medicine platform is the foundation for our expanding suite of products and services. The cornerstone of our platform and core immunosequencing product, immunoSEQ, serves as our underlying research and development engine and generates revenue from biopharmaceutical and academic customers. Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the FDA for the detection and monitoring of MRD in patients with MM, ALL and CLL and is also available as a CLIA-validated LDT for patients with other lymphoid cancers. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are using the TCR-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect, formerly known as immunoSEQ Dx. T-Detect COVID, for which we have applied for EUA, confirms past SARS-CoV-2 infection, the virus that causes COVID-19, and is also the first indication for the T-Detect product line. We are finalizing clinical validation of T-Detect for acute Lyme disease, have identified a clinical signal for Crohn&#8217;s disease and continue to pursue signals for other disease states, in parallel. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our therapeutic product candidates, being developed under the Genentech Agreement, leverage our platform to identify specific receptors on immune cells to develop into cellular therapies in oncology. We also recently extended our platform to identify highly potent neutralizing antibodies against SARS-CoV-2 and we believe this differentiated approach may be leveraged across multiple disease states.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have devoted a majority of our resources to research and development activities to develop our immune medicine platform. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our life sciences research customers, we provide two categories of products and services using immunoSEQ. First, we provide immunosequencing services, the revenue from which we record as sequencing revenue. Second, we provide certain research customers professional support, for which we may receive nonrefundable upfront or recurring payments. We may receive additional payments upon those customers achieving specified milestones. Revenue related to these activities are recorded as development revenue. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clinical diagnostics customers, we sell our clonoSEQ diagnostic test and T-Detect COVID test, which include our immunosequencing services and are thus recorded as sequencing revenue. In the future, we intend to sell other diagnostics products and services, including other indications for T-Detect, which we also expect to record as sequencing revenue. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our current drug discovery collaborator, Genentech, we screen, identify and characterize TCRs in support of our collaboration. We record revenue from this collaboration as development revenue. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, we have sold immunoSEQ as a fee-for-service offering. These research offerings have comprised the majority of our revenue to date, although our business is pursuing broader opportunities. As we continue to expand the use of our clonoSEQ diagnostic tests, develop and commercialize </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T-Detect</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and develop and commercialize therapeutic product candidates with our drug discovery collaborator, we expect our mix of revenue to shift to clinical products and services, which we believe will become our largest sources of revenue. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are actively pursuing opportunities to deepen our relationships with current customers and initiate relationships with new customers. We have an experienced, specialty salesforce that is targeting department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors and research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. As MRD assessment becomes standard practice for patient management across a range of blood cancers, we believe it will be essential for clinicians and patients to have access to a highly accurate, sensitive and standardized MRD assessment tool. We are focused on establishing and maintaining collaborative relationships with payors, developing health economic evidence and building billing and patient access infrastructure to expand reimbursement coverage for our clinical diagnostics. We continue to seek expanded coverage of our clonoSEQ diagnostic test and have successfully expanded coverage through contractual agreements or positive medical policies with Medicare and several of the largest national private health insurers in the United States.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generated revenue of $98.4 million and $85.1 million for the year ended December 31, 2020 and 2019, respectively. Our net losses were $146.2 million and $68.6 million for the year ended December 31, 2020 and 2019, respectively. We have funded our operations to date principally from the sale of convertible preferred stock and common stock and, to a lesser extent, sequencing and development revenue. As of December 31, 2020 and 2019, we had cash, cash equivalents and marketable securities of $806.8 million and $682.3 million, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Follow-On Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we completed an underwritten public offering of our common stock in which we issued and sold 7,200,000 shares of common stock at a public offering price of $40.00 per share. We received $271.8&#160;million in net proceeds, after deducting underwriting discounts and net offering expenses paid by us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Components of Results of Operations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive our revenue from two sources: (1)&#160;sequencing revenue and (2)&#160;development revenue. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sequencing revenue.<span style="font-style:normal;"> Sequencing revenue reflects the amounts generated from providing testing services through clonoSEQ to clinical and research customers and from providing sequencing services through immunoSEQ to research customers. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clinical customers, we derive revenue from providing our clonoSEQ test report to ordering physicians. We bill medical institutions and commercial and government payors based on tests delivered to ordering physicians. Amounts paid for clonoSEQ diagnostic tests by medical institutions and commercial and government payors vary based on respective reimbursement rates and patient responsibilities, which may differ from our targeted list price. To date, the majority of our clonoSEQ diagnostic test revenue has been received from medical institutions. We recognize clinical revenue by evaluating customer payment history, contracted reimbursement rates, if applicable, and other adjustments to estimate the amount of revenue that is collectible. Until 2019, we did not have reimbursement available to us through any government payors for clonoSEQ. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and recognized as we deliver the remaining tests in a patient&#8217;s treatment cycle or when it becomes remote that a patient will receive additional testing and we have not delivered our estimate of total tests. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our research customers, which include biopharmaceutical customers and academic institutions, delivery of the sequencing results may include some level of professional support and analysis. Terms with biopharmaceutical customers generally include non-refundable upfront payments, which we record as deferred revenue. For all customers, we recognize revenue as we deliver sequencing results. From time to time, we offer discounts in order to gain rights and access to certain datasets. Revenue is recognized net of these discounts and costs associated with these services are reflected in cost of revenue. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Development revenue</span><span style="font-style:normal;">. Development revenue primarily represents regulatory or development support services, other than sequencing revenue, that we provide to biopharmaceutical customers who seek access to our platform to support their therapeutic development activities. We enter into collaboration and similar agreements with these customers. When these agreements include sequencing activities, we separately classify those activities as sequencing revenue. These agreements may also include substantial non-refundable upfront payments, which we recognize as development revenue over time as we perform the respective services</span><span style="font-style:normal;">.</span><span style="font-style:normal;"> Additionally, we generate development revenue from the achievement of regulatory milestones.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect revenue to increase over the long term, particularly as the mix of revenue migrates to clinical diagnostics and drug discovery. The pace by which this mix migrates will be determined by the level of customer adoption and frequency of use of our products and services. Our revenue may fluctuate from period to period due to the uncertain nature of delivery of our products and services, the achievement of milestones by us or our customers, timing of expenses incurred, changes in estimates of total anticipated costs related to our Genentech Agreement and other events not within our control, such as the delivery of customer samples or customer decisions to no longer pursue their development initiatives.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the ongoing uncertainties related to the COVID-19 pandemic, we may continue to experience variability in revenue in the near term as our customers&#8217; abilities to procure samples for their research initiatives change, as customer initiatives evolve and as clinical testing is impacted.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Revenue </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue includes the cost of materials, personnel-related expenses (comprised of salaries, benefits and share-based compensation), shipping and handling, equipment and allocated facility costs associated with processing samples and professional support for our sequencing revenue. Allocated facility costs include depreciation of laboratory equipment, allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition. As such, cost of revenue and related volume does not always trend in the same direction as revenue recognition and related volume. Additionally, costs to support our Genentech Agreement are a component of our research and development activities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect cost of revenue to increase in absolute dollars as we grow our sequencing volume and make increased investments in laboratory automation and facilities, but the cost per sample to decrease over the long term due to the efficiencies we may gain as sequencing volume increases from improved utilization of our laboratory capacity, automation and other value engineering initiatives. <span style="color:#000000;">If our sample volume throughput is reduced as a result of the COVID-19 pandemic or otherwise, cost of revenue as a percentage of total revenue may be adversely impacted due to fixed overhead costs.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses<span style="color:#000000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. We are currently conducting research and development activities for several products and services and we typically use our laboratory materials, personnel, facilities, information technology and other development resources across multiple development programs. Additionally, certain of these research and development activities benefit more than one of our product opportunities. We do not track research and development expenses by specific product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A component of our research and development activities is supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. Additionally, the costs to support our Genentech Agreement are a component of our research and development activities. Some of these activities have generated and may in the future generate development revenue. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to continue to increase in absolute dollars as we innovate and expand the application of our platform. However, we expect research and development expenses to decrease as a percentage of revenue in the long term, although the percentage may fluctuate from period to period due to the timing and extent of our development and commercialization efforts. <span style="color:#000000;">While the pace and priorities of our research and development initiatives may continue to be impacted by the COVID-19 pandemic, we expect to continue to increase expenses in both the near and long-term to support our ongoing initiatives, which include our initiatives with respect to COVID-19.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Sales and Marketing Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our sales and marketing expenses to increase in absolute dollars as we expand our commercial sales, marketing and business development teams and increase marketing activities to drive awareness and adoption of our products and services. However, we expect sales and marketing expenses to decrease as a percentage of revenue in the long term, subject to fluctuations from period to period due to the timing and magnitude of these expenses. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel-related expenses, including share-based compensation, salaries and benefits for our personnel in executive, legal, finance and accounting, human resources and other administrative functions, including third-party billing services. In addition, these expenses include insurance costs, external legal costs, accounting and tax service expenses, consulting fees and allocated facility costs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our general and administrative expenses to continue to increase in absolute dollars as we increase headcount. Though expected to increase in absolute dollars, we expect these expenses to decrease as a percentage of revenue in the long term as revenue increases.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Statements of Operations Data and Other Financial and Operating Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our statements of operations data and other financial and operating data for the periods presented:</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-style:italic;;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statements of Operations Data:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,439</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,519</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,978</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,943</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,552</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,685</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,382</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,071</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,663</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,530</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,274</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,668</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,072</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,705</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,157</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,358</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,453</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,486</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,536</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,332</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,409</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of intangible assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">251,199</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,462</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,419</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(152,817</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,391</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,756</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,590</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,785</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,309</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,447</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustment to Series E-1 convertible preferred stock options</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(964</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shareholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,570</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,345</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders, basic and diluted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.11</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.01</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.67</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used in computing net loss per share attributable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; to common shareholders, basic and diluted</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,216,468</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,165,315</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,629,778</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Financial and Operating Data:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjusted EBITDA <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,584</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,476</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,607</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;font-weight:bold;font-style:italic;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for interest and other income, net, income tax (expense) benefit, depreciation and amortization and share-based compensation expenses. Please refer to &#8220;Adjusted EBITDA&#8221; below for a reconciliation between Adjusted EBITDA and net loss, the most directly comparable GAAP financial measure, and a discussion about the limitations of Adjusted EBITDA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">C</span><span style="font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">omparison of the </span><span style="font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Years Ended December 31, 20</span><span style="font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">20</span><span style="font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"> and 201</span><span style="font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">9</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-style:italic;;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,439</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,519</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,080</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,943</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,552</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,391</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,382</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,071</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,311</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue was $98.4 million for the year ended December 31, 2020, compared to $85.1 million for the year ended December 31, 2019, representing an increase of $13.3 million, or 16%.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue decreased to $41.4 million for the year ended December 31, 2020, representing a decrease of $2.1 million, or 5%. The decrease in sequencing revenue was attributable to an $8.6 million decrease in revenue generated from biopharmaceutical and academic customers, inclusive of a $0.9 million decrease in revenue recognized from cancelled customer projects, which was partially offset by a $6.5 million increase in revenue generated from clinical customers. This increase was inclusive of a $0.6 million increase in revenue related to Medicare that was recognized from our deferred revenue because of our determination that additional testing for specific patients was remote.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research sequencing volume decreased by 36% to 22,663 sequences delivered in the year ended December 31, 2020 from 35,491 sequences delivered in the year ended December 31, 2019. The reduction in research sequencing volume was driven partly by the expiration of a translational agreement with a biopharmaceutical customer in the fourth quarter of 2019 and trial enrollment delays and project deferrals from our biopharmaceutical and academic customers. The impact of the COVID-19 pandemic on the operating capacity of our biopharmaceutical and academic customers was a large contributing factor to trial enrollment delays. Clinical sequencing volume increased by 50% to 15,216 clinical tests delivered in the year ended December 31, 2020 from 10,168 clinical tests delivered in the year ended December 31, 2019.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue increased to $56.9 million for the year ended December 31, 2020, representing an increase of $15.4 million, or 37%. The increase was primarily attributable to a $17.7 million increase in revenue generated from the Genentech Agreement, partially offset by a $2.0 million decrease in revenue generated from translational agreements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Revenue</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-style:italic;;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,530</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,274</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue was $22.5 million for the year ended December 31, 2020, compared to $22.3 million for the year ended December 31, 2019, representing an increase of approximately $0.3 million, or 1%. The increase was primarily attributable to a $5.8 million increase in labor and overhead costs, a $0.8 million increase in cost of materials resulting from product mix and a $0.6 million increase in biopharmaceutical partner support and other expenses, all of which were mostly offset by a $5.9 million decrease related to higher usage of our production laboratory to process research and development samples versus revenue samples, as well as a $1.1 million decrease in materials cost resulting from decreased revenue sample volume.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-weight:bold;font-style:italic;;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,072</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,705</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,367</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents disaggregated research and development expenses by cost classification for the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development materials and allocated</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; production laboratory expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,561</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,114</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,447</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,969</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,570</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,399</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allocable facilities and information technology expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,277</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,510</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,767</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software and cloud services expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,521</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,443</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,078</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and other expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,744</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,068</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,676</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,072</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,705</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,367</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $116.1 million for the year ended December 31, 2020, compared to $70.7 million for the year ended December 31, 2019, representing an increase of $45.4 million, or 64%. The increase was primarily attributable to an $18.4 million increase in cost of materials and allocated production laboratory expenses, a $17.4 million increase in personnel costs and a $6.7 million increase in depreciation and other expenses. The increase in cost of materials and allocated production laboratory expenses was primarily related to supporting investments in our T-Detect and TCR-Antigen Map development and immune medicine platform, as well as our drug discovery efforts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Sales and Marketing</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-style:italic;;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,358</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,453</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,905</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses were $61.4 million for the year ended December 31, 2020, compared to $38.5 million for the year ended December 31, 2019, representing an increase of $22.9 million, or approximately 60%. The increase was primarily attributable to $14.5 million in additional personnel costs and $8.7 million in additional marketing expenses. Our clonoSEQ marketing efforts were the largest driver of this $8.7 million increase, followed by increased shared corporate marketing services and, to a lesser extent, additional marketing expenses related to T-Detect and life sciences research. These increases were partially offset by a $1.9 million decrease in travel and customer event related expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-style:italic;;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent of Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,536</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,332</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,204</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $49.5 million for the year ended December 31, 2020, compared to $30.3 million for the year ended December 31, 2019, representing an increase of $19.2 million, or 63%. The increase was primarily attributable to a $10.9 million increase in personnel costs, a $4.6 million increase in legal, accounting and tax fees and a $2.3 million increase in insurance costs, both of which were largely due to the effect of operating as a public company for the full year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Interest and Other Income, Net</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-style:italic;;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except percentages)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,590</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,785</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,195</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net was $6.6 million for the year ended December 31, 2020, compared to $9.8 million for the year ended December 31, 2019, representing a decrease of $3.2 million, or 33%. The decrease was primarily attributable to a $5.6 million decrease in net interest income and investment amortization resulting from reductions in interest rates and related yields, partially offset by the $2.3 million impact of revaluing a convertible preferred stock warrant liability in the year ended December 31, 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Adjusted EBITDA</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for interest and other income, net, income tax (expense) benefit, depreciation and amortization and share-based compensation expenses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation, or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;">all expenditures or future requirements for capital expenditures or contractual commitments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;">changes in our working capital needs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;">income tax (expense) benefit, which may be a necessary element of our costs and ability to operate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;">the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;">the non-cash component of employee compensation expense&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Times New Roman;color:#000000;">the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of our net loss to Adjusted EBITDA for the periods presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,447</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,590</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,785</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,309</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,472</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,791</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense <sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,761</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,124</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,149</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjusted EBITDA</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,584</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,476</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,607</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup> Represents share-based compensation expense related to option and restricted stock unit awards. See Note 13 to our financial statements included elsewhere in this Annual Report on Form 10-K for details on our share-based compensation expense.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses since inception and have incurred negative cash flows from operations from inception through December&#160;31, 2018, and again in the year ended December 31, 2020. As of December 31, 2020, we had an accumulated deficit of $511.6 million.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have funded our operations to date principally from the sale of convertible preferred stock and common stock and, to a lesser extent, sequencing and development revenue. As of December 31, 2020, we had cash, cash equivalents and marketable securities of $806.8 million.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12&#160;months. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. If our available cash, cash equivalents and marketable securities balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our shareholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. This additional capital may not be available on reasonable terms, or at all. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to utilize the existing cash, cash equivalents and marketable securities on hand primarily to fund our commercial and marketing activities associated with our clinical products and services, continued research and development initiatives for our pipeline candidates and drug discovery initiatives</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ongoing investments in our immune medicine platform</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We also expect to make increased capital expenditures in the near term related to the expansion of our office and laboratory space and expect to increase investment in laboratory equipment and operations to support our anticipated growth. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> capital preservation and</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> liquidity. Currently, our funds are held in money market funds and marketable securities consisting of U.S. government debt securities and corporate bonds.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contractual obligations as of December 31, 2020 include operating lease obligations of $149.6 million, reflecting the minimum commitments for our office and laboratory spaces in Seattle, Washington and South San Francisco, California, a commitment to an office lease in New York City, New York and a commitment for server space in Seattle, Washington. See Note 10 to our financial statements included elsewhere in this Annual Report on Form 10-K for more information, including the timing of cash payments related to these lease obligations. Additionally, we have purchase commitments for cloud data storage through our collaboration with Microsoft, software and service license commitments, which are generally fulfilled within one to three years, royalty commitments and minimum commitments for laboratory material suppliers, which are generally fulfilled within one year. Furthermore, in connection with one of our lease agreements, we have an existing letter of credit of $2.1 million with one of our existing financial institutions.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we may experience reductions in our revenue in the near term as a result of the COVID-19 pandemic or otherwise, as long-term revenue from sales of our current and future products and services is expected to grow, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our uses and sources of cash for the years ended December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,683</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,404</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117,044</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(481,697</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,587</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319,916</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities during the year ended December 31, 2020 was $149.7 million, which was primarily attributable to a net loss of $146.2 million and a net change in our operating assets and liabilities of $40.8 million, which were partially offset by non-cash share-based compensation of $24.8 million, non-cash depreciation and amortization of $9.2 million and noncash lease expense of $3.3 million. The net change in our operating assets and liabilities was primarily due to a $43.4 million reduction in deferred revenue primarily related to revenue recognized from the Genentech Agreement, a $5.0 million increase in inventory, a $1.4 million increase in prepaid expenses and other current assets and a $0.9 million decrease in operating lease liabilities. These changes were partially offset by an increase in accounts payable and accrued liabilities of $7.5 million and a reduction in accounts receivable, net of $2.6 million.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by operating activities during the year ended December 31, 2019 was $205.4 million, which was primarily attributable to a net change in our operating assets and liabilities of $254.9 million, non-cash share-based compensation of $13.1 million, non-cash depreciation and amortization of $3.3 million and a $2.3 million fair value adjustment of our convertible preferred stock warrant liability due to an increase in valuation of our common stock, partially offset by a net loss of $68.6 million. The net change in our operating assets and liabilities reflects an increase in deferred revenue of $266.9 million, primarily due to the $300.0 million upfront payment by Genentech, and an increase in accounts payable and accrued liabilities of $6.1 million, primarily due to increased headcount and the growth in operating expenditures and timing of vendor payments. These increases were partially offset by an increase in accounts receivable of $7.8 million, primarily due to an increase in clinical billings, as well as an increase in revenue paid in arrears rather than upfront by biopharmaceutical customers, an increase in prepaid expenses and other current assets of $8.6 million, primarily due to prepaid software, prepaid insurance and interest receivables, an increase in inventory of $1.2 million to support growth in lab operations and $0.6 million in security deposits. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities during the year ended December 31, 2020 was $117.0 million, which was primarily attributable to purchases of marketable securities of $695.0 million and purchases of property and equipment of $18.8 million, partially offset by proceeds from sales and maturities of marketable securities of $596.7 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities during the year ended December 31, 2019 was $481.7 million, which was primarily attributable to purchases of marketable securities of $884.2 million and purchases of property and equipment of $11.2 million, partially offset by proceeds from maturities of marketable securities of $413.7 million.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities during the year ended December 31, 2020 was $293.6 million, which was primarily attributable to $271.8 million in proceeds, after deducting underwriting discounts and net offering expenses paid by us, received from our underwritten public offering completed in July 2020, as well as $21.7 million in proceeds from the exercise of stock options.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities during the year ended December 31, 2019 was $319.9 million, which was primarily attributable to proceeds from our initial public offering, net of underwriting discounts and commissions, of $320.9 million and proceeds from the exercise of stock options of $4.1 million, partially offset by payment of deferred initial public offering costs of $5.0 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Net Operating Loss Carryforwards</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of our NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 (&#8220;Section 382&#8221;) and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. We have completed a Section 382 analysis for changes in ownership through December 31, 2018 and an analysis is ongoing for ownership changes through December 31, 2020. Based on these analyses, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the TCJA, federal net operating losses incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOL is subject to an annual limitation. Net operating losses generated prior to 2018 are eligible to be carried forward up to 20 years. Based on the available objective evidence, management determined that it was more likely than not that the net deferred tax assets would not be realizable as of December 31, 2020. Accordingly, management applied a full valuation allowance against net deferred tax assets as of December 31, 2020. In March 2020, under the newly enacted Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;), NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding the tax year of the loss. Additionally, the CARES Act temporarily removes the 80% limitation, reinstating it for tax years beginning after 2020. <span style="Background-color:#FFFFFF;">However, none of these provisions have an impact on our tax provision.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have prepared our financial statements in accordance with GAAP. Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and related disclosures at the date of the financial statements, as well as revenue and expense recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and or other relevant assumptions that we believe to be reasonable under the</span><span style="font-size:12pt;"> </span>circumstances. Estimates are used in several areas, including, but not limited to, estimates of progress to date for certain performance obligations and transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this <span style="Background-color:#FFFFFF;">Annual Report on Form 10-K</span>, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development and sequencing revenue arrangements may include upfront payments for the performance of services in the future, which have both fixed and variable consideration.&#160;Non-refundable&#160;upfront fees and funding for related development services are generally considered fixed consideration, while milestone payments are identified as variable consideration.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the appropriate amount of revenue to recognize as we fulfill our obligations under these agreements, we perform the following steps to determine the amount of revenue to be recognized: (1)&#160;identify the contract or contracts&#59; (2)&#160;determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract&#59; (3)&#160;measure the transaction price, including the constraint on variable consideration&#59; (4)&#160;allocate the transaction price to the performance obligations based on estimated selling prices&#59; and (5)&#160;recognize revenue when (or as) we satisfy each performance obligation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606,</span><span style="font-style:italic;">&#160;Revenue from Contracts with Customers</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Our performance obligations include sequencing services and services associated with regulatory submission and approval processes. Significant management judgment is applied to determine (1)&#160;the measurement of the transaction price, including the constraint on variable consideration, (2)&#160;the allocation of the transaction price to the performance obligations and (3)&#160;the appropriate input or output based method to recognize revenue and the extent of progress to date.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we&#160;re-evaluate&#160;the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjust our estimate of the overall transaction price.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine the allocation of the transaction price to the performance obligations, we apply the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell the services and estimate the price that a customer in that market would be willing to pay for those services.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To select the measure of progress, we consider the expectations of the performance period which may be based on customer-dependent estimates of samples or internal estimates of the performance period based on both the customer and our expected development timeframes. For our collaboration with Genentech, we estimate the extent of progress using a proportional performance model that uses an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Product and Personalized Product pathways. These estimates are based on our internal estimates and development timeframes, which are subject to revision based on the potential outcomes for both product pathways, decisions made by Genentech, regulatory feedback or other factors not currently known. We regularly review our expectations of the extent of progress, including whether any variable consideration is no longer constrained, and, if any changes in estimates are made, we recognize revenue using the cumulative&#160;catch-up&#160;method.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure share-based compensation expense for stock options granted to our employees and non-employee directors on the date of grant and recognize the corresponding compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of stock options granted to our employees and non-employee directors on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The assumptions used to calculate the grant date fair value of our stock options were:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of our initial public offering, the fair value of our common stock issuable upon exercise of stock options was determined by our board of directors, with input from management and independent third-party valuations, as discussed in &#8220;&#8212;<span style="font-style:italic;">Common Stock Valuations</span>&#8221; below. For valuations of option grants made after the closing of our initial public offering, our board of directors determines the fair value of each share of common stock based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expected term represents the period that our stock options are expected to be outstanding. The expected term of options granted to employees and non-employee directors is determined using the &#8220;simplified&#8221; method, as illustrated in ASC Topic 718,&#160;<span style="font-style:italic;">Compensation&#8212;Stock Compensation</span>, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is based on the midpoint between the vesting date and the end of the contractual term of the option.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of the expected term. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the options.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Black-Scholes assumptions</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The estimated grant date fair value of options granted during the periods presented was estimated using the Black-Scholes option-pricing model with the following assumptions</span><span style="color:#000000;">: </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.68 - $55.23</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.80 - $47.81</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.55</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.27 - 6.08</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.27 - 6.08</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.08 - 10.00</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4% - 1.7%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4% - 2.5%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6% - 3.0%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.5% - 73.3%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.3% - 72.9%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65.0% - 69.2%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for forfeitures as they occur, rather than estimate expected forfeitures over the vesting period of the respective grant.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use judgment in evaluating the assumptions related to our share-based compensation on a prospective basis. As we continue to accumulate additional data related to our common stock, we may have refinements to our estimates, which could materially impact our future share-based compensation expense. As of December&#160;31, 2020, unrecognized share-based compensation expense related to unvested stock options was $74.9&#160;million, which was expected to be recognized over a remaining weighted-average period of 3.0 years.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock Valuations</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For periods prior to the closing of our initial public offering, the estimated fair value of the common stock issuable upon exercise of our stock options was determined by our board of directors, with input from management, considering our most recently available third-party valuations of common stock and our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the grant, which intended all options granted to be exercisable at a price per share not less than the fair market value per share of our common stock issuable upon exercise of those options on the date of grant. We believe our board of directors had the relevant experience and expertise to determine the fair value of our common stock. Prior to our initial public offering, given the absence of a public trading market for our common stock, the valuations of our common stock were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid,<span style="font-style:italic;">&#160;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span>. The assumptions we used in the valuation model were based on future expectations combined with management&#8217;s judgment. In the absence of a public trading market, our board of directors, with input from management, exercised significant judgment and considered numerous objective and subjective factors to determine the fair value of our common stock as of the date of each option grant, including the following factors:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">independent valuations performed at periodic intervals by an independent third-party valuation firm&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prices, rights, preferences and privileges of our convertible preferred stock relative to our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our operating and financial performance, forecasts and capital resources&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">current business conditions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the hiring of key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our stage of commercialization&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the status of research and development efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the likelihood of achieving a liquidity event for the shares of common stock issuable upon exercise of these stock options, such as an initial public offering or sale of our company, given prevailing market conditions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any adjustment necessary to recognize a lack of marketability for our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">trends and developments in our industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the market performance of comparable publicly traded technology companies&#59; and</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. and global economic and capital market conditions.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In valuing our common stock prior to the closing of our initial public offering, we utilized a hybrid methodology that includes a probability-weighted expected return method (&#8220;PWERM&#8221;) and an option pricing method (&#8220;OPM&#8221;), which is a highly complex and subjective valuation methodology. Under a PWERM, the fair market value of the common stock is estimated based upon an analysis of future values for the enterprise assuming various future outcomes. Within one of those potential outcomes, we utilized the OPM. The OPM treats the rights of the holders of convertible preferred stock and common stock as equivalent to that of call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of preferred stock, as well as their rights to participation and conversion. Based on the timing and nature of an assumed liquidity event in each scenario, a discount for lack of marketability either was or was not applied to each scenario, as appropriate. We then probability-weighted the value of each expected outcome to arrive at an estimate of fair value per share of common stock.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For valuations after the closing of our initial public offering, our board of directors determines the fair value of each share of common stock based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October&#160;1 and upon any occurrence of triggering events or substantive changes in circumstances that could indicate a potential impairment.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. We evaluate certain qualitative factors such as macroeconomic conditions, the market and industry in which we operate, cost factors, overall financial performance and other relevant entity-specific events to determine if there are any negative trends or events that could indicate impairment. Key assumptions in this analysis include anticipated demand for our products and services, including industry and regulatory changes, future revenue growth and cash, cash equivalents and marketable securities on hand. These assumptions are determined based on our historical performance and management&#8217;s forecasted results. Management&#8217;s estimates of forecasted results are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our statements of operations. To date, we have not recognized any impairment of goodwill.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 2 to our financial statements included elsewhere in this Annual Report on Form 10-K for more information. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">Item 7A. Quantitative and Qualitative Disclosures About Market Risk </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Interest Rate Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents and marketable securities. As of December 31, 2020 and 2019, we had cash and cash equivalents of $123.4 million and $96.6 million, respectively, held primarily in cash deposits and money market funds. As of December 31, 2020, we had short-term and long-term marketable securities of $683.4&#160;million, held in U.S. government debt securities and corporate bonds. As of December 31, 2019, we had short-term and long-term marketable securities of $585.7 million, held in U.S. government debt securities, commercial paper and corporate bonds. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the United States. As of December 31, 2020, a hypothetical 100 basis point increase in interest rates would have resulted in a $4.3 million decline of the fair value of our available-for-sale securities, as compared to an approximate $3.0 million decline as of December 31, 2019. The additional decline of fair value in this hypothetical scenario is primarily due a larger investment balance as of December 31, 2020 compared to that as of December 31, 2019. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur. Such losses would only be realized if we sold the investments prior to maturity. We do not enter into investments for trading purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_AND_SUPPLEME">Item 8. Financial Statements and Supplementary Data</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Adaptive Biotechnologies Corporation</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Index to Financial Statements</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2020 and 2019 and </span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">For the Years Ended December 31, 2020, 2019 and 2018</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><span style="text-decoration:underline;">Balance Sheets</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS"><span style="text-decoration:underline;">Statements of Operations</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_COMPREHENSIVE_LOSS"><span style="text-decoration:underline;">Statements of Comprehensive Loss</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S"><span style="text-decoration:underline;">Statements of Convertible Preferred Stock and Shareholders&#8217; (Deficit) Equity</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Statements of Cash Flows</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:92.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_FINANCIAL_STATEMENTS_DECEMBER_3"><span style="text-decoration:underline;">Notes to Financial Statements</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Shareholders and the Board of Directors of Adaptive Biotechnologies Corporation</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying balance sheets of Adaptive Biotechnologies Corporation (the Company) as of December 31, 2020 and 2019, the related statements of operations, comprehensive loss<span style="font-weight:bold;">,</span>&#160;convertible preferred stock and shareholders' (deficit) equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control<span style="font-family:Arial;color:#000000;">&#8212;</span>Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 24, 2021 expressed an unqualified opinion thereon.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Critical Audit Matters<span style="Background-color:#F4F4F4;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account<span style="font-weight:bold;">s</span> or disclosure<span style="font-weight:bold;">s</span>&#160;to which it relates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:86.67%;">
<tr>
<td style="width:26.67%;"></td>
<td style="width:60%;"></td>
</tr>
<tr>
<td valign="top" style="padding-left:2.25pt;padding-Right:2.25pt;padding-Top:2.25pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="padding-left:2.25pt;padding-Right:2.25pt;padding-Top:2.25pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Estimation of Total Expected Costs of Genentech Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:2.25pt;padding-Right:2.25pt;padding-Top:2.25pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Description of the Matter</p></td>
<td valign="top" style="padding-left:2.25pt;padding-Right:2.25pt;padding-Top:2.25pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As more fully described in Note 3 of the financial statements, Genentech Agreement revenue is estimated to be recognized over a period of seven to eight years from the effective date. The non-refundable upfront consideration of $300.0 million is recognized using a proportional performance model through an input method based on costs incurred relative to the total estimated costs of research and development efforts. For the twelve months ended December 31, 2020, total revenue recorded totaled $52.8 million and related deferred revenue totaled $212.1 million. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Auditing management&#8217;s estimate related to determining the total expected research and development costs at completion is complex and requires judgment as a result of the uncertainties of the ultimate progression of the customized product paths, timing and path of development and commercialization decisions, which are controlled by Genentech.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:2.25pt;padding-Right:2.25pt;padding-Top:2.25pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">How We Addressed the Matter in Our Audit</p></td>
<td valign="top" style="padding-left:2.25pt;padding-Right:2.25pt;padding-Top:2.25pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process to estimate the total costs of research and development efforts for the collaboration based on evaluating the progress of the collaboration and the likely path of future development based on significant decisions made by Genentech communicated through the joint committees. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To test the estimate of total expected research and development costs, we performed audit procedures that included, among others, observing the quarterly meetings with accounting and the Company collaboration managers discussing the status of the collaboration and the future development for the customized product paths, investigating any changes to the development path. We reviewed supporting documentation to corroborate progress and status of the overall timeline, including meeting minutes from the joint committees.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &#38; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2015</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seattle, Washington</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="BALANCE_SHEETS">Balance<span style="letter-spacing:-0.05pt;"> </span>Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="letter-spacing:0.05pt;"> </span>thousands,<span style="letter-spacing:-0.05pt;"> </span>except<span style="letter-spacing:-0.05pt;"> </span>share<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>per share<span style="letter-spacing:-0.05pt;"> </span>amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">123,436</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities (amortized cost of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">564,036</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">479,791</ix:nonFraction>, respectively)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">564,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">480,290</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,676</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:InventoryNet" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,063</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:InventoryNet" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,079</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:AssetsCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">726,914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:AssetsCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">612,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities (amortized cost of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,429</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,263</ix:nonFraction>, respectively)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:Goodwill" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:Goodwill" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001478320_20201231" decimals="-3" scale="3">598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" scale="3">784</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:Assets" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,116,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:Assets" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">912,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and shareholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,453</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred rent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0001478320_20191231" decimals="-3" scale="3">371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,529</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent liability, less current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,918</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, less current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, less current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">219,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" scale="3">93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:Liabilities" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">373,148</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:Liabilities" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">341,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 11)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000082">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000083">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock: <span>$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000102" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001478320_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000103" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001478320_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000104" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000105" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001478320_20191231" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and 2019&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000106" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001478320_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000107" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001478320_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000108" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001478320_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000109" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001478320_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000084">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000085">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock: $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000110" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001478320_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000111" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001478320_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000112" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001478320_20191231" decimals="INF" format="ixt:numdotdecimal">340,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and 2019&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000114" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000116" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal">137,646,896</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000115" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001478320_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000117" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001478320_20191231" decimals="INF" format="ixt:numdotdecimal">125,238,142</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:CommonStockValue" contextRef="C_0001478320_20201231" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:CommonStockValue" contextRef="C_0001478320_20191231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,253,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">935,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive gain</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001478320_20201231" decimals="-3" scale="3">893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001478320_20191231" decimals="-3" scale="3">671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001478320_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">511,612</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001478320_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">365,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shareholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">743,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">571,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and shareholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,116,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">912,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.05pt;"> </span>accompanying notes<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>integral<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.05pt;"> </span>financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_OPERATIONS">Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="letter-spacing:0.05pt;"> </span>thousands,<span style="letter-spacing:-0.05pt;"> </span>except<span style="letter-spacing:-0.05pt;"> </span>share<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>per share<span style="letter-spacing:-0.05pt;"> </span>amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,439</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,519</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,978</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,943</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,552</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,685</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,382</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">85,071</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,663</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,530</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,274</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,668</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,072</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,705</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,157</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:SellingAndMarketingExpense" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,358</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:SellingAndMarketingExpense" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,453</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:SellingAndMarketingExpense" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,486</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,536</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,332</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,409</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of intangible assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,703</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,698</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,699</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:CostsAndExpenses" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">251,199</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:CostsAndExpenses" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,462</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:CostsAndExpenses" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,419</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">152,817</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">78,391</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">49,756</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,590</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,785</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:InterestAndOtherIncome" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,309</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,227</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">68,606</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,447</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustment to Series E-1 convertible preferred stock options</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shareholders</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,227</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,570</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,345</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders, basic and diluted</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000159" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001478320_20200101_20201231" decimals="2" sign="-">1.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000160" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001478320_20190101_20191231" decimals="2" sign="-">1.01</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000161" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001478320_20180101_20181231" decimals="2" sign="-">3.67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used in computing net loss per share attributable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; to common shareholders, basic and diluted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000162" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001478320_20200101_20201231" decimals="0" format="ixt:numdotdecimal">131,216,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000163" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001478320_20190101_20191231" decimals="0" format="ixt:numdotdecimal">69,165,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000164" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001478320_20180101_20181231" decimals="0" format="ixt:numdotdecimal">12,629,778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.05pt;"> </span>accompanying<span style="letter-spacing:-0.05pt;"> </span>notes are an integral<span style="letter-spacing:-0.05pt;"> </span>part of these financial<span style="letter-spacing:-0.1pt;"> </span>statements.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:1.5pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_COMPREHENSIVE_LOSS">Statements of Comprehensive<span style="letter-spacing:-0.05pt;"> </span>Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="letter-spacing:0.05pt;"> </span>thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">68,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain (loss) on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001478320_20200101_20201231" decimals="-3" scale="3">222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">67,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,388</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.05pt;"> </span>accompanying<span style="letter-spacing:-0.05pt;"> </span>notes are an integral<span style="letter-spacing:-0.05pt;"> </span>part of these financial<span style="letter-spacing:-0.1pt;"> </span>statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CONVERTIBLE_PREFERRED_STOCK_S">Statements of Convertible Preferred Stock<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Shareholders&#8217;<span style="letter-spacing:-0.05pt;"> (</span>Deficit) Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="letter-spacing:0.05pt;"> </span>thousands,<span style="letter-spacing:-0.05pt;"> </span>except<span style="letter-spacing:-0.05pt;"> </span>share<span style="letter-spacing:-0.05pt;"> </span>amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shareholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Loss) Gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2017</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000174" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231" decimals="INF" format="ixt:numdotdecimal">92,656,029</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">561,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000176" name="us-gaap:SharesOutstanding" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" format="ixt:numdotdecimal">12,208,731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="-3" sign="-" scale="3">166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">249,423</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">224,616</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to accumulated deficit for adoption of guidance on</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; accounting for share-based payment transactions</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_srtRestatementAxis_srtRevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" scale="3">140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_srtRestatementAxis_srtRevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" sign="-" scale="3">140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for cash upon exercise of stock options</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000184" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">632,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series E-1 convertible preferred stock for cash upon exercise</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of Series E-1 convertible preferred stock options at fair value</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000187" name="adpt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">134,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested Series E-1 convertible preferred stock option forfeitures</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="adpt:TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="-3" scale="3">767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" scale="3">291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series E-1 convertible preferred stock option share-based compensation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment to redemption value for vested Series E-1 convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred stock options</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="adpt:TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" sign="-" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in redemption value for vested Series E-1 convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock options</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="adpt:TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="-3" scale="3">189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" sign="-" scale="3">189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" scale="3">189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock option share-based compensation</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" scale="3">59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000207" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">92,790,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">560,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000209" name="us-gaap:SharesOutstanding" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">12,841,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" scale="3">107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">295,908</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258,112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from initial public offering, net of underwriters' discounts and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; commissions</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000215" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">17,250,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">320,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">320,850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial public offering costs</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="adpt:AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="adpt:AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock to common stock</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000221" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" sign="-" format="ixt:numdotdecimal">93,039,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">561,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000223" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">93,039,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">561,922</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">561,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock warrant to common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; warrant</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="adpt:AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="adpt:AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of common stock warrants</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000229" name="adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">54,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="adpt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="adpt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for cash upon exercise of stock options</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000232" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,043,767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series E-1 convertible preferred stock for cash upon exercise</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of Series E-1 convertible preferred stock options at fair value</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000235" name="adpt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">249,643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" scale="3">109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted stock units</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000237" name="adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">8,310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in redemption value for vested Series E-1 convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock options</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="adpt:TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" scale="3">964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" scale="3">964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" scale="3">964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock option and restricted stock unit share-based compensation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">68,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">68,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000247" name="us-gaap:SharesOutstanding" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">125,238,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">935,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">365,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">571,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon public offering, after deducting</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; underwriters' discounts and net offering costs paid by us</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000253" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">7,200,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">271,838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">271,839</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to accumulated deficit for adoption of guidance on</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; accounting for leases</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" scale="3">93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20201231" decimals="-3" scale="3">93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for cash upon exercise of stock options</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000260" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,204,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted stock units</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000264" name="adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock option and restricted stock unit share-based compensation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" scale="3">222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001478320_20200101_20201231" decimals="-3" scale="3">222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000271" name="us-gaap:SharesOutstanding" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">137,646,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,253,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">511,612</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:StockholdersEquity" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">743,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.05pt;"> </span>accompanying notes<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>integral<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.05pt;"> </span>financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_CASH_FLOWS">Statements of Cash<span style="letter-spacing:-0.05pt;"> </span>Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="letter-spacing:0.05pt;"> </span>thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:ProfitLoss" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:ProfitLoss" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">68,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:ProfitLoss" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash (used in) provided by operating</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:Depreciation" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,769</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:Depreciation" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:Depreciation" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncash lease expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="adpt:NoncashLeaseExpense" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:ShareBasedCompensation" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:ShareBasedCompensation" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:ShareBasedCompensation" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,698</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,214</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustment of convertible preferred stock warrant</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:OtherNoncashIncomeExpense" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">71</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:OtherNoncashIncomeExpense" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:OtherNoncashIncomeExpense" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,613</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">775</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,231</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="adpt:IncreaseDecreaseInDeferredRent" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="adpt:IncreaseDecreaseInDeferredRent" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" scale="3">488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="adpt:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" scale="3">886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">43,389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">266,927</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" scale="3">649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="C_0001478320_20200101_20201231" decimals="-3" scale="3">276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">597</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">182</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">149,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">205,404</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">694,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">884,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">146,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sales and maturities of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">596,724</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">413,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">153,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">117,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">481,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">736</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,055</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,268</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from public offering of common stock, net of underwriting discounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and commissions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">272,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">320,850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of public offering costs, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001478320_20200101_20201231" decimals="-3" scale="3">321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon the exercise of a common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock warrant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="adpt:ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">293,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">319,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,623</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">30,275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,714</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001478320_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001478320_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">85,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">125,574</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,714</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001478320_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncash investing and financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of equipment included in accounts payable and accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord-funded leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="adpt:LandlordFundedLeaseholdImprovements" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,419</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncash additions to property through lease financing arrangements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition of lease financing arrangements upon adoption of guidance on</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; accounting for leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="adpt:DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock to common stock upon closing of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; initial public offering</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="adpt:ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">561,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock warrant to common stock warrant</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; upon closing of initial public offering</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="adpt:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.05pt;"> </span>accompanying<span style="letter-spacing:-0.05pt;"> </span>notes are an integral<span style="letter-spacing:-0.05pt;"> </span>part of these financial<span style="letter-spacing:-0.1pt;"> </span>statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_FINANCIAL_STATEMENTS_DECEMBER_3">Notes<span style="letter-spacing:-0.05pt;"> </span>to Financial Statements</p><ix:nonNumeric id="F_000364" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Description of Business</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation (&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune conditions and infectious diseases.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in the State of Washington on September&#160;8, 2009 under the name Adaptive TCR Corporation. On December&#160;21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our registration statement on Form S-1 related to our initial public offering was declared effective on June 26, 2019 and our common stock began trading on the Nasdaq Global Select Market on June 27, 2019.&#160;On July 1, 2019, we completed our initial public offering in which we issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000431" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701" decimals="INF" format="ixt:numdotdecimal">17,250,000</ix:nonFraction> shares of common stock, including shares issued upon the exercise in full of the underwriters&#8217; over-allotment option, at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000432" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701" decimals="INF">20.00</ix:nonFraction> per share. We received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701" decimals="-5" scale="6">315.9</ix:nonFraction> million in net proceeds, after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="adpt:SaleOfStockUnderwritingDiscountsAndCommission" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701" decimals="-5" scale="6">24.1</ix:nonFraction> million and offering expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="adpt:InitialPublicOfferingExpenses" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701" decimals="-5" scale="6">5.0</ix:nonFraction> million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Follow-On Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we completed an underwritten public offering of our common stock in which we issued and sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000436" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">7,200,000</ix:nonFraction> shares of common stock, including shares issued upon the exercise in full of the underwriters&#8217; over-allotment option, at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000437" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200731" decimals="INF">40.00</ix:nonFraction> per share. We received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200701_20200731" decimals="-5" scale="6">271.8</ix:nonFraction>&#160;million in net proceeds, after deducting underwriting discounts and net offering expenses paid by us.</p></ix:nonNumeric><ix:nonNumeric id="F_000365" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000365_dcnt_e08ed862-7075-475b-abc9-eb280b55a5e2">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Significant</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Accounting</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Policies</span></p></td></tr></table></div><ix:nonNumeric id="F_000381" name="adpt:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Basis<span style="letter-spacing:-0.05pt;"> </span>of Presentation and<span style="letter-spacing:-0.05pt;"> </span>Use<span style="letter-spacing:-0.05pt;"> </span>of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</p></ix:nonNumeric><ix:nonNumeric id="F_000382" name="adpt:JOBSActAccountingElectionPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000382_dcnt_75dcf508-9d80-4541-ba0a-efd9a095efe6">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">JOBS Act Accounting Election</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective December 31, 2020, we are no longer an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Prior to December 31, 2020, we had elected to use this extended transition period and, as a result, our financial statements may not be comparable to companies that comply with public company effective dates. We can no longer take advantage of this extended transition period.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000365_dcnt_e08ed862-7075-475b-abc9-eb280b55a5e2" continuedAt="F_000365_dcnt_ea7a24c3-c777-4e80-973a-d9ab9dcbc155"><ix:continuation id="F_000382_dcnt_75dcf508-9d80-4541-ba0a-efd9a095efe6">
</ix:continuation><ix:nonNumeric id="F_000383" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</p></ix:nonNumeric><ix:nonNumeric id="F_000384" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of <span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001478320_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001478320_20191231" decimals="-5" scale="6">2.1</ix:nonFraction></ix:nonFraction></span> million as of December 31, 2020 and 2019.</p></ix:nonNumeric>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Investments in Marketable Securities</p><ix:nonNumeric id="F_000385" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities are classified as&#160;available-for-sale, primarily consist of U.S. government debt securities, commercial paper and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; (deficit) equity in accumulated other comprehensive (loss) gain until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</p></ix:nonNumeric><ix:nonNumeric id="F_000386" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations<span style="letter-spacing:-0.05pt;"> </span>of Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a concentration of risk from a limited number of suppliers, or in some cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each balance sheet date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.</p><ix:nonNumeric id="F_000406" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, Net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000441" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="3" scale="-2">13.9</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000442" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231" decimals="3" scale="-2">18.4</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000443" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="3" scale="-2">19.1</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000444" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="3" scale="-2">41.8</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000445" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231" decimals="3" scale="-2">13.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000446" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="3" scale="-2">12.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000447" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231" decimals="3" scale="-2">15.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech, Inc. and Roche Group</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000448" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncAndRocheGroupMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="3" scale="-2">55.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000449" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncAndRocheGroupMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231" decimals="3" scale="-2">42.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* less than 10%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000387" name="us-gaap:ReceivablesPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounts Receivable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:UnbilledReceivablesCurrent" contextRef="C_0001478320_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:UnbilledReceivablesCurrent" contextRef="C_0001478320_20191231" decimals="-5" scale="6">2.4</ix:nonFraction> million of unbilled receivables as of December&#160;31, 2020 and 2019, respectively. The unbilled receivables are amounts that will become due for which we have an unconditional right to consideration.</p></ix:nonNumeric><ix:nonNumeric id="F_000388" name="us-gaap:InventoryPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000388_dcnt_67ab52c5-ed65-4e3d-94a5-1d7eea4ea855">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a&#160;first-in,&#160;first-out&#160;basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000365_dcnt_ea7a24c3-c777-4e80-973a-d9ab9dcbc155" continuedAt="F_000365_dcnt_8510e211-76a6-4232-8e34-3d46947ba51a"><ix:continuation id="F_000388_dcnt_67ab52c5-ed65-4e3d-94a5-1d7eea4ea855">
</ix:continuation><ix:nonNumeric id="F_000389" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</p><ix:nonNumeric id="F_000407" name="adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Useful lives assigned to property and equipment are as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;">
<tr>
<td style="width:223.55pt;"></td>
<td style="width:7.85pt;"></td>
<td style="width:223.5pt;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000452" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen">3 years</ix:nonNumeric> to <ix:nonNumeric id="F_000453" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen">7 years</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000454" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Shorter of estimated useful life or remaining lease term</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000455" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerEquipmentAndSoftwareMember_20200101_20201231" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000456" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen">5 years</ix:nonNumeric> to <ix:nonNumeric id="F_000457" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen">10 years</ix:nonNumeric></p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our statements of operations in accordance with the use of the asset.</p></ix:nonNumeric><ix:nonNumeric id="F_000390" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October&#160;1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our statements of operations. To date, we have <ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:GoodwillImpairmentLoss" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognized any impairment of goodwill.</p></ix:nonNumeric><ix:nonNumeric id="F_000391" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have <ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognized any impairment losses on intangible assets.</p></ix:nonNumeric><ix:nonNumeric id="F_000392" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000392_dcnt_63364807-5628-49fc-ad7b-f0fca8f0fd81">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory and office facilities that we occupy, as well as server space. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of the new lease standard, discussed in more detail below. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our leases contain options to extend or terminate the lease&#59; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory and office facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000365_dcnt_8510e211-76a6-4232-8e34-3d46947ba51a" continuedAt="F_000365_dcnt_7d1e22ac-4402-4960-a957-dd31f8fb584d"><ix:continuation id="F_000392_dcnt_63364807-5628-49fc-ad7b-f0fca8f0fd81">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lease Financing Arrangements</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, due to our significant involvement during the construction process of a leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance. Prior to our adoption of the new lease standard, the cost of the related building was recorded in property and equipment, net and the offsetting lease financing obligation was recorded as a long-term financing obligation on our balance sheet. As of December 31, 2019, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:BuildingsAndImprovementsGross" contextRef="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_20191231" decimals="-5" scale="6">36.6</ix:nonFraction> million of building costs was recorded in property and equipment, net.  </p></ix:continuation><ix:nonNumeric id="F_000393" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level 1: Quoted </span><span style="Background-color:#FFFFFF;color:#000000;">prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;">Level 2: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial instruments consist of Level&#160;1 and Level&#160;2 assets and has included Level&#160;3 liabilities in the past. In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level&#160;3 within the valuation hierarchy. The carrying amounts of certain financial instruments approximate fair value due to their short&#160;maturities.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December&#160;31, 2020 or 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000394" name="adpt:StockholdersEquityConvertiblePreferredStockPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Preferred Stock Warrant Liability</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had issued a freestanding warrant to a venture capital firm to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000461" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231" decimals="INF" format="ixt:numdotdecimal">56,875</ix:nonFraction> shares of Series&#160;C convertible preferred stock with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000462" name="adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231" decimals="2">2.64</ix:nonFraction> in connection with a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231" decimals="-5" scale="6">5.0</ix:nonFraction>&#160;million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the conversion, the fair value of this warrant was classified as a&#160;non-current&#160;liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders&#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20190101_20191231" decimals="-5" scale="6">2.3</ix:nonFraction> million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our statements of operations. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20201231" decimals="-5" scale="6">2.6</ix:nonFraction> million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.</p></ix:nonNumeric><ix:nonNumeric id="F_000395" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000395_dcnt_63f5da3c-7e06-4a0d-b5e8-c82ca964d377">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Revenue<span style="letter-spacing:-0.1pt;"> </span>Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), <span style="font-style:italic;">Revenue from Contracts with Customers</span>. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1)&#160;identify the contract or contracts&#59; (2)&#160;determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract&#59; (3)&#160;measure the transaction price, including the constraint on variable consideration&#59; (4)&#160;allocate the transaction price to the performance obligations based on estimated selling prices&#59; and (5)&#160;recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000365_dcnt_7d1e22ac-4402-4960-a957-dd31f8fb584d" continuedAt="F_000365_dcnt_36a04b3f-7667-46b8-9929-0ce6f4929812"><ix:continuation id="F_000395_dcnt_63f5da3c-7e06-4a0d-b5e8-c82ca964d377" continuedAt="F_000395_dcnt_76a1ce82-9f8f-4e1b-be77-cb065ab5bf45">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue is generated from immunosequencing (&#8220;sequencing&#8221;) products and services (&#8220;sequencing revenue&#8221;) and from regulatory or development support services leveraging our immune medicine platform (&#8220;development revenue&#8221;). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sequencing Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue reflects the amounts generated from providing sequencing services and testing through our clonoSEQ and immunoSEQ products and services to our clinical and research customers, respectively. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clinical customers, we derive revenues from providing our clonoSEQ test report to ordering physicians, and we bill and receive payments from medical institutions and commercial and government third-party payors. In these transactions, we have identified one performance obligation: the delivery of a clonoSEQ report. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test.&#160;Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized as we deliver the remaining tests in a patient&#8217;s treatment cycle or when it becomes remote that a patient will receive additional testing and we have not delivered our estimate of total tests.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research customers, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified <ix:nonFraction unitRef="U_adptPerformance_Obligation" id="F_000466" name="adpt:NumberOfRevenuePerformanceObligation" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development<span style="letter-spacing:-0.05pt;"> </span>Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers&#8217; initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements may include single or multiple performance obligations, depending on the contract. For certain contracts, we may perform services to support the biopharmaceutical customers&#8217; regulatory submissions as part of their registrational trials. These services include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers&#8217; control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone. </p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000365_dcnt_36a04b3f-7667-46b8-9929-0ce6f4929812" continuedAt="F_000365_dcnt_12dd3ee9-c3b3-4aa3-bdbe-768e40b492bb"><ix:continuation id="F_000395_dcnt_76a1ce82-9f8f-4e1b-be77-cb065ab5bf45">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.</span></p></ix:continuation><ix:nonNumeric id="F_000396" name="adpt:ContractBalancesPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months&#59; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or&#160;non-current&#160;based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.</p></ix:nonNumeric><ix:nonNumeric id="F_000397" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and&#160;non-employees.&#160;It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model. </p></ix:nonNumeric><ix:nonNumeric id="F_000398" name="us-gaap:AdvertisingCostsPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising costs are expensed as incurred. Advertising expenses were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:AdvertisingExpense" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">14.5</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:AdvertisingExpense" contextRef="C_0001478320_20190101_20191231" decimals="-5" scale="6">6.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:AdvertisingExpense" contextRef="C_0001478320_20180101_20181231" decimals="-5" scale="6">3.5</ix:nonFraction> million for the year ended December 31, 2020, 2019 and 2018, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000399" name="us-gaap:CostOfSalesPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue includes the cost of materials, personnel-related expenses (comprised of salaries, benefits and share-based compensation), shipping and handling, equipment and allocated facility costs associated with processing samples and professional support for our sequencing revenue. Allocated facility costs include depreciation of laboratory equipment, allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</p></ix:nonNumeric><ix:nonNumeric id="F_000400" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses are comprised of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. <span style="Background-color:#FFFFFF;color:#000000;">We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. </span>Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. <span style="Background-color:#FFFFFF;color:#000000;">Costs to support our Genentech Agreement are a component of our research and development activities.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000401" name="adpt:SalesAndMarketingExpensePolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000401_dcnt_4d2846b5-0823-4a2a-b9b7-845439fde862">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000365_dcnt_12dd3ee9-c3b3-4aa3-bdbe-768e40b492bb" continuedAt="F_000365_dcnt_75c325da-bb0d-4ce7-8a7c-265f21372738"><ix:continuation id="F_000401_dcnt_4d2846b5-0823-4a2a-b9b7-845439fde862">
</ix:continuation><ix:nonNumeric id="F_000402" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are measured at the balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination. </p></ix:nonNumeric><ix:nonNumeric id="F_000403" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share Attributable to Common Shareholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate basic net loss per share attributable to common shareholders by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect is anti-dilutive.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to common shareholders in conformity with the&#160;two-class&#160;method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an&#160;as-if&#160;converted basis. Under the&#160;two-class&#160;method, basic net loss per share attributable to common shareholders is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to common shareholders was not allocated to the convertible preferred stock under the&#160;two-class&#160;method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect was anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric id="F_000404" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented on a regular basis at the entity level. Resource allocation decisions are made by the CODM based on the results at the entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning for levels or components below the entity. As such, we have concluded that we operate as <ix:nonFraction unitRef="U_adptSegment" id="F_000470" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3,&#160;Revenue.</p></ix:nonNumeric><ix:nonNumeric id="F_000405" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000405_dcnt_e91deece-52d1-4e11-9d17-c7dbfbe77d00">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Recently Ad<span style="letter-spacing:-0.05pt;">opted </span>Accounting<span style="letter-spacing:-0.05pt;"> </span>Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-02, <span style="font-style:italic;">Leases</span> (Topic 842) (&#8220;ASC 842&#8221;), intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheets and disclosing key information about leasing arrangements. We adopted the guidance effective <ix:nonNumeric id="F_000471" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> using the optional transition method described in ASU 2018-11<span style="font-style:italic;">, Leases </span>(Topic 842) <span style="font-style:italic;">Targeted Improvements</span>. Under the optional transition method, we recognized a cumulative-effect adjustment in the period of adoption. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, <span style="font-style:italic;">Leases </span>(&#8220;ASC 840&#8221;). </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000365_dcnt_75c325da-bb0d-4ce7-8a7c-265f21372738"><ix:continuation id="F_000405_dcnt_e91deece-52d1-4e11-9d17-c7dbfbe77d00">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In adopting the new standard, we utilized certain practical expedients available. These practical expedients include waiving reassessment of (1) whether any expired or existing contracts are or contain leases&#59; (2) lease classification of expired or existing leases&#59; and (3) initial direct costs for existing leases. We also elected to use hindsight in determining the lease term and in assessing impairment of our ROU assets. Furthermore, we have made a policy decision regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The standard had a material impact on our balance sheet as of December 31, 2020, but did not have a material impact on our statements of operations or statements of cash flows. The most significant impact was the recognition of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" decimals="-5" scale="6">33.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" decimals="-5" scale="6">39.7</ix:nonFraction> million of operating lease ROU assets and liabilities, respectively, and the derecognition of a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="adpt:DerecognitionOfBuildToSuitLeaseAsset" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="adpt:DerecognitionOfBuildToSuitLiabilities" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" decimals="-5" scale="6">36.6</ix:nonFraction></ix:nonFraction> million asset and corresponding liability previously recorded pursuant to build-to-suit lease accounting guidance under ASC 840, which resulted in an increase to retained earnings of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million. The operating lease ROU assets and liabilities recorded at adoption included the derecognition of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="adpt:DerecognitionOfDeferredRent" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" decimals="-5" scale="6">7.3</ix:nonFraction> million of deferred rent recognized as of December 31, 2019, as well as a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="adpt:ReclassificationOfTenantIncentiveReceivables" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" decimals="-5" scale="6">0.5</ix:nonFraction> million reclassification of tenant incentive receivables previously recognized in the prepaid expenses and other current assets line item on our balance sheet. See Note 10, Leases, for additional information regarding leases.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses </span>(Topic 326):<span style="font-style:italic;"> Measurement of Credit Losses on Financial Instruments</span>, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The expected credit losses are recorded through an allowance account that is deducted from the amortized cost basis of the financial asset, and the net carrying value of the financial asset is presented on the balance sheet. The guidance also amends the previous other-than-temporary impairment model for available-for-sale debt securities by requiring the recognition of impairments relating to credit losses through an allowance account, limited to the difference between a security&#8217;s amortized cost basis and its fair value. Furthermore, the standard update removes the distinction between whether an impairment is temporary or other-than temporary. We adopted the guidance effective <ix:nonNumeric id="F_000482" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric>. Given the short-term nature of our accounts receivable, the adoption as it relates to trade receivables did not have a significant impact on our financial statements. Furthermore, impairment of available-for-sale debt securities as of the adoption date was determined to be due to factors other than credit loss&#59; therefore, a credit allowance was not recognized. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <span style="font-style:italic;">Intangibles&#8212;Goodwill and Other: Internal-Use Software</span> (Subtopic 350-40) to provide additional guidance on the accounting for costs of implementation activities performed in a cloud computing arrangement. We adopted this guidance effective <ix:nonNumeric id="F_000486" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> on a prospective basis, and the adoption did not have any impact on our financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No.&#160;2019-12,&#160;<span style="font-style:italic;">Income Taxes</span> (Topic 740): <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span>, which eliminates certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. Among other things, this guidance also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This guidance is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied prospectively, except for certain amendments. We early adopted the guidance on <ix:nonNumeric id="F_000490" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> and the adoption did not have a material impact on our financial statements.</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000366" name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000366_dcnt_d62ffe8a-311d-4546-862e-82ddefbcc33d">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revenue</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We disaggregate our revenue from contracts with customers by type of service, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. <ix:nonNumeric id="F_000408" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000408_cnt_1">The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000408_cnt_1" continuedAt="F_000408_dcnt_1c12edf7-6fab-4a4d-a5d5-e334a41064ba">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,439</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,519</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development support</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,685</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory milestones</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total development revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,685</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">85,071</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;font-weight:bold;font-style:italic;;">&#160;</p></ix:continuation></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000366_dcnt_d62ffe8a-311d-4546-862e-82ddefbcc33d" continuedAt="F_000366_dcnt_8e1ad38e-e5a8-46fc-aa3d-2a95f23aa13d"><ix:continuation id="F_000408_dcnt_1c12edf7-6fab-4a4d-a5d5-e334a41064ba">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></ix:continuation>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Translational Development<span style="letter-spacing:-0.05pt;"> </span>Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2015, we entered into a translational development agreement with a biopharmaceutical customer for access to certain of our oncology immunosequencing research datasets, including full-time employee support, to accelerate the customer&#8217;s preclinical, nonclinical and clinical trial testing. Under the initial terms of the agreement, we could have been entitled to up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231" decimals="INF" scale="6">40.0</ix:nonFraction>&#160;million over a period of <ix:nonNumeric id="F_000510" name="adpt:TermOfAgreement" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151201_20151231" format="ixt-sec:durwordsen">four years</ix:nonNumeric>, which did not include any separately negotiated research sequencing contracts. If the biopharmaceutical customer terminated the agreement prior to the end of the initial four-year research term for any reason other than a material uncured breach by us, then the biopharmaceutical partner agreed to pay us $<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="adpt:AgreementTerminationAmountReceivable" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231" decimals="-5" scale="6">0.8</ix:nonFraction>&#160;million. In May 2019, the agreement was subsequently amended to reduce the services provided, which in turn reduced the fourth year of eligible payments to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="adpt:EligiblePaymentsReceivable" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231" decimals="-5" scale="6">2.3</ix:nonFraction>&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified one performance obligation under this agreement, as the services were determined to be highly interrelated. We determined that any separately negotiated sequencing contracts are not performance obligations under the contract, as the contract did not contain any material rights related to such sequencing contracts. For the identified performance obligation, we assessed the work to be performed over the duration of the contract and determined that it was a consistent level of support throughout the period, and therefore, revenue was recognized on a straight-line basis over the contract term. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized from this translational development agreement, excluding separately negotiated research sequencing contracts, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="adpt:RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20190101_20191231" decimals="-5" scale="6">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="adpt:RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20180101_20181231" decimals="-5" scale="6">9.3</ix:nonFraction> million during the year ended December 31, 2019 and 2018, respectively. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">MRD Development<span style="letter-spacing:-0.05pt;"> </span>Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into agreements with biopharmaceutical customers to further develop and commercialize our MRD product and the biopharmaceutical customers&#8217; therapeutics. Under each of the agreements, we received or will receive non-refundable upfront payments and could receive substantial additional payments upon reaching certain progress milestones or achievement of certain regulatory milestones pertaining to the customers&#8217; therapeutics and our MRD product. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the contracts, we identify performance obligations, which may include: (1)&#160;obligations to provide services supporting the customer&#8217;s regulatory submission activities as they relate to our MRD product&#59; and (2)&#160;sequencing services related to customer-provided samples for their regulatory submissions. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated immunosequencing services. At contract inception, we fully constrain any consideration related to the regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#8217; own submission decision-making. We recognize revenue relating to the sequencing services as sequencing revenue over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered and when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method based on estimates of effort completed using a cost-based model. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We earned $<ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20200101_20201231" decimals="-5" scale="6">2.5</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20190101_20191231" decimals="-5" scale="6">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20180101_20181231" decimals="-5" scale="6">10.0</ix:nonFraction> million during the year ended December 31, 2020, 2019 and 2018, respectively, upon the achievement of certain regulatory milestones by us and our respective customers&#8217; therapeutics. All $2.5 million, $2.0 million and $10.0 million was recognized as revenue within the respective periods, as we determined these amounts were consistent with our estimated standalone selling price and the respective performance obligations were complete. We recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20200101_20201231" decimals="-5" scale="6">3.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20190101_20191231" decimals="-5" scale="6">3.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20180101_20181231" decimals="-5" scale="6">12.8</ix:nonFraction> million in development revenue related to these contracts, inclusive of the milestones, during the year ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, in future periods we could receive up to an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="adpt:AdditionalMilestonePayment" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20201231" decimals="INF" scale="6">313.5</ix:nonFraction> million in milestone payments if certain regulatory approvals are obtained by our customers&#8217; therapeutics in connection with MRD data generated from our MRD product.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Genentech<span style="letter-spacing:-0.05pt;"> </span>Collaboration Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (&#8220;Genentech Agreement&#8221;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="adpt:NonRefundableUpfrontPaymentsReceived" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20190201_20190228" decimals="-5" scale="6">300.0</ix:nonFraction> million in February 2019 and may be eligible to receive more than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231" decimals="INF" scale="6">1.8</ix:nonFraction> billion over time, including payments of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231" decimals="INF" scale="6">75.0</ix:nonFraction> million upon the achievement of specified regulatory milestones, up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231" decimals="INF" scale="6">300.0</ix:nonFraction> million upon the achievement of specified development milestones and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptCommercialMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231" decimals="INF" format="ixt:numdotdecimal" scale="6">1,430.0</ix:nonFraction> million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-family:Times New Roman;">Shared Products. The shared products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among patients (&#8220;Shared Products&#8221;). </span></p></td></tr></table></div></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000366_dcnt_8e1ad38e-e5a8-46fc-aa3d-2a95f23aa13d" continuedAt="F_000366_dcnt_1b142617-7abb-46c8-9221-5383d85179da">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-family:Times New Roman;">Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#8220;Personalized Product&#8221;). </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, <span style="font-style:italic;">Collaborative Arrangements</span> (&#8220;ASC 808&#8221;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#8217;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC 606 to account for the activities related to the Genentech Agreement.<span style="color:#000000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In applying ASC&#160;606, we identified the following performance obligations at the inception of the agreement: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">License to existing shared antigen data packages. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Research and development services for shared product development, including expansion of shared antigen data packages. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Research and development services for private product development. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Obligations to participate on various joint research, development and project committees. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#8217;s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other, as opposed to both. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined the initial transaction price shall be made up of only the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="adpt:NonRefundableUpfrontPaymentsReceived" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">300.0</ix:nonFraction> million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of December 31, 2020. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000366_dcnt_1b142617-7abb-46c8-9221-5383d85179da">

<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Product and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately <ix:nonNumeric id="F_000528" name="adpt:RevenueRecognitionExpectedPeriod" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231" format="ixt-sec:durwordsen" continuedAt="C_14da520d-c8c7-4986-b052-a232a74d43e5">seven</ix:nonNumeric> to <ix:nonNumeric id="F_000529" name="adpt:RevenueRecognitionExpectedPeriod" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231" format="ixt-sec:durwordsen">eight<ix:continuation id="C_14da520d-c8c7-4986-b052-a232a74d43e5"> years</ix:continuation></ix:nonNumeric> from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Product and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">52.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20190101_20191231" decimals="-5" scale="6">35.1</ix:nonFraction> million during the year ended December 31, 2020 and 2019, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000367" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000367_dcnt_4965d449-ae2b-4222-8846-7d5cc0249e65">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value<span style="letter-spacing:-0.05pt;"> </span>Measurements</p></td></tr></table></div><ix:nonNumeric id="F_000409" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000409_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth the fair value of financial assets as of December 31, 2020 and 2019 that were measured at fair value on a recurring basis (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p></ix:nonNumeric><ix:continuation id="F_000409_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">103,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">103,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">671,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">671,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">103,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">683,358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">786,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">121,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">121,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">377,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">377,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">585,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">674,408</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level&#160;2 securities consist of U.S. government debt securities, commercial paper and corporate bonds, and are valued based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000367_dcnt_4965d449-ae2b-4222-8846-7d5cc0249e65">
</ix:continuation><ix:nonNumeric id="F_000368" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000368_dcnt_8fb8b169-85ce-43fd-8001-0e7a7a529238">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Investments</p></td></tr></table></div><ix:nonNumeric id="F_000410" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investments consisted of the following as of December 31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">552,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" scale="3">723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">553,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" scale="3">86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">564,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231" decimals="-3" scale="3">809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">564,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" scale="3">98</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231" decimals="-3" scale="3">98</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">121,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">121,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">285,963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" scale="3">394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">286,356</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">71,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="-3" scale="3">109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">479,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231" decimals="-3" scale="3">503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">480,290</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,548</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231" decimals="-3" scale="3">181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All the commercial paper, U.S. government debt securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective balance sheet date.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest receivables are excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivables of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20201231" decimals="-5" scale="6">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20191231" decimals="-5" scale="6">2.2</ix:nonFraction> million were presented separately within the prepaid expenses and other current assets line item on our balance sheet as of December 31, 2020 and 2019, respectively. We have made an accounting policy election to not measure an allowance for credit losses for accrued interest receivables.</p><ix:nonNumeric id="F_000411" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position and the length of time that individual securities have been in a continuous loss position as of December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than 12 Months</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 Months Or Greater</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">177,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000602" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000601" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">179,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001478320_20201231" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2020 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000368_dcnt_8fb8b169-85ce-43fd-8001-0e7a7a529238">
</ix:continuation><ix:nonNumeric id="F_000369" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment, Net</p></td></tr></table></div><ix:nonNumeric id="F_000412" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net as of December 31, 2020 and 2019 consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000608" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerSoftwareMember_20201231" decimals="-3" scale="3">860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerSoftwareMember_20191231" decimals="-3" scale="3">505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000614" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,852</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000615" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,945</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,716</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Build-to-suit asset cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptBuildToSuitAssetCostMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000622" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:Depreciation" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">6.8</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:Depreciation" contextRef="C_0001478320_20190101_20191231" decimals="-5" scale="6">6.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:Depreciation" contextRef="C_0001478320_20180101_20181231" decimals="-5" scale="6">4.3</ix:nonFraction> million for the year ended December&#160;31, 2020, 2019 and 2018, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000370" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Goodwill<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Intangible Assets</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been <ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:Goodwill" contextRef="C_0001478320_20151231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> changes in the carrying amount of goodwill since its recognition in 2015. </p><ix:nonNumeric id="F_000413" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization as of December 31, 2020 and 2019 consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20201231" decimals="-3" scale="3">325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20201231" decimals="-3" scale="3">128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20201231" decimals="-3" scale="3">197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000636" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000640" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000638" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20191231" decimals="-3" scale="3">325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000641" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20191231" decimals="-3" scale="3">96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20191231" decimals="-3" scale="3">229</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000642" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The developed technology was acquired in connection with our acquisition of Sequenta in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next <ix:nonNumeric id="F_000646" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20200101_20201231" format="ixt-sec:duryear">6.0</ix:nonNumeric> years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000414" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, expected future amortization expense for intangible assets was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000649" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future amortization expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000371" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. </span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accrued Liabilities</p></td></tr></table></div><ix:nonNumeric id="F_000415" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities as of December 31, 2020 and 2019 consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000655" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and contract research organization costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000656" name="adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent" contextRef="C_0001478320_20191231" decimals="-3" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Travel and entertainment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000658" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001478320_20201231" decimals="-3" scale="3">91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001478320_20191231" decimals="-3" scale="3">157</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,062</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,423</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent" contextRef="C_0001478320_20191231" decimals="-3" scale="3">555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,881</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001478320_20191231" decimals="-3" scale="3">556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accrued tax liabilities balance as of December 31, 2020 includes a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" contextRef="C_0001478320_20201231" decimals="-5" scale="6">1.4</ix:nonFraction> million tax withholding liability related to unsettled option exercises as of December 31, 2020. The accrued tax liabilities balance as of December 31, 2019 includes a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" contextRef="C_0001478320_20191231" decimals="-5" scale="6">1.9</ix:nonFraction> million tax withholding liability related to unsettled option exercises as of December 31, 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000372" name="adpt:DeferredRevenueTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000372_dcnt_ead26301-02e7-422d-b4ce-a05f4ad849a2">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Deferred Revenue</p></td></tr></table></div><ix:nonNumeric id="F_000416" name="adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue by revenue classification as of December 31, 2020 and 2019 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20201231" decimals="-3" scale="3">724</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">162,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">219,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current and non-current deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">236,937</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">280,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue from our Genentech Agreement represents $<ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231" decimals="-5" scale="6">55.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231" decimals="-5" scale="6">157.0</ix:nonFraction> million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2020 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231" decimals="-5" scale="6">48.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231" decimals="-5" scale="6">216.8</ix:nonFraction> million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2019. In general, we expect that the current amounts will be recognized as revenue within <ix:nonNumeric id="F_000688" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231" format="ixt-sec:durmonth">12</ix:nonNumeric> months and the non-current amounts will be recognized as revenue over a period of approximately <ix:nonNumeric id="F_000689" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtRangeAxis_srtMinimumMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231" format="ixt-sec:durwordsen" continuedAt="C_2746526e-a007-49fc-b63d-f4920d0158ad">six</ix:nonNumeric> to <ix:nonNumeric id="F_000690" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtRangeAxis_srtMaximumMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231" format="ixt-sec:durwordsen">seven<ix:continuation id="C_2746526e-a007-49fc-b63d-f4920d0158ad"> years</ix:continuation></ix:nonNumeric>. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities.</p><ix:nonNumeric id="F_000417" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue during the year ended December 31, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">280,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions to deferred revenue during the period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized during the period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,823</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">236,937</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001478320_20201230_20201231" decimals="-5" scale="6">61.6</ix:nonFraction> million was recognized as revenue that was included in the deferred revenue balance at December 31, 2019. This is inclusive of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231" decimals="-5" scale="6">1.0</ix:nonFraction> million of sequencing revenue recognized as a result of cancelled biopharmaceutical customer sequencing contracts and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001478320_srtMajorCustomersAxis_adptSpecificPatientsMember_srtProductOrServiceAxis_adptMedicareRevenueMember_20190101_20191231" decimals="-5" scale="6">0.6</ix:nonFraction> million of sequencing revenue related to Medicare that was recognized due to our determination that additional testing for specific patients was remote. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000372_dcnt_ead26301-02e7-422d-b4ce-a05f4ad849a2">
</ix:continuation><ix:nonNumeric id="F_000373" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000373_dcnt_bbd780fa-1b53-4b29-9d15-9816416e36b0">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have operating lease agreements for the laboratory and office facilities that we occupy in various locations, as well as server space. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for our current headquarters in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000698" name="us-gaap:AreaOfLand" contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190831" decimals="0" format="ixt:numdotdecimal">65,500</ix:nonFraction> square feet. </span><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000699" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831">Cash payment for rent of the expanded premises commenced <ix:nonNumeric id="F_000700" name="adpt:LesseeOperatingLeaseRentCommencementMonthAndYear" contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831" format="ixt:datemonthyearen">January 2020</ix:nonNumeric>, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for <ix:nonNumeric id="F_000702" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831" format="ixt-sec:durwordsen">five years</ix:nonNumeric>.</ix:nonNumeric></span> <span style="Background-color:#FFFFFF;">The amended lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In August 2019, we entered into an agreement to rent approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000704" name="us-gaap:AreaOfLand" contextRef="C_0001478320_20190831" decimals="0" format="ixt:numdotdecimal">100,000</ix:nonFraction> square feet in a to-be-constructed building in Seattle, Washington. In connection with the lease, we entered into a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="C_0001478320_20190831" decimals="-5" scale="6">2.1</ix:nonFraction> million letter of credit with one of our existing financial institutions. Due to our </span>significant<span style="Background-color:#FFFFFF;"> involvement during the construction process of the leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance that proceeded ASC 842. The resulting asset and long-term financing obligation recorded on our balance sheet as of December 31, 2019 for the cost of the building was derecognized upon adoption of ASC 842. The lease commenced in <ix:nonNumeric id="F_000706" name="adpt:LeaseCommencementMonthAndYear" contextRef="C_0001478320_20190801_20190831" format="ixt:datemonthyearen">December 2020</ix:nonNumeric>, when the landlord delivered the premises to us for construction of certain tenant improvements. <ix:nonNumeric id="F_000707" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001478320_20190801_20190831">Cash payment for rent begins in <ix:nonNumeric id="F_000708" name="adpt:LesseeOperatingLeaseRentCommencementMonthAndYear" contextRef="C_0001478320_20190801_20190831" format="ixt:datemonthyearen">October 2021</ix:nonNumeric> and the lease term ends in <ix:nonNumeric id="F_000709" name="adpt:LeaseExpirationMonthAndYear" contextRef="C_0001478320_20190801_20190831" format="ixt:datemonthyearen">August 2033</ix:nonNumeric>, </ix:nonNumeric></span><span style="Background-color:#FFFFFF;color:#000000;">subject to our option to twice extend the lease for&#160;<ix:nonNumeric id="F_000711" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" contextRef="C_0001478320_20190801_20190831" format="ixt-sec:durwordsen">five years</ix:nonNumeric>.&#160;We plan to occupy the new building in 2021, once interior construction is finished. In connection with this lease, the landlord agreed to fund $<ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0001478320_20190831" decimals="-5" scale="6">20.0</ix:nonFraction>&#160;million in improvements, which was subsequently reduced to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0001478320_20201231" decimals="-5" scale="6">14.8</ix:nonFraction> million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2020, w</span><span style="Background-color:#FFFFFF;">e have incurred $<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="adpt:TenantImprovementCostsIncurred" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">5.2</ix:nonFraction> million in certain tenant improvement costs, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="adpt:ProceedsFromLandlordReimbursements" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">0.7</ix:nonFraction> million has been reimbursed by the landlord. The remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="adpt:TenantImprovementCostsReceivable" contextRef="C_0001478320_20201231" decimals="-5" scale="6">4.5</ix:nonFraction> million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our balance sheet as of December 31, 2020 and will be reimbursed by the landlord. </span><span style="Background-color:#FFFFFF;color:#000000;">The lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In October 2019, we entered into an agreement to lease approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000717" name="us-gaap:AreaOfLand" contextRef="C_0001478320_20191031" decimals="0" format="ixt:numdotdecimal">14,750</ix:nonFraction> square feet in a separate Seattle, Washington location, pursuant to a lease expiring in October 2029, which is subject to our ability to exercise an early termination right after the third year. In connection with the lease, the landlord has agreed to provide a tenant improvement allowance in the maximum amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="us-gaap:TenantImprovements" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20191031" decimals="INF" scale="6">0.7</ix:nonFraction> million. The lease also requires us to pay additional amounts for operating expenses.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In April 2018, we entered into a lease agreement to lease approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000720" name="us-gaap:AreaOfLand" contextRef="C_0001478320_20180430" decimals="0" format="ixt:numdotdecimal">13,400</ix:nonFraction> square feet in South San Francisco, California. <ix:nonNumeric id="F_000722" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001478320_20180401_20180430">The lease term is through <ix:nonNumeric id="F_000721" name="adpt:LeaseExpirationMonthAndYear" contextRef="C_0001478320_20180401_20180430" format="ixt:datemonthyearen">March 2026</ix:nonNumeric> and provides for one <span style="-sec-ix-hidden:F_000724">five-year</span> extension option.</ix:nonNumeric> We are responsible for our share of allocable operating expenses, tax expenses and utilities cost during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="us-gaap:TenantImprovements" contextRef="C_0001478320_20180430" decimals="-5" scale="6">2.4</ix:nonFraction> million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000726" name="us-gaap:AreaOfLand" contextRef="C_0001478320_20200229" decimals="0" format="ixt:numdotdecimal">19,900</ix:nonFraction> additional square feet and provides for a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="adpt:TenantImprovementAllowanceAndCommenced" contextRef="C_0001478320_20200201_20200229" decimals="-5" scale="6">0.6</ix:nonFraction> million tenant improvement allowance.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, we entered into an agreement to lease approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000728" name="us-gaap:AreaOfLand" contextRef="C_0001478320_20191231" decimals="0" format="ixt:numdotdecimal">3,100</ix:nonFraction> square feet of office space in New York City, New York, pursuant to a lease that expires <ix:nonNumeric id="F_000729" name="adpt:LeaseExpirationMonthAndYear" contextRef="C_0001478320_20191201_20191231" format="ixt:datemonthyearen">November 2025</ix:nonNumeric>, subject to our ability to exercise an early termination right in 2023. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of </span>December<span style="Background-color:#FFFFFF;"> 31, 2020, we were not party to any finance leases. Our leases have remaining terms of <ix:nonNumeric id="F_000730" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20201231" format="ixt-sec:duryear">1.3</ix:nonNumeric> years to <ix:nonNumeric id="F_000731" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20201231" format="ixt-sec:duryear">12.7</ix:nonNumeric> years and include <ix:nonNumeric id="F_000732" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001478320_20200101_20201231">options to extend certain of the leases up to <ix:nonNumeric id="F_000734" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001478320_20201231" format="ixt-sec:duryear">10.0</ix:nonNumeric> years</ix:nonNumeric> and terminate certain of the leases after <ix:nonNumeric id="F_000735" name="adpt:LesseeOperatingLeaseTerminationPeriod" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:duryear">3.0</ix:nonNumeric> years. We adjust lease terms for these options only when it is reasonably certain we will exercise these options. As of </span>December<span style="Background-color:#FFFFFF;"> 31, 2020, it was reasonably certain that we would exercise our option to terminate </span><ix:nonFraction unitRef="U_adptLease" id="F_000736" name="adpt:NumberOfOperatingLeaseTerminate" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction><span style="Background-color:#FFFFFF;"> of our leases after <ix:nonNumeric id="F_000737" name="adpt:LesseeOperatingLeaseTerminationPeriod" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:duryear">3.0 </ix:nonNumeric></span>years<span style="Background-color:#FFFFFF;">.</span></p><ix:nonNumeric id="F_000418" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Other information related to our operating leases as of </span>December <span style="Background-color:#FFFFFF;">31, 2020 was as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000738">11.33</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000739" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001478320_20201231" decimals="3" scale="-2">4.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000373_dcnt_bbd780fa-1b53-4b29-9d15-9816416e36b0">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000419" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of </span>December<span style="Background-color:#FFFFFF;"> 31, 2020 (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,030</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,419</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">149,612</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Imputed interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Tenant improvement receivables</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="adpt:LesseeOperatingLeaseLiabilityTenantImprovementReceivable" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,529</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, less current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Operating lease expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">5.5</ix:nonFraction> million for the year ended</span> December <span style="Background-color:#FFFFFF;">31, 2020. Variable lease expense for operating leases was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="adpt:OperatingLeaseVariableLeaseExpense" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">2.6</ix:nonFraction> million for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2020.</span> <span style="Background-color:#FFFFFF;">Rent expense recognized under ASC 840, inclusive of operating and maintenance costs, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001478320_20190101_20191231" decimals="-5" scale="6">5.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001478320_20180101_20181231" decimals="-5" scale="6">4.1</ix:nonFraction> million for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2019 and 2018, respectively.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Cash paid for amounts included in the measurement of lease liabilities for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:OperatingLeasePayments" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">3.2</ix:nonFraction> million, net of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:PaymentsForProceedsFromTenantAllowance" contextRef="C_0001478320_20200101_20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">2.5</ix:nonFraction> million of cash received for tenant improvement allowances. For the year ended December 31, 2020, ROU assets obtained in exchange for operating lease liabilities was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">109.1</ix:nonFraction> million, inclusive of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231" decimals="-5" scale="6">33.0</ix:nonFraction> million recognized from the adoption of ASC 842.</span></p></ix:continuation><ix:nonNumeric id="F_000374" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Legal Proceedings </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We are not party to any material legal proceedings as of December 31, 2020. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Indemnification Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000375" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000375_dcnt_8d69d69f-c9fa-43d6-a314-3f6f28f789df">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="color:#231F20;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#231F20;letter-spacing:-0.05pt;">Shareholders&#8217;</span><span style="color:#231F20;"> Equity</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;;font-weight:normal;font-style:normal;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Immediately prior to the completion of our initial public offering<span style="font-weight:bold;font-style:italic;"> </span>on July 1, 2019,&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000760" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190629_20190630" decimals="INF" format="ixt:numdotdecimal">93,039,737</ix:nonFraction> shares of convertible preferred stock then outstanding converted into an equivalent number of shares of common stock. As of December 31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000761" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of convertible preferred stock were outstanding.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;;font-weight:normal;font-style:normal;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are authorized to issue <ix:nonFraction unitRef="U_xbrlishares" id="F_000762" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000763" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001478320_20201231" decimals="4">0.0001</ix:nonFraction> per share. As of December 31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000764" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001478320_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of preferred stock were outstanding.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000375_dcnt_8d69d69f-c9fa-43d6-a314-3f6f28f789df">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are authorized to issue <ix:nonFraction unitRef="U_xbrlishares" id="F_000765" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal">340,000,000</ix:nonFraction> shares of common stock. Our common stock has a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000766" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001478320_20201231" decimals="INF">0.0001</ix:nonFraction> per share, no preferences or privileges and is not redeemable. <ix:nonNumeric id="F_000767" name="us-gaap:CommonStockVotingRights" contextRef="C_0001478320_20200101_20201231">Holders of our common stock are entitled to <ix:nonFraction unitRef="U_adptVote" id="F_000768" name="adpt:NumberOfCommonStockVotingRights" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> vote for each share of common stock held</ix:nonNumeric>. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time. As of December 31, 2020, we had <ix:nonFraction unitRef="U_xbrlishares" id="F_000769" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal">137,646,896</ix:nonFraction> shares of common stock outstanding.</p><ix:nonNumeric id="F_000420" name="adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, w<span style="color:#231F20;">e have reserved shares of common stock for the following: </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon the exercise of outstanding common stock options and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; the vesting of outstanding common restricted stock units granted</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000770" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001478320_us-gaapAwardTypeAxis_adptCommonStockOptionsAndRestrictedStockUnitsGrantedMember_20201231" decimals="INF" format="ixt:numdotdecimal">14,483,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the 2019 Equity Incentive Plan</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000771" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">18,617,001</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the Employee Stock Purchase Plan</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000772" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,804,298</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares to be issued upon exercise of a common stock warrant</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000773" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231" decimals="INF" format="ixt:numdotdecimal">56,875</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved for future issuance</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000774" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal">35,961,734</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our 2019 Equity Incentive Plan (&#8220;2019 Plan&#8221;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) <ix:nonFraction unitRef="U_xbrlipure" id="F_000775" name="adpt:PercentageOfAnnualIncreasesInNumberOfShares" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20200101" decimals="INF" scale="-2">5</ix:nonFraction>% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our Employee Stock Purchase Plan (&#8220;ESPP&#8221;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) <ix:nonFraction unitRef="U_xbrlipure" id="F_000776" name="adpt:PercentageOfAnnualIncreasesInNumberOfShares" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101" decimals="2" scale="-2">1</ix:nonFraction>% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2020, our 2019 Plan and ESPP reserves increased by <ix:nonFraction unitRef="U_xbrlishares" id="F_000778" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20200101" decimals="INF" format="ixt:numdotdecimal">6,261,907</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000779" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101" decimals="INF" format="ixt:numdotdecimal">1,252,381</ix:nonFraction> shares, respectively. <span style="color:#231F20;">Effective January 1, 2021, our 2019 Plan reserve increased by <ix:nonFraction unitRef="U_xbrlishares" id="F_000777" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101" decimals="INF" format="ixt:numdotdecimal">6,882,344</ix:nonFraction> shares.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Common<span style="letter-spacing:-0.05pt;"> </span>Stock<span style="letter-spacing:-0.05pt;"> </span>Warrants</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with two transactions in 2012 and 2013, we granted warrants to purchase up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000780" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">55,032</ix:nonFraction> shares of common stock. These warrants were exercisable at any time for a period of <ix:nonNumeric id="F_000781" name="adpt:ClassOfWarrantOrRightsTerm" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of issuance at a weighted-average exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000782" name="adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="2">0.37</ix:nonFraction>, except in the case of a warrant to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000783" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">20,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000784" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF">0.45</ix:nonFraction> per share that would have expired if unexercised prior to the closing of our initial public offering. On July 1, 2019, we issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000785" name="adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190701_20190701" decimals="INF" format="ixt:numdotdecimal">54,792</ix:nonFraction> shares of common stock through both a cash and cashless exercise of the warrants. The impact of these exercises was immaterial to the financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in 2014, we issued a warrant to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000786" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231" decimals="INF" format="ixt:numdotdecimal">56,875</ix:nonFraction> shares of Series C convertible preferred stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000788" name="adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231" decimals="2">2.64</ix:nonFraction>. The warrant is exercisable for a period of <ix:nonNumeric id="F_000787" name="adpt:ClassOfWarrantOrRightsTerm" contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20140101_20141231" format="ixt-sec:durwordsen">seven years</ix:nonNumeric> from the date of issuance. Immediately prior to and in connection with the completion of our initial public offering on July 1, 2019, this convertible preferred stock warrant, which was previously recorded as a financial liability, was converted to a warrant to purchase the same number of shares of common stock. Upon conversion, the financial liability was reclassified to the additional paid-in capital line item on our balance sheet. The warrant to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000789" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal">56,875</ix:nonFraction> shares of common stock remains outstanding as of December 31, 2020.</p></ix:continuation><ix:nonNumeric id="F_000376" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000376_dcnt_9acecfd4-3759-4788-b714-f5a56fe967de">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Equity Incentive Plans</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Sequenta 2008 Stock Plan, as amended</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our acquisition of Sequenta in January 2015, we assumed Sequenta&#8217;s Equity Incentive Plan (&#8220;2008 Plan&#8221;), including all outstanding options and shares available for future issuance under the 2008 Plan, which, prior to the completion of our initial public offering, were all exercisable for Series E-1 convertible preferred stock. Upon completion of our initial public offering in July 2019, the outstanding options were exercisable for common stock. <ix:nonFraction unitRef="U_xbrlishares" id="F_000790" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001478320_us-gaapPlanNameAxis_adptSequentaTwoThousandAndEightStockPlanMember_20201231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> shares are available for future issuance under this plan and <ix:nonFraction unitRef="U_xbrlishares" id="F_000791" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" contextRef="C_0001478320_us-gaapPlanNameAxis_adptSequentaTwoThousandAndEightStockPlanMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> equity awards are outstanding under this plan as of December 31, 2020. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000376_dcnt_9acecfd4-3759-4788-b714-f5a56fe967de" continuedAt="F_000376_dcnt_10436334-43ca-4666-95d1-83805ce8c024">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Adaptive 2009 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted an equity incentive plan in 2009 (&#8220;2009 Plan&#8221;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the option exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Options granted under this plan expire no later than <ix:nonNumeric id="F_000792" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While <ix:nonFraction unitRef="U_xbrlishares" id="F_000793" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineEquityIncentivePlanMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">2019 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan was approved by our shareholders on June 13, 2019 and, pursuant to the resolutions adopted by our board of directors, became effective immediately prior to the closing of our initial public offering. The 2019 Plan provides for the issuance of awards in the form of options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the option exercise price per share shall not be less than the fair market value of a share of stock on the grant date of the option, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, options granted under this plan expire no later than <ix:nonNumeric id="F_000794" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the grant date and vesting is established at the time of grant. Except for certain option grants made to non-employee directors, stock options granted under the 2019 Plan generally vest over a <span style="-sec-ix-hidden:F_000795">four-year</span> period, subject to continuous service through each applicable vesting date. As of December 31, 2020, we have authorized <ix:nonFraction unitRef="U_xbrlishares" id="F_000796" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">22,109,217</ix:nonFraction> shares of common stock for issuance under the 2019 Plan.</p><ix:nonNumeric id="F_000421" name="adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in shares available for grant during the year ended December 31, 2020 were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Available for Grant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000797" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">15,396,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan reserve increase on January 1, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000798" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">6,261,907</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and restricted stock units granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000799" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,291,701</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited, cancelled or expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000800" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">250,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000801" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">18,617,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000422" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the 2008 Plan, 2009 Plan and 2019 Plan during the year ended December&#160;31, 2020 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000802" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001478320_20191231" decimals="INF" format="ixt:numdotdecimal">16,646,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000809" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001478320_20191231" decimals="2">6.14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">398,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000803" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,241,701</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000810" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001478320_20200101_20201231" decimals="2">33.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited or cancelled</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000804" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">235,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000811" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001478320_20200101_20201231" decimals="2">16.17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000805" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">15,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000812" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001478320_20200101_20201231" decimals="2">0.16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000806" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,204,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000813" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001478320_20200101_20201231" decimals="2">4.14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000807" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal">14,433,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000814" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001478320_20201231" decimals="2">12.82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">668,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and exercisable at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000808" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" contextRef="C_0001478320_20201231" decimals="INF" format="ixt:numdotdecimal">7,924,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000815" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" contextRef="C_0001478320_20201231" decimals="2">6.41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000818" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">417,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining contractual life for options outstanding as of December 31, 2020 was <ix:nonNumeric id="F_000819" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:duryear">7.1</ix:nonNumeric> years. The weighted-average remaining contractual life for vested and exercisable options outstanding as of December 31, 2020 was <ix:nonNumeric id="F_000820" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:duryear">5.9</ix:nonNumeric> years. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of options granted was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000821" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_20200101_20201231" decimals="2">21.11</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000822" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_20190101_20191231" decimals="2">6.87</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000823" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_20180101_20181231" decimals="2">4.15</ix:nonFraction> during the year ended December&#160;31, 2020, 2019 and 2018, respectively. The total intrinsic value of options exercised was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">190.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001478320_20190101_20191231" decimals="-5" scale="6">39.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001478320_20180101_20181231" decimals="-5" scale="6">3.8</ix:nonFraction> million during the year ended December&#160;31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="adpt:ReceivableForStockOptionExercises" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="-5" scale="6">0.3</ix:nonFraction> million was included in the prepaid expenses and other current assets line item on our balance sheet for unsettled cash proceeds related to options exercised during the year ended December 31, 2020. As of December 31, 2019, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000828" name="adpt:ReceivableForStockOptionExercises" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231" decimals="-5" scale="6">0.5</ix:nonFraction> million was included in the prepaid expenses and other current assets line item on our balance sheet for unsettled cash proceeds related to options exercised during the year ended December 31, 2019. The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000829" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">21.7</ix:nonFraction> million proceeds from exercise of stock options on our statements of cash flows for the year ended December 31, 2020 includes this $<ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="-5" scale="6">0.5</ix:nonFraction> million, as the related proceeds settled during the year ended December 31, 2020.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000376_dcnt_10436334-43ca-4666-95d1-83805ce8c024" continuedAt="F_000376_dcnt_6788c039-d6ee-49f7-8b72-f1e61fa3d79a">
<ix:nonNumeric id="F_000423" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2020 was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Units</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000831" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">4,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000835" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231" decimals="2">41.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000832" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">50,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000836" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2">28.10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000833" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000837" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231" decimals="2">41.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000834" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">50,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231" decimals="2">28.10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2019 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000839" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20190101_20191231" decimals="2">41.63</ix:nonFraction>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Grant Date Fair Value of Options and Restricted Stock Units Granted</p><ix:nonNumeric id="F_000424" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated grant date fair value of options granted during the year ended December&#160;31, 2020, 2019 and 2018 was estimated using the Black-Scholes option-pricing model with the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.68 - $55.23</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.80 - $47.81</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000840" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001478320_20180101_20181231" decimals="2">6.55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000845">5.27 - 6.08</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000846">5.27 - 6.08</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000847">6.08 - 10.00</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000851">0.4% - 1.7%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000852">1.4% - 2.5%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000853">2.6% - 3.0%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000857">70.5% - 73.3%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000858">64.3% - 72.9%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000859">65.0% - 69.2%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average volatility used in the grant date fair value calculations of options granted during the year ended December 31, 2020, 2019 and 2018 was <ix:nonFraction unitRef="U_xbrlipure" id="F_000863" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="C_0001478320_20200101_20201231" decimals="3" scale="-2">71.4</ix:nonFraction>%, <ix:nonFraction unitRef="U_xbrlipure" id="F_000864" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="C_0001478320_20190101_20191231" decimals="3" scale="-2">68.1</ix:nonFraction>% and <ix:nonFraction unitRef="U_xbrlipure" id="F_000865" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="C_0001478320_20180101_20181231" decimals="3" scale="-2">68.1</ix:nonFraction>%, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair value of common stock&#8212;<span style="font-style:normal;">Prior to the closing of our initial public offering, the fair value of our common stock was determined with input from management using valuation methodologies which utilized certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies used to estimate the enterprise value were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, </span>Valuation of Privately-Held-Company Equity Securities Issued as Compensation<span style="font-style:normal;">. For valuations of grants made after the closing of our initial public offering, the fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<span style="font-style:normal;">&#8212;The expected term of options granted to employees and non-employee directors is determined using the &#8220;simplified&#8221; method, as illustrated in ASC Topic 718, </span>Compensation&#8212;Stock Compensation<span style="font-style:normal;">, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is </span><span style="color:#000000;font-style:normal;">based on the midpoint between the vesting date and the end of the contractual term of the option.</span><span style="font-style:normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<span style="font-style:normal;">&#8212;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the options.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<span style="font-style:normal;">&#8212;As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of the expected term.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield<span style="font-style:normal;">&#8212;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of <ix:nonFraction unitRef="U_xbrlipure" id="F_000866" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001478320_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200101_20201231" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction> in the option valuation model. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant date fair value of restricted stock units granted after the closing of our initial public offering <span style="color:#000000;">is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000376_dcnt_6788c039-d6ee-49f7-8b72-f1e61fa3d79a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000867" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">24.8</ix:nonFraction></span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000868" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_20190101_20191231" decimals="-5" scale="6">13.1</ix:nonFraction></span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000869" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_20180101_20181231" decimals="-5" scale="6">11.1</ix:nonFraction></span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was recognized during the </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year ended</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 20</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 201</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respectively</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000425" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000425_cnt_1">The compensation costs related to stock options and restricted stock units for the years ended December 31, 2020, 2019 and 2018 are included on our statements of operations as follows (in thousands):</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p><ix:continuation id="F_000425_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000870" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231" decimals="-3" scale="3">817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000871" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20190101_20191231" decimals="-3" scale="3">555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000872" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20180101_20181231" decimals="-3" scale="3">398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000873" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,519</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000874" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000875" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000876" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000877" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000879" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000880" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000881" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000882" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000883" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000884" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001478320_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2018, there was <ix:nonFraction unitRef="U_adptOption" id="F_000885" name="adpt:NumberOfEmployeeOptionModification" contextRef="C_0001478320_20181231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> employee option modification to extend the option exercise period, which resulted in incremental stock compensation of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000886" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="C_0001478320_20180101_20181231" decimals="-5" scale="6">0.5</ix:nonFraction> million.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, unrecognized share-based compensation expense related to unvested stock options was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000887" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001478320_20201231" decimals="-5" scale="6">74.9</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric id="F_000888" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:duryear">3.0</ix:nonNumeric> years. Additionally, as of December 31, 2020, unrecognized share-based compensation expense related to nonvested restricted stock units was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000890" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="-5" scale="6">1.1</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric id="F_000889" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" format="ixt-sec:duryear">3.3</ix:nonNumeric> years.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><ix:nonNumeric id="F_000377" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000377_dcnt_fb13dfd2-789c-4544-bc11-94292cc8a52a">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Microsoft Collaboration Agreement</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Summary of Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a collaboration agreement with Microsoft (&#8220;Microsoft Agreement&#8221;) to computationally derive a comprehensive TCR antigen map for purposes of developing a universal diagnostic based on a single blood test.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft&#8217;s Azure cloud services at standard volume pricing with a minimum Azure consumption requirement of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000891" name="adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231" decimals="INF" scale="6">12.0</ix:nonFraction>&#160;million over the <span style="-sec-ix-hidden:F_000892">seven-year</span> term of the Microsoft Agreement, which we expect to meet in the ordinary course of business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000893" name="us-gaap:PreferredStockValue" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_adptSeriesFOneConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171231" decimals="-5" scale="6">45.0</ix:nonFraction>&#160;million as a part of our&#160;Series&#160;F-1&#160;convertible preferred stock issuance.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Summary of Accounting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the Microsoft Agreement meet the criteria under ASC Topic 808,&#160;<span style="font-style:italic;">Collaborative Arrangements</span>&#160;(&#8220;ASC 808&#8221;), as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity.&#160;ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly,&#160;we looked to other guidance to determine the accounting for the respective elements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined that the preferred stock issuance and commitment to use Microsoft&#8217;s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series&#160;F-1&#160;convertible preferred stock issuance was accounted for as part of the Series&#160;F-1&#160;preferred stock issuance.&#160;Since the commitment to use Microsoft&#8217;s Azure cloud services was at market terms and we expect to meet the commitment in the ordinary course of business during the seven-year term, we record the expenses in the period in which the services are consumed. These costs are recorded in our statements of operations based on the underlying activities for which they support.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft&#8217;s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000377_dcnt_fb13dfd2-789c-4544-bc11-94292cc8a52a">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accounted for these collaboration activities by analogy to ASC Topic 845,&#160;</span><span style="font-style:italic;">Nonmonetary Transactions</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any&#160;non-monetary&#160;assets or corresponding&#160;non-monetary&#160;income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.</span></p></ix:continuation><ix:nonNumeric id="F_000378" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000378_dcnt_4d9b4f1b-536d-433b-82fd-d5689c7a5840">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric id="F_000426" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000426_cnt_1">The significant components of our deferred tax assets and liabilities for the periods presented are as follows (in thousands):</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><ix:continuation id="F_000426_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000894" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforward</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000896" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,152</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non qualifying stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="adpt:DeferredTaxAssetsNonQualifiedStockOptions" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000899" name="adpt:DeferredTaxAssetsNonQualifiedStockOptions" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000900" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,755</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000901" name="adpt:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000902" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,706</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000905" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000906" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">230,258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">114,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000908" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">197,527</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000909" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net of valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000910" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000911" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,784</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible and intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000913" name="adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,784</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000914" name="adpt:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000915" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000916" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 740, <span style="font-style:italic;">Income Taxes</span>, requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000917" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">96.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000918" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001478320_20190101_20191231" decimals="-5" scale="6">30.2</ix:nonFraction> million during the year ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the CARES Act was enacted and signed into law in response to COVID-19. The CARES Act, among other things, included several significant provisions that impacted corporate taxpayers' accounting for income taxes, including modification to the utilization of net operating losses and interest expense deduction limitations. However, none of these provisions have an impact on our tax provision.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2018 and an analysis is ongoing for ownership changes through December 31, 2020. Based on these analyses, we do not expect to have any permanent limitations on the utilization of our federal net operating losses. Under the TCJA federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. Net operating losses generated prior to 2018 are eligible to be carried forward up to <ix:nonNumeric id="F_000919" name="adpt:NetOperatingLossCarryforwardExpirationPeriod" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:duryear">20</ix:nonNumeric> years. As of December 31, 2020, we had U.S. federal net operating losses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000920" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">192.5</ix:nonFraction> million and U.S. federal tax credits of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000921" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">18.8</ix:nonFraction> million that will begin to expire in <ix:nonNumeric id="F_000922" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" contextRef="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"><ix:nonNumeric id="F_000923" name="adpt:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2028</ix:nonNumeric></ix:nonNumeric>. We also have $<ix:nonFraction unitRef="U_iso4217USD" id="F_000924" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001478320_20201231" decimals="-5" scale="6">211.9</ix:nonFraction> million of net operating losses that do not expire.</p><ix:nonNumeric id="F_000427" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000427_dcnt_b295c983-3069-4dc8-a619-8ceb7d6d37a8"></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000378_dcnt_4d9b4f1b-536d-433b-82fd-d5689c7a5840"><ix:continuation id="F_000427_dcnt_b295c983-3069-4dc8-a619-8ceb7d6d37a8">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000925" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001478320_20200101_20201231" decimals="INF" scale="-2">21.0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000926" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001478320_20190101_20191231" decimals="INF" scale="-2">21.0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000927" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001478320_20180101_20181231" decimals="INF" scale="-2">21.0</ix:nonFraction>%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000928" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001478320_20200101_20201231" decimals="INF" scale="-2">13.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000929" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001478320_20190101_20191231" decimals="INF" scale="-2">8.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000930" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001478320_20180101_20181231" decimals="INF" scale="-2">5.5</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000931" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001478320_20200101_20201231" decimals="3" scale="-2">25.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000932" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001478320_20190101_20191231" decimals="3" scale="-2">9.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000933" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001478320_20180101_20181231" decimals="3" scale="-2">0.5</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000934" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="C_0001478320_20200101_20201231" decimals="3" sign="-" scale="-2">0.1</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000935" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="C_0001478320_20190101_20191231" decimals="3" sign="-" scale="-2">1.0</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000936" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="C_0001478320_20180101_20181231" decimals="3" scale="-2">0.5</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000937" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001478320_20200101_20201231" decimals="3" scale="-2">5.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000938" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001478320_20190101_20191231" decimals="3" scale="-2">6.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000939" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001478320_20180101_20181231" decimals="3" scale="-2">2.7</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000940" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001478320_20200101_20201231" decimals="3" scale="-2">0.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000941" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001478320_20190101_20191231" decimals="3" scale="-2">0.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000942" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001478320_20180101_20181231" decimals="3" scale="-2">0.1</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000943" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001478320_20200101_20201231" decimals="3" sign="-" scale="-2">66.1</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000944" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001478320_20190101_20191231" decimals="3" sign="-" scale="-2">44.3</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000945" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001478320_20180101_20181231" decimals="3" sign="-" scale="-2">30.3</ix:nonFraction>)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000946" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001478320_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000947" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001478320_20190101_20191231" decimals="3" scale="-2">0.0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000948" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001478320_20180101_20181231" decimals="3" scale="-2">0.0</ix:nonFraction>%</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000949" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001478320_20201231" decimals="-5" scale="6">3.5</ix:nonFraction> million as of December 31, 2020. <ix:nonNumeric id="F_000428" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000428_cnt_1">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the periods presented are as follows (in thousands):</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><ix:continuation id="F_000428_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000950" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001478320_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000951" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001478320_20180101_20181231" decimals="-3" scale="3">229</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000952" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001478320_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000953" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000954" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001478320_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,052</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000955" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001478320_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000956" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001478320_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020 and 2019, we recognized uncertain tax positions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000957" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001478320_20190101_20191231" decimals="-5" scale="6">0.8</ix:nonFraction> million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had <ix:nonFraction unitRef="U_iso4217USD" id="F_000959" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001478320_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000960" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001478320_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions as of December 31, 2020 and 2019.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of net operating loss carryforwards, substantially all tax years since inception remain open to federal and state tax examination.</p></ix:continuation><ix:nonNumeric id="F_000379" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000379_dcnt_5f3b8dcc-1234-4c1e-b24d-56a4b3298c60">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss<span style="letter-spacing:-0.05pt;"> </span>Per Share<span style="letter-spacing:-0.05pt;"> </span>Attributable<span style="letter-spacing:0.05pt;"> </span>to Common <span style="letter-spacing:-0.05pt;">Shareholders</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss<span style="letter-spacing:-0.05pt;"> </span>Per Share</p><ix:nonNumeric id="F_000429" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders for the periods presented (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000961" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000962" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">68,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000963" name="us-gaap:NetIncomeLoss" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments to redemption value for Series E-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000964" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001478320_20190101_20191231" decimals="-3" scale="3">964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000965" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" scale="3">102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shareholders, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000966" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001478320_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">146,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000967" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001478320_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000968" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="C_0001478320_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,345</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used in computing net loss per share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000969" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001478320_20200101_20201231" decimals="0" format="ixt:numdotdecimal">131,216,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000970" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001478320_20190101_20191231" decimals="0" format="ixt:numdotdecimal">69,165,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000971" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001478320_20180101_20181231" decimals="0" format="ixt:numdotdecimal">12,629,778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders, basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000972" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001478320_20200101_20201231" decimals="2" sign="-">1.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000973" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001478320_20190101_20191231" decimals="2" sign="-">1.01</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000974" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001478320_20180101_20181231" decimals="2" sign="-">3.67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p>
<hr style="page-break-after:always" />
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0.19%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive<span style="letter-spacing:-0.05pt;"> </span>Biotechnologies<span style="letter-spacing:-0.05pt;"> </span>Corporation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.13%;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notes to Financial Statements (Continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:continuation id="F_000379_dcnt_5f3b8dcc-1234-4c1e-b24d-56a4b3298c60">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we were in a loss position for all periods presented, basic net loss per share attributable to common shareholders is the same as diluted net loss per share attributable to common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. <ix:nonNumeric id="F_000430" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true" continuedAt="F_000430_cnt_1">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the year ended December 31, 2020, 2019 and 2018, respectively, as they had an anti-dilutive effect:</ix:nonNumeric> </p><ix:continuation id="F_000430_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (on as if converted basis)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000975" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">46,104,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000976" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">92,783,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000977" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">16,125,548</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000978" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">17,183,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000979" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">14,701,626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested restricted stock units</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000980" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptUnvestedRestrictedStockUnitsMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">38,125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000981" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptUnvestedRestrictedStockUnitsMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">4,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000982" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">56,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000983" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">55,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000984" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">55,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000985" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptConvertiblePreferredStockWarrantsMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">28,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000986" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptConvertiblePreferredStockWarrantsMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">56,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000987" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">16,220,548</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000988" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">63,377,132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000989" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001478320_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">107,597,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000380" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="C_0001478320_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retirement Plan</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a salary deferral 401(k) plan (&#8220;401(k) Plan&#8221;) covering employees who have met certain eligibility requirements. Employees may defer up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000990" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="C_0001478320_20200101_20201231" decimals="2" scale="-2">100</ix:nonFraction>% of their compensation to the 401(k) Plan, subject to federal limits. We made $<ix:nonFraction unitRef="U_iso4217USD" id="F_000991" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001478320_20200101_20201231" decimals="-5" scale="6">1.6</ix:nonFraction> million in discretionary contributions during the year ended December 31, 2020, which are fully vested after <ix:nonNumeric id="F_000994" name="adpt:DefinedContributionPlanEmployeeServicePeriodForVesting" contextRef="C_0001478320_20200101_20201231" format="ixt-sec:durwordsen">one year</ix:nonNumeric> of employee service. We did <ix:nonFraction unitRef="U_iso4217USD" id="F_000992" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001478320_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000993" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001478320_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t make any discretionary contributions during the years ended December 31, 2019 and 2018.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<span style="color:#231F20;"> applicable</span><span style="font-weight:bold;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item 9A. Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of disclosure controls and procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of December 31, 2020. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective as of December 31, 2020. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s annual report on internal control over financial reporting</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2020 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effectiveness of our internal control over financial reporting as of December 31, 2020 has been audited by an independent registered public accounting firm, as stated in their report, which is included below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Changes in internal control</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was not any change in our internal control over financial reporting, as such term is defined in Rules&#160;13a-15(f) under the Exchange Act, during the three months ended December&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Shareholders and the Board of Directors of Adaptive Biotechnologies Corporation</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Opinion on Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited Adaptive Biotechnologies Corporation&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Adaptive Biotechnologies Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the balance sheets of Adaptive Biotechnologies Corporation as of December 31, 2020 and 2019, the related statements of operations, comprehensive loss<span style="font-weight:bold;font-family:Arial;">,</span>&#160;convertible preferred stock and shareholders' (deficit) equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February 24, 2021 expressed an unqualified opinion thereon.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company&#59; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#59; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &#38; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seattle, Washington</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not<span style="color:#231F20;"> applicable</span><span style="font-weight:bold;">.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 10 of Form 10-K will be included in our definitive proxy statement to be filed with the SEC in connection with the solicitation of proxies for our 2021 Annual Meeting of Shareholders (&#8220;2021 Proxy Statement&#8221;) and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 11 of Form 10-K will be included in our 2021 Proxy Statement and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 12 of Form 10-K, including with respect to our equity compensation plans, will be included in our 2021 Proxy Statement and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 13 of Form 10-K will be included in our 2021 Proxy Statement and is incorporated herein by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Item 14. Principal Accounting Fees and Services </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="color:#000000;"> information required by this Item 14 of Form 10-K will be included in our 2021 Proxy Statement and is incorporated herein by reference.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item 15. Exhibits, Financial Statement Schedules </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.06%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>&#160;&#160;The following documents are filed as part of this <span style="Background-color:#FFFFFF;color:#000000;">Annual Report on Form 10-K</span>:</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>&#160;&#160; All Financial Statements</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Financial Statements in Part II, Item 8 of this <span style="Background-color:#FFFFFF;color:#000000;">Annual Report on Form 10-K</span>.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>&#160;&#160; Financial Statement Schedules</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted since the required information was not applicable or was not present in amounts sufficient to require submission of the schedules, or because the information required is included in the financial statements or the accompanying notes.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.27%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>&#160;&#160; Exhibits</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;margin-left:6.67%;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exhibits listed in the following Index to Exhibits are filed, furnished or incorporated by reference as part of this <span style="Background-color:#FFFFFF;color:#000000;">Annual Report on Form 10-K</span>.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Index to Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:9.62%;">
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39.38%;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:76.95pt;;margin-right:12.96%;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:13.48%;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="4" valign="bottom" style="width:37.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:39.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:12.96%;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Title</p></td>
<td valign="bottom" style="width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/Furnished</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">With This</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report</p></td>
<td valign="bottom" style="width:6.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:8.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:11.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:39.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519187427/d27753dex31.htm"><span style="text-decoration:underline;">Amended and Restated Articles of Incorporation</span></a></p></td>
<td valign="top" style="width:13.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:10.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38957</p></td>
<td valign="top" style="width:8.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:11.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/1/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519187427/d27753dex32.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38957</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/1/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex41.htm"><span style="text-decoration:underline;">Seventh Amended and Restated Investors' Rights Agreement among the Registrant and certain of its shareholders, dated May 30, 2019</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex44.htm"><span style="text-decoration:underline;">Warrant dated April 21, 2014, issued by the Registrant to Alexandria Equities, LLC</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000156459020006830/adpt-ex43_880.htm"><span style="text-decoration:underline;">Description of Securities</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38957</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/26/2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1&#8224;</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex101.htm"><span style="text-decoration:underline;">Strategic Collaboration and License Agreement between Genentech, Inc. and the Registrant, dated December 19, 2018</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2&#8224;</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex102.htm"><span style="text-decoration:underline;">Strategic Collaboration Agreement between Microsoft Corporation and the Registrant, dated December 11, 2017</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3&#8224;</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519174174/d706383dex103.htm"><span style="text-decoration:underline;">Master Terms &#38; Conditions of Sale between Illumina, Inc. and the Registrant, dated May 28, 2019</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/17/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex105.htm"><span style="text-decoration:underline;">Amended and Restated Side Letter Agreement among Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Long Fund Master Ltd. and the Registrant, dated May 8, 2019</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-bottom:8pt;line-height:10pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex107.htm"><span style="text-decoration:underline;">Form of Amended and Restated Employment Agreement between the Registrant and certain of its executive officers</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:9.62%;">
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39.38%;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:76.95pt;;margin-right:12.96%;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:13.48%;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="4" valign="bottom" style="width:37.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:39.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:12.96%;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Title</p></td>
<td valign="bottom" style="width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/Furnished</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">With This</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report</p></td>
<td valign="bottom" style="width:6.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:8.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:11.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6*</span></p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex108.htm"><span style="text-decoration:underline;">Form of Amended and Restated Employment Agreement between the Registrant and each of Lance Baldo, MD and Francis T. Lo</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex109.htm"><span style="text-decoration:underline;">Form of Restated Non-Employee Director Change in Control Agreement between the Registrant and each of its non-employee directors</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1010.htm"><span style="text-decoration:underline;">Executive Severance Agreement between the Registrant and Chad Cohen, dated May 1, 2019</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1011.htm"><span style="text-decoration:underline;">Executive Severance Agreement between the Registrant and Lance Baldo, MD, dated April 22, 2019</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000156459020038958/adpt-ex101_139.htm"><span style="text-decoration:underline;">Form of Executive Severance Agreement between the Registrant and certain of its executive officers</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38957</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/10/2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1013.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex1012_218.htm"><span style="text-decoration:underline;">Adaptive Biotechnologies Corporation Non-Employee Director Compensation Policy</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1015.htm"><span style="text-decoration:underline;">Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan and form of award agreement thereunder</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000156459019031827/adpt-ex1012_196.htm"><span style="text-decoration:underline;">Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and form of award agreement thereunder</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38957</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/13/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519174174/d706383dex1017.htm"><span style="text-decoration:underline;">Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/17/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex1016_340.htm"><span style="text-decoration:underline;">Form of Stock Option Agreement for Non-U.S Participants</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17*</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex1017_339.htm"><span style="text-decoration:underline;">Form of Restricted Stock Unit Agreement for Non-U.S Participants</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1018.htm"><span style="text-decoration:underline;">Lease Agreement between ARE-Seattle No. 11, LLC and Adaptive TCR Corporation, dated July 21, 2011, as amended by Amendment No. 1, dated August 26, 2011, Amendment No. 2, dated June 30, 2014, Amendment No. 3, dated November 5, 2015, Amendment No. 4, dated December 23, 2015, and Amendment No. 5, dated June 6, 2016</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-231838</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/30/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19&#8224;</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519215526/d777595dex101.htm"><span style="text-decoration:underline;">Sixth Amendment to Lease Agreement between Adaptive Biotechnologies Corporation and ARE-Seattle No. 11, LLC, dated August 2, 2019</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38957</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/7/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20&#8224;</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000119312519215526/d777595dex102.htm"><span style="text-decoration:underline;">Lease Agreement between Adaptive Biotechnologies Corporation and ARE-Seattle No. 12, LLC, dated August 2, 2019</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38957</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/7/2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21&#8224;</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1478320/000156459019042978/adpt-ex103_547.htm"><span style="text-decoration:underline;">IVD Test Kit Development and Supply Agreement between Illumina, Inc. and Adaptive Biotechnologies Corporation, effective September 23, 2019</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:6.52%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:10.94%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38957</p></td>
<td valign="top" style="width:8.66%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:11.4%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2019</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:9.62%;">
<p style="line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39.38%;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:76.95pt;;margin-right:12.96%;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:13.48%;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="4" valign="bottom" style="width:37.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:2.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:39.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:12.96%;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Title</p></td>
<td valign="bottom" style="width:13.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/Furnished</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">With This</p>
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.9pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report</p></td>
<td valign="bottom" style="width:6.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:10.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:8.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:11.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;line-height:8pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</span></p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex211_175.htm"><span style="text-decoration:underline;">List of Subsidiaries</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex231_297.htm"><span style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Power of Attorney (included on the signature page)</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex311_178.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to Rule 13a&#8209;14(a) or Rule 15d&#8209;14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex312_179.htm"><span style="text-decoration:underline;">Certification of Principal Financial and Accounting Officer pursuant to Rule 13a&#8209;14(a) or Rule 15d&#8209;14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex321_176.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="adpt-ex322_177.htm"><span style="text-decoration:underline;">Certification of Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document<span style="Background-color:#FFFFFF;"> &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9.62%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:2.9pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:39.38%;">
<p style="margin-top:8pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)</p></td>
<td valign="top" style="width:13.48%;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
<td valign="top" style="width:6.52%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:10.94%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:8.66%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:11.4%;">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Management contract or compensation plan or arrangement.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K promulgated under the Securities Act because the information is not material and would be competitively harmful if publicly disclosed.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable<span style="font-weight:bold;color:#000000;">.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;;font-style:normal;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of <span style="color:#000000;">Section 13 or 15(d) of the Securities Exchange Act of 1934</span>, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, State of Washington, on February&#160;24, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="3" valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:11.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:88.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:11.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" style="width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.12%;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chad Robins</p></td>
</tr>
<tr>
<td valign="top" style="width:11.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad Robins</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Chad Robins, his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:35.56%;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:43.34%;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:18.86%;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chad Robins</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad Robins</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Director</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chad Cohen</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad Cohen</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal&#160;Financial&#160;and&#160;Accounting&#160;Officer)</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kevin Conroy</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin Conroy</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Eric Dobmeier</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eric Dobmeier</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Goel</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Goel</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michelle Griffin</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michelle Griffin</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Robert Hershberg</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Hershberg, PhD, MD</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Peter Neupert</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peter Neupert</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.56%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Pellini</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Pellini, MD</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February&#160;24, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:35.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:44.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:19.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>adpt-ex1012_218.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex1012_218.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">ADAPTIVE BIOTECHNOLOGIES CORPORATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;"><br />NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Last updated February 14, 2021</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation, a Washington corporation (the &#8220;<font style="font-weight:bold;">Company</font>&#8221;), believes that the granting of cash and equity compensation to the members of its Board of Directors (the &#8220;<font style="font-weight:bold;">Board</font>,&#8221; and members of the Board, the &#8220;<font style="font-weight:bold;">Directors</font>&#8221;) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the &#8220;<font style="font-weight:bold;">Non-Employee Directors</font>&#8221;).&nbsp;&nbsp;This Non-Employee Director Compensation Policy (this &#8220;<font style="font-weight:bold;">Policy</font>&#8221;) is intended to formalize the Company&#8217;s policy regarding cash compensation and grants of equity to its Non-Employee Directors.&nbsp;&nbsp;Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;<font style="font-weight:bold;">Plan</font>&#8221;).&nbsp;&nbsp;Each Non-Employee Director will be solely responsible for any tax obligations incurred by such Non-Employee Director as a result of the cash payments paid and equity awards granted to such Non-Employee Director under this Policy.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="text-decoration:underline;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">ANNUAL CASH COMPENSATION</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;;font-style:italic;font-family:Times New Roman;font-size:12pt;font-weight:normal;text-transform:none;font-variant: normal;">Annual Cash Retainer</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Non-Employee Director will be paid an annual cash retainer of $50,000.&nbsp;&nbsp;There are no per-meeting attendance fees for attending Board or shareholder meetings.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;;font-style:italic;font-family:Times New Roman;font-size:12pt;font-weight:normal;text-transform:none;font-variant: normal;">Additional Chair and Lead Director Annual Cash Retainer</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Non-Employee Director who serves as a lead director or chairman of a committee of the Board will be paid additional annual cash fees as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:10.77%;width:81.73%;">
<tr>
<td style="width:64.42%;"></td>
<td style="width:17.31%;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead Independent Director:</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$35,000</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee Chair:</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20,000</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation Committee Chair:</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15,000</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nominating and Corporate Governance Committee Chair:</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10,000</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All cash compensation will be paid quarterly in arrears.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board in its discretion may change and otherwise revise the terms of the cash compensation granted under this Policy, including, without limitation, the amount of cash compensation to be paid, on or after the date the Board determines to make any such change or revision.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="text-decoration:underline;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">EQUITY COMPENSATION</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Directors will be entitled to receive all types of Awards (excluding Incentive Stock Options) under the Plan (or the applicable equity plan in place at the time of grant).&nbsp;&nbsp;All grants of Awards to Non-Employee Directors pursuant to Section 2 of this Policy will be </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisio</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and subject to Sections 4.5 and 13 of the Plan</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Initial Award</font><font style="color:#000000;">.&nbsp;&nbsp;Each individual who first becomes a Non-Employee Director after the most recent update to this Policy will be granted an Award (the &#8220;</font><font style="font-weight:bold;color:#000000;">Initial Award</font><font style="color:#000000;">&#8221;), which grant will be effective on the date on which such individual first becomes a Non-Employee Director, whether through election by the shareholders of the Company or appointment by the Board to fill a vacancy.&nbsp;&nbsp;The Initial Award will have an estimated fair value of $400,000, using valuation methodologies deemed appropriate by the Compensation Committee of the Board or the Board from time to time, in light of commercial considerations deemed necessary to fulfill the goals set forth in this Policy and to align directors with shareholder interests.&nbsp;&nbsp;Fifty percent (50%) of the estimated fair value target of the Initial Award will be comprised of Nonstatutory Stock Options, and fifty percent (50%) of the estimated fair value target of the Initial Award will be comprised of Restricted Stock Units.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Annual Award</font><font style="color:#000000;">.&nbsp;&nbsp;Each Non-Employee Director will be granted an Award (an &#8220;</font><font style="font-weight:bold;color:#000000;">Annual Award</font><font style="color:#000000;">&#8221;), on the date of the first Board meeting of each calendar year (unless the Board determines to award them on a different date), beginning with 2021, following the election or appointment of such Non-Employee Director to the Board; provided that any Non-Employee Director who is not continuing as a Director during the calendar year following such Board meeting will not receive an Annual Award with respect to such meeting.&nbsp;&nbsp;The Annual Award will have an estimated fair value of $200,000 using valuation methodologies deemed appropriate by the Compensation Committee of the Board or the Board from time to time, in light of commercial considerations deemed necessary to fulfill the goals set forth in this Policy and to align directors with shareholder interests. Fifty percent (50%) of the estimated fair value target of the Annual Award will be comprised of Nonstatutory Stock Options, and fifty percent (50%) of the estimated fair value target of the Annual Award will be comprised of Restricted Stock Units.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Vesting</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to Sections 2(d) and 5 below: (a) the Nonstatutory Stock Option portion of each Initial Award will vest over four (4) years, with 25% vesting on the one (1)-year anniversary of the vesting commencement date and monthly thereafter for thirty-six (36) months; (b)&#160;the Restricted Stock Unit portion of each Initial Award will vest annually over four (4) years following the vesting commencement date; (c) the Nonstatutory Stock Option portion of each Annual Award will vest monthly over one (1) year following the vesting commencement date; and (d) the Restricted Stock Unit portion of each Annual Award will vest entirely on the one (1) year anniversary of the vesting commencement date.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Change in Control</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">In the event of a Change in Control, each </font><font style="color:#000000;">Non-Employee</font><font style="color:#000000;"> Director will fully vest in his or he</font><font style="color:#000000;">r Initial Award and/or </font><font style="color:#000000;">each </font><font style="color:#000000;">Annual Award</font><font style="color:#000000;"> provided that the </font><font style="color:#000000;">Non-Employee</font><font style="color:#000000;"> Director continues to </font><font style="color:#000000;">provide Service</font><font style="color:#000000;"> through such date.</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="text-decoration:underline;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">TRAVEL EXPENSES</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Non-Employee Director&#8217;s reasonable, customary and documented travel expenses to Board meetings will be reimbursed by the Company.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="text-decoration:underline;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">ADDITIONAL PROVISIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Non-Employee Directors.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="text-decoration:underline;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">ADJUSTMENTS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that any dividend or other distribution (whether in the form of cash, Stock, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Stock or other securities of the Company or other change in the corporate structure of the Company affecting the Stock occurs, the Board, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under this Policy, will adjust the number of shares of Stock issuable pursuant to Awards granted under this Policy.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="text-decoration:underline;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">LIMITATIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Non-Employee Director may be issued in any fiscal year cash payments (including the fees under Section 1 above) and Awards (including Awards under Section 2 above) with aggregate value greater than $600,000, increased to $750,000 in the fiscal year of his or her initial service as a Non-Employee Director.&nbsp;&nbsp;Any Awards or other compensation granted to an individual for his or her services as an employee, or for his or her services as a consultant other than a Non-Employee Director, will be excluded for purposes of the limitations under this Section 6.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="text-decoration:underline;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">SECTION 409A</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (a) the fifteenth (15th) day of the third (3rd) month following the end of the Company&#8217;s fiscal year in which the compensation is earned or expenses are incurred, as applicable, or (b) the fifteenth (15th) day of the third (3rd) month following the end of the calendar year in which the compensation is earned or expenses are incurred, as applicable, in compliance with the &#8220;short-term deferral&#8221; exception under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, &#8220;<font style="font-weight:bold;">Section 409A</font>&#8221;).&nbsp;&nbsp;It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section 409A so that none of the compensation to be provided hereunder will be subject to the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In no event </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will the Company reimburse a</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director for any taxes imposed or other costs incurred </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Section 409A.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="text-decoration:underline;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">REVISIONS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board or any committee designated by the Board may amend, alter, suspend or terminate this Policy at any time and for any reason.&nbsp;&nbsp;No amendment, alteration, suspension or termination of this Policy will materially impair the rights of a Non-Employee Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Non-Employee Director and the Company.&nbsp;&nbsp;Termination of this Policy will not affect the Board&#8217;s or the Compensation Committee&#8217;s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such termination.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>3
<FILENAME>adpt-ex1016_340.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex1016_340.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:center;margin-top:16pt;line-height:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADAPTIVE BIOTECHNOLOGIES CORPORATION <br />STOCK OPTION AGREEMENT</p>
<p style="text-align:center;margin-top:0pt;line-height:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(For Non-U.S. Participants)</p>
<p style="text-align:center;margin-top:0pt;line-height:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) has granted to the Participant named in the <font style="font-style:italic;">Notice of Grant of Stock Option </font>(the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Notice</font>&#8221;) to which this Stock Option Agreement (the &#8220;<font style="font-weight:bold;font-style:italic;">Option Agreement</font>&#8221;) is attached an option (the &#8220;<font style="font-weight:bold;font-style:italic;">Option</font>&#8221;) to purchase certain shares of Stock upon the terms and conditions set forth in the Grant Notice and this Option Agreement. The Option has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan (the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of, and represents that the Participant has read and is familiar with, the Grant Notice, this Option Agreement, the Plan and a prospectus for the Plan prepared in connection with the registration with the Securities and Exchange Commission of shares issuable pursuant to the Option (the &#8220;<font style="font-weight:bold;font-style:italic;">Plan Prospectus</font>&#8221;), (b) accepts the Option subject to all of the terms and conditions of the Grant Notice, this Option Agreement and the Plan and (c) agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Grant Notice, this Option Agreement or the Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:1.5%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">DEFINITIONS AND CONSTRUCTION</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-size:11pt;margin-left:144pt;color:#000000;"></font><font style="font-weight:bold;">Definitions</font><font style="font-weight:bold;font-style:italic;">. </font>Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Grant Notice or the Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-size:11pt;margin-left:144pt;color:#000000;"></font><font style="font-weight:bold;">Construction</font><font style="font-weight:bold;font-style:italic;">. </font>Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of this Option Agreement. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:1.5%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk50571661"></a><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">U.S. TAX STATUS OF OPTION</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk50571691"></a>For US tax purposes, to the extent applicable, this Option is intended to be a Nonstatutory Stock Option <font style="color:#000000;">and</font> shall not be treated as an Incentive Stock Option within the meaning of Section&#160;422(b) of the Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:1.5%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">ADMINISTRATION</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All questions of interpretation concerning the Grant Notice, this Option Agreement, the Plan or any other form of agreement or other document employed by the Company in the administration of the Plan or the Option shall be determined by the Committee. All such determinations by the Committee shall be final, binding and conclusive upon all persons having an interest in the Option, unless fraudulent or made in bad faith. Any and all actions, decisions and determinations taken or made by the Committee in the exercise of its discretion pursuant to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Plan or the Option or other agreement thereunder (other than determining questions of interpretation pursuant to the preceding sentence) shall be final, binding and conclusive upon all persons having an interest in the Option. Any Officer shall have the authority to act on behalf of the Company with respect to any matter, right, obligation, or election which is the responsibility </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or which is allocated to the Company herein, provided the Officer has apparent authority with respect to such matter, right, obligation, or election.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;margin-right:1.5%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0.1pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">EXERCISE</font><font style="font-weight:bold;text-decoration:underline;"> OF THE OPTION</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Right to Exercise</font><font style="font-weight:bold;font-style:italic;">. </font>Except as otherwise provided herein, the Option shall be exercisable on and after the Initial Vesting Date and prior to the termination of the Option (as provided in Section 6) in an amount not to exceed the number of Vested Shares less the number of shares previously acquired upon exercise of the Option. In no event shall the Option be exercisable for more shares than the Number of Option Shares, as adjusted pursuant to Section 9.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.2</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Method of Exercise</font><font style="font-weight:bold;font-style:italic;">. </font>Exercise of the Option shall be by means of electronic or written notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Exercise Notice</font>&#8221;) in a form authorized by the Company. An electronic Exercise Notice must be digitally signed or authenticated by the Participant in such manner as required by the notice and transmitted to the Company or an authorized representative of the Company (including a third-party administrator designated by the Company). In the event that the Participant is not authorized or is unable to provide an electronic Exercise Notice, the Option shall be exercised by a written Exercise Notice addressed to the Company, which shall be signed by the Participant and delivered in person, by certified or registered mail, return receipt requested, by confirmed facsimile transmission, or by such other means as the Company may permit, to the Company, or an authorized representative of the Company (including a third-party administrator designated by the Company). Each Exercise Notice, whether electronic or written, must state the Participant&#8217;s election to exercise the Option, the number of whole shares of Stock for which the Option is being exercised and such other representations and agreements as to the Participant&#8217;s investment intent with respect to such shares as may be required pursuant to the provisions of this Option Agreement. Further, each Exercise Notice must be received by the Company prior to the termination of the Option as set forth in Section 6 and must be accompanied by full payment of the aggregate Exercise Price for the number of shares of Stock being purchased. The Option shall be deemed to be exercised upon receipt by the Company of such electronic or written Exercise Notice and the aggregate Exercise Price.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:8.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.3</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Payment of Exercise Price.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:45pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Forms of Consideration Authorized</font><font style="font-weight:bold;">. </font>Except as otherwise provided below, payment of the aggregate Exercise Price for the number of shares of Stock for which the Option is being exercised shall be made (i) in cash, by check or in cash equivalent; (ii)&#160;if permitted by the Company and subject to the limitations contained in Section 4.3(b), by means of (1) a Cashless Exercise, or (2) a Net-Exercise; or (iii) by any combination of the foregoing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:45pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Limitations on Forms of Consideration. </font>The Company reserves, at any and all times, the right, in the Company&#8217;s sole and absolute discretion, to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">establish, decline to approve or terminate any program or procedure providing for payment of the Exercise Price through any of the means described below, including with respect to the Participant notwithstanding that such program or procedures may be available to others.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Cashless Exercise. </font>A &#8220;<font style="font-weight:bold;font-style:italic;">Cashless Exercise</font>&#8221;<font style="font-style:italic;"> </font>means the delivery of a properly executed Exercise Notice together with irrevocable instructions to a broker in a form acceptable to the Company providing for the assignment to the Company of the proceeds of a sale or loan with respect to shares of Stock acquired upon the exercise of the Option in an amount not less than the aggregate Exercise Price for such shares (including, without limitation, through an exercise complying with the provisions of Regulation T as promulgated from time to time by the Board of Governors of the Federal Reserve System).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Net-Exercise. </font>A &#8220;<font style="font-weight:bold;font-style:italic;">Net-Exercise</font>&#8221;<font style="font-style:italic;"> </font>means the delivery of a properly executed Exercise Notice electing a procedure pursuant to which (1) the Company will reduce the number of shares otherwise issuable to the Participant upon the exercise of the Option by the largest whole number of shares having a Fair Market Value that does not exceed the aggregate Exercise Price for the shares with respect to which the Option is exercised, and (2) the Participant shall pay to the Company in cash the remaining balance of such aggregate Exercise Price not satisfied by such reduction in the number of whole shares to be issued. Following a Net-Exercise, the number of shares remaining subject to the Option, if any, shall be reduced by the sum of (1) the net number of shares issued to the Participant upon such exercise, and (2) the number of shares deducted by the Company for payment of the aggregate Exercise Price.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:8.46%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">4.4</font><font style="font-size:11pt;margin-left:144pt;color:#000000;"></font><font style="font-weight:bold;">Tax Withholding</font><font style="font-weight:bold;font-style:italic;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">In General. </font>At the time the Option is exercised, in whole or in part, or at any time thereafter as requested by a Participating Company, the Participant hereby authorizes withholding from payroll and any other amounts payable to the Participant, and otherwise agrees to make adequate provision for (including by means of a Cashless Exercise to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax (including any social insurance) withholding obligations of the Participating Company Group, if any, which arise in connection with the Option<font style="color:#000000;">, including, without limitation, obligations arising upon (i)&#160;the grant, vesting or exercise, in whole or in part, of the Option, (ii)&#160;the transfer, in whole or in part, of any shares acquired upon exercise of the Option, (iii)&#160;the operation of any law or regulation providing for the imputation of interest, or (iv)&#160;the lapsing of any restriction with respect to any shares acquired upon exercise of the Option (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Tax Obligations</font><font style="color:#000000;">&#8221;). The Option is not exercisable unless the Tax Obligations of the Participating Company Group are satisfied. Accordingly, the </font>Company shall have no obligation to deliver shares of Stock until the Tax Obligations of the Participating Company Group have been satisfied by the Participant. <font style="color:#000000;">The Participant acknowledges that the ultimate liability for all Tax Obligations legally due by the Participant is and remains the Participant&#8217;s responsibility and that the Company (a) makes no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Option and (b) does not commit to structure the terms of the grant or any other aspect of the Option to reduce or eliminate the Participant&#8217;s liability for Tax Obligations.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;">Withholding in Shares</font><font style="font-weight:bold;letter-spacing:0.05pt;">. </font><font style="letter-spacing:0.05pt;">The Company shall have the right, but not the obligation, to require the Participant to satisfy all or any portion of a Participating Company&#8217;s tax withholding obligations upon exercise of the Option by deducting from the shares of Stock otherwise issuable to the Participant upon such exercise a number of whole shares having a fair market value, as determined by the Company as of the date of exercise, not in excess of the amount of such tax withholding obligations determined by the applicable minimum statutory withholding rates if required to avoid liability classification of the Option under generally accepted accounting principles in the United States.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.5</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Beneficial Ownership of Shares; Certificate Registration</font><font style="font-weight:bold;font-style:italic;">. </font>The Participant hereby authorizes the Company, in its sole discretion, to deposit for the benefit of the Participant with any broker with which the Participant has an account relationship of which the Company has notice any or all shares acquired by the Participant pursuant to the exercise of the Option. Except as provided by the preceding sentence, a certificate for the shares as to which the Option is exercised shall be registered in the name of the Participant, or, if applicable, in the names of the heirs of the Participant.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.6</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Restrictions on Grant of the Option and Issuance of Shares</font><font style="font-weight:bold;font-style:italic;">. </font>The <font style="letter-spacing:0.05pt;">grant of the Option and the issuance of shares of Stock upon exercise of the Option shall be subject to compliance with all applicable requirements of federal, state or foreign law with respect to such securities. The Option may not be exercised if the issuance of shares of Stock upon exercise would constitute a violation of any applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the Stock may then be listed. In addition, the Option may not be exercised unless (i) a registration statement under the Securities Act shall at the time of exercise of the Option be in effect with respect to the shares issuable upon exercise of the Option or (ii) in the opinion of legal counsel to the Company, the shares issuable upon exercise of the Option may be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act. THE PARTICIPANT IS CAUTIONED THAT THE OPTION MAY NOT BE EXERCISED UNLESS THE FOREGOING CONDITIONS ARE SATISFIED. ACCORDINGLY, THE PARTICIPANT MAY NOT BE ABLE TO EXERCISE THE OPTION WHEN DESIRED EVEN THOUGH THE OPTION IS VESTED. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company's legal counsel to be necessary to the lawful issuance and sale of any shares subject to the Option shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority shall not have been obtained. As a condition to the exercise of the Option, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.7</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Fractional Shares</font><font style="font-weight:bold;font-style:italic;">. </font>The Company shall not be required to issue fractional shares upon the exercise of the Option.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-size:11pt;margin-left:108pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">NONTRANSFERABILITY OF THE OPTION</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the lifetime of the Participant, the Option shall be exercisable only by the Participant or the Participant's guardian or legal representative. The Option shall not be subject in any manner to <font style="color:#000000;">anticipation</font>, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant's beneficiary, except transfer by will or by the laws of descent and distribution. Following the death of the Participant, the Option, to the extent provided in Section 7, may be exercised by the Participant's legal representative or by any person empowered to do so under the deceased Participant's will or under the then applicable laws of descent and distribution.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.15pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-size:11pt;margin-left:108pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">TERMINATION OF THE OPTION</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Option shall terminate and may no longer be exercised after the first to occur of (a) the close of business on the Option Expiration Date, (b) the close of business on the last date for exercising the Option following termination of the Participant's Service as described in Section 7, or (c) a Change in Control to the extent provided in Section 8.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.1pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-size:11pt;margin-left:108pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">EFFECT OF TERMINATION OF SERVICE</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.1</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Option Exercisability. </font>The Option shall terminate immediately upon the Participant's termination of Service to the extent that it is then unvested and shall be exercisable after the Participant's termination of Service to the extent it is then vested only during the applicable time period as determined below and thereafter shall terminate.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:180pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Disability</font><font style="font-weight:bold;">. </font>If the Participant's Service terminates because of the Disability of the Participant, the Option, to the extent unexercised and exercisable for Vested Shares on the date on which the Participant's Service terminated, may be exercised by the Participant (or the Participant's guardian or legal representative) at any time prior to the expiration of twelve (12) months after the date on which the Participant's Service terminated, but in any event no later than the Option Expiration Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:180pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Death</font><font style="font-weight:bold;">. </font>If the Participant's Service terminates because of the death of the Participant, the Option, to the extent unexercised and exercisable for Vested Shares on the date on which the Participant's Service terminated, may be exercised by the Participant's legal representative or other person who acquired the right to exercise the Option by reason of the Participant's death at any time prior to the expiration of twelve (12) months after the date on which the Participant's Service terminated, but in any event no later than the Option Expiration Date. The Participant's Service shall be deemed to have terminated on account of death if the Participant dies within three (3) months after the Participant's termination of Service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:180pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Termination for Cause. </font>Notwithstanding any other provision of this Option Agreement to the contrary, if the Participant's Service is terminated for Cause or if, following the Participant's termination of Service and during any period in which the Option otherwise would remain exercisable, the Participant engages in any act that would constitute Cause, the Option shall terminate in its entirety and cease to be exercisable immediately upon such termination of Service or act.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:11pt;margin-left:180pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Other Termination of Service</font><font style="font-weight:bold;">. </font>If the Participant's Service terminates for any reason, except Disability, death or Cause, the Option, to the extent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unexercised and exercisable for Vested Shares by the Participant on the date on which the Participant</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">'</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s Service terminated, may be exercised by the Participant at any time prior to the expiration of three (3) months after the date on which the Participant</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">'</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s Service terminated, but in any event no later than the Option Expiration Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.2</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Extension if Exercise Prevented by Law</font><font style="font-weight:bold;font-style:italic;">. </font>Notwithstanding the foregoing, other than termination of the Participant's Service for Cause, if the exercise of the Option within the applicable time periods set forth in Section 7.1 is prevented by the provisions of Section 4.6, the Option shall remain exercisable until the later of (a) thirty (30) days after the date such exercise first would no longer be prevented by such provisions, or (b) the end of the applicable time period under Section 7.1, but in any event no later than the Option Expiration Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.15pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-size:11pt;margin-left:108pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;text-transform:uppercase;">Effect of Change in Control</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;letter-spacing:0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a Change in Control, the Option shall be subject to the definitive agreement entered into by the Company in connection with the Change in Control. Except to the extent that the Committee determines to cash out the Option in accordance with Section 13.1(c) of the Plan, the surviving, continuing, successor, or purchasing entity or parent thereof, as the case may be (the &#8220;<font style="font-weight:bold;font-style:italic;">Acquiror</font>&#8221;), may, without the consent of the Participant, assume or continue in full force and effect the Company&#8217;s rights and obligations under all or any portion of the Option or substitute for all or any portion of the Option a substantially equivalent option for the Acquiror&#8217;s stock. For purposes of this Section, the Option or any portion thereof shall be deemed assumed if, following the Change in Control, the Option confers the right to receive, subject to the terms and conditions of the Plan and this Option Agreement, for each share of Stock subject to such portion of the Option immediately prior to the Change in Control, the consideration (whether stock, cash, other securities or property or a combination thereof) to which a holder of a share of Stock on the effective date of the Change in Control was entitled (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Stock); provided, however, that if such consideration is not solely common stock of the Acquiror, the Committee may, with the consent of the Acquiror, provide for the consideration to be received upon the exercise of the Option, for each share of Stock subject to the Option, to consist solely of common stock of the Acquiror equal in Fair Market Value to the per share consideration received by holders of Stock pursuant to the Change in Control. The Option shall terminate and cease to be outstanding effective as of the time of consummation of the Change in Control to the extent that the Option is neither assumed or continued by the Acquiror in connection with the Change in Control nor exercised as of the time of the Change in Control.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:-0.15pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-size:11pt;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Adjustments for Changes in Capital Structure</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to any required action by the shareholders of the Company and the requirements of Sections 409A and 424 of the Code to the extent applicable, in the event of any change in the Stock effected without receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dividend or distribution to the shareholders of the Company in a form other than Stock (excepting normal cash dividends) that has a material effect on the Fair Market Value of shares of Stock, appropriate and proportionate adjustments shall be made in the number, Exercise Price and kind of shares subject to the Option, in order to prevent dilution or enlargement of the Participant&#8217;s rights under the Option. For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as &#8220;effected without receipt of consideration by the Company.&#8221; Any fractional share resulting from an adjustment pursuant to this Section shall be rounded down to the nearest whole number and the Exercise Price shall be rounded up to the nearest whole cent. In no event may the Exercise Price be decreased to an amount less than the par value, if any, of the stock subject to the Option. The</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Committee in its sole discretion, may also make such adjustments in the terms of the Option to reflect, or related to, such changes in the capital structure of the Company or distributions as it deems appropriate. All adjustments pursuant to this Section shall be determined by the Committee, and its determination shall be final, binding and conclusive.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-size:11pt;margin-left:108pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">RIGHTS AS A SHAREHOLDER</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant shall have no rights as a shareholder with respect to any shares covered by the Option until the date of the issuance of the shares for which the Option has been exercised (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date the shares are issued, except as provided in Section 9. </p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-size:11pt;margin-left:108pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">LEGENDS</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates representing shares of stock subject to the provisions of this Option Agreement. The Participant shall, at the request of the Company, promptly present to the Company any and all certificates representing shares acquired pursuant to the Option in the possession of the Participant in order to carry out the provisions of this Section. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_Hlk47018712"></a><a name="_Hlk50571926"></a><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-size:11pt;font-variant: normal;margin-left:7pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;color:#000000;">SERVICE CONDITIONS</font><font style="font-weight:bold;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk29576139"></a><a name="_Hlk47018736"></a>In accepting <font style="color:#000000;">the</font> Option, the Participant acknowledges and agrees that:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk26112501"></a><a name="_Hlk29576174"></a><a name="_Hlk55231168"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any notice period mandated under applicable law shall not be treated as Service for the purpose of determining the vesting of the Option; and the Participant&#8217;s right to vesting of shares of Stock in settlement of the Option after termination of Service, if any, will be measured by the date of termination of the Participant&#8217;s active Service and will not be extended by any notice period mandated under applicable law. Subject to the foregoing and the provisions of the Plan, the Company, in its sole discretion, shall determine whether the Participant&#8217;s Service has terminated and the effective date of such termination.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Plan is established voluntarily by the Company. It is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Option Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The grant of the </font><font style="color:#000000;">Option</font><font style="color:#000000;"> is voluntary and occasional and does not create any contractual or other right to receive future grants of </font><font style="color:#000000;">options</font><font style="color:#000000;">, or benefits in lieu of </font><font style="color:#000000;">options</font><font style="color:#000000;">, even if </font><font style="color:#000000;">options</font><font style="color:#000000;"> have been granted repeatedly in the past.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All decisions with respect to future Option grants, if any, will be at the sole discretion of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Participant&#8217;s participation in the Plan shall not create a right to further Service with the Company or another Participating Company and shall not interfere with the ability of with the Company or another Participating Company to terminate the Participant&#8217;s Service at any time, with or without cause, subject to applicable law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Participant is voluntarily participating in the Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Option is an extraordinary item that does not constitute compensation of any kind for Service of any kind rendered to the Company or any Participating Company, and which is outside the scope of the Participant&#8217;s employment contract, if any.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Option is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, end-of-service payments, bonuses, long-service options, pension or retirement benefits or similar payments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that the Participant is not an employee of a Participating Company, the Option grant will not be interpreted to form an employment contract or relationship with a Participating Company. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The future value of the underlying shares of Stock is unknown and cannot be predicted with certainty. The value of the shares of Stock may increase or decrease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No claim or entitlement to compensation or damages arises from termination of the Option or diminution in value of the Option or shares of Stock and the Participant irrevocably releases the Participating Company Group from any such claim that may arise. If, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen then, by signing this Option Agreement, the Participant shall be deemed irrevocably to have waived the Participant&#8217;s entitlement to pursue such a claim.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk39753296"></a><a name="_Hlk51920414"></a><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-size:11pt;margin-left:7pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;color:#000000;">DATA PRIVACY</font><font style="font-weight:bold;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk54271549"></a><a name="_Hlk57216292"></a><font style="Background-color:#auto;text-decoration:none;">13.1</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Participants outside U.S., EU, EEA and UK.  </font><font style="color:#000000;">This Section 13.1 applies only if the Participant resides outside of the United States, the EU, the EEA, and UK:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk32583393"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Consent</font><font style="color:#000000;">.&nbsp;&nbsp;The Participant voluntarily consents to the collection, use, disclosure and transfer to the </font>United<font style="color:#000000;"> States and other jurisdictions, in electronic or other form, of his or her personal data as described in this Option Agreement and any other award materials (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Data</font><font style="color:#000000;">&#8221;) by and among, as applicable, the Participating Company Group for the exclusive purpose of implementing, </font>administering<font style="color:#000000;">, and managing his or her participation in the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Plan. </font><font style="color:#000000;">If </font><font style="color:#000000;">the Participant</font><font style="color:#000000;"> </font><font style="color:#000000;">does not choose to participate in the Plan, his or her employment status or service with </font><font style="color:#000000;">the Participating Company Group</font><font style="color:#000000;"> will not be adversely affected.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Information Collected</font><font style="color:#000000;">.&nbsp;&nbsp;The Participant understands that the Participating Company Group may collect, maintain, process and disclose, certain personal information about him or her, including, but not limited to, his or her name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all equity awards or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in his or her favor, for the exclusive purpose of implementing, administering and, managing the Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk29575802"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Transfers</font><font style="color:#000000;">.&nbsp;&nbsp;The Participant<a name="_Hlk29575802"></a> understands that Data will be transferred to one or more service provider(s) selected by the Company, which may assist the Company with the implementation, administration and management of the Plan.&nbsp;&nbsp;The Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipient&#8217;s country (</font><font style="font-style:italic;color:#000000;">e.g.</font><font style="color:#000000;">, the United States) may have different, including less stringent, data privacy laws and protections than his or her country.&nbsp;&nbsp;The Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative.&nbsp;&nbsp;The Participant authorizes the Company and any other possible recipients that may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her participation in the Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk29575827"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Time Period; Revocation of Consent</font><font style="color:#000000;">.&nbsp;&nbsp;The Participant<a name="_Hlk29575827"></a> understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan, including to maintain records regarding participation.&nbsp;&nbsp;The Participant understands that if he or she resides in certain jurisdictions, to the extent required by applicable law, he or she may, at any time, request access to Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents given by accepting these Options, in any case without cost, by contacting in writing his or her local human resources representative.&nbsp;&nbsp;Further, the Participant understands that he or she is providing these consents on a purely voluntary basis.&nbsp;&nbsp;If the Participant does not consent or if he or she later seeks to revoke his or her consent, his or her engagement as a service provider with the Participating Company Group&nbsp;&nbsp;will not be adversely affected; the only consequence of refusing or withdrawing his or her consent is that the Company will not be able to grant him or her Option under the Plan or administer or maintain Option.&nbsp;&nbsp;Therefore, the Participant understands that refusing or withdrawing his or her consent may affect his or her ability to participate in the Plan (including the right to retain the Option).&nbsp;&nbsp;The Participant understands that he or she may contact his or her local human resources representative for more information on the consequences of his or her refusal to consent or withdrawal of consent.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk57216307"></a><font style="text-decoration:none;Background-color:#auto;">13.2</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Participants </font><font style="font-weight:bold;color:#000000;">residing in </font><font style="font-weight:bold;color:#000000;">EU, EEA </font><font style="font-weight:bold;color:#000000;">or </font><font style="font-weight:bold;color:#000000;">UK. </font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">This</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">Section 13.2 applies if </font><font style="color:#000000;">the Participant resides </font><font style="color:#000000;">in </font><font style="color:#000000;">the EU, the EEA </font><font style="color:#000000;">or the </font><font style="color:#000000;">UK</font><font style="color:#000000;">, or </font><font style="color:#000000;">if </font><font style="color:#000000;">EU </font><font style="color:#000000;">privacy laws are otherwise applicable:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk57724545"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Data Collected and Purposes of Collection</font><font style="color:#000000;">.&nbsp;&nbsp;The Participant understands that the Company, acting as controller, as well as the employing</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">Participating Company, will process, to the extent permissible under applicable law, certain personal information about him or her, including name, home address and telephone number, information necessary to process the Option (</font><font style="font-style:italic;color:#000000;">e.g.</font><font style="color:#000000;">, mailing address for a check payment or bank account wire transfer information), date of birth, social insurance number or other identification number, salary, nationality, job title, employment location, details of all Options granted, canceled, vested, unvested or outstanding in his or her favor, and where applicable service termination date and reason for termination, any capital shares or directorships held in the Company (where needed for legal or tax compliance), and any other information necessary to process mandatory tax withholding and reporting (all such personal information is referred to as &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Data</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The Data is collected from the Participant, and from the Participating Company Group, for the purpose of implementing, administering and managing the Plan pursuant to its terms.&nbsp;&nbsp;The legal bases (that is, the legal justification) for processing the Data is that it is necessary to perform, administer and manage the Plan pursuant to this Option Agreement between the Participant and the Company,&nbsp;&nbsp;and in Company&#8217;s legitimate interests to comply with applicable non-EU laws when performing, administering and managing the Plan, subject to his or her interest and fundamental rights. The Data must be provided in order for the Participant to participate in the Plan and for the parties to this Option Agreement to perform their respective obligations thereunder.&nbsp;&nbsp;If the Participant does not provide Data, he or she will not be able to participate in the Plan and become a party to this Option Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Transfers and Retention of Data</font><font style="color:#000000;">.&nbsp;&nbsp;The Participant understands that the Data will be transferred to and among the Participating Company Group, as well as service providers (such as stock administration providers, brokers, transfer agents, accounting firms, payroll processing firms or tax firms), for the purposes explained above, which are necessary to allow the Company to perform this Option Agreement.&nbsp;&nbsp;The Participant understands that the recipients of the Data may be located in the United States and in other jurisdictions outside of the European Economic Area where we or our service providers have operations.&nbsp;&nbsp;The United States and some of these other jurisdictions have not been found by the European Commission to have adequate data protection safeguards. If the Participating Company Group make transfers of Data outside of the European Economic Area, those transfers will be made solely to the extent necessary to perform this Option Agreement and take necessary actions in connection with such performance. In addition, service providers may commit to provide adequate safeguards for the transferred Data, such as standard contractual clauses approved by the European Commission. In that case, the Participant may obtain details of the transfers by </font>contacting <font style="font-style:italic;">privacy@adaptivebiotech.com</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;color:#000000;">Participant&#8217;s Rights in Respect of Data</font><font style="color:#000000;">.&nbsp;&nbsp;The Participant has the right to access his or her Data being processed by the Company as well as understand why the Company is processing such Data.&nbsp;&nbsp;Additionally, subject to applicable law, the Participant is entitled to have any inadequate, incomplete or incorrect Data corrected (that is, rectified).&nbsp;&nbsp;Further, subject to applicable law, and under certain circumstances, the Participant </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">may be entitled to the following rights in regard to his or her Data:&nbsp;&nbsp;(i) to object to the processing of Data; (ii) to have his or her Data erased, such as where it is no longer necessary in relation to the purposes for which it was processed; (iii) to restrict the processing of his or her Data so that it is stored but not actively processed (</font><font style="font-style:italic;color:#000000;">e.g.</font><font style="color:#000000;">, while the Company assesses whether </font><font style="color:#000000;">the Participant</font><font style="color:#000000;"> is entitled to have Data erased); and (iv) to port a copy of the Data provided pursuant to </font><font style="color:#000000;">this Option Agreement</font><font style="color:#000000;"> or generated by him or her, in a common machine-readable format.</font><font style="color:#000000;">&#160;To exercise his or her rights, </font><font style="color:#000000;">the Participant</font><font style="color:#000000;"> may contact the applicable human resources representative.&#160;</font><font style="color:#000000;">The Participant</font><font style="color:#000000;"> may also contact the relevant data protection supervisory authority, as he or she has the right to lodge a complaint</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:14.62%;text-indent:0.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:-0.15pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-size:11pt;text-transform:none;margin-left:108pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Miscellaneous Provisions</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:21.54%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.1</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Termination or Amendment. </font>The Committee may terminate or amend the Plan or the Option at any time; provided, however, that except as provided in Section 8 in connection with a Change in Control, no such termination or amendment may have a materially adverse effect on the Option or any unexercised portion thereof without the consent of the Participant unless such termination or amendment is necessary to comply with any applicable law or government regulation. No amendment or addition to this Option Agreement shall be effective unless in writing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:21.54%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.2</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Further Instruments. </font>The parties hereto agree to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Option Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:21.54%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.3</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Binding Effect. </font>This Option Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer set forth herein, be binding upon the Participant and the Participant&#8217;s heirs, executors, administrators, successors and assigns.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:21.54%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.4</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Delivery of Documents and Notices. </font>Any document relating to participation in the Plan or any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given (except to the extent that this Option Agreement provides for effectiveness only upon actual receipt of such notice) upon personal delivery, electronic delivery at the e-mail address, if any, provided for the Participant by a Participating Company, or upon deposit in the U.S. Post Office or foreign postal service, by registered or certified mail, or with a nationally recognized overnight courier service, with postage and fees prepaid, addressed to the other party at the address of such party set forth in the Grant Notice or at such other address as such party may designate in writing from time to time to the other party.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Description of Electronic Delivery and Signature. </font>The Plan documents, which may include but do not necessarily include: the Plan, the Grant Notice, this Option Agreement, the Plan Prospectus, and any reports of the Company provided generally to the Company&#8217;s shareholders, may be delivered to the Participant electronically. In addition, if permitted by the Company, the Participant may deliver electronically the Grant Notice and Exercise Notice called for by Section 4.2 to the Company or to such third party involved in administering the Plan as the Company may designate from time to time. Such means of electronic delivery may include but do not necessarily include the delivery of a link to a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company intranet or the Internet site of a third party involved in administering the Plan, the delivery of the document via e-mail or such other means of electronic delivery specified by the Company. Any and all such documents and notices may be electronically signed.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:11pt;margin-left:180pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;letter-spacing:0.05pt;">Consent to Electronic Delivery and Signature. </font><font style="letter-spacing:0.05pt;">The Participant acknowledges that the Participant has read Section 14.4(a) of this Option Agreement and consents to the electronic delivery of the Plan documents and, if permitted by the Company, the delivery of the Grant Notice and Exercise Notice, as described in Section 14.4(a). The Participant agrees that any and all such documents requiring a signature may be electronically signed and that such electronic signature shall have the same effect as handwritten signature for the purposes of validity, enforceability and admissibility. The Participant acknowledges that he or she may receive from the Company a paper copy of any documents delivered electronically at no cost to the Participant by contacting the Company by telephone or in writing. The Participant further acknowledges that the Participant will be provided with a paper copy of any documents if the attempted electronic delivery of such documents fails. Similarly, the Participant understands that the Participant must provide the Company or any designated third-party administrator with a paper copy of any documents if the attempted electronic delivery of such documents fails. The Participant may revoke his or her consent to the electronic delivery of documents described in Section 14.4(a) or may change the electronic mail address to which such documents are to be delivered (if the Participant has provided an electronic mail address) at any time by notifying the Company of such revoked consent or revised e-mail address by telephone, postal service or electronic mail. Finally, the Participant understands that he or she is not required to consent to electronic delivery of documents described in Section 14.4(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.5</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Integrated Agreement. </font>The Grant Notice, this Option Agreement and the Plan, together with any Superseding Agreement and any change of control agreement, shall constitute the entire understanding and agreement of the Participant and the Participating Company Group with respect to the subject matter contained herein or therein and supersede any prior agreements, understandings, restrictions, representations, or warranties among the Participant and the Participating Company Group with respect to such subject matter. To the extent contemplated herein or therein, the provisions of the Grant Notice, the Option Agreement and the Plan shall survive any exercise of the Option and shall remain in full force and effect.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.6</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Applicable Law. </font>This Option Agreement shall be governed by the laws of the State of Washington as such laws are applied to agreements between Washington residents entered into and to be performed entirely within the State of Washington.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk51920561"></a><a name="_Hlk47017635"></a><font style="Background-color:#auto;text-decoration:none;">14.7</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Counterparts. </font>The Grant Notice may be executed in counterparts, each <a name="_Hlk51920561"></a><a name="_Hlk47017635"></a>of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.8</font><font style="font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Country-Specific Terms, Conditions, and Notices</font><font style="color:#000000;">. Notwithstanding any provisions in this Option Agreement, the Option grant shall be subject to any special terms and conditions set forth in any appendix to this Option Agreement for the Participant&#8217;s country (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Appendix</font><font style="color:#000000;">&#8221;). Moreover, if the Participant relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Participant unless determined otherwise by the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_Hlk40091697"></a>Appendix to</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADAPTIVE BIOTECHNOLOGIES CORPORATION <br />STOCK OPTION AGREEMENT</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR NON-US PARTICIPANTS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk49941825"></a>This Appendix includes additional notifications, terms and conditions that govern the Option granted to the Participant under the Plan if the Participant resides in one of the countries listed below. Capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or this Option Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant understands and agrees that the Company strongly recommends that the Participant not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because applicable rules and regulations regularly change, sometimes on a retroactive basis, and the information may be out of date at the time the Option vests or is exercised under the Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant further understands and agrees that if the Participant is a citizen or resident of a country other than the one in which the Participant is currently working, transfer employment after grant of the Option, or is considered a resident of another country for applicable law purposes, the information contained herein may not apply to the Participant, and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk56168092"></a>CANADA</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Terms and <font style="color:#000000;">Conditions</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk44930015"></a><font style="text-decoration:underline;">Termination of Service</font><font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following provision supplements Section 7 of this Option Agreement:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk44930357"></a>Except as required by applicable legislation, for purposes of the Option, the Participant&#8217;s Service will be considered terminated (regardless of the reason for such termination and whether or not later found to be invalid or in breach of labor laws in the jurisdiction where the Participant is providing services or the terms of the Participant&#8217;s service agreement, if any)<font style="color:#000000;"> as of the date that is the earliest of (1)&#160;the date the Participant&#8217;s </font>service relationship<font style="color:#000000;"> is terminated, (2)&#160;the date the Participant receives notice of termination from employing Participating Company, or (3)&#160;the date the Participant is no longer actively providing service to the Company or any Participating Company, regardless of any notice period or period of pay in lieu of such notice required under applicable law (including, but not limited to statutory law, regulatory law and/or common law). </font>The administrator shall have the exclusive discretion to determine when the Participant is no longer actively providing services for purposes of this Option (including whether the Participant may still be considered to be providing services while on a leave of absence).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Data Privacy</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following provision supplements Section 13 of this Option Agreement: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant hereby authorizes the Company and its representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. The Participant further authorizes the Participating Company Group and any stock plan service provider that may be selected by the Company to assist with the Plan to disclose and discuss the Plan with their respective advisors. The Participant further authorizes the Participating Company Group to record such information and to keep such information in the Participant&#8217;s employee file.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following provisions apply if Participant is a resident of Quebec:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Language Consent</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties to this Option Agreement acknowledge that it is their express wish that this Option Agreement, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Consentement relatif &#224; la langue utilis&#233;e</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Les parties reconnaissent avoir exig&#233; que cette convention (&#171;Agreement&#187;) soit r&#233;dig&#233;e en anglais, ainsi que tous les documents, avis et proc&#233;dures judiciaires, &#233;x&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224; la pr&#233;sente.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Notifications </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34300018"></a><font style="text-decoration:underline;">Securities Law Information</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant is permitted to sell shares of Stock acquired through the Plan through the designated broker appointed by the Company, provided the resale of shares of Stock acquired under the Plan takes place outside of Canada, including, if applicable, through the facilities of a stock exchange on which the shares of Stock are listed. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55314441"></a><font style="text-decoration:underline;">Foreign Asset/Account Reporting Information</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canadian residents are required to report any foreign property (e.g., shares of Stock acquired under the Plan and possibly unvested Option) on form T1135 (Foreign Income Verification Statement) if the total cost of their foreign property exceeds C$100,000 at any time in the year. It is the Participant&#8217;s responsibility to comply with these reporting obligations, and the Participant should consult with his or her personal tax advisor in this regard.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34832859"></a><font style="text-decoration:underline;">Share Settlement of Option</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary in the Plan or this Option Agreement, if this Option is granted to a Canadian Participant it may only be settled in shares of Stock and shall not be settled in cash. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk36642584"></a>GERMANY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk34305873"></a><a name="_Hlk36475647"></a>Notifications</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk49422408"></a><a name="_Hlk44603436"></a><font style="text-decoration:underline;">Securities Law Information</font>.&#160; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant of the Option under the Plan is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in Germany.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exchange Control Information</font>.<font style="font-weight:normal;">&#160; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk49422484"></a>If the Participant remits proceeds in excess of the legally designated amount (currently at &#8364;12,500) out of or into Germany, such cross-border payment must be reported monthly to the State Central Bank.  In the event that the Participant makes or receives a payment in excess of this amount, the Participant<a name="_Hlk49422484"></a> is responsible for obtaining the appropriate form from a German bank and complying with applicable reporting requirements.&#160; In addition, the Participant must also report on an annual basis in the unlikely event that the Participant holds shares of Stock exceeding 10% of the total voting capital of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-7.69%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk49422499"></a>Terms and Conditions</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Prohibition on Insider Dealing</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant should be aware of the insider dealing rules of the Regulation (EU) No 596/2014 of the European Parliament and Council (Market Abuse Regulation) apply in Germany, which may affect transactions under the Plan such as e.g. the subscription or participation, the suspension, the cancellation or an amending order, the acquisition or sale of shares of Stock acquired under the Plan, if the Participant has inside information regarding the Company. The Participant is advised to determine carefully whether he or she has inside information in respect of the Company and whether and to what extend insider dealing rules can apply to him or her. In case of uncertainty, the Company recommends that the Participant consults with a legal advisor. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Limitation of Liability</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant is responsible for compliance with any laws to be observed by the Participant in person in conjunction with the participation in the Plan. The Company cannot be held liable if the Participant violates German law or any other applicable rules to be complied with by the Participant in conjunction with the participation in the Plan including but not limited to insider dealing restrictions under the Market Abuse Regulation. </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;"><a name="_Hlk34121929"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRELAND</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk36128676"></a>Notifications</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34309807"></a><a name="_Hlk54286884"></a><a name="_Hlk54278906"></a><font style="text-decoration:underline;">Securities Law Information</font><a name="_Hlk54286884"></a><a name="_Hlk54278906"></a>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant of the Option under the Plan is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in Ireland.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Director Notification Requirement</font>.<font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Participant is a director, shadow director or secretary of an Irish Participating Company, the Participant is required to notify such Irish Participating Company in writing within five business days of (i) receiving or disposing of an interest in the Company (<font style="font-style:italic;">e.g.</font>, Options, shares of Stock, etc.), (ii) becoming aware of the event giving rise to the notification requirement, or (iii) becoming a director, shadow director or secretary of an Irish Participating Company if such an interest exists at the time.  This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary, as the case may be).&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LUXEMBOURG</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Notifications</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exchange Control Information</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant is required to report any inward remittances of funds to the <font style="font-style:italic;">Banque Central de Luxembourg</font> and/or the <font style="font-style:italic;">Service Central de La Statistique et des &#201;tudes &#201;conomiques</font> within 15 working days following the month during the transaction occurred. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on the Participant&#8217;s behalf. However, as long as the issuer is not a Luxembourg resident financial company, the statistical reporting obligation should not apply.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Securities Law Information</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant of the Option under the Plan is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in Luxembourg.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk49940739"></a>NETHERLANDS</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk40091950"></a>Notifications</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Securities Law Information</font>.<font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant of the Option under the Plan is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in the Netherlands.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.16</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk44926794"></a><font style="text-decoration:underline;">Prohibition Against Insider Trading</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant should be aware of the Dutch insider trading rules, which may affect the sale of shares of Stock acquired under this Option Agreement.&nbsp;&nbsp;In particular, the Participant may be prohibited from effecting certain share transactions if the Participant has insider information regarding the Company.&nbsp;&nbsp;Below is a discussion of the applicable restrictions.&nbsp;&nbsp;The Participant is advised to read the discussion carefully to determine whether the insider rules could apply to him or her.&nbsp;&nbsp;If it is uncertain whether the insider rules apply, the Company recommends that the Participant consult with a legal advisor.&nbsp;&nbsp;The Company cannot be held liable if the Participant violates the Dutch insider trading rules.&nbsp;&nbsp;The Participant is responsible for ensuring the Participant&#8217;s compliance with these rules.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dutch securities laws prohibit insider trading.&nbsp;&nbsp;As of 3 July 2016, the European Market Abuse Regulation (MAR), is applicable in the Netherlands.&nbsp;&nbsp;For further information, the Participant is referred to the website of the Authority for the Financial Markets (AFM): https://www.afm.nl/en/professionals/onderwerpen/marktmisbruik.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the broad scope of the definition of insider information, certain employees of the Company working at its Dutch Participating Company may have insider information and thus are prohibited from making a transaction in securities in the Netherlands at a time when they have such insider information. By entering into and participating in this Option Agreement, the Participant acknowledges having read and understood the notification above and acknowledges that it is the Participant&#8217;s responsibility to comply with the Dutch insider trading rules, as discussed herein.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>4
<FILENAME>adpt-ex1017_339.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex1017_339.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADAPTIVE BIOTECHNOLOGIES CORPORATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTED STOCK UNITS AGREEMENT</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(For Non-U.S. Participants)</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:10.05%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation has granted to the Participant named in the&#160;<font style="font-style:italic;">Notice of Grant of Restricted Stock Units</font>&#160;(the&#160;<font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Grant Notice</font><font style="font-style:italic;">&#8221;</font>) to which this Restricted Stock Units Agreement (the&#160;<font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Agreement</font><font style="font-style:italic;">&#8221;</font>) is attached an Award consisting of Restricted Stock Units (each a&#160;<font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Unit</font><font style="font-style:italic;">&#8221;</font>) subject to the terms and conditions set forth in the Grant Notice and this Agreement.&#160;&#160;The Award has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan (the&#160;<font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Plan</font><font style="font-style:italic;">&#8221;</font>), as amended to the Date of Grant, the provisions of which are incorporated herein by reference.&#160;&#160;By signing the Grant Notice, the Participant: (a)&#160;acknowledges receipt of and represents that the Participant has read and is familiar with the Grant Notice, this Agreement, the Plan and&#160;<font style="letter-spacing:-0.15pt;">a prospectus for the Plan prepared in connection with the registration with the Securities and Exchange Commission of the shares issuable pursuant to the Award (the&#160;</font><font style="font-style:italic;letter-spacing:-0.15pt;">&#8220;</font><font style="font-weight:bold;font-style:italic;letter-spacing:-0.15pt;">Plan Prospectus</font><font style="font-style:italic;letter-spacing:-0.15pt;">&#8221;</font><font style="letter-spacing:-0.15pt;">)</font>, (b)&#160;accepts the Award subject to all of the terms and conditions of the Grant Notice, this Agreement and the Plan and (c)&#160;agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Grant Notice, this Agreement or the Plan.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Definitions and Construction</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Definitions</font><font style="font-weight:bold;font-style:italic;">.</font>&#160;&#160;Unless otherwise defined herein, capitalized terms shall have the meanings assigned to such terms in the Grant Notice or the Plan.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Construction</font><font style="font-weight:bold;font-style:italic;">.</font>&#160;&#160;Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of this Agreement.&#160;&#160;Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.&#160;&#160;Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:12pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Administration</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All questions of interpretation concerning the Grant Notice, this Agreement, the Plan or any other form of agreement or other document employed by the Company in the administration of the Plan or the Award shall be determined by the Committee.&#160;&#160;All such determinations by the Committee shall be final, binding and conclusive upon all persons having an interest in the Award, unless fraudulent or made in bad faith.&#160;&#160;Any and all actions, decisions and determinations taken or made by the Committee in the exercise of its discretion pursuant to the Plan or the Award or other agreement thereunder (other than determining questions of interpretation pursuant to the preceding sentence) shall be final, binding and conclusive upon all persons having an interest in the Award.&#160;&#160;Any Officer shall have the authority to act on behalf of the Company with respect to any matter, right, obligation, or election which is the responsibility of or which is allocated to the Company herein, provided the Officer has apparent authority with respect to such matter, right, obligation, or election.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">The Award.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.1</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Grant of Units.</font>&#160;&#160;On the Date of Grant, the Participant shall acquire, subject to the provisions of this Agreement, the Total Number of Units set forth in the Grant Notice, subject to adjustment as provided in Section&#160;9.&#160;&#160;Each Unit represents a right to receive on a date determined in accordance with the Grant Notice and this Agreement one (1) share of Stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">No Monetary Payment Required.</font>&#160;&#160;The Participant is not required to make any monetary payment (other than applicable tax withholding, if any) as a condition to receiving the Units or shares of Stock issued upon settlement of the Units, the consideration for which shall be past services actually rendered or future services to be rendered to a Participating Company or for its benefit.&#160;&#160;Notwithstanding the foregoing, if required by applicable law, the Participant shall furnish consideration in the form of cash or past services rendered to a Participating Company or for its benefit having a value not less than the par value of the shares of Stock issued upon settlement of the Units.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:12pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Vesting of Units</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Units acquired pursuant to this Agreement shall become Vested Units as provided in the Grant Notice.&#160;&#160;For purposes of determining the number of Vested Units following an Ownership Change Event, credited Service shall include all Service with any corporation which is a Participating Company at the time the Service is rendered, whether or not such corporation is a Participating Company both before and after the Ownership Change Event.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Company Reacquisition Right</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="Background-color:#auto;text-decoration:none;">5.1</font><font style="font-family:Calibri;font-size:11pt;margin-left:40pt;color:#000000;"></font><font style="font-weight:bold;">Grant of Company Reacquisition Right.</font>&#160;&#160;Except to the extent otherwise provided by the Superseding Agreement, if any, in the event that the Participant&#8217;s Service terminates for any reason or no reason, with or without cause, the Participant shall forfeit and the Company shall automatically reacquire all Units which are not, as of the time of such termination, Vested Units (<font style="font-weight:bold;font-style:italic;">&#8220;Unvested Units&#8221;</font><font style="font-style:italic;">)</font>, and the Participant shall not be entitled to any payment therefor (the&#160;<font style="font-weight:bold;font-style:italic;">&#8220;Company Reacquisition Right&#8221;</font><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.2</font><font style="font-family:Calibri;font-size:11pt;margin-left:40pt;color:#000000;"></font><font style="font-weight:bold;">Ownership Change Event, Non-Cash Dividends, Distributions and Adjustments</font><font style="font-weight:bold;font-style:italic;">.</font>&#160;&#160;Upon the occurrence of an Ownership Change Event, a dividend or distribution to the shareholders of the Company paid in shares of Stock or other property, or any other adjustment upon a change in the capital structure of the Company as described in Section&#160;9, any and all new, substituted or additional securities or other property (other than regular, periodic cash dividends paid on Stock pursuant to the Company&#8217;s dividend policy) to which the Participant is entitled by reason of the Participant&#8217;s ownership of Unvested Units shall be immediately subject to the Company Reacquisition Right and included in the terms &#8220;Units&#8221; and &#8220;Unvested Units&#8221; for all purposes of the Company Reacquisition Right with the same force and effect as the Unvested Units immediately prior to the Ownership Change Event, dividend, distribution or adjustment, as the case may be.&#160;&#160;For purposes of determining the number of Vested Units following an Ownership Change Event, dividend, distribution or adjustment, credited Service shall include all Service with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any corporation which is a Participating Company</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the time the Service is rendered, </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether or not</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such corporation is a Participating Company both before and after any such event.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_Ref80704062"></a><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Settlement of the Award</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.1</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Issuance of Shares of Stock</font><font style="font-weight:bold;font-style:italic;">.</font>&#160;&#160;Subject to the provisions of Section&#160;6.3, the Company shall issue to the Participant on the Settlement Date with respect to each Vested Unit to be settled on such date one (1) share of Stock.&#160;&#160;The Settlement Date with respect to a Unit shall be the date on which such Unit becomes a Vested Unit&#160;&#160;as provided by the Grant Notice (an&#160;<font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Original Settlement Date</font><font style="font-style:italic;">&#8221;</font>); provided, however, that if the Tax Obligations (as defined herein) of a Participating Company, if any, will not be satisfied by the share withholding method described in Section&#160;7.3 and the Original Settlement Date would occur on a date on which a sale by the Participant of the shares to be issued in settlement of the Vested Units would violate the Trading Compliance Policy of the Company, then the Settlement Date for such Vested Units shall be deferred until the next day on which the sale of such shares would not violate the Trading Compliance Policy, but in any event on or before the 15th day of the third calendar month following calendar year of the Original Settlement Date.&#160;&#160;Shares of Stock issued in settlement of Units shall not be subject to any restriction on transfer other than any such restriction as may be required pursuant to Section&#160;6.3, Section&#160;7 or the Company&#8217;s Trading Compliance Policy.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref80702373"></a><font style="Background-color:#auto;text-decoration:none;">6.2</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Beneficial Ownership of Shares; Certificate Registration</font><font style="font-weight:bold;font-style:italic;">.</font><a name="_Ref80702373"></a>&#160;&#160;The Participant hereby authorizes the Company, in its sole discretion, to deposit any or all shares acquired by the Participant pursuant to the settlement of the Award with the Company&#8217;s transfer agent, including any successor transfer agent, to be held in book entry form, or to deposit such shares for the benefit of the Participant with any broker with which the Participant has an account relationship of which the Company has notice.&#160;&#160;Except as provided by the foregoing, a certificate for the shares acquired by the Participant shall be registered in the name of the Participant, or, if applicable, in the names of the heirs of the Participant.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.3</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Restrictions on Grant of the Award and Issuance of Shares</font><font style="font-weight:bold;font-style:italic;">.</font>&#160;&#160;The grant of the Award and issuance of shares of Stock upon settlement of the Award shall be subject to compliance with all applicable requirements of federal, state or foreign law with respect to such securities.&#160;&#160;No shares of Stock may be issued hereunder if the issuance of such shares would constitute a violation of any applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the Stock may then be listed.&#160;&#160;The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company&#8217;s legal counsel to be necessary to the lawful issuance of any shares subject to the Award shall relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority shall not have been obtained.&#160;&#160;As a condition to the settlement of the Award, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.4</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Fractional Shares</font><font style="font-weight:bold;font-style:italic;">.</font>&#160;&#160;The Company shall not be required to issue fractional shares upon the settlement of the Award.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_Ref199059841"></a><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="text-decoration:none;Background-color:#auto;">7.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Tax Withholding</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk51333235"></a><font style="Background-color:#auto;text-decoration:none;">7.1</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">In General.</font>&#160;&#160;At the time the Grant Notice is executed, or at any time thereafter as requested by a Participating Company, the Participant hereby authorizes withholding from payroll and any other amounts payable to the Participant, and otherwise agrees to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax (including any social insurance) withholding obligations of the Participating Company, if any, which arise in connection with the Award, <font style="color:#000000;">including, without limitation, obligations arising upon (i)&#160;the grant, vesting, in whole or in part, of the Units, (ii)&#160;the transfer, in whole or in part, of any shares acquired upon vesting of the Units, (iii)&#160;the operation of any law or regulation providing for the imputation of interest, or (iv)&#160;the lapsing of any restriction with respect to any shares acquired upon vesting of the Units (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Tax Obligations</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The Units are not vested unless the Tax Obligations of the Participating Company Group are satisfied.&nbsp;&nbsp;Accordingly, the</font> Company shall have no obligation to deliver shares of Stock until the Tax Obligations of the Participating Company have been satisfied by the Participant.<a name="_Hlk51333235"></a> <font style="color:#000000;">The Participant acknowledges that the ultimate liability for all Tax Obligations legally due by the Participant is and remains the Participant&#8217;s responsibility and that the Company (a) makes no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Units and (b) does not commit to structure the terms of the grant or any other aspect of the Units to reduce or eliminate the Participant&#8217;s liability for Tax Obligations.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref199059876"></a><font style="Background-color:#auto;text-decoration:none;">7.2</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Assignment of Sale Proceeds.</font>&#160;&#160;Subject to compliance with applicable law and the Company&#8217;s Trading Compliance Policy, if permitted by the Company, the Participant may satisfy the Participating Company&#8217;s Tax Obligations<a name="_Ref199059876"></a> in accordance with procedures established by the Company providing for delivery by the Participant to the Company or a broker approved by the Company of properly executed instructions, in a form approved by the Company, providing for the assignment to the Company of the proceeds of a sale with respect to some or all of the shares being acquired upon settlement of Units.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.3</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Withholding in Shares.</font>&#160;&#160;The Company shall have the right, but not the obligation, to require the Participant to satisfy all or any portion of a Participating Company&#8217;s Tax Obligations by deducting from the shares of Stock otherwise deliverable to the Participant in settlement of the Award a number of whole shares having a fair market value, as determined by the Company as of the date on which the Tax Obligations arise, not in excess of the amount of such Tax Obligations determined by the applicable minimum statutory withholding rates if required to avoid liability classification of the Award under generally accepted accounting principles in the United States.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:12pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_Ref80704351"></a><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Effect of Change in Control</font><font style="font-weight:bold;font-style:italic;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a>In the event of a Change in Control, the Award shall be subject to the definitive agreement entered into by the Company in connection with the Change in Control.&#160;&#160;Except&#160;to the extent that the Committee determines to cash out the Award in accordance with Section 13.1(c) of the Plan, the surviving, continuing, successor, or purchasing entity or parent thereof, as the case may be (the &#8220;<font style="font-weight:bold;font-style:italic;">Acquiror</font>&#8221;), may, without the consent of the Participant, assume or continue in full force and effect the Company&#8217;s rights and obligations under all or any portion of the outstanding Units or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substitute for all or any portion of the outstanding Units substantially equivalent rights with respect to the Acquiror&#8217;s stock.&#160;&#160;For purposes of this Section, a Unit shall be deemed assumed if, following the Change in Control, the Unit confers the right to receive, subject to the terms and conditions of the Plan and this Agreement, the consideration (whether stock, cash, other securities or property or a combination thereof) to which a holder of a share of Stock on the effective date of the Change in Control was entitled (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Stock); provided, however, that if such consideration is not solely common stock of the Acquiror, the Committee may, with the consent of the Acquiror, provide for the consideration to be received upon settlement of the Unit to consist solely of common stock of the</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquiror equal in Fair Market Value to the per share consideration received by holders of Stock pursuant to the Change in Control.&#160;&#160;The Award shall terminate and cease to be outstanding effective as of the time of consummation of the Change in Control to the extent that Units subject to the Award are neither assumed or continued by the Acquiror in connection with the Change in Control nor settled as of the time of the Change in Control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_Ref80704147"></a><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Adjustments for Changes in Capital Structure</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to any required action by the shareholders of the Company and the requirements of Section 409A of the Code to the extent applicable, in the event of any change in the Stock effected without receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the shareholders of the Company in a form other than Stock (other than regular, periodic cash dividends paid on Stock pursuant to the Company&#8217;s dividend policy) that has a material effect on the Fair Market Value of shares of Stock, appropriate and proportionate adjustments shall be made in the number of Units subject to the Award and/or the number and kind of shares or other property to be issued in settlement of the Award, in order to prevent dilution or enlargement of the Participant&#8217;s rights under the Award.&#160;&#160;For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as &#8220;effected without receipt of consideration by the Company.&#8221;&#160;&#160;Any and all new, substituted or additional securities or other property (other than regular, periodic cash dividends paid on Stock pursuant to the Company&#8217;s dividend policy) to which the Participant is entitled by reason of ownership of Units acquired pursuant to this Award will be immediately subject to the provisions of this Award on the same basis as all Units originally acquired hereunder.&#160;&#160;Any fractional Unit or share resulting from an adjustment pursuant to this Section shall be rounded down to the nearest whole number.&#160;&#160;Such adjustments shall be determined by the Committee, and its determination shall be final, binding and conclusive.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Rights as a Shareholder</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant shall have no rights as a shareholder with respect to any shares which may be issued in settlement of this Award until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).&#160;&#160;No adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date the shares are issued, except as provided in Section&#160;9.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Legends</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates representing shares of stock issued pursuant to this Agreement.&#160;&#160;The Participant shall, at the request of the Company, promptly present to the Company any and all certificates representing shares acquired pursuant to this Award in the possession of the Participant in order to carry out the provisions of this Section.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Compliance with Section 409A</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is intended that any election, payment or benefit which is made or provided pursuant to or in connection with this Award that may result in Section 409A Deferred Compensation shall comply in all respects with the applicable requirements of Section 409A (including applicable regulations or other administrative guidance thereunder, as determined by the Committee in good faith) to avoid the unfavorable tax consequences provided therein for non&#8209;compliance.&#160;&#160;In connection with effecting such compliance with Section 409A, the following shall apply:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.1</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Separation from Service; Required Delay in Payment to Specified Employee.&#160;&#160;</font>Notwithstanding anything set forth herein to the contrary, no amount payable pursuant to this Agreement on account of the Participant&#8217;s termination of Service which constitutes a &#8220;deferral of compensation&#8221; within the meaning of the Treasury Regulations issued pursuant to Section 409A of the Code (the&#160;<font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Section 409A Regulations</font><font style="font-style:italic;">&#8221;</font>) shall be paid unless and until the Participant has incurred a &#8220;separation from service&#8221; within the meaning of the Section 409A Regulations.&#160;&#160;Furthermore, to the extent that the Participant is a &#8220;specified employee&#8221; within the meaning of the Section 409A Regulations as of the date of the Participant&#8217;s separation from service, no amount that constitutes a deferral of compensation which is payable on account of the Participant&#8217;s separation from service shall be paid to the Participant before the date (the&#160;<font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Delayed Payment Date</font><font style="font-style:italic;">&#8221;</font>) which is first day of the seventh month after the date of the Participant&#8217;s separation from service or, if earlier, the date of the Participant&#8217;s death following such separation from service.&#160;&#160;All such amounts that would, but for this Section, become payable prior to the Delayed Payment Date will be accumulated and paid on the Delayed Payment Date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.2</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Other Changes in Time of Payment.</font>&#160;&#160;Neither the Participant nor the Company shall take any action to accelerate or delay the payment of any benefits under this Agreement in any manner which would not be in compliance with the Section 409A Regulations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a><font style="Background-color:#auto;text-decoration:none;">12.3</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Amendments to Comply with Section 409A; Indemnification.</font>&#160;&#160;Notwithstanding any other provision of this Agreement to the contrary, the Company is authorized to amend this Agreement, to void or amend any election made by the Participant under this Agreement and/or to delay the payment of any monies and/or provision of any benefits in such manner as may be determined by the Company, in its discretion, to be necessary or appropriate to comply with the Section 409A Regulations without prior notice to or consent of the Participant.&#160;&#160;The Participant hereby releases and holds harmless the Company, its directors, officers and shareholders from any and all claims that may arise from or relate to any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>tax liability, penalties, interest, costs, fees or other liability incurred by the Participant in connection with the Award, including as a result of the application of Section 409A.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.4</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Advice of Independent Tax Advisor.</font>&#160;&#160;The Company has not obtained a tax ruling or other confirmation from the Internal Revenue Service with regard to the application of Section 409A to the&#160;Award, and the Company does not represent or warrant that this&#160;Agreement&#160;will avoid adverse tax consequences to the&#160;Participant, including as a result of the application of Section 409A&#160;to the&#160;Award.&#160;&#160;The&#160;Participant&#160;hereby acknowledges that he or she has been advised to seek the advice of his or her own independent tax advisor prior to entering into this&#160;Agreement&#160;and is not relying upon any representations of the Company or any of its agents as to the effect of or the advisability of entering into this&#160;Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:12pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_Hlk50571926"></a><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-variant: normal;margin-left:7pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Service Conditions</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk29576139"></a><a name="_Hlk47018736"></a>In accepting the Units, the Participant acknowledges and agrees that:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk26112501"></a><a name="_Hlk29576174"></a><a name="_Hlk55231168"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any notice period mandated under applicable law shall not be treated as Service for the purpose of determining the vesting of the Units; and the Participant&#8217;s right to vesting of shares of Stock in settlement of the Units after termination of Service, if any, will be measured by the date of termination of the Participant&#8217;s active Service and will not be extended by any notice period mandated under applicable law.&nbsp;&nbsp;Subject to the foregoing and the provisions of the Plan, the Company, in its sole discretion, shall determine whether the Participant&#8217;s Service has terminated and the effective date of such termination.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Plan is established voluntarily by the Company.&nbsp;&nbsp;It is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The grant of the Units is voluntary and occasional and does not create any contractual or other right to receive future grants of Units, or benefits in lieu of Units, even if Units have been granted repeatedly in the past.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All decisions with respect to future Units grants, if any, will be at the sole discretion of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Participant&#8217;s participation in the Plan shall not create a right to further Service with the Company or another Participating Company and shall not interfere with the ability of with the Company or another Participating Company to terminate the Participant&#8217;s Service at any time, with or without cause, subject to applicable law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Participant is voluntarily participating in the Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Units are extraordinary items that do not constitute compensation of any kind for Service of any kind rendered to the Company or any Participating Company, and which is outside the scope of the Participant&#8217;s employment contract, if any.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(h)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The </font><font style="color:#000000;">Units</font><font style="color:#000000;"> </font><font style="color:#000000;">are</font><font style="color:#000000;"> not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, end-of-service payments, bonuses, long-service options, pension or retirement benefits or similar payments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that the Participant is not an employee of a Participating Company, the Units grant will not be interpreted to form an employment contract or relationship with a Participating Company.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The future value of the underlying shares of Stock is unknown and cannot be predicted with certainty.&nbsp;&nbsp;The value of the shares of Stock may increase or decrease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No claim or entitlement to compensation or damages arises from termination of the Units or diminution in value of the Units or shares of Stock and the Participant irrevocably releases the Participating Company Group from any such claim that may arise.&nbsp;&nbsp;If, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen then, by signing this Agreement, the Participant shall be deemed irrevocably to have waived the Participant&#8217;s entitlement to pursue such a claim.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman Bold;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><a name="_Hlk39753296"></a><a name="_Hlk51920414"></a><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-variant: normal;margin-left:7pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Data Privacy</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk57216292"></a><a name="_Hlk54271549"></a>The following provisions shall only apply to the Participant if he or she resides outside of the US, the EU, EEA, and UK:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk32583393"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Participant voluntarily consents to the collection, use, disclosure and transfer to the United States and other jurisdictions, in electronic or other form, of his or her personal data as described in this Agreement and any other award materials (&#8220;</font><font style="font-weight:bold;color:#000000;">Data</font><font style="color:#000000;">&#8221;) by and among, as applicable, the Participating Company Group for the exclusive purpose of implementing, administering, and managing his or her participation in the Plan. If the Participant does not choose to participate in the Plan, his or her employment status or service with the Participating Company Group will not be adversely affected.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Participant understands that the Participating Company Group may collect, maintain, process and disclose, certain personal information about him or her, including, but not limited to, his or her name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Stock or directorships held in the Company, details of all equity awards or any other entitlement to shares of Stock awarded, canceled, exercised, vested, unvested or outstanding in his or her favor, for the exclusive purpose of implementing, administering and, managing the Plan.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk29575802"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Participant<a name="_Hlk29575802"></a> understands that Data will be transferred to one or more service provider(s) selected by the Company, which may assist the Company with the implementation, administration and management of the Plan.&nbsp;&nbsp;The Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipient&#8217;s country (</font><font style="font-style:italic;color:#000000;">e.g.</font><font style="color:#000000;">, the United States) may have different, including less stringent, data privacy laws and protections than his or her country.&nbsp;&nbsp;The Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">recipients of the Data by contacting his or her local human resources representative.&nbsp;&nbsp;</font><font style="color:#000000;">The Participant</font><font style="color:#000000;"> authorizes the Company and any other possible recipients that may assist the Company (presently or in the future) with implementing, </font><font style="color:#000000;">administering</font><font style="color:#000000;"> and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her participation in </font><font style="color:#000000;">the Plan.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk29575827"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Participant<a name="_Hlk29575827"></a> understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan, including to maintain records regarding participation.&nbsp;&nbsp;The Participant understands that if he or she resides in certain jurisdictions, to the extent required by applicable law, he or she may, at any time, request access to Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents given by accepting these Units, in any case without cost, by contacting in writing his or her local human resources representative.&nbsp;&nbsp;Further, the Participant understands that he or she is providing these consents on a purely voluntary basis.&nbsp;&nbsp;If the Participant does not consent or if he or she later seeks to revoke his or her consent, his or her engagement as a service provider with the Participating Company Group&nbsp;&nbsp;will not be adversely affected; the only consequence of refusing or withdrawing his or her consent is that the Company will not be able to grant him or her Units under the Plan or administer or maintain Units.&nbsp;&nbsp;Therefore, the Participant understands that refusing or withdrawing his or her consent may affect his or her ability to participate in the Plan (including the right to retain the Units).&nbsp;&nbsp;The Participant understands that he or she may contact his or her local human resources representative for more information on the consequences of his or her refusal to consent or withdrawal of consent.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.65%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk57216307"></a><a name="_Hlk29575850"></a><a name="_Hlk29575850"></a>The following provisions shall only apply to the Participant if he or she resides in the EU, EEA, UK, or EU privacy laws are otherwise applicable:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk57724545"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-family:Calibri;font-size:11pt;margin-left:45pt;color:#000000;"></font><font style="color:#000000;">Data Collected and Purposes of Collection.&nbsp;&nbsp;The Participant understands that the Company, acting as controller, as well as the employing</font><font style="letter-spacing:-0.15pt;color:#000000;"> </font><font style="color:#000000;">Participating Company, will process, to the extent permissible under applicable law, certain personal information about him or her, including name, home address and telephone number, information necessary to process the Units (</font><font style="font-style:italic;color:#000000;">e.g.</font><font style="color:#000000;">, mailing address for a check payment or bank account wire transfer information), date of birth, social insurance number or other identification number, salary, nationality, job title, employment location, details of all Units granted, canceled, vested, unvested or outstanding in his or her favor, and where applicable service termination date and reason for termination, any capital shares or directorships held in the Company (where needed for legal or tax compliance), and any other information necessary to process mandatory tax withholding and reporting (all such personal information is referred to as &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Data</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The Data is collected from the Participant, and from the Participating Company Group, for the purpose of implementing, administering and managing the Plan pursuant to its terms.&nbsp;&nbsp;The legal bases (that is, the legal justification) for processing the Data is that it is necessary to perform, administer and manage the Plan pursuant to this Agreement between the Participant and the Company,&nbsp;&nbsp;and in Company&#8217;s legitimate interests to comply with applicable non-EU laws when performing, administering and managing the Plan, subject to his or her interest and fundamental rights. The Data must be provided in order for the Participant to participate in the Plan and for the parties to this Agreement to perform their respective obligations </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">thereunder.&nbsp;&nbsp;If </font><font style="color:#000000;">the Participant</font><font style="color:#000000;"> does not provide Data, he or she will not be able to participate in the Plan and become a party to </font><font style="color:#000000;">this Agreement</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-family:Calibri;font-size:11pt;margin-left:45pt;color:#000000;"></font><font style="color:#000000;">Transfers and Retention of Data.&nbsp;&nbsp;The Participant understands that the Data will be transferred to and among the Participating Company Group, as well as service providers (such as stock administration providers, brokers, transfer agents, accounting firms, payroll processing firms or tax firms), for the purposes explained above, which are necessary to allow the Company to perform this Agreement.&nbsp;&nbsp;The Participant understands that the recipients of the Data may be located in the United States and in other jurisdictions outside of the European Economic Area where we or our service providers have operations.&nbsp;&nbsp;The United States and some of these other jurisdictions have not been found by the European Commission to have adequate data protection safeguards. If the Participating Company Group make transfers of Data outside of the European Economic Area, those transfers will be made solely to the extent necessary to perform this Agreement and take necessary actions in connection with such performance. In addition, service providers may commit to provide adequate safeguards for the transferred Data, such as standard contractual clauses approved by the European Commission. In that case, the Participant may obtain details of the transfers by </font><font style="color:#000000;">contacting privacy@adaptivebiotech.com.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:12pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-family:Calibri;font-size:11pt;margin-left:45pt;color:#000000;"></font><font style="color:#000000;">The Participant&#8217;s Rights in Respect of Data.&nbsp;&nbsp;The Participant has the right to access his or her Data being processed by the Company as well as understand why the Company is processing such Data.&nbsp;&nbsp;Additionally, subject to applicable law, the Participant is entitled to have any inadequate, incomplete or incorrect Data corrected (that is, rectified).&nbsp;&nbsp;Further, subject to applicable law, and under certain circumstances, the Participant may be entitled to the following rights in regard to his or her Data:&nbsp;&nbsp;(i) to object to the processing of Data; (ii) to have his or her Data erased, such as where it is no longer necessary in relation to the purposes for which it was processed; (iii) to restrict the processing of his or her Data so that it is stored but not actively processed (</font><font style="font-style:italic;color:#000000;">e.g.</font><font style="color:#000000;">, while the Company assesses whether the Participant is entitled to have Data erased); and (iv) to port a copy of the Data provided pursuant to this Agreement or generated by him or her, in a common machine-readable format.&#160;To exercise his or her rights, the Participant may contact the applicable human resources representative.&#160;The Participant may also contact the relevant data protection supervisory authority, as he or she has the right to lodge a complaint.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;text-decoration:underline;">Miscellaneous Provisions</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.1</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-variant: normal;">Termination or Amendment.</font><font style="font-variant: normal;">&#160;&#160;The Committee may terminate or amend the Plan or this Agreement at any time; provided, however, that except as provided in Section&#160;8 in connection with a Change in Control, no such termination or amendment may have a materially adverse effect on the Participant&#8217;s rights under this Agreement without the consent of the Participant unless such termination or amendment is necessary to comply with applicable law or government regulation, including, but not limited to, Section 409A.&#160;&#160;No amendment or addition to this Agreement shall be effective unless in writing.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.2</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-variant: normal;">Nontransferability of the Award.</font><font style="font-variant: normal;">&#160;&#160;Prior to the issuance of shares of Stock on the applicable Settlement Date, neither this Award nor any Units subject to this Award shall be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant or the Participant&#8217;s beneficiary, except </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="font-variant: normal;">transfer by will or by the laws of descent and distribution.&#160;&#160;All rights with respect to the Award shall be exercisable during the Participant&#8217;s lifetime only by the Participant or the Participant&#8217;s guardian or legal representative.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.3</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-variant: normal;">Further Instruments.</font><font style="font-variant: normal;">&#160;&#160;The parties hereto agree to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.4</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-variant: normal;">Binding Effect.</font><font style="font-variant: normal;">&#160;&#160;This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer set forth herein, be binding upon the Participant and the Participant&#8217;s heirs, executors, administrators, successors and assigns.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.5</font><font style="font-family:Calibri;font-size:11pt;font-variant: normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-variant: normal;">Delivery of Documents and Notices.</font><font style="font-variant: normal;">&#160;&#160;Any document relating to participation in the Plan or any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given (except to the extent that this Agreement provides for effectiveness only upon actual receipt of such notice) upon personal delivery, electronic delivery at the e-mail address, if any, provided for the Participant by a Participating Company, or upon deposit in the U.S. Post Office or foreign postal service, by registered or certified mail, or with a nationally recognized overnight courier service, with postage and fees prepaid, addressed to the other party at the address of such party set forth in the Grant Notice or at such other address as such party may designate in writing from time to time to the other party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref444873145"></a><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Description of Electronic Delivery&#160;and Signature.</font>&#160;&#160;The Plan documents, which may include but do not necessarily include: the Plan, the Grant Notice, this Agreement, the Plan Prospectus, and any reports of the Company provided generally to the Company&#8217;s shareholders, may be delivered to the Participant electronically.&#160;&#160;In addition, if permitted by the Company, the Participant may deliver electronically the Grant Notice to the Company or to such third party involved in administering the Plan as the Company may designate from time to time.&#160;&#160;Such means of electronic delivery may include but do not necessarily include the delivery of a link to a Company intranet or the Internet site of a third party involved in administering the Plan, the delivery of the document via e-mail or such other means of electronic delivery specified by the Company.&#160;&#160;Any and all such documents and notices may be electronically signed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;font-style:italic;">Consent to Electronic Delivery and Signature.</font>&#160;&#160;The Participant acknowledges that the Participant has read Section&#160;15.5(a) of this Agreement and consents to the electronic delivery of the Plan documents and, if permitted by the Company, the delivery of the Grant Notice, as described in Section&#160;15.5(a).&#160;&#160;The Participant agrees that any and all such documents requiring a signature may be electronically signed and that such electronic signature shall have the same effect as handwritten signature for the purposes of validity, enforceability and admissibility.&#160;&#160;The Participant acknowledges that he or she may receive from the Company a paper copy of any documents delivered electronically at no cost to the Participant by contacting the Company by telephone or in writing.&#160;&#160;The Participant further acknowledges that the Participant will be provided with a paper copy of any documents if the attempted electronic delivery of such documents fails.&#160;&#160;Similarly, the Participant&#160;understands that the Participant must provide the Company or any designated third party administrator with a paper copy of any documents if the attempted electronic delivery of such documents fails.&#160;&#160;The Participant may revoke his or her </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consent to the electronic delivery of documents described in Section&#160;</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) or may change the electronic mail address to which such documents are to be delivered (if Participant has provided an electronic mail address) at any time by notifying the Company of such revoked consent or revised e-mail address by telephone, postal </font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">service</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or electronic mail.&#160;&#160;Finally, the Participant understands that he or she is not required to consent to electronic delivery of documents described in Section&#160;</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.5</font><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.6</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Integrated Agreement.</font>&#160;&#160;The Grant Notice, this Agreement and the Plan, together with any Superseding Agreement and any change of control agreement, shall constitute the entire understanding and agreement of the Participant and the Participating Company Group with respect to the subject matter contained herein or therein and supersede any prior agreements, understandings, restrictions, representations, or warranties among the Participant and the Participating Company Group with respect to such subject matter.&#160;&#160;To the extent contemplated herein or therein, the provisions of the Grant Notice, this Agreement and the Plan shall survive any settlement of the Award and shall remain in full force and effect.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="Background-color:#auto;text-decoration:none;">15.7</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Applicable Law.</font>&#160;&#160;This Agreement shall be governed by the laws of the State of Washington as such laws are applied to agreements between Washington residents entered into<a name="_AEIOULastRenderedPageBreakAEIOU65"></a> and to be performed entirely within the State of Washington.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk51920561"></a><a name="_Hlk47017635"></a><font style="Background-color:#auto;text-decoration:none;">15.8</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;">Counterparts.</font><a name="_Hlk51920561"></a><a name="_Hlk47017635"></a>&#160;&#160;The Grant Notice may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:12pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.9</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">Country-Specific Terms, Conditions, and Notices.</font><font style="color:#000000;">&nbsp;&nbsp;Notwithstanding any provisions in this Agreement, the Units grant shall be subject to any special terms and conditions set forth in any appendix to this Agreement for the Participant&#8217;s country (the &#8220;</font><font style="font-weight:bold;color:#000000;">Appendix</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Moreover, if the Participant relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Participant unless determined otherwise by the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;"><a name="_Hlk40091697"></a>Appendix to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADAPTIVE BIOTECHNOLOGIES CORPORATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTED STOCK UNITS AGREEMENT</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br />FOR NON-US PARTICIPANTS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk49941825"></a>This Appendix includes additional notifications, terms and conditions that govern the Units granted to the Participant under the Plan if the Participant resides in one of the countries listed below.&nbsp;&nbsp;Capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant understands and agrees that the Company strongly recommends that the Participant not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because applicable rules and regulations regularly change, sometimes on a retroactive basis, and the information may be out of date at the time the Units vest under the Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant further understands and agrees that if the Participant is a citizen or resident of a country other than the one in which the Participant is currently working, transfer employment after grant of the Units, or is considered a resident of another country for applicable law purposes, the information contained herein may not apply to the Participant, and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk56168092"></a>CANADA</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Terms and <font style="color:#000000;">Conditions</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk44930357"></a><a name="_Hlk44930015"></a><font style="text-decoration:underline;">Termination of Service</font>. <font style="font-weight:normal;"> Notwithstanding any provision of the Plan or this Agreement, the following provision shall apply to Participants employed in Canada on the date on which notification of termination (for any reason, with or without cause) or resignation from Service is delivered:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this Agreement, the Participant&#8217;s termination date shall mean the later of (i) the date upon which the Participant ceases to perform Services for the Participating Company Group following the provision of such notification of termination or &#8206;resignation from Service and (ii) the end of any minimum period of notice of termination (if any) required by applicable employment or labour standards legislation.&nbsp;&nbsp;For clarity, unless otherwise expressly provided in this Agreement or determined by the Participating Company Group, no Units will vest under the Plan following the Participant&#8217;s termination date, and the termination date will not be extended by any period of deemed notice of termination under contract or at common or civil law in respect of which the Participant may receive pay in lieu of notice of termination or damages in lieu of such notice.&nbsp;&nbsp;The Participant will not be entitled to any further payments in respect of the value of any Units that have not yet vested as of the Participant&#8217;s termination date and no Units or any pro-rated portion thereof shall be included in any entitlement to any pay in lieu of notice of termination or damages in lieu of such notice. Subject to any applicable statutory notice </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period, the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administrator</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall have the exclusive discretion to determine when </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Participant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is no longer &#8206;actively providing services for purposes of the grant of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Units</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Data Privacy</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following provision supplements Section 14 of this Agreement:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant hereby authorizes the Company and its representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.&nbsp;&nbsp;The Participant further authorizes the Participating Company Group and any stock plan service provider that may be selected by the Company to assist with the Plan to disclose and discuss the Plan with their respective advisors.&nbsp;&nbsp;The Participant further authorizes the Participating Company Group to record such information and to keep such information in the Participant&#8217;s employee file.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following provisions apply if Participant is a resident of Quebec:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Language Consent</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties to this Agreement acknowledge that it is their express wish that this Agreement, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Consentement relatif &#224; la langue utilis&#233;e</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Les parties reconnaissent avoir exig&#233; que cette convention (&#171;Agreement&#187;) soit r&#233;dig&#233;e en anglais, ainsi que tous les documents, avis et proc&#233;dures judiciaires, &#233;x&#233;cut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;s directement ou indirectement &#224; la pr&#233;sente.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Notifications </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34300018"></a><font style="text-decoration:underline;">Securities Law Information</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant is permitted to sell shares of Stock acquired through the Plan through the designated broker appointed by the Company, provided the resale of shares of Stock acquired under the Plan takes place outside of Canada, including, if applicable, through the facilities of a stock exchange on which the shares of Stock are listed.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55314441"></a><font style="text-decoration:underline;">Foreign Asset/Account Reporting Information</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canadian residents are required to report any foreign property (e.g., shares of Stock acquired under the Plan and possibly unvested Units) on form T1135 (Foreign Income Verification Statement) if the total cost of their foreign property exceeds C$100,000 at any time in the year.&nbsp;&nbsp;It is the Participant&#8217;s responsibility to comply with these reporting obligations, and the Participant should consult with his or her personal tax advisor in this regard.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34832859"></a><font style="text-decoration:underline;">Share Settlement of Units</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary in the Plan or this Agreement, Units granted to Canadian Participants shall only be settled in shares of Stock and shall not be settled in cash. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk36642584"></a>GERMANY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk34305873"></a><a name="_Hlk36475647"></a>Notifications</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk49422408"></a><a name="_Hlk44603436"></a><font style="text-decoration:underline;">Securities Law Information</font>.&#160; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant of Units under the Plan is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in Germany.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exchange Control Information</font>.<font style="font-weight:normal;">&#160; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk49422484"></a>If the Participant remits proceeds in excess of the legally designated amount (currently at &#8364;12,500) out of or into Germany, such cross-border payment must be reported monthly to the State Central Bank.&#160; In the event that the Participant makes or receives a payment in excess of this amount, the Participant<a name="_Hlk49422484"></a> is responsible for obtaining the appropriate form from a German bank and complying with applicable reporting requirements.&#160; In addition, the Participant must also report on an annual basis in the unlikely event that the Participant holds shares of Stock exceeding 10% of the total voting capital of the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-7.69%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk49422499"></a>Terms and Conditions</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Prohibition on Insider Dealing</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant should be aware of the insider dealing rules of the Regulation (EU) No 596/2014 of the European Parliament and Council (Market Abuse Regulation) apply in Germany, which may affect transactions under the Plan such as e.g. the subscription or participation, the suspension, the cancellation or an amending order, the acquisition or sale of shares of Stock acquired under the Plan, if the Participant has inside information regarding the Company. The Participant is advised to determine carefully whether he or she has inside information in respect of the Company and whether and to what extend insider dealing rules can apply to him or her. In case of uncertainty, the Company recommends that the Participant consults with a legal advisor. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Limitation of Liability</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant is responsible for compliance with any laws to be observed by the Participant in person in conjunction with the participation in the Plan. The Company cannot be held liable if the Participant violates German law or any other applicable rules to be complied with by the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Participant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in conjunction with the participation in the Plan including but not limited to insider dealing restrictions under the Market Abuse Regulation.&nbsp;&nbsp;</font><font style="font-weight:bold;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34121929"></a>IRELAND</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk36128676"></a>Notifications</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34309807"></a><font style="text-decoration:underline;">Securities Law Information</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54286884"></a><a name="_Hlk54278906"></a>The grant of Units under the Plan is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in Ireland.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Director Notification Requirement</font>.<font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Participant is a director, shadow director or secretary of an Irish Participating Company, the Participant is required to notify such Irish Participating Company in writing within five business days of (i) receiving or disposing of an interest in the Company (<font style="font-style:italic;">e.g.</font>, Units, shares of Stock, etc.), (ii) becoming aware of the event giving rise to the notification requirement, or (iii) becoming a director, shadow director or secretary of an Irish Participating Company if such an interest exists at the time.&#160; This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary, as the case may be).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LUXEMBOURG</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Notifications</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exchange Control Information</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant is required to report any inward remittances of funds to the <font style="font-style:italic;">Banque Central de Luxembourg</font> and/or the <font style="font-style:italic;">Service Central de La Statistique et des &#201;tudes &#201;conomiques</font> within 15 working days following the month during the transaction occurred.&#160; If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on the Participant&#8217;s behalf. However, as long as the issuer is not a Luxembourg resident financial company, the statistical reporting obligation should not apply</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Securities Law Information</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant of Units under the Plan is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in Luxembourg.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk49940739"></a>NETHERLANDS</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk40091950"></a><a name="_Hlk48749929"></a>Notifications</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Securities Law Information</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant of Units under the Plan is exempt or excluded from the requirement to publish a prospectus under the EU Prospectus Regulation as implemented in the Netherlands.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk44926794"></a><font style="text-decoration:underline;">Prohibition Against Insider Trading</font>.<font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Participant should be aware of the Dutch insider trading rules, which may affect the sale of shares of Stock acquired under this Agreement.&nbsp;&nbsp;In particular, the Participant may be prohibited from effecting certain share transactions if the Participant has insider information regarding the Company.&nbsp;&nbsp;Below is a discussion of the applicable restrictions.&nbsp;&nbsp;The Participant is advised to read the discussion carefully to determine whether the insider rules could apply to him or her.&nbsp;&nbsp;If it is uncertain whether the insider rules apply, the Company recommends that the Participant consult with a legal advisor.&nbsp;&nbsp;The Company cannot be held liable if the Participant violates the Dutch insider trading rules.&nbsp;&nbsp;The Participant is responsible for ensuring the Participant&#8217;s compliance with these rules.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dutch securities laws prohibit insider trading.&nbsp;&nbsp;As of 3 July 2016, the European Market Abuse Regulation (MAR), is applicable in the Netherlands.&nbsp;&nbsp;For further information, the Participant is referred to the website of the Authority for the Financial Markets (AFM): https://www.afm.nl/en/professionals/onderwerpen/marktmisbruik.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the broad scope of the definition of insider information, certain employees of the Company working at its Dutch Participating Company may have insider information and thus are prohibited from making a transaction in securities in the Netherlands at a time when they have such insider information. By entering into and participating in this Agreement, the Participant acknowledges having read and understood the notification above and acknowledges that it is the Participant&#8217;s responsibility to comply with the Dutch insider trading rules, as discussed herein.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:15.37%;margin-right:15.17%;text-indent:-10.05%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>adpt-ex211_175.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex211_175.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">List of Subsidiaries of Adaptive Biotechnologies Corporation</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Organization</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spin Technologies, Inc.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>adpt-ex231_297.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex231_297.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the following Registration Statements:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;">Registration Statement (Form S-8 No. 333-232495) pertaining to the Sequenta Inc., 2008 Stock Plan, the Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan, the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan&#160;and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;">Registration Statement (Form S-3ASR No. 333-239854) of Adaptive Biotechnologies Corporation; </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our reports dated February 24, 2021, with respect to the financial statements of Adaptive Biotechnologies Corporation, and the effectiveness of internal control over financial reporting of Adaptive Biotechnologies Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seattle, Washington</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>adpt-ex311_178.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex311_178.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-top:18pt;line-height:11pt;margin-bottom:0pt;margin-right:2.14%;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-top:6pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER <br />PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="text-align:center;margin-top:6pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Chad Robins, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;line-height:11pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;line-height:11pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;line-height:11pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Adaptive Biotechnologies Corporation;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:11pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;margin-left:7.69%;margin-right:2.14%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;margin-left:7.69%;margin-right:2.14%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:22pt;line-height:11pt;margin-bottom:0pt;margin-left:3.85%;color:#000000;font-size:10pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:52.99%;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.14%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 24, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.05pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chad Robins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad Robins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-top:4pt;line-height:11pt;margin-bottom:0pt;margin-left:53.08%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>adpt-ex312_179.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex312_179.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-top:17pt;line-height:11pt;margin-bottom:0pt;margin-right:2.14%;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER <br />PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="text-align:center;margin-top:6pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Chad Cohen, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:11pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:11pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:11pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Adaptive Biotechnologies Corporation;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;margin-left:7.69%;margin-right:2.14%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;margin-left:7.69%;margin-right:2.14%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:12pt;margin-left:7.69%;margin-right:2.14%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td>
<td valign="top" style="width:2.14%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.14%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 24, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.05pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chad Cohen</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad Cohen</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-top:22pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>adpt-ex321_176.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex321_176.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-top:17pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="text-align:center;margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Adaptive Biotechnologies Corporation (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.14%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 24, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.05pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chad Robins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad Robins</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:13pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>adpt-ex322_177.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
adpt-ex322_177.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-top:17pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-top:6pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="text-align:center;margin-top:0pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Adaptive Biotechnologies Corporation (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;line-height:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;line-height:12pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.14%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 24, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.05pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Chad Cohen</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad Cohen</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:13pt;line-height:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g0vsdaj33nnl000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .A"-T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSMV]L4 >W_% C_A7VJ<C_5UY1\#?^1QF_P"N!K$UJV^(2:5,VL)JHL0/WOG
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M9F/FP(,+'TQCT'6O<*3O0!Q?@/0-4L/!QT;Q'%!,@)18]VX&,@?*01]:U/\
MA!/"F/\ D7M._P# =:Z&B@#Y"M+:%O'$%JT2F ZBL9C(^4KY@&,>F*^G/^$$
M\*?]"]IO_@.M?-%G_P E"MO^PJO_ *-%?7% $<$$5M D,,:QQ(H5448  ["I
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,;Q7_P BGJO_ %ZR?^@FO!_".A1^(M?BT^65HD=6.X#)X&:]Y\5_
M\BIJO_7K)_Z":\+\$:U::!XDBO[W?Y*(P.Q<GD$"O3P3DJ4^7<\O&6]M'FV.
M[N?@[;^0_P!GU)Q* =H:/@GL.M>?:)>WWAGQ3&(WV21S>5*!T89P?K7IU_\
M%O1X[9C8PSS38X#KM'YUYCI%I>>)/%49BC+/+/YK^BC.3S6]!U7"7M]C*LJ2
MG'V.YZI\4W$GA"*0=&E4C\C7G_@?PA!XJ:Z$UP\/DXQM7.<UZ!\4XQ%X0BC7
MHLB@?D:\J\/^*=3\-M*=.\K][C=YB;JG#*;P[]GO<K$N/MUS[6/2/^%/6'_0
M1E_[X_\ KUJ^'OAQ:>'M734(KR21T4@*5QU_&N _X6IXGS_RZ_\ ?D_XUV7P
M^\8:MXCOKJ'4/)VQJ"OEQ[3W]ZPJ_65!N4M#:E]7<THQU,_XS?\ 'MI/^_)_
M):P_!?@&U\3Z.][-=O$RRE JKGL#Z^];GQG_ ./;2?\ ?D_DM<?X;\=W_AO3
MFM+:&-T9R^6'? _PK>BJCPJ]GN85G36);J;'77_PAMXK*:2VU%S(B%@K1\,0
M.G6N.\$:E<:+XN@16(5W\F5 >&[?SK3O?BCKE];/;11Q1F12I*KDX/I5OX?^
M"]0N=8CU74(7AMXCO7>,&1O7Z55YPI2^L,5H3J1]@CK/BGJ]QIOAR.&W8H;J
M3RW8=<8)_I7$^ /!5CXEBGN;Z=MD;;?*0X)]\UZ?XR\-CQ+H;6H.)XSOA/;=
M_P#JS7AS)KWA*_90;BRF'!(R P_J*RPK4J+A!VD:XI.-92FKQ.U\9_#6STO2
M9-1TIY,0\O$YW9'J#3_A)JMTEW/I,H?R67S$W X4CKCZYK*TWXJZS;,JWL<5
MU$.HQM8_CS7IWA;Q3IOB2V\RUQ'<*!YD1ZJ?ZBIK>VA2Y*BNNXZ/LIU5*F[>
M1B?$KQ7-HEA'96,FRZN <N#RB^WO7">#/ DWB@/>W4K16@;&X#)<]Z=\59&?
MQFP)X6! !^)KU7P/"D/@[354 9BR?<YIN7U?#IPW8<OM\0U+9'.ZA\(](DM"
M+&:>&<#AF;<#^%>;V5[J?@?Q,R;BCQ.%E3^%U_\ U&OHRO%/B_"L?B*T=0 9
M+?+>YW&IPE:527LZFJ8\71C3C[2&C1ZE?7<=_P"$Y[J,Y66U+C';*U\V12O!
M,DJ'#HP937M_A25I?A82QR5@E&?Q:O+?">BIKU_<63<.T):,CLP(K;!VIJ=]
MD98N]1P:W/:O!/B1?$>A1S.1]IB 28 ]_7\:\Y^+O_(Q6_\ UR_PK&\)ZW<>
M$?$YBNMRPES%<)UQSUK6^+$J3:[:RQL&1H<A@>".*FE1]GB5;9[#J5O:89I[
MH]/\$_\ (F:3_P!>Z_RJWXBU5=%T.ZOB5W11DH&/!;' JIX)_P"1+TG_ *]U
M_E7%?%W6PL%OH\3C<Y\V5?;^'^M<4*?M*_+YG9.I[.AS>1Y<Z7%Y]JO=I948
M-(WIN/%>P?"?6_MFC2:9(_[RU.4'^P?_ *^:I^"/"B7/@2\::)3+?JWELPSQ
MCY3^!S7%^#-3?PYXQC60L(VD,$B],Y. 3^)S7I5G&O"4(_9V."DI4)QF_M'T
M)7S_ /$?_D>[[_MG_P"@BOH!2& (Y!&0:^?_ (C_ /(]WO\ VS_]!%<>7_Q'
MZ'5C_P"&O4]OT#_D7M._Z]H__016E6=H'_(O:;_U[1_^@BM&N*7Q,[8?"CA?
MBS_R)H_Z^4_D:Y[X-<S:M_NQ_P#LU=#\6?\ D3!_U\I_(USWP9_U^K?[L?\
M[-7?#_<WZG!/_>UZ&[K'POLM7U>YU![Z1&G?>5"=/UK#U?X9Z-HNG2WMWJLB
M11CNG4]@.:]5N)XK:!YYY%CBC&YF8X %>"^-/%4_BK6%MK0.;6-]D"#J['OC
MWI86=:HTE*R0\3"C35[:LYVPTZ?5M32RL8VD:1\(,=O4_A7M?B#3FTGX83V3
M/N:*%0Q]]PS3O /@U?#MA]INE#7TXRW'W!Z5?\??\B7J/^XO_H0JJ^)]K6C%
M;)BH8?V=*4GNT>->#/#D7B;5I+.:9HE2/?E1GN!_6N__ .%/6'_01E_[X_\
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M_'S_ (]-+_WS_(U9^"VJZ?8^%KB.ZO((7,V0LC@'O6[\3?!.H>,8+)+&2-#
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M^BBNJ@^#?C"]F5;^2**//WWG$F/PS7K'@?X=Z=X.B:4'[3?R##SL.@]%'84
M5?B3:+8?"V>S3E((4C'T&!7FOP4OK6Q\17;W=Q'"I@(!D8 'D5[-XWT.X\1^
M%KK3+5E6:4 *6Z=:\;7X'^(U.5N[=?HW_P!>@#VRZ\7:!9V[33:M:!5&?]:,
MGZ5\T^*=2E\:>.9IK%&D^T2B*W7')&>!^M=:OP.\0R,%FOX%4]R=W]:]$\$?
M"[3O"<OVV>3[7J&,"0C"I_NB@#8N-#-K\.9]%LXV+"P>&-.Y)4\?F:^?/AYK
M%MX9\>6MWJ!V1(7A<_W2P*Y/L*^JJ\A\:_!H:K?RZCH<R0R2'<\#_=)]CVH
M]434K*2Q^VK<Q&VQGS=XVX^M?+_Q(U6#7/'=]<6,@F@)5(V7N0H!_45L?\*C
M\= >4J)Y?3_C\&/RS77>#O@L;'48K_7ITE\H[TMTZ;O<]Z /2='L_,\%6-H5
MV,^GQH01T)C KYG1;OP%XZC:6,^98SY&X8W+R,_B.:^L@   !@ 8KE/&?@'2
M_&-L/M"^3>)_J[A.OT/J* +.E^.?#NJV"746J6R!ADI)(%9?J.U>7_$_XF%[
MRVLO#>HLOD$M+<0MPQ[ '\ZI3_ O789"MOJ,$B'N 5_K6YX:^!T5I?1W.N7B
M74:-N%O&N WLQ]* .O\ AC?ZWJ?A*.\UJ8RRRN3$S#DI@8/\Z[6F0Q1P1)%$
M@1%&%4#  I] 'R/9_P#)0K;_ +"J_P#HT5]<5X7;_![7(_%,.IFX@\E+T7!&
M>=H?=ZU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ XI,4M% !1
M110 4E+10 E&*6B@!,4M%% !24M% "8]J6BB@!**6B@ I*6B@!*,4M% !24M
M% !24M% !1110 E%+10 4444 %)2T4 %%%% !24M% !28I:* "BBB@!**6B@
M HHHH *2EHH **** $HQ2T4 )1@>E+10 4444 )1BEHH **** $HP/2EHH 2
MEHHH **** $Q2T44 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 % HH% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0**!0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS<6RRHC?=W,H(!_.@#4HK(\-R:Y)H\;>(HK:+4=S;EMSE,9X[GM6O0 4444
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MS<1'9)ZG'>E8WC-2V-ZD.?UI:*184444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M11'_ %U?^9KN3T/TKGJI*HTCIHN\$V>3+J?BG6O$^K:)8WS)")B!,RC$*C/
M^O\ 2G72^)? $T%]<Z@=0T]WVS)C&,_UK5\#RQ+XS\41LZB1IP54GD@%LU<^
M*4L:>#I$9AN:5=HSUKKE*U14TM'8Y8QO3<[ZFEXHU;4;?PV+G1H&GN9@-FU2
MVT'J>.]<K_PA7BR\B2ZG\1[9F4-L*G@^G%7M6UZ^\+>"])MX(P]]<KY2%CPI
M]?KS58^$_%FKVJ-J?B/;"P#%(QM*]^H%1!."W25QU'SOJV6? VMZIJ<.J:1>
MW!:\M@RQSD=.P/YUS/AS2M>D\<W\,.LB.YA"M<3;/]:NX9'M6C\+(E@\0ZS"
MLAE"#;O8Y+88<UH^$_\ DI>O?]<?_9EK25H.:CV(BG.,'+N2W^MZE%\4;33$
MNW6R=06AP,'Y<_6G>*-;U:_\0Q^&M"D$$VSS)Y^I4?Y-9VJ?\EFLO]U?_0*Q
MM0T2?5OB7?61OWLY77>CAL%AG@4H4X73?:XYU))-+N:EWH7BSPK;2:M%K:WB
MP_/+"5^\O?\ R*Z#5?$LMW\/)-9T^4P3&/.5P2C8Z5@S_#.\2W=KCQ'*(0/G
M,DAVX]\U9U#28M%^%M[:0WB7:;F82(P(Y'3BD^23CK=W[#CSQOI96*EAIOBW
MQCI4%[)K(M("OR+MR7_VCC_/%7_ ^LZK%X@OO#NK7'VB2W^X_P"&<?3%=%X$
M_P"1)TK_ *X#^9KEM&'_ !>'5/H?_0:GFYN>+6B*47'EE?5F/J>D>(/^%B6E
MM_;8^VRQN\%QL_U:?-\N/I7K=A%<06,,5U-YTZJ \F,;CZUQ.I?\E?T?_KU?
M^35WU9XB3:BO(O#Q2<O4XSXE6M_/X9GEM;SR8(AF:/;GS!GI^>*RO %GJ]MX
M>:^DU/?9&!_*M@F-C>N:Z;QW_P B5JG_ %S'_H0K/\'9_P"%=Q_]<G_E51D_
M86\R9Q7MF_(?\.=4OM7\,BYO[AIYO-9=[8S@'VIGBC5K^R\7^';2VN6C@N9B
MLR ##CCK57X3NI\);0PW"9LCTYJMXON8Y/B+X:MPP\R*8,P^I&/Y41@O;-6[
M_D$IOV*=R?XA:_JFB7VDG396'F2'?%C(DQC /?\ *L?5="\7V=A)KK:[F:-/
M,:)5QM'7Z5L>.%#>+?"H89!N_P"JUTWBL8\*:F!_S[/_ .@FJC)14$EN*4>9
MS;>QPMDGBKQW8)=)J TZU4!% 4_O2/XO\^E:/@;4]6@UW4?#^KW'VA[50RN>
MPX_3FMOX>X_X0;3/^N9_]"-8.D?\E7\08ZF%?_05IMJ3G"VB)2<5":>K*UYJ
MFO\ C+Q!=:;HEU]CL;4E)9L=2.N?Q]*KW<?BGP&8+R74OM^GE\2KM^[_ %K1
M^&<D:WOB" L!-]M9]O?&<9K8^(\T4?@N]60@-( J GJ<@\4N:TU3MH/EO!U+
MZF=X[\1WEMX:T_4=(N7A^T2(00/O*03CFDT30_$]QJ=IKEWJX5)2'EM N %/
M\-8OBH$?#_PV">\'7_=KUA0 H &*F;4*:26]RH)U*C;Z6%KQ[QMI^K?\)W8@
M:F 9YA]E.S_4<C'UKV&O-_&?_(_>'O\ KLO_ *%489VD_0TQ,;Q1>\1Z[J?A
M?PW8V7G+>:Q<GRA-C&3GKCUYXK)3P=XPDB%^?$)6Z*[Q'M[^GI3_ (A@Q^*?
M#T[G$(N$!8]!AN:]*#*8PP(*D9!]JMS=."<5N9J'/-J3V.0\#>)[G6$N=/U)
M<:A9G:_'W@.,UV-><>#I([KXCZ_<6W^H\L+P.,@@&O2*RQ$4IZ&U!MPU"BBB
ML38**** "BBB@ K)UK7[31(5:?+2/]R)?O-3=;\0VFBVHD<B61SM2-3DDUQ$
M%S-JWB9[O4(/*/E PQL>!T'%-(F4N57-M?'Q0[KC2KF.(_Q8Z?I1_P )\<DK
MH]T4/W3CK^E2,JL,,H(]"*7: , #'I3L8>W?86S\=027"17ME-:!S@.XXKK$
M=70,K!E/((/6N!O])349<SNWEJ/E4>OK56WM=?L4,-GJFV!#E%8 G^5*Q<:R
M>YZ517+^&O$<][=/INHH$O(QD,/XQ744C9.X4444 %%%% !1110 4444 %%%
M% !5>^LX;^REM;A=\4@PR^M6*0_=/TH \_T7P=H]W!<-+;@E+F1%Y/ #$"M/
M_A!-"_Y]?U-7/#G_ !ZW?_7Y-_Z$:V:8CF?^$$T+_GU'YFD\*^']/LM3OYX8
M0LD,[1H<]%P.*Z>LS0/^/K5O^OMOY"@9N4444@"BBB@ HHHH *!10* "N%^+
M,DJ^!WCB<J9[B.)L'JISD5W5<+\68Y6\$/+$I)@N(Y6QV SDT =G9H$LH%4
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M1[DJQ4A"<BNB\(1)'X9L]B;=R;C[GUI,Z:%[&Y1114G0%%%% !1110 4444
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M7$<ZY4\]P: )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *0\*?:EI#T(]J >QRW@Z**676=0"
MXFFOG5C[#&/YFNJKD_"%Q''?:WI8'SP7C2'Z-T_E765I4^(SI?"%<'=>!KS7
M==DO-:U R6:MF*V0D<>]=Y2&E"<H?".<%/<\N^%\20:_KD48PD<C*H] &P*]
M2KS#X:_\C+X@_P"NS_\ H=>GUKBM:ACA/X857OHTELIHW4,K(00>_%6*JZE<
M1VNG7$\IPB1DDUA'=6-Y?"S ^'MRUSX/M=W_ "RS&/H*ZFN8\ 6WV;P?9?\
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MGT?4M.;3-13[L3/NW8ZC.!S5H:YIO_"TY=(_LF'[>MLKF^P-Y7 XZ4 =M17
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MO:KI_P!GNM2\)SVVFSGY+@R$DKZ@8_K7I=EK%G?Z-%JL4P^QR1^:)#T"^IH
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MX=P?:KM%(!UG=)>VD=Q&&"NH8!NH]C4]9NE_NY;R').)C)D_[5:50RT%%%%
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M)#YJS2B,_-C;QG-9NE-2Y;;FBJP:YCH:*X:Q\=WVH:C EOH<IT^:0HET6X)
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M2M0A^-6L7TEG.EI(K[)F0A&^AJSX!TR^L_B)XNN;FTFB@G,?E2.A"O@GH>]
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M*** "BBB@ HHHH **** "BBB@#'U2W^T:G:+YTL7#',;8/2D_LL_\_\ >_\
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MO@O3+F$76IW:%)+L_*I_N]JZVFHNU5'H*=4':E8**** "BBB@ HHHH ****
M"D/W3]*6D;[I^E '@^M_\AV__P"OA_YFJ%7];_Y#M_\ ]?#_ ,S5"OG,1_%E
MZGZ'@?\ =H>@5ZG\-/\ D!3_ /7=OY"O+*]3^&G_ " I_P#KNW\A75EWQL\O
M/_X*.UHHHKV3Y **** "BBB@ H%% H **** "BBB@ HHHH **** "BBB@ HH
MHH **** &NBR(5=0RGJ",BFQ0Q0KMAB2-3V10!^E244 0O:V\C[Y((F8=&9
M34PX'%%% !2$9%+10!%';01,6CAC1CU*H 34@&.@Q2T4 1RV\$^/-ACDQ_?4
M'^=.2-(UVQHJ*.RC IU% #'C25"DB*ZGLPR*(XHXDVQ1JB^BC I]% $+6EL[
M[WMX6?\ O% 34HXX I:* $  Z#]*" >HS2T4 ':@ #H,444 )@=<48&<XYI:
M* $P,YP/K2D9'-%% ">WI4<MM;S$&6"*0]MZ U+10 U45%VHH51T &!3J**
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M&X ]#7<T4[BC!1V*]I9V]C;K!;1+'&O0+5BBBD4%%%% !1110 4444 %%%%
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MPT_Y 4__ %W;^0KJR[XV>7G_ /!1VM%%%>R?(!1110 4444 % HH% !1110
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M?D\=^&8KHVSZO;^8#C@Y'Y]*K^/O#U[XET-+*UU&.QC\T-.[L0&3N,BN-O\
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MGH&/)_"DM]<TNZA6:*_MRC' )D Y].:\W\+Z'!XYU+4]7UEGG2.<Q1Q;R H
M&,8Z53\<>$+/P]=:==:<6CMY;E4:$L2 WKS25"GS<C>I3K5+<Z6A[$64+NR-
MN,YSQ61+XKT.&Z%N^HP>83CALC\^E<O\0]:DT_P]8V4,YA:[*K(XZA,<UB6]
ME\-4LECFOA)/MPTN9<D^N,4H4%R\TK_(<Z[4N6)ZS'+'+&)(W5T(R&4Y!JM+
MJNGPQ/+)>0!$X8^8.#Z?6O/?AUJZ)?:CH<-VUU:1Y>UD;^X/\BLKPGX<MO$?
MB#5TOWD:UMY<^2K$!B<\G'IBCZNDY<ST0?6&TN5:L]1T_P 0:7JC%;.]BE8?
MPAN?RJY<W4%I"9;B9(HQU9VP*\K\4^'[+PCKVAWND*\/FSX=-Y(.,>OKFK?Q
M+F8W.C_;1(=+9P9@A//3.?PH5",I1Y7HP]O))\RU1VUIXJT2]G\F#4(3)TP6
MQG\ZV <C(KRI_#7@S7;)E\/WL5O>*5*R/*XV\_[5>E:7;S6NF6\%Q,)I(T"M
M(/XJSJPA%>[?YETJDI;ERL^_US3-,S]LO(8F'52PS^76KKAC&P4X;'!/8UYY
M%X'TA+V]N_$M_#=3R2%U!G*E >V,BE3C&7Q,JI*2^$[73]>TS5>+.\BE8?PA
MN?RJW+=6\,B1RSQH[_<5G +?3UKQ?4/[!TOQAI4GABXZ2$3*K,1GL.>W6M[X
MGV\]WKF@06[E)I&=48'!!^6MGAUS))Z,Q6(ERMM:H[F7Q1HL-T+9]1@$I[;N
M/SZ5JQR)*@>-U=&&0RG(-<-<?#'03I$B)"XN_+.)S(Q.[UQG%4O!VL7-G\.=
M0N&<O)9-*D1/^R 14NE"4;P92JS4K31VE]XBTG39A#=WT4<A.-N[)'U]*Y'6
M+\S?$O0_LUTS6\ELS8CD^5N6].#5+PCX(T_7=)&L:R'NI[PEQF1AM&<?TJH?
M#R>'OB;I<$$CM:NC-$K,3Y8P>!GWR?QK2G"FFTG=I,SG.I))M:71ZU4<UQ#;
MIOFE2-<XR[ #]:?7$?%(E?"FX<$2@BN6G'GDHG54GR1<CH[WQ)I&G.JW5]"C
M-T&[/\JOVUW;WD(FMIDEC/1D;(K@]!^'VC7^@VMYJ"RW-U<1+(9&D88R,X&#
MT%5?A[NTG7->TA69K>WE.S<>@7/\ZVE2@XOE>J,(UIW7,M&>@WVJ66F1>9>7
M,<*]MS8)^@J'3M=TS52197D4K#^$-S^5>31:CH7B+Q+?7GB:_*6\;;;:W);&
M.?[OX5'KLOA?21;ZEX5U#R[V&0'RU+_./?/:K6&7PN]_P(>)=[K8]M+!022
M!U)K(F\5:)!=?9Y-1@$F<8#9'Y]*Y3QOKUU+X9TN*Q<I)JC!-X.".F?SS5JS
M^&.@?V;&MS!)+<,F7E,C [CWQFLXTHQC>HS5U9R=H([6*:*>)9(9%DC;HRG(
M-5-0UK3M+7-Y=Q1?[+-S^76N$\$2SZ%XLU/PS)<&6"/YXLG."0#QGVJPW@K3
MI-8O;[Q-J$5P9&)AC,Q78OZ=J/91C*TGH+VTI1O%:G7V'B#2M3;;:7T,C9P%
MW8)_ U>FN8+9 T\T<2DX!=@HSZ<UXMXBA\,:;J&GS^&KS;=I<*KQHS'@]\G\
MOQKKOBN&?PQ:A3AFNDQ^1JWATY12>C[DK$2Y9-K5'5WOB31]/G$-S?PI)G!7
M=DCZXZ5=2]MI+8W*7$1@ R9 XV@?6N,T_P"&VD2:7&^J127%^Z;I96E;);\Z
MS/ -GYA\0>&[MC-90L$VY(X;(/\ (5+I4^5N+V*56HI)26YH^&/$;WOC/7(K
MO4(VMT*);*74#J>GK6^=+MCXLBU'^U9//6(J+/S!M8$'G;UK@?"'A?29_&VM
M026Y,=A(C6XWGY3D^_/3O6O(-OQEM .UJ_\ )JN=.+DU%[(SA4DHIR74[R\O
M[73X?.NYXX4]7;&:J6?B/2+Y&:WU" A>N7 _G7!7-I_PFWQ"N[&]E;[!IRC$
M2L1NS].^33?&W@'3--T";4-*1[>2'!90Y.\$X[GWJ8T:=U&3U9<JT]916B/4
M(Y8Y8Q)&ZNAZ,IR#67>>*-%L;CR+C4(5DS@@-G'UQ7%7.MRZ)\+;1X&*33J(
MD?\ NY[_ )"LG2K3X??V9$=3U#S[UUW3.S2 [CU'%$<.M7*]O(4\0[I1/7;>
MYANHA+!*DL9Z,C BF27]I$[))<PJZ#<RM( 0/4BO+_!.J6NG>-)])TR^-SI5
MPF^/K\K=@,_4TS5=)&N?%:6PDD=(6AW2A#C<HZBCZNN9IO3<?UA\J:6IZ);>
M)]&N[HVT.H0M*#C&[&?IZUJO(D:%W950#)8G  KROQWX+TG0_#W]H:7"\%Q%
M(HW"1CP?J:O>*KV^N_A=:W*%]T@3SBF<XSCM^M)T8RLX/1Z#5:<;J:U1UW_"
M6Z$;K[/_ &C#YF<?>X_/I6PDB2('C8.IZ,IR#7D^F:5\/]7T]+>&58K]XC_K
M)'&U\=3GCK7=>$=)N=&T9;2>^2[56/E.IR OIFE5IPBM+W\QTJLY/6UCH***
M*YSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@".:"*XA:*9 \;#!4CK7
M+W?@+39F9K:2:U)Z"-N,_C7644 >: ZIX?)L[JRFN44GRY8QNR/>GP^(HO,*
M7L,EJQY7S%/(KT? ]*JW>G6=Z,7-M%)[LHS^=.YFZ46><7+R:[J4$&DJ3(AR
M;C'"UTNC^$'@O1?:I<BZG7[BX^4?A72VME;6:;+>".(=]B@9JQ1<J,5$  !@
M=J***104444 %%%% !1110 4444 %%%% !2-]T_2EI#T- '@^M_\AV__ .OA
M_P"9JA6EXAA>#Q#?I(,$S,P^A/%9M?-XC^++U/T+ -/#0MV"O4_AI_R 9_\
MKNW\A7EE>K?#>%X_#SNPP'F8K[C KKR[XV>7G[7L4CLJ***]D^1"BBB@ HHH
MH *!10* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QGXHS?VCXZT;0=
M2OY++1IE)F920&/.,_C@59UKPQ\.O">B37@CCFG,96%#,9"[$=AS]:[[Q+X-
MT7Q;%&FK6YD,7W'1MK#VSZ5C:9\)?".E77VB*Q>1]I4">0N!GV/>@#"^#<JM
M\-[N,?>1I=P^N:A^ W_( U+_ *[#^M=[H/A#2?#EO>0:='*D5VVZ56D+#//3
MTZT[PUX3TKPG;2V^E1R)'*VYO,D+<_C]:!G$_%+_ )&_P5_U]O\ S2H_BY(D
M.J>#99&"QI>DLQZ ?)7>ZSX7TS7K[3[R^CD:;3W,D!5RH!..OKT%,\2>$])\
M5V,=IJL#21QMN0JVUE/L?PH$<=\8IX;CX9R/#*DB^;%\R,"/O#TJE\3[&Z?P
M9X<U6VB,@TUXII .N-JX_6NL3X;>'8_#4GA\0S_8))1,R^<=VX8[_@*3QOK<
MWA+PU%+;:4NH6:XAG1W(VQX"^AS0,+#XB>&YO#R:B^IQ*$C'F(<[@V.F/K7!
M_"34O[8^('B*^ (6:-F3/]W>,?I3(Q\(V"ZR[QK<;=YL]YP&Q]W9TK0^#>G/
M)J>MZZMN8+.YD9+92NWY-V1@>V,4 8.CZ9H5O\2-;TOQ7;(K75P\UM)(< @M
MD#/N#FNE\2:;\-O#-HLUQ9QSNY 6&W<,[?KBNU\2>"-"\6+'_:MKO=#Q)&VU
M_ID=JQ].^$7A'3+Z.[BLI9'C.56:4NOY&@#F?B:;5OA7I+65M);6QFA,<,@P
MR+@X!]Z];M_^/:'_ '!_*LSQ#X8TWQ/IZ6.I1NT".) (W*G(Z=*UE4(BJO11
M@4 >1_#B3ROB%XU<*7V[#M7J>34UA<>#_B3-?IK%C;V=]!.4QO\ +D=0!AB>
M_.1U[5WFD>$]*T35;_4K*.1;F^QYY:0L#CI@=NM8VL?"KPIK>H/>W-G(DS_>
M\F0H#[X'>@1YM#I4/A+XI:9:>$[Y[I)Q^_A#Y51SD'UP.:]^KF/#?@#P]X5F
M>?3+0B9O^6DK;V'T)Z5T] 'DGQIU.]B;2-+2:2WL;J3]_,C$=\;3CVY_"I1X
M(^'&@:6;^>6*;:F[>\Y;<>WRY->@Z_X<TSQ-IQL=4@\V'.X8."I]0>U<O8_!
M[P?87D=REG+(T9R%EE+J?J#UH&<Q\&+F*[N?%4\, MXY94=8@,; 0_%+\$_^
M0WXI_P"ND?\ -Z]%TKPAI&BZE?7]C'+%+>L6F7S#L)/HO0=:/#W@_2/#%Q>S
MZ;'*DEX09M\A;.,XQZ=30!Q/QB_Y"'A/_K];_P!DJC\07FT#QYX<\2NN+,1I
M;R.>BC/S'\FKTC7O"VF>(Y;&344D9K*0R0['*X8XZ^O05:U31;#6=,?3[^W6
M:W9<%6'3T(]Z!&3KGB[1K/PS<7_V^!T>%O*"MDLQ' Q]:XWX$RF;0M:E(P7O
MRV/3*@UMV?P>\'V5VMPEG,[+T$DQ9?R-='X=\+:7X6@N8=+CD2.XE\V0.Y;Y
MO;TH&;5>6Z%_R7K6_P#L'C^:5ZE6-;>%],M/$MQX@B207]Q%Y4C%R5*\=OP%
M CGOB[_R3V^^H_K7$>+-+EO?@AX<NHD,GV6")G4#^'')_2O7]<T.R\1:7)IV
MH*[6\GW@C;3^=/LM&L;'18=(BBW64,0A6.0[LJ.QSUH&>>>'M!^'FNZ)#?QV
M]LA*#S$>3#(>X.:E\&W/@N7QC/:^'=+F^T6RL#>*!Y6,>N<\_2KMS\&O!US<
MR3M:3HSG)6.<JH^@'2NF\/>%M(\+VAM]*M1$I^\YY=OJ>] 'EO@B[M_!7Q'U
MS2-5E$*W+9AE;A6.<_\ UJZGXH>+;"Q\(W-I;744U[=@1Q1HVXG)YZ>V:Z+Q
M+X*T/Q8J?VK:[W3A9$.U\>F>N*R=*^$WA+1[^.\@LGDEC.5$TA=0?7![T <!
MXB34?#'PC\.Z8+A[475QMN73((C;+?UK=L_ OPXTK1HM3N9DG"Q!VD>X)W''
M]W/>O1]:T+3]?TUK#48!+ W;N/H>U<C:_!KP=:7,<ZVD[E&R%DF+*?J#UH Y
M+X/W5I-XL\0&SC\NWE9GA3&,)GCCZ8KH/A?_ ,C5XW_Z_P!?YO76Z=X,T72=
M<EU>QMVAN98_*94;";>.B].U6-'\-:;H5[J-W8I(LNH2B6<LY8%N>GIU- '!
M_'3_ )%6T_Z^%JU\8,_\*M/_ %T@KL/$?A;3/%5DEIJB2/"C;P$<J<_A5K5=
M$L-9TB32[Z'S;61-I7/(]"#V/O0(Y""Z@N/@[.L,T;E=,DW!6!(^5NHKG[31
MYM<_9[M[2W7,HA,H'KMD+'^5=AHWPV\.Z%;:A;V44ZQW\/DSAIBV5YZ>G4U>
MDM5\&^#VAT6S:X2RB9HX'D.2.2>?SH&<U\/?'NDW/A:"UO[R.VO;-"DT<G&
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MECLL9@N\YSQSVX[CBN:UP^$;719=.\.H+N]NF54=?G9>1W/(K:$5*4923O\
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M1-%*@='!5E8<$'K3Z* .<_X0'PD6+'P[IV2<Y\@5OP016\"0PQK'&BA511@
M#H*DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\;^*XUO[.[CTVR<GRPH'(!]#S731B^5O3U9S5FN9+4L:)K7B'0_%T.A:Y/\
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M6L%M;K;PQ*D*C 0#C%1V>G6=AO\ LEND6\Y8(,9-6J* "BBB@ HHHH ****
M"BBB@ K+G\/:1<S/--I\$DC<LQ7DFM2B@"I::996,31VMM%"K=0BXS51O#.B
M,S,VF6Y9CDDK6M10!5MM/M+2V-M!;QI ?X O%0P:'I=M-YT-A DA_B"5H44
M-:-)$*.JLIZAAD51M]$TRUG,\%C DI_B"<UH44 5+W3++451;VVCG5#E0XSB
MH[31M-L'+VEE#"Q[JO-7Z* "BBB@ HHHH *!10* "BBB@ HHHH **1F"@LQ
M ZDFJC:MIR'#7]JI]#,O^- %RBH(;RVN#B"YAE_W'#?RJ>@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS""[MW#Q2$<9]#73T5E&3B[HUE%25F>9?8?B'/#_ &;)+$D)^0W6Y22OT_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6Z$;JXM_L]U&YCECY[=Q0!U5%%% !1110 4444 %%%% !1110 4444 %%%%
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M5$"HH50,  =*ERN:1@D*  , 8 Z8HHHJ2PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "K-@^RZ7T/%5J?$VR56]#F@#H:*0'(!]12T""BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<>)GLTM&DPD,0P^[W&*[;XG?\DCL_P#KC!_):P?$_AKQ_P".=.-YJ$$=ND+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *!10* "N$^+>
MY?!7F*I/EW<3G'8#-=W63XFTHZUX:U#35(5[B%D5B,X)'!H T+4YM(3ZHO\
M*IJY?P#JQU3PI;>:3]IMB8)PPP=Z_P#ZQ744 %<YXL\9:7X2L3->R@S,N8H
M?F?_ .M4GC'Q)%X5\.7.I. \BC;$F>K'@?SKPCPWKWAV_P!=EUWQK?3SW(?=
M%;B%F0>F<=AZ4 =KX9\.ZOX[\0Q^*?$J&.RC.ZSM2,<=N/3O[U[ *\_3XQ^"
MU542ZN H& !;-BN[M+J*]LX;J DQ3()$)&#@C(H FKAO&LW_ !5OA&U )9[W
MS./12,_SKN<UP-N[^(?BK-,C+)8:+"8N1]V9NN/7[M '?4444 %%%% !14<T
M\5M"TT\B1QH,L[G  ]S52QUO2M4D:.PU&UNG099895<@?@: +]%%% !1110
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M=L,";%%7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#)!_'@5ZT.E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9FL<?8F_Z>4'\Z9H7_,1_Z_9/Y+4FLKF&U;LERC'Z#-&F[8Y[N(?>,AE/
M_ O_ -5/H+J:5%%%(85DZFV9U'H*UJP[YMUV] %>BBB@84444 %>/3:=::U\
M0=?M]3UJ>PAA96CVW C!) XYKV&O,+#PM9ZW\1/$1U?3WEMP5:%GW*I..<$8
MS0!+\-KN9=:UG3X[V:ZTVW ,4TASD\9YKG-9N]1U+5]1\36MS*ECIUTD9B5S
MSC /'OS7I&M0V_AGPA>+I5B1B,HD<*$L2W&?4XS7)Z;X&UYO"YMUU@117*>9
M);F)>2><$D9S0!UNK:+;^,=(LIFO;JV0JLP-NX!Y7H?SK@/"/A--:U/5HI]6
MU%5L+KRH]DWW@">N?I77?#62\BT";3+V"6.2RF:,,ZD;QD\C/45!\/K:>#5_
M$S3021J]\2A=" PRW(SUH Q+26>/QYKT'VB5DCM9 H+GCD5RFAR^'9]/WZUX
MAU:VO-Y!CA+,NWL<X-=?#9W0\?:_*;:81O;2!7\LX)R.A[UE>$]>AT'1!97W
MA.]NYA*S^;]E!R#T'(S0!K^)UM[+X3QOI5_=3P//&R3RL0Y!_(U7'B*XO/AS
M?V-T\D>IV(59.2&*GHV?\]*T/%UXWB#X:F6STJYMC]I11;&+# #OM';FJ7Q#
M\,W*V<.L:8DIDDB6*YBC7.[C@X'4\T :NJ^%X]8\,PZM)J-]#-;:>2$BDPK%
M06YK-^'WA9-1T^UUN;5+\S*Y/E^;E#@^]=FD4G_" R1>6WF?8'79CG.P\8K/
M^&L$UOX0@CGB>)PS?*ZE3U/8T =A1110 4444 %%%% &KI;?N6'^U5^LO2C\
M\@]JU*!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 (:Y?7/$EP+[^Q]$B%QJ3#+L?N0CU8^OM5GQ9K,VEZ>D-D-VH7;>5;K
M_M'O^&14WAO0HM$T\(?WEU)\\\S<L['WK2*45S2,I-R?*C.TWP9%Y@O-:G?4
M;UN29#\B'_9 _K7316\, VQ1(@_V5 J6BIE.4MRHPC'83O56YTVRO$9+BVBD
M##!W**M9&>M+4IM%-)G&77AB_P!$G-]X;N&5%Y:QD;*.!V&>1^=;.@>(K?7(
M7 5H;J(XEMY.&0_2MJN/\4Z3+93KXCTI=MY;\S1J.)D[@CUK9/GTEN9.+AK'
M8["BJ>E:C#JVF07T!S',@8>WM5RL6K:,U3NKA1110,IZJ\D>D7CQ9\Q87*X]
M<&O"O!G]A7>MW'_"2?,9 =OF$A=V><D=.]>^SR110L\[HD8'S,Y 'ZUYOK7P
MUTO7;B:\T6_B21FRR*X= 3UZ9-=N%J1BG&6E^IQXJG*34HZVZ$/B/X?:;J<$
M,WA8VZR(V'6*8,I'KG/6NX\,VM_I_AZWM]48&>$;2=V?E'3FO&=4\.>)/!;+
M=K.XA5N)8G^7/N/\17?0^)[G5OA;?:B6VW<411F'<@XS^-:5H3<%:7,K[F5&
MI&,VW&SL2ZE\4;"UU)[*RLI[]D."T/0GV]:M>'/B)I^O:B;![>2SN#PJRG[Q
M]/K7._"&P@>VO[N1$>3<JJ6 )7K78R>#-)D\0IK)B*W"%655X (/7BLZL:,&
MZ;6JZFE*5::4[Z/H5O$_CNV\,:A#:36<LQD4-O1@ /SK,M?BG97NLPZ?:Z?/
M()7"+(& '/?'M7+_ !>_Y#UJ/^F(_F:[_3- T[1_#L%Q#:1F>" RK)MYW%<T
MW3I1I1DUJQ*I5E5E%/1%3Q!\1M.T2^%C%!)>7(.&2+^$_P!:CT7XEZ?JFIK8
M75K-8S,<+YQX)]/;\:\V\+ZO%9>)KO4+K3+C47RQ58DW%"3U-6O&%_+K^I6U
M[8:!?VLL7WB8#\QSD'@5L\+!/D:^9DL5-KF3^1[5JFJ6NCV$EY=R!(HQD^I]
MAZUP9^+ML0\D>C7;P*V#*",5B_$S4KEM&T*TDW#S+=9I-PP=VW'/YU+IGBBR
MMO#$6FCPM?RJT(#2+#D.V/O9^M9T\/%4U*2O<NIB).;C%VL>D:#X@LO$.G"\
MLGRHX=#U4^AKFW^)^FP:O=V%Q:RQ"WW9D+ AB.P'7FN6^%@U&RUJYM9K6XBM
MY82Y,D;*,CIU'N:IZ)8Q7_Q7N(YD5U2=Y-I&02"*%AZ:G-/9('B*CC&V[.H_
MX6Y:17*1W.DW<"-_$_8>N.]>@VMS%>6L=Q X>*1=RL#U%>:?%^SA33=/F2-%
M9789"XR.*Z[P%_R(^E?]<?ZFLJM.'LE4BK7-:52?M73D[G1'I7FGAO5?#EQX
MU>WL]%D@O1)(#.9,C(SGCWKTL]*\0\%?\E-E_P"NTO\ [-2H13C-OL/$2<91
M2[G>:Q\1++1O$;Z1/9RDIC=,' 4 KGI6;<_%JS@?<FE7;VY;"3'Y5;Z9KC?'
MB+)\2Y$<95I(0P]00M>C^.M,LH? =ZL=M&H@B!BPOW>0*V=*C!0NK\Q@JM63
MG9[&]H6MVOB#2X[^TSY;\%3U4CJ*TJ\Z^$+$Z#=*2<"48'IUKT:N2M!0J.*.
MRC-SIJ3.)U?XD6&BZ^=+N;2;"L TP88 ]<=:3P[\1K7Q#K7]GPV,L659O-9Q
M@ 5P7BVQ&I_$\6+':)Y4C)^IKT;7],L=#\*WTUE:I%,MJ8PZ##8P>]=4J5*,
M8JVLCEC5JN4G?1&?J7Q1L+747L[*QN+YDZM%ZCKQ6EX8\>Z?XEN7M5B>VNEZ
M12'EA[5YKX$UR#1$N9Y-%O+^:1L>;#'N"CT^M-N9KB\\<6NJ:;I%_9(\Z>8&
MA(QR >@Z8JYX:"O&VW6Y$<3-VE??H>L^)_%=CX7M$ENLO)(<1Q)U;_"N4;XM
MQ1HLLNAWB1,<!V( /XU?\=WGABSEMI]9LC=W07]U&K$$#/UQUKC/$7BJ^UC0
MYK6'P^+:P5 ?->(@J,C!!Z5%"C"25X[EUZTXMVD>JV>LVNO>')+^S8F-XV!!
M&""!R*\[^#O_ !]:A]%_K6K\,RQ\$7@)X!?'ZUD_!XXN-1/H%/\ .CD4(U(H
M7.YSIR9Z[7GGQ4U_[%I2Z8BR"6X(82*V  .U+??%G3K&^GM7TVZ9H7*E@RX.
M*I^+=:M/$WPZDU2&U,1$X0>8 6'XCZUG1I2A4C*:T-:U6,H24'J5OA7XEB7;
MH!MY#+(SR^;D8X XQ^%:&EZIX>D^(3VL&C/'J.YP;DR9!^7GCZ5/\*+:$^&F
MN/)C\X3, ^T;@,#O7+Z%_P EAD_WY/\ T"MI1C*I4MI8PC*4:<+G;Z_\0K/P
M_K2Z=<6<KYP3*K# !]JR[KXM6<$F5TJZ>W+868\!OIFN7^(,23_$&VBD&4D>
M-6'J"179?$33+2#P.RQ0(@MPOE[5QCH*%2I+D37Q%.K5?/9["7?Q2TV-(_L-
MI<7LC)O=(U/[L>_%:/A7QW8^*)I+>.%[>X0;@CG.X>N:Q?A9IMK_ ,(K-=-$
MC2SNRLS+DX!(Q7,^#5$'Q0NHXQM17D4 =ANI.C2:G%+6(1K5;P;>C/2/%'C+
M3_"\:"XW2W#C*PIU(_I7/6_Q8LC<Q1WNF75I')_RT?H!ZX[UQ'B/4_/^)<LM
MW;/=16]SY?D(,EU4] *U?%^NIXBT=+6V\,W]O.C@I(T'1>XX%5'#048IJ]^O
M8F6)FW)Q>W0]CAFCN(4FB</&XRK \$50UW53HNE27PM);K80/*B'S')Q6'\-
MYKM_"44=W#)$\#F)5D4J2 !Z_6NM8!E((!'H17#**A.SU2.Z,G.G?N>&>$-4
MM?[<NI+S19[Z2ZN-H?&?*!;O]*]/\1>,=/\ # BMS&\]RP'EV\0YQ_2N:^&"
MJ;W7,J#BZ;&1[U'X;CCU;XG:O/>1B5K=,Q;OX3D#I]*[*W+*HVUHCBI.48))
MZLT(OB?"ES$FHZ-?6,4C;1-,A 'Z5T^M^(+?1M$.J>69X< @1L.0>^:B\6Z9
M!J7AN]AF1>(RRL1RI'/%>>"XEN?@QF5BQ61D!/H#@"LHPIU+-*VMC:4ZE.Z;
MOH=)#\2DNIXEM-%OIX7(!F1?E4]QG':N['(!]:P/!EK%!X0TQ411O@1VXZDB
MN@K&MR<UHJUC:CS<MY.]RC<Z1I]Y+YMS:1228QN9<G%><ZQI=E'\5-.M4MHQ
M UN"8P."<M7JE>;ZY_R5[3/^O8?S:M,/.7,U?H9XB$;)VZG;PZ'I<$JRQ6,*
M.O(8+R*\\O$;QUX_DT^24_V78 %D3C?]?QXKU,]*\M^'4;6OC;7K><%9>3SU
MP6R/TIT9.TIO=(5:*O&*V;/0H]"TJ*V$"6$ C QC8#Q]:Y.V\'W^B>-4O]'*
MIIDP_?Q;NGX'WKO*K2W]I;W*6\UQ''*XW(KL!D>V:QC4FK^9K*G#0X'QG#'/
M\0O#<4R*\;%@RGH>E=G_ ,(]H^/^0?!_WS7!?$6R?4O&.A6<4S0O*'42*<%>
MG-0:E\.==MK*2:TUNXGD09$9E8%OI75RIPBN>QR\S4I/EN1>.=/LO#_B32;G
M146*[DD)>.-NN,8X]^:]"UWQ):^'-)CN[P,S. $B7[SMZ5P/P[TC2M2O?MMY
M<W$VJVQY@N&^Z1T([FND^(&AZAJ5O8WFFH)9K&4R"(X^;IZ_2BHHN<:<WMU'
M3<E"4X]2DWQ1\D+)=>'M0@MR0#*ZD* >_2NYL+Z#4;&*[MG#PRKN4UYE_P +
M$W6IL?$F@NL+C8V(R >W?^E>@^&VTMM#MSH^!9;?W:@D[>>1SSUS6=>FHJ_+
M;\32A4<G9RN:O:N-UCXA6NGZF^GV5A<ZC/'_ *P6XSM-=E7G<WB?PWX;U>ZB
MTG3)KJ\E<M.;<%CNSSU]_2LZ,5)O2Y=:3BE9V+-E\2[>74H;._TJ[L#*<*\Z
MX!_2NIUO7+/0=->]NV(0<*HZL?2O)_%GB.\U^.S>317LX8[E )I5(?/I]/\
M"NC\<1K?>+_#-A/N-O*S;T)X;I6\J$7):6_X!A&O))ZW)4^**[4EGT'4(K5C
MS.RG:!ZYQ70^&?%MMXF6Y:W@>)(6QN<CYJU[BRMIK%[5X8S"5QLV\8K@/AC!
M%"NL0$YC63;G...:BU.<&XJS1I>I":4G>YH7WQ*MH]0DM=.TN\U'RN'>!20#
MZ=*FT;XAVVI:JFFW=A<:?-(/D\\8W5DP^,/#WA^XGL] T>XNB6+.T"EOF]\\
MUS>MZY=ZYXDT2YGTMK)1=QJK.I5F^8<&MHT(R5N6WG<QE7E%WYK^1Z3XJUFQ
MTF735O;$W1N+A8XSD?(Q[U)XE\5VWADVOVF!Y$G;;N4@;??]*Y_XE_\ 'QX>
M_P"O]/YU6^*:+)-HB,,JURH(]JRITHRY+];FLZLH\]NEBS/\4$3?+%H6H2VB
MGB<(0I'KTKK-%U^SUO1UU*W8B+!W!NJD=14MU9P1:)-;)$@B6 @+MXZ5P'PS
MMC=^%=4LQ(P#/M4YZ=:7+3G!R2M8:E4C-)N]S0E^)L;S.-/T2_O8$.!-$A*G
M]*V_#7C"S\2":..*2WN8?OP2_>%<%I>L:_X"B.EW6C&XM58OYL:DDCZCC\ZZ
M?PCJ_AG6M8FO;&T-KJC@^8K$Y([\=*NI2BHMQCIW(IU9.5F]>QQJ>+7A^(DN
MK?V7>/\ NVC^S@?/WY^E>T1/YL*2;2NY0<'MFO.+1$/QEF!48\AN,>QKTL5&
M)<7RV70O#*2YKOJ8GB3Q'#X;LXKF:!I5>0)A6 QGOS7-S?$^+<[66BWUW;I]
MZ:-#M]^U+\54\SP_;1YQOG"Y^I%=7HNGVUEHEK;0Q((_*7< .&)'-**IQIJ4
ME=CDZDJCBG9$/AWQ'9^)-/\ M5H2-IPZ-U4^E9&N>/[32M3.G6ME<:A=*,NE
MN,[:R?"MLFF_$K6[&W.VW, E\L=-Q*G/ZU)>>(?#7AK7+@:?ITMWJ4K$S>0"
MQW9YZ_TJO91]HTE<EU)<BN[$EO\ $^ 7L4&HZ1>V"R' >9<#\L51^*^LLNF)
MIBVLVUW23SQ]SC/RUA>,/$]WX@L80^B2VD,<Z?OID(;// _SVKJ?B:,^!X6(
M&?/CY_.M53C"<6X_B9.<I1DDR30_%<5UX3O'N=)N$AL;;<RRC F&#D#\JZ;0
MM1M;SPY:ZA#$+6U>/>$8C"#GO6-JBJ/AE=8 &;%LX'M7/WEU+:?!2T:)BI:)
M4)'H6(-92A&>VFIHIN&_8TI_B;";J6/3M'OK^*-MIFA0E2?RK:\->,++Q'YD
M21R6]U'R\$HPPK@_#WC6XT;1K>TM_#=RZHO,BPGY_?/>F6.IW>H>/[#4H-%N
M;($%)OW3 -G/)K6>'5FK6MUN9PQ$KIWO?I8[C7?'%EH&K+8W4$AW1[Q(IX^F
M.M8S_%)8"KW.@W\%NQP)9%P,>O2JGB*WBN_BOH\,R!XV4D@^RD_TKI_'D$;^
M"=1!1?EC!7CIR.E9*-*/*FKW-'*H^9I[$/BW7XXO!;7MK#+<1W:A5,7501G<
M?RK ^%6NE[%-&^Q3@+OE^TD?(>1Q]:MZ&=_PG<N=V(FQFG?#R[BT[X>&]D3*
MQ/(S;1SCBK:C&E*-NHDY2J1E?H=^**X#_A:^C?\ /O<?E7<VMPMW:QW" A9%
MW &N2=.</B1U0J1G\+)J***@L**** "BBB@ H%% H **** "BBB@#'U;PMHF
MMJPO].@E9CDN$ <_\"'-8O\ PK30T 6VDO[=!_!'>R@?^A5V5% ')6_PV\,P
M7"SO9/<3*<[KB9Y/_0B:Z>WM;>TB$5M!%#&.0D:!1^0J:B@ HHHH **** "B
MBB@#R_XU?\@_P[_V%4_D:F^,?_)/U_ZZ)_*O0;NPL[]8UO+6&X$;;T$L8;:W
MJ,]Z6ZL+2^A\F[MH;B+^Y*@9?R- &9X/_P"1,T7_ *\HO_017F2:NWP\^*>K
M/JRLNEZO*9OM*J2J$DD9^F>:]EBBC@B6*)%CC0;511@*!T %5K_2K#5(?*O[
M2&Y3L)4#8^F: /+?'_Q)TC5O#LNB^'I3J5U?J8F$<; (IZYR!SS5;QUI,VB?
M VPT^XQYT31!\>N:]/T[PKH>E3>=9:9:Q2CI((AN'T.*T+NQM-0@\F\MH;B(
MG.R9 ZY^AH BTO\ Y ]I_P!<$_D*\V^"_3Q%_P!A&3^E>J*BH@10%4#  & *
M@M-/LK#S/L=I!;^8VY_*C"[CZG'4T >7^._^2P^%?^N#?S:O6*K3:=97%U'=
M3VD$EQ$,1RO&"R#V)Y%6J "O%?C9_P C3X6_[:?^A)7M55+O2]/OY(Y+RRMK
MAXON-+$K%?H2.* +*_='TKRP_P#)Q"?]@T_UKU0#%5_[/LOMWV[[)!]KV[?/
M\L;\>F[KB@#.\76DE]X1U6VA4M+):R*BCN=IP*\Y^'/Q&T+1_"D.D:W=K87-
MDS1!71B6&<YX!]3^5>P5AW7@_P /7EW]IGTBT>4G)8Q+S]>.: /)-(UR3Q#\
M=-/U 0216CI(+;S!@L@1AG\2#7N]4TTK3XYX9TL;99H5VQ2")0R#T!QP*N4
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MIQ=M;%/XHZ7>Q:_::HD+SV^!P!D @]#^5-UOQ9?^)_#QTW3-%G1%C'VAB@
M&/N_C5Y](^(4B%'NX64]01D?RI(M$\?P+MBN+>-3V10/Z4XRBHQ3:;0I1DY-
MI-)EWX:"9/"6H6\L$L;H6X=",Y!Z9K/^$=K<07-_Y]O+&"%QO0KGKZU-_9?Q
M%_Y_8O\ /X4?V7\1?^?V+_/X5$O>YO>7O%Q33CH]#T1]&TN1V=].M&8G)8PJ
M2?TKG/'ND^9X+N;;3[55V,)/+B0#@=3@5SW]F?$7_G^B_P _A1_9GQ%_Y_8O
M\_A6,*?+)/G6AK.:E%KD9#\,O$)LU&A365PLDDC/YA3Y1P.#^55-$M+E?BW)
M,UO*(M[_ #E#M^YZU<30?'L4ADCGME<]6" $_I4O]E_$3_G]B_S^%=$G'FDX
MM:^9@E+E2:>AF>-[.YE^(=G)';RO&)8LLJ$C[P[UV_Q%BDF\&W*11O(QVX51
MD]17-_V7\1/^?V+_ #^%']E_$7_G]B_S^%2]7%\R]TM:<RY7J;?PRAE@\&A)
M8WC?S'^5U(/4^M<EX5L[E/B?=RO;RK&99<.R$#[WK6E_9?Q%_P"?V+_/X4?V
M7\1?^?V+_/X47LY/F7O"UM'1Z%+QOHE]H?BZ+Q)I]J9HO,$K!1G#]\_6I=0^
M)6K:C'!;Z+IL\-R2/,9XP?P'M]:G;2?B&ZE6O(B".0?_ -511:#X\@8M%-;1
ML>I5 #_*J7(XKG:;1+4^9\B:3/2-%^W?V3;MJ;*;LKF3:, &K_:N)\+67C"#
M5=VLW<3V>P[DQR3VQQ7;UY]6*C+>YWTW>.QYU\-+>:"\ULRPR1AKEB-ZD9YJ
MKK::AX,\9R:Y:VCW-A>*%E6,9*^WUXS7IV*1D5U*L 0>H(K3V]Y\S6CZ&?L+
M044]4>6ZSX\N/$FGOI6C:3>+/<'8SRJ %'X&KNMZ!+H_PO73HT>2889U49.X
M\GI[UZ##:6]N2888XR>NQ0,U-1[=*R@K):@J+=W-W9D>%D9/"NEHZE66V0$,
M,$<5KT45A)W=S>*LK!7G>M6\[?%G39EAD,8M@"X4[1RW>O1*2JA/D=R9PYU8
M6O./%VCZGHWB&/Q1HT33,>+F)3UXQG'IC%>CTE%.HX.XJE-35CSL?%BV$823
M1=0$V.0$&,_GTJKH>FZEXP\3IXBU2!K>SMS^XA8=>W2O1VL;1I/,:VA+YSN*
M#-3@ # K7VT$GR1LV9JC-OWY71P'BJ":3XA^&Y$B=HT9MS*I('3J:[_'%&*6
MLI3YDEV-(0Y6WW/+O%^DW?AOQ/;^)=)MW=';$\<8SS]/?^E;'BK5]9BTO3=8
MT97>W#!YX/+Y(X[8SZUW.*3%:>WO;F5[$>PM?E=KGENJ?$*PU?3Y;1O#UW)<
MO&47?"IVL1U]173_  ]T>YT?PTB70*2S,9/+)^YGM72+96J2>8MO$),YW!!G
M\ZGQ1.K%QY(JR%"DU+FD[D5RC2VLL:-M9T*AO0D=:\@\/ZTO@C4-1M]4TBYN
M+AYRR3QH"2/7)]>M>RU#+:P3D&:&.0CH74'%*E54$XR5TRJM)R:<79H\?\6Z
MSJOB<6=S!I5U!IL4Z\.GS,WJ0.W6NL\::+>:G9Z?K.F9-]9?/&G0D'D]>_ K
MN0H4    = *Y3QGI^M3):W^B3R"XM6.8 V%D!]1T/3OZUK&M>245:QE*C:+;
MUN8!^(6K7MB+2UT"Z74G&W+)B,'ZG^M4?A]:7%YX>UZWC?;-,"BOGHQSWJY)
MXO\ &5TCVL/AL13,"HDW9VGUP>*Z?P1X>E\/:'Y-RP:YE<R28[$]JN4E"#5D
MKF<(RG-:W."\*^*8/"%K-8WVB7;WGFDF6.,98<=S3-=OM6\0^(=&U-M,GM[!
M;J-8E9<MPP)8@=/_ *U>ORVEM,X>2")V'0L@)%38  P.E1]9BI<RCJ:?5Y6Y
M7+0X+XC02SS^'S%$\@6^0MM4G SWJ+XEP3376AF*&23;=(6V*3CGVKT+%%9Q
MKN/+IL:2H*5]=R"]!.GW  ))B;C\*\[^'MIJ">&=6C@\RVNF?]TSIT//8UZ7
M2XJ(U.6+C;<J5/FDG?8\LT[XAW>E6LEAXCTJ[FNE8ABL:X(]#VI?"T,NN>/&
MUVVTQK"PCBV!2@3<?H*]+FL[>X(,T$<A'0N@-2JBHH50 H&  *U=>*3Y59LS
M5"3:YG=(\IUO46\,?$YM4N+2XFMW@('E+GKD?2O4[>9;FWCG3.V10PS[T36T
M%P )H8Y .F]0<5(%"KA0 !T K.I44TM-4:4Z;@WKHS@/BT2/#4)!P1,#_*J5
ME\29-.TNWM+W1;TW:1*%,:@JW'RGKZ8K5^)]C=:AX>CBM('F<2YVK73Z;9Q'
M2[#SX$,L<"#+*"5.T5NIP5%*2OJS!QFZSY78Y#P-I6H7%YJ/B#44:&XO5*1H
M>,)GC^0KG-+U<^"?$.JKJFDSW#S3EXYD0$XR>A/K7L5136L%QCSH8Y,=-Z@X
MJ%B-7S+1EO#Z+E>J/(?%NO:IXKL8WM-)NH=.@E5F,B?,S=N!^-=+XZBN-4^'
MD,MO"[L&CE90O(4 YXKO5154*H  Z "E*@C! P>U+VZT26P*@]6WN>;VOB)=
M?\!:M8PV5S'+:V14[U^^2#TQ]*T=.T-M9^%EIILBF.4P94.,88$XS79Q6T$&
M?)ACCW==B@9J3%*5;^56UN.-'^9WTL>5Z+XZN/#&GKI&L:3>/+;$HKQJ"&'U
M)K8\/^)-=\2^(_-AM7M-'C7YA*@#,<?XUV\UK;W!'G01R8Z;U!J1$6-0J*%4
M= !@4Y58.[4=6$:,TTG+0\]U>WF;XLZ/,L,AB5&RX4[1\I[UTGC:-Y?!VI)&
MC.YB&%49)Y%=!16;J7:?8M4K)KN<+X=LYY/ABUMY;K,T; *PP:R_AGK<7V(>
M&[FQG64;Y"TB?(1D<<]Z]-Q42VENLQF6&,2'JX49/XUHZR:DFM]2/8M.+3V*
MW]BZ7U_LZT_[\K_A5Y55%"J JCH , 4M%8-M[FZ26P4444AA1110 4444 %
MHH% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %1K#&CEEC4,>I J2B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-7AZ<9S]YZ$UZDH1]U:FOIFCZKX^U!-4US=#IL;9AMQ_%_GUKU""".V@2&%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&&#,T$)/FE1P/?--F5)/FN=E"Q:%&).2!G-24=**@[ HHHH **** "K-B/\
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MYM'AN7U*W0B,%D9P&! Y&*S;E&FO9]RURRF_:=CD?A]8SZ9X\UBRGE:0Q6^
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M 4444 %%%% !1110 4444 %%%% !0**!0 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110!@7#;KAS[U%3I?\ 6O\
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M712:#IDVKIJLEJK7R8VR[CD=O7%:=7+$2LE%VT,X8>-VY(KSV=O<6;VDD2M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .=D_UK_[QIM.D_UK_P"\:;0,*4#) I*GLTWW2#&0#DT
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MLVL31CS9 HPI]<=*J=%648V(IUW=RD>@45YK?R^/M M/[2N+RUO8(OFEACC
M.WOV'Z5T?_"3#4? MUK5BP29+=VP1G8X&<5BZ,DDT[HWC63O=6L=-17ENAZO
MXV\4V N+"[MH$A^5WDC'[QNO Q]*LZ]XJU_2/$EGID)6X:6W ,>P<R'(W9]
M<?E5?5I<W+=7)^LQY>:VAZ5FC->7:MJ7C;PQ'#J6H7EM<VI<>9%'& 5'OP*M
MK?>-/$%JVJ:9+;V-H03'#*@+,!WZ&CZN[7NK!]86UM3T:BN1\!^([W7K"ZCU
M% +NTE\J0@ 9//I]*ZZL9P<)69K":G'F04445)84444 %%%% !1110 4444
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M% &;KUY+I^B7-U 0)(URN1[UYG_PL'7/^>D7_? KT3Q9_P BQ??[@_F*\0H
MZO\ X6%KG_/2/_O@4?\ "P=<_P">D?\ WP*Y2B@#T?PGXNU35]<2UN70QE">
M% KT*O'_ (?_ /(T1_\ 7-OZ5[!0 4444 %%%% !5I/N+]*JU:3[B_2@!U%%
M%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** .=D_P!:_P#O&FTZ3_6O_O&FT#"M#2X\R-)Z#%9];.G)
MLMLD8+'- %NLW56_U8^M:58^HMFZQZ"@2*=%%% PHHHH **** "BBB@ HHHH
M **** "BBB@#8TULVV/0U<K-TIN)%]>:TJ!&+?ILNVQ_%S56M/5$^5'].#69
M0,*L6/\ Q]I5>K%E_P ?:4 ;G>BBB@04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <SX_
M69O!>H"#._:O3TW#/Z4> 6A;P=8^1C9M.<>N>?UKH+JWCN[66WE&4D4JWT->
M:KH7C+PM)):Z!-%/8.^Z,2#)3/;':NFG:=-PO9W.:I>%3GM<L^)/*_X6MX?V
M8\SG?CKTXS4OBP_\7'\+?[[_ -*J:=X)\0?\)7IVO:C<0RR*Y>X^<Y7@@!>*
MZ'7?#M[J/B_1-4A,7V>R9C*&;#<XZ#'-7*44TKWLC-1DTW;J5?%WA.'7;^.Y
MLK\6FK1)\F&P6],XY%<W<W_CCP:BRWICOK),%VSD?0L1FNA\6>%-2N-9@U[0
MIECOXU"LKGA@.E8\VE^//$D7]G:H]O;V;D>8ZI@X]O6KI27*KM->9-2+YG9-
M,;XZU&'5M+\-:AL*V\TQ=@W8?+7IML5^RP[?N[!CZ8K U+P?9W_A6/1 2BPJ
M!"_=2*Y1;?XC642Z=#);20JNQ9B,D#_>QUK*T:D$D[6N:)RIRNU>YI^.+S3K
MGP3JD.FR1,R.OF+$,8.\9S70^$6MV\+6!ML>7Y0Z>O?]<UE>'/ \6FZ+=V^H
M.L]S?9,[XZ9]#W]:Y^/1/&WA;?9Z+-#<6)8F/S!N*_AVIM0E%TXOJ*\HR4VB
M3Q[N;QWX>6'_ %H!Z=>M6/B! ^FZQI'B*!1F"41R8'WL]S],58\-^$=3?7/[
M?\1SK+>+_JHT/"^__P!:NF\2:1_;F@W5@-H>1<(Q[&FZD8RC&^VC!4Y2C*5M
M]3C-0D7Q1\2=/MHRLEG8Q^<QZJV<9!JK\1([Z3Q?HT=I*L,K'$#N?E5N.:WO
M 'A"Z\,P7+WYB:XF(P8VW  9[XK0\9>%AXET]!%+Y5Y 2T#^_I_*FJL(54D]
M%H+V4Y4FVM6<U_8/Q!(_Y"]G_P!]M_A5_P !^&=0T*[U&>^N;6;[0!CR')P<
MG.>*S!'\2506(>VV;=GFX_7=C-=1X/\ #$GA[37%S.9KN<[I3V'L**DVHM-K
M7L*G!.5TF8/PM1<ZR^!N^UN,UL_$'26U/PS))$I-Q:D31$=B.I_+-)X(\.7W
MA\:C]M,1^T7#2IY;9X/KQ74SHDL$D<G*,I5L^AK*=3][S(VA#]URL\JUK7G\
M1^'- TRVWF6]8+,IZLJ<-^HS7J-E:I964%K'_JXHPB_0#%>5_#_15N/%]_='
M+6UA+(D'HK%N@_ FO7*K$N*?)';_ #)PR;7,RKJ7_(-N?^N9_E7'?"?R_P#A
M#^-N_P"T/N]:['4O^0;<_P#7,_RKQ[P=IWB:WT#^U/#T\;>;(R2P2#(^7H1Z
M]312BI49*]M4%67+5B[7T9TOQ,#/J&@I ?\ 23.=F.N?EI?&>1XG\+!NOVA<
M_F*?H7A;6M0U^+7/$TR&2#!AA3H#Z^U:WB7P]>ZMKVC7ML8A%9S"27>V#C(Z
M<>U5SQC:%]DR>64KRMN5_%_BJ^TS4+71](M?.U"X7>"W11G']*Q=4TOQU<Z=
M/)?ZI:1VZPL\BQ95L8SCI6IXS\-:M>:O::WHDRB\MTV%&. 1DG\>O2J":7XY
M\0QFTU>ZAM+-L[S$N';V^AJH.*BFK>?<B:DY-._D2_#C_D1KOOP_\C2?"?\
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MAV]T.ZUB2[,16[NC+%Y;9^7GKQUYKJZ55ISNBJ,7&-F%%%%9&H4444 %%%%
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M %%%% &3KC@01IG[QS^58-;^M1>9;[@.4/7VK I#"D8[4)]!FEJ.7D*HZDT
M+&H6,8&!UI0)"2VW$8X!]Z7H*N)"K:&9&)S%)O\ SX_K0(J4R9Q'"S-T I]0
M7:AX?+;_ ):';0,DB4I$JGL,4^CM4%O*TIDSP Y ]Q0!/1110 445#<R-%;N
MZ]5H FJ"V&!(IZ[R?SJ6-]\2.1C(!Q4<8(N9L]#MQ^5 $U-!8N>/E['UIU2Z
M@ZPQ6J*.5BW,/>@"*!XEU"(2R*@)')-27LD"7CA)%*%OEYZU B #/5CU-.(!
MZ@4 +14:#9(R \=1[5)0 =:T-0@\JWM6 P"G/UJ@/O"N@OXA+HZMTV*&% &+
M9?\ '] ?1\UUM<A;.(KE';. ><5UX.1F@04444P"BBB@#%\6?\BQ??[@_F*\
M0KW/Q-#+<>'KR*%&>1E&%49)Y%>-1:-J4P)BLIW"L5)"$X(ZB@"C16E_PC^K
M_P#0.N?^_9H_X1_5_P#H'7/_ '[- &O\/_\ D:(_^N;?TKV"O*/ FG7D/B02
M26TJI&K*[%3A3QP:]7H **** "BBB@ JTGW%^E5:M)]Q?I0 ZBBBD 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '.R?ZU_]XTVG2?ZU_P#>--H&*!E@/4UT,:[(E7T&*Q+--]R@[9R:
MW:!!6%=G==2?6MT]*YZ5MTK-ZF@!E%%% PHHHH **** "BBB@ HHHH ****
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M!_Q\R_\ H9K:/2L;PQ_QYW/_ %\R_P#H9H V]H]!1M7T%+10(Q-&&+S4\?\
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M110 4444 %%%% !1110 5C:BY>YQ_=&*V:Q;\8NVH JT444#"M^W_P"/:/\
MW16$@RZCU-="HVH%]!B@".YXMI/I6!6]=_\ 'I+_ +M8- !1110 4444 %%%
M% !1110 4444 %%%% !1110 J??'UKHZYQ?OK]:Z.@13U(9M#]16/6]=KNM9
M![5@T#"BBB@#2TISF1.W6M*LO2O]9(?:M2@04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMCID:J9XRWF3O@<Y'/<5T7@""6+Q-XE:1&4-<#!88SP*QO$&BGP_XWOM=O-
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M?%"&66+0?+C9]NHH3M&<#:U5_$D&J>&O'9\56EC)?64]N(;E(_O1@8Y'KTH
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MR;O?%-H T=*ZR&M.L[2ONR'WK1H$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44F:8TT2??D1?JV* O8DHJ$75NQPL\9^C
M"I00>AHUZA==!:*** "BBB@ HHHH **0D 9)P!U-5_[0L\\W4/\ WV*:3>PF
MTMRS15;^T+/_ )^H?^^Q4T<J3)OC<.I[@YH::W!-,?1112&%%%% !12,P52S
M$ #DDTV.1)4#QN&4]"#D4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN^^--F-A[]_I71UA*RE[IO&[C[QYWJWPQ\.V>D7MS$ESYD,#NN9LC(4D5@^
M_ ^C>(=$>[OEF,HDVC9)M&,5ZCK_ /R+NI_]>LO_ *":Y+X3?\BQ)_UV/\JZ
MHUJGL6[]3DE1IJJE;H;5II.E^!M$O9K02+"!YK>8^<G&!7'>'M!F\?32:YKT
MLC6I<K;P*W  /_UJZSXB;O\ A!]2V_W5_P#0A2_#WRAX-LO*QMP<X]<\U,9.
M-)SZME2BG44.B,[5_AGHL]BYL8FMKI%S&Z'O[U:\"W6LRZ)-;:U;RI+;G:DL
MG_+0?_6Q^M=?4;X\MOI6;K2E'EEJ:^QC&7-'0\>\+>%=-\3>(-<&HK*?(E&S
M8^WKG/\ *NKD^%'APH0@NE;L3+FN1\-'Q(/$&M_\(\+0GS1YWVCZG&/UJSX@
M\2>.=,DCL]1>TM%G.%N(EPH_X%FNV:JNI:,OQ..+IJ-Y1-/X?W5WIGB74?#<
ML[3V]N?W9)^[W_*NNUSQAH_A]A'>SDS$9\J,;FQ]*S/!'A--$BEOYKK[5>78
M!:0=,>W^-<A?W</AKX@:A>:YI[7$-P0892O08'('Z5BXQJU7;_AS52E2I+^K
M'?Z+XUT77I1#:W!69ND4HVL?PKH:\VLU\)>)M>M+[3[K[)>1G/E* C2$>U>D
M"L*T(Q=EIZF]&;DKMBT445B;!0**!0 4444 %%%% !1110 4444 %%%% !11
M10 4444 5&^\?K24K?>/UI*8'G_B.'Q+<:^\TNO1Z%HL2XC=9!ND/OGI6;X1
M\07\7CN?19/$":W8O;&=)PP8H1CC(^M9.HK:0>.-5;QI87US [9LVC1GB*=E
MPO?&*/"$$+?$V.YLM#ETG3I;-XX4=2-QRO//K2&;-G)XD\;ZQJ-W8:[)IFE6
M\AA@6$9,A'<_I3?"6I^)H?'5_HNJW[7HM+?]V/NB7KAC[G^E1Z/J\GP]U;4M
M)U'3[IM/DF::VN88F<-GL<#K69X?U'4];\?:[>P6SVMU+9'[+'+PR_>VYS[T
M :DUOXC22YN->\;1:-+(Q,5LDJA47MUH\.>*=5O? .O23W_GW5@[QQ7:=7 4
M$'/XUSFD-X>M]/=-?\/:E?Z\LA#0R1R'S#GJI P!5WPK:W$'@GQ;;RV3VTK2
MLRP;3E04&!0!J^*_$6MV?A+PM<6-])'=WDZQR/\ W\KW_&F>(;;QAX5M+76)
M?$TMTHF7[1;E<)@GD#V&:@\56\[^%?!*K#(S)>Q%@%/R\=ZZOXGQ22^$)%C1
MG;S4X49/WA0!S_C3Q3>KK^EV:ZO)HFGW$ F\]4R7) XSV'/7VK3\*QZ[)JEX
M(_%$.L:6T6%F$@9XY.W0_6J?B+5#8)IEMK/A\:CH<EJF9$C8O$^!UQVZ\5D>
M&[&VG^(=I<^%+&]L]*B1C<O*C)')R. &'6@ ^'NBZVGCO7&?769;2Z"W@V?\
M?1R>>O'0_G7JNMW=Q8:'>W=I"9KB&%GCC R68#@5P/A6^&C_ !'\26=Y;W$;
MZC=AK=O*8JPRW.<8QS7H6IM=IIER]A&DMX(R84DX5FQP#[4"/'-)U;5==TEK
MA/'IM=4=CMLI65 &[(,_SK9^(?\ :R>$O#WVHQ/JHNX\E?N,^X8_I6+?WWAW
M5=,F_M?PO=6_B(97;;0.-S]BIQ@5=U#3M3MO!'A6"\25IEOXV*,"61?,'!H
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M.I3F:[TR&20]6.1_*IC5CRN,EH5*E+F4H[F)I7C&TUGQ0-.TO3A+;HI+W(4
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MNO1AD4ZHXD\N)4_NJ!4E8=3H3=@H%% I#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"HWWC]:2E;[Q^M)3 CDABE(\R)'QTW*#2^3'D'RTRHP#MZ4^B@
M#SV[T#Q;I.MWEWI,MKJ%G=.7%M=\^2?;D5H^#?"5YH]Y?:QJ]V+C5+[&_: $
MC49P!^9KL:HZM=7=GITD]E:&[G7[L(8#=^)- %KR(3)YAB3?_>VC/YTODQ?-
M^[3YOO?*.?K1$S/"C.NQBH)7T-/H 888F"@Q(0OW1M'%*R)(NUU5AZ$9IU%
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MP)!_2LMO%WBM8S(?"$VT#.1*AX_[ZH [IXTD7:Z*P]&&:00Q*RL(T! P"%'
MKF_"/C2T\5I<1K!+:WELV)K>489?0_SKIZ "HV@A=][1(S#HQ4$BI** &^5'
MO+;%W$8)QR10D:1IM1%5?11@54U6ZNK2P>:RM#=3*1B($#//O5+4?$EMI/\
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M4"L+7O\ C\BX_P"69Y_&F(RZZRQ_X\(/]P?RKDSTKK+ YT^W/_3,?RI )J!
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MF6\A0?W@?RYK?U=-VG.>ZD$?G0(P["/S+Z)2,C/-=77.Z(-U\P(Z)G]:Z*@
MHHHI@%%%% !1110 'I7B&L?\AB\_Z[/_ #->WUY#XOTQ]/UR5MI\J8[U;L<]
M:X<?%NEH>QDE2,,3KU1@T44=^.OI7AI-NR/LY22BVSTOX=_\@:;_ *ZFNQKG
M?!FG/I^@1^:I624^80>HS715]-234$F?G>)DI5I27<****T, HHHH *M)]Q?
MI56K2?<7Z4 .HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0![/7.^//^1%UC_KW/\ ,5T5<]XZ1G\#ZPJ*68VYP ,D]*8AG@#_ )$'0_\
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M)O9EQ\H52/KS0 Z\!-E,!R2A_E7;6W_'K#_N+_*N112]Q @7(:10P]L\UV0
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M\=\"M/X5>(+S4;:ZL;R5YC!\R.YR<>A/?K76R_\ (DOC_H'G_P!%UYY\'?\
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MOQ\7([87MR(/MRKY0E;;C/3&<5J_%J^O+-M/^RW4\.[=GRI"N>GI7.2S)/\
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M6_;1;['IN:\:^*^E7T%^NHRW>^SFD"10[V.PA>3CH.AJXW@;QR78C7^">/\
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MMOB/,$$;E0P'TK4^%6NW]^+[3[R5I5M@&5W;+<DC&3]*Z#PY_P DUL_^O/\
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M+B"3=N<QA3S^-<A;V^DV=U*EIXFGAM91ARB8+#T(SS7KW_"">&O^@3;_ /?
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M8"KMW9'IDGBO2+?XA>%K6VC@AN&6.-0J@*. ./6M+_A!/#7_ $"K?_OD4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M, #VH 6BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %4-4&8E/H:OUGZH?W:#U- &
M71110,**** "K^EJ?/9NVW%4*U-*'R2'WH T****!&%=C%U)]:@JWJ(Q=GW
M-5*!A1110 4444 ;6G\6B_4U:JKI_P#QZ+]35J@04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0**!0 4444 %%%% !
M1110 4444 %%%% !1110 4444 ,D3>/>JY4J>15N@@'J* *=%6?+3TH\I/2@
M"M15GRD]*/*3TH K459\I/2CRD]* *U%6?*3TH\I/2@"M15GRD]*/*3TH K4
M59\I/2CRD]* *U%6?*3TH\I/2@"M15GRD]*/*3TH K459\I/2CRD]* *U%6?
M*3TH\I/2@"M15GRD]*/*3TH K459\I/2CRD]* *U%6?*3TH\I/2@"M15GRD]
M*/*3TH K459\I/2CRD]* *U%6?*3TH\I/2@"M15GRD]*/*3TH K459\I/2CR
MD]* *U%6?*3TH\I/2@"M15GRD]*/*3TH K459\I/2CRD]* *U%6?*3TH\I/2
M@"M15GRD]*/*3TH K459\I/2CRD]*8%:BK/E)Z4>4GI0!6HJSY2>E'E)Z4@*
MU%6?*3TH\I/2@"M15GRD]*/*3TI@5J*L^4GI1Y2>E %:BK/E)Z4>4GI2 K45
M9\I/2CRD]* *U%6?*3TH\I/2@"M15GRD]*/*3TH K459\I/2CRD]* *U%6?*
M3TH\I/2@"M15GRD]*/*3TH K459\I/2CRD]* *U &>E6?*3TIP51T&* (XH\
M<FI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM4^[']36C6?J@_=H?0T
M9=%%% PHHHH *V--7%MGU-8];MFNRU0>V: )Z***!&7JBXD1O48K/K5U128D
M;T-95 PHHHH **** -K3_P#CT7ZFK55=/_X]%^IJU0(**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H%% H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % HH% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 53U,_Z+CWJY5#5#^Z0>] &5
M1110,**** +-CC[6F?PK;KGX&*3HP[&N@H$%%%%  >E<Z_WVQZUNW#%;>1AU
M"FL#O0,**** "BBB@#<LCFU2K%5=/_X]%^IJU0(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H%% H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ H%% H **** $)QR>E<5JWCB:?4FT;PQ9_VC?J=LDO2*'URW? ]*A\7:Q?
M:MK$?A'0Y3'<3+NO+E?^6$9]/<\UU&@Z!8^'M.CL[*)5"CYGQ\SGN2>IH Y:
M/P)J>J/'<^(_$%U/(.3!;-Y<8'IQ@FKW_"L/")Y?2@[=V:9R3^M=?10!Q5Q\
M,-!\DKIYN].?^_;W#C]"<52E'B[P:OG"4Z]I:8#(0!/&OKQC/ZUZ%0>1B@#)
M\/\ B*P\1V"W5E)[21,,/&WHPK6K@_$^@3Z'>MXK\/@I<Q\W=HO"7"=SC^\/
M7W-=9HNL6NNZ3!J-HV8IES@]5/H?>@#0HHHH **** ,77_%>C>&$B?5[P6ZR
MG"91FS^0-88^+7@DD#^VEY_Z8R?_ !-<O\:HTEN_#D4@W(]XBL#W!-=P?A_X
M7*D'2(,$8^[0!J:5X@TK6XO,TZ^AN!Z*WS?EUK2KP[QMX5'PZU"R\3>')'@M
MA,$F@WDCGZ]1P:]=MM=LI_#T.MO((K.2$3;GXPI&>: -2BO,9?C5I(EE%MH^
MK74*,0)X8@4;W'-=GX9\4Z;XKTT7FG2YP<21-PT9]"* );3Q+I-]K=UH]O=!
M[^T_UT6PC;^.,4ZS\1:7?ZU>:1;7(>^LP#/%M(VYZ<XP>M>=>$_^2X>*_P#@
M/_H-=/H^LZ+/XWUVQL]-E34[5%:YGPN)>!@#G/IUH [*BN;\*^,['Q8]]';0
MS6\MG,8I(YL;CCN,$\4_Q9XNLO"-E;W%W#-.9Y1#''#C<6/U(H Z&BN?UOQ?
MIOA[0XM3U(O 94!2W.#(21G;CIFN1B^-6E&6/[1HNK6T+G!FEB 5?<\T >G4
M5D7GB*QMO#,VO1,;FSBA,P,75E]LUQ+_ !IT<PQ26^E:G<[TWN(8U8Q^QYH
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M5]ITDOW&NT"ACZ<$UV>K:O9:)IDNH7TXBMXADL>_L* +]%>7_P#"Z]-8%X]
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MO7&$T@Y%NI^5?K7IL%O#:PK#!$D<:]%08 J2B@ HHHH **** "BBB@ HHHH
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M5L/R:+<YZ-?G=WL=-534=3M-)LWN[V7RX$^\V"<?E4.MZM%H>CW&I3QO)'
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MJ<H[HJ%2,]$34445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !0**!0 53U748M)TFZU"?/E6\9D?'H*N5P_Q7N9[?P-/
M' <&XE2!O=6SF@"7X=Z<ZZ1)K=W\U]JCF>1R.=O9?PY_.NSJM80I!I]O%&H5
M5C4 #MQ5F@"O>7L&GV<MU=2+'#$I9F8] *\EU#XWR&Z9=&T.2[MU;:9'R,_E
MFO1O%GAM/%6A2Z5+=/;QR$%F5<G@@^OM3-%TC2O!6@I:)+%%"@)>5@%+GU-
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M10 4444 %%%% !1110 4444 %%%% &%=KMNI![\5!5S4@!=<=US5.@84444
M;6GKBT7CG)S5JHX%"V\8']T5)0(**** "L[55&V-N^2#6C5+4US;!O0T 9%%
M%% PJYIJYN2?053K2TM?]8_?I0!I4444""BBB@ HHHH **** "BBB@ HHHH
M**** "FNB2(4=0RL,$$<&G44 >>^*/AA9:GONM+VVMSC/E@81O\ "O.[>\\1
M^ ]1:,B2( X*-S&X]?2OH:J.J:39:Q:&VOH$EC//S#.#ZCWKLI8MI<E35''5
MPB;YH:,YGPS\1=,UT)!<$6EX>-CGY6/L:[,$$9!!':O&?%'PMN[%FN=%)N(1
MDF(GYU],>M4?#OQ%U;09!:ZB'N;=3@B0_.OT/]*TGA85%S4'\B(XF5-\M9?,
M]UHK)T3Q'INOVJS6-PK$CYHSPR^Q%:U<#BXNS.V,E)704444B@HHHH ****
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M;3PX+N5?W]XYF8D<X/05P.LZ7<6_BNX\+0 ):7]Q'*@'\"Y->TVL"VUM%"@
M5%"@ 55>T8^[]K45"\I:_9)J\O\ #&E6U[\1]:N;B-9# 08PPR <#FO4*\;L
MO$#^'OB!K5PUO+-:$@3F,9*#C!Q]:C#J3C)1W+Q#2<6SK?B9I=K-X6EU Q@7
M-H5>)QP1\P'Y<UA>-M2G;P!HNYGVSF-9@#RXVY(_2F^(_%I\90Q:'H=K<,MP
MX$[21XPH.>/RK?\ %WAF>Y\(6EO9?-<:?L= !]\J,?\ UZUA[BBI[W,IKG<G
M#:QAZ?\ $#3].T^.RM]!NEA10NT1=?KZU#X&O3/X[O6L[2:TL;B!I&B9-HW
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MWC_.V_JN>QKGG"<8>\=$)PE+W3<HHHK W"BBB@ HHHH **** "BBB@ HHHH
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MU"+RKRWCGCSG;(N15FB@"*WMH+2!8;>)8HD&%11@"I:** $P,YP*,#T%+10
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M86M]Y?VJ!)?+;>FX9P?6K  48 P!0!CZ#X7TKP[!Y=A;A7(PTK<LWU-;-%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7JBX=&]1BL^
MM/51\L9]S690,*!R<44Y/]8OU% &_$,0H/\ 9%/I!PH'M2T""BBB@ JIJ(S:
M'ZBK=5[P9M7H PZ***!A6MIBX@9O[QK)K:T\8LU^IH M4444""BBB@ HHHH
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M:,_F7+'S)Y3U=SU-5/#/@Z/1I7O]0N#J&K2\R73CI[*.PKJ: "BBB@ HHHH
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M)$R[\_3-<#\5M?NDDTOPW97D=FVHOB:X=MNQ>.I/ !S^E9;?#SP-_9I2/Q1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPZT&+3=#BOTN)Y&O(E+)(V53&?N^G6I<(JA?K<I3DZUNECM****YCI"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!0U1L1(OJ:RJU=4QY2>N>*RJ!A113
MH_\ 6I_O"@#?A_U,?^Z*?2#H,4M @HHHH *IZB/]$/L15RH+O'V5]WI0!A44
M44#"MVT;=;(?;%85;UIC[,FWIB@1-1110 4444 %%%% !1110 4444 %%%%
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MNY2I-3B^Q@>/O#3W-JNLZ4/)U"T^?='P74<\^M:'A#Q4FO>'S<2_\?5NI$Z
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M4445@= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0*
M*!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A6GA'1[
M+Q)<:_! ZZC<9\R0R,0<_P"SG%;M% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!RNN_#OPSXBNOM.H:<#,>K1,8R?KMZU:\/^"M \,EFTNP6-S_
M ,M'.]OS/-=!10 4444 %%%% !24M% &7I?A_3M'N;RXL8FB>[?S)1O.TMZ@
M=!6I110 5E6GA[3;+6KK5XH6-[=<22NY8@>BY^Z.>@K5HH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHIKN$0LQP!0!FZHX+HG<<UGU+<3&>8N?H*BH&
M%%%% &_;.)+=&'IBI:H:7)F)D/\ ">*OT""BBB@ JCJ;[;<+_>-7JR-2DW3A
M<\** *5%%% PK8TUP;4+W4G-8]7+"Y$,A1ONL: -BBBB@04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9&K^&]-UR:WFOX6=[=@T9#E<$?2M?M113;;5F))+5!111
M2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4"B@4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !65J-P6?R1T'6M6L:_A9+AGQ\K=Z *E%%% PHHI0"2 !DG]:
M +^EY\U_3%:E5;*W,$7S?>;DU:H$%%%% !6%>_\ 'Y)]:W:S=1MF8^:@SZ@4
M 9M%%% PHHHH U]/N#+%L;[R_K5VL_38656D88STK0H$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4"B@4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !3656&& (]Z=10!7^Q6_\ SS%'
MV*W_ .>8JQ10!!]CM_\ GDM/2"*,Y1 /PJ2B@ HHHH **** "BBB@"%K6!CD
MQ+FD^QV__/):GHH K_8K?_GF*5;.!3D1C-3T4  &.@Q1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0**!0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8T%]</XN
MNK%G_P!'CM(Y57 X8LP/\A6S0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!F+J4I\32:9L3REM5GW?Q9+$8^G%:=<^G_(_P W
M_8-3_P!&-704 %%%% !1110 4444 %%%% !1110 4444 % HH% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SUM_P C]??]@^+_
M -#>NAKGK;_D?K[_ +!\7_H;UT- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '/I_R/\ -_V#4_\ 1C5T%<^G_(_S?]@U/_1C
M5T% !1110 4444 %%%% !1110 4444 %%%% !0**!0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <];?\C]??]@^+_T-ZZ&N>MO^
M1^OO^P?%_P"AO70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <^G_(_S?]@U/_1C5T%<^G_(_P W_8-3_P!&-704 %%%% !1
M110 4444 %%%% !1110 4444 % HH% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!SUM_P C]??]@^+_ -#>NAKGK;_D?K[_ +!\
M7_H;UT- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 4=8U:UT/2;C4[TN+:W7=(47<<9 Z?C7$_\+K\'_\ /6]_
M\!S_ (UL?$W_ ))QK?\ UP'_ *$M>;?!SPKH>OZ1J$NJZ;!=21RH$:3/ (-
M'?:7\6/">JWBVT5Z\+MT-PFP'VR37:[AMW=L9KQ'XI?#G2]'T4ZUHT)MS'(
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M7E?Q+\ ^&=-\)7&H65I%8W$6-A0X#GTY]:/@7>7$N@WUJY)@BDW)GL2.1^E
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MF.E>EU_WX:C_ (3'2O2Z_P"_#4 =!17/_P#"8Z5Z77_?AJ/^$QTKTNO^_#4
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M91ZGHEM//;M()H?(1FVG.2IQ_GFO>?#^J-K.B6MZ\$L$DB9>.5"K*W0\'Z4
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M]7C=C)XA\->-KC5['1;J61)90H>V<J0V1G@>] 'U%7+_ !%_Y$#5_P#KD/\
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M9\;^-K"-=-N_LRK&F3 ZJ"0"_)'KFO<[7PUHUK9PVZZ=:LL2! 6B4DX&.>*
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MOA-XUU>4)JFI(L8_B>7>/R!KU_PIX7M/"6A+IUL2QR6DD/5V/4_I6_2-]TT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *!10
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "@44"@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
0H **** "BBB@ H%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g0vsdaj33nnl000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,L""$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBZ:(B(@X.[''- %VBN(\%6'BZTU*X?Q#/));F'$8>=7^?([ ^F:[>@ HHHH
M**** "BBB@ HHKSR/3/' \8).US+_9(NPQ3[0N/*SR-N<].U 'H=%%% !116
M3XFU9M$\/7>H1J&DB3Y >F3TH UJ*\.TO5?'/BBYF?3;Z8F/!=5D"*/SKV/1
MDO8]'M5U%MUX$_>G/\5 %ZBBB@ HHHH **** "BBB@ HHHH **** "BBN<\:
M>)G\+Z,EW' )I)9?*0$X )!.3^5 '1T5R_@+5[S7/#OVV^DWS/,XX& !GH*X
M[XD>(=7TOQ)'!8ZA/;Q&)24C; S0!ZS15/29'FT>QED8M(]O&S,>I)49-7*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **\O^)^O:KI.IV4>GW\]LCQ,6$;8R<BNU
M\(74][X4T^YN96EFDB!=V.230!MT45Q'Q-U2_P!*T6VEL+J6WD:7!:,X)&*
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M/$2RQM@$YH ]1HK(\+W$UWX8TZXN)&DFDA#.['DFM>@ HHHH **** "BBB@
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MQ= _X2*U..3!S^==5XA_Y)(/^O>/^8H \[\'Z;XCU"28Z%=/ J%?.VSF//\
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M=5N+2XM((5B@,H:,G).X#'/UK9NO^2>G_L'+_P"@"O._@_\ \C)>_P#7F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH\N/*11D].0,]C576_B-J^H:LVF^&H1PVU9 @=W([C/ %%@/5Z*\>7QUXO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "'H:\&TU1J/Q/ OOFWWS%E;N=QXKWJO
M(?''A#4['7GUW2(GD1W\UA$,M&_<X],TT!ZZ45D*%05(P1CC%>"6 %E\3XDM
M/E5;W:-OH>O\S6P_Q3UN6T^PIIZ"](V&09+9_P!W'6M#X?>"[W^TQKVKQO&P
M):*.089F/\1';K0!2^*^D-9ZO;:O"-JSC:Y'9QTH\:^*3J?@S1X5;][=('F
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M]>;_ /H24 9FGPI/\288Y!E3?9(^C9KU'XEJ#X'N^.CIC_OH5YCI/_)38?\
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M8S6.G6UO(1@M%&%.*T:* ,Z]T#2-2G\^]TVVN)<;=\D88X]*OHBQQK&BA44
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M;6!_[T<8!K1HH *JWFFV6HQ^7>6L,Z>DB U:HH S[+0]*TYR]EI]M;L>ICC
MK0HHH K7NG66HQ>5>VL5Q'_=D0,*AM]#TNTMY(+?3[:**0%71(P P/4&K]%
M%"PT73-+=WL+"WMF<88Q1A21^%3W=C:7\1BN[>*>,]5D4$58HH S+3P[HUC+
MYMKI=I#)_>2( UIT44 %%%% &9=>'=&OI?-NM+M)I/[SQ FKMM:6UE$(K:".
M&,=%1<"IJ* (;JTM[ZV>WNH4FA?[T;KD'\*@L-'TW2]_V"Q@MM_WO*0+G\JN
MT4 %%%% &9<^'=&O;@W%SI=I+,>KO$":?=:'I5]%'%=:?;31Q?ZM7C!"_2M"
MB@""TL[:PMEMK2".&%/NQQK@#OTJI=>']'OKK[5=:;:S3G'[QXP6XZ<UI44
M(JA5"J % P *SKSP_H]_+YMWIEK/)_>DB!-:5% %:ST^ST^+R[.VB@3^[&H
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MNHP&EC#$"KL,,=O"D,*+'&@VJJC  I]% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS2_^?F^_[_M1_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS2_\
MGYOO^_[5UU% '(_\*\TO_GYOO^_[4?\ "O-+_P"?F^_[_M7744 <C_PKS2_^
M?F^_[_M1_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS2_\ GYOO
M^_[5UU% '(_\*\TO_GYOO^_[4?\ "O-+_P"?F^_[_M7744 <C_PKS2_^?F^_
M[_M1_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS2_\ GYOO^_[5
MUU% '(_\*\TO_GYOO^_[4?\ "O-+_P"?F^_[_M7744 <C_PKS2_^?F^_[_M1
M_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS2_\ GYOO^_[5UU%
M'(_\*\TO_GYOO^_[4?\ "O-+_P"?F^_[_M7744 <C_PKS2_^?F^_[_M1_P *
M\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS2_\ GYOO^_[5UU% '(_\
M*\TO_GYOO^_[4?\ "O-+_P"?F^_[_M7744 <C_PKS2_^?F^_[_M1_P *\TO_
M )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS2_\ GYOO^_[5UU% '(_\*\TO
M_GYOO^_[4?\ "O-+_P"?F^_[_M7744 <C_PKS2_^?F^_[_M1_P *\TO_ )^;
M[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS2_\ GYOO^_[5UU% '(_\*\TO_GYO
MO^_[4?\ "O-+_P"?F^_[_M7744 <C_PKS2_^?F^_[_M1_P *\TO_ )^;[_O^
MU==10!R/_"O-+_Y^;[_O^U'_  KS2_\ GYOO^_[5UU% '(_\*\TO_GYOO^_[
M4?\ "O-+_P"?F^_[_M7744 <C_PKS2_^?F^_[_M1_P *\TO_ )^;[_O^U==1
M0!R/_"O-+_Y^;[_O^U'_  KS2_\ GYOO^_[5UU% '(_\*\TO_GYOO^_[4?\
M"O-+_P"?F^_[_M7744 <C_PKS2_^?F^_[_M1_P *\TO_ )^;[_O^U==10!R/
M_"O-+_Y^;[_O^U'_  KS2_\ GYOO^_[5UU% '(_\*\TO_GYOO^_[4?\ "O-+
M_P"?F^_[_M7744 <C_PKS2_^?F^_[_M1_P *\TO_ )^;[_O^U==10!R/_"O-
M+_Y^;[_O^U'_  KS2_\ GYOO^_[5UU% '(_\*\TO_GYOO^_[4?\ "O-+_P"?
MF^_[_M7744 <C_PKS2_^?F^_[_M1_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^
M;[_O^U'_  KS2_\ GYOO^_[5UU% '(_\*\TO_GYOO^_[4?\ "O-+_P"?F^_[
M_M7744 <C_PKS2_^?F^_[_M1_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O
M^U'_  KS2_\ GYOO^_[5UU% '(_\*\TO_GYOO^_[4?\ "O-+_P"?F^_[_M77
M44 <C_PKS2_^?F^_[_M1_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_
M  KS2_\ GYOO^_[5UU% '(_\*\TO_GYOO^_[4?\ "O-+_P"?F^_[_M7744 <
MC_PKS2_^?F^_[_M1_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS
M2_\ GYOO^_[5UU% '(_\*\TO_GYOO^_[4?\ "O-+_P"?F^_[_M7744 <C_PK
MS2_^?F^_[_M1_P *\TO_ )^;[_O^U==10!R/_"O-+_Y^;[_O^U'_  KS2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4U3@T"2WGU8QW"B"^RPCV_<8]30!C6,DD7PK+Q9WBW;&/]XUT'AJ&"'PY8K
M!L,()P.I/7]:=I&CC3] BTN=UF54*,0,!@2>U8T7AC6M.W6^E:\8+(GY8I8@
MY0>@)Z4 )>)'/\1;*&X ,4=LSPJ1QO[T_5]=UG2[Y!+IEL;%YQ''+YN6()X.
M*LWOA5;VPM5DOI_M]KS'>!OGS[^U5&\,:Q?2P#5=;%Q;PN'5(X A)'J:8$OC
MW_D75_Z^8OYU%XQ.ZUT>&0_Z/)=()/0\< UL>(=(?6],%HDPB(E63<5ST/2I
M=5TB#5]+-C.2!P5=>"K#H12 O"- BH%&T# &.!7&>(-;TV+Q5:P7[M]GM$,A
M54+9<].GI5R+0/$($<$OB-C:H1PD0$A [;NM:>CZ0^FS7L\TPFFNI=Y8+C [
M"@#D=,U6,^$]<L["1V6U#M;D@AMAY'%;NF"ZLO".GMH=G!<2NBEU=]@.1R<^
MN:O7&A^=X@&HK(@C>$PSQ,N?,':LQ/"^JZ:7BT76VMK1B2(98Q($SV7/2F!F
MZCKMYJG@C59);9+>6*80R"(Y &X9-=GIT,$6F6\<"J(A&NT#ITK,TSPS#9Z/
M=6%S,US]K8M,Q&,D^E4(?#>O6<?V2S\0E+(<*KPAG4>@:D OC74K6VBLK"X<
MI#-*&EV*20@]A5/PYK6GOXLO8+!V^S7B"559"FUQP0 ?7@UNV.A26VL_;Y[M
MKC9;K!%O&6&!R2>Y-2:QH[ZC=6%U!,L,]I+O#%<Y4]10!EZ?_P E%U+_ *]5
M_G2:"JS>,=>EF&9HW5(\]0GM6K;:,\'B6ZU8S*5GA$8CV\C!ZYJKJOAR:?4A
MJ>EWS6-Z0%=MNY7'N.] &W<S1VEM+<R858T+,WL*\M.N:8VE&Z\V4:L;LW6?
M*; Y^[GTVXKKIO#>LWMG<17NN&9Y@$($>U N>?E'<BNC-K%]A^R!1Y7E^6![
M8Q0!R.H3Q:IXK\/-*0UK)"TJ*?NE\#^56O$.NZQHK-+_ &9;2:>'55D:3YCD
MXZ4]?!ZR:)#87%TWFVLK/:SQ#:T8)R!5>?PKK6HQ1VNIZ]YUFCAMBPA6.#W;
MO3 >VVY^(D0N "([7="#TR1SBNLP"<X&1WK$UOPZ-3>WN;:Y>TOK<8CG7T]"
M.XIFG:3K4=^EQJ6MFY1!@111"-3]<=:0%*__ .2C:=_UZ-_.B,+/\29A< $P
MV0, /J3@D?A6I<:*\_B:VU83*%AA,9CV\G)SG-1:WX=.I74-]:7;V=_ ,),O
M((]".XH W,#.<#/K2UA:9I6L0WRW.IZR;I4!"Q1QB-3D=P.M;M !1110 444
M4 %%%% !7(Z[_P C]X=_W9?Y5UU<CKO_ "/WAW_=E_E0@.NHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Y3XA?\ (N1?]?<7\ZZNN4^(7_(N1?\ 7W%_.@#J(?\ 41_[
MH_E3Z9#_ *B/_='\J?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLI+-;M;F+[.PR)-PQ4Q@B:W\AD#1%=I5AD$5@KX&\/+<>>+ ;@<XWMM_+.*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M -\@T ;\<L<R!XG5U/1E.139KF"WQYT\<>>F]P/YUS/AW_B1W&HZ/(28[?\
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M-[J&EQF"5XQ&J!B4!)X./6@#I'O;2.3RWN85?^ZT@!_*D>_LXGV27<",.S2
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M@ HHHH **** "J.L::FL:3<Z?)(T:SH4+*,D9J]10!Q=MX%O[2V2V@\5ZC'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *XN'^U/"NIWRQZ9/?:?=3&9/LPW,C'J"*[2B@#DK^'4O%&C39T][&6"5
M)K43G#,PSG([?_7I8_$VL"$0'PW?&['R[BN(B?\ >KK** .<\96US>^&C%!
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M2_\ ?=+_ ,)R_P#SY+_WW6/_ &;+_P \E_.C^S9?^>2_G7;[&CV/+^M8CO\
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M7_Y\E_[[H_X3E_\ GR7_ +[K'_LV7_GDOYT?V;+_ ,\E_.MO8T>QS?6L1W_
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M_P#QX5S5XQ@^6)UX><IKF;.G_P"$X?\ Y\E_[[H_X3A^]DO_ 'W7,?V7??\
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MET*LJDMSL1XXD[V2_@]+_P )P_\ SY+_ -]US']EWW_//_QX4?V7??\ //\
M\>%<9VG3_P#"</\ \^2_]]T?\)P__/DO_?=<Q_9=]_SS_P#'A1_9=]_SS_\
M'A0!T_\ PG#_ //DO_?='_"</_SY+_WW7,?V7??\\_\ QX4?V5??\\__ !X4
M =,?'3 ?\>2_]]TS_A/'_P"?%?\ ONL2+2;@(-\8)^HI_P#94W_/$?F*UC!6
MU/-K8FISM0V-G_A/'_Y\5_[[H_X3Q_\ GQ7_ +[K&_LJ;_GB/S%']E3?\\1^
M8I\D3+ZS7-G_ (3Q_P#GQ7_ONE'CMR?^/%?^^ZQAI4Y.!".?<56FTJ\64@1
M8]&%*221MAZE:I.S>AT?_"</_P ^2_\ ?=+_ ,)P_P#SY+_WW7,?V5??\\__
M !X4?V7??\\__'A61Z)T_P#PG#_\^2_]]T?\)P__ #Y+_P!]US']EWW_ #S_
M /'A1_9=]_SS_P#'A0!T_P#PG#_\^2_]]TA\<L!G[$O_ 'W7,_V7??\ //\
M\>%3PZ3<[<O&"3[U45=F5:HZ<+HW#X\D[62_]]T?\)Y)_P ^2_\ ?=8_]E3?
M\\1^8H_LJ;_GB/S%:<D3S?K-<V/^$\D_Y\E_[[H_X3R3_GR7_ONL?^RIO^>(
M_,4?V5-_SQ'YBCD0?6:QL?\ ">2?\^*_]]T__A.),?\ 'DH_X%6%)I=P$.V$
M9[<BJW]E7W_//_QX5$TEL=F%E4FG*;.G_P"$X?'_ !Y+_P!]T?\ "</_ ,^2
M_P#?=<Q_9=]_SS_\>%']EWW_ #S_ /'A4'6=/_PG#_\ /DO_ 'W1_P )P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA(IIL\K,9/FBC2_M%_\ GNU']HO_ ,]VK-HKKY4>==]S2_M%_P#GNU']HO\
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M #W?\Z910!>AU"81C?.V[ODT_P#M%_\ GNU9M%>O""44CYRK)RFW<TO[1?\
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MJA;ASM&X\USU;OAM09+AO0*/YUI5DU!F5&FG-'2?;;W_ )[O^='VV]_Y[O\
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MIR?\_#5ET4!KW-";4+AP/+G8^O-0_;;W_GN_YU#'TI]8SW/7PRM20_[;>_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@_Y[1_\ ?0KM/-):*B^T0?\ /:/_ +Z%'VB#_GM'_P!]"@"6BHOM$'_/:/\
M[Z%+]H@_Y[1_]]"IFO=9=-VFO4EHIGG1?\]$_.CSHO\ GHOYUXQ]&/HIGG1?
M\]%_.CSHO^>B_G0 ^BF>=%_ST7\Z/.B_YZ+^= #J*9YL?]]?SH\V/^^OYU[,
M=D?-2TDT/HIGFQ_WU_.CS8_[Z_G5"'T4SS8_[Z_G1YL?]]?SH ?2TSS8_P"^
MOYT>='_ST7\ZX<9T/3R[[7R'T4SSHO\ GHOYT>=%_P ]%_.N(],?13/.B_YZ
M+^='G1?\]%_.@!]<MX@_Y"7_ &S']:Z;SHO^>B_G7-^(63[7&^]?F3'7T_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *YGQ5JFI6\D%GH[!;HHT\AV@_NU^OKS^5=,3@9/:N#MSK^J
M:WJ6J:2-/,!?[*OVO=G:O7&.Q)- &Q(=7UG3K2^TO5TLT:+,B&!9-S=^O3O6
M5H%SXAO[$:K=:Z@M(96\Z+[*F653SR!QD5;\)R7-F-2T:^\H7,#&51&3M*MZ
M9[ _SJ#PU;/>> KZVB_UDK3HOU.13 DM)_$WB&(W]G?PZ=:,3Y,9A$A8>I)J
MU?:SJFEZ=9VDL<,^LW3,B!/N<'[Q_#%,\)ZYIZZ!;VMQ<Q6]Q;)Y<D<K!"".
M.]5=<U"W&JZ/K\+^?I\;/%)(@.%YZ_G0!:%AXP3;-_;-M*V<FW-NH7Z;NM0>
M)/\ A)--LKK4X-:C2&,!A;BV4XZ#&XUG^+3ITEHVJV.M3FY=T"0Q77R]?[HY
MK<\6DGP-<DG),*9_2@"B+_6M%TG^U=1U5+U)(P(K<6ZI\[=.15B*T\8NB73:
MI;*S88VA@&U1Z;NM0>(H97\'6-Q$A?[-Y<K*!U QFMV/Q+HTEFET-0@$;#(!
M;YA_P'K0!%XAU&ZL=)C6V*K?W+K%%@9 8]3@]A@TSP_J\MQHLLNHN/M-H66X
M.,?=YSCZ5CZI-J>L>*8AHIM6&GQ!RUSNV;G^G? _6JL,.K6VKZAI^I_95EU>
MTD$9MB=AD"GU[X- %ZUNO$GB,-=V-Y%IED6/DYA$C./4YK7LI=3TS3[J;6[B
M&=80666-=I90.XZ"L'1KK3=0\,Q:/?7TEA<6H"2*)?*?*^Y]:J:3!)>Z)XEL
M;:ZFN8Q(R0/))O) Z<T 7!:^(O%%HM[]M@L[5SOAMS"'R.Q)/(K0ETZUTSPY
M)=ZC;1&ZBB);RR=I;MCGN<4_PYX@TU]!MDENX8)8(Q'+'(P4J1QT/TJCXDOY
M-;.FZ=HTD,K7$GG[I,A"J<\]\9Q6,\/2F[SBF_0N-6<5:+:*.B:?<WL5]IMZ
M8X=251)#*4!VJ?;H:HOH6KIXCBT?^UXBTD)F\W[*N!CMBM*9M=TK7]/U36/L
M A9OL[FUW<!N[9]*TI_^2EVO_7BW\ZCZIA_Y%]R*]O5_F?WF1+8W3WD>@V;0
M27T2>9=7S1X"@G@!>F<5JZ3X8O+6\9-2EM[VV*$APGEL&R.,#MC-0QW46B>/
M=0>^<10W\4;0RO\ =RHP1FMZ?Q#ID23^7>0RR0PM,5C;=P/<<=<4?5,/_P ^
MU]R#V]7^9_><AK#+;:[OMH%&EV<B1W8QG)8\\]>*U_$":?ID,$5I8)/>W3;(
M$+'&?4\]*R+/2O%%]HDZQC2_L]_ND<S%_,^;UP,9%1#49!:Z'JMRC,+!S;W>
M!DH1QDT_JF'_ )%]R#V]7^9_>7!X1UY0LW]H6COG)MS  OTW=:LZ[%#9?8=/
MLK&%]3O.!ECM3 ^8]:I^+&TRXLI-6LM:F^T-M"117.%/;[O6K.J3?V;KGA_5
MKHG[*8#%))C.PE1@GZTOJF'_ )%]R#V]7^9_>);^$]8@G4RWMK<QN"'!AVE.
M.HQUQ61?Z%J]CJUC8G5XG-VQ <6JC;_C7?#7-+:6&)+^!Y)B%14?<2?PK%\0
M?\C;H/\ UT-'U3#_ //M?<@]O5_F?WF3<:?=6$EOHR/!>:I<DOY[1[%BCZ9P
M#SSFK^G>%=1M;Z,WMS;7MJV?,'E>6R\=L=:=JUQ'H_CJSU"Z.VUGMC#YA'"-
MFM\Z[I8E2(7\#NX)54?=G R>G3@=Z/JF'_Y]K[D'MZO\S^\X_P 4(;6^$6EV
MZ[;2+[1=#&=R9''/3C-6=6T":YM?[2TN_BMK7R?,$1A#YXSU-5]/C\2:DU]J
M-@FF?9[YRN+K?N*#C'':KF@SS)X7U'2[O N;$/&P!XQVQ[4_JF'_ )%]R#V]
M7^9_>9>B:7=/I,.N7^HQO9A#));^0 2!QC<*EM-"U?6X!J$$]O802<PP>5O)
M7MDGI5_3;62]^%XMXLF1[=@H'^\:T/#OB#3'T*W66[A@E@C"21R,%*D<=#]*
M7U3#_P B^Y![>K_,_O,>_CDMEL=*AL;:76;A27;<VQ .K=:?%X2UJWFCE>^M
M;I=PWPM#L&._(YIU]J5M9^++#7"^_3;F$P^>%.$/:J?B);&*]MK[3]9GEGN+
MI28DNMR $]E'2G]4P_\ (ON0>WJ_S/[R'Q+H>I:1!)?1:G$87G")"+=<J&/'
M)ZXJQ<:;/X>T]KF^N(M1EG*QVT0B\O#GUP>:V/'O_(NK_P!?,7\Z9XQ1X].T
MV^"EH[2X1Y !G"XZ_A2^J8?^1?<@]O5_F?WF?#X5UT&.Y>[M')(+VIAPH'<;
MNM7?$%O]@6T@T>%(]2GD&Q_O; .2<'BMH>(]'-LD_P#:,&Q\8&_+<^W6N<GD
MUK5?%-S=Z-]B,=FOD!KHMC)ZXQ36%H)W4%]R$ZU1Z<S^\W-(UQ;GPRFI71P\
M49\_V9>#^M95I)XH\01?;K>^ATRU<DPIY D9E]3FLR&WU)!KFB7PA%U>1&XB
M%OG82>N,U?L+S2=:\-6MC=ZA)836JA)46;RG!48[]1709FNE[J&BZ%=7>MRQ
M3O!RKQ#;O'09';FLZ"'Q=J$"WRZG;VHD&Y+3[.&&/0L>:PK:">_\#ZU%#/+<
M^5<YC+N7+*I!Z_2NPTWQ+I,^E0SF^@CP@W([@,I Z8ZT /U;4;G3?#IN)-@O
MB@0!.1YA]/;-9FD7>M:EIEYI\M\MOJUK-M>8PJ<J1D';T[_I5?7+N[UK5M/M
M=%:VD\M!=EI]VPY^[G'/O4-NVL:5XNM[K619A;]/(+6I;;N7H6SWYH CMV\5
M3^(+G21XA0-!$)#)]D3!R<8QBK\NH:Y>W_\ 8VG7<2S6R W5ZT0/S>@7I3]/
M_P"2BZE_UZK_ #J'3[R'1?&.K0W\BPB\82PR2<!NV,T ;.D6^N6T\J:I>PWD
M.W*2+&$;/H0.U8C^(M0'B;S!(/[&6X^R$;1]_ R<]>N16OJ?B73[:PO&M[J*
M:>*+<%1MW)Z<CBN6_L7Q5_PC7V4KI9M\>>>7\W<?FSG&-W-(#J/$&MSZ>]M8
MV$2RZA=DB)6^ZH'5C5);#QA%MF_MFVF;.6@:W55^FX<UD2ZH!=^'_$,RL;81
MM;W#8SY;=,G\:;XN.G_9_P"U+#6IVN994"Q1W7RXSS\HY'%,#H-<U>_74+;2
M-*$8O9EWO*XR(U]<4V'3_%43M')K4$Z.A E-NJF-NQ '6J5Y<IH_C:WO;PE+
M:ZMA&)3T5@.]=(FLZ;)=1VT=[#)-(,JL;;L_E2 Y"=O%4'B&WTD^(4+31&02
M?9$P,'&,8J_<W^MQ7-OH-M=Q3ZDZ&2:[:( 1IV.T<9IU_P#\E&T[_KT;^=1W
M-U%HOC\W-XVRWO;7RDE;HK YP33 T]+M?$-K? :AJ,%[:L#N(A$;*>V,=:W:
MI1ZQITUVEK#>0RS."56-MW Y/2KM( HHHH **** "BBB@ KR+XD?\CA:?]<J
M]=KR;XB1&3QE9 '&Z*MJ'Q_UW,,3_#?S_)G-T5<_LY_[X_*C^SG_ +X_*O8N
MCYVS*1Z4RM#^SG_OBF_V9)_ST7\J\[&+WE(];+I^ZX,HT5>_LR3_ )Z+^5']
MF2?\]%_*N,](HT5>_LR3_GHOY4?V9)_ST7\J *-25:_LR3_GHOY4X:<^/OK^
M5=F#FE)Q?4\[,:;<5)="G15S^SG_ +XH_LY_[X_*O1NCR+,IT5<_LY_[X_*C
M^SG_ +X_*BZ"S*=(>E7?[.?^^/RH_L]_[X_*E*S5BHMQDGV,^BKW]F/_ ,]%
M_*C^S)/^>B_E7B-6=F?2Q:DDT4:*O?V9)_ST7\J/[,D_YZ+^5(91HJ]_9DG_
M #T7\J/[,D_YZ+^5 %7M15P:<X'^L7\J/[.?^^M>S2J*4$SYRO3<*CB4Z*N?
MV<_]\?E1_9S_ -\?E6ET9693HJY_9S_WQ^5']G/_ 'Q^5%T%F4\5'6A_9S_W
MQ33ICYXD7\JX<:KI21Z>73LW!E&BKW]F2?\ /1?RH_LR3_GHOY5P'JE&BKW]
MF2?\]%_*C^S)/^>B_E0!1JA*,2M6[_9DG_/1?RJ&719)&R)4'KQ77@YJ-2SZ
MG%CZ;E2NNABT5K?V%+_SV3\C1_84W_/9/R->IS(\6QDT5K?V%-_SV3\C1_84
MW_/9/R-',@L9-*#@YK5_L*;_ )[)^1H_L*7_ )[)^1HYD&I$.1FEJXFERJ@!
ME4X]J=_9DG_/1?RKPIQY9-'TE.:G!274HT5>_LR3_GHOY4?V9)_ST7\JDLHT
M5>_LR3_GHOY4?V9)_P ]%_*@"HO2EJV-.<#_ %B_E2_V<_\ ?%>OAYJ5-'S^
M+IN%5E.BKG]G/_?'Y4?V<_\ ?'Y5M='/9E.BKG]G/_?'Y4?V<_\ ?'Y47069
M3IC?>J__ &<_]\?E2'37)_UB_E7+BX\T+KH=V GRU+/J4**O?V9)_P ]%_*C
M^S)/^>B_E7F'M%&BKW]F2?\ /1?RH_LR3_GHOY4 4:R-=3,43^AQ_G\JZ7^S
M)/\ GHOY57O-%>XM7C+J3C(X[U=.7+),B<>:+1PU%6VL)%8J6 (.#Q3?L3_W
MQ^5>B>>7]"DYEC/LPK;K TZ)[>\1BZA6^4UU@TUR,B12#7%B(VE?N=M"5XV*
M5%7O[,D_YZ+^5']F2?\ /1?RK V*-%7O[,D_YZ+^5']F2?\ /1?RH QM23S-
M/E'H,_ES7+UZ VE.RE6=2",'BN/N]*EMKEXF8#!XXKJPTM'$Y<0M4S/J[I4O
MEWZ>C#::C^Q/_?'Y4^.U>.17#C*G-=$HW31A&5FF=/15FWLFN($E61<,,U+_
M &9)_P ]%_*O->FAZ*U*-%7O[,D_YZ+^5']F2?\ /1?RH HT5>_LR3_GHOY4
M?V9)_P ]%_*@#@9EV3R)_=8BF5NZUH\D%UY@8;9.<X[UE_8G_OBO2@^:*9YT
MURR:(8FV2HWHP-=>IRH/J*Y;[$_]\5U&D6S7-FH\U=Z<$5AB(Z)FV'EJT.HJ
M]_9DG_/1?RH_LR3_ )Z+^5<AUE&BKW]F2?\ /1?RH_LR3_GHOY4 4:*O?V9)
M_P ]%_*C^S)/^>B_E0!6'2EJS]A=!@NOY4GV1O[P_*MT[H\.K!PFT5Z*L?9'
M_O"C[(_]X4S,KU">#BKWV1_[PI/[/=R2)%_*LY[';@I6FXOJ4J*O?V9)_P ]
M%_*C^S)/^>B_E69Z91HJ]_9DG_/1?RH_LR3_ )Z+^5 %&I5Y459_LR3_ )Z+
M^5+]@=!]\'\*J#U.3&0<J=^Q6HJQ]D?^\*/LC_WA6QY17HJQ]D?^\*/LC_WA
M0!5?I4=7C9L1C<*/[,D_YZ+^58S6IZN#E>GR]BC15[^S)/\ GHOY4?V9)_ST
M7\JDZRC15[^S)/\ GHOY4?V9)_ST7\J *0^\*EJQ_9DG_/1?RI39.."PK2#Z
M'GXZ#TD5J*L?9'_O"C[(_P#>%:'GE>BK'V1_[PH^R/\ WA^5 %-_O4VKWV!W
M/WP/PH_LR3_GHOY5A+1GM8>7-311HJ]_9DG_ #T7\J/[,D_YZ+^5(V*-1R?Z
MRW_Z[I_.M+^S)/\ GHOY56N[)X/L[EP1YZ#CZT >\P_ZB/\ W1_*GTR'_41_
M[H_E3Z0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@W$^G0/*>K%>:=;^(-'NYU@M]2MI97.%1) 2:=/KNDVMQ]GGU"VCF_N-( :
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M;$J,$[I''Q^!^OF7N3VVIBG_ /"#Q_\ /X__ 'R*ZVBLS0Y+_A!X_P#G\?\
M[Y%'_"#Q_P#/X_\ WR*ZVB@#DO\ A!X_^?Q_^^11_P (/'_S^/\ ]\BNMHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1
ME#*58 J>"".M<5XDTG38-=\/QQ:?:QI+.XD5(5 <8'7CFNVKGO$&GW5YK.AS
MV\)>.WF=I6!'R@@8H ORZ%I'D,/[*LL $@?9TX_2N4\-6]E;>#;O4S8VSW-L
M\TB2-$I8%>1SC-=W("8F ZD&N=\,Z1-!X9FL-0A,9EDE#*2#\K?2@"MX7\/Z
M?<:)#?7MM%=W5VOFR23J'///?I4&M6$*WND^&[4&#3Y6>25$8_,,YQGTSFBP
M;Q+X=@_LZ/25U*WCR(9DF"87MD&K6H:5K&IV-CJ!\BWUBU=F5%)V%2?ND_2F
M!3U27PCIDAT^ZT@CR\#S([;\OGZ_K4FIPQ:WXKT_2ILFPA@\\Q9.'XXS4&JO
MXEU[3AIDNA+;%G4O<&X!7@]AUK1UG2-1BO+'5M*$<EW;1^7)"QP)%QC@T :\
M>@:5#=Q74%A!#-%]UHD"?RZURVN00Z_J^H;KB-!I\0C@RX'[W[Q/X=*U;?5?
M$=U-\^A+:0JI+;YP[,>P7&,?C572/!>GS:<L^LV DU"9FDF+.>"23C@XI 6$
M2PUOPJVHSV=M+<"U93(\2LRLH/<\]>:Q[!+73?AT-5BL[<7J0G;/Y0W@DXSG
M&>]:FEZ5>:;;ZWIB6[?8W5FM&W#!W*05ZYZXJQI.BR2>"4TF^0PR/"48'!*G
ML:8#=$\+:4NBPBXLX;B:9-\DLJ!F)/7D\BL_4;"&]\1V'AP!H],MX/-:(,?G
M(Z ]\4^SNO%.DVBZ>=&2]\H;([E9PJX[$@\FI]1TK6)VL=9M_(75H(]LL/.Q
MU/.W- %2\N_"5O?QV,VDF*6.9421+;8-V1CYAC-2S6D6O^.)+>]'F6EA"'2$
MGY6<GJ1WJ'45\0^(C96LVBK91PW"3/*]P&!V^@ ^M7M7TW5+'75UK1XDN&>/
MRKBW9MI<=<@^M &S;Z)IEG>?:[:RA@F"[<Q+M&/H.*XW58X]7NM4U5;A!+92
M!+4%P/N?>Q]3FMM=2\2W45PQT9;55B;8AF#NSXXP>!C-1:;X%T<:7;B_L5DO
M#&#,Y=L[CUZ'UI +K<.G:GX1N-6%E;--+;A_-,2E@>.^,\=*SKR*WTWP)!<V
M=K;PWD\:1>>D8#C<<'GKTJW;:5J4'A;5M'-LQ".PM#N'SH3D#KVYZUH/H;ZA
MX,CTN<>5/Y2X)_@<<BF ZS\):)'I<=N^GP294%I'4%R?7=UJ#Q.8EL;/1HW$
M2W3B,Y;&V,=>35:#4_%EO;+:/H<<TR#:+D3@(??;UJ1]!DUS77EURT5[:"!4
MC 8A6?\ B(P<XSZT ,\/31Z3=:MI,3H\4!-S;X;(V$9Q^!!JCHMII\VDW7B7
M6+<WLTCGAD\S:N< !35Z?PQ%I.L6-WHMCMB;=%=(KGE#WY-1V]MK_A>::"QL
M5U/3Y)"\:"0(\9/;GC% #M.U70TM=6O=&LVMKB"!I)%:+8.!D?+TI_A;0-/N
M-$AOKZVBN[J[7S9))U#GGGOTIVBZ7?W5[JMYJMHMJE]'Y?DB3<0._-5K!O$G
MAR'^SH])74K>/(AF28(0O;(-(#6U3[-X=\,RQ62"%3E(ESP&<^_U-8FD6EKH
MFO0V >.>VU*VQ(I8,#*O)R/<$U;N].U37IM,M]7LXQ;*7EN1&WR9SA5ZYSCF
MDU?P?9VEK'=Z'8!+ZWE610KG+@'D<G'>F!!?Z3IJ>/-(MUT^U6%X92\8A7:Q
M"\9&,&MO5-$TE-)N2NF60*1,5(@7CCMQ5:YL;V?QAI&H?9V$$4$@E;(^1BO3
M\ZVM1B>;3;F*-=SO&0H]3BD!Q>GQVNG?#N/4XK.W%ZL1VS^4N\')&<XS6UHO
MA?25T6#[1907$TT8DEEE0,S%AD\GD=:@LK*.W\$0Z3JK"VDDB9"K<X.3Z5E6
M7B76-)M4T]K"&]\H;([E)]JD=L@C-92KTHNTI)/U+5.;5TF6]1T^&^\26'AT
MADTRWA,S0JQ^?T!HO+KPE;Z@MC+I+1RQ2A%DCMMHW9_O#&:BU)YYGL-9M;RU
M75H%*RQ<^6ZGJ,U3O]9U#Q"UI;SZ?'9)%,LCRO/N!P>P I?6:'\Z^]#]C4_E
M?W&M<6T>O>.I[2]'F6MA"C+"?NEF&<D=ZZ"WT/3+2]%Y;64,$P0INB7:,'V'
M':N8UBX:SUP:WI$L-P[QB.>W8E2X'0@TO_"6:I=PW).GQ6J"%@B&;>[.>F#P
M /\ "CZS0_G7WH/8U/Y7]Q3U2./5Y]3UA;A!-8NHLP7 SL.YN/?I6MKL.G:E
MX/NM46SMFFDM2XF,2EP<>N,U2T[0?"W]GPG4(HI+LKF5R[Y+'D]#5>"0P^%-
M7T?<&V[TM3G_ %BD<?Y-'UJA_.OO0>QJ?RO[B6[CMM,\ V=W:6L$-W/!%&9T
MC4/\P&3NQFMZT\):+%IB6TFGP2$H-\C("Y/<[NM9K+8W_@NVTN>Z2&=+>,<C
M.QU _K5*#Q9K=M;K9/IL$TR (MT)\(<=R,9H^M4/YU]Z#V-3^5_<69;&+6_%
MYTVZ!.GZ=;JR6^XX9N@)]>*6.^\*MK=K;)I;07:S!8G6V\L;@>.1UJ#499[?
M4H=<TRYMGNS"([JV.0LG?@^N:K2:K>:[K6ES75E'80V<PE=GFW[L>F!1]9H?
MSK[T'L:G\K^XT;2SAU_QAJ4VH(L\5BWDPPN,J/4X[UT=MI&FZ;<2W=K:Q6[L
MN',8VC ]AQ7)WMW+H^OSZII+17D-T!YUL6V-D=P2*+CQ+JFH:;>JUG%:[T"1
M1B7<^3U)/ QBCZS0_G7WH/8U/Y7]Q3N DPG\4"=!<Q78,:;QGR5^4@#WR3^%
M:GC6STZ3PA=:A#9VPFD\MQ,L2[SEAWQFHX?#WA#[ D<D<7G^7AI-[YW8Z]<=
M:H7,LMQ\/Y]*?YKJ-PD2Y'SH'!!_*CZU0_G7WH/8U/Y7]QI>(K>WT[P] EA;
M06LUV4A>6*,(VT]>16S%X2T.*RCM?[.@8(!^\*#>3Z[NM4-:^PZOX?6T6\CC
MN$"M&Q!X85G1>+];$:6SZ9 9A@-<F?Y#[[<9H^LT/YU]Z#V-3^5_<:7B407=
MUINA-(J02'S9LMC$:# 'XDC\JAT._.FZ)JUFLBR2::'>,@Y!7!*_RJE#:Z9K
M.L7U[KZ1N $CMU+MC !W$8]2:%M-+TS7T&G!5TV[@>"Z56/RY'!YH^M4/YU]
MZ#V-3^5_<+I5GI5GX>37-7M3?W%WAW9HO-/S=, ]*E35M(@\.:O>:#;O;2*<
M.K)LPY]NU4[+6-2\-1FPA@BU2T0_N727RV4>AR*DTB&.XT[6%U.:&!M2D9Q&
MI+%,^O'K1]:H?SK[T'L:G\K^XVM%\+Z4NBP?:+*&XFGC$DLLJ!F8L,GD\CK2
M^(C%I?AQ--L\0_:&%M$"WW0QYY/MFL.P\1ZSI=O'IIT^&^,>(XKA)]H([9!&
M:TIM'O-?U>S&MVB&T@MRSA&(1Y#Q@<YX%7"K"?P23]"90E'XE8;X>2#1M?N-
M)@E5K>>,30[6!PP^\*Z^N0U#PM#I=S8W^@V&V>&8&1$<_.G<?,:Z^K)"BBB@
M HHHH **** "N1UW_D?O#O\ NR_RKKJY'7?^1^\._P"[+_*A ==1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)9%A
MB>1R J DDT^FR1I+&T<BAD8893T(H Y;3?B#HE_)Y<DKVKYP/.& ?QZ?G741
M2QSQB2&1)$/1D8$'\:Y+5/AUI%[N>U#6DA_N?=_*N6E\+>*?#DAFTV:26,=X
M&Z_5:8'K-%>8Z?\ $F]M'\G5[,N5.&91M8?A79Z7XLT?5MJP7:+*?^6<AVM^
MM(#;HH!!&110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $
M<\\5M \\SA(T&68] *KV&J66J([V5PDRH<,5[&JOB?\ Y%G4/^N)KEOA9_R#
M;[_KJ/Y4 =_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %8^M>)M-T$QK=R_O)& $:<L!ZGVK"\5^.H=
M+W66G%9KSHS#E8__ *]87AWP;>:[<?VKK;OY3G<%8_-)_@* /3X98YX4EB8-
M&XRK#H13ZCAACMX$AA0)&@PJCH!4E !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<I\0O^1<B_Z^XOYUU=<I\0O^1<B_Z^XOYT =1#_J(_]T?R
MI],A_P!1'_NC^5/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4444 %%%% !1110 5R.N_P#(_>'?]V7^5==7(Z[_ ,C]X=_W9?Y4(#KJ***
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M %%%% !1110 4444 9/B?_D6=0_ZXFN6^%G_ "#;[_KJ/Y5U/B?_ )%G4/\
MKB:Y;X6?\@V^_P"NH_E3 [^BBBD 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $.<''6N4\$[6;6I9,?:FOY!)GK@8P/IUKK*YJ^\*S-J4FH
M:1JDFG3S?ZT! Z/[X/>@"/QX3_9-FC?ZE[V)9O3;SG/Z5TT0584"8VA1C'I6
M'!X:,FG75KJM_-?M<XW.P"A<9P5 Z=:HIX5UA4^S?\)-<?8N@C$(#@>F_.:
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MBY%_U]Q?SH ZB'_41_[H_E3Z9#_J(_\ ='\J?0 4444 %%%% !1110 4444
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M(7_(N1?]?<7\ZZNN4^(7_(N1?]?<7\Z .HA_U$?^Z/Y4^F0_ZB/_ '1_*GT
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M\0_AU'Z5LZ7\3XF(CU2T:-NADBY'X@]/UKT,@$8(R*Q=3\*Z/JP)N+1!(?\
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M^E7GAKQ@=9MXSY$LWGQR8X#'D@_C6S=?%.34M,^Q6&FS?VA,FPG@J,]2,<T
M<W\/T$?Q#M8U^ZKRJ/P5JTOBY_R,-K_UQ_K67\.PX\?V0?[X,F[/KL:NB^+N
MF3FXL]21&:$*8W8#A3VHZB/1/#/_ "*VE?\ 7K'_ .@BO%Y_^2G2?]?Y_G6_
MHOQ133O#UOI[V$LMU!&(HV4C:<# SWKD]/:Y?QO;R7B%+B2Z$DBD8(+'/]:!
MG4_%^YD;6;&V)/EI"7 [9)_^M4^A^,=3TO18+.U\'7$D*I@R*'Q)[_<K5^*7
MANXU*T@U2SC,CVP*RHHR2I[_ (?UK%\._%!-)T6.QOK*662!=L;H1R.V<T 8
M=I!JW_"8PZK!H5[:(;D2>6(7*H,\C.!Q7O=>;>$?&WB'Q%K/D_8HFM Q,DF"
M!&O89]:])H8!1112 *\0^*8W>,E7.,PH*]OKQ#XJ MXQ55^\84 IH#UO0=/M
MK'0+.VAB01^2I;C[Q(R2?6O%_$MNFC?$-OL8V*EPDB*O;D'%=)I7Q.DT;3%T
M[5-.F:[MU$:D$#( XSG\*P= L+[QMXT_M"6,B$3":9\?*H'(7\<8H ]-\6V_
MAJ>Q@G\12",*/W9#'=SZ 9_E7.1^/=$L])_LG1=)O;N*./RQ^[&&XZGOG\*R
M?BU:W:ZO:W#*QM/+VH>P/<5+IOQ$M8="M]+L=%;[?Y8A7:!M+=,^M &!\/F/
M_">6A"[,L_R^G!XK8^+W_(<LO^N)_G61X-$FG_$2VBO1Y<PE97![,0:U_B]_
MR'++_KB?YT".Y\$Z#I]MX5L7:TA>:6,2.[Q@G)^M>9^/9GO?B!+#*?D1TB4'
MH!Q7L'A?_D5]-_Z]U_E7G/Q/\.74.JC7;6)GA<+YI49V,.Y]N*!GJ2:;:)IH
ML%A06P3R]F.,8Q6+IW@_1O#K27]E;M]HCC8AW?)Z5QL/Q<5-&$,EC(;X1[ X
M8;"<8SZU'\-H-;U/5GOY[FX73D#%E9CMD9OX?Z_A0!A>#;6/7?'Z&_Q*"[RL
M&_B(!(KVS4+"UO=.EM9X4>$H1M(X'':O%M8T[4O GBT:C;PL8!(6BD(^5E/5
M2?I70:C\7$GTQHK*PECNG7:6<C:OTH Y_P"'\LEAX]6VB<^6S/$WN ?_ *U0
M:_\ \3/XE20W)RCW:1$?[.0,5TOPQ\*W0O#KU]&R)M(@#C!<GJWTK.^(VA7F
MD^)/[<MHV^SRNL@D4<)(.Q_*@1Z__9]I]A^Q&WC-MMV>7M&,5X1X=MUM?B-:
M6Z'*QWNT?@:ZP?%S=I@BCTZ0Z@5V@Y!3=Z^M<?X66=/']@MRK+.+L>8&Z@YY
MH&:OQ3N9)O&/D-EDAB157ZC/]:W+/QKJEMI<5C'X)N&MUC"X ?##'7[G>D^*
MGARZDN8M;M(V=%0)-M&2N.C?3_"HM-^+*6NBQV]S8227D2;%=2-K8Z$]Z ,7
MPE:ZM:>.+2\72;RVADF(8-"^U5;(.3CIS7N=<!X'\6:_XCO6%S9Q?8D!WS@%
M<'L!ZFN_H8!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **X7XB>+
M_P"Q+'^S[.0"^G7D@\QKZ_4UUFBR>;H6GR%MQ:VC)/J=HS0!>HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KD==_Y'[P[_ +LO\JZZN1UW_D?O#O\ NR_RH0'74444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R2*
M.:,QRHKHPP589!I]% '*:I\/]%U#<\41M)3WAX'Y=*XK5O"^L^$XWO;:^_<9
MVEXW*GGMBO8*\_\ B2][=+:V%K;RR1_ZR0HI(ST _P ^M,#R]F9V+,268Y)/
M>M'1M;O="O1<V<A'9T/W7'H14?\ 8VI_\^-Q_P!\&C^QM3_Y\;C_ +X-,1[1
MX=\2V?B"UWPMLG4?O(B>1_\ 6K;KP2RM-<TZZ2YM+:ZBE0Y#*AKUKPUXBEU>
M'R;VTDMKU!\P*$*WN#_2D,Z&BBBD 4444 %%%% !1110 4444 %%%% !1110
M 4444 >4?$S2_L^KQ:@BX2Y7#'_:''\L5S'A_3FU77;2T RK."W^Z.37K?C?
M2_[3\-3A5S+#^\3\.HKE_A?I>9+K5'7A1Y,9]^K?TI@>DHBQQJBC"J  /:G4
M44@"BBB@ HHHH **** "BBB@ HHHH **** "BBH+R[BL;.6ZG8+'&I9B: .8
M\>^(1I.E?9('Q=7(*C!Y5>Y_I7CG4YK2US59M<UB:\DR=YQ&O]U>PJ?3?"NL
MZH1]GLW"'^.3Y0*8C)AE,,R2J 2C @$9%>Y^&?$$&OZ6DT>$F0;98Q_"?\*Y
M/3?A<@VOJ5ZQ]8X1C]37:Z5H.FZ+&5L+98RP^9LDEOQ-#&:5%%%( HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *Y3XA?\BY%_P!?<7\ZZNN4^(7_ "+D7_7W%_.@#J(?]1'_ +H_E3Z9#_J(
M_P#='\J?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% $<UO#<QF.>))$/577(K,'A7P^K!AHM@&!R#]G7K^5:]% #(XHX8Q
M'$BHB\!5& *AO+"SU&'R;VVBN(LYV2H&&?H:LT4 5K+3K+38FBL;2&VC8[BL
M2!03Z\5%?:-IFIR+)?:?;7+J,*TT08@?C6+XI\<6'A=U@EB>XNF7<(D.,#W/
M:L_PU\1X?$>K+IZZ;) [ L&\T,,#KV% '8_8K7[']C^SQ?9MNSRMHV[?3'I4
M%CHNF:9(TEAI]M;.XVLT,04D>G%7J\YU/XKPZ;J=S9'2'D,$A3>)P,X]MM '
MH4]O#<Q-%/$DL;=5<9!JA'HNF:;!.]CI]M;,T9!,404GCVK@O^%R0?\ 0$D_
M\"1_\32-\8K=U*MHDA!&"/M(_P#B:8',^ _^2D6__72;_P!!:O=)(TFC,<B*
MZ,,%6&0:YOP]X;T "UURRTS[/<R*9%/G.VW<#GJ<=SVKIZ3 SK;P_H]E-YUK
MI=I#*/XXX5!_/%#Z!I$EY]L?3+1KDMN\XPKNSZYK1HH *S+CPYHMW,9;C2;.
M60]6>%23^E:=% $4%M!:Q"*WB2*,=%1< 5+169K^KC0M&N-1:$S"$9V!MN?Q
MH TZ*YCP?XQ3Q:+PI9-;?9MF<R;]V[=[#^[68_Q)B3Q2NB?V6Y9KE;?S?.&.
M2!G&/>@#NJH7>AZ5?W N+O3K6>8  221!FXZ<FK]% %"\T72]0V_;-/MI]@P
MOFQ!L#\:LVUK;V<(AMH8X8QT2-0 *FHH CGMX;F)HIXDEC;JKKD&J=GH6DZ?
M*9;/3;6WD/5HH@I_2M"B@#-?P_H\MY]KDTNT:Y+;O-,*EL^N:??:+I>I2+)?
M:?;7+J,*TL08@?C5^B@!D,,=O"D,,:QQH,*BC  ]J<0&!! (/4&EHH RF\,Z
M$TWG-I%B9,YWF!<Y_*M-(TB0)&H51T & *=10 R6*.:,QRHKH>JL,@UG0^&]
M$MYA-#I-E'(.CK H/\JU** "F211S1M'*BNC#!5AD&GTUW6-&=V"JH)8GH!0
M!0M=!TBRF\ZUTRTAE_OQPJIH70=(6]^VKIEH+K?O\X1+OW>N?6J.F>+M-UC6
MY=-L&:8Q1EVE'W>H&!Z]:WZ $(!&",@UER>&M#FF,TFD63RDY+M I.?KBM6B
M@!D44<$8CB141>BJ, 4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK&\3>(;?PYI$EY,09,8BCSR[5J75S#9VLES<2".&-2SL>P%?/GC#Q--XFUAI
MLE;6,[8(_0>OU- &1J.H7&J7\U[=R%YI6W,3_+Z5]$>%7\SPMIK8Q^X4?EQ7
MS;7T1X%D$G@K2V!)_=D<^S$4V(Z&BBBD,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD==_P"1^\._
M[LO\JZZN1UW_ )'[P[_NR_RH0'74444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 UT$D;(PRK#!JGI.EP:/8+
M:6_W S-G'7)S_P#6_"KU% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW8R,X'K7EGPFBCF\1W2RQHX%L3AES_$*M?%N_D.I6>F)\L$<>_:.!D__ %J
M-&\^,4"3E;/27FB'\4LVPG\ #6_X:^(FE^()Q:NKVEVWW4D.5;V!]?KBK/A'
MPUIVF^';3%M&\T\*R2NZ@DEAG^N*\U^(^D0:#XE@N-/7R!,GF!5XVL#U'Z4
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MP(RVY<5[!7D_B^=_$'C6'3(#E8F$(QZYYIH#EAX U^73(;^WMEGAE7>%1_F
M]P?Z5Z[X#@N+;P=96]U$\4L>Y2CK@CYB?ZUT$$*6UO'!&,)&@11[ 8J2E< H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KD==_Y'[P[_NR_P JZZN1UW_D?O#O^[+_ "H0'744
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<I\0O^1<B_Z^XOYUU=<I\0O^1<B_Z^XOYT =
M1#_J(_\ ='\J?3(?]1'_ +H_E3Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH @O+=;NRFMW^[*A4_B*\*TJ[N_A_XPD-U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!1UC44TG2+F]D(_=(2H/=NP_/%>??#G3WOM7NM8N,L4)"D]V/6I_B9J
MY=K?1X#DD^9(!^@_SZ5V'AC21HV@VUJ0/,V[I#_M'K3 V****0!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7(Z[_ ,C]X=_W9?Y5UU<CKO\ R/WAW_=E_E0@.NHHHH ****
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M:?EV'_/0_G1Y=A_ST/YT[KL+WN_XF9]HO_\ GYG_ ._I_P :/M%__P _,_\
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M:C_S\W'_ ']/^-:<,.F*GRR-@^]2>7IO_/1OSK:*5CR<3.4JC2>B,C[1J/\
MS\W'_?T_XT?:-1_Y^;C_ +^G_&M?R]-_YZ-^='EZ;_ST;\ZK0Y_>[F1]HU'_
M )^;C_OZ?\:/M.H?\_-Q_P!_3_C6OY>F_P#/1OSJO>)9B#]R[%R<#FC0/>[E
M2*YN\9:ZG.>WF'_&NF\,ZW*+I;&ZD9UD_P!6S'[I]/QKF*57>-EDC.'4[E/H
M12<4T73JRA)2/5Z*AM)Q<VD,R])$#"IJP/;3NKA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5RGQ"_Y%R+_K[B_G75URGQ"_Y%R+_K[B_G0!U$/^HC_W1_*GTR'_ %$?
M^Z/Y4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BLK5O$>DZ&T::C>)"T@RJD$DCUP*S?^%@^%_^@HO_ '[;_"@#IZ*Y
MC_A8/A?_ *"B_P#?MO\ "C_A8/A?_H*+_P!^V_PH Z>BN8_X6#X7_P"@HO\
MW[;_  H_X6#X7_Z"B_\ ?MO\* .GHKF/^%@^%_\ H*+_ -^V_P */^%@^%_^
M@HO_ '[;_"@#IZ*YC_A8/A?_ *"B_P#?MO\ "C_A8/A?_H*+_P!^V_PH Z>B
MN8_X6#X7_P"@HO\ W[;_  H_X6#X7_Z"B_\ ?MO\* .GHKF/^%@^%_\ H*+_
M -^V_P */^%@^%_^@HO_ '[;_"@#IZ*YC_A8/A?_ *"B_P#?MO\ "C_A8/A?
M_H*+_P!^V_PH Z>BN8_X6#X7_P"@HO\ W[;_  H_X6#X7_Z"B_\ ?MO\* .G
MHKF/^%@^%_\ H*+_ -^V_P */^%@^%_^@HO_ '[;_"@#IZ*YC_A8/A?_ *"B
M_P#?MO\ "C_A8/A?_H*+_P!^V_PH Z>BN8_X6#X7_P"@HO\ W[;_  H_X6#X
M7_Z"B_\ ?MO\* .GHKF/^%@^%_\ H*+_ -^V_P */^%@^%_^@HO_ '[;_"@#
MIZ*YC_A8/A?_ *"B_P#?MO\ "C_A8/A?_H*+_P!^V_PH Z>BN8_X6#X7_P"@
MHO\ W[;_  H_X6#X7_Z"B_\ ?MO\* .GHKF/^%@^%_\ H*+_ -^V_P */^%@
M^%_^@HO_ '[;_"@#3U[0+3Q%I_V*]:58MP;,3 '(^H-,\/\ ARR\-63VMBTS
M1N^\F5@3G\ *S_\ A8/A?_H*+_W[;_"C_A8/A?\ Z"B_]^V_PH Z>BN8_P"%
M@^%_^@HO_?MO\*/^%@^%_P#H*+_W[;_"@#IZ*YC_ (6#X7_Z"B_]^V_PH_X6
M#X7_ .@HO_?MO\* .GHKF/\ A8/A?_H*+_W[;_"C_A8/A?\ Z"B_]^V_PH Z
M>BN:C\?>&9)%C34T+,0H&QNI_"ND!! (Z&@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JO>W<5A8S7<QQ'$A8U8KSCXD:XTCPZ':DL[$-+M]?X5_S[4 9OA2T
ME\3^,9=5NEW0POYISTS_  C^OX5ZS6%X3T1=#T.*$C]_(-\I]_2MV@ HHHH
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MIO[HJ"B@5B?[4W]T4Y)3*X! &*K5-;?>:F%BS1110!W_ (7G,^A0[CS&2GX
MX%;-<]X./_$I<>DIKH:YY;GMT7>G%A1112-0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE/B
M%_R+D7_7W%_.NKKE/B%_R+D7_7W%_.@#J(?]1'_NC^5/ID/^HC_W1_*GT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67KVMV^@
MZ8]W.<MTCC'5V[ 5<O;VWTZSEN[J01PQ*69C7'Z+93^*]77Q#J<96SB/^@VS
M=,?WR/6@# ?2;UO$WA[5=:^:\U&Z;= ?NQQA1M7'XUZ9_96G_P#/G!_WP*YS
MQ7_R-/A/_K[D_P#01774P,>Y_L2SF\J>"W5\9QY8JS#8:9<0K+%:0,C#(.P5
MS'BG_D,?]LU_K73:)_R![;_<%>5AL=.KBZE!I6B=E;#QA1C46[*UPVA6LS0S
M0VZR+U'EBIVM=)2U^TM;0"'&[=L'2N6\2?\ (<G^B_\ H(KH+O\ Y%$_]<5_
MF*SI9C4G4K1:7N7M\BYX6$8TW?XK#/M7A[_GG;_]^Q5NUM](O4+P6T#J#@GR
MQ7!5U_A+_CQF_P!^N?+\VK8FNJ<TK&F*P4*5-SBV:%S::5:0^;/:P*F<9V"H
MK9=%O"X@@MVV#+?NQQ3/$_\ R!F_WUK)\+??O/\ KF/ZUUUL=4AC8X=)6:_S
M_P C&GAXRP[JO=&D;GP\"08[?(_Z9BKL%EI=S"LL5K R'H=@K@I?]:_^\:[G
MP_\ \@:'\:PRW,ZN*K.G-))(TQ>$A1IJ466/[+T\#/V.#_O@5G-<>'U8J8[?
M(.#^[%;C?<;Z5YI/_P ?$O\ OG^=;9ICZF$47!)WON9X/#1KWYNAUWVKP]_S
MSM_^_8J4-H36[3B&W\M2 6\L=:XBM:'_ )%NZ_ZZK7G4,[KU&TTM$W]R.NIE
M].*5F]T=):)HMZS+;V]NY49.(Q5O^RM/_P"?.#_O@5SOA'_CZN?]P?SKK:]K
M+\3+$T%5EN[GGXFDJ51PB9\]CIEM"TTMK J+U.P51^U>'O\ GG;_ /?L5<U_
M_D!W7T'\Q7 UP9GF=7"55""3NKZ_,Z<'A(5H.4GU.]M;?2+U"\%M Z@X)\L5
M8_LK3_\ GS@_[X%97A/_ (\)?]^N@KT\'6E6H1J2W9R5Z:IU'!=#$,N@"8Q&
M*WWAMN/+'6G3MH5M*8I8;=7'4>6*Y23_ )##?]?!_P#0JGU__D+2?05X;SFL
MJ<IV6CM^?^1Z"P%/G4;O57-_[5X>_P">=O\ ]^Q4S?V(MJER8+?RG.%;RQS7
M#UMW'_(IVG_71OYFE0SJO44VTM%?\4.I@*<7&S>KL:_VKP]_SSM_^_8J>U71
M;V0QV\%N[ ;B/+'2N&K?\)?\A.;_ *XG^8IX/.:U:O&G)*S%7P%.G3<TWH=-
M_96G_P#/G!_WP*J74>C63*MQ;VZ%AD9C%:U<GXN_X^;?_<_K7LX_$RPU!U8[
MHX<-256HH2-NVM-*NXO-AM8&3.,[!4W]E:?_ ,^<'_? JCX8_P"0.O\ OFMF
MM<-5=6C&H]VKF=:"A4<5T,1IM 24QM%;A@<$>6*O_P!EZ>!G['!C_<%<-=?\
MA63_ *Z_UKT-O]4W^[7%E^.J8EU%-+W?^"=&*P\:2CR]3&270))1$L5N7)P!
MY8K0_LK3_P#GS@_[X%<-8_\ (6B_ZZ5Z)3RS&SQ<9.:M9AB\/&BTH]3'N?[#
MM)O*G@MU?&<>6*A^U>'O^>=O_P!^Q6-XH_Y#)_ZYK6-7F8K.J]*M*G%*R9UT
M<!3G34FWJ=];VVDW4!FAMH&C&>=@IEK%HUXSK!;V[E/O?NQQ5;P[_P @%_JU
M5/"?_'S=_A_,UZ4,=4E*@FE[Z=_N.26'BE4?\IG?$.RM;?1;1X;>.-OMD8RJ
M@'K7<1_ZI/\ =%<=\2?^0%:?]?D7\Z[&/_5)_NBO4.,=1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444C,$4LQ 4#))H SM=U>+1-)FO)2,J,(O]YNPKSWP1I$VNZ[-K
ME\-T<;E@3_%(?\!_2H/$6HW'C+Q-%IMB2;6)MB8Z'^\QKT[2M-ATG38;* 82
M-<$^I[FF!=HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(Z[_R/WAW_ '9?Y5UU
M<CKO_(_>'?\ =E_E0@.NHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X'QFI&LJW8
MQ ?J:[ZN$^(+FWELI0F=P92<_3%=&%_B(Y,<OW+9S-%4/[1/_/,?G1_:)_YY
MC\Z]2S/#NB_15#^T3_SS'YT?VB?^>8_.BS"Z+]%4/[1/_/,?G1_:)_YYC\Z+
M,+HT**SSJ3 9\H?G3?[3;_GD/SKR<0K5&>]A'>C$TJ*S?[3;_GD/SH_M-O\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<CKO_(_>'?\
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M)%_SP7_OFL37-'#XN8H <## +^M;T)VE9]3"O"\;KH<52JVUU;T.:U/LZ?\
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MUK)\+??O/^N8_K6MXG_Y S?[ZUD^%OOWG_7,?UKTL5_R-8>GZ,Y*/^YR]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML-H>MK!_W[%3!0JA5  '0 4M% 62"BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<I\0O^1<B_Z^XOYUU=<I\0O^1<B_Z^XOYT =1#_J(_\ ='\J?3(?]1'_ +H_
ME3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*XN(K2WDN)Y!'%&
MI9V;H * *NL:O:Z)ILM]=MB-!PHZL>P'O7.^&=)NM1OV\2ZTF+J4?Z- >D"=
MOQJKIMO+XUUE=8O8V32+9O\ 0X&_Y:D?QD>E=WT&!0 4444 %%%% '(^*_\
MD:?"?_7W)_Z"*ZZN1\5_\C3X3_Z^Y/\ T$5UU '$^*?^0Q_VS7^M=-HG_('M
MO]P5S/BG_D,?]LU_K73:)_R![;_<%?/X#_D8UOG^9Z>)_P!UIG*>)/\ D.3_
M $7_ -!%=!=_\BB?^N*_S%<_XD_Y#D_T7_T$5T%W_P BB?\ KBO\Q7/A_P"-
MB_27ZFM7^'1^1Q5=?X2_X\9O]^N0KK_"7_'C-_OUQY)_O:]&;YA_ 98\3_\
M(&;_ 'UK)\+??O/^N8_K6MXG_P"0,W^^M9/A;[]Y_P!<Q_6O2Q7_ "-8>GZ,
MY*/^YR]?\C!E_P!:_P#O&NY\/_\ (&A_&N&E_P!:_P#O&NY\/_\ (&A_&N3(
MO]YEZ?J;YC_!7J:;?<;Z5YI/_P ?$O\ OG^=>EM]QOI7FD__ !\2_P"^?YUT
M\0[4_G^AEE>\OD1UK0_\BW=?]=5K)K6A_P"1;NO^NJUX>$^*7^&7Y'HUMEZK
M\R[X1_X^KG_<'\ZZVN2\(_\ 'U<_[@_G76U]7DO^YQ^?YGB8_P#COY&;K_\
MR [KZ#^8K@:[[7_^0'=?0?S%<#7C<0?[Q'T_5G?EG\)^O^1V'A/_ (\)?]^N
M@KG_  G_ ,>$O^_705[^6?[I3]#S<9_'D>=R?\AAO^O@_P#H53Z__P A:3Z"
MH)/^0PW_ %\'_P!"J?7_ /D+2?05\E+^!4_Q+]3VU_$CZ?Y&96W<?\BG:?\
M71OYFL2MNX_Y%.T_ZZ-_,U.#^&K_ (7^:'7WAZ_HS$K?\)?\A.;_ *XG^8K
MK?\ "7_(3F_ZXG^8JLL_WNGZBQ?\"1V-<GXN_P"/FW_W/ZUUE<GXN_X^;?\
MW/ZU]1G/^YR^7YGCX#^.C3\,?\@=?]\ULUC>&/\ D#K_ +YK9KIP'^ZT_1&6
M)_C2]3SJZ_Y"LG_77^M>AM_JF_W:\\NO^0K)_P!=?ZUZ&W^J;_=KR<D^*MZ_
MYG;F&U/^NQY[8_\ (6B_ZZ5Z)7G=C_R%HO\ KI7HE5D'\.?J+,_BCZ'$>*/^
M0R?^N:UC5L^*/^0R?^N:UC5\_F'^]5/5GI8;^#'T.R\._P#(!?ZM53PG_P ?
M-W^'\S5OP[_R 7^K54\)_P#'S=_A_,U[U+X\)Z/\CSI_#6]5^95^)/\ R K3
M_K\B_G78Q_ZI/]T5QWQ)_P"0%:?]?D7\Z[&/_5)_NBOH3RQU%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115
M+4M6L=(MC/>W"1*.@)Y;V [T 72<#)KA_%/CR&P#V6EE9KH\&0<JGT]36!J_
MBW5O%%R=.T:"5(7.,+]YA[GL*Z/PQX#M]+V7>H[9[OJ%ZJG^)I@8GAGP5=:K
M<_VKKI<HYW"-S\TGN?0>U>F1QI#&L<:!$4855& !3Z*0!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5R.N_\C]X=_P!V7^5==7(Z[_R/WAW_ '9?
MY4(#KJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]+;[C?2O-)_^/B7_ 'S_ #KIXAVI_/\ 0RRO>7R(ZUH?^1;NO^NJUDUK0_\
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MS72T4 <?_9'C3_H8[?\ \!%H_LCQI_T,=O\ ^ BUV%% ''_V1XT_Z&.W_P#
M1:/[(\:?]#';_P#@(M=A10!Q_P#9'C3_ *&.W_\  1:/[(\:?]#';_\ @(M=
MA10!Q_\ 9'C3_H8[?_P$6C^R/&G_ $,=O_X"+7844 <?_9'C3_H8[?\ \!%H
M_LCQI_T,=O\ ^ BUV%% ''_V1XT_Z&.W_P# 1:/[(\:?]#';_P#@(M=A10!Q
M_P#9'C3_ *&.W_\  1:/[(\:?]#';_\ @(M=A10!Q_\ 9'C3_H8[?_P$6C^R
M/&G_ $,=O_X"+7844 <?_9'C3_H8[?\ \!%H_LCQI_T,=O\ ^ BUV%% ''_V
M1XT_Z&.W_P# 1:/[(\:?]#';_P#@(M=A10!Q_P#9'C3_ *&.W_\  1:/[(\:
M?]#';_\ @(M=A10!Q_\ 9'C3_H8[?_P$6C^R/&G_ $,=O_X"+7844 <?_9'C
M3_H8[?\ \!%H_LCQI_T,=O\ ^ BUV%% ''_V1XT_Z&.W_P# 1:/[(\:?]#';
M_P#@(M=A10!Q_P#9'C3_ *&.W_\  1:/[(\:?]#';_\ @(M=A10!Q_\ 9'C3
M_H8[?_P$6C^R/&G_ $,=O_X"+7844 <?_9'C3_H8[?\ \!%H_LCQI_T,=O\
M^ BUV%% ''_V1XT_Z&.W_P# 1:/[(\:?]#';_P#@(M=A10!Q_P#9'C3_ *&.
MW_\  1:/[(\:?]#';_\ @(M=A10!Q_\ 9'C3_H8[?_P$6C^R/&G_ $,=O_X"
M+7844 <?_9'C3_H8[?\ \!%H_LCQI_T,=O\ ^ BUV%% ''_V1XT_Z&.W_P#
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MXT_Z&.W_ / 1:["BD!Q_]D>-/^ACM_\ P$6C^R/&G_0QV_\ X"+7844 <?\
MV1XT_P"ACM__  $6C^R/&G_0QV__ ("+7844 <?_ &1XT_Z&.W_\!%H_LCQI
M_P!#';_^ BUV%% ''_V1XT_Z&.W_ / 1:/[(\:?]#';_ /@(M=A10!Q_]D>-
M/^ACM_\ P$6C^R/&G_0QV_\ X"+7844 <?\ V1XT_P"ACM__  $6C^R/&G_0
MQV__ ("+7844 <?_ &1XT_Z&.W_\!%H_LCQI_P!#';_^ BUV%% ''_V1XT_Z
M&.W_ / 1:/[(\:?]#';_ /@(M=A10!Q_]D>-/^ACM_\ P$6C^R/&G_0QV_\
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M\:?]#';_ /@(M=A10!Q_]D>-/^ACM_\ P$6C^R/&G_0QV_\ X"+7844 <?\
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M^_705[^6?[I3]#S<9_'D>=R?\AAO^O@_^A5/K_\ R%I/H*@D_P"0PW_7P?\
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MBW\J\^^%G_'SJ/\ NK_.O0=3_P"07=_]<6_E7GWPL_X^=1_W5_G3 ]+HHHI
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M]+;[C?2O-)_^/B7_ 'S_ #KIXAVI_/\ 0RRO>7R(ZUH?^1;NO^NJUDUK0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH JZG_R"[O_ *XM_*O/OA9_Q\ZC_NK_ #KT'4_^
M07=_]<6_E7GWPL_X^=1_W5_G3 ]+HHHI %%%% !1110 4444 %%%% !1110
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MDOU-:O\ #H_(XJNO\)?\>,W^_7(5U_A+_CQF_P!^N/)/][7HS?,/X#+'B?\
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M\@*T_P"OR+^==C'_ *I/]T5]">6.HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-W^'\S7NTOCPGH_R/.G\-;U7YE7XD_\ ("M/^OR+^==C'_JD_P!T5QWQ)_Y
M5I_U^1?SKL8_]4G^Z*^A/+'4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 5=3_ .07=_\ 7%OY5Y]\+/\ CYU'_=7^=>@ZG_R"
M[O\ ZXM_*O/OA9_Q\ZC_ +J_SI@>ET444@"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF/&OBT_\M]/_ ._)IX\8^+C_ ,O&G?\ ?DUBYP:E1J;QU;N0\14-=?%WB]F
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M '(_9?'W_02T7_OT_P#A1]E\??\ 02T7_OT_^%==10!R/V7Q]_T$M%_[]/\
MX4?9?'W_ $$M%_[]/_A7744 <C]E\??]!+1?^_3_ .%'V7Q]_P!!+1?^_3_X
M5UU% '(_9?'W_02T7_OT_P#A1]E\??\ 02T7_OT_^%==10!R/V7Q]_T$M%_[
M]/\ X4?9?'W_ $$M%_[]/_A7744 <C]E\??]!+1?^_3_ .%'V7Q]_P!!+1?^
M_3_X5UU% '(_9?'W_02T7_OT_P#A1]E\??\ 02T7_OT_^%==10!R/V7Q]_T$
MM%_[]/\ X4?9?'W_ $$M%_[]/_A7744 <C]E\??]!+1?^_3_ .%'V7Q]_P!!
M+1?^_3_X5UU% '(_9?'W_02T7_OT_P#A1]E\??\ 02T7_OT_^%==10!R/V7Q
M]_T$M%_[]/\ X4?9?'W_ $$M%_[]/_A7744 <%J?AOQ?K<4,&H:AI1@CF64B
M-'!X/TKO%&U%'H,4M% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!5U/_D%W?_7%OY5Y]\+/^/G4?]U?YUZ#J?\ R"[O_KBW
M\J\^^%G_ !\ZC_NK_.F!Z71112 **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "N9\0:29+Q;J-?W4R^5<^@7LWX'G\*V;_5+33H]T\GS'I&O+
M'Z"L.VUJ\U&YFM6:.W,JD0@(7*_[_:N+%SHR7LI;G;A858OVL=C:TVYMOL4,
M27J3E4"[RW+>]<=KMXUYJLS?PQG8H]A_G-3WFE7=F'NKRQLR/^>EN[(P/8^G
MZ5C9).2<DUY^)KSE!4Y*UO7^OS.3,(PBUR2O?7I_7Y$D0^;-65J&/@5,M<\-
MCST3"G%N*C%-+54I61HB0'FIDJNIJ=#6<7J6BRM2K4"FI@:Z8%#Z*3-+6H!4
M;T\FHF-92&1-5=^M3,:@<US3)9 ]0-TJ9JA:N:0B%Z@:IGJ!JR6Y+&-TJ$U*
MU1-6L3)D+5$W6I6J%JZ(F4B-J5&YI&I@/-:6T,F7E/%6;9RLF.QJE&>*G!((
M([5BU9C3LS6BD,4R2#JC!A^%>E6TRW%M',ARKJ"*\Q4[E!]17<^&+GS]*$9.
M6B.T\=NU>CEM2TW#N=U"6MC:HHIBS1M,T2L"Z %@.V:]FYTV8^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI?/^O^&-#M1117H'GA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 5=3_ .07=_\ 7%OY5Y]\+/\ CYU'_=7^=>@Z
MG_R"[O\ ZXM_*O/OA9_Q\ZC_ +J_SI@>ET444@"BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0!Z+]NM/^?J#_OX*/MUI_P _4'_?P5YU_P *POO^@I'^34?\*POO^@I'^34
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#^%:]M:PVD0B@38@[5V4/K%VZMK?U_6Y=?ZO9*E>_P#7];$U%%%=1RA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g0vsdaj33nnl000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0.!* # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 3-+65-K,<.OV^E%29)HV<-["M44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX:7;I+$JRY?:<'I6K:S_ &BUCE(P74'%5RM*XKZV+%%-S2U(Q:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD@D.< \@UU7_  G]B4W""0>V:SK0Y9>IS4H2FK1.N>18U+.P51U)I5=74,C
MJ>A%>?WWC1-1TJ>W-N\<C@@$'C%2:/XPM[#3X[>:)RR]2#UKFE449<K.N."J
MRI\Z1WU%<C_PGEE_SQDH_P"$\LO^>$E/VD>Y/U.O_*==17(_\)Y9?\\9*/\
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M6N#\!1^+DGNO^$D8%,#RL'\Z[R@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ./O_\ DI6F?]>TG\J["N/O_P#DI6F?]>TG\J["@ HHHH ****
M"BBB@!*RM;T.'6H%CF=EVG(P:U:*35T3**DK,\DO/#8MO$$6GB0E9#][TKO=
M%\,6NC2F6)W9R,')XJ#Q/=6VE!+\VZO.#A6/:J.E^.H;NXC@FA*,QP#6$8PA
M*QP4X4:%1KJ=F**3<-N[MC-<O>>-[&UNI("K$H<$ULY*.K.V=2,%[S.HH[5C
M:-XEL]9=HX<B11G!]*TKRZCLK22YE/R1KDTTTU=#52,HW3T))9%B3<[  >M>
M=:WK6OO>R) KK$#\I0=12^(?%T&IZ;]G@#HQ/7-;>@>(--?3;>&:11,J[3N'
M>G2Q$(S[G*\3"<^1,XS^U_$%LI=I)E7N2*ZCP5KUYJ%Q-;W<ID(&02*U/$.H
M:1#;?9;L[?-7@JM<5H.J66BZQ/,&9H=N$]37?I5@VHZEWY9;GK%0B\@:X-N)
M5,H&2M<6?B+#D@6A_.L&R\3"'Q+)J,D;>7(-I7/2L(X:;O<T=5'K-%9FDZW9
MZNC&U8G;][(K3K!IIV9JG=!1BEI*0PH(HHH K_8;?>[^4NYQACCK3X;>*VC\
MN) J^@J:DI60^9O0CFACGC*2*&4]0:6*%(8Q'&H51T I]%%@N]@I'4.I5@"#
MU%+13$10VT5NNV) @)Z"I:**+ WW(1:0B?SQ&OF8QNQ4K*&4J1D'J*6BC0=V
M4TTNS0J5@0;3D<=ZGEMH9P!+&KXZ9%2TM*R'S2>[*TUC;SA1)$C8'&5J*'2K
M.!F:.!5+<'BKU%%D'M))6N5/[.M?*,7DIL)R1BGM9V[A T2D)]W(Z5/2T6#F
MD026D,I4R1JQ7[N1TI'M())5D:-2Z?=..E3T460N9]PQ4/V2'[1Y_ECS/[V*
MFHI@FT%!YI:2@1##:00.SQQJK-U('6IJ**!W;$90RD$9!ZU%!:PVRL(8P@)R
M<"I^U%(+NUB VD+3B8QJ9!T;'-59M%L9I3));J6/4D5HTE%AJ<EU(K>VBMHQ
M'$@51V%2XHI:+$MMZLJ7>GVUZH6XB#@>M00:'86TPEB@4..AK1I:+)EJI)*R
M9FRZ'I\\QE>W4N>^*R?$&A0-I;+:VP\P=-HKIZ"*3@F7"O.#3N>767A^\S*)
M;<_<R,TZ+P]=?V1*[6Q\T-QZUZ=MHQ62H1.UYI5>IY_I>E7-OHMQ(;,-.3A0
MP[5S-Y9W-L^Z>(Q[C7LV.,5Y_P"(M&U:5Y)Y&$D"$D>PK.K22CH=&"QSE5?/
MU*NA^(KZ );1HA1>I/I4LGC>_65PJ)@$@5SMI;W-Q(RVX.X#G'I4!!#,#U!P
M:Q]K-)'I_4Z$ZC;1WFA^*[B^G=+D(H"Y!K.N/&U_'<R(J)M5B!7-VEO<7$A6
MW#;@,G!J!PRR,K?>!YI^VG8B.7T/:/\ (ZVW\;7LDX5D0+BF/XWOAD"-,YKE
M45F;"CF@@@X/:E[:1I_9^'OL=]X>\3W6IZAY$ZJ%QG(KL <UXK;7,UI,)87*
M..XKK=(\5&SA)O9VF9N0OI6]*M=6D>7CLNE&7-36AWU+6#I'B6WU6>2)%*E!
MGGO4R^(;1IKF/G, RU="DK7/)="HG9K4UZ*YN/QC8.I)W#YL 5/?>*+*QDC1
M\_. >.PHYT5]6JWM8WLTF:YJ7QGI\;,/F..G%%MXSL)G93E,#.32]I':X_JE
M:U^4Z7-%<N/&U@9@N&VD]:Z6.19(U=3PPR*:DGL14HU*?Q*P_O161J6OVVFW
M,<$V<OW':LR3QO8K(5"L0#UH<XK=E0PU6:O%'545RG_"<V6?N-5^?Q-9PV"7
M?S%7Z"ESQ[CEA:T='$W**YN/QA926TDWS#9V]:OZ5KD&JVS3(I7;U!IJ:9,J
M%2*NT:M%8%MXKLKJ_%JF[). :EL_$EI>:BUG'G>.]',@>'J+=&U1FJ6HZE#I
MEHUQ-G:/2DTS4X=3M1/%TS@YIWUL1R2Y>;H7J,U0U'58--1&FS\S8&*9?:S;
M6$,4LA.V0C&/>BZ!4Y/9&E14:R*T?F?PD9K E\7V45\;9@V5;:30Y);CA2G/
M2*.DI*SM1UFWTZW2:4G:YPN*FN+^*VLFNG/[L+NHNA>SEV+>:,UC-XAM5TU;
MTY\MCBM.WG2X@25#\KC(HN@E3E%7:)J*KW=U':6SSR'"H,FLK_A*+,QP.NXB
M5MHHYDMPC3E)72-VBLW4-9M].2)IB?WAP,5H*X90P[T7$X22NQ]%)N%%,D6B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)\3Q//X7
MU.*)"\CVTBJHZDE37,_"BQN].\')#>0/#*'/RN,&NQU.]73M+N;UT+K!$TA4
M=\#->5CXZV(Z:/,/^!__ %J /7J*\B_X7M9?] >;_OO_ .M1_P +VLO^@/-_
MWW_]:@#UVEKC/!7C^#QE-<)%9/;F$ DLV<Y_"NSH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#C[__ )*5IG_7M)_*NPKC[_\ Y*5IG_7M)_*N
MPH **** "BBB@ HHHH 2BBEH SM5TBWU>W\FX'R@Y&.U8UOX'T^VN4F5G)0Y
M )KJ:*EP3=V92HPD[M:B!0%"]@,5S-[X)T^\NGG8LK.<G%=/11**EHQSIPFK
M21A:-X8M-&N&GA+%V&.:U;VTCO;22WE^Y(N#5BBFHI*R'&G&,>5;'G/B3PE:
M:5IIN(&<OG&#6OH/A73VTZVN9(LRL-V3ZUU<L,<Z;)%#+Z$4Y$6- JC"CH!4
M*E%.YA'"TXSYDC&U?PW9ZML\T$%!@$5QVF^';<^)9K.:)V@4?*2*],IOEH&W
M!1N/>NB%1PV-72BW<Y2\\&:3%9S2!""J$@UYM#:375P8K>)I&ST4=J]QFB6>
M%HGY5A@UC6/ANPT:62\@5BVT]33CB*D97,JE)\R:V'Z%96ND:5"71(9&0>83
MQDXK26^MG;:LZ%CVS7F7B;Q.-86.**-HA&QR=W6N>BN9HYE99&!!&#FKIQA6
MN^;42Q,+\J/=_>EJCI4S3Z7;2N<LR FKHK!JSL=2=T+1112&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 )4-S"MQ \1Z,"#4U% TVG='-Z-X873+N6<R[
M]XP!CI6;<>!O,N9)%N<!V)QBNVQ14<D7H=$<76C+F3.8T;PJNF3/(TQ?<,8Q
MTJA<>!C+=O*+@A68G&*[;%%+V<;6L4L964N:^IQD7@A8K@2+<'8!TQ67K/A2
M:SB$D :9F8Y '2O1Z0J".12=&-BX9A74N9L\4F@EMGV31LC>A%1FN[\6Z+>7
MMVDMK"'4#!QUK$F\(:G&BLD8;(R1GI7'.A)/0]^AF%*<$YNS,K3[^XL)C);'
MYB,&D^WW(DF<-\THP]=7X5T&ZM[R62[M]J[<#<*D_P"$;G^VZ@[0H4D7]U]:
MM4I\IA/&T%5>APX8C!!/!S4US=373JTV<JN!]*W(?"FI;/FA4,K#J:NZSX:O
MI[B%H(EVA &YQSBI]E*QJ\;0<T<@6)/-)]*Z.7PCJA8E8EZ>M0KX2U7G,2\#
MUJ72F;QQM!K=&%TY]*W8_$NJQJBJQVJ, 8I(_">JLRY@ &>YKTBVL88[:-&B
M7<%P>*TI4Y^APXW&4$EHI'D^H:C<ZA.)+ACN XJG7<^)?#5Q>:@DEG$NPC#=
MJPSX2U;<1Y*]?6HG2G<Z</C*'LULC"JS)>SR6J0,W[M#Q6G_ ,(GJ_\ SP7\
MZUKCPQ>?V+%"D2F8'+<THTIV'5QE"ZU3..#,%*@G!ZBKUCJEY8Q/' Q"L.:T
MU\*:F+23,*[B1@9KH?#NA2VVFS"YA42/T!%5&E.YGB,;0Y.C.!@N)8+A9HR?
M,!R,5+:7MQ:WGVF%CYN:Z'2?#%\NL+)<0A8D;.3WJUHWAJ[MM=,UQ$OD@G!I
MQI2(GC:%GIT.>OM<U"^M_(N&)0G/(I+#6K^Q@,-LQ"YSTKO/$NBF^TPI:Q+Y
MH((IOAG1FL; I=Q+YA;/K6GLI\^YR_7:'L?@^1PNH:S?7P07#'"G([5'=ZK>
M7<423,=L?W:[OQ)H37R0M;1+N1P2/:H]<T*2YLK5+>)=R%=U$J4]=2H8ZA:/
MNG+IXGU581&"2H&,XK%>:22<RL<R$Y)]Z]>AT^!+-8S$N0N.E<)-X8OVUIML
M $)?(/;%*=*>A>&QM"\O=L9-]JU[?0I'<$[4.5J:;7=1GL_L[D^61CIVKL/$
MFA37EG;I:1+N4_-VJ[J&E>=HC011)YQ3 X[XI^RGW,_KM&T?=6YYLU_<M8K:
MDGR0<BK\/B+5(K=8HV.Q1@$"N@E\.W3^'([81+YX;)^F:Z33-,BMK"*)XUWA
M>>*(TI7W"MC:'+\-]3SFY\0ZG/;-!,[;&ZY%9PN9E2, G"'*UZEK.DQW>FRQ
M11+YA'R\=ZY=?#%ZL%FIB4LCY?GM2G2E?<JACJ')\-CGK[5;V]$0N"?D^[6A
M%XIU9(U4$D >E=+XAT*:[6U^RQ)\A&[-=##9P+&H,2Y ]*I4I7W,JF-H\B]R
MYYX/%6KLP'/7^[7HMB[RV44DHP[+DBG?98/^>2_E4PXXK:$7'=GG8BO"I;DC
M8*6DI:T.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :Z+
M(A1U#*PP0:I_V-IW_/E#_P!\"KU% %'^QM._Y\H?^^!2-I&FJI/V*'@9^X*O
MTR7_ %3_ .Z: .7\-^(]*U/6+_3["S\F6T.)&QC=UKJZ\F^&W_(^>)/]\?S-
M>LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q]_\ \E*TS_KV
MD_E785Q]_P#\E*TS_KVD_E784 %%%% !1110 4444 %%%% !28I:* "DI:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYF\?&YZ3;ZY8W4RPQ3JSL"0!3X]8LY4F9)1B'[Y]*\ET74_[/U.*X9"RJI7
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M-#>WT=I)#M4@!2#2C6BW8BGC82ERG;4M)VI:V.X**** "BBB@ HHHH ****
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M=%8#J,T <C??\E*TS_KVD_E785Q]_P#\E*TS_KWDKL* "BBB@ HHHH ****
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M>XN_MD2LI;;M8$Y-956U9HX,9*47%K8]5W \T9KR&#Q'>);PQO=R;EF#,?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+[7K&*QN'CNHRZHVW#=\<5?OX&N;":%#AG0J#^%>:77@O4H+>:9G!5 6(SU
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,?Q4Q3PKJC*<$6LA'_?)KC_@Q!&G@XS*H\R64EV[FNO\
M6?\ (I:M_P!>LG_H)KR+X>_$G2/#7AI+&\28RAB?E7B@"[\9K1VU?2GM?DN)
M'V!EX-==X+^'VGZ);QWERHN+Z0;VDDYP37FOCCQ[IFOZOI=S:I+LMY S[E[5
MW,/QF\/)"BF.XRJ@'Y?_ *] 'I8  P.*6N7\+>.=-\62S)8K(#$ 6WCUKJ*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X^_\ ^2E:9_U[2?RK
ML*X^_P#^2E:9_P!>TG\J["@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#H$VW_ '[%>7^.O"=IX+UG3=7T17MU:8*Z*>!7M6GS&XT^WF/WI(U8_B*
M*FF:!IFC.[:?9Q0,_P![8H&:TZ6B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ./O_ /DI6F?]>TG\J["N/O\ _DI6F?\ 7M)_*NPH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*"C1$$'Z5Q?P?D9O"LR'.([EU'Z59U?XA^'X_"\UQ!?QR3/"0D:YW%L=*?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!44T\,"%YI%10,DL<8JMK-Q/::+>7%LNZ>.%FC&.K <5\_6NM3^*KYH?%NNS
MV,.['D*I"GV/- 'JNO\ Q4\/:,KI'.;NX'2.$9Y^M<-%XP\<^/6DBT.W2SMB
M=K.#T_'K78V'@SPA8:'/<:=!!<MY1*ROACTJA\' !9:D!T%PW\S0!L> O!-Y
MX8:XNM1U%[N\N0-^22!^)KN:** "BBB@ HHHH **** #M4%U:07EL]O<Q)+"
MXPR.,@U/10!R$'PT\*V]^+Q-,4R Y 8Y4?ATKJQ$@B\L* F,8'I4E% &5HWA
M[3]!CFCT^(QK*YD<%LY)K/UCP)X>UVX$]]8(TO=D^4GZD=:Z6B@#-TG0M.T.
MV^SZ=:I G?:,$_4TW6/#^FZ];>1J-K',O8E1D?0]JU** .;T7P+X?T"?S["P
M5)AT=OF(_$UT=+10!Q]]_P E*TO_ *]I/Y5V%<??_P#)2M,_Z]I/Y5V% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO:LKKE6!'M3J\L^$4OB-X[I=7,YM !Y#3=:]3H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#C[_P#Y*5IG_7M)_*NPKC[_ /Y*5IG_ %[2?RKL
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?\"H ])\)^!-.\(S3R64DKF8 -O.>E=77%_#[QF?%FEL;A1'>P';*G]:[2@
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M_P#DI6F?]>TG\J["@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "D;[I^E+2-]T_2@#B_!7_(<\0?\ 7P/Y"NUKBO!7_(<\0?\ 7P/Y
M"NUH 3 -&!Z4M% 7*]Q MQ \3<!Q@D5!ING1Z=:B!"64'J:O44K(KG=K!@>E
M&T44M,FX4AI:,4 8-GX9M[/6[W4UE9GNUPR$<"HM$\(V6B7-Y/ [,UR><C[H
M]!718HQ0!R<?@6SC\/WFD"XD\JZE:5FQR":Z>W@6WMHX!RJ*%Y[U+BC% ',V
MG@ZUL=1O[FVG>.*]4B2 #Y<D8S65;?#N:SC,5MK]W'$6+;%' R?K7=XHQ0!A
MZ'X8LM#9YHRTUS)]^:3J:T=0NVLK1IEB:4K_  KU-6\48[4 <E_PF-QWT>Y_
M*M#1=:;4+ET.GR6_<LXQFMW:/0?E1C'0?E0 E8D'AJ"'Q5/KPE8S31"(IC@
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M/:;'8V486-.I[FM2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M./O_ /DI6F?]>TG\J["N/O\ _DI6F?\ 7M)_*NPH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I&^Z?I2TC?=/TH XOP5_R'/$'_7P
M/Y"NUKBO!7_(<\0?]? _D*[6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y'XD?\BD
M_P#UV3^M==7(_$C_ )%)_P#KLG]: .KB_P!4G^Z*?3(O]4G^Z*?0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8I<444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <??\ _)2M,_Z]
MI/Y5V%<??_\ )2M,_P"O:3^5=A0 4444 %%%% !1110 4444 %%%% !1110
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M@_C7"_$.+7KK3;M+25+:PBBWO(#\S].*AT[4)-.^$:W,;?O1;80Y[XH [?\
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M=O(/-OL1(0>>1UH Z./4K&:VDN8KVV>"/.^595*KCKDYP*K?\)'H?_09T_\
M\"D_QKS'1[1+'X6^+[9/NQ_:%&?]T5<\)Z-X'F\+6,M^EA]I,69"\N#GWYH
M]/@N[>ZB\VWGBEC_ +\;AA^8JH_B#1HW9'U>P5EX*M<H"/UK@?"0MH?%NJ0:
M(\C:0("2,DH'P>F?PJMX#\*Z+K2ZK/J%C'/(+M@&;- 'J5O=V]VGF6T\4R'^
M*-PP_2IZ\UOK >#/%.G-I;.EC=MY<D&XE0>>1GZ5Z0""N>W6@!U)FL+4_%>G
M:=)Y(=KBX[10@L?TZ4[2M2U2_2:6?33;1@?N@[#<?K@T :TES#"Z))-&C2'"
M*S %CZ#UITDT<,9>5U1!R68X _&O)=1M];'Q"\.W6L7*?O;G]W;1_=C (_6N
M@\=R27VM:+H>]EM[F;,X4D$J,<<4 =I;:E8WI(M+RWN,=?*E5\?D:LDX&37F
MVN:%8^$]5TJ^TF-K</,L4B*QPP) Y'XUTFLZEJLEH\%AILQ9L R;EP!ZCF@#
M:M-3M+Z6:.VF61H3AP.QJY7GOP[1[:_U2!H)%/F98N<\\9KT$4 +7(_$C_D4
MG_Z[)_6NNKD?B1_R*3_]=D_K0!U<7^J3_=%/ID7^J3_=%/H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X^__ .2E:9_U[2?RKL*X
M^_\ ^2E:9_U[2?RKL* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *1ONGZ4M(WW3]* .+\%?\ (<\0?]? _D*[2N+\%?\ (<\0?]?
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MFYSN\L9K44 # & * *(TBR%T;@0*)"<GTSZXINK:/9ZU9M:WB%XSV!(K1HH
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M%% !1110 4444 <??_\ )2M,_P"O:3^5=A7'W_\ R4K3/^O:3^5=A0 4444
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M44 %%%% !1110 4444 %%%% !1320!DFA65URI!'J#0 ZBBB@ HHHH ****
M"BBB@ KD?B1_R*3_ /79/ZUUU<C\2/\ D4G_ .NR?UH ZN+_ %2?[HI],B_U
M2?[HI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M'W__ "4K3/\ KVD_E785Q]__ ,E*TS_KVD_E784 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4C?=/TI:1ONGZ4 <7X*_Y#GB#_KX'
M\A7:UQ7@K_D.>(/^O@?R%=H: $S1FN-\5-KHOT&FLXBQSM K"_XJ[^_-^0K>
M-'F5[F;J6>QZ5<3I;6\DSY*HI8X]*@TS4HM4M!<0 A2<8->>;_%7D3B4R-%L
M.\,!TJ?1KCQ#'HNVQMU,>3A\\U7L++<GVFIZ1D8HR/6O,"?%Q))>;\A3[=O%
M8NH][3%=PSP*/J^FX_:^1Z;13(=WE)O^]M&?K3ZYC5'DMYXNUNS^),EL]\YT
MM'"-"5&!GWQGM7<^,=:DTCPY-<6KXN9/D@(_O'I7G][IG]J>)_$L2C]XB!T(
M]16G:7O_  DLVDVKG<+6'S91_M<8_K0!0TKQ/XAE^&&IW]QJ4C:A%<,B3;5R
MH Z=,5L6WAGQK<6<<X\;3@N@;!A3C_QVN9MES\+M?4'!^W2 8^@K8U#0O&-K
MX96[L?$DTI2(-Y/E)DKCH/EH V] U[59+?6=-U&5)+W3E.+B,??XR#]:P_#^
MF^,]?TW^T$\8SPAI& C\I,#!(Q]VM+P;#IQ\&7MW:322W4R.;EI3\X?'(-:O
MPY_Y%2/_ *Z/_P"A&@"'0=<U>RUS^P==*33%=T-R@QY@]_>NOFF2WA>60D*@
MR>*XC5G2[^(VF1V[!F@4F0KVX-=O.\<<#O+@Q@?-D9XH J6.LZ?J(S:W4<A[
MJ&&1]15_->::NMKK5V4T#2KA;D''VJ/,:J?H< UVGAVSU.QTN.'5KQ;JX'60
M#% %O5-2@TG3YKVYW>5$NYMBEC^ %<+X6\7ZIKWCRZMIHY+:Q6W#Q0.N">OS
M'OG_  KT1XTE0I(@93U##(KSW3@%^,E^%  ^QKQ^+4 6-9U'6]=\22Z)H=__
M &>ML@>:X"@L3Z<Y%6/#>L:K9ZK<Z+KURD\L2;X[C&-Z^_:J?AM3!\2=>64X
M:559,GM5I=ES\32%PZI;8?N.] "^+O$*O9/86,^'E0EI@>%&/7UJW\/9?,\*
MP9E,C*2"Q.2>:WY],M+BW>%K>(!U*DA!WJ/2-)M]&L5M+;/E@D\^] &A1110
M 4444 %%%% !1110 5R/Q(_Y%)_^NR?UKKJY'XD?\BD__79/ZT =7%_JD_W1
M3Z9%_JD_W13Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"0.2<4 +140N(2VT31
MEO3<*D% "T45&\T49^>1%^K 4 244Q75QE6!'L:&=4&68 >I.* 'T5&DT3\)
M(C?1LU)0!Q]__P E*TS_ *]I/Y5V%<??_P#)2M,_Z]I*["@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "D;[I^E+2-]T_2@#B_!7_(
M<\0?]? _D*[6N*\%?\ASQ!_U\#^0KM: $Q12T4 0W$"W%O)"WW77:<57TS3D
MTRS6VC8LJ]S5VBG=VL*VHG%+112&+2&EHH P+/PQ#::[?:F)&9KM<,IZ"H=#
M\'VFAW5[<0NSM<G^+^$>@KI:* .1C\"VT?AZ]T@7#^7=3-*S=P373P6ZP6L<
M'544+SWJ>B@#F++P=!IVHZA/:SLD-ZI#P#[H)&,BLVS\#:AI\!M[3Q!/%"6)
M"!!QDY]*[FB@#G] \*6NARRW D>XNI?OS2')-:>IW+VED\J6[7! _P!6!UJ[
M10!Q<?BR]B7;'X<N4'HH4?UK6T;7;K4YVCFTR>V 'WI,8/ZUO44 )6%!X:BA
M\63:\)2998A&4[ #/^-;U% ',:YX175-2CU&VO)+.\5=OF1]Q[U-X>\+0Z%)
M-.T\ES=3G,DLAY/^%=#10 4444 %%%% !1110 4444 %%%% !7(_$C_D4G_Z
M[)_6NNKD?B1_R*3_ /79/ZT =7%_JD_W13Z9%_JD_P!T4^@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X7XE:Y=Z?I]KINGOLO+^7RU<=AW_G7=5Y?\1<_\)IX9)^[
MY_\ 44 5-0^'-_I^B2:I::U>/J4:&0AG.TG&<=:[3P%KDNO>%K>YG.;A<QR'
MW%;=[C^RYL]/*.?RKAO@_G_A&;C/3[4^W]* .^NYQ;6DTQ. B%OR%>2:-H.H
M>/[B\U.^U.Y@M5E9(4B8CI^->F^(\GP[?;>ODMC\JYSX6X_X1%?^NK9_,TP,
M?PM+J'ACQC)X>OKQ[BWE3?"[G)^E-\52ZCXF\:IX=L[N2WM8TW3-&<'M_C3_
M !)G_A:VD[.NSG\J?X?!'Q5U?=UV\?3BD!DZUH5_\/9[35K'4[BXLQ*$GCE8
MGK^->N6TZW-M',A^5U!%<5\6,?\ "$39Z^:N/KS6Q8'4!X+MS8!#>^0-@?IG
M'>@"C?G_ (N7IG_7M)_*NQKS'37\1/\ $BP_MQ+=3]GDV^4/:O310 M%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C?=/TI:1ONGZ4
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M9V@?\\[[_OQ_]>C_ (6=H'_/.^_[\?\ UZ .SHKC/^%G:!_SSOO^_'_UZ/\
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M?]^/_KU@>+O&NF:]HGV"RBNVG>52-T.!W]Z /3XO]4G^Z*?3(O\ 5)_NBGT
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MQ6O_ #[Q_P#?-6** *_V*U_Y]X_^^:/L5K_S[Q_]\U8HH K_ &*U_P"?>/\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBC-
M$;SQ1R)&[J&<X4'O4M<?XF9AXL\.@$@&9L_^.UU_2@!:*3-&: %HI,\4;A0
MM%)G'6DW#U% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS
M0 44F:,T +12;AZC\Z,^E "T4W</6ES0 M%%% !1110 4444 %%%% !1110
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MAX0\//H&E%;AQ)>SMYD\G]YJ .C'2BBB@ HHHH **** "BBB@ HHHH ****
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MK)?Z?>2>6ZR\%2>XZUZRK9 /J* '4444 %%%% !1110 4444 %%%% !1110
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M4?$ET^IV<<@'+G]V3QG%>RP.LMO'(GW'4,OT- $E%%% !1110 4444 %%%%
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M/4]+&F6$<@:8OG+X]*]5@B$%O'"O1%"C\!4E% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!@^+]";Q!H$]G&0LN-T9/9ATKSHW7
MQ'ET[_A'_P"QPJ@>4;SG;M^N/2O8Z* ,7PMHS:'H-O9.09%&7([GO6U110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "44
MM% "44M&* $HI:* $HI:2@ %%%% "TE%% !WHHHH *7%)10 4444 +249HH
M***,T +129HS0!Q_B?\ Y&WP[_UV;_V6NQKCO$__ "-OAS_KLW_LM=C0 444
ME "T4F:,T +129I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8IKC?%OBRYTR[ATO2K<3ZA./E'9?<UV5>-:[)JL_Q/DMM,VK</%@2,/N#UH
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MUQZ>] 'K'A[68]?T6WU&-=HE'(]#WK5KE_ $UE+X3M5L052,;65NH;OFNHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0!0U;5[/1K-KF
M\F6- . >K'T%<KX(\:7'BK5]2C:/R[> XC4C![=:ZG4='LM5,1O(1*(CN56Z
M9KA? <:1>.O$R1J%19%  ' ^5: -SQ?XLFT22"PL(//O[GB-/3W-8=CXD\8:
M9J=O%KMBLEO<-@/"/N?6LGQ=/J#_ !-M;?3@OVEX2L;,,A?>IY!XH\&WEO=:
ME>KJ%G-(%D#C.PGTH ]84Y (Z&G5'#()84D7[K*"*DH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 9+(D4;22,%51DD]JX"\^(B2^*K/2
M=-7S(WDVR2XX_"N\NK>.[MI()1E'&"/:O/O$>EV>E^(O#\5G D:^=S@=>M '
MH]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[G1M'=K['VZ[D,\_L3SC]:ZJBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3V%\+2>U8LKE-W7'N/2LK_A&/&/_ $,Z?]^#_P#%4 =[17!?\(QXQ_Z&=/\
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M]HK@O^$7\8_]#.O_ 'X/_P 51_PB_C'_ *&=?^_!_P#BJ .]HK@O^$7\8_\
M0SK_ -^#_P#%4?\ "+^,?^AG7_OP?_BJ .]HK@O^$7\8_P#0SK_WX/\ \51_
MPB_C'_H9U_[\'_XJ@#O:*X+_ (1?QC_T,Z_]^#_\51_PB_C'_H9U_P"_!_\
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M@O\ A%_&/_0SK_WX/_Q5'_"+^,?^AG7_ +\'_P"*H [VBN"_X1?QC_T,Z_\
M?@__ !5'_"+^,?\ H9U_[\'_ .*H [VBN"_X1?QC_P!#.O\ WX/_ ,51_P (
MOXQ_Z&=?^_!_^*H [VBN"_X1?QC_ -#.O_?@_P#Q5'_"+^,?^AG7_OP?_BJ
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M/_Q5'_"+^,?^AG7_ +\'_P"*H [VBN"_X1?QC_T,Z_\ ?@__ !5'_"+^,?\
MH9U_[\'_ .*H [VBN"_X1?QC_P!#.O\ WX/_ ,51_P (OXQ_Z&=/^_!_^*H
M[VC(K@CX7\8_]#.G_?D__%5S5B?&5WXNNM$_X2!5\E-V_P H\_\ CU 'L5%<
M%_PC'C'_ *&=/^_)_P#BJ/\ A%_&/_0SI_WY/_Q5 '>T9K@O^$7\8_\ 0SI_
MWY/_ ,55S2M \36NHQ37NOK<0*<M&(B-P^N: .QHH%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:[K&A=B JC))KF]
M\86WB#6-1LK9?W=GC]YV;.?\* .F-4H]+LXKY[V.!5N'&&?N:Y74?'=Q'J,]
MMIFERWBVYQ+(HX%:UAXLLKS09-58&)(@?,1NH/I0!T%+7GR_$:X5DN)M&G33
MW;"SX/KUK=U[Q=;:/96TT<;7$MUCR8T&2V1F@#I**XW1O&\EWJ\>F:GI\EC<
MRKNCW=&KL: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#S^U43?%>Z,G+) -H/X5-J@\KXFZ:T8P9+=M^._(I
M_B31M5MO$,.O:+''+,$V2Q,<;A2:#I>LW_B1M<UJ..!ECV10H<XZ?X4P.X%%
M)2T@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZIID.JVAMI]
MWED\@'&:O4AH \T\(6<%A\0]6M[= D:(  /I5WP]^]^(FMR2<LNT#/I@5=T7
M0[VT\;ZEJ,J 6\R@(V>O%0:UI6LZ7XE?6M$@CN//3;+"QQDTP,KQ&[P>,-7\
M@8W:62P'KE:W_"$,7_"N[9=JE7MB6&.I(YJMHN@ZGJ-YJ6IZVD<4UW#Y"QH?
MN+Q_A6/:V?C+1M+ET&UM8)H&+)%<EN44_P#UJ ,6R_Y$_2H,9A_M39CMM^:N
MR^)B(/"P<* R2*5/I4,O@BXM_ MMI=K*IOK=A*'/0OWJI<:?XI\5/:V.K6L-
MK:1.&E=&Y?%(#O\ 3&9M,MF;[QC&:M4R)!%$L:]%&!3Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@!",C!K#U"ZTKPO8RSB..-G)(1?O.WTK:<D(Q49
M(' KR>:S\6/XCEU"[TB.]16_<*[_ "J/IF@!ESIMU:^!=:U"Y4Q-?R[]G]U3
M@?TKM+VW@_X5M)'M7RQIY(X[[*ACBU;Q/H5]I^K:=%8[T*Q[&SSCC]:Y][3Q
MG-HH\.M:P+#M\IKO=_!]/I0!GZ.S73>!TN,E0&.#W(5L?I6[\2R8I-'FBXD%
MTH!'7H:LZUX3NX=&TC^R&3[9I9#1[NC<8(_4U6CTWQ!XFUFRGUJTBM;6S;?L
M0YWF@";PE^]\9:[))_K P49'0<T_3R8_BA?(@PC098#UINJ:;KNC>)9M6T2W
MBN8[E<2Q.<<^M7?"ND:DNHW6LZLJ)=7' C3^$>E '7T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% %*ZL(9Y!<^0CW,:D1,PZ5Y["-4L?B#9W7B%(
MSYP,5L\70'T/YBNG\36.L"[M]3T>4M)!]^V9B%D%9=KI^O>(M;L[W6K:*TM[
M)M\<2-DLW^0* (?AY^]UKQ+*X_>F]*DGKC:M8.L_Z/K/BA(1M5T0N!_P$5NW
M&E^(/#7B._O]%MHKNUOCO:-C@JV,9_05)I'A&^FL=7N=69/MVI?PCH@P,#]*
M -.^AB7X=;0JA19J1Q_LBN&TJ62YD\+).24!;&>_6M?[+XRETL:!):P>0/D^
MT[N=@_\ K5JZSX2N8](TPZ5L^UZ?@J&Z-QS0 >//W=[HLJ#$GVD 8ZXP:[=?
MNCZ5P$%CXC\1:U9W&L6L-I;VAW!5.2Q]:] H 6BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH XGQCK7G7D/ARUN8X9[CF>1G"^7'WZ]ZQO"*V.G>*
M]=MK6>'8L"!,.#N/S=/6NJU;P/HVM:B;Z[A8SLH4L'(X'XUS_A_X?6^F>+KZ
M],+"W 7[.2YZY.>] %GX:_O='OY)%_>/<ONS7)ZD[Q:=K\,0(C^UKP/JM=#]
MA\3^&[^^CTBTANK.Z<NFXX,9(J[9>#;B3PQ>V]ZZ_;KQC(S#H&[?R% %S48(
MC\.60JI46RD?7BN7L29M<\-)*,JMOD9]<5.UGXQN],30);:".V&$:Y#<LH-:
MNO>%K^*WTNYT<H;JP &UNCC'(H C\=HJ:_X>G48E^T;<]\5W@Z"O/[72M?\
M$?B.RU'6[>.TM[+)2)&SN;UKT$4 +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 48HHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ110 48HHH ,4444 &**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !BB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g0vsdaj33nnl000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0%!JP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYR9'7YJ5TAJ+>Q/14'VNWX_?)ST^:I@P;D$$473!Q:W0M%%%,04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7GGCK0O&'B?5(=+TR\CL-#:/_2;@,-[')^7'7ICI7H=% 'A7P7T
MR/1OB%XFTZ-VD6"$+N8\GYAS7NM>,_#'_DK?B_\ W!_Z$M>S4 9NOWO]G:!?
M7G_/*%B/RKS7X&Z-!<>&+CQ!=QI-?7UP^Z1UR1@G^>:] \8PO/X/U6-!EFMV
MQBN0^!4J2?#.V"D92>0,,].: .>^+EM#X7\5>'?%-A D<T<Q$P08#X(QG'XU
M[3"_F0QO_>4&O'?C\P?3]&M5YEEN,JH[XQ_C7K]J,6D(/4(O\J )C15>^MFO
M+"XMDE:)I8V02+U7(QD5YT?A7J9)/_"::MS[I_\ $T >FUYUXNUV;2/B/HA>
MX=+ 6LC3(/NDY.,^]5O^%5:E_P!#KJ_YK_\ $UQGBO07T#48[2;6+C49-FXO
M/C<GMP!1:;^!79OAH49U+5I<J[GJ^B>.M)U6WW2W$=O+N/R2-MXSQR:UCXBT
M<?\ ,2M/^_R_XU\[Q0K+*J&55W'&XC@4^[M1:W,D!F238<;EY!J7'$WTIL])
M83+;?[PCWD^-M !Q]O3BD_X3;0/^?]*\/ATEI]+GOQ<1*D) 9"?F.>F/RK:T
MOP#J>K:?%>6LL+12#(YZ>QK.4JL=X,TC@<NEM71[$OB/1V4,-2M,'UF4?UJ&
M?Q;HELP5]0@)(S\CAOY5Y?\ \*OUO^]#^='_  J_6_[T7YUFJ]3^4O\ LW _
M\_T>E_\ ";:!_P _Z5-!XLT2YSLU& 8_ON%_G7EW_"K];_O1?G1_PJ_6_P"]
M%^=/VT_Y0_L[ _\ /]'JLGB71HXV<ZE:D#TF4G^=5/\ A-M _P"?]*\U_P"%
M7ZW_ 'HOSH_X5?K?]^+\Z2KS_E!9=@>M='I:^--!9@HOX\D]S5S_ (2+1_\
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MD_\ PJ_6_P"]%^='_"K];_O1?G1[>I_*']FX'_G^CUC_ (2+1_\ H)VG_?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>L6*ZM_:\%J\B^9':@E1CL"*Z/X:>.M1\075_H>O0+%J]@,N5& Z@@9Q^(H
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M7<R7$G#NIY-:5U?^*KJR=+J:^DMV7+!@=I%8T=QY=O)$(HSOQ\[#YE^E>O\
MP^U>/7-#>QN]CSP#80<99/\ .!6E3*:E*ESN1Q?ZTX>IB.6%)-+9GD,-W>13
MP2PRNLD?$3*>1]*TM2U+Q%):F/4;B[,#<8EZ&NTUOX7SFY>?2KA1&S;A$_\
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MV/E#!^H/->Z:&ZR:'8LI!4P)R/I7COA[_DY76OH?_10H ?\ #;7+SP3XJNO
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MY&/K\PJE\'K:6U^&NFK,I!<&1<_W3R* .[HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y[QTMT_@;6EL@QN3:/Y83KNQVKC_@2]B? 96#9]J6X?[0
M/XLX'7VKU!E#*589!&"*\.UGX7>*?#>O3:MX$OC'%.VXVVX#;_WUP10![C7B
M5DUJ_P"TA_Q*1^[6%Q>%/NE]AQ_2J4ME\;M2C-K.WV>)QM>0/#T_#G\J[SX;
M_#E?!<,]W>7'VK5;O_73'G ]!0!W]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5YWXC_P"2R^&/^O27^9KT2O._$?\ R67PQ_UZ2_S- 'HE%%%
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MBBB@"&[_ ./67_=->&>$?^1[B_ZZO_6O<[O_ (]9?]TUX9X1_P"1[B_ZZO\
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ME='0 A (P0"#U!KS:'X26ME\2K?Q7970ABCD,K6VWJQ4@X_$YKTJB@ HHHH
MBN4DDMI$B<)(RD*Q[&O%;?X&:Q97LUW:>*3#/,27=4.3^->WT4 >/?\ "IO%
M7_0[3_\ ?/\ ]:M[QS\.KWQEHVFZ<=6$*V@R[%2?,;&,UZ'10!XU!\'O$MM
MD,'C.6.-!A55, #\JZCP7X'UOPWJLMWJ/B*348GBV")AT.0<UWM% 'EOQAOI
M+ZWTWPG99>[U*<;U'.(QU_I7HND:='I&CVFG0DF.VB6)2?0#%95MX0M(?%EQ
MXBGGEN;R1!'&)0-L*\<+CZ5T5 !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !69XB;4D\/WS:.N[41$?(7CEOQX_.M.B@#SOPC<^/Y/#&J/XA@*:HJ_P"B
M*5C&3S_=X].M<,VH?';<VVR?&>/DM_\ &O>9Y4MX7FE8+&@RQ/85Y=X1^)NK
M>,/'$EK9Z4RZ#%O4SX&2?X2?3OTH Y7^T/CO_P ^+_\ ?%O_ (UT_@*[^*4W
MB:-?%=JT>F%&W,5B'.#C[O/7%8/B7Q]XQU[QY<^'O!^U8[0D,P0-NP,DDGI_
M]:NC^&GCO6=2UF\\,^*8TBU6U&5. #)WQ@<<#F@#U.BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\[\1_\ )9?#'_7I+_,UZ)7G?B/_ )++X8_Z
M])?YF@#T2BBB@ HHHH **** "BBB@ HHHH *XSQMX+;Q&89[62**XCX9I,X8
M?A79UD>)K^33/#]Y=1?ZQ(R5^N*BHHN/O'3@ZM6E6C*D[2/ C]HT/6&$<B^?
M;2<,!D9'UKV#POX[L-3AAMKJ?R[PC!WC 8^U>*2RO-*\LC%G<Y))IJL58,I(
M8'(([5YE.M*F]-C[W&Y93QM)<_Q=SZ@!!&12UP_@?QC;ZI91V5U)LO(UV_,?
MOX[BNR-W;JV&GC!]"PKTX34E='P.(PU2A4=.:U1-1358,,J00?2G59SA1110
M 'I7BOC"UUW7M=EF6PG\B/Y(AVQZ_P Z]JHP*WH5O8RYDKF%>C[:/*W8^=?^
M$8UO_H'3?D*]8\#_ &NYT(V&L69W0'"><H8,O_UNE=E@48K6OC'6C9HQHX-4
MI73/&]<\!ZS<ZW<SV=HJPM(2FTA1BL75?#.O:-9_:KP2)%N"Y\SO^=>_50U;
M2+/6K+[)?(7AW!L!B.?PJZ>/FK*6PJF!B[N.YY%X1\<1^';2:&X@FN&D;((8
M''YFND_X6Y9?] ZX_-?\:VO^%;>&O^?63_O\W^-<-XN\#W%KK 31-.F>U\H$
MD-GYN<]3]*V4L+6GJMS!K%48:-'KUG=I=VD5P/E$B[L'M4X8'H<UX)/8^+;"
MU,LO]H0P(.3YQ  _.M[X?^*8K*ZNSK.J.$9 $\YV;G/;K6-3!-1<XNYM3QMY
M*,E8]?HK&L/%6BZG=+;6=_%+,W1%!R?TK8KA<7'=';&2EJA:***104444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 130Q3+B6))
M O(#J#7DVL6>N3>+!J,&A![>W;$41"JK <9X/XUZ]25M1K.FWH8UJ*JJQXEX
MD@\3^([Q;BYTIXU1=JQH<@?K3;.SUJUT*?3#X=603<F9OOCZ5[?@4<5T?76H
MJ*CHCG>"3ES-G@FEZ)X@TS48KN/2GD,9SL< AAZ5I^)(/$/B)H'E\/BW>($;
MHC]X>AYKVG%)BF\=)R4W'5"6!BHN*>AY+')KZ:&=-C\*P!#$8_,XW#/?KUJ+
MP1I.MZ'XACFN-,E$$@V.V1QGOUKUJZN8K.UDN)F"QQJ68^PK-B\2:7-+:QQW
M*,;E2R<]AG_"I6)DXR2CHQ_5X1DFY:HV**HZ9JMIJT#RVLF]4<HP[@@XJ]7$
MU;1G:FFKH**@N[N"QM9+FXD$<,8RS'M5#_A(M./V'$XS>_ZGWIJ+>J$Y):,U
MJ*.U%(HAN_\ CUE_W37AGA'_ )'N+_KJ_P#6O<[O_CUE_P!TUX9X1_Y'N+_K
MJ_\ 6N/$_'$^BR;_ '>OZ'O(Z44#I178?.A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/>.;:YO/
MVM6]F"US):.L8'4G%>:?#3Q;H_A_X2WDKW$4=Y9N[21$X9G(&/S(KVL@$$$9
M!KRG6/@;X7U/66N8IY;7S6+O;QGC\/2@#%^ FG#R=9\2W#[1<RF(%SC@<YS_
M ,"HTO4;?Q'^T0MYI8#VME \<TR=&)0C/YG'X5V?B?2/"VD^!E\,W6IV^DV;
MKLC>4C.1W]ZL_#SP;X>\+Z8TVB3+=-<@;[O.2X]![>U ':T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7G?B/\ Y++X8_Z])?YFO1*\[\1_\EE\
M,?\ 7I+_ #- 'HE%%% !1110 4444 %%%% !1110 51UC3EU72KBR<X$J%<^
MF:O4&DTFM2HR<9*2Z'S;J^CW>CWTEM=1,I4\''!'K4-AIUWJ5U';6L+22.<#
M XKZ-O-.M-0B,=W;QS)_==<TVQTJQTU-EG:Q0KZ(N*XOJ?O;Z'U,>)I*ER\G
MO'AGB/P]/X5NK4BX_>2('&TX*FL62_NYI3+)<2O(3RS,<UZ#\6K.7[=9WF"8
MO+\LGT.2:\VKFK+DDXK8]W+*BQ.&C5J6<CT'P'XTNH-0CTV_F:2"7Y4=SDJ?
MKZ5[ &!&0>*^7U)5@P."#D&NX?XC7J>'8+&W++=*H5YCUQ[>];T,1RQ:F>1F
MV22JU5/#K??_ #/9O-CSC>N?3-/KYN.OZL;CS_[0N/-S][><UZ9\/_&D^IR'
M3=1<-.JYCD)Y<>];T\3&;Y3RL9D5;#4O:IW2W/1:*2EKI/#"BBB@ HHHH *,
M444 9^LZ8NKZ5-8M(8Q*N-X&<5Y_/\)H(;>64:K(=B%L>2.<#ZUZA36570JP
M!5A@@]Q6U.O4IJT68U*$*CO)'SKI&JR^'M9%W JR/$64!N,]176?\+7U/_GS
MA_[Z_P#K5Z,WA'P^[%FTBT))R3Y8K \9>&=&LO"=_<6NF6T4R("KI& 1\PKN
M^M4:LUSQU.'ZM6I1?++0N^!_%%SXFMKN2YA2,PNJ@*<YR*ZROG[P]XJU+PW%
M/'9*A69@S;TSTK9/Q1UX'E8/^_=36P$W4;IVL51QT%32G>Y[117->"]>N->T
M$7EZ8Q*967Y1@8&*Z/S$_OK^=>?*#BW%G?"<9QYD.HI P;D$'Z4M26%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11574+Q+
M"PFNI 2L2EB!U.*:5W83=E<X+XG:^8[9-'M6)DD&^;:>B_YS7E*32HP*R,I4
M8!!Z"M;4=0O+V_O+QXY?/G. W3:O<?B*RWMWW_+$^WW%?0X:G&G3Y3Y_$U)5
M)\R.Q^'^OC2=;^RR2DVUV<$GL_K_ $KVG/&:^;H0\<#H('WA@\;!<$,*]DT+
MQ.9O!DE]<(XGM4V.,=3T']*X,?17,IQZG=@:S47&1S'Q%\4I=L-&M9"JACY[
M$X'';Z5PMO)<S2JJ7#NUJ"81G^5)?-/?7%Q=S12>?+(7Z< &H=/NIK*_BN(@
M2Z-G'K[5Z%&E&G2Y4<-6M*=2[/>_"NN+KVA07>?WH&V4>C#K6W7CW@G63IWB
MF6..!XK"\; 4C[A[?S->P#UKP\32]G.Q[.&J\\"*[_X]9?\ =->&>$O^1[B_
MZZO_ %KW.[_X]9?]TUX9X1_Y'N+_ *ZO_6O,Q/QQ/JLF_P!WK^A[R.E% Z45
MV'SH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M19WDB37UW""QVAUQD?E6-/"RJ2<4]C6IB53BI-;GO-%<QX;\1V4OAZP>]U.
MW+0J9/,D ;=[UTP((R.0:PG%Q=F;PFIJZ%HJ.:>*WB:6:18XUZLQP!5'_A(=
M'_Z"=I_W^7_&DHM[#<DMS2HK-_X2#1_^@G:?]_E_QJW:WEM>Q^9;3QS)TW1L
M&'Z4.+6Z!23V9/116?+KFEPRM%)J%LCJ<,K2@$&A)O8;:6YH451@UG3;J410
M7UO)(>BI("35ZAIK<$T]@HI,CUH# Y (..OM2&+1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.XGXXGW&3?[O7]#WD=**!THKL/G0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O>VD-_936EP@>&9"
MCJ>X-?/\5]XK^#U_>:<-.?4=#FD+PN%SC/4\=^G6O<O$TNH0^&=1ETI-]^L#
M&!1W?M7GWP:\02ZQX<N[37+[S[V&=E:*Y.6"]NO7O0!YEX(^)>H^$=&O;"ST
M.>YNKFZ>92R':-V...>U>B_"KPEK$NN7OC3Q+'LOKOB!'^\@(P3CMQQ7J$6G
MZ7#)YD5K:1N.=RHH-7%=&. X)]C0 ^BBB@ HHHH **** "BBJ>H:M8:3;M<7
M]W%;Q*,EG;% %RBLC2?%&B:X2-,U.WN2.H1N?R-:] !1163J_B?1="V_VIJ4
M%MNZ!VY_(4 :U%9^EZYIFM0";3;V&YC/>-OZ=:T* "BBB@ KSOQ'_P EE\,?
M]>DO\S7HE>=^(_\ DLOAC_KTE_F: /1**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ,9%<%XK^'<6L7#7MC*L%PWWE(
M^5CZUWM)4SA&:LSHPV)JX:?/2=F>16?PIOC-F]NXEA R?+R2?S%</JEH+'5+
MBU (\IRN#7TJ>E><^-? $FI7;:CIA7SG&9(SQN/J/>N.MADHW@CZ++,\G*M;
M$RT9Y)6[X9\3W'ABYFG@@CF,JA2') &#[59M? 7B&YN1$UBT*GK)(1M'Y5WD
MGPX@7PR;"$Q_;&8,T[+SVR ?2L*5*I?F6AZ^/S+ \JI5'S)]BQX:^(=KJ5K-
M)JK06<B/A%!)W#'6NNM-0M;ZU%S;3+)">CCI7AOB7P;=>'(89))1-YC;<(#Q
MQ5./Q+JMKHPTF*4PP DG PW)SUZUO'$RAI41Y%3):&)_>8.6C?W'O#:WIJR>
M6;V -Z;Q5U)$D0.C!E/0@YKYA+$MN))8\YKT+X<^*+F+4ETJZE:2&7B,L<E6
M]/I54\5S2LT8XWA^5"BZD)7MN>OT4UG5%+,0 .YJL-2LB^S[3%N]-XKKO8^=
M46]D6Z*16!&0<TM,D**** "BBB@ HHHH **** "BBB@ HHHH *P-7\(:/K=Y
M]JOK=Y)0H7(D8<?0&M^BG&3B[HF4%)69R/\ PK?PU_SYO_W];_&N5E^$UX9G
M,5];K&2=JG=P/RKUBBMX8JM#9F$\)2ENCR/6[6+P/X=%A!+NU&\!69T<XVYZ
MX/TQ7G=?06J^$-(UF[-S>PO))C&?,(P/:L__ (5OX;/_ "ZR?]_6KMH8Z$(^
M\KMG'7P4YOW=D>&T5ZY/\)M/DF9XK^:)">$V X_'-9>L_#6RTC2YKTZC<R>6
M.$6$$L?3K77''T7I<Y)8&M'6QYO6EH6MW.@:DM[;8+ 8*D\,*IFTN1S]GFQ_
MN&H:ZGR5%;<YESTY7/6#\4+<R78"%56 &'CK)S^G2NBM_%]K+X2.M,RJRH<H
M>S]A^/'YUX+4XO+A;)K-96$#-O*9X)KBGE]-VY3MAF%17YCWGPKXEA\1:6LY
M*)< E7B!Z'_]5=!7SCH6KS:+JUO=Q.0J/EESP1T/Z5] Z9J=MJUC%=VL@:.0
M9'K7G8O"^QE=;,]#"8E5HZ[HNT445QG8%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!7EL+.=]\UK#(Y_B>,$U&=)TXC'V"V
M_P"_2_X5<HI\S[D\L7T.=B\#Z!%?B]6R'FAM_+$KGZ=*VH;&TMWWPVT,;8ZI
M& ?TJQ13E.4MV*-.,=D0W?\ QZR_[IKPSPC_ ,CW%_UU?^M>YW?_ !ZR_P"Z
M:\,\(_\ (]Q?]=7_ *UPXGXXGTN3?[O7]#WD=**!THKL/G0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"GJL%Q<Z7=06DOE7$D96-\XVGUKP27X(>+Y=3DO_[9@6Z<Y,JR,&/XXKWK
M5H[F72;N.SE\JY:,B.3.-I]<U\UZ7J'Q/\0:Q<V>BZ[>7:0/M>X6<^6/^!4
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M%5[V66"RGF@A,\J1EDB!QO(' _&N"/CGQGN('@"Y/OYY_P#B: /1:\[\1_\
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M: "BBB@ KSOQ'_R67PQ_UZ2_S->B5YWXC_Y++X8_Z])?YF@#T2BBB@ HHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !129I: "BCM1F@ HHHH
M**,T4 %%%% !1110 4444 %%%&: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110
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M)]'AZGM*:D+1116)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\(SPN'CDU&-E8'@@UV_C#PE=>+-*LK>VU:XTYH6#EX6P6^7&/UH ZZBO'O\
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M=3M)D#QO;O\ *>Y R/U% &C8WD.H6%O>6[;H9XUDC;U4C(JQ7F'P+U66_P#
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M 4444 %%%% !7G?B/_DLOAC_ *])?YFO1*\[\1_\EE\,?]>DO\S0!Z)1110
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MGQA(=A"Y]S7T%M'H*-H]!6:PB6MS2?$4Y1Y73_%GFGA/P.]Q<R:EK%JB!_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\_.G*&DD>_"I&:]UBT445!84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4A&1@C(]*6B@#S#Q)\%?#>JRWU_#$T5Y/N<8<A Y]@>!6%X>^
M!.@II2C79U>^W'+0S$+CMW%>O:Q:37^D7=I;R>7-+&41\XVD]Z\3;X,>,BQ(
M\5R<G_GX>@#H_P#A1G@G^_)_W_/^-=3X3\ ^%_",[3:1;J+IUVM(TA=B/;).
M/PKRV?X,^.%B)@\4L[CH&N9!G]*E^#UA?Q>-;N#5=7O#J&GAEELYG+*P(P",
MGGKF@#WNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\[\1_\EE\
M,?\ 7I+_ #->B5YWXC_Y++X8_P"O27^9H ]$HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#.U[58]#T&^U25=T=K"TK#.,XKQ'P!X 3XAFZ\5^*9YKA9YB(8E;'3
MG)ZY'(KVSQ!I*:YX?O\ 2W.%NH6B)^M>*?#SXAVO@)+GPGXHCEM6MYB8I-A(
MYXQ]..M 'H6H_![P3?VHA&CQVI'_ "TMCM;\SFN+^&YOO WQ)O?!5W-)-9W*
MF6T8G@8&<_D,?A7;7_Q=\&V%J)VU190>BQ*6;\ATKA_AY)>>._BE>>,I8GAL
M+1&CM@R\-E<8S^.: /<J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KSOQ'_ ,EE\,?]>DO\S7HE>=^(_P#DLOAC_KTE_F: /1**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJFE6FKV;6MY$)(V]>HJ]1
M2:36I49.+YHNS/!_&_A:/PW?1"W9VMY@2N_DC'O^-<K7T-XF\.0>(].-O*=D
MB\QR?W37DFI?#W7-.CGF,:200@L75QD@>W6O.KT)*5XK0^XRG.*4Z*A6E:2[
M]3E*T-&U6?1=4AO8#AD;YAZCN/RK/Y!P:*YDVG='O5*<:D'"6S/IFQNA>6,-
MPO21 V/3(JS7@>F^.M:TRVBMX95>*/@!Q7J/@_QA#XD@:-U$=U&,NN>ON*].
MEB(3TZGY]CLGKX5.;5XG5T445T'D!1110 4444 %%%% '-ZUX)TS7K[[7>O<
MF3& %<  >W%9G_"K?#_]Z[_[^C_"NWHK6->I%63,94*<G=HXC_A5F@?W[S_O
MZ/\ "D_X59H']^\_[^C_  KN**?UBK_,+ZM2_E/'?&_A;0O#FG(;9[AKR5L(
MKR C'?(Q7 YKWC7/!&G^(+W[5>3W.[&T*K  #\J\W\;^'](\.R0VUE+,]P_S
M,'8$*/RKU<'B5)*F]6SR\7AG%N:T0_2_B%J%CHK6CNTLX=?*D)^ZHQQ7;>!/
M&$OB!KFVO"HN$)= !_!G_P"O7BW:KNE:G<:1J45[;'$D9S@]#6M?!4YQ?*M3
M.AC)PDN9Z'J'CSQI<Z-?06>G.HF7YY2>1[ _G47A'Q_/JNN+9WP"B:-0F/[X
MZ_G7F&H7TNHW\UW.Q+RL6^GM44$TEM.DT3%70Y!%2L##V7*UJ4\;/VO,GH?3
ME%87ACQ%;Z_I4,RR)]HVXDC!Y5N_'I6H+^T-U]F%Q$9SG]WO&>.O%>'*$HMI
MH]J,XRBFF6:***DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O//'#?#J[E\OQ(]DURAP2K
M'S%/OM.?SKJ?%VI3Z/X1U74;==TUM;-(@]2!7BOPM^&6E^+](F\1>('ENY)Y
MF41M(>,8.21SGG]* +EOI_P7@F$C3)( ?NOOQ7I/AGQ=X1OIXM(T"YA#!24A
MCC(& *S/^%*>!O\ H$G_ +_/_C6IH'PU\,>&-474=*L/)N54J'\QFX(P>":
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M[)JD&Z5L@%#P/2O3**UI5ITG>.YE5HQJJTCR3_A4>H?]!.V_[X:C_A4>H?\
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MZG)KUBO._$?_ "67PQ_UZ2_S- 'HE%%% !1110 4444 %%%% !1110 4444
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M1@T5O?\ "%^(_P#H$S_I_C1_PA?B/_H$S_I_C6_UBE_,C#V-3L=]X%\70?\
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M:#-H\\K!5;.Y03ZFO54=9$5U(*L,@CN* '45E^(M5?1/#]YJ21+*UO&7",<
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M. N>]8?4?]GYGN;O&_O^5;'OM%(K!E#*<@C(-+7EGJ%+5_\ D"7_ /U[2?\
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MG+1GT/ KSKQI\1;N_OF\+>"U-SJLAV27"'Y8!TSD=_?M0!D:F8-4_:%L?['
M+VT/^F/&.-P))S^&*]N-<9X \ VG@W3S(Y\_5;CYKFY8<L?0>U:?C;6T\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<AXZ\-WGB&SACM-F4;)W&NOIK?=/TJ9Q4E9FV'KSH5%4
MANCYMN(KC1=6D@+#SK:3!P>,BN@M_B/X@AE#&6)U_NLIQ_.LGQ4"/%6I;O\
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MNIPH16. <,#U_"F>#/#]UIWP]M]%U%%2?R7CD .0-V?\:ZVB@#Q+X=?"[5]
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MY*1F@#J[#4=.OH5;3[NVFC[>3(K ?E5ROE[Q)IW@W0S(_AKQA?I<9REK"7V
M_4#FNJ^$/BSQIJWB6.QU62XFTM8V^>6 *. <?-@9YQ0![Q1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>=^(_\ DLOAC_KTE_F:]$KSOQ'_ ,EE
M\,?]>DO\S0!Z)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKTX34U='PF)P]3#U'3J+5!1115& 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=X(4XX[9QC%8R?':SC;='X.*MZJJ@_RKK/!'Q;_X3'Q%'I)T::U#HS>8[9'
M)_I0!B?#[2/$GB?X@2>,?$-J]FMNI6WB>,KG(Q@ ]L'K7ME( %X  'M2T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7G?B/_DLOAC_ *])?YFO1*\[
M\1_\EE\,?]>DO\S0!Z)1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI0V8ZBBBN@\@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMR2P52^NA[5129'3-+7KGYL%%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AKS[XJ:?;-HL=\
M5(N$D"JP[@]<UZ%6%XNT5M?T":RC.).'3_>'2LZL>:#1V9?65'$PFW97/GJI
M+>>2UN$GA8K(C!@1ZBI+ZQN=.NFMKJ)HY%/1AC/O5>O'U1^F)QJPNM4SW'P5
MXQC\0P&WF7R[N)1GG[P]:["OFS2-5N-&U&*\MF(=#R/4=Q7KOA[XC:?JUPMK
M<(;:=CA=QR&_'M7HT,0I*TMSXC-LGG1J.I1C>/Y';T4@-+76?/!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%%;GEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^2R^&/\ KTE_F: /1**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<H/A[X>$F_[&#S]TGBM@Z!I9LOL9LHO(_N8XK3HH5.*V0YXJO.W--OYG*2>
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M4TP\A!&8DX#@$GD]>]=3H^C6&@Z='8:;;)!;QCA5'7W)ZDT 7Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KSOQ'_R67PQ_UZ2_S->B5YWXC_Y+
M+X8_Z])?YF@#T2BBB@ HHI"0H)8@ =2: %HJ+[5!_P ]H_\ OH4GVJ#_ )[1
M_P#?0I717++L345 UW %SYR?]]"O/-3\3ZMKVM2:;H,J00Q,1)<-C'OU]_2H
MG444=&'PDZS=M$MVSTG(-+7EER/%OAR(7IU2"]B5LR1(<G'XC^5=QX>\16NM
MZ3'>!UC8\,A/0THU4W9Z%U\#*G#VD7S1[HVZ*A^U0?\ /:/_ +Z%'VJ#_GM'
M_P!]"M+HY.278FHIB2QR?<=6^AI],FS6YEMXATI-9726O(UOFZ0DX)XS_*M2
MO$?C58OHGB#0O%UJK*T,PCG*]P#GG\.*]DTV]34=,M;V+[EQ"LH&>FX X_6@
M!-1U*STJS>[OKA(($ZNYP*IW'B?1[72HM3GOHTLI2 DI/#9Z5YE\:+^;5M3T
M/P;9J&EO)Q+(0W( ['Z@Y_"D^-FFP:9\,M+TZ!=L,%U#$H'H%84 >JZ5K6G:
MW;&XTZZCN(@=I9#T-:%>%_!VX?P]XPU+PW)D0W,0N;<,?X1GI]<UZOXRUM?#
MWA/4=3)P\,+&/GJV.!0 ^T\6Z%?:G_9UMJ,,EWDCRU;GCK2ZMXKT30[E;?4M
M0BMY67>%<\D>M?/?P\TF33/BIH4LK,9;ZS>Z<'^$L6&/TKH/BM8V^I?&7P]9
MW<?F6\L"*ZYQD&1J /5?^%B^$_\ H-6W_?5;6FZSINKQ>;I][!<J.OEN"1]1
MVKE?^%1>"?\ H"K_ -_7_P :\WU/2X_AM\7]'CT*1H[#41^\M Y8#C!SGWYH
M ^@*J:EJ=GI%FUW?3K! IP7;H*MUYS\;O^2:WG_71?Y&@#L](\0Z5KRR-IEY
M%<B/&_8<XS6G7SC\')Y/#/C"SL9F/V?6;%)U/8N>@_6O?]9U*/1]&O-1FQY=
MM$TC9[X&: *+^,O#\>J_V8^IPB\\P1>5GG<>@JQJ_B32-!,8U.]BMC)]W>>M
M?+=E:7'_  G'AK5;L$S:EJ,=PK$]4,@ _E7I/QOMXKOQ7X4MIUW0S7,<;KZJ
M7P10!Z1_PL7PG_T&K;_OJM#3/%.AZPXCL-3MII#T19!N/X5S_P#PJ/P3C_D"
MK_W]?_&O-?BKX-TGP)_9.O>'-]C<_:1&T:2$AQ@G/)]L4 >\7^H6NEV<EW>S
M+#;Q\L[=!6#_ ,+%\)_]!JV_[ZKGOB1=27WP7N+N48DGM(Y&^IP367\/_AIX
M3U?P1IE]?:4LMQ+"K._F,,G'UH ]$TWQ7H6KR>78ZI;2R'H@D&X_AUK9S7C?
MCOX1Z98:)+J_A:.:QU&S4R 12M^\ [<GBNN^%OBF;Q9X+@N[O/VN%S!,3CYF
M4#GCZT =M116/K7BG1?#LUM%JM\EJ]T^R$.I(8_4#C\: -BBO-M2^-?AC3]0
M-NBW-S"K;7N8H_W:GOR:[G1M:L-?TV/4--N5GMY!PR__ %Z -"BN.\4_$KP_
MX5E-M<SM<7O_ #ZP+N?_  IGA?XG>'_%-S]CAEDM;T_=MKE=K'Z=J .THJGJ
M6I6>D6$M]?W"06T8RTC=!7G\7QN\,2:D("MTEJ6VB]:,^5_C^E 'IE%8FC>+
M-#\0W=S:Z5J"7,UL 9E13\H/3DC!_"LKQ/\ $CP]X6F^RW5R9KS&?LT"EG_P
MH ["FNZQH6=@J@9))P!7GFB?&7PWJ^H+93"XT^9R%0728W$_2L?XY^)K:Q\/
MP:9#J#0WTT@DV1E@6C[\CC% 'JT][;VUFUW+*JVZ+O,F>,>N:BTW5++6+);R
MPG6>W8D!U/!(KD?#?B3PUK_P_P!K7J7%G9VD45]\KC8=HX/&3T[5/H_B#P9X
M>\&1W^FW:PZ%YI19 CD;SU[9[4 =G15:QOK;4[&&]LY1+;SH'C<=&!Z&L]_%
M.C)XB70&OE_M1TWBW"L3M]<XQ^M &S17*^*?B!H/A(>7?W.^[892VB!9V_S[
MUF^'/BQX=\0WHLMTMC=,<)%=+M+_ $[4 =Y1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.&&Z;&(CDGGIT%6=7\1:3H5I#=:G>QV\,QVQNP.&.,]O:@#4HKDO^%F^#O\
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M8P*F&&YG=Z(NMG7LJ?+'EE)]EH>)?\(UXP_Y][W_ +_?_7H_X1GQA_S[WO\
MW^_^O7O&!Z48'I6WU6/<XO[>K?R1^X\[^'>DZW87UX^JQSHC(H3S7W#.3TYK
MT6C HK>$5%61Y.)Q#Q%1U)*USF/B!H,?B/P5J5BX);RC(F!SN7YA_+%<C\$?
M$1N_!,UA=LPGTIV23S#SCD_ITKU0\C'K7S+XGGNOAQXX\16-@)6BU>'$)/0L
M[*S?S(JC [3X?P'QC\3]<\6S[6M[-_LUN#SR. P_ ?K5_P"/W'@FT_Z_XOY-
M75?#7PZOAKP186A'[Z1!-*2,'<W)!^F<5ROQ^_Y$FS_Z_P"/^34 8'BR,^&]
M6\%^+T4^6$2&Y(_N\8'\ZZ+XL7)UI] \*VT@+:G<JTRCJJ C!/MR:N^+=#.O
M?!P6Z1[YX;59H0.N]1Q7%?"*6\\8>,AK>I!RVE6*6H9OXVRW/UZ4 :EY;K:_
MM!Z);H JQZ;M  XXW5B?&">^M_BWH<NFP">\6W0Q1$_>;S&P*Z'5_P#DX[2O
M^O _^S5F_$<'_A>7AG_KE'_Z,:@#3/BKXN,"H\((I(P&WIQ[]:D\*_#OQ!J?
MBR+Q9XSND>ZBYAMH_P" XQR.@X]*]>HH 2O._C=_R32\_P"NB_R->BUYU\;?
M^2:7?_71?Y&@#SO6;673/AUX%\6VB_OM.2,,0.H(&,_E7;?%?6?M_@K3M-T^
M4/-KDJ1Q,G1EXW?SJ;1=$'B'X#V6F<;Y=.4(3V;;P:\^^%LE[XK\7Z3;W:G[
M'X>M]J@]GR<-^./TH M>.=.BTGXB^!;"%=L<!ME _P"VG-:7QS6Y?Q-X76S=
M$NC<((7<9"OO^4GVSBF_%3_DL'A'_KO!_P"C*L_&;_D=?!__ %^1?^C* +.L
M1_&;2-+EO4U?2[P1KN,5O;*7QW/*BN7\':->_%34X;_Q-XACF-DY9K! 5=6#
M=UP!^5?1( V_A7@OQ'T.Y^'_ (RM/&>A(4M9I/\ 2HHQA03UR!V/7ZT =[\7
M(DA^%NJ11J%1(E50.@ (J]\+?^2<:/\ ]<%_D*POB%K5KXA^#%]J=DX:*>%6
MX_A.1D?45E^ ?B?X4T?P5IMA>ZDL=Q#"%=".AQ0!ZMJ;*NEW)<@*(SG->._
MBX-AX<UN]NG,=C%,S;ST&.6_3%.\:_%.+Q)IDWA_PC;75W=WG[HS*F% /H?6
MNZ^'W@Z/PSX(BTB\1)9)LR72,-REF !'/4<4 1'XN>!@<'Q!;\?[+_X5P7QH
M-IXANO"*P2[[2]NE02+W5FP2*]3_ .$&\*$Y/AS2_P#P%3_"O./B];PVNO\
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MT;+\!0IX912OS+7S/H'PGXEC\1Z8)L!)T.V1,]#70U\Z:)K.K:.TLFF%AY@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGOM/M[B5/NLZ9(I[Z)IDE_#?/90M=1 ".4K\RX]#0!S7Q5T$^(/ -_!'N,T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3_"^CQ:5I<;1VL9+*K-N.2<GFJ6F>"=%TGQ'>:]:12K?WF[S6:4E3DY.!VH
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M[?4+.PG2XMWWQL;ER ?H37>T4 >,:O\ \G):?_UYI_.N[^)?_).->_Z])/\
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M<C'/0]Z]OC&(U&,8 X]*YSPWX \-^%6#Z7IZ),!@3/\ ,^/]X\UTU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/5#=#2[DV2JUU
MY9\H,,@MVS7SM:>"?BAI>K7-_I,2:>;A]TD5JYCC;_@('2OI1B%&3T%>(:]\
M5O$>N:]+I/@33OM"P-MDG,9DS[\=!UH AV_&P#&Z']:Z3P./B4/$<9\3M&=.
MV-NVYZX./UQ7,7-_\:=%A-W);0W:'DQHAD('T!KO?AO\1(O&]K/!/;FVU.T_
MU\78]L^W/:@#O**** "BBB@ HHHH **** $I:** "DQ[4M% !@>E%%% !111
M0 5YWXC_ .2R^&/^O27^9KT2O._$?_)9?#'_ %Z2_P S0!Z)1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M3TFPUFU
M^RZE9PW4!.?+E7<,U=HH YJW^'_A&TN$G@\.Z='*ARKK  0:Z6BB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9.0: /7:*\G_ .$(^*)'_)1$_P# 8?X5@ZKKWQ!^&VK6,VOZHFKZ7<2"-GV
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 R65((FED8*B#+,QP *\*O_ (@^
M-_'&JS6?@BU-O9V[E3<X7+_4MQ^5>N>,;"YU3P?JUC9Y^TSVSI'@XY(KB_@I
MJ.FKX0&E*$M]2MI66XA?AV;CYN?7^E '+W-C\:]/B^TC4?M(3YFC419Q^5=K
M\-_B*_BXW&FZG;"TU>S'[V(\;AZ@&O09'2-"SLJJ.I)P*\5T=8-9_:!FU'1(
M\V=I"RW<R'Y'<H0#[]0* /;**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KSOQ'_ ,EE\,?]>DO\S7HE>=^(_P#DLOAC_KTE_F: /1**** "J&MW
MSZ;HEY>QJ&>")G"MT) J_4<T,<\+Q2H'C<;64C((I/;0J#2DFSR+_A;.I_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:;=WK2!]/F6:+8< L#GF@#BIO@=:2.T,?B358M-9L_80Y,>/3K7H>@>']/\
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M/,X^G%>I^!/A_IO@;3VCMR9[R;_7W+#E_IZ"@#KZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KSOQ'_ ,EE\,?]>DO\S7HE>=^(_P#DLOAC_KTE
M_F: /1**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_%5I;WWA74[2[E:&WEMV6
M21>JC'6O!?AM\2-)\ QWFBZCNFM3*98[J ;LY[$#Z5[+XL\<>$]$BEL=<OX\
M2*5DA0%VQZ$+R*Y/P]H?P@\5/MTO3K.24_\ +-VD1S]%+9H M?\ "^O!/_/Q
M=_\ @.W^%;/AKXJ>&O%FL)IFES3M<LI8!X648 R>3]*=_P *E\!_]"Y;?]]O
M_P#%5H:-X \+>'M06^TK1X;6Z4$"1&8D C!ZF@#I**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KSOQ'_P EE\,?]>DO\S7HE>=^(_\ DLOAC_KT
ME_F: /1**** "BBJFIWRZ;IES?.I98(S(5'4X%-*[L)NRN6Z*\Z_X6UI_P#T
M#Y_^^Q4UK\4[&ZNX;=;"<-+(J EAQDXK?ZK62ORF"Q5*^YW]-9@BEF. !DGT
MH'(!KS?Q=\0%ABO=)MK>1+C[GFDC ]:BE2E5ERQ+JU8TX\TCN]*UBTUB&26T
MD#".0QL,\@@XJ_7@O@[Q8_AF\E:5'EMI1\T:G^+UKVG1-5CUK2XKZ*-HUD'"
ML>16F)PTJ+\C+#XF-5>9HT5S?BCQ=;^%S;">WDF,^[&P@8QC_&N>_P"%M:?_
M - ^?_OL5$,/4FKQ1I/$4X.TF>BT5S'A?QE;>)[B>*"VDB,*AB7(.<UT]9R@
MX.TC2$U-7B>=_%CQQJ_@JPTV728K:26ZN/*(G4L.A]".]9,&K?&:XMHYX](T
M$QR('7]YR01D?QU2_:#_ .0=X>_Z_P ?R->M:/\ \@2P_P"O:/\ ]!%24>7Z
M?\6=5TC78-(\:Z/]@DF.$N(P1&3[9SD?C7K:.LBAU(*D9!!K@/C)HMMJ?P^O
M[F51Y]B!/"X'(.<=?3FKGPIU.75OAWID\SEGC3R23U.W H [3G'O7FFA?$+5
M9?BCJ'A+6(;=(TR;62-"I<#UR3G->F5XA\9+23P[XJT/QI;;MT4@CF"CC"D$
M9^N30![?7G'Q"\>ZCX>U[1M$T2.WEO;V51()HR^Q"<9P"/>N\LKV*\TR"]21
M3%)&'W9XQBO'_ R/XR^+>L>)I<M:6!,%L",KG&"/US0!I?%/XCZ_X(NM,M]/
MALY7N(-\IEC8_,,YQ@CCBNN^'GBN7QCX0MM5N$C2Y9F65(^BD$C^E><?&>))
M_B!X5B<920JK#U!<BM#X6&3PUXZ\3>%+G"9E-W" > I(P!^#4 >D>+-<_P"$
M;\,7^JX5FMX]R*W\1S@"O.OA;\3M?\8^(I].U:WLXDC@,@\F-E;.1UR3ZU:^
M+ETVIZAX?\(P%A-J%R)68=-BYR#^E8'PW@CM?C;XDMXEVQQB55 [ .* +U_\
M0O'5Y\0M3\,^';+2YOLK-L^T J2JGN=P%7I=6^,MM$TTNB:(\:#++&^6(]AN
MZUS_ (=O[/3_ -H77YKV[@MHL2C?-($7.>F37KLWC#PW!$TK:]II51DA;I&/
MY T <Y\/_B0GBV>YTR^M#8ZO:_ZR!^-P]0#_ "KOJ\"^'^?$GQRU;Q%IJ$:9
M'OR^,!MR[1^M>^T >4_%GXCZWX)U+3[;28+247$1=_/0L<@GI@CTKK/A[XJD
M\8>$+;59UC2Y<LLJ1]%()'3\*\W^,T23_$+PK#( 4DVJP/<%R*T/A69/#?CC
MQ-X3N,*?--U" > I(P!^#4 >C^+==_X1OPO?ZMA6>WCW*K?Q'. *\\^%GQ-U
M_P 9>(+C3]6M[.)(X3(/)C93G(]2?6K'Q<NFU34_#WA&!F66_N1*Q'38N<@U
MA_#:".V^-7B6"(;8X_-51Z .* -7Q7X_\86OQ&/A;P[:Z=,S1*Z?:5(.3UYW
M 5.=0^-(&?['T#\)/_LZYS7=2M-)_:+CN[Z=((%MDW.YP!S7I[?$?PDJECK5
MM@<\.* .1\*_%749/$Z>'/%FF+I]_+Q'(,JC'L #UR>.M:7Q8\=:OX)L]+DT
MF*VDDNYS$PN$)'3C&"*\]US5(OB1\7-&;P]$TMO8O&TMSL*C"MN.?PZ5N_M!
MC;8^&QW%X?Y"@#2AU;XS3V\<\>D:"8Y$#K^\[$9_OTS3?BSJFE:[#I'C71S8
M23':EQ&"(R?;/4?C7J&D_P#(&L?^O>/_ -!%</\ &?1;;4_A_>W<BXN+';-"
MX'(.X#^IH ]"1U=%="&5AD$'J*=7&_"W59=8^'NEW,[%G5/*R?\ 9X_I794
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M!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN;KXI6WBP7,8@B@6(Q<[CBNZHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /";>%O^ABTO_P "T_QH_P"$V\+?]#%I?_@6G^-9'_"I/ ?_ $+EM_W\D_\
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MWA;_ *&+2_\ P+3_ !K(_P"%2> _^A<MO^_DG_Q5'_"I/ ?_ $+EM_W\D_\
MBJ -?_A-O"W_ $,6E_\ @6G^-'_";>%O^ABTO_P+3_&LC_A4G@/_ *%RV_[^
M2?\ Q5'_  J3P'_T+EM_W\D_^*H U_\ A-O"W_0Q:7_X%I_C1_PFWA;_ *&+
M2_\ P+3_ !K(_P"%2> _^A<MO^_DG_Q5'_"I/ ?_ $+EM_W\D_\ BJ -?_A-
MO"W_ $,6E_\ @6G^-'_";>%O^ABTO_P+3_&LC_A4G@/_ *%RV_[^2?\ Q5'_
M  J3P'_T+EM_W\D_^*H U_\ A-O"O_0Q:7_X%I_C1_PFWA;_ *&+2_\ P+3_
M !KC_%?PO\%V'A;4KJUT"WBGB@9D<.^5('^]5?P-\,_!NJ>#=-O+W08)KB6(
M,\C.^6/X-0!W'_";>%O^ABTO_P "T_QH_P"$V\+?]#%I?_@6G^-9'_"I/ ?_
M $+EM_W\D_\ BJ/^%2> _P#H7+;_ +^2?_%4 :__  FWA;_H8M+_ / M/\:/
M^$V\+?\ 0Q:7_P"!:?XUD?\ "I/ ?_0N6W_?R3_XJC_A4G@/_H7+;_OY)_\
M%4 :_P#PFWA;_H8M+_\  M/\:/\ A-O"W_0Q:7_X%I_C61_PJ3P'_P!"Y;?]
M_)/_ (JC_A4G@/\ Z%RV_P"_DG_Q5 &O_P )MX6_Z&+2_P#P+3_&C_A-O"W_
M $,6E_\ @6G^-9'_  J3P'_T+EM_W\D_^*H_X5)X#_Z%RV_[^2?_ !5 &O\
M\)MX6_Z&+2__  +3_&C_ (3;PM_T,6E_^!:?XUD?\*D\!_\ 0N6W_?R3_P"*
MH_X5)X#_ .A<MO\ OY)_\50!K_\ ";>%O^ABTO\ \"T_QH_X3;PM_P!#%I?_
M (%I_C61_P *D\!_]"Y;?]_)/_BJ/^%2> _^A<MO^_DG_P 50!K_ /";>%O^
MABTO_P "T_QH_P"$V\+?]#%I?_@6G^-9'_"I/ ?_ $+EM_W\D_\ BJX;P1\/
MO"NI^(_$UM>:-#-#:782!"[?(NQ3@8/J30!ZA_PFWA;_ *&+2_\ P+3_ !H_
MX3;PM_T,6E_^!:?XUD?\*D\!_P#0N6W_ '\D_P#BJ/\ A4G@/_H7+;_OY)_\
M50!K_P#";>%O^ABTO_P+3_&C_A-O"W_0Q:7_ .!:?XUD?\*D\!_]"Y;?]_)/
M_BJ/^%2> _\ H7+;_OY)_P#%4 :__";>%O\ H8M+_P# M/\ &C_A-O"W_0Q:
M7_X%I_C61_PJ3P'_ -"Y;?\ ?R3_ .*H_P"%2> _^A<MO^_DG_Q5 &O_ ,)M
MX6_Z&+2__ M/\:/^$V\+?]#%I?\ X%I_C61_PJ3P'_T+EM_W\D_^*H_X5)X#
M_P"A<MO^_DG_ ,50!K_\)MX6_P"ABTO_ ,"T_P :/^$V\+?]#%I?_@6G^-9'
M_"I/ ?\ T+EM_P!_)/\ XJC_ (5)X#_Z%RV_[^2?_%4 :_\ PFWA;_H8M+_\
M"T_QH_X3;PM_T,6E_P#@6G^-9'_"I/ ?_0N6W_?R3_XJC_A4G@/_ *%RV_[^
M2?\ Q5 &O_PFWA;_ *&+2_\ P+3_ !H_X3;PK_T,6E_^!:?XUD?\*D\!_P#0
MMVW_ '\D_P#BJY;5?AOX0@\?:%81:' MK<17#2QAWPQ4+COVR: /0/\ A-O"
MW_0Q:7_X%I_C1_PFWA;_ *&+2_\ P+3_ !K(_P"%2> _^A<MO^_C_P#Q5'_"
MI/ ?_0N6W_?R3_XJ@#7_ .$V\+?]#%I?_@6G^-'_  FWA;_H8M+_ / M/\:R
M/^%2> _^A<MO^_DG_P 51_PJ3P'_ -"Y;?\ ?R3_ .*H U_^$V\+?]#%I?\
MX%I_C1_PFWA;_H8M+_\  M/\:R/^%2> _P#H7+;_ +^2?_%4?\*D\!_]"Y;?
M]_)/_BJ -?\ X3;PM_T,6E_^!:?XT?\ ";>%O^ABTO\ \"T_QK(_X5)X#_Z%
MRV_[^2?_ !5'_"I/ ?\ T+EM_P!_)/\ XJ@#7_X3;PM_T,6E_P#@6G^-'_";
M>%O^ABTO_P "T_QK(_X5)X#_ .A<MO\ OY)_\51_PJ3P'_T+EM_W\D_^*H U
M_P#A-O"W_0Q:7_X%I_C1_P )MX6_Z&+2_P#P+3_&LC_A4G@/_H7+;_OY)_\
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MO"W_ $,6E_\ @6G^-9'_  J3P'_T+EM_W\D_^*H_X5)X#_Z%RV_[^2?_ !5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ$@D'\* .BHHHH **** "BBB@ HHHH **** "BBB@ KS;X<_\C;XP_Z_A_Z
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MC'>@#<HHHH **** "BBB@ HHHH ***R?$7B&Q\,Z-/J5_*J1Q+D+GESV ]Z
M-:BL'PAXD3Q9X?AU:.$PI*3A2<TSQ;XRTKP;IXNM2D;<YQ%$@R\A] * .AHK
MR.W^.,"S))J>A7EI8N<"?;G'H2*]3T^_MM4L(;VSE$MO,H9''<4 6:*** "B
MBB@ HHHH **** "BBN(\8?$[1O"=T+!UEN]189%O N2/3/I0!V]%>5:;\;+%
MM1CM=;TNYTP2'"2N,J/J>U>I12I-$LD;!D89!'0B@!]%<_XO\7:?X/T674+V
M0%@,1Q \NW85<\.:PNO^'[/55C,8N4WA"<XY(_I0!J4444 %%%% !1110 44
M44 %%5K^^MM,L9KR[E6*")2SNW0"O++GXXVTEU(-'T2\OK6/@S;=OUQC/% '
MKE%<IX-\?Z/XTBD%BTD5U%_K+>9<,/\ ZU=50 M%<-XB^)>GZ'XMT_PZD?VB
MZN7"R8;_ %6>G]:[@'*@^HH 6BBB@ HHHH **** "BBB@ HIKLJ*68@*HR2>
MU>7ZO\:M-@U&2QT73[G5)(B5D>,83(]#WH ]2HK@O"'Q4TCQ1?'39(I;'41T
M@F&-WT/>G^,_'UWX5U*&U@T.>_61-YDC/ ]J .ZHKQY_C5?Q(SOX3NU11DDG
M@?I74_#SXA#QY#>2II[VR6[* Q;(;.?\* .XHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYKVP5X?9QS?#/XK6.@V-Q(^B:FA=;=SDQ]1U^H_*O<* "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-S/=R-NEN9(V+M^-?1E% 'FOAKQQXMU77;>SU'PM-9VTA^>=D8!?SKTJBB@
MHHHH **** "BBB@ HHHH *Q/%]O+=^$=5MX(VDEDMI%1%&225.*VZ* .)^$^
MG7>E?#O3;.^MW@N(]^Z-UP1EV-8_Q$\#ZO?Z]8>*?#+QC5+/[T;M@2#'^'%>
MG44 >,7'B?XF>(;5](MO#PL9IAY<ETZE54=R">*[WP!X/B\%^&H].#^9<,=\
M\G]YO\*ZJB@ HHHH **** "BBB@ HHHH *P?&MM->^"-:M;>-I)I;.1$11DL
M2IP!6]10!Q/PHTV\TKP#96E];O!.F=R.N"*R?B#X*U>ZURS\5>%W1-6M%VM&
MQP)5YS^AQ7I=+0!XK<>)_B9XAL7T>'PZME/,ICEN74JH!X."37>_#[P:G@OP
MXMDT@ENI6\RXD_O.?\.E=;10 4444 %%%% !1110 4444 -<[49L9P,X%?-_
MB&#Q7J?Q%GUB]\-WFH6-O(RVUNT3;-H/RG\J^D:6@#QU/B+XXBC6./P1.J*,
M!5B8 5Z=X>O[S4]"M+R_M&M+J5-TD+#!0^E:E% '#_%K3;S5OA]>V=C;O/<.
MZ%8T7).#6IX!M+BP\"Z3:W4313QPX=&&"#N-=)10 4444 %%%% !1110 444
M4 <-\5+O7H/";6_A^UFGNKIO*9HE)9%[GCUZ?C7E_@N_\4>#-/,-MX)N)KF1
MBTMR\;%GKZ)HH \U\->-_%FK:[;V>I>%IK.UD.))F1@%%>@'3K)B2;.W)/<Q
M+_A5JB@#RKXD^&KB]\7^$)M/TS?;P7#FX,47RJ,KC=@?6O4((8X(E2*-8UQ]
MU5P*EHH **** "BBB@ HHHH **** ,7Q7>7]AX:OI],@>:]$9$*(I8[B.#@>
M]> ^$!XL\-:A=:G<^#[J_P!1G<MY\L3$J#V%?3%% 'DMG\0_&\U[;Q2^#IXX
MI)%5W,;?*">37H7B:2Y7POJ+6D+37#0,J1J,DD\?UK8I* //?@SH5WH7@.**
M_MWM[N2:1G1UP0-QQ^E>AT44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g0vsdaj33nnl000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /,""@# 2(  A$! Q$!_\0
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M-'_#0FC?] 2__P"^T_QH ]BHKQW_ (:$T;_H"7__ 'VG^-'_  T)HW_0$O\
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M :^_[[3_ !H_X7]H_P#T!K[_ +[3_&CZO5[![2/<]=HKR+_A?VC_ /0&OO\
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M+_X6+9_\^,__ 'T*/^%BV?\ SXS_ /?0HN@^N4/YCM**XO\ X6+9_P#/C/\
M]]"C_A8MG_SXS_\ ?0HN@^N4/YCM**XO_A8MG_SXS_\ ?0H_X6+9_P#/C/\
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MLJD8[L]"I:\\_P"%LZ=_T#;K_OI:/^%LZ?\ ] VZ_P"^EH)]M3[GH=%>>?\
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M;T^YZ'17GG_"V=._Z!MU_P!]+1_PMG3O^@;=?]]+0'MZ?<]#HKSS_A;.G_\
M0-NO^^EH_P"%LZ=_T#;K_OI: ]O3[GH=%>>?\+9T[_H&W7_?2T?\+9T[_H&W
M7_?2T![>GW/0Z*\\_P"%LZ=_T#;K_OI:/^%LZ=_T#;K_ +Z6@/;T^YZ'17GG
M_"V=._Z!MU_WTM'_  MG3O\ H&W7_?2T![>GW/0Z*\\_X6SIW_0-NO\ OI:/
M^%LZ?_T#;K_OI: ]O3[GH=%>>?\ "V=._P"@;=?]]+1_PMG3O^@;=?\ ?2T!
M[>GW/0Z*\\_X6SIW_0-NO^^EH_X6SIW_ $#;K_OI: ]O3[GH=%>>?\+9T_\
MZ!MU_P!]+1_PMG3O^@;=?]]+0'MZ?<]#HKSS_A;.G?\ 0-NO^^EH_P"%LZ=_
MT#;K_OI: ]O3[GH=%>>?\+9T_P#Z!MU_WTM'_"V=._Z!MU_WTM >WI]ST.BO
M//\ A;.G?] VZ_[Z6C_A;.G?] VZ_P"^EH#V]/N>AT5YY_PMG3O^@;=?]]+7
M?6\PN+:*900)$# 'MD9H*C.,MB2EI*6@L**** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5](:;_P @NT_ZXI_(5\WU](:;_P @NT_Z
MXI_(4SLPO4MT444':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?(?Q(_Y*-KW_7VU<M74_$C_ )*-KW_7VU<M0 4444 %%%% !1110 44
M44 %%%% !3DC>5ML:,[>BC)J6SMS>7UO;!MIFE6,'TR<5]3Z%X.\,^ -&CO9
MHH!<01YEO90-Q/?![#VH ^5WL[F-2SVTRJ.I*$"H>2< 9/I7U78_$+P5XN:7
M2VN8V5L QW:;%D). !GJ<UY?KMEX+T_XNZ/;Z?\ 9ULDEQ?JS#R$/H.WU]Z
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MHHK0D**** "BBB@ HHHH **** "BBB@#T3X4>-6\.:V-/N=SV5ZZIP?]6Y.
M<=,<\_2O:?'/AE/$FB[X65;F >9$V/O<=,^E?*5?1'PA\<#6],_L:^D=K^T3
MY6<Y\Q,\<^HSC'M7'6C*G-5H;HV@U)<DCRAT:.1HW4JZG!![4VO3/B=X3-O<
M-K=G&HAD/[]5&,-_>]\\UYG7TV$Q,<124T>;5IN$K,****Z3,**** "BBB@
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MOA\RI_:-I""X_P!<%ZD>OO7P^+PTJ-1PET.C%TE7A[6&Z//Z***Y#Q@HHHH
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M** "BBB@#Y#^)'_)1M>_Z^VKEJZGXD?\E&U[_K[:N6H **** "BBB@ HHHH
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M_P"2=6O_ %RD_FU>"L,,1Z&O>O W_).K7_KE)_-JZ<XLZ,&NY&$OSL\+O?\
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MZ=\8_P#C^TK_ *YR?S6O,:]3*?\ =4<V*_B,****](YPHHHH **** "BBB@
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MR[E:6>5B[,QSU_I77A:/,^9[&-6=E8KT445ZARA1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K<\,:(
MVL:B VY8(OF<@=?:LBUMI+RZCMX@"[L *]<TNPAT#1MA(_=J7D?&,FJBCNP6
M']K+F>R*_B;7(O#6AM,@0RXV0QD]3]/05X1<W$EW<R7$S;I)&W,:V/%?B%_$
M.KO< %+=!MB4GMZ_4UA59WUJG,[+8****# **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^D--_P"07:?]<4_D*^;Z^D--_P"07:?]
M<4_D*9V83J6Z***#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXG_Z \_YK_C1]=P_\Z#V4^QSM%=%_P (+XG_ .@//^:_XT?\(+XG_P"@//\
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MRL/85?Y3(HK7_P"$7UK_ *!\OYC_ !H_X1?6O^@?+^G^-'*P]A5_E,BBM?\
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MV<NQ@T5O?\(5XC_Z!,WYK_C1_P (5XC_ .@3-^:_XT![.78P:*WO^$*\1_\
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M%% !1110 4444 )1BEHH 2EHHH **2B@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I*6B@!*,4M% "8HQ2T4 )BCBEHH 3%&*** #%&*6
MB@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1B
MEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,4
M8I:* $Q1BEHH 3%&*6B@!,48I:* $HQ2T4 )BC%+10 F*,4M% "8%&!2T4 )
MBC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
M"8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+1
M0 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 E+24M "44M)0
M 8H_"BEH 3\*/PI:* $_"C\*6B@!/PH_"EHH 3\*/PI:* $_"C\*6B@!/PH_
M"EHH 3\*/PI:* $_"C\*6B@!/PH_"EHH 3\*/PI:* $_"C\*6B@!/PH_"EHH
M 3\*/PI:* $_"C\*6B@!/PH_"EHH 3\*/PI:* $_"C\*6B@!/PH_"EHH 3\*
M/PI:* $_"C\*6B@!/PH_"EHH 3%&*6DH *6BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "DI:2@#G6O]8N=4N[:S:'; V/G':I,>)?[UK1I'
M_(PZM_O#^9K?H P,>)?[UK1CQ+_>M:WZ* ,#'B7^]:T8\2_WK6M^B@# QXE_
MO6M&/$O]ZUK?HH P,>)?[UK1CQ+_ 'K6M^B@# QXE_O6M&/$O]ZUK?HH P,>
M)?[UK1CQ+_>M:WZ* ,#'B7^]:T8\2_WK6M^B@# QXE_O6M&/$O\ >M:WZ* ,
M#'B7^]:T8\2_WK6M^B@# QXE_O6M&/$O]ZUK?HH P,>)?[UK1CQ+_>M:WZ*
M,#'B7^]:T8\2_P!ZUK?HH P,>)?[UK1CQ+_>M:WZ* ,#'B7^]:T8\2_WK6M^
MB@# QXE_O6M&/$O]ZUK?HH P,>)?[UK1CQ+_ 'K6M^B@# QXE_O6M&/$O]ZU
MK?HH P,>)?[UK1CQ+_>M:WZ* ,#'B7^]:T8\2_WK6M^B@# QXE_O6M&/$O\
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M Y/,RL:OZPT8U?UAK5HH#D\S*QJ_K#1C5_6&M6B@.3S,K&K^L-&-7]8:U:*
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M&'5O]X?S-;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &5K_ /R#?^!K_,5HP_ZB/_=%9VO_ /(-_P"!K_,5HP_ZB/\ W10!)111
M0 5@7_\ R->G_P#7,_SK?K O_P#D:]/_ .N9_G3B)F_1112&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5FZ__ ,@&]_ZY&M*LW7_^0#>_
M]<C36XGL)X?_ .0!9_\ 7.M.LSP__P @"S_ZYUIT/<$)WI>])WI>](9E:Y_J
MH/\ KJM:B?<7Z5EZY_JH/^NJUJ)]Q?I5OX42MQ:***@H**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#"\0_Z_3_^N_\ 45NCI6%XA_U^G_\
M7?\ J*W1TJY?"B5NPHHHJ"@JEJG_ !X2?A_.KM4M4_X\)/P_G03/X66+;_CV
MB_W14M16W_'M'_NBI:!K8****!A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5F:U_P >\?\ UT%:=9FM?\>\?_704$5/A9I#H*6D'04M!844=J*
M*FH_\@^?_<-+IO\ R#X?]VDU'_D'S_[AI=-_Y!\/^[01]HM4444%A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4-7_X\'JU;_ZB/_=%5=7_
M ./!ZM6_^HC_ -T4$?:)*6DI:"PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@# TC_D8=6_WA_,UOU@:1_R,.K?[P_F:WZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,K7_ /D&_P# U_F*T8?]
M1'_NBL[7_P#D&_\  U_F*T8?]1'_ +HH DHHHH *P+__ )&O3_\ KF?YUOU@
M7_\ R->G_P#7,_SIQ$S?HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *S=?_P"0#>_]<C6E6;K_ /R ;W_KD::W$]A/#_\ R +/_KG6
MG69X?_Y %G_USK3H>X+83O2]Z3O2]Z0S*US_ %4'_75:TT^X/I69KG^J@_ZZ
MK6HGW%^E6_A1*W%HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,+Q#_ *_3_P#KO_45N#I6'XA_U^G_ /7?^HK='2KE\*)6["BBBH*"
MJ6J?\>$GX?SJ[5+5/^/"3\/YT$S^%EBV_P"/:/\ W14M16W_ ![1_P"Z*EH'
M'8****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F:U_Q[Q_\
M705IUF:U_P >\?\ UT%!%3X6:0Z"EI!T%+06%%':B@"IJ/\ R#Y_]PTNF_\
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M1KT__KF?YUOU@7__ "->G_\ 7,_SIQ$S?HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BDHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH[T4
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M%!'VB2EI*6@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MP-(_Y&'5O]X?S-;]8&D?\C#JW^\/YFM^@ HHHH **** "BBB@ HHHH ****
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M%% !1110!E:__P @W_@:_P Q6C#_ *B/_=%9VO\ _(-_X&O\Q6C#_J(_]T4
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MO9KG3IB$<3.3Y?N,].M?3<,T=Q!'/$P:.10ZL.X(R#0!)1110 4444 %%%%
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MDZQ;Q3V%_!,DHR@#X8_@>:Q-7^'OA3Q' &GTZ%0Y\SSK8"-GSW)'7K7GVJ?
M^\TZ66^\+:S)%<A_W,+DIM4]?WF<_I0![3<7$-K;R3SR+'%&-S.QP *\GU?X
MZ6*3RVNA:9/?S*V$D(^1QZX'S5YSXLOO'.F1P>%/$%X_DS."'#%O-!./O?Q
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M /D&_P# U_F*T8?]1'_NB@"2BBB@ K O_P#D:]/_ .N9_G6_6!?_ /(UZ?\
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M5(P%%S$'*YSM)[5JT %%%% !1110 4444 %%%% !1110 4444 87B'_7Z?\
M]=_ZBMP=*P_$/^OT_P#Z[_U%;HZ5<OA1*W84445!052U3_CPD_#^=7:I:I_Q
MX2?A_.@F?PLL6W_'M'_NBI:BMO\ CVC_ -T5+0-;!1110,**** "BBB@ HHH
MH **** "D-+24 4-7UO3M"LGO-2NHX(4!)+'DX]!U/X5YG>_'[0[>]DAM],N
M[F%6PLRL%#CUP>17*ZXM]\3/BU+H<C^38V4C(5#DC8APS#W/I79MJ'PX\+:I
M;^%6TZ&>Y&(V=K=9-K'LS'G//ZB@#KO"_CG0_%L1.G70\] #) _#*3VYZ_A6
M)\2/AQ;>,+(W5H%@U>%<I(!_K0.=K?T/O7 _$;P=)X U.W\6^&Y?L\(F >(G
M[KGD8'=3@\?2F#Q!\3_'D)33[=K33;DC9*B[0F/^F@&: &^ ?B3<^$+N3P_X
MI\U+>)BH=U):(@_J*ZK6_CKHMJ[0:1:SZA(R?NY -J[ST!!Y/:L ? O5;[3Y
MKS5M;9]6Q\JY,BMCIESST]JY[P-K-MX'\22:-XJTFW,)DQYTL"L\+]CDCIT^
ME &?XOUWQ)XHN++7]7T=K:"R81@QQ,HQG=SN_GTKVV.'PQ\5M*TW4)@'-NV_
M[.7&Y"<95AZ<=:ZZYM+'6](:WE5)[*XC' Z,IZ8KQ[5_@MK&FW;3>#]9D@CE
M8[XWF:+8.PW#);OUH ]-\2ZYI?A7PW<-++% J0%8800">PP.O6OGGPGK_BGP
M[)-X@T[2_MD=\[!F,;.-P//"_6NTT_X*:YJLS/XJUMY-BXBV2M,?S;&*R=+U
M76O@[XG;3-25[C0YWSTSE<_>7T//([T =IHOQTT*\D,6JVT^G,B\NPW!F[@
M<C\:]$TW7]*U>&.2PO[>;S%W*HD&['^[UKG;KP=X,\;:9;WJV4#V\G[Q);7]
MV6SZE>M<-J?P-N]/+W?A?6YH[HR?*CL8PB'MO!)..* /;*Y?Q1X_T'PD?*U"
MZ!NBFY8$!+'V..GXUY//XE^)G@&U>/4H/M.GP QBX==RECPIWD9/..M)\/\
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MFOL2OC+0ACQEI@_ZB$7_ *,%?9M !1110 4444 %%%% !1110 4444 %%%%
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M /R#?^!K_,5HP_ZB/_=%9VO_ /(-_P"!K_,5HP_ZB/\ W10!)1110 5@7_\
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M>E[TAF5KG^J@_P"NJUII]P?2LS7/]5!_UU6M-/N#Z5;^%$K<=1114%!1110
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M=-_Y!\/^[2:C_P @^?\ W#2Z;_R#X?\ =H(^T6J***"PHHHH **** "BBB@
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M_J(_]T4$?:)*6DI:"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@# TC_D8=6_WA_,UOU@:1_R,.K?[P_F:WZ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KXMU;_D:+[_ *_9/_0S7VC7Q=JW_(T7W_7[)_Z&: /K
MSPQ_R+&F_P#7NG\JX/XO:[H^C00)+IUO<ZS-&4MI9DSY*'()_G7>>&/^18TW
M_KW3^54_$6N>%]*N8DUZ2U25TS'YT!<[<]CM/O0!E?">SMK'P!:PVMTMPN]V
M=UZ!SU'X&O,[G3/BZ;J8Q:C?B,NVT?:.V>*]TTBXTV[TZ.XTDP&SD&Y#"H53
MGVJ]0!\\_P!E_&'_ *"5_P#^!%']E_&'_H)7_P#X$5]#T4 ?/']E_&#_ *"5
M_P#^!%:&A:=\54\0:>VH:A>M9BX0SJT^04R,Y'TKW>DH 6O-OCG_ ,DX?_K[
MB_K7I->;?'/_ ))P_P#U]Q?UH \T^!7_ ".4W_7&OI2OFOX%?\CE-_UQKZ4H
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,K7_\ D&_\#7^8K1A_U$?^
MZ*SM?_Y!O_ U_F*T8?\ 41_[HH DHHHH *P+_P#Y&O3_ /KF?YUOU@7_ /R-
M>G_]<S_.G$3-^BBBD,**** "BBB@ HHHH **** "BBB@ HHHH \Z^-W_ "36
MZ_Z^(O\ T*N*_9\_X_M4_P"N8_F*[7XW?\DUNO\ KXB_]"KBOV?/^/[5/^N8
M_F* />J*** "L/Q?:ZC=^&+U-)O'M+U8]\<L:DM\O.!CN<8_&MRB@#YS^&?Q
M$U#3_%\UKXAO))$O6$<LEP?F21>!DGH ,BNSU#X/SW_CQ_$RZS$L;WBW0A\@
MDX!!QG/M67\4OA5<W][)KN@Q!Y&&9K9>"3_>6N/\*_%GQ!X486.HHUY:KM7R
MYQAXP#S@]2?K0!ZU\0OAM-XWU73[R+4DM!:1E"K1%]WS9]15[Q;X&E\3>#[;
M0TOD@:$I^],98';[9JF/BUI0\+1Z_-87D5K)/Y*!MN6."<CGIQ7*:M^T#:?9
M2-(TF8SYZW1 7'_ 3F@#?U#5+3X3_#N#2KF[%U?>6T< C&TN22=V.< 9Z^U>
M;?!WP]<>(O&C:U=EI(;)O.>0OAC*3E?J.#FL;3='\2_$_P 4>=,9765MTMPX
MQ'$GM_+BOI7PQX8T_P *:-%IVGQX51EY"/FD;N30!M44E+0 5Q'Q:_Y)WJ7^
MY7;UQ'Q:_P"2=ZE_N4 >>?L\?\A'7O\ KE#_ #:O>J\%_9X_Y".O?]<H?YM7
MO5 !1110 4444 %%%% !1110 4444 %9NO\ _(!O?^N1K2K-U_\ Y -[_P!<
MC36XGL)X?_Y %G_USK3K,\/_ /( L_\ KG6G0]P0G>E[TG>E[TAF5KG^J@_Z
MZK6HGW%^E9>N?ZJ#_KJM::?<'TJW\*)6XZBBBH*"BBB@ HHHH **** "BBB@
M HHHH I:O=&QT>\NQUAA>08]AFOBZ]E\_4+B8]9)6<_B2:^TM5M/MVDW=I_S
MVA:/\QBOBZ_A\C4;J#_GG*R_D2* /K+X;V$%AX TA85VB6W69O=F )KYX^*T
MTDGQ*UE7=F6.4*H/8;5KZ&^&M_#?_#_2&A.1# L+?[R@ U\\_%:&2/XE:RSH
M5624,A/\0VJ* /1?V>8T-GKDA4;A)$ >_1JF_:$E']CZ/$&^;SW)'MMJ#]GE
MU%GKD98;C)$0/;#5/^T)'_Q)M&D"\BX<$^VT4 >8_"^P:^^(6D@(K)%+YCAN
MFT?_ *Z]W^+7BB7PSX/<6CA+N[/DQY7/R_Q?0X/%>$_"Z_:P^(6E$.J)-+Y;
MEC@;3_\ JKW/XO\ AR7Q!X,=[:)I;FT;S4"_W>-WZ"@#Y==FDD9W8LS'))[U
M+:7<]A=Q75K*T4\3!T=3R".]0E65BK*58'!!'(J>QL+K4KV*SLH7FN)6"HB#
MDF@#ZXT+4AXK\ P7NPJ;RT92'.3G!7)_$9KY)U*R;3=2NK%VW-;R-&2.A(.*
M^MM#TX>$O $-F[Y-G:LS%SCYN6Q^9Q7R3J5ZVHZG=7K+M:XE:0CTR<T ?4WP
MHN5N/ASI**"##&4.?7)/]:\2^-@Q\2[SWAA_] %>V?"BU%O\.=*89S+&7/YD
M?TKQ/XUMN^)=X 00((O_ $ 4 =)^SS_R%]<_ZX1_^A&NC^/T49\(V,Q1?,%X
M%#=P-K<5SO[/(/\ :VMG!QY$?/\ P(UT?Q^E0>$;&+</,-X&"]\;6YH \<^'
M=U):>.]*>,XWSK&?H2 :^O*^0OAY:R7?CK2DB4L4G60X] 037U[0 M%%% !1
M110 4444 %%%% !1110 4444 87B'_7Z?_UW_J*W1TK"\0_Z_3_^N_\ 45NC
MI5R^%$K=A1114%!5+5/^/"3\/YU=JEJG_'A)^'\Z"9_"RQ;?\>T?^Z*EJ*V_
MX]H_]T5+0-;!1110,**** "BBB@ HHHH **** "DI:2@!KR)&C.[!549+$X
MK#D\:^&HI1&VMV&X\<3KQ]>:\J\>^(-9\:^,QX+T"7RH(GQ.ZDC+ X8L>N%]
MO6K ^"OA>V=;6\\12_;)> I*9#=3C_Z] 'L=E?V>I0>?8W4-S%G&^)PP_,58
MKYTUG1];^#>NV>HZ;>27>EN2"CGY3TRK#H"?4>E;]]\=Y[L1IH&@RRR$8D\\
M$X/MM)_6@#VS(')X%<QK?Q"\,:!%OO-4A<AMK1P$2.#[J.:\I7P]\3_'+_\
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M@ HHHH **** "LW7_P#D WO_ %R-:59NO_\ (!O?^N1IK<3V$\/_ /( L_\
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MXJ>,/%$AL?#.BO;K,?W$^P[P!SU/RTVV^%OC7Q5-]N\2ZR]NSD++$S_,5''
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M43PUX;VR:E,-K2(=QC)Z =L_6N:C^#WC#6H_[3U+Q L-[.-\D;EBP/U4X]*
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MN+VX/R(QCA0'(50>WUZ_C6K\*=>OM(\=:?;6\K""]F6&://RL">N/45#XR\
M:YX?U^>'[#+<P2N9(9;>,NI4GVSC'3GTK7^%G@?6K[Q?9ZC+:RVMKI\RS2-/
M&5W8/"@'DY]: /IRBBB@ KY__:%_Y#NB_P#7L_\ Z%7T!7S_ /M"_P#(=T7_
M *]G_P#0J .H^ O_ "*%Q_U\-_2O6*\I^ RD>#9V];EOZ5ZM0 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH RM?_Y!O_ U_F*T8?\ 41_[HK.U_P#Y!O\
MP-?YBM&'_41_[HH DHHHH *P+_\ Y&O3_P#KF?YUOU@7_P#R->G_ /7,_P Z
M<1,WZ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *0G )]*6D(R"/
M6@#Y/\;>+M>N/&6J8U:[B2*X>)$AF:-0JD@< XK _P"$FU[_ *#>I?\ @4_^
M-;WC3PCKT'C'5"-)NY4EN'E1X86=2K$D<@8K!_X1G7_^@)J7_@*_^% !_P )
M-KW_ $&]2_\  I_\:S9II;B9YIY7EE<Y9W8LS'W)K2_X1G7_ /H":E_X"O\
MX4?\(SK_ /T!-2_\!7_PH RJ*U?^$9U__H":E_X"O_A1_P (SK__ $!-2_\
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M -PTNF_\@^'_ ':34?\ D'S_ .X:73?^0?#_ +M!'VBU11106%%%% !1110
M4444 %%%% !1110 4444 %>*?M"?\@[1_P#KL_\ Z#7M=>+?M"H?[+T9NQG<
M?^.B@!W[//\ R!M;_P"OB/\ ]!->SUX+\"/$6E:9!JMA?7L5M-,ZRH9F"*5
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M_@,G^%']@:-_T"+#_P !D_PK1HH SO[ T;_H$6'_ (#)_A1_8&C?] BP_P#
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MH **** "BBB@ K-U_P#Y -[_ -<C6E6;K_\ R ;W_KD::W$]A/#_ /R +/\
MZYUIUF>'_P#D 6?_ %SK3H>X(3O2]Z3O2]Z0S*US_50?]=5K33[B_2LS7/\
M50?]=5K43[B_2K?PHE;BT445!04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &%XA_P!?I_\ UW_J*W1TK"\0_P"OT_\ Z[_U%;HZ5<OA1*W8
M4445!052U3_CPD_#^=7:I:I_QX2?A_.@F?PLL6W_ ![1_P"Z*EJ*V_X]H_\
M=%2T#6P4444#"BBB@ HHHH **** "BBB@ I*6B@!DD4<T;1RHLD;##*PR"/0
MBN5U#X:^$]3OQ>W&E1^<#D>6Q1?R'%=;10!5LM.LM-B\JRM8;=, $1H%SCUQ
MUJS2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5FZ__P @&]_ZY&M*LW7_ /D WO\ UR--;B>PGA__ ) %
MG_USK3K,\/\ _( L_P#KG6G0]P6PG>E[TG>E[TAF5KG^J@_ZZK6FGW!]*S-<
M_P!5!_UU6M1/N+]*M_"B5N+1114%!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 87B'_ %^G_P#7?^HK<'2L/Q#_ *_3_P#KO_45NCI5R^%$
MK=A1114%!5+5/^/"3\/YU=JEJG_'A)^'\Z"9_"RQ;?\ 'M'_ +HJ6HK;_CVC
M_P!T5+0-;!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LS6
MO^/>/_KH*TZS-:_X]X_^N@H(J?"S2'04M(.@I:"PHHHH J:C_P @^?\ W#2Z
M;_R#X?\ =I-1_P"0?/\ [AI=-_Y!\/\ NT$?:+5%%%!84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %#5_\ CP>K5O\ ZB/_ '1575_^/!ZM
M6_\ J(_]T4$?:)*6DI:"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@# TC_D8=6_WA_,UOU@:1_P C#JW^\/YFM^@ HHHH **** "BBB@
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M%% !1110!E:__P @W_@:_P Q6C#_ *B/_=%9VO\ _(-_X&O\Q6C#_J(_]T4
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MP_[M)J/_ "#Y_P#<-+IO_(/A_P!V@C[1:HHHH+"BBB@ HHHH **** "BBB@
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M7I__ %S/\ZWZP+__ )&O3_\ KF?YTXB9OT444AA1110 4444 %%%% !1110
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MD5@^,/!>O>"?&/\ PD'AVU,UM)(7B6&(OY>1RK*.<>_O7T/1C(P1Q0!\[/\
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M1">.58<=,5]-TUD1Q\ZJWU&: /&_ GB#QSK_ (MCFU/2_*TX1E9$,)A1>GS
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MD4+%U [$#IGWKA?"EWXO\'S2SZ=X9EDN)>#+<6,C,H] >.*^JJ* /-? &O\
MB/QBFK6/BK2Q;6WDJJ#[,T6\-D,/FZ\5YK>:!XM^&'BN>YTBT-W;S ['2!I$
M9"<X8#I@_P J^E*"H888 CT- 'S[9^-OB1KM_:6\.C)%B96)6T:-6P?NLQXP
M:]_@#BWC\Q55]HW*O0'O3E14X154>PQ3J "BBB@ HHHH **** "BBB@ HHHH
M **** *&K_\ '@]6K?\ U$?^Z*JZO_QX/5JW_P!1'_NB@C[1)2T44%A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &!I'_(PZM_O#^9K?K
MTC_D8=6_WA_,UOT %%%% !1110 4444 %%%% !1110 4AI:\V^-]Q-;?#\20
M321/]LC&Z-BIQANXH ](HKY6\,^$_%OBO2I=0TW4+AHXY#&5:X;)( /K[U8M
M]8\=?#/4(S?BY6WDDWM%.P=)0.,;N2/S% 'U#1Q6'X3\3V?BW08=3LSC=\LD
M9ZQMW!_.O-/"?AOQ/8?$^YN)=9B.GB5V8&X#B9"<[%7)(()'8=* /9Z6HIKB
M&W3?/-'$N?O.P4?K20W=O<@FWN(I<=?+<-C\J )J*2JPU*P,GEB]MB^<;?-7
M.?IF@"U125%/=6]L ;B>*('@&1PN?SH FHJ*&Y@N5+031RJ.I1@P_2GLRHI9
MF"J!DDG % #J*JQZC8S2".*\MW<]%6523^&:LT +15>:_M+=]D]U!&W]UY I
M_6IE=70.C!E(R"#D&@!U%1S3Q6\>^:5(T'\3L /UID-Y:W)(@N892.HC<-C\
MJ )Z*** "BBB@ HHHH **** "BBB@ HHHH RM?\ ^0;_ ,#7^8K1A_U$?^Z*
MSM?_ .0;_P #7^8K1A_U$?\ NB@"2BBB@ K O_\ D:]/_P"N9_G6_6!?_P#(
MUZ?_ -<S_.G$3-^BBBD,**** "BBB@ HHHH 2BO!_CAKEY)KNDZ9I^I%;=H]
MS+#+@"3<5Y(]J[3X5^&=1\.VM\^HZQ#?M<B,A(YC(8L9R#GZ]O2@#T6BH9[J
M"V4-//'$"< R.%S^=$%U!<@M;SQ2@=3&X;'Y4 345'+-%!&9)I$C0=6=@ /Q
M-1F]M1"LWVF'RF. _F#:3]: +%)17@GQ]O;NU\0Z2MO=3PJ;5B1'(5R=Y]*
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MN\FZ@DVC+;) <#WQ0!8HJ&"ZM[D,;>>*4+U\MPV/RI\DL<,9DED5$'5F. *
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M/Q)^*>E^(_#1TG2899'E*R22$<( .1]>>M=-\ O^1*O/^OUO_05H ]7HHHH
M**** "BBB@ K-U__ ) -[_UR-:59NO\ _(!O?^N1IK<3V$\/_P#( L_^N=:=
M9GA__D 6?_7.M.A[@A.]+WI.]+WI#,K7/]5!_P!=5K43[B_2LO7/]5!_UU6M
M-/N+]*M_"B5N.HHHJ"@HHHH **** "JFJ?\ (+NO^N9JW535/^07=?\ 7,T
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ME@H(&WY.U<+XK)_X7G=#/_+]%_Z"M>I_"_Q]HVI:!I>AB5H]2@A$/DE2=P4
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M% !1110 4444 %%%% !1110 4444 96O_P#(-_X&O\Q6C#_J(_\ =%9VO_\
M(-_X&O\ ,5HP_P"HC_W10!)1110 5@7_ /R->G_]<S_.M^L"_P#^1KT__KF?
MYTXB9OT444AA1110 4444 %%%% '->(/ NA^)]4M=0U.&5[BU $124J!@YZ#
MKS724M)B@#DO$/PV\,^)[_[=J-DWVC&&>%S'N]SCJ?>DT#X:>%_#5^+W3[)O
MM"_=:9S)M]QGH?>NOI* ,S7]!L/$VD2Z7J4;O:R%2RHY4\'(Y%+H&@V'AO2(
MM+TU'2UB+%0[ECR<GDUIT4 %<QXG\ Z#XONH+G5X)I)($,:%)2F!G/:NGHH
MJ:;I]OI.F6VGVBE;>VC$<88Y(4=.:MT44 <E_P *Y\.?\),GB'[/-_:"2^<'
M\YMN[.>G2NJ=$EC:.10R,"K*1D$'J#3Z* //[CX,^#+FYDG>QG5I&+$).RJ,
M^@'05TOAWPIH_A6U:WTFT6(-]YR<NWL6ZFMJEH S-=T#3?$>FR6&J6ZS0/\
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M+S%A@XSP?I2ZI\.O#NL:_'K5Y!,U[&ZNK+,P&5.1Q]:ZRDQ0 M%%% !1110
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M$-(UGPY#H%Y%(UA#LV*LA!&WISUJ?P[X:TWPOIQL=+C=("V[#N6.?J:UZ3%
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MM6!X<^&_AKPMJ7]H:7:RI<;2H:24O@'KUKK:2@!:*** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!0U?_CP>K5O_J(_]T55U?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "LW7_^0#>_]<C6E6;K_P#R ;W_ *Y&FMQ/83P__P @"S_ZYUIU
MF>'_ /D 6?\ USK3H>X+83O2]Z3O2TAF5KG^J@_ZZK6HGW%^E9>M_P"J@_ZZ
MK6FGW!]*M_"B5N.HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,+Q#_ *_3_P#KO_45NCI6%XA_U^G_ /7?_"MP=*N7PHE;L6BBBH*"
MJ6J?\>$GX?SJ[5+5?^0?)^'\Z"9_"RQ;?\>T?^Z*EJ*V_P"/:/\ W14M UL%
M%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S-:_X]X_^N@K3
MK,UK_CVC_P"N@H(J?"S2'04M(.@I:"P[4444 5-1_P"0?/\ [AI=-_Y!\/\
MNTFH_P#(/G_W#2Z=_P @^'_=H(^T6J***"PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]\B@"I_;VG?\]_\ QT_X4?V]IW_/?_QT_P"%6_L=M_SPC_[Y%'V.V_YX1_\
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M"I_;VG?\]_\ QT_X4?V]IW_/?_QT_P"%6_L=M_SPC_[Y%'V.V_YX1_\ ?(H
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MOV&T_P"?>+_OD4?8;3_GWB_[Y%&@:E+_ (2/2_\ GX_\<;_"C_A(]+_Y^/\
MQQO\*N_8;3_GWB_[Y%'V&T_Y]XO^^11H&I2_X2/2_P#GX_\ '&_PH_X2/2_^
M?C_QQO\ "KOV&T_Y]XO^^11]AM/^?>+_ +Y%&@:E+_A(]+_Y^/\ QQO\*/\
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M (4?VY8_\]O_ !T_X5:^QV__ #Q3_OFC[';_ //%/^^:/<#WBK_;EC_SV_\
M'3_A1_;EC_SV_P#'3_A5K[);_P#/%/\ OFC[';_\\4_[YH]P/>*O]N6/_/;_
M ,=/^%']N6/_ #V_\=/^%6OL=O\ \\4_[YH^R6__ #Q3_OFCW ]XJ_VY8_\
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M4I2322!*VXE+114E"53U3_D'R8]OYU=IK*KKAAD>AH%)75BC#J-LD"*TG(4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !24M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ7AS5));O7%O;E0D-[Y<6\@ #8IQ^M '3T5''-%,N8I$<#NC T//%%GS)43
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M&]<BM#Q)HFH7WCWPWJ-M;&2UM"WGR;@-F35_QUIEYJWAMK6QA,TWVB)]H('
M8$]:+@=%!+YUO%+C&]0V/J,U)4%HC1V4$;C#+&H(]#BIZ0PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "D-+10 4444 %%%% !129I: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HHHH *BN(
MC-:S1 X+H5SZ9%2T8H RO#FE-HNA6NGN^]H4"EO6M6BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BDI: "BBB@ HHHH **** "BBDH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 2'\H_*>3@CGTQ6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWK7T#Q#?2:[=:#K2Q#4(5\U&A0A'C]>IQU'>@#JJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ869X960KC.,C(#=ZZ33=%TW2%==.LH;8.<L(UQDU!?^&=$U2Y-S?:9;7$Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $Q12T4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69K>@Z?X@LOLNH0"1
M!RI[J?45IT4 4],TRTTC3XK&RA$4$0PJC]3]35RBB@ K!\+0RPV^I"6-T+:C
M.R[AC(+<'Z5O44 )2/DHWT-.HH \;\)>)M1\+6-S8OX8U.Y+W+2!TC91SQ_=
M]JZJ>+7O&@@@N+1]*T9_FN%,@,LO^S[#ZCM7=44[B.:\1>&OMGA^&TTN.&*:
MR=);577*@J<[?QQBLG_A,KU/]$?PO=_V@,)\J?NRV.N[&,9]Z[NBD,H:4MZ=
M)@_M%(H[QD!E6(?*&[XKE?"^L76GS1>&[O1[M)$ED4W 4F(J27!W8QWQUKN:
M* ."\W4/!MY>)+I;W^FW-P9HI+=<M&6)+ K@DUK>']5U+6KY[@Z5]@TY$POG
M+B1W^G! Q[5T]%,5C@VCO? ^KWEQ;V4]]I-_-O81?-)%(<DG &2,D]JUM&U[
M5-<U!9(]+DM-,0LLCW(P[G'&%."!FNFHI#//M4^U>'/B!)K9L;B\MKRW\K%N
MA8QD8ZX!]*[JTG:ZM(IVB:(R*&*-U7V-3T4 <5K5K<2?$S1+A()6A2W8-($)
M53D]37:4M% '->)()I=;\//'$[K'=.7*J2%'EGKZ55\;6MRCZ9K%O;O<_P!G
MW"R/!&/F9>^*Z^BG<#)\/ZTVN6DMP;&XLPDA0+.I5F& <X(''-:U%%( HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKCO$7P^T_P 1:_!JEQ+*I10DD8/# =,>G>NQHH CBC6&%(E'RHH4?04^EI*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5 "CM[4^BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFO\ 2[R?SD-ORT3,?FRHR3VKN:*=P. >.]\>:I9O-826>D6,OF$3J5DF?'&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4=Z*.] &%XR_Y%/4/^N=<;X?FD\%?V7YDCC0M1@C8O(<K!,5!//8$DG\*[
M+QE_R*>H?]<Z9I^G6^K>![&QN4#12V4:G/\ NBF!3\6Z[<1-;:-I$BG4K[@$
M<F./N^/IG\JJ>"M)BT37-<LHG=]K1,[N<EG*98_B2:N>#_!T?AJ.:2>5;F]D
M.#,<DA.RC-.TK<?%GB39]_\ <X^OEB@0W6/&B6EW<6&DV%QJM];X,T4 )5,]
MB1G!XZ59T'Q5%J\WV.YLY['4%3>]O,N.,]CWKF_!X\2!-22.72A=B]D^T"=6
M,F[C^Z>GI^-:<FAZK>>*=+U#4+K2DEM&)*V^\22+@C&">F3^E &3K/B;4(O'
MEH$T&[D%JDZ1[5),P./F''08_6NRU378M)M;>26WN))[GY8H(DW,6VYQBLV^
M_P"2B:0?^G6?^2TGB/7[FTU[3-%T^&W:]N]SK)<*2J  \\=^* (=)\;37-[%
M::OHMWIDL\@2 R*2KD^^!BNOKROQE9:U9VEK=ZGK:22F\C\NVA "CK\PR-W'
MUKMM0T*XU5H)X]9OK("(*4@V8)]>0>: -UONGZ5S7@W_ %6L?]A*7^2U<TK0
MI]+F>676+V]5EQLGV8'OP!5/P9_JM8_["4O\EH&-\1>$K"\M9+VSB2SU*$^=
M%=0C:VX>I'48S3_#GBB+4O!B:U=-DPQDW)1>C*,M@59\4:_9Z)I<GG'S+B8&
M.&!.7=B.PKF; R?#[X9H]Q;^;<.V6A8C D?C!]LB@1<?Q[<PW?F3^'K^+20
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]/45\P_\+P\:?\][+_P&%'_"\/&G_/>R_P# 84 ?3U%?,/\ PO#QI_SWLO\
MP&%'_"\/&G_/>R_\!A0!]/45\P_\+P\:?\][+_P&%'_"\/&G_/>R_P# 84 ?
M3U%?,/\ PO#QI_SWLO\ P&%'_"\/&G_/>R_\!A0!]/45\P_\+P\:?\][+_P&
M%'_"\/&G_/>R_P# 84 ?3U%?,/\ PO#QI_SWLO\ P&%'_"\/&G_/>R_\!A0!
M]/45\P_\+P\:?\][+_P&%'_"\/&G_/>R_P# 84 ?3U%?,/\ PO#QI_SWLO\
MP&%'_"\/&G_/>R_\!A0!]/45\P_\+P\:?\][+_P&%'_"\/&G_/>R_P# 84 ?
M3U%?,/\ PO#QI_SWLO\ P&%'_"\/&G_/>R_\!A0!]/45\P_\+P\:?\][+_P&
M%'_"\/&G_/>R_P# 84 ?3U%?,/\ PO#QI_SWLO\ P&%'_"\/&G_/>R_\!A0!
M]/45\P_\+P\:?\][+_P&%'_"\/&G_/>R_P# 84 ?3U%?,/\ PO#QI_SWLO\
MP&%'_"\/&G_/>R_\!A0!]/45\P_\+P\:?\][+_P&%'_"\/&G_/>R_P# 84 ?
M3U%?,/\ PO#QI_SWLO\ P&%'_"\/&G_/>R_\!A0!]/45\P_\+P\:?\][+_P&
M%'_"\/&G_/>R_P# 84 ?3U%?,/\ PO#QI_SWLO\ P&%'_"\/&G_/>R_\!A0!
M]/4E?--G\;/&4U[;Q//9[7D53BV'0FOI"SD::R@E?&YXU8X]2* )Z*** "DS
M2UY1\5_'NN>$=7L+?2I(%CG@+N)(@QR&Q50@YOE0I.RN>K9I:^:/^%U>,?\
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M@>UTM>)_\++\1_\ /6W_ ._(H_X67XC_ .>MO_WY% ?68'ME)7BG_"R_$?\
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M\BC_ (67XC_YZV__ 'Y% ?68'M=+7B?_  LOQ'_SUM_^_(H_X67XC_YZV_\
MWY% ?68'ME)7BG_"R_$?_/6W_P"_(H_X67XC_P">MO\ ]^10'UF![917B?\
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M *]6_P#0JZ,+_%1G5^$\BHHHKUSC"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /K'X;_\ ).]#_P"O8?S-=37+?#?_ ))WH?\ U[#^
M9KJ:\*I\3.^.R"BBBI&<!\6/^177_KLM>)U[9\6?^177_KLM>)U]7DW^[_,\
MG&?Q HHHKUSE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7@%>_P#C#_D4=4_Z]VKP"@X<7N@HHHI'(%%%% !1110 4444 %%%% !1110
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MX;UGP_)&FK:=-:-(,H)!U%=UX$^'3:OX>UJ_U72IV(M=^G.'*AWPW3!Y[=:
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M3_UZM_Z%7OM>!?'W_D8=)_Z]6_\ 0JZ,+_%1G5^$\BHHHKUSC"BBB@ HHHH
M**** "BBB@ HHKU?X2^!X+Z1O$6LP_Z%;G]RLH^1SZGU ]_6HJ5%37,QQC=Z
M'E%%>V_'/3K"RTG1VL[*V@+SODPQ*FX;1Z"O%[8@74)*;QO'R^O/2II5?:0Y
MK#E'E=B*BO2_B:)M0OM+MK7PN^F&3Y(R8U1IG.!MPO'I^=<H_@?Q-'?1V3Z-
M="YD3>L9 R5SC/6B%6+C=Z X.YS]%7]5T74M#NA;:G9RVLQ&[9(.<5+I'AS6
M->9UTO3Y[HQC+;!TK3GC:]R;/H9=%>Y_!_PR;5-<MM<TF,7$;182YA5BH(;I
MG-<I\-Y4M];UP#P^VKGRR%C2)7"'<<9W=!VXK#ZPM4EL7[/8\WHJ[>QSW.LW
M:K:&.9YWS;H,[#N/R_ATK5N? ?BFTM6N9]$NHX5&YG(& /SK;G2W9-F<[15F
MQTZ\U*\2TLK:2>X<[51!R36EJ?@_Q%HUK]IU'2;BWAS@NZC'Z4<\4[7!)F)1
M7?\ PU\#GQ%JJR:GI\LFEE"?,#%03]0<UB>*_#\OAWQ-<1/82)8FX<6RN?\
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MNC:C>Q>9;6<LB>H%5I[>:UF:*>-HW4X*D=#19B<))7:(J***"0HHHH ****
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M6HL$AD5<EA&%*^A!'O0:1H\RW/':*GO(!:WUQ;AMPBE9 3WP<5!086L%%%%
M!1110 4444 %%%% !7TAIO\ R"[3_KBG\A7S?7TAIO\ R"[3_KBG\A3.S"]2
MW1110=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\A_$C
M_DHVO?\ 7VU<M74_$C_DHVO?]?;5RU !1110 4444 %%%% !1110 5U/P\UZ
M#PYXPMK^XMY)TVE D8^;)QC%<M71>"O$-KX9\1V^HWEBMW$APRGJH]1VS]:
M/7C\=;*?7X;.WT:1X))5BWLX#$DXS@CC&>GM63\<O"=G9+;:[8Q10>8Y2=5&
M#(QY!_0_G6K;>)?A5-<-XD>WC@U,'>('#;LXQ]T?+7GOQ+^(0\;7UNMI!)!8
MVZD*KGYG8XR2 <<8XH C^$/_ "4C3O\ =D_] -=GKO\ R<K8?]=8/_1=><^
M-<M?#GC"SU.\#>1$'#;>O*D5T6J>-=,N_C):^)XQ)]AC>-CD#=\J8- '<?$3
MXGZQX2\:II]A#:FT$:22AXR78DG.#GT%4?C+:PZ@?#&K.F'G$:,G;:WS&O/?
MB3XDLO%'BUM2L XA,*I\XYR"?\:W/'WCK3O$&AZ';:>)!/8B,OO QE5Q_.@#
MOOB7XVO_   FF:7X>M;>W@"$?/$2NT8P%P1TIB>))?%/P9UC4+FU6&Z( F=%
MVK*VX?,!],#\*SHOB!X*\9Z+#'XOMR+NTCS\Q($C8YV[3[=\5GZC\3/#<W@7
M4= TVPDM(B-EJG7*Y!)8Y]<T :7A/_DW+5_^N=S4OAA+;P)\&SXIL;=)-0N8
MU=GDYZOM ^G?%<EH/CO2M.^$.H>&IA)]MG295P!M^;I2^ /B79Z3HLOAWQ%:
MM=:;)\L;  [ >""#V'7CF@#/U/XP^(]9T2[TN]CLFBN4*,RQ$$ _C72?#%/%
MUMX4G:TNM/TO2))"PN[Q/F#$#)'S#CI@T_7?$GPUT/0KW3]!TN.]DO8_O#)5
M6[9+'</PI_A'Q]X5U'P.GAGQ1%Y$-J@Q\S!90O(&1SG/X4 ==XPA^W?"'49;
M^_LM7N+>+?'=VZ_+N# 9')YQQUJC\./%>HS_  QOKAQ!OTRW=8,)QA5R-W/-
M<UJWQ$\)GX>:EX<T6RGM8Y$*0(QSU;)).36+\*O'&G>'?MNEZV7-C> *IVC8
MF<[BW?!&* '^%?%FI>+OB[H%YJ0@$L;LB^2FT8VL?4UV>JZ/9ZW^T-'!>H7B
MBL4G5<\%E'&?:N/OM:\&:#\3]'U/P^G_ !+[;<UR\9)#L0W(W?455\2?$?'Q
M-3Q1H8.Q8$B9)!]]1]Y3]: .E\8?%O7_  YXWO-)LXK3[#:2J@0Q'<RX!(SG
MWI?C!I-MJ6A:-XOBB2WGN%C65,?,^\ C)]L8_&KDWB_X9^)<:YJ]EY>I0@'R
MG)#.1S_"<'GUKS_XB>/E\9:C:"UMWM=/M%VQQDXW9QR0#CC'% 'KWQ-\::IX
M-T/1Y]*6W,MP=KF9-P "@\<BL?Q-J7_"<_!$:U>Q".XB8R )P-RDK^5<=\4?
M'6E>+='TFVT\2B2U8E]X']T"F6?CC2X/@\_AEQ)]N;?CCY>6)% 'I'@K6H-7
M^&VEZ7HFN6MCJT*)$PF&6ROWOER"0<]:\W^+?_"8I<VL7B/R7M5SY$ELA6-S
MZGDX;KWZ5K>$]<^&]YI5G;:Q9O87EK%\T_F,@=N^"AS^=9?Q1^(EAXIM+/1]
M+@<6=H^_SI#RQ *C'/3![\T >8T444 %%%% !1110 4444 %%%% %G3O^0G:
M?]=D_P#0A7VEIW_(,M?^N2_RKXMT[_D)VG_79/\ T(5]I:=_R#+7_KDO\J +
M5%%% !7@7Q]_Y&'2?^O5O_0J]]KP+X^_\C#I/_7JW_H5=&%_BHSJ_">14445
MZYQA1110 4444 %%%% !1110!N^#="'B3Q78Z6T@C65\L2,\*,D?B!BO>_'F
M@^)+W1K30_#,,26 4+.3*$)48 7Z8_E7SII.K7NAZE%J&GS>3=19V/@'&1@\
M&NI7XL^,]Z[M7)&>?W*?X5R5Z52<KHUA.,59GJOQ<\+ZIKOAO3S8Q1O]@#RS
M[I N%"#./7H:^>K3_C]M_P#KHO\ .O6_'/Q;_M'1[>UT&XDA>0,EWN13O4KC
M'\Z\B@<1W,4AZ*X)_.GAHSC!J05&G+0]\^)__(T^#O\ K\3^:U9^*?C[4/"%
MY86^F00&XGB+M+,FX!<XP!D=ZXOQIX_TG7=<\/7=J)?+L;A9)=P'0%>GY5C_
M !3\6Z?XNU6PN=/#A((#&V_UW9K&%%N45)%2FDG8[KXD2+K7P@TO7+R&$W[^
M2WF*N-N_[P'H#5[Q!K!^&7P]TE-&@1IKC"B249Y(W$GU]*X;Q#XYTO4?A5I_
MAZ 2?;(%A#9 Q\HYK7\+?$+0-8\-Q^'?&,*F.)<+</G# <CD<@]N.U+V<U'5
M:)[#YE?3<[+X6>--0\8:?J+:DD(FMF4!HEVA@0??VKCO@E_R-'B+_KE_[.:T
M]#^)O@OP]'=:?IFGRV]HC_(Z\F3KDY)SCTKB_AMXQTWPMK6KW5\)#'=)M3:/
M]HFDJ<FI60<RNM3L_A=IUJ=;\6:L\>^ZMKN2.,GD $L3^H%<S#\;O$4=W,+J
M&SEAVLJHL94AN=IZ],UF>%/B(_ACQ/J-QY;3:7?7#R2P@#=@L<$>^#^M=A<^
M(/A=80OK%MIXN+Z=65[=<EEW#!R"=HZ]JMP:G[T;B3O&R9S?PT'BR\U:_P!0
MT1K2**5S]JEG7*1EOFR%R.?QKUS0()]3TS4M/U3Q%I^MQ2)M/V5<,@;(.3N/
MX5YA\.O&^@:9#JFDZI&]M9WLQ=&!.U$]"1SFMW1?B+X(\-3WMEI5A+#;9^69
M3GS3SSDG.*BK"<I.R'!I+4E^#FO7<NJZEX=98A8V*.T.%^;_ %F.3^-<!\1_
M$^H:[XLFLKL0^5I]S)%!Y:8.-W?GGH*9X)\;1^%?&%UJ#PF6TNV9)<?>52VX
M$?I6M\1+_P $WD:7NA /J5S+YLTBLW&>2"#QGZ5HH.-6]B>:\=SH_BC:I>ZC
MX5MI,;)#&K ]".XJW\1?'FI^"-0L]'T.V@A@CA&3+$2&P!@+R.@ZUQ7Q \;6
M6O-H\NF>8LMD%)+#^(5TUKXV\%>-;:W7QA;>7>6T>!*[,%8\9QM.><5'LY*,
M7)717,G=)D_B>^'C+X.)K-_;QQ7\+KB4KM!)(R5SV(XJQIFNGP[\%K/4(H(Y
M+E';R#(N51]QY(^F:X[QU\0+#4]$C\-Z!:M!I<1 );^/!R,>U5KSQAITWPNM
MO#RB3[9'(68XXQD_XT_92<4K:7%S*YZ)X=\4W7CCX=:W_:T,)N(H9,-&N%QM
MXX]167\(O$6C6VA7FD>?#8:EN)\Z9@!*>@/;D9 Q[5R?@CQEIN@>%M7T^[$G
MG74;+'M'&2"*=X,UWP4=._LKQ%I>UC/YOVL,1D\X)(.1]!3G2LI)+0%+5-G0
M?$RS\<6_AWRM0NK6^TM"N^>",HY/N-QX]Z\9KV+QGX_\/0>&+CPYX=$LZ2G_
M %SN77!Z\L=U>.UOADU#56(J6OH%%%%=!F%%%% !1110 4444 %%%% 'UC\-
M_P#DG>A_]>P_F:ZFN6^&_P#R3O0_^O8?S-=37A5/B9WQV04E+25(S@OBS_R*
MZ?\ 79:\2KVWXL_\BNG_ %V6O$J^KR;_ '?YGDXS^(%%%%>N<H4444 %%%%(
M KU;X/,/*U5<C<3'_6O*:U-!UV\\/:G'>VC9(X>,GY7'H:Y,=0E7H.$=S6C/
MDFFRMJD$MKJMU#.I2196R#UKM/A+;S-XEFN%1C"D#*S8X!)&!^AK>_X2;P3X
MH3=K%NMM(ASF0$%C]5Z_C535_B%I>E:?)I_ANU"O@*LX4!<8Z^I/UKSJE>M6
MI?5U3:>WD="C"$O:.6A:T?6(K3XK:K:%52.Y8HS,W&X#/Z]*?X;\+MIGCC5[
MV8+-#;Y=6Q@AG^?CZ#(KRF&^FAU&.^+%YDE$I+$_,0<\FO2]>^(]A>>&YK:T
MCD2]N(PK,N!@XYYK.O@JU-J-+:228X5823<NAB:;J&M:]X^N-3T9 \F6"F<9
M6.,]CT]\5Z5H+7D]U=17^M6&H*R?-;P+@QGH?XCQVKRWX?>)[7PYJ-P+Q3Y5
MT%4N/X,$\G\ZZNU\6>#-!UBYETZWD,DJ_/.A)5\G)')]:RQN'J.IR1AHDK6+
MHSBH\S>Y0\&P16OQ1U*"",1Q1M*J(O0 '@50\7>,KJ>]N]#MHX$T[S H_=G<
M<$'KGUJOH?BBQT_QW?:O*'^SS-(5P.?F/%<QJ=W'=ZW/=1Y\MY-PSZ5V4L(Y
MUN>HMDOO,I5;0M'N=S\1O^0+X?Q_S[C^2UMV$?B>WTBS%_K5AI:)CR_-&3+W
MY.X?E7'^*/%%IJEIHZV@;S+.,*^X#&>/\*Z74?%OA#5--M[Z]MY)[N  1VY8
M@@COC.*Y:M*LJ4(<O5]#2,HN;=QWQ1LXWTG3=09EDN RIYB<*P(R2/RJWKWB
M.7PYX.TB:UAC:ZD7;&\@R$'&>/<5S?C3QEIVOZ):6UK&R21NK,I' P.@JAXJ
M\266K^'M*LK?=YEKG?GZ"G2PE2<*<)QT3=_04JL4Y.+.NOM2?Q+\*;K4+^&)
MKI%)#*N #NQD>G%>/UV]GXIL8?AW=:(V_P"U2*0/3[V:XBO1P%"5.-2+5E?0
MPK34G%GL'Q M)M1\#:=<6>)(K<*\A5NVW'X\UX_7=^$OB"='L?[-U2 W-F.(
M\ $J/3GJ.]=$=3^'EL[:K%%$]T3O\D!B<^F#\M<E"I5P5Z4H-J^C1I.,:OO)
MV/,K33]235K6&.SE%T75XT=",\\'Z5[1I\FNKJEJNJ:WIL,AP'L43YF!]/FZ
M_A7"7GQ$6X\5V>I)9!;6U)"+@;R"".?SKH;_ ,5>"SJ]IK30R7%^=IW(QS%@
M<9&<5EC57K./-"VG34NCR1O9F+XWM8;;XF::88E3S'A=]H^\V_K72_$'QAJ7
MAJ_LHK 0;98R[>8F3P<>M</XJ\266K^,K'4[</Y$'E;L]?E;)H^('B2R\1W]
MG-9!]L,95MWN:<<)4FZ2J1NDG<3JQCS<K.H\<E-;^'FGZW,FVXPC*%Z#?C/\
MJMZ]J<W@GP;I1T=(E,I4,95W=5+'T[URNJ^*["\^'=GHD8?[5$L8;(X^7K6A
MHOC;2M5TB/1_%$(=4X6;H,#IG'(/;BL_JU54E>+<5)Z>17M(N3L]6C)NO%VH
M>,(['1+P0IYUP/,E5<=^,<\=Z].U&'^S-,M-/TS5;#2_+4'$J_>'MR.]>:>*
MM6\,)8II^@VA#Q/O2Y4G SUP<Y_.MNS\7>&?$MG;6OB.V\J6!?\ 6DD*3TZC
MFC$4)2C&<(-173]0IU$FU)W9I^-4TG5/"DDEQJ%C/J5LFY)(G +'N ,G@U+:
M:RV@_"JPU".-9)4A4(&'&2V*X7Q;JGAF:RCL-$LW5H')6?)PP/7J<GMUJQ?>
M*;"Y^'5MH:!_M4:J&XXX;-..#G*G!-.U^O8'5BI-^1RVLZO=:[J<E_>!/.<
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M444 %%%% @HHHH **** "BBB@ HHHH ^L?AO_P D[T/_ *]A_,UU-<M\./\
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M444E S$\8?\ (HZI_P!>[5X!7O\ XP_Y%#5/^O=J\ H.'%;H****1R!1110
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MFK_]!JR_[]M1_P ,^:O_ -!JR_[]M0!Y-IW_ "$[3_KLG_H0K[2T[_D&6O\
MUR7^5>%VOP!U:"[AF.LV9$<BL0(VYP<U[Q:PFWM(8202B!21WP* )J*** "O
M OC[_P C!I/_ %ZM_P"A5[Y7G'Q'^&][XVU*SNK6^@MUMX3&5D4DDDY[5MAY
M*-1-F=1-QT/FVBO7?^%!:M_T&;/_ +]M1_PH+5O^@S9_]^VKTOK-+N<_LY=C
MR*BO7?\ A06K?]!FS_[]M1_PH+5O^@S9_P#?MJ/K-/N+V<^QY%17KO\ PH+5
MO^@S9_\ ?MJ/^%!:M_T&;/\ []M1]9I]P]G/L>145Z[_ ,*"U;_H,V?_ '[:
MC_A06K?]!FS_ ._;4?6:?</9S['D5%>N_P#"@M6_Z#-G_P!^VH_X4%JW_09L
M_P#OVU'UFGW#V<^QY%17KO\ PH+5O^@S9_\ ?MJ/^%!:M_T&;/\ []M1]9I]
MP]G/L>145Z[_ ,*"U;_H,V?_ '[:C_A06K?]!FS_ ._;4?6:?</9S['D5%>N
M_P#"@M6_Z#-G_P!^VH_X4%JW_09L_P#OVU'UFGW#V<^QY%17KO\ PH+5O^@S
M9_\ ?MJ/^%!:M_T&;/\ []M1]9I]P]G/L>145Z[_ ,*"U;_H,V?_ '[:C_A0
M6K?]!FS_ ._;4?6:?</9S['D5%>N_P#"@M6_Z#-G_P!^VH_X4%JW_09L_P#O
MVU'UFGW#V<^QY%17KO\ PH+5O^@S9_\ ?MJ/^%!:M_T&;/\ []M1]9I]P]G/
ML>145Z[_ ,*"U;_H,V?_ '[:C_A06K?]!FS_ ._;4?6:?</9S['D5%>N_P#"
M@M6_Z#-G_P!^VH_X4%JW_09L_P#OVU'UFGW#V<^QY%17KO\ PH+5O^@S9_\
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M'*P^I5_Y3C**[/\ X5W>?\_L/_?)H_X5W>?\_L/_ 'R:.5A]2K_RG&45V?\
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MMO\ OXU'_"XK_P#Z!5M_W\:O-:*/[+PO\H?6:O<]*_X7'?\ _0*MO^_C4?\
M"X[_ /Z!5M_W\:O-:*/[+PO\H?6:O<]*_P"%Q7__ $"K;_OXU'_"X[__ *!5
MM_W\:O-:*/[+PO\ *'UFKW/2O^%QW_\ T"K;_OXU'_"XK_\ Z!5M_P!_&KS6
MBC^R\+_*'UFKW/2O^%QW_P#T"K;_ +^-1_PN._\ ^@5;?]_&KS6BC^R\+_*'
MUFKW/2O^%QW_ /T"K;_OXU'_  N._P#^@5;?]_&KS6BC^R\+_*'UFKW/2O\
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MN--M'-?\+%N_^?&'_OLT?\+%N_\ GQA_[[-<716?,SY_Z]7_ )CM/^%BW?\
MSXP_]]FC_A8MW_SXP_\ ?9KBZ*.9A]>K_P QVG_"Q;O_ )\8?^^S1_PL6[_Y
M\8?^^S7%T4<S#Z]7_F.T_P"%BW?_ #XP_P#?9H_X6+=_\^,/_?9KBZ*.9A]>
MK_S':?\ "Q;O_GQA_P"^S1_PL6[_ .?&'_OLUQ=%',P^O5_YCM/^%BW?_/C#
M_P!]FC_A8MW_ ,^,/_?9KBZ*.9A]>K_S':?\+%N_^?&'_OLT?\+%N_\ GQA_
M[[-<711S,/KU?^8[3_A8MW_SXP_]]FC_ (6+=_\ /C#_ -]FN+HHYF'UZO\
MS':?\+%N_P#GQA_[[-'_  L6[_Y\8?\ OLUQ=%',P^O5_P"8[3_A8MW_ ,^,
M/_?9H_X6+=_\^,/_ 'V:XNBCF8?7J_\ ,=I_PL6[_P"?&'_OLT?\+%N_^?&'
M_OLUQ=%',P^O5_YCM/\ A8MW_P ^,/\ WV:/^%BW?_/C#_WV:XNBCF8?7J_\
MQVG_  L6[_Y\8?\ OLT?\+%N_P#GQA_[[-<711S,/KU?^8[3_A8MW_SXP_\
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MN>B?\+:OO^@9;_\ ?QJ/^%M7W_0+M_\ OXU>=T47#V]3N>B?\+:OO^@7;_\
M?QJ/^%M7W_0,M_\ OXU>=T47#V]3N>B?\+:OO^@7;_\ ?QJ/^%M7W_0,M_\
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MN>B?\+:OO^@7;_\ ?QJ/^%M7W_0+M_\ OXU>=T47#V]3N>B?\+:OO^@9;_\
M?PUZA:S&XM(9B #(BL0.V1FOFNOI#3?^07:?]<4_D*#IP]24KW+5+110=044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5SWA34+33=6\^[TY[X;2!&@R1[XKIOBY_P AJS_ZY'^E9WPR_P"1QA_W&_\
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M&%'V2V,Y3;ES'8_$/7M/U[5+>;3YC*B1D,2I'IZU3\#ZM9Z-XDCO+Z0QPJK
ML%)Z@^E<U16:PL%0]A?0;J-SYSO_  ]XFTO3_'=_J=Q.5M98V5'V$Y)((XK!
MO]4M)_'KZI'(3:&]67?M/W0P.<5SU':IC@8*3E?=6*=:35CT#QGXPL[OQ+I6
MIZ1,93:(<DH1@Y]_:M;4M?\  OB(P7VH[X[H!2Z[&)('\)(&,?2O*:*R>6T^
M6*3::ZE?6)7=UN>JZ]XT\/ZAX'N-.LB8)F0*EOL/&&'?IT&:Q-6\1Z9=?#FU
MTB*<F\CD0LFPC  YYZ5PM%%/+:<+6;T=Q2Q$I'HOAOQAH\WAS^P?$40$$:[8
MY I;(Z]NX-1:KJ/@RS\,S6.EQM=7,C961E(93V)R.U>?T4_[.I\_,I-*][![
M>5K-'J$GB/PQKOANPM-3O9[.:W'*P*>OY'BH]=\6Z#>>"FTRQ9XY%&U8V4Y.
M#USTYZ_C7F=%3'+*:GS7>]QO$R:L>C>!_%NCZ?X>N=&U<M'&[,=VTL'##!''
MTK.T/4]"T+QJUS;W+G35^Y(R'/(],5Q5%:?V?#FG*[][<7MW9+L==#XM72O'
M5WK%J#/;2RME>FY2?YUU$^J_#ZZU9=6E9A<8#-$(FVEO4\=?\*\IHJ:F70DT
MTVG:V@1KR70[O4?&MOJWCG2]0D4PV%E*-I(R<=SQ]*H_$+7+'7M=AN=/E,L*
MP!"2I'.3Z_6N2HK2G@*=.<9QZ*Q,JTI*S/1?%?BG1]4\(:9I]O.TL\!B,J;"
M.%7!Y(Q4]KJ/@1OL-W%-/IL\+"1HH@Q!([-P0>G:O,Z*Q>60Y.52:+^L2O=H
MZ[X@>)+/Q)J\,ED&,,$93>1C=DYZ5R-%%=M"C&C34([(QG-SES,****V)"BB
MB@"_HG_(>T[_ *^H_P#T(5]-C[M?,FB?\A[3O^OJ/_T(5]-C[M?,9Y_%CZ'I
M8'X6+1117B'<%8'C+_D6+O\ X#_Z$*WZP/&/_(L7?_ ?_0A2>QE7_A2]#R:B
MBBLCY4**** "BBB@ HHHH *TM$UB31;\7"+O4C#+GJ/\:S:*$5";A+F1Z#)K
M7A35"MQ?0+YY7Y@R,2/;BJ>I>(=$@TY[+3;-)$D4]5(4'WSS7%457,=4L;)J
MUE<['2O$>GS:&-+U0-&J+M1TS^'3O5:[N/#]OI<T5K+<7-Q(?E=R04KEZ*.8
M7UR?+9G5Z9K5C;^#KG3Y)2+AP^U=I[]*7PUK=CIVB7MM<RE992Q4;2<_+BN3
MH[4<PEBYII]E8[#0=<TR/P[-I=]))"6)^=022#Z8J];:_H5EHUS96TTF65@&
M=22Y(ZFN!HHYBHXV<8I6V.E\.>((+.VDT_45,EG(><]%]:M7$_A*&UN#!&TT
MKYV#:05SZ?2N0HHYB5BI*/+)7%.-W&<9XS7>:'XAT>WT!+&]E)RNUT*$Y%<%
M1WI)V(HUW2E='H":]X7TH//I]N#,1C"J03^=<CK6L3:S?F>3Y5'"(.PK-HIN
M1=3%3GILCL/$>NZ;J-II\<;-*(7!D0*1QCWJ>"^\,17EO>032VS1_-Y* [2?
M?BN(HHYBEC)*7-8ZB_\ %*_\)1'J=HFZ.-/+(;^(<Y/ZUHWFH>&=1NH[N:YF
MB?'SQJ&PQ]^*X:BCF".,FKWUN;DNI64/B2.ZM$;[)&XP&)/?DBMV^U7P]<:@
MFHM//)*N#Y(!"M]>*X:BCF)ABY1OYG8Z_K>D:CJ=E*=\]O'G>H&WTZY[5:LM
M3\-Z?>F[MKJ9,K_J0IVC]*X2BCG*6-DI.5MSJ(O%KP^(9KT(?LTORM$.X'0_
M6K[77A62]^UM<38/)APVTFN(HH4F$<9-:/4M:C+!+?2M;>8(-WR!SDC_ .M5
M6BBI.64G)W84444$A1110 4444 %20?\?$?^^/YU'4D'_'Q'_OC^=!4?B1[D
MGW%^E.[TU/N+]*=WK8^L6P4444#,/QA_R*.J?]>[5X!7O_C#_D4=4_Z]VKP"
M@X<5N@HHHI'(%%%% !1110 4444 %>A>!/$VD:/I-Q;ZA.4:1\@;"<C'M7GM
M%!<)N#NCU(WWPXZ_9XO^_3UF>$+^*'QO-#IT#-870*#"G"KUS^F*X"NQT/QV
M=#TA;6'38&G0%?.S@L"<\\4&T:J<KO0O?$[4D:^M]*@!5+=-S8/RG/08]L4V
M7Q)I;?#5-'$Y^VB, IL/7?GKTZ5Q5[>3ZA>RW5PV^:5BS'M5>@B55\S?<[CP
M+XBTW1=.U&*^F,;S%=@V$YP#Z?6H_ FOZ=HFI:A-?3&..90$(4G/)/:N+HH$
MJK5O(ZS0O%@T3Q#?3?-)8W,KED'&<MPWY5N_:O PU WAO+AE()^S$/L_EG]:
M\VHH&J[1<U.:WFU&9[3S1;ECL$K9('^%=)X UW3]#O;F2_F,:NH"G:3GKZ5Q
M]%!$9N,N8]9N=;\ 75XUY/&DMPQW%S$^21TKF_%OCK^VK4Z?90F&U!^8GJP'
M]*XJB@N59M=CO/"'B33-*\+:A97<Y2>8N4783G*8'2JNA7/A)]%-OJ FM;P'
MFX7)9L^F.U<;13N)56DCT'Q/XITF7PO#HVF32W!4KB5P01M.><BI[;Q9HFMZ
M EEKKR6T\2A%DB#$G'<8[_6O-Z*+C]O*]SKO$=UX<728+;1YKB:X!^>5B1D<
M?>SU_"MB#Q!X=U3PM:Z?JEU+:R0\XA4]>?:O.:*+A[:2E<])O?%&@'P=<:59
M22*X4H@=22_^T3CO5#3[GP9)IELLLES8W41!9UR6D^I QBN%HHN'MFW>QW_B
M[QM!=):6VD2%E@99!<%<,&'3&:LW'B/PUXDL8GU::XL[Q!M+1 Y(_ $5YO11
M</;RO<ZGQ5>:!+#;0Z*9RR+B1R2%?Z@]ZY:BBD9SDY.X4444$A1110 4444
M%%%% !7TAIO_ ""[3_KBG\A7S?7TAIO_ ""[3_KBG\A3.S"]2W1110=H4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4E+24 <%\6?^173_ *[+7B5>V?%C_D6$_P"NRUXG7U>3?[O\SRL9_$"BBBO7
M.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_HG_(>T[_KZ
MC_\ 0A7TV/NU\QZ)_P A[3O^OJ/_ -"%?3@Z5\QGG\6/H>E@OA8M%)2UXAW!
M6!XQ_P"18N_^ _\ H0K?K \9?\BQ=_\  ?YBD]C*O_"EZ'DU%%%9'RH4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAIIHBJ@G )KR7_A7/B+_ )]X?^_HKV^DH,JE)3=V>(_\*Y\1?\^\/_?T4?\
M"N?$7_/O#_W]%>WT4&?U:)XA_P *Y\1?\^\/_?T4?\*Y\1?\^\/_ ']%>WT4
M!]6@>(?\*Y\1?\^\/_?T4?\ "N?$7_/O#_W]%>WT4!]6B>(?\*Y\1?\ /O#_
M -_11_PKGQ%_S[P_]_17M]% ?58'B'_"N?$7_/O#_P!_11_PKGQ%_P ^\/\
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M5HGB'_"N?$7_ #[P_P#?T4?\*Y\1?\^\/_?T5[?10'U6!XA_PKGQ%_S[P_\
M?T4?\*Y\1?\ /O#_ -_17M]% ?5H'B'_  KGQ%_S[P_]_17L]E$T-C;Q.,,D
M:J?J!4]+0:4Z2AL%%%%!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g0vsdaj33nnl000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4T")@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHS0 449HH **** "BBC- !111F@ HI,TM !11FC-
M !129I: "BBC- !129I: "BBB@ HHHH **** "BC-&: "BC-&: "BBB@ HHH
MH **** "BBC- !11FB@ HHI,T +111F@ HHS10 4444 %%%% !111F@ HHHH
M **** "BBB@ HHHH ***,T %%)FC- "T444 %%&:3- "T449H **3-+0 444
M9H **,T4 %%%&: "BC-)F@!:*** "BDS2T %%%% !129I<T %%&:* "BBB@
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M-(J%RC?+D]:U_&WCI_"4MO&MH)_-]3TJ/1/B%H&M:K%8VMHR32'Y24'%<O\
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M:Z?#VBR7XA$I0_=)KYUT5[W2GBUFWW"**0*Q'^?:O7_&&KPZU\-VO(6!#@9
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M*"9%4,HSUR1_C7D_Q3O=+O\ 4K1-,\MYL88Q#OFNMUV*6'X1,DP(<0IG/U%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '*?$3_D3[OZ?UKS3P)X&LO$NA37,TLL<P8A2K$#\
MJ]:\6:3<:WH%Q8VI02R#@N<"LOX?>&+_ ,,:0]K?M$TC.6'E,2/U H \@73T
M\)>+TM];MS<6P;JW.1ZU[E?RVL_@^XDLBOV=K<F/;TQBLSQUX+3Q3IX,&Q+Z
M,_NW8X&/0U2\+^&O$.F>&KS1]0DMG1D(@9')P3V/'2@#C/A+I5CJ=_J8OK6*
M<(%VB10<<FO5?^$2T#_H%6O_ 'Z7_"O+K#X:^--)EE?3]0MK<R?>\N=AD?E5
M_P#X1#XC_P#0<C_\"7_PH ZCX@Z.)_!<MO9Q!5A&0B#@ '-8/P=U"'^S+BR9
MU69&SM)Y-=GX:TS4[71#:ZY.MS.V0QWE@1^-<=K'PONH]0>^\/7YM97.=I8J
M!^(H [CQ%X@MO#NEO>7# D?=3/+&L&35X_''@B_-E#(C,A #=S7+K\-/$NK3
MK_;VK!X5[+(SD_GBO3-%T2UT/38[&U3$:C!/<_6@#R;X1:E#I^KWFGW3B.64
M#;NXR1V_6O9Y)HXHC([JJ 9))XKS[Q+\+XM1U!M1TJX-I<D[B!P,_P!*Q/\
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M#:HK%_X2S0_^@C#_ -]"C_A+-#_Z",/_ 'T* -JBL7_A+-#_ .@C#_WT*/\
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M 'T* -JBL7_A+-#_ .@C#_WT*/\ A+-#_P"@C#_WT* -JBL7_A+-#_Z",/\
MWT*/^$LT/_H(P_\ ?0H VJ*Q?^$LT/\ Z",/_?0H_P"$LT/_ *",/_?0H VJ
M*Q?^$LT/_H(P_P#?0H_X2S0_^@C#_P!]"@#:HK%_X2S0_P#H(P_]]"C_ (2S
M0_\ H(P_]]"@#:HK%_X2S0_^@C#_ -]"C_A+-#_Z",/_ 'T* -JBL7_A+-#_
M .@C#_WT*/\ A+-#_P"@C#_WT* -JBL7_A+-#_Z",/\ WT*/^$LT/_H(P_\
M?0H VJ*Q?^$LT/\ Z",/_?0H_P"$LT/_ *",/_?0H VJ*Q?^$LT/_H(P_P#?
M0H_X2S0_^@C#_P!]"@#:HK%_X2S0_P#H(P_]]"C_ (2S0_\ H(P_]]"@#:HK
M%_X2S0_^@C#_ -]"C_A+-#_Z",/_ 'T* -JBL7_A+-#_ .@C#_WT*/\ A+-#
M_P"@C#_WT* -JBL7_A+-#_Z",/\ WT*/^$LT/_H(P_\ ?0H VJ*Q?^$LT/\
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M$LT/_H(P_P#?0H_X2S0_^@C#_P!]"@#:HK%_X2S0_P#H(P_]]"C_ (2S0_\
MH(P_]]"@#:HK%_X2S0_^@C#_ -]"C_A+-#_Z",/_ 'T* -JBL7_A+-#_ .@C
M#_WT*/\ A+-#_P"@C#_WT* -JBL7_A+-#_Z",/\ WT*/^$LT/_H(P_\ ?0H
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M#:HK%_X2S0_^@C#_ -]"C_A+-#_Z",/_ 'T* -JBL7_A+-#_ .@C#_WT*/\
MA+-#_P"@C#_WT* -JBL7_A+-#_Z",/\ WT*/^$LT/_H(P_\ ?0H VJ*Q?^$L
MT/\ Z",/_?0H_P"$LT/_ *",/_?0H VJ*Q?^$LT/_H(P_P#?0H_X2S0_^@C#
M_P!]"@#:HK%_X2S0_P#H(P_]]"G1>*-&FE6.._A9V.  PYH V**0'(R.]+0
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M_P"$=T?_ *!\/Y5IT4 9G_".Z/\ ] ^'\J/^$=T?_H'P_E6G10!F?\([H_\
MT#X?RH_X1W1_^@?#^5:=% &9_P ([H__ $#X?RH_X1W1_P#H'P_E6G10!F?\
M([H__0/A_*C_ (1W1_\ H'P_E6G10!F?\([H_P#T#X?RH_X1W1_^@?#^5:=%
M &9_PCNC_P#0/A_*C_A'='_Z!\/Y5IT4 9G_  CNC_\ 0/A_*C_A'='_ .@?
M#^5:=% &9_PCNC_] ^'\J/\ A'='_P"@?#^5:=% &9_PCNC_ /0/A_*C_A'=
M'_Z!\/Y5IT4 9G_".Z/_ - ^'\J/^$=T?_H'P_E6G10!F?\ ".Z/_P! ^'\J
M/^$=T?\ Z!\/Y5IT4 9G_".Z/_T#X?RH_P"$=T?_ *!\/Y5IT4 9G_".Z/\
M] ^'\J/^$=T?_H'P_E6G10!F?\([H_\ T#X?RH_X1W1_^@?#^5:=% &9_P (
M[H__ $#X?RH_X1W1_P#H'P_E6G10!F?\([H__0/A_*C_ (1W1_\ H'P_E6G1
M0!F?\([H_P#T#X?RH_X1W1_^@?#^5:=% &9_PCNC_P#0/A_*C_A'='_Z!\/Y
M5IT4 9G_  CNC_\ 0/A_*C_A'='_ .@?#^5:=% &9_PCNC_] ^'\J/\ A'='
M_P"@?#^5:=% &9_PCNC_ /0/A_*C_A'='_Z!\/Y5IT4 9G_".Z/_ - ^'\J/
M^$=T?_H'P_E6G10!F?\ ".Z/_P! ^'\J/^$=T?\ Z!\/Y5IT4 9G_".Z/_T#
MX?RH_P"$=T?_ *!\/Y5IT4 9G_".Z/\ ] ^'\J/^$=T?_H'P_E6G10!F?\([
MH_\ T#X?RH_X1W1_^@?#^5:=% &9_P ([H__ $#X?RH_X1W1_P#H'P_E6G10
M!F?\([H__0/A_*C_ (1W1_\ H'P_E6G10!F?\([H_P#T#X?RH_X1W1_^@?#^
M5:=% &9_PCNC_P#0/A_*C_A'='_Z!\/Y5IT4 9G_  CNC_\ 0/A_*C_A'='_
M .@?#^5:=% &9_PCNC_] ^'\J3_A'='_ .?"'\JU** ..\%Q)#>ZM'&H5%GP
M .W KL!7)>$/^0EK'_7Q_05UU !1110 48HHH **** "D/0TM!Z&@#A]!TVR
MOO$&LFZMTE*RC&[MUKI/^$=T?_H'P_E6-X6_Y#^M?]=1_6NMH S/^$=T?_H'
MP_E1_P ([H__ $#X?RK3HH S/^$=T?\ Z!\/Y4?\([H__0/A_*M.B@#,_P"$
M=T?_ *!\/Y4?\([H_P#T#X?RK3HH S/^$=T?_H'P_E1_PCNC_P#0/A_*M.B@
M#,_X1W1_^@?#^5'_  CNC_\ 0/A_*M.B@#,_X1W1_P#H'P_E1_PCNC_] ^'\
MJTZ* ,S_ (1W1_\ H'P_E1_PCNC_ /0/A_*M.B@#,_X1W1_^@?#^5'_".Z/_
M - ^'\JTZ* ,S_A'='_Z!\/Y4?\ ".Z/_P! ^'\JTZ* ,S_A'='_ .@?#^5'
M_".Z/_T#X?RK3HH S/\ A'='_P"@?#^5'_".Z/\ ] ^'\JTZ* ,S_A'='_Z!
M\/Y4?\([H_\ T#X?RK3HH S/^$=T?_H'P_E1_P ([H__ $#X?RK3HH S/^$=
MT?\ Z!\/Y4?\([H__0/A_*M.B@#,_P"$=T?_ *!\/Y4?\([H_P#T#X?RK3HH
M S/^$=T?_H'P_E1_PCNC_P#0/A_*M.B@#,_X1W1_^@?#^5'_  CNC_\ 0/A_
M*M.B@#,_X1W1_P#H'P_E1_PCNC_] ^'\JTZ* ,S_ (1W1_\ H'P_E1_PCNC_
M /0/A_*M.B@#,_X1W1_^@?#^5'_".Z/_ - ^'\JTZ* ,S_A'='_Z!\/Y4?\
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MK3HH S/^$=T?_H'P_E1_PCNC_P#0/A_*M.B@#,_X1W1_^@?#^5'_  CNC_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% ')>$/\ D):Q_P!?']!76UR/A#_D):Q_
MU\'^0KK10 M%%% !1110 4444 %!Z&BD/0T <GX7_P"0_K7_ %U']:ZVN2\+
M_P#(?UK_ *ZC^M=;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"G::;;6,LTD";6F;<_N:N444 %%%% !1110 4444 %&,T44
M 5+73;:SN)YH4VO,<N?4U;HHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI>:?;WPC$Z[MC;E^M6
MZ* $ "@ =J6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **2B@!:*2B@!:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "B@TE "T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 44&DS0 M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !110: "BDI: "BBB@ HHHH **** "BBB@ HHHH **#24 +1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%)2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS]T>_/->@4@%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYKTLP1$@M&C,!P2H)H \X^*$;R6>F!$9L$9P*T-<C<_#:-0I+>6O KN6ACD
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M_#R;< UVGA?0SHVA164X5WQE@1D9H YGP7&Z^ +M64AMC<$<]*H_"R*2.^U
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MXIJ1)']Q%4>BC%/I %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E  11BEHH 3%+
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T4
M44 %%%% !11368*,DX YH I:IJ]KI$"RW4@568*/K3[G4K>TL#>S.%A"[LUP
MCEO&7C79RVF6!!S_  LW^14GBBX?7M<M?#EBQ\E"&N"O0 =OTH [JSO8K^U2
MX@.8W&0:LU7L[2.RM(K>)0$C4* *L4 %%%% !1110 4E+10 F*6BB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "C--)P,DX [URFJ^,ECNC9:1;M?78^
M\$^ZOXT =917F.N:SXNLTB>YE@MQ+]U(QROUXK$_X2?Q'_T$#^5;PP]2:ND<
M=7'4:4N63U/::*\5_P"$G\1_]! _E1_PE'B/_H('\JOZG5[&?]IX?N>U45YK
MH'_"3:Y \JZN8]IQ]W-+KW_"2Z';I*VL&0,<8VXK'V4N;DZG5]8A[/VE]#TF
MEKQ3_A*/$?\ T$#^5'_"3^(_^@@?RK;ZG5[')_:F'[GM=)7BO_"3^(_^@@?R
MK;\/S^)==,H75S'Y?^SG-1/#3@KR-:6/HU9<L6>GT5YUKD7B;1;(7+:P7R<8
MVUS?_"3^(_\ H('\J*="=17B.MC:-&7+-GM-%>+?\)/XC_Z"!_*D/B?Q'_T$
M#^57]4J]C+^T\/W/:J*\LT&\\2Z[/)$NJF,H,YVUI:O:^)M*L'N3K1?;VVUB
MZ4E+D>YTQQ$)0]HMCT&BO%?^$H\1_P#00/Y4O_"3^(_^@@?RK;ZG5['-_:>'
M[GM-%>*GQ/XC_P"@@?RK2T34?$FLWWV9=4,9V[LXJ986I%7:*IYA0J248L]8
MHK@M2L/$^G:?-=G6BPB4MC9UKDO^$H\1_P#01/Y5-.A.IK$TKXNE1=IL]JHK
MQ;_A)_$?_00/Y4?\)/XC_P"@@?RK3ZI5[&']IX?N>TT5Y+H^J^)-6OEMAJA0
MD=<9KH+W3/$]G:23G6\A%SC9_P#7K*5*4969U4L33J0YXO0[JBO%CXG\1@X_
MM$_E1_PD_B/_ *"!_*M5A*KZ'-_:>'3W/::*\6_X2?Q'_P!! _E5O3-9\2:E
M?1VPU,IO.,XI2PM2*NT5#,:$WRIGKU%</<Z5XGMK:28ZV3L4G&W_ .O7''Q/
MXC5BO]HG@XZ5G"C.?PFM;%TJ+]]GM-%>*_\ "3^(_P#H('\J7_A)_$?_ $$#
M^5:_4ZO8Y_[4P_<]IHKR#3M;\2:A?Q6HU,J9#C..E=5)HWB>.)G_ +<S@9^Y
M_P#7K*=*4'9G32Q-.K'F@SM:*\7?Q+XC5V7^T2<''2F_\)/XC_Z"!_*M/JE5
MK8YWF>'3M<]JHKQ4^)_$?_00/Y5/9:_XDN[N.W&I%=YQG%#PE1:M#CF5"3LF
M>QT5Q3:-XG6,R?VX>!G&S_Z]<;-XC\1PS-'_ &B3M.,XK.G1E4^$WK8JG12<
MWN>STM>*?\)/XC_Z"!_*C_A*/$?_ $$#^5:_4ZO8YO[3P_<]JI:\8@\1>(Y[
MA(O[1(+L!G'2NS31?%#QJPUSJ,_<_P#KUE4HRI_$=-#$TZ_P,[2BN-_L+Q1_
MT'/_ !W_ .O1_8?BC_H.?^.5D=!V-<IXXUM['3EL;7YKR[.Q .HK4L$N=*TR
M234[WSF0%BY&,5R?AV%_$GB.?7KH$VT)VVX;I]: +\?D^!O!9=L-<L,^[.:E
M\#:))9V<FIW?-Y>'>V>H'I61*S>,_&@@!+:5IY#''W6;_(KN-0M[F33F@L)1
M!+@!6Q]T4P+]%<;_ &'XH_Z#G_CG_P!>D.A^*,?\AS_QR@#L\T5X!K_C_P 0
MZ'K$]@UZTAB.-W3--T/XA>(=:U>"P6\*&9L!O2K]E*US/VL;V/H&BN,_L/Q1
M_P!!S_QS_P"O2_V%XH_Z#A_[X_\ KUF:'94E<8VB>*%4G^W#Q_L?_7KRB\^)
MWB"TO9[<W3-Y3E,YZX.*N,'+8B<U'<^BJ*\-\)>,?$7BG5EL$OS$2"=V,UZ!
M_8?BC_H.?^.?_7I2BXZ,<9*6J.SI*XW^P_%'_0<_\<_^O5'6+3Q/I.E7%\VL
MEQ"A;;MZTDKL=[(] HKYP;XK:^&(^TMP:ZSP3X@\2>,IKI(]2,'V=0>F<YJW
M2DE=D*I%NR/9**XW^PO%'_0<_P#'/_KT?V'XH_Z#G_CG_P!>LS0[*DS7'?V'
MXH_Z#G_CG_UZT-'TO6;6Z\R_U,W$>/NXQ0!KZA?0Z=8RW4[82,9-<5X3M7U/
M4KGQ+?#"-GR=_P#"OK1XLNY==UN#P[:M^[W;IV'85)XLNSIVEVWA[3.+BX 0
M =EZ4P*M@K>+_&+W[J3IMD<1 ]"PKT0  <?A63X?TB/1=&BM8Q\P7+-ZFO,=
M4\4^(+;5+F%;XA4<@ "JC%RV.>OB:=!)S9[+17AW_"8>(O\ G_/Y4H\7^(B0
M/MYI^RD<W]J8=]3W"BN#TZP\3ZA8Q7(UHKO&<;/_ *]6O["\4?\ 0<_\<_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %(:6F2MLB=_[JDT <?XJU.\O-1A\.:6Q6
M><;II!_ G^36[H>@V6@V0@M8P#_&Y'+'U-<_X(B^VWFJ:S)\S33LB,>R@GBN
MUH X'XB?\NGU/]*X2N[^(G6U^I_I7"5[^!_A(^*S;_>&%%'>BNL\P]$^'O\
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MTKT?7/\ D#7/^Y7C8S^.CZK+/]SD>,-]X_6DI6^\?K25["V/F)_$PK9\+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/A^^EMI8&U6YB>!RA0,>F>/TQ6=6HI([\MR^>%DW)[G?T5RW_"*WO_0:NO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0!DZWH5OK=@MG,[I$K X0XSCM5^UM8K.UCMX5"QQJ% %38HH 6BBB@ HHHH
M**** "BBB@ HHHH **** $S5#4]6M],B!E.9'.$C'5C4UZUPMJQM4#S'A0QP
M*H:9HWDR?:[U_/O&ZL>B^P% %6UTNZU6=;S5\JJG,5L#POH3[UT*HJJ H  Z
M 4N*6@ HHHH **** "H;F)9[>2)AD,I!%34A&: ,7PY<!K66T/$ELY0CVSQ^
ME;=9<.G-;ZU+=1X$<J_,/4UJ4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !4;S1Q?ZQU7ZG%0:E>IIVGSW<GW(D
M+&O.M*TW4_&[R:E>7<MO9LV(XD..* /25N[=SA9HS]&%3 UP5[\/OLT#3:;J
M-RLZC(W.2#6[X2O+ZYTH)J,3)<1$J2?XAZT =#165?\ B#3--?9<W2(WIGFI
M=/UFPU0'[)<))CJ >: -"BLJX\0:;:W+P3W2)(@R0345IXHTB\N!!#>(TA.
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M:XCQUX@L=0\*3"PO 9!(O"-@T >A@A@"#D&BJ6CDG2+0G)S$,DU<8A1D\ 4
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M",]#5A];L([);M[E%A;[K$]: -*BL6T\4Z1>S"&&\C9ST&<9K6>9(HC)(X5
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M9),!0#Z]* -JBLF_\0Z9IL@CN;I$?^[FI=/UJPU3(M+A)".2 >: -&BD%+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQL1>VER=Q3N#0!B7M[:KJ%K<Z/IUQ;2I(-P"D BMWQI<S:AJFD:8S,D<X4R
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MG8P]J0'E/@C0[35=:U9[Q/-CCF?:C=,YJ#Q)<VT?BN.PF@D>QMEXACZ&ND\
MZ?=V5]JS7,#QB29BA;N,U%XHT;4;/7XM<TR 3G&)(SWI@<SJMWI4UL#I^DW%
MO<H04=5(KKYFDUGP+ UY=FSW*/,9N">.E9EQJ_B#6%2TMM$^Q,3\TI'2M#Q7
MH6H3>&;:" M/+"077^_0!A/<>$8; VR64EQ(!@R!.IJUX/F,OP_UH9;8@E"A
MNPVU%%J&K-:+:6OAE89MNT2L!CZU8\*6.HVWA;7+*ZM'2:19&7(^\2N.* #X
M>^'+"^T/[7>0B:0R'9NYV@>E5;O2;?4OB@UI,,P!!E0>H"\"NI\ 6EQ8^&HX
MKF)HI QRK=:SX=/NQ\3I+PP/]G*8$F./NT 2^)- TZWTU8ENEL+0.&D5?X_:
MN:U*\\)C3'AM;"1I N!($[^N:Z#Q_I5_>/9W-K#]HCA?+P^M8UQ?ZO?V+6MI
MX96W9EP7(% &CX8F:7X<W>YB0L9 R:J> /#&GW^CFZO8Q,S,0 W0"K_ABQO8
M/ U]:3VSI.5("D=:TO %G<6/AU8KF)HGW'Y6H YW0X4T7Q]J%K:Y$ C+!<\#
M&:=X1TFV\27^HZCJ@\]A,456/  K0M=-NO\ A8UW<R0.+9TP'['K6= -8\':
MM>+8V?VZRG?> C<@F@"IXN\/VVC>(=)EL\I'+,N8\\ YZU/XZU+/B"QL9UD>
MT5-SQQ]6XK*UZ_U?5?$6E3ZA:&VB\Y5CC)YZ]:ZWQ=H-ZU[::SIJ"6X@&&C(
M^\* .7U"ZT6:Q9+71KB&91\CJI!S6K/K%^OPZ0R%TF8B,LW!Q3YM>U^_@^RP
M>'_L\S<&4@8'O6[<>&KB]\(_8+F8O=8W;C_>H @T?P7I$FAQ&:'?+(F6D)YS
M67X!LQI_B75K8,6"8 )/UHL==\3Z9:+IS:.TLB?*DH/%3^!;#4[;7-2GU&%D
M:7!W'H>M 'H->4>']&M=7\=ZP+M?,CB;(4],\5ZO7!^$]/N[;QCK4\UNZ0R'
MY&8<-TH P?%\EO9:]9:2(7&GQ@NT,7\1JOJ-WHLUDR6NC3PS ?(ZK@YKJO&&
MA7S:I;:WIB"2>#AHR.HK-GUW7]0@^RV_A_[/,W!E('% "3ZS?Q?#=7D+I<']
MWENN*U-!\%:5)H,37,7FS3+N:1N3DU;N?#=Q>^#_ .S[F4O=%=V[WK LM=\3
M:-8C37T=YWC&U90>,4 ,URSN/"/ABY@M[XRI-)A0#R@K-L;S08K!4ET:>:1A
M\TA7))K8A\):EJN@7;ZA*PNYCOC0GA?:H[37->TRV%E/X?\ />,;5D &* )?
MAW<3#5-2M5BF2R $D0DSQTXK-\'Z!;:QKVL2W@WPQ7+XCSP3NZUUG@^TU</=
M7VJG9YQ_=PCH@KA_#NH:MI>M:Q=6%H;J+[2ZR1@\_>ZT :_B/2H/#?B#3+O3
ME\D32A&13P:=X[TRT_M_36,*YFDQ)QUI\5MK/BW7;6ZO[(VEI;-N"L>2:O>/
MK&^DGL;VSMVN# ^2J]: ,W7;..Z\4V.@QYBL0-QC0X!Z5M:WX+TA=$G>" 13
M11EE=>#D"LK5+/5M1-KXBM+1H;R/A[=NXI+WQ!XEU>S;3XM%>!Y!M:1CQ0!6
M>]FO/A=<^<Q9HV"Y/?!K9\%>&=..A6=[/")+EOGWMS@@\?RJ*^\/7%A\/);"
M-#+<-@D+W.:Z+PI!+;>&K.*9"DBI\RGJ.30!YWJ$+Z/XIO;C5M,>]MY3F-^H
M K;\,3>&[C7%GLO-M;G'^I.0#^%%Y=>(=%UBZ$MDVJ64K9C!.=H].:JZ=INH
M:WXIM=2;2QIT,'4="U 'IPI:04M( HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 -VCTI:6B@!N!1@#I3J
M* &X&>E& :=10 W'H*-H]*=10 E%+10 T@&FRINA=!U92*DHH Y3PAH-YHS7
MYNQ'B:7<FTYXYKJ<>@IU% "4F!Z4ZB@!.])@=<4ZB@!,#%)@8IU% #<<8H X
MQ3J* &[12XI:* (IT,EO*B_>9"!^5<UX-T*\T6WNDO FZ29G78<\$FNJHH ;
MC%&!Z4ZB@!N,T8%.HH 3%)BG44 -QZ48!ZBG44 )BDQ[4ZB@!*3:/2G44 )B
MC%+10 W;ST%&./2G44 -(!ZC-%.HH ;@>E&*=10 F,=*3%.HH ;@ ]*,<4ZB
M@!N/2BG44 -P.N!1BG44 -P.U&.>E.HH 3%)@=J=10 E)3J* &[1Z48'I3J*
M &X&<T8IU% #2!C&*Y7QGH-[K<FE&S"8MKCS)-[8XXZ?E7644 1QIMC4$<A0
M#3L4ZB@!N!C%&!Z4ZB@"AJOV\:>_]F^7]J'W/,Z5S7AWPYJ:ZS)K&N21O=D;
M45#D**[2B@ %(:6B@!N!2XI:* $P/2CZTM% #=H]*,#TIU% "8Q28'I3J* &
MXS0% ["G44 -Q[48Q3J* &,H(((ZBO/V\-^)M%U.XGT.YAEAG;<8YSP*]#HH
M X33_"^L:CK,.I>(IXV,',<41^45W.*=10 W:!VI:6B@!N!FC IU% "4F/:G
M44 )VI,#TIU% "8I-H]!3J* $I,"G44 -[5R?A#P_>Z->:I)=B/;<W#21[6S
MP3WKKJ* &X]J,#ZTZB@!N*,#.<<TZB@!N..:,8Z4ZB@!N*4"EHH !THHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M64N-1%K;1M,%^_(OW5_&J!FN_$$FRVW06(.&D/#/]/:MRSL8+&!8K= JC]:
M+-%%% !1110 4444 %%%% !1110 4444 %%%% !4<LHAB:1SA5&34E,EC$D3
M(>C#% #8)TN(EEC;*-T-2U@^'G> W&GR?>@<[?<5O4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!U%1>?$&VF5,^FX5(#[YH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %U7^0KJM0&;"?\ ZYG^5(#(?Q-INDV5HEW*59XA@ >@ID7CC0Y95076TL<
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M,LK2*YN'^Y$JC.?>@#?N_%K#P0NJQ8\YQM'^]619>$M2U;3/[2N-3G6ZE&]
M&.!Z5:UC1Y+GX?K';6@@9?W@A3M4^C>.-*MO#T:7$OE7$";3$1R2* %1]8@\
M'7\>I9$L2D)(#R16<NFMK'P]CGEN90T*,W#'YN35E-8U+6_">JW-Y&J08/D@
M+@D5/HO_ "363_KDW\S0!E^ ]$$>@2ZH+B7<8Y%";C@=:9X<UZ?3/AO/?-(S
MS>8RH6.><FMGP/\ \B%(/]B7^M<QHVG2ZE\+)D@!:1)BX4=\$T :>G>%=2UK
M25U2YU.=;J9=Z*K' KJ?"?\ :T5B\&JC+QG"N?XA6+H'C?2K7PU#%=3&*YMH
MPC1$<D@=JU/"6M:EKB7%U=1K';[OW/RX)% '07I(L;@C@B-OY5Y7X:TW5/$4
MEW#)>RQ6D<IY#')->J7W_'A<?]<V_E7F7@CQ-9Z3+>6U^QBC:4E9"/EH N6S
M:CX0\3VVGRW3W%G='"[SDBH?$KW]S\08]/M+EXEN(U4D'H, U)>WR^+?&-C_
M &<K/;6IR\N.*FO1CXM6P](Q_P"@T 0^)=&D\-^&\Q7LTC27*<LYR.#FI?&]
MS=1:)I+6\K+(Q7H>M:?Q*_Y%R'_KY3^M9GC7_D$:+_O+0!6UGP[J-CHC:TVI
MS-=(OF$!CCZ5+I^CZGXJT<:C>:A)$VW]VB,1TKI/%O\ R)%W_P!<?Z4O@_\
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MF!)$FI:KXQU#3X+MXH2V7()R![4FHVNJ^%-<M[.SO9)4O1M7>2<'N:U/#/\
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M\: *.BQBXU*^OSR2WEH?85OCI6?HUH++2H8OXL;F/J3S_6M"@ HHHH ****
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M+;2'TW#(_2O6K.PM;!&2T@6)&;<0O<U%?:3I^IF(WMK'.8CN0N/NFD!9MO\
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M %?3;A;JPAF5L[EZU;KG_#RFRGN]-+Y$,A9,_P!T_P#U\UT% !1110 4444
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M%[#_ 'Y/^^S_ (T;#_?D_P"^S_C1_9T^X?VY2['N?]H6?_/S%_WV*7^T+/\
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M(/[=I=CW_P#M"S_Y^8O^^Q2_VA9_\_,7_?8KY_W/_P ])/\ OLT;G_YZ2?\
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M )^9?^^S1]4D']HP['U+_:=E_P _47_?8H_M.R_Y^HO^^Q7RU_:%Y_S\R_\
M?9H_M"\_Y^9?^^S1]4D']HP['U+_ &G9?\_47_?8H_M.R_Y^HO\ OL5\M?VA
M>?\ /S+_ -]FC^T+S_GYE_[[-'U20?VC#L?4O]IV7_/U%_WV*/[3LO\ GZB_
M[[%?+7]H7G_/S+_WV:/[0O/^?F7_ +[-'U20?VC#L?4O]IV7_/U%_P!]BC^T
M[+_GZB_[[%?+7]H7G_/S+_WV:/[0O/\ GYE_[[-'U20?VC#L?4O]IV7_ #]1
M?]]BC^T[+_GZB_[[%?+7]H7G_/S+_P!]FC^T+S_GYE_[[-'U20?VC#L?4O\
M:=E_S]1?]]BC^T[+_GZB_P"^Q7RU_:%Y_P _,O\ WV:/[0O/^?F7_OLT?5)!
M_:,.Q]2_VG9?\_47_?8H_M.R_P"?J+_OL5\M?VA>?\_,O_?9H_M"\_Y^9?\
MOLT?5)!_:,.Q]2_VG9?\_47_ 'V*/[3LO^?J+_OL5\M?VA>?\_,O_?9H_M"\
M_P"?F7_OLT?5)!_:,.Q]2_VG9?\ /U%_WV*/[3LO^?J+_OL5\M?VA>?\_,O_
M 'V:/[0O/^?F7_OLT?5)!_:,.Q]3?VE9?\_47_?8I/[2LO\ GZB_[[%?+/\
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M7@CQG/-9QOKU6P;B8$=BQI+#-]2GCTMT?4W]I67_ #]1?]]BD_M.R_Y^HO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3I4>.9T<?,IP?K3:Z4<+5F%%%%,D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *U_#/_(PV?\ UT7^=9%:_AG_ )&&S_ZZK_.LJOP,Z,-_
M$1]/P_ZF/_=%/ID7^IC_ -T4^O(/I HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** $-<QXF\)KXAFAD^T-$T?3 KIZ,4TVG="E%25F>>?
M\*R_ZB4GY?\ UZ/^%9?]1*3\O_KUZ)16GMZG<P^J4?Y3SO\ X5E_U$I/R_\
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M+_Z]=_2UA5A&J[S5SJHR=%6AH>:7?PGAOL?:+YWQZC_Z]5?^%+:=_P _+?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:?HUILA4Y,KCYFIVOZ[9W_A[2[.W9_.MUPX(P*]"_P"%/6'_ #]/_P!\TO\
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M+?WD4^OR7B9\II]X)],YK8\7>(+;4]7M+RP9SY,:#)&.0!7H7_"GK#_GZ?\
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MZ?<\3HKVS_A3UA_S]/\ ]\T?\*>L/^?IO^^:/K<0_LZ?<\3HKVS_ (4]8?\
M/TW_ 'S1_P *>L/^?I_RH^MQ#^SI]SQ.M?PQ_P C%9_]=1_.O5/^%/6'_/TW
MY59L?A39V-[%<I=.6C8,!CTJ)XE2C8TI8&4)IL]"A_U,?^Z*?34&U%7T&*=7
M">L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "BBB@""[_U)K.K1N_\ 4FL[O3 ****!!1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E !6?K*I+I<T+-
MC>N!5NXN$MXRSGZ#UK/AADOIO/FR(P>%KCJXMPFH4M9&JH*I!\^QYQ+:3PR;
M'B<<\<=:V]&\+RZ@ADG+1+VR.M=]Y$1 S&AQZK3P !@# ]!7M/'S<$NIX$,F
MIQJ.3=T<G_PA$/\ S\M^5'_"$0_\_+?E76T5E]:J=SL_L[#_ ,IR7_"$0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDKLWGEE6+LCK:*Y+_A*KC_GW_2C_ (2NX_Y]_P!*T_M"D1_9U8ZVFLP4%B0
M.]<I_P )5<?\^Y_*JFH>(;F[MS$$,8/4BHGF5-1;6Y4,MJ.23.L&I6C2;!,F
M?K5H889'(->7!FSD$Y]<UW'ANZDN=/Q(22IP":SPF/\ ;SY&C3&9=["'.F6;
MNT9'\^#AAU J>TNUG3GAQU%6NU5Q9QK<><O#>E;?5Y4ZG/2V?0X?:*4;3W+%
M+24M=YSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 E17$Z01EF/TJ6H)[6.X
M=&?/R]JQK\_):GN73Y;^]L4889+Z7SILA ?E4UJ !5P. * H48 P*Q_%=])I
MOAF^NXL^9'&2N*C"X94]]6RJU7F]"2Z\2:393>3/>Q*_<;JOVUU!=Q"6WD61
M#T*G-?*MQ<S7,[332,[L<DDUU'A7QQJ/AU'BC1KB-NBG)Q7IRP]E='!'$7>I
M]$TE>.?\+<U/_H'?^.T?\+<U/_H'?^.UG[&1K[:)['2UXW_PMS4_^@=_X[1_
MPMS4_P#H'?\ CM'L9![:)Z^\\4;JKR*K-T!.,U(#D9%>">(?B!?ZU:*C6SV\
MD;;ED3(P:30_B;K5@ZQS?Z5&."".:?L':Y/MXW/?*6N$TKXB_;RH;2[E2?1:
M[:WF^T0+)M*[AG#=164DT;)W):***D85RMWXU@M-?_LM[=_O!?,SP,UU5>6Z
MQ9&\\1ZQM_UD*"1,>HH ]1SD9[&N:O/&$%MKZ:4L+.S$ L#P,U<TK5ENO#<5
M\[ $1_/[&N 2W=M7T_4)1\]S<DCZ<4 >L Y&:6N6&JW0\9+I^[]QY6<>_-3^
M+=2N-,L;>2V;:S3*I^A- %O5]<32I[6)HB_VA]H([5)<ZU;VVH6UDV?.G^Z*
MYSQ6Y>YT5SU+@G\JQ]>AU,^,[,1RJ)&_U)/84 =WJ>JO87-M$ML\PF;!9?X?
MK6D#D5R.N:E?:=/H\!=2\QVRG'7I576_$.I6GBO^S[1?,#PC8OHQ[TP.XS65
MK&N)I,ENCQ%_.8*,=JYF35=?T*>*?4@LEK(P#8_AJ?Q=*L[:5*A^5I%(_,4
M=FC;E5O49I:Y36M=N89X--TY5-RZ@DL> *H'5=<T6:*6_>.:W=MK;2/ES2 [
MNDKE-?U2^T^2TU&V;S+)L>8OH#4-]XBN-2U2TL-(<'> \LF/NB@#LJ*:@*J
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M,AZ,,&L?0G9'NK5O^63G'T-;((*YSP>:QM';S=3OY0/EW;:!&W1110 4444
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MDOT2:X<<@C(%=W^%+7J*K/D46SB]E!2NC._L+2_^?&#_ +X%']@Z7_SXP?\
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MGN\LAU+11788A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV,Y^0]A7HZ,'4,I!4C/6D ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ_6@#5HH[44AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!!=_P"I-9W>M&[_ -2:SN], HHHH$%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!4O(YI4"1< ]33[6U2WCP/O'J:GHK#ZO#VGM'N:>T?+RD5S,MO;R3/PJ
M+DUYKJ'BN_N+IFAD,<8/ KT/5%273IHG; =<5Y+=64]O*5>-NO!Q7)BZS4N6
M+/=R:C1E=U#KO#_B\DM#J#C@95ZZ'_A)M+_Y^%KB- \+RZFS27 :.$#@]S70
M#P%:?\]GJJ4JW+<>,I8%5=6:_P#PDVE_\_"T?\)-I?\ S\+61_P@5G_SV>C_
M (0*S_Y[/6O-7['+[+ ?S,U_^$FTO_GX6J6I^*+:.U,EI.K2*?NGO57_ (0.
MS_Y[/5+4O!D-K:EH&DDE/"K4RE7L:4J6 YEJ:&G^-K2X(6Y4Q-Z]JZ"'5+*<
M QW"'/O7#Z=X(N)B&NW$:^@ZUTEIX2L+;!R[8]\4Z4JKW1.,I8*+_=O4WE8,
M,@Y%.J.*%88PB [1TS4E=B/&:5] HHHH$%%%% !4;PQ2,K/&C,O0LH.*DHH
M**** &/&DB[9$5AZ,,TQ+2VB;=';Q(?54 J:B@!"H(P>E-CBCB7;&BH,YPHQ
M3Z* &LH9=K ,#U![TV*"*%<11)&#SA5 J2B@ HHHH **** "C-)01D8H BDN
MH(Q\\JC\:S+SQ'9VW"MYC>@J:YT2UN26;<"?>L:\\)@*6MI.?0URUI5DGRHY
MZCJ_9+%AXC2>5FG98T'W16E_;MA_SV%<Y8>'#)*T=T&0CH16C_PB-M_SU>L:
M<\0UL9PE6ML:7]NV'_/84?V[8?\ /85F_P#"(VW_ #U:C_A$;;_GJU7S8CL5
MS5NQI?VY8?\ /853U+Q';PVI-LX>0\#VJ'_A$;;_ )ZM5/4?"_D6QDMF9V'4
M5-2=?EV)G*LHLS!K]_YN_P TGGI79:1J U&S$IX8<-7GWD2[]@C;=Z8KM/#4
M0M[,JQ_>$\@USX6M)5+2>Y.$=64O(VI(UE0HPR#5.WM9K:<A6S$:OT5WSP\)
MR4^IZ<:DDK!112UT&04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH^Q1^K4 4**O_8H_5J/L4?JU %"BK_V*/U:C[%'ZM0!0HJ_]BC]6H^Q1^K4
M4**O_8H_5J/L4?JU C(N+5+C;O)X-2HBHNU1@"M'[#'_ 'FH^Q1^K5FJ4%+F
MMJ6Y2M8H8I:O_8H_5J/L4?JU:$E"BK_V*/U:C[%'ZM0!0HJ_]BC]6H^Q1^K4
M 4**O_8H_5J/L4?JU %"BK_V*/U:C[%'ZM0!0HJ_]BC]6H^Q1^K4 4**O_8H
M_5J/L4?JU %"BK_V*/U:C[%'ZM0!0HJ_]BC]6H^Q1^K4 4**O_8H_5J/L4?J
MU %"BK_V*/U:C[%'ZM0!0HJ_]BC]6H^Q1^K4 4**O_8H_5J/L4?JU %"BK_V
M*/U:C[%'ZM0!0HJ_]BC]6H^Q1^K4 4**O_8H_5J/L4?JU %"BK_V*/U:C[%'
MZM0!0HJ_]BC]6H^Q1^K4 4**O_8H_5J/L4?JU %"BK_V*/U:C[%'ZM0!0I*T
M/L4?]YJ3[%'ZM1<5BABJXLXUN/-7(:MC[%'_ 'FI/L4?]YJSE2A)IM%QDUL4
M**O_ &*/^\U'V*/^\U:$E&BKWV*/^\U+]BC]6H H45?^Q1^K4?8H_5J *%%7
M_L4?JU'V*/U:@"A15_[%'ZM1]BC]6H H45?^Q1^K4?8H_5J *%%7_L4?JU'V
M*/U:@"A15_[%'ZM1]BC]6H H45?^Q1^K4?8H_5J *%%7_L4?JU'V*/U:@"A1
M5_[%'ZM1]BC]6H H45?^Q1^K4?8H_5J *%%7_L4?JU'V*/U:@"A15_[%'ZM1
M]BC]6H H45?^Q1^K4?8H_5J *%%7_L4?JU'V*/U:@"A15_[%'ZM1]BC]6H H
M45?^Q1^K4?8H_5J *%%7_L4?JU'V*/U:@"A15_[%'ZM1]BC]6H H45?^Q1^K
M4?8H_5J *%%7_L4?JU'V*/U:@"A15_[%'ZM1]BC]6H H45?^Q1^K4?8H_5J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 44F:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8ZQ::C<7$%L^]X3A_:K] "T4E% "T444 %%%% !129I<T %%)FC- "T44F:
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MC('KMK1U;Q;?'56TS1+03W"??9ONBJ&C$#XD:F3T"<_E3'US5M1UFZA\.V,
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M>:>XQ\C'[H_"E\<V367@>VLY'\PI(B%AWY%>@5G:QHUMK=H+:ZW; P;Y3W%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!*6LZ\UNPL)O)N;A4<C.#5;_A*-(_Y^TJ7**W8TF]C
M9I:QO^$HTC_G[6C_ (2C2/\ G[6E[2'<.678V:*QO^$HTC_G[2D/BG2!S]K2
MCVD>X^5FU25B)XMT5AD7J4[_ (2O1O\ G]3\ZT469N<4]6;-%8W_  E>C?\
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M2I<DM&4DWJC9I:PAXNT5B?\ 34XZTO\ PE>B_P#/]'^=4E<ASBG9LVZ6L/\
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M'_S_ ,7YT<K#F7<VZ6L/_A+]#_Y_XOSH_P"$OT/_ )_XOSHY6',NYN45A_\
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M*** "BBB@ HHI* %HIH8'H0?I02!U('UH =124M !13=PW8R,^E** %HHHH
M**** "BBB@ HI#2;AG&1GTS0 ZBDI"P49) ^M #J*:"",@TM "T4W(SC(SZ9
MIU !1110 444E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124
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M3V##_"I_^%<Z3_STN/\ OK_ZU>!CL"\16]HF>[@L<L/1]FU<\C'_ !]W'/\
M'4N:]1'PPT4,S%ISD]V'^%/_ .%9:+ZS?]]?_6KV:%54X*'8^/QV4RQ->55/
M<\KS1FO5/^%9:)ZS?]]?_6I/^%9:)_>F_P"^O_K5K]81R?V#/^8\LS1FO4_^
M%9:)_>F_[Z_^M1_PK+1/[TW_ 'U_]:CZR@_L&?\ ,>69HS7J?_"LM$_O3?\
M?7_UJ/\ A66B?WIO^^O_ *U'UA!_8,_YCRS-&:]3_P"%9:)_>F_[Z_\ K4?\
M*RT3^]-_WU_]:CZP@_L&?\QY9FC->I_\*RT3^]-_WU_]:C_A66B?WIO^^O\
MZU'UE!_8,_YCRS-)D5ZI_P *RT3^]-_WU_\ 6I?^%9:)ZS?]]?\ UJ/K"*CD
M4T[\QQ_A0C^S&Y_C-;V1ZUIP_#C2H%*I-< 9SC</\*E_X5]IG_/>Y_[[_P#K
M5\CC,CE7K.IS;GV^&QBHTHPML9&1ZTW@]2*VO^%?:9_SVN?^^_\ ZU'_  K[
M3/\ GM<_]]__ %JYEP[-;2-_[1CV,;(]16;K9'V(8_OBNJ_X5]IO_/:X_P"^
M_P#ZU'_"O=+W*6EG;!R 6_\ K5MA\BE2JJ;EL9U,<IQY;'2Z?_R#X/\ <%6:
M9#&L42QK]U1@5)7TRT/,"BBB@ HHHH **** $Q7(:WX.FN=4.IZ5>M9W;?>8
M#(-=A10!PUMX*U"ZOH[G7=4:\\I@R*!@?CUK7UOP])J>H:?<1S+&MJ^XJ5SD
M8(KHJ,4 8?B/19-:MX8HY1'Y<@<Y&<U#<>'Y9M>L-1$RA;9-I3'7I_A70XHQ
M0!S7BWPO_P )%;1K%*(9D/#D9XK0BT.W701I4@W1^7L-:N*6@#C8O#>NVENU
ME:ZNJVAR &3+*/3.:L7_ (3\[PRNDV\VUMZNTCC.2&!-=3BEQ0!G3Z:EUHXL
M)6./+"%AZ@=:YS_A&M<^RFP.JH;/[H#)EMOIG-=GBEQ0!Q]YX*7[%:1V$_E3
M6O*,PR*K:IX/U76;4)>ZDID0Y0*F%_+-=QBEQ0!S2^'9_P"V=/OFG4BVB\ME
MV]:WYU>2WD2,A9&0A2>QQ4N*7% &#X9\/C0[242N);B9R\CXQDT>)] &NZ<L
M,;K%,CAXWQT-;U)B@#E+OPO=F:VO;.\$-_'&$>3;P^!Z56B\(ZA)KUMJE[?K
M-)'D,NW Q[<UVM)B@#C_ /A%]2LM1N)]+OTBCG;<RNF>?;FETSPC<6'B(:J]
MYYK.N) PZGVKL,4F* /,?#6EZC/>ZG=:;>B"3[0R,KKD'I[UU^A^'CITMQ=W
M4QN+RX_UDF/T%:EEIEIIWF_98A'YK[WQW-6\4 <GI'A>[TV>\A:Z1]/N79C%
MLY&[WS[U!#X8UG34>UTW5!'9L20CKDKGT.:[/%&* .8?PK_Q3D^G).3-.=SR
MOSDUNZ;:M9:;;VS,&:*,*3ZXJWBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU]SP"BO?_P#A5?A_^[+^8_PH_P"%5^'_ .[+^8_PH^MKL']FON> 45[_ /\
M"J_#_P#=E_,?X4?\*K\/_P!V7\Q_A1];78/[-?<\ HKW_P#X57X?_NR_F/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 E+110 4444 %%%% !1110 E+110 4444 %%%% !1110 4444
M%)2T4 )12T4 %%%% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "
M44M% !1110 4444 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M E+110 4<T44 %)2T4 %)BEHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M9)((UR:A^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[
M8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;
M$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FB
MJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0
M!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/
MMB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]
ML2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:
M*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E
M %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H
M^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJW
MVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9
MHJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB
M4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2
MC[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K
M?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %
MFBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V
M)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ
M*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJ
MM]L2C[8E %FBJWVQ*/MB4 6:*K?;$H^V)0!9HJM]L2C[8E %FBJWVQ*/MB4
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MM:5W_J36=WI@%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0GBDW;<:U%I*S+
MG51$Y6,9Q4MIJ*W!VMPU<,<RP[J>S3U-WAJG+S6+U%)N'J*1F !/6NMU8+=F
M2A+L.I:J1W\,C;2=K XP:M!@1QS4T\13G\+"5.4=T+1116Q(4444""BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **2B@ HHJM->P0_><$^@K*I7IP^)EQIRELBU1444HDC#=,T_</6F
MJT&KIB<))ZBT56NKQ+9<GDGH*HQ:P6?$B_*:Y*F94*<^1O4VCAJDH\R1L4E(
MC!U# \&EKNBU)71@TUH+1113$%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:R(-7W.%D7 /<5J@Y&>QJ<-C*6(5X,JK1E3^(=111748A1110 4444 %%%%
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MU;L<BRQJZG*L,@B@1)1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "F2*S+A6*GUI]%)JZL-.QESV5V^2)\^QK+FMYXR?,4GWKIZ0J&&"
M1[UX^*RF-;52.RCBW#1HPH[*[>-61LKCUI_V"\_O?K6TB!%PHP*6B&3P22<F
M-XQM['-7-O/"1YQSZ<U6)"@DG '6NKEB29=K@$53?2;62-T:/(88/->=7R*;
MJ\T'H=%/'QY+-:BZ5<PW-DABE5P."5.<5>KSF\T_4_!EZ;ZQ+SZ>S9>/J0*[
M+1=<M-;LUGMW&?XD)Y'X5]+1A[."B>9-\S;1JT44E:D"T444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@-0I*6B@ HXHHH
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MGPE;ZOHT=W/>70=NH5^*Z_Q$0WA^Z(((V<8-<9X9U#Q)!HL:V.FQ36XZ.6H
MO:KX(6SL9+FSU&Y62-=PW.:U_!6K2ZIH_P"_):2([2WK7+7&OZ]KERVDR1Q6
M;-PV3UKN?#VCQZ+IB6RD,W5F]30!K4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%&:C>3;TY-85\1"A'FDRH
MQ<F#MM'O7&3>%K[6=<:XU2?-FC9CC4\&NQ5"3N:I:Y<+.O5FZD](]$5-)*R(
MK>WBM85AA0(BC  J:BBO1("BBB@04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 E,F@BN(FBF171N"&&:DHH X=?"M]HVN)=:1,1;.W
M[R,G@"NTC?<HR>>]/QQ43(0=RUYV+G6HR52&L>J-8J+5F345&DF>#UJ2NK#X
MB%>/-$B47%A1116Y(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %/B_UJ_6F4^+_6K]:
M-6BCM12&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M $%W_J36=WK1N_\ 4FL[O3 *9(N]&7U!%/HH$8FB3-;F739^'@/[O_:7M47C
M&*2?PU<QQ(7<C@#J:NZGIINBEQ;OY=U%]UO4>AJ&WUDQDQZA&895[_PF@#G-
M,\636.EV]JVD7;-$FTD+U_6HA%J7BG6[>XGM6M[6 [ANZFNV74+1UR+A"/K5
M>;6K.($(_FN.BISF@"Q>7,=E9L[G@+A?K5;1+;R;0RL,/,Q=L^]58+2YU2X6
MYO5V0J<QQ>OUK=  &!VH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HI**3DHJ[&%1M)C@=:1G).U>:<B!>3UKR*N(J8F7LJ&W5
MFJBHZR$2/G<W)J4445W8;"PH1LMR)2<@HHHKJ("BBB@ HHHH **** "BBB@
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M%6J* $Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%%#T0"$U"6+G"]*4AG;'05(% &!7CU%6Q<^3:*_$V5HJXB*%%/I*6O3I48
M4H\L$9-MO4****U$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4UE##FG45$Z<:D>60T[:D',9]
M14JL&'%!&14>TJV5Z5Y/)5P<_<U@_P #6ZFM26EI!2U[$7=7,0HHHI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !32V!S3JA*L[<]*X\77G
M3C:FKMEP2>XA+2' X%2*H7I2@;1Q2UEA<'R/VM5WDQRGT6PM%%%>B9A1110
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MIH H45?^R1^IH^R1^IH H45?^R1^IH^R1^IH H45?^R1^IH^R1^IH H45?\
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MIH H45?^R1^IH^R1^IH H45?^R1^IH^R1^IH H45?^R1^IH^R1^IH H45?\
MLD?J:/LD?J: *%%7_LD?J:/LD?J: *%%7_LD?J:/LD?J: *%%7_LD?J:/LD?
MJ:0%"BK_ -DC]32_8X_4T7 SJ*T?L<?J:/L<?J:!&?15_P"R1^IH^R1^IIC*
M%%7_ +)'ZFC[)'ZF@"A15_[)'ZFC[)'ZF@"A15_[)'ZFC[)'ZF@"A15_[)'Z
MFC[)'ZF@"A15_P"R1^IH^R1^IH H45?^R1^IH^R1^IH H45?^R1^IH^R1^IH
M H45?^R1^IH^R1^IH H45?\ LD?J:/LD?J: *%%7_LD?J:/LD?J: *%%7_LD
M?J:/LD?J: *%%7_LD?J:/LD?J: *%%7_ +)'ZFC[)'ZF@"A15_[)'ZFC[)'Z
MF@"A3XO]:OUJY]DC]32K:HIR":0%BBD%+0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-'F,2MZ>M9$WBF">U\FU\-R+>,-H+0G /Y5K2Z;JJ^!IHSC[7(-Y5!CCTXH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1UE9(ID#2D=36I\1X99M'MQ%&[D3*<*,]Q6?KVEWL$6EZU91&22V0"2+')%
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MQWFNW))FO)#CV'^37-^,+6ZTWQ%/96?$>K8R!Z]_YUZ?I&GQZ7I5O91#Y8D
MH OT444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**,T %%)0* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>R4[O*4+GUK1H[44 -6-$)*JHSUP*4C/4 TZDH B%O"&W") ?7;4A'&*6EH
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M_*>__P!JV'_/W%_WU1_:MA_S]Q?]]5X!L_VF_.C9_M-^='U=]P_MZ'\I[_\
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MM)2U[Y@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 % HI* .*\9_\AK1O^NM/U>XGM=,F
MFMDWRJN0M1^,O^0UH_\ UUJY=?\ 'K)G^[7PO$:_VN%U<[</\#,SPY?WFH::
M)KR/8Y/'O6S5/3.-/A'M5ROEL2N:JW&-D=,=A:2E_"BN?DEV'<2BBBCDEV *
M***.278 I:2BJC"7,M ;1YY=ZA>:?+?R6D6\F?YO:GV\SW'B%)I!AWMU)'X"
MM&PA6>ZU6)A]YR/TK&TYF_X2)XFSF*/9^ P*_4*B?]G?(XJ/\8Z<4M)2U\.X
MRN?0)A1124N6071%=_\ 'I-_N'^5>+77_'W+_O&O:+O_ (])O]QOY5XO=?\
M'W+_ +QK[;A--.5SYCB+6,2*BBC\:^WNCY*S"BBB@5@HHHH"P4444!8****
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M#_"O5X;BUB]3.O\  =W0*2EK](//"BBB@ HHHH **** "BBB@ HHHH ****
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M_P *^D_Z"L_YC_"NZHK#ZI1_E1K[6?<X7_A7TG_05G_,?X4?\*^D_P"@K/\
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M "BBB@ HHHH **** "BBB@ HHHH 3 ]!1C%+10 4444 %%%% !1110 4444
M%%%% !112$T +14#7ENC;6GC#>A:I58,,J01[4 .HHHH **** "L*?\ Y'&T
M_P"N#UNU7>UB:\2Z*YE12H;V- %BBDI: "BBB@ HHJ-98W9E5P2O4 ]* )**
M** "BBB@ K,UNP^W6+!#MFC.^-AV(K3I#0!GZ-?B_P!/23/[P<.O<&M"JD5K
M;6+32H!&)&WN<\9I_P!NM.GVB+_OH4 6:*8KJZ[E8$'H0:<* %HHHH ****
M"BBB@ HICR+&NYV"KZDTY2&&0<@T +1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !114<DJ1+ND<*OJ3B@"2BJPOK4G N(O^^A4X8,,@Y![
MT .HHHH **** "BBB@ J.1UC1G8X51DU(:@NDBDMVCF8"-A@Y.* ,724?4=2
MFU.4Y124A'MZ_I70"H;:"*VMTBA $:C"BIZ "BBB@ HII8 9)P!ZU"+RW9MH
MGC+>FZ@"Q12 YZ4M !11FB@ JKJ/_(+N_P#KB_\ Z":M4R1%EC:-QE7!4CU!
MH SO#O\ R ;3_=/\S6I4-O!';0+#$,(OW14PH **** "BBFLP498@ =S0 ZB
MF(ZR*&1@RGN#Q3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBDH 6BH9+F&(XDE13Z%J>DJ2KN1U8>QS0 ^BDI: "BBB@ HHHH
M *KWW_'E-_N&K%,D19$9&Y!&"* *>C?\@FW_ -VK]10Q)!$L<8PJ\ 5+0 44
ME,\U#)Y8<;QSC/- $E%)2T %%%% !1110 57OH!<V4T)&=R$8]ZL4&@#&\-7
M@NM(C0@B2W)@<'KE>/Z5LU3C@M=/\Z1=L0E?<Y)P":>+ZU)P+B+_ +Z% %FB
MFA@1D'(]J6@!:*** "BBB@ HHHH **8\B1D;W"YZ9-.H 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HICR)&NZ1@JCN34/V^T[7
M,?\ WT*+ 6:*:K!QE2"/:G4 %%%% !1110 4444 %)37D6-<NP4>I-*"",@Y
M!H Q% G\7EL?\>T&/^^O_P!5;M5XK2&&YFN%7$DN-Q)ZXZ58H **** "BBB@
M HHH- !14<DT<(S(ZJ/<TV.XAF_U<J/_ +IS0!-6##_R-LW_ %R%;M5Q:Q+=
MFY"_O6&"U %FBDI: "BBB@ HHHH **** "BBF-(B%0SA2W !/6@!]%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVDJ6)D;8#C?MXK7TS4[?5K47-JVZ,G&:Q396!\$B/RXS#]GW=.^*B^'P4>'
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M+<01RI]QU##Z5)5'2/\ D$6?_7%?Y5>I %%%% !1110 4444 %%%% !1110
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MEO*C\%&Y8>G2N[7.T9ZXI .HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7S(3OAB.<'!YH V%\;Z2ZL8Y&?:2"%7.*U;#6K+4K1KFWF!C7[Q]*Y;X?6<
MT6\E\M?,>5P6QR16+:%X-,\1+#E0'. O;D4 =A)XTTF.4IYC,JG!<#(%&J7.
MF75UI4TERP+R9AV'AC[U6\-V>GMX-C$R(87CS+Q6'J#::;KP^NEL3;+<X&:
M.KO/%6FV%\]E-*1.J@[0.:DTWQ/I^IWAM(G*S@9V,,&N9BMH;CXJ3-*@8QVX
M*Y[&IM8C6+XBZ6\:A7>,AB.] '1:GXDL-+G6":0M*1G8HR:CL/%6FZC>I:02
MDS,,[2.E<_X65+CQ?K,MT UPCA4W?PK[4SR+:'XGQ?9U"EH27"^O- '?T444
M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?X:>V\-RRS7TLRP_<1NE7T\9S-XB^S^6OV$R>4LG^U78W%O%>0&*9 \;=0:
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M=6L-!,4>E2743,?+=&'!]\F@"P)KB[T#5M-O97D:S)VOGDCWI+2Y'AWP2MW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%%  :2EHH :>:,4ZB@!**6B@"M>V_VJSF@!VF12,UG>&]%;0M*6S:42$$G<
M*VJ* &XI<4M% "8HQ2T4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 )1BEHH 2DQ3J* &XI:6B@!N,U@Z/X>;2]8O[YI@XN3D*.U=!10 E)
MBG44 -Q2TM% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI/\ .K0- "T4R66.&,R2R*B#JS' %*K!E#*05(R".] #J*** "BBB@ HHHH
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M\J )J*;3/M$7G&$2IYH&2FX9_*@"6BBB@ HJ))XI)&C25&=?O*&!(^HJ4\4
M%%1)<0RNR1RH[+]Y58$BI!0 M%%% !1110 4444 %%-=U12SL%4=23@"DCEC
ME7=&ZNIZ%3D4 /HHJ*6:*!-\TB1KG&78 ?K0!+12!@1D'(/<4R66.%-\LB(O
MJS8% $E%-5PX#*05/0@\4Z@ HHHH **** "BD)JNE]:22^4EU"TG]P2 G\J
M+-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114;S
M1Q8\R14R<#<V,T 244#D44 %%%% !13&=58 L 3T&>M.% "T444 %%%% !11
M10 4444 %%%% !140N(C*8A*AD'50PS^5/SQ0 ZBHHYXIB?*E1\'!VL#BI:
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M#:L/+#D=\4P.WUCQCI^B7Z6MTL@+KN#@9'T]:HV'Q#TR^OEM'M[FV9SA'F7
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MS'A9KB=R!GGIUK&S>?\ "Q;!KXVPG*\B ?7KQS0!U>I>.]/TR_N+*6WN'FB
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M:CU>ST?PS97-[,$06Z8SU)VC@55^(/\ R)=]_P  _P#0Q7,:\L<UWX7AN_\
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M1K9'5BV,$[>U<5::RVD^ 9F\J=WFE>-6B_@Y/)]JT?"LB2R>(W0[E)?!_P"
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M-/GM?M;@A8H\X#-ZF@!%^)NF^>%EL+Z*$G F=,+6[JOB>RTK3(=0D#2V\K
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MK%U<P(<B)B<?SKO*,4 <[J/A>&]GL'20Q):-E5 SFK/B#1%UW238M*8P2#N
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M\FX0/'G)4T <YX)TU[>UN-1F&);V0R8/8=JZ:YB$]M+"3@.A7/UJ2-%CC5$
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MR-EX,-AK<E]#J$HAD;+P8^5OKS5:Z^'X^UR3:?J=Q9+*<LD9P/YUV]% '/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*)1^[!)QUXJGXPT>35]#>* 9EC(=!ZD5@:-X\M;*S6RUB*6UN(1MRRG#8]*
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MC'IC-3_$4?Z+8?\ 7=: '>*?$-_%<V>FZ6 +BY ;<>PQ5>U@\8:7?0M-(M[
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MM;L4+D=2*GT;6M8TW71H^LLLID&4E%4=&UM/".IWUEJD3QQ32F1)MI(.2?\
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M>8<#@$9I)]"DG\!*UE8FWD23SU@+$DX/N?2II/'UE+X?:V6";[<(O+,)0Y!
MP?PH EL==OI_ ,^HM*?M 8X/IS71Z1>37'A>&ZD;=*8MQ/OBN/T:&:Z^&5PB
M(3(68[1]:72_&EG#X76P$4S7R1[/*V'.: -'2/$MQ#X;O]1NW\QH7(4&LR"3
MQ5J=O_:$>I00JWS)"6&<5!H]E<:IX"U"!$(F=R=O]*IZ?=^&(-/$>H1W<-Y&
M-K1>8X+'VYH Z >*[N[\'7L^1'>6IV,5Z9JA:?\ "8:II U)+U(D";E3 RV*
MC^SPIX%U.>WT][2.5LJ'8DL..>378Z /^*+@_P"O<_R- &9H?BR67PA<:C>@
M&:V)1L=R#BLFT'C#6;3^TX;M(HW^:.+ Y%0:!ITNI>"-7MH@?,,[%1ZX8U;T
M7QS9Z7H:65Y%+%>P+L$10_,1Z4 6M4U?6;7PU!+=Q^1=^8%;&#D5!XDUO5[>
M^TR#3Y,/.@R".,U6UO4K[5?"\5U>P>3NF'EKCG%3ZM_R,VA<?PC^E %>]N?%
M/AV6UO+V\2:"1P&0#IFMKQ+XBO$^Q:?I8Q>W2AMQ_A%)\1/^0+:_]=E_F*R]
M?6;2M0TC71"\MO'$$D"C)'^<T 5-;G\7>'=.\^>\$T<A +*/N<UZ1IDK3:7:
M2N<L\*,3[E17G'C/QG9ZMH)L]/5Y1(5,K[3B/D?UKMX]5M-)\/Z?->2;$:&-
M0<$\[10!MFN \?R//?Z;IY)$4LF6]Z[N*198ED0Y5AD'UKE/'6D7%[90WMFF
M^>U?>%'4BD!TMK9V]M;)#%$BHJX  JE#X?LK?5WU*)-DSC#;>AKG;#XC::+,
M+?K+;W*##1LAY/M1HFIZGXC\0_;526WTV(857&-],"QX\4VMM9ZE%\LL$RY8
M=U)'%=39S?:+.&;^^@;]*Y?XAOG0HH!G=-,JJ!]172:9$8=,MHV&"L8!_*@#
MFO&6BWMW>6&IV*+-)9L286Z,.?\ &J<GC2W,9M=5T>>#(VN1&2H_&I_%EQJF
MC:U9ZO;++/9*-LT*<_CBHKOQ[X?N;!LPM+,PP(/+RV?2@"]:WVF:#X3DO=.?
MS+8?,H)Z$]JP(7\5ZA;_ -HKJ5O$K#<L)8=*98Z%?7?@G4MT+1-<2>;% ?X1
MSQ^M9]A>>&8M.$=_%>0WD8VM%YCY8^W- '6:?XO9_#=U=7*C[3:Y5\=":RK;
M_A,+ZV.JI=(L9RZPD=119:.E_P"$M0^Q:>]KYW*!V)9\?4U)IWCFTLM$^PW4
M$RWL2&,1;#EC0 _P_KVHW?A[5[BYD/GP%MO^S@5T/A&^N-0\-PW-PY:5@<D_
M4UR'A$27_AO7-L9$DK.0G?ITI_ACQA9Z5H!TZYBF6^B+*(MARQ)XQ0!J^&O$
M%Q)#KT][(72TN'5 >P!-95M>>)?$*/J%KJ$-I Q/EQL1DBHO"%O+JFB>(XBI
M26:=CM/8Y)Q6;H\F@6-F;/6HKNVO(>"-[@-],&@#J]*\27DVFZA:7C+]NM%/
MS+_%[UC:1+XN\0:=]H@O%B120I(Y:I]'M[26PU.]LM/E@B,959978L_YFNA^
M'_'A2#C'SM_2@"KX6\1W4^FWRZC@SV1(9O[V!FLBTG\5>)1+?6=TEO;AB(U(
MZXIWA^U:\D\1P+G<[L!]<5'X;\66OAW3GTW4XY(9H&;;\I^?GM0!IW.IZ[:>
M"]0EU"(175OM"2@@[QN S^M0>*M=U'3_  [HEQ:2?O[@QAO]K*U!J6M7^M^"
MM8N;BV,-M\HAR.6&\<TSQ4/^)!X7&/XX?_0* $U%O%VDVAU:>[1HE.YX@.@K
M8UKQ7/%X>LY[- +N] V+Z9K0\<?\BA?C_8KDM1M9U\*Z'J<,32_944L@&3C%
M !J?_"8Z/ICWTEZLBXRR@#*UV7A_55DT"VN+^YC1W&2TC!<UR/B/QU87_AV2
MVM(Y'FD7#+M/R?6MG1M L==\*V27T;,JC( 8C^5 &SJ^J1#1+N:SNHGDC0D%
M'#8_*N3T.?Q'JL$6JS7JQ6<>2R8Y8"M:^\,Z;H7A_4&L8F0O&<Y<M_,U+X5@
M-QX*2 <&2-E'XYH P(]3U_Q-/-<:?>PV=K&Y5-Q&6QQWK6\,:[??VG/HNJ.D
MMS&F])%/##_)KCM*CTC1Y+BP\00W4$R2$K(KL%89XZ&N@\,1:?=:S<7FEZ=,
ML<41"7,KL2Q]!DT 6-0_X2B^U"X*7<6GVZ-B,.RY8>M)X6U_45URXTG4KB.X
M,:;Q*A!_E6':ZCI;7%U)XDFN?MPD.(<L!CVQ3?#$T=SXWE:&V>VADA*QJXP3
MUYH US?^(?$NIW0TJX6WMK=MH)'WC5+1#J+>.VBU''VA8L;AWZ\U-HNN1>$M
M0O;'5(I(XWD+1R;20:;HVJ?VM\0FNEA>.(QX3<,$CUH WO#FJWAU[4=,OY-S
M1MNCS_=IVD:I>:KXNO@DA^PVP\O'^UQ_]>LGQ[YVC7]OK5JI!93$^WOD'']*
MW/ M@UGH"32C]]<DRN3U.>?ZT ;]]_QX7'_7-OY5Y[H%W-8_"::Y@;;(A<J?
M2O0[[_D'W'_7-OY5YMI8_P"+.W(_WZ )/%]S/-X6T:XQOG=E;ZFI+C_A+].M
M!JDERCPJ S0@=!4/B21XO".@R(A9EV';ZU;U;QO:7NBFPMH)GOI4\LQ;3E3T
MYH L>(/$UU_PC-C?V+[))7"D>^<8JUI,/B."VEO[J=;@O'F* <<U@ZYI\NG^
M$M*AF&)//4L/3+"NOUN:Z@\(R/9AO.$(QM'- ',31^*Y(GNI=5M[4C+>267C
MVJSIOB6^O/ NI7<CC[7:@KYB]^:P;?4?#JZ6#-]JN]19/FCRY.[Z4OAURW@'
MQ$I38P;E".G/2@#8\/GQ-J]O;:I+>K':[<F/'+"K6A^(Y8=)U6]O7WK;.0O%
M:_A/CP79?]<!_*N2TG3I=4\-:[:Q?ZQY6VT 203>*-8B-_#J,%O&W,<189Q6
MQI/BJXFT2^^T(&O;,$-MYW<=:Y+3+CPY:V/D:K%>07<7RLGF.-WTP:Z'PW'#
M%INH7]CI+HC [5E9B91CW- &5I^HZ_K"M=6^MVT;;O\ 4.0"/;FO1M)>[;3X
MC>E3-CYBO0UY1=-X6NXY)F6XL+\9S$@;EO:NS\&WEQ8^%'NM4=UAC)*M(/FV
MYXS2 [/M156QOH-0M$N;9]\3C(.*M4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 7!N!!&)3QOVC=^=3T4 59]/L[I@]Q:PRL.A>,,1^=.2RMHYO.2WB63&-X0
MX^M6** "J=QI=C=/ON+."5_[SQAC^M7** *QL+3>C_9H=T?W#L&5^GI1<6-K
M>!1<6T4N.GF(&Q^=6:* *RV%HDJR):PJZ#"L$ (%-GTVRNG#W%I!*PZ%XPQ_
M6K=% %7[!9[T<6L(:,80^6,K]*Y31]#N5\6:O<7MEFTG8%"X!5NO:NTI<<4
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MP#R_N8C'R_3TJW10!%/;0W*;)XDD3KAU!%,>SMY!'O@C;R_N;D!V_3TJQ10
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MHT1&"A4$$?2I:* (HH(X(Q'#&L:+T51@"I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g0vsdaj33nnl000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .V"%<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7G?$O^]9_P#?M?\ "K%C+\0OMT(O&M?L^[]YMC&<?E2 T/B(H3P7=*H 4 8
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MQ%]:C:0>X'3\: ,#P+_R4#5?K+_Z%7JM>5>!?^2@:I_O2_\ H5>JT@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 48HHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)KIJ* .9_L;Q%_T,<W_?*_\ Q-']C>(O^ACF_P"^5_\ B:Z:B@#F?[&\1?\
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M)KIJ* .9_L;Q%_T,<W_?*_\ Q-']C>(O^ACF_P"^5_\ B:Z:B@#F?[&\1?\
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M)KIJ* .9_L;Q%_T,<W_?*_\ Q-']C>(O^ACF_P"^5_\ B:Z:B@#F?[&\1?\
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M)KIJ* .9_L;Q%_T,<W_?*_\ Q-']C>(O^ACF_P"^5_\ B:Z:B@#F?[&\1?\
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M&%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"FU82=PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%5[ZZ6QL)[MP2D,9=@/0#-9WAG71XBTE;]8C&K,P"D]@2*+ ;-%%% !1110
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MC<,=:["O+/A+_K;WZ?X5ZG4/<N.P4444AA1110 4444 %%%% !1110 4444
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M)OB9_8?FJ+$P%]NP9!P>_P"%+X<\2:A-XJU'1=4E1I$): ! IV<^GX5DQ_\
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M=V#C/(H_LB?3?A1)&@/GRIYTGK@C)S69X5TGQ=>:!!)IGB"*"VYVQ[1E>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFG&WB8R22'=+(>K-6U11<+"$<'Z5RN@^&+C2O$>LZC)*C1WOW% Y7GO75T4
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M !1110 4444 %%%% !1110 4444 %%%% PHHHH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7EI%.\;KL9UR5X[5T=U&TGPQ0*"2+93_ ..US/PSUJPTN.^CNYUC:1@5!/7
MHZ#ZB?%<!=>TX 8 M^/^^C76S:4NK_#F"W*Y9;8.OKD#/]*Y+XK,&UW3F!X-
MMD?]]&O1_#7/AG3QZP+0]$@6K9P?PNU4PSW.E3OM/WD5NV.M9%YO\7?$$0,2
M8%DV<?PJ.OZU#XLM[CPWXLGGM\H)U+*P]^M='\+=*)%SJTRDNYVH3W!ZG\Z;
M[B78E^*T:PZ%ID:C"K,0/^^:T/"MC:W_ ,/EBNX$FC 9@KC(R ,52^+?_('T
M_P#Z[G_T&M;P."W@55 Y*L!^53T'U///!>GV=]XSDM;JVCF@ DQ&XR.#Q76?
M$G0(QHMO<V4"HEK\I51PJ\GC\:Y3PC?6VE^.)9;R411AI$+,< '=7KUP+;7M
M#E6)P\,Z$!AW_P XIO<%L<WX(UU)?!C-(V&LU*G/? KE/!%FVN^,KC4W3,4;
M&0Y[$]*P4U"XT*'5=(<'=+A!@]"#D_I7I_PZT@Z=X=2:08EN#O\ ^ ]J'L"U
M=CL****@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#S6\_Y*_:_P"[4=F ?C'<9'0''Y&NCG\+W$OC
M>'7!*OE(,;>]-@\*W$7CJ773(ODN.%[BJN38;\3!_P 43=9_OK_.M'P;_P B
MK8G_ *9BG^+-&EU_0)K"%PCNP.3[5:T+3WTO1K>SD8,T2X)%*^@^IH-]T_2O
M/_!7_([^)O\ KI_6O03SGWKA&\'ZO9>)[C4]+OU2*ZE#RHR]LY(H0WN9&B '
MXQW9/41/@UT'Q-_Y$Z?_ 'A3M.\)W-GXXFUQY5,4B,H7OS6GXMT277]#DL87
M"NQSDT[ZD]#@?%D<K_#C02C%0KC+_P!WKS5^S\)^+;JTBGM_&\AB=05(5NGY
MUV$/AV&7PK%HM\!(HBV,1ZYSD5RT'@OQ)I(:VTO6C]D/"B09*CVYHN%A-!\(
M7ECXO74;[Q)#?W:IM>,_ZPCCWKT:N6\+^#TT*:6]N;AKK4)?O3/V'H*ZFDRD
M><ZU-##\6=+>9E5?)(!)P,_-7<ZM+''I%V\C )Y+9)/'2N7\2>"&\0>(X+YY
MMD,<>WY3@@\X/YUGS^"?$.HJEE?:VS6*'G:,,P]#S3$<S;6UQ)\+M5EB!\MK
MDN,?W06S7I?@J:";PEIY@QM$>" >AR:O6NAV-IHW]E1Q#[,4VLO][UKCE\#:
MUH]Q-_86K&.VE.?*D&0OTYHW$M"#QVZ3^,-%@A8&=9 6 Y(%,TO%I\7[I;GY
M7DA)C8^AK<\.^!QINH'5-2NGO+\]';HM6/%/@^/79([RVG>UU"+[DR>GI1<+
M=2UXTEAB\'ZF9RNTPD 'N:SO 4*W/@*UA(^5XROYYK*N? VN:O:R0ZOJQE54
MQ$B\ MV)YKK/"^D2:'H-OI\K!GB&"12OH.VIYUH^JR>$/^$AT>67$<()M\\<
MMD9_05V'P]TLV'AU;B8?Z3=L9I&/?/(_G7+>-=%@U/X@:?#;L6GEVF>,=-JG
M.?YUZG#$D$"0QC:B*%4>@%-B2)**Q='M-7@N[E]1NDEA9LQ*HZ"MJI*"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5/O"DI4^\
M* +-%%%26%%%% !1110!'+]VH:FE^[4--$L****8C)U/PUI.L/OO+1'<#[P)
M!_2L^'P#X>@<.MB,CD98G^M=-13N#2&10QP1+%$@1%& H%8VI>$=%U68S75D
MK2'J02,_E6Y12N%D8>G>$=%TN<36UF@D'1B2?YU=U72+/6;/[+?1>9#N#8R1
MR*OT47 S])T6RT6V:"QB\N-CDC)-5=2\*:1JUZMW>6V^9<8;<16U11<+$+6D
M#VOV9XU:';MVL,C%<])X \.RN7:Q&3SPQ_QKIZ*+@96E^'-+T<EK*U2-C_%U
M/ZTFK^'--UQHVOH/,,?W?F(Q6M11<+(K0V%O!8+9)&/LZIL"GGCI6'_P@?A\
M7'GBR&_.[AC_ (UTM%%P,75/"NDZS-%)>V_F-"FQ/F(P*U+6VBL[6.WA7;'&
MH51GH*FHH R=8\.:9KIC-_;^88\[3DC'Y5<L-/M],LTM;2,1PI]T"K5%%PLC
M-UC0K#788X=0A\Q(VW*,D8.,=JGT[3;;2K-;2TCV0KT&<U;HHN!SU[X)T&_N
M6N)[,&1CDD,1DU8GO](\+V,5O-*EM"!B-6/6MFJ&IZ+I^L(BW]JDZH<KN[4[
MBL>+W*KXJ\;LUG$1'++D\=O6O<K6!+6UC@082-0H_"J>GZ%IFE$FQLXX21@E
M16C0W<$K!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444#"BBB@04444 %%%% !1110 4444
M %%%% !1110,**** "J>JVL][IL\%M.8)G&%D'\)S5RB@1RGAOP>=(OY=2OK
MMKR^E&W>P^Z/;\ZZNBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ I4^\*2E3[PH LT445)84444 %%%% $<OW:AJ:7[
MM0TT2PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *5/O"DI4^\* +-%%%26%%%% !1
M110!'+]T5#4TOW14-,EA1113$%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\
M[_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"
M2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFB
MP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(
M_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[
MYH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC
M_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_
MRU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_
M $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\
M+1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%
MK/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7
M+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'
M_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\
MA'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_G
MQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^
M$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S
M_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P )
M)HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/
M_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:
M)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_O
MFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/
M^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^
M:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<
MTC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\
MM4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?
M]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1
M_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_
MT%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G
M_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?
M&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X
M1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA
M_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_
M .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K
M/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_P
MDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\
M[_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"
M2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFB
MP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(
M_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[
MYH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC
M_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_
MRU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_
M $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\
M+1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%
MK/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7
M+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'
M_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\
MA'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_G
MQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^
M$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S
M_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P )
M)HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/
M_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:
M)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_O
MFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/
M^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^
M:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<
MTC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\
MM4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?
M]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1
M_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_
MT%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G
M_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?
M&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X
M1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA
M_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_
M .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K
M/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_P
MDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\
M[_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"
M2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFB
MP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(
M_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[
MYH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC
M_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_
MRU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_
M $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\
M+1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%
MK/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7
M+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'
M_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\
MA'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_G
MQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^
M$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S
M_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P )
M)HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/
M_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:
M)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_O
MFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/
M^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^
M:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<
MTC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\
MM4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?
M]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1
M_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_
MT%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G
M_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?
M&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X
M1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA
M_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_
M .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K
M/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_P
MDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\
M[_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"
M2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFB
MP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(
M_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[
MYH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC
M_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_
MRU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_
M $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\
M+1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%
MK/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7
M+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'
M_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\
MA'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_G
MQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^
M$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S
M_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P )
M)HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/
M_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:
M)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_O
MFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/
M^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^
M:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?]!:S_P"_RU3_ .$<
MTC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1_P ))HG_ $%K/_O\
MM4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_T%K/_O\ +1_PDFB?
M]!:S_P"_RU3_ .$<TC_GQA_[YH_X1S2/^?&'_OFBP7+G_"2:)_T%K/\ [_+1
M_P ))HG_ $%K/_O\M4_^$<TC_GQA_P"^:/\ A'-(_P"?&'_OFBP7+G_"2:)_
MT%;/_O\ +3X?$&CRS*D>IVC.QP%$H)-4/^$<TC_GQA_[YJ2W\/Z7'<1NEG$K
M*<@A>E '34445!H%%%% !1110!7N_P#5CZU2J[=_ZL?6J54B)!1115""BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *=%_K%IM.B_P!8M($:=%%%0:!1110 4444 5[O_5CZ
MU2J[=_ZL?6J54B)!1115""BBB@04444AA1113 ****0!1113 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHI %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ****0!1113 **** "BBB@ HHHH ****0!1113 **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBBD(****8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@04444#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *=%_K%IM.B_UB
MT@1IT445!H%%%% !1110!7N_]6/K5*KMW_JQ]:I52(D%%%%4(X+6?&NH:=XG
M&F10P-"9%7+ [L$X]:[RO&_%TJP^.C*YPJ2J2?8&N_\ ^$^\/_\ /R__ 'P:
M;1"9G>,/&%_H&I0V]M% ZNN29 <_SKI+R[O5T![NRA62[\L,D9Z$\5Y7XYUB
MSUG5K>:R<NBI@DC'I7I.J7\^E^#)+VVVB:*!2NX9'4#I0QIB>&]0UJ]$W]KV
M<=OMQLV=_P!:WZX[P-XDU#Q +G[<8CY8&W8FVLCQ7XPOY-4.D:1E6)V%QU)]
MO2BP7T/2*0]*\R%QXO\ #%J;R\?[1;L,L'?>5_PK4\#^*M2\07UY#>F+9%$'
M78F#G.*+!<J2>/-33Q2VF"&W,(N?*W8.<9QZUZ+7A&J3/;^-;J6)=TBW9*+Z
MG=Q71:V?&=O!_:T]P8H1@[(GP /<4VA)GJM%<KX)\2S>(+&070'GPG!*C 8>
MM=54E!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C;
MWQ#XD@O)8K?1#)$IPK[AS^M9,'C_ %NYU&:PBT<-<P_ZR/(^7]:](KS7P[_R
M5;7O]^F2SH]#UO7+[4!#?Z3]FA()\S(_QJ7Q%XOLM (A96N+MONP1\DUNW,O
MD6TLO]Q2WY"O./ 5D-:UW4];O<2R1S%(MPS@<_RQ0!>;QGKZQ?:F\/R?9NIY
M&['YUT?A[Q+9>(K<O;@QS*/WD+_>6MK (P>E<]:>%+>Q\1RZO;RM'YOWHE^Z
M:0]3-U[QA?Z?XE_L>QL1<R>6''//(^M0?\)/XI S_P (^?\ OH?XU1U&X@M?
MB^DMQ+'%&+49:1@HZ>]=N?$&C@9_M2S_  G7_&F(P?#_ (YCU34CIM[:/:7@
MZ!^C?2NPKR?4+B+Q'\2;&72 62 8EE4<9YYS72^)?%5];:W#H>C11M?.NXM)
M]T#_ "* 3.SHKS^;5O'.DA;B_L[>Z@W ,ELN6_3-=U;3?:+6.8HR%U!*L,$4
MADU%5=1O8].L)KN0$K&N< <FN'MM8\;ZU$;O3+:U@MB3M6<#<1^.* N>A45Q
M'A_Q1JS>(FT/788TN2FY6C& >G^-5/$/C+5],\5IIEI'',CC"Q[>2?K18+GH
M5%><ZCK?CG1[?[?>PV9M%(WHB@MC\ZZJ/Q);'PPNM2?+'Y>XKGOCI18+FY7-
M?\)-)_PE_P#8ODC;MSOK L]<\:ZU&;W3;:UCLR3M651N(K,T*_N;_P")*O>6
MY@N$7;(I]:=A7/5_Z5RWB[Q3/X>EM(K>W$[W!( ]ZZFO//B*ZQZUH3NP55ER
M23@#D4ALL#Q1XI(S_P (^<8SG</\:TO#GC&+6;J2QN;=[2\3_EF_>M6/7]'$
M*9U2SX49'GK_ (UQMK-#KOQ+BOM-&^WMHR)I .">>_?J*8KG>7^H6VF6CW-U
M*(XD&237&#QYJ&HR.-'T:::$'B1\ -]*H?$"YDU+Q)INA#_5&17D']X$BO1+
M.TAL;2.W@0)&@ "J,4 <II?CQ9-0%AJ]G)8W#'"E_NL?2MKQ-K+:%H<NH1QB
M0H0 OKDXIGB+PS:^(X(5G)22)MR.O45D^/(?LW@22$N7\LH"S'D_,*0%2#Q;
MXFN(4FBT'=&X#*0PY'YU')X^U+2Y4.KZ++#"QP74@XKH-"UO2H]!L4?4K17$
M*@J9E!''UK$\>>(](E\/7%C%/%=7$R[8Q$0V#Z\4[ =I9W<-_:1W,#[XI!N4
MBK%<1HMW)X6^'45U>(0\4>5C/7D]*IV6J^/-5LX]0LX[$6TJ[D5@,X_.E8=S
MT.BN>\+ZSJ&IPSQZE9/;W,#;22I"O[BNAH **X*_\4ZWJ'B*YTCP]%!OMO\
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MH"Q2U30/%>HO;#5M0L2D<@9<84Y^H%1Z^IC^)VBBX/[L)@9Z=#6O9^$M8O\
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MB: DL\TOGWLYS+*:BTOPY=6?C*\U=Y$,$R;549SVH ZJN-^)7_(K_P#;5/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "G1?ZQ:;3HO]8M($:=%%%0:!1110 4444 5[O_ %8^M4JNW?\
MJQ]:I52(D%%%(?NG'I5",'6/&&E:+-Y%Q(SRCJD8R16?!\1]$FD",)X<G[TB
M@#^=<'J<G]F^.)KG4K=IX5E)((^\*Z6YN/"'B<1QM(+.8'Y<#D_TJK$7._\
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M;(^79C(3G.&/3K^%8'Q0C\K0]-CR6"S$9/?Y:O>&;"UU#P"L5W"LL8#,%;U
M&* >YQ^@>)C'XL:^U*Z<PX<+D\<GCBO1)O&>CVXB,DQ42C*$]Q7FOA#3;._\
M7/:74"RP /A&Z<'BNH^(>@Q1Z1;7%G"$2V^7:O9>3_.F)7._@GCN8$FB;*.,
MJ?45CW'BS2K;4A8/-^_+!=H]3VK,\&ZTDWA#>[8:T0JV>^!FN2\'VIUWQC-J
M#+NB1C(2>Q/(I6'<];!R ?6EHHI#"BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <5XC\5WJ:PFB:'$LU
MX?OL?X*S;B]\<Z!%]NU!X+RV7ET08*C\J3PXT<7Q.U=;C E9/DW=_NUW6L20
MQ:/=M.RB/RF^]TZ4R68.H^)C<^"'UC390DF.N,[3W%<]I.J^-O$FEQS:?+!
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MB@B\Z\N#B)/ZU@8^(21F]::W,8^8VV!NQZ=*=XM9(_B!H$D^!" 02>F?FKT
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MM;E% 6.;\&Z!<>']/N8+EU9I9S(-OH0*KZ[X:NM3\2V&HQ.@BMR"P/4UUE%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4Z+_ %BTVG1?ZQ:0(TZ***@T
M"BBB@ HHHH KW?\ JQ]:I5=N_P#5CZU2JD1(****H04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "E7[PI*5/O"@"S1114EA1110 4444 1
MR_=J&II?NU#31+"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!A1110(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ****!A1110 4444""BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH&%%%% @HHHH&%%%% !1110 4444""BBB@ HH
MHH ****!A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I4^\*2E3[PH LT4
M45)84444 %%%% $<OW:AJ:7[M0TT2PHHHIB*,VLZ=;W'D2WL*2YQL9AG-70P
M(!!R#WKPGQX[IXONRK$8;C!KT?P!XA&L:.MO*?\ 2+<!6YZCL:IK02EK8Z2Z
MU2PL9%2ZNXH7/0.V":M*ZN@96RIZ&O(_BJS#7+,!B/W9Z'W%>I:<P32K=F.
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MLP4>I.*0QU%,6:)SA9$8^S9IY( YQ0 45']HASCSHR?3<*CO7*64S*>0A(-
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M4-NR,=,TOPO_ .8M_P!=3_.F^'-+\*0:Q?+HBW+SV\3;I#(63IV/0T[X7_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"M?:?:ZE:O;7<*RQ.,$$5RA^&>B9_=O<QI_<65L?SKM*3/O1<#(T3PS
MIGA^-EL8 K-RSMRQ_$UR'Q'C63Q!H".NY6DP01P>17H^:S-3T&QU6YMKBZCW
MR6QS&?2FGJ)K0Y[_ (5KH4KK(1,(VPQB$K;?YUUMG9V]C:I;6T2QPH,*H%3
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MB!G/&3QTKK:*=PL8]QX;LKGP^NBR;OLJ*%'/.!4[Z)93:*FE31"2V6,1@-Z
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M'2M!E::UB9IV&#)(Q8_K6]110"13U/2[35[)[6]B62)QCD=/Q[5R_P#PK'1
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M$A!"L07[8SGIQ4NJZ+#X(\8:.VE2S)!=2!9(VD)R,C-%@N>M,RHNYF"J.I/
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MG'(-\\Y?;@<\9_"J$WAGP;%;-+9>(8X]0"DB?[7U/TS18+GJ_P#6J\][:6I
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MU_Y%*^_W*K?#W_D3;/\ &M_4;"+4[&2TGSY<@PV.M,TG3(-'T^.RML^4G3-
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M KR3QQI%_=>+8YH+262+*Y94)'6O6Z*:>H-(AM%*VD*D8(49%3444@"BBB@
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M9NP H EHK%E\6:'#:QW,FHP+%)G8Q8<XZU/:^(=)O;22ZM[Z%X(OON&&%^M
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M2@0NH907'0U8;Q!I2Z<+\WT(M3P)-W!-%@NC2HK)T[Q+H^K3&&ROX9I!_"K
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4J?>%)2I]X4 6:***DL**** "BBB@".7[M0U-+]VH::)84444
MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3P)H$6FI;O8H[%,-(Q.2?7K7)^'9)=#\0ZWX<\YY+80NT.[L &_PKH+7XDZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4J?>%)2I]X4 6:***DL**** "B
MBB@".7[M0U-+]VH::)84444Q!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.:(]4D7(J:BD,9%$D,2QQ($1!A548 %0VVG65G)));6L,3R'+LB %C[U9HH
MK7&GV=W)')<VT4KQG*,Z@E?I4TD22H4=0RD<@C@T^B@#+_X1O10^_P#LJSW>
MODC-:*1K&@1%"H!@*.E/HH S9O#^CW$IEFTRUDD/5FB!-/.B:65C!T^V(C;<
M@\L?*?45?HHN!6NM/L[Y EU:Q3*.@D4,*@MM"TJTD$EMIUM"XZ,D8!K0HHN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "E3[PI*5/O"@"S1114EA1110 4444 1R_=%0U+,
M0%&2!4&]/[P_.FB6.HIN]/[R_G1O3^\OYTQ#J*;O3^\OYT;T_O+^= #J*;O3
M^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\O
MYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;
MT_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O
M+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^=
M #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J
M*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O
M3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\
MOYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT
M;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_
MO+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^
M= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #
MJ*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;
MO3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^
M\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OY
MT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T
M_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+
M^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^=
M#J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*
M;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3
M^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\O
MYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;
MT_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O
M+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^=
M #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J
M*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O
M3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\
MOYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT
M;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_
MO+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^
M= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #
MJ*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;
MO3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^
M\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OY
MT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T
M_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+
M^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^= #J*;O3^\OYT;T_O+^=
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M'_OM?\*ZFBBX'+?\(6O_ $&=1_[[7_"C_A"U_P"@SJ/_ 'VO^%=311<#EO\
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M'_OM?\*ZFBBX'+?\(6O_ $&=1_[[7_"C_A"U_P"@SJ/_ 'VO^%=311<#EO\
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M'_OM?\*ZFBBX'+?\(6O_ $&=1_[[7_"C_A"U_P"@SJ/_ 'VO^%=311<#EO\
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M'_OM?\*ZFBBX'+?\(6O_ $&=1_[[7_"C_A"U_P"@SJ/_ 'VO^%=311<#EO\
MA"U_Z#.H_P#?:_X4?\(6O_09U'_OM?\ "NIHHN!RW_"%K_T&=1_[[7_"C_A"
MU_Z#.H_]]K_A74T47 Y;_A"U_P"@SJ/_ 'VO^%'_  A:_P#09U'_ +[7_"NI
MHHN!RW_"%K_T&=1_[[7_  H_X0M?^@SJ/_?:_P"%=311<#EO^$+7_H,ZC_WV
MO^%'_"%K_P!!G4?^^U_PKJ:*+@<M_P (6O\ T&=1_P"^U_PH_P"$+7_H,ZC_
M -]K_A74T47 Y;_A"U_Z#.H_]]K_ (4?\(6O_09U'_OM?\*ZFBBX'+?\(6O_
M $&=1_[[7_"C_A"U_P"@SJ/_ 'VO^%=311<#EO\ A"U_Z#.H_P#?:_X4?\(6
MO_09U'_OM?\ "NIHHN!RW_"%K_T&=1_[[7_"C_A"U_Z#.H_]]K_A74T47 Y;
M_A"U_P"@SJ/_ 'VO^%'_  A:_P#09U'_ +[7_"NIHHN!RW_"%K_T&=1_[[7_
M  H_X0M?^@SJ/_?:_P"%=311<#EO^$+7_H,ZC_WVO^%'_"%K_P!!G4?^^U_P
MKJ:*+@<M_P (6O\ T&=1_P"^U_PH_P"$+7_H,ZC_ -]K_A74T47 Y;_A"U_Z
M#.H_]]K_ (4?\(6O_09U'_OM?\*ZFBBX'+?\(6O_ $&=1_[[7_"C_A"U_P"@
MSJ/_ 'VO^%=311<#EO\ A"U_Z#.H_P#?:_X4?\(6O_09U'_OM?\ "NIHHN!R
MW_"%K_T&=1_[[7_"C_A"U_Z#.H_]]K_A74T47 Y;_A"U_P"@SJ/_ 'VO^%'_
M  A:_P#09U'_ +[7_"NIHHN!RW_"%K_T&=1_[[7_  H_X0M?^@SJ/_?:_P"%
M=311<#EO^$+7_H,ZC_WVO^%'_"%K_P!!G4?^^U_PKJ:*+@<M_P (6O\ T&=1
M_P"^U_PH_P"$+7_H,ZC_ -]K_A74T47 Y;_A"U_Z#.H_]]K_ (4?\(6O_09U
M'_OM?\*ZFBBX'+?\(6O_ $&=1_[[7_"C_A"U_P"@SJ/_ 'VO^%=311<#EO\
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MBLS0**** "BBB@"O=_ZL?6J57;O_ %8^M4JI$2"BBBJ$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110(****!A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYT:9X@L-7N[BVM'<RVYQ(&7 % C5HHHH&%%%5KV_M=/C62YF2-6;:-QQD^U
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MO!I,M_*\Q <8.P9/')J]XDU.^\06*PCP[/%,C!DEXX/YT6"YZOG/2@D*"S'
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M#DJ@4_F*Y3X:-(BZI;J[/;13XC).0!CI3;SP5XEO+5X9?$C2*PY5AP?R%/\
MA_JC0SW/AZX@CCGM.=R?QC/4^_-,1WU9>N:_8Z!9_:+V3 /"H.K'VK4KS;7X
MAJGQ-L;*X.8(HQ(%/3-(;-!?B59JR/<6-U# YP)67C^==<=2M%T[[>9U%L$W
M[\\8J'4]&L]4TR6PFC58I%VY4#*^XKS[QU:'0/#6FZ7:SRRP&;:0Q&6')Q3%
M<VC\2+5V9K;3[J:%3S(J\?SKI-#U^RU^T-Q9OG:<,C?>4^]<=9^)[NRLX[6'
MPM,(D7:!A?\ &JWA;^T?^$YDNDTZ6SLKB,F2-L8W>O\ .@+DOA#_ )'K6O\
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M2T^U1Q7MG<6JR'"O(N!_.NR2198UDC8,C#(([BO,]:UV\UG3);.7PS.-XX;
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M+E7&J$@$B<XX^E 'HM%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *=%_K%IM.B_UBT@1IT445!H%%%% !1110!7N_]6/K5*KMW_JQ
M]:I52(D%(1D$'O2T50CQSQ-IM]X=\3-J-O&WE-)O1E&1]#6VGQ400!7TYS-C
MDAQC/TQ7H<UO#<Q^7-$DBGLZY%4#X<TC=N^P09_W!331%F>4:7:7OBSQ2+J2
M-A&SAI'V\!1VSZUZYJE@E]HT]DXW*T>W'T__ %58MK2WM(]EO"D2]PB@5CZ_
MXLL/#SK#="4RR)N0*F0?J:+W':QXXT][:0W&CMN"M( T?^UFO:/"NF_V7X>M
MH",,5WL/<\UYIH5G<>*O%S7[0[(3)YSD#@=P*]D  &!T%-L44>>:MXTU'3-:
M-I?V*_8]V&RO++[&L;Q-JWA>^L"NEV?^EN?O+&5V_IS7JEU86EZ,7-O'+CH7
M0'%58_#^DQ/N2P@!'3Y!2N-HYOP!IUU;^&IO/5E$V[8C#!Z=:XK0=1A\/^,I
MKB^5TC#.I^4Y&6ZXKVM0%4*H 4<  50N-$TVZE\V:SA=SW*#FBX<IQGC6U;Q
M'H-KJVGQLZIDD8YV\]J@\.>/;'3M#6SODD2>!=J *3N_PKT6*WB@A$,4:K&!
M@*!@51DT#2I7WO8P%C_TS%%] MJ<SX6\6:MKVILC6JK:@D[PN,#L,]ZYCQ__
M ,CB/HO\A7K5M:6]I'Y=O"D2^BJ!5>YT>PO)_/GM8WD_O,H)HOJ*VA2UK_D4
M;CV@']*X?X6?\A&]_P"N8_F:]/D@CE@:%T#1D8*D<8JM9Z796#,UK;)$S#DJ
MH&:+Z#:U/-?BC_R%;7_</]*Z'7_^2<K_ -<A_*NIN])L;]P]U;1RL.A90:ED
MLK:6U%M)$C0XQL(XHN%CB/ABH?1+M#_%(0?R%<Y=QW?@SQBU[Y1: L=K <%3
MVSZXKUFSL+6P1DM84B5CDA1BG75G;WD?EW$,<J#H'4&B^H6.!U_XB02V$<>C
M-)]I8@L=I&WV]ZZ7PC<:O=Z4)]6V[F.8QMP<>]78M TJ)PR6, 8=/W8K2
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M1110 4444 %%%% !1110 4444 %%%% !3HO]8M-IT7^L6D"-.BBBH- HHHH
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MA=0&7RQ,F_.,9YI8IHYXUDB=70]&4Y%<M#X=T6/Q&M\FH2&[$FX1>8,9],4
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MC(_51FG8EL]6%%<-/\288B6CT>]EMP?]<HPI'K74:-K-KKFG+>6K?NVX(/\
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MYVY.!D]JS=(URTUGS_LI)\A]CY]:31]<M->T_P"U6C97HRGJIKEOAJ0$UD]
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M*Y/6M$U70_$YU[18#<K-_KX!U/\ G J+4M:\4:]:'3[;1);3S?E>5\C []J
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M06C1L\$X%6%\7>)%MQ$WAJ<W &"V#@GUK5\/6&N-I=U)JMP5N;@$H@_Y9^E
M'(:8/$W@-Y+0:?\ ;+(L7!B&2<^XSCZ5T?A[Q3H^LZUMDT[[)JA4C+I\Q'IG
M%4+/6O%6AB2ROM(EOPKG9.@/(HTK2]3UKQ?'K5WIW]GP1+PI&"Q_R* /1**Q
M;[6+RVUJVLHM-EF@E/SS@'"5L]J0Q:***!A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$;?E &.*Z^B@+#(H_*ACCSG8H7/TI]%% !1110,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $Q1M'H*6B@04
M@&*6B@8A -&,=!2T4""@C/6BB@!, ]A2T44 (1GK1@#H,4M% !2;1Z4M% "8
M'; KSS58_$?BF]ATZXTYK.QCES)*#]]1^->B44 ,AA2"%8HU"HHPH':GT44
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M7V]LEO)X=\Z9%QYI(Y/KUKT&B@5CD/!_AZ]L[FZU75& O+HYV#^ >E=?110
MA /448'3 Q2T4 %)@4M% Q",T8 Z "EHH$)C-+110,0#'2C SG%+10(*3 /7
MFEHH *3 /6EHH&)@ <#%+]:**!"!0.PH  Z4M% "$ ]11@>E+10 F!Z<T8'>
MEHH Y+Q/J/B!9FL-,TSS89DVFXS]W/![UJ>&-&_L/1(;0MNE^](?]H]:V:2@
M!:***!B;1Z#/THP,YI:*!"8'>C ':EHH *3:/04M% PI,#/04M% !28![4M%
M A,#M2]:** $  Z 48!ZTM% "8SUYHP/2EHH&%)@>E+10(0@'J* ,=.*6B@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.B_P!8M-IT
M7^L6D"-.BBBH- HHHH **** *]W_ *L?6J57;O\ U8^M4JM$2"BBBF(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1<+,P?\ A,=#_P"?U/S%'_"8Z'_S^I^8K>_LNP_Y](?^^!1_9=C_ ,^D/_?
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M@47"S,'_ (3'0_\ G]3\Q1_PF.A_\_J?F*WO[+L/^?2'_O@4?V78?\^D/_?
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M@47"S,'_ (3'0_\ G]3\Q1_PF.A_\_J?F*WO[+L/^?2'_O@4?V78?\^D/_?
MHN%F8/\ PF.A_P#/ZGYBC_A,=#_Y_4_,5O?V78?\^D/_ 'P*/[+L/^?2'_O@
M47"S,'_A,=#_ .?U/S%'_"8Z'_S^I^8K>_LNP_Y](?\ O@4?V78?\^D/_? H
MN%F8/_"8Z'_S^I^8H_X3'0_^?U/S%;W]EV'_ #Z0_P#? H_LNP_Y](?^^!1<
M+,P?^$QT/_G]3\Q1_P )CH?_ #^I^8K>_LNP_P"?2'_O@4?V78?\^D/_ 'P*
M+A9F#_PF.A_\_J?F*/\ A,=#_P"?U/S%;W]EV'_/I#_WP*/[+L/^?2'_ +X%
M%PLS!_X3'0_^?U/S%'_"8Z'_ ,_J?F*WO[+L/^?2'_O@4?V78?\ /I#_ -\"
MBX69@_\ "8Z'_P _J?F*/^$QT/\ Y_4_,5O?V78?\^D/_? H_LNP_P"?2'_O
M@47"S,'_ (3'0_\ G]3\Q1_PF.A_\_J?F*WO[+L/^?2'_O@4?V78?\^D/_?
MHN%F8/\ PF.A_P#/ZGYBC_A,=#_Y_4_,5O?V78?\^D/_ 'P*/[+L/^?2'_O@
M47"S,'_A,=#_ .?U/S%'_"8Z'_S^I^8K>_LNP_Y](?\ O@4?V78?\^D/_? H
MN%F8/_"8Z'_S^I^8H_X3'0_^?U/S%;W]EV'_ #Z0_P#? H_LNP_Y](?^^!1<
M+,P?^$QT/_G]3\Q1_P )CH?_ #^I^8K>_LNP_P"?2'_O@4?V78?\^D/_ 'P*
M+A9F#_PF.A_\_J?F*/\ A,=#_P"?U/S%;W]EV'_/I#_WP*/[+L/^?2'_ +X%
M%PLS!_X3'0_^?U/S%'_"8Z'_ ,_J?F*WO[+L/^?2'_O@4?V78?\ /I#_ -\"
MBX69@_\ "8Z'_P _J?F*/^$QT/\ Y_4_,5O?V78?\^D/_? H_LNP_P"?2'_O
M@47"S,'_ (3'0_\ G]3\Q1_PF.A_\_J?F*WO[+L/^?2'_O@4?V78?\^D/_?
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M@47"S,'_ (3'0_\ G]3\Q1_PF.A_\_J?F*WO[+L/^?2'_O@4?V78?\^D/_?
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M@47"S,'_ (3'0_\ G]3\Q1_PF.A_\_J?F*WO[+L/^?2'_O@4?V78?\^D/_?
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MFNEI#"BN%\1>+-2.NKH/A^)7O ,R2.,JO^<51OM0\<^';<:A?&VNK5#F5(U
M(%.PKGH%]=QV%E-=2G$<2[FKA]%\6>(O$%T)K'38QIWF;2[L,X_.G>)]1O\
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M'Q/XIO+AO#ZPP6,+;!+* =Q]1^5%@N>C45Y]:^)=>T#6K>Q\2K$]O<G"7$?
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M.H)(K2\,^)M1?6)-"UV)4OT&Y73[KBBPKERU\27$_CBYT0QH(8HMX;'.>/\
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MG85ST:BN+\+^+;K4A>V&I1"'4K1"6'9N/2N<T7Q1XNU^YNK*Q\C=$YW2NH
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M\^*K2>&O&7B-T@U=VB@4YS(01^E/H39G51ZV=>\!7-VZ!9#$0X'KFN:^$O\
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M3Z".FK(\4*[>&-16,'>8&QBM>FNBR(4< JPP1ZTAO8XOX7R0MX6"1D>8KD2
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M!U%<;X)\0ZCK=[J4=[(CK!)M3:@7 X]*[*AZ %%%% !1110 444?A0 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHR2K',P_NY'_ ->E\,N/$_CFZUO&^WMD$<>>@8@<C\J \CT&TA^SV<,62=B
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M#'V&* .AT+Q4\W@4ZM>_-+!&=[?WCG'^%<[I.AZYXUA_MC4-5GM(I.;>.''
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9WDMC?=Y8SU'T%=?12&>?M\,(;NVD_M+4[F[NRI"32,<+^!-=#:^''M_"/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I4^\*2E3[PH LT445)84444 %%%% $<OW:AJ:7[OXU#31+"BBBF(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ I4^\*2E3[PH LT445)84444 %%%% "$ ]:3RU
M]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU%
M#?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2
MCRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TI
MU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\
MM?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+
M7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44
M -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]
M*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2
MG44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 W
MRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\
MM?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=1
M0 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7
MTH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]
M*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #
M?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2C
MRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU
M% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M
M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7
MTIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44
M-\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*
M/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G
M44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WR
MU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M
M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10
M WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7T
MH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*
M=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?
M+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CR
MU]*=10 WRU]*/+7TIU% #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]*/+7TIU%
M #?+7TH\M?2G44 -\M?2CRU]*=10 WRU]* BCM3J* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g0vsdaj33nnl000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Y",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EI** %HH[T4 %%%% !11
M10 4444 %%%% !1110 444F: %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2J9O6,K
MHD#-L."10!=HJB;RXQ\EFS'W;%)]MN\_-8E1Z^8#0!?HJE]LE_Y]GIAO;K=A
M;(D?]= * -"BJ"WLY.'M&4^@;-.-Y-CBU8GL,T 7:2J'VR][V!_[^BG?;)?^
M?9Z+ 7:6LW^T9VF:*.S9V49.7 IXN[K/SV3*/4.#0!?HJE]KE_Y]GIAO;L'B
MQSZ?O10!H4516]G(^:U8'T#9I/MTW(2V+..Q;% %^BJ'VR\[V! ]?,%.^V2_
M\^ST 7*6J#7EUGY+(L/4N!3HKR4RJDUL8MWW3O!H NT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH **** "BDI: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2H+S_CSF_W#
M5BHIT\V%T!QN4BIDKQ:0/8P-"M(;O39$F17&\]15U?#NGJV[RB?;-3:38'3[
M=HF?=EB<XK0KGI4(\BYEJ1&"MJ1Q0I"@2-0JCH *CN;2"[39,@8>]6:2NAQ5
MK="K*QE)X?T]'#"'..QJW'86\5P9TC DQC(JU14*C".R!12*UQ90W31M*@8H
M<KGM4KQK)$T;#*D8(]JDHJ^5#LB&VM8[2+RH5VKZ4^:%+B%XI5#(XPRGN*DH
MII)*R XB;P;?:1<-<>&;\VRL<M;2<H30+SQV@V&PL7/3?YA'Z8KMZ*8'$VOA
M;5-6U"*^\2722"$[H[6,?(#ZFNS*@)M'3&!3Z* /.-,\*^+=%2:*PU"V2*25
MI,$9/-7O[.\>?]!.T_[YKN:*+@<-_9WCO_H)VG_?-=A9)<)9Q+=,'G"@2%>A
M/>K-% '->(/"-MK,ZWD,K6FH1_<N(^OXUE+_ ,)YIX\H+9WJ#@.S%2?KP:[J
MB@#AUT_QEJ[JM]>PV%OGYA;\L?QXJWX@\')J,4=U9S-#JL _=W X+$>M=;11
M<#C/#?BV5[HZ-KB?9M2CX!/24>HKLA67J?A_3M7FAFNH0TL#!D<<$$&M11M4
M =AB@!:*** "BBB@ HHHH 0UF>(O^1;U'_KW?^5:9K,\1_\ (MZC_P!>[_RH
M J^"O^1,TC_KUC_]!%;M8/@O_D3-)_Z]8_\ T$5O4 )@>@J#[9:^9Y?FIOSC
M&:YGQKX@NM+^PV6G20_;+N81[7/.T]\5>WZ9_96TF/S=N,?Q;O\ &@#H./04
M8'I5>R\S['$)<[]O-3D@=: %P/2C:/2D!!Y!S3N] ')WWA]K?Q1_;XN':%@J
MRVX7C@<'K6F]S#J-Y;_9!N,;;FDQ]T>E;!YH"@= !0 "C%+10 E%+10 4444
M %%%% "4M%% !6=JFJPZ8L?F<M(V%&:T:Y7QM:17-C 7<HZO\C>AH WY#<3P
M(T#*F\ DGM533%/FWRL>3)S^M,M9I].T.W$@:YE5 ,J,9J326+RWC%2,R=/S
MH AM-!C@O/M,DKR.I.S)Z U4U'3K>TTF[LX'8RSY8@G).:Z3%026L32^=Y:F
M4+@,1VJHRL]1/FNFMUL?,?B3PG#HTDXN%4W$O*(.2,U@1-;:?;,\%NYFV['9
MNBYKW_Q!\/?[5CDNHV5+S#%2>Y[5YI:_#+7VDN_MMO(ZC. O&YL9!'KVK[3+
M<9@E2]]I-'+B:<ZE2[>AP.EA/M'ER,5C8Y/&<&O7O"/@+3-=L_M)F>.\B8;6
MC]*Y[PM\/M9FU.:WFMO+*$;]_&T<5[OH&@0:%;F*(YW 9_ 5Y7$,\/4J+V-O
MD:X=.G4]HBWI.G1Z7I\=K&20@ZGO5[M0**^=2LK&\I.3NRE%_P A*;_=']:G
M>WB>5960&1?NL1R*AA_Y"4W^Z/ZU<IA=]"LL)A:5R[-NY /:O-_&BPZGIR6=
M_P#;$1[C=$"NXO[=>!7J!%8FN6-OJ4]K:R&,-NW89,DCV]*Z,-54)J3&FNI\
M[^(_"NJZ=-+;NJ+:L0X7/3/(S^=:/@'P;9)KUG)J<22V\Z,N/1LCK7LVJ>'+
M/5II+5K4CR44+(>C].*J/X2ALH/*CL?,B=U.(SAD;NV:]BMF%.O0Y)K4QLT[
MF[/HL4DZ7,#YDBP(E<Y6/'H.QK7CB5,L%&YOO'UJO96UO9HT$''.YAG)R:N"
MOGVDGH:\SM8*JW/_ !]6_P!3_*K=5+G_ (^K?ZG^5 BW1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 )2U%)/'&0'=5)Z9-/# CKF@5T+2TE% Q:*
M*2@ -9FK:B+2'8IS(W3VJS>WB6D#.QY[#UKC[B=[F9I'.236U*GS.[.7$5N5
M<J(V+.Q9CDGJ:L65U):W*M'GDX*^M5ZU]+LTCC^W7)VQJ,C-=$FDM3BI*3D=
M,ARH/J*=52ROH+Z 2V\@=.G%6A7$U9GK1::NA:***0PHHHH *2EI* "D9@JD
MDX [TN:P=?NY8PL*Y56&2?6JC'F=B*DU"-RV-:M?M'E;CUQN[5I @@$'K7 ^
M];>DZN8RL%PV5/"MZ5M.C971RTL3=VD=+130P(!!R*6N<[1:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<^M #J*;SZTO/K0 M%-Y]:.: '44WFC\: %I:B:4(0&/6GJP8<4 *:S/$?\
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MCD&N!K9TG5C"1#.V4[$]JRJTK^\CHH8A_#(Z;-+3%8,,@Y'8BG5S'>+124M
M!1129H 6BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HI** %HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV=NT]Q*L<2#+.QP!0!R?_"%ZK_T-=_\ ]\)_A1_PA>J_]#7?_P#?"?X5M_\
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M2ST^&"60R.HP6- $!DU8=(H#]2:8KWS7L'VJ.)5R<;"?2M>JES_Q]6_U/\J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_'U;_4_RJW52Y_X^[;ZG^5 %NBBB@ HHHH **** "BDS2YH **** "BBB@
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MLGLI=K#Y2?E-5:Z[*2//3E"5BW?6+VDF?O1G[K"J>:U+"^5H_LEW\T)X!/\
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M]_E_QH S-0^(>D+#?0P_:7EA5D+)%D!L>M9'ACPW<:]H<.I2Z]J:M,S-M67
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG[C?X4H\4:21D7/_ (XW^%.S%S(U]H]!1@>@K(_X2?20,_:>/78W^%!\3:4
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MV-<=\/\ _CWU?_L(3?\ H;5V- !1110 4444 %%%% !52YTRQO'#W-K#*P&
M70$BK=% &=_8.D_] ZV_[]B@Z#I.#_Q+K;_OV*T:* .#\!7=A96VJ0-<6\&V
M];"%PN.!VKK_ .U]-_Z"%K_W^7_&LF7P/X?FN)9GL!YDC;G(=AD_G3?^$#\.
M_P#/A_Y$;_&@#7.K::?^8A:_]_E_QJ,7^D!]XN[(/_>\Q<UF?\('X=_Y\?\
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MS1S152SO$O$8J"K*<,K=15K'O2ZC3N.HJNURJR[">:F5MPS0,=1110 4444
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M7-=75U&K75S+,Y&27<FF<5!:W"2VL;AARHJ?([5RR;OJ?9X905**@M+'7Z#
ML6GJX W.<DUJABARC$'U!Q63H%RLM@(OXD/2M6M8['D8B/[QW-:Q\0W]B0%E
M,B#^%SFNRTKQ/:7X5'812GC:QQD^U>;UQ/Q!UEK.TM[:UF9+DOOW(<%<5M3F
M[V/&Q^$I>S<[69].J013J\6^%/Q6.KM'HFMN%N@,0S,?]9['WKV<'(R#74?-
MO0=124M @HHHH *0TM% &=>6J_8I%09/WJY.=#SQ7878=,R"3"8P5QUK O[)
MXF#'G<,BM8,Y:T;ZHPN]2(]$T>#D5%FM3BV+J25*LE4 Y%2+)[TK%)E[S*0R
M55\RE#%C@4K%<Q;C;DUH67F0JTR@;?NDGM5"",NRKZG%=1;0Q);B)=K8ZU$G
M8WI1N21;D@!=]S8SG%9.ILES$&"L'4XP1UK;Q@8[5"UN&F\PG(QC;6:9T3BW
M&QQ$\9Y'>JO>NDU/3C$Q=1E">OI6%- <UO%IHX)P<61J]2K)5<@J>11DU1G<
MNB6E\RJ88U(H9J12DV6 VX\5?LX3<3*@''?VJI;V[N0JC)-;EM;SVLIBC*[V
M&<D=*B3-J<;LT([417'F(<*5QMQ5JFJ#M&[D]Z=6+.Y*PM%%% PHHHH ****
M "D;I2TAZ4 <G=L4UC477J$!'Y"L>RMH[I#-.=\C<G=SBMR89UZ^!Y!"_P A
M61=VUI:S$I>^06.2F,UT/561C3&1#[%JL20'Y9#AE'3ZXHOB;G4WCE/[N(#:
MG8U=TVUML_:$G\^3IN/;\*=J=K;-^^DF\EQQO]:(NSL69-Q"D41ECQ&Z#*LO
M%7K^YF;2[8Y*&8@.1VJ&VMK2ZF"M?>=C^#&,ULW%O#-;F*4 (!P?2G*2N@;3
M9Y_)J$R:A]F%HICW!<E>?KFNJTZYECM+I 2PB7*$\]NE5S;V0FV_VB,YQ]SG
M\ZW+2V@@M]D6&5NIZYK.,7&]W>YK4G&=N56,FPLX;J(S3G?(W)W4L ^Q:O'%
M <QR<,O8>])<V]K:S$)?^3GDIC.*N:;:VZYG2;SY#P7/:M6]#!+4R]4E>2[G
M+@L(L!4)X^M4896*-*JB)X^59>*Z'4K2V8^?)-Y#]-WK52SL[.XE -X)L'.S
M&,TU)6*Z6'ZI/)):VB-E5EY?''X5AB5S<>3]G79G&,?UKK[N"":V*3X"#OZ5
MAB*Q\S;_ &BVS.,;?ZUSU(2J6Y7:QK2J1A?F5[E[2)I#9SJ26$1(0GZ9JK8V
M\5X7FN&WN6/WNU7V<VAM;2RB1_.) W'CIG-9&IQOI]T0UU;6TC<E Y/].*U=
M-S5D[,YW-7+.Q;+581;G =MK*.AK.UVYG0W4RQF22)MJ(>@'KBM#2;:>=6NH
M);:Z= 3G>>/PQ5>>%[]%O+NZ2SW#&V,;B?K5*FTK-_,7/J8.D:K<3))+<(L3
M1<JX&W/MBNRMM6\R_M&MX)9Y K9"C'IZXK-T[2-*:Z#-<FYD4Y"N,#\JZ2V4
M+J]J% "@-P/PI*T8V>K%+F;OL7E75[GEWBME/]T;F_45CW-B(-=PRO=LUN&8
M2-WW'H.@KKL"N7UEMNOJHBG?=:X_<]1\Q]ZS@VW9%32239"MG'YSE='"Y7(;
M?P?;K3TM^BC1T7"\9;CKTJNDD$>XXU(Y&T@OT_\ 'JD$D<@1HX=28(,</_/Y
MJGED7SP)VLE*E3ID14\XW'BFBW68#?I.-K @%^_YU"T\*2$O#J0..A?MZ_>I
M5O+?<N8=0_O??Z_^/4^60^:).UEYDOS:=$V "'WFFB&2,N1I2G//#]351;JV
M W!=1V]?]9Z_\"J7[5 RL/*U#W(?UX_O4<LA<T2=K19D#'2T4X.%9\$<>U,-
MD@01C2E*LN3A^AJ'S[>/<'CU%@HP3YG_ -E2/=VN"OE:B.G_ "TZ?^/4<L@Y
MHEB*#9E%TA0-O4OG^M/EB?AO[*B;*GHW(YJ!;JV"C]UJ#'&W[_\ ]E2FYM=X
MW0Z@IR1CS/\ [*ERR#FB3?8(VVYTR,#.?O=*JWJ%-*N"-.%N5'#$\C'<4TW-
MN64JFI!2>/WG!Q_P*JVH31MI]S*(M0"MQEV^0?K5QC*XI2C8O^(_^/BQ_P!V
MMS2O^/=?I6%XC_U]A_N_TK=TK_CW7Z5BRT:1Z4-]P_2@]*&^Z?I0,X_X?_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXU2\CM+6(RS2'"J.].CT^YE=45#N8@ >IKZ"\ ^"+?0=*AGN[>)M0/S>9CD
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M%=-NMVXO F3[@8-;E</\)BY^'FG*_P!Y0PY_WC7<"N\^.::=F+1110(****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK@ G;YC@X'XU?M+758+ZVD;5TGMG'[R)U4$_3%+=K$GC/3F4(";:;)&.>4H
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M'AS3Y_#WC&19FLKAM1R^8% ,0!X' Z<UJO\ \E<B_P"O!OZ4"+Y\ ^'&(+6
M)'3]XW^-!\ ^'6X>QR/3S&']:Z1Y$CP7=5R<#)QFG9&,GI4W8[',CP!X; VC
M3P%/4>8W^- \ >&TY33]OK^\8_UKI$=9%W(P9?53FCS8S)Y>]?,QG;GG%.X6
M.;_X0#PYNW?8/F]?,;_&AO 'AM_OZ?NQT_>,/ZUT<DL<0W2.J@G&2:?VS1<=
MCF?^$ \-E=O]G_*.WF-_C2CP#X<482PVC_KHW^-=%'*DJ[HV5AG&0<TOF)O\
MO<-^,[<\T7"QS8\ >' <K88)ZGS&_P :U]+T6QT:%XK&'RU=MS?,3D_C5UY$
MC +L%![DT[((I7 HZS_R"+C_ ':Y[PY]U:Z'6?\ D$7'^Y7/>'/NB@#KD^Z*
M=2)]T4M !1110 4444 8'B?_ (]HO]ZN7KJ/$Y_T>'_>KF*WAL>?B/C-F'_D
M6Y?]^L6MF+CPW)_O_P"-8].)-3H=!X8_UDY]A72US?AC[\_T%=)GBLI_$=E#
MX!#6!KFG?: ;F$@LO# 5%XH\21Z5;F&%@URXX _A]ZY3PWXEEM+UH[R0O#.?
MF+'.TFJC"5KF-:O3YO9LM5)%*\,BR(<,IS6GJ^GK&1<V_P T,G.1VK([5:=T
M<\HN+.VTS4$OH <@2#[PK1K@+*[>RN!*GXCU%=O:7*75NLJ'ANWI64XV.VC4
MYU9EBBDS3'FCC&7=5^IJ#:Z'T9K*N-=M("0K&1O]FLJX\1SOD0H$'K5*+,Y5
MH1.IW#.,BG5PT6HW+7<<CRMPW(SQ7;*=R@CO1*-@IU5/8?124M2:A1110 44
M44 %%%% !1110 4444 %%%% !1124 1RQQR(1*JLO?<*ACGMF1Q"8VV#D+CB
ML[Q5?2:?H4\T?#8QFO$['Q?J&CW<TMM,7+G+*YXJ)3L['51P[J0<CM/$N@_V
MW=W,]K"(F09;U:N$?PTD4/[TLKLV"B]ZZS1/'LFH1W*W,(2XD&%8< U3OI_]
M,ACBPS'GYJ5E;F*=2HG[,PXK&.R*HASM&2IK3:_>>Q>WV*%0<$=:BN((Q,\V
MW#L>>:JS,;>V9P0N>YI/EE&[%&,E5Y$]S0M%W(JN^#T7 K(UMU6?' (/:G0:
MH\T:A  <X##H:YV^U!Y+YA*V"K<YIJ46*I1J47<U[/SG5QC< >OI4AED6_B=
M/FDQA@QXQ5C059[4,_RJ^<<=:=<JL<Y0!<'J]3.'-L;X?$QIZ37S)F57+ER%
MW] 3WI(O-MKJ$6Y<N3D;>]1L(KB(+D@@8/M701_9/L%G]F5O/@'S'UIWE&*2
M,)\DZCET,C5_%M_-.;>>+RHL\*!]TU<\/7UC!))-*$661>6(/2I]0T<ZLKS?
M*LC#@^M<S*LEB_DO'OQP3Z4JC=M33"THSFU>QHZGI4&I:T$LKH$2_I6?=^&M
M0T:]2*[0S*[?(Z=JZ#P5;+<:XDI7"(.,CJ:[&YU_2K'7)(M2V;0N5W+FH2YE
M<ZJD_8R45J7?!.AK:Z7NN8 7<Y&\9-=@JJHVJ, =A7"2_$O357R[*%I6!QM
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METN_6M00?Q(!^@KC-7TA[A5@D8QO&>"1PP]:[69@NNWS'H%!/Y"L2ZU>23+
MQQ0YPI89W5V0<DURG/&2BFV4]#TUXQ!"A+1Q-N:0],^@JYK=FYFE<AO*F3:6
M7^$U8T_56:6.*;:R2<(ZCOZ5+J>IO;RF"(+N W.S=!4S;YG<NWM(V74YC3],
M:VE;RV,LCC:JJ./QKIKRQE.E01J-SPG.T=ZS[?69%9F1XIE7EE5<'%;5QJ"0
M6*W*C.\?(/4U"M9<NPH4%07(E8YEXU:7S"S*<\KCD5;M[*:34+5V!3SV=%!_
MW",TV36G^U;7GA63/W-OZ9K1BE34T5Y6>&:U);=&V,<=?RITU&#;744JGM%9
M/8\]\6^%;C4C%;2RFVEMR5*L#M89X(K?\&Z#<6\=K CM)%:;G>9A@$D'@?G6
MC-)>WQ+"\F$0/R[F)S[U9LI;GS1:7%Y/AQA2KD ^V*Z7B+P]G=7&^?E2MH9?
MV)_L&3N$4X^^O\)J'3]-:W+I&3*\@V@ <#WK4N)KK2BUI92++&BY/F_P_CWJ
MO:>)FB;]^% _B&W'Y>M82HJ4E4ZHTIU9QIN-M#7O+&4:=;K&-[0#D>M<@=#C
M.I?:?,D^]NV;><UW-UJ*Q6<<L.)&E^X :R/[2N?-_P"/B/?_ '=O'TI*?+N1
MR\VQ=L+!S97!F4 S] >W&*YV^TB-F5)HMCIQD)D$>M=99:@+BUDDD&UXN'%9
MLFI74YW*ZQ1Y^4$9)%'M7&[DQQER.Z*.F:(D\L17SDBBYWABN3[4W5]$FC>4
M>?,8)/XNN#[ULV.I2FX6"XVG?]QQQGVHO]2E6=H8,*%'S.U/G;?D*W,[G*:?
MI%W!(R6S"5I!M.X8 'K77V;WUI>62-;+(R*P 1LYX%4(=4GA.]G26,?> 7!
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MQ10!7N[.&]C5)ERH(8<]ZG50BA1T P*6EH H:S_R"+C_ ':Y[P[]T5T.L_\
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M\"ZK!<)>3W<EFH.=D9.3]:]/12J $DX'6EQ2T#C'E"J][_Q[-^'\ZL57O/\
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M*<+[#[$$6P!_O'^=._Y?A_N&BT(,&1W8_P Z/^7X?[AJ.K-ELCD]4_Y&=_\
M=%=58_ZE:Y75/^1G?_=%=58_ZE:DLMT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZA4HX.'0]C44JE_=D]3;'X1Q;KTHVIO8VVB1E(*+@C!XJA_93 &-+F182<E
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MM !1110 4444 %%%% !1110 4444 %)2TE &%XDF"VJ1<99JY>M7Q!/YNH;
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M** "BBB@ HHHH **** "BBB@ JO>_P#'LWX?SJQ5>\_X]F_#^=-;BEL)9_\
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MW\-*$805H:(+R>XGDWZG8;?<>FX'BM"PTXP1RF9MTDPPV.PK/^V-_P \IO\
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M^^C656DJJLSOR_,)X&HYP5[FEX%TRZTGPQ;V]X2),9VD_=]JZ;C%<1Y.J?\
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M[^5(W#8/>O38($MX5BC4*JC Q4F*6G&"CL17Q,Z[O(****LYPI:2EH ****
M"BBB@ HHHH **** "BBB@ HHHH *KWO_ ![-^'\ZL57O/^/9OP_G36XI;"6?
M_'O_ ,"/\ZCN)%C9RP!R.AJ2S_X]_P#@1_G5:]3>YP>@JE\1F[\A5CE02@[0
M1GI6BQ\\@(.V=WI62B$N!QG-:<+K;C#$8QUJI(BF^C'",POESO!XR>U'EM*2
MZ'8#W'>B2:.4;%;.>]*EQ&BA78*14:[FFFPW<(%8.N>,Y]:SVE7S,[>,U>N&
M6X0A#QC\ZS2AW8S5Q1E-ZZ&D9D>!0%'/;TJ*,["&/S#T--5-D0)(SW% 92<
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M8\'/S<G-4=0L=!M+\VEOH*74ZIO?8GW1[U<TO0_#^JV2W(T>*/)(*R)R"*-
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MO1:Y?^W=/_N/_P!^Z/[=T_\ N/\ ]^Z=EW"[['4;(L8VK1LB]%KE_P"W=/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 3%&*6B@!,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAUG_ )!-Q_NUSWAW[JT =>OW12TB_=%+0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% !1110 4444 %%%% "4M%% "48I:* $Q2TE+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 44E% "T4E+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 +1244 +1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1136.T9H 4G%5+K4+:SC+W$Z1
M*.[-BN0\=>/[;PO:^5&/-O9%_=H.@]S7@.M>)M5U^<RW]V\@S\J9^4?A712P
M[GJ<]7$*&A]%W'Q%\,VS[7U.+.<<<U8LO'7AZ_D"0:E"6/0$XKY5H'!R.#70
M\)&VYS+&2OL?9<4\<J;D<,OJ#4@-?,'A7XAZOX<GC1IGN+,'YHG/0>U?0OA[
MQ#9^(--CO+20,C#D=P?2N6K1=,ZZ5:-0VZ*0&EK$V"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0F@ J.29(U+.P4#J2
M<5FZ[KMIH6FRWEW)MCC&<=S7SUXK^(VK>(+B6."9[:R)PL:G!(]ZVI495&95
M:T:9[S?>-M TYREQJ4*L.H!S5.#XC^&)VPFJ19)QS7R^26)+')/4FDKJ6$C;
M<Y/KDNQ]AVFI6E]'OMKB.53W1LU<!S7R)HWB+5-!N%FL+IXR#DKG@_45[[X#
M^(5OXF@\B?$5\@^9,\-[BN>KAY0U1T4L0IZ,[^BFALC(IU<YT!1110 4444
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M!),1W 'S)GK]*ZI) XR*W4DU='NTJL*L>:#T'T4E+3- HHHH **** "BBB@
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MGM]%>(?\+>US_GWM/^^#_C1_PM[7/^?:T_[X/^-%AGM]%>(?\+>US_GVM/\
MO@_XT?\ "WM<_P"?>T_[X/\ C18#V^BO$/\ A;VN?\^]I_WP?\:/^%O:Y_S[
MVG_?!_QHL![?17B'_"WM<_Y]K3_O@_XT?\+>US_GVM/^^#_C18#V^BO$/^%O
M:Y_S[6G_ 'P?\:/^%O:Y_P ^UI_WP?\ &BP'M]%>(?\ "WM<_P"?:T_[X/\
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MC_A;VN?\^]I_WP?\:+ >WT5XA_PM[7/^?>T_[X/^-'_"WM<_Y]K3_O@_XT6
M]OHKQ#_A;VN?\^UI_P!\'_&C_A;VN?\ /M:?]\'_ !HL![?17B'_  M[7/\
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M[7/^?:T_[X/^-%@/;Z*\0_X6]KG_ #[6G_?!_P :/^%O:Y_S[6G_ 'P?\:+
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M^)?^>$/_ ']7_&C_ (59XE_YXP_]_5_QKWO%&*+@>"?\*L\2_P#/"+_OZO\
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MP3_A5GB7_GA#_P!_%_QH_P"%6>)?^>$/_?Q?\:][HHN!X)_PJSQ+_P \(O\
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M]_%_QH_X59XE_P">,7_?Q?\ &O>Z*+@>"?\ "K?$O_/&+_OXO^-'_"K/$O\
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MK_*B?W5'2L>.-Y9%CC4LS'  [UTTTXP5SFJ>]-V-[PUX8U+7V=[&-653@[F
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MQ?\ &C_A5GB7_GC%_P!_%_QKWNBBX'@G_"K?$O\ SQB_[^+_ (T?\*L\2_\
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M** "BBB@ HHHH **** "BBB@ JG>6XFB*D=JN4A&: /'?&O@M=0#2(NV5>C
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M?&'@61;B2YLTPQ.63UKSV>TN+9RDT+HPZY%?65_I,=PIRN:Y'4O!L-QG="K
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M4M%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %)VI:* ,[4+,7$3 CK7CWC7P1]KD:X@79,.^.M>XD BL
MZ\TZ.X4Y&<U49N+NB9Q4E9GR9=Z9=V,ACG@=<=\<54Q7TEJ7A&*XR#$K#Z5S
MDOP]M6?/V5/^^:[(XO3WD<<L)K[K/$EC=SA%9C["NG\/^#;S4YT:=&CAZX/4
MUZI8>!K>%@5MT7WVUU^G:!';A3M%3/%-JT45#").[=RAX9T&/3[:.-$"JH
MQ781KM4"F10B-0!4U<C.RU@HHHI %%%% !1110 4444 %%%% !1110 4444
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M0.0O<UZAIW@BW@8%8$4^H6NNT[0XK8#Y1Q45,4Y*R+IX51=V5_#VC+90(H4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 )C-,:)6ZBI** (/LZ9Z4\1*.@J2B@!,8Z4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2&EHH 88P>HIAMT]!4U% $0A4=JD  I:* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*
M",TM% $9B4]13?LZ>E344 ,$:KT%.%+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,,:GM3/LZ>@J:B@"(
M0J.@J0 "EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT\P<T :=%)GTI: "BBB@ HHI* %HJK-?VMO/'!+/&DLGW$9@"WTJS0 M%%%
M!1110 4444 %%%% !1110 44R218XV=V"JHR2>PJK::I8WSLEK=13,HR0C@X
MH NT50EUC3H;G[/)>0K-G&PN,U*]_:QW2VKW$8G89$989/X4 6J*IKJ=D[RH
MMS$6A_U@##Y?K2#5;$VANA=1& '!DWC&?K0!=HJ.&6.>)98G#HPR&4Y!J2@
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MQ^5 %FBBB@ HHHH **:[K&A=B H&23VJ&UO+>]C,EM,DJ X+(P(S0!8HHHH
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M3\2":[2O%/#$=Y%XNM4T26_:QZR_: 0%'TKVJD M%%% !1110 4444 %%%%
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M6TX&<$YQQBG0>.-%CAC0^&+@LJ@9^S+4GB^QO-1@TKQ1I5L^^$!S"1A@.W%
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M1,CGC.: /5UY SP:6FJ<J#ZC-.I %%%% !1110 4444 %%%% !1110 4444
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M7'IBGT4 ,,:'&54XZ<=*/+4MNVC<.^*?10 P1H"3M SUXH\I-NW8NWTQ3Z*
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M0!PFD>!KN/Q'_;&L7_VN6,GRAV%=U2T4 %%%% !1110 4444 %%%% !17/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+A1WXKV35=+M]8T^6QN@QAE&&VG!J&'0K*'0UT<1EK18_+"MR<4[@>0:%<7
M^'NNRV^0[/\ -M[*>M4DT^6X\)6S[=/MT+9%P\@5]V>]>QZ3X4TO1K*>TMHF
M:&?[ZN<@UE+\-O#ZW0F\J4J&W"(O\F?IBBX'(^*2\>H>$Y+F16*^6&D!R#\W
MK5SQ5=6]W\2-$2*19-HPV#GJ#7<:UX6TS7;2&WO(CMA_U90X*U0M?A_H=G=V
MUU%%+YT!RK%LDGWH X_1K'3A\4=1BGBB$:J716' ;(Y%-TW2+35_BGJ<5[$)
M8T#.%/3.17;W_@C2-0UE=4D65;@$$E&P#BKEGX:L+'6Y]6A5_M4X(<D\8- '
MGVJ&SG\73:=I6E6IN($*M+<'Y0!Z"LWP?N72_%<992!!T3[N?FZ5Z+JG@31M
M6U(W\R2I,WWS&V-WUI]EX(T?3Q>+;1R(EVFR1-W&/;CWH \NN/\ DD8_Z^_\
M*Z7Q7J>E6/AO3XY+6*XU*6W58@XSM![UU;^!](?0O['*2_9=_F8W#.?R]JBU
M/P!HNK21/=+,6B01KM8# 'X47 YCPGH^EZ#H5YJ%Y-%-=S0DO&C<A?2N2O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3VYD\PCYE]LT@.MHK@M&\0^(];U*86\%NMI;W'ER.>I''2N\&<<]: %HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJI=6[F.54.1GU%=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12%
M@.I HW ]#0 M%)D4!E/0@_2@!:*3<!U.*-P/0B@!:*3-&10 M%&:* "BBB@
MJEJRM)I%VB LS1, !WXJ[10!R'@C1X4\+VXO+"(3@MGS(@6ZUH>*X;P>&+J/
M2DVS[?E$?!Q[5O44 >+WMFEUX?$-CHE^]ZH!EFG;.,=<9-=;#:7+>+-%G\AQ
M&EH0S8^Z?2N[^E&*=P.2\"6L]K::B)X6C+7;,-PQD8'-=<.E-R/6E[4@%HHS
M29!Z4 +129I: "BBDR* %HHHH **3-&: %HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BDW+ZC\Z P/0B@!:*** "BBDR*
M%HHHH **,TF10 M%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBD) ZF@!:*,TF1ZT +112$@=Z %HHS10 4444 %%%% !129HR.
MF: %HI,BEH ***,T %%)N'K2T %%%% !1110 4444 %%%% !1110!Q_B*76M
M*UJ'4[2-[NQV[);9.H]ZPM5N)O%]Q:6UEH<UM(DRN]S*@78 03R#[5Z9BC%
M' R_:_"GBBXOVLYKNTNXU!:$9*L !W^E5]4N=9U_0KZ:6R>*W:5!;PLHWD C
M)/ZUZ-BB@#D_$VBSZOX-BMH4)FB1'$9[X'2N2\NVO(H+6U\,W OF($GG'Y%]
M3UKUG%&*=P/,-3T5=(\227E[I<MY93Q@?N#S&P_$>M3Z38O<0:O=6VC&S@:!
MDA+G]X_!KTC%&*+@<79VEPOPS:V,+B;[.X\O'.>:W/"T4D'AFPCE0K(L>&4]
M1R:V*.](#C[BQGF\?R2>4WD/9&/S,<9-9.CZC>^$K:ZTBYTNYG(D=H)(@"&#
M$D9Y]Z]&Q1Q0!Y=/H6HQ>$7>:W8W%W>K.T2\E <GG\Z]/3[B_2G49 H X7Q@
MQ_M2)-0T8WFFLG$L(_>(U8%I9WD'A[Q%*L5S!IC0MY$5PV6'!]S7K.,BJ6KZ
M>NJZ5<6+.469"A8=LB@#SV+7K[4?",.BPZ3<_:IHQ%O(&S:?XLY]*?KOAN33
MKC2+R2R>^MK> 0SQQGD>X_&O0M.LUT_3X+16+") H)[U:I@><Z)9Q:CKADLM
M%>TM$C(,\Y^<DC''/O1I.IWWA*SNM(FTJYFD65V@DC *N&)(SS7HU&* //3!
MK%SKWAJZU" ^<HD,NT<)DK@&IK:RNEU/Q8Q@<+,#Y9Q][KTKO*6D!YD-,U"V
M\.:#J,-I))+82%I(/XBI(SC\JV(_$.IZ[?"&RT^:VM%B8SO.H!)P>!7:8HQ0
M!Y@VF7Q^'TL:VLAF2Z,GEXY(#YK0\0[M4\%VNKQ0R6]S8X=5D&&R/E-=_BL#
M7O#DFN3PA[^6*T7_ %D"CB3G/-,"GX#LI8M%:^N!_I%\YF?/OR/YUUE1PPI!
M"D,8 1%"J!V J2D 4444 %%%% !1129 ZF@!:*0,#T(-+0 4444 %%%% !11
M10 44F:-P!P2* %HHHH **** "BBB@ HHHH **** "BC-% !1110 4444 %%
M%% !7&^+;.:Y\0Z$Z0M)&DV7(&0![UV5)QUH Y/Q?X<^W6(O=.01:E:G?$T8
MP6]JQ-7;4]9T72=6:PD>6REW7%JPY;&.@[UZ/13N!X[XDMKOQ3=K=:3HUS;M
M#'F=GPOF ?PX!K6UR:[-MX<OTTNX MS^\A4#*XR/6O3!C%&,4 >?ZGXEU?7K
M.33M.T2ZA:<;&EFP H/4]:Z[0=+71M%MK%3DQ( Q]3WK2HR/44@.$U(7?AWQ
MG)K"V4MU97401S$ 60C':H;>VOM=U^[UUK22VMTMFAA20#<^>_Z5Z#0<#K0!
MQ6@6=Q%\.I;>2%UF,;_(1STK6\&02VWA6RBGC,<BJ<J>HYK?HH X;4Q=^'?&
M4FLBSFNK.ZB"/Y0!9"/;\JJZAJ/B36M'U.>UM9;>W^40QD 2,,C)_+->AT4[
M@>,W]E'=:/$FFZ'?M<H4:>:<YQR,XR?6NN@M;AO&VEW/D.(EL,,V. ?EXKN*
M*+@<%JFDW&H>.[Y?*<0S:?Y8DQQGBL[^U]1L_"4WAYM'N6O8XC"&4#81Z]:]
M.HI ><"PO/[+\(K]GDW0S@RC'W!D=:GM[BZ\(:[J(EL)[FVNW\V)X0#S@#!S
M]*] R,XS1P?>@#R:WAUV71/$%Q%:36\\]TK[!PQ3"YQ^%4M0LTN]+@33-#OC
M-&Z-/-.<D8(SC)]:]FHQZ4 <!K)N;3Q-HNI"RGFMS:&)_+'*$XZUC_V=!HFI
MWR:EHUS=QSR&2"6'N">AYKU>DRN.M.X'+>"+*2"QGN9-.6Q\]\K'G+;1T)_.
MNJ%%+2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'&H0WDTK0B)/+A09R<#H*[6SGAN;.&:W(,+H"F.F,5Q]C;QR?$_4I'0,RVZ
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MG[,S["<<JWH:;;^-='N+":]\V2.&$[29%QD^WK7'^))=(OM,*:;!MC^WJ)6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN:1K=CK=L9[&8.JG# C!!]Q0!G'P/X?RI&GH-O8$X-:=UH]A>6(LY[9'MU&
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MVL5W;R03H'CD&&4]Q4!TFR.F?V<85^R[=OE]L5=HH SKK0M.O+".RN+9'@C
M5%/\('3%0Z9X:TK2)&DL[54D88+GDUKT4 84O@_0Y[YKM[%#*QRWH3]*L_\
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M2="CTN]O[@2;S=R>801]WK_C6O0 4444 %%%% !1110 4444 %%%% !1110
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MRB>WV@; >X.*O_$DN/";&/[XF3&?7FLNY?7/$]E:Z1-I;VL65,\[D;2!Z8-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTK4[?5]/CO+9B8Y!QGJ*NT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 )BC%+10 E%([K&C.QP%&37)-X\M_WDT5A=264;E&N%3*@@X-
M'748K"U#Q586%G;3+OF>Z&88D&6:F:7XJM[^_-A/;S6EWMW".88W#VH Z"BN
M7N/&MM'<S1V]I<W,5N<32Q+E5IR>-;&30_[56.3R#.L(&.<D@?UH Z:BLG5M
M=M])M+:XF5BL\BHH'JV,?SJGJ7BR"SOOL-M;3WET%W/'"N=H]Z .BHKG[3Q9
M8W>EW5XJR*UK_KHG&&4_2LT?$*T:".[%C=&R; :XV?*#^= '0ZSH\&MV'V2X
M+"/>'ROM5^-!'&J#HHP*Q-3\4V6GK;K&'N9KD;HHHAEF%,TOQ99ZA)<0S1R6
MEQ;KODCF&"%]?TH Z"C%<BWCRV :X6PNFL5;:;D)\H]^M7M2\66EF;6.WBEN
MY[E-\<<0R2/7]* .@HK%T3Q'!K+S0K#+!<0_ZR*5<$5MT )BC%+10 8HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,4F*6B@!
M,48I:* $Q1BEHH 3%%+6=JVJ0Z=93RF5!*D9948]: -"EK%\/Z[%J^EV\[R1
MB>09,:GI6U0 F*,4M% "8HQ2T4 )BC%+10 F*6BB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:
M* /-K"*2XU_QE##GS&0A<=SL%%IK^CV_P_ELIYXTN8XVC>!C\V[)[5Z#%8VT
M$\L\4*)++_K& Y;ZU5D\/Z5+<-</8PM*W5BO6F!Y5-&R6GAB\DN'M;549#.O
M\#$G%;-O%8W'BW3PNMSZE<QY93&-RJ/<YKT-M-LWL_LC6\9MQTC(XIEEH^GZ
M<2;2TCA+=2HH Y?P7&GVGQ$VT9-]("?Q-<M-A? NJ''RI?DGV%>L0V=O;&0P
MQ*GFMN? ^\?6HO[+LOL\EO\ 9H_)E.73'#&@#C=3N[>]UGPK-;3)+&7<;D.1
MG"U-X?C2;QCXDB< J[!6'J"HKJXM(L(%A$=K&HA),>!]W/I1):I;+<W%I GV
MIU))Z;CCC- 'EJ1W?]I_\(?AO+%YYH../*^]C\Z];BC6*)(T&%10H'TKEO#V
MBZ@=;NM:UA(DN9!LCC0YVK764@.$T=2^O>*549)Q@?\  :R]&\0:;8> [JSG
MNHTNT+J8"WS9SZ5Z1%9V\,TLL4*K)+]]@.6^M56T#2GN6N&L83*W5MO)H \X
MTO\ X]?!Q'&9#_[+6[H%G%J&L>*+249CEE*'\178+I=B@A"VL8$!S%Q]SZ5#
M=6[6=M<SZ9:QF[D&[!XWGWH \VT?[3JFJV/AJX4[=,G9Y2>X'*UZNX"P,!T"
MXKF_"VAW=I<WFJ:F(Q?7;?,J=$4=!73X!&* .$\#1H/#FK-M&6N)\^_+5S7*
M^ H)L?NX=19G/H-[5ZS!8VUK$\4$*QHY)95'4GK3%TVS2U:U6WC$#9+)C@YI
M@<#XL\0:9J=SH\%C=1W#&=6.PYVC!ZUIZ7&C?$C6&(!984 /YUT</A_2;< 1
M6$*8.X87O5Q+.WCN7N$B59G&&<#DT <9X1C3^U?$AVC)GP>/K7.PZI+IG@Z+
MR1$IFORGG2+E8N5YKU2&RMK=Y&BA5&E.7('WC43:18-:-:M:QF!CDIC@F@#R
MG69T_M/1P^O_ -I2_:$)5#\B<CMDUU>A*K?$/5VP"1 F/_':Z6/P_I4,>Q+"
M$*&#8QWJW'8VT-P\\<*K*XPS@<D4 <EX8 'C77@,#E?Y"NUJ"*SMX9Y)HHE6
M23[[ <FIZ0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 9VMW-W9Z3<7%E")IT7*H>]<2;SP5KVG_:-2^S6UYC]Z"0KJ>]>C
M$9K,F\.:1<3>=+I\#2$Y+%: /,7BO[KP%<^6\TEE#=;H7;EO+&.?YU+J)TZY
MTFUBF\23W8E9 EM'\S!LC'&>QKUA;>)(/)6-1&!C;CC%48- TJVN/M$5C"LN
M<[@M,#C6A=O%LT$1;?\ V;M7(YZ5A:&8+?1+B&Z\1O8O$[B6V)P>IZ#/>O6Q
M96XNOM/E+Y^-N_'.*J7&@:5=W'GSV,+R_P!XK0!YI!#!IMMH-_NG.FQSLS/,
MN,9SS]*[)_$FDWWB"UL[*..]G96)FC(/E#BNCDLK::V^SR0HT.,;".,5#9:1
M8:<6-I:QPENI44 >:K>6Z^&/%5F9D%SYLK>63SCUJRLT6F:UX>U&^^6R-KY8
MD;[JM_DUW[Z)ILDTLKV<1DE&)&Q]X>]33:=:3VHM9;>-X ,!".!0!PVLWUKK
M?BW3QI<JSFWC=II(SD 8/!-6/!<:?\(KJGRCYI)<_K776>DV-@K+:VL<0;KM
M'6I8;&VMH6BAA5(V)+*!P<]: .:^'F/^$84#M-)_Z$:ZVH;:T@M(O*MXEC3)
M.U1Q4U( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M BN2HMY"REEVG*CJ1BO)#/9VEI=7FBZ\;/;(Q?3[D?>;/(QD5Z^1FLV3P]I,
MUS]HDL(6E)SN*\YH \TU.:YNM0T#5+R9M/AD@P94& C';^6:T+2&RNO&%F(]
M:GU*ZB4L&0;E4<<$YKT:XL;6[M_(G@22+^XPXJ*RTBPTXL;.UCA+=2HZTP.'
M\+ZSINC:3J%AJ<T=O=12N720X+9]/6L1&$GPWFGB4^6NHK)QV4,IS7IM[HFG
M7LAFFLXI)L<,PYK-\*:%+INC3V5]$A629FV]1M- '+^*_$.F:A8:+;6EU'/(
M;B(D(V=O(ZU32(VGC#4TO-8?3&E"O&Y.!(N!WKT6+P[I,/\ J["%?F#<+W%3
MWND6&HA?M=K'-MZ;ATH \WLXK1]/\17-M>SWA,6R29E^5CD=#6Q)&B_"6,!1
MC[*AZ>PKLHM,LH+0VL5M&L##!0#@TXV-L;3[(85^S@;?+QQB@#S?3[F'2_$6
MCWM^PCM9;!425_NAN.]:FKZM::Z-6LM(MUGF%J=UU&<@\'Y:[&?2[&YM5MIK
M:-X4&%0C@4MEIMGI\1BM+=(4/4*.M 'E-K+9#PILN?$LL:B,H]F/O?0#-7[J
MWTB.WT6WEO;K3[I8"8+QQMXRW!KOW\/:3)<_:&L(3+G.[;WJ>\TNROXEBNK:
M.5%^Z&'2@#CO!FJWDVN7UA+=Q:A#$H(NXUZ]."<FN]JK9:=9Z=&8[2W2%2<D
M*.M6J0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<YXE\,6.L6T\\EMYMT(BL9]^U='10!R'A'
MPC9Z98VMU-:&/4$4AB3R*Z^BB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>]NITWJF=JA?4FL?Q0H'PXA '01X]JS=9U6:+5["RN[]].T\VH83)QO//&:
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M?E6#IJ@S>#LC^$_R%=#*!_PM2$X_Y<SV^E %_0_%?]H?;8=0M?L5U9\RH3D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_Y]9?RI/MS_ //K+^5 %VBH()VFSF)TQ_>%3T %%%% !1110 4444 %%%%
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M_4]>GY53MM(N;N_M%B\.0V2QG,TLA+?]\]*Z'PQIUS8W&KM<Q;%GNF=/<9-
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M]L2_] ZY_P"^3_A1_;$O_0.N?^^3_A0!JT5E?VQ)_P! ZY_[Y/\ A1_;$O\
MT#KG_OD_X4 :M%97]L2_] ZY_P"^3_A1_;$O_0.N?^^3_A0!JT5E?VQ+_P!
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MS+_T#;G_ +Y/^%']LR_] VY_[Y/^% &M163_ &S+_P! VY_[Y/\ A1_;,O\
MT#;G_OD_X4 :U%9/]LR_] VY_P"^3_A1_;,O_0.N?^^3_A0!K45D_P!LR_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %!HHH XC5_AY9Z[XH;5=0F9HMJA85X!P.]=78:79:9 (;*VC
MA0=E%6\4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g0vsdaj33nnl000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *>",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **2EH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC_A8_BG_ *"?_D)/\*Y6BBR#F9U7_"Q_%/\ T$__ "$G^%'_  L?Q3_T$_\
MR$G^%<K119!S,ZK_ (6/XI_Z"?\ Y"3_  H_X6/XI_Z"?_D)/\*Y6BBR#F9U
M7_"Q_%/_ $$__(2?X4?\+'\4_P#03_\ (2?X5RM%%D',SJO^%C^*?^@G_P"0
MD_PH_P"%C^*?^@G_ .0D_P *Y6BBR#F9U7_"Q_%/_03_ /(2?X4?\+'\4_\
M03_\A)_A7*T460<S.J_X6/XI_P"@G_Y"3_"C_A8_BG_H)_\ D)/\*Y6BBR#F
M9U7_  L?Q3_T$_\ R$G^%'_"Q_%/_03_ /(2?X5RM%%D',SJO^%C^*?^@G_Y
M"3_"C_A8_BG_ *"?_D)/\*Y6BBR#F9U7_"Q_%/\ T$__ "$G^%'_  L?Q3_T
M$_\ R$G^%<K119!S,ZK_ (6/XI_Z"?\ Y"3_  H_X6/XI_Z"?_D)/\*Y6BBR
M#F9U7_"Q_%/_ $$__(2?X4?\+'\4_P#02_\ (2?X5RM%%D',SJA\1O%.X?\
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MG^%<K119!S,ZK_A8_BG_ *"?_D)/\*/^%C^*?^@G_P"0D_PKE:*+(.9G5?\
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M_P#03_\ (2?X4?\ "Q_%/_03_P#(2?X5RM%%D',SJO\ A8_BG_H)_P#D)/\
M"C_A8_BG_H)_^0D_PKE:*+(.9G5?\+'\4_\ 03_\A)_A1_PL?Q3_ -!/_P A
M)_A7*T460<S.J_X6/XI_Z"?_ )"3_"C_ (6/XI_Z"?\ Y"3_  KE:*+(.9G5
M?\+'\4_]!/\ \A)_A1_PL?Q3_P!!/_R$G^%<K119!S,ZK_A8_BG_ *"?_D)/
M\*/^%C^*?^@G_P"0D_PKE:*+(.9G5?\ "Q_%/_03_P#(2?X4?\+'\4_]!/\
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MKE:*+(.9G5?\+'\4_P#03_\ (2?X4?\ "Q_%/_03_P#(2?X5RM%%D',SJO\
MA8_BG_H)_P#D)/\ "C_A8_BG_H)_^0D_PKE:*+(.9G5?\+'\4_\ 03_\A)_A
M1_PL?Q3_ -!/_P A)_A7*T460<S.J_X6/XI_Z"?_ )"3_"C_ (6/XI_Z"?\
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M_P#(2?X4?\+'\4_]!/\ \A)_A7*T460<S.J_X6/XI_Z"?_D)/\*/^%C^*?\
MH)_^0D_PKE:*+(.9G5?\+'\4_P#03_\ (2?X4?\ "Q_%/_03_P#(2?X5RM%%
MD',SJO\ A8_BG_H)_P#D)/\ "C_A8_BG_H)_^0D_PKE:*+(.9G5?\+'\4_\
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MG^%<K119!S,ZK_A8_BG_ *"?_D)/\*/^%C^*?^@G_P"0D_PKE:*+(.9G5?\
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MV4L=V ,GC%=+\4?#?V>\77+51Y,YQ,%7HWK[YY_*MG1/^2.7W_7O+_Z#3YM
M4-7<\>HHHJC(**** "BBB@ HHHH **** "O0/A%_R-%S_P!>K?\ H2UY_7H'
MPB_Y&BY_Z]6_]"6E+8J'Q'LT_P#Q[R?[I_E7S!>?\?DW^^:^GY_^/>3_ '3_
M "KY@O/^/R;_ 'S4P-*I!1115F(4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444#.OT?X<ZQK6E0:A;36BPS E0[D'@D<\>U7_\
MA4FO_P#/>Q_[^-_\37*VOB/6K*V2WM=4NX84X6-)2 /PKV;PK?W=U\.5O)[F
M66Y\J4^:[9;(+8YJ&VC2*BSSN^^&&MV%E-=RS69CB7<P5VS^'%<G8:?=ZG=)
M;6<#33/T5:N3>*-=N(6AFU>\>-QAE:4D$5ZA\/=/M=%\(2ZS/&$GD#,TC=D'
M3'IFG=I:B23>ARR?";7F0,9K-2>Q<Y'Z5AZ_X+UCPZOF742O#Q^]B.5!]*?J
M'CGQ!>WLDZ:E<0*QXCBD*J*ZNS^(NG7OA:33]>2>:X=6C8QKPRXX.<]>M'O(
M/=.+\.>&+[Q/<30V3PHT*AF\UB!S] :Z/_A4FO\ _/>Q_P"_C?\ Q-7?A#M_
MMG5-@(7RUQ],FL_QIX@U^T\7ZC!::C>Q0(X")'(P4?*.E#;O8:45&[(KSX7>
M(+2V:8?9Y]HSLB<EC^8KC)8WAE:.12KH=K*>Q':O7_AAJNNZA+>+J4L\]JJ@
MI+-DG?D<9/MVKA_B)%!#XUO5MT14(1B$'&XJ"?UH3ULQ22M='*UI:/H6H:[=
MBWL8"Y_B;HJCU)K.52S!0,DG KV^R$/@KX<BZCC"7;0AVW\[I2.G\Z).PHQN
M<;_PJ37<<W%EGT\QO\*YG7?#.I^'I_+OH<(3A95.5;Z&ISXU\1-=&?\ M:Z!
MW;M@D.WZ8]*ZO6_'FD:_X1%E>PSF_*9.% 4..A!STHN[CM%HYKP[X(U/Q-92
M75E);JD<GEGS6(.< ]@?6N>N(6M[F6!\;XW*$CID'%>Q_"#_ )%N\_Z^C_Z"
MM>7ZII=^VK7C+:2D&=R#M_VC0GJ#CHF7=#\%:EK^FS7UK);K%%G<)&(/'X5S
MKH8Y&1L94X->S?#FWFMO!]^LT;(QW<,,=C7CES_Q]2_[Y_G0GJ*2LD:OAWPO
MJ/B:>2*Q5 L8R\DAPH]!]?\ "F>(?#=]X:O%MKT(2Z[E>,DJ?;->I^"X(_"G
M@*75[F,;Y5\]]I^\O\/XX--^(%I#XC\&0:S9JS>4OFIG@A#][(_ 4N;4KD]T
M\84;F"CO7=1_"C7I8DD6>RPRAAF1N_X5P\7^N7ZU[AXZO;VP\&036$\T,W[L
M;HB0<<>E.3%!)HXG_A4FO_\ />Q_[^-_\37*ZWH&H:!="WOX"A/*..5<>QK;
MT+Q%XJFUJUCCO;Z<M( T;L2",\_I7;_%ORSX<LC+Q+Y^0!Z[3FB[0^5.-T>-
M5V5E\--;OM,BOXY+58I8_,56<[L8SZ5@^'=,;5]?L[)>/,D&21Q@<_TKWN36
MK/3]?LM" C02PL5^;&TC "X]P3^5$G84(W6I\XL"K%6&&'4$4 %B%4$D] .3
M76_$;1VTKQ3/(JMY%U^]5L8&3U ^G%:/PIT>&_UR>]F ;[&JLBL,C<<X/U&*
M=]+BY?>L5-/^&&OWUJL[""WW=$F8AOKP*;JGPTU[3;1[G;#<*@RRPL2P'<\@
M5I^/?&NK)X@FTZRN9+2*U;;F)R&<XZD_TIO@_P"(\VG//'KMS<W,##,;8WN&
M^I/2INRK1O8Y;P[X8OO$UW-;6;Q))"F]O-)'&<>E=)_PJ37_ /GO8_\ ?QO_
M (FL'5/$!3Q%>7^@S3V,5P>D9V$^N<>_-=E\+]<U74]?NHK[4+BYC6V+!99"
MP!W#FFV]Q146[&7_ ,*DU_\ Y[V/_?QO_B:QX? ^IS>(Y-#62W%U'&9"Q<[<
M?7%;_P 1?$&L:?XOFM[/4KJ"$1(0D<A !(YIGPRO+F^\:R7%W.\TS6SY=VR3
MR*5W:X6C>Q'_ ,*DU_\ Y[V/_?QO_B:3_A4FO_\ /Q8_]_&_^)K5^(>H>(;;
MQ/Y>F75[';^0AVPN0N><]*Y%M:\8(C.^H:F%49),C<4TV-J*T*.D>'[O6M9.
MEVS1+."PR[$+\N<]O:NH_P"%2:__ ,]['_OXW_Q-5?ABQ?QO"[G+,DA)/<[3
M6S\1M:UJP\1+%87UW#%Y8.V)R!^E#;N))<MV9<_PI\000O('M92HR$1SEOIQ
M7&R6<\-Z;2:,QS!]C*W8YQ7J?PSU;7]0U"Y6_FN+BU6/.^8DX;(X!/M7/_$3
MR_\ A8*[#\W[K=^E";O9C<5:Z,SQ!X%U3PW8+>7DELT9<(!&Q)R?J/:KFF_#
M/6M4TVWOH)K,13H'4.YR ?7BNY^+/_(K1_\ 7PO\C7E-OXFUVV@C@M]5O(XD
M&U(TE("CT H3=A-),Z?_ (5)K_\ SWL?^_C?_$UB>)/!NH^%X();Z2W=9F*K
MY3$G('?(%>G^"[35;+3&UGQ#JURRLA98I925C7U;/>O//'?BT^)=26. %;*W
M)$6>K'NU)-W'*,4CE[2VDO;N&VA&9)7"+GU)Q73:U\/-9T+39+^X:WDACQO\
MIR2.V>16G\*='-YKLFHR*WE6BG:<<%CQC\CFO28M2LO%4.L:8BHZ0GR3NYW'
M'7'L?Y4.5F$8)K4^>HHS-*D:D;G8*,^]=U_PJ37_ /GO8_\ ?QO_ (FN+O;:
M33M2GMF;]Y!*5W=.0>M:L'BWQ";B-3K-Z07 (,Q]:IW)C;9G0?\ "I-?_P">
M]C_W\;_XFLK7_ >J^'-.^W7DMLT6X+B-R3D_A7J/Q'U"[T[PC]HLKF6WF\]%
MWQM@X.<\UXM>Z_J^HP>1>ZC<W$60=DDA(S4Q;94E%:&QK'@/5=$T;^U;F6V:
M ;>$<EOFZ=JP-.TV[U6[2ULH&FF;HJU[/\0_^2<G_MC_ #%0?#S3;?1O!LFL
M[5>:>-YF..0JY^7/I\N?QH4M+AR*]CDD^$VO,@8SV:DC."YX_2LO6_ &N:';
M&XEB2>%1EW@)8(/?(%1ZEXZU^^OI)H]2N+>-B=L<+E0!VXKO/AKXJO-;^TZ5
MJ3FX9(RZR/R2N<$'UZT_>0K1;L>5:7ITVKZG;V%NR"6=MJES@9K:\0>!M7\.
M6BW5WY,D).TM$Q(4^_%;BZ1%HOQ?L[6' B,XD15& H8$X'TKUC5;:SU.UDTJ
MZ8'[3&V$S@D#J1^8I.6I48)IGS?IUC+J>HV]C"5$MQ((T+'@$UJ>(_"5_P"&
M/)^VO WG9V^4Q/3Z@5<TG2KC1?B+I]C<KAX[Q,$="-W!%=5\8?\ F'?5J=]2
M%'W6>5T4451 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5U'P[_Y'G3OJ_P#Z :Y>NH^'?_(\Z=]7_P#0#2>Q4=SZ"HHHK$Z@HHHH
M *6DI: $HHHH **** "BBB@#R+XR?\A'2O\ KB_\Q7F5>F_&3_D(Z5_UQ?\
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M[_#_ .)KEO!UQ]K^)%G<[=GG7,DFWTR&.*Y2M_P3<P6GC'39[F5(H4D)9W;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSU .<8]_6N2^%NIV>GZIJ$M_=PP"2-<-*X7<<G/6N>\;7$%YXQU*>WE26%Y
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M  HN@LRC15[^QM5_Z!EY_P!^&_PH_L;5?^@9>?\ ?AO\*+H+,HT5>_L;5?\
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MAO\ "C^QM5_Z!EY_WX;_  HN@LRC15[^QM5_Z!EY_P!^&_PH_L;5?^@9>?\
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MAO\ "C^QM5_Z!EY_WX;_  HN@LRC15[^QM5_Z!EY_P!^&_PH_L;5?^@9>?\
M?AO\*+H5F4:*O?V-JO\ T#+S_OPW^%']C:K_ - R\_[\-_A3N@LRC15[^QM5
M_P"@9>?]^&_PH_L;5?\ H&7G_?AO\*+H+,HT5>_L;5?^@9>?]^&_PH_L;5?^
M@9>?]^&_PHN@LRC15[^QM5_Z!EY_WX;_  H_L;5?^@9>?]^&_P *+H+,HT5>
M_L;5?^@9>?\ ?AO\*/[&U7_H&7G_ 'X;_"BZ"S*->@?"+_D:+G_KU;_T):XW
M^QM5_P"@9>?]^&_PKNOA587MKXEN'N+2XA0VS -)$RC.Y?45,GH5!.YZ]/\
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M9E&BKW]C:K_T#+S_ +\-_A1_8VJ_] R\_P"_#?X4[H5F4:*O?V-JO_0,O/\
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M?X4?V-JO_0,O/^_#?X4KH+,HT5>_L;5?^@9>?]^&_P */[&U7_H&7G_?AO\
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MLRC15[^QM5_Z!EY_WX;_  H_L;5?^@9>?]^&_P *+H+,HT5>_L;5?^@9>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %+24M "4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2TE+0 E%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MM)2T )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %+24M "4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT4E%(8M%)5;4$E?3KA(=WFF,A-IYS0!:I,^]?/\ +H'Q%,S[4U;;N./]*/\
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MZ\53\;W=O?> +NZM95E@ECRCH<AA2BYWC?8;4+/E/(?AMJ=EI'BV*ZO[A+>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2TE+0 E%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK*P-W=PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV&C6T4K_ 'FVEO?OFM^BJ$)M!&"!CTJG_9&F?] ZT_[\+_A5VB@"E_9&F?\
M0.M/^_"_X5;CBCAC6.)%1%X"J, ?A3J* *&I:)IFL0M%J%C!<(PP=Z<X^O6H
M-)\,Z)H48CTS3;>V .057)!^IYK6HH YSQ9X/L?%-FHD+6]]"=]M=Q</$XZ'
M/<>U:NDPWUMI5M#J5PEQ=H@629%P'('7'O5ZB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "EI*6@!**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[*O_ #!ST?Y?Q.>_X2^+_GPNO^^11_PE\7_/A=?]\BNA\B+_ )YK^5'D1?\
M/-?RH]E7_F#GH_R_B<]_PE\7_/A=?]\BC_A+XO\ GPNO^^170^1%_P \U_*C
MR(O^>:_E1[*O_,'/1_E_$Y[_ (2^+_GPNO\ OD4?\)?%_P ^%U_WR*Z'R(O^
M>:_E1Y$7_/-?RH]E7_F#GH_R_B<]_P )?%_SX77_ 'R*/^$OB_Y\+K_OD5T/
MD1?\\U_*CR(O^>:_E1[*O_,'/1_E_$Y[_A+XO^?"Z_[Y%'_"7Q?\^%U_WR*Z
M'R(O^>:_E1Y$7_/-?RH]E7_F#GH_R_B<]_PE\7_/A=?]\BC_ (2^+_GPNO\
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MV_Y]XO\ O@4<U/L'+/N<!_PMVR_Z 6K?]^U_QH_X6[9?] +5O^_:_P"-=_\
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M_P!CMO\ GWB_[X%'V.V_Y]XO^^!1S4^P<L^YP'_"W;+_ * 6K?\ ?M?\:/\
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M?Z?_ %ZY!OBVI8F/0-0*=B4Y_G69K42:S\7#!>+YD-M!N2,G*Y'M79@!0
M!T K:%--&%2MRNQSW_"VS_T+]_\ ]^Z/^%MG_H7[_P#[]UT5%5[)&?UAG._\
M+;/_ $+]_P#]^Z/^%MG_ *%^_P#^_==%11[)!]89SO\ PML_]"_?_P#?NC_A
M;9_Z%^__ ._==%11[)!]89SO_"VS_P!"_?\ _?NC_A;9_P"A?O\ _OW7144>
MR0?6&<[_ ,+;/_0OW_\ W[H_X6V?^A?O_P#OW7144>R0?6&<[_PML_\ 0OW_
M /W[H_X6V?\ H7[_ /[]UT5%'LD'UAG._P#"VS_T+]__ -^Z/^%MG_H7[_\
M[]UT5%'LD'UAG._\+;/_ $+]_P#]^Z/^%MG_ *%^_P#^_==%11[)!]89SO\
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M%?\ D4])_P"O6/\ ]!%:]9'A7_D4])_Z]8__ $$5KT,$%%%%( HHHH ****
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M (\;C_KFW\J\V^#OW=>_Z^$_DU:Q_AR,I_&CU"BBBLC4**** "BBB@ HHHH
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MM'_Z"*O51T7_ ) 6G_\ 7M'_ .@BKU<9Z(4444 %%%% !1110 4444 %%%%
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MNLZ?%9V<1ZB5"JGNQP<GZ5[KX?T>#0-!LM+MU"QVT07 Z9ZD_B<F@#2HHHH
M**** "BBB@ HHHH **** "BBB@""]_X\IO\ </\ *L#P;_QYW/\ UW/\A6_>
M_P#'E-_N'^58'@[_ (\[G_KN?Y"N*I_O,/0ZH?[O+U1TU%%%=IRA1110 444
M4 %%%% !1110 4444 %%%% !1110!!>?\>-Q_P!<V_E7FWP=^[KW_7PG_LU>
MDWG_ !XW'_7-OY5YM\'?NZ]_U\)_)JUC_#D93^-'J%%%%9&H4444 %%%% !1
M110 5S_BCQIH?@V&VEUNY>!+EF6,K$SY(QGH..M=!7B?[0H!@\,@C(-U)D?@
MM '3_P#"\? 7_04F_P# 63_"MWPO\0?#GC&[GMM%O'GE@3S) T+)@9QW%7M/
MT#1FTVU)TBP),*9)MD]![5:%GI^D07%U;6%O"4C+-Y,2H6 &<<"@#0HKE_!?
MC6T\:V=Y<VEK-;K;3>2PE())]1BFZMXYM-)\:Z5X9DM)WN-1SLE4C8F!GGO0
M!U5%<!XE^*VE^&?$UQH-Q87DUVEN)HO)4-YS'HBCKG].*P8/C5)::E#'X@\.
MWFG6<[A4N&0X0'NW^ H ]=HK!\3^+=+\)Z"^K:A+^[V_NHU^_*>RJ/\ .*\]
M_P"%UWL!^V7?A'4H]+;[LNSYP/4\XQ0!ZO?7]IIEG)=WMQ'!!&,M)(P4#\ZH
MZOXFTO0]"_MF_G*6.U7$BH6R&QC@<]Q7D7QJ\9VVI>#K*TLK6YEM]0B6Y6[5
M?W2@/C:Q]<K70:7\1=/_ .%9MJ.H^'[S[-IT<-NT-Q&O[[Y5&Y=W!% 'IMG=
MPW]E!>6[%H9XUEC8C&589'Z&IZYN_P#%^DZ'X0M==NQ]GM9H$>&$#D[E!" #
MOBN"'QJU$*+^3PAJ"Z23Q+L^<#UZXQ0![#17-V_C33;WP9+XGL]\]I%$9&1>
M&R.J\]ZXI_C6M_;QC0/#M_?3M&';Y<I'ZJ2._P!* /6:*XCP+\1[3QG-<V1L
MYK'4+4#S;><8/X"L_P 2?%FVTW6YM$T;2[K5[^%1YAMURD;>C'Z=Q0!Z/6/?
M^*-*TWQ!I^AW4[)?Z@&-O&(R0V,YYZ#IWKAM"^, N=?M]$UW1;G2[NX;"22<
M1]..IY]*@\;?\ET\"_\ 7.7^34 >L4452U748-)TJZU"Z<1PP1EW8CH!0!E2
M>.?#T7BE/#;7Z_VH^,1!21D]MW3/MUKHJ^7FT34KWPM>?$Z,RKJZZAYZ*%PH
M0<E^>U?1>@:U%KGAJSU:U!D2>$.HZ$G_ /70!K45S'@WQK9^,K:]EMK>6V:T
MN&@>.5@6)&.>.W-,UGQO;Z1XNTSPVMC/=7=^A=6B90$ )SG)]B: +^G^+-(U
M3Q!>:':W#/?V:;YHS&P"C('4C!ZBMNN/T/Q7I6I^.-6T.VTLP7UG$'FN=BCS
M!D#&1SW'7TK!U_XNI::W<:1H6C7>JW-N^R62-#Y:D=0>^10!VVI^*-*TC6M-
MTB\G9+S4F*VR",D.1C/(X'7O1_PE&E?\)5_PC7GM_:GD?:/*\LXV>N[I7C6H
M^,8/%WQ0\".+.XLKRVN)%GMKA"K)G;@_0X->HGQ1I@^)7_"-G32=2^Q?:/MF
MU?N?W<_>H Z%M3LDU&/3FNHOMDBEU@WC?M'?'7%6Z^;)/B%L^- \0G0=4;R[
M1K?[&(_WIZ_,!Z<U[-HWCVRU?Q;>^'#:7%K=VT:NIFP!*",G;WXH ZVBN;\8
M^,;/P;IT-U=0RW$D\HAA@BQND8GH,\5O6LQN;2&<QM&9$5RC=5R,X/N* )J*
M** "BBB@ HHHH **** .&^*__(ER_P#74?R-;?@K_D2=%_Z](_Y5B?%?_D2Y
M?^NH_D:V_!7_ ").B_\ 7I'_ "K9_P )>IBOXK]#>HHHK$V"BBB@ HHHH **
M** "BBB@ HHHH **** /))/^2R7?_7NW\Z[&N.D_Y+)=_P#7NW\Z[&NJG\)P
MU_B"BBBK,0HHHH **** "O(_%_\ R6K0_P#KC'_Z&U>N5YSXC\,ZM?\ Q0TK
M5[>UWV,$:+)+O48(8D\9S4S6AI3:3U/1J\M^$]RL.K>)=,E1TN1>//M92/E)
MP#7J5>>>+?!NJ1ZX/$_A>;R]2&/.@+8$XZ=^.G^<T23T80:=T^IZ'63;^)=)
MO->GT2WNA+?0)YDB*"0HX_BZ9YZ5Q<^L_$VYMFMT\-V=NSC;YZS E/?!:MGP
M+X,?PQ#<W5].ESJ=XY>:4#@9[#^M%VV/D26IP^B>#8/%7C#Q:\VHWUI]GOR
M+60+NR6Z\>U5/%W@J;P?<6^IO<7FJZ%N"W4,LQWCUZ8X/_ZZ]!\%Z'J.E>(?
M%-U>6_EPWMX);=MP.]<MSQTZCK74ZEIUMJNG3V-Y&)()D*.I]#4J%T6ZC4O(
MI>&&TE_#MG)HD:QZ>Z!HE4$8^N><_6M>O//A]HWB+PO?WND7UNTFD[RUM<*Z
ME0?IG=SQ6I;>-UO_ !A:Z/9VKFUE$FZXD0KEE4G"@XSTZU2EIJ9RC=Z'7T44
M51F%%%% !1110 5RGQ$_Y%2;_?7^8KJZY3XB?\BI-_OK_,4GL73^)'H^B_\
M("T__KVC_P#015ZJ.B_\@+3_ /KVC_\ 015ZN,]$**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHNTUNQN]6T29B+66WA3?TST']:Q[6TE^(GCW3M6L-"N-'TZQ;,T[QK&[N,L
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ML*G8V:*QO^$GTO\ Y^!^5'_"3Z7_ ,_ _*CZS2_F#V%3L;-%8W_"3Z7_ ,_
M_*C_ (2?2_\ GX'Y4?6:7\P>PJ=C9HK&_P"$GTO_ )^!^5'_  D^E_\ /P/R
MH^LTOY@]A4[&S16-_P )/I?_ #\#\J/^$GTO_GX'Y4?6:7\P>PJ=C9HK&_X2
M?2_^?@?E1_PD^E_\_ _*CZS2_F#V%3L;-%8W_"3Z7_S\#\J/^$GTO_GX'Y4?
M6:7\P>PJ=C9HK&_X2?2_^?@?E1_PD^E_\_ _*CZS2_F#V%3L;-%8W_"3Z7_S
M\#\J/^$GTO\ Y^!^5'UFE_,'L*G8V:*QO^$GTO\ Y^!^5'_"3Z7_ ,_ _*CZ
MS2_F#V%3L;-%8W_"3Z7_ ,_ _*C_ (2?2_\ GX'Y4?6:7\P>PJ=C9HK&_P"$
MGTO_ )^!^5'_  D^E_\ /P/RH^LTOY@]A4[&C>_\>4W^X?Y5@^#?^/.Z_P"N
MQ_D*9JGB>WEMGM[-6EED7:"!P,UH^'-/;3]- D)\R0[V'H:Y^=5<0G#9(W<'
M3H-2TNS8HHHKO.,**** "BBB@ HHHH **** "BBB@ HHHH **** (+S_ (\;
MC_KFW\J\V^#OW=>_Z^$_DU>DWG_'C<?]<V_E7FWP=^[KW_7PG\FK6/\ #D93
M^-'J%%%%9&H4444 %%%% !1110 5XE^T4GFVGAM-Q7=<RC(ZCA:]MKRKXU>&
MM9\11: -(L);LV]P[R^7CY 0N"<GV- %:T^#5Q-9P2_\)UX@3?&K;1,<#(^M
M=?HGA1_"?A;5;5]8OM3,J/)YEVVYE^3&!STXKI[)&CL+>-QAEB56'H<"I98U
MFA>*091U*L/8C% 'DOP#(.B:X,]+\Y_6J_C&1&^/_A! P++NW 'IE:HZ5I?C
M[X;:WJL.C:"FL:;?3-,@1\>62>,D\YQQBG0>#O%]Q\4O#GBK5K<RR3.9+L0@
M".T4*0BGIDX(SQUH T6LH+S]IF7ST#^1I:S1Y_A8;0#^IJ_\?$4_#D.5&X7L
M.#CD=:MP:#JB_'JYUQK*0:8VEB$7/&TO\O'KV-3?&+0]2\0>!?L.E6<EU<_:
MXG\M,9VC.3S0!R?C\F]\3_#ZRNHA):FX0D.N0Y)4$'UZ"O8+^QL[W2[BRO(T
M-I)$8Y%)P A&#].*XOQIX(O?$WAW2#8SBUU?3&$MNSD@*W&<X^@KEKK5_BMK
M6CMX??PS':/.I@EU%W!4J>"<=LCO0!+\6K#2]*^$2:?H[1FQMY%6,))OQEP>
MN3W-7/B1_P D-M_^O.V_DE2^(/AK-'\'1X:TT)/?P*K[L;?-?=N/U..!GVK-
MU.V\7^)OA)=Z3>^&I+2^MQ#!;PJX8S(H7YO;I0!D>,<7U[\-=(NY-NG36<4D
M@)XW!!BO=9K:![)[9XD\@IM*;1MQCTKSSQ-X N?$O@#1+>%EM-9TVWA:(N/X
MU0 H3V&?Y5C?\)%\6)[(Z0?"\<=PP\HZDSC9Z;MOI0!A>%HX['0?B9I=I(QT
M^T.VW3>650=_3\A78_ :".+X=[U4;GNY"S8Y/"T[2?A[/X9^%VJZ7'B\U>]@
M8S.@Y=R.%!/4#G&?6M'X0Z+J.@^!4LM4M'M;D7#L8WQG! P>* .2TE%B_:1O
M@@V^9 [/CN=IJ:?X@0P^)=0M? ?A/^T=0\S;<W 41QO@#.#D=_6M"P\-ZQ%\
M=;C6WL)5TQH&47!QM)*GWS6%IVF^/?AMK.IP:/H4>N:=?2M<JR,$*,3W/7/'
M3I0!SWCW5?%FKZKX;F\2>'[?2534(EBVNKNYW9ZY)Q[=*[KQM_R73P+_ -<Y
M?Y-7+>)_"WC_ ,3ZEHGB#4[ %HKM -/M\9MX@V26)QDY^O6NY\4Z%JNH?%KP
M?J]M8RO8V<<GVB;C$1(. >?>@#T>O*_C?K<\/AVV\/:>KOJ&K2;%C4#YT'WE
M_45ZI7E"^'-9U[XW?VSJ>G7,.D::A%F[R?(TBD88 'H: ,.VO/B)!X03PT?A
MY')8"V^S$-=@%DQCKNJ]\#]8N[)M4\'ZK"UO>64OF+&[Y(!ZH.>@QG\:]EZ5
MY-XG\+:WI?Q8TOQ7H%A]H@FQ%>K$!N4$_,QSZ@_I0!!I,1\&?'.]LV\I+'78
M#/'@[5BV@\>F25_6G^ $'BOXF>(O%CH3;6TGV2U60Y:-P &([8//YU>^,OA'
M4O$N@6=YHT$DFI6<H98X\!V!P,9]N372?#OPT_A;P=9V-PB"]8&2Y9>K.23S
M[@$#\* //O#<CQ?%KQS)&2'33&92.Q&VM3X"PQ2>%+S47(:^N[IFN&)RV03C
M-6?"GAO5+3XL>)-2O;"2/3KNU\N*5\;9#E<C\@:R?["\9?#?Q!J$WA?34UG2
M-0D,OV4$(T3'G\ ,D<4 3_$"U@B^,_@.X2)5FFF<2,!RVW;C/YFIC_R<R/\
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MHA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^&O^>ES_ -^O_KT?\+3\-?\ /2Y_[]?_ %Z+!=':T5Q7_"T_#7_/2Y_[]?\
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MOB0U)QV,_P#L33?^?*#_ +X%']B:;_SY0?\ ? K0HJ?8T^Q7M)]S/_L33?\
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M11[&GV#VD^YG_P!B:;_SY0?]\"C^Q--_Y\H/^^!6A11[&GV#VD^YG_V)IO\
MSY0?]\"C^Q--_P"?*#_O@5H44>QI]@]I/N9_]B:;_P ^4'_? H_L33?^?*#_
M +X%:%%'L:?8/:3[F?\ V)IO_/E!_P!\"C^Q--_Y\H/^^!6A11[&GV#VD^Y3
M@TNRMI/,AMHD?U50#5O%+15QA&.R)<F]PHHHJA!1110 4444 %%%% !1144=
MQ#+(\<<BL\9PX!Y6@"6BBB@ HHHH **** (+S_CQN/\ KFW\J\V^#OW=>_Z^
M$_\ 9J])O/\ CQN/^N;?RKS;X._=U[_KX3^35K'^'(RG\:/4****R-0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1110 4444 %%%% !
M1110 4444 %%%% "8I:** "BBB@ HHHH *\Y\=^&_&_B.]_L[3=4M;?0+@*+
M@\K,HS\P!'48[9&:]&HH IZ3IEOHVE6NG6D:)#;QA%"+M'N<>YY_&KE%% !1
M110 4444 %%%% !1110!PWQ7_P"1+E_ZZC^1K;\%?\B3HO\ UZ1_RK$^*_\
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M_P#_ .M1[4/JZ(_^$FT3_H)0?]]4?\)-HG_02M_^^JD_X5%X7_NWO_?_ /\
MK4?\*B\+_P!V]_[_ /\ ]:CVH?5T1_\ "3Z)_P!!*#_OJC_A)]$_Z"4'_?52
M?\*B\+_W;W_O_P#_ %J/^%1>%_[M[_W_ /\ ZU'M0^KHC_X2;1/^@E!_WU1_
MPDVB?]!*#_OJI/\ A47A?^[>_P#?_P#^M1_PJ+PO_=O?^_\ _P#6H]J'U=$?
M_"3Z)_T$H/\ OJC_ (2?1/\ H)0?]]5)_P *B\+_ -V]_P"__P#]:C_A47A?
M^[>_]_\ _P"M1[4/JZ(_^$FT3_H)0?\ ?5'_  D^B?\ 02@_[ZJ3_A47A?\
MNWO_ '__ /K4?\*B\+_W;W_O_P#_ %J/:A]7(_\ A)M$_P"@E!_WU7*>,=;@
MUV.VT32)5N9KB0!ROW5YXY^M==_PJ+PO_=O?^_\ _P#6K=T+P7H?AUO,L;0>
M=VFD.YQ[9I.K=%1H).YKZ= ]KIEI;R8WQ0HC8Z9"@&K-)2UB;A1110 4444
M%%%% !14%M=V]W&7MYDE56*$J<\@X(_ BIZ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *6DI: $HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH S=1\/Z3J^W^T-/@N".F]:S_\ A _"O_0#M/\
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MSG?^$#\*_P#0#M/^^31_P@?A7_H!VG_?)KHJ*+@<[_P@?A7_ * =I_WR:/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -^#7,?V'IG_ #Y1?E1_8>F?\^47Y4?57W#Z_'L=/_PMOPK_ ,]KG_OP:/\
MA;?A7_GM<_\ ?@US']AZ9_SY1?E1_8>F?\^47Y4?57W#Z_'L=/\ \+;\*_\
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M6_OD!4N0.I_VOKZUZB#D CO6;5C=.XM%%%(84V218HVD<@*JEB?04ZJNI_\
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M-U=O'&J&/.Y9-W!Z8 H2N-R:1]!UGV&N:=J=U-;6EU'+-#GS%4Y*X./YUA>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^OM>83W8>UL@/O,,,_T!_G77>$OAG!9A+S6@LUQD,D/\*8]?4_I7HRJJ*%4
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M!E89!!R"*+A8?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:_YGJM%%%:GFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:_US7/$FF_V; ITF%Y(2KDF4CH#]:Y[X*_\ (R>*O^O@_P ZB^$__)4_%_\
MN_\ LXH [_X>^,QXT\/M>311V]]#*T5S;H2?*8$X&3[<U67QM=7/Q,E\*V5I
M!);VT FN+AG.0.. !QG)[UQND7<?PZ^)WB'3KB0Q:?J,+7EIYG26; 9L?^/"
MM/X,V!NM.U;Q5<1J)]6NY)$!'S1J&/RY].GY4 68O'VNZQ;>+(--T2&YN=)N
MOLT<:R$>8IWY8YZ?='YUR'P0U;Q-'I+6%IH<4FEM-(YOGDP%DX^4@<X_"N@^
M&'_(?^(W_7__ /'*G^ ?_(@R\?\ +[+_ $H Z'X>>.&\9Z=>-=016M_:W#1R
M6Z%CA>,,<^O/Y47WC*Z3XDV7A2QM8)DEMS//.SG]UC/''?COZUQR7,?@7XY7
MQN)EATS6[<322R+@"0;L*#_GK5SX1V\NKZSXC\87*[9+^Y,*+CC:N,,/K0!Z
MQ1110 4444 %%%% !1110 4444 <-\5_^1+E_P"NH_D:V_!7_(DZ+_UZ1_RK
M$^*__(ER_P#74?R-;?@K_D2=%_Z](_Y5L_X2]3%?Q7Z&]1116)L%%%% !111
M0 4444 %%%% !1110 4444 >+ZQ_R5>\_P"N)K7K(UC_ )*O>?\ 7$UKUZ6'
M^ \7&_Q HHHKH.0**** "BBB@#+U/Q%I&C2+'J%ZENSC*A@3G\A5#_A/?"__
M $%X?^^6_P *V+O2["^8-=V5O.P& 98PV/SKS7Q#I=A#\3-+M8[*W2W>)"T2
MQ@*?F/45A4E..J.FC"G/1WN=YI_BS0M5O%M+'48YIV!*H%8$X&3U%:%[J%II
MUNT]Y.D,0ZLQJ*VT72[.<36VGVL,H& \<2J1^(K@;. ^//&%W+?&3^S-/?;'
M%_"S@XP?YTW.2TZB5.$FVM$CJAX\\,,P4:O"23_=;_"MZ">*YA66"19(VZ,I
MR#69+X7T.6%XSI5FH88RL*@C\<5D^$/#^I>')[RVDDB?37<M OF$LG/'!&.1
MUIIS3LQ.-)QO'?S+]SXT\.V=S+;7&J11S1,5=2K?*1VZ5%_PGGA?_H+Q?]\M
M_A6#X3TRQU#Q)XI-Y9P7!2]^4RQAL<MZUTE_X:\.O9R1SZ?9Q(ZD%E14(^A'
M2I4ZC5U8MTZ49<KN;4,T5Q$)(9%=&Z,IR*?7G7PJFO#9W]NZG[#')^Y8^O<?
MEBO1:TA+FC<QJP]G-Q"BBBK,PHHHH **** "L#QC_P B_+_O+_,5OU@>,?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWT'\Z:W$RSX5_P"13TG_ *]8_P#T$5KUD>%?^13TG_KUC_\ 016O0QA1112
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ME:3X,LX&MHIWNH%EFDD0$OO&<?@#BN-^$T)BU?QII=IB*$74J1H.BX+*OY4
M=?K?Q8\):!JDFG7E[(UQ$<.((RX4]P2.X]*W/#7BW1_%EFUUI%T)50X=",.G
MID=J\8T/6[GX8"^T_P 0^%GO5,^[^T%3(?.>2Q!!_"N[\ :AX*UC7M0U+P_(
MT>H3@//;N-G7.2HXS^% 'H]%%% !1110 4444 %>>>#_ /DJOB+_ 'S_ %KT
M.O//!_\ R57Q%_OG^M-;"9ZE1112&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!!>?\>-Q_US;^5>;?!W[NO?\ 7PG\FKTF\_X\;C_KFW\J\V^#OW=>
M_P"OA/\ V:M8_P .1E/XT>H4445D:A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '#?%?\ Y$N7_KJ/Y&MOP5_R
M).B_]>D?\JQ/BO\ \B7+_P!=1_(UM^"O^1)T7_KTC_E6S_A+U,5_%?H;U%%%
M8FP4444 %%%% !1110 4444 %%%% !1110!XOK'_ "5>\_ZXFM>LC6/^2L7G
M_7 _SK7KTL/\!XN-_B!11170<@4444 %%%% !1110 4444 %%%% !1110!'/
M+%#"\LS*L:*2S,< #WKE$\[QC<HVQH=#@D#+D8:Y93D'V7/]:ZJXMXKJWDMY
MT#Q2*5=#T(/6LJ/PEH42A4L%51T"R. /UK.<9-^1M3G&*=]S950JA5& !@#T
MI:15"(J*,!1@?2EK0Q"BBB@ HHHH *P/&/\ R+\O^\O\Q6_6!XQ_Y%^3_>7^
M8J*GPLUH?Q$>Q:+_ ,@+3_\ KVC_ /015ZJ.B_\ ("T__KVC_P#015ZO)/H
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M_#>EHZE76TB#*PP0=@XKS/X:Z=J$'B7QDS6\]LTUU*8))(RH)+'!&1S7KM%
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M?_0VQ?\ ?O\ ^M7IE%'LXA];J=E]R/,_^$,\=_\ 0VQ?]^__ *U'_"&>._\
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MDXRLBY-5:+FUJF>E4445H<84444 %%%% !1110 4444 %%%% !1110 4444
M07G_ !XW'_7-OY5YM\'?NZ]_U\)_)J])O/\ CQN/^N;?RKS;X._=U[_KX3^3
M5K'^'(RG\:/4****R-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,EO&K ]B%%7***XST HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKPS_ -A)/YBO1%^Z*\[^*7_'UX9_["2?S%>BK]T5*W9M/^'$6BBBJ,0HHHH
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M0_ *Z_KFG-!>+%NFM8R#L?GC.:P!HLW@SX%WUM [6]]%I\DTDD3$$2E>6!_
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MBL3RO3KU6O4Z /*?%GQ(\2Z9X^F\,:#H,.HR)"DHS)M8Y )]N]0_\)G\5O\
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MZ9H ]IHKRGP_I'C3PMXRM;5=5NM=\/7(+37,QWLAP0!DDXYQTKU:@#AOBO\
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M *"-O_WW7@G]@6']Q_\ OLT?V!8?W'_[[-'U"IW#^UZ/F>]_\)!I'_01M_\
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MY1_#N*X_D: /H#2KB2[TJUN)<>9)&&; QS5RL[0/^0!8_P#7%?Y5HT %%%%
M!1110 4444 %%%% !1110 4444 %%%% %'6O^0)>_P#7!_Y&N#^#?_(#U/\
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M\+B)Y=-6-HPLK;FP23G/J">*YO0OA+IFC66HV!O[R:QO8O*,)DQL7<&X]^*
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M_P#KVC_]!%7JHZ+_ ,@+3_\ KVC_ /015ZOG3[(**** "BBB@ HHHH ****
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M$_C1]3W_ $7_ ) 6G_\ 7M'_ .@BKU4=%_Y 6G_]>T?_ *"*O5\Z?9!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2TE+0 E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&_\ H,6WYFC_ (37PW_T&+;\S1R2[!SQ[F]16#_PFOAO_H,6WYFC_A-?#?\
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M]^:]%\/Z>^E>'["PD8,]O L;$="0*TDFJ:3,XM2J-HTJ***Q-@HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "EI*6@!**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .M1_P *A\+?W+O_ +__ /UJ[RBCVL^X>RAV.#_X5#X6_N7?_?\ _P#K4?\
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M .M1_P *A\+?W+O_ +__ /UJ[RBCVL^X>RAV.#_X5#X6_N7?_?\ _P#K4?\
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MSUM_^_\ 1_PKCQM_SUM_^_\ 1]?I]@_L>KW16HJS_P *X\;?\];?_O\ T?\
M"N/&W_/6W_[_ -'U^GV#^QZO=%:BK/\ PKCQM_SUM_\ O_1_PKCQM_SUM_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***8)8VW8=3M^]@]*5T@'T5!'>VLS[([F)V]%<$U/0FGL%PHJ*6
MZ@@QYLT<>>FY@*='+',NZ-U=?53D4<RO8+H>:*IWUI'=/;EYFC,;[E"MC<?2
MK195(!(!/ R>M%]=1#J*C:>)9%C:1 [?=4L,FO/_ !7?7OB/QI;^";#4&L(?
MLYNKZ:(?O&08 12>!G=GIVIWN,]$[45YW-\']%>SCBBU'5()H_\ ENER=Q/O
MGC]*Z/PIIVOZ9:36VN:G'J.'_<S;-K[?]KM^E '0T5X39>%T\:?%KQE:7VIZ
MA!#9R(T2V\VT<_\ ZJZC_A2>D_\ 0=UO_P "1_A0!Z=17+^$_!%IX0-P;6_O
MKKSNOVJ3=CZ5S][JFL>.?$-UI&@7[:=I.GMY=[>Q@&29R,&-<YQC)YQVH ](
MHKR^_P#AYH&FV,=C(-6F:0$M?K.Y>/\ +C]*@TS6-5\#:MI]I?ZB=3\,W["&
MWO)R ]L?X0YX'3/7GBI4TW85U>QZO12 @C(I:H84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !14-Y<"TLI[EE+"&-I"!WP,
MUB>"_%</C3PW#K4%K);1RNZ".1@2-IQU% '0T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %+24M "4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *6DI: $HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O+<7=E/;,Q
M431M&2.V1BL7P5X4A\%^&H=%@NGN8XW=Q(ZA2=QST%;=W<"TLY[E@2L,;2$#
MO@9K&\'>*+?QCX=BUBUB>**1W0*XY^4XH WZ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!!,_\ ?!_QH_X0V[_Z"9_[X/\ C4>VJ_R$\\^QU^]?[P_.C>O]X?G7(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07MO]LL;B
MVW;?.B:/=C.,C%87@7PH/!?A:'11=FZ\J1W\TILSN.>F37244 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2TE+0 E%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',^*_];I?_7R/Z5TH
M^Z*YOQ9_KM+_ .OD?TKI%Z"L*?\ $D1'XF+1116Y84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>^&;&<'NA_E7/^"_
M^/&Z'_3<_P A707O_'C/_N'^5<_X*_X\KK_KN?Y"N:?\:)G+XT=111172:!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSXS_ /?7_P!:N#\J/_GFG_?-'E1_\\T_[YH^I>8?ZP+^0[S_ (7-I'_/C/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!S7BS_ %VF?]?(_I72CH*YKQ9_KM,_
MZ^1_2NE'05A3_B2(7Q,****W+"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KP'Q[X[\:6OQ+;P[X?O2/-*I!#L3ECGNPKWZOF#Q]K$/A_P"/$.KW$;R0
MV<L<KI'C<P!/3- &O?\ BKXO^$1'J.M6IFLU.60JC*0.N[9R!7J/PU^(4/CW
M1Y)7B6WOX#B>%3D>S#V^OI7G'BKX]:-K?A?4=+M-)OXYKN!H0\VS:NX8SPU3
M? ?0-5TG2-:UXVI+3Q>7;V[C:TC+EAU['.* />**^?(/!GC;Q!JE_J/B?Q)-
MH!D<F&$WFS=QQ@*< =OP-5/A5XJUO2_B.WA>YU)M2M;B5T,DDIDP54G<I//:
M@#T^\/CS_A:<'V93_P (IE?,.8_^>?/^U]ZN_KPK5]3U!/VFK*Q6^NELV,>;
M<3,(S^XS]W..M8GQDU_5](^)L0T^^NHU6*,K"DS*A) [ XH ^CI-WEML^]@X
M^M<'\.CX[^TZG_PF*D1?)]DYC/=L_=_#K7(> _!WC>P\3Q:MXBOKJ2VEM9)'
MC-RQ$4G&%9<X]>G%0_L_ZGJ&H:CXC6]OKFY$?E;!-,S[>7Z9/% 'N=%?*/A#
M4O%FN>,;_0M-UJXCDO/,0R3S.PC09W;<YP<=Q5KQ,?%?PF\8V,G]OW5_$R"5
M?-F9U922&5@W&>#S]* /J2BO)/BO\1+S0/"&FKIKI%?ZI"KL>IB1ER2/QXKE
MM,\ >.K/PU#XFM_%$[W8B^TK;23NZF,KGD'C.#0!]"45\^_ ?6M2U;Q3J9O;
MZYG0PEPDLS.J_,.@)KZ"H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"O>_\>,_^X?Y5@>"O^/*Z_Z[G^0K?O?^/&;_ '#_ "K \%?\>5U_UW/\
MA7-/^-$S?QHZ>BBBNDT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \'
M\9?\E)N_^N=4ZN>,O^2DW?\ USJG7JX7X#X[.O\ > HHHKI/'"BBB@ HHHH
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M][90Z,IZ,,&N:\*> M"\&37DNCQSHUWM\WS)2^<9QC/3J: /!/@U_P ED?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ'T7_D!:?_U[1_\ H(J]5'1?^0%I_P#U[1_^@BKU>(??!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2TE+0 E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'->+/]=IG_7R/Z5THZ"N8\7,J-IKL0%%P"2>U=)&X>-64Y4C((K"G_$D1'XF
M/HHHK<L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (;JTM[ZVDMKJ%)H9!AT<9!%<W_PK7P5_T+&F?]^!7544
M 06EG;6%K':VD*0P1J%2-!@*!V%3T44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!7O?\ CQF_W#_*L#P5_P >5U_UW/\ (5N:E*L.FW#N< 1G
M^58O@M'73IW*D+)*64GN,"N:?\>)F_C1TM%%%=)H%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%% @HHHH *SM9_Y![?4?SK1K.UG_D'M]1_.HJ_ SKP7^\0]3Z'T7_D!:?\
M]>T?_H(J]5'1?^0%I_\ U[1_^@BKU>(??!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2T
ME+0 E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2TE+0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g0vsdaj33nnl000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0P"!L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ I.]+47E_O-^X_2@"2EI*6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HHHH
M**** "BBDH 6BDI: "BBDH 6BDHH 6DHHH 6BDI: "BDHH 6BDHH 6BDI: "
MBDHH 6BDHH 6BBDH 6BBDH 6BDHH 6BDI: "BBDH 6BDHH 6BDHH 6BBDH 6
MBDHH 6BDHH 6BDHH 6BBD- "T44E "T4E+0 44E% "T4E% "T4E% "T444 %
M%)2T %%)2T %%%% !1110 44E+0 44E% "TE%% !FEI** %HI** #-%%% "T
M4E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1>8?.V;>/6I:3
MO0 "EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BDHH 6BBDH 6BDHH 6BBDH 6BDHH 6BDHH
M6BDHH 6BDHH 6BBDH 6BDI: "BBDH 6BDHH 6BDS10 M%%% !124M !1124
M+124M !1244 +124M !124M !1110 44E+0 E+244 +1124 +1124 +1244
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M[-'T;15/3)Y[G38)KF+RIG0%DST-7*\9JSL=BU%HHHH&%%%% !1110 4444
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M.SE3C<^8]0 &IW0 P!*V/S-?0'A2RMG\*Z6S6\;,;9,DJ.>!7S_J/_(4N_\
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M[;2;[=$N""5E48.??UKP34;*?2-4EMWW+)"_!Z'CH:^G37@_Q+1%\6S,IR6
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M5ZQ59E)_69:BPT5[-'%?$T!?"$B@  , ,5Y1X)94\9:6S$ ";DGZ&O6/B?\
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M\4[TTSU/X;?\BK%]378]JX[X;?\ (JQ?4_SKL>U>?BOXTO4Z*7\-'S[\0O\
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M0]5->1BL)7H*TOA.RE5IS>FYL4"B@5P'0+1110 4444 %%%% !1110 4444
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MN*[,'3E4P3A!V9A6DE6NSZ"_X1'P]_T"+3_OV*4>$O#ZL"-)M 1T_=BO%/\
MA/\ Q)_T$7H_X3_Q)_T$7KE>6XJWQ?B:K$4NQ]!X 3 ' &*^9=9_Y#-Y_P!=
M37T-X=N9;SPY8W$[[Y9(@S,>YKYXUG_D,W?_ %U-7DZM5FF+%N\4SWWP2?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 AKSCXK:R(-*CTU"-\QW-SR
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M%/,O]YD+#?PT<7\3_P#D4I/]\5Y'X0MH;SQ9IL%Q&LD3RX9&&01@UZY\3_\
MD49/]\5Y1X'_ .1TTK_KM_0UZ. E;!3:.>NOWR/<!X0\/?\ 0(M/^_8J*X\)
M>'UMW(TFU! Z^6*Z"HKG_CVD_P!TUXL:L[KWF=CIQML?,0 74MH& )< ?C7T
MKI?_ "";;_KF/Y5\U_\ ,3/_ %V_K7TII?\ R"K;_KF/Y5Z^;.\(')A59L\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#QVWFR*<J\O)%=,!@  8 I:6IG4G-WD[CC",=@I*6BH*"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&O=!T%>??":YTBY\+1FPMXH+A/EG ;+$^IKT$5A6?O6[&D-KBT445D6%%%%
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M 4444 %%%% !3-Z[MN>:?3/+7S-^.: '4M(*6@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HHHH *AN;=+F(QR=#4U% '//:WNE,9+=C)".J^U:UC=B\MQ*%*]CFK1
M(P12*BH,*H ]J '44QF5%+,0 .Y-.!R,B@!:*2EH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F>8OF;<_-
M3Z9L7?NQ\U #A2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHI"<#-  :@N[C[-;M+M+;>PJ56#C*D
M$>HIQ4,"",@]J .>$5]J[EI"8H,_=K:M;9+2$11YQ[U.  ,  44  I:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2*6C95."00#3
MZ* .>%U>Z7*1<9DB)^]Z5LVUW%=Q[XF!'<5))$DJ%74,#ZU#:V4-F'\H8W')
MS0!:HI!10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %9FJ:@UJ!%$I:5NG%:=1M"CL&906'0D4 ,M3*;=#,,
M.1SBIL4M% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"K>VWVJV:+<5)[BLB"[N-+E6"ZRT70-Z5T&*AN+6
M*YCV2KD4 2(ZR(&4Y4]#3J9%&L,:H@PH' JEJ>I)9184[I3T% &AFEK-T>Z-
MU:;F;+@_-6E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5%^\\WMLJ6F;UW[,_-Z4 .%+2"EH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0 49JEJEPUM
M8NZ'#=JJZ5JRW*^5*0)0/SH U6<*N6. *P[R_EOY?LEF#@_>85MNBR(489!&
M#4-I8PVBD1+UZD]: $L+3[';B/>6[G/K5NDQ2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)BEHH AN#(L+&( O
MC@50TW499Y6MYXRLB\YQ6IBFB-0Y<* QZG% #J6D I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *3-+3>M %#4]32RCPI#2GH*Y.:5YY3)(Q+$UTEWH4=Q(9%F=6/8\U
ME3:'>Q?=4./]DT 6O#<V)98>Q&X?6NDKCM/\RSU*)I(V'S;3^/%=C0 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6]I>0S31_?1&R5^M+-K&GV^H1V,MY$EU(1LB+?,V?2O(/A.2?'^O D_>D_\
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M:3_UV_J*])O9'B\/2R1L5=8<@CMQ7FWQP_X]M)_Z[?U%>CZA_P BU-_UP/\
M*I?PQ*7Q,XCX/:M?ZMIFH/?W4EPR3D*7/05E>,/%6L>)?%)\)^&I?):-L33J
M>N.3CVJQ\#O^01J7_7P:R?A,\5KX\UVWO1LO')$8<?-U)/Z5=DI2?8F^B19?
MX0ZQ;6GVRTUR;^TP-QYX)K3^''C;4;G5KCPYX@RM]#Q&2N"V/7\.:]2[9KQ&
M4K=?'YC8XRI&]E((/[OFE&3FFI%-<KT-/XR:YJND7.EC3+N6%G/*H?O'-5;?
MX=>(O%5I_:6N:Q+%/( \,2\!,\X-+\:O^0QX?_ZZK_Z%7L47$2C':FY<L%82
M5Y'C7A/6M:\'>,X_"^M3M<03G;"Y['M^%;_Q;\3WVBZ=9V5A*8);UBIF_N 8
M_P :PO'/_)9O#O\ OI7I'BGPOI_BK238WPP3_JY <,A]12DU>,F"NTTCS(?"
MO5I--35;'7I9-191("&X)KT_PG8:IIV@06^KW?VFZ7[SX_2O*;WPKXW\ Q27
M^E:J;NQA&^1">BCG!!_I7HOP]\7/XQ\/?;)X!#<1.8I0OW2< Y'M@T5;M7W0
M1T=CK:\<\6>+=9\3>)F\->%W9$0[)YU'0CKSV]*]C[5XE\*I8X?B/XDCF94D
M>24(&."?WN>/PJ:6EY%39-+\(=9M;<7MEKDO]HCYCD\9]JV?AQXUO;F[E\-:
M]\NI6N5#L<%\<8]S7IQZ<UXG-)%=?M Q/9$/&BJ)#'R PZY_&JC)U$U(EKE>
MAE_&32M7M]36]N;WS+&9SY,/]S_/%=3X&\*^+K2[L;Z\UGS=/VAO)SV]*A^.
MO_(*TW_KHW]*]+\._P#(O6'_ %Q6G*;]DA**YC3I:2EKF-@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J+$GF
MYS\OI4M1^8OF;,_-0 ^EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!*\X^-O_ "(/_;W'_)J]'KSCXV_\
MB"/^ON/^35=+XT3/X69\_@U?%/PIT8VZ*+^&T1HG[].E9OA3XG)H.@W6EZ[O
M%_8J1&&_Y:>@KT7P'_R(>B_]>B?RKF_%WPGLO$FNV^I0SBVRX^U*!]]?;T/6
MM8SBWRS(:=KQ.9\!Z!>^-M?E\3Z\CO;ALVZN.#Z8]JSO"R!/CHRJ,*'D '_
M#7N]G9PV%G%;6Z!(XU"@ 5X5X7_Y+L_^_+_Z :N$^;F]!25K'H?Q7U"[TSP9
M+<65P\$P< .G7K6MX4N)KOP39SW$C22O; L[=2=M8'QE_P"1$F_WU_G6WX,_
MY$'3_P#KU'_H-96]Q%7?,><_";_DH&O?[TG_ *%4WB[_ )+OX?\ ]^*H?A-_
MR4#7O]Z3_P!"J;Q=_P EX\/_ ._%6K_B/T(^R=Y\1[VYT_P/?W-I,T,R+\KK
MU%,^'6H7%YX$L;R]G:20H2\CGK4?Q3_Y)]J/^Y_C6/X2CFF^"CQVX8S/92A
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MX7,?PQHW]@>'+/32X=H$PS#N<Y_K6LZAT*, 5(P0:=BC%9MW=RCQK7? >O\
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MQ+$#M;U4XS@UG*$EJT-23-6EI*7O4E!1110 4444 %%%% !1129H 6BDS2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !47
MF+YFSG-2TG&<\9H *6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^%[#0/&>F36">6ES*K-&.@.>U>@?$GQ%)H'P_C^S3>5=W(6*,CTXW?H:\O\
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MT)-%VU5R3XC>"=(D\)7-Q9V,%O<6XWJ\:XZ59^%NJ7&L?#Z,2$F6!F@#$\G
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MZEMT'UJ/8]4HJCI*7"Z;#]JD,DQ7+,?>KU<+5G8Z4[H6BBBD,**** "BBDH
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M&"0>HHKZ'<\L****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 444'I2&;'AO3_M^JH"/DC^8YZ5Z<JA5 ' %<_X3TS['IJS
M,O[R;D^P]*Z&O Q=7VE1^1Z>'ARQ"EHHKE-PHHHH **** "BBB@ HHHH 2EH
MHH **** "DI:* "DI:* "BBB@!**6B@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** $I:** "BBB@!*,4M% #<4N*6B@!**6
MB@ I*6B@ I*6B@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**6B@!C
MJ'0J>A&*\LUW3CINJ21*N(V.Y/IZ5ZK7,>,=-^TV(N4'SQ?RKKP=7V=379G/
MB(<T;]CSZEI*6O?/-"BBB@04444 %%%% !1110 4444 %%%% !1110 444E
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M0AS2.C50JA0. ,4ZBEKP#U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 )12TE $-S ES;O#(,HXP17D^
MHVC6-]+;OU5N#CJ*]>KCO&FFAHTO8U^9?E?'<5VX&MR3L]F<V)AS1NCB>U%)
M17NGG"T444""BBB@ HHHH **** "BBB@ HHHH *2EI*!GH7A>T&G:(]S(,,X
M,A^@_P#U5STOB[4C*^QUV;CMR.U9C:Q?M:_9C<MY6,;0,<51KAIX3WI2J:W-
MY5M$HG?^&-<FU1YH+I@9 ,K@=JP;VR-CXK10/D>3</QK$M;J>SF\VWD*..,B
MI9]2N[FX2>68M(GW6P.*7U649MPV8_;)I7.X\:?\@$?]=5_K7#Z?J$VG72SP
MGIU'8T^ZU>_O8?*N9R\><XP.M4:TP^'<*;A,FI5YI<R/5M-U.+4]/\Y"-V,,
M/0UY=<?\?4O^^?YU+::C=6.[[/,4W?>QWJN268LQR2<FEA\,Z,V^@5*W/%7.
MH\#?\A*X_P"N7]:I>*_^0W)]!_*LNSOKFPD9[:4QLPP2 .13+BYFNY3+.Y=S
MW-.-"2KNIT$ZB]GRE[P[_P C!9_]=/Z&ND\<?\>\'^]7%P3R6TZ31-MD4Y4U
M/>:G>7ZA;F<R = 0*)X>4JRJ=!QJ)0Y3H_"FNQ0+]@NFPI/R,3P/:M#4_"EO
M?N;BUD",W/'0UP/2KUKK.H68*V]TZ@]CS_.LZF%FI\])V*C67+RS.GL_!*HP
M:ZGW '.U:E\1:M9VFG?V=;;6)7;A3D+7+W&O:G=)LENW*^V%_E6<26.22<]<
MTHX6I.7-5>PW6BE:".W\##-C=CU?^E-G\%&:XEE^T8WL6_,URMGJ=Y8*RVTQ
MC#')P <U:_X2/5O^?QO^^1_A42PU95'*#W&JL'&TC7N?!A@MI)?M&=HSBF>"
M/^/^;_=K(D\0:I*A1[IBI&"-HYJK:7US8.7MI3&Q') %:>QK3IN,WJ1[2$97
M1;\1?\AZ[_WS6GX8U\64GV6Y8^2Q^4GL:YR>:2YF::9]TC'+&HZV=!2I*$B5
M5M/F1Z/XN97\.R,I!!9<?F*\XJW+J=Y-:?99)V:$8^4BJE+"T'1BU(*U3G=S
MH_"L&GW$DT=V5\TC"!CQC_&KMUX(<RYM9QL)Z-VKD Q5LJ2".XK2A\0ZK;QA
M([QPH]0#_.HJT:O.YTV.$X<MI([NUAA\.Z*4EFRJY))/4GM7,^&IOM/B.6?&
M-Y)K!N]0N[YRUS.\GMV_*F6MY/92^9!(4?U K.&#DH2N]67*NFU;9&YXT_Y#
MB_\ 7)?YFN<JQ=WEQ>S>;<R%WQC)QTJO750I>S@HLQJ3YI7+FE_\A2U_ZZ+_
M #KT#7=".L>5B39LKS6.1XI%D0X93D&M/_A(]6_Y_&_[Y'^%88C#U)S4X=#2
MG4BHVD;O_"#'_GYK!O+9]"U50C[FC.X&E_X2/5O^?QO^^1_A5"YNI[R;S9Y"
M[^I%.E3K7M4=T$YPM[IZ)!<V/B33?*<KYA'*GJI]JQ)? \GFCRK@&/WZUR<4
MTL+;HG9&]5.*TU\2ZNB[5O&P.F5'^%9?5JM-_NGH5[6$E[Z.LMM$TW1+662Z
M=7+*<E_3T%<UH9B;Q1&8!B(L=H/IBLJYO+F[<O/,[DGN>/RID%Q+:SK+"Q21
M>C#M6D,+-1?,[MDNK&ZLCI?'/_(3MO\ KE_4UK^&_P#D6Y?]UOZUPUY?7-_(
MKW,ID91@9'05+;ZM?6T!AAG*QG@K@5,L+)TE#JAJLN=R*C_?;ZTE!Y)/K25W
M)6C8Y[ZW/3M*_P"15M_^N _E7 Z;J#:9J2W R5#?,/441ZWJ,5L+=+EA$%VA
M<#I5#J<GO7'1PSCS*6S-YU;VMT/2[BWT_P 26*E74MC((/*UA#P/+YV#<#RO
M7O7+074]LX>&5T8'/!K1/B;5RI4WC8/^R/\ "LUAJ]/2F]"W5IR^):G4RZ;I
M&B:7*D^UF=><GYC]*RO!FW^TYM@PN#CZ9KF)IY9VW32,Y]6.:EM+ZYL7+VTI
M1B.H%6L+/V;3=VR?;1YD[;&KXP_Y&&7_ '%_E5#1?^0U:?\ 7056NKJ>\F,U
MPY>0C!.*9%*\$JRQMM=3E3Z5T1I.-'D>]C)S3GS'7^.NMG_P+^E<;5J\U&[O
M]GVJ4R;/NY XJK2PU-TZ?+(*LE.5T20_\?$?^\/YUW'BW_D!6WX?RKA 2""#
M@CH:MW.J7MW"L4\Y=%Z @5-:BYU(R6R*A-1BT4Z6BBNHQ"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JWIMD^H:A%;J/O'D^@JI7;^"]-V1O>R*-S<)G
MJ!7-B:JITVS6C#FE8ZR"%+>!(HQA5& *DH%%?/-W/52L+1110,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!#5>\MDNK62%QPXQ5FD--.SN)JZL>/WMLUI>2PN""K57KL/&
MNF['CO8UX;AZX^OHL-5]I33/*JPY96%HHHK<R"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH&%%%% @HHHH **** "BBBD 4444P"BBB@ HHHH **
M**!A1111H 4444""BBB@ HHHH **** "BBBD 4444P"BBB@ HHHH&%%%% @H
MHHH **** "BBB@ HHHH ****!ZA1110(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH L6%J]Y>Q0(.6/->L6ELEK:QPH,!%Q7(>"M-W&2]D
M7I\J9%=MVKP\=5YY\JV1Z.&IVC<*6BBN$Z@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU\ZVV[GK)65@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[&'8Y/\ X0:U_P">\E'_  @UK_SWDKK**/K-7N'L8=CD_P#A!K7_ )[R4?\
M"#6O_/>2NLHH^LU>X>QAV.3_ .$&M?\ GO)1_P (-:_\]Y*ZRBCZS5[A[&'8
MY/\ X0:U_P">\E'_  @UK_SWDKK**/K-7N'L8=CD_P#A!K7_ )[R4?\ "#6O
M_/>2NLHH^LU>X>QAV.3_ .$&M?\ GO)1_P (-:_\]Y*ZRBCZS5[A[&'8Y/\
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ME%'UFKW#V,.QR?\ P@UK_P ]Y*/^$&M?^>\E=911]9J]P]C#L<G_ ,(-:_\
M/>2C_A!K7_GO)7644?6:O</8P[')_P#"#6O_ #WDKH=/L8M/M4@BZ+W]:MTM
M1.K.:M)E1IQB[H2EHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *3%+10!R'Q"T ZSX>D>&/=<V
M_P Z8&21W'^?2O _:OJAU#J589!&"*^??'6A?V'XCF2- MO,2\0 P /0?2O?
MR;$V;HOY'GXRG]I',T445]&>>%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 % ZT5TW@30?[<\0Q"1-UO 0
M\H(R#['ZUC7JJE3<WT+A%RE9'K'@#0?[%\/1>8FVXG^>3(P1[5UE-10JA0,
M# IU?#5:CJ3<WU/:A'EC86BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 0BN*^(^A?VGH#3QIF>W^88';O7:U'-$LT+1N 5
M88(-:T:CI34UT(J14HV/EGH<&BMSQ=H[:+XAN;?;B,MN0XZBL.ON*-158*4>
MIXLXN+L%%%%:D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%='X(TFUUGQ EI=H6B*DX!K*M55*#G+H5&+D[(YRBO9+[P
MMX*TVX-O=R)%*!G:SX/-5;OX=Z)JVFR76AW)\P#Y0&!4UY\<VI/5II&[PTCR
M6BM?0]-2X\46>GW2Y1YUC<?C6_\ $/P]8:!<6JV4942*=V374\9!553ZLR5*
M7+S'$T9KTG2O %MKG@BWO+8F._92V2>&P3Q^E>>7=I-8W4EM<(4D0X((IT,7
M3K2<8[H)TI02;(<T5Z!\/?"VFZ_IE_-?1EWAD"J0>GRYKF;+3H)O&*Z>ZDP&
MY:,CV!-2L9!RG'^4?LG9/N8M%>V7G@GPEIY076V(N#M#/C-4W^'GAG5$9K"]
M*N1A51P1GZ=:Y5F])ZV=C5X61X_16YXF\,7GAF^$-Q\T3\QR#HU=9X9\):7J
M/@NXU&>(FX1'(;/H,UTU,=2C353=,RC1DWRGF]%=%X-TFVU?Q3%8W2YA8/D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN:]>Z_>?:+M\X^ZO8"LRBGA\!2H/F6K%.M*:L%%%%=QB%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *2EHH 3%>3_%?0-K1:O"@ ^Y+_0_RKUFLW7M-35=(N+1
MP#O0XR.AKIPE9T:JDC*M#GA8^9J*L7UH]C?36T@(:-RIS5>OMXM2BI+J>*U9
MV"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 5ZG\*=
MR9=7F0'^&(YS^->;:=92:AJ$-K$"6D<+Q7TCHNFQZ5I-O:1@#8@!XZFO$SC$
M<D/9K=G9A*?-+F9H4445\P>H+1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMM_T$YO^^1_A7J-%']HXG^8/J]/L>7?\*=MO^@G-_P!\C_"C_A3MM_T$YO\
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M  IVV_Z"<W_?(_PH_P"%.VW_ $$YO^^1_A7J-%']H8G^8/J]/L>7?\*=MO\
MH)S?]\C_  H_X4[;?]!.;_OD?X5ZC24?VAB?Y@^KT^QP_ASX<6N@:FM[]I>=
ME& K*.*[BBBN:K5G5ES3=V:P@H*R%HHHK,H**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_,'_ 'Z_^O1_PMGQ5_S\P?\ ?K_Z]']FU@^LP/HNBOG3_A;/BK_GY@_[]?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** $Q2%<C!Z4ZB@#YY^*WA_^R/$
MGVJ)=MO=@N.?XN_\ZX'M7TS\0/#X\0>%[B)%S<1#S(O7([5\SD$$J1@@XKZ'
M 5O:4^5[H\ZO#ED%%%%>@8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+2HC.Z
MHH)9C@ 4G9*X'>_"CP]_:WB/[9*N8+0!SS_%V_E7T&!@8%<SX"T >'_"UM;L
MF)Y!YDO^\:Z>OF,76]K4;Z'IT8<L1:***YC4**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &%0P(/0]:^<_B9X=.A^)I)8TVVMT2Z8(X/<8_*OHZN+^)/A
MX:YX:E>-<W%N"Z''/TKKP=;V=5=F8UH<T3YQ%%*5*L5;J#@TE?2IW1YH4444
MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "NV^&/A\ZSXFCGD3=;VN)&)/?M_6N*52[!5
M&23@"OH_X;^'AH?AF$R)BXG&]R1S]*X,?6]G3LMV;T(<TCL5    Z4ZDI:^=
M/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(Z+V_G7>U\UC:WM:CMLCTJ,.6("EI*6N,V"BBB@ HHHH **3-&: %HI,T9H
M6BBB@ HHHH **** "BBB@ HHHH **** "BDS2T %%%% !1110 44F:,T +12
M9I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>]T?[/9.I^8GD?I2>"-?BU>^UA8=.AMG@<99.LAYZ_E0!W(ZTZO/&\6>+@[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "M7PWH\FNZ]:V$8R'?Y^.-HY/Z5DU[1\'?#K0V\VL3IAI/ECR.U<N+K
M>RIMFE*'-(]3LK:.RLH+:)0J1($4>P&*L4E+7S+=STTA:***0PHHHH ****
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M9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44E%P+^C:9+J^K6]C$,M*X!SG@9KZFTC3XM+TNWLHEPL2!?Q[UY1\&O#[&6?
M6YD( _=PY^G)_6O917SV85N>IRKH=^'A97#%+117GG2%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE &;KFD6^
MNZ1<:=<_ZN9=N1U!]:\O_P"%&_\ 4</_ (#_ /V5>Q8HK6G7J4](,B5.,MSQ
MW_A1O_4</_@/_P#94O\ PHW_ *CA_P# ?_[*O8:*T^N5OYB?80['CW_"C?\
MJ.'_ ,!__LJ/^%&_]1P_^ __ -E7L-%/ZY7_ )A>P@>/?\*-_P"HX?\ P'_^
MRH_X4;_U'#_X#_\ V5>PT4?7*_\ ,'L('CW_  HW_J.'_P !_P#[*C_A1O\
MU'#_ . __P!E7L-%'URO_,'L('CW_"C?^HX?_ ?_ .RH_P"%&_\ 4</_ (#_
M /V5>PT4?7*_\P>P@>/?\*-_ZCA_\!__ +*C_A1O_4</_@/_ /95[#11]<K_
M ,P>P@>/?\*-_P"HX?\ P'_^RH_X4;_U'#_X#_\ V5>PT4?7*_\ ,'L('CW_
M  HW_J.'_P !_P#[*C_A1O\ U'#_ . __P!E7L-%'URO_,'L('CW_"C?^HX?
M_ ?_ .RH_P"%&_\ 4</_ (#_ /V5>PT4?7*_\P>P@>/?\*-_ZCA_\!__ +*C
M_A1O_4</_@/_ /95[#11]<K_ ,P>P@>/?\*-_P"HX?\ P'_^RH_X4;_U'#_X
M#_\ V5>PT4?7*_\ ,'L('CW_  HW_J.'_P !_P#[*C_A1O\ U'#_ . __P!E
M7L-1^:/-V;3]:/KE?^8?L(=CR+_A1O\ U'#_ . __P!E1_PHW_J.'_P'_P#L
MJ]AHH^N5_P"87L('CW_"C?\ J.'_ ,!__LJ/^%&_]1P_^ __ -E7L-%'URO_
M #!["!X]_P *-_ZCA_\  ?\ ^RH_X4;_ -1P_P#@/_\ 95[#11]<K_S!["!X
M]_PHW_J.'_P'_P#LJ/\ A1O_ %'#_P" _P#]E7L-%'URO_,'L('CW_"C?^HX
M?_ ?_P"RH_X4;_U'#_X#_P#V5>PT4?7*_P#,'L('CW_"C?\ J.'_ ,!__LJ/
M^%&_]1P_^ __ -E7L-%'URO_ #!["!X]_P *-_ZCA_\  ?\ ^RH_X4;_ -1P
M_P#@/_\ 95[#11]<K_S!["!X]_PHW_J.'_P'_P#LJ/\ A1O_ %'#_P" _P#]
ME7L-%'URO_,'L('CW_"C?^HX?_ ?_P"RH_X4;_U'#_X#_P#V5>PT4?7*_P#,
M'L('CW_"C?\ J.'_ ,!__LJ/^%&_]1P_^ __ -E7L-%'URO_ #!["!X]_P *
M-_ZCA_\  ?\ ^RH_X4;_ -1P_P#@/_\ 95[#11]<K_S#]A#L>/?\*-_ZCA_\
M!_\ [*D_X4=_U'#_ . __P!E7L5)BCZY6_F#V,.Q0T728-$TFWT^W'[N%-H/
MK6@*,45S-MN[-4K"T444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!'_P"^3_C1]4J![:)]*BBOFW_A=7B?TM_^^3_C1_PNKQ/Z6W_?)_QH^JU
M]M$^DJ*^;?\ A=7B?TMO^^3_ (T?\+J\3^EM_P!\G_&CZK4#VT3Z2HKYM_X7
M5XG]+;_OD_XT?\+J\3^EM_WR?\:/JE0/;1/I*BOFW_A=7B?TMO\ OD_XT?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"1TJ]2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]P'K6\\:2HR2*&5A@@C(-.^HCQ;X<:E)K'Q'N]0E14DN$=V5>@.*/$&F^?\
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MPW#W$:9(D?&3GFM>J]G;+9V<%LK,RQ($#,<DX&.:L5(PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M444 %%%% !1110 4444 &*2EHH *2EHH **** "BBB@ HHHH ,4444 %%%%
M!1110 G%%+10 F*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DHHH \8^.'A;S
M((/$%NGS1_N[@*O)'9B?08Q^->&9K[*UK38M8T>ZL)TW1S1E2#7R)K>E3Z)J
M]SI]P"'A<KDC&1ZUZ6#J77*^ARUHV=RC124M=IB%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445HZ%
MI$NN:W:Z=$#NF<*2!T'<TF[*[!*[L>Q_ _PL8;6;Q!<Q@--^[MPR<A>[ ^AS
MC\*]EQ5'2=/ATO2K:Q@0+'#&% %7A7BU9N<FSNA'E5A:***S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $KS#QY\*6\6:RFHV5W!
M:.5Q+O5B7]*]0I*J$Y0=XB<4U9G@O_"@=2_Z#5K_ -^VI?\ A0.I?]!JU_[]
MM7O-%:_6:O<CV43P;_A06I?]!JU_[]M1_P *"U+_ *#5K_W[:O>J*/K-7N'L
MHG@O_"@M2_Z#5K_W[:C_ (4%J7_0:M?^_;5[U11]9J=P]E$\%_X4%J7_ $&K
M7_OVU'_"@M2_Z#5K_P!^VKWJBCZS4[A[*)X+_P *"U+_ *#5K_W[:C_A06I?
M]!JU_P"_;5[U11]9J=P]E$\%_P"%!:E_T&K7_OVU'_"@M2_Z#5K_ -^VKWJB
MCZS4[A[*)X+_ ,*"U+_H-6O_ '[:C_A06I?]!JU_[]M7O5%'UFIW#V43P7_A
M06I?]!JU_P"_;4?\*"U+_H-6O_?MJ]YJ/>_F[=OR^M'UFIW#V43PK_A06I?]
M!JU_[]M1_P *"U+_ *#5K_W[:O>:6CZS4[A[*)X+_P *"U+_ *#5K_W[:C_A
M06I?]!JU_P"_;5[U11]9J=P]E$\%_P"%!:E_T&K7_OVU'_"@M2_Z#5K_ -^V
MKWJBCZS4[A[*)X+_ ,*"U+_H-6O_ '[:C_A06I?]!JU_[]M7O5%'UFIW#V43
MP7_A06I?]!JU_P"_;4?\*"U+_H-6O_?MJ]ZHH^LU.X>RB>"_\*"U+_H-6O\
MW[:C_A06I?\ 0:M?^_;5[U11]9J=P]E$\%_X4%J7_0:M?^_;4?\ "@=2_P"@
MW:_]^VKWJBCZS4[A[*)X+_PH+4O^@W:_]^VKK/ 7PK;PEJ[W]Y=PW;[<1[%(
MV>O6O3J3BE*O4DK-C5.*=PHI:*Q+"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ I,4M% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4W*[L9Y]*=4?E+YF_O0 ^EI!2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "44A(QG-5K74+2]>5+:YCF
M:)ML@1L[3Z&@"W124M !1110 4444 %1;I/.QL^7UJ6F[EW;<C/I0 M+24M
M!1110 4444 %%)5:YO[6S>)+FXCB:5ML8=L;CZ"BP%JBF@Y%+0 M%(*6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *2EHH 2C%+10 4444 %%%% !1110 4444 %1
M9D\[&!LJ6F;TW[<C=Z4 .%+2"EH **** "BBB@ HHHH *2EI* "C%+24 +11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )11FDH 6
MEI** "EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9L
M7=NVC=ZT^HOWGG?[% $E+24M !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444E !FBDI: "BC-% "T4E+0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:&2 ;"Z ^HKM?#GC31/$ZXL+M3-C)B;AA^!ZU3IR2NT)23.CHI*6H*"BBD-
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MAHC9HJ&WNH;N!9K>59(V&593D&I0<UD6+1124 +129HS0 M%%)F@!:*3-+0
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M$E='ET/QMTN."-#IE_E5 .(Q_C5JR^,^F7M_;VJ:;?*TTBQ@M&,#)QZUWO\
M8&D?] ZV_P"_8I4T/2XW#II]N&4Y!$8XJW*#V0E&7<XGXA*S>)_"Q ) NCG
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M"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH A>WAD.7
MB1OJ*D2-$&$4*/84ZBB[ **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *,444 %%%% !BC%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ J/S%\S9GFI*;M7.['/K0 HI:04M !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 &**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 &*,444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** (GMX9?OQHWU%.2-(QA$"CV%/HHNP"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BVOYN=WR^E2
MU'YJ^9LS\U $E%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4W SG SZXIU1;&\W=O^
M7TH DI:04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g0vsdaj33nnl000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .]",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BFLP12QX &2:H_VWIX.#<#\C6<ZL(?&[%*,I;(T**S_ .V]/_Y^!^1H
M_MO3_P#GX'Y&H^M4/YU]X_9S[&A16?\ VWI__/P/R-']MZ?_ ,_ _(T?6J'\
MZ^\/9S[&A16?_;>G_P#/P/R-']MZ?_S\#\C1]:H?SK[P]G/L:%%9_P#;>G_\
M_ _(T?VWI_\ S\#\C1]:H?SK[P]G/L:%%9_]MZ?_ ,_ _(T?VWI__/P/R-'U
MJA_.OO#V<^QH45G_ -MZ?_S\#\C1_;>G_P#/P/R-'UJA_.OO#V<^QH45G_VW
MI_\ S\#\C1_;>G_\_ _(T?6J'\Z^\/9S[&A16?\ VWI__/P/R-']MZ?_ ,_
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M]G/L:%%9_P#;>G_\_ _(T?VWI_\ S\#\C1]:H?SK[P]G/L:%%9_]MZ?_ ,_
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M_;>G_P#/P/R-']MZ?_S\#\C1]:H?SK[P]G/L:%%9_P#;>G_\_ _(T?VWI_\
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MOO#V<^QH45G_ -MZ?_S\#\C1_;>G_P#/P/R-'UJA_.OO#V<^QH45G_VWI_\
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M'UJA_.OO#V<^QH45G_VWI_\ S\#\C1_;>G_\_ _(T?6J'\Z^\/9S[&A16?\
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MI_\ S\#\C1_;>G_\_ _(T?6J'\Z^\/9S[&A16?\ VWI__/P/R-']MZ?_ ,_
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M]G/L:%%9_P#;>G_\_ _(T?VWI_\ S\#\C1]:H?SK[P]G/L:%%9_]MZ?_ ,_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *3M2T4 0W/_'M+_N'^5<$_P!]OK7>W/\ Q[2_[A_E7!/]]OK7
MSN=[Q/0P742BBBO /0"BBB@ HHHH$%%%% !1110,****!!1110 4444 %%%%
M PHHHH$%%%% !1110,**** "BBB@04444 %%%% PHHHH ****!!1110 4444
M#"BBB@04444 %%%% !1110,****!!1110 4444#"BBB@ HHHH$%%%% !1110
M,**** "BBB@04444 %%%% PHHHH$%%%% !1110 4444#"BBB@04444 %%%%
MPHHHH$%%%% !1110 4444#"BBB@04444 %%%% !1110,****!!1110 4444#
M"BBB@ HHHH$%%%% !1110,****!!1110 4444 %%%% PHHHH$%%%% !1110
M4444#"BBB@04444 %%%% PHHHH ****!!1110 4444#"BBB@04444 %%%% !
M1110,****!!1110 4444 %%%% PHHHH$%%%% !1110,**** "BBB@04444 %
M%%% PHHHH$%%%% !1110 4444#"BBB@04444 %%%% !1110,****!!1110 4
M444#"BBB@ HHHH$%%%% !1110,****!!1110 4444 %%%% PHHHH$%%%% !1
M110 4444#"BBB@1N^&/^/F?_ '1_.NGKF/#'_'S/_NC^==/7V&5?[LCR,3_%
M84445Z)SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $5S_ ,>TG^X?Y5P+??;ZUWUS_P >
MTG^X?Y5P+??;ZU\[GF\3T,#U$HHHKP#T HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** N%%%% !1111H 4444 %%%% !1110 4444 %%%% 7"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHI@%%)2T %%%%( HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?\ OL4?V#J'_/%?^^Q7944?V+A^[#ZY4.-_L'4/^>*_]]BC^P=0_P">*_\
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MNP^N5#C?[!U#_GBO_?8H_L'4/^>*_P#?8KLJ*/[%P_=A]<J'&_V#J'_/%?\
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MN'[L/KE0XW^P=0_YXK_WV*/[!U#_ )XK_P!]BNRHH_L7#]V'URH<;_8.H?\
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M%% !1110 4444 %%%% !1110 5EZWX>TWQ##'#J4+2QQDE5$A49/K@\UJ44
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M /GY7\C_ (4?VQI__/ROY'_"N-HH [+^V-/_ .?E?R/^%']L:?\ \_*_D?\
M"N-HH [+^V-/_P"?E?R/^%']L:?_ ,_*_D?\*XVB@#LO[8T__GY7\C_A1_;&
MG_\ /ROY'_"N-HH [+^V-/\ ^?E?R/\ A1_;&G_\_*_D?\*XVB@#LO[8T_\
MY^5_(_X4?VQI_P#S\K^1_P *XVB@#LO[8T__ )^5_(_X4?VQI_\ S\K^1_PK
MC:* .R_MC3_^?E?R/^%']L:?_P _*_D?\*XVB@#LO[8T_P#Y^5_(_P"%']L:
M?_S\K^1_PKC:* .R_MC3_P#GY7\C_A1_;&G_ //ROY'_  KC:* .R_MC3_\
MGY7\C_A1_;&G_P#/ROY'_"N-HH [+^V-/_Y^5_(_X4?VQI__ #\K^1_PKC:*
M .R_MC3_ /GY7\C_ (4?VQI__/ROY'_"N-HH [+^V-/_ .?E?R/^%']L:?\
M\_*_D?\ "N-HH [+^V-/_P"?E?R/^%']L:?_ ,_*_D?\*XVB@#LO[8T__GY7
M\C_A1_;&G_\ /ROY'_"N-HH [+^V-/\ ^?E?R/\ A1_;&G_\_*_D?\*XVB@#
MLO[8T_\ Y^5_(_X4?VQI_P#S\K^1_P *XVB@#LO[8T__ )^5_(_X4?VQI_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 59L/\ C\7Z&JU6=/\ ^/Q?
MH:BI\++I_$C;J.?_ (]Y?]P_RJ2HY_\ CWE_W#_*N ](X/O11WHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M".H]B.QH4D]@E"2W+5%5-1U.TTJU:YO)ECC4$\GD_0=S7$S?%:P25ECT^>1
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MI %%%':@ HKFM'\80ZOJOV!+22-L,=Y<$<5TM !1110 4444 %%%% !1110
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M_P#'O+_N'^525'/_ ,>\O^X?Y5P'I'!]Z*.]% !1110 4444 %%%% !1110
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M=K7BNPT601/NFGZF.,]![FL/P?<-:>$;^X09:(NX!]0HK&\)Z7!X@U>ZEO\
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MP>T?-S''?#W5IKK1!9744B2V@"J73:"G;'TQ7*DGQ-\3P/W4L$$@ZCAHU/\
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M32:[;LD3LH4<JI/I7HU%*^H6([?BWCSUVU)112&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M=-X;_P"/.;_KI_05S-=-X;_X\YO^NG]!0!M4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24
MM)0!Q/Q8_P"1!NO^NL7_ *$*QO@I_P @+4/^OG_V5:V?BQ_R(-U_UUB_]"%8
MWP4_Y 6H?]?/_LJU7074]0JM??\ 'I)]*LU6OO\ CTD^E*.Z%/X68E%%%>@>
M8%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JS8?\?B_0U6JSI_\ Q^+]#45/A9=/XD;=1S_\>\O^X?Y5)4<__'O+_N'^
M5<!Z1P?>BCO10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %=-X;_P"/.;_KI_05S-=-
MX;_X\YO^NG]!0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!Q/Q8_P"1!NO^NL7_
M *$*QO@I_P @+4/^OG_V5:V?BQ_R(-U_UUB_]"%8WP4_Y 6H?]?/_LJU7074
M]0JO??\ 'I)]*L5!=HTENZJ,DBE'<4OA9A459^P7']P?G1]@N/[@_.N[GCW/
M/]G/L5J*L_8+C^X/SH^P7']P?F*/:1[A[.?8K459^P7']P?F*/L%Q_<'YBCV
MD>X>SGV*U%6?L%Q_<'YBC[!<?W!^8H]I'N'LY]BM15G[!<?W!^8H^P7']P?F
M*/:1[A[.?8K459^P7']P?F*/L%Q_<'YBCVD>X>SGV*U%6?L%Q_<'YBC[!<?W
M!^8H]I'N'LY]BM15G[!<?W!^8H^P7']P?F*/:1[A[.?8K459^P7']P?F*/L%
MQ_<'YBCVD>X>SGV*U%6?L%Q_<'YBC[!<?W!^8H]I'N'LY]BM15G[!<?W!^8H
M^P7']P?F*/:1[A[.?8K459^P7']P?F*/L%Q_<'YBCVD>X>SGV*U%6?L%Q_<'
MYBC[!<?W!^8H]I'N'LY]BM15G[!<?W!^8H^P7']P?F*/:1[A[.?8K459^P7'
M]P?F*/L%Q_<'YBCVD>X>SGV*U%6?L%Q_<'YBC[!<?W!^8H]I'N'LY]BM15G[
M!<?W!^8H^P7']P?G1[2/</9S[%:BI+B"2VA,LPP@ZG-)#$\\0EC&5/0FCGCW
M#V<^PRBI_LDW]W]:/LDW]W]:.>/</9S[$%%3_9)O[OZT?9)O[OZT<\>X>SGV
M(**G^R3?W?UH^R3?W?UHYX]P]G/L045/]DF_N_K1]DF_N_K1SQ[A[.?8@HJ?
M[)-_=_6C[)-_=_6CGCW#V<^Q!14_V2;^[^M'V2;^[^M'/'N'LY]B"BI_LDW]
MW]:/LDW]W]:.>/</9S[$%%3_ &2;^[^M'V2;^[^M'/'N'LY]B"BI_LDW]W]:
M/LDW]W]:.>/</9S[$%%3_9)O[OZT?9)O[OZT<\>X>SGV(**G^R3?W?UH^R3?
MW?UHYX]P]G/L045/]DF_N_K1]DF_N_K1SQ[A[.?8@HJ?[)-_=_6C[)-_=_6C
MGCW#V<^Q!14_V2;^[^M'V2;^[^M'/'N'LY]B"BI_LDW]W]:/LDW]W]:.>/</
M9S[$%%3_ &2;^[^M'V2;^[^M'/'N'LY]B"BI_LDW]W]:/LDW]W]:.>/</9S[
M$%6=/_X^U^AIOV2;^Z/SJ>S@DBN59QA0#4SG%Q=F53A)25T:U1S_ /'O+_N'
M^5+YJ^OZ4R5PT+J.I4@5Q'H'"]Z*O_V1>9_U0_[Z%']D7G_/,?\ ?0H H45?
M_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H
MH45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\
M?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/
M,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D
M7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z
M%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">
M8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\
M_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?
M_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H
MH45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\
M?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/
M,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D
M7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z
M%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">
M8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\
M_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?
M_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H
MH45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/,?\
M?0H H45?_LB\_P">8_[Z%']D7G_/,?\ ?0H H45?_LB\_P">8_[Z%']D7G_/
M,?\ ?0H H45:;3[E;B. H/,?[HS4_P#8=_\ \\A_WT* ,ZBM'^P[_P#YY#_O
MH4?V'?\ _/(?]]"@#.HK1_L._P#^>0_[Z%']AW__ #R'_?0H SJ*T?[#O_\
MGD/^^A1_8=__ ,\A_P!]"@#.HK1_L.__ .>0_P"^A1_8=_\ \\A_WT* ,ZBM
M'^P[_P#YY#_OH4?V'?\ _/(?]]"@#.HK1_L._P#^>0_[Z%']AW__ #R'_?0H
M SJ*T?[#O_\ GD/^^A1_8=__ ,\A_P!]"@#.HK1_L.__ .>0_P"^A1_8=_\
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MH4?V'?\ _/(?]]"@#.HK1_L._P#^>0_[Z%']AW__ #R'_?0H SJ*T?[#O_\
MGD/^^A1_8=__ ,\A_P!]"@#.HK1_L.__ .>0_P"^A1_8=_\ \\A_WT* ,ZNF
M\-_\><W_ %T_H*RO[$O_ /GD/^^A6WHEI-9VTB3+M8OD8.>U &I1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %)2TE '$_%C_D0;K_KK%_Z$*QO@I_R M0_Z^?\ V5:V?BQ_
MR(-U_P!=8O\ T(5C?!3_ ) 6H?\ 7S_[*M5T%U/4****D84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.G_Y#ME]#_6MNJBV\
M;W"RLN70?*?2K5 "T5POCKQW?^%=7TK3=.T8:E<:@'V()2ARI' X.>M9D?Q,
MU[3\W'B7P;=Z=IZ\/<(WF8/T(% 'IM%065Y;ZA90W=K()()E#(Z]"*GH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "DI:2@#B?BQ_R(-U_UUB_]"%8WP4_Y 6H?]?/_
M +*M;/Q8_P"1!NO^NL7_ *$*QO@I_P @+4/^OG_V5:KH+J>H4445(PHHHH *
M\1^&'CG0?#>@W]EJ=T8IFU"60+M[' _I7MM>>?"71;BP\-7T>IZ>\$S:A*ZK
M/%ABI"X//:@#.T.\_P"$U^*EOXETN"5=*T^U>W>:1=OF.=W _P"^A3?">N>,
M_&FHZFO]HVEGIMC>F(O'!^\?:V=O7C([UZHD:1C$:*@]%&*\]^$^EW^F0^(A
M?V<]L9M4>2/S4*[U/<9ZB@!=8UCQ)XA\6W?A[0+F*PL;6,"ZORNY@Q ("\C!
MYQCZTNDZ_K'AKQ79^&/$-ZFH)?1YLKQ%P[,.H<9/OSFL;6] BT7QU=W]_P"'
M'U;1K\!O,A1G>W< 9) Z@X/YUK^%[+0[_P 2>?8^#);*&U7?#J%PK(2W3"J?
MJ>] &K>_$WPOI]]/9W%\5G@<QNNWH1UK+\:^.);6QT,Z5=1VMIJ[_-J,JY6W
M3CG'X^O:N^-K;L26@B)/4E!S7->,;U;.WMK6?PY-JVFW!*7 A3=Y2\<[0.1U
M]* (?#MOXG$%S'-KMG?VCVZFRO1#EBYSDL-W(''?FE\*>+9;_P +WM[JZ&.Z
MTQY$N]J;<[!NR%[<$5RW@G3+F+XBWEYHVGWVG>''MP'BND9 [\XV ]A6=X]T
MC4K#Q;/9:2)TB\3>7'+*IW>6P;YSM';;C- &Q+XU\1P?"R^\4N]J97G!LOW7
M BWA?F&>O6EEF^(,/AR'Q/)J5K+*D*S/IT-N=C1DYZ[NNWGIQ6I\0]$N&^%D
M^DZ?;27$R)"BQPH26PRY( _$UT*6\W_""K;&)_/_ +,$?EX^;=Y6,8]<T <3
M;3_$#6M /B6._M[$JK36^GO =LD?4;FSS\O(.*MWGC^\D^%UOXDTX(UXQ5)%
M>/@OT8 ?7I756%O-'X%M;9HF6==,2,QD?,&\H#&/7->5&PO]+^!$=K=6LMO=
MK=DB*9"I!+'&0: .I^P_$'4;;^WTU2/3[C:7BTB2,E .H#G/WOPI;WQ+=>+?
MA+?:KI\XLYTAD2Y!CW?,H^95.1CKP:E'CS5;727M-2\-:A)KB QM';0L8I3T
MW*^" I_&G>&_!5]IGPNO="F=/MMZLKD=D9P/ESWQCK0 _P"&/VZS\!V-YJ.I
M0-IXMMT:>3L,0!.2S9Y_(50TJZ\:>-Q-J-MJ,6C:6)B;0+#YC3*IQR<C*D@U
M-X%N_M/A:W\(:CI6H031V[P3O)"RIMYYW$8YS5?PQK6J^"[.3P_K&AWLEO:L
MPLKBSA:19%))"G'?)ZT ;O@_Q3?7^JZEX>UI(QJ^G$&22$?NY4.-K#T/(XK
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M110 4444 4M4N9+6P>6+&X$=1D=:AL9WN;..5\;FSG ]Z?K,;RZ9(D:EF)'
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MV?BQ_P B#=?]=8O_ $(5C?!3_D!:A_U\_P#LJU7074]0HHHJ1A1110 4444
M%)2T4 )@'@C-  ' &![4M% !2$9ZTM% %>[BFDL9HK6189F0B-R,A3V.*Y'1
MO!VJIXP;Q%KVJ17DR1>7;10QE$B!R#P2?6NVHH 2EHHH *P/%_A^3Q+H9T^*
M=(&,BOO=21Q6_10 W:N<[1GUQ2TM% "!0"2 ,GJ<4$ ]0#2T4 )12T4 )12T
M4 )M&=V!GUQ12T4 -"J"2% )ZG'6EI:* $P,Y(%+110 4444 %%%% "'H:K5
M7ULE=+D*D@Y7D'WJ/2R6TZ(L23SDD^] %RBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &O(D8R[JH]2<4H((R#D&J>I6;WD*HC!<'/-6XU*1(A_A4"@!U%%
M% !1110 4444 %%%% "8&<X&?7%8?B33]=U"$1Z-J<%ENC9)&DC+'G&",'@C
MG\ZW:* ,+PCX=3POX?ATX2^=*"7FE_ON>IK=HHH **** ,B71GD\60ZSYRB.
M.T-N8\<DEMV<UK!54?* /I2T4 !YX.*0 *,  ?2EHH 3:,YP,FEHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)J***9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $4MS# RK(X4L<#BI:R-8_X^
M+7_?'\ZUZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *[6;RZE!<!E"Q
MY!ZFM*JBSQ).L3.!(X^5?6K5 "T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% $M%<WI>LN)O*NI"RMT<GI6GJFHBRMP4P97^Z/ZT :-%8>@7=Q<RSB:1GP
M0">G6MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I*6DH XGXL?\B#=?]=8O_0A6-\%/^0%J'_7S_[*M;/Q8_Y$
M&Z_ZZQ?^A"L;X*?\@+4/^OG_ -E6JZ"ZGJ%%%%2,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT4!<;L7.=HSZXIU%% M1"H;J ?K1M7^Z./:EHH'<0@$8(R*145/NJ!]!3J*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I*6DH XGXL?\B#=?\ 76+_ -"%8WP4
M_P"0%J'_ %\_^RK6S\6/^1!NO^NL7_H0K&^"G_("U#_KY_\ 95JN@NIZA111
M4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH 1N5-5J@UQF72Y"K%3E>0?>HM+);
M38BQ))!Y)]Z +E%%% !1110 4444 %%%% !1110 4444 %%%4-1UG3])B,E[
M=)$!VSD_EUH*C%R=HHOTA('4XKSG5/B@JDIIEIN()!>7H1ZC']:Y&XUKQ#KL
M@'G7,H#<"%2 N>W']:R=5+8]&EEE62YI^ZO,]AO?$6DZ?$\D]]#\GWE5PS?D
M.:YZ]^)>CP*/LJ37.>H"E<?G7'V/P^UV^D)N%6W!&[?*V[=^7-=!:?"R'R!]
MLOY/-SSY(&W]12YJCV1K]7P5+XYW]""]^*<C(/L5@%;/)F.1^E4O^%H:M_SZ
M6GY-_C786_P^T"&%4DMC,P'+LY!/Y&M&T\*Z+9#$-A&,_P![YOYT<M3N+V^!
MCHH7/,KGXAZW.3L>.'/]P?XU53QQKZ,";YF]BH_PKV3^R]/ Q]BM_P#OTO\
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M?]?/_LJUL_%C_D0;K_KK%_Z$*QO@I_R M0_Z^?\ V5:KH+J>H4445(PHHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *2EI* .)^+'_(@W7_ %UB_P#0A6-\%/\ D!:A_P!?/_LJUL_%C_D0;K_K
MK%_Z$*QO@I_R M0_Z^?_ &5:KH+J>H4445(PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,W7?\ D$R?[R_SJ+2O^09%]#_.M"[MX[JW:&7.T\G!Q4$$*6T*Q)G:
MO3- $E%%% !1110 4444 %%%-DD2&)I)&"HHR2>@H&DWL$DB11M)(P55&23V
MKS7Q7X_\Z-['2&(4\/< \_1?\:S_ !CXSDU>5M/TYF%F#AF'64_X5=\'>!&E
MD34-6CQ&.8X"/O>Y]O:L93<G:)[%#"T\/3]MB-^B,KPOX+N];N%N+Q7AL_O%
MC]Z3Z?XUZQIFEVFDV:VUG$(XUZ^I/J?>K:J%4*H  [4M7&"CL<6*QE2N]=%V
M"BBBK.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&574JPRI&
M#D4M% 7.'\1_#VTOE:YTS;;3A>(E7",?Z5P=G?ZSX/U$J5>%B/FA?[K"O=*S
M-9T"PURW\N\A#%<[7'#+]#64J?6)Z>'S!I>SK>]$I>'/%=EK]JF&6*[Q\\)/
M(/MZBN@KP[6O#VI^%[_SD+B)6S%<)Q]/H:[KPKX\@U%8K/46$5W]T.3\KG_&
MB,];2'B<"N7VM#6)UM]9"]B5"Y3!SD#-6(UV1JF<[0!FHKF[BM$5Y<[2>,#-
M3*P=%8=&&16IY8M%%% !1110 4444 %%%% !7.^*+#4;U83I]Q/"4R7,<A (
M]".]=%37*A&+$!0.2:BI%RBT:4IN$U)'E:,8Y%;J5.:V8I%E0,ISD5EWLEO+
M?3-:!C 6RAVX!'M[4R*>2%LH?P-?(XF@^9IGT-E.*9M4A34F'_$L5FE!&X!R
MN1]16?\ VGM3+)T')S73>%+B*>%W#!G?E2!P5_KS58##2E73>QS5Y.G!NUSH
M+7?]EB\P$/M&X$YP>_-2T45]?:R/$;ZF%KO_ !]VOT/\Q6[69J=A-=SP/%MP
MG7)K3KBP].4:TVUN:U))PBC&U>9Y+F&S5BBN?F/UJ5=$ACDCDCE=&4Y//6I]
M0T\7T:C>5=3D'%4X-/U S*9[DA$.1@YS7/.G)5GS1;OL:1DG#1V*=].LFIM%
M=%S#'P%7KTIMK,EOJ*&U\SRVX96&*TK[2Y))OM-K)LE[^]+965XD_G7,V<<;
M1SD5S>PK>VLT][W-.>'():_\AVY_W!_2JNF?\ARY_P"!?SK0AM)8]4FN#MV.
MN!S]*ALK":#4YKA]NQ\XP?4UO[&?-#39D<\;/T+6I_\ (-G_ -VLW3-/'D)>
M2,2R\HH[ 5K7L+SV<L28W,N!FFV,+P6<<4F-RC!P:WK4'4K\SV2_$SA/EIV7
M<YU);>>:22],KN3P%'2KFDR2-]I@B9MNW]V6&,&I)=)N8)6>REPKGE3QBKEG
M9SPP2"6;,D@/./NFN*CAZWM;23ZZF\ZD.6Z9@I%%#(ZW\<H8G(85H:L4?3[7
MRFRN\ $_2DETO4)&,33[X2>I/]*75;9;;3[:!22!)UJ%"I"E--:#O%SCKJ,N
MM)CAT_[0)&\U1N)SUILFH3-I4(W$.Y*E_85*=,OI=L?VDFW('4]!]*O2Z7$]
M@MJ#MVG(8>OK5QHU97<%96^\ESBK7=]2A<Z1#;V!F21A(@W;L]:;/<-<^'PS
MYW!PI)[T[^RKYSY$EQ_HXX'/]*NW>GEM,6UMP/E(/S&J5&I)2<8M*UOF'/%-
M7=S+N=/2+2ENBS&4XR<U8G2YNM$@*$L?XQGJ*NW=G+-I2VZXWC'4U'_9]Q_9
ML,"S>7(G)V]Z;PTDVDG9H2J)I7[F=8&R2XBWB2*8'!R>":9=W$=SJ+_:3((D
M. JBKD.E74MRDEY("$Z8.<U/>Z9(\YN+639(1@CUK)4<0Z6VB97/!2W,^PF$
M>J(EKO$+G!#"NEK-L+2[CE\VZFR<8"YR*TJ]' 4Y0@^;J<]:2;T"BBBNXQ"B
MBB@ HHHH **** "BBB@ HHHH **** "BBCO0 44R25(4+R,%4=S6#?:P\NZ.
MW^1.F[N: -.\U2&U!4'?(/X1_6L.:\NK]]G)!Z(M2V>DS71WRY1/<<FMZWM(
M;5-L2@>I[F@#)M=#9L-<M@?W5[_X5KP6L-LN(D"^_<U-10 4444 %%%% !11
M10 4444 %%%% !1110!G3_\ (>LOH?ZUMU2%K')=QW#9WQCY<'BKM !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 57N[.*\5%DW81MPP>]6**F<5-68TVG="* JA1V&!2T44TK*P@HHHI@%%%%
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M>BN?Y&MUT5U*L,J>"#7+:KI36;>=%DPD]OX: .JI:P-&U8OBVG/S=$;^E;U
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHWJ* .RHJI87JWMJL@P&Z,!V-6Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "DI:2@#B?BQ_R(-U_P!=8O\ T(5C?!3_ ) 6H?\ 7S_[
M*M;/Q8_Y$&Z_ZZQ?^A"L;X*?\@+4/^OG_P!E6JZ"ZGJ%%%%2,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"GJ5L]Y8O"A 8D')]C4-E UM:)$Y!9<\CZU=GFC@B
M+RN%4=2:KQR),@DC8,IZ$4 /HHHH *CGFCMX7FE8*B#+$]A4E><_$;Q'M7^Q
MK<L&8;IF!P,>GO[U,I**N=&&H2KU%!'*>(=6N?%6OXMTD="?+@BS_3IFO5O#
M&@0:#I:1(G[]QNE<]2:Y7X=>&@D8UFZ1@[<0J?3U_'^E>BU%./VF=N88B*2H
M4_A04445J>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 45F:U+)%;(8W93NYP<5=AE7[/&6<<J"<GV
MJ7**W8[,9J%C#J-E+:W"AHY!@YKQ;5M*OO"&N(Z,<*V^&4=&'O7M#ZE:(VUK
MA 1[UA>)HM,UO36MI')D',;H,E3_ (5S5:]%*_,CT<#6G2ERM7B]RWX9\10^
M(M.$RC9.G$L>>A_PK<KR+P_IVLZ#J2W,,D!C/$D9<X8?E7?'Q$^>(%_[ZK%9
MEATM9"Q6#Y:G[K5&_17.MXAF(PL*J?7-0G7+TGAE'_ :F6;4%W9@L+49U%%<
MM_;-^PQD?@E0O>WK]9)1],UG+-Z?V8L:PDNK.OHR!WKCQ-?-TDG/XFI1%JD@
MR//(_P!ZDLUYOA@P^JVWD=274=6'YTGFQ_\ /1?SKE39:BWWHI3]33?[-O?^
M?=Z3S.MTIC^K0_F.L\V/_GHOYT>;'_ST7\ZY/^S+W_GW>I%T:\;_ )9X^IH6
M98A_\N@^KT_YSJ/.B_YZ+^=)Y\7_ #T7\ZYP:#=G_GF/J:7^P+O^]%^9_P *
MKZ[BGM2%[&E_.=%]HA_YZ+^=)]HA_P">J_G7/?V!=_WHO^^O_K4?V!=_WHO^
M^C1]=Q?_ #Z#V-+^<Z+[1#_ST7\Z//B_YZ+^=<[_ &!=_P!Z+_OH_P"%']@7
M?]Z+_OH_X4?7<7_SZ#V-+^<Z/SHO^>B?G1YL?_/1/^^JYLZ%>#_GF?HU1MH]
MXO\ RSS]#2>/Q*WI!["GTF=1YL?_ #T7\Z/-C_YZ+^=<G_9=[_S[O1_9E[_S
M[/4?VG7_ .?17U:G_.=;YB'HZ_G2[E[$?G7(C3[]>D$@J06NICHDP_&KCF57
MK3$\-#I(ZNBN49=3C^\9Q_P(U$9[X=9)A^)H>:VW@P6%OLSL**X];R]7_EK*
M?J34R:K?IT8GZKFB.;T^L6)X271G545RW]MW_P#>7_OB@:[>]V4_\!%7_:]#
MLQ?5)^1U-%<ZGB&8##0JQ^N*=_PD4G_/NO\ WU6BS3#VW)^K5+G045BP^((S
M_KHF7_=YJ7^W[3^[+_WR/\:TCF&&?VR7AZBZ&K16!>:JDTD#02,BAAN&<<5J
M#4K-C@7"$ULL51EM)$NE-="W13!+&PR'4CZTX,#T(/XUJIQ?4BS%HHHJKB"B
MBB@ HHHH **** "BBB@ J.>9+>%I)&  IY(4$DX Y)KFM2O3>W 2,'8IPH]3
M0!#(\VHWG=B3A1Z"NDL[5+2 1J!G^(^IJ#2['[)#N<#S7ZX["K] !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6:T>74[>X!4+$#
MD'J:TZJI/$DZQ,X#N/E7UJS0 M%%% !1110 4444 %%%% !1110 4444 %%%
M% !5/4;%;VU9,#>.4)[&KE% ''6-U)IE]B16 ^ZZUUZ,'0,#D$9%8>O:?N7[
M7$O('SX]/6DT"_R/LCG..4.?TH WZ*3O2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP> 78 4Y6#*&4@J1D$'K0 M%%% !1110 4444 %%%% !1110 4444 9&L?\
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M4'#9Z5H5BS_\AVR^A_K6U0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !24M% '):S9FTO=Z#$;\KCL:W]+NQ>62-GYU^5OK1JEH+NR90/G7YEK
M T:[-I>^7(<*YVGV- '6T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !24M)0!Q/Q8_Y$&Z_ZZQ?^A"L;X*?\@+4/^OG_ -E6MGXL?\B#=?\ 76+_
M -"%8WP4_P"0%J'_ %\_^RK5=!=3U"BBBI&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1124 (ZJR$,H(]"*K !1A0 !V%1ZQ-)#ILCQMM8$<_C4%A.6TU)IFZ EF-
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MBB@ HHHH **** "BBB@ HHHH JW5ZEK)&C(Q+G Q5JLC6/\ CXM?]\?SK7H
M**** "BBB@ HHHH **** "FNZQHSL<*HR33JQ];N]D8MU/)Y;'84 9DKOJ.H
M<?QG SV%=/!"L$*QH,!165H=IM4W+#D\+6S0 4444 %%%% !1110 5&T$3YW
M1H<^HJ2BI<(O=#3:V,^71;.13M383W!JE+X>Z>3-]=XK=HKDJ9?AY[Q-8UZD
M=F<J^D7T+DHA8#^)6Q4275]:@D/*H/\ >'^-=?361'&'56'H17)+*K:TYM&J
MQ5_B5SG8M?G0*'C5\=3WJ_#KUL[8=6C'J>:LS:7:3MN:( _[/%4)?#R8)BF.
M>P8<5/)CZ/POF17-0GNK&I%>VTRY29<'U.*GZ]*Y:71;R$C8HD_W#T_.HEFO
MK1S\T@(Z[N0*:S*K3_BTV+ZO&7P2.NHKFHM?N$&'59/<\5?BUZWD8*ZLF>I/
M2NFEF>'GI>QG+#5(]#6HJ"*]MIAF.93^.*GSGI7;&I"?PNY@XM;A1115B"BB
MB@!\2J7W%02!P<=*GK(DGD36+6)6PC@[A^=:] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7):S:&TO=Z<(_S+CL:ZVJ&KV@N[%@/OI\
MRDT .TRZ%W8H_P#$!AJNURV@W?DW9@;.V3]#74T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI'=&K1445S#.NZ.164]"#4U=D91ELS)IH****H04444 %%%% !1110 4444
M%%%% !1110 4444 %)2T4 <?JEN;+4BRC )WH:ZBRN%NK2.4'.1S]>]4->M!
M/:>:!\T?/3J*J>';O#/;,>#\RY/Z4 =%124M !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/:K:(&\EFR<8B.X_I26^NZII\FPRL=GR^7*.!189Z-17.Z?XMM+DK'<KY#G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %)2TE '$_%C_D0;K_ *ZQ?^A"L;X*?\@+4/\ KY_]
ME6MGXL?\B#=?]=8O_0A6-\%/^0%J'_7S_P"RK5=!=3U"BBBI&%%%% !1110
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ME/$-UDK(VM-TR#3+<1PK\W\3=V-7:**HXPHHHH **** "BBB@ HHHH ****
M"BBB@".:&.XB:*9 Z,,$&N(U[PZ]@3=6NYH,\@=4_P#K5W=(RAE*L 5(P010
M@..\/^)#&R6EZV4/"2'M[&NQ!! (.0:X?Q#X>-FS75JI,!.64?P?_6J7PYXB
M,)6SO')C/$<A_A]C[4P.THI 00",8]:6D 4444 %%%% $4MS# RK(^TL<#CK
M4M9&L?\ 'Q:_[X_G6O0 4444 %%%% !11534;D6UF[ _,WR@&@#"U*<W=\0I
MRJ_*O^?K70V< MK5(\8(&2/>L+1[;S[OS7Y5.>>YKI* "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@#B?BQ_R(-U_P!=8O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *2EI* .)^+'_(@W7_76+_T(5C?!3_D!
M:A_U\_\ LJUL_%C_ )$&Z_ZZQ?\ H0K&^"G_ " M0_Z^?_95JN@NIZA1114C
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &2.(XV=CPHR:\'U^^E\3^+'-OB022"*$*.J]OQKT
MWQ_K8TK0'BC?%Q<?(@#8('=O\^M<?\,]#-WJ;ZG,F8H.$W*>6/<'VQ^M8U/>
M:B>Q@$J%*6(EZ(]/T?3H]+TJWLXL[8D"Y/4U>H'2EK8\B3<G=F;KO_()D^J_
MSJ+2O^09#]#_ #J_>6R7=LT+DA3R<>U0V\"VT*Q(257IF@1)1110 4444 %4
M-3OELX"!_K&X4>GO5N>9((FDD.% KE)'FU*^'4EC@#'05YN88ITH^SI_$SHP
M])2?,]D2:;9-?7.^0$Q@Y8^IKJE4*H51@ 8 J&UMDM+=8D[#D^M3UI@<+["&
MOQ/<5>JZDO(****[C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,K7?^/6/_ 'JT;?\ X]HO]P?RIY /4 _4
M4M !1110 4444 %%%% !5'5M033;!YF(W8PBDXW&KI( ). !U)KS[Q%J9U/4
M?*B;=#&=J8'4TT!!I=E+K6K?.003OE)]*]'CC2&-8XU"HHPJCH!69H.EC3=/
M56"^<_S.<?I6K0 5D^)-(36]$GM"/G(W1\X^8=*UJ*EJZ*A-PDI+H>(^$]6?
MP]XC59B1$[>5,,X'H"?IUKVU&5T#*05(R".]>4?$70?L>HC4X5/DW!_>8'1O
M\XKK/ 6N_P!K:*+>5LW%M\C;F&6'8X].WX5E3?*^5GK8^*KTHXF/S.LHHHK8
M\<**** "BBB@ HHHH **** "BBB@ HHHH **** &2Q)-$T<BY5A@BO/]<T:7
M2;GS8P3;L?D?^Z?2O0ZBG@BN86AF0-&PP0:: P?#FOB\1;2Z;_2 /E8_QC_&
MNCKSS5M(N-$NQ-"6,.[,<@ZCV-=3H.N)J</E2$+<H.5]?<4"1M4444AF1K'_
M !\6O^\/YUKTA4'J ?2EH **** "BBHYYE@A>5NBC/UH Q=<NM\BVZG[O+8]
M:NZ/:^1:[V&'DYY'('I6+;1O?Z@-W.YLL3Z5U0 50HZ 8H 6BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,Z?\ Y#UE]#_6MNJ0M(Y;R.X8MOC'R@'BKM !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)X@L]\*W*#YD
MX; ZC_ZU,\/7FY&M7/*\KD]JVY(UEC:-QE6&"*X\^9I>I]_D;MQD4 =E2TR*
M198ED4@JPR,&GT &*:44]0#3J*32>X%.73+.9BSP(6/4XJA+X<M64^6SJQZ9
M.0*VZ2N>IA*-3XHFD:LX[,Y:;PU<(N8I5<^XQ5272M0MV'[IF/8IS7:48KCG
ME-%_"VC6.*FMSBO[2U"VDVO+(&7JKU<A\27*M^]1'7T7BNF,4;9RBG/M5231
M[&3=F!03W%9O XJG_#J%^WI2^*)1A\2P-_KHV3Z<U=BUFRE7/G*OLYQ5*7PU
M 4/E2N&[;N15*7PW<HN8Y$D/ITI>UQ]+XHIBY</+9V.FCFCE0/&X93T(-/S7
M%RZ9J%M@&-SG^X<_RI/M^HVQ56ED3'\+"J6:2C_%@T'U5/X)7.UHKE8_$=T"
M-ZH5'7 YJY'XFB+ 20LH[G.:WAFF'EUL1+#5%T-^BLV/7+&5]HD(/JPP*MQW
M=O*VV.9&/H&S77#$4I_#),Q<)+=$])1FC-:W1(M%)2TP"DHHH 6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *2EI* .)^+'_(@W7_76+_T(5C?!3_D!:A_U\_\ LJUL_%C_
M )$&Z_ZZQ?\ H0K&^"G_ " M0_Z^?_95JN@NIZA1114C"BBB@ HHHH ****
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M\Q_N(<GCJ:ZCCMVKRL#2E7J/$U/D=5>2A%4XA1117M'&%%%% !1110 4444
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M10!%]L6*^BMBA+2@X.>E7ZQ)_P#D.V7T/]:VZ "BBB@ HHHH **** "BBB@
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MQQD^7%][W:MWPSI7V"Q$T@(FF&2",%1V%<UX<TTZEJ7F2#,41W-[GM7H &
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M %%%% !24M)0!Q/Q8_Y$&Z_ZZQ?^A"L;X*?\@+4/^OG_ -E6MGXL?\B#=?\
M76+_ -"%8WP4_P"0%J'_ %\_^RK5=!=3U"BBBI&%%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 96O?\ 'JG^]6C;_P#'M%_N#^5$UO%.NV9
MP!Z&GJ JA0, <"@!:*** &R2+$C2.P55&23T%><ZK>RZSJV(_F4MLB7&./\
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M/G)_MVR'J#_6MJJ'V02WT5R6P8@<#UJ_0 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH:FG)O1G3F&&47[:G\,C0HHHK0\P**** "BBB@ HHHH **** "BBB@ HHHH
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M5^L2?_D.V7T/]:VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LO4M(CO?WB827U['ZUJ48H
M XR.>[TJY*\J0>5/0UTECJ<%ZN%.V0#E34UW90WD1211GLPZBN9O=,N=/?>I
M+)V=.U '74M<[8Z^5"QW0R ,!QU_&M^.6.9 T;AE/<&@!]%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 )12T4 %)2T4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!Q/Q8_Y$
M&Z_ZZQ?^A"L;X*?\@+4/^OG_ -E6MGXL?\B#=?\ 76+_ -"%8WP4_P"0%J'_
M %\_^RK5=!=3U"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 E%%5K^]ATZRENKAU2.-<DDT,:3;LC%\8^)(] TERKX
MNY05A7&>?7Z"O,/".A2^)M=,MUO>!#YDSGG<?3-5M1O[_P 9>(54?>D;9#'G
MA!_GO7LOAW1(=!TB*RB.XCYG;&-S'J:Q7ORUV1[,[8&ARKXY?@:D:+%&J(,*
MHP!3Z2EK8\4**** "BBB@ I*6D/% &;K=REO8,"%9GX"L*PM$M//N3*P^2/V
MX)INM7OVN]*@_NX^!@\'WK9T=%338R!@MDD@=>:\-?[7B[_9B=K_ '5'S9?H
MHHKW#B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **S-:EDBMT,;LIW=CBJ.N:V
M=/T^**)LW$J#G/W1CK0!G>*=:$K&PMS\JG]XWK[58\*Z*8E%_<*-S#]VI'0>
MM9/A_2#JMXT]QN,*G<Q_O&N_551 J@!0,  4V M%%%( HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "DI:2@#B?BQ_P B#=?]=8O_ $(5C?!3_D!:A_U\_P#LJUL_%C_D
M0;K_ *ZQ?^A"L;X*?\@+4/\ KY_]E6JZ"ZGJ%%%%2,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "DI:0]* &.ZQHSNP"J,DFO&_'
M?BG^W;U;*Q=FLXFQD'B1O7'^>M;/Q \8HROH^GR;CG$\BG@?[/\ GTJ#X?>#
MY)IH]8ODVQ#F!&'+?[7T_P :QE)R?*CV,)1CAJ?UBMOT1O> /"O]DV?V^\A"
MWLHX##E%]/8^M=N* !C%%:I)*R/,K5959N<NHM%%%,R"BBB@ HHHH 3O6?K%
MY]CLF(.)'^5>>?K6@:X_6KPW=\8T)*)\H /!/K7!F&(]C1=MV;T*?/,K6UE/
M=QRRQJSE<< =372Z;&\5A$CJ58 Y!^M3:9:"TL%3'S,-S'U-2U6 P_L:2ON]
MQ5ZG//R"BBBNTQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJGJ6HPZ9:F:8Y[*HZL
M?2@#.\47*V]@AR-Y;Y0>]<C86ESK6HA6+/G!D<]E_P \4VYNKG6M1#2ORQPH
M/117?Z7IUOIUFD<"C) +-W8T]A%BUM8;.W2"! D:C@#^=3444AA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,FACN(7AE0/&ZE64C((I]%#&G9
MGB7BGP_<>&]7$L*LMLS[X)%_A/7'U%>D>#_$T.NZ>L;N!>1+B1">3[BMC5M,
M@U?3I;.=0RN."1G![&O%;FVU'PCKZYW1R1MN1AT=:P?[MW6Q[=.4<=2Y)/WU
MMYGN]%9/A_7;?7M-6YA;YU&)$[JU:U;)W6AXLX.$G&6X4444R0HHHH ****
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M%%% !1110!2EAE?6;214)1 =S#H.M:]0Q=34U !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3)(TE0I(H93U![T^B@#'N= MI26B8Q$G)[C\JQYM)OK5@
MX0MCD,AZ5V%% ')0:U>V^%=MZYR=_7Z9K4M_$-O(,3(T;$XXY%:%Q86UR/WL
M2DXQG'(K+N/#D;<P2E>.C<YH UH;J"X&8I5?'7!J:N0ETB^M^1&6YXV'-$>J
MW]JY5I"2!C;)VH ["BN>@\2$*!-#EL\LIQ^E:$6MV4IQYFS_ 'QB@#1HJ.*>
M*==T4BN/534E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!Q/Q8_P"1!NO^
MNL7_ *$*QO@I_P @+4/^OG_V5:V?BQ_R(-U_UUB_]"%8WP4_Y 6H?]?/_LJU
M7074]0HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)10
MM%)03CDT &>*\Y\=>./LZOI>ER RGB653G;[#WI/''CH0"32]*D!E^[+,O\
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MUM5G&S,NHPW.X 1 \>M:- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %)2T4 %126\,RE9(U8'KD5+10!F3:%9RD%5,>.R&LZ7PW* QBF5
MO12*Z2B@#CI=*O[=?]6Q!_N'/\J3[?J-L55I9$QT5A78TUHT8Y9%/U% '-Q^
M(KD,/,C0KWP,&KD?B.!FP\+(/7.:OOI=E(Q9K=2QZ]:I-X=MF+$22+GH.,"@
M"S%K5C*VT2X/^T,5:2[MY&VI/&Q] PK!;PU*,E9T/H,56.AZ@C$J@X[AQ0!U
MM%<7Y>H0R?<G##N 33VU744.'GD!]"H_PH [&BN77Q'=!<&.(X[G-6(O$@V_
MO8"6_P!DT =!16+'XCMV;#Q.@]2<U8&NV'_/5O\ O@T :5%5H[^UE&5G3'NV
M*D%S QP)XS]'% $M%("",BEH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,>T7^X/Y4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS7_"?^&/^@K!^='_  G_ (8_Z"L'YT6 Z6BN:_X3_P ,?]!6#\Z/^$_\,?\
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M\'YT6 Z>BN8_X6%X6_Z"\'YT?\+"\+?]!>#\Z+ =/17,?\+"\+?]!>#\Z/\
MA87A;_H+P?G18#IZ*YC_ (6%X6_Z"\'YT?\ "PO"W_07@_.BP'3T5S'_  L+
MPM_T%X/SH_X6%X6_Z"\'YT6 Z>BN8_X6%X6_Z"\'YT?\+"\+?]!>#\Z+ =/1
M7,?\+"\+?]!>#\Z/^%A>%O\ H+P?G18#IZ*YC_A87A;_ *"\'YT?\+"\+?\
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MM_T%X/SH_P"%A>%O^@O!^=%@.GHKF/\ A87A;_H+P?G1_P +"\+?]!>#\Z+
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M4?\ "D3_ -!P?^ __P!E7KWXT?C1S,+'D/\ PI$_]!P?^ __ -E1_P *1/\
MT'!_X#__ &5>O?C1^-',PL>0_P#"D3_T'!_X#_\ V5'_  I$_P#0<'_@/_\
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M/M73?\*1/_0<'_@/_P#95HZU_P EJT3_ '6_] ->FT[L+'D/_"D3_P!!P?\
M@/\ _94?\*1/_0<'_@/_ /95Z]^-'XTN9A8\A_X4B?\ H.#_ ,!__LJ/^%(G
M_H.#_P !_P#[*O7OQH_&CF86/(?^%(G_ *#@_P# ?_[*C_A2)_Z#@_\  ?\
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MB?\ H.#_ ,!__LJ/^%(G_H.#_P !_P#[*O7OQH_&CF86/(?^%(G_ *#@_P#
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M_P *1/\ T'!_X#__ &5'_"D3_P!!P?\ @/\ _95Z]^-'XT<S"QY#_P *1/\
MT'!_X#__ &5'_"D3_P!!P?\ @/\ _95Z]^-'XT<S"QY#_P *1/\ T'!_X#__
M &5'_"D3_P!!P?\ @/\ _95Z]^-'XT<S"QY#_P *1/\ T'!_X#__ &5'_"D3
M_P!!P?\ @/\ _95Z]^-'XT<S"QY#_P *1/\ T'!_X#__ &5'_"D3_P!!P?\
M@/\ _95Z]^-'XT<S"QY#_P *1/\ T'!_X#__ &5'_"D3_P!!P?\ @/\ _95Z
M]^-'XT<S"QY#_P *1/\ T'!_X#__ &5'_"D3_P!!P?\ @/\ _95Z]^-'XT<S
M"QY#_P *1/\ T'!_X#__ &5'_"D3_P!!P?\ @/\ _95Z]^-'XT<S"QY#_P *
M1/\ T'!_X#__ &5'_"D3_P!!P?\ @/\ _95Z]^-'XT<S"QY#_P *1/\ T'!_
MX#__ &5'_"D3_P!!P?\ @/\ _95Z]^-'XT<S"QY#_P *1/\ T'!_X#__ &5'
M_"D3_P!!P?\ @/\ _95Z]^-'XT<S"QY#_P *1/\ T'!_X#__ &5'_"D3_P!!
MP?\ @/\ _95Z]^-'XT<S"QY#_P *1/\ T'!_X#__ &5'_"D3_P!!P?\ @/\
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M?^@X/_ ?_P"RH_X4B?\ H.#_ ,!__LJ]>_&C\:.9A8\A_P"%(G_H.#_P'_\
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M(RIT!([5SOC;QW_PC16UL;=+J^*^8ZOG:B#N<?YXH [6DJ."0RV\<A != Q
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M0[**X>W4*EN[$94#H/?ZUQL>FZIJWBO1KV/P[_8ZVK>9=3?*HDZ97Y3ST[T
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MRAMRDB':OG,0>RG!P3WI >@T444AA1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH ***XJ7XL^"X)I(I-9 =&*L/)DX(X/\- ':T5P__"W? _\
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M\>K*;EY1$J>4_P!XG&,XQUH ["BDS7,:U\0?#/A[4&L=3U(07*@$IY3M_(4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI>K76M/J%C!=& 1B,3(' SNSP?H*L>$+2"Q_:&U*UM8EB@B\]4C08"C:.@H
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MK/\ :T,,QA9S!'-@JS%R#P>#Q5SXWZ3H.DMIDVE);VFH;\-%;*$PG)#8'?-
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MWTIU, U"$E$ "QMO'RC';_&NF^,+K%\4_#$CL%15A9B>P$QH ]B\2Z_;^&-
MN=7NHI)8;<*62+&XY('&?K4'AKQ39>)?#4>NPQR6]J^_(FQE=I().,^E<]\7
M+RV_X5GJ(\],SK'Y8S][YU/'X5QNDS30?LU7#P%E;$@+*<$#SJ .AU+XY>'+
M*_DMH+6]O5C_ .6T"KM/YD&NH\'>.](\:V<DM@S131MA[>; <#L>.,'VKY_\
M$Q>)UTN631/#=OJ,,K$-+)#'(>.WS<@5T'P^\.>+-/\ B-'J<NCFTAD<K<[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(J]110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g0vsdaj33nnl000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 5F")@# 2(  A$! Q$!_\0
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M #V3_OJ@"6BH?M4'_/9/SH^U0?\ /9/^^J )J*A^U0?\]D_[ZI?M4'_/9/\
MOJ@"6BH?M5O_ ,]D_P"^J/M5O_SV3_OJ@":BH?M5O_SV3_OJC[5!_P ]D_[Z
MH FHJ'[5!_SV3\Z/M5O_ ,]D_P"^J )J*A^U6_\ SV3_ +ZH^U6__/9/^^J
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M@"6BH?M5O_SV3_OJC[5;_P#/9/\ OJ@":BHOM4'_ #V3_OJD^U0?\]D_[ZH
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M/^^J )J*A^U6_P#SV3_OJC[5!_SV3_OJ@":BH?M5O_SV3_OJC[5;_P#/9/\
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M^^J )J*A^U6__/9/^^J/M4'_ #V3\Z )J*A^U6__ #V3_OJE^U0?\]D_[ZH
MEHJ+[3!_SV3_ +ZH^TP?\]D_[ZH EHJ'[5;_ //9/^^J/M5O_P ]D_[ZH FH
MJ'[5!_SV3\Z/M5O_ ,]D_P"^J )J*A^U6_\ SV3_ +ZH^U0?\]D_[ZH FHJ'
M[5!_SV3_ +ZH^U0?\]D_.@":BHOM4'_/9/SI/M4'_/9/SH FHJ'[5;_\]D_[
MZH^U6_\ SV3\Z )J*A^U6_\ SV3_ +ZH^U6__/9/SH FHJ'[5;_\]D_.C[5;
M_P#/9/\ OJ@":BH?M5O_ ,]D_.C[5;_\]D_[ZH FHJ'[5;_\]D_[ZH^U6_\
MSV3_ +ZH FHJ'[5;_P#/9/\ OJE^U0?\]D_[ZH EHJ'[5;_\]D_[ZH^U6_\
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M^U=6_P"?RX_[Z-']JZM_S^7'_?1KZK_L/3/^?&#_ +XH_L/2_P#GP@_[XHY
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MVKJO_/Y<?]]&OJO^P],_Y\8/^^*/[#TS_GQ@_P"^*.0+GRG_ &KJW_/Y<?\
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M]\4?V'I?_/A!_P!\4<@7/E3^U=5_Y_+C_OHT?VKJW_/Y<?\ ?1KZK_L/2_\
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M^U=6_P"?RX_[Z-']JZM_S^7'_?1KZK_L/2_^?"#_ +XH_L/2_P#GP@_[XHY
MN?*G]K:M_P _EQ_WT:/[6U;_ )_+C_OHU]5_V'I?_/A!_P!\4?V'I?\ SX0?
M]\4<@7/E3^UM6_Y_+C_OHT?VKJW_ #^7'_?1KZK_ +#TO_GP@_[XH_L/2_\
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M[Z-)_:NK?\_EQ_WT:^K/[#TO_GQ@_P"^*/[#TO\ Y\8/^^*.0+GRI_:NK?\
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M_?%'(%SY4_M75O\ G\N/^^C1_:NK?\_EQ_WT:^J_[#TO_GP@_P"^*/[#TO\
MY\(/^^*.0+GRI_:NK?\ /Y<?]]&C^U=6_P"?RX_[Z-?5?]AZ7_SX0?\ ?%']
MAZ9_SXP?]\4<@[GRI_:VK?\ /Y<?]]&C^UM6_P"?RX_[Z-?5?]AZ9_SXP?\
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M]\4?V'IG_/C!_P!\4<@7/E3^UM6_Y_+C_OHT?VMJW_/Y<?\ ?1KZK_L/3/\
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MQ1R"N?*G]JZM_P _EQ_WT:/[5U;_ )_+C_OHU]5_V'IG_/C!_P!\4?V'I?\
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M5_V'I?\ SXP?]\4?V'I?_/C!_P!\4<@7/E3^U=6_Y_+C_OHT?VKJW_/Y<?\
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MBN'4,K!E/((-4=1UO3])V"^N4AW_ '=W>@1HT56L[ZWU"W6>TE66,]&%6,T
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M/6@9LT4G:EH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1S31P1/+(
MVU$&68]A0!)16!_PFGA__H)0_K0/&GA\_P#,2AHN.QOT51LM7L-1&;2ZCE]E
M;FIKN\@L;=KBYD$<2]6/:@"Q169IVO:9JLC)97:3,HR0O:M.@ HHI*!"T44E
M,8M%9^HZUI^D[3?7*0[ON[N]26>IVFH6QN;6=981U8=*0BY16-#XIT:>Z%M'
M?QM,6VA!US6QGB@!:**2@!:***8!1112 **** "BBB@ HHHH **** "BBB@
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M1!J<4#Q)S\KD9_2BX&W17!:5\3[+5=;CTR.PN$=VVAV*X_G7>=J %HI.:6@
MHHI,T +1252U'5K+2H#->W"1(!GYCR: +U%5-/U"'4[".\MFW12#*G%<3_PM
M2Q&M_P!F?V?<;_-$6_*XSG&>M 'H-%-5MR*WJ,TZ@04444 %%%)F@!:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K6B_P!6OTK)K6B_U:_2HF5$
M?1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D/\
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M6)R2 !7E-_=ZEXY\4^0LA(=\1JS?*BTV["L>[6OB/1[R3R[?4('?TW8K4SD
MBO ?$O@*[\+V4>HQ72RJI&XJ<%37H7PR\2SZWI,EO=/OFMN-QZD4E*^@-'>T
M4450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0T >>?%;7+G
M3=(BM;5S&;@D,PZXK@O"'@.;Q5!)=/>+%&K8/.6)KU#XA>&)?$6C#[-_Q\P$
MLH_O>U>+VE_KOA:Y=(FGMF!PRD'!J);E(T_%G@>]\*R131RF>)S\KH#E3[UZ
M3\,-8N]0T22"]WF2 X5GSDBN*L/BK>DI%J]E!=PYY+*,C\,5ZKX<U;2]9T[[
M3IB(@Z.JJ 1]<4U8-T7FUC3TN# UY")<XVEN<U'=^(-*L91%<WT,;_W2W-?/
M_BQY(_&EX\1(D$QVGWS71)\-=9UC36U6XN5-S*OF;')R>]/F"Q[5;7EO>1"2
MWF21?53FN.^(N@_VY8VL?VVWM=C$YF8C/2O,_!NOWOAKQ&EG,[B!I-DL9/ K
MLOC$0VDV##NY/\J5] L;G@G1?[%\.74'VR"YSN.Z$Y'2O)-!_P"1\A_Z^C_.
MO1OA9_R*-Y_O-_(5YCI]Y%8>+_M4QQ'%<,Q_.D^X'TA<7UM91JUS/'$#TWG%
M1VVJ6-Z^RVNHI6ZX1LUX+K^N:AXXU^.W@4^5NVPQ@\ >M>K>&_#5IX,T*6ZD
M4/<B/=))C]*I2%8Z:\U&SL(]UW<QQ#_:;%5;7Q'I%Y)Y=O?PN_INQ7A%U=:C
MX\\4>4LIVR.?+5F^5%JYXF\!WGA6VCOX;L2JIP60X*FES#L>_@YI:X3X:^)I
M=<TAK>Z8O<6_!8GEA7=U2U$%%%% @HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\1_\ (O7W
M_7(UJUE^(O\ D7K[_KD:!GSEX>T9]?UB'3XY%C:4_>;H*[N3X-7PC8QZA 6'
M0'//Z5P.AZO/H>JQ7]L@>2,\ UV4OQ;UYHR%MHD)'4#_ .M62MU*U.:M9]2\
M)>(Q&LA2:&0!@&X85[EX@MCKG@YD,\<!GC4EY3@"O#](,?B#Q3'+JMTL0D<,
M[-W]J]F\<HD?@.X2(Y144*1Z52V$S$^'?AC^P]0N)?[2M+G<N-L+$D?I7>3:
MO86LWDS7<22?W6;FO(_@[_R%[O\ W*QOB6Q7QK,R_> 4C\A3YK(+:GN5WKFF
MV&W[3>PQ[N0"W:I;/4[*_!-I<Q3#_9;->,V'P]U;Q#I/]J75YB1DS&KDG([5
M@^%[V[T#Q;#&'*GS?+D7/!HY@L?1Y/&3Q69<>(M)M9?*FU"%'S@@M7-_$GQ%
M/HN@JEJY2>XX5AV%>8>%?!5]XN>6Y>;9$#\TC<DFG?421U'Q>N(;F#3Y()4D
M0DX93D5O?#!=_@N1<[=VX9/;BO+/%>A:CX<N4L+N8R0#YHCDXKU'X:?\B/+]
M'_E4IW8V<]H_@G[-XJCO/[8L'Q,S>6KG<>3QTKUFZU"TL0OVJXCBW=-[8KYZ
M\._\CW%_U\M_,UVWQE_U6G_4_P!::>@6/2WUC3X[87+7D(A/1]W6H[37]*OW
M"6U]#(QZ -S7B'A;PIJGBVTV&Y,5C!PN3QGZ5D:QI5YX2U_R/-(DC.4D4XR*
M.8+'TQFLZ[UW3+!]MU?0QM_=+<UR^I^*YK#X>PZF/^/F:,*I]&(ZUY7X>\.Z
MCXVU69S-[R2N2:;8K'ORZSISVWVA;V$PY^]NXJ>UO[6]4M;3I* >2ASBO /%
M?A?4O"<0@:X,EG,<C!XS]*[;X-_\@Z]_W_\ "DI:CL>I44E+5$A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"B[ ^@8[A)+99U^XR;Q],9KEH?B+HTVK#3E,GGF0Q].,UO6?_(#A_P"O<?\
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M@>]1#PWXO\4WL9O8;A@./-F!  J$VAL]F@URQUW1+FYL)?,C"$$XKQ7X>_\
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M10 4444 %%%% Q*UXO\ 5K]*R#6O%_JU^E1,J(^BBBLQA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !60_WV^M:]9#_?;ZU<"9#:***T)$
MQ2]Z** $Q1[4M% #?:EI:*!B=**6B@!,44M% #=HSD@'ZTM+10 4F*6B@!,9
MH  Z #\*6B@0F**6DH&!%(5!Z@'\*6EH$)C'2BEHH 3%&*6B@!,48HI: &A0
M.@ ]>*6EHH&%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M2B@ HV@]0**/QH&(% S@ ?04'I^%+10P/ ==T?49/',TJ6<S1FXR&"'&,U[S
M"O[B,,.BC@BG^4A.=BY]<4ZDD 48%+24Q!CVHHHH&&*,>]%%,0A&: H'0 ?2
MG44@$Q2T44#"BBB@ HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1129H 6DHHH ***,T#"C'%+VI*8!
M1BBBD(,44M% Q,4%0>H!^M+24 &*,4<T4 ':BEI* #%':BCG]:!&%XLT:76]
M GM('*3$90Y[UXI:S^*O"NI%TBN-Z<8="RFOHBHWABD/S1HWU -)JXTSY]U7
M4/%'C&>*&XM78 X5(XR!^->N^!/#DGAW0EAGQY\AW/CM72I!"ARD2*?90*DH
M2LPN+WHI.U+3$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4F*6B@!,48I:* $Q1BBEH *2EHH *3%+
M10 F/>BEI,X')Q0 M%-# G@@TM,8M)2T4A!1124#%I*6B@04F*6B@!* **6@
M!*.U%% PQ2T44"$HI:*!A24M% A**6FDXZG'UH&.HIH8$\$?G2YXH0!13'FC
MC_UDBK]30DT<G,;JX]CFBX#Z*6BF(0TM%%(!*!UI:*!A28I:BDN(HB!)*B$]
M S 4 28HI <C(Y!Z4HH 6BBDSW- !BC%-WC^\/SIU !BBD) ZF@,#P"#^- A
M:,5&;B$2^694#]E+#-24 +28I:* $HQ2T4 (!12XHH *3%+10 E+110 4444
M %%%% !1110 4444 %%%% !1110 4444# ]*UHO]4OTK)K6B_P!6OTJ)CB/H
MHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R'^^WU
MK7K(?[[?6K@2QM%%%:$A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1124 <9\0O$U]X:L+>:R";G?!W"O/%^*WB)_NQQ'Z*37
M4_&/_D$6?_70U3^$ZZ<VF7?VQ;4MO&/-"Y_6H=[E+8Q!\6/$"',D,6WW4BNY
M\%?$*/Q'/]BNHUANL97'1JM^*8?#/]@W/GK8@A"4\L*&SCCI7C_@E)'\968M
MP>)<\>E%VF!](9H_&L;Q'XCM?#FF-=W)RW1$'5C7EDOQ9UR>5GMK-!$IZ!<X
M'O5-I:"L>VTE>?>#_B5%KER+&_B$%RWW&'W6KL]6U6VT;3I;VZ;;'&/SIIA8
MOT5XO=_%O59[MET^S01Y^4$98BIY/B_=+8*/L*K>*V&#="*7,@L>K:C.]KIU
MS/']^.-F7/J!7F7A7X@:QJ_B6.PN5C\EF8'"G/&:Z7PUXJN-=\+7>H7$$8:-
M6^0<@X&:Y?PGXS_M/Q/'9_V390Y+#S(XP&'6AL#UJBL/Q)XGLO#5@9[ELN>$
MC'5C7E]Q\7=8FE8VUK&J \#&>*&PL>V4M>7>&?BLE]=I::K"L+.<+*O3\:[?
MQ)K#Z/X=N=2@59&B3<H)X-"86-JBO'[+XPW'DS&YLT,@'[I4[GWJD?BWK<-Q
MNELXPAZ(011S(+'MM%87A;Q)!XFTI;N(;'!PZ'L:W:8!1110(**** "BBB@
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MQ;2?H!6O\71CQ':J.@B_PK6U:P^V?".TF"Y:%0P/X4#.,\0>(3JVBZ79AB3
MF&'OQ5GQ9IPT[0-&CQAGBWM]37/:)9M?ZS:VJC.^0 UWWQ:B$#:;$HX2("DM
M@.Y^&W_(FVOXUPGQBC5=8M)!U,>#^9KN_AM_R)UKCU-<!\79Q-K]O"O5(\8]
M\U3V%U/1_ 4K3>$+,DGA<<UT]<_X,M6L_"ME&PPQC!/XUT%4A!1110(****
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M6\<2C"HH4?A4M%%,04444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %9#_?;ZUKUD/]]OK5P)8VBBBM"0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P _C1_PI6R_Z#5[_G\:.<+'9?;+;_GO'_WT*/MEM_SWC_[Z%<;_ ,*5LO\
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M?_?0H^V6W_/>/_OH5QO_  I6R_Z#5[_G\:/^%*V7_0:O?\_C1SA8[+[9;?\
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MME_T&KW_ #^-'.%CLOM=M_S\1_\ ?0H^V6W_ #\1_P#?0KC?^%*V7_0:O?\
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M?QHYPL=E]LMO^>\?_?0H^UVW_/>/_OH5QO\ PI6R_P"@U>_Y_&C_ (4K9?\
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M]]BN-_X4K9?]!J]_S^-'_"E;+_H-7O\ G\:.<+'9?;+;_GO'_P!]"C[9;?\
M/>/_ +Z%<;_PI6R_Z#5[_G\:/^%*V7_0:O?\_C1SA8[+[9;?\]X_^^A1]LMO
M^>\?_?0KC?\ A2ME_P!!J]_S^-'_  I6R_Z#5[_G\:.<+'9?:[;_ )[Q?]]"
MC[9;?\_$?_?0KC?^%*V7_0:O?\_C1_PI6R_Z#5[_ )_&CG"QV7VNV_Y[Q_\
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M]]"N-_X4K9?]!J]_S^-'_"E;+_H-7O\ G\:.<+'9?;+;_GO'_P!]"C[7;_\
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M6W_/>/\ [Z%<;_PI6R_Z#5[_ )_&C_A2ME_T&KW_ #^-'.%CLOM=M_S\1_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%)FDSQ0 ZBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]'FNECFL;B*,G&\X_P : /7J*HZ5JMGK.GQWMC,)89!D$5>H **** "BBB@
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MB-,XW8'^- 'KM%9NC:U8Z]IZ7EA.)86[CM63XP\:V/@ZVAFO4=Q*<*$_S[T
M=117D_\ POC0/^?:X_(?XUO^$OB;IGB[5386<4J2!-V7 Q_.@#N:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F,P49)
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MM?,?Q="I\0KK9@<+GZU] _#\LW@?2BW7R5_E0!T]%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:K\0[>:%"8TD:1B.PYKJ!\!]:,PC;4HO(SU_^MFO5/ _@*Q\&6;+"?-N9/\
M62G^E '8#I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #2<<GM6'8>+
M=)U/6I]*M)_-N8,^9M&0/QK'^)OB@>&?"D\B/MN9QY<0[Y/_ -;-9OPFT$:3
MX4.J7(W7=[F9W;KCJ*=M!7U.YU'5[#28/.O[J*WC'\4C 5DV7C[PQJ%R+>VU
MBU>4G 7S!S7C%PEU\4?B9/8O<R)IMNS#"GC:#BN@\8_!S3M/T":_T1YHKJV3
M?@M]X#^M.R%=GM2L& *G(/<4ZO,O@YXJGUWP\]C>.6NK-MI8]2O;^M>F]J3&
MF-9PB,['"J,DFL%_&WAR.1D;5[564X(,@J?Q3>?8/#&HW!.-L#<_A7@?PZ^'
M=MXVM;V_O;F:)1*0NP^M-(&]3W0>./#;, -8M"3P!YHK=BE2:-9(V#(PRK#N
M*\GC^!.CQNKB_N3M(/WA_A7J=C:K964-LA)6)0H)Z\4FET!,LT444AA1110
M56O+R&PM9+FYD6.&,99V/ %1:KJ=OH^G3W]TQ$,*[F(%?.OCWXBZIXR@F@TJ
MWFBTJ+F1P#\P]SZ4TKB;L?0^D:W8:Y9_:M.N$GASC<IR,U?)Q7F?P._Y$8?]
M=3_,U;^+?BF7PYX8\JTDV7=T=B$=0.YHMK8+Z'0ZEXX\.:3/Y-YJUM'(."ID
M&15[2O$.E:TF[3KZ&X Z['!(KR7P/\)+/5=&CU7Q#)+-<7(W!"WW0?ZUEW_@
MS6O GCBTN?#RW,]B[ L "<#/(.*=D*[/;]:UNTT'3WOKYBL"D L!G%3Z;J=K
MJUC%>V<JRP2#*LIJ&_L(]:T.2TNH\K/%A@1T)%>2?"_69O#WBW4/"-_(0@D)
MMPWYX_*E8;9[;1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&
M!110 48HHH **** "BBB@ HQ110 4444 %%%% !@4444 %%%% !BBBB@ HQ1
M10 8HHHH ,48HHH **** "C%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 8HP*** "BBB@ P**** "BBB@ Q1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@XZXXQ_6EI<-CW.-UEC5U.589!'I7@OQ1B&B?$_2=5A&QIF0L1W.['\J]KT
MR?V!8^8/G\E<_E7C/QQ;?XET*-?O[E_]"H6XWL>YVTGG6L,O]] WYBIJIZ6I
M32K,$\B%,_D*N5)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY]YO^^*7[4?^?>;_ +XH L456^U'_GWF_P"^*/M1_P"?>;_OB@"S15;[4?\
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M^?>;_OBC[4?^?>;_ +XH LT56^U'_GWF_P"^*/M1_P"?>;_OB@"S15?[4?\
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M* +-%5OM1_Y]YO\ OBC[4?\ GWF_[XH LT56^U'_ )]YO^^*/M9_Y]YO^^*
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M ,^\W_?% %FBJWVH_P#/O-_WQ1]J/_/O-_WQ0!9HJO\ :C_S[S?]\4GVH_\
M/O-_WQ0!9HJM]K/_ #[S?]\4?:C_ ,^\W_?% %FBJWVH_P#/O-_WQ1]J/_/O
M-_WQ0!9HJM]K/_/O-_WQ1]J/_/O-_P!\4 6:*K?:C_S[S?\ ?%'VH_\ /O-_
MWQ0!9HJM]J/_ #[S?]\4OVH_\^\W_?% %BBJ_P!J/_/O-_WQ1]J/_/O-_P!\
M4 6**K?:C_S[S?\ ?%'VH_\ /O-_WQ0!9HJM]J/_ #[S?]\5.K;E!((]B* '
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!?\ Q(M/-^;,[.??'- #KNX\:>"[FVN;N:[MS)ADWL<-[5] ^#/&<7B'P?\
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M  H ^5?"WAK4?%NJC3M/=?.*Y^=L"NKU+X-^,M'M6NUC694&2(7)859^ _\
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M2OI7 ?$_XGWNNFXT&&!8+2*7:S#JV*[SX#>';?3]+GU,7<,UQ<#!2-@=@]Z
M/9J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "LCQ'HD'B+1+G3+C[DJXSZ&M>DQS0!\N7WP[\9^#]5,^E1SNJYVSV^>E)
M;> ?&WC#55EU2*X4'AI[C/ KZC*@]<&@* ,  ?A5<Q/*97AO0X/#VA6NFP#Y
M85P3ZFM>BBIW*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<BOI.O+/@SX0FT'19=1O8BEU=$;588*K_G%>IT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !69XC_Y%K4O^O63_ -!-:=9GB!6D\/:BB*69K:0
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MHR23BOB_1[3Q;H%Z+O3;&_@G QO6W)_F*VKO6/B3K$)M9VU1XWX*^25S^.*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %(0",$9I:* (_)B_P">2?\ ?(I?)B_YY)_WR*?10 U8T4Y5%!]A2E0P
MP0"/0BEHH @6SME;<MO"&]0@S4V .E+10 4444 %%%% !1110 4444 %%%%
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M-UK6;70M,EU"[8B",98BN+_X75X3_P">\O\ WS2L.YZ-163X?\0V/B335O\
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MPKX+TGPC9^3I\7[Q@-\K#YFJM$*S9OW+B*UD=C@*I))KP?X0(;WXCZQ?@90
M\_7->D_$[7QH/@N\=6 FF4Q1C/<UC_!GPV^D>&C?W"XN+UM_/7;V_K0M@>YZ
M;1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 (1Q7GMSX N;;Q_#XCTBX2!&/^D1$?>Y
MYKT.DXIW%80 XYI<4M%(84444 %%%% !1110 4444 %%%% !28I:* //_%O@
M:]\6>)+*6ZNE&DVQW& #EC7=6]O';6\<$2A8T 55'85-Q10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 =JKFW<G/G./:K%% %;[,_P#SW>C[,_\
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M_P#/=Z/LS_\ /=_TJS10!6^S/_SW?]*/LS_\]W_2K-% %;[,_P#SW>C[,_\
MSW?]*LT4 5OLS_\ /=_TH^S/_P ]W_2K-% %;[,__/=_TI?LS_\ /=_TJQ10
M!6^S/_SW?]*/LS_\]W_2K-% %;[,_P#SW>C[,_\ SW?]*LT4 5OLS_\ /=_T
MH^S/_P ]W_2K-% %;[,__/=_TH^S/_SW?]*LT4 5OLS_ //=_P!*/LS_ //=
MZLT4 5OLS_\ /=_TH^S/_P ]WJS10!6^S/\ \]WH^S/_ ,]W_2K-% %;[,__
M #W?]*/LS_\ /=ZLT4 5OLS_ //=_P!*/LS_ //=_P!*LT4 5OLS_P#/=_TH
M^S/_ ,]W_2K-% %;[,__ #W?]*/LS_\ /=_TJS10!6^S/_SW?]*/LS_\]WJS
M10!6^S/_ ,]W_2C[,_\ SW?]*LT4 5OLS_\ /=_TH^S/_P ]W_2K-% %;[,_
M_/=_TH^S/_SW?]*LT4 5OLS_ //=_P!*/LS_ //=_P!*LT4 5OLS_P#/=_TH
M^S/_ ,]W_2K-% %;[,__ #W>C[,__/=ZLT4 5OLS_P#/=Z/LS_\ /=_TJS10
M!6^S/_SW?]*/LS_\]W_2K-% %;[,_P#SW?\ 2C[,_P#SW?\ 2K-% %;[,_\
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M-% %?[,__/=_TI/LS_\ /=_TJS10!6^S/_SW>C[,_P#SW?\ 2K-% %;[,_\
MSW?]*/LS_P#/=ZLT4 5OLS_\]W_2C[,__/=_TJS10!7^S/\ \]W_ $I/LS_\
M]WJS10!6^S/_ ,]WH^S/_P ]W_2K-% %;[,__/=_TH^S/_SW?]*LT4 5OLS_
M //=Z/LS_P#/=_TJS10!6^S/_P ]W_2C[,__ #W?]*LT4 5OLS_\]W_2C[,_
M_/=_TJS10!6^S/\ \]WH^S/_ ,]W_2K-% %;[,__ #W?]*/LS_\ /=_TJS10
M!6^S/_SW?]*/LS_\]W_2K-% %;[,_P#SW?\ 2C[,_P#SW?\ 2K-% %;[,_\
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M/LS_ //=_P!*LT4 5OLS_P#/=_TH^S/_ ,]W_2K-% %;[,__ #W?]*/LS_\
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M;[,__/=_TI?LS_\ /=_TJQ10!6^S/_SW?]*/LS_\]W_2K-% %;[,_P#SW?\
M2E^S/_SW?]*L44 5OLS_ //=_P!*/LS_ //=_P!*LT4 5OLS_P#/=_TH^S/_
M ,]W_2K-% %;[,__ #W?]*/LS_\ /=_TJS10!6^S/_SW?]*/LS_\]W_2K-%
M%;[,_P#SW?\ 2C[,_P#SW>K-% %;[,__ #W>C[,__/=_TJS10!6^S/\ \]W_
M $H^S/\ \]W_ $JS10!6^S/_ ,]W_2C[,_\ SW?]*LT4 5OLS_\ /=_TH^S/
M_P ]W_2K-% %;[,__/=_TJ=054 G/N:=10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%4M4U*WTG3IKZZ<)#$NYB: +M%
M?.NN_'#7+W4)(M#MUC@4X4E=S$>N*M>%/CAJ"ZDEKX@C1H7.#*JX*_457*R;
MH^@**AM[B.ZMXYXF#1R+N4CN*FJ2@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KS7XV32Q>!)%CSAY0K8],&O2JY_QCX>
MC\3^&[G36.'<90^AIK<3V/'_ (":3I]Y)J5S<0QRS1[57<,X!S7/_&K1K+2?
M%RM9(L7G1!W11QGGFJ-E#XP^&^N3"VM9 Q^4_(61Q6+XMFU_4;M-5UZ-TDN!
M\@92.!Z#\:TZD=#Z.^$VIOJ?@.Q,C%GB'EDGV_\ UUW5>9? ^-D\"J6Z-*2/
MR%>FUF]RUL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %(3@$GICFEK \8ZZGAWPO>ZBQ&Y(SL'JW:@#G-4^,7A
M?2M2GL)WN#+"VUBD9(S79Z1JMMK6EP:A9L6@F7<I-?&<PN=0DN+PHTGS;I'Q
MTS7N?P(\1-<6%SHLTF6A/F1@GL>WZ4 >SD@ GL!FO.+GXV>%;2[EMI3=;XG*
M-B(]0<5Z-)_JW_W37QM<6BWWC2>U=B%EOF0D=LOB@#WX?'/PD3C==#_MB:Z;
M0/'WA_Q&PCL;Y/-/2-SAORK@&^ FFR6X,>HS*Y7(SCK^5>5>)_#>I_#_ ,0Q
MQ>>0P^>*5.-PH ^N68*I)[<UYW>_&CPO87TUI,;KS(7*-B(D9%;'@'Q&_B?P
M;!>RD&<*4D/J0*^9]9MEN_'-Y;L2%DNRN1[F@#WH?'/PD3]ZZ'_;(UT7A_XA
M>'O$DODV-ZHF/2.3@G\*X,_ 33)+<-'J$RNRY&<8_E7CVK6%YX-\5R6BS$36
MLH*NIZ]Z /IKQ3\0M%\(7,4&IF8/*NY?+0GBN>_X7IX2_O7?_?DT_4? ]G\1
M=(TK4[NYDB?[.!\O?K7F/Q,^'%EX+TJSNK6YDE::;RR&QP-I/]* /3/^%Y^$
MO[UW_P!^36YX8^).A^+=0:STTSF54WG?&5&*\6^&GPXLO&FFWES=7$D302!
M%[Y%>F:9X#T[X<6U_KL-U)(T=NPP_3M0!T?B3XA:!X6?RK^ZS-_SSC^9A]15
M+0OBMX9UZ[6U@N6BE8X43+MS^=> >'=+N?B%XV$5W.P,[&21\]!G_P"O5_XB
M^!/^$&O[62TN'>"8?*Q/*D=?YT ?4P8$ @Y![USOB'QSH7ACY=0O%$A_Y9KR
MWY5C^ ?$LNL?#I;T[I+FVC:-@.2S*,_U%>'6_AK7/%_C?RK^&ZC%Q*Q:21"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/>,[S5
M-/\ #%W=Z0%-W$NY0RYXKH::Z*ZE& *D8(/>@#YU\+?&:YBU*4^*%6:!A\OE
MQ\J?UKEO'7B=_'OB>,V%NXA $<,8')_"O<-:^#GAK5[U[I8Y+=W.66,@"M+P
MS\-/#_AB87%M;F6X[22\D?2KNB.5FAX'T4Z#X1L+!AATC!?ZUT=)C%+4W+04
M444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/M'FARH/M7J*^*]"CME9]4M@ HS\_M7@7QA\7VOB76+>VTZ3S+>V4@L.C,:
M.X^ LC-X7U-&SM61=OY-7C&NW)L_&U[<!=QCNF8 _6OH#X/:-)I7@7S95*R7
M1,A!';''\Z\%U*-)OB#<QR#*->$$'N,T =\WQ\U(6XCBTR!2%V@DG_&N"@LM
M9\<^)FF$$DLUS("[A?E45],0> ?#'DQL=)MR2H.=M;>GZ-IVEIMLK.&$?["
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%9EYKVFV%]#97%TB7$QPD9/)H TZ*K7-];V<7FW,R1
M(>-SG JI_P )%H__ $$K;_OX*+!<U**HVVKZ?>2^7;WD,K]=JN":O4 %%%%
M!BBBB@ HJ&>ZAM8C+/*D2#^)S@5F)XKT*27RDU2V+YQCS!0%S9HJ-)%D0.C!
ME/((/!HDF2&,R2NJ*!DEC@4 245BCQ7H33>4-5M=^<8\P5K)*LB!XV#*>A!R
M#0!)167+K^FP:JFF2W2)=N,K&W4UI@T +1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <[XUT[4=6\,75AI;*MQ,-N6.,"O-OAY\*-3\/
M>)H]2U0PLD0)0(23N_*O:L4M "5P_P 3?!DOC#0$@M-BW<3AD9NF.]=S10!Y
M+\,? OB#PAJ-R+UX6M9TP0C$X/;M7&:I\%?$MWJMW<QO;;)9F=<L<X)SZ5]&
MT4 ?-0^!_BEN&FM]O^^?\*ZSPK\#8K2YCNM:N!*4.X1)T/UKVFB@"%($AMA#
M$@1%7:J@<"O![GX0^(9?%TNIA[?R&N?-'S'.,_2O?J* &1*5B13U"@4^BB@
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M,^E>,_##P#J7]M2>)_$*$7,A+1HXYR>YKVBAA$P/&%OJEUX<N8M'<I>L/W;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!!=6T5W:RV\R!HY%*L#T->+>$8[GP
M!\2+G19U?[!?-F%L?+G/'\Z]PJO+96T\J2RP1O(ARK,HR*:8FB; 8<C((J/[
M);[MWD1[O7:*FHI#$  Z"EHHH **** "DI:* &>5'_SS7\J3R8O^>:?]\U)1
M0 P1HIR$4>X%.(SU _&EHH A%K!NW"&/=Z[14N!C@8%+10!Y+\7M2N=1:T\*
M::CO<73@R;1P!7>^$M"B\.>';73HE *+\Y'<]ZU6L;9KH7+01F8='*\U8I]!
M6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]UO^^31]K3^Z_P#WS5BC% %?[6GHW_?)H^UI_=;_ +Y-6,"CB@"O]K3^Z_\
MWS1]K3^ZW_?)JQQ10!7^UI_=?_ODT?:T_NO^56.** *_VM/[K?E1]K3^ZW_?
M)J?'L*7% %?[6G]U_P J/M:?W7_*K&** *_VM/[K_P#?-'VM/[K?E5BC ]*
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M_?)JQBB@"O\ :T_NM^1H^UI_=;_ODU8XHH K_:T_NM^5'VM/[K?E5BB@"O\
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M?:T_NM_WS5BC% %?[7'Z-_WR:/M:?W6_[Y-6** *_P!K3^Z__?-'VM/[K?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!XI\;_%][I[V^BV<C1"5"\C+U(]/UKC/"OPIUCQ5I2ZD;Q8HI/N[FR37>_&
MGP5=ZS'!K%@ADD@4J\:C)(]?TKRK0/'GB/P@/LT,K+"I_P!3*O _.@!/$7AS
M7? 6L1HTS@GYHY8SP:^A_AQXBE\2>$H+JX!%PA,;Y[X Y_6O,K#XQ:9J\T,7
MB31XI O E SMKV?0)-*GTN.XTA8A:R<CRZ .5\;_ !/TSPM'+;1-Y^H 8$:_
MPGWKYSFUF\UGQ.M_=2L999U/7IR*]WU#X0QZWXPN]7U*Z_T>1PRQ+W'O7C7B
MFR@TWXCW-G:H$ABN8U11V&%H ^L--_Y!=I_UP3_T$5:JKIO_ ""K/_K@G_H(
MJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1124 ?/GC*_U/QM\1AX=MKIH+
M:-]A .!QU-=1'\"=)%OMDO[EIL??![_E6%X_\(:YH?BW_A)M"C>16;>VP9*G
MOQ3M/^.=_9%8M9TEMPX+ $']: ,.\M-:^%7C"W\BYEN+*0Y ZAA7T59W*W5E
M%<#@2*&Y[5Q&C^.?"/C26*.98OM(^ZDZ_P J[Q8T6((@ 7& !0!Y9X\^*]OI
MOFZ5HH:XOSE&903L-<I\$KFYNO&=]+=,YF="6W>O->I67@#0],O+O4A;B:ZE
M)<O)SCZ5YM\) !\2-8 X +?UH ]YHHHH C::-&PTB*?0L*3[3#_SVC_[Z%>:
M>-/A_KWB#76O;#5VMH2H 0,17._\*C\6?]##)_WV: /;?M$).!-'S_M"I,UX
MI9?"GQ3;WL,SZ^[*CABN\\BO9X$:."-&.650": )#7GGCCXI:;X9BEM+9O/U
M#!&T=$/O7HE>4W'P?AU;Q9=:OJ=SNADDW+"O?IUH \,BU:[U;Q7#>W,K-)+<
M*QY]Z^P;+_D'V_\ UR7^5?)NLVD-C\1WM;=-D4=TJJH[<BOK*R_X\+?_ *Y+
M_(4 <'XY^*.F^&8I;2W;S]0P1L'13[U\\+JUWJWBB.]N96,LLP9N?>O=[SX0
M0:MXLN]7U*YW0R2%UA7O]:\9\06<%A\1I[6V0)#'=;54=AF@#ZPL/^0?!_US
M%?//Q3\1ZSK7BIM)MA/';1N(T500&-?0]A_R#[?_ '!4=SIUC(?.EM(6=/F#
M%!G/UH ^9M?^&^O>&M!CUF2YRIP756Y7/XUZ1\$_%EYK%I<Z;?2F5K<9C=N3
MCTKA/B/\1=2UJ2YT80B&SBDVY ^]BN\^"&BV5GI4U]'=QS74_#(IY04 >NT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1VHHH \T^)?Q)?PA(NGVMOONIDR
MKGHM?.VLWFHZCJ!O=2,AFF.\%QU!]/:OJ[6?!&CZ]K<.I:A#YSQ+M5">*\/^
M-]O#:>+[:&")8XU@4!5& .!0![/\,O\ D0-+_P"N0_D*Q/B7\2)/"#K86MOO
MNI4W*YZ+6W\,O^1 TO\ ZY#^0JSK/@C2-?UF'4M1A\YXE"JA/% 'RCK5UJ-_
M?&]U+S3+.-X+C&1[5]4?#?\ Y$/2_P#KG_4UXU\=K>&U\46,,$:QQK:* JC
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MQS,B#RQT_*@#Z6HKY@/Q5\<H-S.V/>#_ .M70>$_C=J']IQ6VN1H\$C!3(H
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M7P6\;W-[*?#]Z=X1-T+>P[?K7MM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "
MT444 %%%% !1110 4444 %,>*.3[Z*WU%/HH :D:1C"J%^E.HHH **** "BB
MDS0 M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 8J)K>%VW-$A/J14M% "
M!0!@# I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M% $8AC5
MBRHH8]P*DHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3/K0 M%)FC- "T444 %)
MBEHH **** "BDHS0 M%%% !1110 44F:6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)?#G73K_ (-L[IVS*B^6Y]2*ZV@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'E_QRNF@\%>2IQYLJ@_@16W\*K9+?X?Z<5'^L4L?S-9/
MQLL7NO [R(I8PR*QQZ9%:/PEO$N_ %BJMDQ94_F: .+^/R[H]*7UDQ_.O1/
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ML+GPUX]LO%-O&Q@+*SD#N#DBO04^*?AS^PQ?&]3S/+SY7\6<=* /-]7Q/^T
MH3G$HZ?[@KZ!'W1]*\$^&=C<>*?B#>>)YXV$$;,4)'4D8_E7OG:@#'\3:Y_P
MCNA7&I&$S>4,[%ZFO+O^%^)_T YZ]CN+:&[A:&>-9(VZJPR#6=_PB^A_] RV
M_P"_8H J^#_$P\5:&FI+;M!N8C8U=#4%K9V]C"(;6%(HQT5!@5,1F@!CJ)$:
M/.-P(ZUY+X@^"=E>17-U;7L_VIMSC><@GKCI6%<^*-:\%?$V4ZQ-/)ILK87=
M]T*>XKT75/B=X;LM)>ZCOXY9"A*1KU)QQ0!Q'PA\5WL.KW'A?42&\G(C. ,8
M[5EX\KX_+OXS+Q_WS4OPBTFZU?QC?>))HF2#<Q0D8R2?_KT_XI65SX=\>V/B
M:&)F@+*78#T&* />:\ OQYW[0$6SG$@KT5?BIX;;0_MYO%#[,^3_ !9QTKS_
M .&UK=>*?B)=^*)(66V5B5+#N3P* /=I5W0L#T*UX/\ "QOLWQ3U>W3[A#?U
MKW.]G6WLIIG.%1"2:\1^#D+7OCC6-3"_N^1GW.: /=Z*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,OQ#IBZSH-Y8.!^]C('UQQ7EGP<U!])U+4_#%
MZ?+EBD+1AN_/^%>SXK@M?\ O>>++/Q!IEPMM<1L/.&/OB@#3\8>!=/\ &0MA
M>S2Q^0VY=G>NAL;1+"PM[2,DI!&L:D]P!BIUSM&>N.:=0!QNM_#S3==\20:W
M<3RI/#C"KT.*Z+5-'LM9T][*^A66%A@@BM#%% 'DUU\#-+:9FM-1N8$8\H&.
M/YUT_A3X<:+X4D\^W0S7./\ 6R<D5V5% '/>+/"EIXNTL6%Y))'&&W93K5[0
MM&@T#1K?3+=F:* 84MUK3HH Y+Q9X"T_Q==6L]Y-+&UMRH3O736MNMK:Q6Z9
M*QJ%!/M4^*,4 %<UXP\&V7C*RBM;V62-(VW IUKI:* ,_1M,BT72+738&9HK
M=-BENI%7\>U+10!P.N_"O1M<UW^UC--;7&0W[KC)'>M'Q1X$L?%FEV=A?W,P
M6V((=>K8&.:ZVB@#R?\ X4)X?_Y_KO\ S^-6+3X'>&[>4/)+<3 ?PL<#^=>H
M4F* *>F:59Z/9):6,*Q0IT517":Y\'-%U[6;C4Y[JX26=MS*O05Z110!Y.OP
M&\/ @F\NC_GZUT.@_"WPYH-PMQ%;^=,IRK2\XKMZ* $    X KRCXT:T?[-M
MM MCNN;R094=<5ZN>AQ7!1^ 9+KQT_B'4[@3JG^HBQPM &WX'T/_ (1[PI96
M# "14#/_ +QZUT=(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#B;?X:Z9;^+V\1K/,;EF+%#]WIBNVHHH Y+Q;
MX"T_Q?<VL]Y-+&UN<J$[UT]M MM:Q0*25C0(,^PJ:B@#CS\/M./C1?$_GR_:
M@<[/X:D\7>!-/\826[WLTL9@.5V5UF** (;6!;6VCMU.5C4*":Y.S^'>FV?B
MV3Q$D\QN9"24/W>F*[*B@"EJFGQZKIL]C,Q6.92K$=16/X1\'67@ZSFMK*62
M197WDO72XHH Y'Q5\/-%\6,);N,QW _Y:Q\-7)1? O3?-'GZG=2PJ>$+'_&O
M6Z* ,O1=!L-!TU;&PA6.(#L.3]:P]$^'^G:%XFN=<MYY6GGSN5N@S7848H *
M*** "BBB@ HHHH *YCQ7X'TGQ="%OH]LBCY95&&%=/10!Y!;_ 31X[C=-?3/
M&#D**],T30K#0+!+.PA6*)?0<GZUIT4 <MXI\":-XM3-]%MF PLJ<$5PZ? +
M2!/E]0G,>?N@5[#10!B>'/#&F^&+'[+IT(0'[S'JWUK;HHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,?Q+H\6O>'[S3I>DJ$ ^AKS/X/:I-I5]?\ A2_.R6!]T0;OZ_TKV,UR6H>!
M+*Z\5V_B""9[>ZC/SA.C_6@#?U32;+6;)K2^@2:%NH85Q'_"E_"WVCS?*EQG
M.S><?SKT4# I: *&E:19:-9):6,"0PKV4=:OT44 %%%% !1110!BZ_X8TKQ)
M;B'4K59 .C8Y'XURL'P9\*PSB0PR. <A6<X_G7HE% %2QT^UTVU2VM($BB08
M"J *9JFDV6L63VE] DL+CD,,U>HH \Y_X4QX6^T>;Y4NW.=F\X_G7<:5I-EH
MUDMI8P)#"O15%7J* . ^+/B#^Q_"$UO"W^DW?[M%'7!ZT_X5^&O^$?\ "D3R
MK_I-R?-DSVSVJ_K/@:TU[Q);:I?3R21V^"EN?NYKJU140*HPH& !0 ZBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%0;;G^^GY4;;G^^GY4 3T5!MN?[Z?E1MN?[Z?E0!/14&VY_OI^5&VY_O)^5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4AI:* /GCXQW&N:1XI66&[N([.505VGY01BNM\
M!_%;1IM!@M-7N?)NX5"LS\AAZYKT#Q'X9T[Q1IS6>H0AEZJW=3ZBO)[W]G]?
M,8V>JD*3P''0?E0!D?%[QEH.OPP6FEJLLD;$M,%Q_P#KKH?@+8W$&E7][*&6
M"1@%)Z''7^=,TOX!VT5PLFH:BTJ \H@QG]*]7M]%MK'1#I=BH@B\LHNWMQUH
M ^>?BMX]GU[5I-,M'*6-LVTX/WSZU+\-K_P7H 74=9N6DOC]Q#$2$KJ9O@#%
M//)*VM2;G8L?E'^%,_X9\A_Z#,G_ 'R/\* /1O#WC[0/$MX;33+AI)57)!0C
MBNIKSGP-\+8_!FK/?+J#3EUV[2/_ *U>C4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5#$A'JW% 'AGBS5;SQ_\0ELH2S6XF$42KV7/)_G7T=H&BVVAZ);Z=;QJJ1H
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M>-+FXCB:0X0,>IH M44@((!!ZTM !1110 4444 %%%% !1BBB@ HQ144L\4
M!EE2,'H78"@"6BJO]HV7_/Y;_P#?U?\ &E&H63<+=P'Z2"@"SBBFJP895@0>
MX-,EN(8 #-*D8/0NP'\Z ):*J_VC8_\ /Y;_ /?U?\:?'=V\IQ'<1.?]EP:
M)Z*2H'OK2-BKW4*L.H:0 B@"Q15;^T;+_G\M_P#OZO\ C4L<\4O,<B./]E@:
M )**,U4AU*SN+E[>*YC>9/O(#R* +=%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 0W,\=K;23R,%2-2Q)KY?U:YNOB/\1Q!$S-"TI1!V" ]:]K^+&K_ -E>
M"+K:VV2?]VO/^?2O/?@-H@FO;O5G7/E@(A/J?_U4 >VZ/I5OHVEP6%L@6*)0
MH KA?$7PJM_$_BUM5OKHBWV@")>IQFO2J3% 'RC\3-+M='\;M9640CAC50%'
MUKZ6\*?\BKIO_7$5\[?&#_DH\_T7^=?17A3_ )%73?\ KB* -BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O(/CV,Z!9 =YOZ&O7Z\A^/)QH-BWI.
M/Y&@"Y\,_ &E0>&+>_OK2.XN;I Y,HW8!'O7%_$OP^G@?Q/8:WHQ\B.5\[%.
M ",?IS7KGP]U.WU'P5IKPR*3'"J. >A KS7XYZG!>7FFZ3;L)+A6)=5YQG&*
M )OBWXIGD\+:3:P2F,7J[Y"#CCC_ .O5SPA9?#W2M$A%W<V<]U(F96EY.?QK
MF?BOI,EGI'AZ656\M(1&_MC'^-=;H'PL\':UHUM>P[W\Q 3B0\'OWH X/Q<^
MB^'/%VGZIX6O4*/(#)'&QPO//Z5Z5\4KG[;\,!<_\]51C^.*YKQ'X6^'OAC4
M+>SNDN7GE(PL;DXYXSS71_$Z.&+X6K';AEA54"!NN.,4 8'PA\!Z5J&@_P!K
MZE +B21BJ*_( !]/PK'^+OA:Q\-ZIINHZ5']G\UOF5#@ @BO2?@]_P D\L_]
MY_\ T(UROQZ_X]M)_P!\_P Z )_B5XCN8/AKIZ)(RS7RJ&8'!QCG^=7_ (<?
M#W1X?#%O>WUI'<W5RN]FD&<9KFOB;922_#C0+M%)2!%#8[9 _P *]+^'NJV^
MI>#-/>"16:.,(RYY!H \7^+'@RT\-:U:76GKY=M<MS&.BMGM^E>MZ]_R2B3_
M *\Q_*N%^.FJ6\ESIEA'(K2H^]@#T_SBNZU[_DE$G_7F/Y4 <W\#O^1/O_\
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MOX8>)O$%BFIZEKLL,\HWJARQ_GQ4.C>)/$?P^\71:-KMP]Q9S,%5F)/!X!%
M'OC.JC+,%'N::TT:#+2*H/JPKS?XQZC<6O@V*XLIWB+.I#*<'!Q7">&_#OBS
MX@Z8ES<ZO);V<8V1\D[L>U 'T&DJ2?<D1OH<U)7S;-+XD^&?BZRM;C4))[64
MCC<=K+]*^C+>=;BWCF3[KJ&'XT 35Y'\>9)(O#MD8W9,RGH<>E>N5Y#\?/\
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M);,'['<MLN%'3)IOP"O'-KJ5D3\J-O /;M79_%32EU/P->_+EX1YB_4?_KH
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M2/\ WF]:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI_@PW+C#7;[^G89Q_.O3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ,4F*6B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH BN8$NK:2"10R2*58'WKQ3P[YOPZ^)-QI=S
MD:?J+?NF/0$\_P#UJ]PJC?:/I^HRQ2W=K'+)$=R,PY4T 67AAG"F2)' Y&X9
MIX 4    = *4  8';BEH B:WA=P[1(S#HQ49J3 QBEHH J2:98S-NDM(6;U*
M"IXX8H5VQ1JB^BC%244 ,DBCE7;)&KCT89I51(U"HH51T %.HH BD@AE(,D2
M.1TW+FI    !@#I2T4 %1R0Q3#$D:N!V89J2B@!JHJ*%50JCH .*=110!#);
M02MNDAC=AW90:5[>%T"O$C*.@*@XJ6B@"M]AM/\ GUA_[X%/6TMT.4@C4^H0
M"IJ* $Q4+6=L[%GMXF8]R@.:GHH K_8;0'(MH1_P 5*D4:#"(JCV&*?10 E>
M+?$2YG\9>-+'PM89:&%@]PPZ5[5VJA;Z/I]K>R7D-K&EQ)]^0#DT .TS3X=*
MTZ"RMQMBA0*!]*NT8%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1147VF$'!< B@"6BHOM,/\ ST%'VF'_ )Z"@"6B
MHOM,/_/04?:8?^>@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\ /04?:8?^>@H
MEHJ+[3#_ ,]!1]IA_P">@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\]!1]IA_Y
MZ"@"6BHOM,/_ #T%'VF'_GH* ):*B^TP_P#/04?:8?\ GH* ):*B^TP_\]!1
M]IA_YZ"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_P ]!1]IA_YZ"@"6BHOM,/\
MST%'VF'_ )Z"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_ST%'VF'_GH* ):*B^T
MP_\ /04?:8?^>@H EHJ+[3#_ ,]!1]IA_P">@H EHJ+[3#_ST%'VF'_GH* )
M:*B^TP_\]!1]IA_YZ"@"6BHOM,/_ #T%'VF'_GH* ):*B^TP_P#/04?:8?\
MGH* ):*B^TP_\]!1]IA_YZ"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_P ]!1]I
MA_YZ"@"6BHOM,/\ ST%'VF'_ )Z"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_ST
M%'VF'_GH* ):*B^TP_\ /04?:8?^>@H EHJ+[3#_ ,]!1]IA_P">@H EHJ+[
M3#_ST%'VF'_GH* ):*B^TP_\]!1]IA_YZ"@"6BHOM,/_ #T%'VF'_GH* ):*
MB^TP_P#/04?:8?\ GH* ):*B^TP_\]!1]IA_YZ"@"6BHOM,/_/04?:8?^>@H
M EHJ+[3#_P ]!1]IA_YZ"@"6BHOM,/\ ST%'VF'_ )Z"@"6BHOM,/_/04?:8
M?^>@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\ /04?:8?^>@H EHJ+[3#_ ,]!
M1]IA_P">@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\]!1]IA_YZ"@"6BHOM,/_
M #T%'VF'_GH* ):*B^TP_P#/04?:8?\ GH* ):*B^TP_\]!1]IA_YZ"@"6BH
MOM,/_/04?:8?^>@H EHJ+[3#_P ]!1]IA_YZ"@"6BHOM,/\ ST%)]IA_OB@"
M:BHOM,/_ #T%'VF'_GH* ):*B^TP_P#/04?:8?\ GH* ):*B^TP_\]!1]IA_
MYZ"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_P ]!1]IA_YZ"@"6BHOM,/\ ST%'
MVF'_ )Z"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\
M/04?:8?^>@H EHJ+[3#_ ,]!1]IA_P">@H EHJ+[3#_ST%'VF'_GH* ):*B^
MTP_\]!1]IA_YZ"@"6BHOM,/_ #T%'VF'_GH* ):*B^TP_P#/04?:8?\ GH*
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MHOM,/_/04?:8?^>@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\ /04?:8?^>@H
MEHJ+[3#_ ,]!1]IA_P">@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\]!1]IA_Y
MZ"@"6BHOM,/_ #T%'VF'_GH* ):*B^TP_P#/04?:8?\ GH* ):*B^TP_\]!1
M]IA_YZ"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_P ]!1]IA_YZ"@"6BHOM,/\
MST%)]IA_OB@":BHOM,/_ #T%'VF'_GH* ):*B^TP_P#/04?:8?\ GH* ):*B
M^TP_\]!1]IA_YZ"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_P ]!1]IA_YZ"@"6
MBHOM,/\ ST%'VF'_ )Z"@"6BHOM,/_/04?:8?^>@H EHJ+[3#_ST%'VF'_GH
M* ):*B^TP_\ /04?:8?^>@H EHJ+[3#_ ,]!1]IA_OB@"6BHOM,/_/04?:8?
M^>@H EHJ+[3#_P ]!1]IA_YZ"@"6BHOM,/\ ST%'VF'_ )Z"@"6BHOM,/_/0
M4?:8?^>@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\ /04?:8?^>@H EHJ+[3#_
M ,]!1]IA_P">@H EHJ+[3#_ST%'VF'_GH* ):*B^TP_\]!1]IA_YZ"@"6BHO
MM,/_ #T%'VF'_GH* ):*B^TP_P#/04?:8?\ GH* ):*B^TP_\]!1]IA_YZ"@
M"6BHOM,/_/04GVF'^^* )J*A^TP_WQ4H(89!R* %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *C\B(G/EK^5244 1^1%_P \U_*C
MR(O^>:_E4E% $?D1?\\U_*CR(O\ GFOY5)10!']GB_YYK^5'D1?\\U_*I**
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ML\7_ #S7\JDHH C\B+_GFOY4>1%_SS7\JDHH C\B+_GFOY4>1%_SS7\JDHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&>YAM8FEGE2-!U9S@5CI
MXS\//+Y2ZK;%^G^L%>/?&?6]9NM=72;1+A+- ,E%.')]Q]:YV_\ A1K&G>%/
M[=EN5#J@=HLG< ?ZT ?3D4T<T8DB=71AD,IR#27%S#:Q&6>5(XQU9C@5X9\$
M/%E_-J,FBW,K2P[-T>XY*XJ#XS:[K%WK?]D6L=PEG$.2BG#GZB@#V)?&7AYI
MO*&JVQ?I]\5M12I-&LD3AT89#*<@U\QW_P )]9T_PK_;KW*[E3S'BR<@5U/P
M/\4WT^H3Z+=3/+$$W1ECG;[?I0![O1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 449HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $Q12T=Z /D;Q]_R4G5/^OG_
M  KZIT3_ ) =C_UQ7^5?*_C[_DI.J?\ 7S_A7U1HG_(#L?\ KBO\J .-^+>M
MW^A>%EN=/G,,ID W#ZUXS;_$;QCJ5I_9]K<32S,V=R#YL>GM7JWQT_Y$Q?\
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MR;50[&D3EF;T%1?!.1H]'U]USN6 E?K@5YA97EW%XJ-W;P">Y%PSK&1G+9-
M'6SZK\1/#\$>IW4UXL)YS(VX?B*]A^&WCX>,-+=+@*E_ /W@'1AZBO--<\8^
M.==TB;3KK0OW,HP<1#BG?!S2=8TSQ6YN;*:&!X3EF'!Z4 9_B;XB^(]+\97L
M,-\_D0S$+'VQZ5%9>)/'FK:O:W(EO$AGE55*Y"8SZ5@^*XA-\1;V)AP]U@_G
M7U5I%G#;:1:0I&H5(Q@ 4 6K42+:0B5MTFP;C[XJ>DI: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?F';W-?1=K_R(Z?]>G]*NW/AW1[RX:XN=/@EE;J[+DUH"&-8?)" 1@8V]L4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME>[_  &_Y%>Z_P"NW]!0!ZU1110 4444 %%%% !1110 4444 %%%% !1110
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M[!_PS]:8YU:3\O\ ZU<-\1/AO_PA4%M<17#7$,I(+$=#0!]*Z??)J6C07D;
MK-$&!_"ODR'_ )*%_P!Q$_\ HRO:/@IXC;4?#$VES/F2TSL!/.T__7S7A\]T
MMCXUGNI 2D5\SD#T#YH ^QHO]1'_ +H_E7B_[0$L?V'38N/,+D@>W-:!^/&@
MQP )97+.JX _R*\E\9^*[SX@>((7C@90OR0PKSUH ]4^ J./#.J,<[6D7;^3
M5XMXC\W_ (3#4/)SYGVEMNWKG-?3/P\\.OX:\%PVDR[;AU,DH]"1TKYRO?\
MDHLP_P"GT]O>@#1:/XA7$>PQZFRD=!&W3\JU/"GPEU[6=2CN-4B:VM@X:0R?
M>;\*^E($3[/'\B_=';VJ7 '08H AM+9+2TAMXQA(D"@>PKR7]H+_ )%O2_\
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MP?2@"U17!^#O'<FM:S?:/J4*VU];N=J]-PKO* "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 )@$8[5Y9J?@_5=%^(=OKV@0[K>X;%S&#C'J:]4I,4 (O(!(QQ3L444
M&*,444 %%%% !1110 48HHH *,444 %%%% !BC%%% !BC%%% !BC%%% !BC%
M%% "&O+-1\(:MXH^(R7VJ0[-*L_]4"?O8KU2DQS0 BJJJ%4  # %.HHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$I,4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% %?SY?^>#?F*//F_YX-^8JQ10!7\^;_G@?S%'GS?\ /!OS%6** *_GS?\
M/!OS%'GS?\\&_,58HH K^?+_ ,\&_,4>?-_SP;\Q5BB@"OY\W_/!OS%'GR_\
M\&_,58HH K^?-_SP;\Q1Y\W_ #P;\ZL44 5_/F_YX-^8H\^7_G@WYBK%% %?
MSY?^>#?F*//E_P">#?F*L44 5_/F_P">#?F*//E_YX-^8JQ10!7\^7_G@WYB
MCSY?^>#?F*L44 5_/E_YX-^8H\^;_G@?S%6** *_GS?\\&_,4>?-_P \&_,5
M8HH K^?+_P \&_,4>?-_SP/YBK%% %?SYO\ G@WYBCSY?^>#?F*L44 5_/E_
MYX-^8H\^7_G@WYBK%% %?SYO^>#?F*//F_YX'\Q5BB@"OY\W_/!OS%'GS?\
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M>#?F*L44 5_/F_YX-^8H\^;_ )X-^=6** *_GS?\\&_,4>?-_P \&_,58HH
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M+Y<(...2?PH U:*Y[PSXRTGQ9'*^ER.XB.&W(5_G6Y//';0/-*P6-!N8^@H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?%?B:V\
M*:+)J5RC.J\!5ZDU\T>-O'.I^,[@RR(T5E&?DC4' ^M?3'BCPS;>*M+%A=NR
M1;@QV]37FGQ0\+:5X9^':V^FVRQ@S#<_5C^- $7[/_\ QZ:C_O"O1/B'J']F
M^"-2GS@^7M'XUYW\ /\ CTU'_>%=/\9$O+CP>;:SMY9FDD&X1KGC!H \+\$^
M#'\97EQ%]L2U6$!B\G0YKT"W^ <_F)*NM1.H(/"UPGA_P1XOU".1].M;F!/X
MLL8\_GBK>B^+O$G@7Q"+:^FG958"6&5BW'MF@#W/QWJ[^%/ 4A1_WPC$*,/7
MIFO"_ '@F3Q]JETUS=/''&-SN.22:]'^,VHKJ/@+3[J(_NYW#C]*K_L_J/L>
MI-W+ ?RH \UUK2[OX>>-5BAN&/D.'1\_>6OJ30=2&K:'9WRG_71*Q^N.:^?_
M (ZJ%\70D#DQ<U[!\+Y&D\":>6[)B@#LJ*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#F/B!]H_X0G4_LV?,\H].N._Z5\^_":RT.]\52
M+KIBPJ9C69L*6S7TCXGU:UT7P]>7UXH>&.,Y0_Q9XQ7RE9Z3J'C3Q)<'1++R
MB[%]J' 0?6KCL1+<W?BY9:'9^*8UT/R0K(#((6RH;BO5(--UW5O@S;6-BA-Y
M+"H 9MORX]37A^H:-J7@KQ#;-K=D)2K!PKG(<5]3>$M<M?$'AVUOK2,1QLH'
MEC^ ^E#V!*[/(?AW\(KJ#6)IO%&GJ8HP/+0R!@Q_ UA?&?PWHV@:Q;'2XUA>
M5"9(E/ ]Z]L\;>-[#P=ICS3.KW3#]U"#R3_A7SC##K7Q,\7EB&>25OG;^&-<
MT)L&D>X_#2S_ +=^%UO9:BI>"12G)Y*T]O@QX04%FMF ').\UV>@:1%H6B6N
MG0CY84"UA?$KQ&OAOP?=3@XFE'E1_4\9_6E?4=M#YV\8Z=H[>+!I'AF!BJN(
MMP).YJ^B/AWX.B\(>'TAY-S, \S>_I7D?P3\-C6/$%QK5VNY;<DKGNY__77T
M:!1)] BA:***DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *0FEKQOXH?%.;1[I]&T9L7*_ZV7^[["@#U][B&,X>:-?JP%.21
M7&496'J#FOE*RTWQYXHB-[;_ &^>,GAS(0#].:;8^,?%O@W51%<W%R&C8;X)
MV)!'XT ?65%8/A/Q);^*-!@U&W/+#$B_W6[BMS- #J*:'4\;A^=+0 M%-W#U
MH+ #)('XT .HINX'H<UA>+_$B>%O#UQJC1&7R\!4!ZD\4 ;V:6O)_A7XXU3Q
MAKFJ27[JL21@Q1KT7FO5LCUH =132P'5@/QHSZ4 .HII8#J0/J: P;H0?H:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/O*L<LYKZ BC6*)(T "H H [ 4 /HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %&*** "BBB@ HI*6@ I,4M':@ Q124M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !124PS1B01EU#GMGF@"2BD[4F<=: '44F<T9H 6BF[QZBES
M0 M%)FFEQGJ/I0 ^BDSFEH **** "BBB@ Q124A<#J10 ZBDS29XH =13-XS
MC-.S0 M%)FDWCU% #J*3-)D^E #J*;O ZD49H =1433(CA6=0QZ FI,T +11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_M&ZT:\P 9K17(]SUKWI_"6@R7/VAM+MS+UW;:N3:1IUSL$UE!)L&%W(#@4
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M3]<<T :5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH :[B-&=CA5&37'2_%+PE!,\3ZEAT8
MJPV'K767:E[295&2R$#\J^5=2^'GBB74[J1-+E*-*Q!]1F@#WS_A:_@__H)_
M^.&C_A:_@_\ Z"?_ (X:^>O^%;^*_P#H%2TG_"N/%?\ T"9: /H;_A:_@_\
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MAO\ A:_@_P#Z"?\ XX:/^%K^#_\ H)_^.&OGK_A7'BO_ *!4M)_PKCQ7_P!
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M&C_A:_@__H)_^.&OGG_A6_BO_H%2T?\ "N/%?_0*EH ^AO\ A:_@_P#Z"?\
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M_CAKYY_X5QXK_P"@3+2_\*X\5_\ 0*EH ^A?^%K^#_\ H)_^.&C_ (6OX/\
M^@G_ ..&OGG_ (5QXK_Z!4M'_"N/%?\ T"I: /H;_A:_@_\ Z"?_ (X:/^%K
M^#_^@G_XX:^>?^%<>*_^@5+2_P#"N/%?_0*EH ^A?^%K^#_^@G_XX:/^%K^#
M_P#H)_\ CAKYY_X5QXK_ .@5+1_PK?Q7_P! J6@#Z&_X6OX/_P"@G_XX:/\
MA:_@_P#Z"?\ XX:^>?\ A7'BO_H%2T?\*X\5_P#0)EH ^AO^%K^#_P#H)_\
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M6OX/_P"@G_XX:/\ A:_@_P#Z"?\ XX:^>O\ A7'BO_H%2TG_  KCQ7_T"I:
M/H;_ (6OX/\ ^@G_ ..&C_A:_@__ *"?_CAKYY_X5QXK_P"@5+2_\*X\5_\
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M^.&OGG_A6_BO_H%2T?\ "N/%?_0*EH ^AO\ A:_@_P#Z"?\ XX:/^%K^#_\
MH)_^.&OGG_A7'BO_ *!4M+_PKCQ7_P! J6@#Z%_X6OX/_P"@G_XX:/\ A:_@
M_P#Z"?\ XX:^>O\ A6_BO_H%2TG_  KCQ7_T"I: /H;_ (6OX/\ ^@G_ ..&
MC_A:_@__ *"?_CAKYZ_X5QXK_P"@5+2?\*X\5_\ 0*EH ^AO^%K^#_\ H)_^
M.&C_ (6OX/\ ^@G_ ..&OGK_ (5QXK_Z!4M'_"N/%?\ T"I: /H7_A:_@_\
MZ"?_ (X:/^%K^#_^@G_XX:^>?^%<>*_^@5+1_P *X\5_] J6@#Z&_P"%K^#_
M /H)_P#CAH_X6OX/_P"@G_XX:^>O^%<>*_\ H%2TG_"M_%?_ $"I: /H;_A:
M_@__ *"?_CAH_P"%K^#_ /H)_P#CAKYZ_P"%<>*_^@5+1_PKCQ7_ - J6@#Z
M%_X6OX/_ .@G_P".&C_A:_@__H)_^.&OGK_A7'BO_H%2T?\ "N/%?_0*EH ^
MA?\ A:_@_P#Z"?\ XX:/^%K^#_\ H)_^.&OGG_A7'BO_ *!4M+_PKCQ7_P!
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M/_Z"?_CAKYZ_X5QXK_Z!4M)_PKCQ7_T"I: /H;_A:_@__H)_^.&C_A:_@_\
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M)_\ CAH_X6OX/_Z"?_CAKYZ_X5QXK_Z!4M'_  KCQ7_T"I: /H7_ (6OX/\
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M_P *W\5_] J6@#Z&_P"%K^#_ /H)_P#CAH_X6OX/_P"@G_XX:^>?^%<>*_\
MH%2T?\*X\5_] F6@#Z&_X6OX/_Z"?_CAH_X6OX/_ .@G_P".&OGK_A7'BO\
MZ!4M)_PKCQ7_ - J6@#Z&_X6OX/_ .@G_P".&C_A:_@__H)_^.&OGG_A7'BO
M_H%2TO\ PKCQ7_T"I: /H7_A:_@__H)_^.&C_A:_@_\ Z"?_ (X:^>?^%;^*
M_P#H%2T?\*X\5_\ 0*EH ^AO^%K^#_\ H)_^.&C_ (6OX/\ ^@G_ ..&OGK_
M (5QXK_Z!4M'_"M_%?\ T"9: /H7_A:_@_\ Z"?_ (X:/^%K^#_^@G_XX:^>
M?^%<>*_^@3+2_P#"N/%?_0)EH ^A?^%K^#_^@G_XX:/^%K^#_P#H)_\ CAKY
MY_X5QXK_ .@5+2_\*X\5_P#0*EH ^A?^%K^#_P#H)_\ CAH_X6OX/_Z"?_CA
MKYZ_X5QXK_Z!4M'_  KCQ7_T"I: /H7_ (6OX/\ ^@G_ ..&C_A:_@__ *"?
M_CAKYY_X5OXK_P"@5+1_PK?Q7_T"I: /H;_A:_@__H)_^.&C_A:_@_\ Z"?_
M (X:^>O^%<>*_P#H%2TG_"N/%?\ T"I: /H;_A:_@_\ Z"?_ (X:/^%K^#_^
M@G_XX:^>?^%;^*_^@3+2_P#"N/%?_0*EH ^A?^%K^#_^@G_XX:/^%K^#_P#H
M)_\ CAKYY_X5QXK_ .@5+2_\*X\5_P#0*EH ^A?^%K^#_P#H)_\ CAH_X6OX
M/_Z"?_CAKYZ_X5QXK_Z!4M'_  KCQ7_T"I: /H7_ (6OX/\ ^@G_ ..&C_A:
M_@__ *"?_CAKYZ_X5QXK_P"@5+2?\*X\5_\ 0*EH ^A?^%K^$/\ H)_^.&NL
ML;Z#4;.*[MGWPRC<K8ZBOD[_ (5QXK_Z!4M?3O@ZTGL?"FGVURA26.(!E/8T
M ;U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1@44
M4 %%%% !1110 4444 %%%% !1110 48HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "C HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1@444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1@444 %%%% !1@444 %%%% !1110 8%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48HHH **
M** "BBB@ HHHH **** "C HHH ,"BBB@ HHHH **** "C%%% !1110 4444
M%%%% !1110 4444 %%%% !1BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ,4444 %%%% !1110 4444 %
M%%% !1110 4444 &**** "BBB@ HHHH *,444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1BBB@ HHHH **** "BBB@ HHHH ,4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1BBB@ P/2BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHWE
M2,9=U7ZFG [AD'([&@!U%)G'4U7-_:*VTW,0;T+C- %FBF*X==RD$'N*=F@!
M:*;O7^\*-ZYQD4 .HHJ)IXD;:TB@^A- $M%-!R,@TZ@ HHHH **** "BBB@
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MR:Z@M\>=,D>>FYL4 345$D\<D>])%9?4'BHTOK5W")<1,_\ =##- %FBBB@
MHHHH **** "BBB@ HHHH **3-+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%1K*C,0KJ2.H!J2@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH \Y^*DTL5M8>7(R9DYVG&>#7::+)C0+*1STMT))_P!T5Q'Q9_X]M/\
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M)+]^5%/\Z .W:Z@5MK3QAO0L,U(&!&0<CL17G)^&URUKYC:Q<&YVYY;C-1>
M]4U"VURYT2]E:41Y ).<$'% 'I>\;L;AGTS35GC=BJ2(S#J W(KR#Q9>ZDGC
MB6WL9Y \@"*H8XYKH/#_ (/U/1]2BU&^U$O$BEG4,>OO0!Z"SA1EB /4FFI-
M'+GRY$?'7:V:\J^T:OX[UR:WM[IK:QA;JIQQ_C4NK>%-6\,0#4M-U*>41'+J
MS=J /5**P?"FO#7]&CN6&)5^60>];M  3BHOM4&[9Y\>[TWC->?>*I]<U;Q#
M'I%EYT%KD;I%! /XTR]^'-S#9M-!J]PUPJY^9N#0!Z1N]^/6@.&Z$'Z&O._
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MN33[L2SV>>)&.<>] 'HE%%8?BG4+O3M%EELHFDN#PH49Q0!L/-%%S)(B?[S
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M)K.EQWSZW,9Y%W81\A?8T >HYR,@TZO/O!ZZ]IFL3:=?"66T7A96Y'YUZ#0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?Q5IVG6YWQH%9\?F?TK;^)$+P^$XHXA^[C90V/3C%4OAWX:O;"^GOM2MWCD
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MDZ5BZ<GB;P==3Q06#3P.QQZ&H]:TOQ3XC$=]=6;85L)",<"@#I/$7_)-X?\
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M%'Y4N* #%&!UQ2T4 &!28S2T4 )@>E+110 4444 %)M&<XHI1TH ,48HHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>X8?:$<JP'IQ0!TU%<+)XHO[OQS_ &39%/LT7^L)'IR?TJC?>+=;UC69M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#KE_6N+\??\C;I7U7_ -"H K^-QY_BS2H),^60G!Z=:]2@1(K>-$4!54
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MX/T._NC<SV*-(3DD$C/Y&H/!6BOHF@I%*,32?,X/:M;5M1BTO3IKN9L+&N:
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MX\57=OIVAI,%#9:09%6?&/AJ\BL+"^MM\UQ:J!)CDG'>@#T>"-(K=$10%"@
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MF^9R"2*Z;P?IFI:L=0O]0>9(;A66-&)[^U9.D:A=^ M8N+2]@D:RD;A@/R-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M15=#U5AD&GT4 5[>RM;3=]FMHH=W7RT"Y_*BXL;2Z(-Q;0RE>AD0-C\ZL44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%
M&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&
M*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M#%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*
M** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #
M%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&**
M* #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%
M&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&
M*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M#%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*
M** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #
M%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&**
M* #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%
M&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
- #%&*** #%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g0vsdaj33nnl000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 04"$H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHI* %HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BDS1F@!:*2EH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%)FES0 444F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***3- "T4F:6@ HHHH **** "BBB@ HHHH **** "BBB@
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M78.>/<O\T<U0_MO3/^?V'_OJC^V],_Y_8?\ OJCV<NP<\>Y?YHYJA_;>F?\
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M^?V'_OJC^V],_P"?V'_OJCV<NP<\>Y?YHYJA_;>F?\_L/_?5']MZ9_S^P_\
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M_/[#_P!]4?VWIG_/[#_WU1[.78.>/<O\T<U0_MO3/^?V'_OJC^V],_Y_8?\
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M?V'_ +ZH_MO3/^?V'_OJCV<NP<\>Y?YHYJA_;>F?\_L/_?5']MZ9_P _L/\
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M* "BBB@ HHHH 0UXM\7?^1CM/^O8?^A&O:37BWQ=_P"1DM/^O8?^A&N_+/\
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M)O&,WB&UMK46ZV]O <JB>N,#]*P>7576VT-/;QY#T/6-6'_">:4B78^S[&+
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MEXS_ .1PU3_KNU<63?QS7&?"85%%%?5GF!1113 **** "BBB@ HHHH ****
M"BBB@ HHH569@JJ68] !DFDVEJPM<2ND\$:O#HWB2&XG_P!6P*$D],\9_6N?
ME@F@8+-%)&Q&0'4@_K3C:W(A$Q@E$1Z/L./SKGK>SJTW%O<TC>+NCU&_\&Z=
MJ/B)M3;4(392C?(N\9Z4SP;_ &1I_C34HK";_1EM<!Y'')W+TKS#[1.%P)I
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M5<(M(]%^&^I?:/$U]=7<B(\L8)).!GFN@TC0M-\-:O=ZW<ZG"^[.T!A\N?\
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M?0PJU/::BT4E%=QD+1124P%HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOHL]*^<_&G_(XZI_UW:N+)OXYMC/@,*BBBOK#RPHHHH **** "BBB@ HHHH
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M/_H)KG:Z'P+_ ,CMI?\ UU/_ *":Y<;_ +O+T-*/QH^B:6D%%?#GN(6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7BWQ=_Y&.T_
MZ]A_Z$:]H/6N,\6^ D\4ZC%=M?M;F./R]HCW9Y)SU]ZZL%6C2K*<MC"O!SA9
M'A%+7J__  IR/_H,2?\ ?@?_ !5'_"G(_P#H,2?]^!_\57T7]L8<\_ZK,\H_
M&DKUC_A3D?\ T&)/^_ _QI/^%-Q_]!A_^_ _^*H_MC#A]5F>4_C1^->K_P#"
MG(_^@Q)_WX'^-'_"G(_^@Q)_WX'^-']L8</JLSRC\:/QKU?_ (4Y'_T&)/\
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M&)/^_ _^*I_VOAP^JU#R>BO6/^%-Q_\ 08D_[\#_ !H_X4W'_P!!B3_OP/\
M&C^U\.'U6H>3TM>K_P#"FX_^@S)_WX'^-'_"G(_^@Q)_WX'^-+^U\.+ZK4/)
MZ*]8_P"%-Q_]!B3_ +\#_P"*H_X4W'_T&)/^_ _^*I_VOAP^JU#RBC\:]7_X
M4Y'_ -!B3_OP/\:/^%.1_P#08D_[\#_&C^U\.'U69Y117J__  IR/_H,2?\
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M*<C_ .@Q)_WX'^-'_"G(_P#H,2?]^!_\51_;&'#ZK,\H_&C\:]7_ .%.1_\
M08D_[\#_ .*H_P"%.1_]!B3_ +\#_P"*H_MC#A]5F>3TM>K_ /"FX_\ H,2?
M]^!_C1_PIR/_ *#$G_?@?XT?VQAP^JS/*/QI*]8_X4Y'_P!!B3_OP/\ &C_A
M3D?_ $&)/^_ _P#BJ/[8PX?59GE"GYA]:^D/"G_(LV'_ %Q7^5<,/@Y&"/\
MB<2?]^!_C7HNE6']F:;!9ARXB0+NQC.!7EYEC*>(BE#H=6&HR@]2Z>E?.?C/
M_D<-4_Z[M7T77GFL_"V/5]8N;\ZH\?GN7V"$';G\:YLNQ$*%7FF:8FFYQLCQ
MFEKU;_A3D?\ T&)/^_ _^*I?^%-Q_P#08D_[\#_&O=_MC#G#]5F>4?C25ZQ_
MPIR/_H,2?]^!_P#%4G_"FX_^@Q)_WX'^-']L8</JLSRFC\:]7_X4Y'_T&)/^
M_ _QH_X4Y'_T&)/^_ _^*H_MC#A]5F>44?C7J_\ PIR/_H,2?]^!_P#%4?\
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M !5'_"G(_P#H,2?]^!_\51_;&'#ZK,\HHKU?_A3D?_08D_[\#_XJC_A3D?\
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M /"G(_\ H,2?]^!_\51_PIR/_H,2?]^!_P#%4?VQAP^JS/**/QKU?_A3D?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I*6DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T %+24M !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F:6D- %/4
M=7L-(@$VH7<-M&3C=*X4?K266L:?J-DUY9W<,]NN<RQN&48Z\BO-/CQ%Y_A2
MVA'!DG5<_4@5R'A77I/#/PU\2:3YB+<VH"PL3RY<C( ^C&@#W+3?$NC:Q<M;
MZ?J5K<S(NYDBE#$#UP#6KFOGKX2Z=%X>^(MTK,P0Z)'<R;NQ<1L?YUU#?$/Q
M)XEOKUO"5A#+86)/F2R'_6?3GVH ]=S1FO,H/BDM]X"O]7A@$>H6(Q-;L>C?
MY%84_P 2O& \(6?BA-(A33@W[T$_-(O]X<]* /8+[5++341[VYB@5V"*9& R
M3T S4_G1Y4;URPRHSUKS3Q=XGM[OP;X?U:?3HYUO+F/;'(3\A+ 9&#6!XLN_
M$J_%;0$L%C!:U8VT9?"LNUL[AGZT >VYHS7FOBGXA7UCK%GX8T>UCN=>FC4R
M@GY8FQDTOASQ[J,7B)O#?BFVCM]0*[HI$/RR?3F@#TG-&0!DUXK>_%'Q/<>)
M;_1-&T@7$EO<;?, .%0'!SS7L:&1K4&50LA3Y@.QH HP>)]$N=1.GP:G:R78
M)!A652V1[9S1J7B;1='N%@U'4K6UE9=P2655)'KR:^<-/#:-\1I-?1U'_$T-
MNRMT )'-,^*LO_"2:_KVI>:K1Z6((8BG(8,S=Z /I74/$.DZ5##+?ZA;6T<W
M^K:60*&^F:HIXZ\+R2+&FN6#.QP +A>3^=>4?%^:SMK/P9-J$?F6B$&5?5=H
MS7*^*-7\ Z[HXM/#.C3Q:IN7RVB5\YXH ^DM1US3-)MH[B_O8+:&0X1Y9 H8
MXSP35"'QOX9N)4BBUNQ>1SA56=22?SKRGXF6D@\ >";6^0ES?0I*KGGE,$&M
M[QQ\+/#I\+S7NF6JV%U:Q^:DD1/)'US0!ZL&!&0<@T9KR#PAXSUF\^%$5YIE
ML]_J5M((65NI'//Z5Z9X?NKV]T&SN=1@\B[DC#2Q_P!UL<B@#4HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M0TM(>AH!G)ZSXTCTC47LVM'D*@'<& ZC-9__  L:+_GPD_[[%8'C3_D99_\
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M_P#P@^I^B_G1_P (/J?HOYUZA]H@_P">B_G1]H@_YZ+^='U^N']CX3N>7_\
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MOYT?\(/J?HOYUZA]H@_YZ+^='VB#_GHOYT?7ZX?V/A.YY?\ \(/J?HOYT?\
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M.YY?_P (/J?HOYT?\(/J?HOYUZA]H@_YZ+^='VB#_GHOYT?7ZX?V/A.YY?\
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MH@_YZ+^='VB#_GHOYT?7ZX?V/A.YY?\ \(/J?HOYT?\ "#ZGZ+^=>H?:(/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[?WC^=7SISR7<D3R1QE%W$]J9/IICM/M,<JRQAMIV]C5<]*]B.2O:^I4WO\
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MRR["X]Z3'O111S(.678,>]+^-)11=!RR["_C1^-)11=!RR%K7\+_ /(RV/\
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M_P"D=9_PBVD_\^B4?\(MI/\ SZI7)_\ "Q;G_GRC_P"^C2_\+%N3_P N4?\
MWT:/JV*#Z_E_](ZO_A%])_Y]4H_X1;2?^?5*Y/\ X6+<_P#/E'_WT:/^%BW/
M_/E'_P!]&CZMB@^O9?\ TCK/^$6TG_GU2C_A%M)_Y]4KD_\ A8MS_P ^4?\
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M  L6Y_Y\H_\ OHT?5\2'U_+_ .D=9_PBVD_\^J4?\(MI/_/JE<G_ ,+%N?\
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M]?R_^D=9_P (MI/_ #ZI1_PBVD_\^JUR?_"Q;G_GRC_[Z-'_  L6Y_Y\H_\
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M?R_^D=9_PBVD_P#/JE'_  BVD_\ /JE<G_PL6Y_Y\H_^^C1_PL6Y_P"?*/\
M[Z-'U?$A]?R_^D=9_P (MI/_ #ZI1_PBVD_\^J5R?_"Q;G_GRC_[Z-'_  L6
MY_Y\H_\ OHT?5\2'U_+_ .D=9_PBVD_\^J4?\(MI/_/JE<G_ ,+%N?\ GRC_
M .^C1_PL6Y_Y\H_^^C1]7Q(?7\O_ *1UG_"+:3_SZI1_PBVD_P#/JE<G_P +
M%N?^?*/_ +Z-'_"Q;G_GRC_[Z-'U?$A]?R_^D=9_PBVD_P#/JE'_  BVD_\
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M  L6Y_Y\H_\ OHT?5\2'U_+_ .D=9_PBVD_\^J4?\(MI/_/JE<G_ ,+%N?\
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M***+ %%%% !^%'X4446 /PH_"BBBP!^%%%%%@"C\*2B@!?PH_"BB@ HQ110
M?A11246 6C\*2EHL ?A1^%%%%@#\***2BP"_A1^%)2T6 /PH_"BBBP!1244
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M-)4E&3/BL9@<3+$2G")4&M6,@WW6F)+/_$^[&3^516FNR0:JU]+&')0H%4X
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M_A!=5_Z9_G1_P@FJ_P#3/\Z?M,-;<GZOCKWY3-M-;-K=)+Y(91'Y;*3U'/\
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MU7_IG^='_"":K_TS_.CZY1[A_9>)_E.6HKJ?^$$U7_IG^='_  @FJ_\ 3/\
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M*_E.7HKJ/^$$U7UC_.E_X035?^F?YT?7*/<7]F8K^4Y:BNI_X035?6/\Z/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!33T-.IIZ4">QY+XT_Y&6?\ W5_D*Q[ *;^'< 5W<@]ZV/&G_(RS_P"ZO\A6
M-9$"]B)(^]WKZ.C?ZNCX'%_[V_4U=:LXGD%[:KB-GPZ ?=-6=:TS[3X@BMH
MD:F!68] .N352QOHX=2FMYSFUF?#^WO6MJ\EN_B5D\\)'+:",.#T)S7.W4A)
M(Z8QI5(-^9B3Z.BV\LEO=),8C\RC/2IW\/QPP023WL<9F'R@Y_PJ>VLVT:*X
MGGDA?<A55!SFHO$<BR16!4@XBYP>G)JO;5&TD]!>PH*/-):F1=VS6EU) Q!*
M=QWK9\/VRW&GZAF-781_+D=.15*]N1#J<C!$D!1!\PS_  BM#1+D"RU-\K&S
M1\ <>E:U)3=-'-0A355WV,_3M/G^WQ>;#E!G.<>AIEGI9N;=[F640P*<!V[G
MTHTNXE_M*'?,^WG.6]C6A:*-3\/"PBD19XY=^'.,CFHJ3J1D:4J=&:91GT:9
M9(5@83)+]UUK7T;2;>+4R#<13,B-NCQWI;6XAT5K2":4/(&RX!R%%2:9I[6N
MM-=RS0^6ZMMPW)S6<JLVFFS:%"E&S1BQ:4)87N9YU@B+E4SWJY_8HL+VW)D2
M9)48K@<=#4CP_P!M:7;V\,D226[L&#'&1ZU?NQ]DDTH%U;RXVY'0]:AUJFUS
M2.&I?%8YRYTUH+=KB9Q&S-\D?<BI6TUY[^.W:1%)B5MP& !C-6K^7^V[5IL*
M+FW)! .-RTZ21?[34AA_Q[+W_P!@5M&K/9G-*C2Z%*;242S>XANDE\LX91GB
MDBMUU2[CCC*HL<(+OCCCK4FELHTR^!(R5&,FHM$WB]S%,J2[?E#CY7]C6C<U
M%OL9*--R5EHR*\L$MX5EBG652<$ 8(IVC(KWV& 8;&X(]JU-:5?[.W7"0I=,
M_'E=Q6?H*[]45-P&Y&&2>*<*CE2;8JE*,:ZC$SW ,[#I\V/I5J33)8[]+8D?
M. 5;L0:NW?ARZA26<S0%5RV _-7K6>)M&6_?'FVZF(9YSGI_.E*OHG$N&%7,
MU,IKX>7[(]S)>1I&K;<\\FED\/)"\8DO$59<>6>?FR,^E.EE5_"2 L-YF)Q4
MNKR(TFBX8?+$N>>G2L?:U;[G3[##V6A1709C>W%L\BH81DDG@BFW.D""V2YA
MN$GC+8)':MV]A6^UC48UF5 T0PV>*R9K;^S-.>":96EE<$(IR !_^NCVU1K?
M47U:E'IH6;O0HY]3\O[3'%),?DCQV[5FPZ0S23K<2K"L)PS-ZU=64-XPB=G!
M42C!ST%6;I%U*6_M8Y8UD\[<NX_>JO:5(Z7,_949ZVZF5/H_EFW:*=)(YG"!
MAV-7%\,[K@VWVR/[0%+;.:4VZZ='9V\DZ-*;A795/W1D?X5);RC_ (2V:0N,
M$-\V?]FCVM5WLQ^RHJUT49]$$=K)+%<+*T1PZ+VHAT:-Q"LMVD<DO1.3BK6E
M,GDZD'< ,?7_ &A6H;=8);>>S^S-"JJ2\AR>V:F5>I'0N.%HR=T<E>6K65Y+
M;OUC;&?6K<, M](>Z9#ND;:A(X%3>)\?V[,0000#D<T^XG67PQ!$H.8Y/FXK
MH<Y.$6^IQJG"-2:70M(CKH,#V$<32G_694$Y_&LS4)'F\F.>U\FX'!8+@,/H
M*LVFGM<6L<MA=A)@,R1EL8-6M3D\K38H;Z5)+WS=P93G:O'4_G7/S<LM-3JY
M54AKH8\&FM-J@LMX!)^]^%7X-+5[*X1Y4C\F<AI#Z8J_9:>R:W'?&>'R6Y4[
MO:JYM!?PWL23HDGVDE0QX?BJG6E+85+#PBKM$,6B1I?6>ZX1[>8\..GTI^M:
M.@O[G[/(F(E!V#M2%4T\65I).&D682/@Y"#FI;R3R/$S,61HIQ@GJ,&H52IS
MWN6Z5+DY;:F7::4]U;QR[U422B-0>_6K4N@JL\ELEW&UPN<)SS5J4I!K-A91
M%2L3#.W^\>M66L&M?$$VI/+%Y"RLQ^;D>V*IUZE]R8X:D8MKHTDL#SSMY,:G
M )!.33VT"X%_! A#)-RDG8CO706NK-=:<8[(0><LA9EE Z>U5;Z]EEN[&WGN
MXXI8V))B480GM4+$5N:QK+"891NC(N=(2""61+I':(X9<$5$T27&E"=%_>1-
MM; [5OWT1>RN'U 6V0O[MXSR?3I6192BWT&[WK_K6 4_E6M.K.4;O<YZU&G&
M5EM8QJ6D(HKT4>2]Q:**3% A:*3%&* %HI,48H 6BDQ1B@!:*3%&* %HI,48
MH 6BDQ1B@!:*3%&* %HI,48H 6BDQ1B@!:*3%&* %HI,48H 6BDQ1B@!:*3%
M&* %HI,48H 6BDQ1B@!:*3%&* %HI,48H 6BDQ1B@!:*3%&* %HI,48H 6BD
MQ1B@!:*3%% "T^+_ %J?6F4Z+_7)]145/A9I1_B(]SMO^/>/_=%35%;?\>\?
M^Z*FKY.6Y^ET_@04444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]#2TE 'DGC0'_A)9^/X5
M_D*Y_!]#7MMQI%A=2F6:UBDD/5F7)J'_ (1_2_\ GRA_[YKU*.8*G!1L?-8G
M(YUJKFI;GC&#Z&E(8G/)/K7L_P#PC^E?\^4/_?-'_"/Z5_SY0_\ ?-:?VG'^
M4Q_L"HOMGC!W'@YH(/H>.E>S_P#"/Z5_SY0_]\T?\(]I?_/E#_WS1_:45]D?
M]@5?YSQ?GWI?F'3BO9_^$>TO_GRA_P"^:3_A'M*_Y\H?^^:?]J*UN47^K]2]
M^8\8P?0THW#D9'O7L_\ PC^E?\^4/_?-'_"/:7_SY0_]\TGF<7]D%P_46TSQ
M@[B><_C1E_\ :KV?_A'M*_Y\H?\ OFC_ (1[2O\ GRA_[YH_M*/\H_[!J_SG
MDUM>P16XBFL1*P;<'#[3].E,O[^6^E4E/+C081!T6O7/^$>TK_GRA_[YH_X1
M[2_^?*'_ +YK)8VFI<W*:O)JSCR\^AXP-P.1D4<^AS7LW_"/:7_SY0_]\T?\
M(]I7_/E#_P!\UK_:4;_"8_V!5M;G/&><<9_*DY!SR*]G_P"$>TO_ )\H?^^:
M/^$>TO\ Y\H?^^:/[37\HO\ 5ZI_,>,G<>N3^%)R.1FO9_\ A'M*_P"?*'_O
MFE_X1[2_^?*'_OFA9E'^4?\ J_4O?F/&,N1@DXJ[/?[[%;2&$Q1AMS?.6W&O
M6O\ A'M+_P"?*'_OFD_X1[2_^?*'_OFH>/@W?E-%DE9*W.>,_-C'.*3YB>_%
M>S_\(]I7_/E#_P!\TO\ PCVE?\^4/_?-7_:4?Y3/^P*G\YX_!=/#%,FW/F#&
M2>E0'<>3G->S_P#"/:5_SY0_]\T?\(]I7_/E#_WS4K,()WY2WD=9JSF>,8;.
M<'-'S9R ?K7L_P#PC^E?\^4/_?-'_"/Z7_SY0_\ ?-5_:4?Y2/[ J?SGC!W$
MYY_&CYLYYS7L_P#PC^E_\^4/_?-'_"/Z5_SY0_\ ?-']I1_E#^P*G69XQS[T
M?-C'.*]G_P"$?TK_ )\H?^^:/^$?TK_GRA_[YH_M*+^R-9#56TSQ<[B>0:LP
M7;PPR0E2T<@Y7..:]?\ ^$>TK_GRA_[YH_X1[2O^?*'_ +YI/,8M6Y060U4[
M\YXP"P/&:0Y)R<U[1_PCVE_\^4/_ 'S2?\(]I7_/E#_WS3691O?E#^P*MK<Y
MXR2W3FCYL\9%>S?\(]I7_/E#_P!\BE_X1[2O^?*'_OFE_:,?Y0_L&K_.>,$,
M3R":L6=REM-YLEN9BO*Y; %>O_\ "/Z5_P ^4/\ WS1_PCVE?\^4/_?-*680
MDK.(XY%5B[\YY$M[(-2%ZR!F#[\=*CO+F2[NY9V4KYC%B >F>U>P_P#"/:5_
MSY0_]\T?\(]I7_/E#_WS2^OPO?E*>25FK<YXP-P]11R>2#^5>S_\(]I?_/E#
M_P!\TG_"/:5_SY0_]\U7]I1_E(_L"K_.>,DL1@Y(J:6Y:2".$)M1.W7)KV'_
M (1[2_\ GRA_[YH_X1_2_P#GRA_[YH_M&'\H_P"PJO\ .>+X/<48/H:]H_X1
M[2O^?*'_ +YH_P"$>TK_ )\H?^^:K^U%_*9_ZNS_ )CQ?!]#1SZ&O:/^$?TK
M_GRA_P"^:/\ A'M*_P"?*'_OFC^U%V#_ %=G_,>+\^AHY]#7M'_"/:5_SY0_
M]\T?\(]I7_/E#_WS1_:B[!_J[/\ F/%^?0T<^AKVC_A'M*_Y\H?^^:/^$>TK
M_GRA_P"^:/[478/]79_S'B_/H:.?0U[1_P (]I7_ #Y0_P#?-'_"/:5_SY0_
M]\T?VHNP?ZNS_F/%^?0T<^AKVC_A'M*_Y\H?^^:/^$>TK_GRA_[YH_M1=@_U
M=G_,>+\^AHY]#7M'_"/:5_SY0_\ ?-'_  CVE?\ /E#_ -\T?VHNP?ZNS_F/
M%^?0T<^AKVC_ (1[2O\ GRA_[YH_X1[2O^?*'_OFC^U%V#_5V?\ ,>+\^AHY
M]#7M'_"/:5_SY0_]\T?\(]I7_/E#_P!\T?VHNP?ZNS_F/%^?0T<^AKVC_A'M
M*_Y\H?\ OFC_ (1[2O\ GRA_[YH_M1=@_P!79_S'B_/H:.?0U[1_PCVE?\^4
M/_?-'_"/:5_SY0_]\T?VHNP?ZNS_ )CQ?GT-'/H:]H_X1[2O^?*'_OFC_A'M
M*_Y\H?\ OFC^U%V#_5V?\QXOSZ&CGT->T?\ "/:5_P ^4/\ WS1_PCVE?\^4
M/_?-']J+L'^KL_YCQ?GT-'/H:]H_X1[2O^?*'_OFC_A'M*_Y\H?^^:/[478/
M]79_S'B_/H:.?0U[1_PCVE?\^4/_ 'S1_P (]I7_ #Y0_P#?-']J+L'^KL_Y
MCQ?GT-'/H:]H_P"$>TK_ )\H?^^:/^$>TK_GRA_[YH_M1=@_U=G_ #'B_/H:
M.?0U[1_PCVE?\^4/_?-'_"/:5_SY0_\ ?-']J+L'^KL_YCQ?GT-'/H:]H_X1
M[2O^?*'_ +YH_P"$>TK_ )\H?^^:/[478/\ 5V?\QXOSZ&CGT->T?\(]I7_/
ME#_WS1_PCVE?\^4/_?-']J+L'^KL_P"8\7Y]#1SZ&O:/^$>TK_GRA_[YH_X1
M[2O^?*'_ +YH_M1=@_U=G_,>+\^AHY]#7M'_  CVE?\ /E#_ -\T?\(]I7_/
ME#_WS1_:B[!_J[/^8\7Y]#1SZ&O:/^$>TK_GRA_[YH_X1[2O^?*'_OFC^U%V
M#_5V?\QXOSZ&CGT->T?\(]I7_/E#_P!\T?\ "/:5_P ^4/\ WS1_:B[!_J[/
M^8\7Y]#1@^AKVC_A'M*_Y\H?^^:/^$>TK_GRA_[YH_M1=@_U=E_,>,8/H:=$
M#YR<'J*]E_X1_2_^?*'_ +YH&@:6#D64.1_LU,LS35K%T^'YQDGS%ZW_ ./>
M/_=%34T !0 .!2UY+U9]1%620M%%%(H**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDS1N4=2* %HIN]?[P_
M.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O
M]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G
M0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZB
MF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_
MO#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z
M-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_W
MA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^=
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M'YT +12;U_O#\Z-Z_P!X?G0 M%)O7^\/SHWK_>'YT +12;U_O#\Z-Z_WA^=
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M'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT
M.HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN
M]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P
M_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>
MO]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?
MG0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 Z
MBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U
M_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\
MZ-Z_WA^= #J*;O7^\*4$$9!S0 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 G>JES81W4@=W=2!CY3BKE% &;_8T/\ SUE_
M[ZH_L:'_ )ZR_P#?5:5% &;_ &-#_P ]9?\ OJC^QH?^>LO_ 'U6E10!F_V-
M#_SUE_[ZH_L:'_GK+_WU6E10!F_V-#_SUE_[ZH_L:'_GK+_WU6E10!F_V-#_
M ,]9?^^J/[&A_P">LO\ WU6E10!F_P!C0_\ /67_ +ZH_L:'_GK+_P!]5I44
M 9O]C0_\]9?^^J/[&A_YZR_]]5I44 9O]C0_\]9?^^J/[&A_YZR_]]5I44 9
MO]C0_P#/67_OJC^QH?\ GK+_ -]5I44 9O\ 8T/_ #UE_P"^J/[&A_YZR_\
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M_/67_OJC^QH?^>LO_?5:5% &;_8T/_/67_OJC^QH?^>LO_?5:5% &;_8T/\
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M?^>LO_?5:5% &;_8T/\ SUE_[ZH_L:'_ )ZR_P#?5:5% &;_ &-#_P ]9?\
MOJC^QH?^>LO_ 'U6E10!F_V-#_SUE_[ZH_L:'_GK+_WU6E10!F_V-#_SUE_[
MZH_L:'_GK+_WU6E10!F_V-#_ ,]9?^^J/[&A_P">LO\ WU6E10!F_P!C0_\
M/67_ +ZH_L:'_GK+_P!]5I44 9O]C0_\]9?^^J/[&A_YZR_]]5I44 9O]C0_
M\]9?^^J/[&A_YZR_]]5I44 9O]C0_P#/67_OJC^QH?\ GK+_ -]5I44 9O\
M8T/_ #UE_P"^J/[&A_YZR_\ ?5:5% &;_8T/_/67_OJC^QH?^>LO_?5:5% &
M;_8T/_/67_OJC^QH?^>LO_?5:5% &9_8T/\ SUE_[ZJ[;6ZVT7EJ6(!SR:FH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***3- "T444 %%%% !1110 4444 %%)FEH **** "BDS1F@!:**,T
M%%)FEH ***3- "T4F:,T +1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-YIU-- !FES[UYWXIU_4;#798+><I&%7 QZBL7_
M (2O5_\ GZ/Y5/-8X:F/A"7*SU[-&:\A_P"$KUC_ )^C^5'_  E>L?\ /T?R
MHYD1_:5,]>S1GWKR'_A*]8_Y^C^5'_"5ZQ_S]'\J.9"_M*GV/7L^]&?>O(?^
M$KUC_GZ/Y4?\)7K'_/T?RHYD']I4^QZ]FC/O7D/_  E>L?\ /T?RH_X2O6/^
M?H_E1S(/[2I]CUW-&:\B_P"$KUC/_'T?RH_X2K6/^?H_E1S(/[2IGKV:,^]>
M0_\ "5ZQ_P _1_*C_A*]8_Y^C^5',@_M*GV/7LT9KR'_ (2O6/\ GZ/Y4?\
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M-&:\A_X2K6/^?H_E1_PE6L?\_1_*CF0?VE3/7LT9KR'_ (2K6/\ GZ/Y4?\
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M-&:\A_X2K6/^?H_E1_PE6L?\_1_*CF0?VE3/7LT9KR'_ (2K6/\ GZ/Y4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUK>6K;)HB<X-4_@R57X:V)) ZYS7EMGJ>I:1XN\:ZOIK?NHE(##H&( S]>:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )12T4 >D_#_\
MY!$O_73^E=?7(?#_ /Y!,O\ UT_I77ULMCZ?"_PD%%%%!T!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%UK0K[2W<HEW \)8=0&&*T,48H \EM/@W<V%F+2U\4WT-N!CRT.!76Z!\/\
M1]#T"XTL1>>+H$7$C]7)[UUN*,4 >3I\)KZV@DTJRUZ>'2'E\WR@.5.<@ _6
MM_Q=X!;Q+HFFV::A)%/8,KI,>2S 8R?SKN<48H X#6/AP-<TFP^U7S#5[/!2
M\4<DBG^'? ^I6'B!]:U76I;J=TV-$.$..F1[<UWF*,4 >:W_ ,,KF#6KV_\
M#^JO8)??Z^(#(]R*L1_"VSC\%W>@&\E=KM_,EG8Y):O0L48H \[B^&TT_P /
M'\*:AJ321B57CD Y558,!^8J]XC^'EIKNEZ= +E[>[T]5$%PG48KML48H \X
MT_X9R7&N6^J^)-2?49+48@C885?0UN+X)MT^($WBP7#>;) L/E8X   _I75X
MHQ0!QR> H$\=S>*!=/YTD>SR\<"KOA[PS<Z+J-[=3ZM<7B7!!6.4\1]>GYUT
MF*,4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI#0
M!Y1XT_Y&6;_=7^0K 5V1PZG# Y!':O4M6\'VNK7[W<DTJLP (4C' ^E4?^%>
MV7_/S/\ F/\ "H:;=T>+6P5651RB<M'XA7R_W]E%-+C_ %C#DUF3:A<SWOVM
MI")>Q':N\_X5[9?\_$_YC_"C_A7EE_S\S_F/\*+,GZIB&K,Y9?$0\O+V4+3?
M\]".<UD7%S+=3-+*VYC^E=__ ,*]LO\ GXG_ #'^%+_PKRR_Y^9_S'^%#3"6
M$KR1Q4FKRR:3'8;0%3@MW(SG'YTVQU-[&VN850$3KM)]*[;_ (5[9?\ /Q/^
M8_PI?^%>V7_/Q/\ F/\ "BS#ZI7O<YB#Q(J6<5O-8QS>4, M6??ZK+>CR@BQ
M0 Y$:# KM_\ A7MC_P _$_YC_"C_ (5[9?\ /S-^8_PHLQRPN(DK,\YJY9W[
MVEM=0A0WVA-I/IU_QKNO^%>V7_/Q-^8_PH_X5[9?\_$WYC_"ERLS6!K+8XC3
M=2^P,X>%)HW^\C4FH:BU\5 18XU^ZB]*[C_A7EE_S\3?F/\ "C_A7ME_S\3?
MF/\ "G9E_4Z]N4\YI:]%_P"%>V7_ #\3?F/\*/\ A7ME_P _$WYC_"ERLS_L
M^J>=45Z+_P *]LO^?B;\Q_A1_P *]LO^?B;\Q_A1RL/[/JGG5%>B_P#"O;+_
M )^)OS'^%'_"O;+_ )^)OS'^%'*P_L^L>=45Z+_PKVR_Y^)OS'^%'_"O;+_G
MXF_,?X4<H?V?6/.J*]%_X5[9?\_$WYC_  H_X5[9?\_$WYC_  HY6']GUCSJ
MBO1?^%>V7_/Q-^8_PH_X5[9?\_$WYC_"CE8?V?6/.J*]%_X5[9?\_$WYC_"C
M_A7ME_S\3?F/\*.5A_9]8\ZHKT7_ (5[9?\ /Q-^8_PH_P"%>V7_ #\3?F/\
M*.5A_9]8\ZHKT7_A7ME_S\3?F/\ "C_A7ME_S\3?F/\ "CE8?V?6/.J*]%_X
M5[9?\_$WYC_"C_A7ME_S\3?F/\*.5A_9]8\ZHKT7_A7ME_S\3?F/\*/^%>V7
M_/Q-^8_PHY6']GUCSJBO1?\ A7ME_P _$WYC_"C_ (5[9?\ /Q-^8_PHY6']
MGUCSJBO1?^%>V7_/Q-^8_P */^%>V7_/Q-^8_P *.5A_9]8\ZHKT7_A7ME_S
M\3?F/\*/^%>V7_/Q-^8_PHY6']GUCSJBO1?^%>V7_/Q-^8_PH_X5[9?\_$WY
MC_"CE8?V?6/.J*]%_P"%>V7_ #\3?F/\*/\ A7ME_P _$WYC_"CE8?V?6/.J
M*]%_X5[9?\_$WYC_  H_X5[9?\_$WYC_  HY6']GUCSJBO1?^%>V7_/Q-^8_
MPH_X5[9?\_$WYC_"CE8?V?6/.J*]%_X5[9?\_$WYC_"C_A7ME_S\3?F/\*.5
MA_9]8\ZHKT7_ (5[9?\ /Q-^8_PH_P"%>V7_ #\3?F/\*.5A_9]8\ZHKT7_A
M7ME_S\3?F/\ "C_A7ME_S\3?F/\ "CE8?V?6/.J*]%_X5[9?\_$WYC_"C_A7
MME_S\3?F/\*.5A_9]8\ZHKT7_A7ME_S\3?F/\*/^%>V7_/Q-^8_PHY6']GUC
MSJBO1?\ A7ME_P _,WYC_"C_ (5[9?\ /S-^8_PHY6']GUCSJBO1?^%>V7_/
MQ-^8_P */^%>V7_/Q-^8_P *.5A_9]8\ZHKT7_A7ME_S\3?F/\*/^%>V7_/Q
M-^8_PHY6']GUCSJBO1?^%>V7_/Q-^8_PH_X5[9?\_$WYC_"CE8?V?6/.J*]%
M_P"%>V7_ #\3?F/\*/\ A7ME_P _$WYC_"CE8?V?6/.J*]%_X5[9?\_$WYC_
M  H_X5[9?\_$WYC_  HY6']GU3SJBO1?^%>V/_/Q/^8_PH_X5[8_\_,_YC_"
MCD8?V?6/.J*]%_X5[8_\_$_YC_"C_A7ME_S\S?F/\*.5A_9]4\ZHKT7_ (5[
M9?\ /S-^8_PH_P"%>V7_ #\S?F/\*.5A_9]8\ZHKT7_A7ME_S\S?F/\ "C_A
M7ME_S\S?F/\ "CE8?V?6/.J*]%_X5[9?\_,WYC_"C_A7ME_S\S?F/\*.5A_9
M]8\ZHKT7_A7ME_S\S?F/\*/^%>V7_/S-^8_PHY6']GUCSJBO1?\ A7ME_P _
M,WYC_"C_ (5[9?\ /S-^8_PHY6']GUCSJBO1?^%>V7_/S-^8_P */^%>V7_/
MS-^8_P *.5A_9]8\ZHKT7_A7ME_S\S?F/\*/^%>V7_/S-^8_PHY6']GUCSJB
MO1?^%>V7_/S-^8_PH_X5[9?\_,WYC_"CE8?V?6/.J*]%_P"%>V7_ #\S?F/\
M*/\ A7ME_P _,WYC_"CE8?V?6/.J*]%_X5[9?\_,WYC_  H_X5[9?\_,WYC_
M  HY6']GUCSJBO1?^%>V7_/S-^8_PH_X5[9?\_,WYC_"CE8?V?6/.J*]%_X5
M[9?\_,WYC_"C_A7ME_S\S?F/\*.5A_9]8\ZHKT7_ (5[9?\ /S-^8_PH_P"%
M>V7_ #\S?F/\*.5A_9]8\ZHKT7_A7ME_S\S?F/\ "C_A7ME_S\S?F/\ "CE8
M?V?6/.J*]%_X5[9?\_,WYC_"C_A7ME_S\S?F/\*.5A_9]8\ZHKT7_A7ME_S\
MS?F/\*/^%>V7_/S-^8_PHY6']GUCSJBO1?\ A7ME_P _,WYC_"C_ (5[9?\
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MHMJT$+NRLV[+=:U*M;'MT(.%-184444S4**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M )^8_P#OJC^U['_GYC_[ZKQC>_\ ?;\Z/,?^^WYT<P?VF^Q[/_:]C_S\Q_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #N*]C\.?\
M( L_^N8KQSO7L?AS_D 6?_7,5<#U,L^)FK1115GMA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 444E &-XB2YDTXBT@BFDS]V7I7'"#7,?\ (+T_\Q_A7>ZEIT6I
MV3VLQ<(_4H<&N:'P[TSM<WO_ ']_^M6D)61Q8B@YRN9(@UO_ *!FG_G_ /6J
M.ZGU2QMVGGTZS"+U*_\ ZJVS\/M.4'%Q>?\ ?W_ZU<?-$+)-8M4D=HXL!=YR
M>U:QM(\^M3E36QLR:L[/8Q6UE;F2X0'!'?%:"IJO>QLQ^/\ ]:N820C4=$(/
M/DC_ -!K0\(:5'KL=R]Q-,#&P VOCUJ)TU:Y-&HY2Y3=5-3[V5I^?_UJMVBW
M_P!IBWVMNJ[AN(/('Y4Y?!UD/^6]S_W\JW9^&[2SN%F5YG9>0';(KF<$>K"$
MEN; IV*3%+5G2@Q0*6B@84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !32:=32* /*O&BD^))L GY5Z#
MV%<_M;^Z?RKVZ2S@E?<\2LQ[D4W^S[7_ )XI^52XW9Y=7 .<G*YXGL;^Z?RK
M0>^"Z:+2" H7 \UQ_%BO7/[/M?\ GBGY4?V?:_\ /%/RHY28Y?)=3Q/8W]T_
ME1L;^Z?RKVS^S[7_ )XI^5']GVO_ #Q3\J7*3_9K[GB>QO[I_*C8_P#=/Y5[
M9_9]K_SQ3\J/[/M?^>*?E1RC_LU]SQ/8_P#=/Y4;'_NG\J]L_L^U_P">*?E1
M_9]K_P \4_*CE%_9K[GB>QO[I_*C8W]T_E7MG]GVO_/%/RH_L^U_YXI^5'*'
M]FR[GB>QO[I_*C8W]T_E7MG]GVO_ #Q3\J/[/M?^>*?E1RC_ +-?<\3V-_=/
MY4;&_NG\J]L_L^U_YXI^5']GVO\ SQ3\J.4/[-?<\3V-_=/Y4;'_ +I_*O;/
M[/M?^>*?E2_V?:_\\4_*CE#^SGW/$MC_ -T_E1L?^Z?RKVW^S[7_ )XI^5)_
M9]K_ ,\4_*CE%_9GF>)[7_N'\J-K_P!T_E7MG]GVO_/%/RH_L^U_YXI^5'*'
M]F>9XGM?^X?RHVO_ '#^5>V?V?:_\\4_*C^S[7_GBGY4<H?V9YGB>U_[I_*C
M:_\ =/Y5[9_9]K_SQ3\J/[/M?^>*?E1RA_9GF>)[&_NG\J-C?W37MG]GVO\
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MHY@_M*GV/7LBC(KR'_A*=5_Y^#1_PE.J_P#/P:.=!_:5/L>O9'M1D>U>0_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWU&*SV@S'%Y<4V]O4<'Z5KZ!&T$%_/*3''Y)4;N-Q/:KD=PUO;:8ZP^9\I!
MZXYZ4[(T]E&:O:QS4EK<0KNDAD5?5E(I8[2YE0/'!(RGH0I-=+<VL=S8W$MM
M>3>4A!ECF!/?MFK]V-.A>U19[E%2-3&(A\IXZ\4<I7U5-G$K;S/(8TB<N.J@
M<T26T\(#2Q.BGH64BNHDC,FHWEU%(T$( #D+\QZU-?QVQ\)N8'EF(G&&FZ_K
M1RB6%5CE#8W07<;>0#&<E338K:>8$Q0N^.N%S74^9'=2$I/<V]TXVF-QE!Q^
M5+;1VD>C(LTTR?O#N:$=3[XHY0^K19RC03+*(VB<.>BD<_E3I+2YB0M)!(JC
MJ2I KI+RZCBU6PDABEGV1G[R_,W6DN;<7MG<M:74W"[Y8YLXZ]!2Y27AUK8Y
M>-#)(J*,ECBM/^Q_,U9;"&4LP'[QL<*>_P"%5M)S_:D&.N[^E:VA3X\1SF=R
MKR(Z GU)%"1%*$7N5EBT-K@VPDN@"V!,<8_+%4+BR>*\:WB/FXZ%.<C\*3[%
M<M<^3Y+A]V,8K;T:U%E>7D5PY5EC&3'R1UZ4[7+Y.=VM8P9+:>$ RPN@)P-R
MD9K1U728M.N(HU,T@>$2< <'_"M2\DLO[%GCCEN9<NI#2K]TY]35C6/^/^/_
M *\?Z&CE1;H146<E':7$J;XX)&7U"DT?9;CS#'Y+[U&2NTY KI+> QV-HUW<
MRHI&8UA!Y^N*9?M.OBJ(P;RQ1 V>XVC.:.4EX=6N<V(9#&9!&VP'EL<"F5TW
MB;8D*)99^REVWE1QNS7-%67J",^M2T<]6GR.R-#3-/2\\V:XE,5K$,NXZ_05
M,L.D789(FG@D )5I2,-5BSS>>%KJUB3,D4@E8CJR\UE6MA-=3;-K* ,EB, 4
M[:&MDHJRO<8EI<29,<,CJ.-RKD4B6EQ*"4AD;!P<*36N9YK7PX%BD*[IB"5/
M7&*EU5IH;+3A8M)Y+1[B4[ODYSBBPU1CN9=GI[3SR12AT9$W8QS4$EI<0IO>
M%U7/4J0*Z9)Y4O(II4'G?9CNR.OIFJNGSR7.CZJ9F+X (#'..1TIV17L8-6,
M-;.Y<?+!(PQU"FI+:VC=I5N?,38N>.Q]ZVM3NI8AI,<;E ($)VG&[@=:I>(G
M/]L.P^7<H) XS2L1*E&.IGK974BAD@D93T(4\U)9V?VL3("1,B[E&.N.M=+#
M(E]]F0M/:76 D84?(?0UBVL,EIXC\EI,LLF&9>].PY4E%IF3R"0>U%27.W[5
M+MY&\U%4,Y9*SL+1112$%%%%, HHHH ***2@!1U%>R:!_P @6U_ZYK_*O&QU
M%>R:!_R!K7_KFO\ *K@>KEGQ,U**3M2U9[04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD_X0+3/[TO\ WU1RL'A,0]V>>)>S+ T&\F-CD@\\T^_NA=2(5'"KCIBO0?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -H -+2T -Q1@TZB@!F*7'M3J* &X
M[=*2GTE #<<T[%%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^Q1_9-A_SYV__?H?X4<IF\MD]Y'BA8D8)) I0[@8#-CTS7M7]DZ?_P ^=O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX4;U_O"OFK_A(M9_Z",__?5'_"1:S_T$9_\ OJC^Q:O<7UR)]*[U_O"C>O\
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M_P#WU1_8M7N'UR)]*[U_O"C>O]X5\U?\)%K/_01G_P"^J/\ A(M9_P"@C/\
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M -]4?V+5[B^N1/I7>O\ >%&]?[PKYJ_X2+6?^@C/_P!]4?\ "1:S_P!!&?\
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MYBBVN<^64_7V]*F.:5G?W2GAX]SREM.O5M4N6M)A _W92AVG\:L?V#K 3?\
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M "+DW_7;^@KT ]*^'Q?\>7J>W1_AH\%^)O\ R.US_P!<X_\ T$5Q]=A\3?\
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MNPHHHK<@**** "BBB@ HHHH **** "BBBI8'M7PF_P"1<F_Z[?T%>@=J\_\
MA-_R+DW_ %V_H*] -?#XO^/+U/;H_P -'@OQ-_Y':Y_W(_\ T$5Q]=A\3?\
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MPHHHK4@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.<'!V8M%%%;$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=%X%_P"1VTO_ *ZG
M_P!!-<[70^!?^1VTO_KJ?_037+C?]WEZ&E+XT?1-+2"EKX<]Q!1110 4444
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M4445ZASA1113 **** "BBB@ HHHH ****5P"BBBDP/:OA-_R+DW_ %V_H*]
M/2O/_A-_R+DW_7;^@KT#-?#XO^/+U/:H_P -'@OQ-_Y':Y_W(_\ T$5Q]=A\
M3?\ D=KG_<C_ /017'U]7EW^[Q/+K_&PHHHKO,0HHHH **** "BBB@ HHHH
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M_P"0E<_]=6_G56K.I?\ (2NO^NK?SJM7W=#^&CQ)_$PHHHK0@****8!1110
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M;1!(X=A#M@YR3_6O1325I2JRI2YH[D3@IJS/$O\ A5&N?W[?_ONC_A5&N?\
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MB/\ PJC7/[]O_P!]T?\ "J-<_P">EO\ ]]U[=11_:N)[A]4IGB/_  JC7/\
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M*/[5Q/<?U6F>(_\ "J-<_OV__?='_"J-<_OV_P#WW7MU%+^U<3W#ZI3/$?\
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M\*HUS_GI;_\ ?=>W44?VKB>X?5*9XC_PJC7/^>EO_P!]T?\ "J-<_P">EO\
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M\*HUS_GI;_\ ?=>W44?VKB>X?5*9XC_PJC7/^>EO_P!]T?\ "J-<_P">EO\
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MX IANX%17::,*YPI+#!^E $]%(#GI2T %%%% !1110 4444 %%%% "8I:**
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MHQ12TS8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\<T+#!1U!!_"N3\5?$6Q\+V.EW4MM+.FH[?*"#GE<BJ-K\4[8ZQ:V&HZ;<V
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M:.(YC4H"%/MZ5;HH 0  8 Q2T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4AI::: /*?&O_ ",LW^ZO\A7/=J[;Q1X=
MU+4-<EN+>'=&54 Y]JQO^$1UG_GV_6LVG<^>Q%"HZC:12%ZG]C_9-K;]^[..
M,5GUN_\ "(:S_P ^WZT?\(AK/_/M^M*S,G0K/H85;#:A97UG%%?B5)8AM22(
M Y'N,BI?^$1UG_GW_6C_ (1#6?\ GV_6FDQPHU8]"/\ M*SMUM8+193''*)9
M&<8+'V&?2HKO4HI]=:^56$9/0CGIBK/_  B&L_\ /M^M'_"(:S_S[?K1J:2C
M7?02WU:V.G26<S3Q R%PT/)(.>",BD_M2Q06:Q1RJ+=VZ\[@>_7K[4[_ (1#
M6?\ GV_6C_A$-9_Y]OUI^\.U>UK%6+4TBU::Y*N896.Y<X.#3GGTJ*&<PB>6
M60802* $]^O-6/\ A$-9_P"?;]:/^$0UG_GV_6CWA1C72M8CCOM.N8K4WRSB
M6 ;"4&0Z@Y&>>.M0:WJ$.HWJRP(R(%"X:KG_  B&L?\ /O\ K2?\(AK/_/O^
MM)W%*%:2LXF'WHK<_P"$0UG_ )]_UH_X1#6?^?;]:7*S'ZM5[&'16Y_PB&L_
M\^WZT?\ "(:S_P ^WZT<K#ZM5[&'16Y_PB&L_P#/M^M'_"(:S_S[?K1RL/JU
M7L8=%;G_  B&L_\ /M^M'_"(:S_S[?K1RL/JU7L8=%;G_"(:S_S[?K1_PB&L
M_P#/M^M/E8?5JO8PZ*W/^$0UG_GV_6C_ (1#6?\ GV_6CE8?5JO8PZ*W/^$0
MUG_GV_6C_A$-9_Y]OUI<K#ZM5[&'16Y_PB&L_P#/M^M'_"(:S_S[?K1RL/JU
M7L8=%;G_  B&L_\ /M^M'_"(:S_S[?K1RL/JU7L8=%;G_"(:S_S[?K1_PB&L
M_P#/M^M'*P^K5>QAT5N?\(AK/_/L/SI?^$0UG_GV_6CE8?5JO8PJ*W/^$0UG
M_GV_6C_A$-9_Y]_UHY6'U:KV,.BMS_A$-9_Y]_UI?^$0UG_GV_6CE8?5JO8P
MJ*W?^$0UC_GV_6C_ (1#6/\ GV_6CE8?5JO8PJ*W?^$0UC_GV_6C_A$-8_Y]
MOUHY6'U:KV,*BMS_ (1#6?\ GV_6C_A$=9_Y]OUHY6'U:KV,,?>'UKV70/\
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M_"G[2EIJ5UI]U+NRQPT1]<XZ5RPU2Z\/ZKI)\)Z^=2:[E4)9N,F/D85CGO\
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M_OHT>?-_SU?_ +Z-'.@_M-=CW#>G]X4;T_O"O#_/F_YZO_WT://F_P">K_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC\Z.0/[,GW/)**];_P"$3TC_ )]1^='_  B>D?\ /J/SHY _LR?<\DHKUO\
MX1/2/^?4?G1_PB>D?\^H_.CD#^S)]SR3-)7KG_")Z1_SZC\Z/^$3TC_GU'YT
M<HUED^Y2\"_\@0?[YKJ:JV5A;V$/E6T>Q,YQ5JK/7I0<(*+%HHHH- HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TE
M&1J7AK1]7N!-?V$,\@&T,Z D"O.G\,:,/B_'I@L(?L9L/,\G8,;OFYQ7K=>>
M2?\ )=(_^P9_5JN#W,YHZ:/3]!\)VLU[%;PV<0'[QU7%$/B_0KC4(;&'4(I+
MF895%//3-4?B+_R)&H?[E5O!?A'0[/0["\33X6NC&'\YU!;)]#196NP;:T1T
MFF:S8:P)_L,ZRBWD,4N/X6':JSZOH^J7UQHC31RS 8EA([5R?PI(V>(N?^8G
M)69H1'_"X=2(_NC^0H4=PYM"+XI^&-'TCPJEQ8V$,$OVA5W(H!Q@UT7@_P (
MZ#+X5TB^DTV!KEK9)&D*#)..M5?C-_R)D?\ U\K_ ":NE\%C/@;1AZV4?_H-
M4V^1$I>^<#J'G>/O'<NDBY9=+LQB158J2?P^E=K_ ,*]\,BV\G^S(/NXW[!G
MZYKC?"H70/B=JEM>R+&UR=T1/\62:]9W+C=D8I3;6PXKN>;_ !&TR#2_A_;:
M?!DP13QJH8Y.-X_QJU-X(\.R>$3.;&&*46QD$B  A@,]?K2?%EUF\(;8Y!D7
M,:DJ>AW"N2\0^&O$-CX<M;K^V[Z^TYE4W$!8C:GTS5+X29;G5?"74KZ^T"Y@
MNBS1V\ICA=NZ_6K'_"(ZE_;:2*8/LRSM(92<M@DG[N,9[9S6YX-ETF3PU:_V
M,%6U"XVCL>^??.:Z"HD]31+0.].I!2U!84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %--.I#TH Y'7/&+Z1J
M;VBVJR!0#N+8ZC-9O_"Q)?\ GQ7_ +[_ /K5D>-/^1EG_P!U?Y"L*"%IYTB4
M@%S@9J&W<\.MBZL:CC%G:?\ "Q)/^?%?^^__ *U'_"Q)?^?%?^^__K5BGPO.
M"1]IM\^F^L6>"2UN&AE7:ZG!%%V1+%8B)VG_  L23_GQ7_OO_P"M1_PL23_G
MQ7_OO_ZU</S1@^AI<S(^NU^YW'_"Q)/^?%?^^_\ ZU'_  L23_GQ7_OO_P"M
M7#X/I0,FCF8?7:_<[C_A8DG_ #XK_P!]_P#UJ/\ A8DG_/BO_??_ -:N'YHY
M]#1S,/KM?N=Q_P +$D_Y\5_[[_\ K4?\+$D_Y\5_[[_^M7#X/O5NST^6]AN)
M8RN($WMD]J?,RHXRN]CK?^%B2?\ /BO_ 'W_ /6H_P"%B2?\^*_]]_\ UJXR
M6%HA'R#O3<,=OK4?..0?RI<S$\971V__  L23_GQ7_OO_P"M1_PL63_GQ7_O
MO_ZU<1@^GZ4@]J.9B^NU^YW'_"Q)/^?%?^^__K4O_"Q)?^?%?^^__K5R2Z=*
MVFM?9'EJVTC/-5*.9C>,KK=G<?\ "Q)?^?%?^^__ *U)_P +$D_Y\5_[[_\
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MC*XB6/\ >\A>AZUR];5UK%JVDM86UJT:EMVXMFL6ID<N(DI-!1114G.%%%%
M!1110"/1/A]_QX7'^^/ZUVG:N+^'W_'A<?[X_K7:5JMCZ;"?PD%%%%,Z0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *::=24 <'XE\+:AJ>LR7-NJ&-E4#+ =!63
M_P (/J_]R/\ [Z%>I48I-(XYX*G-N3/+?^$'U?\ NI_WT*/^$'U?^ZG_ 'T*
M]2Q12Y41_9](\M_X0?5_[J?]]"C_ (0;5_[L?_?0KU+\**.5!_9](\M_X0;5
M_P"['_WT*/\ A!M7_NI_WT*]3HHY4']GTCRS_A!]7_NQ_P#?0H_X0?5_[L?_
M 'T*]2_"C\*.5!_9](\M_P"$&U?^ZG_?0H_X0?5_[L?_ 'T*]2_"BCE0?V?2
M/+?^$'U?^['_ -]"C_A!]7_NQ_\ ?0KU*C\*.5!_9](\M_X0;5_[L?\ WT*/
M^$&U?^XG_?0KU+\**.5!_9](\M_X0?5_[B?]]"C_ (0;5_[B?]]"O4J*.5!_
M9](\M_X0;5_[J?\ ?0H_X0;5_P"ZG_?0KU*BCE0?V=2/+?\ A!M7_NI_WT*/
M^$'U?^ZG_?0KU*BCE0?V=2/+?^$'U?\ N)_WT*3_ (0?5_[J?]]"O4Z2CE0?
MV?2.=\)Z/=:1:2Q704,S9&#FNDI!2U1V4X*$>5"4M%%!84444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%(35>:\B@<*^<D9X% %FBJ7]IV_\ M?E2_P!IV_\ M?E0!<HJG_:=
MO_M?E1_:=O\ [7Y4 7**I_VG;_[7Y4?VG;_[7Y4 7**I_P!IV_\ M?E1_:=O
M_M?E0!<HJG_:=O\ [7Y4?VG;_P"U^5 %RBJ?]IV_^U^5']IV_P#M?E0!<HJG
M_:=O_M?E1_:=O_M?E0!<HJG_ &G;_P"U^5']IV_^U^5 %RBJ?]IV_P#M?E1_
M:=O_ +7Y4 7**I_VG;_[7Y4?VG;_ .U^5 %RBJ?]IV_^U^5']IV_^U^5 %RB
MJ?\ :=O_ +7Y4?VG;_[7Y4 7**I_VG;_ .U^5']IV_\ M?E0!<HJG_:=O_M?
ME1_:=O\ [7Y4 7**I_VG;_[7Y4?VG;_[7Y4 7**I_P!IV_\ M?E1_:=O_M?E
M0!<HJG_:=O\ [7Y4?VG;_P"U^5 %RBJ?]IV_^U^5']IV_P#M?E0!<HJG_:=O
M_M?E1_:=O_M?E0!<HJG_ &G;_P"U^5']IV_^U^5 %RBJ?]IV_P#M?E1_:=O_
M +7Y4 7**I_VG;_[7Y4?VG;_ .U^5 %RBJ?]IV_^U^5']IV_^U^5 %RBJ?\
M:=O_ +7Y4?VG;_[7Y4 6Z*J?VG;_ .U^5']IV_\ M?E0!<HJG_:=O_M?E1_:
M=O\ [7Y4 7**I_VG;_[7Y4?VG;_[7Y4 7**I_P!IV_\ M?E1_:=O_M?E0!<H
MJG_:=O\ [7Y4?VG;_P"U^5 %RBJ?]IV_^U^5']IV_P#M?E0!<HJG_:=O_M?E
M1_:=O_M?E0!<HJG_ &G;_P"U^5']IV_^U^5 %RBJ?]IV_P#M?E1_:=O_ +7Y
M4 7**I_VG;_[7Y4?VG;_ .U^5 %RBJ?]IV_^U^5']IV_^U^5 %RDJI_:=O\
M[7Y4?VG;_P"U^5 %L4M4_P"T[?\ VORH_M.W_P!K\J +=+5/^T[?_:_*C^T[
M?_:_*@"Y15/^T[?_ &ORH_M.W_VORH N453_ +3M_P#:_*C^T[?_ &ORH N4
M53_M.W_VORH_M.W_ -K\J +E%4_[3M_]K\J/[3M_]K\J +E%4_[3M_\ :_*C
M^T[?_:_*@"Y15/\ M.W_ -K\J/[3M_\ :_*@"Y15/^T[?_:_*C^T[?\ VORH
M N453_M.W_VORH_M.W_VORH N453_M.W_P!K\J/[3M_]K\J +E%4_P"T[?\
MVORH_M.W_P!K\J +E%4_[3M_]K\J/[3M_P#:_*@"Y15/^T[?_:_*C^T[?_:_
M*@"Y15/^T[?_ &ORH_M.W_VORH N453_ +3M_P#:_*C^T[?_ &ORH N453_M
M.W_VORH_M.W_ -K\J +E%4_[3M_]K\J/[3M_]K\J +E%4_[3M_\ :_*C^T[?
M_:_*@"Y15/\ M.W_ -K\J/[3M_\ :_*@"Y15/^T[?_:_*C^T[?\ VORH N45
M3_M.W_VORH_M.W_VORH N453_M.W_P!K\J/[3M_]K\J +E%4_P"T[?\ VORH
M_M.W_P!K\J +E%4_[3M_]K\J/[3M_P#:_*@"Y15/^T[?_:_*C^T[?_:_*@"Y
M15/^T[?_ &ORH_M.W_VORH N453_ +3M_P#:_*C^T[?_ &ORH N453_M.W_V
MORH_M.W_ -K\J +E%4_[3M_]K\J/[3M_]K\J +E%4_[3M_\ :_*C^T[?_:_*
M@"Y15/\ M.W_ -K\J/[3M_\ :_*@"Y15/^T[?_:_*C^T[?\ VORH N453_M.
MW_VORH_M.W_VORH N453_M.W_P!K\J/[3M_]K\J +E%4_P"T[?\ VORH_M.W
M_P!K\J +E%4_[3M_]K\J/[3M_P#:_*@"Y15/^T[?_:_*C^T[?_:_*@"Y15/^
MT[?_ &ORH_M.W_VORH N453_ +3M_P#:_*C^T[?_ &ORH N453_M.W_VORH_
MM.W_ -K\J +E%4_[3M_]K\J/[3M_]K\J +E%4_[3M_\ :_*C^T[?_:_*@"Y1
M5/\ M.W_ -K\J/[3M_\ :_*@"Y15/^T[?_:_*C^T[?\ VORH N453_M.W_VO
MRH_M.W_VORH N453_M.W_P!K\J/[3M_]K\J +E%4_P"T[?\ VORH_M.W_P!K
M\J +E%4_[3M_]K\J/[3M_P#:_*@"Y15/^T[?_:_*C^T[?_:_*@"Y15/^T[?_
M &ORH_M.W_VORH N453_ +3M_P#:_*C^T[?_ &ORH N453_M.W_VORH_M.W_
M -K\J +E%4_[3M_]K\J/[3M_]K\J +E%4_[3M_\ :_*C^T[?_:_*@"Y15/\
MM.W_ -K\J/[3M_\ :_*@"Y15/^T[?_:_*C^T[?\ VORH N453_M.W_VORH_M
M.W_VORH N453_M.W_P!K\J/[3M_]K\J +E%4_P"T[?\ VORH_M.W_P!K\J +
ME%4_[3M_]K\J/[3M_P#:_*@"Y15/^T[?_:_*C^T[?_:_*@"Y15/^T[?_ &OR
MH_M.W_VORH N453_ +3M_P#:_*C^T[?_ &ORH N453_M.W_VORH_M.W_ -K\
MJ +E%4_[3M_]K\J/[3M_]K\J +E%4_[3M_\ :_*C^T[?_:_*@"Y15/\ M.W_
M -K\J/[3M_\ :_*@"Y15/^T[?_:_*C^T[?\ VORH N453_M.W_VORH_M.W_V
MORH N453_M.W_P!K\J/[3M_]K\J +E%4_P"T[?\ VORH_M.W_P!K\J +E%4_
M[3M_]K\J/[3M_P#:_*@"Y15/^T[?_:_*C^T[?_:_*@"Y15/^T[?_ &ORH_M.
MW_VORH N453_ +3M_P#:_*C^T[?_ &ORH N453_M.W_VORH_M.W_ -K\J +E
M%4_[3M_]K\J/[3M_]K\J +E%4_[3M_\ :_*C^T[?_:_*@"Y15/\ M.W_ -K\
MJ/[3M_\ :_*@"Y15/^T[?_:_*C^T[?\ VORH N453_M.W_VORH_M.W_VORH
MN453_M.W_P!K\J/[3M_]K\J +E%4_P"T[?\ VORH_M.W_P!K\J +E%4_[3M_
M]K\J6._AED5%W9;IQ0!;HI,\TM !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 AINQ2<D T^B@!OEI_='Y4>6G]T?E3J* &^6G]T?
ME1Y:?W1^5.HH ;Y:?W1^5'EI_='Y4ZB@!OEI_='Y4>6G]T?E3J* &^6G]T?E
M1Y:?W1^5.HH ;Y:?W1^5'EI_='Y4ZB@!OEI_='Y4>6G]T?E3J* &^6G]T?E1
MY:?W1^5.HH ;Y:?W1^5'EI_='Y4ZB@!OEI_='Y4>6G]T?E3J* &^6G]T?E1Y
M:?W1^5.HH ;Y:?W1^5'EI_='Y4ZB@!OEI_='Y4>6G]T?E3J* &^6G]T?E1Y:
M?W1^5.HH ;Y:?W1^5'EI_='Y4ZB@!OEI_='Y4>6G]T?E3J* &^6G]T?E1Y:?
MW1^5.HH ;Y:?W1^5'EI_='Y4ZB@!OEI_='Y4>6G]T?E3J* &^6G]T?E1Y:?W
M1^5.HH ;Y:?W1^5'EI_='Y4ZB@!OEI_='Y4>6G]T?E3J* &^6G]T?E1Y:?W1
M^5.HH ;Y:?W1^5)Y:?W1^5/I* &^6G]T?E1Y:?W1^5.HH 3RT_NC\J/+3^Z/
MRI<T9H 3RT_NC\J/+3^Z/RI<T9H 3RT_NC\J/+3^Z/RI<T9H 3RT_NC\J/+3
M^Z/RI<T9H 3RT_NC\J/+3^Z/RI<T9H 3RT_NC\J/+3^Z/RI:* $\M/[H_*CR
MT_NC\J44M #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+
M3^Z/RIU% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3
M^Z/RIU% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^
MZ/RIU% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z
M/RIU% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/
MRIU% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/R
MIU% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RI
MU% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU
M% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU%
M #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU%
M#?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #
M?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?
M+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+
M3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3
M^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^
MZ/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z
M/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/
MRH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/R
MH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH
M\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\
MM/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M
M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M/
M[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M/[
MH_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M/[H
M_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M/[H_
M*G44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M/[H_*
MG44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M/[H_*G
M44 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M/[H_*G4
M4 -\M/[H_*CRT_NC\J=10 WRT_NC\J/+3^Z/RIU% #?+3^Z/RH\M/[H_*G44
M -\M/[H_*DV*#D*!3Z* $I:** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I#2TAH 2CFN!^+7B74?"WA=;_391',)5!)'49Z5'
MHGCW_A(OAO=:Q:R(E];PG>H/*L.^* /0LFE%<+\+_$EWKO@"'5]8N%,QEE#R
M-P %8@5T]IXBT6^N%M[35;*>9NB1SJS'\ : -2BJS7]HMZMDUU"+IEW"$N-Y
M'KCK3)-4L8;LVDEW MR$\PQ-( P7UQUQ0!<HKAO#7Q$L=>\0:IIS3VL2VK[(
MCYHS+ZD<\UT1\4Z )?*.M6'F;MNS[0N<^F,T :]':LJY\2:)93M!<ZM90RJ
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M>GTTC@T 5Y+VVA?9),BL.Q-,_M.S_P"?B/\ [ZKS;QH[CQ), Q VKW]A7/\
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MT +129HS0 M%)FC- "T4F:,T +129HS0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB'=>7\LS*7>0Y08S@>G^'%8.G^*M8TCX?>(M,LVE%O;W3Q13,Q8A-Q&T9Z4
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MS17LW]A:9_SXV_\ W[%']A:9_P ^-O\ ]^Q1R"_LQ]SQFBO9O["TS_GQM_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7[?5KFTO&&!Y8X'ZU<\+_#VUT*^O=1N[J34+Z\79)),/X>F.IKM:* /-F^%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HI** %HI** %HHH
MH ***2@!:*04=Z %HI,T4 +1244 +12<TM !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4AI:0T %(#Q45T)3:R" XEV
MG;]:\>U&3XI6,%Q=27.R"(%B=L1P!51C<F4K'L]%>&:-J?Q-UZR^V6%X7AW%
M=VR,<_E7J_A4:PFAPC76W7W.\X'K[<4Y0L*,[FX*6D%&:@L6FTN:JW]VEE93
M7,A 2-2QH!EG/-&:\Y^'OCB;Q%J5_;74C,0^Z$$ 87TXKL/$MU/8>&-3N[9]
MD\-L[QL!T(!(-4XM.S)4DU<ULT9KPK0=8^)/B&S-YIU[YL*OL)V1CG\178>&
M/'.I'7O[ \16RP7FWY'7^+ZTW3:)51,]%!I<UQK:??6MWKL]DTZS%XQ;EG+#
M'RE@ >.N:T/#2ZJ+S5&U0*'=XR@0G:!MZ#-18NYT=%)2T#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^)?911-C!<*-Q'N:V:*')L2BD)TI:**104444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M =#D5GZAK-GIQ"S2$L?X5&2*P?"%Y?3:AJ-O=REQ$$* ONQG/?\ "I=(,?\
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MKGN3TJ7-<SXPC\VQL4\TQ;KR+YP<%?F%4#-?V\E_#!>R3K:[9 Q;.1GYA^5
M':YJO)?VT7F;YE'EL%<9Z$]!6-X;U&75Y+J^$A:T9@L(/L!G]<URNH63I<>(
ME6\D+M=P ;CTR$.?PZ4 >EYHKB9KC4-'N-1@%Y+<%+8.ID/1B5']:;X>EUC^
MW(!=W"&&2!F,9F+$G(Y _P ]:8CJK[5[+3I$CN9@C."5'KBHO^$@TW[,;@W
M$8."2#UK"\06L]WXOTU+<Q!Q;RG]Z@8=5[&H/$EF;72+".X6'<;I-Y1 JGF@
M#JK/6+&_?9;W"NV,[>]2-?VRWJV9F47#+N"9YQ7+ZJB0Z]H)TM85<NYF*8^Y
MM&<X_&N>NKN\GU&;7X[*5@LP$,WI$I&X?GNH ]2S2U6L[N*[MXIHW4^8@; -
M6:0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**YBY\4/_9UPR6DT-VL7F1QR+RPXYQ^-6M#?4KSP_'-<W %S,@96,>-N?;-
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MRQ,!\K-[5*_BF!9V5;>5X$(#S ?*I- &_17-R^+H(Y[J..VFE6U/[Z11\JC
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M=-O;-M-O[>$3306RP20EL9&.Q^M9L6C:S;W2ZL+>)YS,7:W!QA3GOZUW&**
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M-YRP_# JVFDZEH]S975M EV4A\N90=I)]0:Z_!HI@9&@:;+86LC3G]]/(97
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M:A^TZM965XIOL#RE9/G5V4EP">.U=TNCV"VK6PMD\ESEEQU-,BT+385<):H
MXPV>XZTP.2-UJ&DRSJEW)<%[19<28X8[>F/K4&F7.KQ:@LKW0:.2W=FC,BL0
M<9W "N[-C;%]YA0MMV9QV]*A@T33K:9I8K5%=E*D^QZT7$<;IZ7HTW0=0?4[
MF22^\L3*VW'S*2>U48_MMKI\5M:WTC&6[D#Y95QC'>O2%L+5(8(EA41P8\H8
M^[C@8JN^B::Z,K6J8=MY^OK0%CBXKG41;VUA<ZEY<4UTRO.K*2@ 7"Y''.34
M.L6^9+.RCU9[E1>H XP6CY7C.,5W7]A:;]D-M]E3R2V\KC^+UHBT33H%58[6
M,;7WCC^+U_2@+&5X9FN%N[^QFG:=8'^1GZXP*Q]4U'68IYM/M9B7MKCSI9".
M3!C<<?RKMXK6"&1Y(XU5W.6('6D>RMWE>5HE+NAC9L<E?2D,XNWUFXU*ZM+^
M*9A9WLS".-EY"JC _F1FC1/^0EIOUE_]"%=BFFV<<<*);HJP_P"K 'W>W%.C
ML+6)T=(55DSM('3/6@#F=7>2\\2-8S:@UE!%#OCP0/,)Z]?3^M<K875\ME'8
M6]R7CENIBTX8)OQM[GBO3+W2;+4)$DNK=9&0$*3U -1G0]-:W%O]DC\H,7"@
M8P: .&MX[^74=*^W7I"QSL$*LIR..":B-[K5U(+Y+D12"<#8TB@8#8QMZ\_U
MKT :/8+%'&+9 L3;D]C3'T+39+C[0UJADW!LX[B@#E1+?2QZU>O?3*\$BQQQ
MC&U,HN<?F:26RNX[B&W&JW16:T,[$[<[@/I7:"PM=DJ>2NV5MSC'WC_D4YK.
MW9U<Q+N5-@..B^E '%V&J7LL]NKS$_\ $JE<G R65U -51)J&FV.EZ@FH7$\
MMU"&=' P21GL*[I--LXV!6! 1&8Q@?PDY(IWV"UV0IY*;81A!C[HH X'1;C6
M'O[*Z-R&69OWJ-(IX/L.:W?&-MY_]D,;IX%6^C!*X[GKSZ5M0:+IUK<>?#;(
ML@Z$5/=V5O?1".YB#J&# 'L10!P:VD\%I?ZC!?SQLE]M"+C:>%JHU_K5]))=
MI<B*2-P%1I%4<8XP>>:]&&GVHA:(0KY;-N88ZGUJO)H6FRSB9[1#("#G'I0!
M1U^.2Z\(S[Y6BD,&YF3UQDUS#WUW9V216]XS 6D15^"1G;_C7H4D,<T+0N@:
M-AM*GTJJNCV"1^6+9 N N,=J ./BTV\EN]0B;5[O9! LJ@;?O%-WI5"\U?4F
ML-+9+MDDFTGS&<*,[\IST]S7HZVD"M(PB4&10K''48QBH#I%@5C4VL>(X_+0
M8Z+QQ^@H XZ[.H:+<W$,=]/<%K4N2^/E;U'%3Z8[6NNZ3%'JTMS]HBD::-BI
M ( P>/QKK;JPBN%D8*HF9"@<C.!6!I/AB2VU6._N#$KPAE01#J#W- #_ !#O
MFUC3;,WSVD$@D,C*0,X&1R:YYX9[[["LM_+(L-]L5OE.X  ^E=[>:;::@%^U
M0K)L^[GM21:99PQI'' @6-MRC'0T 97B.XEB.G6B3M!#<RF.688R@"D]>G)&
M/QKG%W:9_:YMKTS?Z1"!*V#V'IQ7>75I!>PF*XB#H>QJ"+1["&%HH[9 C$,1
MCJ13N!P\^HW=OX@1I;R1HGE*H8V7'?Y2.M6;666>%M3FUIH;KSB! <87_9QC
M-=:=#TUKD7)M4\T-NW8[TG]A::;O[2;2,R[M^<=_6BX')-K]Q'X>G+WG^EB]
M:,=-P'IBJOVZ\MM7@EN+Z5XI)PH,;K@=.".M=LV@Z8T[S&TC+NVYCCJ?6@Z#
MIAG\[[*GF!MP/O0!PL=_=V>I6TMU?S21S3A Z.I!R< $=15^"XN+^VTJ&>_>
MWCF>;S)%VC.&;'\A75#P_I8F$HM(]RMN'UJ631[":!87MD,:$E1CIGK0!Q<5
MS>RVL%F-1F*O>M%YPQDK@G'3%%X-0M9;[3X=3D(AN8PID*AF#1EBH/3K_*NV
MBTNR@CC2.W15C;<HQT/K1<:5971D,UNCF0AF)')(&!^E(#"\&W;W5E=H\TKR
M1R;2)"#MZ]"*R[[6=4LY6B$A,-E*TD[D?,T8Z#\:[.RT^UT]&6UA6,,<MCO3
MI+"UF,IDA1C*NU\C[PH X]]3N[C2["]$S>7>ZDK1@@9$3'A:P;6R\V'2X1>R
M[GNV!((RG(KTW^S[7R88?(3RX2&C7'"D=,5#'H^GPRB2.V16#;@<=#3N!D^&
MKR53=VEU<^8()=B/(0">E6/%=U]ET.1Q</"Q=0&3&>6 QSZU9N]$M+LJ2FS$
MHE)7@EAC'\JMW5E;WUN;>YC62,X.UO:D!YU!J6IVD>H)]K?B-2F75MN64=OK
M5^6]O]&^T)'=23[[5)1Y@!*DE0<8^IKKHM"TV%75+1 ''S<=:LFPM6?>T"EM
MFS)'\/I3N!R6GV<=OXTLF347O"UG*3N8';\R>E'BV6]CU.(PW3+"L9+1HZJ>
MW/-=/::/86,WG6]NJ28QN[XI;S2+&_E62Y@5W48#&@#G-#UX76JMYMR5MC:Q
ML@E(7YOFS_2LR%GU:'PU)=W[PO)'.6F! )_/BNRET+39D1'M4P@PO&,"EDT/
M3I;>"![5#' "(U_NYI <9'=7SQ0V0OY2C79B\X8W%<"HEAU"'13J1U:Y9XKU
M(T4XQM,H4@\>E=Y'I5E$L:I;H!&=R\=#3SI]J;<P&!?*+ARN.,YSG\Z=P.(U
M>ZU"74]0A@O#$L=T@" JI8>5G&3[U26^O+O38UAOY@T;E9$=U#'&>AZ5W]QH
M]A=,[36R,78,QQR2!C^51_\ "/Z7Y0B^R)M!ST[T7 Y#1M8GN-1L8TN)67[/
M<;Q( 2&4J!R/QINES7*V^AWYU66:XNF3SX25QSU&.HKM;?2+"U9&AMD5D!"D
M#H#U_E38=#TVWG$\5JBNO(('2@#D<7OV0:I_:5QY@O1'Y?&W;D<=*II?7=MJ
M]D]UJ$K1S7"H'C92#DC"E>HKT+[!:^5Y7DKY>_?C'?UJK_8&F>>LWV1-ZL&!
M]".](#'\:6_G0Z>WVEX0MTG3&#\P]:RKJ6>2VO+QM6DAGMY0L465PP!';W_K
M7<7=E;WT8CN(Q(H(8 ^HJK+H6FSRB22U1F&,?A0!B^)FDO/ [2RLT+LL3,/3
M+K6)-87#:OJT\6HRH((8R"F/G.!R>*] GM8;JV:WGC5X6&"IZ5&FG6D:NJ0J
M ZA6XZ@=* ."N=2U74/LT23%%%NKE]ZIEL>]=1H$MS-X5B:[D$LPCP9 0=_O
M6A-HVGW$:1RVR%4&%&,8JS!:P6ULMM#&$B48"CIB@#C_  =8ZBVC6DOFVOV?
MD[?+^;&?7%6M*>S&N:P+IH!^]'$I'3 ]:ZBWMXK6%88$"1KT4=JI7&A:;<SM
M--:JTC?>;IF@#A8KF[70;BQMHV9;Z]9+./&/W0P7_P#9JUO"<UQINHW.FWL0
MMHV4/ I/8 #_ !-=:+&V#0L(5!@SY>!]W(QQ2S65O<2+)+$K.HP"1R!0!*C*
MR[E8,IZ$'-/J.&)((A'&NU%Z"I* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1^>A.?\ &F(FD\6VXB@\BUGGN)L_N$ W+CKG)QVIK>,K,6]K)]GG,EQ*T0B
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "DI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $IKHLB%74,IX(/>GT4 -Z<"EI:* $HI:* $HI:* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g0vsdaj33nnl000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /B!*H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "DS0:\^^(^KZAIFJ>&8[*ZDA2XOA',%_C7!X- 'H5%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !112&@!:*A>XAB=(Y)HT>0X168 L?;UJ6@!:*8S!5+,0%'4D]*K0:G874OE
M6]];2R?W(Y58_D#0!<HJ*6:*"(R32)'&O5G8 #\:CM;ZTO-WV6Z@GV]?*D#8
M_*@"S7F/Q6_Y#'A'_L)#_P!!->G5YC\5O^0SX1_["(_]!- 'IU%%% !1110
M44E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "
MT4E% "T444 %%)10 M%)10 M%)10 M%)10 M%)10 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJN<_X0G_ *>C^5'_  A7_3T?RH]G0_F#EI]SHSJMB/\ EYC_ .^JC_MS3O\
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7=(L]-U34([,>>C/G!(Z8&?6O26TFQ"DBVC_ .^17G^BA8_'.  JAG'Z&J6
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M*K5<S9>*M)BLH8VND#*@!&?:K'_"7:1_S]I^=<[IROL>O3QE'D5Y(WJ*P?\
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MZM"N1JS/=A)2BFA:***184E+10 E(:6DQ0!R%]X/DN+V2:*Y"J[;L%>14/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7F/Q6_Y#'A'_L)#_P!!->G5YC\5O^0QX1_["0_]!- 'IU%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^^C1_P (;K?_ #_#_OHT>QI_S!]>Q7_/EGH'VB'_ )Z+^='VB'_GHOYUY_\
M\(;K?_/Z/^^C1_PANM_\_H_[Z-'LJ?\ ,'U[%?\ /IGH'VB'_GHOYT?:(?\
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MQ^*W_(8\(_\ 82'_ *":].KS'XK?\ACPC_V$A_Z": /3J*** "BBB@ HHHH
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MVL$7DP)'N+;% R>IHAMHK92L2!03DX'>I:UA'E5CAKUO:S<@I:2EJS$****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KS'XK?\ACPC_V$A_Z":].KS'XK?\ACPC_V$A_Z": /3J**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *0C(I:* .(\0Z#!8V[W41;<S_=[
M<UJ>$KE9-,\D?>C.#6MJ<:26$P=0PVD\US_@\JHN@2!\]=WM'4P[4NAT\SE3
MU.L%+3/,7^\/SIV:X3F%HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *2EI* $-8^I6%_<W&^WO#%'MQMV]ZV<4A'%-.S(J0
M4XV9XXQOK35YI;?<TR,07"YJ"XO+Z6T6*8MY(/'R]\UZW::1:632M$AS*VYM
MQSS63KNB62Z')&%.(P67YN_6NZ&)BVDT?,5\GJP@Y*9D>$7U'48=_P!L*QPN
M%V8ZC@UW@KRSPQKTFES_ &-(0ZSRC+%L8Z"O0++4VNK^YMV0*(L8;/7I6.(@
MU*YZ.58B#HJ-]34%+3<BES7,>R+1110 4444 %)2TE %:^'^@S_[A_E7'^!?
M^/J]_P!XUV-__P >4W^X?Y5QW@7_ (^;W_?->9B?]Y@0]T=S2TE&:],L6BDS
M1F@!:*3-% "T4E% !11FB@!:2C-&: %HI,TM !1110 44E% "T4E% "T444
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MN7K7=:<MVEHHO65INY4<5OA<2ZRO8:=RY11178,**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN(^H^OK61I/PWE75K;4O$&KSZK/:-NMP_"H?7'K7H&*,4 %>9?%;_D,>$?\
ML)#_ -!->FXKS+XK?\ACPC_V$A_Z": /3J*** "BBB@ HHHH **** "BBB@
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MV HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !7F/Q6_P"0QX1_["0_]!->G5YC\5O^0QX1_P"PD/\ T$T >G4444 %%%%
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M3 ([=Z[(TW.CH?.5\7'#YA>3T/6*6N2MO'NFRIF97A;/W2,_RJ;_ (3G1_\
MGJW_ 'P:YW1FNAZZQ^':NI'3TE<S_P )SH__ #U;_O@T?\)SH_\ SU;_ +]G
M_"CV4^P_KV'_ )CIJCFF2")I9#A%&2?2N=_X3G1_^>K?]\&L?4?'=M<VT]O'
M:R8=2H?([CK51H3;V,JN98>$;\QV]K=17<"S0MNC;H:GKS[0/%\=K;6^G_8Y
M9'SMRI'.37?J<J#ZU-2G*#U-L+BZ>(C>#N.I:2EK,Z@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!#7#>-O'T?AJ673SI.H7,CVY<300ED
M7.1R?PKN37):1XEN==&JP7>@W5LELA"^:%_?]>!@T <9X?\ B_'%H\*3^']6
MFD&<O%;G:>>V!4FI_$[4-::SL=$T'5H+B2X0/)- 54)N&>2/3-3P?$2^TZ/[
M+;>!=36&,D*%"8Z_[U6;;XFZK/=0Q-X+U.-7<*7(3"Y.,_>H ](AW&&/?]_:
M,_6I,4D;;HU8C!(!QZ4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O,?BM_R&/"/_82'_H)KTZO,
M?BM_R&/"/_82'_H)H ].HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $HQ12T <Y?^%8;R[>X$K*7.2*J_P#"&1 ?\?#5
MUE!Z5NL55BK)FBJR1YM;R+HVN'<2R1$@X[\5T8\8V>/]5)6E=:!I]Y,9IH,N
M>I!(S^50_P#"+:5_SP/_ 'V:WG7HU+.:=S1U(2^(J?\ "96?_/*2M;2]4BU2
M%I(E8!3@YK+U#PU8164KPP'S%7*_,:YS3-9N]*A9(X,J3DE@::H4ZL+TMQJ$
M9KW3T:BL/0-9DU6.4RHJLA XZ<UN#I7%.#A+EEN82BXNS%HI*6I)"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:
M* *&J:7!JEKY$X)7.>*YA/ =O]O<L3]FVC:,\YKMJ2KC5E%61RUL%1K2YIHY
M3_A!-,_V_P Z/^$$TW_;_.NKI:?MI]R/[/P_\IR?_"!Z9_M_G1_P@>F_[?YU
MUE%'MI]Q_P!GX?\ E.4_X0/3?]O\ZAN/ ECY#^3N\S!VY/>NPI#]TTU6G?<F
M678=JW*>2:3:/8^*[>WD(+(^"1]*];7[HKS)O^1^7_KI_2O35Z"M,0[V;./*
M(*"G%;)BTM%%<Q[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 AKR^ZC^+9NY?LUWI0@W'8&C&<=OX:]0-<QHFE>(K.343J6KI<K,,6P"8
M\H\__6H Y#R_C%_S^:3_ -^A_P#$U+;1_%S[7#]HN]*,'F+YFV,9VYY_A]*9
M>Z1XUM'=IO&MI"N[@.@R!4VGZ)XWGN(95\8VL\(<,RH@)9<\B@#TR/=Y:[\;
ML#./6GTU-P10QRP R?6G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5YC\5O^0QX1_P"PD/\ T$UZ
M=7F/Q6_Y#'A'_L)#_P!!- 'IU%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>8_%;_D,>$?\
ML)#_ -!->G5YC\5O^0QX1_["0_\ 030!Z=1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )12T4 -Q
M7*>*=)@6![Y%;SBP!YXKK*CFB2:,I(H93U!K2E4=.7,BH2Y7<XO0_$-MIM@(
M)4D+!B<@5UFGZA#J-L)X<[<XP>H-8VMZ);1:9*]O;CS ,C:*P=%UN?3V2V"
MQL^3GK79*E"O%SI[F[BJBYD>AYHIB.&0-GJ,T_(KS['-86BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD\?GW3G]V51@<@8XX'K0![M;@"WB .1L&#Z\5+44"E((T/54 /Y5+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7F/Q6_Y#'A'_L)#_T$UZ=7F/Q6_P"0QX1_["0_]!- 'IU%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %)2TE "$ CFN1\1Z/=W&H)/:1Y4*!QZUU]%:4JKI2Y
MD5";B[HX/[)XC"_ZR8 >]3^&]2O9-5-O<3,ZX.0QZ$5VC $8KSY<:=XI9!)A
M1+C/U_\ UUV4YJO&46E<Z(R]HFK'H0Z4M-4@J"#P1Q2UYYRBT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% "4C=#2TC=#0)['F3?\C\O_ %T_]EKTU?NUYDW_ "/R_P#73_V6O35^[717
MV1Y65[U/4=1117.>L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M- "T4F31F@!:\Q^*W_(8\(_]A(?^@FO3:\R^*W_(9\(_]A(?^@F@#TZBBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:];ZUXPU6#4+BS!6UAACQ$N1]XC ^;GKCL*] HH 05YE\5O^0QX1_P"PD/\
MT$UZ=7F/Q6_Y#'A'_L)#_P!!- 'IU%%% !1110 4444 %%%% !1110 4444
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MZRS^,VNW-[! _@B>-99%0O\ :#\H)QG[M 'L5%,C<O$KD8+ $CTI] !1110
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MY*GL,YKT\+3C4IR@==**E%H]41PZ*ZG@C(I]9&F:J;U(Q';2B,C_ %A'RUK
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M !1110 4444 %%%% !7F/Q6_Y#'A'_L)#_T$UZ=7F/Q6_P"0QX1_["0_]!-
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M:-2PPQ R*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^2KZ?_UZ'_V:NXKA]0_Y*OI__7H?_9J .XHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC[@C%
M1E@.!3Z* ./UN35[BPECFM(TA!R6#<X!^M9NA:Z^GLEN47RF;ECG(KJM?:Y^
MP&.W@,N\$-@_='K7G:YCF!(Y5N1]*]?"0C5I.+1VT4IPLST^/4;>2T:Y5LQ+
MG)QZ<5/;W,=U LT9RC#(-<!#KS1:=):>5D.6.<^IS5JP\5-9VT<'V<,JC&<U
MRSP-17:1E+#R6QW6:6J&FZG#J4'FPYP#@@U>KCE%Q=F8--.S%HHHI""BBB@
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M5@/J: %HHHH **** "BBB@ HHHH *X?4/^2KZ?\ ]>A_]FKN*X?4/^2KZ?\
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M/^2KZ?\ ]>A_]FH [BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ7X5L]6VA'E7$B@' 8=<5%HLEM)X"MVM<>2;/C'^[6%\%RI^'-J5^Z97Q^E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUP: /1,TR:>.",O(<*.IKSZ_NM1\6>+[W1;#4Y]/M[!5:1HU&78XQR0>*T/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVEE;6-NMO:P1PPKT2-0 /P%1+I5@C7#+:0AKDYF(0?O/][UH X[1/B!X9M-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2K''?0L[' 4'J:Y#_A*;Z]\<V=O;RJNE-N52#_K".I^E 'H5%(.E+0 4444
M%%%% !1110 5P^H?\E7T_P#Z]#_[-7<5P^H?\E7T_P#Z]#_[-0!W%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:%% %#5-'L-9MQ;ZA:I<1 [@K=C]1S2Z9I%AHUN;?3[6.WB)R0G<_4\U>HH
M**** "BBB@ HHHH **** "BBB@ KA]0_Y*OI_P#UZ'_V:NXKA]0_Y*OI_P#U
MZ'_V:@#N**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P )EH'_ $$4_P"^6_PH_P"$RT#_ *"*?]\M_A0!NT5A?\)EH'_013_OEO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<<$%2> <<9[5ZEBC% "5YG\5O^0QX1_["0_]!->FXKS+XK?\ACPC_P!A(?\
MH)H ].HHHH #S5!]%TR1R[V%NS'DDQ+DU?HH S_["TK_ *!]M_WZ7_"C^PM*
M_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_[
M"TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*
M_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_[
M"TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*
M_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_[
M"TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*
M_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_[
M"TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*
M_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_[
M"TK_ *!]M_WZ7_"C^PM*_P"@?;?]^E_PK0HH S_["TK_ *!]M_WZ7_"C^PM*
M_P"@?;?]^E_PK0HH S_[#TK_ *!]M_WZ7_"I;?3;*T??;VL,3'NB ']*MT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T
M>GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:
M+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\
M/EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5
MYA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]
M/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO
M_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J
M^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-
M'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T_
M_$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_
M #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKX
MO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T
M>GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:
M+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\
M/EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5
MYA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]
M/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO
M_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J
M^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-
M'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T_
M_$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_
M #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKX
MO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T
M>GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:
M+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\
M/EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5
MYA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]
M/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO
M_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J
M^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-
M'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T_
M_$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_
M #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKX
MO?\ /EHO_?T__$T >GT5YA]J^+W_ #Y:+_W]/_Q-'VKXO?\ /EHO_?T__$T
M>GT5YA]J^+W_ #Y:+_W]/_Q-)]J^+W_/EHO_ '\/_P 30!ZA1FO+_M7Q>_Y\
MM%_[^'_XFK>EW'Q0.J6PU*TTE;(R#SC'(2P7OCY>M 'HM%(.E+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*3-&: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYS-X';.[:+J3:#V''%>E"@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "JNHWG]GZ?/=^3)-Y2[O+C&6;V%6J0T
M>5M\9V4D?\(5X@X.,^0?\*T-$^*]OK<.I-%H&I12V,?F/"Z_.W3@#UKHO&OB
M2+PSX<FNR0;B0B*WC[O(> !^I_"H/ _AYM%T4378#ZE=GSKF0\MN;G;GT&<4
M <I_PNE@/^1*\0_]^#_A71>"?B##XUFNXXM)O;$VQ ;[2 ,DYX_2K/CKQ"=!
MT/;;_-?7;B&W0<DL>^*L^$/#P\/Z''#(Q>[D_>7$AZLYZT =!2T@I: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#Q5XKLO">FBZNTDF
MD<[8;>(9DE;T KEXOBS!'=6,>I^']3TV"\($<\ZC:,],XZ?C74:WX6L]=U32
M[^Y>02:=-YL2KT)XZ_E7G?Q.\2P:O<IX5^S2VY-P$>\F0A$]PU '?^*_&5AX
M3TN&\N$EN'N&V6\$(R\I]%_,5SD7Q9@34+&VU3P_J>FQWC!(IIU!7). #CIS
M6Y<>$++4_P"PKJYN))#I)$D.TY#-QS^@KS[XC^)[?Q%?Z?X?$$MGMNT+W4ZE
M5&&'W3ZT >TJ0RA@>",BGU6LXQ%8P1A]X6-0'SG=QUJS0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4AZ4M0W<ABLYY%ZI&S#\!0!QGB
M#XE6>CZS_95EIEYJUTJEI5M!D1\9P3TS6GX1\9V/BZUE>"*:UNH6Q+:W"[9(
M_J*YCX16RW%MJ^M2'-Q>7CASCLIQ_2HW7^R?CE&ML=JZE:;IQCKMP!_*@#U
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ME:5X/T'19VGL--@BE8YWA!D4 7]&ADM]%L89AB6.!%<'U &:OTF*6@ HHHH
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MN09D!';=3T>*4;D*L/4<T <-\-M!U6PDUC6=8B6"ZU6X\XP#G8/\FN^I!2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3XWM_$5M<V6
ML:"[S"V;-Q: _P"M3V]ZY;7M9U[Q_I3>'X/#-Y8)<$":>Y!"JO?''6O7?K5>
M&\M)Y6CAGB>1>JJPR* . \;>$]0.B>'[O2(_/OM#F65(NGF#C(_2LG5;_7_B
M*EMHAT&ZTVT\U7O)+@$!E!!(''L:]=J)IX(ITB:1%D?[JDX)H +6W2UM(;>,
M82) BCT &*GHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *:X#(5(R",$4Z@]* /((/[<^'?B35&@T6XU+3+^3S8A; DQGN,8^M:W@K
M2-5U3Q5?>+=;LS;&91':02?>C48Y]NGZUZ#<7-O;('N)4C7. 7.*E1E= R$%
M2,@CI0 X=*6D'2EH **** "BBB@ HHHH **** $/2J]ZK264ZHBNQ0A4;H3C
MH:L&N%\;Q^-F>;^P#9_8/LYW^9G?NYSCGTQ0!Q.G:/\ %71;V<Z7I]A%8NY9
M;?[2NT?3FMRVNOBU]KA^TZ;IJP>8OF$7 R%SSW]*H^&X?BA_8D'V=M/$?.!.
M#OZGKEJM:AH7Q,UK[-!?7%A';I.DCF!B&(# D?>]J /5H]WEKOP&P,_6G&F0
MH4@C1OO!0#^5/Q0!#<7$=O$TDC *HSR:AT^_34;5;B,84].]9^O:+#J49EEE
ME78IPJM@&D\,KY>B(HZ+D"M.5<MSD]K-5N5K0?J7B*VT^X^SJDD]QC/EQJ2<
M59T[5K?58&:U?YU.&5A@J?<5D>'D2ZU/4KF5095E* ^PS45K_HWCJX@A 2.2
M$.RCH3ZU3@MC*->I=2>S=C7:+6=QVS6N.W[L_P"-5-1-JD]I_:B MS^]'" U
MT %-DACF&)$5AZ,,UFI:G3.C=:&#HR)_:UU):9-F5 !!RI;OC\,5T%-2-(EV
MHH5?0"L_6=0ETZS\Z*W:8YP0*'[S!+V,+LT2P YID<T<P)C=6 .,@YKE+,RZ
MX1]IU'RQG#01G:?UKIK*S@L8!% N%^O6G*/+N*E6=1W6QGZYX@BT0P^9$SB1
ML9!QBM2WG2X@2:,Y5QD8KE/&$0GOM/B89#.1C\#5WPW>[-,GMY6'F6C%#]!T
MJG!<B:.>.(DJ\H2V)[KQ)%;:W#IOE%WE.-P/ IFJ>)#IU\+6.REN'*[OW=<O
MM,_B&QOV S-<':<]JU-3O4L?%22NCN/*QA5)-:>SCH<OUNJU+6VOX%H>+Y$(
M:XTJZAA'WI&4X4>O2M2\UR"UTC^T55I(R 0!P36'JOB:VET^6+[++EUVC>A
MY]ZBU*T-GX',32;\X.<Y%3R)VT-57J)M*5]"XOBZ<X8Z/=A#SNVGI^5;NFZK
M;:I!YMNV0."",$&EL%4Z=#E1R@_E6!I(%MXMOK>+Y8BH;:.F?6I:B[V1M"=6
M#CS.Z9UE)1VK.O-;LK3Y6E#2=D3DG\!6:3>QV2G&*]YFC16=IFH3WQ=GMFBC
MZJ6ZFM!AO5E]1BAJS'&2DKHSKO6;>TO;:T8$R7#;5QVJY<7,5I;M/*VU%&2:
MXJ^TJ/3?%>EM')(_FR$G>V<5L>*7WP6UH<A9Y0I(K1P6AQ+$32DY="2W\56L
MTRAXIHX7($<SH0K?C6I=B[DC4V<D2D]2X)_K63XBMXXO#,P"C]VF5XZ&M/1F
M+Z3;,Q)8H,DTI))71=*<W/V<^UR!8M8.1)/;8(/W4.?YU@W^G:E:6T7F30/N
MN8SNV').X8SS79TC(K8W*#CGD4E-HNIAE-:L;")!$OFD%\<D#BO-?BK_ ,AC
MPC_V$A_Z":])N(WEM98XW,;NA57'\)(X->+>,=$U72-?\-/J6LR:@LE^!&KJ
M!L.#SP*C<Z$K:'M]%%% Q"<#)KP[XP>*M0OX)+#1V<6%I*J7DRG +'HH/?H:
M]+\?ZK>Z/X/O;O3XI);H+M18T+'GV%>&:_XFT^/X;C28M+U*.\DG2:XN9X'4
M._.<DC'>@#V'QAKEQH/PTDOK5B)Q H5L9QD5C67PXL[_ ,,1:BU[=C5I8?,%
MWYG*FK5CJ>F?$+P/=Z;<17.GP1Q*C2W*&,9(/(+ >E9UOH7Q!M-*.F+J]D-,
M6,HMX,&0)ZCG&?PH Z;X9Z_=>(/"$=Q>,&GAD:%F[MM[FNS%>:?!.+9X(?YB
MW^E2#)[]*]*% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5D^(=>M?#>C3ZE=[C'$.$49+'L!6M7C7CKQ"\?C^WM=3TV_N=(M$$JI!"S
M*\F3C.!VP* *O@>36)OB_+=:Q,3)=V9F2+.1&AW8'Z9_&MW6A/XM^);^'+BY
MDATVT@$KQQ'!E)[&N0M/B#9?\+975$TK4%A:U$ A\AMXY/.,9QS7<>(?#>H7
M7B6+Q#X7U*"'56@ FM9F'SJ?4=1UH R]7MHOAQXKT0Z5/(ME?S>3+!(^5'!Y
M'OQ7K:L& (Y!&17@7C32O$MQK7AT^)+N$SRW02&*W^XN,G)Z\\$=:]Z@0QP1
MQGJJ!?R% $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(
M:6LSQ!?2Z9H5Y>P0M--#$61%&230!Q7Q*\17SHWAC0R#?7$#27,P^;[/$!G)
MQT)X'/K3_A5*_P#PJ6VD+,7$<IW$Y/>N#T+QK::7HFK2WVCZM)JFHK(9I3:O
MA<@X&=O0?TK>^$>MVFI_#_\ L.5+BV6*-O,N74JF">S$8H Y_P &:?H.M:$;
M[Q#XG^R7TMQ(/*DNU0[0>#@U[+X6T.TT/3/*LKN2YAE.\2.^[.?0USFG?"?P
M;'I B^Q)>[@66Z>0D\]P0<8JC\,);G3M9USPTTSW%G82CR)"<X!S\N?;% 'I
MPI:04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '!?$9
M=:O)-&TK2Q<I;WMSLNKB!"3$G')/0#D]:YOQOX,L_!_AB;7=&N;FWOK4!R_F
M9\SZUZ!XL\5V?A331<W"O++(VR&&,9:1O0 5QO\ PC'B+QY<0W/B6066DJXD
M2PC/+CT<T =UIVK(/"MOJE](L:BW$DKL< 8')KQ^UU?5==^+.B:K<%HK"?S!
M:Q8(RH!^;WSS6O\ %'5GM=1TOPT=/O6T156:X:UB9RX!X3@'T_6N<UCX@:?)
MXX\/7EOI&H1064;((3;L&88/08YH ^A:*K65TM]90W2HR+*@8*XP1GU%6: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FR.L<;2-PJ@D
M_A3J@O5+V%PJC+-&P'Y4 >4:)I0^(VOZO?ZM).^F03>5:QJQ53CJ?KG-7O",
MT_A;Q[?>%;FYGEM)XQ-8^9\Q XR,^@Y%3?!^9$T?4;!R1<V]Y)YBGMEB1^A%
M17K?;/CI8^0"_P!ELR)B/X,XQG\Z /3ATI:!10 4444 %%%% !1110 4444
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M &/H/AK2?#.G?8-)M5MX,Y.#DD^Y/)K!\._#+0] UB;5@)+N_E=G$TYSMSV
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MEV,W6IS-+O\ 5.@_E0!W<$$=M;QP1+MCC4*H'8"IJ** "BBB@ HHHH ****
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M_HI&K_\ ?!_^+H_X5=XF_P"BD:O_ -\'_P"+H ]0R/449'J*\O\ ^%7>)O\
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M-_T4C5_^^#_\71_PJ[Q-_P!%(U?_ +X/_P 70!ZAD>HHR/45Y?\ \*N\3?\
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MD'2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH
M2BEHH 2BEHH 2BEHH 2BEHH 3%%+10 4F*6B@!**6B@!*6BB@ HHHH ****
M"BBB@ I*6L;Q5JK:)X5U+4E3>UM SA<]: *.I^+/!]EJ?DZEJ^G17L!QMED
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\7:9+K7A'5--A<))<6[(
MK$< UMT=1@T ><?#?Q/IJ?#.S2>989--@^SSHY^8%1UQ3_A%:RQ>'KR\<8AO
M+R2>'W4XP?TK9O\ X>>'=0U+[=+9[9"Q=UC8JKGW KIK>VAM8$@@C6.-!A54
M8 H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI:*
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:_W3]*=01F@#S[X<_\
M'_XA_P"OT_\ H*U@IIVFZ+\<M0O-<$7_ !,X%DL'<<*0 I![9^4UZK:Z=:6+
M2M;0+$96W.5_B/K5+7?#>E^(K=8M1MEDV_<?HR?0T <!KS6]S\9?#7]FF-S%
M'(;GR<' *MC=C\*?\.)8O#_B#Q1HM_*L=TUZUVNXX!1B2.?^!"NUT#PCH_AQ
M<V-OB4C!E<EG(^IIFO>#=&\12+)>VY\X?\M8V*L1Z<4 <+I< \4_$CQ5K-A(
M#:+8_P!G[B.LF%Y'M\IK0^%FK66G>$YM(N9TCN-+E>.7<<;L$\@>G%=WI6C6
M&BV0M+"W2&+J0.Y]36/JO@#P_K%\MY<6I6;.YS&Q7?\ 7% '-_"E&N]2\6:]
M",V&IZB7MG/5U!;)QVZBO3*KV5C;:=:1VMG"D,$8VJB#  JQ0 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$-QKWB4/91LNR#3XYV*H> 21T.>?SH [^O,=()U'XTZK)<,-UE;JD(]CC/\
M*O3J\UU6(Z-\8-.OB!%:WT!B9O[[\8!_(T .^,?_ "!]&_["D7\FKTCL/I7
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MD39#:PX)D.,$L>XZ]:NZ[&-?^+NCVJ;E328S<-(HR"3@;3Z?>_2@#TRBDI:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,48I:* $Q1BEHH 3%&
M*6B@!,48I:* $K#\3>'8O$-C'&9##<0R"2&8#E"*W:3% $<*.D*+(VYP &;'
M4U)BC%+0 F*,4M% "5Y[XH\ :EXIUK==:VXTCS4D^QA./E(.,Y]17H=)B@"*
MVMTM;:*")0$C4*H ["I<4M% #6!*D X)'%8/A_PXND7E_>RR^==7DFYWQC [
M"N@I,4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g0vsdaj33nnl000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /9" ,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI
M*6@ HHHH **** "BBB@ HI,TM !1110 4444 %%%% !129I: "BBB@ HHHH
M**2C- "T444 %%%% !1110 4444 %%)2T %%)FEH **** "BDSS2T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4E+2'I0!"UW;HQ5YXU8=06%"7=O(P5)XV8] &!-
M>0>)O^1DOO\ KI_2M+PMH^HPZ_97,EG*L().\KQ@J:]"6"C&E[1R/"AF\YXC
MV,:=[.USU.@D 9-%17*DV[@#)(K@2NSVY.T6QOVVU!P;B+_OL4?;;7_GYA_[
M[%>13>'M7,\A&GSX+''RU'_PCNL?] ZX_P"^:]%8*E:_M#P7F^(4K>Q9[.K!
ME#*P*GH12UGZ%#)!HMI%*A1UB4,IZ@XK0KSI*SL>[3DY04FMR.2XAA.)940G
MH&8"F?;K3_GYB_[[%<1XZTJ_OM5@DM;629%BP2HS@Y-<K_PCNL?] Z?_ +YK
MNI82G."DYV/'Q.:5Z-5PC2NEU/8X[F"5ML<T;GT5@:EKSKP9I&H6>M>;<VDL
M4?ED;F&!7HE<U:G&G/EB[GH8/$3KT^>4>5B/(L:[G8*H[DX%1?;K3_GXB_[[
M%9?BNVFN_#UQ#!&TDC8PJC)/(KS+_A'=8_Z!T_\ WS6N'P\*L;RE8YL;CZN'
MFHPI\Q[#]MM/^?F+_OL5.,$<=*\7_P"$=UC_ *!T_P#WS7L=LI6UB5N"$ /Y
M5.(H1I6Y97N7@,;4Q/-SPY;$M0M=VR,5:>,,.H+"I37E>O:'JD^M7,L5C,Z,
MY(8+P:6'HQJRM*5B\=BIX>"E"',>G?;K3_GYB_[[%21RQRC,<BN!W4YKQK_A
M'=8_Z!T__?-=[X&L;JQTV=+J!X6:7(#C&1@5K7PT*<>:,[G-@\QK5ZG).GRK
MN=93))8XES(ZH/5CBG5S7C:SN;W1EBMH6E<2@[5&3CFN6G!2DHMV/1Q%5TJ3
MG%7:Z&]]NM/^?F+_ +[%*MW;NP5)XV8] &%>._\ ".ZQ_P! Z?\ [YK5\.:)
MJ=MKUM+-8S)&I.69>!Q7=/!THQ;4SQZ6;5YS471:N>IT4#I39!F,X]*\X]UN
MRN1?;;4''VF+_OL4?;;7_GYB_P"^Q7D4WAW6#/(1I\^"Q/W:C_X1W6/^@=<?
M]\UZ2P5)J_M#P)9OB(MI46>S)(DB[D<,OJ#FG5A^$;:>TT&**XB:.0,<JPP>
MM;E>?.*C)Q3/<HS<Z:G)6;(Y+B&%L23(A]&8"F?;;7_GYB_[[%<-XXTJ_OM8
MBDM;669!" 2HR <FN7_X1W6/^@=<?]\UVTL)3G!2<['D8C,Z]*JX1I72ZGL:
M7,$K;8YD9O16!J6O./!FCZC9Z[YUS:2Q1^4PW,,#.17H]<U>G&G/EB[GH8/$
M3KT^><>5B,RJNYB !U)J'[;:?\_,7_?8J#68GFTFYCB4L[(0 .]>2_\ ".ZQ
M_P! Z?\ [YK7#X>%5-RE8Y\=CJN'DE"GS7/8?MMK_P _,7_?8J<>W2O&!X=U
MC</^)=/U_NU[' "MO&IX(4 U.(H0I6Y97*P.,J8GFYX<MB2HGNK>)MLDT:MZ
M%@#4IKS/Q;HVI7?B"::WLY98RJ@,J\=*FA2C4ERR=C7&XF>'I\T(\S/1?MMK
M_P _,7_?8J2.:*;/ER(^.NTYKQO_ (1W6/\ H'3_ /?-=KX%T^\L$N/M5N\.
MX\;QC-;UL+3IP<HSN<6$S*M6JJ$Z5EW.RILDL<2[I'5%]6.*=7->-[.YO=$6
M*UA>603*2JC)Q@UR4XJ<U%NQZ=>I*G3<XJ[70WOMUK_S\Q?]]B@7EJQP+B(D
M]!O%>/\ _".ZQ_T#I_\ OFI['P_JR:A;NVGSA5E4D[>@R*[I8*DDVJAXT,WQ
M$I).C8]@%'N::G"BDD!,; =<5YW4]V^ER,WMJ#@W$6?]\4?;;3_GYB_[[%>2
M7/A[5S=2D:?.06.#MJ'_ (1W6/\ H'3_ /?->E'!4FK^T/!EF^(C)KV+/9HY
M$E7=&ZLOJIR*=6!X.M9[/P]%#<Q-%('8E6'(Y-=!7GSBHR:1[=&;J4U-JS9%
M)/%%CS)$3/3<<4S[;:_\_,7_ 'V*Y+QWIUY?+:_9;>2;:QW;!G%<7_PCNL?]
M ^?_ +YKLHX6G4AS2G8\O%9E6HU7"-*Z[GL<=S!*VV.:-F]%8&I:\Y\&Z1J-
MGKGFW-G+%'Y9&YEP.HKT;M7/7IQIRY8NYW8/$3KT^><>5@2%4DG '4U!]MM/
M^?F+_OL4S4D:33+I$!+-$P '<X->0_\ ".ZQ_P! Z?\ [YK3#T(54W*5C#'X
MVKAFE"'-<]A^VVO_ #\Q?]]BIE974,C!E/0@UXQ_PCNL?] Z?_OFO5?#T$MO
MH5I%,A21(P"IZBGB,/"DDXRN+ XZKB)-3I\IIU$]U!&VUYXU8=BP!J4]*\R\
M6:-J5UXAGF@LY98F"X95R#Q65"E&K+ED[&^-Q,\/3YH1YF>C?;K7_GYB_P"^
MQ3XYX9B1'*CXZ[6!KQS_ (1W6/\ H'3_ /?-==X#TR^L+N\:ZMI(59%"EQC/
M)KHK86G3@Y*=SAPN9UZU50E2LGU.YILDB1+ND=5'JQQ3JY_QA:3WFB-%;1-+
M)N!"J.:Y*<5*2BW8]6O4=.FYQ5VC9^VVG_/S%_WV*47EL3@7$1)Z .*\=_X1
MW6/^@=/_ -\U9L/#^KIJ-J[:?.%65"25Z#(KNE@J25_:'BPS?$2DHNB>OT4U
M<[0*<>E><>\M5<A:[MD8JT\88=06%)]NM/\ GYB_[[%>7:YH6J3ZY>2Q6,SQ
MM*2K!>"*H?\ ".ZQ_P! Z?\ [YKT8X*DTFZAX-3-\1&3BJ-['LL<B2KNC=67
MU4YIU<]X-M+BST-8KF%HI Q^5ASU-=#7#4BHR<4[GM4*CJ4U-JS9')/%#CS9
M%3/3<<4S[=:_\_,7_?8KE/'FGWE_#9BTMY)BC,6"C..!7G4T$MM.T,T;1R+P
MRMU%=F'P<:T;\VIY..S:>%J<O)==SW8$, RD$'H13JHZ/_R!K+_K@G\A5ZN%
MJSL>S"7-%2[A1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ I#2TAH X?5? T^HZI<7:WJ(LK;MIC)Q^M=E:P_9[6&+@E$"Y]<"IJ
M.U:SK3FE&3V.:CA*5&;G!:O<6BBBLCI$VCTHVCTI:*!604444#$P#VHVCTI:
M*!60F *,4M% Q,"C:/2EHH%9";1Z4N***!V"DVCTI:* $VCTHP!TI:*!60F*
M,9I:*!B;1Z48%+10*R"BBB@8FT>E&T>E+10*R$Q2T44#$P/2C:/2EHH%9"
M4M%% Q,4;1Z4M% 6$VCTI:** L%)M'I2T4 )M'I0 !TI:*!604F :6B@8FT>
ME&T>E+10*R"DQ2T4#$VCTHVCTI:*!60F!2T44#$P#1M'I2T4"LA-H':EHHH&
M%)M'I2T4!83:/2EHHH"P4FT4M% ";1Z48 Z4M% K(*3 I:*!B;1Z4;1Z4M%
MK(,4444#$VCTHVCTI:*!60F!2T44#$(&*XC6/ \^I:K/>)>)&LI!"E"<< >M
M=N:*TI594W>+.?$86GB(\M1$%E ;6Q@MRVXQQJA/K@8JQ24M9MW=S>*25D%%
M%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(>E
M ,YV]\8:=8WDEM+OWQG#8%;\,@FA25?NNH8?C7CWB?\ Y&2^_P"NG]*];T[_
M )!MK_UR7^5=F(H1ITX274\G 8VI7KU*<MHEJBBBN,]8**** "BBB@ HI**
M%HI*6@ HHHH ***2@!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2N>O_
M !?I^GWLEK+O\R,X; KH3TKQ[Q7_ ,C->_[X_P#0177@Z,:T^61Y>:8N>%I*
M<.YZ[;S+<V\<R?=D4,/H:DJEH_\ R!K/_KBG\A5ZN62LVCT:<N:";"BBBD6%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU9V.R$N:*EW"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAET*'/F6[Y$[#'WAQT[]/6NOM/&$6K>"&\1:19S7;>7E;4<.7!P5Z=CGMVH
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M-R<=/P/0UZ)I5[)J.F07<UJ]J\J!C"Y^9,]C0!=HHHH **** "BBB@ HHHH
M**** "BBB@ I*#TKA]9\:7&G:M<6B0*RQD $GV!K2E1E5=HG/B<53P\>:H]#
MN*6J]E.;FQMYR,&2-6(^HS5BH:LS>,E)704444AA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4AZ4M(:!,\:\3?\C)??]=/Z5ZWIO_(,
MM?\ KDO\JXK6/!&H:AJUQ=130!)7R Q.?Y5W-I$T%G#$V"R(%./85WXJK"=*
M"B]4>+EN&JTL15E-63V)Z***X#VPHHHH **** "BBB@ K*\2?\BQJG_7K)_Z
M":U:RO$W_(K:K_UZ2_\ H)IQ^)$R^%GCN@-_Q:GQ"?\ IX3_ -EIUTW_ !:+
M33_T_/\ S:H?#[?\6D\1GTN$_P#9:6Z;_BSVF'_I^?\ FU>C;WOF>8X:?(OL
M?^)KX/\ >.+^E>TI]P?2O$F;_B;>#/>*'^E>VK]Q?I7-B-D=&$5G(=1117,=
MH4444 %%%% !1110!R?Q-_Y)OKG_ %[_ /LPK!/_ ";S_P!P3_V2NV\1:-'X
MA\/WFDRS-#'=1[&D49*\@]/PJE_PBD)\"?\ "+?:I/)^Q_9//VC=C&,XZ9H
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M2&:YMQ;F J-J@8YSU_AIWC+PK#XQT Z3/=26R&59/,C4$_+GCGZT <K\7/\
MDD4GUM__ $):ZZ/_ )$)?^P8/_151^*?"D/BCPLVA37,D$9\O]ZB@GY2#T/T
MK473E&B#3/,;8+;[/OQSC;MS0!P7P=_Y)1'_ -=)_P"9H^""*/ 3L% 8WLN3
MCG^&NH\*>%(?"GAE=$AN9)XP7/F.H!^8YZ"G>#O"L/@[0SI<%S)<(9FEWR*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44AH **R;CQ)IEK</!-<!9$.&'I6I&ZR1JZG*L,@^U4X2BKM&<*L)MJ+O8?1
M114F@4444 %%%% !1244 +574;,:AIMU9,Q59XFC+#MD8JS2T7 \IL? 6L:?
MX#UW1RL3W%U<*\&U^"H*]>.#Q45QX'UN3X;V.CK#']LBNVE==W&TEO;WKUJB
MME7E?\3)T8L\SB\#ZK)J/AN>01)%I\48F^?G*]0*]+'0#TI:*B=1RW*A34=A
M:***@L***2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBLJ_\1:=I
MNKV&EW,CK=7[%8%"$@D>I[=* -6BBB@ HHHH **** "BBB@ HHHH 2EKG(/%
M0E\;77AQM.N$\F$2K==4?...GOZ]JZ.@ HHHH *2EJEJ]^=*TB[OUMY+@V\1
MD$,?WGQV'O0!=HK'\,Z\OB30X-26TFM?,ZQ2CD?IS6Q0 4E+7%^,_&\WA^^L
M]*TVP:^U.\SL13PG3!(].?TH [2BLKP]J%[J6E)-J%DUG=#AXR<\^WM6K0 4
M8HHH ***S$U_3Y/$,FA+(_V^.'SF38<;>._3N* -.BL#Q?XE_P"$4T3^TOL$
MMZ/-6/RHC@\YYZ'TK;@E\^WCE"E=ZAL'J,T 24449H **** "BBB@ HHHH *
M*** "BBLFY\1Z9:7+P37 61#AA51A*3M%7(G4A35YNQK4@IL4JS1)+&<HX#
M^QI]3:Q:=U=!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %(>E+2&@'L>->)O^1COO\ KI_2O6]._P"09:_]<E_E7D_B:&0^([XB
M-R#)V7VKUC3@1IMJ#P?*7^5>EC&G1IV/G\IC)8JM<MT445YI] %%%)0 5!/>
M6MKC[1<0PYZ>8X7/YU/6#XB\(Z5XG\G^THW?R<E-LA7K]*:MU$[]#1_MC3/^
M@C:?]_E_QJXK*ZAE(96&00>"*\&\ >#](\0ZKJMO?QR/';,1'MD*X^;':O<+
M4VEM;PV<,J;8D$:+O!. ,#^5:U::@[)D0FY*[%GO[.U?9<7<$3'G;)(%/ZTD
M.HV-Q)Y<-Y;R.?X4E4G]*\F\>V$&J?%+2+&Y!,$Y1' ."0?>K?BGX<6^@Z6^
MK^&Y;FWNK4;V42$[E[\Y["J5*-E=[BYWK9;'K%%<+8_$&TM?!.G:KJ0)N)QY
M8BB^9F8$CO\ 3-/M?B)&M[!:ZKIEU8O<\P,ZC:P[9.:S=*>NA2J1.T\V/S?+
M\Q?,QG;GG\J?7C\?B2Y_X6L;O^SM0*_9"OV0 ;_KC.*Z_5?'L-MJ?]DZ;8SZ
MAJ(4,\48&$[D$YZ@54J,DTNXE43.RHKF?#WC73]>%U'MDM;FT&9X9A@J!U/T
MS6#<?%:S^T.;+3[JZLXF*RW")Q]5YYJ52FW:PW.*5ST&22.)=TCJB^K$ 4UY
MXHPN^5%W=-S 9KRGXA>+(]7\&12Z=#=+#*Z-Y^-H4YY4G/6NVTE8?$FE6LM[
M87$!MUV()N"V4P6&">,&FZ3C%28<Z;LCH89HYXQ)%(DB'HR-D5)5/3=.M=)L
MDL[./9"A)"YSU.35RLF6%%%% &+XNUF7P]X4U'5H(DEEM8MZH^<'D#G'UKC?
M"WC?Q9XMGT^ZMM"A@TAV5;FX9^<C[^T9Z>G%;_Q._P"2;:[_ ->__LPJ;X>(
MJ?#W0=JA<V49.!U.* ,/Q+X]U-/$H\-^%M,34-012;AY"0D7XY'(ZU13QUXH
M\-ZC:P>+=(A2RN9!$EU V<,>Q&>GX5BZ5!=Q_&'Q/;C6_P"R9[DJ\3- K^>!
MUQNX&*Z'Q)X<.J64>G:SXW1H[B0+$/L<8;>.?E(.0>* .D\8>,+?PKI4=P(_
MM-S.P2W@0Y,A/]*Y.X\3?$RSLGU*;PW9&)06:!7)95'?AN:I>.;+^P/$_@:\
MNB\NFZ:/(GN7&>> "?<XS7J,VKZ=;V3W<U[ ENB;V<N,!?6@#!O/&]OIW@B'
MQ'>VLL#2H-MJ^!(6)QC'UKE_^$D^)<]M_:L/AZT%MMWI;F3EDQD'[W7%5OB]
M*FL>'O#^M:=)Y^FPW@EDN8UW*BY W8/7D5T=E::E=:?#<P>.5$#QAE_T*(8&
M/3- &CX,\8Q>+= >]$!M[N#*7%NW5'']#@UQ6A_$KQ;XL@D@T;0(/M$,C":=
MF(B5?X<9.2W7/X5TW@?P_8Z3!K>H66L_VH=0F+32B,(%D7=N Q[FLWX(?\B-
M<''/]H3?R6@"SX4\=:E<^(7\.>)M.2QU0@M!Y>2LJ@<]SSP:X7Q?K7C%OB9H
MADT2W6YMY9?[/@$G%RN2 S'/''TKK?$/_)>?"_\ UXR?^U*@\=R)!\7_  5-
M*P2)1)N<]!UH [OPQ>:W?Z,LVOZ?'87WF,##&VX;>QSDU/KVMVGAW1KC5+UB
M(85S@=6/91[D\5H)(DB[HW5E]5.:X+XRV\UQ\.KL1(TFR6-V11U4,": ,RR\
M6_$/6[3^TM.\.6L=FV3"DKD-(N>_S<5TW@SQD?$JW5K>6AL=4LVV3V['OZKZ
MCWK2\.ZOIUYX;T^>WO(6B^SH,AQP0,$<^A%</X;==6^-VM:M8+YNGQ68MGF4
M?*)!MR/KP?RH 9/\2?$EWXLUCP[HV@PW5Q:3F.*7)"A 3DN<]>F,>]>C:(^H
M2Z-:OJL:17Q3,R(> <GI7 ?#O_DH_CW_ *_%_F]>GT >:^,/B3J'ASQ4FBVF
MEQWCRQ@P@9W,Y[=>E5+KQ;\0-!B&IZOH%LVGCYIUB?+0K[<\FJ/B/4;+3/CG
MI4]\42,Q[1*YX0D8!_I^->A^*M;TK3O#-]<7TD4T B(,08-O]L4 17_BJ-?
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M]VRLV.2!T_G1\00%\=>%7  <S$%AUQ0!Z;2TE+0 4444 %%%% "'I7COBO\
MY&>]_P!X?R%>Q'I7D'BJ*0^)KTB-R-PY ]A7H9<TJNIX>>QE*@N7N>I:/_R!
MK/\ ZX)_(5>JEI&1H]F",'R4_D*N5PS^)GL4OX<?06BBBI- HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI* &&)"<E13\"C(HH$DE
ML+1110,**** "D/2EH- 'D?PDYU[7L_WV_\ 0JZZT^'.A66O+K,/VG[4LK3#
M=+E=QSGC'O6WIOA_2M'FFFT^RCMY)CF1DS\W>M*MJE7FDVC.,+*S/(?&MS!9
M_%G1;FYE6*&-XV=W. H'<UK^-?B)HXT2XL-,N4O;JZ0Q 1'<H#<'GUKK]4\*
MZ'K5R+C4=.BN)0,!WSG'YU'I_@[P]I=R+BRTJWBF (# $_SJO:0LKK5$\DKN
MW4\3\2:!>Z/IGAF6Y)MAY>QY1SL<NS _@"#6CJEK97367V[QY)J69%*1)'YA
M4^XW<5[;?Z;9ZG:-:WMND\#=48<5F6/@SP[IET+FSTF"*9>C@$_S-:?6KK7<
MGV.NAQ-UJ%GI7QJ-S?W,=M!]@QYDK;5R>G-<C;K<6WCK5+>?Q*^CRR'/VD?=
MD'49.1BO:-4\*:%K5U]IU'38;B8*%WOG./P-+J7A70]7,9O]-AG,8VJ6!X'X
M5,:\5]UANDV>5Z;IANK[7AI?B=]2U$V?[V7R\*ZY7H^XY]*U/A]XJT/1? SV
MNI7<<=Q#)(6@8C>V3T [UZ/I>@Z7HD3QZ;916ZN<L$'7\ZH7/@CPW>737-QI
M%N\S')<YY/YTG6C)6EL"IM:HX7QKJ%EJGPIAN=.M&M;;SD5(BFT#GM[>]>C>
M']2L=2TB![&ZBN%C14<QL#M;:.#[U->:/I]_I_V"ZM(Y+7C]T1QQ]*32=$TW
M0X'@TRT2VB=M[*F>3TSS]*SE.+C8M1:=R_112UD:!1110!0UG2+77=(N=+O=
M_P!GN4V2;&PV,YX-/TK3+?1M)M=-M-WV>UC$4>\Y.T=,FKE% ',^)_ >@^+F
MCDU.W;SXQA9H6VOCTSZ5D:9\(?"NFZA%>B&XN)(CE5N)=Z@]CC%=[10!2U32
M;+6M/DL=0@6>WD'*L,UPR?!/PDK*2+]E4YV-<9'\J]&HH SX]$TV+1UTA+2(
M6"IY8@V_+CZ5Q#_!+PDSN0+Y%=BQ1;C"CV QTKT>B@#,T;0=.T#24TW3H!%;
M(,8'5CW)/<FHO#?AK3_"NF-I^FB40-*TQ\Q]QW-C//X5L44 8UWX8TZ]\3V7
MB&42_;K.(Q18?"[3G.1_P(U#XI\':3XPM(K?5$DQ$^]&B?:P/U].:WZ* ,CP
MYX=LO#&DKIM@TS0AV?,K[FR>O-:<]O%=6\EO/&LD,JE'1AD,#P0:DHH \[G^
M"WA*:>214O(5<Y,<4^U1]!BNOT'P[IGAO3Q9:7;+#$,;O5CZD]S6K10!BZ3X
M7T[1M7U34[02_:-2D$EQO?(R,]!VZFMJBB@#R+Q#HMAK_P 7UT_481+!):<C
MN.G(K:MO@QX3MKJ&<I>3")MRQRS[E/U&.179MHFFMJPU4VB?;@NT3\[L>E7Z
M *.IZ1::KI$VEW"L+::,QL$." 1CBG:3IEOHVE6^G6F_R(%VIO.3C.>35VB@
M#&M_#&G6OBF[\11B7[?=0B&3+_)M&,8'_ 15;Q/X)T3Q=%&NJ6[&2,Y2:([7
M'MGTKHJ* .'T?X3^%M&U*/4(H)[B>(AD^TR;PI'0@8ZBNCU_P]8^)+%;._$G
ME*X<>6VTY!R*U:* (X(5M[>.%,[(U"KGK@#%0ZC80:IIUQ8W.[R;B,QOM.#@
M^AJU10!CV/AK3]/\-'0(!+]A,+0G<^6VL"#S^-3:#H=GX<T:#2K#S!;09V>8
MVX\DGK^-:5% &+'X6TZ+Q;+XE42_VA+ (&._Y-HQV]>!2S^%].N/$L.OR"7[
M=#'Y:$/\N/I6S10!6O\ 3[74[*2SO84F@D&&1QD&N!?X)>$F=B/MZHQR46XP
M/ITZ5Z/10!GZ+HEAX?TN+3M-@6&WC' '4GN3ZDUS.N?"KPSKVJR:E/%<0W,O
M^L-O+L#'U(QUKMJ* .<\+^!]#\("4Z7 PEEX>65MSD>F?2J_BCX>Z'XNO(;O
M45N%GA4JK0R;<CWXKJZ* .;U'P1I&J>%;;P[=?:&L;?9LQ)A_E'&3BMV2S@F
MLFLYHUDMVC\MD<9#+C&#^%3T4 ><R?!/PB\CL%OD5FW&-)\*/8#'2NVTK1-/
MT324TS3[=8+5%("J,9SU)]S6A10!C^'_  UI_AJVF@T\2[)9#*WF/N.XTFJ^
M&-.UG4K&_NQ+Y]D^^+8^!GW'>MFB@ HHHH **** "BBB@ IAB0G) I])F@32
M>X8XQ2T44#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *0TM(W2@'L>6>(-=U*WUV[BBN75%?"J.U>EV+M)86[L<LT:DG\*\B\3
M?\C)>_\ 73^E>MZ=_P @RU_ZY+_*O1QD(JE!I'@Y55G/$UE)WL6Z***\X]X*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!#TKR[Q'KFI6WB"ZAAN62-6& .W KU$]#7COBK_ )&:]_WA_(5WY?&,
MJC4D>)GE2<**<';4]8TN1I=*M9')+-$I)]3@5;JCH_\ R!K+_KBG\A5ZN*?Q
M,]>DVZ<6^P4445)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2'FEI* .<O?!6EW][+=3&?S)#EMKX'\JZ"&)8($B7.U%"C/H*?15RJ
M3DDI/8QIT*=.3E"-F]Q:*2BH-A:*2B@!:*** "BDHH 6BDHH 6BDHH 6BBDH
M 6BDHH 6BDHH 6BBB@ HI*6@ HHI* %HI** %HI*6@ HI** %HI** %HHI*
M%HI** %HHI* %HHI* %HI** %HI** %HHI* %HHHH **** "BDHH 6BDHH 6
MBBDH 6BDHH 6BDI: "BDI: "BDHH 6BDHH 6BDHH 6BDHH 6BDI: $-<[?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;*45%62&21I*I610RGL:A^P6O_/!/RJQ134FMB94XRUDKE;[!:_\\$_*K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7,^._\ D6)?^NB?SKIJYGQY_P B
MQ+_UT3^=;8;^+'U./'_[K4]&<U\//^0M<_\ 7'^M>E]J\T^'G_(6N?\ KC_6
MO2NU;X_^.SDR3_=$+11WHKB/7"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<SX\_Y%B7_KHG\ZZ:N9\>
M?\BQ+_UT3^=;8;^-'U.3'_[K4]&<U\//^0M<_P#7'^M>E=J\U^'G_(6N?^N/
M]:]*[5OC_P".SCR3_=$+WHH[T5Q'KA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,^//^18E_ZZ)_.NFK
MF?'G_(L2_P#71/YUMAOXT?4Y,?\ [K4]&<U\//\ D+7/_7'^M>E=J\U^'G_(
M6N?^N/\ 6O2NU;X_^.SCR3_=$+WHHHKB/7"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ I**#2 *CFFCMXFDE<*BC))J*]O8-/M7N
M+APD:#))KRO7O$EUKER8X]R6^["1CJ?K75AL-*L_(\_'YA#"Q[R>R-'Q'XSF
MNY7MM/<I;_=+CJWT]J@\/>#[C4S'<70,5H>1_>85K^&_!858[O4ERQ^98CV^
MM=VJA1M48 [5U5<3"C'V=#[SS<-E]7%3]OB_DBM8Z?;:=;B"UB6- <X ZGUJ
MU117FMMN[/H(Q45RQT0M%%%(H**** "BBB@ HHK,UW7M.\.:9)J&IW"PP)Z]
M6/H!U)^E &G17C5U^T%ID=PZ6^C7,L:L0LAE W#UQCBND\)?%S0?%-W'9,KV
M-[(2$BF;(;_@73)]* /0:*X;Q5\2;;PMXEL-%ETZ:=[S9ME20 +N;;TQ4WC3
MXB67@N]L+2XM);B6\Y41MC:,XSTH [.BHXI5FB2500KC(W#!_*I* "BHKB9+
M:VEGDSY<2%VP,G &37&^#?B7IGC+5;O3[:VG@E@RR%^1(@.-W3CJ.#0!V]%%
M% !1110 45PWCKXDVW@>XMX9].ENC."04D"XQ]17:6TPN;2&<*5$J*X![9&:
M ):*** "BBB@ HHHH 0TUXUD0HX!4C!!I])0#2>C.'\0^!TFS<:8JQM_%%T!
M^GI7+:9K>H^'KHQ?,$5_WD#^O?Z&O8:Y_7_"UIK"-(H$5SCB0#K]:]"ABU;V
M=;5'A8S*VI>WPNDOS-#2=9M-7M5FMY 21\R]U/O6A7C&=1\-ZH5!:*5#^#C_
M  KTSP]XA@UNUR"$N$'[R,G]1[5GB<)[-<\-8LVP&9*L_95=)HW****XSUPH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5ZC9:R!!J4Q6.%I0,JV3N7/8G(KV>/7_  S/XG^PI=V;ZPJ;0,#S,<G&?SH
MY#QI\3M6T+Q&VBZ/H#WDR*&9Y%;:P(SE=O;G'-5_!_Q=NM7\2KH>O:6FGW,I
MVP[ W+>ASZUCZAXY\0^*_&MWI?A9K.Q6W1H&GNE =@&Y^;!(&>PKC;>VO+/X
MP:5#?ZF-0NUFC\R97+ ''*@GTZ4 =)^T#_R$M,_W&_I7N6E_\@BR_P"N"?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "=J9)(L4;.Y 51DD]A3^E<
M)XV\1E-VF6K?,?\ 6N.WM6M"C*K-11RXO%1PU)SD8_BOQ(VKW'V6U)^S(<9_
MOG_"M[PAX56V1-0O5S,1F-.RCU^M97@[PU]MD74+H'R4/[M#_$?4^U>E* H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR?P3KOB]?$-]>:'9M=W5S)ONML0;&3DG':@#W/X@^.9?!5M8R0Z>]XUS*5.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<WEW&"28)2H0_D ?UKTZVMX;2WCM[>-8X8U"HBC  H EHHHH **** "BBB@
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M^PQQ]:V/A!HM_)XA_M@0D644;QF1N-S$=!ZXH=K KGN5%%%04%%%% !1110
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MB^1\#&/3],5T%<-2#A)Q?0]JA556FIKJ+1114&H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:RM7\.Z
M;K4?^EVX\U00DR<.A/<'UK5K@/B)X]'AZ+^SM/<'49%R6Q_J@>A]S_A36H&5
MK_B6;PD9M+U.6#6[61"L:LP\V,XZ/[?@*\LU#6;O4L6T:K!:[OW=I "$4^PZ
MTVPLKSQ!JRPB4--,V7EF<  =R2:]0L?AUHEEIJ,=>MQJB/YB3K*I53C@8/;O
MTJMB-S,\(?"JYOFCO=;S!;X!6#^-OKZ?2O9;*RMM.M([2TA6*",85%' %<3H
M'CP_VS#X=U<(]\<(EU P:.4]CQT)ZUWM2[E(6BBBD,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!*Y7QUJ36>CB"-V62X;:"/3N/RKJC7E'C6^^UZ^\2EML(V$'UKKP5/VE57V1
MY>;XAT<,[;O0O_#_ $U9KR:]= 5B^5#W#?\ ZJ](%8WABP&GZ';QG;O9=S,!
MUSS6I+=00\22HOU;%9XNLIU')O0VRS#>QP\8K=ZDU%8T_B?3(0P$^]E_A /-
M94WC9/+/D6K;^V\C'Z5YM3'4(;R/7AA*T]HG6T9K@Y?&5](N%BB0^HS5$>(=
M7=L+=/D]@H_PKFEFU"]HW9T+*Z]KNR/2LCUHR/45YA+=:I<'<[7+?12/Y5%_
MQ,3_ ,_7_CU9O-7TILM99WFCU3(]11D>HKRS;J/_ $]?^/4;=1[_ &K_ ,>I
M?VM+_GVQ_P!F+_GXCU/(]11QZUY7G41_S]?^/5935-7MEPLLRC_:3_$52S7^
M:#0GEK^S-,]+HKSF'Q/JD3Y>?S!Z,!5^/QK=!AOMHBO?!.:N.;8=[Z&<LLKK
M;4[>EKF(/&=I(X62*2,?WCR*UK;7-/NB1%<H2.N>/YUUT\71GM(YIX:K#XHF
MC13$D21=R,&![@T[-=":>Q@+124M, HHHH **** "BBB@ HHHH **** "BDI
M: "BBDH 6BDHS0 M%4;G5["TC9YKJ)57KALG\A6+>^.M+MP/(+W&>H08Q^=!
ME*O3CNSJ*2N NOB))O'V2S7;W\T\_H:S;OQQJMP/W92#_<&?YTN9'-+,**/4
M:,UY(/$FOSJ0MU*X/]V,?X54>75Y6+,;PD^@84N9$/,%]F+9[-D>M&1ZUXN%
MU8_\_G_CU+LU?_I\_-J.87]H/^1GL^1ZT<>M>+[=6_Z?/_'J<DFL1MN4WF1[
M-1S!_:#_ )&>S9HS7DA\2Z_"H#74J ?WHP/YBK5KXXU6#_6%)_\ ?&/Y4<R*
M68T^JL>HT5P-K\1),G[79C;V\H\_J:U[/QSI5P"9B]N1V<9S^5.Z-X8RC/9G
M3USWC+3/[0T21E4>9#\X)[ =?TK5MM6L;N-7AN8V#=/FP?R-69%66)D(!5A@
MCUK2G-PFI+H.M"%>E*&]SS/P)J7V75VM7+;)QA5'0,._Y"O3^U>,W\,FC^(I
M%W<Q2[LKQP>:]?LK@7=E#.HP)$# ?45VX^"<E574\K)*K498>6\66**2EKSS
MW0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV*\V4==3U9X:E5C>QY'IWB'5-%E\LLQ1>L,H/']:[S1_%MAJF(RWD3_W'/\
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 8I,4M% "4M%% !24M% "8HI:*
M "BBB@!,4M%% !1110 F*7%%% !1110 E+110 F*6BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *3O2TAH ,\5SFN^)([-6M[8AYCP2.BU%XC\0_9@UI:MF4C#,/X
M:Y_1M&GUBXWON$(/SN>_L*\C%XR4I>PH:L]/#86,8^VK[#-/TJ\UJX:3)VD_
M/(U=_IVFP:=;+%"H&.K'J3ZU-;6L5I L,*!448 %35T83!1H+F>LF88K%RK.
MRTBN@4M%%=YQA1110 E5M18)I\[$X 0_RJS61XH<Q^'+QEZA/ZBKIJ\TC'$2
MY:4GY,\[\&1"7Q)#D?=4M^6*];'2O*? G_(R+_UR;^E>K5V9@_WMO(\K(DOJ
M[EW8M%)2UP'MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#*?X3ZBO=HI4FB66-@R,,J1W%?&8K#2P]1PEMT/9IU%4CS(DHHHKF- HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^?FM'2M%T_1H3'8VR1;@-[ ?,^.['N:!EU$$<2H.B@ 4^BBD 4444 %)2T4
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MLO#.G6-UY\0E8B1Y5220LB.Q)+ =CR>?>DOO#&G:A?37D_G&66,(=LA &.C
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M2E[2JET/.S3$^PP[:W>B(_ ^G?;=;\]\[8!OY&02>/ZUZIBN<\&Z7_9VBHS
MB68[W!_3]*Z.GC*OM*KMLA95AO8897W>HM%%%<IZ04444 %%%% !1110 444
M4 %%%% !1110 E<)\0-.&R#4$3I\DC9_+^M=Y61XDLA?:%<Q%2S!2Z ?WATI
M/8PQ-/GI-&+X!U SZ=):2/EH6^5?1?\ ]>:[&O*_!=XUIX@6(D*DH*/GVZ?K
M7J?:B.QE@9\U*SZ"T4E+3.P**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ\)0]K/79;GF9IC/J]&R^)[">'-)DUS5U\X,\2G?,Q/7VS[UZ]&@C1448"C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]D6>?^>*?R%?.Y[O ]# ]2[1117SYZ 4444 %%%)0 M%)5#5M6MM(LVN+A\
M<*O=CZ"G%.3LB9SC"+E)V2&:UJT.D:?)<2$;@,*N>IKRG%]XCU?O+-*?P4?T
M%2:AJ%[XEU5>"68[8HQT45Z1X;T"'1K(94&X<9D?N?;Z5ZB4<'3N_C9\U)SS
M6ORK2G'\2YHVE0Z3I\=O$H! RS8ZFM"BEKRY2<G=GTE.G&G%1CLA*6BBD6%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]4_Y!5W_UQ?\
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MH$FGL+1110,**** "BBB@ HHHH **** "BBB@ HHHH 2O/O%<CKKK@.P&Q>
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M7^5>AUYYXM_Y#TG^XO\ *O*S?^ O5'HY7_'^3.Q\/?\ (#M/^N8K3K+\/?\
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MM?%Y\-_BX=5E#RVTT[7&8QM$B,<E,GTR* /H"S\-:+8V+65MIEM';,,-&L8
M;ZUX5\7_  A:>$=7L-<T9!;1SR_ZI?NK(O.0.PZ<5[!I_P 1O"VHZ4VH1ZM;
MQQKG*3.$?CT4\FO%?B'XO?XD>(;'1M#@DEMHI,1':=SL>"V.R@?RS0!W?CJR
M'C7X16NK1NS3VL:3G"9,C ;6'YDG\*L_!#7_ .T/!LMC*[M-I[X8MV4YV@?0
M"NZTG18K#PO;Z04"A;812!?[Q7#'\\U\U-?WGPX\3Z_IMNUPD<D4D$&3@\GY
M)#QSQG\Z -JS/_"P?C;YOG&2UBF\R/S!G]W&<[?IUKK_ -H(!/#>C*H 473
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M6=2J_3<>,T =S12 @@$'(/((I: "BBB@ HHHS0 4444 %%%% !1110 4444
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M[5,AVYPO3 '/:MR_^']E?^ K;PD]Y<+:P! )E"[SM.?3%=?10!C:!X>@\/\
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M:*2_F1PZ/.<8(]A@'\:]"50JA5 50,  <"EHH **2EH **** "BBB@ HHHH
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M49K<]4%+6;H>H+J.FQRY&\#:X'8UHU[E.:G%274\B<7"3B^@M%)2U9(4444
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M)N5QC'3(Y]Z]*HH \H\)?!6'P[KT.J76KR736_S1+&GEX;U)R<C&>*]7HHH
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ML4OYCI**YO\ X3C1/^?A_P#OTW^%'_"<:)_S\/\ ]^F_PH#ZQ2_F.DHKF_\
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M$48"CT KD-7^%OA;6M8?5;NUF^U2-N9HYBH)]<"@#%\2ZYJVJ>.X?#-AJ?\
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M++P9)7WL!Z GH* .EKR[P7_R6GQM_NQ_TKU*L;3_  QIFF>(-0UNVCD%[J
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M_=M_X]_A1_PKS4?^?NV_\>_PKTBBCE0?V?0['F__  KS4?\ G[MO_'O\*/\
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MT X% $'@?PQI&G^)-3U&Q\13:K>8$-SO X/!'('/&*H?"E%_X2#Q>Q4;AJ+
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MH3E!-*77/K@T <3XC\.ZE8_"#P^DF^Z-G<QW<Y&<I&03WYXW 5ZQ8^)=&O\
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MW#0-O(.XJ2,C'TJMJ>MZY:^,M.TNUT@3:;<*3+=9^X!C/?C&>_7M0!U%%%%
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M,O;VKN?"VOQZM9+$[8NH@ X/?W%)=F<F#K.+]C/='0TM)2U1Z(4444 %%%%
M!24M)0 &L7Q%JPTZR*H1YTG"#/3WK2O;R*RM7GE;"J,_6O.;F>XUS5<HI+2'
M"+Z"O.S#%>SCR0^)G=@L/[27/+X43:!I9U._!D&88SN?/?VKT=%"(%48 &!5
M'2=.CTVQ2%0-V,LP[FK]:8'#>PIZ[O<C&8CVU339;!2T45VG(%%%% !1110
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M2N!\8>.[[3M<A\-^'=/%]K<H#L),A(T/<GCUZYH ["#1M-M=2GU&"SBCO+@
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M+6;G4-"UVW\O6-,($SJ %<'H<#H:Y/1?%'C[Q5K&KZ7IMY:PK:7+XNIHA\J
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M9:,OV>-6.09,G#KV[5V-_P#$'PII=_-8WNM6\-S"VV2-@V5/ITK/^%>@G0_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%%%
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MU:=% "* J@*  .@%+110!5U'3K/5K"6QO[=+BVE #QN.&P<_TKGO^%:>"_\
MH7;+_OD_XUU=% &-H_A30M FDETK2X+2208=H@1FMBEHH **** "BBB@ HHH
MH **** "BBB@!*#10: /&]4ED&OW8#MC[0W<_P!ZO88?]4OTKQO5?^1@N_\
MKX;_ -"KV2'_ %*?2IB>;@&W*?J/I:2EJCT@HHHH **** "BBB@ HHHH ***
M* "BBB@!*P=4\,Q:G?&Y>=E) & /2MZBLJM*%5<LU=%TZDZ;YHNS*]A:"QLH
MK96+"-=H)[U9HHK2*25D2VV[L****8@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHS0 44F:6@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "DI:* $JAJNF)JMJ('<H V<@5?HJ9P4X\LMAQDXNZ,
MG1M$CT<RE)6?S,9R.F*UJ.]%*G3C3CRQV'.<IOFEN%+115DA1110 4444 %%
M%% !24M% "5G:KI$&J0;9!AQ]UQU%:-%1.$9QY9;%0G*#YH[GF5U:7FA7P.2
MI!RCCHPKK="\1QZ@@AN"$N!^35K7VGP:A;-!.N5/0]P?45P>KZ%<:3+YB9:'
M/#C^'ZUXLZ57 SYZ6L.QZT:E/&1Y*FDNYZ-G-+7%:)XJ,2K;WQ)4' D[_C79
M1RI*@=&#*1D$5ZF'Q5.O&\6>=7P]2C*TD/HHS1728!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 %%%!H Y'Q
M3X36_P!U[9*%N?XT[/\ _7KD=(UB_P##M\T6QBI.)(6_I7IVHZK:Z;%NG?!/
MW5'4UY[J=ZVKZCYH@4,?E3:.2/2O/Q>-A1TCK+L*EE$J]3VL'RKJS3U?Q3+?
MP^1;*T4;#YB>I]J30O#<E[(L]TI2W'.WNW_UJYV_%WI-W&LD!1QAQO7@UW>@
M>++34TCMYL0W1XV]F/M_A7)A\)/$3]KB/N.^KF="@WAJ#UZLZ..-(D5(U"JH
MP !TI])FEKVDK*R.&]PHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !24$US.O>+K;3-T$&)KG'0'A3[T
M&=2K&FKR-75M8M=(M&FG<9Z*@ZL:\RU+5]0\1WJQA6.X_)"AXJ&*+4O$FI8R
M\TK'ECT0?T%>C:!X9MM%7S/]9<D8,A'3Z>E3JSS6ZF+=EI$H^&O",>G[;N\
MDN<<*>0O_P!>NL[44525CTJ5*-*/+$*6BB@T"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH :>1BN/'@*$7PN?MLF?,\S&P>N
M<5V-%!G4I0J6YEL I:2EH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.]7*]6,XS5XNYYTHN+LT+12"EJB0HHHH **** "BBB@ HHHH **** "BBB@
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M0R-]W\/>N1QJWB*[SB6XD(^@']*ER.&MC8I\M/5FQKOC2XOO,M[+,5N>-_\
M$W_UJJZ)X5O=8;SI]T,.>6<<M]/\:Z?0_!-O9$37Q6>8$$*/NK_C76JH4 *
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M='/XZTB.(M$[RL.BA2,_G6<_Q%MRIV6,H;MEA44'P[RO^D7A#?[ S_.KEO\
M#ZQCD#37$LJ]U(Q_*C45\9+;0Q9O'^HN&5(($!Z'!R/UK)DUS6]04P_:9Y0>
MJHN?Y"O1;?PEH]M*)$M<L/[S%A^M:D-C:P-NBMXHV]50 T68?5*\_CF>46_A
MW6M13S%MY& ./WC8/ZUT%G\/7+YO+L;".D0P0?QKOL"EI\J-88"DM9:F+I_A
M?2[ (4MU>51_K'Y)_I6NJ*BX50 .P%/HQ3.N-.,?A5A*6BB@L2EHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2
MBEI* "EHHH *2EHH *2EHH 2BEHH 2EI*6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBDH ***6@!*6BB@ HHHH 2EH
MI* "EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g0vsdaj33nnl000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -E!K$# 2(  A$! Q$!_\0
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M4?V;;^C?]]5=HH I?V;;^C?]]4?V;;^C?]]5=HH I?V;;^C?]]4?V;;^C?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:+>RB..\4,>F[BMZ.19%#(P93T(- $E%9^I:Q9:3&KWDZQAC@9[U)9:A;:C
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MXU[II?\ R +;_K@/Y5YUX^T]-,\'Z3:HN-C'/Z5Z+I?_ "+]M_UP'\J /._
M'_(Y:G_OM_.O5<5Y5X _Y'+4O]]OYUZK0!Y7\2O^1FTGZ_U%>B:F/^)+<?\
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MU/\ <#JJGK7=:-HMIH=BMK:)A1U;N30!POQ4_P!;IO\ OG^E=U90)<Z%!#(
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M_P >8_WC5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI:* $Q28IU% "8HQ2T4 )BC%+10 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBFMH9ROFQJ^TY&>QH 2?_CRD_P!P_P JY7X?@C3+O(/^O:NO*Y&".*CAMXH
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M CX<WHP<XD_K6_X4&/!UN",'RFX_.MQ;2%(#"L2B,]5 XI\<"11B-%"H.P%
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M10 4444 %%%% !1110 4444 %5-1_P"/-OJ*MU4U'_CS;ZB@"*BBB@"33/\
MCS'^\:N53TS_ (\Q_O&KE !1110 4444 %%%% !1110 4444 %%%% !1110
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MEEAQ\\<ASFL?Q$DVB^*K/7([=Y;8IY<H09*ULV'BF+5+Y+>TMIBA'S2,N M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFH_P#'FWU%
M6ZJ:C_QYM]10!%1110!)IG_'F/\ >-7*IZ9_QYC_ 'C5R@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M01WJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9H N;AZBC</453^P#_GJ_P"9H^P#_GJ_YF@"YN'J*-P]15/[ /\ GJ_YFC[
M/^>K_F: +FX>HHW#U%4_L _YZO\ F:/L _YZO^9H N;AZBC</453^P#_ )ZO
M^9H^P#_GJ_YF@"YN'J*-P]15/[ /^>K_ )FC[ /^>K_F: +FX>HHW#U%4_L
M_P">K_F:/L _YZO^9H N;AZBC</453^P#_GJ_P"9H^P#_GJ_YF@"YN'J*-P]
M15/[ /\ GJ_YFC[ /^>K_F: +FX>HHW#U%4_L _YZO\ F:/L _YZO^9H N;A
MZBC</453^P#_ )ZO^9H^P#_GJ_YF@"YN'J*-P]15/[ /^>K_ )FC[ /^>K_F
M: +FX>HHW#U%4_L _P">K_F:/L _YZO^9H N;AZBC</453^P#_GJ_P"9H^P#
M_GJ_YF@"YN'J*-P]15/[ /\ GJ_YFC[ /^>K_F: +FX>HHW#U%4_L _YZO\
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MC</453^P#_GJ_P"9H^P#_GJ_YF@"YN'J*-P]15/[ /\ GJ_YFC[ /^>K_F:
M+FX>HHW#U%4_L _YZO\ F:/L _YZO^9H N;AZBC</453^P#_ )ZO^9H^P#_G
MJ_YF@"YN'J*-P]15/[ /^>K_ )FC[ /^>K_F: +FX>HHW#U%4_L _P">K_F:
M/L _YZO^9H N;AZBC</453^P#_GJ_P"9H^P#_GJ_YF@"YN'J*-P]15/[ /\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U'_CS;ZBK=5-1_X\
MV^HH BHHHH DTS_CS'^\:N53TS_CS'^\:N4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%)10 4M)29H 7M29J.2>.%"TC!0.I)KG-2\86ML"EM^]D]0>*RJ5H4]9,U
MIT9U':*.E>5(U+,0 .Y-<_J7BRSM R1-YD@[ UQ=_KE[?L=\I"_W14%GIEYJ
M+XAB9A_>(X_.O,J8^<WRTD>I3R^,%S5F7-0\1WU^2/,V(>PJE:V5U?RXAC9V
M/4UUVF>#(TQ)>MO;^Z.E=3;V4%L@6*,*!Z"IA@JM5\U1CGCJ5%<M)'(:9X,R
M ]XV?]D5U=KIMM9H%AB5<>U6P,4M>E2PU.GLCS:N)J57[S$ I<4M%=!SB44M
M% !1110 4444 %%%)0 M)1FFDT .IK.%!). .IK#UKQ5INBJ1-*'EQQ&IY_^
MM7F>N>-]1U8LD3&" GA5ZX]ZZ:.%G4>B,9UHQ.^UWQOI^F!HX6$TPXPIX!KS
M76/%&HZQ(?-E*QGH@/%4]/TJ^UBX\NUB>1B>6QD#ZUZ)H/P]M[3;-J+"64<[
M!T%=RC1PRUU9S7J57H<5X=\.ZAJM[%)%&RPJP+2&O;XP415/857MVLX2((&B
M4C^!2*M"N#$5W5E<ZJ5/D0ZEI*6N<U"BBB@ HHHH **** "BBB@ HHHH ***
M* "JFH_\>;?45;JIJ/\ QYM]10!%1110!)IG_'F/]XU<JGIG_'F/]XU<H 0]
M*YGQOK,^C:&9;;B:1@BL?X<]ZZ<UF:WI$&MZ:]G<#Y6Z$=0: .1M_ CW\$&H
M2ZO<->,@82 C"D\^E=AIL%U9:6D-S/\ :9T!R^,;O2N*:T\3^%(F:"47ME%R
M%;J%KK/#NN1:_IHNHUVL#AU/8T <3XO;Q#);-=SS"UMDE 2)#RW/4UZ#I!+:
M5;,Q))C&37._$3_D71_UU6NAT@@:/;D]HQ_*@"MXCUA-%TF6X/,A&V-1U9NU
M<)X474+?QF([VYD=I8O-92>!G/%:)O8/$?C F>=!I^GGY59L!W_R*9'=VH^)
M?F"9/+\C .[CO0!J^--5NH3:Z982&.XNFVEAU [UEZEX.N=.TLZA9ZG=&[A7
MS"&?(..M.UQP_P 0M*)(*8^4]N]=IJNW^R+O/3R6_E0!1\*ZLVLZ!!=28\S&
MU_J#BMVN,^&P;_A&CGIYKX_[Z-=G0 4444 %%%0S2M$N54M]* )J*I?;)/\
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MLD_YX-1]LD_YX-0!=HJE]LD_YX-1]LD_YX-0!=HJE]LD_P">#4?;)/\ G@U
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M;)/^>#4 7:*I?;)/^>#4?;)/^>#4 7:*I?;)/^>#4?;)/^>#4 7:*I?;)/\
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MLD_YX-1]LD_YX-0!=HJE]LD_YX-1]LD_YX-0!=HJE]LD_P">#4?;)/\ G@U
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MY0V6HZ=&7DLR/D'4BJE]XKOM5TTZ?9Z9.MS,NQBRX"^IKT(C(IHB13E44'U
MH RO#6DG1=#@M&.7 W,?<\FMFFTZ@ HHHH *3%+10 F*7%%% !BC%%% !BC%
M%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !
MBC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%
M% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !B
MC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%%
M !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC
M%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM"#_ &ORH_M"#_:_*@"W153^T(/]K\J/[0@_VORH MT54_M"#_:_*C^T(/\
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MQ[OO7U%&]?[P_.O"/^$GUC_G^E_[Z-,/B35SR;Z;_OHT?V?/N'UI=CWK>O\
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M04ZB@!NQ?04;%]!3J* &[%]!1L7T%.HH ;L7T%&Q?04ZB@!NQ?04;%]!3J*
M&[%]!1L7T%.HH ;L7T%&Q?04ZB@!NQ?04;%]!3J* &[%]!1L7T%.HH ;L7T%
M)Y:_W13Z* &A0O08IU%% !1110 54U'_ (\V^HJW534?^/-OJ* (J*** )-,
M_P"/,?[QJY5/3/\ CS'^\:N4 %)BEHH 3%+BBB@!,4N*** $Q1BEHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I*6DH **3-&<4(!:#6;J&N6&F1EKFX13_=SD_E7#ZM\2OO1Z?#
MQT#M6U.A4J/1&<ZL8[GH4]W#;1EYI%11W8XKD]7^(.GV2E+;]_)[=*\RO]:U
M#4I";BX=L_P@\5/IGAK5-58>1;L$/\;C KNA@H0UJ,YI8B4M(EO5?&>J:FQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-14/VF'_ )Z+^='VF'_GHOYT 345#]IA_P">B_G1]IA_YZ+^= $U%0_:8?\
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M+'T*>E.)YY:^']2N\%;=E![MQ6U:>")6(-S, .ZJ/ZUV@G@ P'4?C2_:8?\
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MOYUY>YVI6)J*A^TP_P#/1?SH^TP_\]%_.@":BH?M,/\ ST7\Z/M,/_/1?SH
MFHJ'[3#_ ,]%_.C[3#_ST7\Z )J*A^TP_P#/1?SH^TP_\]%_.@":BH?M,/\
MST7\Z/M,/_/1?SH FHJ'[3#_ ,]%_.C[3#_ST7\Z )J*A^TP_P#/1?SH^TP_
M\]%_.@":BH?M,/\ ST7\Z/M,/_/1?SH FHJ'[3#_ ,]%_.C[3#_ST7\Z )J*
MA^TP_P#/1?SH^TP_\]%_.@":BH?M,/\ ST7\Z/M,/_/1?SH FHJ'[3#_ ,]%
M_.C[3#_ST7\Z )J*A^TP_P#/1?SH^TP_\]%_.@":BH?M,/\ ST7\Z/M,/_/1
M?SH FHJ'[3#_ ,]%_.C[3#_ST7\Z )J*A^TP_P#/1?SH^TP_\]%_.@":BH?M
M,/\ ST7\Z/M,/_/1?SH FHJ'[3#_ ,]%_.C[3#_ST7\Z )J*A^TP_P#/1?SH
M^TP_\]%_.@":BH?M,/\ ST7\Z/M,/_/1?SH FHJ'[3#_ ,]%_.C[3#_ST7\Z
M )J*A^TP_P#/1?SH^TP_\]%_.@":BH?M,/\ ST7\Z/M,/_/1?SH FHJ'[3#_
M ,]%_.C[3#_ST7\Z )J*A^TP_P#/1?SH^TP_\]%_.@":BH?M,/\ ST7\Z/M,
M/_/1?SH FHJ'[3#_ ,]%_.C[3#_ST7\Z )J*A^TP_P#/1?SH^TP_\]%_.@":
MBH?M,/\ ST7\Z/M,/_/1?SH FHJ'[3#_ ,]%_.C[3#_ST7\Z )J*A^TP_P#/
M1?SH^TP_\]%_.@":BH?M,/\ ST7\Z/M4/_/1?SH FHIB2K(/E(-/H **** "
MJFH_\>;?45;JIJ/_ !YM]10!%1110!)IG_'F/]XU<JGIG_'F/]XU<H *S]1U
M:TTORC=R"-9&VJQZ9K0JEJ.FVNI0>3=PK(@Y /8T 8FOWF@W.D3FYDMY,H=N
M""V>W2J7PYCN(M!D:;<(C(3%O_NYJKX:\&11W-Y)J-N2!,?)5FR-O:NY2"-(
M?)1 J8QA1CB@#C?B!>VTF@^6D\;.)!P&&:Z#1+RWFTNWB2=&?RQD!AGI5"?P
M-H]S(SRI(Q8Y/SG_ !JUIGA;3])N?/M@X;&.6)H Y/P]<)X?\=ZO973>6ETP
M>-FX!P3_ (U:\;7\.IM9:7:.)II)02$.<#(KI]6\.:?K)5KJ+]XO1UX-1Z7X
M7T[2IO.@BW2]F<Y(H Y/Q1$VD:WHVI,#Y48".1VKHM=\0V$/AZ>5;A':2(A5
M5LDDUM7VG6VHV[0740D0]C6);^!](@G67RF?:<JK,2* $\"64EEX9@$JE7D)
M<@^Y)KJ*8B!$"J  !@ 4^@ HHHH *CDB64889%244 5_L<']P4?9(/[E6*3\
M: (/LD']RC[)!_<J?\:/QH @^R0?W*/LD']RI_QH_&@"#[)!_<H^R0?W*G_&
MC\: (/LD']RC[)!_<J?\:/QH KFS@*D;*YR[\)++.SPR[5)SMQTKJ\48H Y$
M>#"1S<_I0?!9_P"?K]*ZZBE8=SD/^$+;_GZ_2E'@S YN?TKKJ,4K!<Y+_A#1
M_P _/Z4?\(;_ -//Z5UM%+E&I,Y1?!J8YG)H_P"$-C_Y[FNKHI>S0_:,Y/\
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M$<TW_GV7]:U\T4>PI]A>WJ?S&1_PCFFY_P"/9?UJ6+0]/B.5MD%:5%-4::Z
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M"#[)!_<H^R0?W*G_ !H_&@"#[)!_<H^R0?W*G_&C\: (/LD']RC[)!_<J?\
M&C\: (/LD']RC[)!_<J?\:/QH @^R0?W*/LD']RI_P :/QH @^R0?W*/LD']
MRI_QH_&@"#[)!_<H^R0?W*G_ !H_&@"#[)!_<H^R0?W*G_&C\: (/LD']RC[
M)!_<J?\ &C\: (/LD']RC[)!_<J?\:/QH @^R0?W*/LD']RI_P :/QH @^R0
M?W*/L<']P58HH CCB2,?(,5)110 4444 %5-1_X\V^HJW534?^/-OJ* (J**
M* )-,_X\Q_O&KE4],_X\Q_O&KE !1110 E%+10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 )12T4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U'_CS;ZBK=5-1_X\
MV^HH BHHHH DTS_CS'^\:N53TS_CS'^\:N4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/SH =13=Z_WA^=&]?[P_.@!U%-WK_>'YT;U_O#\Z '44W>O]X?G1O7^\/SH
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MT>X?8(_[S_G1_9\?]Y_SJ07=N>DR?]]4\3Q'I(I_&ERL?,B#[!'_ 'F_.C[
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M/^/,?[QJY5/3/^/,?[QJY0 4444 %%%% ";1G-+110 4444 &*,444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 54U'_CS;ZBK=5-1_X\V^HH BHHHH DTS_C
MS'^\:N53TS_CS'^\:N4 %%%% !1110 44F>:,T +1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 E&*6B@!"*ADMH9?OPHWU4&IZ2FF
MT*R*#Z1I\GWK.#_O@51G\(Z+<9WV2<_W216Y2U2J36S$X1?0Y&?X>:-)]Q7C
M^A)K7T;P_9:)%LM8_F/5SU-:])WIRJSDK-B5.*U2%Q2T45F6%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5-1_P"/-OJ*MU4U'_CS;ZB@"*BB
MB@"33/\ CS'^\:N53TS_ (\Q_O&KE !1110 4TG%.JGJ7F?V=<^5_K/+.V@#
MG/%7BVVTVU,=K<JUV& *KS@5M:)J]KJUDDD$ZRL -X'8UQ7@;^R)ENHKY(CJ
M'FG<)>IYKN+'2;"PEDDLX$B,O+;1UH FOM3M--MS/=S+$@[DUDVGC71KRZ6W
MCF<.QPI9< US-]+!KGCZ:WU&4#3]/7E&;Y=W^176V<F@W;*MH]M*4/ 0@XH
MTKJ]M[*W:>XE6.,#)8FL.'QUH<UPL(N&4L<!F7 /XUB>,&;4?$.F:/DB!VW.
M/7%;.O\ ARPF\.SQ"W16BC+(RCD$"@#I4=74,IRI&013JY;P'>2WGA>W,KEG
M0E,GV)%=2.E !1110 444F: %HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *2EHH 2BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,TM !
M1110 54U'_CS;ZBK=5-1_P"/-OJ* (J*** )-,_X\Q_O&KE4],_X\Q_O&KE
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MI5A^= &MFC-8^J>)-.TJ58IY293_  (I8C\JM:;JMEJMOYUG,)%Z'@@@^X-
M%[-+FL7Q!K7]CVT;)&))I9 D:'N32ZAXAL=*CC%[(5F=<^6BEC^@H V,T9K-
MTO7+#6(RUI-N*_>4@@C\#574?%.F:9<_9YI6:4?>6-"VWZX% &YFC-4;75K*
M\L?ML%PK6X&2_3'UK+3QIHK70A^T,,G:':-@I/UQ0!T6:7-5+F_MK2U-S-,J
M0@9W>M9=CXMTF_N1;QS,DC?<$B,N[Z9% &_12#I2T %%%% !1110 4444 %)
MFJ&J:UI^D0&6]N4C'8=2?PJ>WNXKFSCNXW_<R*'#>QH L9HKG9?&FBPW)B:X
M; ."XC;:#]<5O0S1SQ++$P=&&010!)FC-8>MZW+IUW8VMO"LTUS)M*D]%[G^
M=-OO%FEZ?.8)97:1?OA(V8+]2!0!OTF:K66H6NHVJW%K*LD3=&%4G\1:8FIQ
MZ?\ :5:X?HJ\T :V:,TAY%8CZVY\3II,,2LBQ>9-(3]ST'\Z -S-+FN>N_&.
MCV=RT,DSDH<.RQL0OU.*UX;ZVGM!=1S(8"-V_/&* +.:*YT>,]&-UY)G8#=M
M$AC;:3]<5J7^KV.FVJW%S.%C;[N 3N^F* +V:,UBZ9XGTS59S!!,5F'/ER(5
M)'XBK>IZQ9:3 )+N4+GHH&2?P% &A161I7B+3M6=H[>8^:O6-U*D?G6MF@!:
M*** "BBB@ HHHH *J:C_ ,>;?45;JIJ/_'FWU% $5%%% $FF?\>8_P!XU<JG
MIG_'F/\ >-7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "D/2EI#Z4 ><W.IQ'QM<R36LET;=<11JN<'U_2NHT3Q!::I/) L!M[A/O1N
MH!Q6+)(_A_Q?<W4T#M:W*YWJ,X/^32Z>S7?B*ZULQ-#:Q1X!88+=: )]5)U?
MQA9:>/F@M/W[XZ;NV?RKII+2V>59Y88VD1<!V4$@5SO@^%[AKS5I1^\N9#M/
M^R.E,\8ZS=6GDV-M'(/.'[R5!]U: *]A$EYXZFNK- (84VR,HP&-=/J4UO8V
M$]S(D?R*3DJ.M8OAW4-.MTCLK6&97;EG9<;CZTSQ8+B_NK/2X48QR.&E8= !
M0 [P59,MI/J4R8FNW+].W:H92VL>/8X_O6VG)N/IO/\ ^HUT5P\6DZ/(^0L<
M,?%8W@FVD&DR:A./W][(96)[@]/YT ;TEK:+,US)#%OQ@N5&<5QNCJ#K^K:G
M:+MMEC(! P"PS4WBW6+C[6FF1QRI"W,LJ#MZ"K^C7NGRVATRUAE0%""67&<T
M 5_!5M#-87%W)&KRSRL79AG-5_"\*IK.OZ6I(MQ)N !QC(&<?G4>B:DWAP75
MA>V\ORN3$RKD,*N^%K:: ZEK%W&R-=.65>X4#_ZU %&?3+73/'6CPVL012K$
MGN3@]35CQH&6_P!-FE0M:I)^\XR!6=J&MQS^+]/ODMYS# I#G9[&NJO=9LA8
MQS7,#O!)V*9_2@#E_%&HZ;+=:9-9.AG28 ;%QQ7H$1S&I]17!O!#KFLVD>GZ
M>(+.%][R>6%W>U=ZHP !0 ^BBB@ HHHH **** "FL<*3Z4ZFL 01VH \RT+6
MHTU#4;Z6QFN[IYBNY5SL4=AG\:[?1-9M-6MWDMU\MD.'0C!4^]<QHEX?"]SJ
M%E>V\FUI3)$ZKD,#2Z69=/M=9UB:,PK=-^Z0\'H * +MD#J_C">ZZPV@V+GI
MFNDE@LX?-N98H@<9=V49Q]:R_"=BUKI"RR?ZR<F1L^]8?BG5I[C5%TPQS1V(
MYFD1?O>U $OA"V\Z?6[N >5:W,Q$6!@'&>16/#JZ^'(KW2IK7[0[,2LJ@$'/
MJ:ZO3]1M;FPDL-.ADB*1'9N7%<_H=U9Z?I,]IJEG(UXS'S"4SO\ QH Z/PE:
M"QT)-TBMO)<[3P/:J/A]&U/Q%?ZJW,:GRHL^@_\ UUFV,MQI'A*\=U:/SG*V
M\9Z@'I75>'+#^S]%AC/WB-S?4T 6+F*QLX;BYEBA12I:1BHYX[^M<5HT<MIX
M7UB\0&.*>1FA7VZ9I=?U:34=;-A<Q3QZ="07VKGS#Z?2MT7%MK6BW-A91/&%
MBPH9<4 1Z!IUM)X/4-$A,T;,YQU/6JWA"!-3\-S6=P6,23,@ .. 35;3-=?3
MM ;39K6;[7&#&H"\&M7P_"= \.^;=*VYV,CJHY!/- %'P]:PV?C35(((UCC6
M-0 HQZTS5Y$M?'EM<WZ_Z'Y6(V894-533M;BA\6W]Z]O.(9U4(=OUKIM6U33
M8?+CO[8RHXR,QAA0!S=W?V3^-["2P92SC;(4&,BO0%Z5P^EV:ZIXA2]ALA;6
M=N/D&P+N-=R* %HHHH **** "BBB@ K+\0),^AW:P9\PQG&*U*AGD$4+R,"0
MHS@4 <-I^H:.OA"2TG")*(V#JR<[O_UUH^!+LGP?')(Q*Q%P"?0$XJGJ>J:;
M=0R1V.EB2]E!3=Y(&,]\TZ[C/ASP7#8(<W,Y"#']YN3_ %H M>%H_M]]?ZS(
M,^:YCBS_ '0?_P!5)K^L6&G07-JM@7D<'.V,8)^M;FD62Z7HUO;*O,<8W8[G
M'-9$_B>QVS0W-G+Y@R-A3.Z@#"<OIGPTN&20%G!!VG[N>U=$=)M4\&M;")-O
MV<G.WOC.:P;/0;J[\':C"T90SN9(8CVXX%6!XBD?PV;#[+-]O,?E;-O?IF@#
M0\+7WD^#8YI6R(589/L31X1M?,@NM1E'SW;D\_W>G]*S+Z&72_"]AHX/^DW+
M!6 [9.3^E=C:P)I^F1Q(ORQ1]!WXH S-?73[#0+E6@B4.I"J%&68UR]^MQIO
MPWMH)"RM,Z(P[@'G%,.K+J>MFXU2"=;>W8B*$+P?<UN:^!XE\+2&SC??$X=%
M88)(H L:]I-K#X1EMDB0"&/Y#M'&*-*L8-9\,V!O 9 B@X)X/U'>LN^\02:K
MH(L8;:87LJA'4KPIK<BGC\.Z#;0SJ[%5V_(,\T 9?@9%C;44C4*HF( ';I57
M3+BWT_Q=JIU0!9)"#%(ZY&W Z4SPAJBV]Y=Q2P3*9YBRDKQBMG5M6TE;EX;V
MR,TD?W<Q!LT 9.A75L?'M\+$CR9H@S!1@9X_PKO:X_PM822ZK=ZO+;BW20>7
M#%C&%KL* "BBB@ HHHH **** (I8Q+$T;9PPP<&N'OM+M-+\6:0EK$%W,2S'
MDL?<UW,D@CB:0YPHR<5Y]J^MQW/B73[N.WG,4).\[* .]GM8+@KYT22;3D;Q
MG%<?KL45YXLTN"SC7SH&WR,@QM''6M'6_$+P:*+FRMY'DEX4;>165X>U*RL3
MOFCN'O9S^\D9._YT =5K-^-+T>XNSUC0D9[G%97AC3TM_#WFW48=[C,T@9<Y
MS5;Q7(=1O]-T6/D3R>9,OH@Q_P#7KH;RX&FZ?YBQ,ZH -J^E '#>(M3M-8:U
MT^VM?)VS ^:R;0N#VKLKC2K;4;&"&Y)DCC . QPV!W]:YC7M6M=:TX6EI9R-
M<N1@E,;#FNA6[&AZ);"Z#NP4*=HSSB@#&\"QI%=ZRD:A46Y(  Q@<UH^,+QH
M-)^SQ']]<,(U Z\US_A'54M-1U!9H)E^U7!:,E>W-:4V=9\<1H.8+%-S>FXX
M_P#KT ;NGZ5!;:1;V4L2.L:C(9<C-<]XLBM[F_TVQM8D^U+,&R@P4&16_K^I
M2Z7I<EQ%$TL@'RJOK7)Z%JEI;2M>WL<\E]+]YBGW?84 7+M!=^/["TN/GCAM
MRX5AD;N><?A3O%D:66MZ->0*$D,XC8J,94__ *Z361+8^)K'78X7DMS'Y<FT
M<J/7]:2ZE;Q1KM@+>&1;6U;S7=QC)]* +/B[2;,Z;<7S1[Y\  MSCD=*U=-#
M'PQ$$SN-OQ^59/C#58QI\U@L4K3,!C:O'6KGAK58KG3(X!'(KPQ@,&7VH P?
M"U[I]EI=W;:@%2Y\QO,$B\MDG\ZM_#Z5#!J4$)/V>*Y/E?0DU)J&LZ3)YF-,
M\Z\&0 T(SGZU>\'Z7-I^EO)<ILN+F0RNOIGM0!T8Z4M%% !1110 4444 (:H
MZD]M#:-<7,(E6+Y@"N['TJ\:RM8U9=+$320/+&Y(8J,[: .0-Y#KOBVQ>"'[
M.EN<EW7:6]A73>*[XV>B.D;8EF_=KCOGC^M<_J=Q'K^J6"Z;;2*T<H9IBN,#
M(J]?@ZKXJM+('=':J'D],T :^F6$-GX?CAFB5U5-[J5SD]:Y#Q%J=KKDMEI]
MM:^21,K&9TVA /0UW6I7G]GV33>4T@7&54=JX_Q#JEKKFF?8[&SD>ZD90K%,
M;#D<T =5?:3:ZC911W.Z1(AD88X; [^M87@9$BDU1(U"J+@@ #  R:UY+P:+
MHENMT'=A&$)49.<5S7A'54MKV\CE@F7[1.60E>V30!L^,[EAI:V,)Q-=N(P!
MZ=ZU;73+=-,M[22%'CC PK#(K YU?QON',%DN/;=_D5L^(M4ETG2)+B"!II?
MNHJCO0!@>+(X+K4M-L+2-?M0F5LHHRB@BB=/MGCJUMK@!XX8<JK<C//-5?#^
MIVEI(UY>1SR7\Y^=BGW?85:U?S=.\26NLI"\ENZ;7VCE>M #O$L267B72+J%
M0C.^Q]HQD8-=)/%8V=M-<RPQ*I4L[%1S7,RR/XE\0V<L,,BVMJ=Q9QC)_P F
MJ6O:L^H:U]AN8IX]/A;YMJ_ZPCM]* #0Q)9^%M:OT4I#/*[P)C&U<G_&M?PY
MIMN?!D0:-&,T6]F(Y)(J=+FUUG1KBPLX7C41[5#+@5C:3K<FF^'O[+N+:;[9
M$OEJ O!H U/ KG^R9(<DK%(5%=76!X3T^6PT=1.NV:1M[#ZUOT %%%% !111
M0 4444 (:X'Q=?(/$]A;SQ/-"B[_ "E&=QY[5WQKC?$<<MCXCL=76%I844I)
MM&2.O^- %K3?$]G/J$=C+9O:3,/W0= -WTIGC&=I5M-*A)\RZE ;'91R?Y50
MN93XC\3:;+:P.MO:$O)*XQV/%6]. UGQC=7IYALE\N,_[7&?ZT ;=S'::?ID
M?G0B2.!0 -F3Q7'/>0Z[XOL9((?LRV^26<;2_3BNQU?5%TQ$=X'DC8X8J,XK
ME-5N(O$&IV":;:NKQR;FF*[=HH MVR+?_$2[,RAQ;0A45N0"<\_I1J426/CS
M39X5"M<*4<*,9Q_^NH[H3:#XP.HO"[VEQ$%=E&2"/_UU) \FN>*8K\0NEE9H
M<,XQEC0!-XH8ZCJ5CI,9SN<228[ '_ZU=(;*W9(A)"C^6,*64'%<UX=4ZGK]
M]JK\HA\J(^W^35GQ?K%UIMFD5I$[23<%U'W1ZT 9TT<=]\0;22Q156TC/GN@
MP#GM^HI^BHFH>--7N9@',(6- PS@<?X4>'=2TZP1+=(IVGF;]Y(R=6-1^9)X
M<\77EQ+#(UG=J&#H,X;B@!_EI9_$(1Q*%2XA.]0, ]*U=?CT^PT&Z4P0J'4@
M*%'S$UF:>)=3\1S:RT+K;PQE8]PY;_.*RFU<:GK;3:G#.MM W[J(+P?<T %Z
MEQ9?#NWM7+1M.ZH?4*>M=%K.F6J^#I8E@C"QP;E^4<$#K5?7E_X2/PM*;"-Q
M)$P=%88/%5+SQ VH>'_[/@M9OMLJ>45*\#MF@#H/"L[W'ANRD<DMLQD_4UM"
ML[1+(Z=H]K:GED3GZ]:T10 4444 %%%% !1110 E<):W%O8>,M1?4QM\P#R7
MD&1CCI7>5S>L:II4=PT-]9>;(OW<QALT 8NCWELWCRY2Q(\B6/<P48&>*NZT
MW]K^++#2NL%O^_F]"1C _4TS0+3_ $Z[UN6V%M'LVQ)C&%'_ .JI_"*&]FOM
M9D'S7,A"9[*,XH U]6N;/3XDNKBW\QE^52$W,*Y3094U/Q?<:E'&+>-8]HC(
MP6Z\XKI=4UR'3;I8KBWD:)AG>JY KGX/^)QXOM[RRMGB@B7]Y(5QOH L>$XT
MO-3U2\G59)/.V@L,X'%-T919^/-3MH1MB= ^T#C/%0Z=<OX8UB_BNH9#!._F
M1NJY_#]*ETGS?[0U3Q%<1F*(QD1ANI '_P!:@":[']M>-H;?K!IZ^8_H6/3^
M==-):VOFFXDAC,BC&]E&0*Y_P5;NUC<:G.#YU[*7R?[N>!^6*J>+M8N8[F/3
MH8Y5BD_ULJ#.!0 S1D#^)=4OK9 +8+C*C )J?P1!'<V=U?3*LD\TS;F89JUH
M-_IWDKIEG#*OR'YF7&?>LK0[YO##W>G7D$I3S2T3J,[@: '^&HHU\2Z_II0&
MU#AA'CY><YXJWXR2SBT86D<$7G2,%B14&0<U!H<<]H-6\03P.&N"62+'.T=*
MS--U:*;4FU/589VF!_=1[,A!0!9UB*1?[!TR<Y4X,@]2.:O^-K.&+1[>YBC5
M)+>5"C*,'J!3/$J2WD>GZQ:1,X@?)3'.*AU?47\2QVNG6<$H#2*TS.N H'/]
M* .RM)#+:0R'JR G\JL5'"@BACC'15 J2@ HHHH **** "D-+2&@#D_&.CV9
MT/4M0>/?<"'"LQSMY'0=JU?#RA_"^GJP!!MTS^59/C+5HQH]]IJPRO/+%A=J
MY'45-X:UB-M#M[;RI1+;VX#!EQD@4 /\2II]CX?GC^SQ#>I5$"#DFK/A>UEL
M_#]M'-G=C.#VKD8M774-9:\U2"<11-^YA"9'U-=7>:Y"OAV>^A#)A2$!&#G'
M% &;IA;5_&=W?'F&S7R8CVSW_G5C6]8L-*\^'[ 9)77G;$/F)]35KPI8FRT6
M,N/WLQ,CGU)JM/XGLU>:"ZM)1(I*@%,[J (/!5D%T&96?B>1F**?N D\>U4-
M2TNUTSQ1I2VT8&YB68]3]35[PA;2VJ7][)$T,$KEHXL=!ZUE:WK4=SXAL+B.
MWG,<#$.=E '?SRK! \KG"JI))KE_!T!N_MVMRCYKV4[ >R#I_.CQ-JPNO#\<
M%KN$U\PC12,'!ZUT&G6B:;ID-M']V) M %+65T_3](N7D@B"LIXV#+&N3:.?
M3_A\(W)0SR\#T4FFW6KG4]=;^T89ULK=OW<87.\CUK;U9U\1>')DL8G5HL%5
M9<=.: )KK2K5O!3P^4@"V^\''<#.:?X72+4O#6GS7422-&/E+C.,<9K(EU^6
M?PY_9L5K-]N9/)(*\#L3^53:A=7/ACPM9V5M [SNH4E1G9GJ: &W\<=YXYL1
M9HN8 3*Z#@?6GW"+>_$&..8!DAB)"D9&>*;X<U'3]/01^7</=3MF25DZD_CT
MI=86?2O%D&JB)Y+9DVR%1TZ4 +KL267B_2;F%0K3$HVT8R.*[->@KB]\GB+Q
M1:7$4+K:6HR&88R3C_"NT% #J*** "BBB@ HHHH *J:C_P >;?45;JIJ/_'F
MWU% $5%%% $FF?\ 'F/]XU<JGIG_ !YC_>-7* "BBB@ HHHH **** "BBB@
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MZ* (EA1/NJ%^@K/T[1HK&^N;L.SR3G))[5J8HQ0 A 88-,6"-#E44'V%2T4
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M)IG_ !YC_>-7*IZ9_P >8_WC5R@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **3(HS0 M%%% !1110 4444 %%%% !1110 44F:7- !1110 4444 %%%%
M!1110 4444 %%)FEH **** "BBB@ HHHH **** "BDS1D4 +11FDS0 M%)FC
M- "T4F:7- !129HR* %HI,T9H 6BBB@ HHI,T +1110 4444 %%%% !1110
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MK/\ S_S?]]&C_A)]9_Y_YO\ OHT?V?/N'UI'O&X?WA2[A_>%>#?\)/K/_/\
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MTH+@=2*XSPYJ5U:W>KZ==SM.MB-Z2-U(QFH=-L]1\2V\NHR:E-;JS$0QQG@
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M] 'I6X4FX9Q7(:_?7FDW5IK2R.;,@+/$3P,]ZL^%YKO5I[C6)I&%O,=L$6>
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MC704F* ,#4]&_M'PY':,,3I$-A]& K!\-Z5K&F:/J0FCS<RY">_:N]Q1CVH
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MC8@2+'Y9E)X('3]*[S%&V@#BCX=N9_!]M:,H%U =P4]"<U):S7VV*%]"02#
M9^W\J[#%+CVH Y;6--O-:U2VLY(]NG1C=)C^(^G\Z7PU87VBWMUI[)NT\'=;
MOZ#TKJ,48H  :6BB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJ/\ QYM]
M15NJFH_\>;?44 14444 2:9_QYC_ 'C5RJ>F?\>8_P!XU<H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ JIJ/_'FWU%6ZJ:C_P >;?44 14444 2:9_QYC_>-7*I:8?]#'^\
M:N9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:
M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
M6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
M %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1
MF@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,
MT9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*
M3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6
MBDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
M%HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F
M@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T
M9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3
M-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6B
MDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %
MHI,T9H 6BDS1F@!:*3-&: %HI,T9H 6JFH_\>;?45:S534C_ *&WU% $6:*,
MT4 .6P>,;4N749Z 4[[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y
M^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_P _<GY444 'V2;_ )^Y/RH^R3?\
M_<GY444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_
MY^Y/RH^R3?\ /W)^5%% !]DF_P"?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?
M\_<GY444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_ #]R?E110 ?9
M)O\ G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3
M?\_<GY444 'V2;_G[D_*C[)-_P _<GY444 'V2;_ )^Y/RH^R3?\_<GY444
M'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R
M3?\ /W)^5%% !]DF_P"?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<GY444
M 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_ #]R?E110 ?9)O\ G[D_
M*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<GY44
M4 'V2;_G[D_*C[)-_P _<GY444 'V2;_ )^Y/RH^R3?\_<GY444 'V2;_G[D
M_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\ /W)^
M5%% !]DF_P"?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<GY444 'V2;_G[
MD_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_ #]R?E110 ?9)O\ G[D_*C[)-_S]
MR?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<GY444 'V2;_G
M[D_*C[)-_P _<GY444 'V2;_ )^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_S
M]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\ /W)^5%% !]DF
M_P"?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_
MS]R?E110 ?9)O^?N3\J/LDW_ #]R?E110 ?9)O\ G[D_*C[)-_S]R?E110 ?
M9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-
M_P _<GY444 'V2;_ )^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_S]R?E110
M?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\ /W)^5%% !]DF_P"?N3\J
M/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_S]R?E110
M ?9)O^?N3\J/LDW_ #]R?E110 ?9)O\ G[D_*C[)-_S]R?E110 ?9)O^?N3\
MJ/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_P _<GY4
M44 'V2;_ )^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3
M\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\ /W)^5%% !]DF_P"?N3\J/LDW_/W)
M^5%% !]DF_Y^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N
M3\J/LDW_ #]R?E110 ?9)O\ G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W
M)^5%% !]DF_Y^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_P _<GY444 'V2;_
M )^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/
MW)^5%% !]DF_Y^Y/RH^R3?\ /W)^5%% !]DF_P"?N3\J/LDW_/W)^5%% !]D
MF_Y^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_
M #]R?E110 ?9)O\ G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]
MDF_Y^Y/RH^R3?\_<GY444 'V2;_G[D_*C[)-_P _<GY444 'V2;_ )^Y/RH^
MR3?\_<GY444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !
M]DF_Y^Y/RH^R3?\ /W)^5%% !]DF_P"?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH
M^R3?\_<GY444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_ #]R?E11
M0 ?9)O\ G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/R
MH^R3?\_<GY444 'V2;_G[D_*C[)-_P _<GY444 'V2;_ )^Y/RH^R3?\_<GY
M444 'V2;_G[D_*C[)-_S]R?E110 ?9)O^?N3\J/LDW_/W)^5%% !]DF_Y^Y/
MRH^R3?\ /W)^5%% !]DF_P"?N3\J/LDW_/W)^5%% !]DF_Y^Y/RH^R3?\_<G
BY444 'V2;_G[D_*FO8O(,/<N1Z8HHH L?91_>-%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g0vsdaj33nnl000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'V",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML:R1NKHPRK*<@BGTAA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8Q_"B@9_^O4]%^P6,?2_"NB:/&4LM.@CR<DD;CGUR<UL4M%(84444 )2T44
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M/5?!^@ZR%%WIL+,H.UD&PC/TQFMVB@#R.^^%NK:/)]K\-:M+NC(=8G;#%O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ?3UHW$>V453TW4K35K&.\LIEEAD&00>GL:N4AA1110 4444 %%%% !1110
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MW .V*=^,G^ZW]#7J0P1D8QVKWTTU='!ZBT444P"BBB@ HHHH **** "BBB@
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M5B1^,/#DS!8]:LG8G  E%;"2)(@=&#*PR"#UH ?1110 4444 %%%% !1110
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MZMXKB%MT<JAU/J",BO%J0<)69ZD)*2NB6BBBH*"BBB@ HHHH **** "BBB@
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M$&X8Y[KG]1]:>Z$>KT444AA1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !24M)0!R_CSQ,OAKP[),I_P!*GS'
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MA>PZE807MNVZ&9 Z'V-?6T:JJTU-'SU6FZ<W$LT445J9A1110 4444 %%%%
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M*6D,Y?QG<S26UKHMIO\ M&I2>4Q0 [(N-Y.?]DFN@L[2*QLH;6%%6.) H"J
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MD"YPBE@/6O,/"LATCXM7-N28+:Y#83H'X^7]<U2V$>S4M%%2,**** "BBB@
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M]*XD?:'JM+533;EKW2K.Z88::!)"/0E0?ZU;I#"BBB@ HHHH **** "BBB@
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M0(2L4;/[]*Y6W3[/)<NO/G_>SVYS7FXK,Z</X;N=='#<T7S([O3;IKRR6=@
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MZ*6BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBE$JY'6DG.F[ID2A8ZG1[:ZF=;J=V6,<(GM6]6'X>O6EB:W<Y,?(/M6Y7UN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO)B6\M3P.M<5:@M\7],QSAT)Q_NFNG$1M3N8X?XSW:BBBO,/0"BBB@ HHHH
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MUS3;N988+M'D;HHSS7U.78E5**N]3PZ])QF[+0T:*04M>@<X5PWQ;_Y$.?\
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M&'#*"1DUC-RI'J*]&C*+6AY]6,D]3'9MS$^IS6!X  N_BA?-,NXQ1R%">Q#
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M))F_NQ)N-8WC+74U71(_)TW4(XRP/FSP%$ ^M:4M)(XLQ5\-/T//J***] ^
M"BBB@ HHHH **** "EI**8R&3[U-IS_>--KF>YZ=/X4%*OWA24J_>'UI+<J?
MPLGHHHKI/*"BBB@ HHHH$%%%% !5>^D\JRE?VQ5BL[69=EEM_OG']:F;LCJP
M</:5XQ\SUCX0V2V_@_[4.MS*Q/\ P$D5Z#7/>"-,72O!^G6ZDD-&)>?]OYOZ
MUT-><S]!2LK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444AH \P^,]B\VCV%X =MO(RM_P+
M'^%=!I5U'>Z5:W$)S')&"#2?$ZPDO_ ]X$./((G;Z+DFL;P%>1W?A&T5/^6
M,3?4<_UKIH/H<N(6ESH+B!9ES_$.AK->-HSAA@UL4UXU<889KLC.QQF/15Y[
M$'[C8'H:A^Q3>WYUISIBL5N]+WJ<6<GF!6(&?QJU'9(OWOF-#F@L5(+=ICG&
M%]:TD0(@5>@I0 !@#%+6,I.104444@"BBB@#+\2:%'XBT@P (+Z'YK:1NO\
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M1110 4444 %)2TE 'BOBF,^'_BO%>N/,6^PP4'&-PV?TKM*Q_C%IDC:99:M
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M?0[?K7[OF*=EHT\Y4QQ'!Y#MTK0O-&ELH5EC_>C&)!C\_P *ZM5 &  ![4I
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M9.,9_'--;".]I:**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]$JAK+[='NR#AO*;!!]JX_6/B+&D8CTR/>S+S(_1?I[UQ=_XAU34B/M-Y(P
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ****  \BO&K@CP;\8/.)86E\27DD7@!SEL8]#@5
M[+7GWQ7T(W^@)JD*YN; [LYZ(>O'U IH3/0.O-+7,^!=?/B'PO;7,CEKE!Y<
MQ.,EAU.!T!KI12&+63XBUE-#T>6Z.&F;$<,>>7D;A1^9%:U<;$P\4>,6DPS:
M;I!VKG:4EG(Y/KP"/Q% &MX6T<Z3I"F;!O+EC-</DG<S<]_08'X5N444 %%%
M% !1110 5S/CS_D4[G_>3_T(5TU8/C"'S_#5TF.P/Y'-5#XD<V,5\/->3/%:
M***](_/0HHHH$%%%% !1110 4444QH@;[Q^M)2G[QI*Y7N>K'9!2CJ*2BA;C
MEL6**!THKI/)>X4444""BBB@ HHHH&5=0G\BS=NY& *]3^$VBMIWA<WDH(DO
M7,F&7!4#C'XXS7E,5E+X@\1V>DVX+;G&\#&0.K'\J^CK2V2SLX;9/NQ(J#Z
M8KBKRN['VF38;V5#F>[)J6BBL#UPHHHH **** "BBB@ HHHH **** "BBB@
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MZG!K&E6]_;N&CF0-QV/>KU>1?#S6)?#7B"[\*ZJY13)^X+#C=]?<8_&O7:3
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M6.KJXRK T,BNR[P2%[9H V;:4S6Z2,,%AG%351M$D<ARQ"#HHX%7J "BBB@
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MXTUW$>@^$-"7P[X;M; ;3(!OE*DD%SU(S6[112&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5%<01W-O)!*JLDBE2&&0:EHH \9\+3R^!/B#<:#<L_V*[<+&[X
M&>?D;V'6O9>.N>*X#XI>&!JNB?VG;H/M=D"QXY9.X]SQQ6C\/_%*>(]!19I%
M-];_ "3)T/LV/?G\J>^HB_XMU>33-+6"UYO[U_(MEY^\>"WX9S5W0=)BT72(
M;2-1N W2-CEG/))]:?+H]K/K,&J2&5KB!"D8,AV#/4[>F?>M"D,**** "BBB
M@ HHHH 2L[7EW:)>#_IBW\JTN]4-:_Y UY_UP?\ ]!-5'=&5=7I27D>#4445
MZ2V/SJ7Q,****"0HHHH **** "BB@]*!K<K]S1117,>LM@HHHH L#I10.E%=
M*/)>X4444""BBBF,*@N[A;:V>0]0.![U/533].F\5>([?2[8GR@V7?'11]X_
ME6=27+&YWY=A7B*R71;G??"+PX\<,^OW<9#S_+;[@#\O=@>HYR/PKU2H+&SA
MT^QAM($5(HD"J%&!5BO/;N?=Q2BK(****0PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT^.'381);1_*I\L''M7IFBC4?[.C;5)8WN6Y(C7 7V]Z\]T?P%-J>EP7@O\
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MJ:9IUOI6G06-K&J0PKM4 8^I_.K=9MW-!:***0!1110 4444 %%%% !1110
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MZ**0D 9- "TUI$3[S 52GO"3MCX'K54DD\G-6H-[BN:1NX1WS]*:+F)I 2V
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MHH *S;Z/;*''1JTJIWLJ[/+'+']* ,&^C/$@'3@U2K9=0<HV#ZX-9LUL\1)
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M_A&/$'[BZA;RX9).,^BG/?T]<BO4JXWQSX&@\3VGVBVVP:G",QRCC?CG:?\
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MPW328Y=O\\5OTE+2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZR*^\VV[I],]1[&FZ!\0(IIOL&M1FTNU;9N8$ GW]#75"JGN<=2BXZHZV_\
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M:*(S::=%YL9RLSJ&<?\  JWJ6BD,**** "BBB@ HHHH **** "BBB@ HHHH
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MB4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% "4M%% "5SFJ^ _#FL!C/IT:2,VYI(0
M$<GW(KI** /+;WX.0)<-<Z5JLMNR\Q1LF2#_ +V?Z5E7GACXC6MI*LE\;Z%Q
MM,/GM)D?0BO9Z*:DR914E9GSC-I/BNQB,UWH\ZQ#J3'BL\ZK<@X-BP/X_P"%
M?3I /!&:;Y:?W%_*M56D<$\JPLG=Q/F8:M)_%:2#\#2_VL3TMI"?H:^EFAB=
M2K1J5/4$4R.RM8V#);QJWJ%I^WD9O)L+_*?-1U:;M9N?S_PJ2"ZU*^D$-IIT
MCRL<* ">:^E_+3^XOY4;%!X4#\*7MY%QRG")WY3QZWO_ (GS0)8)8&WCV!!(
M8=NT#CK3(_A;XEU>],NO:JN& S()#*Q].N*]E%+6?,=_)&UF>>:9\(-"M(U^
MV237<P;.[.Q2/3;S7:Z?I&G:2KII]E!;*_+") N?RJ]12NRDDMA.U%+12&)2
MT44 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !24M% "5GZEH6EZO@ZA807! (5I$!*_2M&B@#
MSC4O@YHEQ&!87$]H^<DM^\!_#(K N/AMXNTYS%I.JA[5!\N9BA_[Y&:]FHJE
M.2V9+BGN>',OQ#MF*'2WD"<;EAR#^-5W\<ZG:$176BGS5X;+$<_E7O%-\M#U
M1?RK58B:ZD.C!]#Q:'XG2*H5M&=<?W7)_I5D?$Z#'S:=.&KV#RT_N+^50M8V
MKN6:WC+>I6E[:0O80/()/B>P'[K2)&_WF(_I4"_%"^<[4T(DGI^]/_Q->V"*
M,  1J .!Q1Y:?W%_*E[:0>P@>,?VS\0;T>=9:,ZP/]W]SN_6I5\)_$+56\^>
M_%JDA^:/SV3:/]T"O9  !P,4M)U),I4XH\OT_P"#-BD_FZEJ,UR"/FC5=G/^
M]FNQTGP7H&C",VFG0^;'RLSJ&?\ [ZK?HJ&VR[(2BEHI#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***2@!:*** "BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BDHH 6BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HHHH ***2@!:*** "BB
MDH 6BJMQJ5C:/LN;VWA;TDE53^IIUO?6EYG[-=03XZ^5(&_E0!8HI*6@ HHH
MH **2B@!:*2CO0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%(:* %HHI* %HHHH ***
M2@!:*2B@!:**2@!:*2B@!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HI*6@ HH
MI* %HHHH **** "BBB@ HHHH **** "BBD[T +124"@!:*** "BBB@ HHHH
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MI].T^ 7M^AQ)EL(GKSZ_A0!Z;17S$GQN\9+,KM<6S1YR4^SJ,CTSBO6OA_\
M%6Q\82FQNXELM2 RL>[*R#_9/K[4 >AT5R?Q)UZ^\->";O5--=$NHWC"ET##
MEP#P?8UY)H7QTUFW6\?65CNV\H?9HTC$8W[AG)';&: /H>O.?B7\2;OP+>V$
M%MI\%TMU&SL97*[<$#M]:X[PQ\7_ !!>1>(+^^2">&QM/M$-N%"8)E1<%@,G
M :O._'/CB\\<ZE!=75O';QP(4BB0YQG&>>_(H ^G/!GB&;Q1X9MM5G@2!Y<Y
M1"2!^=;]?-_@KXO7>@:79:''I,$T:OM\UIB#S[8KZ"U75[/1=+EU&_E$5O&N
MYF/\J +V:*^>_$?QXU:>Z:/0;>*U@1SMEE4.TB]LJ>!^!JOHGQWU^UN_^)O#
M!>P,0#L01E!GDC Y..QH ^C*\"^,<OBZ'Q5&]K-?)IYC @^QLZ_7=M[YS7LO
MAOQ+IWBK2DU#39=T9.'4_>0^AKSGXL_$'7_".N65KI,T*130&1@\0;G<1WH
M[7X=OK,G@C3VUU9!?%3GS,;BF?D)_P" XZ\UU5<5X%\2:CKWPX76KYT:\*S'
M<J!1\I8#C\!7D&G?&OQ2=4A6^N[<6N_]YBW4'% 'TG17@<WQLU?5?%%K:Z3%
M':Z>TVS]X@9Y%)X)_NGZ5ZMXO\:Z;X-TM;J^8O-(,10)]YS_ (4 =-17S7J7
MQT\4W-X7L!;6<&.(_+$GXY(KH/"?QWE>YAM?$=NFQVVF[B&,9[E>@% 'NM%1
MP31W$"30N'CD4,K#H0:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "J]\6&GW)3(;RFQCKG!JQ10!\A7M_XO%_<!+O7-OF
MMC$DN,9-9\NO^)+>3RYM7U6-QR5>YD4_D37V;7R]\;?^2EW7_7"'_P!!H YB
M+5O%EQ'YD.H:U(AZ,DTI'Z&O8_@7<:S/+K7]K37\F%B\O[4SG'WLXW5T?P6_
MY)Q;?]=I/Z5Z#0 M%%% #)94AB>61@L:*69CV ZU\_\ CWXS7MW/-IOAYOL]
MLK%'N, M)VX]![CFNV^-OB"YT;P?':VI9&OY?):17*E% R>GKC'XUXU\,O"*
M^+_%203%?L=LOG7"DD%EZ #\2* ,);77O$$H?9?W[$<.Y9^GN:57U_PY+E6O
M[!@W.&9 3Z<<&OL6PT^TTRSCM+*WC@@0?*D:@#]*KZUH>G^(-.DL=1MTFA<?
MQ#E3ZCT- 'E_PP^+-SK]^NBZZ-UY)S!<1QX#?[+ =/8_G7L%<CX,^'>C^"S/
M+: SW,Q/[^0?,J]E'H/YU-XV\<:=X+THW%RPENI,B"W4_,Y]_04 =325\TW_
M ,<_%=Q=O)9&VM(3TB\H28_$BNK\&?'+[7<PV'B*!4=\*+N+HS$_Q+P /I0!
M[#JC,FD7K*2K"!R"#@@[37RQX:\0:U+XWLHI-7U!XS=8*-<N01SQC-?4FINL
MFA7KHP96MG(([C::^2O"_P#R/EC_ -??]30!]*_$VXGM/A[JTUM-)#*L0*O&
MQ5AR.A%>2?!+6-4O_'KPWFI7EQ$+*0[)IV=<Y7G!->K?%7_DF^L?]<A_Z$*\
M;^ __)0W_P"O&3_T)* /I>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /%_CWJ=_IPT/[#?
M7-MO\[=Y$K)NQMQG!YKQV#6O%%UN^SZGK$VWKY<\K8_(UZQ^T/TT'ZS?^R4O
M[/?W=8^D?\S0!Y1-J_BNW3?/J.M1)_>>:51^9->J_"_XLW5Q?QZ'XAF$@E^6
MWN2 "IQPK>N?7GDUZOXN@TZX\+:BFIK$UN+=R?, ."%/(SW]*^2M$"CQ7IP@
MY47T6PG_ 'QB@#[0I:\Z^+/B[5_"&@:==:7)''/-<>7(7C##&TGO[BF_"+QA
MJ_C#2]2GU>6.1X)E1"D87 *Y[4 >C45PWQ6\3ZGX3\*PW^E2(EPUTL1+H&&T
MJQZ'Z"L;X2>.=;\7RZBNK2Q.(-FS9&%QG.>GTH X;XUZSJECX^\FTU*\MXOL
MD9V0SLBYRW. :]?^&MQ-=?#[29[B:2:5XLL\C%F//<FO$_CK_P E$_[<XOYM
M6G9_%Q/#'@32=(TB%9[];<B61_NPGG''<^WTH ^A:6OFK2_CKXGMKQ7U 6]Y
M!T,0C$?XY KWCPIXJT_Q=HJ:C8.?[LL;?>C;T- 'AGQCUK5;+QW-#::G>6\0
MC7"13L@^Z.P->O\ P^N+NY^'5G,TSS731-M>1BQ+=LDUXE\;/^2@S_\ 7-/_
M $$5[5\-6*?#>Q=>JQ,10!XA!<_$$>.E3S=3-Z;LEDW-Y6<\\'Y<=?:OJ+M7
MSJ_Q?\6CQ.U@+FW\@7)CQ]G7.W..M?0\DJ00M+*X1%&68G  H ?FBO#O&'QT
MEANYK+PW#&R(<"\D&<GOA>A%<UI_QS\5V]VLE[]FNX0.8O*$>?Q S0!]+4M<
MIX)\<Z=XUL'EM0\5Q%CS87'W?<'TKJZ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FJ,5TJZ92581,00<$<5
M\@0>+?$-I=I.FM7Y:-]P#W+LI^H)P:^OM6_Y!-W_ -<F_E7QGING3:OJ]OI]
MN5$UQ)Y:%C@9/K0!]4_#_P <6OC315F $5]%\MQ!GH?4>Q_I775\@Z%K>L_#
MSQ4T@B:.XA;9<6TG1QW!_P :]B\<?%NRC\'0G1;D_P!HW\60J_>A4\$GT/7'
MTH R?C%\1I$F_P"$?T2]9"A!NIH&P0>H4,.1VZ5RGPIUS5[OXCZ5!<ZK?3PN
M9-T<MP[*?D;J":X:/3[V]L;W4@C-#;E6FD/JS8'XY-=5\(?^2G:1]9/_ $6U
M 'U92U1U?5;30]+N-1OI/+MX%W.<5X'KWQWURYN\:)#%9VZL0ID02-(,\$@]
M#CTH ^B:*^>_#?QWU:"\6/7X(KJWD<!I8E"-&O? '!_&O?+"_MM3L8;VSF6:
MWF4/&Z]&!H L4M?/OC3XL^*M$\8ZKIME<VZVUM.4C#0*2!]:?XF^.FHETM]
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MA&F.Q !Z]:V? M]\/Y]/CL_$MF(KU3@3[0$9?<^M:FNZM\*]-/EZ?I+7\H8
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IZM_R";O\
MZY-_*ODCP/\ \CYHW_7VO\Z^M]6_Y!-W_P!<F_E7R1X'_P"1\T;_ *^U_G0!
M[9\6?AN?$%F=;TI#_:4*?O(A_P MD'I[CGZYKP;0?#]]XAUV'2K2%VF=]KX'
MW!W)]A7V</NBL;1O"FCZ#?7MYIUHL,UX^^5@/T'H/;WH X#Q]X:L?"OP6NM.
ML8E0*\)E<#F1]ZY)]37EGPA_Y*=I/UD_]%M7MOQG_P"28ZC_ -=(?_1BUXE\
M(?\ DIVD?63_ -%M0!]/ZO!87.DW4.IK&UDZ$3"3[N/>O"K+6_A9X8%Y!'82
MZO,TI*2S6ZNF,G 4D],=^]=5\>[VZM?"=G#!(\<5Q=;)=K8#C:3M/X@'\*\]
M^%5KX*D^W7'BN>U69&401W3@(RD<G!ZG.* .3\5ZUIFN:D+K3-%BTI -K1Q/
ME7]#C P:]_\ @A-+-\.HO-=GV7,B+DYPHQ@5XM\2=2\-WFN1V_ABPM[>SM@R
MM- H F8XY^@QP?>O9O@7_P DY7_K\E_]EH \/^)7_)1]>_Z^C_(5[YX2^%_A
MK3= MEN]-M[^YD02237$88DD=L]![5X'\2O^2D:]_P!?1_D*]7\*_'#1TT*"
M#7DGBO85V$PQ;E< <'KQ]/:@#F/C/X&TOPV]GJNEIY$=W(8WMU'R*0,Y7T^E
M=C\ ]0N+GPI>VLTA:.UN-L2_W5(R?U)KS?XH_$5/&MW!:V,133;5MT;.,.[$
M<D^@[8]J]/\ @7HUUIOA"XN[A0JWL_F1#/.T#;S^(H \(UN#[5XXU*WW;?-U
M*5,^F9"*^EM$^%_A72=*BM)=*M;V91\\]Q$&9F[GGH/:OF;7YFM_&>J3)C?'
MJ,KKGU$A->YZ)\==!DTF$ZREQ#?A<2K%%N4GU!SW]* ///C#X,L/"FN6L^FC
MR[>^#OY&.(RN,X]N>E>L?!6^GOOAW")W+>1,\,?L@ P/UKQ;XE>.CXWUR-[>
M+98VNY+<,/G;.,D_7 X[5[?\'](N='^'MNETH5[B1KA1W"L!C/OQ0!\_>%_^
M2D:7_P!A-/\ T97O?QM_Y)O=?]=HO_0Q7@GA?_DI&E_]A-/_ $97O?QM_P"2
M;W7_ %VB_P#0Q0!Y+\'O"FG>*/$ET-33S8;2$2B(CAR3C!]J]&^*G@/P];>!
MKS4;'3+>RN+/:ZM!&$W98+@X[<URO[/?_(PZQ_UZ+_Z&*]/^+'_),=:_ZYI_
MZ,6@#R?X N__  F%\FX[#9$D9XSO6JWQVU&>X\<I8N1Y-I IC'?YP"?Y58^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7E/CKX07'C'Q1+K$>L16JR1HGE-
M 6(VC&<[A7JM% '.>!_##^$/#46D272W+([-YBIM!S[9-=)24M !1110 5R_
MBSP'H?C"-3J,!6X1<)/$0' ],XZ5U%)0!X+<?L]WGF,8->A*%CM5K<Y [<[J
MFT[]GR1;R)]1UI9+8-^\CBA*LP]FR<?E7NM% &%X;\):-X4M/L^E6HC) #RM
MR[X[DU/X@\.Z;XFTN33]3@\R%QPPX9#Z@]C6K10!X;??L]F2]E>QUU(;8M^[
MCE@+L![D$9_*M3P]\!M,L9_-UJ^:_P!K HD:^6OT8'.:]>I: *L]FCZ7)8P@
M1(T)A0 <*-N!^5>0:5\#+K3?$%OJ9UZ%UBF\PQBV()]L[J]HQ10!B>+="?Q-
MX9O=(2=;=KA-HD9=P7G/2N*^'_PFN/!7B1M5EU>*Z4V[0^6L!0\D'.<GTKU"
MB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\N9E@ ]UY_\ 9J]LK.T/1K30-'M]-LT"PPK@>I]S6A0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445G:SKFG>']/:_U2X$%LI +E2<9.!TH T:*XC_A;G@?_
M *#:_P#?F3_XFC_A;G@?_H-K_P!^9/\ XF@#MZ*SM(UW3-=M5N=-O8KB-AGY
M3R/J.HK1H **** $H[TM% "4M%% !1110 4444 %%%% !1110 4444 %%%%
M!16!K_C/0/#$L4>KZ@EN\HRJ[68D?@#6O8WUMJ5E%>6<RS6\J[D=3P10!8HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'<WJ8_UD0VC_ ,>P: /4**Y#0_B9X6UZ2.&WU-([AUW&*8%-OMDC'ZUUJL&
M92"I&01WH =17*:G\2?">C:A+87^JK#<Q'#H8G..,]A736US%>6L-S V^&9%
MD1L=5(R#^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEW.X_P# @<T ?8-%>3_!KQU>^(X+G2=2D>:ZM4$B2D?>3(')[G)K;^)OC_\
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M+#UQ0!T=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,GV:8 >Q=@?TKBOV@?\ D;=,_P"O'_V=J]*^%=NEY\)=/M9,^7-'-&V.N"[
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M< #-3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 5\W_'C2Y[;QC#J3[?)NX J8/(*8!S^=?2%<WXV\(VWC+P_)ITS^7*#OAE
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M_,RG<[GW; X]J]C^!FC7NE^$KF:\B,:WEQYL0/4KM R1]10!ZE1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M S5^BB@#'U?PMH6O.CZII=O=,GW3(O(K.3X<>#HY%=/#UD&4Y!V'@_G74T4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g0vsdaj33nnl000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0vsdaj33nnl000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /< ]P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***3- "T444 %%%% !124M !1110 4444 %%%)0 M%)FEH **** "
MBBB@ HI,TM !124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E
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M=L8_G5>S?4CVJZ&M144 <0J)/OXYJ2H-2.2YAB.))44^A;%5IM4M(ADRJ?\
M=YIE[I<=[*'=W4@8P*H1:-"UW)$9'P@R.E<TW7N^5&B]GU9KVEY%=H6B)(!P
M<C%6.U06UK#:(5B3;GD^]3UM#FY?>W(=KZ&=)K%I%(R,S;E.#\IZTW^W;/\
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MLKH<9MNS19HI**@T%HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTSS5^W,GD+YH^?O522W0H2;T9-129HS4%BT444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR0.3ZTZCI3)9EACWMT^E9;CV0^EJ**9)DW(<BI!1J%[BT444#"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5[$;;8#T)'ZU8JG9S+^\4L!ASWJY1=-Z"BK(6BDR*C\^+_GHOYTFTMQC9/\
MCZA^C5-55YH_M41WKC![U/Y\7_/1?SI.<>XDF252FR=1A]@<U:5T?[K _0U
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M-:6L<19>2BXS5RV8O;HS=<56MC6DIQ=INXZ3<8G"'YR#M^M89L-6)S]HZ_\
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MJL&&0<TZMD[DA1113 KSVD4W)&&]15(VMS;G,1+#/8UJ]J*I3:(E33(X"[1
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M %S1FO*_&?C74I/$5OH_AV8F1)!O,7S&1O[OT]?I7IMF9S9P&Z55N#&#*J]
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MHH)XJ#4KW\4UQ83PV\WD3/&527&=A(X->8Z+XOU7PSX@ETCQ3-))&[?)._\
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M#]X\GZU-3;U%%:#(XTB0)&JH@Z*HP!3;B>.VMI;B4D1Q(78XZ #)J6J=]^]
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M>S51?]+N"Q'[N,X ]34#7YEC\L+AF.,U?AC6*,(!T%8.+CN=*DIO0DQQ2TE
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M5)BTH9C&SYR2.H^G>DW8UA2E.+DNAZ.**04ZF9!1110 4444 %%%% !1110
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MO<TV-K6*[$,DRM=.-P4GDCU J]VJ;I;!RM[C4C6- JK@"N"^(WAU9[/^V;5
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M;-1>*]6M/'OBK2;'0]^4)#7)C(ZXY(ZX&.OO7M,:E(U4G. !FFW8;=C+\/\
MAZQ\.:9'964> .7<_>=O4UK44^*)YG"J*S;ZL25V$43S.$0<ULV]JD"X RW<
MT6]ND"8'4]3ZU/7'4J<ST.ZE245=ATI:2BL386BBBF 444E "T4E% "T444
M%%%% !1110 4444 )41A7[1YN3NQC':IJAV2?:-^_P#=XQM]Z$)DHI:2EH&%
M%%% !1110 4444 %%%)0 M,D=8T9W8*JC))/ %#NL:,[L%11DL3@ 5X%\3_B
M@^J/)HFB3,EFIVSSKUEQV'^S_/'I6E*G*H[(F4E%%OQY\8+G^T#8^&I@D,+8
MDN<<N0?X?;^==Y\/_B%:^+[$0S%(=3B7][%G[W^TOM_*OEZK6G:A=:5?Q7EE
M,T,\1RK+7?+"1Y++<YE5=[GV?17"_#WXAVOBZR%O.4AU.(?O(LX#^ZUW->=.
M+B[,ZE)-7%J"XMDG7!'S=C4]%).VJ!I/1G/RQ/"^QQS_ #IE;MQ;K.F#U['T
MK%EB:%RK#']:ZZ=3FT9PU:3B[K8H:KIT6K:9<6$S.D4Z[6*'!'XUP$]YK'A1
M$\/^'/#LA*M_Q]R ND@_O$C&#7I=%;)V,;G@L4\FM6][<>*==N?-L%?_ (EY
M/E2,>P4G@].F*[?X3^'_ .S]%EU5PPDOC\@+ CRQ]T_7)-8_C30O^$A^)-EI
MD=F(HVB$DUS'\K,N?FZ\$CZ=ZUO%GCZUT>S71_#[+<:@1Y2F)<K'VR,<$^PK
M1MM613/1:*\5CD\5^"=2L]<U29Y[6]P+H,=P3)Z$#H0.1COQ7LT$R7$$<T9R
MDBAE/L1FH:L)JQ)4D,K0R!U/U^E1T5+2:LP3L[HZ".194#*<@U'-<I$=OWG/
M1167;S.O[M6"ASU/:M.&W2$9Y9C_ !'K7%.'*]3NA-S6A&(9;AMTQVIV05:1
M%1=JC ':G"BH;-%&QY;X_P!-NM(UB'7[.20AG&\8)"D?T/ KO?#VLV^N:3%=
M0R*S8 D _A;OQ5K4;&'4K&:UF&4D4J?;WKRWPQJ,W@_Q/<:5?;UMYGVKQD9/
MW6XZY&!67PR/0BO;T;+XH_D>NT4@((R*6M#A"J_VZU^V?9/M$?VC;N\K<-V/
M7%22RI&,NP'MZUY/XP@NM#\30:]:JX21]WS9P&'4'V.:3T5S:A3567+?4]6E
MG2+J<D] .M0%;BYZGRH_3N146CS6U]I\%[!EUF0,&8'/ZUI55^QA*+O9D44"
M1+\HY]3UJ6BL/Q7K-UH>BR7MK;K,R$9W'"J,]3Z_A2;*A#F:BC=I*Q?#&O)X
MAT>.\"A)/NR1@YP1_0]JVJ2UU'*+C*S#M62_^AWN[&$/MVK6JGJ,6^#>!RO\
MJTIO6S,:BTNNA;'(SZTM5;&7S;< GYEXJUVJ6K.Q46FK@:J75T;=D&W@]35N
MJM[#YL!QR5Y%.-KZA.Z6A81@RAAT(XIU4]/E,D!4YRO%7*4E9V"+NKBT444B
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I#2UGZYJ TS1KJ\^
M4M%&64,<;B!TH*BFW9'F?B%CXE^(,-A&C20P,J.N_P"5E!RQ'/H?TKUB*)(8
M4C0850 !Z 5YA\.=,EN[F\UDLNXL40MR0>I_0UZ/]HFB)$T1([%>]333:N=.
M-FHR5-=$7*#44=Q%(/E852UW4UTG1KF];)\I,C'KT%4U8Y8KG=D:5%<;X UG
M5M9LKFXU)]Z!P(F"!?7/2NRI)IJY52FZ<G%A0>E%(?NFF0>4^/KYM;\16NB6
MK;A&X#X4DJQ//X 8->A6-G+I=C#;PA6CC0#:!C'J:Q]$\$Q:5KTVJRW4EQ,Q
M.PL>1GKGUKK:F*L[LZ<14C*$:<-E^97CNXWX.4;T;BIP>/6F2PI*N'4&J-QO
MTZWEN!*/*12Q#G]*O0Y%>]A9M:T^WU.'3I+A1=3#Y(^YK1KR#PFKZ_XTFUBX
M#B&)BZL3]UB?E7\LUZZ&!'!S]*A-M7.G$4E2:C?4=11F@G JC @N+E;=0S9.
M>@%2Q.)(U<=ZRGW7EY@?<!Q^%:Z@*H Z 54HV2,XR<FV(Z*PPP!'O51H)8&W
M0-\O=#5PT8I)V*:3*\5VC-M?Y''4&H[^X\N+8/O-[]*DN(H6C+2 <<Y[UC.Q
M<C<2<# S6M."D[F-6HXJPVBBBNLX@KR;QS=W/B7QQ9^$[>XDMH01YI)^5CMW
M9XYZ<<]Z[C7_ !=9:!J%A93))+<7CA52,<JI.-Q]LUR/CC1K[1_$]MXPTR W
M'ED>>@Y(XVYQZ8JX[C1IWWPJT"735AM8Y(+J-1B=7.YB!W!XY/I5#P+>+<Z5
MJNA^(3%,-.E*LTQW<<YR3Z5%<?&*VDLWBLM+NS?LN$5E!7=^!S^E96A^!O$F
MNVLEUJ%XEI:ZC,)[J/;B5QSZ#&#GIFJL[:C/2O#5EH$>F17&A00"W<$K(HRW
M/;)Y_"MNJFF:;:Z1IT-C9Q".&)< #O[GU-7%4NP51DGI638DKL=%$\SA4'-;
M-O;K!& .2>I]:+:W6&,#'S'J:GQ7'4J.3L=M*DHJ[W"BBEK(W$[4E+7EOQKU
M:_TW0[);.ZEM]\VYC$Q4G'3D=O:JA%RERH4G97/4ATI:\U^&GQ,A\36ZZ;J;
MK'JT8X/03CU'O[>_%>DYHE%Q=F$9)JZ%I*6J]W=V]C:R7-U*L4,2EG=C@ "I
M&3YHS7F5T^I^.8;O5#+=:=H-E'(]JD;F.2Z<*?G)!R%]!GL.*[KPV[R>&-)D
MD9G=K.$LS'))*#DTVK"3N:E%%%(84444 %%%% !1110 E1[I/M&W:/+QU]ZD
MJ/>?/V;3C&=W:@3)!2TE+0,**** "BBB@ HHHH *;FG4TT <_P"-M(O-=\)7
M^G:?-Y5U*@*-DC."#C(]<8_&ODZ\LKC3[N6TNX7AGB8JZ.,$&O2/#GQ,O_#?
MBZ_AU&:6ZT^6Z=7#L6,7S$ KGM[5Z%XX\$:;X_T=-7TF6/[>L>Z*5.DP_NM[
M^_MBNVDW1?O;,YYI35T?-U%3W=I<6%W):W<+Q3QL5='&"#6GX8\,:AXKUB.P
ML(SR<R2D?+&O<FO0E-*-S"S;+7@?1]:U;Q+;)HC/#/&P9KC^&(>I_P .]?6<
M898T#G+!0"?4UQNF:98^!]+@T31(5N=3GYRPY8]Y)".BCT]^!3?#L%S8^/M7
MM)[V>Y+65O,YD<[=[-)DJO1>@X&.E>36J>UE<ZH1Y4=M1116!J%0W%NDZ;6Z
M]CZ5-10FUJ)I-69S\L30OL8<_P Z96Y<VZSQ$$?-V-8C*R,588([5V4ZG,CA
MJT^1F/XBTB;6-(N+>TN?LETZ%4G"C('IGJ ?;FN-B^$MG'X?,/VEAK&=ZW@8
MC:W8#V_6O2:*V3:V,;V/'Y_#/CGQ++::;K3>3I\)P\NY?F [X'))'2O6[:!;
M:UAMU)*Q(J GJ<#%2T4V[@V%%%%( K7L+CS8]C?>4>O6LBI(96AD#KU%95(<
MR-*4W&1O=Z6FQN)$# Y!IU<1Z%[H*X+XDZ#]JTY=3MUQ/;'YBH.XKGMCT)S7
M>%@HR3@53FN#-F**+S%/#%AQBCEYM&:4ZSI34D8?@G7QJ_A^-I6436X$<@R>
MW0\]R.:W3<33G; N%_OFJ^FZ):Z>A6.)%W,7*J,#)K3  &!QBFM":K4Y-QT1
M7BM%4[Y#O?U-4/$NBIKFB3V>%\PC,9;.%;L:UZ6D]=PIOD?-$XKX?V>KZ;:7
M%CJ-OY<,;YB8MDD]QUZ<#\Z[6DX'/%02W<<??<WHO-)(JK4YY.3)ZI:G%#=6
M$]M,5VNA7!Y^G%.!N9QVB7]2*DBLXX^3\[>K<U32ZF<9.]T>7^ KUM%\376C
MW#E5D8JF5(W,.GZ9->L5A3>%;"?Q)'K;;OM"+C:#P2!@'\N*W:B*LCIQ-6-6
M2DMPI& (P1P:6BJ.>Q3M;5K>1V+ @]*N48HS3;N)))!2$ @@]#2T4AE>"U6W
M9BI//Z58HHH;OJ))+8!2TE+0,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!*\_^*FH>3I%O9  ^?)N)SR-N/\:] )K'U;PUIFM7$$][!O>$Y'.,
M^Q]14R5T;4)QA44I="+PCIG]E^'+2!D19=FYRH^\3W_+%;E(B!$"*,*!@"G4
MT9SESR<GU()+6*0\KCOD<5YY\2[MX;:UTN*69I)WWD9X*],'\2*])[UDZCX<
MT[5=0M[V[B,DMO\ <!/R_B.]$KM6+H2C3J<[*?A>U71-!M;1X)(F*AG#'.&/
M)_6M])DD&48&GX&,57-G"Q#!=I'0KQ5*QE.4I2<NY9S15,K<P#Y6$JCD[NM<
MWHGCF'5]<N=/-N4C3/ERALAL=<^E)Z#A"4TVEL=A135=74%6!!Z4Z@05S/C>
MQU/4/#TMOIH5V<CS(R.67T'OG%=-VHH>I4).$N9'-^$/#Z:-H$<$J SR8>7*
M@$$]O?%;/V1HB3 Y7_9/(JW10G960JC]I)RENRG]J>)ML\9'. PZ5/N2>(A6
MR&'45(P# @C(-5VLU!W1,8V/IT_*GHS.S0MM:K;[L$DGN15BJ0GGA.)DW+_>
M7M5B.>.0?*P/M3E=[A%I*R):*2F2R"*)G/85*5RFRAJ-P<B%>G5JSZ5V+L6;
M&2<FDKNA'EC8\ZI/FE<*9-(8H9)%1I"JE@B#EO8>]/K@M8\<7Q\7P^'M%LC-
M*LJ"XE89VC.6X]-O>M$KD'&Z#K]E-XUU#5_%,S++;*QM8Y01@@XVA>F<?KS7
M4>"]3U/5=0UCQ)?S.NDLA6*%VXP#U"].@Q]:O^,]'\(ZA*D.K75O9:A+\R2@
MX=CTY]17"W&@^*]-MX/#*S+/I6H38CDC.X 9W?AP,XK2Z:+/0/!E]HOB-;C4
M+;1;>VGMYV59!"H)!)PP;KG'7ZUV54-&TJWT32;?3[8*$B4 D+C<>YQ[GFK]
M9LAA^%:UC:^4F]Q\Q_2JUA;>8_FMG"]/>M85RUI_91UT*?VF ZTM%%<YU!11
M10 G:O(?CQ_R!K#_ *Z&O7NU>0_'C_D#6'_70UMA_P"(B*GPL\(MYYK6>.>"
M1XI8SN1T."I]0:^H/AKXS3Q9H"B>53J5L MPN,$^C?0\_E7RV*[CX4:XVB^.
M+5&>7R;P^0Z(>&8\*3ZX)KOQ-)2A?JCGIRLSZAK@YK>/X@ZTX:X8^'].EVM"
MN0+J8<\^J#CCU!KH/%NHG3/#-Y*C2+/(GDP&/[WFO\J8_P"!$59\/Z<FEZ!9
M6:!UV1@L'.3N/S-G\2:\Q:*YU/5CM61(O#M]'&H5$M)%55&  $/ IGAC_D5-
M'_Z\H?\ T 5+K7_( U'_ *]I/_034/AG_D5-'_Z\H?\ T 4N@=36HHHI#"BB
MB@ HHHH **** $IGF+YOE_Q8S3Z9N3S=N1OQTH$[CZ6D%+0,**** "BBB@ H
MHHH *::=2'I0!\::U_R'M0_Z^9/_ $(UV7PT^(%SX6U*.PN=\VF7#A67/,1)
M^\OX]1[UQNM?\AW4/^OF3_T(U1KV>13II,X>9QE<^H/&GPWTOQJT-X)OLUVH
M'[^-0?,7T/K]:?#IUE\./"JV>CVXN=0G81Q!L!KB4YQGVZ_2F?"?7'UKP-:B
M>:-[BUS RH,;5'"9_ 5;:U76/B*TLT2&/1H%"!OFW/+A@WL5V$?C7ER<E[CZ
M'4DG[RZFKX?TB73[4SWSK-J=QAKF8=V]!Z*.<#M698_\E0UC_L&VW_H4M=97
M)V/_ "5'6/\ L&VO_H4M0F4=;1114E!111VH 2J=];>:F]!\X_6KE(:<9-.Z
M)E%25F<[C'%%7;^WV/YJYVL>?:J5=T)*2N>?.+B[,****L@**** "BBBD!H:
M?<8)B8\=15F2[YV1+YC^@Z5C5NVWE^0IC4 'GI7+5@HNYV49N2L0K;22G=<-
MD?W1TJTJA0 HP!3J#6+;9NDD%-#*20""1UIDDT<8RS@>E>66^N7^B^/;B*\N
M2UO<N<;Y#M12<J<>H''XU+=MS>E2=1/EZ'JS,%Y) JL]YD[84,C>W2A;0.V^
M9S)SD#L*LH@1<*  *K1&'O,S=2-W'IUQ< ;Y(T+)"IQN('3-<_X%\2MK<4]O
M=1*EW <L5&,KG^==FPW+@UY%B3P?\1%2('[-<N %\P\JQQD_0Y-1*3378Z\/
M2A.$H]>AZ[2TBD,H(.12U1S;!3=ZEMH8;AU&:<:\KU#4KWP]\1MTUY*UI.P+
M;^@4]A].*ENQM1HNJVENCU2EIBG*@^M#.J*22!@51B]!Q.!FN?T3Q98Z]?7%
MK;1S+)!][> ,\XXYK6:\0G;&&D8CC KRJU8^%_B-B2.:*UN'PJYSO#<#ZC<:
M4KHZ,/3C54EU2/7J6D4Y7/K2TSG(IPQMW"'#8X-5M.F9T96.2IZYJZ1D<UEQ
MC[/J17'#' ^E7'5-&4VU),U12T@I:@U"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH :?K0*JZA(4MR!_%Q3[$,+5<MG/3V%/ETN3S>]8L8HHHI%!
M17'>.O%-SX>AMA8M";B1_F209^7'7&?6NFTNXDN]+M;B7'F2Q*[8'&2 323U
ML:2IRC!3>S+>****9F87B[5/[)\.75PLA20J4C8=F/2N9^&.E[=/NM1E#>9<
M-LPPX*CG/ZFJWQ3U(G[)IL4@.XEY(QU[;3_.NYT"P73-$M+53N$<8&3WJ-Y^
MAW->SPR[R++64>=T9,;8X*TW-U#V$BCTZU<I*TN>?RF3J?B*QT>T,]\[1 ?P
MXY8^@]:O6-]!J-G%=6[;HI%#+7FWQ,OOM>J6.DQR1E<AGQ]Y7/ S^!KO-.TO
M[%IEM!%+M>.-58@<$@<G%2FFVCIJ4E"E&3W9K49JGYMS$"9(PXSP5J1+N%R1
MNVL.S<55F<RDC/\ $NMKH.BS7A!+CY8P!U8],^U5_"&L7>MZ*EW>0>5(6(!Q
MPX_O#V_PKC_B-?3ZAK%GH-L#O8ACEN'+' 'X8_6O0-&T]-*TBVLTSMB3')R:
MA.\CLG3C"@F]V:&*KS6L<AW8VMUW"K&:*I.QR-)[E,?:8.#^]7U[U4OKD3!4
M7@#J".]:CN$C+-C %84KF21G]36]%<SN<U9\JLF,HHHKK.0*\@U6P\7^'/%^
MJ7FAV#W$5\ 1((S)A?Z'.:]?HIIV&G8\=OO!,%MH-YKWBR^FDU"5-P5&^ZYX
M4'U[5V7PRW-X$L"_/+XSV^<U+K?@/3=?UQ+^\:01K& T4;8#L#G+>HQQBNG@
M@BMH$AAC5(T 554< "FY75@;)*DAB,TH0=^IJ.M?3[?RX=[#YF_E6%2?*BZ4
M.:1:CC6.-57H!Q3Z**XCT5H%%%% !1110 G:O(?CQ_R!K#_KH:]>[5Y#\>/^
M0-8?]=#6V'_B(BI\+/!.U;O@O_D=]$_Z_8O_ $(5A5N^"O\ D=]$_P"OV+_T
M(5ZM7X&<D?B/I/QX/^)'9_\ 83M/_1RUU..*Y?QY_P @.S_["=I_Z.6NH'2O
M%Z':MRCK?_(!U'_KVD_]!-0^&/\ D5-'_P"O*'_T 5-K?_(!U'_KVD_]!-0^
M&/\ D5-'_P"O*'_T 4= ZFK1112&%%%% !1110 4444 )3-B>;OP-^,9I]1^
M2OG^;D[L8QGB@3)!2T@I:!A1110 4444 %%%% !2'[M+2'[M 'QIK7_(=U'_
M *^9/_0C5&KVM?\ (>U'_KYD_P#0C5&O<I_"C@EN>[_ '_D$ZU_UWC_]!-=_
MI'_([^(_]RT_]!:N ^ /_()UK_KO'_Z":[_2/^1W\1_[EI_Z ]>36_B,ZJ?P
MHZ.N3L?^2HZQ_P!@VU_]"EKK*Y.Q_P"2HZQ_V#;;_P!"EK.)HSK*6DI:D844
M44 %)BEHH 9)&'0H>A'-84T1AE9#VZ>];YJG?P>9#O ^9>?PK6E/ED8UJ?,K
MF111178< 4444P"BBB@ J_IL^UC$>AY'%4*53AL\^^*B<5)6+IR<971M27D2
M':#N?H *CS=3CM$I_.I8(XEC!C P>:GQ7#HMCO2;W*\=I&AW'YFZY-<'\3=(
MEDAMM6@!)MSAPJYXZ[B?08_6O1*:R!UVL 0>H(J9*ZU-Z$_924D97AK4)=3T
M"TNID9)7C&_<NW)QU'M6N*:JA0%4  = *=3U)D[NZ"O/?BAI22Z9%J2*HDA8
M*[8Y()P!^9KT(XJCJUJE[I=S;,RKYL;(&8< D8!J6KJQ="I[.HI&9X,U5=5\
M.6TA=#*B[)%4_=(Z _ABNAS7G/P\M]2THZA;SVS"W#Y0E2"S=,_3%=V1=RY
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MH.S(J1NB:)Q)&KCH1FGU%;(T<"JWW@.:EI/<J.P4444AA1110 4444 %%%%
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MG-)117>>;N%%%%, HHHH *FM8C-.H[#DU#6IIL6(S(>K=*RJRM$TI1YI%X#
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MBDQ2T4"LA/I1CUI:*!B$"E%%+0*PE+24M PHHHH **** "BBB@ J.9/,C9<
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MBBB@!L@S&P]17/,NUBOH<5T1Z5@W"E+AP?7-;T'K8Y<2M$R*BBBNLY HHHH
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MLHQ<%LQ:***9F<=\2A_Q2,W_ %T3_P!"JWX!B1/!]BZJ SJ2Q'<[C53XE_\
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M7_(B:K_US7_T-:J'Q(:W*'PK_P"1&M_^NLG_ *$:[6N*^%?_ "(UO_UUD_\
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MLN2T5$_G>:FW;Y?\6:)O-VCRL;L\Y]*+!<EI:CD+[#Y>-W;-"%_+&_&['.*
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M8XP.>O%=Q';QM&K%2I(!(W&O+/&?/Q<T;/3]Q_Z&:]<%:3TBBG%$'V2/T/\
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MQ_0<<>]%6HH1N$8MNR/3?A=X3'AKPM$\\12_NQYDV]1N7T7(Z@=?QKNJ:!@
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M5R&&#Z5T46]4SFKI:-#:***Z#F"BBB@84444 :6F. KIWSFM$5BV,GEW(!(
M;@UM#I7#55I'?1E>(M%%%9FP4444 %%%% !1110 4444 %)FBO*OB=\3TT1)
M=%T64-J1^6:93Q /0?[7\N*J$'-V1,I**NSU-)4?A75B.N#3J^2/"_C+5/"^
MM#4+>9I%<_OXG.1*N><^_7!KZ?\ #7B73_%.D1ZAI\H93Q)'GYHV[J:TJT)4
M]Q0J*1L4445B6%07EG;ZA9RVEU"DL$JE'C<9# U/11U ^9OB-\.;CPG=M>V2
M-+I$C?*W4Q'^ZWMZ&O/Z^TKRSM[^TEM+N%)H)5*R1N,A@>QKP'QU\(+O1UFU
M'0]]W9[LFW"Y>)?ZC^5>CA\3?W9G-4I-:H\KHI6!5BK @@X(-)7=N8!1113
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MY%;\+B2)6!!R.<5S]:FFRYC,9[=*YZ\;JYTX>5G8T**04M<IV!1110 4444
M%%%% !1256N[^SL45KN[@MU8X!ED"9/MF@+GF?Q/^)RZ(DNBZ-*#J3#$LRG(
M@'H/]K^5?/LDCRR-)(Q9V.2Q/)->J_%KP!=V.I77B6RW7%G<N9)QC+1,>_\
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M6^3[1LV?)C.ZA7$[$M+2"EH&%%%% !1110 4444 %<!\9?\ DFU]_P!=8O\
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M0M>"9F&T=JN444VV]Q**6PM%%%(84444 %%%% !1110 4444 %%%% !1110
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M*>2$Y1L>U:<%_')A6^5OTKEG2E$[*=92W+M%)D$45D;"T44E "T444 %%%%
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M0M2N+KP[K.F^3JD981W 9@S<^A.,]^G2O0/#/@<>'KRZ>349[VVDC$<<,YW
M#@G(Z9R./:FVD#L6/ UMI_\ PAUC]FLQ&CQ#S5>,C>V.3SU!/X5TD<4<*;(H
MU1>N%&!3E540(BA548  P!2UFV2V%%&.<#)S6C:6)#"24=.BU$YJ*U+A!R>A
M%8P(TO[W@CD*1UK7'2H)X!*O!VNO*L.U)!.6/E2#;(OZUQSDY.YVPBH:%BBB
MDS4&I%/!'*/F&&[,.HKDM?UFX+_V; V6Z.Z]3[5=\0^(!;!K2T.9SP6'\/\
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MBI<UD2PRV<WF1D[<\?\ UZT+><7$>X<'H:<HVU0H3N[/<L4AHZ4R618HR[=
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MZ#:***9(4444P"BBB@ JW_S"_P#@=5*M_P#,,_X'6<^A=/J5****T("BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ,A%O<EU8$$?.@//UJXK*ZAE.01P:;74F+OH9<KS7DVQ 0N>!_C6C;VZVZ8
MY[GUJ4*!R!C/6EJI2NK+848).[$Q5::-H&\Z(=?OKZU:H/(Q4IEM$<4JS(&4
M\?RJ2LV1A;7!:$Y'\:5>BE69 RG.:;5B8ROH9MMH-O;ZE->L3))(Q89'"YK5
M I:*S45'8UE-RW"BBBJ)*E[<^2NT??;I45C:%3YLGWCT%6I+>.24.PRPZ5,*
MOFLK(SY6Y78 4M%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M%
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M*#THH[4BRK>@LB(IY9@/K3C:6^<^3'_WR*CD DOH@&Y0$D5<I2A&RN3%N[$
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M"0N,>]-8F[LXM$^RLKIFU0:05%<W,=K"9920HK=NRNR%Y#IR!!)G^Z:2W4)
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MD(1;1DL3R[G+?G085H3G[L79'.:)X-,SF\UAFEF9MVPG/_?7K]*[9$5%"J,
M#  I0*6@JE2C35D&****#4**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**6
MB@!I (YI%4*,*,#VI])0 5'YL9D*!UWCJ,\BGUC:AIDSW#7%NYW=2N<5E5G*
M*NE<J,5)V;-FEKG[;6)[9_*NT)Q_%CFMF"ZAN$W1R ^W>IIXB$].HY4Y1W$N
MY=D6U?OMPN.M201B*)4':J\?[^Z:7JB<+]:N5T/:QDM7<*SKK2+:XRP78YYR
MO<^]:-+6<Z<9JTBXR:U1SR:9J%K,##*".YSVK?3.T;NN.<4M%32I*GL5.;EN
M+136R5(!P>U<_(VK6C[F+2*#Q@9!_*E4J^SZ!"',=#16'#KW(6XB*G."1V_"
MKW]I6\MN[12J& .-QP?UHAB*<^H2IRCT'6W[R>67.5SM JY4%HA2W7.-QY-3
MUNW<RBK(*ANF*6SLO7%2U5O=S+&BGEFQ0MPD]"6W7%O&".0HJ7'.<4=J6I:5
MREL)45Q EQ$8Y!E34U%#BFK,%H85QHUM%L^>3+, .15RVTB&UG$R/)D=B:FO
M$+R0 ?WLU;K/ZO25FD5[6;;384R12\;*#C(QD4^BM&KJS).?_L*?/_'R/R-+
M_85Q_P _/Z&N@HKF>$@:^VD<_P#V#/\ \_/Z&KNFZ=)9R.SR[PP ''2M.DJH
M8:$'="E5E)685EW]I%=WT2R%AE<#::U*J3*?M\#=L$5OR1FK2,G)QU1470+8
M'):0^Q(J_;VL-LI$*!<]?>IZ*SC1A!W2+<Y/1@*#116I(E+110 E54)2^<'
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M'']Q /H*M.*(:FV-MFD:!6D&&-3445'6Y:5E82G4E+0,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "DI:* "DQ2T4 )BC%+10!%+;Q3+MD167T(J*'3[:WG,
ML485B,<=JM45'LXWO8?,[6$Q52[>X1U\E=RXYXS5RDK1.S):NC,749$!$D>2
M/PJ[;7(N$) P1U%2%%/4"DCC2,$(H /I3;36Q,8R3WT),TF['6BJ>H6CWEOY
M:R;#G.<5E-M)M&BW+FX'I2'H:YY;#58<K')A?9J0G6+=P3OD]AR*YEBFOBBS
M7V2>S-?3U*Q.3W8U<KG4O-5C4*+<X'3,9K;LI)9;5'F7;(>HQBMJ==5'9(S=
M-P1/103BJ#ZD%=E\LG:<=:W46]C.4E'<OTM9O]J =8CCZU?C?S(PXXR,T.+6
MX1FI;#J**J7-Z+>0*4SD9ZT)-Z(;DEN6Z*SO[4'_ #R/YTPZA,[8C0?3&:KV
M<F0ZL34HK-6YO21F+C/]TUI#IS4N-BHRY@S2-(JC+$ 4V9#)$R X+#K5#^S)
M/^>P_*G%)[L4G);(NBZ@9@!(I)XZU-5*/3XT96)8LISUJY2E;H./,]Q&)P<=
M:S6-]+(0 4Q^ K3I *$[!*-S-73I'^:23#=^]68]/A4Y(+>QZ5:I:;G)DJG%
M#$B2,810![4[%+14F@F*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *2EHH 2BEHH 2BEHH 2BEHI6 3%%+1
M18!#3=BD\J/RI]%,!GEI_='Y4X#%+10)*PE-**3D@&GT4#LAGEI_='Y4!%!X
M4?E3Z*-160E%+10,2EHHH 2BEHH *2EHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>29
<FILENAME>adpt-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-23T07:52:05.9530220+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b31e096b02284e6886ec6a280547abc3 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:adpt="http://www.adaptivebiotech.com/20201231" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adaptivebiotech.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.adaptivebiotech.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adpt-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adpt-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adpt-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adpt-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations" id="Role_StatementStatementsOfOperations">
        <link:definition>100030 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss" id="Role_StatementStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" id="Role_StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity">
        <link:definition>100050 - Statement - Statements of Convertible Preferred Stock and Shareholders&apos; (Deficit) Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" id="Role_DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenue" id="Role_DisclosureRevenue">
        <link:definition>100090 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestments" id="Role_DisclosureInvestments">
        <link:definition>100110 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100130 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>100140 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenue" id="Role_DisclosureDeferredRevenue">
        <link:definition>100150 - Disclosure - Deferred Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquity" id="Role_DisclosureShareholdersEquity">
        <link:definition>100180 - Disclosure - Shareholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans" id="Role_DisclosureEquityIncentivePlans">
        <link:definition>100190 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement" id="Role_DisclosureMicrosoftCollaborationAgreement">
        <link:definition>100200 - Disclosure - Microsoft Collaboration Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholders" id="Role_DisclosureNetLossPerShareAttributableToCommonShareholders">
        <link:definition>100220 - Disclosure - Net Loss Per Share Attributable to Common Shareholders</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlan" id="Role_DisclosureRetirementPlan">
        <link:definition>100230 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100240 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>100250 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueTables" id="Role_DisclosureRevenueTables">
        <link:definition>100260 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100270 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
        <link:definition>100280 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100290 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100300 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>100310 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueTables" id="Role_DisclosureDeferredRevenueTables">
        <link:definition>100320 - Disclosure - Deferred Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100330 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityTables" id="Role_DisclosureShareholdersEquityTables">
        <link:definition>100340 - Disclosure - Shareholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables" id="Role_DisclosureEquityIncentivePlansTables">
        <link:definition>100350 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonShareholdersTables">
        <link:definition>100370 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" id="Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails">
        <link:definition>100400 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" id="Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails">
        <link:definition>100410 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" id="Role_DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails">
        <link:definition>100420 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" id="Role_DisclosureRevenueAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" id="Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
        <link:definition>100450 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" id="Role_DisclosureInvestmentsAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" id="Role_DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails">
        <link:definition>100470 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100480 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
        <link:definition>100510 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
        <link:definition>100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails" id="Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Accrued Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" id="Role_DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails">
        <link:definition>100550 - Disclosure - Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Deferred Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails1">
        <link:definition>100570 - Disclosure - Deferred Revenue - Additional Information (Details1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1Default" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default">
        <link:definition>100570 - Disclosure - Deferred Revenue - Additional Information (Details1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" id="Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails">
        <link:definition>100580 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Leases- Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" id="Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails">
        <link:definition>100600 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" id="Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails">
        <link:definition>100610 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" id="Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2">
        <link:definition>100620 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" id="Role_DisclosureShareholdersEquityAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Shareholders&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" id="Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
        <link:definition>100640 - Disclosure - Shareholders&apos; Equity - Summary of Reserved Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" id="Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails">
        <link:definition>100660 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails">
        <link:definition>100670 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>100680 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails">
        <link:definition>100690 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails">
        <link:definition>100700 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" id="Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100720 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail">
        <link:definition>100740 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail">
        <link:definition>100750 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
        <link:definition>100760 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
        <link:definition>100770 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" id="Role_DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>100780 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" name="LesseeOperatingLeaseLiabilityTenantImprovementReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_SequencingRevenueMember" name="SequencingRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_DevelopmentRevenueMember" name="DevelopmentRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" name="TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" name="TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" name="ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" name="TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" name="AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" name="AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" name="StockIssuedDuringPeriodValueCommonStockWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" name="StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" name="ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_LandlordFundedLeaseholdImprovements" name="LandlordFundedLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" name="DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" name="ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" name="ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_DeferredRevenueTextBlock" name="DeferredRevenueTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" name="BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_JOBSActAccountingElectionPolicyTextBlock" name="JOBSActAccountingElectionPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock" name="StockholdersEquityConvertiblePreferredStockPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ContractBalancesPolicyTextBlock" name="ContractBalancesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_SalesAndMarketingExpensePolicyTextBlock" name="SalesAndMarketingExpensePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" name="ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" name="ScheduleOfReservedSharesOfCommonStockTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" name="ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_SaleOfStockUnderwritingDiscountsAndCommission" name="SaleOfStockUnderwritingDiscountsAndCommission" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_InitialPublicOfferingExpenses" name="InitialPublicOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_CustomerAMember" name="CustomerAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_CustomerBMember" name="CustomerBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_CustomerCMember" name="CustomerCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_GenentechIncAndRocheGroupMember" name="GenentechIncAndRocheGroupMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="adpt_NumberOfRevenuePerformanceObligation" name="NumberOfRevenuePerformanceObligation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_DerecognitionOfBuildToSuitLeaseAsset" name="DerecognitionOfBuildToSuitLeaseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_DerecognitionOfDeferredRent" name="DerecognitionOfDeferredRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_ReclassificationOfTenantIncentiveReceivables" name="ReclassificationOfTenantIncentiveReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_DerecognitionOfBuildToSuitLiabilities" name="DerecognitionOfBuildToSuitLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_DevelopmentSupportRevenueMember" name="DevelopmentSupportRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_DevelopmentRevenueRegulatoryMilestonesMember" name="DevelopmentRevenueRegulatoryMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" name="RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_AgreementTerminationAmountReceivable" name="AgreementTerminationAmountReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_EligiblePaymentsReceivable" name="EligiblePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_TermOfAgreement" name="TermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_TranslationalDevelopmentAgreementsMember" name="TranslationalDevelopmentAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_MRDDevelopmentAgreementsMember" name="MRDDevelopmentAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_GenentechCollaborationAgreementMember" name="GenentechCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_CommercialMilestonesMember" name="CommercialMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" name="RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" name="ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_AdditionalMilestonePayment" name="AdditionalMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_NonRefundableUpfrontPaymentsReceived" name="NonRefundableUpfrontPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_RevenueRecognitionExpectedPeriod" name="RevenueRecognitionExpectedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" name="AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" name="AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_ComputerSoftwareMember" name="ComputerSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_BuildToSuitAssetCostMember" name="BuildToSuitAssetCostMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" name="AccruedClinicalAndContractResearchOrganizationCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" name="AccruedPurchaseOfPropertyAndEquipmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" name="AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_ContractWithCustomerLiabilityCurrentAbstract" name="ContractWithCustomerLiabilityCurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" name="ContractWithCustomerLiabilityNonCurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_GenentechIncMember" name="GenentechIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_MedicareRevenueMember" name="MedicareRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_SpecificPatientsMember" name="SpecificPatientsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" name="LesseeOperatingLeaseRentCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_LesseeOperatingLeaseExtendedTermOfContract" name="LesseeOperatingLeaseExtendedTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ProceedsFromLandlordReimbursements" name="ProceedsFromLandlordReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_TenantImprovementCostsIncurred" name="TenantImprovementCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_TenantImprovementCostsReceivable" name="TenantImprovementCostsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_LesseeOperatingLeaseTerminationPeriod" name="LesseeOperatingLeaseTerminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_NumberOfOperatingLeaseTerminate" name="NumberOfOperatingLeaseTerminate" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_TenantImprovementAllowanceAndCommenced" name="TenantImprovementAllowanceAndCommenced" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_OperatingLeaseVariableLeaseExpense" name="OperatingLeaseVariableLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" name="TwoThousandAndNineteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_NumberOfCommonStockVotingRights" name="NumberOfCommonStockVotingRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" name="CommonStockOptionsAndRestrictedStockUnitsGrantedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_PercentageOfAnnualIncreasesInNumberOfShares" name="PercentageOfAnnualIncreasesInNumberOfShares" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ClassOfWarrantOrRightsTerm" name="ClassOfWarrantOrRightsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="adpt_SequentaTwoThousandAndEightStockPlanMember" name="SequentaTwoThousandAndEightStockPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_TwoThousandAndNineEquityIncentivePlanMember" name="TwoThousandAndNineEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_ReceivableForStockOptionExercises" name="ReceivableForStockOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_NumberOfEmployeeOptionModification" name="NumberOfEmployeeOptionModification" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" name="MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" name="MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_CollaborationArrangementDisclosureAbstract" name="CollaborationArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_MicrosoftCollaborationAgreementMember" name="MicrosoftCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_SeriesFOneConvertiblePreferredStockMember" name="SeriesFOneConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_DeferredTaxAssetsNonQualifiedStockOptions" name="DeferredTaxAssetsNonQualifiedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" name="DeferredTaxLiabilitiesTangibleAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="adpt_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_NetOperatingLossCarryforwardExpirationPeriod" name="NetOperatingLossCarryforwardExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="adpt_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_ConvertiblePreferredStockWarrantsMember" name="ConvertiblePreferredStockWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" name="DefinedContributionPlanEmployeeServicePeriodForVesting" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>30
<FILENAME>adpt-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-23T07:52:05.9530220+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b31e096b02284e6886ec6a280547abc3 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="adpt-20201231.xsd#TemplateLink" roleURI="http://www.adaptivebiotech.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets" xlink:href="adpt-20201231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10330.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="adpt_IncreaseDecreaseInDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NoncashLeaseExpense" xlink:type="locator" xlink:label="adpt_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" xlink:type="locator" xlink:label="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_NoncashLeaseExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_IncreaseDecreaseInDeferredRent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseLiabilities" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="10270.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:href="adpt-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:type="locator" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:type="locator" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" xlink:href="adpt-20201231.xsd#Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:type="locator" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:type="locator" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="locator" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>31
<FILENAME>adpt-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-23T07:52:05.9530220+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b31e096b02284e6886ec6a280547abc3 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="adpt-20201231.xsd#TemplateLink" roleURI="http://www.adaptivebiotech.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10120.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11390.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" xlink:type="locator" xlink:label="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" order="12740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="13460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="13640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" order="13680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="13820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" order="14000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" order="14040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" order="14180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" order="14220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="14360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="14540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_InitialPublicOfferingExpenses" xlink:type="locator" xlink:label="adpt_InitialPublicOfferingExpenses" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SaleOfStockUnderwritingDiscountsAndCommission" xlink:type="locator" xlink:label="adpt_SaleOfStockUnderwritingDiscountsAndCommission" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="adpt_SaleOfStockUnderwritingDiscountsAndCommission" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="adpt_InitialPublicOfferingExpenses" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ReclassificationOfTenantIncentiveReceivables" xlink:type="locator" xlink:label="adpt_ReclassificationOfTenantIncentiveReceivables" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfDeferredRent" xlink:type="locator" xlink:label="adpt_DerecognitionOfDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfBuildToSuitLiabilities" xlink:type="locator" xlink:label="adpt_DerecognitionOfBuildToSuitLiabilities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfBuildToSuitLeaseAsset" xlink:type="locator" xlink:label="adpt_DerecognitionOfBuildToSuitLeaseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:type="locator" xlink:label="adpt_NumberOfRevenuePerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:type="locator" xlink:label="us-gaap_BuildingsAndImprovementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:type="locator" xlink:label="us-gaap_UnbilledReceivablesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="adpt_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="adpt_SeriesCConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnbilledReceivablesCurrent" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BuildingsAndImprovementsGross" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_NumberOfRevenuePerformanceObligation" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_DerecognitionOfBuildToSuitLeaseAsset" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_DerecognitionOfBuildToSuitLiabilities" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_DerecognitionOfDeferredRent" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_ReclassificationOfTenantIncentiveReceivables" order="11830.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:type="locator" xlink:label="adpt_GenentechIncAndRocheGroupMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerCMember" xlink:type="locator" xlink:label="adpt_CustomerCMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerBMember" xlink:type="locator" xlink:label="adpt_CustomerBMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerAMember" xlink:type="locator" xlink:label="adpt_CustomerAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerAMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerBMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerCMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncAndRocheGroupMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="adpt_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="adpt_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="adpt_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerEquipmentAndSoftwareMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10400.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueRegulatoryMilestonesMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueRegulatoryMilestonesMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentSupportRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentSupportRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentSupportRevenueMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueRegulatoryMilestonesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureRevenueAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:type="locator" xlink:label="adpt_RevenueRecognitionExpectedPeriod" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:type="locator" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdditionalMilestonePayment" xlink:type="locator" xlink:label="adpt_AdditionalMilestonePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" xlink:type="locator" xlink:label="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_EligiblePaymentsReceivable" xlink:type="locator" xlink:label="adpt_EligiblePaymentsReceivable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AgreementTerminationAmountReceivable" xlink:type="locator" xlink:label="adpt_AgreementTerminationAmountReceivable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TermOfAgreement" xlink:type="locator" xlink:label="adpt_TermOfAgreement" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:type="locator" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommercialMilestonesMember" xlink:type="locator" xlink:label="adpt_CommercialMilestonesMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentMilestonesMember" xlink:type="locator" xlink:label="adpt_DevelopmentMilestonesMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="adpt_RegulatoryMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:type="locator" xlink:label="adpt_GenentechCollaborationAgreementMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:type="locator" xlink:label="adpt_MRDDevelopmentAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TranslationalDevelopmentAgreementsMember" xlink:type="locator" xlink:label="adpt_TranslationalDevelopmentAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_TranslationalDevelopmentAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_GenentechCollaborationAgreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_2" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_RegulatoryMilestonesMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_DevelopmentMilestonesMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_CommercialMilestonesMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_TermOfAgreement" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AgreementTerminationAmountReceivable" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_EligiblePaymentsReceivable" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalMilestonePayment" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionExpectedPeriod" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12010.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:type="locator" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:type="locator" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:href="adpt-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_BuildToSuitAssetCostMember" xlink:type="locator" xlink:label="adpt_BuildToSuitAssetCostMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ComputerSoftwareMember" xlink:type="locator" xlink:label="adpt_ComputerSoftwareMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="adpt_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="adpt_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerSoftwareMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_BuildToSuitAssetCostMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10620.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityNonCurrentAbstract" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityCurrentAbstract" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityCurrentAbstract" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityCurrentAbstract" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_ContractWithCustomerLiabilityCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SpecificPatientsMember" xlink:type="locator" xlink:label="adpt_SpecificPatientsMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MedicareRevenueMember" xlink:type="locator" xlink:label="adpt_MedicareRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncMember" xlink:type="locator" xlink:label="adpt_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_MedicareRevenueMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_SpecificPatientsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncMember" xlink:type="locator" xlink:label="adpt_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10230.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1Default" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1Default">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncMember" xlink:type="locator" xlink:label="adpt_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10100.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:type="locator" xlink:label="adpt_OperatingLeaseVariableLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfOperatingLeaseTerminate" xlink:type="locator" xlink:label="adpt_NumberOfOperatingLeaseTerminate" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:type="locator" xlink:label="adpt_TenantImprovementAllowanceAndCommenced" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementCostsReceivable" xlink:type="locator" xlink:label="adpt_TenantImprovementCostsReceivable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementCostsIncurred" xlink:type="locator" xlink:label="adpt_TenantImprovementCostsIncurred" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:type="locator" xlink:label="adpt_ProceedsFromLandlordReimbursements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="adpt_LeaseCommencementMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="adpt_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA" xlink:type="locator" xlink:label="stpr_WA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseExpirationMonthAndYear" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseCommencementMonthAndYear" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_ProceedsFromLandlordReimbursements" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsIncurred" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsReceivable" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementAllowanceAndCommenced" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_NumberOfOperatingLeaseTerminate" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_OperatingLeaseVariableLeaseExpense" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12700.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ClassOfWarrantOrRightsTerm" xlink:type="locator" xlink:label="adpt_ClassOfWarrantOrRightsTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:type="locator" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:type="locator" xlink:label="adpt_NumberOfCommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="adpt_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="adpt_SeriesCConvertiblePreferredStockMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_NumberOfCommonStockVotingRights" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_ClassOfWarrantOrRightsTerm" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" order="11600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:type="locator" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10340.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfEmployeeOptionModification" xlink:type="locator" xlink:label="adpt_NumberOfEmployeeOptionModification" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ReceivableForStockOptionExercises" xlink:type="locator" xlink:label="adpt_ReceivableForStockOptionExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NonEmployeeDirectorsMember" xlink:type="locator" xlink:label="adpt_NonEmployeeDirectorsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequentaTwoThousandAndEightStockPlanMember" xlink:type="locator" xlink:label="adpt_SequentaTwoThousandAndEightStockPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_SequentaTwoThousandAndEightStockPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="adpt_NonEmployeeDirectorsMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_2" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ReceivableForStockOptionExercises" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_NumberOfEmployeeOptionModification" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10930.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" xlink:type="locator" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" xlink:type="locator" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SeriesFOneConvertiblePreferredStockMember" xlink:type="locator" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MicrosoftCollaborationAgreementMember" xlink:type="locator" xlink:label="adpt_MicrosoftCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MicrosoftCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adpt_SeriesFOneConvertiblePreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_PreferredStockValue" order="10310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncomeTaxesTable" xlink:type="locator" xlink:label="adpt_IncomeTaxesTable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncomeTaxesLineItems" xlink:type="locator" xlink:label="adpt_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="adpt_ConvertiblePreferredStockWarrantsMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommonStockWarrantsMember" xlink:type="locator" xlink:label="adpt_CommonStockWarrantsMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:type="locator" xlink:label="adpt_UnvestedRestrictedStockUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_UnvestedRestrictedStockUnitsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_CommonStockWarrantsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_ConvertiblePreferredStockWarrantsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>32
<FILENAME>adpt-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-23T07:52:05.9540457+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b31e096b02284e6886ec6a280547abc3 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" />
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability tenant improvement receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" xlink:to="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities (amortized cost of $564,036 and $479,791, respectively)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable securities (amortized cost of $118,429 and $105,263, respectively)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and shareholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent liability, less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 11)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2020 and 2019; 137,646,896 and 125,238,142 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost of short-term marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Amortized Cost Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost of long-term marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Amortized Cost Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sequencing revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SequencingRevenueMember" xlink:to="adpt_SequencingRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sequencing Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sequencing Revenue [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DevelopmentRevenueMember" xlink:to="adpt_DevelopmentRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and marketing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling And Marketing Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fair value adjustment to Series E-1 convertible preferred stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion To Redemption Value Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common shareholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gain (loss) on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" xlink:type="locator" xlink:label="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" />
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity value vested convertible preferred stock option forfeitures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" xlink:to="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity adjustment redemption value for vested convertible preferred stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:to="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:label xml:lang="en-US" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in redemption value for vested convertible preferred stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity value change in redemption value for vested convertible preferred stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital, initial public offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" />
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, common stock warrants exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" />
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, common stock warrants exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" />
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares restricted stock award vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restatement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RestatementDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restatement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period, Accounting Standards Update, Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revision Of Prior Period Accounting Standards Update Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, Beginning Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update Extensible List</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters&apos; discounts and commissions and net offering costs paid by us</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters&apos; discounts and commissions and net offering costs paid by us, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Initial Public Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock warrant to common stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Common Stock Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Common Stock Warrants Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash upon exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Vested</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock option and restricted stock unit share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Stock Option And Restricted Stock Unit Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested Series E-1 convertible preferred stock option forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested Series E-1 convertible preferred stock option forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Value Vested Convertible Preferred Stock Option Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E-1 convertible preferred stock option share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to redemption value for vested Series E-1 convertible preferred stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to redemption value for vested Series E-1 convertible preferred stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Adjustment Redemption Value For Vested Convertible Preferred Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in redemption value for vested Series E-1 convertible preferred stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Redemption Value For Vested Convertible Preferred Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in redemption value for vested Series E-1 convertible preferred stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Value Change In Redemption Value For Vested Convertible Preferred Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock option share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NoncashLeaseExpense" xlink:type="locator" xlink:label="adpt_NoncashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NoncashLeaseExpense" xlink:to="adpt_NoncashLeaseExpense_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="adpt_IncreaseDecreaseInDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="adpt_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in deferred rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncreaseDecreaseInDeferredRent" xlink:to="adpt_IncreaseDecreaseInDeferredRent_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liabilities .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" xlink:type="locator" xlink:label="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" />
    <link:label xml:lang="en-US" xlink:label="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock upon exercise of common stock warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" xlink:to="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LandlordFundedLeaseholdImprovements" xlink:type="locator" xlink:label="adpt_LandlordFundedLeaseholdImprovements" />
    <link:label xml:lang="en-US" xlink:label="adpt_LandlordFundedLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Landlord-funded leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LandlordFundedLeaseholdImprovements" xlink:to="adpt_LandlordFundedLeaseholdImprovements_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:type="locator" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" />
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:to="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:type="locator" xlink:label="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock to common stock upon closing of initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:to="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" xlink:type="locator" xlink:label="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" xlink:to="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustment of convertible preferred stock warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_IncreaseDecreaseInDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Capital Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales and maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from public offering of common stock, net of underwriting discounts and commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of public offering costs, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon the exercise of a common stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Upon Exercise Of Common Stock Warrant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments For Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash investing and financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of equipment included in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LandlordFundedLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Landlord-funded leasehold improvements</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LandlordFundedLeaseholdImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Landlord Funded Leasehold Improvements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash additions to property through lease financing arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Fixed Assets Acquired1</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Lease Financing Arrangements Upon Adoption Of Guidance On Accounting For Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant Upon Closing Of Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredRevenueTextBlock" xlink:type="locator" xlink:label="adpt_DeferredRevenueTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredRevenueTextBlock" xlink:to="adpt_DeferredRevenueTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Microsoft Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:type="locator" xlink:label="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and use of estimates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:to="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Use Of Estimates Policy [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_JOBSActAccountingElectionPolicyTextBlock" xlink:type="locator" xlink:label="adpt_JOBSActAccountingElectionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_JOBSActAccountingElectionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">JOBS act accounting election.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_JOBSActAccountingElectionPolicyTextBlock" xlink:to="adpt_JOBSActAccountingElectionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_JOBSActAccountingElectionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JOBS Act Accounting Election</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_JOBSActAccountingElectionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">J O B S Act Accounting Election Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Goodwill Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Intangible Assets Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock" xlink:type="locator" xlink:label="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity convertible preferred stock policy text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock" xlink:to="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Convertible Preferred Stock Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractBalancesPolicyTextBlock" xlink:type="locator" xlink:label="adpt_ContractBalancesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract balances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ContractBalancesPolicyTextBlock" xlink:to="adpt_ContractBalancesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Balances</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Balances Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:type="locator" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales and marketing expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:to="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales And Marketing Expense Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Concentrations of Risk Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of estimated useful lives of property plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Useful Lives Assigned to Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Disaggregated by Type of Products and Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position Fair Value Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Intangible Assets Subject to Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Amortization Expense for Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:type="locator" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of deferred revenue by revenue classification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:to="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Revenue by Revenue Classification</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Revenue By Revenue Classification Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset And Liability Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Information Related to Operating Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciles Undiscounted Operating Lease Cash Flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:type="locator" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of reserved shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:to="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reserved Shares of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Reserved Shares Of Common Stock Table [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:type="locator" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share-based compensation, shares available for grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:to="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unvested Restricted Stock Units Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Grant Date Fair Value of Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Compensation Costs Related to Stock Options and RSUs Included on Statements of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Change in Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Income Tax Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SaleOfStockUnderwritingDiscountsAndCommission" xlink:type="locator" xlink:label="adpt_SaleOfStockUnderwritingDiscountsAndCommission" />
    <link:label xml:lang="en-US" xlink:label="adpt_SaleOfStockUnderwritingDiscountsAndCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock underwriting discounts and commission.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SaleOfStockUnderwritingDiscountsAndCommission" xlink:to="adpt_SaleOfStockUnderwritingDiscountsAndCommission_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_InitialPublicOfferingExpenses" xlink:type="locator" xlink:label="adpt_InitialPublicOfferingExpenses" />
    <link:label xml:lang="en-US" xlink:label="adpt_InitialPublicOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_InitialPublicOfferingExpenses" xlink:to="adpt_InitialPublicOfferingExpenses_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Subsidiary Or Equity Method Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Subsidiary Or Equity Method Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-allotment Option, at Underwritten Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Consideration Received On Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SaleOfStockUnderwritingDiscountsAndCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts, commissions and other costs</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SaleOfStockUnderwritingDiscountsAndCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Underwriting Discounts And Commission</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_InitialPublicOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_InitialPublicOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="adpt_SeriesCConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SeriesCConvertiblePreferredStockMember" xlink:to="adpt_SeriesCConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02 (Topic 842)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2016-13</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201613 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2018-15</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201815Member" xlink:to="us-gaap_AccountingStandardsUpdate201815Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201815 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update 2019-12</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201912 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerAMember" xlink:type="locator" xlink:label="adpt_CustomerAMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer A.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CustomerAMember" xlink:to="adpt_CustomerAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer A</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer A [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerBMember" xlink:type="locator" xlink:label="adpt_CustomerBMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CustomerBMember" xlink:to="adpt_CustomerBMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer B</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer B [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerCMember" xlink:type="locator" xlink:label="adpt_CustomerCMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer C.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CustomerCMember" xlink:to="adpt_CustomerCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer C</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_CustomerCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer C [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:type="locator" xlink:label="adpt_GenentechIncAndRocheGroupMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech, Inc. and Roche Group.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechIncAndRocheGroupMember" xlink:to="adpt_GenentechIncAndRocheGroupMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech, Inc. and Roche Group</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Inc And Roche Group [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:type="locator" xlink:label="us-gaap_UnbilledReceivablesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledReceivablesCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unbilled Receivables Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="adpt_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LaboratoryEquipmentMember" xlink:to="adpt_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="adpt_ComputerEquipmentAndSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ComputerEquipmentAndSoftwareMember" xlink:to="adpt_ComputerEquipmentAndSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="adpt_FurnitureAndOfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture and office equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_FurnitureAndOfficeEquipmentMember" xlink:to="adpt_FurnitureAndOfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Finitelived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:type="locator" xlink:label="us-gaap_BuildingsAndImprovementsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingsAndImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Building costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingsAndImprovementsGross" xlink:to="us-gaap_BuildingsAndImprovementsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingsAndImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Buildings And Improvements Gross</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, weighted average exercise price of warrants or rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average exercise price of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Current Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value adjustment of warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:type="locator" xlink:label="adpt_NumberOfRevenuePerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of revenue performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfRevenuePerformanceObligation" xlink:to="adpt_NumberOfRevenuePerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of revenue performance obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Revenue Performance Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Advertising expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfBuildToSuitLeaseAsset" xlink:type="locator" xlink:label="adpt_DerecognitionOfBuildToSuitLeaseAsset" />
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfBuildToSuitLeaseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of build to suit lease asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DerecognitionOfBuildToSuitLeaseAsset" xlink:to="adpt_DerecognitionOfBuildToSuitLeaseAsset_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfDeferredRent" xlink:type="locator" xlink:label="adpt_DerecognitionOfDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of deferred rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DerecognitionOfDeferredRent" xlink:to="adpt_DerecognitionOfDeferredRent_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ReclassificationOfTenantIncentiveReceivables" xlink:type="locator" xlink:label="adpt_ReclassificationOfTenantIncentiveReceivables" />
    <link:label xml:lang="en-US" xlink:label="adpt_ReclassificationOfTenantIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of tenant incentive receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ReclassificationOfTenantIncentiveReceivables" xlink:to="adpt_ReclassificationOfTenantIncentiveReceivables_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfBuildToSuitLiabilities" xlink:type="locator" xlink:label="adpt_DerecognitionOfBuildToSuitLiabilities" />
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfBuildToSuitLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of build-to-suit liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DerecognitionOfBuildToSuitLiabilities" xlink:to="adpt_DerecognitionOfBuildToSuitLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, early adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Early Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfBuildToSuitLeaseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognized portion of build-to-suit asset</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfBuildToSuitLeaseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Build To Suit Lease Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfBuildToSuitLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of build-to-suit liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfBuildToSuitLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Build To Suit Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of deferred rent</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DerecognitionOfDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Deferred Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ReclassificationOfTenantIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of tenant incentive receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ReclassificationOfTenantIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Tenant Incentive Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentSupportRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentSupportRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentSupportRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development support revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DevelopmentSupportRevenueMember" xlink:to="adpt_DevelopmentSupportRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentSupportRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Support Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentSupportRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Support Revenue [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueRegulatoryMilestonesMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueRegulatoryMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentRevenueRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development revenue regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DevelopmentRevenueRegulatoryMilestonesMember" xlink:to="adpt_DevelopmentRevenueRegulatoryMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentRevenueRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Revenue Regulatory Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentRevenueRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Revenue Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:type="locator" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" />
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition milestone method expected milestone receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AgreementTerminationAmountReceivable" xlink:type="locator" xlink:label="adpt_AgreementTerminationAmountReceivable" />
    <link:label xml:lang="en-US" xlink:label="adpt_AgreementTerminationAmountReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination amount receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AgreementTerminationAmountReceivable" xlink:to="adpt_AgreementTerminationAmountReceivable_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_EligiblePaymentsReceivable" xlink:type="locator" xlink:label="adpt_EligiblePaymentsReceivable" />
    <link:label xml:lang="en-US" xlink:label="adpt_EligiblePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Eligible payments receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_EligiblePaymentsReceivable" xlink:to="adpt_EligiblePaymentsReceivable_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TermOfAgreement" xlink:type="locator" xlink:label="adpt_TermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="adpt_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TermOfAgreement" xlink:to="adpt_TermOfAgreement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TranslationalDevelopmentAgreementsMember" xlink:type="locator" xlink:label="adpt_TranslationalDevelopmentAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_TranslationalDevelopmentAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Translational development agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TranslationalDevelopmentAgreementsMember" xlink:to="adpt_TranslationalDevelopmentAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_TranslationalDevelopmentAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Translational Development Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TranslationalDevelopmentAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Translational Development Agreements [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:type="locator" xlink:label="adpt_MRDDevelopmentAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MRD development agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MRDDevelopmentAgreementsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MRD Development Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M R D Development Agreements [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:type="locator" xlink:label="adpt_GenentechCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechCollaborationAgreementMember" xlink:to="adpt_GenentechCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="adpt_RegulatoryMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RegulatoryMilestonesMember" xlink:to="adpt_RegulatoryMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentMilestonesMember" xlink:type="locator" xlink:label="adpt_DevelopmentMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DevelopmentMilestonesMember" xlink:to="adpt_DevelopmentMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommercialMilestonesMember" xlink:type="locator" xlink:label="adpt_CommercialMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommercialMilestonesMember" xlink:to="adpt_CommercialMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected revenue through milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Milestone Method Expected Milestone Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AgreementTerminationAmountReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement termination amount receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AgreementTerminationAmountReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Amount Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_EligiblePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eligible payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_EligiblePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Eligible Payments Receivable</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" xlink:type="locator" xlink:label="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" />
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognized excluding separately negotiated research sequencing contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" xlink:to="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized excluding separately negotiated research sequencing contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognized Excluding Separately Negotiated Research Sequencing Contracts</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability milestone method revenue recognized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Milestone Method Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdditionalMilestonePayment" xlink:type="locator" xlink:label="adpt_AdditionalMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdditionalMilestonePayment" xlink:to="adpt_AdditionalMilestonePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payment</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:type="locator" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived" />
    <link:label xml:lang="en-US" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payments received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonRefundableUpfrontPaymentsReceived" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payments Received</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:type="locator" xlink:label="adpt_RevenueRecognitionExpectedPeriod" />
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition expected period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueRecognitionExpectedPeriod" xlink:to="adpt_RevenueRecognitionExpectedPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition expected period</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Expected Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from collaboration agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Security Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Information By Category Of Debt Security [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:type="locator" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt securities current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:type="locator" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt securities noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Noncurrent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 12 months, Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less than 12 months, Unrealized loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">12 months or greater, Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">12 months or greater, Unrealized loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ComputerSoftwareMember" xlink:type="locator" xlink:label="adpt_ComputerSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ComputerSoftwareMember" xlink:to="adpt_ComputerSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_BuildToSuitAssetCostMember" xlink:type="locator" xlink:label="adpt_BuildToSuitAssetCostMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_BuildToSuitAssetCostMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Build-to-suit asset cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_BuildToSuitAssetCostMember" xlink:to="adpt_BuildToSuitAssetCostMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_BuildToSuitAssetCostMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Build-to-suit Asset Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_BuildToSuitAssetCostMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Build To Suit Asset Cost [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, at cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Goodwill [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased Intellectual Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired Developed Technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Carrying Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense After Year Five</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:type="locator" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and contract research organization costs, current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:type="locator" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" />
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued purchase of property and equipment current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and contract research organization costs</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical And Contract Research Organization Costs Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Travel and entertainment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes Current</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Purchase Of Property And Equipment Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:type="locator" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" />
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued tax withholding liability related to unsettled option exercises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:to="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued tax withholding liability related to unsettled option exercises</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Tax Withholding Liability Related To Unsettled Option Exercises</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityCurrentAbstract" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability current abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ContractWithCustomerLiabilityCurrentAbstract" xlink:to="adpt_ContractWithCustomerLiabilityCurrentAbstract_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityNonCurrentAbstract" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityNonCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability non current abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" xlink:to="adpt_ContractWithCustomerLiabilityNonCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total current deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityNonCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ContractWithCustomerLiabilityNonCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Non Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total non-current deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current and non-current deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncMember" xlink:type="locator" xlink:label="adpt_GenentechIncMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechIncMember" xlink:to="adpt_GenentechIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Inc [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MedicareRevenueMember" xlink:type="locator" xlink:label="adpt_MedicareRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MedicareRevenueMember" xlink:to="adpt_MedicareRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Medicare Revenue [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SpecificPatientsMember" xlink:type="locator" xlink:label="adpt_SpecificPatientsMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Specific patients.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SpecificPatientsMember" xlink:to="adpt_SpecificPatientsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specific Patients</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Specific Patients [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Current deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, expected to be recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred revenue balance at December 31, 2019</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions to deferred revenue during the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized during the period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred revenue balance at December 31, 2020</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="adpt_LeaseExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LeaseExpirationMonthAndYear" xlink:to="adpt_LeaseExpirationMonthAndYear_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease rent commencement month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, extended term of contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA" xlink:type="locator" xlink:label="stpr_WA" />
    <link:label xml:lang="en-US" xlink:label="stpr_WA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seattle, Washington</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_WA" xlink:to="stpr_WA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_WA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">WASHINGTON</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfLand_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of square feet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfLand_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Land</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, rent commencement month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Rent Commencement Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, extended term of contract</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="adpt_LeaseCommencementMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LeaseCommencementMonthAndYear" xlink:to="adpt_LeaseCommencementMonthAndYear_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:type="locator" xlink:label="adpt_ProceedsFromLandlordReimbursements" />
    <link:label xml:lang="en-US" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from landlord reimbursements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ProceedsFromLandlordReimbursements" xlink:to="adpt_ProceedsFromLandlordReimbursements_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementCostsIncurred" xlink:type="locator" xlink:label="adpt_TenantImprovementCostsIncurred" />
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement costs incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementCostsIncurred" xlink:to="adpt_TenantImprovementCostsIncurred_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementCostsReceivable" xlink:type="locator" xlink:label="adpt_TenantImprovementCostsReceivable" />
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement costs receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementCostsReceivable" xlink:to="adpt_TenantImprovementCostsReceivable_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letters Of Credit Outstanding Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commenced moth and year</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Landlord contribution for leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from landlord reimbursements</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Landlord Reimbursements</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement costs incurred</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Costs Incurred</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tenant improvement costs receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Costs Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TenantImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TenantImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod" />
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease termination period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseTerminationPeriod" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfOperatingLeaseTerminate" xlink:type="locator" xlink:label="adpt_NumberOfOperatingLeaseTerminate" />
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfOperatingLeaseTerminate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating lease terminate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfOperatingLeaseTerminate" xlink:to="adpt_NumberOfOperatingLeaseTerminate_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:type="locator" xlink:label="adpt_TenantImprovementAllowanceAndCommenced" />
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowance and commenced.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementAllowanceAndCommenced" xlink:to="adpt_TenantImprovementAllowanceAndCommenced_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance and commenced</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance And Commenced</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease termination period</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Termination Period</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfOperatingLeaseTerminate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating lease terminate</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfOperatingLeaseTerminate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Lease Terminate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Imputed interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tenant improvement receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Tenant Improvement Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:type="locator" xlink:label="adpt_OperatingLeaseVariableLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease variable lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_OperatingLeaseVariableLeaseExpense" xlink:to="adpt_OperatingLeaseVariableLeaseExpense_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease variable lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Variable Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash received for tenant improvement allowances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Tenant Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU assets obtained in exchange for operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Converted1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:type="locator" xlink:label="adpt_NumberOfCommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock voting rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfCommonStockVotingRights" xlink:to="adpt_NumberOfCommonStockVotingRights_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of vote for each share</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Voting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Common Stock Warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:type="locator" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options and restricted stock units granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options And Restricted Stock Units Granted [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares of common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:type="locator" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual increases in number of shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increases in number of shares</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Annual Increases In Number Of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share reserve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ClassOfWarrantOrRightsTerm" xlink:type="locator" xlink:label="adpt_ClassOfWarrantOrRightsTerm" />
    <link:label xml:lang="en-US" xlink:label="adpt_ClassOfWarrantOrRightsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or rights, term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ClassOfWarrantOrRightsTerm" xlink:to="adpt_ClassOfWarrantOrRightsTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ClassOfWarrantOrRightsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercisable term</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ClassOfWarrantOrRightsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period, common stock</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award outstanding number.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequentaTwoThousandAndEightStockPlanMember" xlink:type="locator" xlink:label="adpt_SequentaTwoThousandAndEightStockPlanMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_SequentaTwoThousandAndEightStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sequenta two thousand and eight stock plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SequentaTwoThousandAndEightStockPlanMember" xlink:to="adpt_SequentaTwoThousandAndEightStockPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_SequentaTwoThousandAndEightStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sequenta 2008 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SequentaTwoThousandAndEightStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sequenta Two Thousand And Eight Stock Plan [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nine equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2009 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nine Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NonEmployeeDirectorsMember" xlink:type="locator" xlink:label="adpt_NonEmployeeDirectorsMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-employee directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonEmployeeDirectorsMember" xlink:to="adpt_NonEmployeeDirectorsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Employee Directors</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Directors [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Valuation Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique Option Pricing Model [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity awards outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award increase reserve shares available for grant,</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" />
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment awards granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" />
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment awards forfeited, canceled or expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Available for Grant, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, 2019 Plan reserve increase</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Increase Reserve Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, Options and restricted stock units granted</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Awards Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Options and forfeited, cancelled or expired</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Awards Forfeited Canceled Or Expired</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Available for Grant, Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" />
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Subject to Outstanding Options, Options outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Outstanding Options, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Options, Options forfeited or cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Options, Options expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Options, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Subject to Outstanding Options, Options outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Outstanding Options, Options vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price per Share, Options outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Options forfeited or cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Options expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price per Share, Options outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Options vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Option outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual life options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual life vested and exercisable options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ReceivableForStockOptionExercises" xlink:type="locator" xlink:label="adpt_ReceivableForStockOptionExercises" />
    <link:label xml:lang="en-US" xlink:label="adpt_ReceivableForStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Receivable for stock option exercises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ReceivableForStockOptionExercises" xlink:to="adpt_ReceivableForStockOptionExercises_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ReceivableForStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsettled cash proceeds related to stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ReceivableForStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivable For Stock Option Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Outstanding, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted Stock Units Outstanding, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling And Marketing Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfEmployeeOptionModification" xlink:type="locator" xlink:label="adpt_NumberOfEmployeeOptionModification" />
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfEmployeeOptionModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of employee option modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfEmployeeOptionModification" xlink:to="adpt_NumberOfEmployeeOptionModification_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfEmployeeOptionModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of employee option modification</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NumberOfEmployeeOptionModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Employee Option Modification</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" xlink:type="locator" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum service consumption requirement amount under license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" xlink:to="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" xlink:type="locator" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum service consumption requirement term under license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" xlink:to="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CollaborationArrangementDisclosureAbstract" xlink:type="locator" xlink:label="adpt_CollaborationArrangementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="adpt_CollaborationArrangementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Arrangement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CollaborationArrangementDisclosureAbstract" xlink:to="adpt_CollaborationArrangementDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_CollaborationArrangementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangement Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Fair Value Off Balance Sheet Risks [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Off Balance Sheet Risks [Table]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MicrosoftCollaborationAgreementMember" xlink:type="locator" xlink:label="adpt_MicrosoftCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_MicrosoftCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Microsoft collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MicrosoftCollaborationAgreementMember" xlink:to="adpt_MicrosoftCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_MicrosoftCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Microsoft Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_MicrosoftCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Microsoft Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SeriesFOneConvertiblePreferredStockMember" xlink:type="locator" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series F one convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SeriesFOneConvertiblePreferredStockMember" xlink:to="adpt_SeriesFOneConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F-1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series F One Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Off Balance Sheet Risks Disclosure Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum service consumption requirement amount</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Service Consumption Requirement Amount Under License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum service consumption requirement term</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Service Consumption Requirement Term Under License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">preferred stock investment</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:type="locator" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, non qualified stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:type="locator" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, tangible and intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards General Business</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non qualifying stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Non Qualified Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tangible and intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Tangible And Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncomeTaxesLineItems" xlink:type="locator" xlink:label="adpt_IncomeTaxesLineItems" />
    <link:label xml:lang="en-US" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_IncomeTaxesLineItems_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncomeTaxesTable" xlink:type="locator" xlink:label="adpt_IncomeTaxesTable" />
    <link:label xml:lang="en-US" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncomeTaxesTable" xlink:to="adpt_IncomeTaxesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Carryforward Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards, Expiration Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_OperatingLossCarryforwardsExpirationYear" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity period for net operating loss carryovers</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforward Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Limitations On Use</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="locator" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:label xml:lang="en-US" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Fair value adjustments to redemption value for Series E-1 convertible preferred stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used in computing net loss per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:type="locator" xlink:label="adpt_UnvestedRestrictedStockUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_UnvestedRestrictedStockUnitsMember" xlink:to="adpt_UnvestedRestrictedStockUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommonStockWarrantsMember" xlink:type="locator" xlink:label="adpt_CommonStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockWarrantsMember" xlink:to="adpt_CommonStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="adpt_ConvertiblePreferredStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="adpt_ConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrants member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ConvertiblePreferredStockWarrantsMember" xlink:to="adpt_ConvertiblePreferredStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="adpt_ConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_ConvertiblePreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:type="locator" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" />
    <link:label xml:lang="en-US" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan employee service period for vesting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:to="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees maximum annual contribution of their compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer discretionary contribution amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee service period for vesting</link:label>
    <link:label xml:lang="en-US" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employee Service Period For Vesting</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>33
<FILENAME>adpt-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-23T07:52:05.9540457+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b31e096b02284e6886ec6a280547abc3 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/role/TemplateLink" xlink:href="adpt-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="adpt-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets" xlink:href="adpt-20201231.xsd#Role_StatementBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Goodwill" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="adpt-20201231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:type="locator" xlink:label="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" xlink:type="locator" xlink:label="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:type="locator" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:type="locator" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:type="locator" xlink:label="srt_RestatementDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:type="locator" xlink:label="srt_RestatementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" order="12730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="13450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="13630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures" order="13670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="13810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" order="13990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions" order="14030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" order="14170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" order="14210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="14350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="14530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="14890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="14910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="14930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="14950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="adpt-20201231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" xlink:type="locator" xlink:label="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:type="locator" xlink:label="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:type="locator" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LandlordFundedLeaseholdImprovements" xlink:type="locator" xlink:label="adpt_LandlordFundedLeaseholdImprovements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" xlink:type="locator" xlink:label="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncreaseDecreaseInDeferredRent" xlink:type="locator" xlink:label="adpt_IncreaseDecreaseInDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NoncashLeaseExpense" xlink:type="locator" xlink:label="adpt_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_NoncashLeaseExpense" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="adpt_IncreaseDecreaseInDeferredRent" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseLiabilities" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="adpt_LandlordFundedLeaseholdImprovements" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="12920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" order="13040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="adpt-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenue" xlink:href="adpt-20201231.xsd#Role_DisclosureRevenue" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenue">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="adpt-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestments" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="adpt-20201231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilities" xlink:href="adpt-20201231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenue" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenue" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenue">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredRevenueTextBlock" xlink:type="locator" xlink:label="adpt_DeferredRevenueTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="adpt_DeferredRevenueTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="adpt-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="adpt-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquity" xlink:href="adpt-20201231.xsd#Role_DisclosureShareholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement" xlink:href="adpt-20201231.xsd#Role_DisclosureMicrosoftCollaborationAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholders" xlink:href="adpt-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonShareholders" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholders">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlan" xlink:href="adpt-20201231.xsd#Role_DisclosureRetirementPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:type="locator" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractBalancesPolicyTextBlock" xlink:type="locator" xlink:label="adpt_ContractBalancesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock" xlink:type="locator" xlink:label="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_JOBSActAccountingElectionPolicyTextBlock" xlink:type="locator" xlink:label="adpt_JOBSActAccountingElectionPolicyTextBlock" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:type="locator" xlink:label="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_JOBSActAccountingElectionPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_ContractBalancesPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SalesAndMarketingExpensePolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueTables" xlink:href="adpt-20201231.xsd#Role_DisclosureRevenueTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="adpt-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsTables" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="adpt-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables" xlink:href="adpt-20201231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueTables" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:type="locator" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="adpt-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityTables" xlink:href="adpt-20201231.xsd#Role_DisclosureShareholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityTables">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:type="locator" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:type="locator" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersTables" xlink:href="adpt-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonShareholdersTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_InitialPublicOfferingExpenses" xlink:type="locator" xlink:label="adpt_InitialPublicOfferingExpenses" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SaleOfStockUnderwritingDiscountsAndCommission" xlink:type="locator" xlink:label="adpt_SaleOfStockUnderwritingDiscountsAndCommission" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="adpt_SaleOfStockUnderwritingDiscountsAndCommission" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="adpt_InitialPublicOfferingExpenses" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ReclassificationOfTenantIncentiveReceivables" xlink:type="locator" xlink:label="adpt_ReclassificationOfTenantIncentiveReceivables" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfDeferredRent" xlink:type="locator" xlink:label="adpt_DerecognitionOfDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfBuildToSuitLiabilities" xlink:type="locator" xlink:label="adpt_DerecognitionOfBuildToSuitLiabilities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DerecognitionOfBuildToSuitLeaseAsset" xlink:type="locator" xlink:label="adpt_DerecognitionOfBuildToSuitLeaseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:type="locator" xlink:label="adpt_NumberOfRevenuePerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:type="locator" xlink:label="us-gaap_BuildingsAndImprovementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:type="locator" xlink:label="us-gaap_UnbilledReceivablesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="adpt_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="adpt_SeriesCConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesLineItems" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnbilledReceivablesCurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BuildingsAndImprovementsGross" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_NumberOfRevenuePerformanceObligation" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_DerecognitionOfBuildToSuitLeaseAsset" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_DerecognitionOfBuildToSuitLiabilities" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_DerecognitionOfDeferredRent" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_ReclassificationOfTenantIncentiveReceivables" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:type="locator" xlink:label="adpt_GenentechIncAndRocheGroupMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerCMember" xlink:type="locator" xlink:label="adpt_CustomerCMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerBMember" xlink:type="locator" xlink:label="adpt_CustomerBMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CustomerAMember" xlink:type="locator" xlink:label="adpt_CustomerAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="adpt_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerBMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerCMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncAndRocheGroupMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="adpt_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="adpt_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="adpt_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerEquipmentAndSoftwareMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueRegulatoryMilestonesMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueRegulatoryMilestonesMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentSupportRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentSupportRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentSupportRevenueMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueRegulatoryMilestonesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureRevenueAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:type="locator" xlink:label="adpt_RevenueRecognitionExpectedPeriod" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:type="locator" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AdditionalMilestonePayment" xlink:type="locator" xlink:label="adpt_AdditionalMilestonePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" xlink:type="locator" xlink:label="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_EligiblePaymentsReceivable" xlink:type="locator" xlink:label="adpt_EligiblePaymentsReceivable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AgreementTerminationAmountReceivable" xlink:type="locator" xlink:label="adpt_AgreementTerminationAmountReceivable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TermOfAgreement" xlink:type="locator" xlink:label="adpt_TermOfAgreement" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:type="locator" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommercialMilestonesMember" xlink:type="locator" xlink:label="adpt_CommercialMilestonesMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentMilestonesMember" xlink:type="locator" xlink:label="adpt_DevelopmentMilestonesMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="adpt_RegulatoryMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:type="locator" xlink:label="adpt_GenentechCollaborationAgreementMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:type="locator" xlink:label="adpt_MRDDevelopmentAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TranslationalDevelopmentAgreementsMember" xlink:type="locator" xlink:label="adpt_TranslationalDevelopmentAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_TranslationalDevelopmentAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_GenentechCollaborationAgreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_RegulatoryMilestonesMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_DevelopmentMilestonesMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_CommercialMilestonesMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_TermOfAgreement" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AgreementTerminationAmountReceivable" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_EligiblePaymentsReceivable" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalMilestonePayment" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionExpectedPeriod" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:type="locator" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:type="locator" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:href="adpt-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_BuildToSuitAssetCostMember" xlink:type="locator" xlink:label="adpt_BuildToSuitAssetCostMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ComputerSoftwareMember" xlink:type="locator" xlink:label="adpt_ComputerSoftwareMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:type="locator" xlink:label="adpt_FurnitureAndOfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="adpt_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerSoftwareMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_BuildToSuitAssetCostMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:type="locator" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:type="locator" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:type="locator" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityNonCurrentAbstract" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ContractWithCustomerLiabilityCurrentAbstract" xlink:type="locator" xlink:label="adpt_ContractWithCustomerLiabilityCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityCurrentAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_ContractWithCustomerLiabilityCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_ContractWithCustomerLiabilityNonCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SpecificPatientsMember" xlink:type="locator" xlink:label="adpt_SpecificPatientsMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MedicareRevenueMember" xlink:type="locator" xlink:label="adpt_MedicareRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequencingRevenueMember" xlink:type="locator" xlink:label="adpt_SequencingRevenueMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncMember" xlink:type="locator" xlink:label="adpt_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DevelopmentRevenueMember" xlink:type="locator" xlink:label="adpt_DevelopmentRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_MedicareRevenueMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_SpecificPatientsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_GenentechIncMember" xlink:type="locator" xlink:label="adpt_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_li0l2" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:type="locator" xlink:label="adpt_OperatingLeaseVariableLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfOperatingLeaseTerminate" xlink:type="locator" xlink:label="adpt_NumberOfOperatingLeaseTerminate" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:type="locator" xlink:label="adpt_TenantImprovementAllowanceAndCommenced" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementCostsReceivable" xlink:type="locator" xlink:label="adpt_TenantImprovementCostsReceivable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TenantImprovementCostsIncurred" xlink:type="locator" xlink:label="adpt_TenantImprovementCostsIncurred" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:type="locator" xlink:label="adpt_ProceedsFromLandlordReimbursements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="adpt_LeaseCommencementMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="adpt_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA" xlink:type="locator" xlink:label="stpr_WA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseExpirationMonthAndYear" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseCommencementMonthAndYear" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_ProceedsFromLandlordReimbursements" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsIncurred" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsReceivable" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementAllowanceAndCommenced" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_NumberOfOperatingLeaseTerminate" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_OperatingLeaseVariableLeaseExpense" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" xlink:type="locator" xlink:label="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:type="locator" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ClassOfWarrantOrRightsTerm" xlink:type="locator" xlink:label="adpt_ClassOfWarrantOrRightsTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:type="locator" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:type="locator" xlink:label="adpt_NumberOfCommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="adpt_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="adpt_SeriesCConvertiblePreferredStockMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_NumberOfCommonStockVotingRights" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_ClassOfWarrantOrRightsTerm" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:type="locator" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember_li0l2" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NumberOfEmployeeOptionModification" xlink:type="locator" xlink:label="adpt_NumberOfEmployeeOptionModification" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ReceivableForStockOptionExercises" xlink:type="locator" xlink:label="adpt_ReceivableForStockOptionExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NonEmployeeDirectorsMember" xlink:type="locator" xlink:label="adpt_NonEmployeeDirectorsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SequentaTwoThousandAndEightStockPlanMember" xlink:type="locator" xlink:label="adpt_SequentaTwoThousandAndEightStockPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_SequentaTwoThousandAndEightStockPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="adpt_NonEmployeeDirectorsMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ReceivableForStockOptionExercises" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_NumberOfEmployeeOptionModification" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:type="locator" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" xlink:type="locator" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" xlink:type="locator" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_SeriesFOneConvertiblePreferredStockMember" xlink:type="locator" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_MicrosoftCollaborationAgreementMember" xlink:type="locator" xlink:label="adpt_MicrosoftCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CollaborationArrangementDisclosureAbstract" xlink:type="locator" xlink:label="adpt_CollaborationArrangementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_CollaborationArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MicrosoftCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adpt_SeriesFOneConvertiblePreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_PreferredStockValue" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:type="locator" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="locator" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:type="locator" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncomeTaxesLineItems" xlink:type="locator" xlink:label="adpt_IncomeTaxesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_IncomeTaxesTable" xlink:type="locator" xlink:label="adpt_IncomeTaxesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="adpt_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesTable" xlink:to="adpt_IncomeTaxesLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="locator" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" xlink:href="adpt-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_ConvertiblePreferredStockWarrantsMember" xlink:type="locator" xlink:label="adpt_ConvertiblePreferredStockWarrantsMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_CommonStockWarrantsMember" xlink:type="locator" xlink:label="adpt_CommonStockWarrantsMember" />
    <link:loc xlink:href="adpt-20201231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:type="locator" xlink:label="adpt_UnvestedRestrictedStockUnitsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_UnvestedRestrictedStockUnitsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_CommonStockWarrantsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_ConvertiblePreferredStockWarrantsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="adpt-20201231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails">
    <link:loc xlink:href="adpt-20201231.xsd#adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:type="locator" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>adpt-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adpt="http://www.adaptivebiotech.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adpt-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001478320_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001478320_20210219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2021-02-19</instant>
        </period>
    </context>
    <context id="C_0001478320_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRestatementAxis_srtRevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRestatementAxis_srtRevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptCustomerCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncAndRocheGroupMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncAndRocheGroupMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerEquipmentAndSoftwareMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adpt:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adpt:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adpt:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentSupportRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentSupportRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentSupportRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151201_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:TranslationalDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20190201_20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptCommercialMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerSoftwareMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerSoftwareMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptBuildToSuitAssetCostMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:BuildToSuitAssetCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtRangeAxis_srtMinimumMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtRangeAxis_srtMaximumMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_20201230_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtMajorCustomersAxis_adptSpecificPatientsMember_srtProductOrServiceAxis_adptMedicareRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:SpecificPatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtStatementGeographicalAxis_stprWA_20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_0001478320_20190801_20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_0001478320_20191001_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_0001478320_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_0001478320_20180401_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_0001478320_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001478320_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001478320_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMinimumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190629_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_adptCommonStockOptionsAndRestrictedStockUnitsGrantedMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockOptionsAndRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190701_20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20140101_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">adpt:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPlanNameAxis_adptSequentaTwoThousandAndEightStockPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:SequentaTwoThousandAndEightStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtTitleOfIndividualAxis_adptNonEmployeeDirectorsMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adpt:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMinimumMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMinimumMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_srtRangeAxis_srtMaximumMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MicrosoftCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapStatementClassOfStockAxis_adptSeriesFOneConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adpt:SeriesFOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MicrosoftCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptUnvestedRestrictedStockUnitsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptUnvestedRestrictedStockUnitsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptConvertiblePreferredStockWarrantsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:ConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptConvertiblePreferredStockWarrantsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:ConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_adptPerformance_Obligation">
        <measure>adpt:Performance_Obligation</measure>
    </unit>
    <unit id="U_adptSegment">
        <measure>adpt:Segment</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_adptLease">
        <measure>adpt:Lease</measure>
    </unit>
    <unit id="U_adptVote">
        <measure>adpt:Vote</measure>
    </unit>
    <unit id="U_adptOption">
        <measure>adpt:Option</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001478320_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001478320_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001478320_20200101_20201231" id="F_000007">0001478320</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001478320_20200101_20201231" id="F_000009">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      id="F_000472">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      id="F_000473">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      id="F_000474">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231"
      id="F_000483">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231"
      id="F_000484">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231"
      id="F_000485">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000487">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000488">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000489">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000491">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000492">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000493">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831"
      id="F_000701">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831"
      id="F_000703">2032-10</adpt:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="C_0001478320_20190801_20190831" id="F_000710">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <adpt:LeaseExpirationMonthAndYear contextRef="C_0001478320_20191001_20191031" id="F_000718">2029-10</adpt:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="C_0001478320_20180401_20180430" id="F_000723">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="C_0001478320_20200101_20201231" id="F_000733">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract contextRef="C_0001478320_20180401_20180430" id="F_000724">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001478320_srtTitleOfIndividualAxis_adptNonEmployeeDirectorsMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      id="F_000795">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <adpt:MinimumServiceConsumptionRequirementTermUnderLicenseAgreement
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231"
      id="F_000892">P7Y</adpt:MinimumServiceConsumptionRequirementTermUnderLicenseAgreement>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="C_0001478320_20200101_20201231" id="F_000259">us-gaap:AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001478320_20201231" id="F_000738">P11Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20200101_20201231"
      id="F_000845">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20190101_20191231"
      id="F_000846">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20180101_20181231"
      id="F_000847">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000851"
      unitRef="U_xbrlipure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000852"
      unitRef="U_xbrlipure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000853"
      unitRef="U_xbrlipure">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000857"
      unitRef="U_xbrlipure">0.705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000858"
      unitRef="U_xbrlipure">0.643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000859"
      unitRef="U_xbrlipure">0.650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20200101_20201231"
      decimals="2"
      id="F_000841"
      unitRef="U_iso4217USD_xbrlishares">17.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20190101_20191231"
      decimals="2"
      id="F_000842"
      unitRef="U_iso4217USD_xbrlishares">7.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20200101_20201231"
      decimals="2"
      id="F_000843"
      unitRef="U_iso4217USD_xbrlishares">55.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20190101_20191231"
      decimals="2"
      id="F_000844"
      unitRef="U_iso4217USD_xbrlishares">47.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000848">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20190101_20191231"
      id="F_000849">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20180101_20181231"
      id="F_000850">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000854"
      unitRef="U_xbrlipure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000855"
      unitRef="U_xbrlipure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000856"
      unitRef="U_xbrlipure">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000860"
      unitRef="U_xbrlipure">0.733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000861"
      unitRef="U_xbrlipure">0.729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000862"
      unitRef="U_xbrlipure">0.692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001478320_20201231"
      id="F_000082"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001478320_20191231"
      id="F_000083"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001478320_20201231"
      id="F_000084"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001478320_20191231"
      id="F_000085"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001478320_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001478320_20200101_20201231" id="F_000030">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001478320_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001478320_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001478320_20200101_20201231" id="F_000031">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001478320_20200101_20201231" id="F_000021">001-38957</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001478320_20200101_20201231" id="F_000006">ADAPTIVE BIOTECHNOLOGIES CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001478320_20200101_20201231" id="F_000032">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001478320_20200101_20201231" id="F_000022">27-0907024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001478320_20200101_20201231" id="F_000023">1551 Eastlake Avenue East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001478320_20200101_20201231" id="F_000024">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001478320_20200101_20201231" id="F_000025">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001478320_20200101_20201231" id="F_000026">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001478320_20200101_20201231" id="F_000027">98102</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001478320_20200101_20201231" id="F_000028">(206)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001478320_20200101_20201231" id="F_000029">659-0067</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001478320_20200101_20201231" id="F_000015">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001478320_20200101_20201231" id="F_000005">ADPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001478320_20200101_20201231" id="F_000016">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001478320_20200101_20201231" id="F_000011">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001478320_20200101_20201231" id="F_000008">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001478320_20200101_20201231" id="F_000018">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001478320_20200101_20201231" id="F_000020">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001478320_20200101_20201231" id="F_000010">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001478320_20200101_20201231" id="F_000013">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001478320_20200101_20201231" id="F_000014">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001478320_20200101_20201231" id="F_000033">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001478320_20200101_20201231" id="F_000019">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001478320_20200630"
      decimals="0"
      id="F_000012"
      unitRef="U_iso4217USD">3590000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001478320_20210219"
      decimals="INF"
      id="F_000017"
      unitRef="U_xbrlishares">139219503</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000034">The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the registrant&#x2019;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2021.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">123436000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">96576000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">564036000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">479791000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">564833000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">480290000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">10047000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">12676000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">14063000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">9069000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">14535000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">14079000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">726914000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">612690000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">39692000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">60355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">99350000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">118429000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">105263000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">118525000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">105435000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">2138000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">2138000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">10225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">11928000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">118972000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">118972000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">598000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">784000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">1116414000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">912302000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">3237000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">4453000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">13162000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">4371000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">11950000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">8124000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">371000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">3529000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">73319000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">60994000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">105197000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">78313000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">6918000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">104333000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">36607000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">163618000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">219332000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">93000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">373148000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">341263000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000102"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000103"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000104"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000105"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000106"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000107"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000108"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000109"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000110"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000111"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000112"
      unitRef="U_xbrlishares">340000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000113"
      unitRef="U_xbrlishares">340000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000114"
      unitRef="U_xbrlishares">137646896</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000116"
      unitRef="U_xbrlishares">137646896</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000115"
      unitRef="U_xbrlishares">125238142</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000117"
      unitRef="U_xbrlishares">125238142</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">12000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">1253971000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">935834000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">893000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">671000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">-511612000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">-365478000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">743266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">571039000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">1116414000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">912302000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">41439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">43519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">32978000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">56943000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">41552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">22685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">98382000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">85071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">55663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">22530000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">22274000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">19668000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">116072000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">70705000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">39157000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">61358000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">38453000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">24486000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">49536000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">30332000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">20409000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">1703000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">1698000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">251199000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">163462000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">105419000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">-152817000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">-78391000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-49756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">6590000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">9785000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">3309000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">-146227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">-68606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-46447000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">964000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">-102000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">-146227000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-69570000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-46345000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001478320_20200101_20201231"
      decimals="2"
      id="F_000159"
      unitRef="U_iso4217USD_xbrlishares">-1.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001478320_20190101_20191231"
      decimals="2"
      id="F_000160"
      unitRef="U_iso4217USD_xbrlishares">-1.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001478320_20180101_20181231"
      decimals="2"
      id="F_000161"
      unitRef="U_iso4217USD_xbrlishares">-3.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001478320_20200101_20201231"
      decimals="0"
      id="F_000162"
      unitRef="U_xbrlishares">131216468</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001478320_20190101_20191231"
      decimals="0"
      id="F_000163"
      unitRef="U_xbrlishares">69165315</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001478320_20180101_20181231"
      decimals="0"
      id="F_000164"
      unitRef="U_xbrlishares">12629778</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">-146227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">-68606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">-46447000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">222000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">778000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">59000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-146005000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-67828000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-46388000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231"
      decimals="INF"
      id="F_000174"
      unitRef="U_xbrlishares">92656029</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">561333000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="INF"
      id="F_000176"
      unitRef="U_xbrlishares">12208731</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">24972000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">-249423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_20171231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-224616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_srtRestatementAxis_srtRevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_srtRestatementAxis_srtRevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">-140000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000184"
      unitRef="U_xbrlishares">632805</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">1168000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">1168000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="INF"
      id="F_000187"
      unitRef="U_xbrlishares">134065</adpt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">100000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <adpt:TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">767000</adpt:TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">476000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">291000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">767000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <adpt:TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">3000</adpt:TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <adpt:TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">189000</adpt:TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions>
    <adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-189000</adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions>
    <adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">-189000</adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">11146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">11146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">59000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">59000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">-46447000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">-46447000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="INF"
      id="F_000207"
      unitRef="U_xbrlishares">92790094</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">560858000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000209"
      unitRef="U_xbrlishares">12841536</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">37902000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">-107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">-295908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_20181231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">-258112000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000215"
      unitRef="U_xbrlishares">17250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">320848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">320850000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <adpt:AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">-4986000</adpt:AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts>
    <adpt:AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">-4986000</adpt:AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000221"
      unitRef="U_xbrlishares">-93039737</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">-561931000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000223"
      unitRef="U_xbrlishares">93039737</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">9000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">561922000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">561931000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <adpt:AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">2602000</adpt:AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant>
    <adpt:AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">2602000</adpt:AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant>
    <adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000229"
      unitRef="U_xbrlishares">54792</adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised>
    <adpt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">9000</adpt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <adpt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">9000</adpt:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000232"
      unitRef="U_xbrlishares">2043767</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">4413000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">4413000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000235"
      unitRef="U_xbrlishares">249643</adpt:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">109000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000237"
      unitRef="U_xbrlishares">8310</adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <adpt:TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">964000</adpt:TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions>
    <adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">-964000</adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions>
    <adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">-964000</adpt:ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions>
    <adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">13124000</adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue>
    <adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">13124000</adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">778000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">778000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">-68606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">-68606000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000247"
      unitRef="U_xbrlishares">125238142</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">935834000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">-365478000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">571039000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000253"
      unitRef="U_xbrlishares">7200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">271838000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">271839000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">93000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20201231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">93000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000260"
      unitRef="U_xbrlishares">5204254</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">21538000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">21539000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000264"
      unitRef="U_xbrlishares">4500</adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">24761000</adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue>
    <adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">24761000</adpt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">222000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">222000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">-146227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">-146227000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000271"
      unitRef="U_xbrlishares">137646896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">1253971000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">-511612000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">743266000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">-146227000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">-68606000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">-46447000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">6769000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">6093000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">4301000</us-gaap:Depreciation>
    <adpt:NoncashLeaseExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">3266000</adpt:NoncashLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">24761000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">13124000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">11149000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">1703000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">1698000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">-773000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">4463000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">1214000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">2266000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">-6000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">-71000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">-359000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">18000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">-2613000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">7817000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">-775000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">4994000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">1231000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">3046000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">1362000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">8576000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">318000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">7495000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">6149000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">2185000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <adpt:IncreaseDecreaseInDeferredRent
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">78000</adpt:IncreaseDecreaseInDeferredRent>
    <adpt:IncreaseDecreaseInDeferredRent
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">-488000</adpt:IncreaseDecreaseInDeferredRent>
    <adpt:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">-886000</adpt:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">-43389000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">266927000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">-649000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">276000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">597000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">182000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">-149683000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">205404000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">-32259000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">18803000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">11200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">6299000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">694965000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">884217000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">146503000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">596724000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">413720000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">153538000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">-117044000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">-481697000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">736000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">21748000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">4055000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">1268000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">272160000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">320850000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">321000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">4986000</us-gaap:PaymentsOfStockIssuanceCosts>
    <adpt:ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">9000</adpt:ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">-12000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">-20000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">293587000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">319916000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">1248000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">26860000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">43623000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">-30275000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">98714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001478320_20181231"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">55091000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001478320_20171231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">85366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">125574000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">98714000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001478320_20181231"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">55091000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">4679000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">773000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">832000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <adpt:LandlordFundedLeaseholdImprovements
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">2419000</adpt:LandlordFundedLeaseholdImprovements>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">36607000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <adpt:DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">36607000</adpt:DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease>
    <adpt:ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">561931000</adpt:ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering>
    <adpt:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">2602000</adpt:ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000364">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Organization&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Description of Business&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adaptive Biotechnologies Corporation (&#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#x2019;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#x2019;s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune conditions and infectious diseases.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We were incorporated in the State of Washington on September&#160;8, 2009 under the name Adaptive TCR Corporation. On December&#160;21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Initial Public Offering&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our registration statement on Form S-1 related to our initial public offering was declared effective on June 26, 2019 and our common stock began trading on the Nasdaq Global Select Market on June 27, 2019.&#160;On July 1, 2019, we completed our initial public offering in which we issued and sold 17,250,000 shares of common stock, including shares issued upon the exercise in full of the underwriters&#x2019; over-allotment option, at a public offering price of $20.00 per share. We received $315.9 million in net proceeds, after deducting underwriting discounts and commissions of $24.1 million and offering expenses of $5.0 million.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Follow-On Offering&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, we completed an underwritten public offering of our common stock in which we issued and sold 7,200,000 shares of common stock, including shares issued upon the exercise in full of the underwriters&#x2019; over-allotment option, at a public offering price of $40.00 per share. We received $271.8&#160;million in net proceeds, after deducting underwriting discounts and net offering expenses paid by us.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701"
      decimals="INF"
      id="F_000431"
      unitRef="U_xbrlishares">17250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701"
      decimals="INF"
      id="F_000432"
      unitRef="U_iso4217USD_xbrlishares">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701"
      decimals="-5"
      id="F_000433"
      unitRef="U_iso4217USD">315900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <adpt:SaleOfStockUnderwritingDiscountsAndCommission
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701"
      decimals="-5"
      id="F_000434"
      unitRef="U_iso4217USD">24100000</adpt:SaleOfStockUnderwritingDiscountsAndCommission>
    <adpt:InitialPublicOfferingExpenses
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701"
      decimals="-5"
      id="F_000435"
      unitRef="U_iso4217USD">5000000.0</adpt:InitialPublicOfferingExpenses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200701_20200731"
      decimals="INF"
      id="F_000436"
      unitRef="U_xbrlishares">7200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200731"
      decimals="INF"
      id="F_000437"
      unitRef="U_iso4217USD_xbrlishares">40.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20200701_20200731"
      decimals="-5"
      id="F_000438"
      unitRef="U_iso4217USD">271800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000365">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Significant&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;Accounting&lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;Policies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of Presentation and&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Use&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;JOBS Act Accounting Election&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective December 31, 2020, we are no longer an &#x201c;emerging growth company&#x201d; within the meaning of the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Prior to December 31, 2020, we had elected to use this extended transition period and, as a result, our financial statements may not be comparable to companies that comply with public company effective dates. We can no longer take advantage of this extended transition period.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of &lt;span&gt;$2.1&lt;/span&gt; million as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments in Marketable Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities are classified as&#160;available-for-sale, primarily consist of U.S. government debt securities, commercial paper and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#x2019; (deficit) equity in accumulated other comprehensive (loss) gain until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentrations&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of Risk&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are subject to a concentration of risk from a limited number of suppliers, or in some cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each balance sheet date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts Receivable, Net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.9%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.4%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.1%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.8%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Genentech, Inc. and Roche Group&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;* less than 10%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounts Receivable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, we had $0.9 million and $2.4 million of unbilled receivables as of December&#160;31, 2020 and 2019, respectively. The unbilled receivables are amounts that will become due for which we have an unconditional right to consideration.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a&#160;first-in,&#160;first-out&#160;basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;"&gt;
&lt;tr&gt;
&lt;td style="width:223.55pt;"/&gt;
&lt;td style="width:7.85pt;"/&gt;
&lt;td style="width:223.5pt;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years to 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years to 10 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our statements of operations in accordance with the use of the asset.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October&#160;1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our statements of operations. To date, we have not recognized any impairment of goodwill.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory and office facilities that we occupy, as well as server space. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of the new lease standard, discussed in more detail below. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory and office facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Lease Financing Arrangements&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2019, due to our significant involvement during the construction process of a leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance. Prior to our adoption of the new lease standard, the cost of the related building was recorded in property and equipment, net and the offsetting lease financing obligation was recorded as a long-term financing obligation on our balance sheet. As of December 31, 2019, $36.6 million of building costs was recorded in property and equipment, net.  &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level 1: Quoted &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Level 2: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our financial instruments consist of Level&#160;1 and Level&#160;2 assets and has included Level&#160;3 liabilities in the past. In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level&#160;3 within the valuation hierarchy. The carrying amounts of certain financial instruments approximate fair value due to their short&#160;maturities.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December&#160;31, 2020 or 2019.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock Warrant Liability&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series&#160;C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0&#160;million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the conversion, the fair value of this warrant was classified as a&#160;non-current&#160;liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders&#x2019; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our statements of operations. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize revenue in accordance with ASC Topic 606 (&#x201c;ASC 606&#x201d;), &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1)&#160;identify the contract or contracts; (2)&#160;determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3)&#160;measure the transaction price, including the constraint on variable consideration; (4)&#160;allocate the transaction price to the performance obligations based on estimated selling prices; and (5)&#160;recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Overview&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our revenue is generated from immunosequencing (&#x201c;sequencing&#x201d;) products and services (&#x201c;sequencing revenue&#x201d;) and from regulatory or development support services leveraging our immune medicine platform (&#x201c;development revenue&#x201d;). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sequencing Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sequencing revenue reflects the amounts generated from providing sequencing services and testing through our clonoSEQ and immunoSEQ products and services to our clinical and research customers, respectively. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For clinical customers, we derive revenues from providing our clonoSEQ test report to ordering physicians, and we bill and receive payments from medical institutions and commercial and government third-party payors. In these transactions, we have identified one performance obligation: the delivery of a clonoSEQ report. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient&#x2019;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test.&#160;Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#x2019;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized as we deliver the remaining tests in a patient&#x2019;s treatment cycle or when it becomes remote that a patient will receive additional testing and we have not delivered our estimate of total tests.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For research customers, contracts typically include an amount billed in advance of services (&#x201c;upfront&#x201d;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Development&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers&#x2019; initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements may include single or multiple performance obligations, depending on the contract. For certain contracts, we may perform services to support the biopharmaceutical customers&#x2019; regulatory submissions as part of their registrational trials. These services include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers&#x2019; control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Balances&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or&#160;non-current&#160;based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#x2019;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and&#160;non-employees.&#160;It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Advertising &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advertising costs are expensed as incurred. Advertising expenses were $14.5 million, $6.6 million and $3.5 million for the year ended December 31, 2020, 2019 and 2018, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cost of Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of revenue includes the cost of materials, personnel-related expenses (comprised of salaries, benefits and share-based compensation), shipping and handling, equipment and allocated facility costs associated with processing samples and professional support for our sequencing revenue. Allocated facility costs include depreciation of laboratory equipment, allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses are comprised of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. &lt;/span&gt;Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Costs to support our Genentech Agreement are a component of our research and development activities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Sales and Marketing Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are measured at the balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share Attributable to Common Shareholders&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We calculate basic net loss per share attributable to common shareholders by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to common shareholders in conformity with the&#160;two-class&#160;method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an&#160;as-if&#160;converted basis. Under the&#160;two-class&#160;method, basic net loss per share attributable to common shareholders is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to common shareholders was not allocated to the convertible preferred stock under the&#160;two-class&#160;method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect was anti-dilutive.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have determined that our chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM reviews financial information presented on a regular basis at the entity level. Resource allocation decisions are made by the CODM based on the results at the entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning for levels or components below the entity. As such, we have concluded that we operate as one segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3,&#160;Revenue.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Ad&lt;span style="letter-spacing:-0.05pt;"&gt;opted &lt;/span&gt;Accounting&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2016-02, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt; (Topic 842) (&#x201c;ASC 842&#x201d;), intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheets and disclosing key information about leasing arrangements. We adopted the guidance effective January 1, 2020 using the optional transition method described in ASU 2018-11&lt;span style="font-style:italic;"&gt;, Leases &lt;/span&gt;(Topic 842) &lt;span style="font-style:italic;"&gt;Targeted Improvements&lt;/span&gt;. Under the optional transition method, we recognized a cumulative-effect adjustment in the period of adoption. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, &lt;span style="font-style:italic;"&gt;Leases &lt;/span&gt;(&#x201c;ASC 840&#x201d;). &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In adopting the new standard, we utilized certain practical expedients available. These practical expedients include waiving reassessment of (1) whether any expired or existing contracts are or contain leases; (2) lease classification of expired or existing leases; and (3) initial direct costs for existing leases. We also elected to use hindsight in determining the lease term and in assessing impairment of our ROU assets. Furthermore, we have made a policy decision regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The standard had a material impact on our balance sheet as of December 31, 2020, but did not have a material impact on our statements of operations or statements of cash flows. The most significant impact was the recognition of $33.0 million and $39.7 million of operating lease ROU assets and liabilities, respectively, and the derecognition of a $36.6 million asset and corresponding liability previously recorded pursuant to build-to-suit lease accounting guidance under ASC 840, which resulted in an increase to retained earnings of $0.1 million. The operating lease ROU assets and liabilities recorded at adoption included the derecognition of $7.3 million of deferred rent recognized as of December 31, 2019, as well as a $0.5 million reclassification of tenant incentive receivables previously recognized in the prepaid expenses and other current assets line item on our balance sheet. See Note 10, Leases, for additional information regarding leases.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses &lt;/span&gt;(Topic 326):&lt;span style="font-style:italic;"&gt; Measurement of Credit Losses on Financial Instruments&lt;/span&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The expected credit losses are recorded through an allowance account that is deducted from the amortized cost basis of the financial asset, and the net carrying value of the financial asset is presented on the balance sheet. The guidance also amends the previous other-than-temporary impairment model for available-for-sale debt securities by requiring the recognition of impairments relating to credit losses through an allowance account, limited to the difference between a security&#x2019;s amortized cost basis and its fair value. Furthermore, the standard update removes the distinction between whether an impairment is temporary or other-than temporary. We adopted the guidance effective January 1, 2020. Given the short-term nature of our accounts receivable, the adoption as it relates to trade receivables did not have a significant impact on our financial statements. Furthermore, impairment of available-for-sale debt securities as of the adoption date was determined to be due to factors other than credit loss; therefore, a credit allowance was not recognized. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-15, &lt;span style="font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other: Internal-Use Software&lt;/span&gt; (Subtopic 350-40) to provide additional guidance on the accounting for costs of implementation activities performed in a cloud computing arrangement. We adopted this guidance effective January 1, 2020 on a prospective basis, and the adoption did not have any impact on our financial statements.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No.&#160;2019-12,&#160;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt; (Topic 740): &lt;span style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;, which eliminates certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. Among other things, this guidance also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This guidance is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied prospectively, except for certain amendments. We early adopted the guidance on January 1, 2020 and the adoption did not have a material impact on our financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <adpt:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000381">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of Presentation and&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Use&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates.&lt;/p&gt;</adpt:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock>
    <adpt:JOBSActAccountingElectionPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000382">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;JOBS Act Accounting Election&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective December 31, 2020, we are no longer an &#x201c;emerging growth company&#x201d; within the meaning of the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Prior to December 31, 2020, we had elected to use this extended transition period and, as a result, our financial statements may not be comparable to companies that comply with public company effective dates. We can no longer take advantage of this extended transition period.&lt;/p&gt;
</adpt:JOBSActAccountingElectionPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000383">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0001478320_20200101_20201231" id="F_000384">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of &lt;span&gt;$2.1&lt;/span&gt; million as of December 31, 2020 and 2019.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-5"
      id="F_000439"
      unitRef="U_iso4217USD">2100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-5"
      id="F_000440"
      unitRef="U_iso4217USD">2100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001478320_20200101_20201231" id="F_000385">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities are classified as&#160;available-for-sale, primarily consist of U.S. government debt securities, commercial paper and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#x2019; (deficit) equity in accumulated other comprehensive (loss) gain until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001478320_20200101_20201231" id="F_000386">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentrations&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of Risk&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are subject to a concentration of risk from a limited number of suppliers, or in some cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each balance sheet date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts Receivable, Net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.9%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.4%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.1%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.8%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Genentech, Inc. and Roche Group&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;* less than 10%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000406">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts Receivable, Net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.9%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.4%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.1%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.8%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Genentech, Inc. and Roche Group&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;* less than 10%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="3"
      id="F_000441"
      unitRef="U_xbrlipure">0.139</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231"
      decimals="3"
      id="F_000442"
      unitRef="U_xbrlipure">0.184</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="3"
      id="F_000443"
      unitRef="U_xbrlipure">0.191</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="3"
      id="F_000444"
      unitRef="U_xbrlipure">0.418</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231"
      decimals="3"
      id="F_000445"
      unitRef="U_xbrlipure">0.135</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerBMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="3"
      id="F_000446"
      unitRef="U_xbrlipure">0.122</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptCustomerCMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20180101_20181231"
      decimals="3"
      id="F_000447"
      unitRef="U_xbrlipure">0.154</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncAndRocheGroupMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="3"
      id="F_000448"
      unitRef="U_xbrlipure">0.558</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncAndRocheGroupMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231"
      decimals="3"
      id="F_000449"
      unitRef="U_xbrlipure">0.421</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000387">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Accounts Receivable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, we had $0.9 million and $2.4 million of unbilled receivables as of December&#160;31, 2020 and 2019, respectively. The unbilled receivables are amounts that will become due for which we have an unconditional right to consideration.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-5"
      id="F_000450"
      unitRef="U_iso4217USD">900000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-5"
      id="F_000451"
      unitRef="U_iso4217USD">2400000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000388">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a&#160;first-in,&#160;first-out&#160;basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.&lt;/p&gt;
</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000389">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;"&gt;
&lt;tr&gt;
&lt;td style="width:223.55pt;"/&gt;
&lt;td style="width:7.85pt;"/&gt;
&lt;td style="width:223.5pt;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years to 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years to 10 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our statements of operations in accordance with the use of the asset.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000407">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;"&gt;
&lt;tr&gt;
&lt;td style="width:223.55pt;"/&gt;
&lt;td style="width:7.85pt;"/&gt;
&lt;td style="width:223.5pt;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years to 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years to 10 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231"
      id="F_000452">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231"
      id="F_000453">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231"
      id="F_000454">Shorter of estimated useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerEquipmentAndSoftwareMember_20200101_20201231"
      id="F_000455">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20200101_20201231"
      id="F_000456">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20200101_20201231"
      id="F_000457">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="C_0001478320_20200101_20201231" id="F_000390">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October&#160;1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our statements of operations. To date, we have not recognized any impairment of goodwill.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000458"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="C_0001478320_20200101_20201231" id="F_000391">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000459"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000392">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory and office facilities that we occupy, as well as server space. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of the new lease standard, discussed in more detail below. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory and office facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Lease Financing Arrangements&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2019, due to our significant involvement during the construction process of a leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance. Prior to our adoption of the new lease standard, the cost of the related building was recorded in property and equipment, net and the offsetting lease financing obligation was recorded as a long-term financing obligation on our balance sheet. As of December 31, 2019, $36.6 million of building costs was recorded in property and equipment, net.  &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_20191231"
      decimals="-5"
      id="F_000460"
      unitRef="U_iso4217USD">36600000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001478320_20200101_20201231" id="F_000393">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level 1: Quoted &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Level 2: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our financial instruments consist of Level&#160;1 and Level&#160;2 assets and has included Level&#160;3 liabilities in the past. In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level&#160;3 within the valuation hierarchy. The carrying amounts of certain financial instruments approximate fair value due to their short&#160;maturities.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December&#160;31, 2020 or 2019.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <adpt:StockholdersEquityConvertiblePreferredStockPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000394">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock Warrant Liability&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series&#160;C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0&#160;million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the conversion, the fair value of this warrant was classified as a&#160;non-current&#160;liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders&#x2019; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our statements of operations. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.&lt;/p&gt;</adpt:StockholdersEquityConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231"
      decimals="INF"
      id="F_000461"
      unitRef="U_xbrlishares">56875</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231"
      decimals="2"
      id="F_000462"
      unitRef="U_iso4217USD_xbrlishares">2.64</adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231"
      decimals="-5"
      id="F_000463"
      unitRef="U_iso4217USD">5000000.0</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20190101_20191231"
      decimals="-5"
      id="F_000464"
      unitRef="U_iso4217USD">2300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20201231"
      decimals="-5"
      id="F_000465"
      unitRef="U_iso4217USD">2600000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000395">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize revenue in accordance with ASC Topic 606 (&#x201c;ASC 606&#x201d;), &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1)&#160;identify the contract or contracts; (2)&#160;determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3)&#160;measure the transaction price, including the constraint on variable consideration; (4)&#160;allocate the transaction price to the performance obligations based on estimated selling prices; and (5)&#160;recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Overview&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our revenue is generated from immunosequencing (&#x201c;sequencing&#x201d;) products and services (&#x201c;sequencing revenue&#x201d;) and from regulatory or development support services leveraging our immune medicine platform (&#x201c;development revenue&#x201d;). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sequencing Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sequencing revenue reflects the amounts generated from providing sequencing services and testing through our clonoSEQ and immunoSEQ products and services to our clinical and research customers, respectively. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For clinical customers, we derive revenues from providing our clonoSEQ test report to ordering physicians, and we bill and receive payments from medical institutions and commercial and government third-party payors. In these transactions, we have identified one performance obligation: the delivery of a clonoSEQ report. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient&#x2019;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test.&#160;Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#x2019;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized as we deliver the remaining tests in a patient&#x2019;s treatment cycle or when it becomes remote that a patient will receive additional testing and we have not delivered our estimate of total tests.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For research customers, contracts typically include an amount billed in advance of services (&#x201c;upfront&#x201d;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Development&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers&#x2019; initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements may include single or multiple performance obligations, depending on the contract. For certain contracts, we may perform services to support the biopharmaceutical customers&#x2019; regulatory submissions as part of their registrational trials. These services include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers&#x2019; control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <adpt:NumberOfRevenuePerformanceObligation
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231"
      decimals="INF"
      id="F_000466"
      unitRef="U_adptPerformance_Obligation">2</adpt:NumberOfRevenuePerformanceObligation>
    <adpt:ContractBalancesPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000396">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Balances&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or&#160;non-current&#160;based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#x2019;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.&lt;/p&gt;</adpt:ContractBalancesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001478320_20200101_20201231" id="F_000397">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Share-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and&#160;non-employees.&#160;It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000398">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Advertising &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advertising costs are expensed as incurred. Advertising expenses were $14.5 million, $6.6 million and $3.5 million for the year ended December 31, 2020, 2019 and 2018, respectively.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000467"
      unitRef="U_iso4217USD">14500000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_0001478320_20190101_20191231"
      decimals="-5"
      id="F_000468"
      unitRef="U_iso4217USD">6600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_0001478320_20180101_20181231"
      decimals="-5"
      id="F_000469"
      unitRef="U_iso4217USD">3500000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000399">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cost of Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of revenue includes the cost of materials, personnel-related expenses (comprised of salaries, benefits and share-based compensation), shipping and handling, equipment and allocated facility costs associated with processing samples and professional support for our sequencing revenue. Allocated facility costs include depreciation of laboratory equipment, allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001478320_20200101_20201231" id="F_000400">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses are comprised of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. &lt;/span&gt;Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Costs to support our Genentech Agreement are a component of our research and development activities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <adpt:SalesAndMarketingExpensePolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000401">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Sales and Marketing Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.&lt;/p&gt;
</adpt:SalesAndMarketingExpensePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000402">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets and liabilities are measured at the balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000403">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share Attributable to Common Shareholders&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We calculate basic net loss per share attributable to common shareholders by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to common shareholders in conformity with the&#160;two-class&#160;method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an&#160;as-if&#160;converted basis. Under the&#160;two-class&#160;method, basic net loss per share attributable to common shareholders is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to common shareholders was not allocated to the convertible preferred stock under the&#160;two-class&#160;method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect was anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000404">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have determined that our chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM reviews financial information presented on a regular basis at the entity level. Resource allocation decisions are made by the CODM based on the results at the entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning for levels or components below the entity. As such, we have concluded that we operate as one segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3,&#160;Revenue.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000470"
      unitRef="U_adptSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000405">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Ad&lt;span style="letter-spacing:-0.05pt;"&gt;opted &lt;/span&gt;Accounting&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2016-02, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt; (Topic 842) (&#x201c;ASC 842&#x201d;), intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheets and disclosing key information about leasing arrangements. We adopted the guidance effective January 1, 2020 using the optional transition method described in ASU 2018-11&lt;span style="font-style:italic;"&gt;, Leases &lt;/span&gt;(Topic 842) &lt;span style="font-style:italic;"&gt;Targeted Improvements&lt;/span&gt;. Under the optional transition method, we recognized a cumulative-effect adjustment in the period of adoption. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, &lt;span style="font-style:italic;"&gt;Leases &lt;/span&gt;(&#x201c;ASC 840&#x201d;). &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In adopting the new standard, we utilized certain practical expedients available. These practical expedients include waiving reassessment of (1) whether any expired or existing contracts are or contain leases; (2) lease classification of expired or existing leases; and (3) initial direct costs for existing leases. We also elected to use hindsight in determining the lease term and in assessing impairment of our ROU assets. Furthermore, we have made a policy decision regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The standard had a material impact on our balance sheet as of December 31, 2020, but did not have a material impact on our statements of operations or statements of cash flows. The most significant impact was the recognition of $33.0 million and $39.7 million of operating lease ROU assets and liabilities, respectively, and the derecognition of a $36.6 million asset and corresponding liability previously recorded pursuant to build-to-suit lease accounting guidance under ASC 840, which resulted in an increase to retained earnings of $0.1 million. The operating lease ROU assets and liabilities recorded at adoption included the derecognition of $7.3 million of deferred rent recognized as of December 31, 2019, as well as a $0.5 million reclassification of tenant incentive receivables previously recognized in the prepaid expenses and other current assets line item on our balance sheet. See Note 10, Leases, for additional information regarding leases.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses &lt;/span&gt;(Topic 326):&lt;span style="font-style:italic;"&gt; Measurement of Credit Losses on Financial Instruments&lt;/span&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The expected credit losses are recorded through an allowance account that is deducted from the amortized cost basis of the financial asset, and the net carrying value of the financial asset is presented on the balance sheet. The guidance also amends the previous other-than-temporary impairment model for available-for-sale debt securities by requiring the recognition of impairments relating to credit losses through an allowance account, limited to the difference between a security&#x2019;s amortized cost basis and its fair value. Furthermore, the standard update removes the distinction between whether an impairment is temporary or other-than temporary. We adopted the guidance effective January 1, 2020. Given the short-term nature of our accounts receivable, the adoption as it relates to trade receivables did not have a significant impact on our financial statements. Furthermore, impairment of available-for-sale debt securities as of the adoption date was determined to be due to factors other than credit loss; therefore, a credit allowance was not recognized. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-15, &lt;span style="font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other: Internal-Use Software&lt;/span&gt; (Subtopic 350-40) to provide additional guidance on the accounting for costs of implementation activities performed in a cloud computing arrangement. We adopted this guidance effective January 1, 2020 on a prospective basis, and the adoption did not have any impact on our financial statements.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No.&#160;2019-12,&#160;&lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt; (Topic 740): &lt;span style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;, which eliminates certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. Among other things, this guidance also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This guidance is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied prospectively, except for certain amendments. We early adopted the guidance on January 1, 2020 and the adoption did not have a material impact on our financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      id="F_000471">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      decimals="-5"
      id="F_000475"
      unitRef="U_iso4217USD">33000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      decimals="-5"
      id="F_000476"
      unitRef="U_iso4217USD">39700000</us-gaap:OperatingLeaseLiability>
    <adpt:DerecognitionOfBuildToSuitLeaseAsset
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      decimals="-5"
      id="F_000477"
      unitRef="U_iso4217USD">36600000</adpt:DerecognitionOfBuildToSuitLeaseAsset>
    <adpt:DerecognitionOfBuildToSuitLiabilities
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      decimals="-5"
      id="F_000478"
      unitRef="U_iso4217USD">36600000</adpt:DerecognitionOfBuildToSuitLiabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      decimals="-5"
      id="F_000479"
      unitRef="U_iso4217USD">100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <adpt:DerecognitionOfDeferredRent
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      decimals="-5"
      id="F_000480"
      unitRef="U_iso4217USD">7300000</adpt:DerecognitionOfDeferredRent>
    <adpt:ReclassificationOfTenantIncentiveReceivables
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      decimals="-5"
      id="F_000481"
      unitRef="U_iso4217USD">500000</adpt:ReclassificationOfTenantIncentiveReceivables>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231"
      id="F_000482">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000486">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000490">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000366">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We disaggregate our revenue from contracts with customers by type of service, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sequencing revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,439&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development support&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,443&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Regulatory milestones&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,071&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;font-weight:bold;font-style:italic;;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Translational Development&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December&#160;2015, we entered into a translational development agreement with a biopharmaceutical customer for access to certain of our oncology immunosequencing research datasets, including full-time employee support, to accelerate the customer&#x2019;s preclinical, nonclinical and clinical trial testing. Under the initial terms of the agreement, we could have been entitled to up to $40.0&#160;million over a period of four years, which did not include any separately negotiated research sequencing contracts. If the biopharmaceutical customer terminated the agreement prior to the end of the initial four-year research term for any reason other than a material uncured breach by us, then the biopharmaceutical partner agreed to pay us $0.8&#160;million. In May 2019, the agreement was subsequently amended to reduce the services provided, which in turn reduced the fourth year of eligible payments to $2.3&#160;million. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We identified one performance obligation under this agreement, as the services were determined to be highly interrelated. We determined that any separately negotiated sequencing contracts are not performance obligations under the contract, as the contract did not contain any material rights related to such sequencing contracts. For the identified performance obligation, we assessed the work to be performed over the duration of the contract and determined that it was a consistent level of support throughout the period, and therefore, revenue was recognized on a straight-line basis over the contract term. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized from this translational development agreement, excluding separately negotiated research sequencing contracts, was $2.3 million and $9.3 million during the year ended December 31, 2019 and 2018, respectively. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;MRD Development&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have entered into agreements with biopharmaceutical customers to further develop and commercialize our MRD product and the biopharmaceutical customers&#x2019; therapeutics. Under each of the agreements, we received or will receive non-refundable upfront payments and could receive substantial additional payments upon reaching certain progress milestones or achievement of certain regulatory milestones pertaining to the customers&#x2019; therapeutics and our MRD product. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the contracts, we identify performance obligations, which may include: (1)&#160;obligations to provide services supporting the customer&#x2019;s regulatory submission activities as they relate to our MRD product; and (2)&#160;sequencing services related to customer-provided samples for their regulatory submissions. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated immunosequencing services. At contract inception, we fully constrain any consideration related to the regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#x2019; own submission decision-making. We recognize revenue relating to the sequencing services as sequencing revenue over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered and when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method based on estimates of effort completed using a cost-based model. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We earned $2.5 million, $2.0 million and $10.0 million during the year ended December 31, 2020, 2019 and 2018, respectively, upon the achievement of certain regulatory milestones by us and our respective customers&#x2019; therapeutics. All $2.5 million, $2.0 million and $10.0 million was recognized as revenue within the respective periods, as we determined these amounts were consistent with our estimated standalone selling price and the respective performance obligations were complete. We recognized $3.4&#160;million, $3.7&#160;million and $12.8 million in development revenue related to these contracts, inclusive of the milestones, during the year ended December 31, 2020, 2019 and 2018, respectively.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, in future periods we could receive up to an additional $313.5 million in milestone payments if certain regulatory approvals are obtained by our customers&#x2019; therapeutics in connection with MRD data generated from our MRD product.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Genentech&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Collaboration Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (&#x201c;Genentech Agreement&#x201d;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $300.0 million in February 2019 and may be eligible to receive more than $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones and up to $1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-family:Times New Roman;"&gt;Shared Products. The shared products will use &#x201c;off-the-shelf&#x201d; TCRs identified against cancer antigens shared among patients (&#x201c;Shared Products&#x201d;). &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-family:Times New Roman;"&gt;Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#x201c;Personalized Product&#x201d;). &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, &lt;span style="font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt; (&#x201c;ASC 808&#x201d;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#x2019;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC 606 to account for the activities related to the Genentech Agreement.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In applying ASC&#160;606, we identified the following performance obligations at the inception of the agreement: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;License to existing shared antigen data packages. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Research and development services for shared product development, including expansion of shared antigen data packages. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Research and development services for private product development. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:7.87%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:2.27%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Obligations to participate on various joint research, development and project committees. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#x2019;s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other, as opposed to both. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We determined the initial transaction price shall be made up of only the $300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of December 31, 2020. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur. &lt;/p&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Product and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately seven to eight years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Product and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognized revenue of $52.8 million and $35.1 million during the year ended December 31, 2020 and 2019, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000408">The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sequencing revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,439&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,978&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development support&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,443&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Regulatory milestones&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,071&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,663&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;font-weight:bold;font-style:italic;;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">41439000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">43519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">32978000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">54443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">39552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">12685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20200101_20201231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20190101_20191231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueRegulatoryMilestonesMember_20180101_20181231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">56943000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">41552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">22685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">98382000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">85071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">55663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231"
      decimals="INF"
      id="F_000509"
      unitRef="U_iso4217USD">40000000.0</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:TermOfAgreement
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151201_20151231"
      id="F_000510">P4Y</adpt:TermOfAgreement>
    <adpt:AgreementTerminationAmountReceivable
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231"
      decimals="-5"
      id="F_000511"
      unitRef="U_iso4217USD">800000</adpt:AgreementTerminationAmountReceivable>
    <adpt:EligiblePaymentsReceivable
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151231"
      decimals="-5"
      id="F_000512"
      unitRef="U_iso4217USD">2300000</adpt:EligiblePaymentsReceivable>
    <adpt:RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20190101_20191231"
      decimals="-5"
      id="F_000513"
      unitRef="U_iso4217USD">2300000</adpt:RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts>
    <adpt:RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20180101_20181231"
      decimals="-5"
      id="F_000514"
      unitRef="U_iso4217USD">9300000</adpt:RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts>
    <adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000515"
      unitRef="U_iso4217USD">2500000</adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized>
    <adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20190101_20191231"
      decimals="-5"
      id="F_000516"
      unitRef="U_iso4217USD">2000000.0</adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized>
    <adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20180101_20181231"
      decimals="-5"
      id="F_000517"
      unitRef="U_iso4217USD">10000000.0</adpt:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000518"
      unitRef="U_iso4217USD">3400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20190101_20191231"
      decimals="-5"
      id="F_000519"
      unitRef="U_iso4217USD">3700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20180101_20181231"
      decimals="-5"
      id="F_000520"
      unitRef="U_iso4217USD">12800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <adpt:AdditionalMilestonePayment
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptMRDDevelopmentAgreementsMember_20201231"
      decimals="INF"
      id="F_000521"
      unitRef="U_iso4217USD">313500000</adpt:AdditionalMilestonePayment>
    <adpt:NonRefundableUpfrontPaymentsReceived
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20190201_20190228"
      decimals="-5"
      id="F_000522"
      unitRef="U_iso4217USD">300000000.0</adpt:NonRefundableUpfrontPaymentsReceived>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231"
      decimals="INF"
      id="F_000523"
      unitRef="U_iso4217USD">1800000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231"
      decimals="INF"
      id="F_000524"
      unitRef="U_iso4217USD">75000000.0</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231"
      decimals="INF"
      id="F_000525"
      unitRef="U_iso4217USD">300000000.0</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_adptCommercialMilestonesMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20201231"
      decimals="INF"
      id="F_000526"
      unitRef="U_iso4217USD">1430000000.0</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:NonRefundableUpfrontPaymentsReceived
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000527"
      unitRef="U_iso4217USD">300000000.0</adpt:NonRefundableUpfrontPaymentsReceived>
    <adpt:RevenueRecognitionExpectedPeriod
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231"
      id="F_000528">P7Y</adpt:RevenueRecognitionExpectedPeriod>
    <adpt:RevenueRecognitionExpectedPeriod
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231"
      id="F_000529">P8Y</adpt:RevenueRecognitionExpectedPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000530"
      unitRef="U_iso4217USD">52800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptGenentechCollaborationAgreementMember_20190101_20191231"
      decimals="-5"
      id="F_000531"
      unitRef="U_iso4217USD">35100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000367">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Value&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Measurements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables set forth the fair value of financial assets as of December 31, 2020 and 2019 that were measured at fair value on a recurring basis (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;671,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;671,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;683,358&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;786,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;377,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;377,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;585,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674,408&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level&#160;2 securities consist of U.S. government debt securities, commercial paper and corporate bonds, and are valued based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.&lt;/p&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000409">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables set forth the fair value of financial assets as of December 31, 2020 and 2019 that were measured at fair value on a recurring basis (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;671,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;671,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;683,358&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;786,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;377,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;377,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;585,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;674,408&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000532"
      unitRef="U_iso4217USD">103283000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">103283000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">671777000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">671777000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">11581000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">11581000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">103283000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">683358000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">786641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">88683000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">88683000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">121867000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000544"
      unitRef="U_iso4217USD">121867000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">377243000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">377243000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">86615000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000548"
      unitRef="U_iso4217USD">86615000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000549"
      unitRef="U_iso4217USD">88683000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000550"
      unitRef="U_iso4217USD">585725000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000551"
      unitRef="U_iso4217USD">674408000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000368">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Investments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale investments consisted of the following as of December 31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;552,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;553,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,497&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total long-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;285,963&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;286,356&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;479,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;480,290&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total long-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All the commercial paper, U.S. government debt securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective balance sheet date.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued interest receivables are excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivables of $2.5 million and $2.2 million were presented separately within the prepaid expenses and other current assets line item on our balance sheet as of December 31, 2020 and 2019, respectively. We have made an accounting policy election to not measure an allowance for credit losses for accrued interest receivables.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position and the length of time that individual securities have been in a continuous loss position as of December&#160;31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less Than 12 Months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12 Months Or Greater&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;177,554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179,066&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2020 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.&lt;/p&gt;
</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000410">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale investments consisted of the following as of December 31, 2020 and 2019 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;552,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;553,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,497&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564,036&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total long-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;285,963&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;286,356&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;479,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;480,290&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total long-term marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">552539000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000557"
      unitRef="U_iso4217USD">723000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000567"
      unitRef="U_iso4217USD">553252000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">11497000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="-3"
      id="F_000558"
      unitRef="U_iso4217USD">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="-3"
      id="F_000563"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="-3"
      id="F_000568"
      unitRef="U_iso4217USD">11581000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">564036000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">809000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231"
      decimals="-3"
      id="F_000564"
      unitRef="U_iso4217USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231"
      decimals="-3"
      id="F_000569"
      unitRef="U_iso4217USD">564833000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000555"
      unitRef="U_iso4217USD">118429000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000565"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000570"
      unitRef="U_iso4217USD">118525000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231"
      decimals="-3"
      id="F_000556"
      unitRef="U_iso4217USD">118429000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231"
      decimals="-3"
      id="F_000561"
      unitRef="U_iso4217USD">98000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231"
      decimals="-3"
      id="F_000566"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20201231"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">118525000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000572"
      unitRef="U_iso4217USD">121866000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000590"
      unitRef="U_iso4217USD">121866000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000573"
      unitRef="U_iso4217USD">285963000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000579"
      unitRef="U_iso4217USD">394000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000591"
      unitRef="U_iso4217USD">286356000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="-3"
      id="F_000574"
      unitRef="U_iso4217USD">71962000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="-3"
      id="F_000580"
      unitRef="U_iso4217USD">109000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="-3"
      id="F_000592"
      unitRef="U_iso4217USD">72068000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231"
      decimals="-3"
      id="F_000575"
      unitRef="U_iso4217USD">479791000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231"
      decimals="-3"
      id="F_000581"
      unitRef="U_iso4217USD">503000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20191231"
      decimals="-3"
      id="F_000593"
      unitRef="U_iso4217USD">480290000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000576"
      unitRef="U_iso4217USD">90750000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000582"
      unitRef="U_iso4217USD">146000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000594"
      unitRef="U_iso4217USD">90887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="-3"
      id="F_000577"
      unitRef="U_iso4217USD">14513000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20191231"
      decimals="-3"
      id="F_000595"
      unitRef="U_iso4217USD">14548000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231"
      decimals="-3"
      id="F_000578"
      unitRef="U_iso4217USD">105263000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231"
      decimals="-3"
      id="F_000584"
      unitRef="U_iso4217USD">181000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231"
      decimals="-3"
      id="F_000589"
      unitRef="U_iso4217USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_20191231"
      decimals="-3"
      id="F_000596"
      unitRef="U_iso4217USD">105435000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20201231"
      decimals="-5"
      id="F_000597"
      unitRef="U_iso4217USD">2500000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20191231"
      decimals="-5"
      id="F_000598"
      unitRef="U_iso4217USD">2200000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000411">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position and the length of time that individual securities have been in a continuous loss position as of December&#160;31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less Than 12 Months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12 Months Or Greater&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;177,554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179,066&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000599"
      unitRef="U_iso4217USD">177554000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000602"
      unitRef="U_iso4217USD">12000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="-3"
      id="F_000600"
      unitRef="U_iso4217USD">1512000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0001478320_us-gaapInvestmentTypeAxis_us-gaapCorporateBondSecuritiesMember_20201231"
      decimals="-3"
      id="F_000603"
      unitRef="U_iso4217USD">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000601"
      unitRef="U_iso4217USD">179066000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000604"
      unitRef="U_iso4217USD">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000369">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net as of December 31, 2020 and 2019 consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,767&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,717&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,945&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,716&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Build-to-suit asset cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,607&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, at cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense was $6.8 million, $6.1&#160;million and $4.3 million for the year ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000412">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net as of December 31, 2020 and 2019 consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,767&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,717&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,568&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,185&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,945&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,716&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Build-to-suit asset cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,607&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, at cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20201231"
      decimals="-3"
      id="F_000605"
      unitRef="U_iso4217USD">27767000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20191231"
      decimals="-3"
      id="F_000606"
      unitRef="U_iso4217USD">20773000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231"
      decimals="-3"
      id="F_000607"
      unitRef="U_iso4217USD">3600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231"
      decimals="-3"
      id="F_000608"
      unitRef="U_iso4217USD">2450000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20201231"
      decimals="-3"
      id="F_000609"
      unitRef="U_iso4217USD">2717000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptFurnitureAndOfficeEquipmentMember_20191231"
      decimals="-3"
      id="F_000610"
      unitRef="U_iso4217USD">1568000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerSoftwareMember_20201231"
      decimals="-3"
      id="F_000611"
      unitRef="U_iso4217USD">860000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptComputerSoftwareMember_20191231"
      decimals="-3"
      id="F_000612"
      unitRef="U_iso4217USD">505000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000613"
      unitRef="U_iso4217USD">7185000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231"
      decimals="-3"
      id="F_000614"
      unitRef="U_iso4217USD">1852000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000615"
      unitRef="U_iso4217USD">21945000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="-3"
      id="F_000616"
      unitRef="U_iso4217USD">14716000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptBuildToSuitAssetCostMember_20191231"
      decimals="-3"
      id="F_000617"
      unitRef="U_iso4217USD">36607000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000618"
      unitRef="U_iso4217USD">64074000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000619"
      unitRef="U_iso4217USD">78471000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000620"
      unitRef="U_iso4217USD">24382000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000621"
      unitRef="U_iso4217USD">18116000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000622"
      unitRef="U_iso4217USD">39692000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000623"
      unitRef="U_iso4217USD">60355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000624"
      unitRef="U_iso4217USD">6800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001478320_20190101_20191231"
      decimals="-5"
      id="F_000625"
      unitRef="U_iso4217USD">6100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001478320_20180101_20181231"
      decimals="-5"
      id="F_000626"
      unitRef="U_iso4217USD">4300000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000370">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Intangible Assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no changes in the carrying amount of goodwill since its recognition in 2015. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets subject to amortization as of December 31, 2020 and 2019 consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquired developed technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,028&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased intellectual property&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,225&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquired developed technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,301&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased intellectual property&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,397&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,928&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The developed technology was acquired in connection with our acquisition of Sequenta in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next 6.0 years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, expected future amortization expense for intangible assets was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,726&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future amortization expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,225&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="C_0001478320_20151231"
      decimals="INF"
      id="F_000627"
      unitRef="U_iso4217USD">0</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000413">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets subject to amortization as of December 31, 2020 and 2019 consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquired developed technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,028&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased intellectual property&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,225&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquired developed technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,301&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchased intellectual property&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,397&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,928&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231"
      decimals="-3"
      id="F_000628"
      unitRef="U_iso4217USD">20000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231"
      decimals="-3"
      id="F_000631"
      unitRef="U_iso4217USD">9972000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231"
      decimals="-3"
      id="F_000634"
      unitRef="U_iso4217USD">10028000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20201231"
      decimals="-3"
      id="F_000629"
      unitRef="U_iso4217USD">325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20201231"
      decimals="-3"
      id="F_000632"
      unitRef="U_iso4217USD">128000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20201231"
      decimals="-3"
      id="F_000635"
      unitRef="U_iso4217USD">197000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000630"
      unitRef="U_iso4217USD">20325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000633"
      unitRef="U_iso4217USD">10100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000636"
      unitRef="U_iso4217USD">10225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20191231"
      decimals="-3"
      id="F_000637"
      unitRef="U_iso4217USD">20000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20191231"
      decimals="-3"
      id="F_000640"
      unitRef="U_iso4217USD">8301000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20191231"
      decimals="-3"
      id="F_000643"
      unitRef="U_iso4217USD">11699000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20191231"
      decimals="-3"
      id="F_000638"
      unitRef="U_iso4217USD">325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20191231"
      decimals="-3"
      id="F_000641"
      unitRef="U_iso4217USD">96000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20191231"
      decimals="-3"
      id="F_000644"
      unitRef="U_iso4217USD">229000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000639"
      unitRef="U_iso4217USD">20325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000642"
      unitRef="U_iso4217USD">8397000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000645"
      unitRef="U_iso4217USD">11928000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001478320_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20200101_20201231"
      id="F_000646">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000414">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, expected future amortization expense for intangible assets was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,726&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future amortization expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,225&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000647"
      unitRef="U_iso4217USD">1699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000648"
      unitRef="U_iso4217USD">1699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000649"
      unitRef="U_iso4217USD">1699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000650"
      unitRef="U_iso4217USD">1703000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000651"
      unitRef="U_iso4217USD">1699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000652"
      unitRef="U_iso4217USD">1726000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000653"
      unitRef="U_iso4217USD">10225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000371">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Accrued Liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities as of December 31, 2020 and 2019 consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical and contract research organization costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Travel and entertainment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,767&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,062&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases of property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,423&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,162&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accrued tax liabilities balance as of December 31, 2020 includes a $1.4 million tax withholding liability related to unsettled option exercises as of December 31, 2020. The accrued tax liabilities balance as of December 31, 2019 includes a $1.9 million tax withholding liability related to unsettled option exercises as of December 31, 2019.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000415">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities as of December 31, 2020 and 2019 consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical and contract research organization costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Travel and entertainment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,767&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,062&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases of property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,423&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,162&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000654"
      unitRef="U_iso4217USD">3219000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000655"
      unitRef="U_iso4217USD">1011000</us-gaap:AccruedProfessionalFeesCurrent>
    <adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000656"
      unitRef="U_iso4217USD">1781000</adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent>
    <adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000657"
      unitRef="U_iso4217USD">30000</adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000658"
      unitRef="U_iso4217USD">91000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000659"
      unitRef="U_iso4217USD">157000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000660"
      unitRef="U_iso4217USD">1767000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000661"
      unitRef="U_iso4217USD">2062000</us-gaap:AccruedIncomeTaxesCurrent>
    <adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000662"
      unitRef="U_iso4217USD">4423000</adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent>
    <adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000663"
      unitRef="U_iso4217USD">555000</adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000664"
      unitRef="U_iso4217USD">1881000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000665"
      unitRef="U_iso4217USD">556000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000666"
      unitRef="U_iso4217USD">13162000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000667"
      unitRef="U_iso4217USD">4371000</us-gaap:AccruedLiabilitiesCurrent>
    <adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises
      contextRef="C_0001478320_20201231"
      decimals="-5"
      id="F_000668"
      unitRef="U_iso4217USD">1400000</adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises>
    <adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises
      contextRef="C_0001478320_20191231"
      decimals="-5"
      id="F_000669"
      unitRef="U_iso4217USD">1900000</adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises>
    <adpt:DeferredRevenueTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000372">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Deferred Revenue&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue by revenue classification as of December 31, 2020 and 2019 was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sequencing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,463&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sequencing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;724&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,459&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;162,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;219,332&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current and non-current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;236,937&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue from our Genentech Agreement represents $55.1 million and $157.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2020 and $48.1 million and $216.8 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2019. In general, we expect that the current amounts will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately six to seven years. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in deferred revenue during the year ended December 31, 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions to deferred revenue during the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized during the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69,823&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;236,937&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, $61.6 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2019. This is inclusive of $1.0 million of sequencing revenue recognized as a result of cancelled biopharmaceutical customer sequencing contracts and $0.6 million of sequencing revenue related to Medicare that was recognized due to our determination that additional testing for specific patients was remote. &lt;/p&gt;
</adpt:DeferredRevenueTextBlock>
    <adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000416">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue by revenue classification as of December 31, 2020 and 2019 was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sequencing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,463&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sequencing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;724&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,459&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;162,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total non-current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;163,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;219,332&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current and non-current deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;236,937&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20201231"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">15463000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20191231"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">12482000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">57856000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">48512000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">73319000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">60994000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20201231"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">724000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20191231"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">1459000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">162894000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231"
      decimals="-3"
      id="F_000679"
      unitRef="U_iso4217USD">217873000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000680"
      unitRef="U_iso4217USD">163618000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000681"
      unitRef="U_iso4217USD">219332000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000682"
      unitRef="U_iso4217USD">236937000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000683"
      unitRef="U_iso4217USD">280326000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231"
      decimals="-5"
      id="F_000684"
      unitRef="U_iso4217USD">55100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20201231"
      decimals="-5"
      id="F_000686"
      unitRef="U_iso4217USD">157000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231"
      decimals="-5"
      id="F_000685"
      unitRef="U_iso4217USD">48100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231"
      decimals="-5"
      id="F_000687"
      unitRef="U_iso4217USD">216800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231"
      id="F_000688">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtRangeAxis_srtMinimumMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231"
      id="F_000689">P6Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtRangeAxis_srtMaximumMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231"
      id="F_000690">P7Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000417">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in deferred revenue during the year ended December 31, 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;280,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions to deferred revenue during the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue recognized during the period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69,823&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;236,937&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000691"
      unitRef="U_iso4217USD">280326000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000692"
      unitRef="U_iso4217USD">26434000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">-69823000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000694"
      unitRef="U_iso4217USD">236937000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001478320_20201230_20201231"
      decimals="-5"
      id="F_000695"
      unitRef="U_iso4217USD">61600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001478320_srtProductOrServiceAxis_adptSequencingRevenueMember_20200101_20201231"
      decimals="-5"
      id="F_000696"
      unitRef="U_iso4217USD">1000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001478320_srtMajorCustomersAxis_adptSpecificPatientsMember_srtProductOrServiceAxis_adptMedicareRevenueMember_20190101_20191231"
      decimals="-5"
      id="F_000697"
      unitRef="U_iso4217USD">600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000373">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Leases&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;We have operating lease agreements for the laboratory and office facilities that we occupy in various locations, as well as server space. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for our current headquarters in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately 65,500 square feet. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.&lt;/span&gt; &lt;span style="Background-color:#FFFFFF;"&gt;The amended lease also requires us to pay additional amounts for operating and maintenance expenses.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In August 2019, we entered into an agreement to rent approximately 100,000 square feet in a to-be-constructed building in Seattle, Washington. In connection with the lease, we entered into a $2.1 million letter of credit with one of our existing financial institutions. Due to our &lt;/span&gt;significant&lt;span style="Background-color:#FFFFFF;"&gt; involvement during the construction process of the leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance that proceeded ASC 842. The resulting asset and long-term financing obligation recorded on our balance sheet as of December 31, 2019 for the cost of the building was derecognized upon adoption of ASC 842. The lease commenced in December 2020, when the landlord delivered the premises to us for construction of certain tenant improvements. Cash payment for rent begins in October 2021 and the lease term ends in August 2033, &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;subject to our option to twice extend the lease for&#160;five years.&#160;We plan to occupy the new building in 2021, once interior construction is finished. In connection with this lease, the landlord agreed to fund $20.0&#160;million in improvements, which was subsequently reduced to $14.8 million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2020, w&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;e have incurred $5.2 million in certain tenant improvement costs, of which $0.7 million has been reimbursed by the landlord. The remaining $4.5 million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our balance sheet as of December 31, 2020 and will be reimbursed by the landlord. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;The lease also requires us to pay additional amounts for operating and maintenance expenses.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In October 2019, we entered into an agreement to lease approximately 14,750 square feet in a separate Seattle, Washington location, pursuant to a lease expiring in October 2029, which is subject to our ability to exercise an early termination right after the third year. In connection with the lease, the landlord has agreed to provide a tenant improvement allowance in the maximum amount of $0.7 million. The lease also requires us to pay additional amounts for operating expenses.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In April 2018, we entered into a lease agreement to lease approximately 13,400 square feet in South San Francisco, California. The lease term is through March 2026 and provides for one &lt;span style="-sec-ix-hidden:F_000724"&gt;five-year&lt;/span&gt; extension option. We are responsible for our share of allocable operating expenses, tax expenses and utilities cost during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $2.4 million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately 19,900 additional square feet and provides for a $0.6 million tenant improvement allowance.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In December 2019, we entered into an agreement to lease approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025, subject to our ability to exercise an early termination right in 2023. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As of &lt;/span&gt;December&lt;span style="Background-color:#FFFFFF;"&gt; 31, 2020, we were not party to any finance leases. Our leases have remaining terms of 1.3 years to 12.7 years and include options to extend certain of the leases up to 10.0 years and terminate certain of the leases after 3.0 years. We adjust lease terms for these options only when it is reasonably certain we will exercise these options. As of &lt;/span&gt;December&lt;span style="Background-color:#FFFFFF;"&gt; 31, 2020, it was reasonably certain that we would exercise our option to terminate &lt;/span&gt;two&lt;span style="Background-color:#FFFFFF;"&gt; of our leases after 3.0 &lt;/span&gt;years&lt;span style="Background-color:#FFFFFF;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Other information related to our operating leases as of &lt;/span&gt;December &lt;span style="Background-color:#FFFFFF;"&gt;31, 2020 was as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000738"&gt;11.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of &lt;/span&gt;December&lt;span style="Background-color:#FFFFFF;"&gt; 31, 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,030&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,419&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,463&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,612&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Imputed interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Tenant improvement receivables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,529&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Operating lease expense was $5.5 million for the year ended&lt;/span&gt; December &lt;span style="Background-color:#FFFFFF;"&gt;31, 2020. Variable lease expense for operating leases was $2.6 million for the year ended &lt;/span&gt;December&lt;span style="Background-color:#FFFFFF;"&gt; 31, 2020.&lt;/span&gt; &lt;span style="Background-color:#FFFFFF;"&gt;Rent expense recognized under ASC 840, inclusive of operating and maintenance costs, was $5.3 million and $4.1 million for the year ended &lt;/span&gt;December&lt;span style="Background-color:#FFFFFF;"&gt; 31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the year ended &lt;/span&gt;December&lt;span style="Background-color:#FFFFFF;"&gt; 31, 2020 was $3.2 million, net of $2.5 million of cash received for tenant improvement allowances. For the year ended December 31, 2020, ROU assets obtained in exchange for operating lease liabilities was $109.1 million, inclusive of the $33.0 million recognized from the adoption of ASC 842.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190831"
      decimals="0"
      id="F_000698"
      unitRef="U_utrsqft">65500</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831"
      id="F_000699">Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LesseeOperatingLeaseRentCommencementMonthAndYear
      contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831"
      id="F_000700">2020-01</adpt:LesseeOperatingLeaseRentCommencementMonthAndYear>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract
      contextRef="C_0001478320_srtStatementGeographicalAxis_stprWA_20190801_20190831"
      id="F_000702">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <us-gaap:AreaOfLand
      contextRef="C_0001478320_20190831"
      decimals="0"
      id="F_000704"
      unitRef="U_utrsqft">100000</us-gaap:AreaOfLand>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_0001478320_20190831"
      decimals="-5"
      id="F_000705"
      unitRef="U_iso4217USD">2100000</us-gaap:LettersOfCreditOutstandingAmount>
    <adpt:LeaseCommencementMonthAndYear contextRef="C_0001478320_20190801_20190831" id="F_000706">2020-12</adpt:LeaseCommencementMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="C_0001478320_20190801_20190831" id="F_000707">Cash payment for rent begins in October 2021 and the lease term ends in August 2033, </us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LesseeOperatingLeaseRentCommencementMonthAndYear contextRef="C_0001478320_20190801_20190831" id="F_000708">2021-10</adpt:LesseeOperatingLeaseRentCommencementMonthAndYear>
    <adpt:LeaseExpirationMonthAndYear contextRef="C_0001478320_20190801_20190831" id="F_000709">2033-08</adpt:LeaseExpirationMonthAndYear>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract contextRef="C_0001478320_20190801_20190831" id="F_000711">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_0001478320_20190831"
      decimals="-5"
      id="F_000712"
      unitRef="U_iso4217USD">20000000.0</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_0001478320_20201231"
      decimals="-5"
      id="F_000713"
      unitRef="U_iso4217USD">14800000</us-gaap:LeaseholdImprovementsGross>
    <adpt:TenantImprovementCostsIncurred
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000715"
      unitRef="U_iso4217USD">5200000</adpt:TenantImprovementCostsIncurred>
    <adpt:ProceedsFromLandlordReimbursements
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000714"
      unitRef="U_iso4217USD">700000</adpt:ProceedsFromLandlordReimbursements>
    <adpt:TenantImprovementCostsReceivable
      contextRef="C_0001478320_20201231"
      decimals="-5"
      id="F_000716"
      unitRef="U_iso4217USD">4500000</adpt:TenantImprovementCostsReceivable>
    <us-gaap:AreaOfLand
      contextRef="C_0001478320_20191031"
      decimals="0"
      id="F_000717"
      unitRef="U_utrsqft">14750</us-gaap:AreaOfLand>
    <us-gaap:TenantImprovements
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20191031"
      decimals="INF"
      id="F_000719"
      unitRef="U_iso4217USD">700000</us-gaap:TenantImprovements>
    <us-gaap:AreaOfLand
      contextRef="C_0001478320_20180430"
      decimals="0"
      id="F_000720"
      unitRef="U_utrsqft">13400</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="C_0001478320_20180401_20180430" id="F_000722">The lease term is through March 2026 and provides for one five-year extension option.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LeaseExpirationMonthAndYear contextRef="C_0001478320_20180401_20180430" id="F_000721">2026-03</adpt:LeaseExpirationMonthAndYear>
    <us-gaap:TenantImprovements
      contextRef="C_0001478320_20180430"
      decimals="-5"
      id="F_000725"
      unitRef="U_iso4217USD">2400000</us-gaap:TenantImprovements>
    <us-gaap:AreaOfLand
      contextRef="C_0001478320_20200229"
      decimals="0"
      id="F_000726"
      unitRef="U_utrsqft">19900</us-gaap:AreaOfLand>
    <adpt:TenantImprovementAllowanceAndCommenced
      contextRef="C_0001478320_20200201_20200229"
      decimals="-5"
      id="F_000727"
      unitRef="U_iso4217USD">600000</adpt:TenantImprovementAllowanceAndCommenced>
    <us-gaap:AreaOfLand
      contextRef="C_0001478320_20191231"
      decimals="0"
      id="F_000728"
      unitRef="U_utrsqft">3100</us-gaap:AreaOfLand>
    <adpt:LeaseExpirationMonthAndYear contextRef="C_0001478320_20191201_20191231" id="F_000729">2025-11</adpt:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_0001478320_srtRangeAxis_srtMinimumMember_20201231"
      id="F_000730">P1Y3M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_20201231"
      id="F_000731">P12Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="C_0001478320_20200101_20201231" id="F_000732">options to extend certain of the leases up to 10.0 years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="C_0001478320_20201231" id="F_000734">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <adpt:LesseeOperatingLeaseTerminationPeriod contextRef="C_0001478320_20200101_20201231" id="F_000735">P3Y</adpt:LesseeOperatingLeaseTerminationPeriod>
    <adpt:NumberOfOperatingLeaseTerminate
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000736"
      unitRef="U_adptLease">2</adpt:NumberOfOperatingLeaseTerminate>
    <adpt:LesseeOperatingLeaseTerminationPeriod contextRef="C_0001478320_20200101_20201231" id="F_000737">P3Y</adpt:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000418">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Other information related to our operating leases as of &lt;/span&gt;December &lt;span style="Background-color:#FFFFFF;"&gt;31, 2020 was as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000738"&gt;11.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001478320_20201231"
      decimals="3"
      id="F_000739"
      unitRef="U_xbrlipure">0.046</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000419">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of &lt;/span&gt;December&lt;span style="Background-color:#FFFFFF;"&gt; 31, 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,030&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,419&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,463&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,612&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Imputed interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(35,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Tenant improvement receivables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,529&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000740"
      unitRef="U_iso4217USD">7828000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000741"
      unitRef="U_iso4217USD">13554000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000742"
      unitRef="U_iso4217USD">13318000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000743"
      unitRef="U_iso4217USD">13030000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000744"
      unitRef="U_iso4217USD">13419000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000745"
      unitRef="U_iso4217USD">88463000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000746"
      unitRef="U_iso4217USD">149612000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000747"
      unitRef="U_iso4217USD">35848000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <adpt:LesseeOperatingLeaseLiabilityTenantImprovementReceivable
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000748"
      unitRef="U_iso4217USD">5902000</adpt:LesseeOperatingLeaseLiabilityTenantImprovementReceivable>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000749"
      unitRef="U_iso4217USD">107862000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000750"
      unitRef="U_iso4217USD">3529000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000751"
      unitRef="U_iso4217USD">104333000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000752"
      unitRef="U_iso4217USD">5500000</us-gaap:OperatingLeaseExpense>
    <adpt:OperatingLeaseVariableLeaseExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000753"
      unitRef="U_iso4217USD">2600000</adpt:OperatingLeaseVariableLeaseExpense>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001478320_20190101_20191231"
      decimals="-5"
      id="F_000754"
      unitRef="U_iso4217USD">5300000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001478320_20180101_20181231"
      decimals="-5"
      id="F_000755"
      unitRef="U_iso4217USD">4100000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000756"
      unitRef="U_iso4217USD">3200000</us-gaap:OperatingLeasePayments>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000757"
      unitRef="U_iso4217USD">-2500000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000758"
      unitRef="U_iso4217USD">109100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001478320_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20201231"
      decimals="-5"
      id="F_000759"
      unitRef="U_iso4217USD">33000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000374">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments and Contingencies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Legal Proceedings &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We are not party to any material legal proceedings as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Indemnification Agreements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000375">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="color:#231F20;letter-spacing:-0.05pt;"&gt;Shareholders&#x2019;&lt;/span&gt;&lt;span style="color:#231F20;"&gt; Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;;font-weight:normal;font-style:normal;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Immediately prior to the completion of our initial public offering&lt;span style="font-weight:bold;font-style:italic;"&gt; &lt;/span&gt;on July 1, 2019,&#160;93,039,737 shares of convertible preferred stock then outstanding converted into an equivalent number of shares of common stock. As of December 31, 2020, no shares of convertible preferred stock were outstanding.&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Preferred Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;;font-weight:normal;font-style:normal;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;We are authorized to issue 10,000,000 shares of preferred stock, par value $0.0001 per share. As of December 31, 2020, no shares of preferred stock were outstanding.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are authorized to issue 340,000,000 shares of common stock. Our common stock has a par value of $0.0001 per share, no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time. As of December 31, 2020, we had 137,646,896 shares of common stock outstanding.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, w&lt;span style="color:#231F20;"&gt;e have reserved shares of common stock for the following: &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issuable upon the exercise of outstanding common stock options and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; the vesting of outstanding common restricted stock units granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,483,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future grant under the 2019 Equity Incentive Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,617,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future grant under the Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,804,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares to be issued upon exercise of a common stock warrant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares of common stock reserved for future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,961,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our 2019 Equity Incentive Plan (&#x201c;2019 Plan&#x201d;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furthermore, our Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective January 1, 2020, our 2019 Plan and ESPP reserves increased by 6,261,907 shares and 1,252,381 shares, respectively. &lt;span style="color:#231F20;"&gt;Effective January 1, 2021, our 2019 Plan reserve increased by 6,882,344 shares.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Stock&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Warrants&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with two transactions in 2012 and 2013, we granted warrants to purchase up to 55,032 shares of common stock. These warrants were exercisable at any time for a period of ten years from the date of issuance at a weighted-average exercise price of $0.37, except in the case of a warrant to purchase 20,000 shares of common stock at an exercise price of $0.45 per share that would have expired if unexercised prior to the closing of our initial public offering. On July 1, 2019, we issued 54,792 shares of common stock through both a cash and cashless exercise of the warrants. The impact of these exercises was immaterial to the financial statements.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Separately, in 2014, we issued a warrant to purchase 56,875 shares of Series C convertible preferred stock at an exercise price of $2.64. The warrant is exercisable for a period of seven years from the date of issuance. Immediately prior to and in connection with the completion of our initial public offering on July 1, 2019, this convertible preferred stock warrant, which was previously recorded as a financial liability, was converted to a warrant to purchase the same number of shares of common stock. Upon conversion, the financial liability was reclassified to the additional paid-in capital line item on our balance sheet. The warrant to purchase 56,875 shares of common stock remains outstanding as of December 31, 2020.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190629_20190630"
      decimals="INF"
      id="F_000760"
      unitRef="U_xbrlishares">93039737</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000761"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000762"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001478320_20201231"
      decimals="4"
      id="F_000763"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000764"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000765"
      unitRef="U_xbrlishares">340000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000766"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="C_0001478320_20200101_20201231" id="F_000767">Holders of our common stock are entitled to one vote for each share of common stock held</us-gaap:CommonStockVotingRights>
    <adpt:NumberOfCommonStockVotingRights
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000768"
      unitRef="U_adptVote">1</adpt:NumberOfCommonStockVotingRights>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000769"
      unitRef="U_xbrlishares">137646896</us-gaap:CommonStockSharesOutstanding>
    <adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000420">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, w&lt;span style="color:#231F20;"&gt;e have reserved shares of common stock for the following: &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares issuable upon the exercise of outstanding common stock options and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; the vesting of outstanding common restricted stock units granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,483,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future grant under the 2019 Equity Incentive Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,617,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future grant under the Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,804,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares to be issued upon exercise of a common stock warrant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares of common stock reserved for future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,961,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001478320_us-gaapAwardTypeAxis_adptCommonStockOptionsAndRestrictedStockUnitsGrantedMember_20201231"
      decimals="INF"
      id="F_000770"
      unitRef="U_xbrlishares">14483560</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000771"
      unitRef="U_xbrlishares">18617001</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231"
      decimals="INF"
      id="F_000772"
      unitRef="U_xbrlishares">2804298</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231"
      decimals="INF"
      id="F_000773"
      unitRef="U_xbrlishares">56875</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000774"
      unitRef="U_xbrlishares">35961734</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <adpt:PercentageOfAnnualIncreasesInNumberOfShares
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20200101"
      decimals="INF"
      id="F_000775"
      unitRef="U_xbrlipure">0.05</adpt:PercentageOfAnnualIncreasesInNumberOfShares>
    <adpt:PercentageOfAnnualIncreasesInNumberOfShares
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101"
      decimals="2"
      id="F_000776"
      unitRef="U_xbrlipure">0.01</adpt:PercentageOfAnnualIncreasesInNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20200101"
      decimals="INF"
      id="F_000778"
      unitRef="U_xbrlishares">6261907</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20200101"
      decimals="INF"
      id="F_000779"
      unitRef="U_xbrlishares">1252381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101"
      decimals="INF"
      id="F_000777"
      unitRef="U_xbrlishares">6882344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000780"
      unitRef="U_xbrlishares">55032</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <adpt:ClassOfWarrantOrRightsTerm
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      id="F_000781">P10Y</adpt:ClassOfWarrantOrRightsTerm>
    <adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="2"
      id="F_000782"
      unitRef="U_iso4217USD_xbrlishares">0.37</adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000783"
      unitRef="U_xbrlishares">20000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000784"
      unitRef="U_iso4217USD_xbrlishares">0.45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190701_20190701"
      decimals="INF"
      id="F_000785"
      unitRef="U_xbrlishares">54792</adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231"
      decimals="INF"
      id="F_000786"
      unitRef="U_xbrlishares">56875</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20141231"
      decimals="2"
      id="F_000788"
      unitRef="U_iso4217USD_xbrlishares">2.64</adpt:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <adpt:ClassOfWarrantOrRightsTerm
      contextRef="C_0001478320_us-gaapStatementEquityComponentsAxis_adptSeriesCConvertiblePreferredStockMember_20140101_20141231"
      id="F_000787">P7Y</adpt:ClassOfWarrantOrRightsTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000789"
      unitRef="U_xbrlishares">56875</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000376">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Equity Incentive Plans&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Sequenta 2008 Stock Plan, as amended&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with our acquisition of Sequenta in January 2015, we assumed Sequenta&#x2019;s Equity Incentive Plan (&#x201c;2008 Plan&#x201d;), including all outstanding options and shares available for future issuance under the 2008 Plan, which, prior to the completion of our initial public offering, were all exercisable for Series E-1 convertible preferred stock. Upon completion of our initial public offering in July 2019, the outstanding options were exercisable for common stock. No shares are available for future issuance under this plan and no equity awards are outstanding under this plan as of December 31, 2020. &lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Adaptive 2009 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We adopted an equity incentive plan in 2009 (&#x201c;2009 Plan&#x201d;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the option exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Options granted under this plan expire no later than ten years from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While no shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2019 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2019 Plan was approved by our shareholders on June 13, 2019 and, pursuant to the resolutions adopted by our board of directors, became effective immediately prior to the closing of our initial public offering. The 2019 Plan provides for the issuance of awards in the form of options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the option exercise price per share shall not be less than the fair market value of a share of stock on the grant date of the option, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, options granted under this plan expire no later than ten years from the grant date and vesting is established at the time of grant. Except for certain option grants made to non-employee directors, stock options granted under the 2019 Plan generally vest over a &lt;span style="-sec-ix-hidden:F_000795"&gt;four-year&lt;/span&gt; period, subject to continuous service through each applicable vesting date. As of December 31, 2020, we have authorized 22,109,217 shares of common stock for issuance under the 2019 Plan.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in shares available for grant during the year ended December 31, 2020 were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares Available for Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for grant at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,396,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019 Plan reserve increase on January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,261,907&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options and restricted stock units granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,291,701&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited, cancelled or expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for grant at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,617,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option activity under the 2008 Plan, 2009 Plan and 2019 Plan during the year ended December&#160;31, 2020 was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subject to&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,646,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;398,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,241,701&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited or cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(235,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,204,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,433,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;668,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,924,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;417,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average remaining contractual life for options outstanding as of December 31, 2020 was 7.1 years. The weighted-average remaining contractual life for vested and exercisable options outstanding as of December 31, 2020 was 5.9 years. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value per share of options granted was $21.11, $6.87 and $4.15 during the year ended December&#160;31, 2020, 2019 and 2018, respectively. The total intrinsic value of options exercised was $190.4&#160;million, $39.1 million and $3.8 million during the year ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, $0.3 million was included in the prepaid expenses and other current assets line item on our balance sheet for unsettled cash proceeds related to options exercised during the year ended December 31, 2020. As of December 31, 2019, $0.5 million was included in the prepaid expenses and other current assets line item on our balance sheet for unsettled cash proceeds related to options exercised during the year ended December 31, 2019. The $21.7 million proceeds from exercise of stock options on our statements of cash flows for the year ended December 31, 2020 includes this $0.5 million, as the related proceeds settled during the year ended December 31, 2020.&lt;/p&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2020 was as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-weight:bold;;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Units&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested outstanding restricted stock units at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested outstanding restricted stock units at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2019 was $41.63.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Grant Date Fair Value of Options and Restricted Stock Units Granted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated grant date fair value of options granted during the year ended December&#160;31, 2020, 2019 and 2018 was estimated using the Black-Scholes option-pricing model with the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$17.68 - $55.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$7.80 - $47.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$6.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000845"&gt;5.27 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000846"&gt;5.27 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000847"&gt;6.08 - 10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000851"&gt;0.4% - 1.7%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000852"&gt;1.4% - 2.5%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000853"&gt;2.6% - 3.0%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000857"&gt;70.5% - 73.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000858"&gt;64.3% - 72.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000859"&gt;65.0% - 69.2%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average volatility used in the grant date fair value calculations of options granted during the year ended December 31, 2020, 2019 and 2018 was 71.4%, 68.1% and 68.1%, respectively.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows: &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fair value of common stock&#x2014;&lt;span style="font-style:normal;"&gt;Prior to the closing of our initial public offering, the fair value of our common stock was determined with input from management using valuation methodologies which utilized certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies used to estimate the enterprise value were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, &lt;/span&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;span style="font-style:normal;"&gt;. For valuations of grants made after the closing of our initial public offering, the fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;span style="font-style:normal;"&gt;&#x2014;The expected term of options granted to employees and non-employee directors is determined using the &#x201c;simplified&#x201d; method, as illustrated in ASC Topic 718, &lt;/span&gt;Compensation&#x2014;Stock Compensation&lt;span style="font-style:normal;"&gt;, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is &lt;/span&gt;&lt;span style="color:#000000;font-style:normal;"&gt;based on the midpoint between the vesting date and the end of the contractual term of the option.&lt;/span&gt;&lt;span style="font-style:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;span style="font-style:normal;"&gt;&#x2014;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the options.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;span style="font-style:normal;"&gt;&#x2014;As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of the expected term.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;span style="font-style:normal;"&gt;&#x2014;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The grant date fair value of restricted stock units granted after the closing of our initial public offering &lt;span style="color:#000000;"&gt;is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation expense &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$24.8&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$13.1&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$11.1&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; was recognized during the &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;year ended&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, 20&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 201&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;respectively&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The compensation costs related to stock options and restricted stock units for the years ended December 31, 2020, 2019 and 2018 are included on our statements of operations as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total share-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,761&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2018, there was one employee option modification to extend the option exercise period, which resulted in incremental stock compensation of $0.5 million.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, unrecognized share-based compensation expense related to unvested stock options was $74.9 million, which is expected to be recognized over a remaining weighted-average period of 3.0 years. Additionally, as of December 31, 2020, unrecognized share-based compensation expense related to nonvested restricted stock units was $1.1 million, which is expected to be recognized over a remaining weighted-average period of 3.3 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptSequentaTwoThousandAndEightStockPlanMember_20201231"
      decimals="INF"
      id="F_000790"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptSequentaTwoThousandAndEightStockPlanMember_20201231"
      decimals="INF"
      id="F_000791"
      unitRef="U_xbrlishares">0</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineEquityIncentivePlanMember_20200101_20201231"
      id="F_000792">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000793"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001478320_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      id="F_000794">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000796"
      unitRef="U_xbrlishares">22109217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000421">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in shares available for grant during the year ended December 31, 2020 were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares Available for Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for grant at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,396,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019 Plan reserve increase on January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,261,907&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options and restricted stock units granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,291,701&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited, cancelled or expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for grant at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,617,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000797"
      unitRef="U_xbrlishares">15396254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000798"
      unitRef="U_xbrlishares">6261907</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000799"
      unitRef="U_xbrlishares">3291701</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000800"
      unitRef="U_xbrlishares">250541</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000801"
      unitRef="U_xbrlishares">18617001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000422">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option activity under the 2008 Plan, 2009 Plan and 2019 Plan during the year ended December&#160;31, 2020 was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subject to&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,646,654&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;398,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,241,701&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited or cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(235,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,204,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,433,560&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;668,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,924,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;417,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000802"
      unitRef="U_xbrlishares">16646654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001478320_20191231"
      decimals="2"
      id="F_000809"
      unitRef="U_iso4217USD_xbrlishares">6.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000816"
      unitRef="U_iso4217USD">398379000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000803"
      unitRef="U_xbrlishares">3241701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001478320_20200101_20201231"
      decimals="2"
      id="F_000810"
      unitRef="U_iso4217USD_xbrlishares">33.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000804"
      unitRef="U_xbrlishares">235541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001478320_20200101_20201231"
      decimals="2"
      id="F_000811"
      unitRef="U_iso4217USD_xbrlishares">16.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000805"
      unitRef="U_xbrlishares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001478320_20200101_20201231"
      decimals="2"
      id="F_000812"
      unitRef="U_iso4217USD_xbrlishares">0.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000806"
      unitRef="U_xbrlishares">5204254</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001478320_20200101_20201231"
      decimals="2"
      id="F_000813"
      unitRef="U_iso4217USD_xbrlishares">4.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000807"
      unitRef="U_xbrlishares">14433560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001478320_20201231"
      decimals="2"
      id="F_000814"
      unitRef="U_iso4217USD_xbrlishares">12.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000817"
      unitRef="U_iso4217USD">668458000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000808"
      unitRef="U_xbrlishares">7924779</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
      contextRef="C_0001478320_20201231"
      decimals="2"
      id="F_000815"
      unitRef="U_iso4217USD_xbrlishares">6.41</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000818"
      unitRef="U_iso4217USD">417801000</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001478320_20200101_20201231" id="F_000819">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="C_0001478320_20200101_20201231" id="F_000820">P5Y10M24D</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_20200101_20201231"
      decimals="2"
      id="F_000821"
      unitRef="U_iso4217USD_xbrlishares">21.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_20190101_20191231"
      decimals="2"
      id="F_000822"
      unitRef="U_iso4217USD_xbrlishares">6.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_20180101_20181231"
      decimals="2"
      id="F_000823"
      unitRef="U_iso4217USD_xbrlishares">4.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000824"
      unitRef="U_iso4217USD">190400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001478320_20190101_20191231"
      decimals="-5"
      id="F_000825"
      unitRef="U_iso4217USD">39100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001478320_20180101_20181231"
      decimals="-5"
      id="F_000826"
      unitRef="U_iso4217USD">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <adpt:ReceivableForStockOptionExercises
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231"
      decimals="-5"
      id="F_000827"
      unitRef="U_iso4217USD">300000</adpt:ReceivableForStockOptionExercises>
    <adpt:ReceivableForStockOptionExercises
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231"
      decimals="-5"
      id="F_000828"
      unitRef="U_iso4217USD">500000</adpt:ReceivableForStockOptionExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000829"
      unitRef="U_iso4217USD">21700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000830"
      unitRef="U_iso4217USD">500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000423">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2020 was as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-weight:bold;;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Units&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested outstanding restricted stock units at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested outstanding restricted stock units at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28.10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000831"
      unitRef="U_xbrlishares">4500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231"
      decimals="2"
      id="F_000835"
      unitRef="U_iso4217USD_xbrlishares">41.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000832"
      unitRef="U_xbrlishares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000836"
      unitRef="U_iso4217USD_xbrlishares">28.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000833"
      unitRef="U_xbrlishares">4500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000837"
      unitRef="U_iso4217USD_xbrlishares">41.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000834"
      unitRef="U_xbrlishares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20201231"
      decimals="2"
      id="F_000838"
      unitRef="U_iso4217USD_xbrlishares">28.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20190101_20191231"
      decimals="2"
      id="F_000839"
      unitRef="U_iso4217USD_xbrlishares">41.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000424">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimated grant date fair value of options granted during the year ended December&#160;31, 2020, 2019 and 2018 was estimated using the Black-Scholes option-pricing model with the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$17.68 - $55.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$7.80 - $47.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$6.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000845"&gt;5.27 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000846"&gt;5.27 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000847"&gt;6.08 - 10.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000851"&gt;0.4% - 1.7%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000852"&gt;1.4% - 2.5%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000853"&gt;2.6% - 3.0%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000857"&gt;70.5% - 73.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000858"&gt;64.3% - 72.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000859"&gt;65.0% - 69.2%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001478320_20180101_20181231"
      decimals="2"
      id="F_000840"
      unitRef="U_iso4217USD_xbrlishares">6.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000863"
      unitRef="U_xbrlipure">0.714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000864"
      unitRef="U_xbrlipure">0.681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000865"
      unitRef="U_xbrlipure">0.681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001478320_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueOptionPricingModelMember_20200101_20201231"
      decimals="2"
      id="F_000866"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000867"
      unitRef="U_iso4217USD">24800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_20190101_20191231"
      decimals="-5"
      id="F_000868"
      unitRef="U_iso4217USD">13100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_20180101_20181231"
      decimals="-5"
      id="F_000869"
      unitRef="U_iso4217USD">11100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000425">The compensation costs related to stock options and restricted stock units for the years ended December 31, 2020, 2019 and 2018 are included on our statements of operations as follows (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;817&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total share-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,761&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231"
      decimals="-3"
      id="F_000870"
      unitRef="U_iso4217USD">817000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20190101_20191231"
      decimals="-3"
      id="F_000871"
      unitRef="U_iso4217USD">555000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20180101_20181231"
      decimals="-3"
      id="F_000872"
      unitRef="U_iso4217USD">398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000873"
      unitRef="U_iso4217USD">8519000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000874"
      unitRef="U_iso4217USD">3934000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000875"
      unitRef="U_iso4217USD">2896000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000876"
      unitRef="U_iso4217USD">6627000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000877"
      unitRef="U_iso4217USD">3480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapSellingAndMarketingExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000878"
      unitRef="U_iso4217USD">2891000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000879"
      unitRef="U_iso4217USD">8798000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000880"
      unitRef="U_iso4217USD">5155000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000881"
      unitRef="U_iso4217USD">4964000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000882"
      unitRef="U_iso4217USD">24761000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000883"
      unitRef="U_iso4217USD">13124000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000884"
      unitRef="U_iso4217USD">11149000</us-gaap:AllocatedShareBasedCompensationExpense>
    <adpt:NumberOfEmployeeOptionModification
      contextRef="C_0001478320_20181231"
      decimals="INF"
      id="F_000885"
      unitRef="U_adptOption">1</adpt:NumberOfEmployeeOptionModification>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_0001478320_20180101_20181231"
      decimals="-5"
      id="F_000886"
      unitRef="U_iso4217USD">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001478320_20201231"
      decimals="-5"
      id="F_000887"
      unitRef="U_iso4217USD">74900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001478320_20200101_20201231" id="F_000888">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="-5"
      id="F_000890"
      unitRef="U_iso4217USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      id="F_000889">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000377">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Microsoft Collaboration Agreement&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Summary of Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2017, we entered into a collaboration agreement with Microsoft (&#x201c;Microsoft Agreement&#x201d;) to computationally derive a comprehensive TCR antigen map for purposes of developing a universal diagnostic based on a single blood test.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft&#x2019;s Azure cloud services at standard volume pricing with a minimum Azure consumption requirement of $12.0&#160;million over the &lt;span style="-sec-ix-hidden:F_000892"&gt;seven-year&lt;/span&gt; term of the Microsoft Agreement, which we expect to meet in the ordinary course of business. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of approximately $45.0&#160;million as a part of our&#160;Series&#160;F-1&#160;convertible preferred stock issuance.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Summary of Accounting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The terms of the Microsoft Agreement meet the criteria under ASC Topic 808,&#160;&lt;span style="font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&#160;(&#x201c;ASC 808&#x201d;), as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity.&#160;ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly,&#160;we looked to other guidance to determine the accounting for the respective elements.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We determined that the preferred stock issuance and commitment to use Microsoft&#x2019;s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series&#160;F-1&#160;convertible preferred stock issuance was accounted for as part of the Series&#160;F-1&#160;preferred stock issuance.&#160;Since the commitment to use Microsoft&#x2019;s Azure cloud services was at market terms and we expect to meet the commitment in the ordinary course of business during the seven-year term, we record the expenses in the period in which the services are consumed. These costs are recorded in our statements of operations based on the underlying activities for which they support.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft&#x2019;s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We accounted for these collaboration activities by analogy to ASC Topic 845,&#160;&lt;/span&gt;&lt;span style="font-style:italic;"&gt;Nonmonetary Transactions&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any&#160;non-monetary&#160;assets or corresponding&#160;non-monetary&#160;income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement
      contextRef="C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231"
      decimals="INF"
      id="F_000891"
      unitRef="U_iso4217USD">12000000.0</adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement>
    <us-gaap:PreferredStockValue
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_adptSeriesFOneConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171231"
      decimals="-5"
      id="F_000893"
      unitRef="U_iso4217USD">45000000.0</us-gaap:PreferredStockValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000378">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of our deferred tax assets and liabilities for the periods presented are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,433&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,035&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,981&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,152&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non qualifying stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,096&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,755&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,052&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,706&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,983&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,892&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,258&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(197,527&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(100,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,731&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tangible and intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC Topic 740, &lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;, requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $96.6 million and $30.2 million during the year ended December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the CARES Act was enacted and signed into law in response to COVID-19. The CARES Act, among other things, included several significant provisions that impacted corporate taxpayers' accounting for income taxes, including modification to the utilization of net operating losses and interest expense deduction limitations. However, none of these provisions have an impact on our tax provision.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2018 and an analysis is ongoing for ownership changes through December 31, 2020. Based on these analyses, we do not expect to have any permanent limitations on the utilization of our federal net operating losses. Under the TCJA federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. Net operating losses generated prior to 2018 are eligible to be carried forward up to 20 years. As of December 31, 2020, we had U.S. federal net operating losses of $192.5 million and U.S. federal tax credits of $18.8 million that will begin to expire in 2028. We also have $211.9 million of net operating losses that do not expire.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.7&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66.1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44.3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30.3)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $3.5 million as of December 31, 2020. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the periods presented are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions in 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions in 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,052&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions in 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020 and 2019, we recognized uncertain tax positions of $1.4 million and $0.8 million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had no accrued interest or penalties related to uncertain tax positions as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of net operating loss carryforwards, substantially all tax years since inception remain open to federal and state tax examination.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000426">The significant components of our deferred tax assets and liabilities for the periods presented are as follows (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,433&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,035&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carryforward&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,981&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,152&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non qualifying stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,096&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,150&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,755&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,052&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,713&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,706&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,983&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,892&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,258&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(197,527&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(100,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,731&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tangible and intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ROU assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000894"
      unitRef="U_iso4217USD">105433000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000895"
      unitRef="U_iso4217USD">79035000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000896"
      unitRef="U_iso4217USD">18981000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000897"
      unitRef="U_iso4217USD">11152000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <adpt:DeferredTaxAssetsNonQualifiedStockOptions
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000898"
      unitRef="U_iso4217USD">12096000</adpt:DeferredTaxAssetsNonQualifiedStockOptions>
    <adpt:DeferredTaxAssetsNonQualifiedStockOptions
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000899"
      unitRef="U_iso4217USD">9150000</adpt:DeferredTaxAssetsNonQualifiedStockOptions>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000900"
      unitRef="U_iso4217USD">11755000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <adpt:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000901"
      unitRef="U_iso4217USD">31052000</adpt:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000902"
      unitRef="U_iso4217USD">59713000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000903"
      unitRef="U_iso4217USD">1706000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000904"
      unitRef="U_iso4217USD">2983000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000905"
      unitRef="U_iso4217USD">1892000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000906"
      unitRef="U_iso4217USD">230258000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000907"
      unitRef="U_iso4217USD">114690000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000908"
      unitRef="U_iso4217USD">197527000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000909"
      unitRef="U_iso4217USD">100906000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000910"
      unitRef="U_iso4217USD">32731000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000911"
      unitRef="U_iso4217USD">13784000</us-gaap:DeferredTaxAssetsNet>
    <adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000912"
      unitRef="U_iso4217USD">5760000</adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets>
    <adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000913"
      unitRef="U_iso4217USD">13784000</adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets>
    <adpt:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000914"
      unitRef="U_iso4217USD">26971000</adpt:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000915"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000916"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000917"
      unitRef="U_iso4217USD">96600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001478320_20190101_20191231"
      decimals="-5"
      id="F_000918"
      unitRef="U_iso4217USD">30200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <adpt:NetOperatingLossCarryforwardExpirationPeriod contextRef="C_0001478320_20200101_20201231" id="F_000919">P20Y</adpt:NetOperatingLossCarryforwardExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000920"
      unitRef="U_iso4217USD">192500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000921"
      unitRef="U_iso4217USD">18800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000922">2028</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <adpt:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001478320_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000923">2028</adpt:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001478320_20201231"
      decimals="-5"
      id="F_000924"
      unitRef="U_iso4217USD">211900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000427">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.7&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66.1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44.3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30.3)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000925"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001478320_20190101_20191231"
      decimals="INF"
      id="F_000926"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001478320_20180101_20181231"
      decimals="INF"
      id="F_000927"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000928"
      unitRef="U_xbrlipure">0.138</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001478320_20190101_20191231"
      decimals="INF"
      id="F_000929"
      unitRef="U_xbrlipure">0.081</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001478320_20180101_20181231"
      decimals="INF"
      id="F_000930"
      unitRef="U_xbrlipure">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000931"
      unitRef="U_xbrlipure">0.252</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000932"
      unitRef="U_xbrlipure">0.098</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000933"
      unitRef="U_xbrlipure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000934"
      unitRef="U_xbrlipure">-0.001</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000935"
      unitRef="U_xbrlipure">-0.010</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000936"
      unitRef="U_xbrlipure">0.005</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000937"
      unitRef="U_xbrlipure">0.057</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000938"
      unitRef="U_xbrlipure">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000939"
      unitRef="U_xbrlipure">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000940"
      unitRef="U_xbrlipure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000941"
      unitRef="U_xbrlipure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000942"
      unitRef="U_xbrlipure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000943"
      unitRef="U_xbrlipure">-0.661</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000944"
      unitRef="U_xbrlipure">-0.443</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000945"
      unitRef="U_xbrlipure">-0.303</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001478320_20200101_20201231"
      decimals="3"
      id="F_000946"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001478320_20190101_20191231"
      decimals="3"
      id="F_000947"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001478320_20180101_20181231"
      decimals="3"
      id="F_000948"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001478320_20201231"
      decimals="-5"
      id="F_000949"
      unitRef="U_iso4217USD">3500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000428">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the periods presented are as follows (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions in 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions in 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,052&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions in 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001478320_20171231"
      decimals="-3"
      id="F_000950"
      unitRef="U_iso4217USD">1031000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000951"
      unitRef="U_iso4217USD">229000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001478320_20181231"
      decimals="-3"
      id="F_000952"
      unitRef="U_iso4217USD">1260000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000953"
      unitRef="U_iso4217USD">792000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001478320_20191231"
      decimals="-3"
      id="F_000954"
      unitRef="U_iso4217USD">2052000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000955"
      unitRef="U_iso4217USD">1437000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001478320_20201231"
      decimals="-3"
      id="F_000956"
      unitRef="U_iso4217USD">3489000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000957"
      unitRef="U_iso4217USD">1400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001478320_20190101_20191231"
      decimals="-5"
      id="F_000958"
      unitRef="U_iso4217USD">800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001478320_20201231"
      decimals="INF"
      id="F_000959"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001478320_20191231"
      decimals="INF"
      id="F_000960"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000379">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/span&gt;&lt;span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Net Loss&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Per Share&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Attributable&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;to Common &lt;span style="letter-spacing:-0.05pt;"&gt;Shareholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders for the periods presented (in thousands, except share and per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(146,227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(68,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value adjustments to redemption value for Series E-1&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; convertible preferred stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(146,227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69,570&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,345&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares used in computing net loss per share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131,216,468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,165,315&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,629,778&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders, basic and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since we were in a loss position for all periods presented, basic net loss per share attributable to common shareholders is the same as diluted net loss per share attributable to common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the year ended December 31, 2020, 2019 and 2018, respectively, as they had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock (on as if converted basis)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,104,469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,783,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,125,548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,183,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,701,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,220,548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,377,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,597,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000429">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders for the periods presented (in thousands, except share and per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(146,227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(68,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value adjustments to redemption value for Series E-1&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; convertible preferred stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(146,227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69,570&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,345&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares used in computing net loss per share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131,216,468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,165,315&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,629,778&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common shareholders, basic and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000961"
      unitRef="U_iso4217USD">-146227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000962"
      unitRef="U_iso4217USD">-68606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000963"
      unitRef="U_iso4217USD">-46447000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000964"
      unitRef="U_iso4217USD">964000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000965"
      unitRef="U_iso4217USD">-102000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001478320_20200101_20201231"
      decimals="-3"
      id="F_000966"
      unitRef="U_iso4217USD">-146227000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001478320_20190101_20191231"
      decimals="-3"
      id="F_000967"
      unitRef="U_iso4217USD">-69570000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_0001478320_20180101_20181231"
      decimals="-3"
      id="F_000968"
      unitRef="U_iso4217USD">-46345000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001478320_20200101_20201231"
      decimals="0"
      id="F_000969"
      unitRef="U_xbrlishares">131216468</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001478320_20190101_20191231"
      decimals="0"
      id="F_000970"
      unitRef="U_xbrlishares">69165315</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001478320_20180101_20181231"
      decimals="0"
      id="F_000971"
      unitRef="U_xbrlishares">12629778</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001478320_20200101_20201231"
      decimals="2"
      id="F_000972"
      unitRef="U_iso4217USD_xbrlishares">-1.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001478320_20190101_20191231"
      decimals="2"
      id="F_000973"
      unitRef="U_iso4217USD_xbrlishares">-1.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001478320_20180101_20181231"
      decimals="2"
      id="F_000974"
      unitRef="U_iso4217USD_xbrlishares">-3.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000430">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the year ended December 31, 2020, 2019 and 2018, respectively, as they had an anti-dilutive effect:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock (on as if converted basis)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,104,469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,783,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,125,548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,183,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,701,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nonvested restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,220,548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,377,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,597,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000975"
      unitRef="U_xbrlishares">46104469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231"
      decimals="INF"
      id="F_000976"
      unitRef="U_xbrlishares">92783867</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000977"
      unitRef="U_xbrlishares">16125548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000978"
      unitRef="U_xbrlishares">17183546</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="INF"
      id="F_000979"
      unitRef="U_xbrlishares">14701626</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptUnvestedRestrictedStockUnitsMember_20200101_20201231"
      decimals="INF"
      id="F_000980"
      unitRef="U_xbrlishares">38125</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptUnvestedRestrictedStockUnitsMember_20190101_20191231"
      decimals="INF"
      id="F_000981"
      unitRef="U_xbrlishares">4952</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20200101_20201231"
      decimals="INF"
      id="F_000982"
      unitRef="U_xbrlishares">56875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20190101_20191231"
      decimals="INF"
      id="F_000983"
      unitRef="U_xbrlishares">55961</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptCommonStockWarrantsMember_20180101_20181231"
      decimals="INF"
      id="F_000984"
      unitRef="U_xbrlishares">55032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptConvertiblePreferredStockWarrantsMember_20190101_20191231"
      decimals="INF"
      id="F_000985"
      unitRef="U_xbrlishares">28204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adptConvertiblePreferredStockWarrantsMember_20180101_20181231"
      decimals="INF"
      id="F_000986"
      unitRef="U_xbrlishares">56875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_20200101_20201231"
      decimals="INF"
      id="F_000987"
      unitRef="U_xbrlishares">16220548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_20190101_20191231"
      decimals="INF"
      id="F_000988"
      unitRef="U_xbrlishares">63377132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001478320_20180101_20181231"
      decimals="INF"
      id="F_000989"
      unitRef="U_xbrlishares">107597400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="C_0001478320_20200101_20201231" id="F_000380">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Retirement Plan&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We maintain a salary deferral 401(k) plan (&#x201c;401(k) Plan&#x201d;) covering employees who have met certain eligibility requirements. Employees may defer up to 100% of their compensation to the 401(k) Plan, subject to federal limits. We made $1.6 million in discretionary contributions during the year ended December 31, 2020, which are fully vested after one year of employee service. We did not make any discretionary contributions during the years ended December 31, 2019 and 2018.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_0001478320_20200101_20201231"
      decimals="2"
      id="F_000990"
      unitRef="U_xbrlipure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001478320_20200101_20201231"
      decimals="-5"
      id="F_000991"
      unitRef="U_iso4217USD">1600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <adpt:DefinedContributionPlanEmployeeServicePeriodForVesting contextRef="C_0001478320_20200101_20201231" id="F_000994">P1Y</adpt:DefinedContributionPlanEmployeeServicePeriodForVesting>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001478320_20190101_20191231"
      decimals="INF"
      id="F_000992"
      unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001478320_20180101_20181231"
      decimals="INF"
      id="F_000993"
      unitRef="U_iso4217USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273546519224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADPT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIVE BIOTECHNOLOGIES CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001478320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,590,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,219,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0907024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1551 Eastlake Avenue East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-0067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549587320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,436,000<span></span>
</td>
<td class="nump">$ 96,576,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities (amortized cost of $564,036 and $479,791, respectively)</a></td>
<td class="nump">564,833,000<span></span>
</td>
<td class="nump">480,290,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">10,047,000<span></span>
</td>
<td class="nump">12,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">14,063,000<span></span>
</td>
<td class="nump">9,069,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,535,000<span></span>
</td>
<td class="nump">14,079,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">726,914,000<span></span>
</td>
<td class="nump">612,690,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">39,692,000<span></span>
</td>
<td class="nump">60,355,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">99,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities (amortized cost of $118,429 and $105,263, respectively)</a></td>
<td class="nump">118,525,000<span></span>
</td>
<td class="nump">105,435,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,138,000<span></span>
</td>
<td class="nump">2,138,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">10,225,000<span></span>
</td>
<td class="nump">11,928,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">118,972,000<span></span>
</td>
<td class="nump">118,972,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">598,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,116,414,000<span></span>
</td>
<td class="nump">912,302,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,237,000<span></span>
</td>
<td class="nump">4,453,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">13,162,000<span></span>
</td>
<td class="nump">4,371,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">11,950,000<span></span>
</td>
<td class="nump">8,124,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Current portion of deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">3,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">73,319,000<span></span>
</td>
<td class="nump">60,994,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">105,197,000<span></span>
</td>
<td class="nump">78,313,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent liability, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,918,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">104,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,607,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">163,618,000<span></span>
</td>
<td class="nump">219,332,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">373,148,000<span></span>
</td>
<td class="nump">341,263,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2020 and 2019; 137,646,896 and 125,238,142 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,253,971,000<span></span>
</td>
<td class="nump">935,834,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">893,000<span></span>
</td>
<td class="nump">671,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(511,612,000)<span></span>
</td>
<td class="num">(365,478,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">743,266,000<span></span>
</td>
<td class="nump">571,039,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 1,116,414,000<span></span>
</td>
<td class="nump">$ 912,302,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273550039608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost of short-term marketable securities</a></td>
<td class="nump">$ 564,036<span></span>
</td>
<td class="nump">$ 479,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost of long-term marketable securities</a></td>
<td class="nump">$ 118,429<span></span>
</td>
<td class="nump">$ 105,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">340,000,000<span></span>
</td>
<td class="nump">340,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">137,646,896<span></span>
</td>
<td class="nump">125,238,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">137,646,896<span></span>
</td>
<td class="nump">125,238,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273548011192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 98,382<span></span>
</td>
<td class="nump">$ 85,071<span></span>
</td>
<td class="nump">$ 55,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">22,530<span></span>
</td>
<td class="nump">22,274<span></span>
</td>
<td class="nump">19,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">116,072<span></span>
</td>
<td class="nump">70,705<span></span>
</td>
<td class="nump">39,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">61,358<span></span>
</td>
<td class="nump">38,453<span></span>
</td>
<td class="nump">24,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">49,536<span></span>
</td>
<td class="nump">30,332<span></span>
</td>
<td class="nump">20,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">251,199<span></span>
</td>
<td class="nump">163,462<span></span>
</td>
<td class="nump">105,419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(152,817)<span></span>
</td>
<td class="num">(78,391)<span></span>
</td>
<td class="num">(49,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">6,590<span></span>
</td>
<td class="nump">9,785<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(146,227)<span></span>
</td>
<td class="num">(68,606)<span></span>
</td>
<td class="num">(46,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Fair value adjustment to Series E-1 convertible preferred stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(964)<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (146,227)<span></span>
</td>
<td class="num">$ (69,570)<span></span>
</td>
<td class="num">$ (46,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common shareholders, basic and diluted</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted</a></td>
<td class="nump">131,216,468<span></span>
</td>
<td class="nump">69,165,315<span></span>
</td>
<td class="nump">12,629,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember', window );">Sequencing Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 41,439<span></span>
</td>
<td class="nump">$ 43,519<span></span>
</td>
<td class="nump">$ 32,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember', window );">Development Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 56,943<span></span>
</td>
<td class="nump">$ 41,552<span></span>
</td>
<td class="nump">$ 22,685<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_SequencingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273541157384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (146,227)<span></span>
</td>
<td class="num">$ (68,606)<span></span>
</td>
<td class="num">$ (46,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain (loss) on investments</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (146,005)<span></span>
</td>
<td class="num">$ (67,828)<span></span>
</td>
<td class="num">$ (46,388)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273632220120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>Revision of Prior Period, Accounting Standards Update, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Gain</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Revision of Prior Period, Accounting Standards Update, Adjustment</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="num">$ (224,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 24,972<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="num">$ (166)<span></span>
</td>
<td class="num">$ (249,423)<span></span>
</td>
<td class="num">$ (140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,208,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, Beginning Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,656,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Vested Series E-1 convertible preferred stock option forfeitures</a></td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures', window );">Vested Series E-1 convertible preferred stock option forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Series E-1 convertible preferred stock option share-based compensation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Adjustment to redemption value for vested Series E-1 convertible preferred stock options</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions', window );">Adjustment to redemption value for vested Series E-1 convertible preferred stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions', window );">Change in redemption value for vested Series E-1 convertible preferred stock options</a></td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions', window );">Change in redemption value for vested Series E-1 convertible preferred stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Common stock option share-based compensation</a></td>
<td class="nump">11,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="num">(258,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">37,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(295,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,790,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Ending Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,841,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us</a></td>
<td class="nump">320,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">320,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts', window );">Initial public offering costs</a></td>
<td class="num">(4,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock</a></td>
<td class="nump">561,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (561,931)<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">561,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,039,737)<span></span>
</td>
<td class="nump">93,039,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant', window );">Conversion of convertible preferred stock warrant to common stock warrant</a></td>
<td class="nump">2,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised', window );">Issuance of common stock upon exercise of common stock warrants</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised', window );">Issuance of common stock upon exercise of common stock warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">4,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,043,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue', window );">Common stock option and restricted stock unit share-based compensation</a></td>
<td class="nump">13,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions', window );">Change in redemption value for vested Series E-1 convertible preferred stock options</a></td>
<td class="num">(964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions', window );">Change in redemption value for vested Series E-1 convertible preferred stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(68,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 571,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">935,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="num">(365,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,238,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update Extensible List</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us</a></td>
<td class="nump">$ 271,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">271,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">$ 21,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">21,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="nump">5,204,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,204,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue', window );">Common stock option and restricted stock unit share-based compensation</a></td>
<td class="nump">$ 24,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(146,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 743,266<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1,253,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
<td class="num">$ (511,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,646,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in redemption value for vested convertible preferred stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares restricted stock award vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, value, common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity adjustment redemption value for vested convertible preferred stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, shares, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity value change in redemption value for vested convertible preferred stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity value vested convertible preferred stock option forfeitures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177168-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549369400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (146,227)<span></span>
</td>
<td class="num">$ (68,606)<span></span>
</td>
<td class="num">$ (46,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">6,769<span></span>
</td>
<td class="nump">6,093<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">3,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">24,761<span></span>
</td>
<td class="nump">13,124<span></span>
</td>
<td class="nump">11,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets amortization</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Investment amortization</a></td>
<td class="nump">773<span></span>
</td>
<td class="num">(4,463)<span></span>
</td>
<td class="num">(1,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of convertible preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">2,613<span></span>
</td>
<td class="num">(7,817)<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(4,994)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
<td class="num">(3,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,362)<span></span>
</td>
<td class="num">(8,576)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">7,495<span></span>
</td>
<td class="nump">6,149<span></span>
</td>
<td class="nump">2,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(43,389)<span></span>
</td>
<td class="nump">266,927<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="num">(276)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(149,683)<span></span>
</td>
<td class="nump">205,404<span></span>
</td>
<td class="num">(32,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(18,803)<span></span>
</td>
<td class="num">(11,200)<span></span>
</td>
<td class="num">(6,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(694,965)<span></span>
</td>
<td class="num">(884,217)<span></span>
</td>
<td class="num">(146,503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">596,724<span></span>
</td>
<td class="nump">413,720<span></span>
</td>
<td class="nump">153,538<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(117,044)<span></span>
</td>
<td class="num">(481,697)<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">21,748<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of underwriting discounts and commissions</a></td>
<td class="nump">272,160<span></span>
</td>
<td class="nump">320,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of public offering costs, net</a></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(4,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant', window );">Proceeds from issuance of common stock upon the exercise of a common stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">293,587<span></span>
</td>
<td class="nump">319,916<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">26,860<span></span>
</td>
<td class="nump">43,623<span></span>
</td>
<td class="num">(30,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">98,714<span></span>
</td>
<td class="nump">55,091<span></span>
</td>
<td class="nump">85,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">125,574<span></span>
</td>
<td class="nump">98,714<span></span>
</td>
<td class="nump">55,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">4,679<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LandlordFundedLeaseholdImprovements', window );">Landlord-funded leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Noncash additions to property through lease financing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease', window );">Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases</a></td>
<td class="nump">$ 36,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering', window );">Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock to common stock upon closing of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liabilities .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LandlordFundedLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Landlord-funded leasehold improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LandlordFundedLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock upon exercise of common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545628104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Description of Business</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adaptive Biotechnologies Corporation (&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and aims to understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that we are tailoring to each individual patient. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer, autoimmune conditions and infectious diseases.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in the State of Washington on September&#160;8, 2009 under the name Adaptive TCR Corporation. On December&#160;21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Initial Public Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our registration statement on Form S-1 related to our initial public offering was declared effective on June 26, 2019 and our common stock began trading on the Nasdaq Global Select Market on June 27, 2019.&#160;On July 1, 2019, we completed our initial public offering in which we issued and sold 17,250,000 shares of common stock, including shares issued upon the exercise in full of the underwriters&#8217; over-allotment option, at a public offering price of $20.00 per share. We received $315.9 million in net proceeds, after deducting underwriting discounts and commissions of $24.1 million and offering expenses of $5.0 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Follow-On Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we completed an underwritten public offering of our common stock in which we issued and sold 7,200,000 shares of common stock, including shares issued upon the exercise in full of the underwriters&#8217; over-allotment option, at a public offering price of $40.00 per share. We received $271.8&#160;million in net proceeds, after deducting underwriting discounts and net offering expenses paid by us.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545553432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Significant</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Accounting</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Policies</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Basis<span style="letter-spacing:-0.05pt;"> </span>of Presentation and<span style="letter-spacing:-0.05pt;"> </span>Use<span style="letter-spacing:-0.05pt;"> </span>of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">JOBS Act Accounting Election</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective December 31, 2020, we are no longer an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Prior to December 31, 2020, we had elected to use this extended transition period and, as a result, our financial statements may not be comparable to companies that comply with public company effective dates. We can no longer take advantage of this extended transition period.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of <span>$2.1</span> million as of December 31, 2020 and 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Investments in Marketable Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities are classified as&#160;available-for-sale, primarily consist of U.S. government debt securities, commercial paper and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; (deficit) equity in accumulated other comprehensive (loss) gain until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations<span style="letter-spacing:-0.05pt;"> </span>of Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a concentration of risk from a limited number of suppliers, or in some cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each balance sheet date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, Net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.4%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.8%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech, Inc. and Roche Group</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* less than 10%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounts Receivable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we had $0.9 million and $2.4 million of unbilled receivables as of December&#160;31, 2020 and 2019, respectively. The unbilled receivables are amounts that will become due for which we have an unconditional right to consideration.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a&#160;first-in,&#160;first-out&#160;basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Useful lives assigned to property and equipment are as follows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;">
<tr>
<td style="width:223.55pt;"/>
<td style="width:7.85pt;"/>
<td style="width:223.5pt;"/>
</tr>
<tr>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 7 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of estimated useful life or remaining lease term</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years to 10 years</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our statements of operations in accordance with the use of the asset.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October&#160;1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our statements of operations. To date, we have not recognized any impairment of goodwill.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory and office facilities that we occupy, as well as server space. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of the new lease standard, discussed in more detail below. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory and office facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lease Financing Arrangements</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, due to our significant involvement during the construction process of a leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance. Prior to our adoption of the new lease standard, the cost of the related building was recorded in property and equipment, net and the offsetting lease financing obligation was recorded as a long-term financing obligation on our balance sheet. As of December 31, 2019, $36.6 million of building costs was recorded in property and equipment, net.  </p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1: Quoted </span><span style="Background-color:#FFFFFF;color:#000000;">prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">Level 2: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial instruments consist of Level&#160;1 and Level&#160;2 assets and has included Level&#160;3 liabilities in the past. In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level&#160;3 within the valuation hierarchy. The carrying amounts of certain financial instruments approximate fair value due to their short&#160;maturities.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December&#160;31, 2020 or 2019.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Preferred Stock Warrant Liability</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series&#160;C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0&#160;million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the conversion, the fair value of this warrant was classified as a&#160;non-current&#160;liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders&#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our statements of operations. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Revenue<span style="letter-spacing:-0.1pt;"> </span>Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), <span style="font-style:italic;">Revenue from Contracts with Customers</span>. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1)&#160;identify the contract or contracts; (2)&#160;determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3)&#160;measure the transaction price, including the constraint on variable consideration; (4)&#160;allocate the transaction price to the performance obligations based on estimated selling prices; and (5)&#160;recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue is generated from immunosequencing (&#8220;sequencing&#8221;) products and services (&#8220;sequencing revenue&#8221;) and from regulatory or development support services leveraging our immune medicine platform (&#8220;development revenue&#8221;). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sequencing Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue reflects the amounts generated from providing sequencing services and testing through our clonoSEQ and immunoSEQ products and services to our clinical and research customers, respectively. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clinical customers, we derive revenues from providing our clonoSEQ test report to ordering physicians, and we bill and receive payments from medical institutions and commercial and government third-party payors. In these transactions, we have identified one performance obligation: the delivery of a clonoSEQ report. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test.&#160;Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized as we deliver the remaining tests in a patient&#8217;s treatment cycle or when it becomes remote that a patient will receive additional testing and we have not delivered our estimate of total tests.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research customers, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development<span style="letter-spacing:-0.05pt;"> </span>Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers&#8217; initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements may include single or multiple performance obligations, depending on the contract. For certain contracts, we may perform services to support the biopharmaceutical customers&#8217; regulatory submissions as part of their registrational trials. These services include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers&#8217; control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or&#160;non-current&#160;based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and&#160;non-employees.&#160;It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising costs are expensed as incurred. Advertising expenses were $14.5 million, $6.6 million and $3.5 million for the year ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue includes the cost of materials, personnel-related expenses (comprised of salaries, benefits and share-based compensation), shipping and handling, equipment and allocated facility costs associated with processing samples and professional support for our sequencing revenue. Allocated facility costs include depreciation of laboratory equipment, allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses are comprised of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. <span style="Background-color:#FFFFFF;color:#000000;">We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. </span>Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. <span style="Background-color:#FFFFFF;color:#000000;">Costs to support our Genentech Agreement are a component of our research and development activities.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are measured at the balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share Attributable to Common Shareholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate basic net loss per share attributable to common shareholders by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect is anti-dilutive.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to common shareholders in conformity with the&#160;two-class&#160;method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an&#160;as-if&#160;converted basis. Under the&#160;two-class&#160;method, basic net loss per share attributable to common shareholders is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to common shareholders was not allocated to the convertible preferred stock under the&#160;two-class&#160;method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect was anti-dilutive.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented on a regular basis at the entity level. Resource allocation decisions are made by the CODM based on the results at the entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning for levels or components below the entity. As such, we have concluded that we operate as one segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3,&#160;Revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Recently Ad<span style="letter-spacing:-0.05pt;">opted </span>Accounting<span style="letter-spacing:-0.05pt;"> </span>Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-02, <span style="font-style:italic;">Leases</span> (Topic 842) (&#8220;ASC 842&#8221;), intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheets and disclosing key information about leasing arrangements. We adopted the guidance effective January 1, 2020 using the optional transition method described in ASU 2018-11<span style="font-style:italic;">, Leases </span>(Topic 842) <span style="font-style:italic;">Targeted Improvements</span>. Under the optional transition method, we recognized a cumulative-effect adjustment in the period of adoption. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, <span style="font-style:italic;">Leases </span>(&#8220;ASC 840&#8221;). </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In adopting the new standard, we utilized certain practical expedients available. These practical expedients include waiving reassessment of (1) whether any expired or existing contracts are or contain leases; (2) lease classification of expired or existing leases; and (3) initial direct costs for existing leases. We also elected to use hindsight in determining the lease term and in assessing impairment of our ROU assets. Furthermore, we have made a policy decision regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The standard had a material impact on our balance sheet as of December 31, 2020, but did not have a material impact on our statements of operations or statements of cash flows. The most significant impact was the recognition of $33.0 million and $39.7 million of operating lease ROU assets and liabilities, respectively, and the derecognition of a $36.6 million asset and corresponding liability previously recorded pursuant to build-to-suit lease accounting guidance under ASC 840, which resulted in an increase to retained earnings of $0.1 million. The operating lease ROU assets and liabilities recorded at adoption included the derecognition of $7.3 million of deferred rent recognized as of December 31, 2019, as well as a $0.5 million reclassification of tenant incentive receivables previously recognized in the prepaid expenses and other current assets line item on our balance sheet. See Note 10, Leases, for additional information regarding leases.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses </span>(Topic 326):<span style="font-style:italic;"> Measurement of Credit Losses on Financial Instruments</span>, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The expected credit losses are recorded through an allowance account that is deducted from the amortized cost basis of the financial asset, and the net carrying value of the financial asset is presented on the balance sheet. The guidance also amends the previous other-than-temporary impairment model for available-for-sale debt securities by requiring the recognition of impairments relating to credit losses through an allowance account, limited to the difference between a security&#8217;s amortized cost basis and its fair value. Furthermore, the standard update removes the distinction between whether an impairment is temporary or other-than temporary. We adopted the guidance effective January 1, 2020. Given the short-term nature of our accounts receivable, the adoption as it relates to trade receivables did not have a significant impact on our financial statements. Furthermore, impairment of available-for-sale debt securities as of the adoption date was determined to be due to factors other than credit loss; therefore, a credit allowance was not recognized. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <span style="font-style:italic;">Intangibles&#8212;Goodwill and Other: Internal-Use Software</span> (Subtopic 350-40) to provide additional guidance on the accounting for costs of implementation activities performed in a cloud computing arrangement. We adopted this guidance effective January 1, 2020 on a prospective basis, and the adoption did not have any impact on our financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No.&#160;2019-12,&#160;<span style="font-style:italic;">Income Taxes</span> (Topic 740): <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span>, which eliminates certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. Among other things, this guidance also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This guidance is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied prospectively, except for certain amendments. We early adopted the guidance on January 1, 2020 and the adoption did not have a material impact on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273636880872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Revenue</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We disaggregate our revenue from contracts with customers by type of service, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,439</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,519</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,978</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development support</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,443</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,685</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory milestones</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total development revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,685</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,071</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;font-weight:bold;font-style:italic;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Translational Development<span style="letter-spacing:-0.05pt;"> </span>Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2015, we entered into a translational development agreement with a biopharmaceutical customer for access to certain of our oncology immunosequencing research datasets, including full-time employee support, to accelerate the customer&#8217;s preclinical, nonclinical and clinical trial testing. Under the initial terms of the agreement, we could have been entitled to up to $40.0&#160;million over a period of four years, which did not include any separately negotiated research sequencing contracts. If the biopharmaceutical customer terminated the agreement prior to the end of the initial four-year research term for any reason other than a material uncured breach by us, then the biopharmaceutical partner agreed to pay us $0.8&#160;million. In May 2019, the agreement was subsequently amended to reduce the services provided, which in turn reduced the fourth year of eligible payments to $2.3&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified one performance obligation under this agreement, as the services were determined to be highly interrelated. We determined that any separately negotiated sequencing contracts are not performance obligations under the contract, as the contract did not contain any material rights related to such sequencing contracts. For the identified performance obligation, we assessed the work to be performed over the duration of the contract and determined that it was a consistent level of support throughout the period, and therefore, revenue was recognized on a straight-line basis over the contract term. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized from this translational development agreement, excluding separately negotiated research sequencing contracts, was $2.3 million and $9.3 million during the year ended December 31, 2019 and 2018, respectively. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">MRD Development<span style="letter-spacing:-0.05pt;"> </span>Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into agreements with biopharmaceutical customers to further develop and commercialize our MRD product and the biopharmaceutical customers&#8217; therapeutics. Under each of the agreements, we received or will receive non-refundable upfront payments and could receive substantial additional payments upon reaching certain progress milestones or achievement of certain regulatory milestones pertaining to the customers&#8217; therapeutics and our MRD product. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the contracts, we identify performance obligations, which may include: (1)&#160;obligations to provide services supporting the customer&#8217;s regulatory submission activities as they relate to our MRD product; and (2)&#160;sequencing services related to customer-provided samples for their regulatory submissions. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated immunosequencing services. At contract inception, we fully constrain any consideration related to the regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#8217; own submission decision-making. We recognize revenue relating to the sequencing services as sequencing revenue over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered and when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method based on estimates of effort completed using a cost-based model. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We earned $2.5 million, $2.0 million and $10.0 million during the year ended December 31, 2020, 2019 and 2018, respectively, upon the achievement of certain regulatory milestones by us and our respective customers&#8217; therapeutics. All $2.5 million, $2.0 million and $10.0 million was recognized as revenue within the respective periods, as we determined these amounts were consistent with our estimated standalone selling price and the respective performance obligations were complete. We recognized $3.4&#160;million, $3.7&#160;million and $12.8 million in development revenue related to these contracts, inclusive of the milestones, during the year ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, in future periods we could receive up to an additional $313.5 million in milestone payments if certain regulatory approvals are obtained by our customers&#8217; therapeutics in connection with MRD data generated from our MRD product.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Genentech<span style="letter-spacing:-0.05pt;"> </span>Collaboration Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (&#8220;Genentech Agreement&#8221;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $300.0 million in February 2019 and may be eligible to receive more than $1.8 billion over time, including payments of up to $75.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones and up to $1,430.0 million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the agreement, we are pursuing two product development pathways for novel T cell immunotherapies in which Genentech intends to use TCRs screened by our immune medicine platform to engineer and manufacture cellular medicines: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-family:Times New Roman;">Shared Products. The shared products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among patients (&#8220;Shared Products&#8221;). </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#231F20;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#231F20;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"/><span style="color:#000000;"/><span style="font-family:Times New Roman;">Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#8220;Personalized Product&#8221;). </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in ASC Topic 808, <span style="font-style:italic;">Collaborative Arrangements</span> (&#8220;ASC 808&#8221;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#8217;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC 606 to account for the activities related to the Genentech Agreement.<span style="color:#000000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In applying ASC&#160;606, we identified the following performance obligations at the inception of the agreement: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">License to existing shared antigen data packages. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Research and development services for shared product development, including expansion of shared antigen data packages. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Research and development services for private product development. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Obligations to participate on various joint research, development and project committees. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#8217;s control of product commercialization. Specifically, under the agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other, as opposed to both. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined the initial transaction price shall be made up of only the $300.0 million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the transaction price as of December 31, 2020. We excluded the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur. </p>

<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Product and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize the revenue over a period of approximately seven to eight years from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Product and the Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized revenue of $52.8 million and $35.1 million during the year ended December 31, 2020 and 2019, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273544113400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value<span style="letter-spacing:-0.05pt;"> </span>Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth the fair value of financial assets as of December 31, 2020 and 2019 that were measured at fair value on a recurring basis (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,777</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,777</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">683,358</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,867</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,867</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">585,725</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,408</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level&#160;2 securities consist of U.S. government debt securities, commercial paper and corporate bonds, and are valued based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273626105080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Investments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investments consisted of the following as of December 31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">552,539</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">553,252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,497</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,036</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">809</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,833</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,429</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,525</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,429</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,525</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,866</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,866</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,963</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286,356</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,068</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479,791</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480,290</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,887</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,513</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,548</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All the commercial paper, U.S. government debt securities and corporate bonds designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective balance sheet date.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest receivables are excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivables of $2.5 million and $2.2 million were presented separately within the prepaid expenses and other current assets line item on our balance sheet as of December 31, 2020 and 2019, respectively. We have made an accounting policy election to not measure an allowance for credit losses for accrued interest receivables.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position and the length of time that individual securities have been in a continuous loss position as of December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than 12 Months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 Months Or Greater</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177,554</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,512</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,066</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2020 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545486232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment, Net</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net as of December 31, 2020 and 2019 consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,767</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,450</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,717</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,185</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,852</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,945</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,716</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Build-to-suit asset cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,607</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,074</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,382</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,692</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,355</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $6.8 million, $6.1&#160;million and $4.3 million for the year ended December&#160;31, 2020, 2019 and 2018, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273640157432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Goodwill<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Intangible Assets</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in the carrying amount of goodwill since its recognition in 2015. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization as of December 31, 2020 and 2019 consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,972</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,028</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,301</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,699</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,397</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,928</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The developed technology was acquired in connection with our acquisition of Sequenta in 2015. The remaining balance of the acquired technology and the purchased intellectual property is expected to be amortized over the next 6.0 years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, expected future amortization expense for intangible assets was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,726</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future amortization expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545357768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. </span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accrued Liabilities</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities as of December 31, 2020 and 2019 consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,011</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and contract research organization costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Travel and entertainment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,767</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,062</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,423</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,881</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">556</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,162</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,371</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accrued tax liabilities balance as of December 31, 2020 includes a $1.4 million tax withholding liability related to unsettled option exercises as of December 31, 2020. The accrued tax liabilities balance as of December 31, 2019 includes a $1.9 million tax withholding liability related to unsettled option exercises as of December 31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273546048584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DeferredRevenueTextBlock', window );">Deferred Revenue</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Deferred Revenue</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue by revenue classification as of December 31, 2020 and 2019 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,463</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,856</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,319</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,994</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,459</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,332</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current and non-current deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,937</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,326</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue from our Genentech Agreement represents $55.1 million and $157.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2020 and $48.1 million and $216.8 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2019. In general, we expect that the current amounts will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately six to seven years. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue during the year ended December 31, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,326</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions to deferred revenue during the period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,434</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized during the period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,823</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,937</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, $61.6 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2019. This is inclusive of $1.0 million of sequencing revenue recognized as a result of cancelled biopharmaceutical customer sequencing contracts and $0.6 million of sequencing revenue related to Medicare that was recognized due to our determination that additional testing for specific patients was remote. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273543998664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We have operating lease agreements for the laboratory and office facilities that we occupy in various locations, as well as server space. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for our current headquarters in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately 65,500 square feet. </span><span style="Background-color:#FFFFFF;">Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.</span> <span style="Background-color:#FFFFFF;">The amended lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In August 2019, we entered into an agreement to rent approximately 100,000 square feet in a to-be-constructed building in Seattle, Washington. In connection with the lease, we entered into a $2.1 million letter of credit with one of our existing financial institutions. Due to our </span>significant<span style="Background-color:#FFFFFF;"> involvement during the construction process of the leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance that proceeded ASC 842. The resulting asset and long-term financing obligation recorded on our balance sheet as of December 31, 2019 for the cost of the building was derecognized upon adoption of ASC 842. The lease commenced in December 2020, when the landlord delivered the premises to us for construction of certain tenant improvements. Cash payment for rent begins in October 2021 and the lease term ends in August 2033, </span><span style="Background-color:#FFFFFF;color:#000000;">subject to our option to twice extend the lease for&#160;five years.&#160;We plan to occupy the new building in 2021, once interior construction is finished. In connection with this lease, the landlord agreed to fund $20.0&#160;million in improvements, which was subsequently reduced to $14.8 million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2020, w</span><span style="Background-color:#FFFFFF;">e have incurred $5.2 million in certain tenant improvement costs, of which $0.7 million has been reimbursed by the landlord. The remaining $4.5 million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on our balance sheet as of December 31, 2020 and will be reimbursed by the landlord. </span><span style="Background-color:#FFFFFF;color:#000000;">The lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In October 2019, we entered into an agreement to lease approximately 14,750 square feet in a separate Seattle, Washington location, pursuant to a lease expiring in October 2029, which is subject to our ability to exercise an early termination right after the third year. In connection with the lease, the landlord has agreed to provide a tenant improvement allowance in the maximum amount of $0.7 million. The lease also requires us to pay additional amounts for operating expenses.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In April 2018, we entered into a lease agreement to lease approximately 13,400 square feet in South San Francisco, California. The lease term is through March 2026 and provides for one <span style="-sec-ix-hidden:F_000724">five-year</span> extension option. We are responsible for our share of allocable operating expenses, tax expenses and utilities cost during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $2.4 million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately 19,900 additional square feet and provides for a $0.6 million tenant improvement allowance.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, we entered into an agreement to lease approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025, subject to our ability to exercise an early termination right in 2023. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of </span>December<span style="Background-color:#FFFFFF;"> 31, 2020, we were not party to any finance leases. Our leases have remaining terms of 1.3 years to 12.7 years and include options to extend certain of the leases up to 10.0 years and terminate certain of the leases after 3.0 years. We adjust lease terms for these options only when it is reasonably certain we will exercise these options. As of </span>December<span style="Background-color:#FFFFFF;"> 31, 2020, it was reasonably certain that we would exercise our option to terminate </span>two<span style="Background-color:#FFFFFF;"> of our leases after 3.0 </span>years<span style="Background-color:#FFFFFF;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Other information related to our operating leases as of </span>December <span style="Background-color:#FFFFFF;">31, 2020 was as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000738">11.33</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of </span>December<span style="Background-color:#FFFFFF;"> 31, 2020 (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,554</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,318</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,030</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,419</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,463</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,612</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Imputed interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,848</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Tenant improvement receivables</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,902</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,862</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,529</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, less current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Operating lease expense was $5.5 million for the year ended</span> December <span style="Background-color:#FFFFFF;">31, 2020. Variable lease expense for operating leases was $2.6 million for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2020.</span> <span style="Background-color:#FFFFFF;">Rent expense recognized under ASC 840, inclusive of operating and maintenance costs, was $5.3 million and $4.1 million for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2019 and 2018, respectively.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Cash paid for amounts included in the measurement of lease liabilities for the year ended </span>December<span style="Background-color:#FFFFFF;"> 31, 2020 was $3.2 million, net of $2.5 million of cash received for tenant improvement allowances. For the year ended December 31, 2020, ROU assets obtained in exchange for operating lease liabilities was $109.1 million, inclusive of the $33.0 million recognized from the adoption of ASC 842.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273551811768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Legal Proceedings </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We are not party to any material legal proceedings as of December 31, 2020. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Indemnification Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545567464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="color:#231F20;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#231F20;letter-spacing:-0.05pt;">Shareholders&#8217;</span><span style="color:#231F20;"> Equity</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;;font-weight:normal;font-style:normal;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Immediately prior to the completion of our initial public offering<span style="font-weight:bold;font-style:italic;"> </span>on July 1, 2019,&#160;93,039,737 shares of convertible preferred stock then outstanding converted into an equivalent number of shares of common stock. As of December 31, 2020, no shares of convertible preferred stock were outstanding.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;;font-weight:normal;font-style:normal;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are authorized to issue 10,000,000 shares of preferred stock, par value $0.0001 per share. As of December 31, 2020, no shares of preferred stock were outstanding.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are authorized to issue 340,000,000 shares of common stock. Our common stock has a par value of $0.0001 per share, no preferences or privileges and is not redeemable. Holders of our common stock are entitled to one vote for each share of common stock held. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time. As of December 31, 2020, we had 137,646,896 shares of common stock outstanding.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, w<span style="color:#231F20;">e have reserved shares of common stock for the following: </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon the exercise of outstanding common stock options and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; the vesting of outstanding common restricted stock units granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,483,560</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the 2019 Equity Incentive Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,617,001</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the Employee Stock Purchase Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,804,298</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares to be issued upon exercise of a common stock warrant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,875</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved for future issuance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,961,734</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our 2019 Equity Incentive Plan (&#8220;2019 Plan&#8221;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our Employee Stock Purchase Plan (&#8220;ESPP&#8221;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) 1% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2020, our 2019 Plan and ESPP reserves increased by 6,261,907 shares and 1,252,381 shares, respectively. <span style="color:#231F20;">Effective January 1, 2021, our 2019 Plan reserve increased by 6,882,344 shares.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Common<span style="letter-spacing:-0.05pt;"> </span>Stock<span style="letter-spacing:-0.05pt;"> </span>Warrants</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with two transactions in 2012 and 2013, we granted warrants to purchase up to 55,032 shares of common stock. These warrants were exercisable at any time for a period of ten years from the date of issuance at a weighted-average exercise price of $0.37, except in the case of a warrant to purchase 20,000 shares of common stock at an exercise price of $0.45 per share that would have expired if unexercised prior to the closing of our initial public offering. On July 1, 2019, we issued 54,792 shares of common stock through both a cash and cashless exercise of the warrants. The impact of these exercises was immaterial to the financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in 2014, we issued a warrant to purchase 56,875 shares of Series C convertible preferred stock at an exercise price of $2.64. The warrant is exercisable for a period of seven years from the date of issuance. Immediately prior to and in connection with the completion of our initial public offering on July 1, 2019, this convertible preferred stock warrant, which was previously recorded as a financial liability, was converted to a warrant to purchase the same number of shares of common stock. Upon conversion, the financial liability was reclassified to the additional paid-in capital line item on our balance sheet. The warrant to purchase 56,875 shares of common stock remains outstanding as of December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273548801176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Equity Incentive Plans</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Sequenta 2008 Stock Plan, as amended</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our acquisition of Sequenta in January 2015, we assumed Sequenta&#8217;s Equity Incentive Plan (&#8220;2008 Plan&#8221;), including all outstanding options and shares available for future issuance under the 2008 Plan, which, prior to the completion of our initial public offering, were all exercisable for Series E-1 convertible preferred stock. Upon completion of our initial public offering in July 2019, the outstanding options were exercisable for common stock. No shares are available for future issuance under this plan and no equity awards are outstanding under this plan as of December 31, 2020. </p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Adaptive 2009 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted an equity incentive plan in 2009 (&#8220;2009 Plan&#8221;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the option exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Options granted under this plan expire no later than ten years from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While no shares are available for future issuance under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">2019 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan was approved by our shareholders on June 13, 2019 and, pursuant to the resolutions adopted by our board of directors, became effective immediately prior to the closing of our initial public offering. The 2019 Plan provides for the issuance of awards in the form of options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the option exercise price per share shall not be less than the fair market value of a share of stock on the grant date of the option, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, options granted under this plan expire no later than ten years from the grant date and vesting is established at the time of grant. Except for certain option grants made to non-employee directors, stock options granted under the 2019 Plan generally vest over a <span style="-sec-ix-hidden:F_000795">four-year</span> period, subject to continuous service through each applicable vesting date. As of December 31, 2020, we have authorized 22,109,217 shares of common stock for issuance under the 2019 Plan.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in shares available for grant during the year ended December 31, 2020 were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Available for Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,396,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan reserve increase on January 1, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,261,907</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and restricted stock units granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,291,701</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited, cancelled or expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,617,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the 2008 Plan, 2009 Plan and 2019 Plan during the year ended December&#160;31, 2020 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,646,654</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398,379</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,241,701</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited or cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(235,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.16</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,204,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,433,560</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.82</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668,458</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and exercisable at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,924,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average remaining contractual life for options outstanding as of December 31, 2020 was 7.1 years. The weighted-average remaining contractual life for vested and exercisable options outstanding as of December 31, 2020 was 5.9 years. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of options granted was $21.11, $6.87 and $4.15 during the year ended December&#160;31, 2020, 2019 and 2018, respectively. The total intrinsic value of options exercised was $190.4&#160;million, $39.1 million and $3.8 million during the year ended December&#160;31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, $0.3 million was included in the prepaid expenses and other current assets line item on our balance sheet for unsettled cash proceeds related to options exercised during the year ended December 31, 2020. As of December 31, 2019, $0.5 million was included in the prepaid expenses and other current assets line item on our balance sheet for unsettled cash proceeds related to options exercised during the year ended December 31, 2019. The $21.7 million proceeds from exercise of stock options on our statements of cash flows for the year ended December 31, 2020 includes this $0.5 million, as the related proceeds settled during the year ended December 31, 2020.</p>

<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2020 was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Units</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2019 was $41.63.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Grant Date Fair Value of Options and Restricted Stock Units Granted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated grant date fair value of options granted during the year ended December&#160;31, 2020, 2019 and 2018 was estimated using the Black-Scholes option-pricing model with the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.68 - $55.23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.80 - $47.81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000845">5.27 - 6.08</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000846">5.27 - 6.08</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000847">6.08 - 10.00</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000851">0.4% - 1.7%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000852">1.4% - 2.5%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000853">2.6% - 3.0%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000857">70.5% - 73.3%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000858">64.3% - 72.9%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000859">65.0% - 69.2%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average volatility used in the grant date fair value calculations of options granted during the year ended December 31, 2020, 2019 and 2018 was 71.4%, 68.1% and 68.1%, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of our common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair value of common stock&#8212;<span style="font-style:normal;">Prior to the closing of our initial public offering, the fair value of our common stock was determined with input from management using valuation methodologies which utilized certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies used to estimate the enterprise value were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, </span>Valuation of Privately-Held-Company Equity Securities Issued as Compensation<span style="font-style:normal;">. For valuations of grants made after the closing of our initial public offering, the fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<span style="font-style:normal;">&#8212;The expected term of options granted to employees and non-employee directors is determined using the &#8220;simplified&#8221; method, as illustrated in ASC Topic 718, </span>Compensation&#8212;Stock Compensation<span style="font-style:normal;">, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is </span><span style="color:#000000;font-style:normal;">based on the midpoint between the vesting date and the end of the contractual term of the option.</span><span style="font-style:normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate<span style="font-style:normal;">&#8212;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the options.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<span style="font-style:normal;">&#8212;As we do not have sufficient trading history for our common stock, the expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of the expected term.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield<span style="font-style:normal;">&#8212;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of zero in the option valuation model. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant date fair value of restricted stock units granted after the closing of our initial public offering <span style="color:#000000;">is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.8</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.1</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$11.1</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was recognized during the </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year ended</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 20</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 201</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respectively</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation costs related to stock options and restricted stock units for the years ended December 31, 2020, 2019 and 2018 are included on our statements of operations as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,519</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,896</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,891</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administration</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,155</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,964</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,761</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,124</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,149</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2018, there was one employee option modification to extend the option exercise period, which resulted in incremental stock compensation of $0.5 million.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, unrecognized share-based compensation expense related to unvested stock options was $74.9 million, which is expected to be recognized over a remaining weighted-average period of 3.0 years. Additionally, as of December 31, 2020, unrecognized share-based compensation expense related to nonvested restricted stock units was $1.1 million, which is expected to be recognized over a remaining weighted-average period of 3.3 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273544138072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Microsoft Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Microsoft Collaboration Agreement</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Microsoft Collaboration Agreement</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Summary of Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a collaboration agreement with Microsoft (&#8220;Microsoft Agreement&#8221;) to computationally derive a comprehensive TCR antigen map for purposes of developing a universal diagnostic based on a single blood test.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft&#8217;s Azure cloud services at standard volume pricing with a minimum Azure consumption requirement of $12.0&#160;million over the <span style="-sec-ix-hidden:F_000892">seven-year</span> term of the Microsoft Agreement, which we expect to meet in the ordinary course of business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of approximately $45.0&#160;million as a part of our&#160;Series&#160;F-1&#160;convertible preferred stock issuance.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Summary of Accounting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the Microsoft Agreement meet the criteria under ASC Topic 808,&#160;<span style="font-style:italic;">Collaborative Arrangements</span>&#160;(&#8220;ASC 808&#8221;), as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity.&#160;ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly,&#160;we looked to other guidance to determine the accounting for the respective elements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determined that the preferred stock issuance and commitment to use Microsoft&#8217;s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series&#160;F-1&#160;convertible preferred stock issuance was accounted for as part of the Series&#160;F-1&#160;preferred stock issuance.&#160;Since the commitment to use Microsoft&#8217;s Azure cloud services was at market terms and we expect to meet the commitment in the ordinary course of business during the seven-year term, we record the expenses in the period in which the services are consumed. These costs are recorded in our statements of operations based on the underlying activities for which they support.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft&#8217;s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accounted for these collaboration activities by analogy to ASC Topic 845,&#160;</span><span style="font-style:italic;">Nonmonetary Transactions</span><span style="color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any&#160;non-monetary&#160;assets or corresponding&#160;non-monetary&#160;income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273754538168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of our deferred tax assets and liabilities for the periods presented are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,433</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,035</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforward</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,981</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,152</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non qualifying stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,096</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,755</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,052</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,713</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,706</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,983</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,892</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,258</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,690</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(197,527</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,906</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net of valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,731</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,784</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible and intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,760</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,784</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC Topic 740, <span style="font-style:italic;">Income Taxes</span>, requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $96.6 million and $30.2 million during the year ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the CARES Act was enacted and signed into law in response to COVID-19. The CARES Act, among other things, included several significant provisions that impacted corporate taxpayers' accounting for income taxes, including modification to the utilization of net operating losses and interest expense deduction limitations. However, none of these provisions have an impact on our tax provision.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through December 31, 2018 and an analysis is ongoing for ownership changes through December 31, 2020. Based on these analyses, we do not expect to have any permanent limitations on the utilization of our federal net operating losses. Under the TCJA federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. Net operating losses generated prior to 2018 are eligible to be carried forward up to 20 years. As of December 31, 2020, we had U.S. federal net operating losses of $192.5 million and U.S. federal tax credits of $18.8 million that will begin to expire in 2028. We also have $211.9 million of net operating losses that do not expire.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66.1)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44.3)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.3)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $3.5 million as of December 31, 2020. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the periods presented are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,031</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,052</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020 and 2019, we recognized uncertain tax positions of $1.4 million and $0.8 million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had no accrued interest or penalties related to uncertain tax positions as of December 31, 2020 and 2019.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of net operating loss carryforwards, substantially all tax years since inception remain open to federal and state tax examination.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273544075864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="color:#231F20;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;color:#231F20;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss<span style="letter-spacing:-0.05pt;"> </span>Per Share<span style="letter-spacing:-0.05pt;"> </span>Attributable<span style="letter-spacing:0.05pt;"> </span>to Common <span style="letter-spacing:-0.05pt;">Shareholders</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss<span style="letter-spacing:-0.05pt;"> </span>Per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders for the periods presented (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,447</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments to redemption value for Series E-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(964</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shareholders, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,570</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,345</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used in computing net loss per share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,216,468</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,165,315</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,629,778</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders, basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.01</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since we were in a loss position for all periods presented, basic net loss per share attributable to common shareholders is the same as diluted net loss per share attributable to common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the year ended December 31, 2020, 2019 and 2018, respectively, as they had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (on as if converted basis)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,104,469</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,783,867</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,125,548</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,183,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,701,626</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,125</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,875</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,961</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,032</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,875</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,220,548</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,377,132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,597,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273551905448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Retirement Plan</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;color:#231F20;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#231F20;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retirement Plan</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a salary deferral 401(k) plan (&#8220;401(k) Plan&#8221;) covering employees who have met certain eligibility requirements. Employees may defer up to 100% of their compensation to the 401(k) Plan, subject to federal limits. We made $1.6 million in discretionary contributions during the year ended December 31, 2020, which are fully vested after one year of employee service. We did not make any discretionary contributions during the years ended December 31, 2019 and 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273625283480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Basis<span style="letter-spacing:-0.05pt;"> </span>of Presentation and<span style="letter-spacing:-0.05pt;"> </span>Use<span style="letter-spacing:-0.05pt;"> </span>of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, including the fair value of stock, the provision for income taxes, including related reserves, and goodwill, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_JOBSActAccountingElectionPolicyTextBlock', window );">JOBS Act Accounting Election</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">JOBS Act Accounting Election</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective December 31, 2020, we are no longer an &#8220;emerging growth company&#8221; within the meaning of the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Prior to December 31, 2020, we had elected to use this extended transition period and, as a result, our financial statements may not be comparable to companies that comply with public company effective dates. We can no longer take advantage of this extended transition period.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to maintain certain balances under lease arrangements for some of our property and facility leases. We had restricted cash of <span>$2.1</span> million as of December 31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities are classified as&#160;available-for-sale, primarily consist of U.S. government debt securities, commercial paper and corporate bonds and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; (deficit) equity in accumulated other comprehensive (loss) gain until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations<span style="letter-spacing:-0.05pt;"> </span>of Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to a concentration of risk from a limited number of suppliers, or in some cases, single suppliers for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government debt securities, U.S. government agency securities, commercial paper and corporate bonds with high-quality accredited financial institutions. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that represent more than 10% of our total revenue or accounts receivable, net balances for the periods and as of each balance sheet date presented, respectively. Revenue from these customers reflects their purchase of our products and services and our collaboration efforts with Genentech.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, Net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.4%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.8%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech, Inc. and Roche Group</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* less than 10%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounts Receivable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we had $0.9 million and $2.4 million of unbilled receivables as of December&#160;31, 2020 and 2019, respectively. The unbilled receivables are amounts that will become due for which we have an unconditional right to consideration.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a&#160;first-in,&#160;first-out&#160;basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements and furniture and office equipment. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Useful lives assigned to property and equipment are as follows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;">
<tr>
<td style="width:223.55pt;"/>
<td style="width:7.85pt;"/>
<td style="width:223.5pt;"/>
</tr>
<tr>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 7 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of estimated useful life or remaining lease term</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years to 10 years</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We review long-lived assets for impairment whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses are classified within our statements of operations in accordance with the use of the asset.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October&#160;1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. Goodwill impairment exists when the estimated fair value of our one reporting unit is less than its carrying value. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in our statements of operations. To date, we have not recognized any impairment of goodwill.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have not recognized any impairment losses on intangible assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory and office facilities that we occupy, as well as server space. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of the new lease standard, discussed in more detail below. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory and office facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lease Financing Arrangements</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, due to our significant involvement during the construction process of a leased building, we qualified as the deemed owner of the building under build-to-suit lease accounting guidance. Prior to our adoption of the new lease standard, the cost of the related building was recorded in property and equipment, net and the offsetting lease financing obligation was recorded as a long-term financing obligation on our balance sheet. As of December 31, 2019, $36.6 million of building costs was recorded in property and equipment, net.  </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1: Quoted </span><span style="Background-color:#FFFFFF;color:#000000;">prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">Level 2: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:7.87%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:2.27%;white-space:nowrap" valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial instruments consist of Level&#160;1 and Level&#160;2 assets and has included Level&#160;3 liabilities in the past. In certain cases, where there is limited activity or less transparency around inputs to valuation, financial instruments are classified as Level&#160;3 within the valuation hierarchy. The carrying amounts of certain financial instruments approximate fair value due to their short&#160;maturities.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December&#160;31, 2020 or 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock Warrant Liability</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Preferred Stock Warrant Liability</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had issued a freestanding warrant to a venture capital firm to purchase 56,875 shares of Series&#160;C convertible preferred stock with an exercise price of $2.64 in connection with a $5.0&#160;million credit facility entered into in 2014. Immediately prior to and in connection with the completion of our initial public offering, the convertible preferred stock warrant converted to a common stock warrant. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the conversion, the fair value of this warrant was classified as a&#160;non-current&#160;liability in the balance sheets, since the underlying convertible preferred stock had been classified as temporary equity instead of shareholders&#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that were outside of our control, including liquidation, sale or transfer of control, holders of the convertible preferred stock may have caused its redemption. Prior to conversion, the warrant was subject to remeasurement at each balance sheet date, with changes in estimated fair value recognized as a component of interest and other income, net on our statements of operations. During the year ended December 31, 2019, we recognized $2.3 million of expense related to the revaluation of the convertible preferred stock warrant liability in the interest and other income, net line item on our statements of operations. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the convertible preferred stock warrant converted to a common stock warrant immediately prior to and in connection with the completion of the initial public offering, the $2.6 million financial liability was reclassified to the additional paid-in capital line item on our balance sheet, thereby concluding the need for revaluation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Revenue<span style="letter-spacing:-0.1pt;"> </span>Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue in accordance with ASC Topic 606 (&#8220;ASC 606&#8221;), <span style="font-style:italic;">Revenue from Contracts with Customers</span>. Under ASC 606, for all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1)&#160;identify the contract or contracts; (2)&#160;determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3)&#160;measure the transaction price, including the constraint on variable consideration; (4)&#160;allocate the transaction price to the performance obligations based on estimated selling prices; and (5)&#160;recognize revenue when (or as) we satisfy each performance obligation. The following is a summary of the application of the respective model to each of our revenue classifications. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue is generated from immunosequencing (&#8220;sequencing&#8221;) products and services (&#8220;sequencing revenue&#8221;) and from regulatory or development support services leveraging our immune medicine platform (&#8220;development revenue&#8221;). When revenue generating contracts have elements of both sequencing revenue and development revenue, we classify revenue based on the nature of the performance obligation and the allocated transaction price. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sequencing Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue reflects the amounts generated from providing sequencing services and testing through our clonoSEQ and immunoSEQ products and services to our clinical and research customers, respectively. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clinical customers, we derive revenues from providing our clonoSEQ test report to ordering physicians, and we bill and receive payments from medical institutions and commercial and government third-party payors. In these transactions, we have identified one performance obligation: the delivery of a clonoSEQ report. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted as necessary based on actual collection experience. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test results. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test.&#160;Revenue recognition commences at the time the initial billable test result is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized as we deliver the remaining tests in a patient&#8217;s treatment cycle or when it becomes remote that a patient will receive additional testing and we have not delivered our estimate of total tests.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research customers, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified two typical performance obligations under the terms of our research service contracts: sequencing services and related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Development<span style="letter-spacing:-0.05pt;"> </span>Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We derive revenue by providing services through development agreements to biopharmaceutical customers who seek access to our immune medicine platform technologies. We generate revenues from the delivery of professional support activities pertaining to the use of immunoSEQ and our MRD product in the development of the respective customers&#8217; initiatives. The transaction price for these contracts may consist of a combination of non-refundable upfront fees, separately priced sequencing fees, progress-based milestones and regulatory milestones. The development agreements may include single or multiple performance obligations, depending on the contract. For certain contracts, we may perform services to support the biopharmaceutical customers&#8217; regulatory submissions as part of their registrational trials. These services include regulatory support pertaining to our technology intended to be utilized as part of the submission, development of analytical plans for our sequencing data, participation on joint research committees and assistance in completing a regulatory submission. Generally, these services are not distinct within the context of the contract and they are accounted for as a single performance obligation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When sequencing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional sequencing services is not considered part of the contract. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. Variable consideration related to progress-based and regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue recognized will not occur. Progress milestones, such as the first sample result delivered or final patient enrollment in a customer trial, are customer dependent and are included in the transaction price when the respective milestone is probable of occurring. Milestone payments that are not within our customers&#8217; control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary method used to estimate standalone selling price for performance obligations is the adjusted market assessment approach. Using this approach, we evaluate the market in which we sell our services and estimate the price that a customer in that market would be willing to pay for our services. We recognize revenue using either an input or output measure of progress that faithfully depicts performance on a contract, depending on the contract. The measure used is dependent on the nature of the service to be provided in each contract. Selecting the measure of progress and estimating progress to date requires significant judgment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ContractBalancesPolicyTextBlock', window );">Contract Balances</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, contract liabilities. We classify deferred revenue as current for sequencing revenue, as we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For development services, we assess the performance obligations and recognize deferred revenue as current or&#160;non-current&#160;based upon forecasted delivery times, which are customer coordinated. In certain circumstances, the customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation includes compensation expense for stock option and restricted stock unit grants to employees and&#160;non-employees.&#160;It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option grants using the Black-Scholes option-pricing model. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising costs are expensed as incurred. Advertising expenses were $14.5 million, $6.6 million and $3.5 million for the year ended December 31, 2020, 2019 and 2018, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue includes the cost of materials, personnel-related expenses (comprised of salaries, benefits and share-based compensation), shipping and handling, equipment and allocated facility costs associated with processing samples and professional support for our sequencing revenue. Allocated facility costs include depreciation of laboratory equipment, allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses are comprised of laboratory materials costs, personnel-related expenses, equipment costs, allocated facility costs, information technology expenses and contract service expenses. <span style="Background-color:#FFFFFF;color:#000000;">We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. </span>Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. <span style="Background-color:#FFFFFF;color:#000000;">Costs to support our Genentech Agreement are a component of our research and development activities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SalesAndMarketingExpensePolicyTextBlock', window );">Sales and Marketing Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales and Marketing Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses consist primarily of personnel-related expenses for commercial sales, account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility costs.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets and liabilities are measured at the balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share Attributable to Common Shareholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We calculate basic net loss per share attributable to common shareholders by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, common stock warrants, stock options and nonvested restricted stock units are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect is anti-dilutive.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of our initial public offering in July 2019 and the related conversion of our convertible preferred stock into common stock, we calculated our basic and diluted net loss per share attributable to common shareholders in conformity with the&#160;two-class&#160;method required for companies with participating securities. We considered our convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on common stock, holders of convertible preferred stock would have been entitled to a share of such dividend in proportion to the holders of common stock on an&#160;as-if&#160;converted basis. Under the&#160;two-class&#160;method, basic net loss per share attributable to common shareholders is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of shares of common stock outstanding for the period. Net loss attributable to common shareholders is determined by allocating undistributed earnings between common and preferred shareholders. The net loss attributable to common shareholders was not allocated to the convertible preferred stock under the&#160;two-class&#160;method, as the convertible preferred stock did not have a contractual obligation to share in our losses. The diluted net loss per share attributable to common shareholders was computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, convertible preferred stock warrants, common stock warrants and stock options were considered common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to common shareholders, as their effect was anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented on a regular basis at the entity level. Resource allocation decisions are made by the CODM based on the results at the entity level, which is determined to be a single reporting unit. There are no segment managers who are held accountable by the CODM for operations, operating results or planning for levels or components below the entity. As such, we have concluded that we operate as one segment. We present disaggregated revenue from contracts with customers by type of service. See Note 3,&#160;Revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;">Recently Ad<span style="letter-spacing:-0.05pt;">opted </span>Accounting<span style="letter-spacing:-0.05pt;"> </span>Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-02, <span style="font-style:italic;">Leases</span> (Topic 842) (&#8220;ASC 842&#8221;), intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheets and disclosing key information about leasing arrangements. We adopted the guidance effective January 1, 2020 using the optional transition method described in ASU 2018-11<span style="font-style:italic;">, Leases </span>(Topic 842) <span style="font-style:italic;">Targeted Improvements</span>. Under the optional transition method, we recognized a cumulative-effect adjustment in the period of adoption. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, <span style="font-style:italic;">Leases </span>(&#8220;ASC 840&#8221;). </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In adopting the new standard, we utilized certain practical expedients available. These practical expedients include waiving reassessment of (1) whether any expired or existing contracts are or contain leases; (2) lease classification of expired or existing leases; and (3) initial direct costs for existing leases. We also elected to use hindsight in determining the lease term and in assessing impairment of our ROU assets. Furthermore, we have made a policy decision regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. We have also elected not to record on the balance sheet a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The standard had a material impact on our balance sheet as of December 31, 2020, but did not have a material impact on our statements of operations or statements of cash flows. The most significant impact was the recognition of $33.0 million and $39.7 million of operating lease ROU assets and liabilities, respectively, and the derecognition of a $36.6 million asset and corresponding liability previously recorded pursuant to build-to-suit lease accounting guidance under ASC 840, which resulted in an increase to retained earnings of $0.1 million. The operating lease ROU assets and liabilities recorded at adoption included the derecognition of $7.3 million of deferred rent recognized as of December 31, 2019, as well as a $0.5 million reclassification of tenant incentive receivables previously recognized in the prepaid expenses and other current assets line item on our balance sheet. See Note 10, Leases, for additional information regarding leases.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses </span>(Topic 326):<span style="font-style:italic;"> Measurement of Credit Losses on Financial Instruments</span>, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. The expected credit losses are recorded through an allowance account that is deducted from the amortized cost basis of the financial asset, and the net carrying value of the financial asset is presented on the balance sheet. The guidance also amends the previous other-than-temporary impairment model for available-for-sale debt securities by requiring the recognition of impairments relating to credit losses through an allowance account, limited to the difference between a security&#8217;s amortized cost basis and its fair value. Furthermore, the standard update removes the distinction between whether an impairment is temporary or other-than temporary. We adopted the guidance effective January 1, 2020. Given the short-term nature of our accounts receivable, the adoption as it relates to trade receivables did not have a significant impact on our financial statements. Furthermore, impairment of available-for-sale debt securities as of the adoption date was determined to be due to factors other than credit loss; therefore, a credit allowance was not recognized. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No.&#160;2018-15, <span style="font-style:italic;">Intangibles&#8212;Goodwill and Other: Internal-Use Software</span> (Subtopic 350-40) to provide additional guidance on the accounting for costs of implementation activities performed in a cloud computing arrangement. We adopted this guidance effective January 1, 2020 on a prospective basis, and the adoption did not have any impact on our financial statements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No.&#160;2019-12,&#160;<span style="font-style:italic;">Income Taxes</span> (Topic 740): <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span>, which eliminates certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. Among other things, this guidance also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This guidance is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied prospectively, except for certain amendments. We early adopted the guidance on January 1, 2020 and the adoption did not have a material impact on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and use of estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ContractBalancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ContractBalancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_JOBSActAccountingElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>JOBS act accounting election.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_JOBSActAccountingElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SalesAndMarketingExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SalesAndMarketingExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity convertible preferred stock policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273544465224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentrations of Risk Percentage</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, Net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer A</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.4%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.1%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.8%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer B</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer C</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech, Inc. and Roche Group</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* less than 10%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Summary of Useful Lives Assigned to Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Useful lives assigned to property and equipment are as follows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:454.9pt;;">
<tr>
<td style="width:223.55pt;"/>
<td style="width:7.85pt;"/>
<td style="width:223.5pt;"/>
</tr>
<tr>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years to 7 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of estimated useful life or remaining lease term</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td valign="bottom">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years to 10 years</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273543931080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue Disaggregated by Type of Products and Services</a></td>
<td class="text">The following table presents our revenue disaggregated by type of products and services for the periods presented (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,439</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,519</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,978</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development support</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,443</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,685</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory milestones</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total development revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,685</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,071</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,663</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;font-weight:bold;font-style:italic;;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273626050504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth the fair value of financial assets as of December 31, 2020 and 2019 that were measured at fair value on a recurring basis (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,777</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671,777</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,283</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">683,358</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,867</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,867</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,683</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">585,725</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,408</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273548801176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Investments</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investments consisted of the following as of December 31, 2020 and 2019 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">552,539</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">723</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">553,252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,497</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,581</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,036</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">809</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564,833</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,429</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,525</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,429</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,525</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,866</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,866</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,963</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286,356</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,068</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479,791</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480,290</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,887</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,513</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,548</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-term marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the gross unrealized holding losses and fair value for investments in an unrealized loss position and the length of time that individual securities have been in a continuous loss position as of December&#160;31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than 12 Months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 Months Or Greater</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177,554</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,512</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total available-for-sale securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,066</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545479560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net as of December 31, 2020 and 2019 consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,767</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,450</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,717</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,568</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">505</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,185</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,852</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,945</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,716</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Build-to-suit asset cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,607</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,074</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,382</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,692</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,355</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273640402216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets Subject to Amortization</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization as of December 31, 2020 and 2019 consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,972</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,028</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired developed technology</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,301</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,699</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased intellectual property</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,397</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,928</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense for Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, expected future amortization expense for intangible assets was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,703</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,699</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,726</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future amortization expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545413160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities as of December 31, 2020 and 2019 consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,011</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and contract research organization costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,781</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Travel and entertainment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,767</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,062</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,423</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,881</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">556</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,162</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,371</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545367656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock', window );">Schedule of Deferred Revenue by Revenue Classification</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue by revenue classification as of December 31, 2020 and 2019 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,463</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,856</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,319</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,994</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sequencing</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">724</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,459</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,332</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current and non-current deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,937</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,326</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in deferred revenue during the year ended December 31, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,326</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions to deferred revenue during the period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,434</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized during the period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,823</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.82%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236,937</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of deferred revenue by revenue classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273544100648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Other Information Related to Operating Lease</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Other information related to our operating leases as of </span>December <span style="Background-color:#FFFFFF;">31, 2020 was as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000738">11.33</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Reconciles Undiscounted Operating Lease Cash Flows</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities as of </span>December<span style="Background-color:#FFFFFF;"> 31, 2020 (in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,554</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,318</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,030</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,419</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,463</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,612</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Imputed interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,848</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Tenant improvement receivables</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,902</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,862</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,529</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, less current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273544056296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock', window );">Summary of Reserved Shares of Common Stock</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, w<span style="color:#231F20;">e have reserved shares of common stock for the following: </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issuable upon the exercise of outstanding common stock options and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; the vesting of outstanding common restricted stock units granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,483,560</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the 2019 Equity Incentive Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,617,001</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future grant under the Employee Stock Purchase Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,804,298</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares to be issued upon exercise of a common stock warrant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,875</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.96%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved for future issuance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,961,734</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of reserved shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549535096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock', window );">Summary of Changes in Shares Available for Grant</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in shares available for grant during the year ended December 31, 2020 were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Available for Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,396,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 Plan reserve increase on January 1, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,261,907</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and restricted stock units granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,291,701</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited, cancelled or expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for grant at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,617,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the 2008 Plan, 2009 Plan and 2019 Plan during the year ended December&#160;31, 2020 was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,646,654</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398,379</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,241,701</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited or cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(235,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.16</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,204,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,433,560</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.82</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668,458</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and exercisable at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,924,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2020 was as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-weight:bold;;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Units</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested outstanding restricted stock units at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimated Grant Date Fair Value of Options Granted</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated grant date fair value of options granted during the year ended December&#160;31, 2020, 2019 and 2018 was estimated using the Black-Scholes option-pricing model with the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.68 - $55.23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.80 - $47.81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000845">5.27 - 6.08</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000846">5.27 - 6.08</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000847">6.08 - 10.00</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000851">0.4% - 1.7%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000852">1.4% - 2.5%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000853">2.6% - 3.0%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000857">70.5% - 73.3%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000858">64.3% - 72.9%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000859">65.0% - 69.2%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Compensation Costs Related to Stock Options and RSUs Included on Statements of Operations</a></td>
<td class="text">The compensation costs related to stock options and restricted stock units for the years ended December 31, 2020, 2019 and 2018 are included on our statements of operations as follows (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">817</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">398</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,519</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,896</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,480</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,891</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administration</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,155</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,964</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,761</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,124</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,149</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of share-based compensation, shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545357048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The significant components of our deferred tax assets and liabilities for the periods presented are as follows (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,433</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,035</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforward</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,981</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,152</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non qualifying stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,096</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,150</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,755</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,052</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,713</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,706</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,983</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,892</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,258</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,690</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(197,527</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,906</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net of valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,731</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,784</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible and intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,760</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,784</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66.1)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44.3)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30.3)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Change in Unrecognized Tax Benefits</a></td>
<td class="text">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the periods presented are as follows (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,031</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">792</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,052</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions in 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,489</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273626094904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders for the periods presented (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,447</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustments to redemption value for Series E-1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; convertible preferred stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(964</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common shareholders, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(146,227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,570</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,345</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used in computing net loss per share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,216,468</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,165,315</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,629,778</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common shareholders, basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.01</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the year ended December 31, 2020, 2019 and 2018, respectively, as they had an anti-dilutive effect:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (on as if converted basis)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,104,469</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,783,867</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,125,548</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,183,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,701,626</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonvested restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,125</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,875</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,961</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,032</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,875</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,220,548</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,377,132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,597,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273632257448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2019</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,160<span></span>
</td>
<td class="nump">$ 320,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued</a></td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 315,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SaleOfStockUnderwritingDiscountsAndCommission', window );">Underwriting discounts, commissions and other costs</a></td>
<td class="nump">24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_InitialPublicOfferingExpenses', window );">Offering expenses</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment Option, at Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary Or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_InitialPublicOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_InitialPublicOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SaleOfStockUnderwritingDiscountsAndCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock underwriting discounts and commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SaleOfStockUnderwritingDiscountsAndCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273632168936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Performance_Obligation </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 2,138,000<span></span>
</td>
<td class="nump">$ 2,138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment losses on intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase stock | shares</a></td>
<td class="nump">56,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266,000<span></span>
</td>
<td class="num">$ (6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 99,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">107,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (511,612,000)<span></span>
</td>
<td class="num">(365,478,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 (Topic 842)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle, accounting standards update, early adoption</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 33,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DerecognitionOfBuildToSuitLeaseAsset', window );">Derecognized portion of build-to-suit asset</a></td>
<td class="nump">36,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DerecognitionOfBuildToSuitLiabilities', window );">Derecognition of build-to-suit liabilities</a></td>
<td class="nump">36,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DerecognitionOfDeferredRent', window );">Derecognition of deferred rent</a></td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ReclassificationOfTenantIncentiveReceivables', window );">Reclassification of tenant incentive receivables</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">Accounting Standards Update 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle, accounting standards update, early adoption</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member', window );">Accounting Standards Update 2018-15</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle, accounting standards update, early adoption</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">Accounting Standards Update 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle, accounting standards update, early adoption</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember', window );">Sequencing Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_NumberOfRevenuePerformanceObligation', window );">Number of revenue performance obligations | Performance_Obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=adpt_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted-average exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, weighted average exercise price of warrants or rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DerecognitionOfBuildToSuitLeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of build to suit lease asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DerecognitionOfBuildToSuitLeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DerecognitionOfBuildToSuitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of build-to-suit liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DerecognitionOfBuildToSuitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DerecognitionOfDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derecognition of deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DerecognitionOfDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfRevenuePerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of revenue performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfRevenuePerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ReclassificationOfTenantIncentiveReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of tenant incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ReclassificationOfTenantIncentiveReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was early adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520240&amp;loc=SL120174030-210619<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_SequencingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=adpt_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=adpt_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273626267160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerAMember', window );">Customer A | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerAMember', window );">Customer A | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.10%<span></span>
</td>
<td class="nump">41.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerBMember', window );">Customer B | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerBMember', window );">Customer B | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerCMember', window );">Customer C | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember', window );">Genentech, Inc. and Roche Group | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">55.80%<span></span>
</td>
<td class="nump">42.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273547999112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, useful lives</a></td>
<td class="text">Shorter of estimated useful life or remaining lease term<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273551991272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 98,382<span></span>
</td>
<td class="nump">$ 85,071<span></span>
</td>
<td class="nump">$ 55,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember', window );">Sequencing Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">41,439<span></span>
</td>
<td class="nump">43,519<span></span>
</td>
<td class="nump">32,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentSupportRevenueMember', window );">Development Support Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">54,443<span></span>
</td>
<td class="nump">39,552<span></span>
</td>
<td class="nump">12,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueRegulatoryMilestonesMember', window );">Development Revenue Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember', window );">Development Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 56,943<span></span>
</td>
<td class="nump">$ 41,552<span></span>
</td>
<td class="nump">$ 22,685<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_SequencingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_DevelopmentSupportRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_DevelopmentSupportRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_DevelopmentRevenueRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273551916248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 61,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (69,823,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,382,000<span></span>
</td>
<td class="nump">$ 85,071,000<span></span>
</td>
<td class="nump">$ 55,663,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_TranslationalDevelopmentAgreementsMember', window );">Translational Development Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AgreementTerminationAmountReceivable', window );">Agreement termination amount receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_EligiblePaymentsReceivable', window );">Eligible payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts', window );">Revenue recognized excluding separately negotiated research sequencing contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_TranslationalDevelopmentAgreementsMember', window );">Translational Development Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember', window );">MRD Development Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember', window );">MRD Development Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AdditionalMilestonePayment', window );">Additional milestone payment receivable</a></td>
<td class="nump">313,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_NonRefundableUpfrontPaymentsReceived', window );">Non-refundable upfront payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,800,000<span></span>
</td>
<td class="nump">$ 35,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_RevenueRecognitionExpectedPeriod', window );">Revenue recognition expected period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="nump">1,430,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_RevenueRecognitionExpectedPeriod', window );">Revenue recognition expected period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AgreementTerminationAmountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination amount receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AgreementTerminationAmountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability milestone method revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_EligiblePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_EligiblePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NonRefundableUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NonRefundableUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueRecognitionExpectedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition expected period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueRecognitionExpectedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition milestone method expected milestone receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized excluding separately negotiated research sequencing contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_TranslationalDevelopmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_TranslationalDevelopmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273546370344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 786,641<span></span>
</td>
<td class="nump">$ 674,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">103,283<span></span>
</td>
<td class="nump">88,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">683,358<span></span>
</td>
<td class="nump">585,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">103,283<span></span>
</td>
<td class="nump">88,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">103,283<span></span>
</td>
<td class="nump">88,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">671,777<span></span>
</td>
<td class="nump">377,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Debt Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">671,777<span></span>
</td>
<td class="nump">377,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">11,581<span></span>
</td>
<td class="nump">86,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 11,581<span></span>
</td>
<td class="nump">86,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273550075752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Available-for-sale Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember', window );">Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 564,036<span></span>
</td>
<td class="nump">$ 479,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">564,833<span></span>
</td>
<td class="nump">480,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember', window );">Long-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">118,429<span></span>
</td>
<td class="nump">105,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">118,525<span></span>
</td>
<td class="nump">105,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Debt Securities | Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">552,539<span></span>
</td>
<td class="nump">285,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">553,252<span></span>
</td>
<td class="nump">286,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Debt Securities | Long-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">118,429<span></span>
</td>
<td class="nump">90,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">118,525<span></span>
</td>
<td class="nump">90,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds | Short-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,497<span></span>
</td>
<td class="nump">71,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 11,581<span></span>
</td>
<td class="nump">72,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds | Long-Term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273626273464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273546956936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair value</a></td>
<td class="nump">$ 179,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized loss</a></td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair value</a></td>
<td class="nump">177,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized loss</a></td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair value</a></td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized loss</a></td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273548846040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 64,074<span></span>
</td>
<td class="nump">$ 78,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(24,382)<span></span>
</td>
<td class="num">(18,116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">39,692<span></span>
</td>
<td class="nump">60,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">27,767<span></span>
</td>
<td class="nump">20,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">2,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">2,717<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 21,945<span></span>
</td>
<td class="nump">14,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_BuildToSuitAssetCostMember', window );">Build-to-suit Asset Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_BuildToSuitAssetCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_BuildToSuitAssetCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273552161976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 6,769<span></span>
</td>
<td class="nump">$ 6,093<span></span>
</td>
<td class="nump">$ 4,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273541141816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 118,972,000<span></span>
</td>
<td class="nump">$ 118,972,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Purchased Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273547097192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 20,325<span></span>
</td>
<td class="nump">$ 20,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,100)<span></span>
</td>
<td class="num">(8,397)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">10,225<span></span>
</td>
<td class="nump">11,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Acquired Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,972)<span></span>
</td>
<td class="num">(8,301)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">10,028<span></span>
</td>
<td class="nump">11,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Purchased Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549204680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 10,225<span></span>
</td>
<td class="nump">$ 11,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273543959384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 3,219<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent', window );">Clinical and contract research organization costs</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Travel and entertainment</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Tax liabilities</a></td>
<td class="nump">1,767<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent', window );">Purchases of property and equipment</a></td>
<td class="nump">4,423<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 13,162<span></span>
</td>
<td class="nump">$ 4,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and contract research organization costs, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued purchase of property and equipment current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273544128760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises', window );">Accrued tax withholding liability related to unsettled option exercises</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued tax withholding liability related to unsettled option exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273547081288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ContractWithCustomerLiabilityCurrentAbstract', window );"><strong>Current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Total current deferred revenue</a></td>
<td class="nump">$ 73,319<span></span>
</td>
<td class="nump">$ 60,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ContractWithCustomerLiabilityNonCurrentAbstract', window );"><strong>Non-current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Total non-current deferred revenue</a></td>
<td class="nump">163,618<span></span>
</td>
<td class="nump">219,332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total current and non-current deferred revenue</a></td>
<td class="nump">236,937<span></span>
</td>
<td class="nump">280,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember', window );">Sequencing Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ContractWithCustomerLiabilityCurrentAbstract', window );"><strong>Current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Total current deferred revenue</a></td>
<td class="nump">15,463<span></span>
</td>
<td class="nump">12,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ContractWithCustomerLiabilityNonCurrentAbstract', window );"><strong>Non-current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Total non-current deferred revenue</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember', window );">Development Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ContractWithCustomerLiabilityCurrentAbstract', window );"><strong>Current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Total current deferred revenue</a></td>
<td class="nump">57,856<span></span>
</td>
<td class="nump">48,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ContractWithCustomerLiabilityNonCurrentAbstract', window );"><strong>Non-current deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Total non-current deferred revenue</a></td>
<td class="nump">$ 162,894<span></span>
</td>
<td class="nump">$ 217,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ContractWithCustomerLiabilityCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability current abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ContractWithCustomerLiabilityCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ContractWithCustomerLiabilityNonCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability non current abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ContractWithCustomerLiabilityNonCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_SequencingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549245224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">$ 73,319<span></span>
</td>
<td class="nump">$ 73,319<span></span>
</td>
<td class="nump">$ 60,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">163,618<span></span>
</td>
<td class="nump">163,618<span></span>
</td>
<td class="nump">219,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">61,600<span></span>
</td>
<td class="num">(69,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember', window );">Development Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">57,856<span></span>
</td>
<td class="nump">57,856<span></span>
</td>
<td class="nump">48,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">162,894<span></span>
</td>
<td class="nump">162,894<span></span>
</td>
<td class="nump">217,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember', window );">Development Revenue | Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">55,100<span></span>
</td>
<td class="nump">55,100<span></span>
</td>
<td class="nump">48,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">157,000<span></span>
</td>
<td class="nump">157,000<span></span>
</td>
<td class="nump">216,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember', window );">Sequencing Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">15,463<span></span>
</td>
<td class="nump">15,463<span></span>
</td>
<td class="nump">12,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">$ 724<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_MedicareRevenueMember', window );">Medicare | Specific Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_SequencingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_SpecificPatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_SpecificPatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273541500168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue - Additional Information (Details1) - Genentech, Inc. - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, expected to be recognized</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_GenentechIncMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, expected to be recognized</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_GenentechIncMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, expected to be recognized</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273552288728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue balance at December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Additions to deferred revenue during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized during the period</a></td>
<td class="nump">$ 61,600<span></span>
</td>
<td class="num">(69,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue balance at December 31, 2020</a></td>
<td class="nump">$ 236,937<span></span>
</td>
<td class="nump">$ 236,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273542825544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases- Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">19,900<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">14,750<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Cash payment for rent begins in October 2021 and the lease term ends in August 2033, <span></span>
</td>
<td class="text">The lease term is through March 2026 and provides for one five-year extension option.<span></span>
</td>
<td class="text">options to extend certain of the leases up to 10.0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear', window );">Lessee, operating lease, rent commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseExtendedTermOfContract', window );">Lessee, operating lease, extended term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-11<span></span>
</td>
<td class="text">2029-10<span></span>
</td>
<td class="text">2033-08<span></span>
</td>
<td class="text">2026-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LeaseCommencementMonthAndYear', window );">Lease commenced moth and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Landlord contribution for leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ProceedsFromLandlordReimbursements', window );">Proceeds from landlord reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TenantImprovementCostsIncurred', window );">Tenant improvement costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TenantImprovementCostsReceivable', window );">Tenant improvement costs receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_TenantImprovementAllowanceAndCommenced', window );">Tenant improvement allowance and commenced</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseTerminationPeriod', window );">Operating lease termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_NumberOfOperatingLeaseTerminate', window );">Number of operating lease terminate | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_OperatingLeaseVariableLeaseExpense', window );">Operating lease variable lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Cash received for tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 (Topic 842)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Seattle, Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear', window );">Lessee, operating lease, rent commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseExtendedTermOfContract', window );">Lessee, operating lease, extended term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseExtendedTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, extended term of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseExtendedTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease rent commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseRentCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease termination period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfOperatingLeaseTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease terminate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfOperatingLeaseTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_OperatingLeaseVariableLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease variable lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_OperatingLeaseVariableLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ProceedsFromLandlordReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from landlord reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ProceedsFromLandlordReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TenantImprovementAllowanceAndCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance and commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TenantImprovementAllowanceAndCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TenantImprovementCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TenantImprovementCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TenantImprovementCostsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement costs receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TenantImprovementCostsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273551923976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases- Summary of Other Information Related to Operating Lease (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">11 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273626085912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 7,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">13,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">13,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">13,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">13,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">88,463<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">149,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest rate</a></td>
<td class="num">(35,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable', window );">Tenant improvement receivables</a></td>
<td class="num">(5,902)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">107,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(3,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">$ 104,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability tenant improvement receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273541276104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000,000<span></span>
</td>
<td class="nump">340,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of our common stock are entitled to one vote for each share of common stock held<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_NumberOfCommonStockVotingRights', window );">Number of vote for each share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,646,896<span></span>
</td>
<td class="nump">125,238,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ClassOfWarrantOrRightsTerm', window );">Warrant exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted-average exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised', window );">Stock issued during period, common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=adpt_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ClassOfWarrantOrRightsTerm', window );">Warrant exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted-average exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares', window );">Percentage of annual increases in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,261,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="nump">6,882,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares', window );">Percentage of annual increases in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,039,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,790,094<span></span>
</td>
<td class="nump">92,656,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, weighted average exercise price of warrants or rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ClassOfWarrantOrRightsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights, term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ClassOfWarrantOrRightsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfCommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfCommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual increases in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PercentageOfAnnualIncreasesInNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=adpt_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=adpt_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549170648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">35,961,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember', window );">Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">14,483,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Grant | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">18,617,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Grant | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">2,804,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Exercise of Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">56,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273626153112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Option </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life options outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted-average remaining contractual life vested and exercisable options outstanding</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value | $ / shares</a></td>
<td class="nump">$ 21.11<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 190,400<span></span>
</td>
<td class="nump">$ 39,100<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 21,748<span></span>
</td>
<td class="nump">$ 4,055<span></span>
</td>
<td class="nump">$ 1,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted-average volatility</a></td>
<td class="nump">71.40%<span></span>
</td>
<td class="nump">68.10%<span></span>
</td>
<td class="nump">68.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 24,761<span></span>
</td>
<td class="nump">$ 13,124<span></span>
</td>
<td class="nump">$ 11,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_NumberOfEmployeeOptionModification', window );">Number of employee option modification | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense related to unvested stock options</a></td>
<td class="nump">$ 74,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Option Valuation Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized share-based compensation expense related to unvested RSUs</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_SequentaTwoThousandAndEightStockPlanMember', window );">Sequenta 2008 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber', window );">Equity awards outstanding | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember', window );">2009 Equity Incentive Plan | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember', window );">2009 Equity Incentive Plan | Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance | shares</a></td>
<td class="nump">18,617,001<span></span>
</td>
<td class="nump">15,396,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance | shares</a></td>
<td class="nump">22,109,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant | Non Employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value | $ / shares</a></td>
<td class="nump">$ 28.10<span></span>
</td>
<td class="nump">$ 41.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Units | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ReceivableForStockOptionExercises', window );">Unsettled cash proceeds related to stock options exercised</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfEmployeeOptionModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employee option modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfEmployeeOptionModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ReceivableForStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable for stock option exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ReceivableForStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_SequentaTwoThousandAndEightStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_SequentaTwoThousandAndEightStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adpt_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adpt_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549437128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) - 2019 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Outstanding, Beginning Balance</a></td>
<td class="nump">15,396,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant', window );">Shares Available for Grant, 2019 Plan reserve increase</a></td>
<td class="nump">6,261,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted', window );">Shares Available for Grant, Options and restricted stock units granted</a></td>
<td class="num">(3,291,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired', window );">Shares Available for Grant, Options and forfeited, cancelled or expired</a></td>
<td class="nump">250,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Outstanding, Ending Balance</a></td>
<td class="nump">18,617,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase reserve shares available for grant,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment awards forfeited, canceled or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment awards granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273660235672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Outstanding Options, Options outstanding, Beginning Balance</a></td>
<td class="nump">16,646,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Subject to Outstanding Options, Options granted</a></td>
<td class="nump">3,241,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Shares Subject to Outstanding Options, Options forfeited or cancelled</a></td>
<td class="num">(235,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares Subject to Outstanding Options, Options expired</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Subject to Outstanding Options, Options exercised</a></td>
<td class="num">(5,204,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Outstanding Options, Options outstanding, Ending Balance</a></td>
<td class="nump">14,433,560<span></span>
</td>
<td class="nump">16,646,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable', window );">Shares Subject to Outstanding Options, Options vested and exercisable</a></td>
<td class="nump">7,924,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Options outstanding, Beginning Balance</a></td>
<td class="nump">$ 6.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Options granted</a></td>
<td class="nump">33.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Options forfeited or cancelled</a></td>
<td class="nump">16.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Options expired</a></td>
<td class="nump">0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Options exercised</a></td>
<td class="nump">4.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Options outstanding, Ending Balance</a></td>
<td class="nump">12.82<span></span>
</td>
<td class="nump">$ 6.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Options vested and exercisable</a></td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Option outstanding</a></td>
<td class="nump">$ 668,458<span></span>
</td>
<td class="nump">$ 398,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and exercisable</a></td>
<td class="nump">$ 417,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273552186136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 21.11<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted Stock Units Outstanding, Granted</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted Stock Units Outstanding, Vested</a></td>
<td class="num">(4,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance</a></td>
<td class="nump">$ 41.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">28.10<span></span>
</td>
<td class="nump">$ 41.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested</a></td>
<td class="nump">41.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance</a></td>
<td class="nump">$ 28.10<span></span>
</td>
<td class="nump">$ 41.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273552314472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">70.50%<span></span>
</td>
<td class="nump">64.30%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">73.30%<span></span>
</td>
<td class="nump">72.90%<span></span>
</td>
<td class="nump">69.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="nump">$ 17.68<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="nump">$ 55.23<span></span>
</td>
<td class="nump">$ 47.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549352552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 24,761<span></span>
</td>
<td class="nump">$ 13,124<span></span>
</td>
<td class="nump">$ 11,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">8,519<span></span>
</td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">2,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">6,627<span></span>
</td>
<td class="nump">3,480<span></span>
</td>
<td class="nump">2,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 8,798<span></span>
</td>
<td class="nump">$ 5,155<span></span>
</td>
<td class="nump">$ 4,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273626058232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Microsoft Collaboration Agreement - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">preferred stock investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MicrosoftCollaborationAgreementMember', window );">Microsoft Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement', window );">Minimum service consumption requirement amount</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement', window );">Minimum service consumption requirement term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MicrosoftCollaborationAgreementMember', window );">Microsoft Collaboration Agreement | Series F-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">preferred stock investment</a></td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum service consumption requirement amount under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum service consumption requirement term under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MicrosoftCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MicrosoftCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adpt_SeriesFOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adpt_SeriesFOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273545895576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 105,433<span></span>
</td>
<td class="nump">$ 79,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">Tax credit carryforward</a></td>
<td class="nump">18,981<span></span>
</td>
<td class="nump">11,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DeferredTaxAssetsNonQualifiedStockOptions', window );">Non qualifying stock options</a></td>
<td class="nump">12,096<span></span>
</td>
<td class="nump">9,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">31,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">59,713<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,983<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">230,258<span></span>
</td>
<td class="nump">114,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(197,527)<span></span>
</td>
<td class="num">(100,906)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">13,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets', window );">Tangible and intangible assets</a></td>
<td class="num">(5,760)<span></span>
</td>
<td class="num">(13,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DeferredTaxLiabilitiesRightOfUseAssets', window );">ROU assets</a></td>
<td class="num">(26,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxAssetsNonQualifiedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, non qualified stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxAssetsNonQualifiedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, tangible and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273625276600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 96,600,000<span></span>
</td>
<td class="nump">$ 30,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_NetOperatingLossCarryforwardExpirationPeriod', window );">Maturity period for net operating loss carryovers</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. federal net operating losses</a></td>
<td class="nump">$ 211,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">3,489,000<span></span>
</td>
<td class="nump">2,052,000<span></span>
</td>
<td class="nump">$ 1,260,000<span></span>
</td>
<td class="nump">$ 1,031,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">1,437,000<span></span>
</td>
<td class="nump">792,000<span></span>
</td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. federal net operating losses</a></td>
<td class="nump">192,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">U.S. federal tax credits</a></td>
<td class="nump">$ 18,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NetOperatingLossCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carryforward Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NetOperatingLossCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273549954808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">25.20%<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(66.10%)<span></span>
</td>
<td class="num">(44.30%)<span></span>
</td>
<td class="num">(30.30%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273541191544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 2,052<span></span>
</td>
<td class="nump">$ 1,260<span></span>
</td>
<td class="nump">$ 1,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 3,489<span></span>
</td>
<td class="nump">$ 2,052<span></span>
</td>
<td class="nump">$ 1,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273552407016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (146,227)<span></span>
</td>
<td class="num">$ (68,606)<span></span>
</td>
<td class="num">$ (46,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Fair value adjustments to redemption value for Series E-1 convertible preferred stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(964)<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (146,227)<span></span>
</td>
<td class="num">$ (69,570)<span></span>
</td>
<td class="num">$ (46,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share</a></td>
<td class="nump">131,216,468<span></span>
</td>
<td class="nump">69,165,315<span></span>
</td>
<td class="nump">12,629,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common shareholders, basic and diluted</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273551968248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">16,220,548<span></span>
</td>
<td class="nump">63,377,132<span></span>
</td>
<td class="nump">107,597,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,104,469<span></span>
</td>
<td class="nump">92,783,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">16,125,548<span></span>
</td>
<td class="nump">17,183,546<span></span>
</td>
<td class="nump">14,701,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember', window );">Nonvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">38,125<span></span>
</td>
<td class="nump">4,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">56,875<span></span>
</td>
<td class="nump">55,961<span></span>
</td>
<td class="nump">55,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_ConvertiblePreferredStockWarrantsMember', window );">Convertible Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,204<span></span>
</td>
<td class="nump">56,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_ConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_ConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140273544266056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employees maximum annual contribution of their compensation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adpt_DefinedContributionPlanEmployeeServicePeriodForVesting', window );">Employee service period for vesting</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DefinedContributionPlanEmployeeServicePeriodForVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employee service period for vesting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DefinedContributionPlanEmployeeServicePeriodForVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&"P ?M]*:9Y?[ +=Y=[B/U!+ P04    " #B@UA2%6Y_EK<"  !1!P  &
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M+@"W@*U:[,T.:#;6_0'+8XY#/?F/-1N=,GTC)3> ;G+P@D9..RC[+)*D#'"
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M.H.0>G,T(-3'*PD/=1,>%QNC!@(!B8^0>EVUAV ?GF0:]"E,0V$8R#.BQEH
M! 0C]5G.<X-<I'189@89J-;:)AG$SS65CUT:!$-UQBN#T)A"Z*M4\:,;?M_=
MDD%1-\<Y[';0N Y3JO=6;,?&SC.<;D9T.)P9-;5$ I_X8:16#9.=WU2('Q?]
M%I=W*4_6&5MP7>]-P(<JV]_KM&_J8MW\S.*VJ.MBU;Q<LI@S "' OU\41?WX
M1OQR8_NKJ=._ 5!+ P04    " #B@UA2O AE.F,(  #D(P  &    'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;*5::V_C-A;]*X+1#S/ >"P^]!HD 29V!RVP
M;8-FN_N9D6A;'4ET*2J9[*]?4I(EF2]GVB^))!\^SN7E/?=2NGEA_&M[I%0$
MW^JJ:6]71R%.GS:;-C_2FK0?V8DV\I<]XS41\I8?-NV)4U+TC>IJ \,PWM2D
M;%9W-_VS!WYWPSI1E0U]X$';U37AK_>T8B^W*[ Z/_B]/!R%>K"YNSF1 WVD
MXH_3 Y=WFZF7HJQITY:L"3C=WZX^@T\[C%6#'O&?DKZTB^M 47EB[*NZ^;FX
M785J1K2BN5!=$/GOF6YI5:F>Y#S^&CM=36.JALOK<^]?>O*2S!-IZ995_RT+
M<;Q=I:N@H'O25>)W]O(3'0E%JK^<56W_-W@9L>$JR+M6L'IL+&=0E\WPGWP;
M#;%H &)' S@V@'H#[&B Q@;HK0WPV* W]6:@TMMA1P2YN^'L)> *+7M3%[TQ
M^]:2?MFH=7\47/Y:RG;B[E$00>4ZBC9@^V!+VF/P1?I"&ZR#/QYWP;L?W@<_
M!&43_/O(NI8T17NS$7)8U7B3CT/<#T- QQ  !K^P1AS;X,>FH,5E!QLYWVG2
M\#SI>^CM<4?SCP$"'P(8PM RH>V;FX/,TGSW]N:IAPV:E@#U_2%'?[^=*">B
M; [#)BA%25M/MWCJ%O?=8D>WO\J@4;'6NF!#RZAOJ2+#\]T:X!C"Y&;SO+2C
M!1>G<1A?PG86&(XQGGN[(!!-!"*O73X7?TK_'WQ3,!ED<M;D946#9F2FGJKK
M7'GMNZZEA?34]\&)L^=2.EKP]!HPBVT_>8P;3W.+O<;=41EE\Y+TL8M^DU&X
MI39##[W$"\O$29QI5K: P@QI-C9!&(7 ;N%D8I'X740:5-FNHC)R^F@DQN (
MQK%]\'0://4._G@DG*Y5S"Z"G-5J[*OF3(UY0)S$0+.GB0((0*P9U((" &=V
M4ME$*O.2^KD1I#F43])+2=M2Z;FD9ER4_^NIV2AEYC224%O\K0449ZE&R IR
M\ 'AK _A%4;/=-B%5ZF,/2UGD"0Z%0MHC7&LN[L-!B# #CH+N0->.E](R8-G
M4G5R@:;XHJ1/!I=G*NFII9-[>T\YEXXI]3?_&KP0SDDC;$HS#G?ADLNM,;(Q
M46O']@%PI@*]5'X31\JMZP#-==#WB 6#HDR?M@E:@]0Q[UGN@%_OMD>Y16BK
MLHI%>!YW2U,$54F>RNIJJ :S$ *_$G[.<]8I%9$AFY;/1"[Q!R4<5MMA<SUC
M8#BQB5HG*4AT^YFP)(D<]IME$417=V0C&'^USC^R;*\LPSH!"PQ !'0"%A@*
ML<MU9_4$?OE\X/1$RN(<ZH=U9\J?9<XK-YX*-KU#6"F:4K@&*(8Z10LLC1)C
M:UI@R.GDL[("O[1./G<BKZ27 \F0Y#GOZ(6'6PF:<IO@+-+YF:AXJ5\C/1,%
M0>KRP5F[@5^\=^< J=;*&A=->4UTP;)@UCAUF7Z68.#7X#F?'O*::]8V=7.=
MI@X7A[-N0K]N+BPDMVMG36>@30L12O4$T8*3&I/IZ?K.UE_L2FG@K)G0KYE.
MH8$668/Z#MO:4%%FS-V" BETS'T62>@7R5^_OSZP,K4I(<[B5%<&"Q"&$0[U
M[-/6(8(P<BW6K*[0KZY#OO;F:A+.*@K]*OK0\?Q(5+"6V9*TH;2<>.W#&OVK
M*T^U/1#<0XM4@C0U4EPK#L PU UGP<70E>?"656A7U4OZ-6$?Z6BC]LME8KD
M]@N+0,:9= P]6MN :8JAD3/8@+(VCQ8&NV0XBRZ\)KHLI[1H@SUG=="2:M3=
MFHB1X?=1-X4SRN)$K[.V%AP&*('&PIHX$*$(.?0 SE(,KU2Y_A!07MTP(U]3
M2:6#)B$V"%N .)6UF+'4%IU'+N&9I1FFW@#PI6Q(D[\] ,RZ"OVZ>ND_]!OE
M>2GE5?K,4"6QDRH,[;8S-59Z/DYURYDP'$:1;C9+H0MCAYN@6;"17[ OZ9VZ
MIZK,)3FIXLJ6?858UZP9R/;U@WK8-07E+VJ72%!1MF/6I_:5PI=MZ[()LHAZ
M D&L[8NM!8=@F$:A@_ LZ\@OZP_D]5S\ZFQSUHK662,ABU0CJ%>8-A3.7(D5
MFA4=^17]<IVD@3OI[E1?H* [R4N9N%PX*KG$>.IZ9.JS0V+0XIP7_:T\:CNV
MTZHQS>UM(.AR@EG5T?53XCXX+D/B_FH(&1W!4BQG*$KU8V0+#H$L WHM9L$!
MB%T[>Y9VY)=VQ;%L<MY7 ^\*.ER]5P<0BOJ'P0 JBWF6HGC>OERJ B]SH8XG
MY>]6_J960W4^KM,W85C6J_J1EP4FBVWH.C! L_ CO_!OWTPR(")XHH>R:<:8
M]TJ)-?-'IEAG:0)T*;3 HBC,]&,&"RR-D.N &<W*C_S*_WW$J3J#\% VU1K
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MPPJ23-(@'*KLV'Q+A5K>TM8VCT#'B AGYSAV1*M:XB["H?P'E$J"PJ:GU%<
M)&PL,A1)SW:$#->INKY6@J@%W\$5R6EK"G(0KPNVSX+"PD-6/'%0IHK'>[?.
M A\=7J)/X&71=S,J4W)0:MV\VT?I$:)%X,YJQ#6U2*XY.7'(QTMVE&(=39 B
MM&F8OUU\V&Z2J":#-ETDXSP>3C/\0HZBEF:!G3G1(@84^9:^&QU@+6N4V*=.
MN@!GH@/74"MHR+DA/Q%OH2S']*J;:Z3R95513 FN<D<+Q<=3;.=^.+788?ZD
M$=<[,RS141^08Z*J1VL3FAW0E@@'NI&63(6JJ#K< -([#DO^/#I^%(/".)QL
M<4];W*"AXNCA7EPRE$V1^%7Z4GX2/VL[YR,U?J>)]]+=4-C 'B38J/*[#DTA
M"7R4!$;]:0J]Q(\QAVZI@&&AO.^P/&:OQ:DS.QCG^]DXRS+A<=9PVZON41]S
M$NDN\NY7]!A=V_M!=UQ4J?UP\QT.I9A 2Z<0/=^W0&'1*G>DUK9/^GBR([\#
M=\LO>*/S%C%3G^79! 1;Y%>D$/,#79(0@%(\VYWM3X[P::@U!QDDT(:Y4 NB
M$K4D*Q! Z+AN&79-BP>HF<)VIB]H=AS>Q>**^^Y-9FO@&-B!&]WA4N"37,_V
M)]FP:H*\@G?+G4NS2<2W?>CXJ^V+N"$KUGP"F0<: /Y!,CT53X0S^]^'<^_)
M<.8'L\GAOQ).-GP8L5:J>'AU?O*U+];IUE4"I\4B7IC0B1DVW2K6L^L[V5FZ
MBFR6IPL=:AD?(!Z'8 73;'*P/Q(N79+2(-@V7DSF-N":$Q^YY9'C!7A?6?3(
M?L ;K&^JIW\#4$L#!!0    ( .*#6%*&%.<+M"<   )^   8    >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&ULU5WKC]M&DO\^?P7A2P[)0B//PW8<YP&,QW8N
M01Q[/?$:A\-]H,B6Q)@B%3Y&5O[ZJ_I557=3(L?.[N+N%@$<C4@VJZOK_=*W
MN[IYWZZ=ZY(/F[)JO[NW[KKMD_OWVVSM-FD[K[>NHBO+NMFD'?W9K.ZWV\:E
M.1[:E/<OSLX>W=^D177O^V_QW>OF^V_KOBN+RKUNDK;?;-)F_]25]>Z[>^?W
M[(LWQ6K=\1?WO_]VFZ[<C>O>;E\W]-=]OTI>;%S5%G65-&[YW;VK\R=/'_#]
MN.%OA=NUT>>$=[*HZ_?\QX_Y=_?.&"!7NJSC%5+ZWZV[=F7)"Q$8O^N:]_PK
M^<'XLZW^ GNGO2S2UEW7Y;LB[];?W7M\+\G=,NW+[DV]^P^G^WG(ZV5UV>+?
M9"?W7E[<2[*^[>J-/DP0;(I*_I]^4#Q$#SP^FWC@0A^X -SR(D#Y+.W2[[]M
MZEW2\-VT&G_ 5O$T 5=4?"@W74-7"WJN^_ZF6%7%LLC2JDNNLJSNJZZH5LGK
MNBRRPK7?WN_H)7SK_4P7?"H+7DPL>'Z1O*RK;MTFSZO<Y<,%[A-T'L0+ _'I
MQ9TK/G/9/+D\GR479Q=G=ZQWZ;=\B?4N)]8;V6;R7U>+MFN(1/[[CA<\\"]X
M@!<\^.?A].X%+^8G'UDS>9JV19O\NG8)\>8V;5+0?+U,ED655EF1EDG;I9TC
M?NK:I*B2K*Z8I8MN3Q37K9,?KJY>$Y?]WA<-+;=)*V))OCGI:OKKO4LRUW3$
MY(EKNX*XP;6SY+<^7\F":94G:4N<O>7WMDFW3KLD72Z)]^BSHX6W==,YNFG#
MH+<,&=WO]-&R2!=%672\$_Y;'BE3?B(OVJRLVY[!2F6UG"[P"OQY;'\S6CO9
M$:?S_Z=>W[A;5_7Z0O>!I%Q+?^1]PWCEA[:N*>J\982VM*K+Y\D[!Q&0U'T3
M\) 0HM<%<6I#QU-BJ:9P5>:P<DU+-;P9=\MG=X2D'2WIRH* 84PO&-:TK:MT
M4;JD)PYJ $M6-%F_H1W2LNT\>>[?G39T6TL[HY-I:9&&($AY"?HB*_N<-C-+
M%GV75'5':*;SIGN[>A:#OZ0MUBO:9<L@ +E$&O[ :3L0_KRC>E$6JU3 MX,B
MOJG:5(3LEG P?)KH#(S5"IF)2',-G5&[)D!/&9\YW;7A \#*LP"ZG'!:-,EM
M6O8X<WH\>S^3 VKJVP+:@5](#]'"29=^8-(,2Q@=\2DVMWR- 5_5=;XKRG+&
M)$%WX9@(L\1!=+X!.2M7,4[+/:UX6Y=T2@QJZ3XD!9VD4H^R3>"'F;^;X21>
M*O?,G@1^1"@$$*D.68%H+"\RS[-]1^1.B'553FL1T_M7N ^=8[GJJ9/9H-B
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M(/9T3J+5^.VXIGA&LK/WE8JW&IV3.V>39?):DK"T(#ZA8^G0YM\>AW4G]S%
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M9%> !C""[(!S,N!SHK:@P$X("5D3!-1'YH8S#)@\PH?AK5:)]BQ;F1R0PN"
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MWH]9:@FX:+L]#ZL;PR!LAV5,V1MNR.=\@4\Z]\43YY47Q!L66OT&& I-:[8
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M8+KY,-!LK%JYQ_A<63SMW;(0Z$V:+N!\H93=;XA!]W7F_!]02P,$%     @
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M65%0[IS!KQ)R[N:? B;9ZXF#+OHRR5JYUT$N.2$W3=B/NG*%97^O<I'O*Y@
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M,EB-8ECB:[<3.8K8M??VGH;'CJ5AEQ_5U!V1-[I1^4[?P2#2F]IVX$<F(B2
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M\(DI]D<^$_I=U*\>D_H[%Y&QR'CH R!N^BCCNU.'7(V< (LD39TG0\I#CAI
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M;"!,^)03;IRN_><35+?3I;_,2>+$YPUXOM)X1VMO6$'_/>WQOU!+ P04
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M%HDETY7ESB)#NB%^U?H*#^H8#L1%(C<,!7AE?@ @GR%B NU@-]PYQKIYAQG
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M@"@]-&*P([9D)K-1,4OA-Y[ZD[*C?DAR?'T3JTUIBS\:$&S&:L?R"P9N@G+
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MJ-SJN>KTI"_HX2E[JQNWLNQU4U'U&& $HWO+TYWE5^E!Q%=4#MF8QRQ-TN0
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MF:XIZR9.KT,CM- .;548KM#'DO$'L+_4*+OMQ"OH.^.+/P%02P,$%     @
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M6=*\1^T<Z+Q0RNXV+D'_!9G] E!+ P04    " #B@UA2C!+F'9<I  !=BP
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M,^,/CE_2;=S%[1?H](:@/D883FI+6 _F95%>O?J[EL"!@O!7/WUH&#,A[I"
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MI<%7[L0:!S<H:X#W&RG-_F #C+^"Y6]02P,$%     @ XH-84NSG _8Q P
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MJM4&YQ@W19EH":<,]/3H$U]1I2'+6J'^ YF65)T-/0W(YMR;;5"N&Q3\"DJ
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M8HG?#*"= IX72MFGA2/HOD*6/P%02P,$%     @ XH-84@1:Y?[, @  U04
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MJ>9NYI("2M;6YDYNW\$NGTY@+FO=_9-M[YLD+LE;;62S Z."AHO^R1YWZW
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MGULUMZ@$L+A/* IN'D 98?6CL (46A!LZ>R>2&>GO9]^F#+*?O:.9DF$SFC
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M)5I!'-\N'$\4WY8;]#E7>KM?'FZ +D&8 #V^XER]GI@]?_V.9_P_4$L#!!0
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M">Z"U?5&Z1NJ^OU4/?8=IPI#]MOMMZ?8L'%87?Q3H&?)<Y)+D+*%]O,N0QU
M[ [?=S>*K\KSZR>N%,_*RR6C<R8* _W[@G/U>E,<B==_@8S_!U!+ P04
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M'59P[Q%I#&"_%$(_34QK'6[2["]02P,$%     @ XH-84N*.TA_M @  9P@
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MO3#K$3D)6GNSY#8-%G9A!/N!/Z T;#7-QOI>K:&OZ#?(U0N(=S>JX<2W(Z+
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M:40**.F&VR>U_0R=GPO'ERMN_#_9=K5)1/*-L4IT8%0@F&R?=-?E< !(1T<
M60?(O.ZVD5=Y1RU=S+3:$NVJD<T-O%6/1G%,ND-968V[#'%V<0<E: T%>8(7
MD!L@9^2Z*)A+C')R+]MC=_F]NP-+&3?I>ZSY!!*DA;P>8$U^CBL=?H #]RXP
M69$E: ^7.9#'-6>5)QJ0#[L&SP1[?F7"U:F2K'#+E#1O"U:6:DO0#UR1+,G2
ML\3]9K%%PTYVG'?F;EISV5%S*&V8#AQ)\B\\QIQ"6%D(*_-\PV-\S-"JTM :
M(8]E2.WG%RPE]Q:$^=73:!@:#7VCT5NGHO>IPCXSJ\@:<#U7E61_H/A?*OWD
M:4:$DK8V/4)'0>BHE^L!3UIL1 _316"Z.&VVX]!H?,IL^\G'Y!6H[DMV$F1.
M^I.ENS>2G0:FZ6F3O0R-+D^9;#_YY'BR\<'UY[XD#U173!K"H42JY'R";YYN
M;^=V8E7C;\2ULGB_^F&-'S30K@#W2Z7L?N(NV?")7/P%4$L#!!0    ( .*#
M6%+L$PP=B0(  )P&   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;*V5
MWV^;,!#'_Y43ZD,KK85 0G^((#5$U?8PJ6K6]6':@P,'6 6;V2;I]M?/-@1E
M"VFK:2_@'_>]^]P=-M&6BV=9(BIXJ2LFYTZI5'/CNC(ML2;R@C?(]$[.14V4
MGHK"E8U DEE17;F^YX5N32ASXLBNW8LXXJVJ*,-[ ;*M:R)^+K#BV[DS<78+
M#[0HE5EPXZ@A!:Y0/3;W0L_<P4M&:V22<@8"\[ES.[E)0F-O#;Y2W,J],9A,
MUIP_F\FG;.YX!@@K3)7Q0/1K@PE6E7&D,7[T/ITAI!'NCW?>[VSN.I<UD9CP
MZHEFJIP[5PYDF).V4@]\^Q'[?&;&7\HK:9^P[6T]!])6*E[W8DU04]:]R4M?
MASW!9'I$X/<"_[V"H!<$-M&.S*:U)(K$D>!;$,9:>S,#6QNKUME09KJX4D+O
M4JU3\1)S% (S>, -LA;A'%;Z2\G:"H'GD)2$%2B!,CBP/%VB(K229UKSN%K"
MZ<D9G!C++R5O)6&9C%RE$4T@-^UQ%AV.?Q0GO8!@\@%\S_=&Y,D_RUU=F*$Z
M_E =W_H+COC;I7HG> T)9TKHSPZ>J"HAL;U! =]NU]*N?W\E8# $#&S Z5OM
M$'WD-:D(2Q&(T@U(L5[KB%V"D^NQ^G3N9]:].<&;V+_R C^,W,T(UG3 FKZ*
M=9MEU)PZ"8J;0_(G8]8*R@I0)4*#@O)L#*P+$.Z#A=-@.LXU&[AFKW+M^B,P
MY06COS34>V 6LX,JA9/0\P:8#GEV@'P>7E_YP3AS.#"'_ZO%HT=@$1ZV. BO
M@\N_Z-\TZ^C=O;O#W-N?B2BH;G2%N19Z%Y?:@^CNPFZB>&.ODS57^@#88:E_
M'RB,@=[/.5>[B;FAAA]2_!M02P,$%     @ XH-84K8MCA 4"   SR0  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C N>&ULM5I;;^.Z$?XKA%L4>X DEBCY
MEB8!DLUE4VR:Q6:WY^'@/- 2':M'$EV*R@7HC^^0E$5?Z)&3GNS#1I(Y,]]<
M.#,<Z>19R#^J.>>*O!1Y69WVYDHMCOO]*IGS@E5'8L%+^&4F9,$4W,K'?K60
MG*6&J,C[- B&_8)E9>_LQ#S[)L].1*WRK.3?)*GJHF#R]8+GXOFT%_:6#[YG
MCW.E'_3/3A;LD3]P]7/Q3<)=O^629@4OJTR41/+9:>\\/+Z-!YK K/A7QI^K
ME6NB59D*\8>^N4U/>X%&Q'.>*,V"P9\G_IGGN>8$./[3,.VU,C7AZO62^[51
M'I29LHI_%OFO6:KFI[UQCZ1\QNI<?1?/7WBCD &8B+PR_Y/G9FW0(TE=*5$T
MQ("@R$K[E[TTAE@AH/$. MH0T V"<+2#(&H(HGTEQ U!O$&P4X=!0S#8EV#8
M$ PW" :[=!@U!*-]=1@W!.--@G 'P:0AF)APL/XSSK]DBIV=2/%,I%X-W/2%
MB2!##3[/2AWL#TK"KQG0J;.O'"*E.B3G:9KIZ&,YN2WM'M*Q^.F2*Y;EU2\G
M?072-$T_:3A?6,YT!^>0W(E2S2MR5:8\]=#?=-!3A$$?U&QUI4M=+RC*\9I/
MCPB='! :T.#GPR7Y]-=?9NIO?PE'X[][\'W&N5WRY(A$H>863A VESB;^T0Y
M-MV@KG!NY_7C6[A==W!;2. 6&&[C;FXW>QNL-;\)/P^K+V^P?3>PV_VY+=5$
MPBUJMU9DV$8[MU95<4Z,BN225XG,%F93_?855I);Q8OJ=T1.W,J)C9QXAYQ_
MUL642R)F4"EJ)CF9Z2+Y7X(8Y,)R'!J.NAX^G86321"<])]6-\#VJBC<7'3I
M816/!ANKKCRK OUO?=FU9UD4;Z[ZTH%KS8J#UHH#U(K66P<$V@@)N:]\)+EV
MG'Y@G*8$X2^*E[Y,=H6RUOW*<;5@"3_M04-2<?G$>V>?634G"_8*C8,BD'"A
M<X"+*7_,RHID)8&\(+1;8;.$A)4I47-N(1'%94$ B5D'.QZJ!"R+H@/BV^*X
MVC_6N685R)&B?IR3.R:3N18_-.(74CQE*:\,5@'Q.X,FY?"5,VGM8KH?:ZLC
M7V[ 85C"REF9)%Q"Y2EU6+>:5Z1>Z"5A<!00+;I"ML^P=?SP?8XW#DE$ 1Y*
MN'%3H>N1L886[@L$7)3VY6$8(*!'+>C17J#O6]!?+>BKEZQ2&K VW'T;NE?6
MJ+\I68/G6%[QWWWP<:&:V!=A[Z*Z>2O5FIW&K9W&[W.NC3*>VK '6R7@6PFM
MM\\LN(R!+Q2M9=Y!N*;FI%5STJ&FWL'\99%)V[=U1NIGG"%$ZN P#'WM3"?A
M9"O$K16["*/H,!C[K-@I<7@81(@5P\ UPT&''96RI321'!IBGQH-B\%*]:$;
MM6Q=^DHK'N[AQ67&2<&)'=FF@Y_NLPY#BEF&.FP4QP8X<B%3NT^R:6W"3-<"
MLZ'F(D])5N@B85*E;S=<-2+6+!<$GC;@QK,RC,>8D5U3%D:H(M^D2#B'VCF3
MHB#Y4BW)LV):RVHG^IN&[VK7,<(0N?8MQ/NW'[QD4%Q6K =&KI2N[DDMY8ZS
MTW8/-* 8'-<'A1T=P2XXDB<\>V+3W)O.&ZZK+HL'&"!7GT.\:GH L3P7SPPV
MB2]=-.S6PBS&D+BB&^)%"4-B-FJ[=[W'Y=$6KB$&R]6X$*\C]^O%33<N_!D.
M\KJT>5V%LPN[>ZO0%:80S\Z;V#2FK+1%"G[*A#^Z<:91)T#J4C[%4[X[/8D=
M4#F<I7:=4V\:[JO[D/K]25T=H'C>WK09U'7HK_WBPZV8&F"[CKJ$3_&$OPGB
MB<E,[_T],-%MDV"!3EWNIGCN_JYW7"/9EZ._-/1KYH@\!>;6LS#&BCAUV9SB
MV;PYUV6I*8ZL$'5I4WE>ZW833C0%&+"6-GU V%E[YF#<+,]4QJL#4G+SBT+2
MS3(=^ZL#]9R0L>I 776@>'4PZBU%&Q51E%YP@^WX0&/650J*5XKO]S\)@X8?
M#"ZF^O1H#<Y?DCDK'[D]NF[$]8KAO6"'GL'%! T55TXH7DZV\K8>S!^*V6$-
M-U8/+Z31%J3))!H@B%PEH7CJ/W_XJ8=@T$]3\NF'6&0)&<<4&X915PGHY$/'
M89%+Z1&>TM]IUVB[L8^B /%TY#)ZA&?T._:2%76!:><2<T0_UHXK\TL\W;ZQ
M\;J,MI,JUB%'+J=&>$[=;G#T:[SU2NWU*,XVI+:/(&-[7JX(/$G9*]981"Y3
M1GBFO .$'3YWB2T:?JS/74Z*WIB3]C4USC8TEB91:^AQIZ%=THKPI/7 F5(Y
M/R"_0FT"I$J4&%^7L**/35BQ2UCQOCWHWA/\JWB[\1SJUL^_UV*7JN*N(<3_
M,0?OX.V?>3<37NCKF)G(+2#F,CWL=9.0?[ 2[/)JWAP= &4MEX'$9GI@8R;$
MRZ-\RG-H3B1/=[ %#6H[QDY$62E9V]?N>NC3S)RW6QIHRCPS>,UCJH<T5E!6
M&7NU@I84VQ#,\-Y-^"-Z0*IZ^F^>*(U.J^>LK9ZSA"^GX@Z EJU'\#:%'6%Q
MZ$I+W#'D^3-'X1VRS' J"#'<KE#%>*'ZH&EXA]2.$76\\OX.KT-_SI"Z0TCW
ML#EVI2WN>E?VUG'S50='O0=VO!GIKWS<4'#Y:+Z,T<D!#E;V96S[M/WZYMQ\
M<[+Q_"(\O@X]SV_"XUO[;8UC;S_UN6/2O([+^0Q$!4<C4$+:KV?LC1(+\VD%
M) $E"G,YYRSE4B^ WV="J.6-%M!^PW3V/U!+ P04    " #B@UA2($;05B,"
M  "[!   &0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6R55&%KVS 0_2N'
M8=#!&CM.FFXE"30-8X65AH2M'\8^*/8Y%I4E3SHWS;_?24Y,!DE@7VR=I/?N
MO;NSQUMC7UV)2/!>*>TF44E4W\6QRTJLA.N9&C6?%,96@CBTF]C5%D4>0)6*
MTR09Q960.IJ.P]["3L>F(24U+BRXIJJ$W<U0F>TDZD>'C:7<E.0WXNFX%AM<
M(?VH%Y:CN&/)987:2:/!8C&)[OMWLZ&_'R[\E+AU1VOP3M;&O/K@,9]$B1>$
M"C/R#()?;_B 2GDBEO%GSQEU*3WP>'U@_QJ\LY>U</A@U(O,J9Q$GR/(L1"-
MHJ79?L.]GQO/EQGEPA.V[=W;8019X\A4>S KJ*1NW^)]7X<C0#HZ TCW@#3H
M;A,%E7-!8CJV9@O6WV8VOPA6 YK%2>V;LB++IY)Q-/V.;,E=PZIM"I@"GJE$
M"X^Z[;@OW1*5(,R!##S7:'E3;R @X6J.)*1R'\<QL1Q/&F?[U+,V=7HF]1RS
M'@SZGR!-TN1?>,PN.BMI9R4-?(.S5IQ#A+ETF3*NL0B_[M>.+#?^]P7Z04<_
M"/3#,_0OH<&87XLW+L$&>23]T/M2J% *0EO!E=2P0V%/%^1RAGZ_A<( *J.I
M=)!^@5SLW 7UPT[]\/_4YUPFTV@";B>>TGJ9;]@;)1].Z8J/9M%_UD_";J1V
M7*."B9+>[4T$MOU4VH!,'<9S;8B'/2Q+_KN@]1?XO#"&#H&?^.Y_-?T+4$L#
M!!0    ( .*#6%+0\^-E&P,  %D)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8R+GAM;(V6WT_;,!#'_Q4KX@$D1N+\:HK:2D"%AK0)1&%[F/;@IM?&PK$S
MVVGAOY^=E+1;G<)+8SN^^WS/5]]EM!'R114 &KV6C*NQ5VA=7?J^R@LHB;H0
M%7#S9BED2;29RI6O*@EDT1B5S ^#(/5+0KDW&35K#W(R$K5FE,.#1*HN2R+?
MKH&)S=C#WOO"(UT5VB[XDU%%5C #_5P]2#/S.R\+6@)75' D83GVKO#E-8ZM
M0;/C!X6-VALC&\I<B!<[N5N,O< J @:YMBZ(>:SA!ABSGHR./UNG7L>TAOOC
M=^^W3? FF#E1<"/83[K0Q=C+/+2 ):F9?A2;K[ -*+'^<L%4\XLVV[V!A_):
M:5%NC8V"DO+V25ZW![%G$.(>@W!K$#:Z6U"C<DHTF8RDV"!I=QMO=M"$VE@;
M<93;K,RT-&^IL=.3;V!"4E_0K,T*$DOT"+G@.66@T#-?4)6+FFM8H/L*)-&4
MKU!CA&Z(*M"M2:M"IU/0A#)UADX0Y>BI$+4B?*%&OC8:+<G/MWJN6SUACYXI
MY!<HPN<H#,+@>39%IR=G_WKQ381=F&$79MBXC7K#5 H 34TT3*A: OIU-5=:
MFC_%[R/NH\Y]U+B/>]P;L=@5:VN5-%;V?JPG@RS,1O[:P8H[5OP1*W2Q6JMT
MCX6C)(G=L*2#)1_!(A<L<< BW!-9VL'2CV"Q"Y8Z8$$4N&&##C;X"):X8 ,'
M+,9#-RSK8-E1V%,!IF0N-4@7,CM 9EF<1F[DL$,.CR.%)@S5^Q>8-=>V(F^F
MJFKGW1P>!A\/4QRZI>!@5V2"HV+NRJJV"JC1(4%I9 H).(M#<*#@2Y1D<<\_
M"^^5.7S\.( 3KA$M*RG68 _ ])0<Z)K,3:%S2L&'4I)AT'<6NTJ$PT\D1G3%
MM,T*HV1.&=6T1TQXF)E@D*5]:G:%"Q^O7+8P7II&(Z4]DDI(VRN="B)79L*>
MBX%WU0P?+V?W_0=Q;I:4^I2X^*#0XB".HO_OD+_7*.U'QW<B5Y0KPUD:P^!B
M8#S(MH^W$RVJIG?.A3:=N!D6YML'I-U@WB^%T.\3VXZ[KZG)7U!+ P04
M" #B@UA2ROHC%@X&   6'@  &0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX
M;6RU65UOVS84_2N$L6$;T,8227T5CH'629L$ZV;46/LP[(&1Z%BH)+H492=#
M?_Q(238M6Z*4K,Z#HP_>P\/+>P\OJ<F6\:_YBE(!'M,DRR]'*R'6;\;C/%S1
ME.07;$TS^6;)>$J$O.4/XWS-*8E*HS090\MRQRF)L]%T4CZ;\^F$%2*),SKG
M("_2E/"G=S1AV\N1/=H]^!0_K(1Z,)Y.UN2!+JCX:SWG\FZ\1XGBE&9YS#+
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MX+I'G:CJUZ!>&+EV-_!2&KK/W32G!Q255:#_*RG-?F$W:)[D\1]02P,$%
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MV\SPK0/2 /#[1@C]W#$3-*^GZ?]02P,$%     @ XH-84I0<J8P) P  Q D
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M!N#[E93FK6$':+YM9O\#4$L#!!0    ( .*#6%(8#U?O5@,  /(,   9
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M*UW VMM:?Y2 , /T\XIS]=@P$PR?.:O?4$L#!!0    ( .*#6%+BKTZ8HP(
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M&.CG"\[5?F%>T,RZH_\!4$L#!!0    ( .*#6%(462)VK@(  " '   9
M>&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;(U5;6_:,!#^*U:T2:VTD1<@ZRI
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MG+NRETY6^W\1V?][R[OO4$L#!!0    ( .*#6%)Z! -=7 (  "$N   :
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MZV2SA$!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O0[V-0&]#O8U
M;T.]C4!O0[V-0&^;;'83Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>CMJ+<3
MZ.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[9./E01Z.^KM!'H[ZNT$>COJ[01Z.^KM
M!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>@?J'01Z!^H=!'K'Y&<3 KT#]0X"O0/U
M#@*] _4. KTSZIT)],ZH=R;0.Z/>F4#OC'IG KTSZIT)],ZH=R;0.Z/>F4#O
M//E9D$#OC'KG[]1[&#^/9;CU?*WQ^=])]7BYM]P>?UU^G40)5U><Z_N*X?DO
M4$L#!!0    ( .*#6%(N* K8%0(  /PL   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:WT[;,!0&\%>I<HL:U_\W1+D!;C<N]@)><MI&36++-JR\_9P4D#:Q
M"E2D?3>-6MOG._&1?E>]^O$4*"T.0S^F=;7+.5PREIH=#2[5/M!85C8^#BZ7
MKW'+@FOV;DM,K%:&-7[,-.9EGFI4UU>WM'$/?5[<'<K/J?/CNHK4IVIQ<]PX
M9:TK%T+?-2Z7=?8XMG^E+)\3ZG)RWI-V74@794/%WDR85OX=\'SN^R/%V+6T
MN'<Q?W-#V<4./4OYJ:=4GR[Q1H]^L^D::GWS,)0C=0J17)MV1'GHZV/1B]/)
MN=PP'3_YV?ESF5.!9>=]]"&5B47Z>-S+2*;3RU *4<S=Z5=\32RESWX_FJ;=
M4OO.['*]OWS<S_-(;'Z<?\=_SOBU_@?[$"!]2) ^%$@?&J0/ ]*'!>GC"T@?
M7T'ZX"N41E!$Y2BD<A13.0JJ'$55CL(J1W&5H\#*4605*+(*%%D%BJP"15:!
M(JM D56@R"I09!4HL@H4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL$D56
MA2*K0I%5H<BJ4&15*+(J%%D5BJP*15:%(JM"D56CR*I19-4HLFH4636*K!I%
M5HTBJT:15:/(JE%D-2BR&A19#8JL!D56@R*K09'5H,AJ4&0U*+(:%%DMBJP6
M15:+(JM%D=6BR&I19+4HLEH46>W_E/6G]_M/CI^?]>"Z\26?S7]ZOOX-4$L!
M A0#%     @ XH-84@=!36*!    L0   !               ( !     &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #B@UA2_VN,R.X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #B
M@UA2F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( .*#6%)\&_[KH08  )$:   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #B
M@UA2?".*&!8'  "*'@  &               @('D#@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ XH-84D4T;[8> P  J0H  !@
M         ("!,!8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( .*#6%(:6@"V1@4  .@3   8              " @809  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #B@UA2%6Y_EK<"  !1!P
M&               @($ 'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ XH-84@F1?M52"0  034  !@              ("![2$  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .*#6%*\"&4Z8P@
M .0C   8              " @74K  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " #B@UA2;KR+PB$&  "U#@  &               @($.
M-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ XH-84H84
MYPNT)P   GX  !@              ("!93H  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( .*#6%(+3>CO=1$   \T   9
M  " @4]B  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MXH-84L")=:/2 P  < D  !D              ("!^W,  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " #B@UA2HF/"5J4&  "I$0  &0
M            @($$>   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( .*#6%+UPJ+#3 ,  ! '   9              " @>!^  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ XH-84I().V&\ P
M%PD  !D              ("!8X(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " #B@UA2&/=ABQH#   Q!P  &0              @(%6
MA@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .*#6%*_
MN#D+QP0  !T,   9              " @:>)  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ XH-84O?@R>]?"0  /AD  !D
M     ("!I8X  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .*#6%+&6S6@[0@  .H5   9              "
M@8RY  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ XH-8
M4J-TWKZ2!   )0L  !D              ("!L,(  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " #B@UA2T$M.4.,"  !-!@  &0
M        @(%YQP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( .*#6%*,$N8=ERD  %V+   9              " @9/*  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ XH-84G-?=96. P  "0@
M !D              ("!8?0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " #B@UA2A\/1&NL"   6!@  &0              @($F^
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .*#6%+LYP/V
M,0,  ,('   9              " @4C[  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ XH-84M=-G"=@!   Q0L  !D
M ("!L/X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #B
M@UA2$LA#W1L#  !Y!@  &0              @(%' P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .*#6%*-\'?H9@,  )$(   9
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M970S-2YX;6Q02P$"% ,4    " #B@UA2];NJV6@&   .$0  &0
M    @(%3%P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M .*#6%)19G*OW@0  *T+   9              " @?(= 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ XH-84O*Z3T!N!     L  !D
M             ("!!R,! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " #B@UA21%&=MWT#  "'"P  &0              @(&L)P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .*#6%(<W43 70<
M +<F   9              " @6 K 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ XH-84M6-FK-& P  [@T  !D              ("!
M]#(! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #B@UA2
M'H<N@"<#  "8#   &0              @(%Q-@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( .*#6%+'V4326 ,  !,,   9
M      " @<\Y 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ XH-84HRYQ*Q"!0  ,AL  !D              ("!7CT! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #B@UA2(I4GX^ #  #O$0
M&0              @('70@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( .*#6%)1F"UYX 0   X9   9              " @>Y& 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ XH-84M"_AXQ(
M @  _@0  !D              ("!!4P! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " #B@UA2]&>C2<L"  "R"   &0
M@(&$3@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( .*#
M6%*RY)HYR@,  "<0   9              " @891 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ XH-84EA"EHU< @  P04  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( .*#6%*+D<PU+0(  + $   9
M  " @3!D 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
MXH-84GT-H*P$ P  80L  !D              ("!E&8! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " #B@UA2(%VNF+@#  #(#P  &0
M            @('/:0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( .*#6%)\P(CG;P(  "X'   9              " @;YM 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ XH-84NP3#!V) @
MG 8  !D              ("!9' ! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " #B@UA2MBV.$!0(  #/)   &0              @($D
M<P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( .*#6%(@
M1M!6(P(  +L$   9              " @6][ 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ XH-84M#SXV4; P  60D  !D
M     ("!R7T! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .*#6%(-=?7Z/00  #H0   9              "
M@<R4 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ XH-8
M4F:4:&ED P  $@T  !D              ("!0)D! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " #B@UA2*N]RFM0#  !$#P  &0
M        @(';G $ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( .*#6%*((#2)G ,  $D-   9              " @>:@ 0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ XH-84I0<J8P) P  Q D
M !D              ("!N:0! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    " #B@UA2 ?BPX9X#  ! #   &0              @('YIP$
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( .*#6%)_LP\3
MP@,  .<,   9              " @<ZK 0!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L! A0#%     @ XH-84A@/5^]6 P  \@P  !D
M ("!QZ\! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " #B
M@UA2XJ].F*,"   P!P  &0              @(%4LP$ >&PO=V]R:W-H965T
M<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( .*#6%(S[7BP>@,  /8)   9
M          " @2ZV 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#
M%     @ XH-84G8H$YG! P  ]PX  !D              ("!W[D! 'AL+W=O
M<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " #B@UA2%%DB=JX"   @
M!P  &0              @('7O0$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM
M;%!+ 0(4 Q0    ( .*#6%(>2^*R10(  ( +   -              "  ;S
M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ XH-84I>*NQS     $P(   L
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64$L%!@    !6 %8 D1<  -+. 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>245</ContextCount>
  <ElementCount>476</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity</Role>
      <ShortName>Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenue</Role>
      <ShortName>Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Microsoft Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement</Role>
      <ShortName>Microsoft Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss Per Share Attributable to Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueTables</Role>
      <ShortName>Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenue</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholders</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails</Role>
      <ShortName>Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails</Role>
      <ShortName>Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Accrued Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Accrued Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails</Role>
      <ShortName>Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Deferred Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails</Role>
      <ShortName>Deferred Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Deferred Revenue - Additional Information (Details1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1</Role>
      <ShortName>Deferred Revenue - Additional Information (Details1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails</Role>
      <ShortName>Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Leases- Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases- Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails</Role>
      <ShortName>Leases- Summary of Other Information Related to Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails</Role>
      <ShortName>Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails</Role>
      <ShortName>Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails</Role>
      <ShortName>Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails</Role>
      <ShortName>Microsoft Collaboration Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="adpt-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="adpt-10k_20201231.htm">adpt-10k_20201231.htm</File>
    <File>adpt-20201231.xsd</File>
    <File>adpt-20201231_cal.xml</File>
    <File>adpt-20201231_def.xml</File>
    <File>adpt-20201231_lab.xml</File>
    <File>adpt-20201231_pre.xml</File>
    <File>adpt-ex1012_218.htm</File>
    <File>adpt-ex1016_340.htm</File>
    <File>adpt-ex1017_339.htm</File>
    <File>adpt-ex211_175.htm</File>
    <File>adpt-ex231_297.htm</File>
    <File>adpt-ex311_178.htm</File>
    <File>adpt-ex312_179.htm</File>
    <File>adpt-ex321_176.htm</File>
    <File>adpt-ex322_177.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g0vsdaj33nnl000001.jpg</File>
    <File>g0vsdaj33nnl000002.jpg</File>
    <File>g0vsdaj33nnl000003.jpg</File>
    <File>g0vsdaj33nnl000004.jpg</File>
    <File>g0vsdaj33nnl000005.jpg</File>
    <File>g0vsdaj33nnl000006.jpg</File>
    <File>g0vsdaj33nnl000007.jpg</File>
    <File>g0vsdaj33nnl000008.jpg</File>
    <File>g0vsdaj33nnl000009.jpg</File>
    <File>g0vsdaj33nnl000010.jpg</File>
    <File>g0vsdaj33nnl000011.jpg</File>
    <File>g0vsdaj33nnl000012.jpg</File>
    <File>g0vsdaj33nnl000013.jpg</File>
    <File>g0vsdaj33nnl000014.jpg</File>
    <File>g0vsdaj33nnl000015.jpg</File>
    <File>g0vsdaj33nnl000016.jpg</File>
    <File>g0vsdaj33nnl000017.jpg</File>
    <File>g0vsdaj33nnl000018.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adpt-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 31,
   "contextCount": 245,
   "dts": {
    "calculationLink": {
     "local": [
      "adpt-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adpt-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "adpt-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adpt-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adpt-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "adpt-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 632,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 45,
    "http://www.adaptivebiotech.com/20201231": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 53
   },
   "keyCustom": 84,
   "keyStandard": 392,
   "memberCustom": 35,
   "memberStandard": 46,
   "nsprefix": "adpt",
   "nsuri": "http://www.adaptivebiotech.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Revenue",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Investments",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment, Net",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued Liabilities",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:DeferredRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Deferred Revenue",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenue",
     "shortName": "Deferred Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:DeferredRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Leases",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Shareholders' Equity",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Equity Incentive Plans",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Microsoft Collaboration Agreement",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement",
     "shortName": "Microsoft Collaboration Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss Per Share Attributable to Common Shareholders",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholders",
     "shortName": "Net Loss Per Share Attributable to Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Retirement Plan",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Revenue (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Investments (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "adpt:DeferredRevenueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Deferred Revenue (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueTables",
     "shortName": "Deferred Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "adpt:DeferredRevenueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Leases (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Net Loss Per Share Attributable to Common Shareholders (Tables)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Organization and Description of Business - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Organization and Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190701_20190701",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Statements of Operations",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:UnbilledReceivablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails",
     "shortName": "Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_srtMajorCustomersAxis_adptCustomerAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails",
     "shortName": "Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_adptLaboratoryEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails",
     "shortName": "Revenue - Schedule of Revenue Disaggregated by Type of Products and Services (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_srtProductOrServiceAxis_adptDevelopmentSupportRevenueMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "adpt:DeferredRevenueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201230_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Revenue - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapTypeOfArrangementAxis_adptTranslationalDevelopmentAgreementsMember_20151201_20151231",
      "decimals": null,
      "lang": "en-US",
      "name": "adpt:TermOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
     "shortName": "Investments - Schedule of Available-for-sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapInformationByCategoryOfDebtSecurityAxis_adptAvailableForSaleSecuritiesDebtSecuritiesCurrentMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Investments - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
     "shortName": "Investments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails",
     "shortName": "Investments - Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Comprehensive Loss",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
     "shortName": "Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20151231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Accrued Liabilities - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails",
     "shortName": "Accrued Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adpt:AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
     "shortName": "Deferred Revenue - Schedule of Deferred Revenue by Revenue Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Deferred Revenue - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
     "shortName": "Deferred Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "adpt:DeferredRevenueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_srtProductOrServiceAxis_adptDevelopmentRevenueMember_20191231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "adpt:DeferredRevenueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Deferred Revenue - Additional Information (Details1)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
     "shortName": "Deferred Revenue - Additional Information (Details1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "adpt:DeferredRevenueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_srtMajorCustomersAxis_adptGenentechIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2021-01-01_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "adpt:ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock",
       "adpt:DeferredRevenueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails",
     "shortName": "Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "adpt:DeferredRevenueTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity",
     "shortName": "Statements of Convertible Preferred Stock and Shareholders' (Deficit) Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200229",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_utrsqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Leases- Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases- Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200229",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_utrsqft",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails",
     "shortName": "Leases- Summary of Other Information Related to Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
     "shortName": "Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
     "shortName": "Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Equity Incentive Plans - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
     "shortName": "Equity Incentive Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
     "shortName": "Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails",
     "shortName": "Equity Incentive Plans - Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
     "shortName": "Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_adptTwoThousandAndNineteenEquityIncentivePlanMember_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20180101_20181231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Options Granted (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails",
     "shortName": "Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20180101_20181231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails",
     "shortName": "Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
     "shortName": "Microsoft Collaboration Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_us-gaapTypeOfArrangementAxis_adptMicrosoftCollaborationAgreementMember_20171201_20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
     "shortName": "Net Loss Per Share Attributable to Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Net Loss Per Share Attributable to Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
     "shortName": "Net Loss Per Share Attributable to Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Retirement Plan - Additional Information (Details)",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Organization and Description of Business",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Significant Accounting Policies",
     "role": "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adpt-10k_20201231.htm",
      "contextRef": "C_0001478320_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and contract research organization costs, current.",
        "label": "Accrued Clinical And Contract Research Organization Costs Current",
        "terseLabel": "Clinical and contract research organization costs"
       }
      }
     },
     "localname": "AccruedClinicalAndContractResearchOrganizationCostsCurrent",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued purchase of property and equipment current.",
        "label": "Accrued Purchase Of Property And Equipment Current",
        "terseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "AccruedPurchaseOfPropertyAndEquipmentCurrent",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued tax withholding liability related to unsettled option exercises.",
        "label": "Accrued Tax Withholding Liability Related To Unsettled Option Exercises",
        "terseLabel": "Accrued tax withholding liability related to unsettled option exercises"
       }
      }
     },
     "localname": "AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment receivable"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant.",
        "label": "Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant",
        "terseLabel": "Conversion of convertible preferred stock warrant to common stock warrant"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital, initial public offering costs.",
        "label": "Adjustments To Additional Paid In Capital Initial Public Offering Costs",
        "terseLabel": "Initial public offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Option And Restricted Stock Unit Requisite Service Period Recognition Value",
        "terseLabel": "Common stock option and restricted stock unit share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_AgreementTerminationAmountReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination amount receivable.",
        "label": "Agreement Termination Amount Receivable",
        "terseLabel": "Agreement termination amount receivable"
       }
      }
     },
     "localname": "AgreementTerminationAmountReceivable",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt securities current.",
        "label": "Available For Sale Securities Debt Securities Current [Member]",
        "terseLabel": "Short-Term Marketable Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrentMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt securities noncurrent.",
        "label": "Available For Sale Securities Debt Securities Noncurrent [Member]",
        "terseLabel": "Long-Term Marketable Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and use of estimates.",
        "label": "Basis Of Presentation And Use Of Estimates Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Use of Estimates"
       }
      }
     },
     "localname": "BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_BuildToSuitAssetCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Build-to-suit asset cost.",
        "label": "Build To Suit Asset Cost [Member]",
        "terseLabel": "Build-to-suit Asset Cost"
       }
      }
     },
     "localname": "BuildToSuitAssetCostMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in redemption value for vested convertible preferred stock options.",
        "label": "Change In Redemption Value For Vested Convertible Preferred Stock Options",
        "terseLabel": "Change in redemption value for vested Series E-1 convertible preferred stock options"
       }
      }
     },
     "localname": "ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, weighted average exercise price of warrants or rights",
        "label": "Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights",
        "terseLabel": "Weighted-average exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adpt_ClassOfWarrantOrRightsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights, term.",
        "label": "Class Of Warrant Or Rights Term",
        "terseLabel": "Warrant exercisable term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsTerm",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_CollaborationArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement Disclosure [Abstract]",
        "label": "Collaboration Arrangement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CollaborationArrangementDisclosureAbstract",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "xbrltype": "stringItemType"
    },
    "adpt_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options and restricted stock units granted.",
        "label": "Common Stock Options And Restricted Stock Units Granted [Member]",
        "terseLabel": "Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted"
       }
      }
     },
     "localname": "CommonStockOptionsAndRestrictedStockUnitsGrantedMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants member.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_ComputerSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer software.",
        "label": "Computer Software [Member]",
        "terseLabel": "Computer Software"
       }
      }
     },
     "localname": "ComputerSoftwareMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_ContractBalancesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract balances.",
        "label": "Contract Balances Policy [Text Block]",
        "terseLabel": "Contract Balances"
       }
      }
     },
     "localname": "ContractBalancesPolicyTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_ContractWithCustomerLiabilityCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability current abstract.",
        "label": "Contract With Customer Liability Current [Abstract]",
        "terseLabel": "Current deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrentAbstract",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability milestone method revenue recognized.",
        "label": "Contract With Customer Liability Milestone Method Revenue Recognized",
        "terseLabel": "Milestone revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_ContractWithCustomerLiabilityNonCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability non current abstract.",
        "label": "Contract With Customer Liability Non Current [Abstract]",
        "terseLabel": "Non-current deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNonCurrentAbstract",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adpt_ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock to common stock upon closing of initial public offering.",
        "label": "Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering.",
        "label": "Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant Upon Closing Of Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock warrant to common stock warrant upon closing of initial public offering"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockWarrantToCommonStockWarrantUponClosingOfInitialPublicOffering",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_ConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock warrants member.",
        "label": "Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A.",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C.",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_DeferredRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_DeferredTaxAssetsNonQualifiedStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, non qualified stock options.",
        "label": "Deferred Tax Assets Non Qualified Stock Options",
        "terseLabel": "Non qualifying stock options"
       }
      }
     },
     "localname": "DeferredTaxAssetsNonQualifiedStockOptions",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, tangible and intangible assets.",
        "label": "Deferred Tax Liabilities Tangible And Intangible Assets",
        "negatedLabel": "Tangible and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTangibleAndIntangibleAssets",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_DefinedContributionPlanEmployeeServicePeriodForVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employee service period for vesting.",
        "label": "Defined Contribution Plan Employee Service Period For Vesting",
        "terseLabel": "Employee service period for vesting"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeServicePeriodForVesting",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_DerecognitionOfBuildToSuitLeaseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of build to suit lease asset.",
        "label": "Derecognition Of Build To Suit Lease Asset",
        "terseLabel": "Derecognized portion of build-to-suit asset"
       }
      }
     },
     "localname": "DerecognitionOfBuildToSuitLeaseAsset",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_DerecognitionOfBuildToSuitLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of build-to-suit liabilities.",
        "label": "Derecognition Of Build To Suit Liabilities",
        "terseLabel": "Derecognition of build-to-suit liabilities"
       }
      }
     },
     "localname": "DerecognitionOfBuildToSuitLiabilities",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_DerecognitionOfDeferredRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of deferred rent.",
        "label": "Derecognition Of Deferred Rent",
        "terseLabel": "Derecognition of deferred rent"
       }
      }
     },
     "localname": "DerecognitionOfDeferredRent",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease.",
        "label": "Derecognition Of Lease Financing Arrangements Upon Adoption Of Guidance On Accounting For Lease",
        "terseLabel": "Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases"
       }
      }
     },
     "localname": "DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones.",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_DevelopmentRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development revenue.",
        "label": "Development Revenue [Member]",
        "terseLabel": "Development Revenue"
       }
      }
     },
     "localname": "DevelopmentRevenueMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_DevelopmentRevenueRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development revenue regulatory milestones.",
        "label": "Development Revenue Regulatory Milestones [Member]",
        "terseLabel": "Development Revenue Regulatory Milestones"
       }
      }
     },
     "localname": "DevelopmentRevenueRegulatoryMilestonesMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_DevelopmentSupportRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development support revenue.",
        "label": "Development Support Revenue [Member]",
        "terseLabel": "Development Support Revenue"
       }
      }
     },
     "localname": "DevelopmentSupportRevenueMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Items",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "adpt_EligiblePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible payments receivable.",
        "label": "Eligible Payments Receivable",
        "terseLabel": "Eligible payments receivable"
       }
      }
     },
     "localname": "EligiblePaymentsReceivable",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and Office Equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_GenentechCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech collaboration agreement.",
        "label": "Genentech Collaboration Agreement [Member]",
        "terseLabel": "Genentech Collaboration Agreement"
       }
      }
     },
     "localname": "GenentechCollaborationAgreementMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_GenentechIncAndRocheGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Inc. and Roche Group.",
        "label": "Genentech Inc And Roche Group [Member]",
        "terseLabel": "Genentech, Inc. and Roche Group"
       }
      }
     },
     "localname": "GenentechIncAndRocheGroupMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_GenentechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech Inc.",
        "label": "Genentech Inc [Member]",
        "terseLabel": "Genentech, Inc."
       }
      }
     },
     "localname": "GenentechIncMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adpt_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adpt_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred rent.",
        "label": "Increase Decrease In Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease liabilities .",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_InitialPublicOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering expenses.",
        "label": "Initial Public Offering Expenses",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "InitialPublicOfferingExpenses",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_JOBSActAccountingElectionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JOBS act accounting election.",
        "label": "J O B S Act Accounting Election Policy [Text Block]",
        "terseLabel": "JOBS Act Accounting Election"
       }
      }
     },
     "localname": "JOBSActAccountingElectionPolicyTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_LandlordFundedLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Landlord-funded leasehold improvements",
        "label": "Landlord Funded Leasehold Improvements",
        "terseLabel": "Landlord-funded leasehold improvements"
       }
      }
     },
     "localname": "LandlordFundedLeaseholdImprovements",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_LeaseCommencementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commenced moth and year"
       }
      }
     },
     "localname": "LeaseCommencementMonthAndYear",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "adpt_LeaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration month and year"
       }
      }
     },
     "localname": "LeaseExpirationMonthAndYear",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "adpt_LesseeOperatingLeaseExtendedTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, extended term of contract.",
        "label": "Lessee Operating Lease Extended Term Of Contract",
        "terseLabel": "Lessee, operating lease, extended term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedTermOfContract",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_LesseeOperatingLeaseLiabilityTenantImprovementReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability tenant improvement receivable.",
        "label": "Lessee Operating Lease Liability Tenant Improvement Receivable",
        "negatedLabel": "Tenant improvement receivables"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReceivable",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_LesseeOperatingLeaseRentCommencementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease rent commencement month and year.",
        "label": "Lessee Operating Lease Rent Commencement Month And Year",
        "terseLabel": "Lessee, operating lease, rent commencement month and year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentCommencementMonthAndYear",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "adpt_LesseeOperatingLeaseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease termination period.",
        "label": "Lessee Operating Lease Termination Period",
        "terseLabel": "Operating lease termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_MRDDevelopmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MRD development agreements.",
        "label": "M R D Development Agreements [Member]",
        "terseLabel": "MRD Development Agreements"
       }
      }
     },
     "localname": "MRDDevelopmentAgreementsMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare revenue.",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_MicrosoftCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Microsoft collaboration agreement.",
        "label": "Microsoft Collaboration Agreement [Member]",
        "terseLabel": "Microsoft Collaboration Agreement"
       }
      }
     },
     "localname": "MicrosoftCollaborationAgreementMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum service consumption requirement amount under license agreement.",
        "label": "Minimum Service Consumption Requirement Amount Under License Agreement",
        "terseLabel": "Minimum service consumption requirement amount"
       }
      }
     },
     "localname": "MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum service consumption requirement term under license agreement.",
        "label": "Minimum Service Consumption Requirement Term Under License Agreement",
        "terseLabel": "Minimum service consumption requirement term"
       }
      }
     },
     "localname": "MinimumServiceConsumptionRequirementTermUnderLicenseAgreement",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_NetOperatingLossCarryforwardExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryforward Expiration Period",
        "label": "Net Operating Loss Carryforward Expiration Period",
        "terseLabel": "Maturity period for net operating loss carryovers"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardExpirationPeriod",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_NonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee directors.",
        "label": "Non Employee Directors [Member]",
        "terseLabel": "Non Employee Directors"
       }
      }
     },
     "localname": "NonEmployeeDirectorsMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_NonRefundableUpfrontPaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront payments received.",
        "label": "Non Refundable Upfront Payments Received",
        "terseLabel": "Non-refundable upfront payments received"
       }
      }
     },
     "localname": "NonRefundableUpfrontPaymentsReceived",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_NumberOfCommonStockVotingRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock voting rights.",
        "label": "Number Of Common Stock Voting Rights",
        "terseLabel": "Number of vote for each share"
       }
      }
     },
     "localname": "NumberOfCommonStockVotingRights",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adpt_NumberOfEmployeeOptionModification": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employee option modification.",
        "label": "Number Of Employee Option Modification",
        "terseLabel": "Number of employee option modification"
       }
      }
     },
     "localname": "NumberOfEmployeeOptionModification",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adpt_NumberOfOperatingLeaseTerminate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating lease terminate.",
        "label": "Number Of Operating Lease Terminate",
        "terseLabel": "Number of operating lease terminate"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseTerminate",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adpt_NumberOfRevenuePerformanceObligation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of revenue performance obligation.",
        "label": "Number Of Revenue Performance Obligation",
        "terseLabel": "Number of revenue performance obligations"
       }
      }
     },
     "localname": "NumberOfRevenuePerformanceObligation",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adpt_OperatingLeaseVariableLeaseExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease variable lease expense.",
        "label": "Operating Lease Variable Lease Expense",
        "terseLabel": "Operating lease variable lease expense"
       }
      }
     },
     "localname": "OperatingLeaseVariableLeaseExpense",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration Year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "adpt_PercentageOfAnnualIncreasesInNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual increases in number of shares.",
        "label": "Percentage Of Annual Increases In Number Of Shares",
        "terseLabel": "Percentage of annual increases in number of shares"
       }
      }
     },
     "localname": "PercentageOfAnnualIncreasesInNumberOfShares",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adpt_ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock upon exercise of common stock warrant.",
        "label": "Proceeds From Issuance Of Common Stock Upon Exercise Of Common Stock Warrant",
        "terseLabel": "Proceeds from issuance of common stock upon the exercise of a common stock warrant"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUponExerciseOfCommonStockWarrant",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_ProceedsFromLandlordReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from landlord reimbursements.",
        "label": "Proceeds From Landlord Reimbursements",
        "terseLabel": "Proceeds from landlord reimbursements"
       }
      }
     },
     "localname": "ProceedsFromLandlordReimbursements",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_ReceivableForStockOptionExercises": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable for stock option exercises.",
        "label": "Receivable For Stock Option Exercises",
        "terseLabel": "Unsettled cash proceeds related to stock options exercised"
       }
      }
     },
     "localname": "ReceivableForStockOptionExercises",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_ReclassificationOfTenantIncentiveReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of tenant incentive receivables.",
        "label": "Reclassification Of Tenant Incentive Receivables",
        "terseLabel": "Reclassification of tenant incentive receivables"
       }
      }
     },
     "localname": "ReclassificationOfTenantIncentiveReceivables",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones.",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_RevenueRecognitionExpectedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition expected period.",
        "label": "Revenue Recognition Expected Period",
        "terseLabel": "Revenue recognition expected period"
       }
      }
     },
     "localname": "RevenueRecognitionExpectedPeriod",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition milestone method expected milestone receivable.",
        "label": "Revenue Recognition Milestone Method Expected Milestone Receivable",
        "terseLabel": "Expected revenue through milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognized excluding separately negotiated research sequencing contracts.",
        "label": "Revenue Recognized Excluding Separately Negotiated Research Sequencing Contracts",
        "terseLabel": "Revenue recognized excluding separately negotiated research sequencing contracts"
       }
      }
     },
     "localname": "RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_SaleOfStockUnderwritingDiscountsAndCommission": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock underwriting discounts and commission.",
        "label": "Sale Of Stock Underwriting Discounts And Commission",
        "terseLabel": "Underwriting discounts, commissions and other costs"
       }
      }
     },
     "localname": "SaleOfStockUnderwritingDiscountsAndCommission",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_SalesAndMarketingExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing expenses.",
        "label": "Sales And Marketing Expense Policy [Text Block]",
        "terseLabel": "Sales and Marketing Expenses"
       }
      }
     },
     "localname": "SalesAndMarketingExpensePolicyTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred revenue by revenue classification.",
        "label": "Schedule Of Deferred Revenue By Revenue Classification Table [Text Block]",
        "terseLabel": "Schedule of Deferred Revenue by Revenue Classification"
       }
      }
     },
     "localname": "ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of property plant and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]",
        "terseLabel": "Summary of Useful Lives Assigned to Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reserved shares of common stock.",
        "label": "Schedule Of Reserved Shares Of Common Stock Table [Text Block]",
        "terseLabel": "Summary of Reserved Shares of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfReservedSharesOfCommonStockTableTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share-based compensation, shares available for grant.",
        "label": "Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block]",
        "terseLabel": "Summary of Changes in Shares Available for Grant"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_SequencingRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sequencing revenue.",
        "label": "Sequencing Revenue [Member]",
        "terseLabel": "Sequencing Revenue"
       }
      }
     },
     "localname": "SequencingRevenueMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_SequentaTwoThousandAndEightStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sequenta two thousand and eight stock plan.",
        "label": "Sequenta Two Thousand And Eight Stock Plan [Member]",
        "terseLabel": "Sequenta 2008 Stock Plan"
       }
      }
     },
     "localname": "SequentaTwoThousandAndEightStockPlanMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C convertible preferred stock.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_SeriesFOneConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series F one convertible preferred stock.",
        "label": "Series F One Convertible Preferred Stock [Member]",
        "terseLabel": "Series F-1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesFOneConvertiblePreferredStockMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase reserve shares available for grant,",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Reserve Shares Available For Grant",
        "terseLabel": "Shares Available for Grant, 2019 Plan reserve increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable",
        "terseLabel": "Shares Subject to Outstanding Options, Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number",
        "terseLabel": "Equity awards outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life vested and exercisable options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment awards forfeited, canceled or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Awards Forfeited Canceled Or Expired",
        "terseLabel": "Shares Available for Grant, Options and forfeited, cancelled or expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment awards granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Awards Granted",
        "negatedLabel": "Shares Available for Grant, Options and restricted stock units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adpt_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adpt_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adpt_SpecificPatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific patients.",
        "label": "Specific Patients [Member]",
        "terseLabel": "Specific Patients"
       }
      }
     },
     "localname": "SpecificPatientsMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, common stock warrants exercised.",
        "label": "Stock Issued During Period Shares Common Stock Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of common stock warrants, Shares",
        "verboseLabel": "Stock issued during period, common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares restricted stock award vested.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Vested",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, value, common stock warrants exercised.",
        "label": "Stock Issued During Period Value Common Stock Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_StockholdersEquityConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity convertible preferred stock policy text block.",
        "label": "Stockholders Equity Convertible Preferred Stock Policy [Text Block]",
        "terseLabel": "Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "StockholdersEquityConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adpt_TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity adjustment redemption value for vested convertible preferred stock options.",
        "label": "Temporary Equity Adjustment Redemption Value For Vested Convertible Preferred Stock Options",
        "terseLabel": "Adjustment to redemption value for vested Series E-1 convertible preferred stock options"
       }
      }
     },
     "localname": "TemporaryEquityAdjustmentRedemptionValueForVestedConvertiblePreferredStockOptions",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, stock issued during period, shares, new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity value change in redemption value for vested convertible preferred stock options.",
        "label": "Temporary Equity Value Change In Redemption Value For Vested Convertible Preferred Stock Options",
        "terseLabel": "Change in redemption value for vested Series E-1 convertible preferred stock options"
       }
      }
     },
     "localname": "TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity value vested convertible preferred stock option forfeitures.",
        "label": "Temporary Equity Value Vested Convertible Preferred Stock Option Forfeitures",
        "negatedLabel": "Vested Series E-1 convertible preferred stock option forfeitures"
       }
      }
     },
     "localname": "TemporaryEquityValueVestedConvertiblePreferredStockOptionForfeitures",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_TenantImprovementAllowanceAndCommenced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance and commenced.",
        "label": "Tenant Improvement Allowance And Commenced",
        "terseLabel": "Tenant improvement allowance and commenced"
       }
      }
     },
     "localname": "TenantImprovementAllowanceAndCommenced",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_TenantImprovementCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement costs incurred.",
        "label": "Tenant Improvement Costs Incurred",
        "terseLabel": "Tenant improvement costs incurred"
       }
      }
     },
     "localname": "TenantImprovementCostsIncurred",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_TenantImprovementCostsReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement costs receivable.",
        "label": "Tenant Improvement Costs Receivable",
        "verboseLabel": "Tenant improvement costs receivable"
       }
      }
     },
     "localname": "TenantImprovementCostsReceivable",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adpt_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adpt_TranslationalDevelopmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Translational development agreements.",
        "label": "Translational Development Agreements [Member]",
        "terseLabel": "Translational Development Agreements"
       }
      }
     },
     "localname": "TranslationalDevelopmentAgreementsMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_TwoThousandAndNineEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nine equity incentive plan.",
        "label": "Two Thousand And Nine Equity Incentive Plan [Member]",
        "terseLabel": "2009 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndNineEquityIncentivePlanMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_TwoThousandAndNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nineteen equity incentive plan.",
        "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adpt_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock units.",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Nonvested Restricted Stock Units"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://www.adaptivebiotech.com/20201231",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r101",
      "r109",
      "r196",
      "r341",
      "r342",
      "r343",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r101",
      "r109",
      "r196",
      "r341",
      "r342",
      "r343",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r101",
      "r109",
      "r196",
      "r341",
      "r342",
      "r343",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r167",
      "r275",
      "r281",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r497",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r497",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r167",
      "r275",
      "r281",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r275",
      "r279",
      "r465",
      "r496",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r275",
      "r279",
      "r465",
      "r496",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r290",
      "r299",
      "r300",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r497",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r290",
      "r299",
      "r300",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r497",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r103",
      "r104",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r130",
      "r198",
      "r199",
      "r344",
      "r377",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r103",
      "r104",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r130",
      "r198",
      "r199",
      "r344",
      "r377",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r109",
      "r198",
      "r199",
      "r344",
      "r377",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision Of Prior Period Accounting Standards Update Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r275",
      "r280",
      "r499",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r275",
      "r280",
      "r499",
      "r532",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r168",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "Seattle, Washington"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02 (Topic 842)"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update201613 [Member]",
        "terseLabel": "Accounting Standards Update 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201815Member": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).",
        "label": "Accounting Standards Update201815 [Member]",
        "terseLabel": "Accounting Standards Update 2018-15"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201815Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update201912 [Member]",
        "terseLabel": "Accounting Standards Update 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r376",
      "r377",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update Extensible List",
        "terseLabel": "Accounting Standards Update Extensible List"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r169",
      "r170"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10310.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Investment amortization"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r40"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Travel and entertainment"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r17",
      "r475",
      "r487"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes Current",
        "terseLabel": "Tax liabilities"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r40"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r230"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r55",
      "r56",
      "r57",
      "r488",
      "r509",
      "r513"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive gain"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r97",
      "r98",
      "r100",
      "r398",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Gain"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r344"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r100",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r374",
      "r375",
      "r376",
      "r377",
      "r467",
      "r468",
      "r469",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "auth_ref": [
      "r242",
      "r245",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.",
        "label": "Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock",
        "terseLabel": "Adjustment to redemption value for vested Series E-1 convertible preferred stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition",
        "terseLabel": "Common stock option share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs Policy [Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "verboseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r303",
      "r331",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r214",
      "r220"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10110.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Intangible assets amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area Of Land",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r147",
      "r156",
      "r162",
      "r187",
      "r393",
      "r399",
      "r423",
      "r474",
      "r486"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r52",
      "r94",
      "r187",
      "r393",
      "r399",
      "r423"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Noncurrent [Abstract]",
        "terseLabel": "Long-term assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r179",
      "r200"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r176",
      "r180",
      "r200",
      "r477"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r178",
      "r200"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10300.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Short-term marketable securities (amortized cost of $564,036 and $479,791, respectively)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r178",
      "r200"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Available For Sale Securities Debt Securities Noncurrent",
        "terseLabel": "Long-term marketable securities (amortized cost of $118,429 and $105,263, respectively)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r305",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r8",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings And Improvements Gross",
        "terseLabel": "Building costs"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r96",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Purchases of equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r31",
      "r84"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10290.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r85",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r13",
      "r85",
      "r90",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r79",
      "r84",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r425"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Noncash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r102",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r337",
      "r338",
      "r339",
      "r374",
      "r405",
      "r424",
      "r436",
      "r467",
      "r468",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r109",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r337",
      "r338",
      "r339",
      "r374",
      "r405",
      "r424",
      "r436",
      "r467",
      "r468",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in CCYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "auth_ref": [
      "r102",
      "r189",
      "r192",
      "r195",
      "r340",
      "r375",
      "r405",
      "r424",
      "r436",
      "r469",
      "r502",
      "r503",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was early adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Early Adoption",
        "terseLabel": "Change in accounting principle, accounting standards update, early adoption"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r103",
      "r116",
      "r197",
      "r344",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r92",
      "r94",
      "r119",
      "r120",
      "r121",
      "r124",
      "r126",
      "r134",
      "r135",
      "r136",
      "r187",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Warrants issued to purchase stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r387",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Microsoft Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r237",
      "r478",
      "r492"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Total shares of common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2020 and 2019; 137,646,896 and 125,238,142 shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock voting rights description"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r288",
      "r289",
      "r301",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r64",
      "r67",
      "r480",
      "r495"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r140",
      "r141",
      "r167",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r167",
      "r420",
      "r421",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r167",
      "r420",
      "r421",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r137",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r140",
      "r141",
      "r167",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r140",
      "r141",
      "r167",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration By Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract With Customer Asset And Liability Table [Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r254",
      "r255",
      "r276"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "periodEndLabel": "Deferred revenue balance at December 31, 2020",
        "periodStartLabel": "Deferred revenue balance at December 31, 2019",
        "totalLabel": "Total current and non-current deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r254",
      "r255",
      "r276"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "positiveTerseLabel": "Current deferred revenue",
        "terseLabel": "Current portion of deferred revenue",
        "verboseLabel": "Total current deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.",
        "label": "Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination",
        "terseLabel": "Additions to deferred revenue during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r254",
      "r255",
      "r276"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, less current portion",
        "verboseLabel": "Total non-current deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Revenue recognized during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Shares Converted1",
        "terseLabel": "Conversion of convertible preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r291",
      "r298",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r465"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost Of Goods And Services Sold",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost Of Sales [Member]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost Of Sales Policy [Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs And Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r139",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities Available For Sale Amortized Cost Current",
        "terseLabel": "Amortized cost of short-term marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities Available For Sale Amortized Cost Noncurrent",
        "terseLabel": "Amortized cost of long-term marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r184",
      "r202",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer",
        "terseLabel": "12 months or greater, Fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r184",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss",
        "negatedLabel": "12 months or greater, Unrealized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r184",
      "r202",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months",
        "terseLabel": "Less than 12 months, Fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r184",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss",
        "negatedLabel": "Less than 12 months, Unrealized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r183",
      "r201",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position Fair Value Table [Text Block]",
        "terseLabel": "Schedule of Gross Unrealized Holding Losses and Fair Value for Investments in Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r40",
      "r433"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit Current",
        "terseLabel": "Current portion of deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r44",
      "r433"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit Noncurrent",
        "terseLabel": "Deferred rent liability, less current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards General Business",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r354",
      "r367"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent",
        "terseLabel": "Employees maximum annual contribution of their compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r82",
      "r228"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Acquired Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r275",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueScheduleOfDeferredRevenueByRevenueClassificationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Schedule of Revenue Disaggregated by Type of Products and Services"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share attributable to common shareholders, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r355"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r355",
      "r380"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r355",
      "r380"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r355",
      "r380"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r355",
      "r380"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r355",
      "r380"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r355",
      "r380"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "terseLabel": "Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Grant",
        "verboseLabel": "Grant"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r100",
      "r104",
      "r112",
      "r115",
      "r133",
      "r196",
      "r245",
      "r252",
      "r341",
      "r342",
      "r343",
      "r376",
      "r377",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r82",
      "r240"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "terseLabel": "Fair value adjustment of convertible preferred stock warrant",
        "verboseLabel": "Fair value adjustment of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r406",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r407",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r410",
      "r411",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r291",
      "r292",
      "r297",
      "r298",
      "r407",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r291",
      "r292",
      "r297",
      "r298",
      "r407",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r407",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r90",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Off Balance Sheet Risks Disclosure Information [Line Items]",
        "terseLabel": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]"
       }
      }
     },
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease Liability Noncurrent",
        "terseLabel": "Financing obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r448",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Asset Useful Life",
        "terseLabel": "Amortization period of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r219",
      "r222",
      "r466",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r219",
      "r470"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r215",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r219",
      "r466"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10100.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administration"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r207",
      "r209",
      "r473"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r90",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill And Intangible Assets Goodwill Policy",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r90",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill And Intangible Assets Intangible Assets Policy",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r82",
      "r208",
      "r210",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r82",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment Of Intangible Assets Finitelived",
        "terseLabel": "Impairment losses on intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r356",
      "r363",
      "r369",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r90",
      "r352",
      "r353",
      "r363",
      "r364",
      "r368",
      "r373",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase Decrease In Other Operating Capital Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Information By Category Of Debt Security [Axis]",
        "terseLabel": "Debt Security Category"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Purchased Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest And Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r49"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10320.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r50",
      "r90",
      "r132",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r471",
      "r484",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Summary of Other Information Related to Operating Lease"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r8",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements Gross",
        "terseLabel": "Landlord contribution for leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Reconciles Undiscounted Operating Lease Cash Flows"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Remaining Lease Term",
        "terseLabel": "Operating lease remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters Of Credit Outstanding Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r94",
      "r157",
      "r187",
      "r394",
      "r399",
      "r400",
      "r423"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r94",
      "r187",
      "r423",
      "r476",
      "r490"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r94",
      "r187",
      "r394",
      "r399",
      "r400",
      "r423"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line Of Credit Facility Current Borrowing Capacity",
        "terseLabel": "Line of credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r59",
      "r62",
      "r66",
      "r83",
      "r94",
      "r103",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r115",
      "r122",
      "r147",
      "r155",
      "r158",
      "r161",
      "r163",
      "r187",
      "r423",
      "r479",
      "r494"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r117",
      "r118",
      "r123",
      "r126",
      "r147",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "totalLabel": "Net loss attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired1",
        "terseLabel": "Noncash additions to property through lease financing arrangements"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r440",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r447",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases Rent Expense Net",
        "terseLabel": "Rent expenses"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "U.S. federal net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r40"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r60",
      "r63",
      "r391",
      "r392",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r53",
      "r55"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Change in unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income Expense",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Over-allotment Option, at Underwritten Public Offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r72",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments For Proceeds From Tenant Allowance",
        "negatedLabel": "Cash received for tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Payment of public offering costs, net"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r305",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock par value",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock outstanding",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019",
        "verboseLabel": "preferred stock investment"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10330.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of underwriting discounts and commissions",
        "verboseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r76",
      "r77",
      "r95"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds From Payments For Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r336"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r59",
      "r62",
      "r78",
      "r94",
      "r103",
      "r114",
      "r115",
      "r147",
      "r155",
      "r158",
      "r161",
      "r163",
      "r187",
      "r391",
      "r395",
      "r396",
      "r401",
      "r402",
      "r423",
      "r481"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r233",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r90",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property and equipment, useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r229"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment [Member]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r231",
      "r491"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r90",
      "r231",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment, useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r171",
      "r173",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivables Policy [Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r350",
      "r548"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r90",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r7",
      "r16",
      "r89",
      "r533"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r252",
      "r344",
      "r489",
      "r508",
      "r513"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r100",
      "r104",
      "r112",
      "r115",
      "r196",
      "r341",
      "r342",
      "r343",
      "r376",
      "r377",
      "r504",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r154",
      "r159",
      "r160",
      "r164",
      "r165",
      "r167",
      "r274",
      "r275",
      "r465"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue from collaboration agreement"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueScheduleOfRevenueDisaggregatedByTypeOfProductsAndServicesDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r278",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1",
        "terseLabel": "Deferred revenue, expected to be recognized"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r446",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale Of Stock Consideration Received On Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale Of Stock Number Of Shares Issued In Transaction",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Public offering price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r140",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Available-for-sale Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r303",
      "r330",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Compensation Costs Related to Stock Options and RSUs Included on Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "auth_ref": [
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.",
        "label": "Schedule Of Fair Value Off Balance Sheet Risks [Table]",
        "terseLabel": "Schedule Of Fair Value Off Balance Sheet Risks [Table]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r215",
      "r218",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r215",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]",
        "terseLabel": "Summary of Intangible Assets Subject to Amortization"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule Of Goodwill [Table]",
        "terseLabel": "Schedule Of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r305",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r311",
      "r320",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under 2008 Plan 2009 Plan and 2019 Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Estimated Grant Date Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r45",
      "r92",
      "r134",
      "r135",
      "r241",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule Of Subsidiary Or Equity Method Investee [Table]",
        "terseLabel": "Schedule Of Subsidiary Or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule Of Unvested Restricted Stock Units Roll Forward Table [Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense for Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r138",
      "r140",
      "r141",
      "r142",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]",
        "terseLabel": "Schedule of Concentrations of Risk Percentage"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10090.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling And Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling And Marketing Expense [Member]",
        "terseLabel": "Sales and Marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Restricted Stock Units Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance",
        "periodStartLabel": "Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Roll Forward",
        "terseLabel": "Restricted Stock Units Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Roll Forward",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Restricted Stock Units Outstanding, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate",
        "terseLabel": "Weighted-average volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRSUSIncludedOnStatementsOfOperationsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "periodEndLabel": "Shares Available for Grant, Outstanding, Ending Balance",
        "periodStartLabel": "Shares Available for Grant, Outstanding, Beginning Balance",
        "terseLabel": "Shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Shares Subject to Outstanding Options, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Shares Subject to Outstanding Options, Options forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Options forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Shares Subject to Outstanding Options, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Option outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r313",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Shares Subject to Outstanding Options, Options outstanding, Ending Balance",
        "periodStartLabel": "Shares Subject to Outstanding Options, Options outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Options outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Options outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost",
        "terseLabel": "Incremental stock compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r302",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r90",
      "r305",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r326",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-average remaining contractual life options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r92",
      "r94",
      "r119",
      "r120",
      "r121",
      "r124",
      "r126",
      "r134",
      "r135",
      "r136",
      "r187",
      "r245",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r97",
      "r98",
      "r100",
      "r104",
      "r112",
      "r115",
      "r133",
      "r196",
      "r245",
      "r252",
      "r341",
      "r342",
      "r343",
      "r376",
      "r377",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r100",
      "r133",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r47",
      "r245",
      "r246",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r245",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r245",
      "r252",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Shares Subject to Outstanding Options, Options exercised",
        "terseLabel": "Issuance of common stock for cash upon exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2008Plan2009PlanAnd2019PlanDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r48",
      "r245",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r245",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Proceeds from initial public offering/ issuance of common stock upon public offering, net of underwriters' discounts and commissions and net offering costs paid by us"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r252",
      "r304",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation",
        "terseLabel": "Series E-1 convertible preferred stock option share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation Forfeited",
        "terseLabel": "Vested Series E-1 convertible preferred stock option forfeitures"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r245",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock for cash upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r94",
      "r172",
      "r187",
      "r423"
     ],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r432",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r432",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r432",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary Or Equity Method Investee [Line Items]",
        "terseLabel": "Subsidiary Or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r358",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary Of Income Tax Contingencies [Text Block]",
        "terseLabel": "Schedule of Change in Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "U.S. federal tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Limitations On Use",
        "terseLabel": "Tax credit carryforwards expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity Accretion To Redemption Value Adjustment",
        "negatedLabel": "Fair value adjustment to Series E-1 convertible preferred stock options",
        "negatedTerseLabel": "Fair value adjustments to redemption value for Series E-1 convertible preferred stock options"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Temporary Equity, Ending Balance",
        "periodStartLabel": "Convertible preferred stock, Beginning Balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Temporary Equity Ending Balance, Shares",
        "periodStartLabel": "Convertible preferred stock, Beginning Balance, Shares",
        "terseLabel": "Convertible preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndShareholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r374",
      "r375",
      "r376",
      "r377",
      "r467",
      "r468",
      "r469",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r291",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Debt Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValueForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
        "label": "Unbilled Receivables Current",
        "terseLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "UnbilledReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r351",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions",
        "verboseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique Option Pricing Model [Member]",
        "terseLabel": "Option Valuation Model"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Exercise of Common Stock Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted",
        "verboseLabel": "Weighted-average shares used in computing net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20201231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL82887624-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 3.C)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177168-122764"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5558-128473"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39927-112707"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120520240&loc=SL120174030-210619"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r549": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r550": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r551": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r552": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r553": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r554": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r555": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r556": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r557": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0001564590-21-008124-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-008124-xbrl.zip
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M1L%$Y&&:%S8&4W.G%W+V#90=X(X?F?? )B N/JPK W[=D'W2AC=AA,<MU0L
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M7(?\_07;V*JW1=S.ML^]B#\,.0"0UK_4@2PXCYK5 8T  63CD(5M:Q(D\"?
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MQ#8BP8@$(Q)**!*F%/LTG[XH+$ 1WO$8BQ@H 7EG!-\/J'LCL'_X=R!,"YR
MX(I$5Q ,-DX^T+.4#'??-!PUW-UP=\/=R\_=@QXY[Y'MCK!H!#_H/IDQ<&:
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MP*(?'_2\XGSM-YK)_EX'=1L16S)&842L$;%&Q)90Q.9LH.D6G5+@4E-0518
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M=QNUO8+K\W0RF:$2-/!2[(A@0ZD5%47):"SD"AIH.F#B("Z$*+UR2D&%MZB
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M@HVW"U+@F:[&IDDBJJ9O6ZBF>+CR/(2_&06KS$B3:F]:/.Y/LN(W23FR7:[
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M^!P??A,>0@I%I/["M#NU+*Y%/Y$J%=;:WZK)%X$JFW2X2(ZD,XT#ZIF/I1P
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MC#^S;I%D<Q0L4-/<2! PF1RIKWPL#$CNU=8?O3@Y<92WX0ME%B-3%,RT!'5
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MW;GK&T"NABX88S_2A^EPN3)S2SXM_I'" PEK).^_=^YBR5M([J^G 3O+U(S
M7>L,1Y<63&B7T\:O8$N<6UO"X5'^+AO+F<9?./P-)M<7(2%A@]V,?J$K\Q8
M[KMO/OH9^MQB< V8XYPO6EW2'""6&3I433R%+?V82(!)[(3"W*2D!\%K70FD
M@^/I,019WV+& ? ;>'*-NFY!GV@ USNBKA!JM.V;V]+N,,'JXD0<FSI[<]*
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MUD'5;;S>@^@\R,L*!9:M:N4J\DJLMZ/AWH./#W'DF="U@N_JT[\X[]Y1;\?
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M]3GB][[4[S^Z$_7[G3*[8[>[4V;?G3([[)19,*];[M3ME-EM/G/N^]O29%2
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MI27AMM<QB,0[Z+ U+&C.5B:VWU'L@0N?H\9S,OJ;%,!R=,*5P^8,A9I<:KB
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M.$8(V')7L9\DC3E.X6MOL4I85T$?M-?536T?1PL4GW,=%&#*MC; ];1/1^R
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MIX.PO?GQU>R=Z*48<DY+U=36QB> 70@+$%M?9B___@Q7#^$>>_;(2@*/PSK
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MBY,W(BPQ3U,7D"8Y]*AF$:V[:#;1;L!P$DJV'=\_>G$$AR! Z*%P7*B0([3
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M>0]UG,TNP&HGMB&GB%S>D!B:^@1YG3<%5'9=(C9^62VTINW:J%3_,PH91.X
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MQR;?EI@S%J.?3]7$(=+(1"Z2#:'AA.]6R]=%A]SDR/NPD6Q"_L]G?T9W@<6
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M-2B83"LFV;X)U[D +]G@/P%$--Q?.55_?Z:[G,^ZW;;8_X[EV[65UOME[8^
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M9S]3I?RL;*Q;W@5;7N69"[;6\ 9Z)=8.XT^]B# [51$>IE=R\N=/_OS)GW^
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MA(.K'4$1D\=0?<TP<^B8 @!GY<X+) %432K3HRN0HQ%"V3.9,W&M.T=-3$
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M;P]3A"XM/E8OTM*X_Q?,\ &YP:]5R-=>6#6[$:F\-(^&J;OXT.>S5U6XB*8
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M/+YJ[5=61ZV6)]5\G )V4LTGU7Q2S<>EFMEMD@#?:(/M>!KE_.,T\I$V@@U
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M-;BL%H RTVHP,' 7\@&'?%$BYBSR;;WN/<URCY_?=J+P#57$ZP5R@LLEX&V
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M9@6KX?.-$&,/G+F?BOUI*LWS[HKN QI4[/\]RF*:@68IJU@?N=DS'$4=(#>
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M6B>9+X*G=XH&CT#,H_N$^H?' H>'Z4['?8UJ#6:]0FRW0O:U>/04B)R,I>/
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MS5$N0,&1/U/>O;0<!3>R*I 5K56%/M/!E4M[/JF#CL0KIR<$*KZ?]QI0?L?
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M8S39+8-3F18+OU!@=NUB:]KF86U'P)BG;:,/PP9KA5.0RSL;5D1PBQ(W?5J
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M. C 3K!Q^&],Q<XA2R2]BO64%<V7+9#X+^H^J62HF@=ZG^I.Q8560 @9,8A
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M1V.VJ(<$.^KBP%$+,XV3\$>*R8EZ\HB3!D4P/>.1*]* PC>?1"]XYJ7ZX(7
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MXW@[*@XXWEE!IV#)1;G_B;G:ONW&N\5K7O<_MX^27]\LOGKQ\G<B27F++,O
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M51(G-D-UXJ9SE;C2.Y+M1YBG?RO[>WK0L6W\^^O,>:=E?@A6!"/DH/3UP)I
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M[(6% 8#%LB2\YQ:!']70$6_QU&K]'0NB\9*\!Q32E=:9#G],9@HH[IU26V@
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MFC'Z&D:^+1]H'Z!DXD2UN-Q7C_9' '\PWHS2#+B<]*+JKOC"+JIN476+JKM
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M5IJ(-EOBL>W><Q82'^K CO<=/R#^TIPN)G&"TR\W.Q\;"?F9^B979D0.$8F
M8.D!'<G(QY<JJU-Z+.;#S"CY@#F:-F0/\828! OE.'+#?-]+X0!=5!1K(<30
M2$JGTES+S?KI)OU+ZIAXZ)L2/$:FY/&_K.57N1G#^HTV1 V4Z&W* B.08"(X
M7U2AVS5 RZ,V.^&X=$5F96#UGPZJ54&K"^I<K:NG1]PQLSP)IWN9IX:7^@B[
M+"SDR?9(7OE6J.Z-D&;K%1B;#:('+ BL&3#V&(4\1;^ M^SJ]V%7W[=M)5K)
MOH[0GYPY/.9E51[8E7[9TRH?XQRM2%,=&;;#HG(VRO.IZ<R+2J=!5YE'A>/>
MPM&^9ZL8,5'2/;Q@N_:1=AHGU5ZLMFZ^+'I7)'V@@1YGGWA#1!X=E3'[X>G1
M+1X51TB#NFFW-X=VP\5[?&S[3Z20Y5N^K.RB3T^Z\W L5TBC1AIOH+.<<6WY
M^D0UP3G2Y\HX^V,X])H7#!R5$3%<:!2$#5(-28O(:0 =HE%<^<S'?!-C&>[/
MN& RIR]+Z61W5B2[_C;-CQPE+)B4,W,4B3P$LHWT"A_*NK+%XLS#\<CLE3*E
M=CC0O82?R714*[8PI!R!__K(<JBIE8$U9E413]D:EQI& CR4H*$8]U-^.[C,
MNZ[MY!9G1(@B=D_=N!BC.YNWY1<E3\#EBT<JP9Q#FOHV5$S :-JK/YKC:Y]P
M /2 L1Y]%,(TFU5ZU@^UTO21NUHSMHPE8%-H*2\CDH5[0M!K)__%4GP= D>H
MD N!U8Y@JVHKV]IT[#F_"(^WYYHHB81H1?NV;BI??FOAUECTBH#8T$F8-/M)
MTMAR< LU\7%,^&[EDNN#M%\JW,F4B!=*:8S!(JL:;[JX4CU M]@/_H3RDB3O
MCJ/R$L03WK18<*X+YBH;^$S&=(&>Q:C9>4/X*X_@Z&U;YK4V=E*D/NKC8)'.
M> '$&DB*DX:,I,1@*<8ZE6R9*8$8P;8/\.MI%6&#^!%D8WOB/9-QVYD2@:Z?
M/G*9)+2EVG,R:PY-YY;"/J#\I^XY:T/7^3 PQEY@S*)CUY;**5R!TC/ELA^#
M"R572)V1H=*P WO?/HJ]4Z0H 22]2[W;\[$A5QU#_4ILY&]8V'0CFWQDCEZW
MBJ7C_L\DM!!0^?S%YR^*U:MOWO$.<NZ?COU?+18?HT:OLTC.+Y4']J^O7BOO
MZZ^T[H@N*U+27I:/R%:Y$R1TPLG, 9=_%V;%O_[YG88-0:S]%$NOI 2@?T90
M&4.(VR?XD21ZNMK*NTB0E8S_OL'_ZVZG\W[U.F:^E;R7'I&L=+S@CM:!8YZ_
MK!M27XCI_,HF)D]D?:,@9I+?A E?-P/;$5IGJH4_B4F>;G5'8B6Y1)SR92^2
M:_IBZAZ#A,Y1M$P6$I@P)Y'=4R0LI.S6ZE]T9)XKR^2L"?Q.F'=7OWRYD0JL
M7ZU>Z5J1RL+D6"';)***X$6T8C-Y5R'13$D6Q;9?=.1*IHVYN#;M03/7:B;8
M4E][M/\'=!JGP_@64?X_%2G^RY<%W-$G[PD'@MG+'/A96*](;?R7]-VO0EB]
MV]R39T 6@%W,5W_YZIW=3+M(TK#5QS%$+=/J^V++%7DA.PE?5 BL_Q#?_S9E
MK%]*PH9^'"?Y<L..XN<O/OMU',C;E]^\3 /9Q"R##C\F$LP"Y](\%)2K&R3J
M-;["$BCF!X@2&Z\237[E1$$,1[^]?^HA$9I\T<HNKSC4NAVP3=.!EUKQ,:VK
MU'K2:<9.ZERC>#FSJ87Q9(\MH[&Z002ZW0TXI1Q]X!T2^\5\ @-*Y,MOW7A1
M:(TV$1O!_-]&21Z[TGJ1"BJ<_IZYE#U#L[@T-D3@@""^2J@^^/=IC)OMSQ*-
MT^$HI3?R-S;R:.]W)2G<^QB=0=*HK21IC*X]2=EP3D9EIDFAVW0_X@%#083?
MW'NWY[;T,\UXKAXJ2W6S:[ G 7"$%G5UF6^V12SZ9H.B2,)-2]CS8*#?O-+K
M'#K3IPK9=1(GSY"@&C1:2:$9H+=V7=)YPAF![\Q7![4#8;<KFX#B'SXV/+IH
MK<;=_>;EJUA0P5J'[4_7@9G &&0$V=F^=M$.H0#&Q]0W',OL.5/G3QZM0[F#
M100'-%L&WH6 6#*+*XFL635P:5N'7:C$>)G='A@**E/YMZ@,<8VS*D)T]O1G
M>-*E3V"F-*]MCI37J10Z'%3$9?(O_+0)!TTVY6*+XXC/$!WNR>#-QG,MD]=R
MG8A\2Q)W_DKT:E;0[TMZX&!4U?P\IZJP=G6W&?;2<4$_FVB#?.3QGDV/NWXA
MN$B/W^5"H%]AL'+9CTIJM%AQ')7E83:'%;MT2!%*I3EKLXFKK&XI^JW*7J!W
M3_6X2D"I;N0?\_ELW:#95^FBSJ:3(:J2_OT4+O ;"U'D!R3)9)7]VZ$C9_I>
M1"Y=QT,M57DQ*BMIFIH/2EPB$::I%;XC$X.6#/U+X:<2O(1,/-*8L-\#.SCQ
MNEL!7RH,:#DS[E0CV?BD,+AYP;^8LP#38::3KV<<CCY;[S2 P+<H9':I!?HM
M-N"XX&D==FW[WNK#X\NV2??XL 1*(5,(0<X8QU):%#W[UB5[4F^9%PWI/UEQ
M9%[,\$8?%L,U;I+163MSHTF!Q:G^.'1U7PF<<\K0N(7L:<X;>$T^\X'II>22
M#NL32U?__F+3U1<>2;J,QFXD4K[[X=MB-FBB1G57'L(P;I2RZ(Q9[S!$?FQK
MKH!5U 4S2B9-'8($GQG (S/:DJ[I1=J6A:RT=6AQG?[<B$+-\@)V#6F[KI:V
M"0-Q(?MXPNO-1K=H[:RZVA!CG@IKU>.& /;VD'_3(GAMAM9X?)ST.=C)^9&?
MK#RV\'JJ0!X^E5R>-<?"[Y2$A*ZY.#'2#ZYI"-WV9)MPZ\O<6B:OUQTKZ<&U
M>O;;U3=9&RX=RB)%".J."S8D]860>&$#*.>.IYAW"7T4IX'4!SUNIOU7##:U
MR3=MIR?2>E7VBH.0JC/U\&?]-)+GA3KGPEQN("BRAE[5P,:#C M'&M;J-"IT
M4G#;B,R0P7>XI+SK4O.ICD9L$WDRVY6G1RT]P;4ZAMXCW8]2J^:L>] ?/VC)
M1;KQI5,@8D=,!DTSQ'IZOM"&":1[)EQ"=ZBTJZ7-<_:QD"Y) -R@1I)#H6V2
M)D_VR#6R.P6[)K'Z3Y.CR&'-77Z]WV+9L"FFN32I_">3?0.GB1<XVU6L*;VH
M.<;&MB*UN/E8V9-'L*7[M1UB;T,.=,OY6!1P,R^VM(DHI06*Y*7^VK*O&:9N
MRCS>KK[3<]EN?=#B.=>3Q>G'* TUU:2:7^O[)?.(G&ULGZ,%H9]NK,MNOF32
M&@D*77]!2:+C6*8#G1X9V43.-?(" $SJ,B3S5HS#,6MR7RV9;14MQQ3DMVZ*
M6!_BJMM-Z ^Q1DL:SF9*/N]"$\18[UH08Z&FUU]''GE^)]4C-'&$9"\Z6EG,
MGKKC1F8B3K1:\B:K4[PMW65>NMDK(:8 W\4PN62]-KQ9]\]S3E9N5_!Z/CK[
M?CQ:2 M.UFI!%H<83(Q\J/7?%_CF<#4QA.C;E,K>FS$Z0M,J3=,B=\@NUEHR
MQZ=%"+?=Y8=9J_*T\=#J;D<M$OJ;CSKTDZHZM9CTX-ZQMI-A\8&>]K2S'P5Y
MI8<BBZ_*/K.WRVO)R2-M4+K^C@Z-5\WM9#SU951J2>.7\WJXB.&PY\O:0ELC
M2K-327@ U(/;#RM<>_;SMW785;9A#EWIE*7A,G>[4%:B4Z5"KUKUFXY<!E()
MGO]ISL!.S;E07O[H"&9O$:7<.6LZG?I45XO7_MM0QEI]0RS:YN!5_%'NS+2I
MH":VH/F]8=L$:\C(!,AP=6&'>6O:IR+Q4+/%@4?07WX<D)+ =#?:1?:5E$*B
M"E_N5#*!4A.:7!-;Y#7' [-VRO535L*?NG/3>G#/*LHM#Z05[TNF/#?D(#1*
M(*Z%!IN*X\+:;7!*Q%QSY0:PKYSM>>K>^.-@N9A1873^':EB6ZONG,(KCH!!
M"L]'MMF@EN88F_UI]J'A@FB-<$$[>RO#-V7;#;/[X;IYHU*7[7L&YF/A\=>R
M<?79P.PP?M"P2JWM336O<*Y=LG^I-M I\?X??B:XX"Z+1$X@+W-A-NH?F$'"
M?7)T<MPO'4;P,HG$SK)%6KHNL&V]-#!%V)VSLK7M[!UM<]>*6^L04P3K/96
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MBNQQI\#,9=<(#A;&[M#.+',Q:],+Q-KJH6Z30T9NW2*WK_CT+7)[D=N+W+Y
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MYB1C>*@)A.@BUQ<<V_GCD!E[ZW!\Q)-FSX"W5M=&76GKU/46_#J&'LXZ1H<
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M_J.P/Z)ALL\"+]P)XW,0H:D.;=T %*#MIHH!,96_4R4@<K,YYCIA:)#7.(C
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ML>/DY)E[IJ)2N$+JUM%KI''IH9ME/5'):S$"Y1!CZB.-NW+=AECJ<.7Y*J8
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M;>XZ#E;Q '/A;]>2Q97+MDAQQ)W"W/2K.YC1C4\%R344%-<5%UFIQ\!'"L$
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MA1AHH0F\XJ.W".U%:"]"^P*%]N-]@.A-#";:VD\&,KN Q0FJB<(!_Y@'@E@
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M<L1O\M,?88'><5.6M'@I0D ^&#89I?%+3'2S1/+N'6@"<K;#"%V%R[AP1&O
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M6O)%K1G_W^/IQ!>V^W@ER]O@#VV-XQ-OU)BK) <]G4+<XO#GATL$-X0G[U+
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MMD3V/#OVO1=)'M! ]/6+5X>GX='@?OI:+L<N7PYQXH3O]Y$&HA1>O!ITP\%
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M^I]\(LV>WX5-(M3ZX5304?H#4KM90%KQ-+:C!_I4>J %+&(GR.*%#="0>]L
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M(:^@6BIB>#;L -@%^7N<([N"0D>> M4%)Q9G$]CLNRK']82+6[I0R7Q:);B
M"Z!Q@G3&KY8YZ"Z[KAH6A]5P8<\(GJ*^C9-J@ILHU:S@BP0\#"1'Q3Z)QXR
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M+-J-N.9J\Z/1R3T??58]M )%KNU'KLQU2YS,.>9<@_B^J+KCNB0TKO[G$.@
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M#=BJF_ $_/\O V2HT1MV-AC#CHWW8B#&=R(TFI9IX)JA83MAPZ&LM_JOS&O
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MX,8';DC.'1Q)!YZ?QX8[0Q"":K8SQ$9PG;2'\WI]%Z=PC_.+B&W7%\ZE'?J
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M^#8='638>-' @1F>&9X2$"25A ]$B0#!"D$#!V8-9@U*0)!4$F8-(D"P0M#
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M$ Y4$' 0WC]7*@@XL"7-N0O(J>7)MKL70]8D>*=FD7(\:KMMJ6\S%<2*7XA
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M%I[+WGR@E'3>6U1YUR6-MW?_9:?7& XD9LJ-H;C*NN"<\/ZY4D%P;@N<Z^\
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M&S3Z.TPS$N%GXW>6%M2[=$9'H:.4&UN3*+RW8A"?F-*A0<*,J.[<2RT]LMB
MZ6OTR'I1SR2AU"NWP'H1M4[9--K<,JK-Y<AT[0=0M;>@::\"]Q>M9I]N)@?Q
MAO<O!XUA1SI3'@4'2F=*(86@[HE02E!W3ZA;F]ZP6]3=A3^^U^X"ZO))!1?4
M9:M !'79D$)0]_@I):B[']3MUL8O[!AU=Q$1Z'<;_>Y(4/<8.'!7?5)V,TY4
M8@7V&N,J/49MH,5N.H* N\S1.!E2KMF!32ROG2=@=->=HY%WZ3_(N,KVL-'J
M[2[0(&/"3S$O45#["%2]H/;)D%)0^V"H7>O0MB/4?B8^L1EJ]T;MQN"23^&
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M2RRCO4;,%NVV21[[[J>2?&;O_WQ0;?XFUJ*?SE]4B/\:#VJ^Y$F9>IDGZ(*
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M6,,++"@A( /P@N?#^SLA@"4\!9/$ 8]0[6FM,/&B&(G7*/\9IHG^<VQGNP
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M2LE9&.]6#V@3/9"W%#.XO,A)[^,$W;#H8<7@L,F?<NPH>D+3LI1(%>@[6Y@
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M1??!I@FR81IGO7JT%\Q.BL?E]Z8HK.DRA E(I7#L6,&17P79369VE'CX+'+
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M.;#YVV0P INIHH#J1U$-9(EF]@)/0Z/PZ%?7CUV]0I.,65R<1:=-$4CY-F$
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M9;&]DG//;*B:(;-N[3AX@5U*R+R;MQ-<(*^P",)E7@LF-G5P:<"NV_,CN3#
M!KU7+62PC0'+=U\UCSWY8*A@ HO5E%EAEMPPABWMH[#A-:L8;1V@'I^5LW98
M2PXL<#!H_#7S[&0])(L$9]'$62S&@,\2;@'&"_PU1$7"=W!U@7,V-1 )XXLO
M]JP8'1*R7/CB^%6+P0_ 1[T5XX6Y1QZ:!(Z/K[:YB5_:8[GI>LY@4FT^2DG
M0^YFL%&-MEI6QUTXS5YVW;1;P_7+!A3N:7^ 8# ^WUA2Z(L9@C,="T.)P(Q
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M3&_OVEWG;JM3B2:)!>;R17:]=J-DOLA!=*X[&#4&(W4NSJSB<RM1IU;.Z[Q
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M)N$'6,W<96@V/C2:FI'FA!K[-X9Q1;[F!YK+PA#_X&DP*^V5F8$V"?P9GT3
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M6U=73L73R=?7R==33PUR]^3N-SF Z]8 N?&+UROUP* +,BHI1I7;,2N]#/7
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M-^F:]K [,@WNBL$I)?Y' #^Z6N&EN=^2KOZ7FS:\C[G88]8"F:8_2YC@/R?
M(\ !'+-KSD-VF_SCC28!I-V6B<9K@[WBP\+/%8&D%$?0=>K#4M^YK6OD_4C+
MW.K>M .[\B;C/-LH8+7@.!0932L933F102O81[W%X>XUOHUB64CAYFVRKC6Y
ML-,I<?A? O\5OJ*KYYL'/%A39L<N^SQ9\AKO7N4_[ETS#)V)8_'BR8_XCBH\
MR@73D50/@9"0-GY-_VGEI+62E>"=1 Z2+R;'@ GX+?\EU'YP %*F?AS"!\(?
M;U'#.W'8'&7]?EOSTKEY+5BE\-6'^&4QK%LSCOPW!_CH$YV<GCF#]V+C2919
M='1=P.@0OI"(*I"ZTFESW[M-[LK*:(_%RX)7$>XI /$J51ZUMWOBW(7ZP,.?
M/0OD%*$0-61/%T$NQI$1J*BCBQ14#!5 1>_L<^I0;]#!3<39<4:E;$,UU**>
MY]MK.1U_MZ.FIL@O7KI:,:9"?E$YM:B2@KURK5U[9329.Z#92Z%+]5)0J#0,
M59"HKQJH-(RRJJ$5HH0:"!_(^NNK!L('9553^Q5R;>VCU+] ^\#^C9F'N1CJ
M%3D@G*:2^PK?H:&>&BI=?QD4^D;=PY/QZYCN?1^'(!,6I/G>FV_"A$'T)?#M
MV(H^!P\L>'8L=O?-"?_!G,>%UY09CG_P_(T#;[3V&MU^=16PR4%<N9\F>"3K
M)W@D>-P.'@LMI\X"CP=<+M6-1G=(+:N4,T55#F9/G$"I_M;^/:P]US]KRRI*
MI+R,L"/5_;P055'=SR/1(^.$]"CCF"L,'_0&C6&%!46/57V#"HJ>W[\0+*NC
M"X+E*U 5P?*18+FC!BP?4A-KV.CIZM>I)%A6*2/AQ+$,8]#J]-36C"CT;56<
M@TX71=5!YU/T-3GH!E3-/:$:NMRKO"A1L0JH6*'IV(%4[*!@QZ#3Z.C%FGIT
M;T]%6U/O2C-AM&I^G3#Z>G1)&'TNC"YT+SL8HP^(?/3;C=&H6'&8,%I%6U,E
MB^-X=S$45\ GWVM6'=Z@*Y17=LZP!:S6W&NIH:?M&%"]V8VJNJM]^J8::B"$
M(80A/1'"7*'N:H\P=,W_U#J@:_X*F;\:8J^]%U)##729<8\X=Z']]-HX]R??
MLTYZW3]S3FVH$P G5Z"X*R @).NOKQH("/< PD+/YW,!X2$7^QO=GCJI7.0G
M%#L1IGO]=*]?;86H&V>DE+D+415=(#P201J>EB =YVJ_WC<:PPI3Z>@2X?7Z
M&()F=71!T'P%JB)H/A(TCY2!Y@."%S"OQG!07=5>@N9+B&G0_?ZJ-2/N]WM'
M2(*G^X/JH#3='R1=TOU!92G9<+<>"EM1L@,#'YU&7Q\J<SA$[$I=?T(XK8XN
M"*?KH$O"Z7/A]&[-'+;$Z8.B(*-&IZ-.<P;"Z0O/[+#]>.PRS6C5,0J21$!,
MSSY*1.2(1TS'T-O%K28USBUVA^:<\FK)M/9N=G7NBYZ5:))(5HYD[=82XE@A
M$*/3;XPZ ^4/F%9Z_EHY$&5S/PB8E?'H!,P$S 3,!P#S;DTACA;S&+8;'4/]
MADMJ O/9L4"&/'Z*3) ._-9VGM\FNOP4@P$YUF["R,W]^\Q<^_,H-X*]G]IM
M];K?GW.IOE\*0&B3P)]I?AQHOS$/1LBLJ7;W%#"&25;PH7G 0OA7J'VW^R*O
MNMQX&$1_F/_Q@^2K89H8EH[]HV?)E+#J4KQ[J<OHW[SM]5IZP5]HH#H798+A
MGCT$=9R[\&>7E=X;M-JKA>5/M&C*UH3*TA<7PF;:V'1-SV)A WX3SAD\&3[\
MVM#,$!_[GEE\C%I';V@XSGT54W4QWE-HI00/<UKI#H]@P<>YQ'IV61EZOU5,
M73B]!>NCEO;1TYY@XH'I-K07IK%O^"5XOQGE!S$#1@+^^@7&J(T9/-WRGSS
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M,_'^%HK^$TS2><; Z4$K#C:W:S0<:K)NVB)OQ$[<K^!A%K*6":^ %8?"O\S
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MK3 SYSCP\HB+.(0@H &V._+17;$P4AB[B0&D&+ZBBOI6O'[08M!'P*\A"XN
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M$?V(3\0T(74#UB_BTF<]MC&'^/%U]A$Q8H>=\\8R?BDZ!\>0>*T6 6_G>9:
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M/4E&LPB&CY+ND$'2';**Q(8TD.Z!3@V?)7\T =W::6FMS%#G>_3MUU"C*CT
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M7+K6C=C;)=_,AFCGYO9S!N[4 FHBY'D!.0ZH6P*7==>]CK_U;O)V9N5N7*\
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M@6ON*M<LFP+(:IR4:U;2?[IL4*ZYE&O.C2@^$==<_KQ!;VN]AJYUF\HU2Z<
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M&&#98,DW\<.$$Q-=/?#73SZS1!#23"C$/M^!H$$$OQB^LN=A9S([#"EJ-WE
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MV1)0/E ^4#Y0OB-2ON[E%U"^Y,KWB%\=VQF^H<ZK3VR/S[.ZQH ,\40*04Q
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M8M?EP2S"[=9AW?\=FRL4.L.I=(9Q1O:CZ1+WCLN;O2=/W%$/D1 =!_@7/ZI
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M=AH@5+/FP415SI6):[JBUZ!]K;7L(_4M:%OIVI;:4EHP=JVW[!63OXV]J*%
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MEPPW].-N5=5L80Z*!IP)G F<"9P)G)DG9W9<:J KIS<D=.?^I,)5>*&RH#U
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M/P-\K2I-V'/,-V&]@3^TV"__#U!+ P04    " #B@UA2D@RMR] :   F/0$
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M='-&EN6MQ3:U+%=@[/*H0;A#$$WF_TE0K72Y"=ST;.MJYJB*<K/)H\WT?C>
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M6U22_:E<CI:VJ&I[M6!EK8J45U+3_(P]GP#;_QGYLU% ?3R'Y!:!)^0B?ZE
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MN>Y4(4A7\M%P2RB[/,(OT0G;!^O)K(O/43"GO!>LE)2+J5(L00OZO8H<F\P
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MBU>&T<Y2?1X:=9#:I$)ZT,5-3"=&[QKHH"PG(-' K05M3&T&)1JXXZ"+J\W
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MCJYC_\W1)(J.[NAG^.@.8( >0?"F@!H1OOT6;9A'MB3&V5]_?U7AWM,#BMY
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MEKVX[#?NN]'?Q6(Z%FRY \%^JUF! Z'SQ7<I84Z70\6!_#E9V=RMF+M4SSP
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MIP/*:@V1AYYS0ZG7X>N&I4<JQ$2+INFCY#5FC,U_3(Z,F!72#4SJ?9P18XZ
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MEI^$#9=/><.0[,!XD9]&F:28SB_"**43",76E8O'N4F<16%!QQBH([,Y3L*
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M Q0PL%CH)J@K$CK,%B89W5&@3(.3JWRT@1F,=+R^^1W#ZV*2# _7])@]B?A
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MLY>FG\WISZ/\^31=T_]<_GV?O$2(3GE.B_,HRUZ3].G/$=HK[0YI"C3G1@G
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M'B;1@J^7QR?TL><72-9C=/FU:Y>=V@4T?[+Q$.R FB5Y0S.R*_SR:=Q* _"
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M7_RK3F2:CUJLV"[]%<XV,"GVF;E[&X*Y\78C\$F<7QR5O3#=% [&P*96,,!
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MG>)BHJ,A$A..1 !^U+]P$T:X&A!N=/MTNENG\]XV#2->>6J=K^OB@]*=4SR
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M5*IT.&&,%>\Q7G].$"*Z7:<%,27-M6L/OB;CAJ9@<W:U@)S26R(S8FOLKLE
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MGDBT?\Q)!TU7U!F=0!2O'V#QC->\C#/D);\,,X741#O)VU"!\KC)0[,S*A7
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MI5/9CWNZ\[_:W,-XGR5% O/SB%[%/7LUB2=G4!97^NV@W0];)0)(\GQ/PJ;
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M.=Q*&/LX\Z@P:NH*!(2S:+O?P3C9)/$M\4/BC1IEGP>_;LA\MS@O 5="@9W
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M;EZH*#'EN"=Q9&*DD\C8JWH"60\AY_H118R-'!')"%M0L62%F[=U#C"4<;O
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MT>!*=KTZ/^1QBO-I!JI)P:&JM2BZ-UNF\0VGBS8UPD MUTSQ0T9L(.YE*GG
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M>J2>*'<['W5H+4GW_2T)7.I<PL^$=V,-@<[99<>T!;.%SSMD-84$*8TJ/NZ
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MIER\D,!V0R4BKY9Z[Q*_HTG7$5>_;PNA&;^#*F7!H41-INT(*F>4/J0ZG)#
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M^:W6E?IS.$?MU-O\5D67J_>?IB->UZHCQ^ES1U%6%_Z!J?"B#5IRY-0;A\Q
M3KR'#X>RHS"B@X-28-=U%*>V"U7/K="L\.G2HS_:=(+=)3'8EF4YHU*M45IZ
ML[^OJ7_F4=:]<+XH#8#9QJ^N>8H&5N3:QX@PML61;E30@TOA<$X"KI?/%]?,
MEI)U:@1QS=9@F6Y*QL$FIV:^^!J[#OP.F?L\QA%>7<GGPC!T,K:6AF/4M^&$
MS@.XNZ+L+S,[??0PLZC[0IQ9&)(H3'X**WHL DHK\E*K?PTWB@?WR&7,Q%F"
M(%,-K^ E0I]3[(574XB6EI)"Z3OUX@4>ITYJG8;G0,P.UFD,>$9_)Q%[T6*6
M1)RFGAFFUT.V-ZY @H3L%,Q\AY\?&RZ@)!KLW UM$!W LTR5F?9CZ4*$_7^F
M;CY;'MMLW-G+_F'+^[OSF["27LPT*^!^34/+^QK0> U?L-E0)E]BXLQ!)[(R
MHQ$./5U\Z6RY..&MJZU9JQFEEK>-C^2<;'PEV3PO7NS$@'K'4A*2[%EM6$MP
MIJF5*&/T%JXL%VZQT]?O(0$N2R0=ZD)'4-4Q2V#$)L0)+^$Y>FN])G<S:%")
M&;+E5-&DI?26XBC,Q9JH@XL=?7D3C[;U#]B>(@I&TK*B&=1958L-I\(](L3H
MZ-Z;I8#+[L8*8KKGU+KYD@"Q84E*&:U3AGJ/L^9:L<K[H92J]OT*]S5<Y-^L
MB"67O,X7WZS@3Y+8;N6:[$@0URE!'VCVJ&X]3S&"O<P-U@#4V.CUUH,;"A:
M*6;K%<%U^<!0'=;95"B1:JGW..OLF:)8(I52U3'+_8="HE'F_&3V&6 ;,TL,
MU7YF>0;/3K:7?G>CI[,XC.B*!->N]>AZR$XP:-)2>GD)H!LL$X/@AK[@;L33
M5,3U>6:(OQ,4B4)D^ME!F8T\!&G-KAX0R_"3("8.<BW:CM#/[&\#LK9<9[,0
MB?TV9"PF!STUHK>;O=@(_<R>74X^3*;U$F\1ZG<?WQ&;N,_8@N]B]'JZR7:N
M&QGM!$-5QRR3S9^[#%@L5G8P,).J(:)C#I>6&R3AI#PJ<K[8Y-MBYM% 2%-;
ME( DH2TK%D?X3RMUI2:&;78*0%Z!(%NY\2I,-5IAWU_;$;3,?HNE*S^R_"5S
MN./E?Q,E;6T,2Y)'Q&=114%*>\H.:**+(0YY];<Z,#PGZX#8+AJY[>_T-/LI
MA&2S&&K?=CVR%>+Z0 7?:C(W2S?C:[)B+=PHC0%&F:?RKX;U?E=HM>A];0H]
M8?)8MY8]<$KH#"?"LVZ:M-URF5X:6L%!H>7'.T?NO=F%H-4@U\U%P-? [-+
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M5"!.^/WNNU$(9]J[I &;A IX)(?J:_<4=WMQ#6<VB(A6#T@5H[4TCE8,G-R
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M(*7/BW?Y0M:L9AIZ*K;!POG$V40/P'K'JSA)JP!F8,&1Q=J:J:G ^C0&F?E
M[T$D%J)B95&OHJ::4U8D)HGF5<%H@9@6(V]YJ1N4V;:*A'[^[]SE4S1??$>L
MAR A'7,Y>[+\);GRBXW>7=]VX>K@/[J/+-^Q B?\OG;@_%VM6*?< )2J-!0:
M,V4UXPT5F9D#.@Z_0;L")!]FJ#B S/9>$RZ1?G8%@PT5DPV'Y_!G+1LD'TL'
M(AMS5"[2[LDR\2UAIEI#1$N;>0=>&I$;\O<AAOFRKZ5N_0T*68W26Q(DJC%[
M<L$3-FT/+'SKBQ'3TC-UXW<LZ$4E#48QD N3U-H3=N;\(T[;NLT7OUL!J_>
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MS+&<[I[MNZ<F;#P'[<-TL+= $\L$R.'[.)W?!H5[-]DCA^[+I.OLBKY6*6[
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MJ?Q>8KW#("JL-?QM=YWA1ZQ.LQ/;$5.3[DGP[-HD%*\PT$"@8Y[G03:@:)&
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M?>:D#]7W>:S#^9EO3W:M@RIX2X*$#]\F\T?/7>;E\&R65.BNX%?FBWOX:;B
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M?*_S7&>^XKD^7P'H/MNE?QV',N(60 )NRB)C@OT4/P@5$9Q\QG*Q7#&T"=/
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MF>&.XS@*UT_G7>9(9^Y;F,P,]H$X"YQV H_@0/@R>BC39U%>R+G:3T_TJ,R
M,#23R> 'T'YRIH$(IM,HQVW&798K !^4:ACK"CT6CFYO3Q+!5[NZ!G6L#/%
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MM0V4:7N0J]5S[0A^<^4<O#X&ZGD%)K=? I-//3#Y:'CJXXR(&/Z#]]JO)ZS
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MLLQ=.BIGDC9T!,M'V%T9N]2#>C(@Y<MB;BJEUHAC7]B5NX\^&W)L#<>MI18
M(W-\O0[LTA;)EU?51FU>95SPP'A$Y3-\5'@EO,H8R6!HM'33*8Q!/(FR4.Y]
ME)RG\3F;V-5$1I=E5T7CJ'**!GO KL]($%JQVM8F 9:G%GISZ EG!#))OE-(
M-'A>P<S>2S#S)9CY4X*9UYC#75.]3=[ -*E$%\9?>(#W%_\&14Z:X%R/:W4:
MG(/^-HK[>:2, HK!$*<=+>1;*'I8&ZSW$>\;F")3RA!6C A6DW,C6VJ,'GGI
M"T3F0V4H]W;7[DZ9JB^GN\81( ';03FUO'JUJ*K-CES/L8+=2M(+T '.=!N
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MG01?^\>G!_L'7_N'IR=WK>+^9.E5H?>]O<W>[KH8#F1I6Z(7[2'W>T60!UM
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M$6%+DQ&PHW_IA,-H[+CC_"!CT7 >#_5>8_+B=&;VA31'')49=GI#GUZ:?2=
M1ULYXD'"DM8J-FW%2]V1HT3:1" I],=49Y;PC,S\" ZW6K=GXOV=!EDU8@](
M9P27,,=D<]1IKRQ:X%2;CRB@V!H52-J V[)9QY%3*KV48@'=+@,:TV'SGB:S
M@&:?N"Y5===M][9WU_:D'>1^_Q TK?NZK=?Q1=R'HXRK@9D*%KHVG+/IGD+
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M3X(AK$0J%= >IE0UBOY[Q3_6+O982FXX;P6^N[%\W%5JO"=."0I'P_\2;(A
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M>&9VV\[/L]M^>3-,PTLTW]Y,BFD,__C_4$L#!!0    ( .*#6%(*/F4+T4D
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MX!;%%>S.$KW<&C[ @"^;&?CP85W5L#/-11PX-E>@KK%+1B T[9CF%!^B<,-
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MA":C-!<I<5D4WQ3(Q!3TX)C?D=72=N[D?L "I*@OXY;/#=:XY5)P]3NL=#Y
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MYYTEG\^_%<PDA*&)QSEW_>BKQ"O<HDE6,D,[$%$UM8;'S= '<[; ,P*_;*_
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MFDS^^@:?"/S_%V: 4J$72(F PT;=3.G/$VI0.'D]H9N9K+WWP".B*()OI*Q
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MS.$0AI(.9IFAL-VQ<&6>ZQSQJBVQJPW/FW7L$DYE;+C'L3"#Y%2G"INU1#H
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M#U6AZFXGSUNOUKZ!1+=%L(,WT\-U1?6/H5];34@=2AO8@3F!:\U?6/CRA+2
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MWN*)._>&GCVO,XT6U?GH,6<X\XF448^8"D:":*2B;UZCL3#[9AJ57*/-:^(
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MEJ[,LKU-3;2XJZJ "/1GU,7!Y32,6$WR,JD,!&[C?"/XDI=5\'DXI*8\5+
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M:Y@5/^R<MC>3T[E+ZUEPG[K>?X(MF+Y4>6W&7?'^CYG2_M_\%5!+ P04
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M@".8D&N8:8+Y Y9WX*(<JO@2Q BE(1X4ICPD-)R0.#0J9E M-2P %XUP0TD
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M^\]%)-[(Q$@#D>C>0MW?/AQ6*P<-G5"%9)\1%_6RW^=PN:-W+21W"%7,@C^
M.4=/"[HB3*/7Y7J()3!;0+F-:^"US[4GI(ZA'$8[E!2.!41*>LR'9$UV /1]
M!BS"(7O[IS>DX8"1IF?(52P@1V6/%BJU'>9Z4:GY[FK7-K_((" 'QO7KFV4%
M;V1PKL,*4@J[E4JQ]OR\;GEK;<M,F(Y=YPQY7T$HNKOA7>>T3XTT0.\ITZ!A
M@#H;6G\8'O,8]?=HK-<O@N'W'@-,35IR 7T9*Z@ %M,CKNT2'7*QT-:#)XIF
MB_OY (%B GX CB<1_1G0YI/@ =[DL-"'OF@IN$^-[6A/<Y^#^5  [O8=;,@B
MQ)IBC7L!EFUHNW%@%_12,^B0X<86BBBP$"\6%.,0();MQ&Q/ 4JX'8KYC17X
MU6.8,8($H"I^*D(#VS=/,A;PUDR8L8!WRP)Z&0M('PMH@_IC"Y6(::S?9QZ>
M*PN97A$5OUF?KP'][G)UH-Q2 "@(L*U=.+XG8W-W#]8A)_0F-\.]AO[#^_ZD
M-]W%L'2&.4W@P3FL/ /L#+ S$V: _8X!V\L .WV ?>JP<!E3\>Q>$K"V=U8"
M-\>GI$*W0XXX2A 9YS;.75UNB0M+<>EYL4+DG%OWKJ@UD-I .CZ#!75I#RKZ
M,Z;V(<6=.XKT@0*8X6+NI.,> +,]=H@G$NTQ>->O7=>K(=4W00)8DU-+&9AO
M Q16'U3+$!!E0@2_9B(Y@[B0/_]D%64TX3W2A'0#7L82,I:P8:%JFWZD+.U3
M(PTLX6_OJ]LGT?PIQ\C/ULBX9)_'^=ER&9%Z;=#,+P?P;WI'8Y\;J=S:'O/8
M!*@R"#B8A-T3D.A)JNRJW^?0/UO)#K !6/]KC"_ -QI]2F'8GS&'[ENZ$H>>
M/1*XN^%]^K<RVK<8RK,5?X;E&99G&_4IQ_*F$ 0WT#E -1XLPR-J'F< K$F8
M_6;#?,SH-<;-F9ZNI-W6NWU>;WKX_5%PG>QMN]-V*Y;5U(>"FMVLJN^$]AX7
MW-@B"C4%S,(&[[7.$QT',$9 8"M,$LU8^9A MN+.8#HS80;3[QVFLYWT-,)T
M."%]!4O6/( FLPMM@%W[<'J"SWD7ON;A2(H1PQAV2 ?),_8J69NS(!)RPN#N
M>"C=:IS>0G] ZV<)\#\<M<EP]*E/JVW^-8,;:]%)^FAZD PO][:^W+IDX?-G
M._A6T04G*?".D]];E^>75U]R'\[LWTWE2?/N<3]4P33AR@ZP<O&@-I?813VY
M)-?V_G[Q\/!C(Q%RJEE[PI2XC,2..SSF&9I&[E'6F'\2$:]OFP<34O,.P%-P
M8G5RQGHJQM=Z5/?SI%JN5E:[CQ>W2JU8KF9&>9@2OI@!]HK5;%;DCD\F]8W/
M@&G2R4R!B:OZ5#Q\8%;,.,TZKU%]/A,MP&ZA7"S7IJ9Z'<N5=&GNI:9S1BPY
MB-D<SMQM3P<];W;RW.>]7D/?#E3>I;H#[ON";5;=#D*>6]WS6GO%MV*G;6PO
M8 /J,Q7 \(KS(?/^J75'F?=_\^K.O/_FO?^[<NZ<]<G93=SSTAUT>D^>_A':
M3]^(?1EOO-4J>4&/N:TJ>7]^;>>;XN#1(G!I2\[-G8[('-Q6#-W,P64.+G-P
MRPYNYM^:GB?CT)Y"2QS<[I)W>V#G%>6OKOR?-,LJ>\P+/U>U\XC_+_9W-IN3
M_^YW5$K^C^#_ 5!+ P04    " #B@UA2.TI;N6 &   &+P  $@   &%D<'0M
M97@S,C%?,3<V+FAT;>U:6V\:.11^K[3_P9VH52HQ-PBY0!J)$-)&FPT14.WV
M:67&AO'68\]Z3 C[Z_=X+@0(:4G;)*0ABH"QCWTN/N?[,/;AZY-VL_?YLH4^
M]OXX1Y>?CL_/FLBR7??/2M-U3WHG6<>.X_FHI[!(F&928.ZZK0L+6:'6<<UU
MQ^.Q,ZXX4@W=7L<-=<1W7"YE0AVBB77TVZM#TY:^4TS,NV::4_B 2:QM>ETI
M^W_[>[L.B$&G6_0>NH7\:]M&%Q]04XHKJC15Z*KJ>$[9J7K(MHU 7Y()O+\Z
MC%&B)YR^MS2]UC;F;"AJB@U#78^P&C)A:QG7_+U8USD3U ZIZ:OY?CP5Z$NM
M953SH"6=@PE"A:YY;^H#*;0]SD;T)2?U0'*I:EM>^I=U)^P_6O/-X/1Q@"/&
M)[4>BVB"+N@8=62$12YJ#*T)J2+,,U7:A'@ #= J:"9UA17#H!_E@M91ZSID
M?:91I>SXAVY\M-SI (RF:M;KW>?L=+/5Z9V=GC4;O;/V!61JI_NI<=%#O?9]
M(N ]YPCX^^B3TW6:#NJVFFD4_$K5*Z%&%S5.VI>]ULF+#$L1C -O%[5/4>]C
M"W4;G>/&1:MKM_\Z;WU&C6;/])0]K_P$45D,A'7T5O23N'ZW*?^,$LT&DZ^6
M;GD56WYL07(G\D#_T!J="11((6A@V .-F0Z1#BEJ"#'"''5H+)5&<H :!,>:
M75%TS*2F02C @2$#TYI2@0Q.AV^;H6^W]LMEK]Z448S%)'WRZ^\0=)^"4N1[
M]N\(S$K5#%@2@)H)Q0I1" Y!)S2@41]HI.*7("_*'L()B''HFAK7I<%( =V!
M=BP(:ET'(19#"J9$$4L28PG\&TF"-44A510\F#4N\ZNPK83.4 #D!2M;0O%(
M)2.($=(2W=3UVRU_=Z^>ES58A(F,-=@T*YW+F&P'=:FA6/6QH(G=ON9T@AI!
M&DJ3[27HQ^FH:(*^"#D&!X>TEF4>85<HS;?W%J<#;4&3QGU.45\J0M5[R[/
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MM8]>95B*8.QYVZASC'J?VJC;O#ALGK6[=N>OT_87U&SU3$_9\^Y5+@\4E?E
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M!(<K@/L:XE<\C]<0OX;XS*GR&N)7$^*9,(YFRPY8P&@,0230FD)V@?^8*2"
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M]/>(_NIE[..@\8L.R2,BYDL-R>O#M<USQ0#18H"T6^"6;1^O >Y%I.X:X-8
MMP:XVP!WC6_-() CH2$N!<!]N(5N/[A%6HE?]*E;LX,-0G0H37"RLZ<LR':S
M68+ZU#0/1DJP)*0$)9)3/C&G17$09#O.L_O<RQQ9%<0,+*0N!D^/U)ISN/!T
M+!-Z\R34[@^<?KJA!4SIFUWZ(#\>#,KZ$Z3H@"HJ M-CO $_P!!CS\W]]!(:
MAQ3N%8HPH3"2"98YF84'YB<F<T=[2S#N$"O":9)Z888=4D$5Y."U!<8O#O:/
M\-"H1\DH"'/MSMR)[_G-^.6.EM__=-%]</)A-#;<_.<X#3?_X<__4$L#!!0
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M'T?;>[8-&F4Y:$<CJJ;S7=(S[+,"Y1>F 9U]6+ZU)72#0)DE^<.@/""T ZN
M?F'LM'ZF%5R1HB9N2+6460&78QU+ZI%AQ!SIE?!4*^S*('N52#33AL:J,@4$
M(F,_$. Y#;H$?]B/AI,<N0?H2EL>V>C[N*M5X8TM%'VAM//:3)_"(U= ?L"6
M TH9O.PG;]G WM>&.$C1/XM^VS9%SY4'Q_^GD@,EK%0^NV?@(1>250.UAJ3M
MBANJ^>V<S?)J1G)YZ'HHE,?27=+\A4F:C+UZ93/U:@-4+DISRT$@@"O>)YE[
MB1(@H<IF4P3K)W:03'BU;N$T'PNU4,D#P#O=ZN@S_4'N\K(*53N2V'8,M91
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M&P(NNPYO&.%Z<DUP%3F*+;<3/#_?-XE\J>VW9Z-:8.41T1(&'9+3$@)7*#P
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M-N!-D/<K;C8T("SLLH0=VE3Q5<J6<QR9 \L*+J6KU8JNL&9$8-]2$&X2NN*
M&YJ?J)J&JE8>%W2E&@$MP @W3QNNZ0(4FAJ1*:0_89O%2:V'J7*.E0W"MJI
M"7HL4VK4VC$9V7Z"+;W@7Y<E-6*6VQ'4-;KTWE-X )11<51H6VI'6^010!Z]
MGZV.QV)@7'8K3JDG]!"<CD6/<0K;R^I6]B*;Q]J9\X-[V4H#M?D.]*IIG3Z<
ML06BWI;,#WUOA;:_&?5K DWZX0'[#;F%@+(R G]WOF<^VET+RP= 7'%@C+:N
M7KHL2M&[XKG_U/V_5)4T7(_8TMBA7SDA'^?HIA$>0<WM=X1R5**G1$>%P/69
M]71>.%=>@KR62961@9!K0H^FKH!78RS'Z$AG^E*:-&Z.>CS+>7N)': =8R(U
MR4*U/]:'M3$\/]Y*T["W==P\1JT@NF 5>$[>LH(TMC8JSE],812\*-M2(F=L
MA5\DQO:^F#N7XACB-[:XTL0X%F4SW*R.;WB685%,Q39S#Y3@6_L2^$?4I7C8
M_<[4-7 S1E?QGHT=,6'2SAXG+BU_8.\72P7%Z53*U?$BY[3?BSDL24*=D8KH
M>K?!)=[7O]Q(FM,9W-L RE_KSN?YIG85Y\%?T70#P#O ,B.$+R?5P)JP1K.;
M0N=WWZM;H(=<))D'!GI6_\=2X8EK6_VR'74SN$>:6S0A26=BQ:R6?9D7'V&[
M95!2F_:60S6WJD"S@"X__Y'X0*SPW_3$(PN:)Z8F]Y!#Z*MG\.<Y[DO74P<5
MVK,*JG@?H53H1%IV(+(HB;!CCABBR#<S3&$]O(H-J1_Q],_$#V-]+BNR$60T
M)1K0J["4>H+Q],U;A_7Y6V[ZC 2#\DZ-(;I:X@:J!P#-]&/F&.GX'E3$OER0
M<>8SNO)JQ[XMN4GB,*<IY<!A'$2>H*@G6!=?D_]L;KW8R/2EYI;F9*&F_13R
MDN*3^ "5"\005)Z6L?[;)RDT(6%8P.]'B'==TL#7HPO1PC(J2SHX-.I5]-]'
MX5*#ZO];&?A_+'K-HYIBL<NMP:ZB4VO,_8R&Z1<2OQ(@9,E'_H&B;U>6G28Q
M$OVR#<?=$(&%FNG0!@6K$0E$7FJM*)XJ3\C);#?.V3-'D5]@3]++ELB/W[\W
MM.F\W3R(2!FY@&^]Q)!I\\Q#]39=(@*.G:F</LXN3BXT-ZN[M>"6VC)1(<@@
M9P7H$U#2X(S9+)^N=1T:6XITUCYW+\VAC5_Z=VW#.N;_G*G2[$0F;>V'ILRU
MLSO*XC6%Q0'0"=L$=8*5WC#S5IZ61)"I@TKT5Q;=,>9EI "E\0E9&=3ZE$#Q
M=G0W6_Z.9[K,T<EC7[&^-I@I6!CUS)S@')D>K9NZ>NB$3Q9FG0H?^H>+&W=^
M7QM,EU%979I"V,WB \]ZC([46NIGI:N2&<2ZS4VX\W.U.K^/#OF<THY^J6SL
MJ#W>IOV1&[;O-GV950?+D]Z.LQ@N:S$6ALVG*+LL4>W@EJ3H,XRJDK;H?9UD
M#WC;<,R+GNKEO:K=B^.ZA(Q0[I<G62LITS/L%3$V>;XN#A2"?UJR"OS3%Z$X
M3]P3U']ZD4E,U%WR&.L;+DL.B+:ZJ>1O66NI%-0Z\BCZ];I./KI)]\!?AQSW
M%'^-LI)G$'5)36[(E0IB2_PDZF&#0W5/(EKN'25"]GSNTER=+7GZ'LF2!542
MDLKP.=>!4F)UNH%OG$^+&D5$;<RCDY@?ET[9APT+ZS(L:'!M!W7A4/":%:L$
M/4]DV^0MQ-^3N:%I'GL9CPTH.(F@)T"J=^Q4>%X:(F(RWJI%?=EXO<$V ]J.
M$8F"YG+8G<X.4O?-5)<',@H2MTUOM_267MN(UCJLMC$LF/RB^!SME-* E_FZ
MJ?2'E874/:GX.:&"E#[?YA\CQE99GQ>3DR<5 S*KUS"_79@8Q:DHHLR5PE25
M7UB/[TM;L[!G#ZQ>M*"(TJXE-LGU4R=C1FC#OKYU%XQ3UG;_ :!.Z$$&(^="
M?JTM)'6=VW:JLRO(C)[8L$!W'1 =X^H,WM5=#SK;39JC0>GB"1:4A>U)'(E&
M;#&=).A_/XX3N+UEO/G5P(6 )MN_?Q6=X26QD<?5I/_^='!;RM[L2EGYG_V5
MV7_Q*F]2O!!KW'8Y&Z;.OYPS"U')B8+Q52_1M#L_'D[*.J+!AG5JW X%97_V
M.&C@$=<(9S0A2EYNS5 (1C?N&CP G)H^5;/8+%*5JS[G41E@1W) 7*RU0FX'
MGBO%46^42\])W]KJA5$/&W*U-#C1?GRE6WXING2@#%BE\3;*-3CX88! SE:K
MB=:R"9$%YL3>3T=KZ]6;M]=EM1^1#\!J0U&QD5UISAZBL$42XV&N41-48O/F
M201X_8='_P:Y5Q\4]4<AS:M*MJ?778,JW6W?^G4)6#I&E1O9$2$_+%FOL1E.
M!GF-=[H >L'VI@T$%6L0VQ8DZ9*.L;_(*U'/8U<7$L>OD^M_OMPC':G+=D9&
MLWUK%E0R;SLAEN3,T?1R]8*^G_X^6>GEGQK:]]6B3A\S>4;\C[^K-BVT3G8Q
MDO$5Z-;-S!Y,HI.I8O<'C"+\^%!3E*F[KD[ 'V1P:OJG\MAM=H;)NRU@/$+1
M7%'6Y[J\?0#HJ<X1OCI7L'#<!NM$C8J;E\(B5KI2EGSLH#2FT/J>+>=-=O.]
MIZ?2-,"CP%//I$R(R$)=-$!Q_4"9L%.C)?D>&Z6>_B-K>,U%#*-]FR%%M/PX
M:2OYPW)<^0M" 1*=@T.6<^9]D.B2,K6U.$:Y?*ZR?EWM]RH'HWX*G\U5)65M
M4TB%C[_^,=_.M >8[8;MR]/2I*KKYT<\LWQC2^)9D/OU:]U.+ GJ"KCNEAH(
M>6"]-EKR>>U0(4!/OK:M^>- NLX/SMP!\F(NC&AM&I >CCZ6-*;YN1^-XR>N
M D2!4%M/\\@761\/F13R:&@GO>5N%O 75]'0X5M?W2,R"#A;PXZ,CPRR\H'B
M/__3YW\ DD3J%@#&X^E_OE-?S4*3NF'7LA^M.13C703?]RK=_YZ<W37]:FTC
M]HX6H=LH& JLE)O;9IA')M-!'9WTL^#<]HJ<JL+R%:_ZKE.KWQ0H,\0XB$P:
M4RCYY/-:4.WWB)>VH$^GW8N?[.VJ+I@F=IJHOJI*V1X<O1_>O=(UPW[_,E8Z
MO;XQ<-*7^?2)37S1SZGI2O0KTAN!>XZ%*E)[:,Q@^6@RT:GH?#.J-(V5.OIN
MZ^RRW#A9CQ>;V^W "!(<W$[/;5?=W)^;O$GC^9;9CKN<A=EDA-*U?6 O@'L*
M;6OEQ2SJ\)6Q"_XN[#=C>KZ[><B>7\:%F;:1Z=,K?X>UNUF]L@:]LN=4E8,?
M8N4N]X>](MB$?+]2^E MQP9)!M@=TI?5T9]QA5YPAP3]X)05N.&<J,1XG2J:
M@E?5+VJZH*3T7#7PS27X".@]->Q?UJ#D@VRX#B_\ZFC3VAA+=6?R8;3JLA(X
M\XW)?H6]15VXZYDZY9 [,+JV4BYHGNXTV_Y=X:9MRLA/XY.C\-SA377W7R-4
MI<I$0UJQP[N&U28@3R>L$GLP'$0XB9PE7PL*G[GXN>MWP7]$[_:&$UAPG;6]
MTD;^5C%2"8F.]B''5<.X5 4.]B"G4PD.[I?FGM; $CNE,EXC6N+\JSL84380
MU<R:\J2X7_F)CI@;?3G^MAN=^Y)N.L+])BJLD>YIG,(!M_^W$[_<+ $Q"M,[
M^;,R$\V>!>?,%!+?/\&=O6Y$]?ZZPT1ZZLY=AV!\Q1?D"WW2TKN<)< RMK_:
M_ L#O^0*MM^M_FH:)7'P0\3<PM(]<[T\EQMSG5;:_8,,5R";IE7WU!+4TGOC
M(#:2G(2Q]:^&87G;M)P6PY-RLRC?_!>7A'@R*D(,>HOD"[8TP)U4#C0>U:'%
MS#B% .36>N"."I;!4Y!^3$->U1&WZ-1("L[D9R\!^Q*'R"..R"SP$G!+Y[/@
MBN(JH$PL2=U++#5&:(4K'\7'TDO\9W7:G_(GEFRS*PQ97J*;:MN^,U]8SWX4
MI0,!J<.!>0G%*BLE,&1!7,V]X-U6CQ$RI3_RT?U$<3/^Q2>Z!!Y"6>\Y\N\&
M6W3YPUX5,V1,.["AB[VY?:VY#QURQ=^X*<RK&IVGE#EK)KP%(;FY"K1FQ:$!
M2/QG*TKZ=QOI1KWXCG_%^]M+F,SXG[S>1L]6\$[@D/A'P1?:%F,Y_W3*Z? 4
M8U?W2$3*UYNJEI;ARXXL7IVL?V!WZ$WU!_NYLCU(6$HZC@9X6:@MIJ2N7C_J
MB"DIO5H-K$>65Q;<TI)B!*DQ6GOK_)82Y/U7*N+ ;[WL5R,1[16#NKM.G%9M
MVW/C9.(4:1QZP=B4(?GRJ^_MM6R2&0*N;W.5AT^!%9IX71\TOSE4B'N*%U$[
MS V/C Q=O!\W:*8H:_X5XU1<H$XRTA(B.")1SFP\+'(P3-H8_:X@JQ-I1"2C
MG/D1._P:NB+QMHKY;\;I62G.5V(=CT<W'K,<ZVUV+!-76?IR9ITG*5J3D;!]
ME='^]'/UB7?70);16V=>.;8JZ/AJ$"G1FFR,OXF0(I@X$4009AXB+MKV\G5.
MDQ7R@"3$+S]^3(;%SG!)BCH<M:(0:>GR35.]J,U3K"I9_?=0K)NZ:]_:RB?W
M<L1A#=B%CBWPB..O?NSY$M-"KK*<H+;1_,_+M^$K99[T.WE5(@2Z4E_)/__2
M3&DYF:F J(MEA0UR'^FAE&,!["_C J>);@.6S-W1SR]%=I>&5A25L]>E/Y3B
M1)&]448#R0HY!6 '!W_@MF]#');O4:(:X1[8F/GOVADU@#UJD^YR2._Z87ZV
M5Z>5\GI<(IQ.(*YE?82=#^.EV_%&7+G),+2U]N=-?Z/K[,I7.]_&OV['7='I
M#633ZS;4XM\,*'?R0GR*17E^]HCVA!TO#F^^/DD!NV:&Q1+ZQD:MW^EUR3!]
M5CEY/0&F;1B0>@ \]:-[ 'C_=3=-$QD:W90+##R\&S?^'77+3!DI H,SY?V1
M39<@<M^]FE7'E?='B04%9U2<?YI69E&C:76DUK<D'H._J\!8*PMD0H7L_="%
M@U ?#L-^3#&L^E6V>9_'Z'.!>R_Y^7<,N?)RWH#(M-#^PV"GSL&L%+F*V; K
MPQT7J0F<Y5KDC9H6OF5=>@ 8[KSW7?]X//+Q5SM:<\;!QW>K#-O'=+,"QQN=
MHYZL5U$&GS:;$J+DM]T? .A]VS/U162?7\)-AF71K^3KU"4\>2(O[;5CAA@3
MD?[^#/>H):,EWHW"&7J=BQ)DZ[$SB\K(/&7N>7'RWY5"M[8C@P+DF(F+"S]H
MGNEPWU@O[M:GF4R]R.Z %I+@^Z8_S._.3NFI1G_Q-Z?8(PF+S^]B00$QJ/J,
MU6M&OX!WV01G:LNRK[,AW],M^'8)M_K]B,Q*1G=-5KA5@?Q=>*]&R>J@Q$IR
M,VXN\E^^W'9-U-Z"U[\R/K53.O(F8B4 X<@*9Q]?EL]H=3VQI#D]]&Y_I7,"
MW:-L8*\;R^$%:LB?7</BMY(N/ZFE[%</VJ;Z/0"Z^3Q^+B^INUC0'EE'I^B>
MZ9Q?GYK.Y=M_D"+0]:>5,L(7/RQ;UU^3#]<M%4%JINT8><]QY<5FI ?CZZ"H
MEN8'V%X)*R'B_>+%R267E/Y\Z4+O0JDMI#>_'<_BH8A9-XLT+(A!2ADL+F8X
M>@*Q:T(''F<ORKUR5S^^RY.W<D9VR-D1K;COJ1LU1G<_ &SCBF^ZIG2_%)#T
M5D@23]1E+!HZTBUCCZF3P5AYEKI^]?6MF.K$&1K9M<Y]<Z;V>:/MFEXD+G;J
MVW7TXBFFX:P"N\>1C?T*</(L1V^(5#TZ+'K[F^09^<" ;Z5/!31U9]R(48,L
M^CJK:->$O"'D;+,U<<_:][+^N+(=6^+0A VBC/<DAIS, ^\YT*FB2*1$!WFW
M;>DF*1!:EIN0?BD\5)3R4F#*NZ)9/#]<3 D>M8,%;.L[<B9Q';LMAW7T]_]6
M+T I397TTK#!6A7&?IO22V 5AG?UEDD2:[)*(%-;\E)5:',DH)H0A6G]MC2G
M9*%X/V)XJ74W3W<[>LP':>2RSILM,QX >O]S#?\Q% S7]L@(V3!(0/L :'2'
MMG5#HFN#=3FG6*TL=983ILZ0898]$CU\:L4=&WKT.$44>$*:&#/5H,T]>' 5
M-CV0(F$N<Z1/YCPO9SZIF\VI;8A+R-*L_5=Q^2;$&,R"WE']=QJ/!P1BY32I
M!9UK?MZ,PUZ:"EJ /@ \[5/(5:,A_'4_H39-*9LD-@22T+N:#=E]S2TMB.X
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MR*::S[B(OCNA$>X:VW%#T_ [W3&A+%(W0KX"HX]!\+/<I[JHES^"A-X7/+7
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MA=#!W=W=W8*[-A(LN+MK\_'N<_<Y^SWW['OO]^,9H\=XJFL\97/-N5;5*D7
MW9DJZ>[>"';*<O&WCP?YJ*JTQ>BH<8Z^-@W.-K?PZ0Z0#U2VF5Z56V'3L8*W
M@.<G2##.NA_X-3)+O$7Q,Z4G+KL)SI0_[[3'<+&O#B7 UW7YO 1MRL72VR*"
M+F(T3PB"-]TE3=, %*^@WB% 0RUI-2OV1^:\BYI.CLV9=S]H"12:A60$VTCN
M/)>. #W_RDG(GU="-9S3LJ##I",A1^+=R<:'DW2H.JF37PC# D"0 ,\F4L2$
MY,7LT(8&<?(W9 B 2'Y'@E=4F3#:M]$Q+W='J:)WS-Z'VOJ+KNL#]?S4,;WO
M)1P=>$*(%>.K,^)[1I,CN</R7*5GIW%R.!N8 K-@="^Y$\+__[A/P> )N6=R
M2<9#"!MRCNF<A=?MO!/CC@%9J#SC("34=7>I9>5FZ6*UQ46MH=H36@5S_IVM
M9-=WD\>EC3";J)^-+_:5[D@TA46J-D"H7.O/)A-_/&3.KGBY$-QW:V1GKM<O
M+H1RK46[EXS:**N6!9^74*C73EBJW.\T5@87N^PT[1U W45<++)-E(B2NPH"
M;-DO:-++F(_YTVA^-(O9K#*J$"E#^L/<\&[N,*V1Q394A1--!C,D[_HN7>D*
M=]=HA7!V^UC=7N(0"8K8OA*0!&SQBBRW\'2YQN0<_+:A:GN!U%EJYW<]W5_Q
M57P:<W%?KA#?QV>B%/PT^.5L]I#OZT>GN<1:,Q5%$)*Q[/Z:P+%;J,5A#D8@
M9E*^^HO:$=X9/LP<UK(*[A)TT\&F8T221Z':+@?>P)6<1^\C@%RUQ<P!?:/8
MB?V4(;PO(V(F Z7E&SUD'(2'_3LM'#^0CZ=$+104@437QWK65PCN.F:.?!;N
M>0JQ%&F6JB;Z3CBMW[?+[3=7\&>13%<D#$P;3.SX6AJD+C4_%(4C%KI9M9W9
M].$EKIZOG:V3#@@WI=!L3O/GQB/ 1+/;8M/(*-XFV:&HXKD9$2(IO1NG,62@
MH[)VBI+,ZP'2XZ[2V!#UZ[@FE;(J4=#0QI?]6.FBA%'WKH.,K1HQZ &>DTBB
MQE,XHW -.QNV313-PRUO..8(R@YN_T-5,N+T2<!)($S6M;XT2_Q<"U7$ .4[
MZT7Y_'J\T/*%WLS%L)YS60\^$7M3W@Y>+98FVW*G[WW^"":YC%E:Y7%:R#WO
MA-IV8DYS+0-[#[7>J=^(X"^D-,G?QWD^1I,7%"5[<;IGBN9G5[Z.+]Z-RM!6
MJH8-]2:M?*O:J_,WE4:.X+EI573'[MHB=M76#Y[),%%E3\N<8ZQ-LR!A]GY&
MSV_8^RTU^\'T 2<Y:4$)E5X\PR7I5</5>0DG T78$P=FP1RH2!'OFL#)^>B/
M9SMD%U*T:R8*?)6U'M(+GPIG[N9NR(&"N5=$F=\"D%_B5$,-,_Y;>/RY8WY=
M_V5(DX!36 L8KFE])Q;CEVS$ER^LGQD;&>L3\*_GSZGIC-.1(R)\_THE(<Y)
M+&L.:1219J]]!XO=I)RV[1SA^)1?>#&.E8JNF-K!A:RP824T41?@&;R12E[\
M#48OH1.)UUG*AUDBIH$JL6_'.KT"PH&\^H?CN)2XEXP_K'._T3.MTD)&^!EY
M)\'5U65I3X?*5KFO6OY7ED8D2NUUH!-AYK I'L/3 O8>JVR9^VJ;'+9B.MG7
M8Y9<9+TXI-"O$.G*?* ^1><@!J%?),S@Z_D3R=PH,N8*_H42%ZO7*+K;$SFW
M(-Q 8Y=:;-JM?4>1 ]SMR$K5K_/9C"C_P?$N=(K&5#_GJT5S2/T6:_COP)51
M?)-4*A505J74.YW,<)V*O?.2VQ-I,^F&8YH?:S.L-5]FFY*1.7L+M\9N9XJW
M78=KFW)$/,QE^E'H70L.T>UGTM.C5XI5WJ:<&\9\V(P-7W9@&S)VP:LBO?)U
MUV1CC<CS7?E)DIJ>JOC XP&$,USPN US$\/-*0L)A799YO<4>87RYO?FW&NI
M/U#HT:][=.YB[JB3^SF\=A<H;?4IZ/%RO@Z.BA$YV'?=S%PHT\RSJ_T8QNI)
MBQ#+];P]\HO/VG=+K,*A0UW!P70-UR.15U4_@ULTR$+<\L^3\BH)&Y7CNYB3
M:SE+!=H13/7PPZ>I:B(P"0F2#6<2) GE"35KIOC8G-<S!^GQ*>TNVUG.-F_O
M@_RX:<%,IWA>%66F4(=. )=)6MQWK<%-RMBM,.,&M>RK/*R>8LJY$DT4+6Q$
MJVO$_\8?"@G?VB18G@G/GB%#.6GV%3XPL>X-6=^0V!N%DB%J]G$'G/<Z'P'S
MJD!>YL.FP,TPU#<<A0B!B5S)/9&L-V#F.(9+(P6<GPRFVT)0PA=RA_G9%0 E
MX/(,/.-X :].#B?QHQPRP5Q6CCV=48O?R,9\Z5)'"95956)>$PT.A2QEK_F;
M7NFM')>T,%:7:@U-=,>QNJ'EOE^A3F';SKB[R]K:4,^ZG-ZB'0X\6X!308\;
MA]X-?%A#A5C'M!'"=$F<;EJQ1\37LFYT5#;$]VIY.M5L $%N"C;A7IP.M!=?
MZC44.\'<\=',IP,MX@;E[.^RUCXI@D*NCO]729 9*X1CON^,U"*E:#4A@05E
MHZ%)5H UP1/88_W940T2-LU/CE0=<)N%:2$H.L-2,I;[<B'AX'<^47.Q!:;O
MS']JWXU*TA]V1E76JVGPSF#4#SCRQ]@6*?_:$"8(9K%U+E*4G!F3:V/*$',%
MTG35Q7%[!1XQ,1RLIZ[(^8NW'M,$(TB]4+&;&,ZT?KA6.<=UX6F23@8E4$1M
MS3;PW*W-HFWM:*9EF;#?LD=8Z3S/%P]_#K&IO^*\XIUY<SS:,0G:,FO,9KPL
MB(]O'LGB4R,-XKK?F]B3C)1:#.WF*U8T@XJT+M:2[<U.Y,QB;@RQ"^Q "VOV
M8Z<O(V7M^\)[<E*2EP$\<!J/H1LMD<231T!08. YBK)&P.(8<P>D7&FJ#0WN
MA1X%?@3XZU@Z$'^/7^"*_#@<B>\SNHINC2<_N#9*1AR%F9 W_U8R(F+#USIO
MX4QSW(J5!X^V73KK&7.P;DVRHM[ 3PLJW6$<>>57YJ$17R=X7D((*<^?-^MI
MP4L1[YT;^6BD8]8G/YJG9&T0+#=<GO-?C+G+G"C&5C %: _,X!.\T]Z()O.;
M307:M?/C:6$8I_<I+ZH'1&IT$G.NV!RDFAF[16SN@L>)V1-UMR^MYV=C/W?X
M/&?N?^\VM<WT(NN%A4TGW8$"Q.4 *M(BH41* '5JW;3<67PWL5HH9KN]I-$^
M]S3?9!H;WH(B!LFB:9MF2:9*(2T1NDG,).*BQ+AIR6?)DRD_*PRY:$K8FSY@
M*+J<I;&@TA;6$87$U"S@12V"2+M[OC)7 4;/2?>$T:SPG2MG.HE<;+_&1=J@
M 4Y[[X'\&JA:1-?"K^Y!YK&-/B\S[3?";]?J&N\<2F6['.,\\4Y6KW\J^.\2
MV8>ZUU$\2(PB[?) 8_V8LE9+]!#8)3+KL]N77Y.<G9:U;:7(91+X=@\,[)4R
M!K8]\<=+W(68_%;C-[]OU]WR[C#!H_A0)'>8$&_F!FV/S(HDT"CO\\>M*$Y&
MV?BV)_CIWR2Y$5+6-)=;@Y=S13X<BI$%MKCBI1B;L^ZY*;!&$83318K$FI+$
MLXMDFDSL</.U!%]9.1Z7_N'J>8-V<H,A@#J6&:/8]%(^TO692MT"U%RFA?Z@
MQD]@F%K1**]$I;9"^?AHT(N^";99H'K[=3=/I/A[+Y%H$T20S#<-A#OB0*7]
M[P[ T:7JWK1JBNX;X5*)RO,NWHGNZ[%^8%Z-#0>/??Z?RM-F!D\\BQ2M1"]-
M#W,=:B@W'MD^'4R-7X?6F7ZS42*LW_^ZG!WJE*<*5-WL-AC,P[S?HXO.BM'Q
MY9[1IZ<C8<E>[BH%KJ($4Q\?%$.AGZMV\?VPV#F%)OFWYII4?5<'YG;%]5-?
M1"Q[G+"@Q9AC15R_4V4DRS5)XS-M)9AB'1:1<+LT84,'#8T$QH()'/B;SS3G
M7=:T,&8)(SV@?X8"/ZQ!!_4=>TL43K3\&'FE\E46_VCP0B\KZO5E"-;]DB]W
M-%7(_??OQ5:=RH]GXV>%O;Q<6*S( Y'*=):J)Z3 =7Q^G:E,D[SR6X\ (\(V
MFQ"$KL5>LM-ER>[@A'T*3R<W][P:?:?5VX7#WJC=+GBC9TVN:=E'DZO+*T:"
MEUTR!&735;K&;:+60J1BDK39%-"!LR$RM;2TNA:-4@^"+&0%7VYHI&;SN'^(
M'=W>-M]>9 D/3U9EC%G1%_C,ZU<W87R!)8(54M;S>>UA^;(G>=WF+)M29Q)[
M.U SQEIVB98!HMP(@V*32F5-83(44AZ_73YTN>.R[YG'/?&7\B.&F'3A%>H.
MO=?0G0]"#-8H)1"WP(1:M> SWX< <'2#BU7Z'WK]B05*BDW>2])AI==LXP];
M_5C;+</L[#6P?1'*@1D9CI<TD7R"18N%EK&_!I;6P&PASPN749=;*9P=C*H0
MOVL$Z]YJ][4OQR"R;31]I)VGO](N?XGPQ71- &:9LI'2T5$D'?/745>E?YVT
M.EMYF*\BB>WUZFDT+3/1L]##C#%#[2:SJQ'#U0TH+Y20E.Y6>2DWS=KGX,'D
MQA4C'B'^\KMC:B]93]D$6?0[0MNFK/YFW,*V[S5W(=AW5S;]U,]L?,GK-IEO
M9HK7]=CZG.,ZIN=JBXP\T!"0(8R<*26>=JY[S!9[X==;2,,6!:&*#JS"C$ 6
M<XBRHJG\XJ$4U5B_>& \PJ^&V4(_+BFP#[&] P53A@@7+BOLELUN;%C9%,)^
MU@@BC2D$B'$9!"1P:7/F,UA^ZX.,J!A7F:YM2LS624@ETN'8NH;Y,AXU2V"4
MQWUZ0_=R7.P/11Y?41&)MCR(,I+)@8HU.K5C',3XY?G_4ZZP8:H/Z2\/)"!6
M;&^D^107U<7>.LXUS:(E5A;_M0D$\ST,Q<@L-!.&_ORYX(M;J*17KI:E@+6;
M VX&=Y/@JD"S&"YN3(,O2[-.T%9B?764H9V,3'?&CA0(.7V,#@/SA6&ENTCI
MKY4'YC(:6987 %@[WE:-5*9I?\G.YUVLKO'B]/!@6U$,@1Q\>*N$[=DYJ^)+
M L"S RG!3-_GS3.K>4'\P_J-I%7E]0V;X+Q,5_*R\S+)8IX_J#M*MP^M%3;(
M=_E*2'S$8Q$'#Z8[-80:(7R22RC'Q\>/@,#W 9,6\*RA^'42YGW,'"LI"Y(\
M2IVV9F[XF@^,CHO]D*9TX],7-[T@_*&P"E*QZ30[VXZ.53-MR@@*0U"/;;LU
M,]2:&9)=/7@3P2QVN6W<J*^2->3^>B7I0+:+@^S]]&HB769X)8C2P(GY:%0;
M0X#^P@>"M]WSBPG?!'&\;3JFW?E^BS]Z<][)X*S@C;B)<?YS8A_\Z&_U<WQF
M6/$5ORA]VD=S5%OKS_1IF6MDMQ3W2H,92D>()ILJ46ESI5CEODX,?Q0C.M68
M!0B\4XO'9=/0[ 55W4'N]W!44%\?RNKLJ5_!>(GU5NN5Y&KJ3X^$D7TWV0?2
M9#MW9$_>.)MULX-W.+A3RN(_C]>G>(KM"XV\WJP_H(%.\Q.K/P(,]VSX1B*W
MKA32^V0SSOE33".)OM[BPYA ]ZEO3V+*([(?)L37RBQEK=VP5&[C.O^\5=OU
M$YUD6N=FG#]:Z-T(QFAJ$S"':P*G2GC=5DNH>T7^1%.R]0>'UJ^'UA/L'6E.
M$D6'*"8O/TNTF+68'?QK+(K=N7+%# S( !L+#UM6"JIPA=6@3>M"(/MM!94C
MUM<SSJ\DT\,MA8+U2(P+XU:6X=0H"O!;^$4O.(]E[#!' J01**DJ"7RG8YP)
MT_ZO!(__+0!%]55'J]JE@:<BV+&@D#32(\OS$;"X1OR7+^M_UT]_90Z=I'0(
M(5ST+0R.E 7('59D\90KRD=V+3_3?'DBL.JW&T8=E/FMWS#/_*Q,Q6;6J^K^
M9$<5G$<?VI<@ <*[=SGQW;H3G+TVU0[OF(W<(FE N?9H2W%*PT1\4+UN[1)A
M%G?@C+NJ,#KRJF[],]"J6:3JF.&0H]7M8L BPBM&/ZAQVB$6.6B7 '%JN/3
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M"(GE>_OT_-S%B$W/#WJK6C\^SXJ&4'[^DE7Z"(B))JD@N26?:-&EC20 LQ)
M ,^V7[H$=J9\46M*&M:O/&20?V,KM.LEHAEV&91)*8U%4:%YP3IINB7#;OI%
M<>:K>CI<?@'T_D89PNBDH$$CVM!BGD;WA7EO#,*F%PM,^4VDJ$2\C&X$G38O
MM62C6?)I#_)]>3$JN5] G=@ H6NTM=$1V@%]N,M-0(F^OKVI:<-2W8XMJ1==
MYL>)+)85\"9@VX:RV^XX?I[OP,T* <PA,^^:D7\]_J8*;6$O8H3'O6/F>4,F
MZKHUW3@77\13E8<%_N)OTFEP$[/6%'+-)7IN26_M?)$KA2I9[X"<OV U6;)1
MCQU&AU.!X279@@%RFU6I*>'_HQ H$[D"@G>NAS64$)UBOB[:0[ F*==C? CZ
M6?3N2CDMQHMAIO3["VN[\WSI&KL\+ FP*0?< <?0UYH^^!43$W11A%W&]1FX
M:U5\JM=UP&,F+I[<FL03MS2=WIO[&83V-P5G?W\M169Y)T"L1=&8RJ=.\,\G
M>S;K<9C$;&X4L-LQ>%YKW09.%(I8&WQ2S,-'$]GU,+S@:F^;$;=IE@I;#FSK
MSRRJD[Y1#2&JH?2=3VB_Q^G;G-3+X<1/==*=YG]P2%GKC[49Z0GE<3(*=;49
M=3UD>P3@JQ@3!01$]U/6X8?B@ID'"C@7/*K4PT)9S0[(NRZ7/D^^YR!3(7/%
M$%^SM-F!U1^RFOQQIQ^CFH02*Z_[[K(1I*@?ZJ)8.Z_?0C"?+S&.Q!1N>WY@
M_L:Z(UGUS<EFQ%8V!V1S IN3XH -2C5Q[->##%XZ>:((Y!@8>R*?4#>944UG
M.,?&-@9WN.5?KBJ1W*)I;^6:%A_DCTH>3\7ZD"7@]@2\>+[X"_@QN(ZOTN4>
M:%EHDFA1&I$GHF?T-I0@#H"!V()/=8/W<44E=E38*4M[0>^&5N3LU-@O]UYH
M8TCL>AC7UBGK(9$S[YJZ*Y%*ALKT6M!+TA]99\)4^Q9DX-$U&VU$%V8/'"*5
M:CP%%E?##<'?%)/MUQTO"_W5<P8": SLX$_6\TSK>]J[#R=LC3N-2<6NU7I^
M8S)\8FUU;;@[7)GR-HXZA-2E =DYA5=.CI?LE>J+DA4BV+%.>MZ  D)^XV&7
MF,E=3Z[O1XI?%DWFT*-M^0I%-[F8DNEN^E$^>""[80 ;C^>;4PDF]",2%HM7
M&(9L)6BY6.?*HQH*0#A@@G]U]L>0[?"/UQF?GLPL9>=?I0D83@8;.9F^Z'_)
M2,6(]+>XCZ4)?%+PR;R%5/\<=NI0NG5,XXAQH'\>$LGBB_&%SR:LIU6FN;)^
M\G"CNBE@)96:?GOM!=%Y&(;[M[;C/S_+5N"&L7NRL3M3G15Z^$."P-2EJ6U-
MSF/1I+4'4C8/:F7$4L4A3''G,V+/[>Y.M\F$ W0WSY)J(JU!SB&OL#BGKJS1
M;^;TIIO7'#+>\XHM;R4,S90,.$U17AY\:D>9[5Y19FLV%CT1,L0PS^A,+C9=
M8X4]3_UC%.VDW+ >01!8\ C N+A(UHEEQ;#])4@#GR'.-8GE1YE8'F<5AVXI
MI"67;X2Y4%)DALEZON3H+%>?O;Y3JDZ]=(N<AIYQ18PL[D_H%YYK^OF$QJQ/
M%QP8V!5B;8A9@'"@R!ER"VK9.S6-E_PQ;#C4TYDF;(9//&"LM><_>(#Z?/')
M6['AV6D*( 6NCB^/D@%W<M]*D6Q$/.+C!/4TZ\^?;E)IE1K<N!(=P3X[J>GD
MEF8A/U<8DSW)/S_D?*](V7,F""F9Q;2:;J&&_6:O96X)(T_KY.<Z8:A-M*Q>
MDDE[W3G8X*G-LVPK00J</DA7,U.V@$=6?$RG*6COE@*Q'Z(_42SQYS7[3+RS
MEQQ+\GO3E?3B!L;Z&"T@ S!)WT3T@KZ54TYNS^I7- RA/"6L;<UMH.]U5/I#
MD8R&S*(-7\4-S*^^U$UO+'G&69FVGQ-7QLR/71?VB5D63=D&QN52;1B]QZT
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M$Z5V';R;=YR552K3BY ,K7@$:,]K/:"J[@&CGGY'9A5[S;+//W5?;%50%O>
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M"Q3XI@=Y#8'EME$;M!Z118'UL,QG>LF5@4M'.<I_W-+D_+-7B3O\A\OGNH1
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M/Y-F9/S>RM5XG=*2W<5-SHK'(X[:B'YE^#Z1EY>;29++R@92!($U/OBA7,'
M7U\-/GBU)FLYR='$U*@U=I.ZA ZP<8*0INT2SKDZR9F#^0LB@[:MSAHA\I>J
M$2M>,R$S,J^G2E\Z^!^;7DYFJ/_:V=1DL];/_P02^TFVID0OPO6^06>I+''4
M*>ZME/AI$3ILA5)T0:8\;$=+-!%>+V 2[2J<N3S.I[5 TS A:E0G&7.[(7 7
MM_,0NRFH-:](-AN(ESTCL$A/D]2CZ)TYRLY:AHQ\((7Y7T/4,@EY5+-72S78
M& ")K+-WCT#<.ZC\;[K%T&NEF(OKR>(3I#X8R&X,=E7;C/.(;-YX]YSEL=11
MH@M?WKS_5UI6N'T/.$(V2VH4["?5IE1?@"S5ELU'M9)X\L%,D"^G__G8!).0
M,HJV(=>$8L@REN*MLA#H^:]-XB%*1+6"NU&7?'7@+Y=(:2X:^4]\&55\;(C=
M'2Y8G<-&TKN!&88A&WD."]IH1UD1,&-&8WMA. %P$<G0=<<V5FQ:]E/'62;Q
MZ-S=<9'+&"<]C\QCI>R.'.DXUB'*[J_8Y*KG'<;R9>FGX?1>NNX%1IA3JQ%6
M(:CA$? ;%84^@'N439%S_OJ,IRLHKZ0'4J[KX%GUZ4A/>@4+G7*OB(DF6EW4
MO*%5NU/I <'UDUQVM8M-+[Q )G_\=*V]45X>I_/*\C57Q<NA4I[,E?20JXT:
MBH6'>&DY0R'V:5'(>(U\7GI8BV=9"7O>K:L]:NJR6/B7+GBH7]VY)R]33EE1
MU0,HD&\5H3<N*K@]LOU"UO0#;?4HO2X3-@$G]AL9D:M0S0-?43H]Y$A6:6T%
MP45WP+1$OTUM%_%FHWM$D"@FY.H#F'N^+E3H)RQ%-D(5A[+(10R]B<R:!'@"
M$:QYT6O*1-[D8[[F"&7N=<CL<2O+V/165%IE#["ML'5$7"A]Z2+?LCW*\ UJ
M(^J:9#@N/EBV_]P54%%>M*.%13[1KI=$O:Y*>P^P^L2P.U;IM$A:V:VG-EI1
MDQO6D,.IS[@32&._G70FWVUS8[3\?*_(KDW/2"]69Y6XA::82='Q'"SR-7K#
M\A5?YQ!65R$I)?WV#[S?U]JH?5T7=9N4 ?*KZ>AM1ZAM(]9)/#?%*]0CU/7/
M-E'Y294 F\(K#>'V7^Y8%70*QQ0L@V1_&CRET*%<..M:-I)PTU.$8B Y>_N4
MX]\@/E+R@FCS -%*ZW+6+\K]QZG7Z< 43P[C&0)7O$-5V2:5!+0]7H0E74")
MD:-#K9H$%ZY58X/E?>O,;:'^?NX]%'$K8ECFLDUO.IA?J*S7,$L[5,+'?5B1
MIJI'HL$?[',D-WJ /2[$6[Q16H:#!1OX['T_$@F[H#@]G#3;DT?P%Q@_W[,W
M/ZVX<5A*Y>L29-Y!N&)6O\6E:^B8-:7G"FO\O%H%Z7OM@X7,V%F3YE;1Z[I1
MHB$SG44M\AP)GVTSQ'RAKX_R).Y[6+;#%!N7BLI;+$$;<$^)VR4Z3-/DM[8O
MUQ#JH^A&[85) <,5/_4U,MSAR4E#S D]W4.7!)]NW.POYA*#;^3N 7*7>$U?
MD$"W4:3J\8)L7X66M F7I?6>H?_/04@$*6D'ES6['@4<1)Y7PKWS?Y'4/2[4
M>X!9-_;?B^JZQQ->?KT[++*ZD2(*<(O-RX#M\?^S;0V#X%U(S=&BOYYSH.4]
M@-+A%N)8LWLC;4>Y_)!"E@IBJW6FL=L_?[" GO,/PEIXG#V#Q.)=2CZ0/#\5
M8=Q>%)3Q-VAS6M^\'CX;(<)P5R=[$]_(H'0/B+2MOG4T6F.1!3'2J^D2Y&5]
M1Y@%XE=VS",1GM"@%T@;G4Z3R#PN>P%B@WF6\IPQO3#XDU> 4-RH;7G0*]R.
M1V^?@3K='[R/U>-"8+^7).K="P,U*@>2U?#T-\5IM1%!1L?4ULUG ]!3GH+
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M:]0K.X=N$3'TWT_FOIO^'M+R')%*F*H=5(6%>.+?3;/?7#4RS#Z\I'1+>'/
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MAPJ2*LH>ITP;$_?,C@B3<(:?>!<YR0/2S:JM+6:SA#QA5.T"X"F),[&,W[U
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MO&X !:OOL"6&FEJ2*(7A#N"LZ12#YDBE2?-'#\B-F=/O2 S/-A-T*'U;"M*
M%"/+(15.ZZR##)M01R$GB/(:G5(H97:)E%-C2^.C'[*P'4U/ET(/\K2>)E 9
MQ7TBY)H='V4>]F%7UZ!%:W4?7>))636&M8Z#&0BAS&59*I7#I+.&>*4#W7OS
ME#3,:T6N^W1-SVG#.05$4LS0L!LBCXEX72GN]V>AX(#E$.[G"NSW2==?:W[;
MTVVURL69O,_!2F=N*J>8H" C'L17OGOUZDT[J0*.("/%&:9453 O^PU,4RIU
M?G6U+]>764]PI*!6M26MIOE]8H5EG'VIO7<@2O6DC+5+H&K;(\:JKJOJT;T*
MD3O IZ(2M1AFU>SB=^^#=H<Q18/>]E(<_/:]HF?7)?4TFB[Y\;2U8:KL+Z*\
MEZ;! FE<]:0$@S>';#DJ"6(F79KK7Z*=^"R2:$)?VDH^+J8JJWP4C]?RV>G-
MM[<?P/ 8=//+-XZN(9E'N25!JK)9!0!<!31VB1N3DR[>L.*X,9Y?W("Q8":K
MF4@&#$TR_6:1TZK_C7EL2MQ5_.@U1RYY6#T79Y#H=:V[1G\)4]ABVGQB#0PJ
MD?E?8&#_KK@]]O;9"'W*4U:,^D1+5XQ<(@T1<JR;Y9%3!+*QM%0J8.T[%UF<
M>@*_M YQ]"1/1?L#,ZHCG1B[H(^B.EH^9UY[,;NYX?Z_)XIH,GI:JQKM:-U1
MMR20)S%DCXYI6IC2;WH+! _T!9'%/&L)(XX<,ML[6>.=+X=(%((XMBF\"00K
M8#%OZ?);#I9ZZC]REO&E23Z-!1=U\(7.736>TB3O:SYA%=D0?Z7J5UVD&*/T
MAKVN!EC&E(9^^YC^%T0<;ZG%8=&S%8[REI73G_6K("%9<A2A\Q8LEX+B9;)]
MHV6?(5,KX7!LD>BXBG/V;XZ4K5$\6W"M9$M<I6D3VCK0\H!!+186!B6GE&1Z
MN%14TH<=CM\%/*'HZ]N&;&.1+=-,M%&%;C</B5OW_6=UT\6SYW]YB1_%;L%E
MILFGN8'VC_M8[P6=7FJ5<<+GZ[9ZGCG#?NW(-3D3\<SK06FJ(\(&GACF&6!V
ML!I4KM-%Q$$.Q5DR4Q3WT_[6!Z3C3][#^/K@DQXC7[MLO4ZVG0RI/;V13A42
MY"OG6[JO:)G7[#\8[^.[WY+?QF^=DB#::3 <4E1]OS[$OV7=1KEC;^8*F#_^
ME!;TG)9.V[(LGE">:RELC+H#K+2=^D$%C+FY_6W6>@3D//&<GP$?KHKDVK;]
MG*R8*Y42_S"B"18LMLMF9EGXD>1I'C;X;*6A]'*S;[F:>U=9L4NL1!=>8D,9
M@(28O!^3Z!.$6);%QO2*Y[F;\Y63(CUJU!)T3_3'ZC6,E'T(XT=AT'_L8Z+^
M/4._>_K:8)"(<KXML.9%*QHV;;5/8 K3'HBQ&,6PI5$PA(UC\;7@'>XFLEDE
M1T@Y]R@;L>R*>';IK7#WUL$3=7D>,;P&H0T@"XI1?6(&P?[_L>M6%Y.[DOWO
M)VEQD[I,5S)[=X#FWH6L)S'G_VZ'% >H@</>/H6R6 X!N)C?K,FU<RX:.0^I
M?8&_?4,Q[^VIP59?29)JVOR*-.+OME9*OZ9V\L ;3-[6B>3RW>2@FN4323WN
MN@.PFZ#Z+?J&ITZ !FA0]AM%TZ3^_H4 (+#[.WGTAWI267S3\/'7L(RB?!V#
M]D*=7C?KJ\5X-T;3PF)BDQ;/'B4?M^4=B$"W ,N<C*-7$9<,,&3XR;"]4_M(
M/@K4>0LZ(HQT\^;[:+,7WK)69O11ARS5EO8.4 #\M?TDRTOQ\"3$2FPG6&9S
M1";\:/3SS,D00J^T1'O12])9B;Y'6/HC=;)@2[C?AYQ8#N4/S)&XD0K[8NQ6
MH<47XGNC_71<%$H-^ =J/??H]::I%_>H)2?+N%M$2K?:E(LHC6F_6>#/7Y*&
MG6^-M^)TBN'2T;4T?0!3'MCDALG2\*9](WS2MY4: 2FJBQ(A%R6P*;@#=-":
MGJ'>4(E*#6F%A>]%J$ DQ .<H[MIV*O8IIZ7D1FIQ6L\>\FF ?L$^$96FV)6
M1P:+L.=Q0O G,+V.@4UD3RHC0? E7-8L8-CC\=MS/R$\6<0T+<>319)R7%0Y
M1V<M$VF"F/IGZ]#+:9K5U7W7#@XJ<K;L6/"C7+5VFIQU"MOOPNC5VAN+Q:]G
MU@0)F_NM*K7Z1T3!#RM0BE))(P^#_B*QT\U1/J8(8A?GIR,,?0O7XC<>&ZGS
MOYB4BYU7%,2PJ#%J*FF2N:V*;EYR%P-'Y"E<AVJLI?')FXRF.\ X)A"_$9<1
MVT3V 3:PFMNK+O!&YBCV18_0PA9\FG%97Z/,3%^X_T=J'?U['R0ZG@PXQ YW
M,3=549DV2E_7->=<YNU*W-.5^(Q?]$!3.2"7.\VT#JK&]WE#?!R3F%MG,DHP
MX)&UIYP2E_/!5LE >V!LIA4J!>Q0R/S\>4$%!B?O5IMP5&M8&:_".(-T]245
MN^;U+^^[&^IIYCO)<.BI3<7E8MOEWC)&)[NR$\"8A3*/?1-8C@^?V$GI&;D=
MD3=@&&U\51[@ \2[L%_1I_P1?)6^D4FO?G)X>FCLX<KITHI8]^%7.=X!EO0F
M/F*]6LDW])D*)YRVS_@9-;0G6?A]>]A/Y;K!7U_3#MYTPCN=8_#IXUNIFC S
MR^O[VME%VU3^")<</<6TG$S:(6CN]F>-.JN$Y^%21K8'![ 1ZN-3OM4OKP2D
M)-%LQ4R(_YWSU/\JI/[Y_5CL-V*B9F?04[$Y%XT*^Z/PXT_EP<3ODC_ C5]D
M7N+<607=);J5/#.?XWHU6,NG&30.<"[*KU 2X<Q&YT=>$9G'WA0WJ)P9@Y@B
M6L_HD?<6KJ]>]N0E+A+6JO=S#=H$VX0=ZDW$_%A]L4_M0$OF7/(6\/K10^/L
MIT+/VJV #<SJMJ8)UHY*2HKJ!'.]'J9>UIN00JR4#?1YKP(!X CZ,GC]UZJ0
MRM>:O<OI9'>5GMDX,88,N2/1/!;7+O,Q=9"'F<?ER7*K<,OO917_AS?5.PG^
MH0VD&P99DQZ>Z*W.8_XEL59/RN&KG'J>?D?7+O[N"9\+C6"C". ?68/\QH/[
MR.GDWL"5Y$MZ;O?YKH_ZS9]P4EUW],&F?,OSLD!O;9.L!NZ*:H9!PGCPB_-"
M*-C%!),WDVAC&D2/T2UM+M'T4Q%^T>,4J?#U09OSBZ.PLY(8W6R&7QW]ED.T
MQ:E5HKO&_HM$+;?Q3_3J=M^[1VHW3YPTA]3,V=6,4&U8GNRCB+[=\G_6Y]'5
M?ZG["R?U_<&MRX]VVRB6*9ISEI:)GEO<9.SBSN7]JG=!7A6]O2K+AMN@LLBJ
M&.>UO,ND6N8#NBP%4,(A?ZM;N26&>:T9RD>T5FDD<WMOR(4QSTF9F\3!FX"T
MJ:$F,3LAT_SIH#CO*XK.B!QLU0\%?BS%RR:JD08)%T%I>K<#L#.\$!NVCI&'
MP%*@8M)LNP6I-&9JH"*1DM1P<,X_LWK_8B"1>]]/HH^)'J;)V)8L]F0>L(FL
M!7*S[P?FKE3F)V?._<X:J=51[&.RQJ4L%08)2$((<H*_J&41YBYITV<5? 0/
M!YJO:1>="1:1+)M9ASRY3,7:?MY$5H**!8I0I'OG]+_HX^6:XC*]!DJ1WF%H
M[>#D*?(ML;'Z]_M'YZW;06<Y=X 1\/6V3UW]#]&]SR*589--CKIQQ=V[@S6:
MAF<I_R8=-J$+CXN,E[RMN8D+V,M$681A!>;VQ=O$.4+V65S[HVYQ@0K^(>[!
M*7FC+D9B^5F>?<\6&X9,R"VNNC**AI@16?-#RX92\J?@WKX@L5.$XE9N'ZXE
M)$ SNT8].VP-H5*8F[ M?SD.@UJ9LLS-LV47HA"Y".YPE\+O/%$LNQ[IGT]?
M)C[7'P=S[@)EX<J ,J?NGYQBE!,Y38JLC1%J->\HK.$>[U./>2?&&R#/Y:9O
M7]0.8WQ*5,P+!A1R51O;VWOX3[[U(G9WKY\2? UZQ1=:<A6ZV@  #3NMK0C.
M\O8:3.Y&[8;3JENE,QZ6^BDF=J?-&S+M1? (,KIY+-V27(0X."S]6:,,#YWC
M?<,<Y+ )^':]\V74"^)0Z%YT_:H4J?74SEIEWS_(U&:3C&I'U' 1._JUJE;\
MZ3?3IOIHXYG<6!:5P5ZI84<E_9A1#VM39!1*U?T.@!@[:2 1P +N]5%H?PV^
M$;["#F5TW*A)>WJV/M<C-HA@^8W;)UO1*Q[N0G\85E:R3"#>Y0;7TYV7LGTV
MAU.SD9Y+_S%^<K+1%3B@:E4!ZG;A>P8Y?%LN&&;+2I.Z7#8&A78WP#_)?WLP
ML12P[ETH3J^ K:^1(SLW_5F5ID&J#7=DJ*A]ZZ?)4'D#DBS"_S%8?:LCM#(S
MU:Y7;=.<%C>NT+&<F7Z/PX^0]H.:VIB:)_G4 /;\87^$1)W$'+;PPN_8$R+.
MOSG$F)99. S9WINJC,.5"GD>9653\#MPFL)E$<U*9]G\@'602V/X?><ECMR.
MM]<3IC7BKTEES30P!6%-YZU"$".RUARV$.ZL!2_EX<@BL/A!:2F_=3/;K#.;
M7X[*EZ3RJC3]%-H/MD6"],/B:-)3OL"A\6[L?>#X]TMS* CT *?Z#5, A"PY
M'9< [R\X-G&("2R7$G[7J'9*%Z= ')^X(B1S-!-+EIB7[0O,K]-D41=AHB5P
M],!B7+P=D[V3;)8J?NIL?ZP=1ZFX)GO>H,5YX Z^,Q[8]T%\K%7TJ$:*M*"G
M-V/:4XZQJKJT9&0,J3]OPEO%'M57!3YW=86V6X@FU\JQH\Q*PZB;&]2=R)\U
M2B0 %CV28Z(FB'NW$,QK/<7G37YDG>8:$4YW "QPVK>;9AQK[Q?8$\\Q8*=:
M:%$? 4N@,!X+@JFIRLB I'^DQ<XON>B4@6U@SGT433(SPQZ7&1W-U-3JU=7H
MQSW 1\)37"*2=1-E>>FBU4(KXITG&&1/*I4M?/XG1GHYBS8*!N6R-OH_#?O]
MAPA,0 -,LP?"PL0T'U =>3:[7;BL].V_( GG-\@M<PPJCG3H!>_IESSM_D@?
MU.7!5!>AT"?F/N]J/'%8%@;6>(+0A7S?H"Y)QKK9&\Y"76P88BC5>7A.7A:4
M\UZ8%B,=E%PR?_7RSQF>>L;>&.H509J-_A)RWJ'WB(SJE!"8FX3&*YOKS?-7
M/Q&-\JII:1TPN";;C-YS0W;?^5IW=12^97<\@+7H?FZVDH SL1+HC64V&OH$
M^JCQ#D!V43S7@3T[GH<RI7NEO(6-.L3^40LS9S5C&9_?9$?F!6;9%/V ?K!B
MBZ%\[EA1HIZ,DGDMBK;#:_.+CWBDHI#[_1Q3^T1;HMWN0$TN85<H#Q7T1M+^
M:]=M/)(M@:VC\!O00$N7C>PE"8=EODZLHUO^V:C"].0_9^Z3"61QM09_UB-Z
MW.J4?G.0A&X[=/.5?4M'']\!GEXK-GIKG!P0%TNNG7'ZNOH;]V#IL:UTRRO(
M>\3X!^<."/4<8=OQ%TI@!^X\BY<4;7]V=MDCI(E+B0%FXAM\+0C=+[9ZQRI%
M!7,=/M/RW\,OU7<#FLE%U+5%Z_Y48ZOW.0T8XP9?'6/"8+[22+Y]DCQ*$,T:
ML-S!*,:)#AB4N:/CV'58-TU15J@.%RR0[W2(@T$M+<C^.XGY7R.6^CO ZZ\7
MM.HE/K^?W@%\L2["5&K;ZO_TGU__:S^X5)QB:P+YDV32VN;LS[CL\;ZHO<1M
M?",4\,&MLYS<BDH\2+SJ5#&ONJ$^_IAE18CI2+/V5W",_O:9AVP 0B0ISZ%M
M,:Q\E&AG#O@5XR5^>-OLS&V+26.Y90FHL[V\G!HBZD (!+WE)T=7+7[F/5ZE
MZYH2H)[WH)SM_4RJ=N2:5M8K%*AK34DH8#MW_I8^S26G@ ^FYKD/"B!36PY8
MMRGD0>K*(_E29LQU(@:T)%>-[D6GGWK\;&=<.]S;%]88GAH17H@H-+X#))9;
MPC ]W7,1C\]+@ IO;6Q%QVXQPQ1$AH@FH?4*[Z&5VL!!JH$ /3.J$CO&W, G
M*HS[L?,: W[;1,+B<4OM \G/+82X"Q,:54C=JW>)SI1$@YI&OL_TJ=RV*BZ+
MM*K_@)(GT02:="E6>'WSF/Q(<UBLD]G\%<8\ES9C?"Y^>9(V[!&;^HN)8(AJ
M??U ,="SKZ4HT6OPQH<JW?VI0 KE',,-\AMMD56!:9;L0C6#GS'/[\X("KHI
M :2?^Q,[?L80W)T]53UD%.)'S3E!1?E#SXWQN&2%%;3-<6C1]INMNG#>*&4Q
MC5-PG]79<X,7DTI3_6)RHK'7 8H/6W^%'%S_.6?^FRY/Z$Y_S,WUVN!UDP1
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MOE\$=;EZF.;WD,P7B;],3V_,SW#BB U[SFMQ,[36FFI@_KV?[$//AC7^Y+=
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MONH=U<A519/9 TH-\?3GD0@RJH!5%NHDWY_^Q&$D(K]GZT')J/CC,PY0H;H
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MRK#!4IT_D?6U,3[.&B<L8KVHMO8VL3N+.8=RJP]G2Z^J1#.E)B$0_2RYQ:!
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MF#_-87H,-(VRZ;QIO/U6*XN[-0V=E1,@N[=U>C78MQ >\! 4F/%8_Y<*N@?
M?L(HGK; WL92.N(&8M&1F-42U[CD7EIX3*1T6;[#'F\_='GV4Z\'-<ZGKYSY
M5E(_[#LRTVQ>I1'MGZO+'-T)]WGHY1Y%SQ0SE=V]L!3PY.+[:9+_9Z-WBMOS
M\]L? @98/U!(EC#,X/ U8<X>_+'X8H-7&#F+8;#JJH;* ">?#3L.C$Y2AMS#
MN$\.DC7DS$%FK2\6]N%*T9SJ1 "AW-==C+&>#8POKI8W1NR[/55:MHGF7=U"
M7\I2BK8+*PP?$"JO+JD3GUS7"A5OK\Y<'W',N;I)S6.MDC7^&OIMXVO;>/&@
M97I<3OJOILY ]*"#@Y?(\N/-$&S]5(H.DG A7ME?+)R%M,C9@<6J@COAG0*?
M"R8O-;"=X2M7;)0LAO&J3K?)54%4)7 F(?R2/%N"\X$5;-.I@@_YRA7256WZ
ML]/7S[B8X>#:8&4U2P1,2M_^;U_<_^K4I'\9^G 80*%9B/O'V>[WI1O0C\YM
MJ/9DW8][9W[+3PQCB(.F&7)VD:-N9EW^7MQNCT]3,_3&%Q]*%GEDWL,5D<_,
MA 1;D%RG".DDC+2[)]>#Q(NIM% O3?+$NN#XOKBW+N7'0=+/B*E7Y5\,MGG>
M9?\!J!JF5;FO=*0T"N?KW.X>GG PW[Y $O\AJW8W!"5N-KI9TC:Z4>4IO',Y
M7=[YN?*4WA**\@DSV%6(>.4*W0A@_H(<-3UC&\W"?4I$MK=WP @&5-/&:< <
M,(I!#1DA(WX<&IV6=;2-S< *A5X.AX^KME\XSSKS%!:52OB)Z210GS[E/^="
M&FL9#F^;>6UK>=ON!R+KZ5[KPP)4\N.[-[_.K\SE"_TTFE:FRWT*9:VH,^;$
M+=M'9CWJ5KV<'( )FC:P/#G,?U[SBR)GU\B0T$#/;)R%EOG]IU>O*O04%#OL
M#OA*2D2T*3HXH]0N/Y,[$,6-&$HE,8L-'VM=-]<SQ2&BM@PAW^3M6_!+M.7F
M[/H]-FC1G?<XWND;_.?-BK=[;NHRO4PCZ=%-X#C4C6<!9Q?[>'_22NZ66WYE
M-D.M/[U>%[D2XFC:T$2HT*L#JX&+ZD4IC04UHI#E%QPDI2F;E9N&3[[WE"TQ
MP#^'>9IRP6P)8!W*4F<K&=#-D+J'Q[)=*QWU''AWPX*7/83,5&!TK&KZI%.V
M4]K]!OQE<"*^*F$^II-<'N9Y![\#!K\F!07=SYN=ZY)TMHP*+&\6_"%_?]0.
M555T7H0S95< WT"&@3_EV!V\F+4A8?WBYMZNGU%9K0)>Q34/F:T:>WHY_ 'X
M_P$8D.TRR$-NF7GW"X_&#MC(+A.2 RMQ[#Z=-O@8"5)DH7-(U/T-')WB@O=(
MX WSV[)&(7O9ZHX3S<>$XH41H_I+_85XNYYW@SF@S2 NC,:G#[N_F]] 9_#-
M:*XLQ8#B_K>%DV$R<3X??2J^=O*S<,FQ%56#Q$%U$$TA-I&!M@^IR!%K+O.(
MZ[.4;'6S7;;&.>+,@NH+ITN[.PLD;(EVR&FC>\UZ8B05XFU,@\+I%CI=:<>G
MEW@19Y-0HZK5$5Q8$?#^]H.Y*=6V\>LW^HU'.=A".P/)#7OH+AE9H[5-9X-*
M9_QGU7IOE3?/JS:=0]1NCD1$3PED2)X-5;$(-=5U]0*^A&H^OY0?&CZ?3[K4
M42<N[[CNS?T82),/K<4HNI?I4VJYG6X9ITVL/N8?JR,P\6KI73-,[!U4#4:5
MQ4QN3MT(2Z0D!C>!,=.<!I%B%;0P AY[-@D?L65ZL2D2KS9I[].-D93XD$><
MO<U[QUZ:OK5A 2$ F^P+JK>,Y*E((Q)[3^52DY>,?7O@@&MYI&F1TDG@&J19
MF>T:0L*VPTJ;^)NL#+K$]0Q_YF/3GCRDW-"(U/OH]^K/PPMPU-W'7YH#LW:Z
M^4[,FN<Q&<M:9GU\5KD7.ZGX3#IPV9YY9ZC>-SVPI?NY5SJ=KAO-8D)I=V#^
M$'Q(G:$\B"3T"5BM"K@2@ T;!<G#"SCQ22X1<6R83,C8:O;FWZX ^Y%_D[_\
MO\7Q9">!41IK$)<"QO8R0I[2]39R7IK4L7JVE19JU(14W$$8[ \G_Z.1/QA)
MKXEM(BLS7U_Y6K$_]CRV\:SR6^#R14S#9=G7B;[!X &0>"R%+4E'H[*BC8M/
MX]KOC39F$TI]6>4:,HY6C(U;YBD<D)R*3E7WOBWR=(VY6KY0L"S#6Z:+[_YJ
MXDN":XL$ Z]CR'@HJ>Z6FZM]/(KG:0*]EJ#CG;M5L&8L@VX@](B=>T],"#FD
M4G.AX5\4XJ^FVQ*9^>X]M3$HMC^B&]K/Q3;+QB[<O\(KL"8!QG8VO][-[<KT
M-MR!71!*_?4^X45%1 )TDU3([6D=?8J7@$_6YIK2D@X2[EW3M2[[Z:6LVUT@
M7P1#9FLKP=H,&L6+ZJ;.6OZJES/@$C>]_A1%9[#I*5(^>.R.;9Z*J=8-22M^
MTQ"MB3,L?U=VF:"_F*PE%LU<R$2<=>7^+E-7::L:+"BA8L3F0GWEYYB@WB61
M@()VV=@)L%US"S5R"=1_*!FA?">=-"%[8<WGQ VGG/,]S,H_:7WP#8VJY"MA
MD9ZLI^-"QBRS6Y7J3&IJ6N[3F)+,+12O3W4XI2;A&STIZU%+*KZ,7,Z');A9
M3?4P_T[G68Q"[91";RJ7+N.NA4?5W4R00YI=FHZZ'#3)3><*=UX9&09$L5=]
MW/Z5ORFTBH96/5FP5TLZ9J#ZY"]:N$WP#+A(-(XZZ\^+LK0YDG'\>:'>BFZY
M\3*W)-E4YJOEM_(6@_7TW)%"&#(%71OG/(C>-TM!6M_1"N9];[/\)1D[@(IX
M1%QS[96PPP\ T1:QT@&GC>3Z2M[1AYK.M ;Y?,0.#R*7+>053U"QT2'3(2[6
M5B7:L+7W>U5L$B:\=Z)3C22%\YNV&H6B]#G"O,11(=GSE=W2V?I'?@;K]/UO
MXE_?3U-_617KLJ4UG5=XL//;'=V54=99;JD;='8COKO_VH/Y<4E!IM&[ 8%6
MXL*A$^X1/^P;Y,KN-=0?RG%&ZGV(+_ 9K[ !F4SM'A[RO/!$-HN)\8&Z;X4M
M9)@^I+?A]&;[0&(I?P , X'F]LF5JUVE[QTM'[C!Q[!R:(JC5K)87/4OMSN\
MQQ$B3@SD^/<%Q9,6N)Z+.OOR;\]5ZGP:L0WZ6Y+!H0DE% $?"KL_*I5(- C!
M!SKU;P^@LGZ":T[,O*LFM&*M'*;YUA[2BV*,XY535KQ&RZ$0NY0KES>XR+BU
M71$=X/8&FK3.)<K7? _=?C+L.AS+_U,X7KZ5"L9C^X<AKN"!:Q=V)%WL$H"^
M1MY9*\\=V]+JCJ"BR]DN:2:7_@!J;I&">+BW9]6_&K86^40+TK3@7X^BDR)M
M=.#G^YK['OOSHB-7-CLG^>G/YL=DLP?N95EE-KI?N?5]XN5HJR,,QE8$8 =
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M&VUMNEB6P$2?01]=C'5Z&L6&%6&KGL')N\1G9H;0PF+ZN:-!7?$>W$-YAK4
M99#OM%[TN(_,C4R!9\27YUXEG3A:I[4,K>VE9<%"K!K&[ADFP[LH9V6N)YO@
MZS!K_2GYOSOR;VWOW!*#'T7Y_ '<NE58%8ZE/]"[<.C*_P>PS_X'L+O[\T)K
MR>JH5<_ZSA8[@-^?I&)0=J^0V1^"2DU[@;8[*K8(&I&,BK8XZ4HR(,KD-[;/
M5L.\>H\7M;>WV]S<CN$#?WK2(1?TJ*U2@:(-YE$+70N64!J)%!B5&C3188B
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M5/.Z.XC?/(4FC1J7;DSD\[C.+L$F%+UVQIL.#VDN3[AIXHI>\[-Q'#&T@S'
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M$PFS[GKO7;C=6=HIT@I>Z-3>3&'R83<<MAZN%-K<8C@(NS_(8F;OA%#J1+)
M.48))->FW_M@ *_N90<U9 ,?:=!VUA>(M\"3A\HFB^A/6.N2+!=^19 M* ;@
M&2RZO(&6UY,[;H?$VOSS3Y:/A6Z)\S<EBQ^5<")ECD=]V>$/:Z)T[GTCWN;-
M)%6<48M;(Y&B__KQJ=U:481'=H'14YKANU,1*D$$7.L\.\_&DB.ZU!)X3%N@
MW%E/_NJ]_@?_T]!F#H[[.$AJV0%7QP#LMT\O7=&Q6PGN%X%\D*WHJ];NK=]/
MB?%RN]T[_B/KXX^(@_MGX[U:18(<-O?RKOEO\Y:0O0]7?0U=]S!@I%S7R]?6
M7.+(@/)^/'X Y4Z[=H7K,+ZE.O_%%!'PK$5L'9F!^7X@RJ4JEG05TE''<R=?
MI)0\E^#BT5H3XOK^WB4VZ\4 :HS/LH6>JBK<2]K(6XWC=3WO-? M%L^M0K$V
M:;#+E2]98BMW1*%+UW/^>;1U>,5W4[I<60[IY!:# =3C,8!5/I<3JBI.&9TR
M\[-2;\@8S==1!=FH@VQ7WFZ%M)>4RAVA%OH*BXM]K0.YSU-/]C:-8\F7MEJ_
M]M1G1HN/A>2)PWY*<V7LX&^3'1W++9M!ZM&<9C2GCS! MN>T3_-1$<^&9;U
M-IVJ=U<7,_50B!HM!KB/%OZQ/QZ=16;%K*RA;C]D8,B<D:GN2E] ]<#?[\ZH
MED+>'W7][L6SL%5X:X<YGNO S7FU/-LKH:WGN]Y\(YV+F5UT23@FY,9NV4%?
MLR.?[;S,7:)*F-+LS2NNW^\'>0X$P_ERP/IJYWB))).3JTJ.CT-&Q^<HL7[,
M"Z $LK<FA!9L8R#6\X]F/EL*QLPNPR#T:[=0!'EJ;C0GJ>_U[*WDA#*JMKVL
MV1J&H4#;?F>0:Q/!Q@>KG-8*MVBE\P,6;7N-LS&G5]:5KPF_TRE&17454C[!
M#P,[+?ITA"Y]D-'PT9OW\K+U;K[Y_D?I("/2K"_,-3O#3SK1" 7R*?!6B&\+
M+9CIO#';>>]=1[O?$[CU/BQ^22Z 7]HYRWC*>!YD-_28@X\M#C] L'.\7I4;
MNYGM,M6-1?#AV7']0])><M%^F7*S2 1+L!'I._.=FTH3-,FYB3@P+R)GTVQ*
MK&\7()2[0/C*UVABY>UBQ\EGWV)Y!QY#:!K>)CBDGOA^L;=NR#I@-:BNUIL&
MN@MUGN"9APKG3DB+Y6TX]Y3*S-6WP5I956B[\^!<&=V( <*-LX?E=X>-.K]V
M!6+5<IV-]_W>-OIW2L :/N;M"1KE3*/.G<^OVTRI\"4=76P59OB)0^C Y%NF
M8WQNR30ZDB\+'44]9MX4-2Z/US88(SBK2S9*F<S;B=WSVV_=X0@]S]98MJ$;
M4#WNN0J(VICIRI%<(1%1WL;?67U=%_.9KL.H68+-N!*F*OK4.LC[LIX5S'0D
M:N#/X2SG/IXH&))G3 WT9A4(@@N(?CP5[#'-XEG/ FB32'SN:Z(@"!4X R)H
MV+HN M$VP(D:]3^TC/"-';UZ*'GB76[JDFX\-&CT.8.74O4]*JG/R;-KN4AM
M<.>W.%]>T5-[X3C/Y))[I@]?*Y<>TZW637-C?T>@');459<$ER TZCZV=/.E
M\HV&LY(OEG.-UN%JBU,B#9:M[G&G@JW44<ZK99+1)E9@_'U8'13(+S 20<=X
MO"RB@MT"!S+[E46ECI=Z,R$L$0/X"FGS:DSCWQ!3.D'/>C45CV%Q4.!@HY%V
M*T%]9:V%F=.!I^?M_/AN8DLJ:-GOOBE7()Q)+(2CKJ%IS'I4A/>;[!![:@R[
M=-[.^"\) Y!RK7&C;JD[>Z2;FEE;.!:K6K&^4Q9;$;SDAPC1DJ+IBKJ%]WWH
MK*SK66YM-O>3=IA0)089?KRV)QT#FM55+XF>A[&R-_+T_?.5-=>88Y<;>3%
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MBC\,5TE$<\X3G4)9-LRFFYQ]8_O>3S'1@GZ?C)G2_U0)^%Q(,;1*8RT&,,,
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ME]N=,0##I%CKUQX%O(.[-\$R=DWM8$YZ_! WMN+;X>&];TP[).9#G!PO28V
M-^#4)=!<^F@Q7.QE%6J.D8^K=V/R<K?FURLVX<!V(U#;$H63CXVJJ;'8OOC
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MW]!BM"KDJ63[1MPL@8*>J?$."Y#[SXI[__/@+"KT  ";&-UL9_QJLM[T\7P
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MS:OT/X4>]6TO=EIWIVZ*F<;[2G80R_G ,-M(U,=$Y9$FG;]_AY[!\MS[;C6
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M(V*57I(\Y2%G+P%_;-E'=UI_SGO*W'?WL@S6ZB/IZYDY4[LP,?CUL*Z+F%"
MGK0 :1Y. =LT0M'3[L-*OXIR9E0/</AN*B)T]M.USIW<NBIXS5B9 \E61%K*
M,[_[-=ZN*&'E2.H0ZQ<H=?++3IH.E9P7Z2%T348O?Y]_Y/>R?H*MLT]XI#SQ
M*?\908 L+L+DJ'D+@BB5CU)SK:W)G,*O!.T&XP_H05#%I3R;^G%1FL69.ZZ8
MKE,KNF<I.2]HV.:=L(CYUQW%R.*E/%ZEG:"N!N[8%F#2&.R<5B6BV0%B7_[
M$+%9*,E-M>%_WQ JR?7=(I)DG[X6H/SW)D+%RNK1D@G;KZR\? !8SKYQJ[P_
M-OR\F'/,V_[Y/L69DB9C/OZNN"D=N>'C:NQ[ UF>==W%KWPAM25O##1(3X!*
M0"C>KO%F)6YKY)4>.5]T+@L6I4FASVOGZ4(;8DAJIPV1OM/653\'18\D'*^"
M>>B;/JVY+PH3N!B%?_]G5CB3(N(_+"K\/PV,#(C,7T-M67,:&L"FX1R-*=$
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MS)=.KH(TK,1Q5UPPW +,]W""[*>Z"+T4,#=-<MY5]F)#3;X3=(U9-6\Q^/0
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M?X7>I;<1Y7VCE1>SPAN+5G[Z6>!%=/Z>GA<PI/1\0H<$M:&'Q=N7V3[W?<C
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M&(NET!2D<(G^HP7GT SUUN;<8HRX7ISV?R8/^.F5Z#G5]<YOSMRQNQMNTNR
M-9&<LF[AH-99/Z=><EQ<#+,;L-IY_J3.)OGX6;6'BYU 5PGJ6/@N<WJ+IW6?
M9UH#X]G*RFN*' JRIZMI4F:N)&7-RP,&8MR3 >(.J #LQ)CV_,F&]X+YP;6
M:4NS'LF1GHMRDR+!Z$2K(O$-@S<D;B(]H_%A$"-40E$O+RYJL1/;LD(B28=.
MYNKN40_[7)>LEJ]ZQQ.;85R*9(;SO%I2</)2.YAS=V"3KK7M5-"7!X#124Z&
MM!2)1O9K"SUI]X2:B7<_GCMALJIN1TC1LO[A"\)_% AR?K+B GZGV*,\LCC
ME]\*\3N0]/8O:05TC(Y_2<9\O DM7/>_8/TVOI65\CN2,$B@#!8GQ&/C;4)F
MVD&=-6Y(?8(]\UE7M^X]-08$9I,Q4F-U$1%UU""!_6NKO:*<&C\R(7>?P1JJ
MC!D4:7I0O,^E/%K.4QP<3V\%%(XR@*?E=>3KL:@4$.SV%(K6\M26:,6RL'_7
M4 U 430@>(MKR691DA+,C,_T:T"V[*."%-ZBX^\:F&B:M:_0\G]U+2,#^TLF
M9<))>E8&N@TS@07%>>7<D8XX&[GTZU"A8S,)(QQ)\)5&_4;X1>5H2_Z/C%/.
MU_=.]CN&I08IG^\/6F*8J11V#PVF:]34IA ._D/5-6E9:0%X)&,R]L\4F .E
M",WI :K<(W-=H_TK+Z057O[ 6UT4.AE/[2K/WSGL,P_!^+'<Z]_9Y-"@LTH_
M\!)](I''+Z>-#_:1+9]YVLH)MX:$^_,C![NW/IN/<U)2Q 5-&U<,0WJ2&$XM
M!)1 L2#QE9A7AC"G"T,^3KWXLRYE9!!0RL#K>2F67)!@7#YS]DX:OF[U%#?L
M\( &(U* <.-QCF.ZAD!$Z5J.%[_3!T5(]%R!7T+0KQ;P=6O^?%N)Z/O#_.&I
M'E-V9XC2Z%RV2+BFJ1:?="*NJG[PW^_._=]7(C3JX@?=<J)5GJ$A;AWSS((H
M3[#A8H[^4XYW42XKQ)JK#N9APC3W2"MW_2XRH;X;"?&P*0-]5$BRR518^I-Y
MO]JED4BM<BJG0F=C"MR:A-I!+ZK?^Z-D6%2'B&6H@K4(*,+/RE_ !/5XXPX[
M%.;NUPAVV^7/PY]BL$N+YTP,,J^LZ.BDVZRTX\OE)]:TTBZ3/!'1:B5CC/-(
MTI[F9.^EF'JV"D4S'1SG/K]*HH6;5+5PK%JYI/RL[3"O==MRW!!-*)N,7,W5
M]?"\96IVL2A4&W?HC^^JZNX !XN3[LIGCRG=_):%?U1:Q/^3B$N*"T#?NI,L
MI\M ^_3JR48(^7Z,.HBGU5"$;2AZV=PXT/"B4WMFP<;K(R%-Y6 <V:>6%C\V
M5;_NY"ZH#&JPFN%D&?C-C2A8M-K-4**3PNEH[\ PR-86+^<9!@,>[CL$Q:KJ
MZ.X)BM!W##V3)9,P81I+Z:-5[R^KE6JEKVDK5*7P9IW^:C.U%UD> &#SJWOH
M+K-U98M:[AV?5_&4Q05>+OFJS/C6SP< HE_D<@O: X":Z@$P10=/W&TM[O=Y
M]C??)Z8>C17!F1/YE=&7&E4I![+A_TB>F[H<.AH]8C+/IM&+.\O+CS7>J%V#
M'%R?A\DF:M&Y2GF>$DX4%';O=\-"UD#C;.0*%<FO"AR9D:Z@,%#:L!Q-G).R
MNI1O$CXFAC"NB<<$W19S158X<T' [^!3Z=$SC_0CB%?XP,MXNW4T4_I/P.X*
MRQ*;X2!+)T5\I9S"@11RY9VFJ+9"8[R%ZI!HJ=Z.G0.MO8X6S#7"%J!7776E
M#>%7C'R8<D&Y6[A&*FT2+T8D9XX[WLF7$NZ*"Q+:>LF9?%6-&$Z:QW_\,OP?
M6N2(A84\ "CX_?<:X-)--^NBE ^ 7BSRFT,@N"R2_B1[U\'<_S!1! ,:0KY7
MWA9V;S-L VTC*3Q[K4?BTP)WW>;Q.%KK':!_ +B$/EHY)[+O?^G$$+ ^?H0/
M?;U?9G[/$8N87U;SKK3*CT^<F'1EIKJ1UCU),E]A,EU+QK':BP*G!'?1R@O
M%</8I\:Q-D/"!BOUE6GEI>J\AT[+_@@/@/^/N[>,BO-+]H6; "$)! +!G> T
M$MPM"=(0K/'&@DNCP9U L,:")[@&M]"-6W )[N[N[G#)S)Q9_SEC:[WG77?N
MO1_J2_?3O7?5?O:O9->N>C9TH![DQ[09#[Y9#@HA;QB)K@A=:E&+9;PF3J6N
MSH Q1;R'_,?S'/X?)<8'4$BKKX.UCZ['+*IX.?+S$0D7^!SRE-H4>_6B1Z.8
MHE&T0J.)@C7</&;=R/BT!4N4XW/ _J-M[=7YJRIQ]I_UQ'7V(K*_?S,JPR 0
M*L=<^W'#EHFN9>?,<7<EWB3L[Y!1_>,&"#L;%:%S,+1[IE>3<Y#V8$:IY[K^
M_.,E+%4=&7:Z9 %>)L71?-\3_/*OF-E81_DAYY')JBY<KJ:^6=@74<Q)UN#,
M+3M=A"[GXJE9G:Q!H"\]8+S\V=XO]8;4R&4CL'7,N,EOO;:>LO%O<UV55+D%
M+QQZ1:#5$TSOJOF%S;.F?[PT!Y:G'G; # _NPK=Q0\XF)2?BJ\Y+4%)<64U=
MOW\\XN\R<.7.7F+YZ/W"XFBNMXG^27V,$UZTGD[<PN@SC_XETPC=@CPVRH?-
M.?RWF5RGH@%>;!_N 1/CQW;W &:RB$U=30685(!Q' _3QL<GI\7,3CA\"6K;
M _-8FL.Q5Q3*:Z'C+ L1+^F#'(PY7K!F7!IIWR%&QMOE67'LXC;.E.5TT"5P
M57S^'9/J!(>8^K??4#0O0S^571#O;/<U4'-Z_NBU/]HQD%H"%J"4Z-(G)O;$
M/^746SQAXI**P?J637F'-_XP-AYP<4Z2$XA]I:ZL#',N8E-^C]!ZBB7VP%K2
MWA]9>Y6 FT('D\ (?2U>PG"(&<SCGVL=\>JQ8,87I[.K\:(QK[+LMP43PO 9
MT[W2K9RQ:'5^.PU'-0'KT'L .G2S8/+)S-(:52!:8[T#WG+<\>R%/:2S6T@.
M,1)15W\/D#DM0)] H//MZ=MV+@LI?B,4V+-;B=M 2. J"[[Y3VO2_U^("1CR
MM8C2]?OOFE&IF_MB.$K:XV>KJWO9>(4O$'#KQ')F(P(4(ROK3XV30G<J_5AM
MN?U0VW/>RK!7LUQ:Q$96,.&F;3$R"9:/S9I6"-!2B$J5*X )9W?\ Z4IE2UA
MA*V=NL/^"]I6Z-G7*6Z6,GJF-])2*,?GDO:AIVG/N_\:YXCF@C^\+W1F?^C^
M]=>N7O]]QK"E+73IT$K.#@Q#WR,^I<N$4 L>2;-%@K@US<=*0H/5@:7]7$@F
M,!E.,70)6J+?092XWZ/\3EPDC9;"G&<?Y2V5F+&+<GOF^? 1ZNP*#T^OG>TU
M-1B)[Y02:V1D! #_?;@E@1L#@(--8 #(7R,Q?TZ#_'=UN+XQYV'(47_!DP1Q
M)8)T JX)4^A&P_R#872M0P?"@6YK=;S99)(7O:P>N>%+=N>)0_EZVCV%6RMI
M!CH5&2G-]6BR97(B[7RX']%HSKD7AQ5(@NV],10,K/1?WX0L13I@8#R#R$#.
M%4C_NYYE+$1F1+&58,%%%K*XTRN]R%C2J&+7CFJ8X-YYS>^"'0%&>M@>,4]M
MED 5K,@^ZS,IB$TWLL'ZP2+K)^TG:'B;AIY;BM^.)Z7V#O',1<ZY&,T9H;TB
MG_^E=L_*3D/9U>4]%&U=.CLPY^G#>)W4J7)J(W/"1G3Q24@XO8O'VYN2\46'
MMUYS@UN">M6WM<@0P3(3D:SQ\AA]X:S;P@JIQQS%24'&N$IZX+]!XP<"/XB3
M\5/EHHZ; A;43B>/CL.INZ% []V4=H<KE*SU/1&-8I.?'LMXT0WS(7L"W:"U
MWIKX5_L9-V^!RYGU!Y.-;?E8F)0,6BSIYH\;@SA>=_G76$4+8'&UB;"&Z#B(
MN;WQHXC@WJ)9,*ES;N4U5#QDW@]%HHR@D <VLH9M53M)!:;TC>"JJT6 #K*@
M%(',9Z'6H>Q%^46&5F39,8KO7@>EBYT5<'> M8<L3S?>1L483J+^779]#%P1
MC6S9"GW7J='F$R@!^QC &7L/V+;7F'LZ[M7A8&E-T\IQ^^L!HKS]W=XRU<12
M4X9BZ\HMZ3">Z'RHT_HL[]$Y/7 /N-K234@Q8<(,DX!0<(YUR !)6B U6U/O
M/[Z\7B$Q0CF.G#\L"ATE_TR7@T?#\C F_G\Z@/$_)>H7F30^:&!H6$U]U5CQ
M*H^ZDP'4L ;HVH+D8ZM9M24O1L;NI]5 71?0+VT#?WR4XUAI4"]Y7"E:9 _4
MMZ.ZYNZM>W7P^HC5T))Y<QBK@_FEL"?2]U>JGAO9>W*%6+;9-!_E>T)QEH36
MJ04;SLECKOD\@$OTX2[%V54I5I-F:U'";7957[( KGAT]47FQ%;98]^XLZ))
MT)7X9M)",9 "[LY[;[9C#AHC/'@_#!="H-/^85G,04\I'7&1!K^=,%C?_=1W
MHS;^7,61^AI4"X27]6!*60S?#?E=\[Q+F*QL(PPK;%"*[OCU=#=\Y0ZQ'J?+
M<=!:LSY%($EMK;<7SG,SB?S=?3P#NC9D]8K,.)H]'XC''L!!O8!*>=:#'*$D
MYW,/>+Z59T<Q,?T+7'WDT?S4F!0[Y=J%:']?!]7.R<0,(<L'AH+8<!2C4'6*
M2)%ST4-9O;27AVIE(K_%R[=H_U!L953K[$?ST[0#45OH,KX%+F*(B]C4?@U4
MD!D;Y:IL?-UKXS16J8AC&,.ZP/'Z8XY?FX1A>G9V_83K'#2D_-N:_GD0(:G3
MTE?2N-1\[3#.M\/%V7;V>*<5%':_REY;>KK9:X$E:,]#3@NPX"!BT/=W:044
M7\JE>;'<*D7]+?=H!E>=;01EC=GY[B@%?(4/F&X@$(GB&0O?-[IF.#A?%U!I
MUN\!Y&F8CC8FHUSUU HSFS3#N,F1#2YC'-+TM[N9Q_GC:@7NRRSJ?</[^RB2
MSP/0HXD[8KHZ9T00 Q,N3G,MK017S3*[+$O^#%Y;G\)38[$R=>A*'#W-\PA%
M1LM_A3:1>F0B1YEA][FDR-*,%QN-X.QI?$!@EDUW;[D_^!ZP2BZ!['5_AXXJ
M&/07QJPXRB>:+Z:K+8\$;!6X!Y-9Z49I&TQFC$(E.Z4(\>2%,=WEZ-"!9!(+
M+D^/5MD#FNB_J"01 [I&K%E>-@V%L8*4#*-HF8;8'40L5G#D/<WGF =WZ4>X
M:@-X'\DF3BS$&[?D&DW-?"#%](4K!.A[OEKJ TUF5T<:)7C6U0(?\=T BIZ_
ME9,3WYF<*9FTQG=LZI-&,3Q-P_36Q7%1$]11:^<WJ:C4HX-ZORX72*V17!ZQ
MOQP;\S.G+4XHL:,&V?,?&W]L74GY2E;5M#Q4N,4#S)U$U%8K=O#CZ1,867R[
MSGSTI4\'?G*(%L0M;?/]ZT^C+E*E-B ER1=VFCR4A'0[X5^ZJ.-%<\XQ4T2O
M8&(35FD+&%>?YFK0>Y^!V%;JA_?GNI<^X!N\$.A$NZ99(!<8\F[FM:Q!'8N*
MDL99MXN2% PVX:?[BG?#;HQ7DC"X65GA/_AQG/>QV#U X>M2C8 %:ZOJ"6$.
M^(]*%3GT(C/B0MP:U/%2XAZ0#NL\?/=Z?K.!,$3>9>H>T!]B[A]OB\3Q48KR
M _'X11KG@E::>R^^]WZ97.-!46@#GN^^0H @RQMTAP1@T..6*@9ZOJTG_;BM
M3ISX+Z15%GVCL+(_N+RZ.@<?C/ ZGS]V73%PQD-&'H9%MP@47HU_7JBOEBL7
M>B=*V-6AUY[_NR]"),_PEAD1?EB!!8'H"^YZ'FC4F=-A@03Y $]T^"TTI]Y4
MEB0PK**F_5?.P"=MTP?G=R7O(N*NBOX8;U+OP?<5V+ZK%CWB>O3: S5/=VL.
MS_=8,;6ORLFR88!OAZ\XI6H_0$H$#7Z5,'QH==H6!XNP7(1H!:6;]!^4 V;.
M%DYWQ8)//<%\.[1:LEF\<D?T<=TRE7G] "RW>B-MS>FLXPZ6CIC:605,6PZI
M"FADHM@P5ZT>O,.>()79?U4GK7"G!Z$2WD1*D=MKM=% $2&/?\YZE!@;J*_,
MR/#MYP>T[U+DOI^2UEOC1T"E(>^_%+7*TDXM&$63/VG:<RTN:;F"N\T%0KTI
MR T\NJ6[(T=(G0MK-T?OJ,Q?/^*5@@IBGT[?X7W*THY =<E4&;)^S,R*O6_U
MZ*,+2BG-^:4+[I/$)=J9<^P0J"M/BX%A=37E[7X2(%57O'CK:5MOE#;](^F6
MB%9UM&*-]XW/$2%=DC9LOOU4:+DS/)ZOJXK+6SY7?CYIIZ>9[(B^!R#A(H4M
MCH\BPG@N5\?H0-0U4;C&P7S(A+O[6E.MY5,;!/82[)H9G[X9-6T1\+=]3"$9
MTE(:='0,WUN:4VOXIIKYQ2<'&>U1C965C(O:I:PUT&RALJ3;C,A4*DH3#F7,
M^=+%_(6Z_,5CD**[*A:.SJQF&/=N,8:NU8YMYR._:BW^[9."*?H;'Z[]J].0
M>X X7OQ2_RE$ZO;SXIV<-'K#JZHJQ #K=T1\=[(A+6GHPG*1R854VUOM3T4V
MAM<B.8!'&HEAR]<].Q;SH80YGQ%HND_\@VX**" 'JVVG :F%FZRO1HO2);5M
M:4E<E:^&L1'%NC-3>AMY*-DX2P<23 L>/641QX\R#KE[5\LW0\P=!ES/(YM7
M54@+*-R:R%^%Z-E@Q2GCK1!_#5_"7XQLM4EMKA12O:M]=P\H31+]-<#1EYZ]
M%=WLU5'4:\/D5WDNK1IA>3B\J5+'LB28++.U+S.RJ,$MR_P4STW@,)!"&[99
M$/7#C/XBTN.LJ[*S_*G@IQ:1!:E-&$#(N&1F\Z5F4:'EG.;U^[L 6D%IT1"L
M[IJJ+%"F)K8?$,,74[R8E"ZG1+90 36VJ"VVA\3X99]*27RL)2#'5]+BW,=Z
MY:[5BFXWDZ#&*&#NW=LDI($[H0'JH@>S[U]630+&'GIEKXI5**4FR.N1I\0.
M]5(&X$?6,'25<%?'Z4 U:-VZKY6%/CB5<'(4+RI,=KB277KB\1_WF"5Z80WS
M"NI)/T;K]HGX-6ZJNF,%[NOC>Z&O9,O4YK#(P(0;H]0?7+BM\E%?%B2K(_EW
MT>_?]S/7O;%9?'4@?04]!8\_"+/#9@Y8IF?,F$*]1_G%3Y9OS.?XX-!4K,Y.
MT='7]B=X_1Y"==CS,UI"@>=!SUA=.ON@PW=T6#?T?8UG'L/=IEE*(%E=_1/Q
M?QYRCP$HFA7;M$\M#-SPVS'QO>SDD>K#5'#+_=V U>G]2B;^Y*H>MM ;QV37
MM.#&P:(&"<HD]M-B@:2](4%!',UPD' O3\/R<PG%K+0(3/#'Z&CNDT;T;8'>
MZE2%,M<E-%0_AO5#;O<[O'L S'OC)?WM6>HRV,6^@W>.I RJ96;H8#(;)WIK
M<3IRB-KB@LW=0GRY-MT[/<W'O6YPZ%+S\H=,[R09E]E0PNB6BU?>8K*AQ">3
M$4O=)Q.[:LPY] ?<T3I2P4(VGDM:?+O%^F%X)+9,T/@2*2RF8H+\*%-A"7(;
MYP]%<IPM"0VEA!,:LARY74)($7G;ZG4O%R]N))8(=TUGSQS!1U9[:);7X^D7
ME1TO+O1Z!D_,J(\SM=D!5D%NAF/5=AK=D?FY@^J110)*=NLI0<?0?;3M*\?J
ME.WWL=1DTE2-D84<3_BH41Q+0(,-P-FL.37$(SGDZ!KID<=*X8ENQ,L(D'JK
M"'4LO):"6?[:P!]-SSMO6S6P)&C-KH3$]01/^LVX'_L&,CURO=.A!_,A[I?"
MP)U<#5.H]%NLH6K!6O0B7D6>2ENX,C5 U=\&0X<I7M'9+%!&:1:?&PO+HD8U
MB==YS KCY0OJCTU[G?V&FQ+S@0@M,@X6F;7>S/)X$EKFUQ\Y!-?J"99,;X(A
M]->;]X",7L%VT2/02<2U_CT@C?AX<PV/)F^6S75B3N55R4H$;4&"6CIK;-Y/
MUZ=4&;8NPE)V*ALE:MG<8$PV$_LW\AQ@J>$I^73\@N]:<V^:"G.?=AC.J$X=
M-7Z^.@-;O3+=/&Y]>M-TLST*7"P8<K#@$PFL?LHH 7)\QI#Q@^&?[;<'KY<+
M"74E@(0_BTSU*85/">5@QUE$<-&4Z@SMUW(,MV/=P&7!_A\77A]H&&F^JOYL
M=UT_*=9:/,T$Y?=\5"%<EJL^H:=8U(TC.'>@5TH5_B9J%9HMX3!S@B!49#3+
MJ!O>4/OY#][]1VKT,"[_4?@W7 !=J$UH2L<]8#1A.HM:2%%"FK&M+45Y45@)
M7F]L^"46IESV<\=3SJV*GZ@$>!@0?YM81&1(&&Y?[]HO? ^ [-6QY24K2 1(
M\<>*2/5_9#*X(B5DY),;C']K$1<5EWOB^Q\/P?S/" .+H(UF2JY&,KSW;-IC
M9POM*P<T-6"*04B6I#J<#E[%.0.B7>JAWM,)B?P4GE'K/D&\UFVF=%/IP%0L
M^CGRYPTPC*<U.-FOBWI7BF/Q)@>% 4#/OR J9"_WQ*_=7L[=OF"3YTS^_'D.
M?FC&2E?W ;#;TH.]>!J^9O7J%+EIHS:=VAZ[J<1S>"\M3@I>/\6V&X]#0&W/
M9M)YNKVK(4(_RBR.OS;T=/F7=11(9"02T]F**I :^?C[5XW#:S8,:,60+->5
MQ(H=#0>^\V>?Q\.ZFTY&Y"B51_J<H#-WSUPT^IB"!,,VU^^)WS+#6+Z:")6U
M-XF&T&]K0$YWXLO$#J5HU!A6J:+X\?D)%WR[27RK.MLYW& D59#6+CL:+TI]
M9S.TZ>!@UCB<  ZL)PJ'IF7+V8ZS!>$#E@FR50:R$0CS ]1DV8)'$1%??-VB
MGL[N;^J$T7$$%!5.;,2EFC<F&\C["6M<(<V,:1.?E;L_FIDT0]U-C3$O?O=>
MJG@(T6Y1&;(D&C*6P#T4;6ZDT#69Q/C!.]:M%$D,8"N -/6),$$O>-<1_9)K
M,W+7D="'S8;A)^6Y\LW;N?(;A67T$O3TE&5)5\N>7<W,Q*/.#J)"!=C8D.:T
MAHOOD"'J;&'SZTY^P<86O"D:IP<;-W#05.Y YVVG_A8#$A>9FISI>]FU2NG,
M^*]G,C08(FEVO4;:+L57;"_N 882F<'%3UB.M!_AN>,OK_:306'#"-G]0&)$
MNY_]T^K*6JLQ5I)T>F21R1*I 2[IDP+G.(64JY7+>)Q*FK)UY E3Y*D0#90Q
MQY!9>A#O/6"R617&2;-%#_@NS'=9P/;FT/,>$+3S?"TUH^ -:3J; ^Z*N]5Y
MD2B!=V=Z@?=X^3V :<7KI1Y$ZP)LG+)%.+W+[%3G0^XW%N[C"-$+LF;CW@ZC
MVY>#@M(_RU#\FBOF0$-#'DLN=/G> :K18A;NO?%;J?AL;7AZ@MM#!NX ^QYK
MP8.XOKP[* R\B 7Q71FIDQR4Q6N-<B>[[2+K?!.3I!?$^V$K2B7ALZ.G.<XR
MWEMU<$9%X=+B0./ASJ"=,#!X6D#FU*FCT5//B8@)Y<">##2$X*VQ=] '-KQ^
MHO^UJ#B'*'9)U\\7;8M3C$2$\G!GCFPD[4?=T%-WO^NH2D  41-].-->YE)M
M/;::E994%(GR^?< /2[Z$21MJ;8?:# N? ,  $?!)J46BP1*[-CQV1%=R[W*
MVIJ5FET"%X/&Q'#8O^O&K)1,.&RW(=,8;[;05]I8I[.EJAC:*L)1?7"Z6T=
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M_@#F/4P46(-V2(JX+O_5,O=;S7M 5%C:/6 </G^%H^J),W?<<L<V6J3\OEI
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MR6$\'?7^Z+5(GUO19S.XAL!KS4G+"HP2M%,WWOC64X,'\[C33?]?W;0'2;
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M'O(@4].[NXC#DG<9U< %QK%4H42!W&532=)(Z>.?B[U0ZG/3DIM3BF5=OQ=
M'+\13/.1!_3^TC(?6^FU8L .+K$V@N_@=6Y?B>2XYA%9J7P]^W1^J..)E^V&
M74*NB2T)S^U)H$^^!S3S%]T#^GGN 8V9-U!9\4&$H!R$OU@QR(?R9N&LN#U4
MG5;H1RP_(]V)@(4)'I-$6W;)%V4CU(P/ I%M(K 3R% 'TKII2\+8\G7Y^)U;
MQ&'6[[EK_6'N=1TQ0]8W_?O">-]&=0AF]%U,FH^:QXQKP42)P+A^O-H';%7*
MRA,7=^"S4'&D6[OZ)D)57ET_-$6B] W]D8BE.O7?K)9NL(2]P>O7):SF/ Z*
M[?*AK@:1ZWX/PWN/IEY?B;;7)@LP4@TOA.O2J"!5]W-;Q!4\]PL@J\2?Y M5
MV<[*^A+;<Y$H,\*V3Q4U"))X3RK"W^N(JX;8:(?STYA*%F2+N*2X_LUPZB>>
M+U4K1I;B'%YQ"ZV)0>$95>FQ0Y]CHKU=1X7:"Y>6AJY]_0:&!G4CFVS5IQZ7
ML=P<27[.E)9)?>W0/U;P)^%Z]W/> [RE+L8SE'0MCVK SE:WZ^FD[86&W5'7
MH108$[H:XARS>1B]L3VFL+F,N-K<(96TM!I21PN!:'M/&4@AQXRY\XMF3NKT
M9YSAT*#_)MVL0G8^!@.:;+K1L-*+Z@$Y"18%P;]YI'A? 29M216N2Z:(W.^A
MF@!Y/<&GZ!QB"5S*T:&E^5SLW#IE=7H/B#Z3H#?GORS3(<.KMV O0'M*.)2_
MJ9!,_K=;19VK"%VM<M1J[=N3, IFCR:7XCG88H"Z# =8;G/-28&]@*$*CCAZ
MV.CUG/U\17IO1ZT=^;,_/0V+Z+G^7[Q]95C4W[KV*-("(MT@#0)*QY!*-P@C
M+2(2(R ]Y!#2)2THW=U=T@C2W3%TSI!##2_^]]G[W2?V><_Y\GY8<\VG]5O7
MD_?]K'A^<@3=>\CTWSV$BV13G3-'1$3P[$0<ZZ. *0EQ0JH\WVH$-ZK#;0ZA
M5,2&>[(UU:C/#JZ-8%:BCA;>G73^N'D5=Z;PH7[<(I0PB>(SAKVAY-]\SNZ/
MXEN>AO82^04R+*EF?9+@=B+25#@I0\H+E%UN0H^V[_US_U3,ZH#_FVD]>;QC
MJN-2M<?86.>*J8SAZ"=G1&P)K1X3LR.*9;S,;HS0,ON U74P=)NM-'0B_JT#
M'XX.C4@!X[#D*O74'6 KZ2\_L8(C7?7U8&84/]^I'\F73;5@Q-3KZBCR'Z).
M*O7B]3CY6U>)GU17:TUGQ\=' =<$(@AT&R9+67RQ0[YS7O\4P\GZCS;M-MZ_
MHZ:FVN(YA/R[-!A7%^FT*B<?U2F\]L :NCDQ<B8&&=-^L7P5(_IC<D^I^G)=
MUBF"N3@_S>VK[UFW6_=A?,$._+*.(5ZQYW52F4IQBZM*[)O*)SVK"I_6IR7$
M< ^RG#VR/M$RCZ:D_NZ"*S>)+VVR4KFGE3B?!:P>/#6B'_H0;?*[1_"\!^Q2
MAH:MG9XE_JM'C:^$_=6[G.S,)GSMKX@V9?4BJ%+5_ZT?YM^ *<!@-\#JVRU$
MMV0[$]1B2.RR;0041O*IU[BW<!%.QY>?&<HY]_^N*OZ]\,T169337CC;TKR+
MQ1AX2%!CG/GCP]IAR ]&X>,!LYXS<=Z+SL:O[<X<CM0#(]->JU'$G44_Z7\$
M'XXX8*^V='_:U3>O+;(>,4PW%R>P-S8JV0:ETK8\[1E</_SM$+G4TZ(P1%Y_
M/*Q()Z(5_ZDRKSJG1*AQWQV>65^&"VFW#9W=??S4T)1I?ZEWJ4F'/MP_VMA+
MGS>'6X]VDXI$G0@?\M(R,[1OYZ]<=GF]Q@'KN=B:*$/Y<6Y3PM5#K.IZ0%RS
M?FDCH*+8_IFHZ.Y(%*7P%5MF:_7)7[M OL-JIV^^0LNB;E>U63_,3&U$9^V&
M/Z"T6<7\^AH/1?+XW%6W_EJV>F0K+XG"$.5\F,J(4+]YUDC[77*V:^DS=OAI
MQV:54QJEI01WO9$@JDN>/PM[,Y\A*EU<NHR4(MZ5SG(5DF)'\.C2KF!M J0)
M2WM,@ <VH,<[%^G9#G,YHPN4U:R 1[;ES^.&J?):/0-BK$#YC'^\?).C^F:S
MTD(LCYF5BKQ:9WZ046/\B'3H<$HA[R,.85/L>&K\XDX: :L=MLF 1Z[D>:GD
MZ/3OK;**;M5/YAR:6G;V'7'K!V:#VT6)5SKGB>[/CVQ2.?T>$*:J$:C%%Y#Y
MWBCS@Y]9\1&;?G5E&][3;Y9EBG70C\E@.1>YXE .<[.Q@+!&9,7C4[QUP)/7
MSW-VZG,U""#65/DC,'3I1,U=\,[M<S.E:KK3;LFO94G%XU[[V+<[@%OPS@!A
M&*[]#F746"L8F-B&E9J (;%G'LJ6V<Q8_S>F"B8R09#4AGUZ^_6D#IM<7+VM
MY@T#>^O;I,DB'$W'[Y5<NW,UM;$?QQ>$R>DX+LQVC+4+K$&MC!.^#-_MN^QY
M9(DKAPN0:=HZE]DNDAR1H9PC-V*K$'[+KLA'B4P.6W5C+0H]J?A""542#HXE
MR6\V N.FUV17H8]9H@')SG@NG;&WRZ9& L2@)*WL0L5^^9&1#)PG&GXC]V@[
M?>9_VGDMIQ#ZCY)7*LF?'K&]J$:Z/Y#;EK^H[6KM#M W_0TBQQ+;E5",(?-4
MO0XCYS"*CZ+$TCVU09:91#[W/]W"^J>!9]<([BZE=1-@-U.D<U1Y@]<[U9)]
MS!E&^Z@;V7!M<E-S\C+*<RRFH3TB2[2 #7>5BT!GO(8UX1*GQXR>[H60",G<
M& Y["7XA?SS;<19=U[F0?F (5\NWW]UQODTT!"6?H? 09!C*3>@6=1_>"I05
MLW\7F9KJ&PY6#1!U>#,\97\I^(#B%GX?E\^PV@GSQ:7RM$;BP[*"(N@"(L0Y
M?Q]Y<I4-> &C>Y2 X0/7J^.2^J>[;-:K^E^LL[\#BU"$DH30X7M8  U"3MNL
MBDN<J(WI4TW.L\>54]79^QI,:,0'9WT)8'=DZ23Y#6E3FA 0SC @>?[F9EEB
M;F<[S\PZ;E+AN*K_#K#Z%$%V<RQY@81&?()8=%YU!]:1=,\1XA0]]!SQL.\!
M-^<4:"IL!F(\B8GYI!2Z0:ML12B!T$)757SC(N!L-D#PY48V]CKKKW6,03N8
MUW@NUY?_3.9>0@+,7T4-YRW>KI-J-NN^D&==5I@T2%UY<QI7(^^@JRML1[PM
MVII5[':NH,_S_/&EK]O64H7D/RW'/86XQ#$&PN&8R/=IHYDA>Y?RO2'N&7W3
MPX;/DQ-C8]H*VSFJVE$<+YLUS5SS+6,,9OT^/L\&S$,PI^K5D:^;[W$],.IO
MHI=E*34SP,:IW(RU2)I!&IB$GE,PA>_K/D+]^<K[J#A-91E=[D!:?IU8PD;0
MMT4(J.NIL<H.Q=S82Y-E_*2KZ7O%3':TT@K$9[N9W#SS_@/TY?\T&4&4;G6<
M"[E[?V5HUF)>4A.R&*LML%3JTNR0B6O(G '1P/#(M">.N+++9?J#7[V7:MYL
MPF&OMM&-*<+7_<=$JG^);JHWT%.R^"WXY3#DBPR)K\0[\18^HPTN9N)(RW>F
MV(XL7<6++E,>@Z2[N*9)*2^RA+<D:O)D^4HU-W7_O2F,WN?4Q'M2%'V?H3MO
MP)-L!1OR9.=>$ON!8T*10UC+1\765'NAWXDUW[@RFYL-U]P!\/=<D[M.YN54
MGGMK;_K>@OG^-AW+/TU 7$Z\P<HR.PB15&X;Y[)]>JM45<^9N-C#F9.372BZ
MTR[#P?8389SBD;\31A*3\%68R7:^V_[?&[_BO?%SFC+HWAO_T*DZWEY"\F3Q
M!6$TCL3;RW1$E,ITYIBFC"Y_E@R_3B:CWQM?8S/'59,GXA.ET33%ZU%_Z2!?
M\Q6(Q!,(]I2/_W=FQA)D(YX;98/>U]7G(R2RM:=/K!$?DA40P0JI)>E%=LI.
MG(G-NSW7J&3Z(,B$.P0NSZH1M+K7 *TN));JNT?GHQAAR#(8[[(=HZ60[DSY
MM%1T[V>:U01+P[4>[8> <]C$9A._43[9B%9HQ8!?AJB:8<=%3F:HQ;]\I#!.
M4R=WXOG!^O%F0PA=Z=0[/)7LK")*U7W]S"3B$'XPTR<:\@\O1##2=.K_U1VP
M_V\CYJ\N'=;LAZ:UJB=*T64J%3^SYY3VG[9VQ;TAO4B8-F@.@<7:&87C<[@3
MQ\6/S('EB#655>0E80#)\IF+IUP?(2QFFPNOYA\4>72]"*DV\%GNR E:-2SS
M/WRD7_1:GK<4<W40,A/E2(?M*JY/>XYCOS^$BOFSO9IA^;_HO<G1LIA--C6,
MWF4*L_?#*B*.&Z_-UPJ-J0)6=1D3IBFR;$X[U?Y<AQ5"SPJA^,@A@\<&UNC9
M_DB3(A[D=([H\V ='PXY+(%N2-#/O<\]6RJX5+!O32_/3\OD$CA(S/;W;K>&
MUWBOZJVN/5D':2)J%H2^,HTHE%$]]L-3-1;)L[Z*"BH3]-PM](88?@:/5JN3
MO-W=S:?JKS^BHH42Z'>T/G6ZW2@4>Z&7(XI:OYUU$;+,X@<Q[ 9 ZKJ+3%B[
M2$_P8SICSX8XYXKZO5_HMS[GO@/XLTCVQAI=?B@)"1D( ^6ZZ1!KFGQT8_A3
M8M)ZA6J5O B05P_VY27J(?^8"<5]%;E]9A(*/>;<;CN*NGW8?$^FSEV%6ADK
M0\>?J;^@612<+E,OAKS2';=Y-U'*]9&0C<$HJ-\^= A*!A'J9!<ZUZG^N%(J
MY2ML=CAY,N,IJ^1$@S5NLX=,.6/OT=YR&!E"=@RT*4OQ;GF+>^BF^"*:SUUL
MF*9T7V %'L"XO?IZZ52FOQLAD\%W !+9$J,>:GEZTR= &QIT=]T:Z"H!H=74
MQ<7<C] *[M<OE="\.:<R6W#BK&2^1UQ,?_X"$U$"42 DQ!M)T]PI]->PXQ.D
M6A3H!@3L5!$2.8[PL2V#:)A011!'.X;P)WQ.W-Y&5&P^4G]NKF.'B4V.Z',?
MP#6_E0X9JRCZ> ZC%-%+\1ST>_4M46RL1OGQ56%LY#"<<X['<LPC*PHU-U6S
M3#1OC54DF!V>^2*DYPVBV[VE"E*^^W(PWWAF3C]1<SUOR+Z7VO=7Z;.Y$VEX
M5!=Q<K^9Q _ZN0\@@D#;YBBE[3/V9C+2!OP:@>M%0U6.\@CSQ\&0==]Q&K"*
M2>M:!BZG509_R_SB[KL;(S^VFCV1IP*@F(=&/NUF/QR-W8R6NV[U!W0G/WVH
MK%>,IV<(_;%R6/JTQ;-&T30SVV&-ZX!*6I88Y!9\'QT>9&3(V I<8TD-[8S0
M_0:-(5@3G^9=2)&<7/C8)._UD"IEB2DZ(AU-9$#]%GR;9;9]9^7V->*B8;+$
M\>LTTDM?OV8QG?ZCXY_2$Y='Q][Q6_H7X:4U@L<V0M*8K_P'IF4?\^^V" J_
M3(J@YKU(63;+0)!%,%3I<7TB5_PLH75O/VVW[C#^6S$-!$NFVJ;C'8"+V?$G
M24XZ1'1+ZT-]$P;G>P?IZ]^<8Y^JKVTD'I!4*U/B]W-6ZA289@THZ[D"DR&&
M<F:25L%C-*&B9$$'3LI>%7ACY9?KC+'ZI_?4/GOS,NF4OT F[@U]<4!F*(?J
M_SP:A;*A476[LDQW3O/BK_!LVANZ=L(E:RWZ=@CHOI6&];HJX_NO$YZHK!#\
MW*Q$T<RS7QM-(QX274W<9OTN.GJ_%KWT/ZFQ)F?=5N4>':,6[=K$7"[]14[3
MU11MC7.R_]0W_S\U$U9BMV*[Q[4\Q3L%C'(74[N[G]_T\>(9/2*,EHJ+G0W@
M(M;X5XWH'W . PWN  P[D@LF&\9!QFYKRY<$BJA[$,QQ7 5=X7GC+F*"0*GL
M>XK? >C%U*\V.=4J;_[Q7ZOI'FIV1&5T@Y!1$_<+F?G-5M@8O[LS9SZYER4Z
MWS46K_D+A\_7<-GGYE.KX'BIK6S6//_32W.#C$,VM-+_EK,VW %(D75J<._(
MZ8M#1;-:ML0CA26_YC04V6:Q^C>@"-UL%:K*X_2F0HH6(>N82H (B JOCO6R
MH*ZP>5]"7>1_=G6/NCR]DY<.+24KLB0,PY-."(2%TPGL[ZD,BA+?[NIA]SVZ
MP?-@B2KBSEF=Y]+7*"_I;ASZF4K$*&Z)IA9Z+/G4TVG<Z3JH=M2&$O7&)E=>
MS,PN@QH5KRZ+O+03&(XOV;&Q+I8B>+! QEHP=#^Q96;1[-*\-6GTHM[O6&GZ
MA<@\/TZTWE2.V'84E6BQ;L=&\WJ8*9/S,-"+#2TOLYD:-0(R*PW"N@/41NA^
M:@4N+B[/&]#@"Q I%31YV,=@6*+-;Z>_<?RU/O^+A:]&L1N@*.MF$B#!:P#V
M9K1AU:A6%O^M1?'J*>Y#B*3^&3"R&E -2H"TP9AK?=<>Y%B=AT'Z7 89/@&6
M_&E_;+;(""Y3UN5C^-#)?I9\@F+J7G&SX1J;M;6UH.I_V3.Q;G%"4K B2?$*
M9H2US/2>/<LAI@O?Q=W[O8]H(2=!=^,)!-R9J%_8P?*"VX4H?#KF#M I/7@'
MD%*X QRMIA.X9#:?M"^3GMJ1&/?F]459> Y\K30S2Y,5V8O2/^4 Z'.B==/R
MC $9S<Y3E#Q?/NK%.3XV*R]C2X,=9I[T??(4IZY=N2D^G.UM%?ZWN4Q(G=)(
MADG"MS^=L6(2UBTZ;N?M[!F@.!&U42O7FBQ9(GPO6(2)$J$Y *<XT!=EQ(66
M%1-8G4"6N5Z2LZK6_L@W]."&#&$@C_CPR_S9=W&I4L\&@OZM4?7Q*1_QAZ$G
MP\%TA(= @D*]GT[K]77UJCVJ723M[73Z!Z<E<C0&2C43[QXS-(282RU*,0)'
MT/LYAU ,GNI1[:[G4Z3G8:[.SXZ<WLM-BF/UEN(IPWB"A8P)X5/Q!;],B:N,
M:RG%M["/#]/Q4:&;0(:U/(20/\C8PSS@^^#MB @= ^,5*)%@#G__=&25=4XN
MG0"2V1PE@SS*-E;X:CT5,ZLPZ/_LA#+*V_$*5#2_\,K5CJ:[.8Q)B^V#L\@C
M2D#"?PFUMH!F][X8?P<H];^DW-Y+043=^(%0C03KX$2J&VP:<A.8_$3&"K3-
M[0[P %4S,TVS FWYM_]3>A;7U:J.!!=)?PZ3N'6!FNO(=&-^JJ$5:(&'JJT2
M>HU"HNA%U(=#3SO'FGNUI<U+?S^QI\[PN8F 7&9NQ'&<6Q0D2IB+>HWNI*]_
M3,BHB1VL#GPU^?7EC:RZ<;71F,6WR91[.%KXY']SRBZ.-JY: T.N8G6/ZSU-
M%<LLIB*Q ^>0@-WC75&FUO<8,<";2OD)4.FX'LE$$1M]^!-99XWNH83OI;W?
MPP?8UKP.<A9.Q,EZR725RI?1@%+O7EQW--U*OJV8@!'8B I"@X0E$_7;IVX(
MP=[Z8*#T2QK I3H2A.>6LYM,,J3W(=S/Y1>%L/7N.<13K=RS^$3'T_;!\:3A
MR*&'P.<[ /'^W%9'CX[A)3[UM0NJ)BT'<K7VD$@C:E#]*+W36Z>M<%>0EA&^
M>-!2TV]K6?GFC'R+Y(NE3N>DEN6I:51&:.Z$<4M46GX.?1$)XR-J2J5KA::B
M'_=)7/L_1;Z;_QC<3PF^3)7P!%O4XW:]=+Y:!]7@G- %K.'QR31.<.<H),C/
M_]J7O'4N*X*@L.KD\WK,W]EO"N&>D2!FZM4)0^(RH^3>%@KK*ZK)FXO_%NPS
MMB(D=C4+A0FDT7;3;CNMGU"AW(4>-N"&#1ITD2G1Y"1]6WD6SK,QUFA$]_/Y
M]<>)-)S/GCE[IP+VG9H9)1:N,\=;W]Y71'3B4G'O;Z[YZR!(-N63^"HVAA?I
MQII:,-M=YNSU#A' %2?&#>T#(^:<^):X9YR0!'X:G^ZWQ9QFY@(#>(337_JM
MQKS'BC83OTUJ% 60HZ435U>#"/?_:FOVOSN3.48)6&EE6&0'*YO #/N\@T+'
MX33I_J_Y#H=3UV'CU"!6F%A/(^)Q/HA6BC#*^PXPU4(D?1\Y2:?X=S8";]19
M<NP<?V<<K>5P]\03_[\2_=1U;K,1=!THN;?WYTR:Y9]"SS3J52>JM>W<.HGV
MH^FYE[H5#3H7_8[R&W?PN[^I\]A+'L;OKAYQR"\V3QPYAIO&?.CZPS>M61;@
MWDU"3-3K^% =MZAGET)/39IDXTJR>_9,G;9WM2KW=>B%EO06ILBEJV-4AX^X
M;JB2_K_90T4- <FVOFX11J)7@2SZ_K5G_EOJ6IAOI%@R8/;?NAWPW^<"*@11
M3R6$3J&F-7+45N7DDEDON+=?#:ID9-;+*(^$6JV!*MV,-]EF3:.^4DP#T]3=
M ?N6I:[MJ6PF9$@7<4V;[#KFW[:1DL%F3.Z1X(QT],PJ@5LC?AJ<DS<Q[,P&
MEA??8!0?M^BF*IMQUU9A7+C74G,U545Q'PZ0E(!=MFR:_ZI90L59&;%E*@V$
M"#3QOMKJV(P@[3OYL/0AQ\'MJ0NE4?<UYR_JE_PY9A0? 191[H ZV<^I:,CP
M5/[Z-O]K"0.+6JJ)Z./*+>H[0,V!!D1R[74K*R(R*T/<3Z;63X;IL:)-*:F/
M.,X_ N0K8R]86? Q4M*H8MRL7-G7J5"YBK#N^;W<24C:(?-K,D@9+B$4\[&A
M(L3OE>]Q86J61,WL3N*O@IV$NM&L3,/7E1P*+_JQA@A: /K_$3*Q'?PY5M<C
MH'Y)?D^^]C;:3CG.A:&3K&/-CCIW@&B_(U0KU1U INQ#T*V2%\=[MV\$D=[9
M<5K_G8'%)WFDOUU>2-J2XWWR@/Y*-X7K]4Y/9O7DJ,:/]".R]U0&D .N,2Q?
M+'\T 0%B'::82N;:,]/[Z($F9M+H08>_"[(/X$$OCF$S_:J@Y58FCC18"TLQ
M:6]</)G7-_AE?:CY+OA9;)6+ HU;Z5%WVC'KGLD93 CE ^Z7P+T#_!)%2%X?
M0[<+ 3F9GJ8(XS(+5[!5'N[BVY6?Y:\Z>%P8VX1A2SECWD)@73(R46BP4YG@
M%6]_ >7E!^'M +>;':C%3!:O=64<AG0U1B_]^RH>^I V2X6)GFRJR?=8NZX:
MZ,A6'DC=:\0C0LAWE;<VK Q?5,D2^K_ 7#Q@5R [A%C/!8H,/O6]8'OSF>TF
M;A*1BT:&Z2UG\FT&HW2V92DQYLF";:_P' =!>-JQ2C,/ZL;DBFD$W4MYK2Z\
MU"G,"R0WUC>>\<6K<.?@@E'1MXG6AWHR Q'414L_;E8''PIB:BP,'](!=DN?
M'J6""^KK0KS1]]].<%JQ=3V8B*<H=5QY1(C'I_6#_D2O(^%0:D>*$OJXE=48
M\EWKN_P4+)3S]%$6ST!S9%'=/$9.*^*PS Z1L-Q1L'X'L.CKP]?>W!1?]*[I
MM;2,1HT1/6/3>:KH([D7S]<M&E$;=?WJ5;[)R\@YUN FF##&<RB?%&T&0JCK
M O44GGB>FK)Q>0>PO$=0D*9 ?,>;(D808JC$#.[=VTWH)CE']-R\,HWG]PP0
M)(:HZ[Y2/0JR.0VCJK?-3C#_5OT4$X=L(JI$?DW]4O" Y[9/\E04D)]&<N-8
MM*VY:#DG=P>H0CL?R/%WMX@=KR,ODT):(=!01$:"=M4]7Y<-WBFDW]X!SGWV
MV=OP,L-OGHVWRW;.*S=%MO&!DF_HP^_AO$>9-$&_Q*!H.@WF$" =/ZU'DM29
M#?A**,B3Q_0\;&;]^*:C*<0[0.;B:K/0$DHF,,AH$*6*&/2MUFMX>FFL%T[[
M@',G];+4=37@+"H Z)'_%AGVP;4I7&93EUP.,]4+N357[2V\UZA6[90BJ5P?
M>HQ@LC"S"WHD!+@'.C1L:-JPW&BW0BMWEXKWM!["B5O'/3+^,=37#I@P'4\Z
MA'Q'&CR\??7 3HUTE..YK QFI)K(QYWP5'!+*R(P8N6(P!(.CHF/ 4.F!V;T
M@OI%R_+(2^5[]:&=+:".Z>22XG/"95ZWOA&E5C"=3,.P][=T C7XC?YK4:[&
M;6_U<S?#+M.>,7'PQAW@L;4H?B(,7!1%J(];1,B4WO/^J6-L))Z[Y/ZUO1N3
M:#,OL,2*+N$]WH6T6%746/->QS0M;2VB9AR93)*H?L+<7TE*\:L7;<E'7/OU
M="O)WM5@;;SYZHSWN$.WV<ES'9 P:VR:M4E$XYRE,7$5_-:/RKEQY;DA6X@P
M>Y2:_(;*^(TF/$RI-?2\9TR8.T,L*YIKF</]S3T*.?WF:;\29N,A%W'XH?9R
M/)R(8J-<-/;GF@]!@ E^-3^\)K<""B8YF-S%?O/;)[CW':;9D8&Q"-(N'4Q+
MUYA,)?SI\ !FI66I\? SG_^N<*GR*K1;E7=:K@:.JEPV3U@FE.:6T#61$Z_8
M!;OV+I-4JPHI-8U77W]I:4EF)#^.7'\0B+T@?"1%/?Q3W'U[<1GBK?O1EY&O
M-V'UA10]@8.C\;Q7WNRN[KUWM-:&KE$'SCX[I*#9Z_5^A-3:';7UE'4J(4]Y
M_*( Q=S'!-OEG,M'VVJ+U)=+R3&TRNSHQWVW<GC\E1L\[62'"_%RLI'8J YC
MH*^+E$%I#+GX)Q_? >9P41).;5F@JATL)OB&'VV$%;GP'>"S!L:'5DEX.&^S
M%B1(75Y&)^XW+]8!*&/*Z0"LD+JETAQX^ 0G,:#N\16(T!G.UTGFZFCXRS$_
M*'Z@EMGPPX\[@$NC%V:'"RT!_* G+0]XA&O[->D;4>SI0Q^)#^- \7PP'U@H
MV=Y,,-GSANVRHOE8XMN@*QC1>@-AFN$'[)GL/KJM-3N"3==*4C;!Z='6T@C]
M^U[Z2/]Y2/'],A;_1\3P^6RX5Q2M50V=TT!JFUK>GA0M;C'$^T(Q2&["&9LB
M;Q)71:>7'L.0^F+(T<2X\PY B[@#U$O&0TQZNW%+(4YL@$>Q (+SF!:R-<%F
M?H*@"VW_Z]G,)_+^?KB//]R3R9ZCC-@U:/?W,!,)G6KT,4%&":W"5,FC=*CH
M&%*V2"BPV<MK=2#$Y%=]]%J$_46V=OL=H%6ZF.X1Q*!WFO1XCY:2YU.59\3+
M>#->_&;;7;X%'?6G.\8\\++@XK.R)W;7!O6F#I%4PC *:K10P$59Z/*QVIGZ
MA61&&1]2C]4GL:,RZND=X(-7TP%75$W <A5N9$M5\I&G6T%WB2=#FM87F\C-
M!27B5#DY>V,;^/RJ2Q*,!T^QP-AP0?[9 K^!V3L, .;XDL_+9@U/29ZN)DFD
M;()DE5<FUY+\5>5\T$+O)ZC^59R%Y;"AHZ%0@#<Q$MK1Z-/F:][0J/G%:N9)
M*@S@:#0(\)Q=TZE']/8$CG$OW"9PME69X@OVE/AYUQPEVP6<JK)TS<[NU"*Z
M.O$?F6U=74W[0^:6CGZFD29VX5$-V@@,SR5:SI$3Q23=%,WR0X-19%/\,#?:
MHD</()9;]E06%"NTJ@#>\=6ZP&*@TMQ&2VBO("\CX)/<&5H-I+N[9;B++GQ<
MSZ3< V)+*8A]O$8L!KG8,<[)\S0>%; C[<V<[>:/'HA3[*!+ZJT5?4<+'JA!
MN,&7UU8GS0FXJL=K>LRH7@?W,O-Z\;*A;>-*XEG6"G*9V^0:R'_JQ*/L =B5
M0$#==P L?8@\J'R:_P/IZ##/5<YUT;.3KV+X/T#E5G< PF:N_!W5?/DB@U[*
M+7:^+][BQ,?@;F\&9 N*"1+8*S>R$F-@F=TE;[6P#^&*[,<\'@2X>HM6T@H@
M9<%%<OOC<SVQ/UA4PC&FZ))8X462CP3N  <$& -FG$VJ>:WD=>8B<Y@C.(?5
M*:2<!+CS.^@/ VH)%<BNNS_WG@QZ3DQ?I.$#U<MV:@\^1_\B_BH=Z__KD@GH
MV ,5!<Q52<++O04O6^UCIMB;^V[:TQ9['.MVIAKO_1CK$7PIO!"@Z?3SP?QZ
M#A(O7: UVJ-TL%[1!:5?Q"VAL_7Y7*Q-27V.""6[2(=JG;\#2/$_J((GHA1N
MH,IIM]A% ZTX.[7Z:6$Y@5=3G,'=34]B\DV3S^B^M!W+PZX,[P#;JL;*\#"3
M\6:QM1#N,Y&;;RJ/,RI2+=&FO!D\^4=XFOE<7<TMT ,6L^V$8[!^+E=_"$0K
M4^^HD'BP=V*X,SWW?.B0*^H[J3I6$, 7&6/E"46$*<1*-8P[L0H)@3A&%88I
M<(+EL"^$64H]\>$E0]&9"[O3(T!MXZ_/\-J/D;NBD?<X<_"_ZM2M4U:-%,!Z
M#<)1\D_%T\\NB'L3G\V_8#0JKS[&Y=2Q.:NP'+Y^I;/+RY;Y))SLN<[7#7;%
M);5]?25]I4RI:3R8F$-BA1HQNO.<>D'I5O+6C<%'UC&5]*>C@E*T-Y2KOZT\
M5,2,(IOQU)00'UI)&Z_EOOJF.?8HI=DI+90RMB=Z<'^L94*WK[>8:K*&X+2.
M?7E;47V;8O7GFN2!B,P_H/,ZT!R!JP)7[2X60B@=.!3_JJK%HDT]&[%LS!9=
M"K,H-/ K7WS-++5XKQ+OF"KG6Y?>3G?@7&[Z?L+HNY<Z3.L_"*;RD>H]E";A
MGUB:QO7..ZZ9\+-MQ.5WI&CP2#;=+WI2".2FOJM&3GG41;XB'LJSE,/$S-^"
ME\G7)=ERP9(P^W?)/_HP_P';V86B0U5FZ3N.UJ+A:U26@7I1VON8C@?&!O;7
M4I8(8WX-*R$^*:J'=B^XY4NQ!@$>&%;@%'A9!+\=N8$B=Z+(Q["'"C]LS&\(
M-(^,2 #$23FEZFK(@$QK;Z[$3I<CAF;5&3'\*0Y>MRL-3+U_?J%$LYNX&A#W
M*R,2,B="S/NB_9%S 5N&)4NLK@5S(82TX\AQ+M:.03P0=%S*IP$O+<I[:?8@
MYF5LJ\1G\;WI'1S_=D#H?DYD$1Y5([!933.H\#*SP23Z!".#,/!*5GSH:*AP
MNMA3:FS-R(CY@ZYB;$"OBKV>"Q1?VV <_3#%<4-"J=J6%Y= W?J\O*&;I<':
MTD'N1Y:D19-\RJB11,X*W1.K;+)JWH+M]V)1ZYPIR7,>+IQ 7KG.?.=G+=:0
M4!T);!;!Y#&EKC>:LM;TF:'L/O^);2CE#WTN?'OUP( 2&B!0HCAJL\_\H)&O
M0.=FT$*TW*\YQ=_U@YGFQ%H+E3I2W5TS9\(VAD0S)N279(2DVL@^M/J]WQ2]
M4&NWZSILJ9FZ-]C25"M<?'-8'2UAHFM)_76H_L>0_*7.QZ0CU:$^W#>>F4TT
M/*M7$9766C$SF\+7W@(+G3BR3PL+P_$[LKO=''HGXFQH\"TWB+VR"K27S,5H
M!,?5@@9J AB-D33>-0ZA^NLV=2[NT5_>E1#3YV2&RO[-C]X(@7"MK 0&_'29
MN&=.B1\(D&Q(PEL]1>X $G62B7< _3HG@C )TNE#6%7H07K#9P6]B<);(5H^
M*9I!8A^_!YCTQU@Y?Z^C#?ZWE]F9Y8$%CWB>AY,0?XB=RRF%]I"UF<%O9MJM
MH*Y^'K35%)-I3-11P%J]&KNG#&B#;JP+7C^!*+^6 .)G'+X^&( R 3C)M^^@
MF(TZ[PT)[7E6?^,D;9I(8*L$[/LN\1\^^)^U\T_CBT7H?:K^\DJ13 (:=WUQ
M-'1X.6@WIO&ZH ?Z]+'6J"SZ7Y<U/>-AW]G/Z$*36^(K[5(]3BAY"E@!H*F:
M$Y*+FQ_86R@SSCM !@Y@1^()\M(I:;[C:GV3F:!R<AW(:7'HX3B^,,VU2G#)
M_14ZHP2]36V"AAL#^N\Y@'J6 4E]>&#CVR!6NMXHS>49T'?/%ZZ):X%A3.%Z
M<RY,J5MF&IB-GG+(6+N5[9BA4?2>DA>7C ?D9Y(CKJ5XK6PWTO";$2-DE#RN
M*<-//+L-VRLA@12$K<B!!.?\DD#G3!>B>V/QTMSOG8/44?ADVY/MZ<1&3NXR
MA$S/\3!'SY.,(0_/]$T?<;XN;WZ(-X7B6@IUQL?7EA>E\MS$]_JM@I]T@5I9
MX*JM)="-VURYKS1AOL<5:%$=]250Z=C.Y0=ESU6/EWJ#ET0(%:A40B%T$6*K
MH+!3<;[5M-G#,RS3^AHKY6[& +.&$"KI/:0&>ANVI\R4<UE(W1)=X[%$+^!;
M[@Q\F9U\L[FN1[\W^$B"X>V2M;O!_.Z3YO=S"[F/?40X>SV3YY#*WHUY/;A-
M&UJ9:Q3K@/-?)!YKS:/SGJ8C%DE^\N1U']]_!CR-406X"M'R(+C2.FW4#2?X
ME\NM=;L]ZW/57KQ]#$.4\JD@V]=2K,?F>I7'$_9TK'!5$)U?H[>H>;P)] ^]
MF:U=*/,Z!FT-</NXLW2D!A_[^HA-^T>>Q<-9^I<D,12=RO-3]6;$8+%^4NEX
M=L&IO%/-8C3QJ2&YXMT'L$^*..:O['TP'1P-Q:.ZT\@LW<]:TL).UP,ISN&C
M;LS$/^R.HE$D&0C6GN0.R-1PQY7YOKN[@AD+(C'NN<*NQV/0#T_YRJ;*B155
M^6["O41S7A4PJMB=*+5UXL'.,AUS)*P]^?7H"\OU9OQBT2=F[_&L=J^:YUC;
MN01WL3+BO@L3QGQ8*,9Q8H27NL+(;F+N"16TA0 5(I %H[ND=[>X]3"XS]+$
M#RSD$>KW$B:2+]A.]M3:5?S\+'()2T+CAP6.1,VOW38B;Z9MC>RYTH1:^R8;
MW>1I2Y9&]2#O9U7PNG98X5+@2UDQ0-'D-U]?Y#1>WN]EHAO=JZC@,P\#<5[,
MCL[GN]^,^]/3?M]:HM6.H.@A_F^0YFLT[BARX+Q1YL+E6_E'/@YB4XF^S:K.
M]O#:"QUE#P,WFYM.RE=/WI#O=!LB?B2+(!5+YK?K2"OGY^<+H5E]Q62;QO5'
MAFV=PY?/*.O&K ']8R@>9"<H$,PEIFJPJ/ C+Q;?A>TH\FS44PQ9E _6OX3?
M 8)M.DP4%$)@JFTO*#@ZZP G>E  0]3@%,L,<#C.ME?X5V%%OLF<5;P4VB"0
MX&I5B@;:518RO*H<-^94GY6F'>W@X+AA0=Y_,03^VH8L@0VBJ<V6;'?,;9I]
M8TVXM_L)FZ,)UWR@JRM^&&)S7&<BT[G"A#TLCND%MG^4(9'!,H6G0;HU+6YD
M_]@Y;E'!!BC\=?NY[S23TZ[H"*8S_+J++)49GM.: ZT:_OICWQ!G"D&:YYBU
M398<D!.[-/S0]NV3E3H@ZA4KO%1[Y>@F=D^RH(B.Z,9,R-^3MXYT)*BA,;8O
MY'LF-5&,&!P/X-;=>[]V#8,48U5JV>RT)4Z!LH'R8PF[//?31<:>@36"H#J)
M9Y5A_<GD)DYV?7K$'Z+L^\KH)K,0)$<^5-J30/M'7U5I-\;].<E.C0DPYVN<
M3?"@ZT%[=$>&T.V'/KS\;>&TW)/O4_M[[X6M^NU2AMQ[+7+=]<A@F0#UW%HT
M+QBZ2H=@+E>>?9NM3NWQ&598>;[M5KSL\Z+W/.*]3=CF8^Y]Q_!)+UD=J%68
M1B'@A"COUCX=WP.&45"Z#$E@JU'&J*VKC7E=^5'%K2"Z[VQ;4O2<!P>,8FR&
M+QX,5>6(?YE"$&%%OVS";2]%._>]=%8%I'[_L(70/_LXQ;\(ZB3SZ[A:VH@9
M.7J;_1BT<8BI!%A%$4$*]XS:IDK,:ZK]A*M8N%:Q&ZK"?SB7"<&G@TMOQ!!4
M!HGJY1[S\TFL?EC:!68LT!QGDX=MZT)K!!<$J  ].@*!%"$Y9%V11!ZO3.P
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M1WMY&7W(6//]K&QTN#*.7SGQUF.K-4FSP0\S*340^WHH_!D,*G\^8O)?PC"
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M5JX?KSHLG';V+PR-[ O:8L,-'O.=F!$NY[/M,>6Y\LA"*/7R$-^P(9J&M4-
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M+@ J4R/1#P"/]0&)%^QI3$RS*1".WDF@ 1.$W7W66X ?;O#=LJFZ6 O'1NA
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M',<=+)\6;M<=-IY:[9S:4CLHI#,T02]'B&4_XO=G\VHQ=2C"N@-JY"L[,^P
M_O7EJ)?K?_QE6IM;$UAKHC;5B!IQ/M*P7[T+DK&-0C/< J)N.-%XI>[.*Y7L
M8ZX?/MG.,V4&J,I(7%0E=0$I(4CVZ:<3]=%6-F7*7F5;D0]7H/,2!_+,R4K@
MNR<[^'8_8HI<23"N&C1B@C\W7*U/:!@?TS!WG-6O"##MI9W7>N8[F;"GI%*7
M$2="@TYZB=VFH'4XV].&B9C&U?9]WRLPI,<+Z-*.ZZ01@[Q$JKC%%1J@EOMC
M37K-S2D&J2VLOW<M2&BFJ^TDGP[Z LXE>:"8T#6I.'S[B443AV/SL1?[>EB"
M0VU83K]/&X1&V@IYH$R%UHJG1JR4<W%OU.1*)P2/4>(<"1O2K<71#2,[";HK
MC;IJ"1J2C4G$K1+VS.S";@1W99^@21(*B[XE%/8A.=/95WQ)N'#_E,#XT7/]
M=>,BVOO.U-,6NX3JO]V#&;QPJ[1++@U H6@[4$B?*%P[LDXE_("74I*?SOTB
MT,PRYFH<7Z\*JUDS(6T%#']?W91H]TRZ?P"A'.#42G7BW<\P,W7#3S2H._PP
M=HA)>XC'=F_-+F(?]J2E:5R7AR!5<&!?&;G7^H_';Q\Q&(28352*2)DCE'Z_
M>T7\W,UP^S\TM OS@LBC3+AP1]J\"XB<ICLCY=6:_.V.?&\!SY906K7G2]+P
MUW_22/!+31 S']BF3W<JWS-*HO?] NLW#)(6,=[F#WKQ(L];MAA2L2>ZI][2
M9:7(\K)HN^;]ERDY=<W0PUFI"*BN$O$SQ_QI31&/?X1 _OW*(S=!5PYA6O*N
MD;&:5':+.'/Q9-OA))UGIB7>^M!51K;Z%!I4YE+5,4AWO:BRV;WKY-23IE-7
M)R;T^6EJ8PZ,I!;\6[VH@S:K_>F9F53)#?<'5T7R7D+E$,(<'-U_CDLGJ@\=
M,[02<N5]^Q>;#,AO#1AU+DLZ"ZFMXN7G"&AM5&D$EL(481D=?'D_T<K]3(IL
MTNJ_5.Z[4.+,]E_);W]9->? OC]CD,.4G5;B]J591%8\V$SU2!K,>,[TYI+,
M&![>>T3D*"H$;XBV>QAO_3N,2@7X$I\*>4,C%HB#Z1)V\F%/1#CE.G9#)U@I
M@OI\H6[RS/VKD @X)$Q:PRIOT7AQF ^QJ$;+8.CN3/=SQ"OH<PXT/.VX,T+V
M6;@J^CRZ6"W/&"2\RFOV.J?-)QXJ?C +\U?"I/FS>>)]+X97SN:*;YOBO)C:
M];WK-T[)1R5,&K+&W:;AD.>4Q>#A%])<>%4D/FC01<N6@&B09<%JUJ-LAZ7
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M6S$"'_VE.\QKC04)2;27UH&^>_[:R')2JNW$'=\@5^XA&T\YH>?;O<M)^M+
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M=3KFQ2S_>5'7<-2">LD:DV_-]D/?,/)[Y J@-^U2M E(C>6>]+<JOP78(RQ
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MZB<,=:10JII<\8@EB,V&*._4+/GB?5B.3%\'Q>ZI(8/\C9"A7PQ/)?0J0"%
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M4M@@C3'.M*Y4(#V\I.V,?P_2%LAN;S):&'+#3*0T?N#D#L/<NV-<:&*KJ%9
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M^UU5^F$YV9WG/0"D)>#=) U)/:4#6K//L!HE$Q_C\ IS<JF."L;4$R+7TWL
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ML!FL)V3.',]3#33^^D6M/CB[0\-RX!TR?-_BX( C=7=W&.V%Z]<O]Q2(_GE
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M;GN]-#9\$:(0D_OM1IR@'^%[X.H9TXY8%%U&QAE/])&4_LSO6'19?I=__1[
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M5B[<)2U4NQ,FT( E-(/&C"IA33#[LN^DL D9!"#_)I9XJP/[&!@3BO#J09X
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M5B+1H^DHX0I9UZV!2"J@RR/>;%N^*^O%#*)#T[I%/NO20=)&[JF)L?U'=];
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M(<7:C'2U#MJ!RX*#O;"!PG,6SLI4:XO"98Q\FAG--*,B)<XG)?N!P4%2$ 2
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MK.U>U]FC$]VARO*D,S8?2GV[\#NS3 GM5$+7W=^PI^KGG1!OA&YF/7E7WT
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MRM/"1[>)X)+ZSQ<?X+3D]X4.SW1+4K^N1_5L>/3((A!E2KHQU:!_O3VGFM[
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MN.[3_P]H[&T^+>P^CD,YU4TC XFLQH:K"GS%5Q)J:-Z)B[W'F)O9]P_O8D$
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M_6S/A(9$FQ:JY2*S\>RC&_(7!)(5WA+$9KIXD;_2_-T'="*B!N2 >*;PA#8
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MR[IG0U>3Q_I;T.RLDWL"A6DSDAZL/9QJ1 ]PO(+EP:GOJT#"_4"@ 5W\"H/
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MSBKK6+KC)FCE+6A4DE5'\/+YA8^W(X?:>HE(5KG<GFK*[$_3<@,M1_+*NA/
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M'*](7C["%?0[19<D7'R:[)1X R6*<XM>;:8]S:?)>5<U34S8S+_OFPH'M+V
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M8UU%'2^OCIN4]WB>5%NANF^\![^UIUO9[WVKJF11:.ZA>4]3(';">Z_;75N
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M^[ 21 XKX=NNO].6G49+XA]$23[YY 3"_Y\0&.Q_WP'_6UCH_@H!M+X*.H(
M6E]'[GKP'8/@^>W:B(30_!6"U%]BH>D8A*:?L;#^G87UG['0_!,(?RT1)Q!.
M(/P1A/+L>2)S09<-H[_IE0==0A9Q'_L4<>P!HD?5.88W>B#G:G%6MF&C>9I0
M;N9BVVM'IAN(D0N#>/3A"L@GV[$M-BX^!)#&'*5_)EPY^_:'!1'^_0SD((8>
M^>/L-!&C!1')^TO\#:7[CJ9C7S1>-HE%WHFK6YN;&+HS[KT !PQL(2Y/P/T-
M<E@O<L$@1-:6DU?=E]"IJU89C<#+^=/"H8T0D2W."(AJ%<Q>X^ 7WMX/WR3M
MEO>WH#,C"%]&+1Z/89UVGCK'FD&Y"^#I*1!DKD3#%@ZP*V?GJ(5![,U,4;?>
M+]B"MDH15\%:Q'F)[X@?E#SF>/.907,#E^F6Q\REH"F4KM=B07%!]1N<GA#5
MVF\(OF/UUU4>$\[<.-.!;=S=9\]8Z+@?1UN;#0?H]R&J$+S=#3R*<%.5OA2A
M.QI&I'$ A<UQ/QY"U/K=M318OP\.0.JT9>"L R&+N^U3H.W!]9@@4,ZH1C\<
M\#48ST5;X.ZN)VPO ^<P<-\F)%'\=\&Z9;4YWZP@/0,//=,=&OIGB+'^<\1^
MS]V_P-A?=?F_:NQ?AO\O2OW)7/[K@?T;X/\+R_\OB_V9,E-R[Y&6>X 6_D;N
MK;4GXK(YWU?";AJIX-O;B-E9V.M87=0<KR<AS"LQ1(I<.@>Q!_CG[OSISP']
MIV\"NKJ7 ;=8"77+U.$ *UFQ=TME]7'%N%#W(:.-# [LBZ&(AV >4\15GTGY
MB9EQ;[4MA6)MFK7K_AA_4/D(UJ2N23 <X+58 0<X,"D(OX$#(H>F86>ZXFZX
M37B4/^S8SDB,,=ES62]8N@Y[?1T\RI=*/0L'\.AZCNMC,Q?A\U^W=[(MM.,]
MY;"L_*"I? ,S<)W)IO(SS9!\N>40]\"GT![[_I$>)O??6I)#FC"UWJ%TA8A;
MI:..^]DL###*[A%D[6;G56'JUV\/=\EN,]W?O.GVVEM86;M*;3%BA[<3HJ>+
M-R8?7W_U]'NK&MN->16O>.1'-_ZQ_V82^>4XQ0%:R0_6-P(CES=2]3G5%87:
MD\MQ\ O#*/('AL"X>^DQ%]0!K8K-2R\FC2:RJ$9W]H/ >7JVPQP\'!<O,F8V
M.7AG]C(QC00:DS:EQZ$%D+SH3HEIO50D]_YYZY1NJJ:R)6KD/KF >/S[;9>'
M/(XA)K1;L3CKN$ZG0_?.QAH0M"9&9GH9,U\1W*BA>);NO^'^J)YLF80-ER-$
M:Z$]WS$U6NYL=XM<1YAW!@WC.\VVIRK""V7J[QIV72E:T";8DFC-E,!9.0-V
M<\,X-5KB]/GK:=O=!F.E^=RK$<QU_ 5K6*7SE(*T3[(+&83UKQ+K7*LY96^7
MF(4JZN/>Q D"#EPUAJKGYP(Q1JH2AP;5[SB2:@UHJ+[<ISKW\4VY@_/'*VQ,
M299Q@I:IRH)3GS(%J>ZJ#V<+XDH9\ _3DN:8Z-_([K]7/5VC9-CV()PUN6W&
MF)VS)\:*)MKBUGGEI12+;8ND=,4J?'*/\PV!A!?&P[":DG3*M0.H$IN<7F X
M..QV9K%(O,FG+\_4@G7H2U$_D39:-_4?G)<<U>E9'<1=H./M2-BK<,-*>V*M
M:Y0B=KGHXUNKY[6XO/961,.4?LW/ WS>.].H2UK ENY>1*]TO:W"KBOOTLN;
MZ<.$S1[";WR'^?8K:\Y3X\%77E;"QD?6C-&4W%L^:[^>W>U)%? 6T0EPULN;
M?ZL;>KJV,(G6L*39 J9T/[%[@&FPX'3Z7=;HN@PMT;K*T@YB#WE']P[EU+1<
MXXK6"=F(JJWB%^\V<08@,;ROW;8!XZG*PH;Y-U@PJB\QH%:]V]/HZLK"?[<<
MZW\G6UZ.-NM=( A61.UL-AO?\LB-&5U<EV*M3LL_]IFAAJ^#BX'@QT6[TR[D
ML3?_%2/C):H^*!L<</,B:&^*JO9^;^:.*8S[!GBS2>;CYKU6YY <"5Z%Q?]K
MO\G\<S9)\7,L[WRF1%A=!6Z'/-KOMY$CN-F+&#3?+ 6M \=4EN(2>)/Z.5.K
M*T&23N<*HU:6'RV:(D;\8/!>=RRIIK$Z.5O#E,!K)<2E]6G$+ARPF7P_:5,8
MWR+<CKWI]B85'#"7EKT"$14W-K8^5*IMOIHEHMY-8N%!?7;$Q%8V,\>3*Y=-
M2@G_GEY+JP96KG^AS]BI"L)51;20#%M\^AV$R90@P?-=9@_0N03@@#;]AY5X
MTC8+EG3&C!]K/E[.\%1T[I0M9-1C$_8;ENZ"]"O:@_?U\G7RX0!=5[NTHO2Q
M@M=U0'^V%X2:H,G2UGUHBH4]?DYV@8+_E(4JMT5=NO89FP]O J8^)JC[8N9J
M"UT2I]")?/*/WJY$[H2)W'[)D5+C(N9\YR/9I.KK/CE0;GD1F')KEOJS_S:'
M4).MMPBL-1<."*?8E2X8#E=11@D-3;<*KX'-0E-XEE_-1G><1\-&:3:&RF<H
M?Q64V(_0AP,XI-9B_((FUU3$KO>-#H/\\?$A"6L9S_Y&**Y!;$M_Z=!D(F*$
M@A"UU=ZRRX"NBC5X+D#4=L<C_ EB8,UVK=</6_&!/S<4XZ?6GU$X;HOT$Z,!
M-H/)+$;T;Y6O5X,H0=F+X&D7>VD3IZUGQ>%DF<@0F5FVQ295^[]I0[AZ858)
MD_SD<$"VFNFG+60SWT&<@U_5P=H#B!$4)C1Q$GVA=VB5TWV_<U<"\0"()*SU
M""K=$70/<5B+72O&<<@&7R%+?C>$O:4=/&ZK!G%:BT'@^ 7FXR+/_T@DX>]9
M^<I-;]XW"-]X; #VAVL[+QHMX3'G;Z/_C)J;X*?6X62Y!P$SE_^"OA]E?FKG
MFTS!G[;S!S*'"6 &_5*&:]IY ;P4T>#NB<B7W,\C]T04#O" G%_RIX$HTAYD
MD0[\HDBC]H.GOHJ,'DGD'TD8_2 QAI08^ID-A[\K\?=MG$C\@<0O,A<$.2RD
M47];;">K-NH*X%J33,91N_QO\EV4;N0S9R5EV3\4B#T>!/)B2MU_]>]>W^N_
M8?,)< $(D4>_Q!LUVZ>J,V>N[GW'^0[F/[^X+=91HB^->"RZ9GMMG\J&[!P[
MBX"TT4[PS$-8$!RPD-OQXNZS034XH*R\IU#3:"=D!SQR"G'7EA->25S*Z0+-
M1\,!BAT9E<9/GNC5;0@IDJ<_'$)3)(\\$X?\I-\_N%%0Z,:_Q/2B8$%77&_%
MG,_?4ESXP$,OWRWML"-+!R5ESX!"\0*I&%[%LU\-I.*T)>YQ<T&^U6JNMKO#
M"*Z42D9<5BJ0DRABKM1F:$IX'\QD$$V! T#G/(^D3&_"VITT>K/(ZPY>:XV1
M@0,B7O,?F69[#>&+^-Z8\&/CX;NRM]T\%7_B\^!=V"Q.G;K-7ZDNV&SQXF)]
M :WXS96OK^A\%SJ:65$7<QOY%FZ8',S^,O!("/GNKECF?#^FIDVO%^+1]<C;
MD=31E WO>3[^-&OT(U^@,?)N\/3G]J;7$*%@I*;<+Q2WD+'\A+Z@?[ M#$$!
M%X)V6PGOQ9\3WY'0M[G@<H^J#CQ&<8#Q0,ASYW@CI_Z/K4@3'F:',UM^'^BA
M6--1(Q_OWS:!?LWL UB'TQ^E^F'FK\BK.,K)TY)W5@DRK= 7>!N+1+ID'6F3
M7I/!I\A6XL-:7' 2>RP$RH5Y,5LB__Q_[Z-?8K@H_OM_1OCOVD0W )[(2YF4
MC-%&! 8$<2D;&%V*B+.R3S<V'_=4!\69B;-E7BNZP0P'.)<[H::BP '<Z1%C
MMX:UD\"]O+#<^AHX8)5]I6TS'[AWUAR(6L^,YUU1&U3>DY.R$MKU1,\Y_#TO
MIASN[%_Z:O9/Q_J,<P^Y&1J._7_%Z0R=,?N#UU.F#DKA!R]P&B%?X(R)%"'
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M .>5KM2%:F$RE!+K:'&0^@0V65<H%$&(^36IZ73]K][T0@OST5-;Z74),/Q
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ML>*MH%*I'#X!?'"J^9]^(Q0V/@0 +R 3,3VG'^[V-O1@5%X&04)JQ1M=< B
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M:E\2DMT=9Y.A'_E$1.8N\DZ[>\IKW=,8=W"F[ZET5E&;?4_; #P"W<FW,NW
MH.IRD(>Z]NJB>L"HUO-/PNOIT+O;=@[&R7H%5C!]#3UTGAS2\J%]<FPQ^D(E
M)NJ1)=.F6TGS;3+<,FEQZFQ=5&?N -1S5#8G10.+; ;C90>(?4P,2E:(7K6E
MC;_-7;C!]Y00L$V!.?Q!EB#CY5+ZPL99/VM %N4=CBET;E,%J9I1)9N0S/AS
MP5F^IJGZ1&#3@59+"HGS5>4V)Q*+5L@SK-!<[&94;G5IY[(:GYQ5J(T=7'+I
MZ3+);NN5W54/MQLI6;@EE?-R3$[39?0Y7EV]CLK;%&LOJH7X=GH"+ ,RC4>=
M5@Y^LP\*+"N3EMA(RNY!>!>M_,1;ZDHJ2*UY.Q]T,%%EZ\:>X361"S*?Y4EY
MNZQ<"E:YWCD:P68]V*"E]MJ:-5K%*YFSB0M',L3/24M@A3 U?UB'J&-'KFZ@
MF\&@V9/+N?"EK(_,]/LUE1ESO9CJ=+[X<&R2-BG[3Z\,59/W#?#N+T\&XWI8
MAD)R:AEIHV(X%S_">PI'W[3GY&)KW5.&41>5%)86&GBZ*PB_F<CB[AX=$U,S
M="ZL"&Y&-QK83".CJ83W[11'##U@6A@SX_X8BADQ#A5YEC'B(/1 U.:R+HV'
MSAE*-S\TWE*P3H])=JZF5J.DOGK?[-:F,+WB("=C!018&_+,G\IC5K(QF2&7
MN/GI7,@L1M7"D];+)*%WLZE'/OG@%CR<+/(V$"KZD,?!>-U$A=N^.3S--^(6
M^%RO[58B1F&8#IG\A^WZV@]SS_+S;]//&)YX;F7UOM:T2U)9SIY;MSJ(VCS4
MOP29[PNN_*3"",+(LT>6C;YFQKL+!Z=L,?37D!WN\.IU9.&H7!&5<9=M>;MB
MO+EK<_H0@$V.N<*.$#*(W*+X%\K+,G-A,0K1;0A.BE5"K4D3SI*O*+GI4&&6
M=45*+9?*9&ZR>820@*VK>RDHT4"%"*K2D=J"<_KA$[3Z#Z9*0Z'+AP"IBDR/
M1=%0 [;@ %&7JVX;J<F3%F$<\=%2T93K')P,*9[O+\>%>-<ZB6*9U[!?RX?8
MEJ?4K[T+4L&M*,TJ*V:I/I/3X*M)0T/^)LVQXAZ\B+<.?"N5K4SHH7ML3K&U
MI,\#E0VM?7"ZB#/P44#R)0H?@:>]^^S=Z0L:$7H+A@]=S_C?;':X"2YE&+6Q
M&"8Y!.CHYZ\TE<MK46HI/5F]I91W4TY,,["/U8O^J=GYN=TXPE9CLOD4/,M'
MN@YVTOZ-PS84EW T:-Z%J>>G[[.;IVP7;\(DG*58S8.X*37(IKM+T9-G;/4J
MA-,61V6K#\+=^WCT8]VJE)7U:T:EH]L&AP=585,#+1W"!^,]:0DI5/.;[;/^
MC4QQ.B1V+Q8498=Q+;E2&.QJ"_/DJ(D'6@1A&02GAE_D,? HP"5LKE*/'RA%
MA5>,/UZY)&]7T"M"P,[&S3].P@#%K(R>H;M6%<5P*^*93W<5W!Q8U:K5XKD9
M*F#==B*( ]D9\<O$;1NG"20(6[>BZ58RG3&.1%]/S2P,8R)H)BJ2=A;6;Z]O
M5[[N.>(@(9]MD$5Y.Q/]^5H^VGXR&S(BV HLQ.%QBP>+7^1X[5?$4V:0,;?.
M463CU4VG,,4N8,6T7" G'T)AKE>UB&&Z4^:*'X&Y;&'K4F1Y.H&(,/$TS\3%
MCW/U^N[:CSF4_'OU7RUIN,84XQ+K#O?V[4]G5[4W4W R"BUBK;/!X,J7WZ7B
MPZ4YA )[D9;6]3KF]QN!T,!+N&D.5T<E=@B?@N8\#@'T.V6.R[OP#G)\I"%K
M5R,*,U8ST+FWU:V>%&@WSJAR;,,00MC2B)*"M8Q87)$=6!UD]8Y^Y,9@1;BI
M)K+ NUUG?QH;F0-E;=0$\*5_OOWH12/QHL''U%P[11"V7&NB;J:^^ @Q7Y_B
M,G6AZ9M:%Y'9K=OQPBTK(0QY<%8W2RA>K9:&VNVWEC2XI",G,;H,J9,R7BSU
MU_ +$)VWV<-<XNB'-K.QKIV3\OX4%4Y,;8X/3MBFJ#;!2Y,;JCV9PQ\@3VR&
M]GXJ9(JMXH0^IVS8KD>KL?G3C+4W)%RG;</V5B2QV@(2QM;I/OB!;RQLA-_K
M:4U[4FSQHGP5Q\6YQ_)4UM[%P3OY==SEW9W\RYVR$3T]H]<-2TN<L<Y2&I[4
MB0 %GEVN5S0HNF+#--['*Z0])I%HJZI4I3*^:7FAY:.!@D\D)K^!):5D@8QT
MK;#.&)EL%9"Z;_5!;-M";$\Q[,PTV%?)@!"JI<&:7RN#Z(P,6-LRP=:8+C_7
M9=E+7>+S@"D*3&&?]MSQ32HBQ\7,OEEM5;SO%L[6X[(NH.5@BU_DIK=,NI/4
MLO=FN(WQTQS%0=:I<T_LGSO,B4!<.9U+<9:2Y&S<0KU4U+ [[TQ8IKN-W^CJ
M^&3WMMA<AT3@V2YY.-<VNV3P_+/K%.J7A<TGF3O1"4)CK2FDNN<1\,E*@[-W
M! O5V0]N"FNS+N[D9AYX3IL_!HN:CWA+=:KD=6CI%B +^G=A.AH0A8Y#@+-R
MZHY?=&'>Z9N^0: [FV-IDW<L-YUZ85DUDE)*=S?AN">=<%Q/QZ8W- HK$[/I
M/(GQH'_UL\D^ DK@R@IPKRHV^0JR;4#6HT,$X<8O?$ 7O_01AX!CC<0A -5)
M"!"!5A9H]A+*L>V%2C8EWK(!=\XB0>"R"$O9-'W0ZL4B9$6=MC^;YC"(.QI;
M$UE3Y4&;]N#ON9(T0VK9BU,KXT5"UQ+CM4+=T+ H2H1EO6>M@PI=WQ9;O$38
M:A]#3T)G+BZQM<K8GGBNHJ*G)0W D%Z(>]RIUC0$^"*/R5A\SZSY5%ZY21K7
MA9+55#IMBQ C6[GD1WZ]D_0'047),^V7%IBIW'&7G6J-&Y?79*"//6HG"\CU
M@WP,ZS4<W[[+5SG;E9$7VGJ;W8WDWOV<FUP8&U,S,MS:A#%;;P(Y:J?5!E0'
M!Y4\W:>L@CD&ZN^DX*;/FBD+F<'-B&-))$M>*"H8/]_ %B'644R1,PS<C.OP
M2Z$I7HELBPZN)K*E<4ME6I*A<I'WOTA#.\X&E*]J%OA@'W@A&*<DN=*2K0ML
ME//P)H5/FAA4KL)C2)>BR-)#74$ L<+69PVO-K8:"R7!OM9*$/?\ULE'@(F)
MD.8N7K+9(%F_5K+:M';/8!]"JN>[%R0E")S]Q$5: ^DM">NYKJ<Y\ 0\\QO@
MNNM*ZQJ5O+ OD-*GZ':E/%"#C(@C38SD/7RWYPU\1:F?_W)^!Q7EA38>NA#X
MRSPRO/DTQM>MV,TGY6,HDVBB)C/F+@GN*#LW2L%O/NE:,EQL'6!G89Q*F?*7
MK1BEZ&Z!7BT/R'7"]G\MU%&LO0U.=:_1GNP,;#!LA2:*I &KQ4S'PM]4DM2&
M";:N@0KK-Y)WV\YN JFD0PTU'AD LTB";P^OP?*DTEIQJVQ]2AA3<!K47+FF
M D;1UE,4"EYL,-$]>=U\JH:E4.+V19%DWKQ24VM]LXF'KN)Q>3JW!*S01Y]E
M:GMCMT;)XYF8U1.OSX1U6DB<*(VX'BS2I0G5/$>V_& -#;$T);7&26C(X]3[
M<$PW/:=>A50,5WKM:A#>R5?T]UT92ZW218JG966B$O$X*BL_>@K@R]8X_QTK
MFRU43B$C?[\HTFD2#P%\;&UP_A'5';+<BMU9R#J>4N'PELU1JR/&="4^PY6G
MYE?G\0G&*H@@$YJYAP#4/L?HRYM^!K7EUW^<R(<<ZW5^.H]_- UG"ZX6$^^7
MZ-Q 9YTA6=CA)T\D:)D=8NM9ZACK,,B[/5_SY HQ<;I^4.G&<]>\0&$#<V/#
MZRK2G33=HYZC5A^CBV4*KYQX-\P^%+>\F*B78DUO>%%T.%OYA+#54Z-&F,(:
M)P.=EJ^I'F\!$]B*1V%+H7,=%W>F6*_09U9.2]:8V?<Y[G;W7EU6E[UD@D'6
MW(5Z++D6*MC.5)GU()7ZJK/A!L,<<];\#?U-AA5..R=+H%]/)?^4UYI4U:YV
M:-S<.[9+FD$C7*<PN@WJ=*,_ 8=P4W?($_78?$J61UDMRUPP7ZF5M-RI [+!
M#)[U]#V6O=V<)F%U?8/IDIF&9&3&>OIMCPYBC5?E3&<M%Z&BVZ\V=WW\$P<4
ME6L0#]7DT<T[BD"G),@*/'-W$DQ\4_SDUDDOOX\I2'SY*&9&U4Q9L?G-!HAT
MNV^W6<J#Y]KJ+<RK@\[8, *)T9[,2..N13;,**I H=:K<SVEDWXY\EILHK[&
M XZ#:TKK$"RA1-'1O:F0&>_ZL#VF$+.DH;?H3B&#79:*9TO9L!C8LKFEKT^/
MCUP_,Z/"+J#&&,WNJ-Y#(P:561$L(K&&WKL-KRBZ6[()0H^ B-1N1]L8VJ7)
M-QK2/X@9/IF\Y*_$1%"&5205IAE1(U[BERDI0#!+.OK[\H%."=G\QKW?S#A>
MC?,PP!!XD(8B]H-GB)=EZ%^+\Z1?+LZ;_U%QS@!GA<TO@$<'.#7A*WP4E@.V
M]A\S*.+2&;6)YLY2+F@HR'#@@N&6!UQWETLYF;P[!H3?:Z,72"MBIO?J]VD%
M9&'SWO-<8QJ6X;88@;M)*EULNC9N,/LT2WPJ87;HIN9*N&>N+^NCBZEJ3U_B
M<")D-.J*)]]JQ'KR,,5:%3FL+G"'K+YC$ B\-S.L[I@)>R9F5K4EW*E9X%?9
M=P7GN@2M@Q!&2*-3S;+2]B2:R693IN#[%N_*!FX=\HT)_$"_QK'0KD0/6_+D
MJ+F@"P:["[D%9R(-&"G,K&<\',);H:^XF2!8?:^LS)2*5L<$&XAA$E,JDJ)#
MR9_H]]S5N6(_QF6)\8\>>)<,II7+B$_= 7KSO9O=-9N[C)T]6(>L\8%<Z.]G
M5!QLQDKZ6W&8J._S83T!"*DPG,B)#VS,GYQ7RKJL:[MO.X$^YM2\^8'I<B?&
MU,Y9,KH0\3SCS8R+[AE\0C1-6/L6"RI"@@P2\VY;%'.,FZHX<WV6<&>QJ-OJ
MFNI88*#%VK!'[)CJ!8HA/5DI$G9)SCNZ/O:99S8W,^CBDN6Y;3),2Z5U-PV\
MC3[LWRUXK9*<?QXXML.7*H&C+YMI+]2EXS=*2"1[KF;944U%3T"AR4],-=YY
MP]O(@O=FGAPWOSF+4CVGTH..9/ZP$^;0GJ)=V@QQ9Y"6&'\6C,.<"QE)%2_B
M?SNIZ?M#\+OB.+0>-2$-^CXA/:(#P1*?)ZIIC>TH-U^)W/?A3#RP,IY2%?"O
MM9\:!^V0LDGL+G;7^T-(^XF7+SV6%'"0_(0<[^'/-LQ@"&4^*%E]3"Y@&_[J
M6=9,4,'ET_E,EZ 1Q .!0-=KI>_\D!6S1"I5FG>RS 2/E=(*;_@AX"RY1XS<
MIQ#BVS!Z']ZGN$UY!.O6I9K%65UC \N!CV&.YKM@5TDE9CK9;-^,'M7'ME.N
M;)C !=4+#(."+Y]=)89BT)_BY^EV==D_:ZF^E3D(XR+S=?+U^XA0@@=*22$:
MX&.H@)65.G<#HF%M1LL,Z%6_^*[@+E&9<C&<*72,*3724%H_?\)A*8"<H2ZI
MECV P0@HKY.EJY#GI4*QP@JUO!R7'G\69+<D2^.41WRM8W%T3RSL]9(Z4SK7
MU'+&G5@""7I96\\YQO5# %YS'$DXO>A9P]2E+>P%HG.E>[+]RC-P/+&#A!"E
MU[G$>EWH%*0:G6G6>52B3=?])GMYL_?(0V-49SY8,\L7^%@J=[ 'I-I<2Y!_
M:B\TDH)Y9N-,6OR+KO(U+_72?(_$0!JK%J#\=/L\>.A*IWK/.AF;D:QVOI;>
M=>&V&W%F#FN/*M/>.UY3;H)']=O<I6->A?M*BG"(*/.-R:>-R5.$UA"9"5;Z
MAKT6$FF*\=B8X?<[Q^.CQU6"U*3"F9_E+ *JBGU[(<1RTJPHY&A^O'N;6'(0
M^*@?5<Y"%CVN0\;[)+;$" \!*PO O=@=2?-# 'D'I-A@E*C&+E)SQU_R$/ Z
M$'9@:3PEH]^&FBQGR$!-EJ> !S\@+G,+[S]$#O/A.3)._N2KV5][P$G;8O-&
M^V=Y0WDF3+C3]@5+BSW&ZM3*L_#]\[SU'D_HI'FFX54Z$A3GYY<HAGHZ4V#N
MWU\!<_.,,?'N59WO3\KQT0V@X+]3Y<>UON0%]Y("8V4'TLXQB071)6;-E#.N
M\/,Y)-H8ZD^>QCJ)94T>SBE;X+;/%]^W;;;TJ).2S\[Q'?13V'D31_V5%DF/
MC/DW"ISSS*EE$IH?\II)AC$^]DVV3KZXEZV\/E[!+S=$O7*FL-LBE/!V^>-;
M*4'.A2I"F>L9;''QI GT1F ,]V=9"RS;B0^S5\*TIJ0)6F-J**6K,M5M]F>#
MPI[:LU%G.? F$U0-GNXER!Z ^V[&).Y=A=Q (,VH9/0-D?2V0[+ 9.H]/1*<
M?0"[3DC&&+9(M<3RHG\<4PM8.M5-5(<+,"M@2AA!5YJSO-['<HW$QM8?GFYP
M.B<Q4$3*OJTAT4U8U^YZ<KHBN\]ZD,^VPUL-PVU(,+=EK B<"3+*TA,7LF$?
M](B"<<!J1H5-0'?U57>Z1,_;.5Y,.".10)?%1TJGMEM<[V!;ET@U0('72\:H
M<C)?-@I&7)1_3)#/3=LP%95!%9^PZE:TIL2;O:#1M0].%]Q%O#+,@%B2M^X!
M >9MD'-YJ7.V]I#SN085N='.3[2LI-_3\!@T)-,B&F5%QG:;N7#="+,@3\NC
ML2>D*2?4)+/!Z&5F^%+@1)>8Z<Y'1I-XP:SI3,A@./#WV-4/I>3&;TO-9N]#
M@%5P=#RS-_#^.04^454<.UVD39_^E>J2U<>@;=]J)%RH)J242-;P_(/17OY\
M'#.)C0P!UL!X^NSXZ[J+]T<24F$7D<VJ9#K$<1BQ%XL@$$0VASS(1G*I>'.6
MH60/C#=0/QL NW $ Q.%["U"MV4N3^VO([O/\KG^I%@4B.KC!&OH/KVW.<(6
MM3W6 E*5! =-Q5<<;*D,"@#["B-&-T1TD+WKMW\+?0>V7.B2/$AQ7P3^FW&(
M"FVFTQ0Z2+T= RZ_8X/MS!@? AS:#P'G8I40!RB(86%1%"^\R0]7@"@6MU!;
MB(M!HX\-(H>/,POYYP8Y!$0$'0*V!NT<J'[#3<5/@"SQ(?IC=J[==!$4/[PX
MAA9>("GQ2P1_ SA2VO1W?6<8Q4 7E"1,=N-OU4"^_>Y'@."O'(%00R_U_X;E
M80$0$H/I/V;YU[@1^F&D_P6(D-F]NV8+V$T75O"BE,=R=/":J&*V<Y]8M5I#
M'4-2+1.3B;B1V:3VBH='-G=U'2^@FVWI@AA$?]DM_#&@U>G]B<S/NECK0 G2
M<$'@F52+02>44<6%I?J>^)0[Y \L6382:1X3!_^+Y/ _C*@B[R9/]?>@\RTP
M'>PAHT]9L0<HSY2G_E>"P8O?V6S%<3K*?]G3]S:_L?(9&7((:91IX+Z3YA;Z
M1AKT.Z[-6=JC]YW_\#W1-W%]#D$_,I'[5:!7_UB@'?\CH?/?@ .M;<\1U)^A
M_&$^KG/=3E'>1(6V*I]3\]R'N;OI3P59TBP"6O7:O=C<7H']K5U'RS/>&6P%
M9Y9>XXB[7F1DJE(@+"ET@9-ETN73X\3+'AW<HC_*^%MR2H<A8Y/Y-RU]S6S'
MW/*W ?#S?W^3!FE_4/5_$HD"RO11KG'^C_+Q#.U1R-+[G5T=V?!G]S(][EX_
MS>G2?Y#3*WYJ=L?<XZ^'#.B?>/K/(L%?$FOD#[[^0P[\S/OOQ_FC,N?GB?1_
M 9*9%7MZ^$49]<UM#)!C6;I'<(CZY1P-.3EJH8MOQ@1X M#O-ZC0\'5Y24]G
M\.X.3.<'<:LOC1H5\$QTI+XVM&+DM77]0:I]"NL:;\>NI;YM6\X=2OQCIY?^
M-9LV_?\O!?T7T?\Q1%_3]K\2N([:A*-,-KZ;]KLX?12UROV"_ZBX.'(*XZ.(
MA$ "X/Y!'"CW^-- /QV/XH09Z7S\?^!\QG&)*!#0?_WSOXC^?T5TY+9IHQFN
MG.6^8UP,.T-X^#CR+PMXSF3(Q<0D:+F%*6FN:PEAGRF)/L7YVC(^'3WJER]X
MNBDJ *"FTS^[.))?'\EJ.I6P>2(:T8,Z'[49LK=->V*!@"CRDF<K"W.PUR*,
M0+93OM,XSGK!.&W2XHZ6CXPZ[HCNB0."D_"@S9JSB3XLML9/Z+)F"<W"LP;O
MU7^XPXJF[?&P2WJ@^FET0B"%E EF)G'4V:1W6;.WS?*[BIU#/]Q)X<IFX=A%
MG<P4<NLNI@"U;BN B9JV58BJ1I(SMLFC=8OO#O5SJAA_-I6E1[F9GBTE12XG
M$>L^^(ZY2-09AG:&-N>#^JPG^=M]G7 [$I$_)B#UBZ-5$7HLV?UFY)Q:R0M)
MY00OAC ZQAN. 6@\^,^GXIE^-T=$3:?[QQ_S+WHH\-\]1=!B0,[B]*"+O'U!
MTS< O>A!_;4D2%5M/E),Q!5+T2+34T'T <JA7/H,[LA0Y6EX"."]!1F^!]V6
MRQ]>&V<_6*>=O+?[B7S*4, 4M)QE6#%59[PW+7D(P"3L1]AK(T.9,VD#;Y%0
M4;^DDL0^HZ+QSDHH8A?_V @"'\J_O1;]]KKF^VL'LV#S_'W=6A1^IN_X+W[%
M3\2WT<33UN<Q!AE55X3 O(:W/L0B"*D*]K=;D29W[KKK]]?]/WGM-&=1$IY'
M4(.L@KX-*O2=4O,KG[G;;O\#\H58<-,E%Y]U@?&.TP3\3FJ+TUR 77C>I:UT
MFF/#@K[3^A8#3KOU6_D&(PB9OL)RO'8P@YKGQ1+4'AM7^"<B5O\C&1QAR(\I
MC-R6"_JB-N1H[E]'\]$$*L4.+"3]"HGNQTS@*Z[)?ZR"__#PUYV_O!:J$7TZ
M/H_Z<7$_2;2='EE5LN0UE\I803WQ4GH]0OE8?*G.V[^\%N8AZKCA7UE@<.EK
M-$*YY*6X6J;_V5//I-2#_OEK\GX:5?_RR< N2 HF2O5&0E6)%&LW0YM3(#DO
MFR=X!Y9MX3[6F*,'!>YY#F8]2S)=DHS:J^-T-QO)]^'MP<"5!>8]UQVPW_X5
M(=6+UJG9F:UP8GPTUW&;] U<TFD(SE/F1:8T-?>+>D[G.^S?8E!$!,8FV1.$
M"MU4V5:4*5:L#;B5ZO?DSM9&4CFE'M$0V79PPO9B7X=BLT7?=0H^OU"P[@']
M4.R*QQ18E]&>+D$Y]"/EN5;3,WVQ%6D S7UY6<@%:WV85'E0'_$#T60-LT)2
MS16E)2\+"9SI8J*^4K:QT/XRH1:9!T':E%.]8/D5\L8-(*DU[[#D*Q&J0$)+
MS-4PWY"6;?<1RF65++UQ['.#8KE2R2%P[9%$GKOK4;B:RQ8%_MO\HG[[626Z
M&&]+S2-M1QRY;@\"^04+_<[$59QEB"6X*LYBO9G6G**8 9RV=8R.GO.?\9W?
MZ6&KA$6G,X^5!_-ZCBSA],]:2>NKB&WKQ6DU6H[X[CS"N#E61E1]6=SE.BL0
M?VA@]NEC@4MAXY0>&P8@ N5MQ='\<+MWM52?5N[&W*F;-!:/Z)[DA+F5D\]R
M4O:$0%R-KY5KUHB_?LZ_.4':[2TJNR+HM-PIX#(J+ZM3W=1NI.M/<W+"M.\Y
MUP+>6&GP$$56^X88SKBXW8";PD/[^F765KNQL9DAZL)VUL%KRO<,U&7O>9V^
M9$GJJV*.7>N_+[3LY:M?H. +;H%+G>YEN8/.EC&NB(LM,=Y?3=6]Y)H'L*\K
M?6)?!,T?V-A]A!&O6W$^-6.?S2IEEK!C9NQ#8 B'X!G>[F:HMP2IY/" M>TB
MT]4)S,UJ[T(:XCDEF>05G(H1U8MZXPX+J1+%#'ZA#Z-T(L(Z/BI;"XZ_?Y9_
MN;8GD7'D!77H6;,F(7N=2U&X\BM6-8H@['XYAY#!C/2ES"<OK[&\AT?H(VZ4
MPO<=1N-"ZN;$WI*Z7WT]3A')[R2SKQ<+J6(>,SX[IUN &Z<H=)GLH_;=2_F*
M:RE#-"O70\=4W1V)'6BYL^K,.L\T8'",4S["*!"EK]1?XZBJ<V[<1&<;M:5V
M9Z_#-I;K8C,4M%[?D_<ZSX_^Y GY62"?R@PK@ZG^<F%3(_$]'K=::[!K7C+B
M@D%QW=N4&3B+WM8MULW5_H0106OBW<N &6[FY4. XK*JUU;O[$585"Z$LVFG
MSWIA9SV%,[$V"*I8EMF>*^HMR>@F'^_FA0Y+WGS'"826\HT;$PH;Q/<V&\2D
M"EGXWT?3Z/<_8'!>?D6H<FD%UXWU$( WRVYKGNNDZ9OC'$P,H\A0 *SCXFW7
M]=="3F^(B==&$)_44K[EXITE1WZMJ% 5??MJD!XZV]CIJVT2#/">&'_Q]NAM
MH3&N\-.=CSS.=CEMIGYRPXAJW$BT]F'G/;U\XTR-9TU#O;CL<YXF>*A<Q0"P
M*3&)"33> ]S"6$V>_DNG^<>QYKH\YXZMJUAE@2%F#P%7E38L>-E0%]M!4(?L
M5GKO%Q$LX^#R#^4$3;6,03P:O0.:M:][^!+?.;DBIB@\2%"CF4**K@BV,K89
M;5W$=]P"H'D]OC![(_24SSTSWP6QV)- 6T:<L.MY+.E7[/3ZZ$X3VW:7\%R>
MW62^?>-=N.?Y6X]F\9AJU_V2FXH:6O4510VL=(P-S%GSO=Y6/S<1.'ONO*?_
MP[9(T:*"$E$KU9![)S*G]3%3Y!D75<Y:6\PI+F#7L,S,;3H7YJY5^O#!.:;U
M%^,MU7=K:P."1&!7)^_98.#/ZT\+UI,(6%P6*WU [?M49::[:303'[>F"QYD
MDA^M1I<G9[_OZD;J<U,T )I2HC)U2\!B<JAC[Y%?&\F5%/2+->PT?4&K?9@I
M= 5R3-'.F+$IR8,^]2$<_+-+12VT Y5"4J:RS(P)60%"-]#<3LIVE 4%8N?>
MDG?7#KDQ7[/>R$//3,!2GDA",W@32U)-Q,.+V?QTD%]0W.2_LG@4K<O!X*,%
M<.=$W]&5*'6N0T"%365TQ-W\BHU62* 2+IAQ^VV\J #!?^_^^EL?5/9-MG0P
MT,;H2Z=P8Q>;/VW ._QH>2/.CZ>LU4OB:G. UBEHF8;UUNB!JW?:Z-[358'-
MI]D+Q+#3I8KO(\_E5N#-]@W&M[8DY=^RT96QA;8]Y_5E[V%I)#T]1F@C*,F.
ME;D9G]\YOT#<-]1SZ6V;7 R:OPK&&(2Y*O+2/@>II*A9T.V5.C>GR2?GT53\
MH^W%<[NY10^<+35X D?%FK)]<M'Z6M7T3+G-6PWQFHF;N*Y0260E4Q>X3!*Z
M6/L]Z%4+=.$CJ-0'X2]<Z4G/'627*.Q2Z19]N(SE7*\?BB#T";#'&J+UH"/'
M]V_R XX)+8(4  N&3Q=2U58-G_A<6@O/2CKQUB;QX^R%=RJ* IQT#1>O/,$=
M5Z)Q+6?@SZAG;9\A\NVO)WXMTES]1.?$.R7[)Z)<I[JN6W US'N%8J5RFGM]
MP+##=5VWL[F?.1/D6SC=?/$E2*3 4LO SJAG2W:E%1,+W_(DL*H(1& OD+5<
MYA-LR92;DQ!;T'2&XY,9O7=&+9=&JD*O/J=AZ_.20X T92Q:&2UZDABP>J61
MS$^N-Z6*G?(:6Q/T$9=,&O_]CHTGL9*="^GYJ^46:ED[</QL/?[QAZUO3VUW
M9BMNW[8O.P30:TW5EK!V,:>MM]Z>>N12?V"Q[)44A<M7D%N0^^))@<N=&,GG
M;H7HR^_<H_0N#(>N=QK*SF^\N1\-&_>",]FLB KD+3]UO";5(7"U[QK0CC<0
M)WR%PYC- )/$FWSV5#E%4X!7!B]2(ZI,K]H]13\Y=Q@'"-&>9,_'EN4T\DQ,
M)<[-?:%QQW5+OT0BSWK8!\-S$7$E.$>:)]SK112$^4#8"$1JF6A_SZF.R"K$
M,)=R6.BD ?=S(2_05@4.+?J@R\UZ$8^QCJ'%6V0U-YM<WQ6_9&"N$DW"Q>XC
M$X=PSO@S]IM"]?NCSD07N S=>%WC&W4)3?#4XRY6'@99W;;HQ'[E2VV/6L\;
M5CSL<<9'4YY/T\K;8^BOZYG0:*8_-S[ST(&E[D&,]\)5W3$.;Y$3^'NV,L6T
M: # $RRI]K_L,2&ZZ$WV!M_N3X4]2^^O)2?KRL,V4_2TMA*4N<NQF6J\?=\R
M<F?SP.!V."RBYE'2[&W?!RJ)FZ"/M_,/]G)\;LIO(#5^QB4'V; ,IP&7W0Q
M:PN['3DL%@R\+@1/;T=K.>C@@\<>!UW-HW1#]UUDH5?]C'#K '5C,[\\LM$S
M[@EY:!(KRW/F$)";NM#3@RD04$\:(T]<APE4BQ3Q6)+R<+#,")03E+C',>.1
M\_O!VI/C8I77+P[+YG-:!)FSKJ!?-?FP^H!CQ,M#8D$4G]  WRRIX-E<VXC=
MQMR"^/=!H=OWV5",Z>U5Y]DIU,KEL7K*ADRDO-'2*#)W<A*W64^*#JNB"9(_
M??Y!U,FMN5:YW_]4=\OY$ERDA\)G3[S(HVN8<4SN=-4C34XGWPCKN4<&MJ\X
MO6>;3[!<>52H7X0B.PM)]B$@C6;_VF78_AXB-[R65M8OQ]UUR&/@*V[(=[+,
M<H I,O-J[8J17_G\SCII*F\:.,M5P A2=37U$  KF!,Z0NJ8:Y:YFZ=21T90
M]!-!-57/=MM=LI"=^@K\[><2@:[=[S9O3*?!OK+VG5L?6:!L2F]U3 %H]'P/
M9*I_(Q9Q 5L'X5"AH/1WDR'$@'N<YWD0I^I7>CZI;>B7>=$SF'\=_(B:X8W8
M'TG?.M"#?*7SZ$U2VC#R#?0K4W+'F*J**4 !@[XPI8'"RR'GH)"A<>Z[3C[K
MV_(8$3>W7'O*@N\> EXS91R8 YM*!ZSYY1H. 8)+<RIOX_BI\M\:8SGA)*$!
MG95DH*+,\7>$UZX=H*X^J_Q?<$W8_Z7G)!BXLO2E>R9O6*'QO'4( ,G,U<<+
MD=Z\+_R@6]22_F8(8,7XHA>B/>2TH&![_X%'5OI]T*B#GAW^B9Y%'!Y'A<W3
M+ZD#1-3YKTS7V@"]3U_R>BE]V<8I5B,260"8+1^T5CASRV=\G L);PNDT_95
MH![C@P$5@J7;+>Q4G?HBDF.:;3^HM!2)1CX2IG0PA_>5ORCN2&66(PF]HZ7%
M<>HUGK1#""ZEP$3])^A(WTUDUQK6JR(1LW\AOZPS2K9(E.5N?X3-9"FT1B$O
M(6MY6\)NC'AQ@X5/\?XE.821%=:*JI2-I-M^F6?.I7X?^KC+M]\:*=5JG"#&
MF:S"$0-85]24-!CF&J,IWQG&%SS])):CQKX;XJ90"X7FP7!F$&2^"84^DI2A
M1 >/R,QG5%ZLH%?NNKIMD)U0/#.V^M3H5;;+DPI:F(3"_$@GHV&BS4BN!X?J
M$F?2R0\8052Y3N.6K07RH,S]3 ?Q\V"TD<8T>QJ<LEAKS\<EG4:Q(%9)=CRT
MUZ9S"ZIB-C=W(HR#RK5OEI B+&6G'G0N?I(W8HSV$^# :C@;A8M;UE'*G+!/
MMR>BH ]6<.@JR:['OK#1Q@EF9!/-P)TM%EZ.*+>D+@F\)U_8"/5UUH@X!(CL
MONJO4EOU>J"!6&R'-KWKG^XS#$MC)+PA.#&1'=6F>Z*U4"??>U) _BU^!1D.
M!P%S4%%;>Z225&<2&J"6Z5\PJ8<\>NN==[$'8I,_'Y>UND0L>LW:[TGV#1+P
M<P=G<X3]\%KW(6 I5NJ3MDV@^:FS9KEV/NN(Y5@S"+*5W5E%AC#P(:#<F]R^
MX@A.B"-R,P0A/<!.L^5,XH\Z]P]W[=,A("+C$.!PF7L',I5R"!@61-UJIMID
MYS*!.I]U('((&&X-B63>WX#L3;=/-1\">%01NZSFKI\Q624F[4\/1<24<L&"
M$;85!^NZWQ%R?(#H97SBJ;:U]6!/W'+^/9+8,% N?#5BM(Q'X/KZ!L'HT!<Z
MWWTEY7%1]9X8A&Z1J[-+$@ED;17)CL(P"^55W9E%G0/&^X54%-.VOV7ZBW"$
M.(&;(?/'8=8@OP/!76#KW<*>.1@51((AI3+Y72H57Z1B >PSR%HDZ=RK\D;"
MJ0"G6K^(PN8K/M)I)#\: RAF46"E(%CH%YE,'I=)>GTA2IM?9,+^129?L9E'
M(3J5H29#D4='I"TC4Y7Q9V;;8[^*>(KO(*&$?+0,5$J+!",817S3[U<)MSGM
MB3U#2AYB+;4D(:E"]DUM-M_D0SIV?!S<MF_4ZGUE^;$Y%(6EY;RMY NE^A>#
MD?>;;QJ';;!UR2BM)S='T/-YW!05.-7[4-)#@1;SZDU!.MTHQE>UE^+CHIYA
M2:&F:9FH?O]QY+_/_^+')>CU!ZRCB][843>Z:<@+817HYI3WKJU=_KB2N.^5
M RFN:)!EBD\-#J8[J3&IL2-K;#Z)M!7BD/9^O> .)3XC+Q\/>=("# *,S<?4
M5TZV3I% 0$9W:N4CJ#NC@OIZ>O0H35U#FWEX3FD>Y)ON*[F59FSCQG,%TER*
M;_&4_EAI>#*Y*$3SO=$= IQ W8*"&?Q7"Y4:/HGH=Q+$(-PK9P:\K,;]I69N
M+YD_DZ7;3W[I#]P3ZO -'*?;BY_R%]-SA/&$!<TUR..JZANF^S"SEK@_.17G
MO8QC<A/,9,1&XIEQ;;>^5>HVH?5*KNWD&XF/N5P3!:\7\ Q/.NB%<V?9YJH/
MZ&W=3KA):;W&NXAC+DUV>=WHH&_"DL1%_Z"41?6C7KM-B7+\$]+-.<7;^1\2
MHAE%]2S6KAIV-E9%F@JX>Y\IR?$MZ$PW&M-3>Q@31DAS*5$@?E DM!OP<)SJ
M^>FT!AB.+ST#P>FGYQD4B/(YF=X&-1E$!A.[^3LMGB*\YWVI#.=IKY)G18X-
M$S)86!'HL293>(RF$Y'@4>C!V(I7=XIC&&47C-D_REUY-K%1/Q[2DN.RR\6U
MQOD@:Z'R^DW_[78U.]K8<T%^05$3=J@=FB__[)(<GW7)H1=I,/%EYOT7H!'!
MXI!/J--FKMQ$K*0GY"D"Q5P0%PD]:!,L_GV7V_SW^>&AUM/#!A#'L@4G6;L*
M=R2>'U85./E*DT'GSKN*Y1!K<\3+S4/ VT/ N6?JDX*;>@9<$G#6UL?9O4-"
M'"K19\=RZ;!N"1 GI5^_EE=@,V7B>Z7YYO0I-#.E]I!*9./061VY3EBP#]N6
M2O3B!C&^P)-Y\=8'T#BUGJ@MP<)N+JA?5CM8EDHM/_E@')WJS1BR,QR]O3RY
M4-&7Z:BS3YL#9.'$:@^)-DV=Z<G'=&#KTM/O[:?C)NT^M1+L&MY-)%/ 6 _0
M/ 0XG[V!)$VW]2:E\'G.&UH45YQZWAT"]'O?EF;DUE<\:]&IB&<2,MO #\C]
MI[ZI20LG2MM]P C8[D0(RE<,JDXPG"..>\E'*2[C>H^AEYD;E*@ZP+IU'N/U
M"%X(,MN>B?!%)L_8M633KE7]$1VZ-6J;%]U+#97%KYW@(8EA82$;%=OWUZ$[
M&\!PX++[#'!M%L0ISMCZJ9M\?I73+(?"2)"^.AJ#8$[UZTO0*%X':*K+T<+L
MK%8>8<L:AV6KH(&DT9;$)Y\W(P@'_3<1$K3U9?EX?K=4LKX/CVSD>"@0#D)3
M0@QT(_05N3:<,'IG3 I:Z<#*&3!5SP9Q$)M=8HT&IA,4UE-VZQOP_C5;H?U=
M:)N/+"::S%,8C4V<2>6;U_64CS<5XB?#:OK:I'F$)'? 28> *IHX" Q9AB'5
M+/$ V1]*[K0WU63O)@]-!?!TK4I,<;=I8ES-:4A>9%/LCW9/)W.YZ;6B$OU3
M H%=]%O</D%EQK\GXQXHAV9@582A!VD:7\0 ^3KR!.Y\XQ:WG\=/!,J!OL?B
M *.,^1G*NXB62/-&V@S%[Y1W?&?G"*F//]M<Y&=D\\<5@+&IN1<A%*+P9<3-
M?W[$]F.">/VG//JS!GXAYP=[\-;R7Y1"!5*,O<GBD!0M-6,UW$!#\IHV4]EW
M,)4 TBLQM3$>M*Q_SVD0_WW^]/E_[+UU5%Q/ES;:!(<$ L$]N&OCFA L!'=W
M[0#!G280(+A#<+?@TC1.<'=O+'APUR"7_%Z?^6;6W'=]=V;N3/YXUJH^NYY=
MTJ>K]NZS:Q]Q61DQ0J+$P!IO_>]R8*.G)W U7)G4:*<%1]UA(FP]^>@H/MWO
MA4;H#+L/4U(U2F?291X -..B/Y' ZL7^"\.6VSD39^2HL"%/W"8>>[B?/6I=
MSZ]:7]=-OJP,4@R130I4PSF=X)9:9;L-)@KZ&:_3YH,UNG<FB-XYL0+*(0#S
M3^+UG0&UM/>(06^<DLVKC4I0[SL$^EG6.60C5XQ@Q2+E.3N),T14<B35<,%&
M5! ',)KTW"HK>)..QMSR#;A]9?+S_8_[UP&D'2FOV4)\",;.(M'RNL(_L<M>
M!.CU9I(8SDA\?[QK?W!>:4BWQ,I]+-.>H[9">QH; =%8X[T-?KR99_H? +1E
MB6TF(DAC0:5QX)MG*G;1V(DM'P2"TM8.20=R0Q/T6 >-)=0996Y%XF&//[KF
MH][:$W UQ<^ZY0J+W>0U+T9\L:NTKSKZO960OD4LT:X8T+0K*Z^I<=R\#@93
M_:.-@E73"VP-NH!Y$;)+"%EG1<CS1AX7J[A1=52YO1E^;Q2B]-X4FP(0""_L
M4Y.!IV=^%#B[3HC/4<3H0=I>S_;\"M3)(T(":;B?;VF92%)=$-,,+SH;4KZ2
M2=A2.TI4;FD9935L8!Z;[S<)F&^XL^ZYI11(O(!)YV-6,^^_C$NM1:4[6"/<
M3YW>\C<;-SV:*K]@5X.@A^=4'F9X;3:@!0O+88\*3A0ALKPR^F<<;SG@COBX
M+S^I8S=;KK6=96TQA2+&ZNP.EU;K427-X[*!^^A!/0!NIJ+7%*X)+1X SN"H
M$OJ75EO2<;ZZW\VSH(X=I:'%1!$<%E:_XI,4KH\-?AX^ $JE;IEEP%M=X,/6
M>XAQ!OHP*KD5="3_IBL=E<66B% #5-2&HQ?-K$Y)]Z]IHG^F?;@=\_]AY<@I
MTFA0OP!N[XR]]]*X__D V%7Z!XJN"&8>/&V$.;E>^<*!Z(KQX_TMPO3H@#X
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M2G\PY']3_WVJ\I\^;O]+*<+)Q,^<DYP!A8/(_D2@N>^+/TJ1+*(-HHRZ8\D
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MC745<6,*Y/UZL0G_S4>#-R'__&XA/IX0=9;Y[H]S 'U_G -P/!]UF[B7E'D
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MHW^>EFGS@TO)^,#)25EYE/T_^DCH-_[' $YPFCST ;"N.MFZZP]F7"@1Q7\
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MC/33BQY'-+D70>'?S*CJBKCT/?,,]-MR=@2LBW5TYV0VV\/<.5ZD>@-62Q9
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M(7[, DXM1K[X6+#2G54+6:+F_8*OWL++0&G",'/CSM0(L0> L-7GG7*()XO
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M%%'^Z$3RKK#)@=4!9V\HSX3.0>1@J,>:V\4M_>2S0AM#WU[C8,5>ARM2N=?
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M.]VWWBQNIN^-.]0K+TO);CM+'_IISWVTIWNI%G$H]<#&K2</XK!8;*<]S[K
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MP]J2- >B,N];W4V3<?$,H&I6:P%[UO0X@^H.6661F$_J!/?5S4<&\1G .=%
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MHK2X:NWUTT]#9M%&'$1[*,<E_S8LC8K=&=3>FI^]"Y<KN/6=EP5$DK/H$;W
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MAM/,XW.]UBQX(3D:7!SQGI+U#GKD7?FN#>6 >$:B5NH1%TN4?PF8M)&?,%H
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MI[:=+08$\7K?V9<W5\%6+4U+6"W90)$K>M@)J^'<"(/C(SS5DS!=8H*</X*
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M%@Z+$>]5\B^PU21'\H>TDH+Z*P*DJV\RW&\D%[4'.4IPOB!Z6Y&R(/)X%YR
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MUBM .7]DE9!-)#D'N=OAX;!T+UUNJGMHBU<-N\(%!#D0C6"99MJ+(/#FN:C
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MV<8+,3I'?WKJ<E4]'9F2D*-)AOZ5F?68XJ2CM"ZO(VSR=0;47B*'5NV-O&W
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MJ5_R^ZL1/0W#Y >+FK0N->!.+^J(96I)LO%AE0 <M.1)I/S(Q5XL^KY\,::
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MZ[J8SNH#45(7#DD+:^:^KZJAZ!P>:$>CA1:AF:1%W(KYI&5.*2^*^:YK3F;
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M<<)#J!#_P'U^QS3^_=HS1(W[K*A/43YJ7^@#+S$D/^DM$!NK&^2!VVY/)I[
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MUO 0<K[$(;TLUE=#;1G7(X(-/E^E8A5J!QKH]#/9?YJ;Q-Z0QF\C_(,]3XR
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M[G+97HPI5<TA4GJWJPT!G<,RT;:R[9?J!88U"$)_-J]=VNQ>G8(&/D@ZI03
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MF@JIIS,?Z9FW3Z7$\KJ^^&B6MHBA.*@$TX<0)ZN.CNY$J[V1HLG?U> >#+[
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M)1#'P%%C7A$04#G0[Q4;_OD$7.FQQS> P^T_<,<ZY,UJR=IET7SQ*-2+021
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M7Z>&\R9%;2DA@D]U&>+^51.3,X]GF&&6VXA$.]?Y2#W9ZU&-'YTV$3K7BQO
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M$!JYLC,W@,?3UXUO7,3_.=\:8B.J0JL])\%OT*0;$ H 4P55:MG>:?.TOL_
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M@,EI;+?#:J\3]:MV!U\!S$JDKG7/I.I@ETLR=AX-? _6MC"(?YK5]'#[6',
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M>2U.2_$Y%3Y6MH@?*,1J_'49^$B68L"CG^_9WNJ)7F(BD6:4EY.''W=DAC@
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MYL2B+8Q0DK3U8%P!U?(?"NYS^L8N*<%@ZA%!S!P+2P-<G]L#9P)#O84]C<B
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MWU$+E6M?LF=LQGZ_)]_=KRN3\&5UPA6_LQ'$*\>>T^+$3C<XJ_'I5)YJFZS
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M[K4[1]&"D0!ST"EVUV^CIQD7\)/Y(XMPI?7QS8'3N][W.0\>SHX@ =]LU)"
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MN/TZOZR'4"[TN_B^9&@@E,LV\ND%3G])4>Z^3:#4+J]AN 8]^BQBDH:H5LZ
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M:O]7M>,'#AJWD-AG^NE@]@GQ*K0O)]?A<*;8;R\'*^$MR32LQNM7<'^VUOU
MA&/DZAAC&I1PGG5L<_"YZ6=W+HQJ! >DSVX 49>V+1&VW2Z,EP9>TR6UDC,
M&1.*-!DEIY6XIH6;N:\$$':^N"88?XZ93J7YP\40(>TI@&B>N=9,ABN?;$X*
MY\^ /YK[=ESGR#AQ'GG6I9L7,"99)%K\T%+1O7]Z:1QB3!R<YP*4.=F7AYA:
MKUB$\3];.G73I,3O[E8BDWH>X@>3_2'XX4>RL7@U;:<%7[.RAOOUD37I6XGN
MF/C#R"08I&Q-@LP MSI<'WI#"7^#W51,"0NX'W0Y]*IC^NIM[+2+ZAJSS+@@
ME5,9R33OH4);*CM%:!.;$2%)T"MQ#;4I^1M-R7RXGOQY3]#/#JVC%*=8._ZR
M<6\AE#R=]G_8F*H)'(D=A K482(!)2I62 "4!Q;#(,#$? 4BH#WXA:.I<-+;
M4?OJ9']FK()Q_"D>IUYJR7GQ<< \\5;TNO+A@,7"P6E#'X-JAYP([<\O-*UW
M::!+VG)*EZ&:I52#L1#-;RY.2V O>AW=C)^][E5>& WM4'NG>+KPMQ%[#YR^
M1J@YEY78(DBT)WHOL>V**X/+MS#V\%S3S<JZ11(8H>$1<R9^#.J&^2,7)0-
MBKW8>3T-+ACC6LDT9QW:22>UU[:;<E J54/4%KOU.+_#^T?\8U%U.RO*)_E5
M*\$OK#)[;>P_,,1%,G8[TEL99XCMH)-V:#14YX6Q<Y#*-]7XR0<8C;9,:?0)
M">X.N:=\IL&$FK6NBTR3\MMZ!J*M"#[X[(ZV9]6:X8V:F?]'AN*O4BGI.E,P
M$E#.!JD\^'7OQO'7UT&K_0N^:8L*UP:2M&?@[I(LAIN4+%XTM__*!_C/Z!]Z
M>O"_?=J0(4@HB^MGT,Z?UEH\B=!^6J;AG^M+V7<35'V_\O]R[5#*JG'24KDF
MN'PY?WM%/F\@P.)Z&'2)=88$!'*X.]34D-2<]M/>]&.]H!<#H"Q(5=OII9D3
M6U>L<92RV]A8=>,2UKG>7)^LN=25GAN!*A)@; DYV[!% CPH@.75P&MH'1+0
M@LM%,[:V0C@'\YGQ8*]PI&T*2)5% G1J]MO92OB&A'=?@ME+,V/PI%@H+LIP
M78+T#6@9+\<5K"9I.9E?U=8!QR.&_?Z+[2V8WST4QQ$C1=WY=&LO-7$@\U00
M-DVNM3NA:GVG\5&<(D%VQ,ZOF1+8B@)BXF1R39.[\[8++ARTB2#==8W:?^^X
M)AM-?K6W,AY/$Q50WI.?A94.$"N85)7[CT>6!7N@KOC39D.*3R]%[$<+]'CH
M<8!,=(YG%&;W5!\+IZOZ$23'95LM<7R&3[MZZ*-5/[=SLDSKDD%'WH0':_'>
M-\_4H0[:C>C->_$A\::<@U'Y][/NH9$3'WF10^]3(&*C9;\E8,P9TW9 .NK%
M!-;L<,L*#,HOP@C")V>L<BR$K8/)=;%-0WY<)S'$PI5PS&*(_K.V_F?2^4>7
M:6__C_Y4.E[F[_>Y)/Q^/>I_ZV,8P9 -[J"9T+K\XPM-O:!!&N*3FQ\?,F<Q
M,)_>I;@AU,ND =R"67Y<5'+YP6WJ9/<RFGY43GXXM0%GU@4+S;%@D-]05$H#
M-"HFBJMF$UDIY<!9QG7%<D1/]KNE/;- B<G!SR_3P'9[G"6\D@&TH1]A>;TD
M-*2./EJIZ[MQGP/Q.,5&+$=.9KI</&2+7J8V?(H0N=?>--J)7O9!@CI\ML2K
M]Q)8V7T);A0MR;)>471[3R+\,B%7;EP+=#D]O&'%R_6 P<U6LVC8$1ATLMN0
M,A0Y3B-UWU<@L&U8K&84,T,9U34E(BA#>:VZ;83E-S?4N^TBL[N7TX-C$8JJ
M#YC"+5=;U^PDD0 )>> ) P3*&PH-6IHLLHAZ+//P%@74UT%?!F'XB#?2K7<.
M24B I.65/+U\%E??GW5U"RZVU@S UK<;4+P5&PPR4=L6 2_BN24[BQ7E9;<-
MUYP@PDT%4JQRYJ68$8)K*A!1E1N,R.?;"[2*5591"TT;6$<CI58R*!>9>Z,S
MD7VQ1S>4<5@;7\/E??2-1@H1&A')J$X776T@78C#>SVT=V/:B8A27G:*#54+
MQ0Z"E"\UV]!T7&'6^!-(B%IWYDE.M*YGDID]X]U"K3O^T;0Q7#Y0]%T#TZ5N
MK%5,[9G'6I@<>0]J3F\H)'6CB8%\?OGR?%]["X#&$(EA+6QG>4>$]NI,>OP"
MM_73Q&'>+&?+)\D?0(I*L)6-^4._>;*U$ >Y20"+)?,]H<.U^L#,5(98_KW2
M>HR"N1V=MVDO8D>4JFLC+BPRL2!O1C.]>0P[;T1KTZRB%?[4SPFLV)%2T-7\
MR[@"N0I#T.7,RRRL\2ZR+["I&V:TB$[JIA<X7,6VZ1V9(2B%[L*X__BAF&1.
MIC=W4J?P$Z5M_LB/)L/.\:1"\"(E>KD(!DMB60D,0)ZJ!$XL\U9(+PMKQEXQ
M-ZZYU%HSX?('7F&E[W9X83^8@3^K49J3P* Z1"G+PIJ%0_PA G0^XQA*ON13
MB!(^;Y4'V/J8<A5)P]43[,_B;J$=A1:HM.Y*36F"Q<O:X[-O"JW.I9Z680GK
MAP):TYL3G\ASN63T<VB=\\EHFJV\O!__AHKYXIC\JH1R>>2SM46S?S5*9&_O
M!TUE>I,3J;:3A3&\E]XIY'P@_@\\>5-L\\3%;Z4S\75<]&.3'KIPT4:-G*E!
M?J<*O44Y>C\^M@-W-$-QE\ZN"9<D+5"%QC1/S<,[S++)40R9K'P]R[@S@Z4^
M Y"N_1-X2\RYK*_AX$E-XFSO$9&7GN90];GL%Q-"%U8%(_F[.:I;+J+9L-_F
M\__Q]<JELOJ_K7-UMAX-P(M*_YC*EW"<_']]Z]]?$M^H/"4]3A$.15[V[F>+
M2VR0S14ZCSFUG3T2, UGN?@OCK9KU&>&.LVQF]9'L7K.1=)3M::/6**D@.M\
M!=OBYEUXY5R&+=P.MVNZ#8"#]N7O]!7^F>?&2A6Z6A\[E.$K@C]?:1K94WF2
M[D'N',<L:V4&WC34&S93*7;N!T&5 ;NV+M'=XPKYX7RJ%,YJ<*7(D%M[1;S8
MF0TJ)4Y2':E>4J<P\/;I4XCP,?AB7^204.E=AZ3H&]_R9*HOHS?J'(0P&Z7)
M<\KXU&D&EW6SP"D)EC83S10/YI98=J^-MTP.3V3DU2;HFP%VRXS01U#&FOG@
MA8?<A2T:=TN8I0_<_#N1 ()Y*WNQ*AWVYJ3YCO0W(=@"-D?A;]:]&&2I#(0<
M0HE)/WDPM^VPSO/6/0M^6V.Q_MH8RZ3P2^H#@'YA>,[NJ9!S>;69<=005A3D
M3:WT4U'*WE$IS*Y'ZWX,89P?.NB\Q?<NRT!?Y2>4FE[O7J9]A@P0G]]HAGI(
M_197!#A->_? :A&,!&S,<UQAGN:B1Y+P/@PBEOC-,J9(F[ADWJ  +D7H)!-A
M+SJ1N#\5A83],ATL(7>G5AEDA6VP^*SST"@?/_<($F,&6B$]-*][!,EMKC+Y
MTB+D,>@I\P E<-@.26 UW8:ZIA"%2P><C&O*P'V#P'4.]-U4.@L:R4OG@.0J
M.33;'="7T4[G^Y=6SD2%TP=)70D;--5M5D"23VS6B;CB_65._!0RGD%>R826
M$%)=#E]Q:OD/QFPY!I(TVY\B\)FN-1^LCA!:I-(\4<@'C2_I"W4(%T84K12D
MXTN,BC.#&JI_ZBQ+3*L)=40M1 ,-@#&6'B@3&<FD\MMV$.%36E(KM[>U^;VN
M.7,*%K"[HU6,C?WV,NDI&T,5F$0M-U6C;F'YQ=,-8 [ S(/B-G$$Q;/4>E<D
MX%<1RJ'\@+*JYWRE6:LSB]->/Y" @XN!$23@N0[P%@OU;T;)/;&C)/I/H6GD
M\X^ZA;-0CFDX"+((_!DQ(OQU?1)H7>=WK'3Z,8"?VFQ1ZZLW5Y7CS=0QMH>T
M.,-TG#+BIX44Q@>Z@3H ANNJ,1)09F"<L6N[+\X?UF-X\4Y/' E([T?$'([M
M-"C[%Q\=.^P_-(IY^E$;DP$M;5<1I^P)_-6$APB/3C;8V24K?G3UQ3D3$C"C
MY0;IP=8NO6>X&VY#+KA"U6(FGG6OZ59ZZA,8_MJ1VFQ9M^^*ATB/4+=<J 0)
M('5IE8"2)-+5C.?Z'#Y\\>(] &]U=12S<D%_85E'UM&&I0FO,:9]@[ASOY68
M]Y![][ 8G'KY6M!LI9SGP)7IM-2P,_&PN[93S)+8OH$4FWQD"7_2R_^L"/BH
MRDIA][CL*$/; +>(S#;B43_3^9T%NN$;6+VQHUVY)0F^1?%G!MDSP,T)KANV
MOD2LWVZ.)$!I2Q%:.UV?]M@%76'FF*[.#CR'AD.G(G!G]60="](!7'779QG7
MQE%$&&Q]BLJJ!@BHP9K-P79CH!OW)9GLK_3]FU^/!('CU:)"4'K%&>MWXRZ)
MP[LP=:<'9#<8%W!6[Q.;( =:/.W^RR%NJZ1^LBV)0@F#-I-IV<!J3Q'5Z1F5
ML4/32K(',3_$/[N%4  N5TA< F#FLK=N\\'AR2\[;MUN5V?8Q-GG<%]8,_RP
MJ6Y\S#ZNZ(UI-TL&+Q!U=;#QHIQ;K-7&^629UA&*-[P^OO^NSO=YC,GIQC(W
MT4?OE[NT) =E+Z>I7[47CPW?#V:*1[M:_5@CZKK^(7.'_F>M[O<6V6^<T18J
M[\]&MTOLD  27A$1"S ?J\6[%_HA=O?)<'>LS#N?I$BM?=I:90N]_X0NCIP>
M2PXUCVZE$D)%7#3?Q4+!#T822..J^BNIOB:OWFC6<P2 Z4XV6RH]!L XY6R^
M\DLA(:MN,[$>C$%"3;(.%3UA#\H%34>@6-50:X14@?9NX&D[E?ME&(8R"D=Y
M\]J(<TE$QU2.&UCX0Q7X.R  7!N8U3ICW/JC[J*B>?W:)7D\]>8O%S?KQ3#9
M3AVGI+4%15V9,V6L?M8&'_D/:?M!9X8!-Z\I\ .-ZB9F^IXPQ1.[S+==T.8
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MVO&_N2'Q_Q?T!V_$<>H??/WHTZ9:W<87)2M'/WV5UUD[JHH:6_T1G!%+$IL
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M=>2%TU[(W\X*W?=TTTR!T7=UML_G+)7FX03CU!$:V84(4WDQ-O<!"HDE #@
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MB#">0JD#Y=.2;<;,P6=$O\+*!FBJ7+TNGA-OIF;0QAW+_E:M!,&UU_EO#XD
MV#[>+\=ZB3P+6AM8T*>#=D0?62XPW:I!'%0O<Q$[^<SI&G]*J46IL7I+D!5.
M\=4N6W[X.(3B"S5*9+=Y=E2.1'O>> %6-8;LE_& T!>VNR]*_>HWZP_'G/-(
MB%2EZ57^GF]G?SSEV-#PAP.0.^CY_QI--/=?+<7HWWR<5MOMLM8F?3?<66C
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M^5Y3:\?7VS8H_>HV=LE"2#$AZDN,-1."AHO&2UALW_2G.'PFVE:2KRU8T5T
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M-5[[B*^6-1C 3B%UW&)LTR36OW,67B73NVWJH8UCP1)D'DU ]M:B\ ?S8"1
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MLGU!SSZ?O:Q*J&1X\9T\NXP%X[R3@6I&S$=HDZ[-+;)W3@8GU?_BO];H_ 6
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M., T9[Q]!%J!P[#@\'4GG-L(0-3PEHM\R%U!-S1?TT?X%3J/[X!14 5TQ%6
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MK#0E*$^>[9PK*9_.>23-WD=X:\>[(Y"'(O]>9<,409]_]7##HE)-40_,DW]
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M!C-0(WWCJ)H.UFII =ZXOEZU@.B]3@%'(?7C6,V4!>V^XWK%$&%*B]X"'^%
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MM5PN]#PKXW0?O/9]S1$H,14>_I T&5_12_!(!"CYJ^!2&+RSCW%W33/^>P[
MHB*K/22\"B4HBC'X[V"A^P=>! *9Z)CY$0CR$#[^2=_Q>PX9'/CTZ@&9S+X
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MONWF6C,^6_^AF]+; <I2^FZ#-[!U^X52Z;HW.IFE]$_192ZD'^>3-LAD5W'
M"AW"N9-UQNLH;Y>?[@5@RD-_S(R2M:-O;$W=Y3Z)&ELS\$^T#V!YAD@1&K_
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M)7W/9BU9J*&-VMU1WO..R?><&5/XG:::)0?WX5S L.-Z6-I>0__$CA((7E0
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M7V_AZIEV[OZN 45O*-WD;EZ:=26V2Y2"S<Z;ZFPBLO?X\)<SU^8D%PQ3E23
MO$T+B3:+C^28Q@4(EA+MO5$9&S8S2DS3"QI-&4Q,R^J*:QML4="!.A5&_J8V
M#VV1+Q\%J!H!UF;7N=]52>(T4%JT<E>'&[I59?RV8FH.A5&X,F4X@!^QT<69
MDT]^H7('2=Q1L62)LN&V\!R;:\G$)T.G:*SP(,UC:SQQ?8I'-_3@5T2LQ7U6
MPTZ2#G\5TFFT>MC;_2+PS9^>+2K.>OD9$6$L2[!P87C%"!UQ%5S7M4F$[(9$
M!G7=!/';9+1#F5MN]COIP[I>O^+VCOS+CQ+1BU7&,XW>G.X+_AZ_6=7K'W04
MD%,(84Q!?8Q=3Y$"T8<?888BGX_8;\C.>6X8J:Y3S$+VHS"9Q*428#@G(ZIP
MTJN!Z;"J@(!RVC[;VU[=!A&<< 9>=ORM 9M2;5S$ BR4Q/N+'+/>ZVU1:XMZ
ME,[.,)5D"238& M40]"F>+_"9/PXN.;.J%0'K&0_>M^N:H2%SPJ2*3\_W[6)
M"#U.@FP6H;R16.!G.7?=<9+2D[*?>]E7L@GD0V5Z<K2]W)HUNQ9ML\<I :.T
MR,9736V-N8PI[:_Q]))=HQXO8K;AZ%7WM2'FN]FGV\5!>?PA3WJMXO),N)M]
M?X>M33-NRZP)[P2,QVD_]_&EY_[9F2.C,V>!'(R?K)'.:FRH%[B(="/\@E9W
M^5;7U9T3_MJ'(GOPPL_#CG('<_<KXOI3FW>\0^Q,Z1#C9":S4L2"R"VY4T[Z
MO0GPZGP>3P+CUES $PT5\VN28F.D85+CLM2 \6Z8QZ<A7J=GZAK!- IC4D:0
M'N'JSBX7_XI]V/00Q<OR9 G.%^6!7-0#]ZQ37U-O"E*D[^5"^ZAH1QN%F^N?
M6V!<4^A=-+>LVJK+/X,Q)(E80#.D4%+#RI>+9&OP 4A%EAEA6Y4'\8&\JZ2F
M@ R)<YYU=U4!+F@9S&J2NM3E!,3Y\W=3V90_R-,KLYJ8QL/G?2P&M4TA*9NT
MF<U.3'AA9^B8>^O;Z#<#6* )^MW4+D9U3^8-%C"TFRTC]%MA2>IW[<_-F%^R
MJL)1HK3L0":>U \1PDVX^/L\M/$SX'F"$]A9[Y"41.FB\I@(\OVZ)D(5E2L"
MV:S!D;]6C/1\>CG<CG[O)OCF3A@EA>@?L>VG;%R5(QUJ@U=LQ%=8X."M62UZ
M2I/VQ?VK*(LW"V Y3MKCPNE&PKHV%SZ;0=/M4N*F8R6Y#?=G6ZG[?1-,S+[\
M6TR#U[^U@J4;C]D'7=:?*^L,R8V&/7Q4];,#"_"8$*"U_LA_I;-H\US>(K*&
M>F6"0M0,W_1(N(>5%-%!I0*D!L+DFCP24:X#D1P)[_5F7YWO2/(H97/&X\;+
M-L1*49F'U>.1\ODA]P RRM26\9:JQ*WPFW 0E&;>0-S!XJ@*.O):W "7D#9J
MKNZ#Q=JZ3G$P]).*I?WCPA _I@7XS3^[SIL".QXIL/H-"%5,.\QL8:_O+FVH
M$)Z1H2V1?YM^=H?_1H2'J-P37=;\GWX;]^+8Y64F/%28D<GGDNH0.-C_62\E
M^WW.*RK3A-8".#7CBOM%F/)UP\AUFI\F-).PVG?U=W73A?'+<>VW1NGG/>G'
MR^B*M [$]!!B]'150JPD1B^]+9A'OM\_-RZ!\PE"!?JIA_FX%'+;A-V'# N0
MB]RJG46!^V_5H6RW0;#B!^2U$@[XZ(X*R6ESY%Q\D5R;46-CO6-XK=!++;2Z
M!;+S0\!Q+-0I*M+"%&]PQLPU[C2-:7G'+&,7PQLCFNSD2,@ISJYR"'BY<=R9
MV9B#X+*&S7>YY<=C 7(L8$!2Y8**&U \BTL>R"J-WS)G2I6,KIFCGT54-V$$
MIJO/4L(6X.!@(KJBF[O?RKQ,.).S<Y@'42S >]/9<$B!%19P6QERX?M\LU/:
M^#7UNLU10GE)S2?02@V'!W[OQ$;N"')M//H8LLPYEK-&?4E7B<ELHV)GFXIW
M" 45)N?^G@^L84'%NO^:W&AN:-!<Z Q["?K-L.(AY^Y0.A[(-=P7$W]6<V_:
M"\=CXJU^Z[='&S2X<M.+[T],1&6+MNO"(V[U,;9!XK/)'%OO/=9ZP8;![V!I
M=S6?\I8>9W0;+=NK>A[*N_9=ON=$T==V5.U^S@AJ^\FL= 2#=\.0J5(IL<UW
MUBTTV$EWIFA&VDT&Z!W)4-Y,?&M2EV8\+2;*;S1TFT8]]&D6_-9$.T^%NZ3S
M"D@AA>:*C7I?8_TY.W\,_.NUVA.86#6[1KK+ZW</L@>>8Q@TYD#(FH3PD2H&
MSZIGS0PI)4;!]AM*B:IU M.1]-HL!-O#>0%Y+3P",CGK-@+]<[F$M.YY7(D4
M7D&##2ZA6"#H776 HFK"V7OV(&76OEJN7-\_"45,9JJO3V7L^C$BL(8T!M!N
MFX\VK5LLCY *\OM8A**I<!HY^#?83&J?@ZLI5\M.HGP]S?8=IU5]59DJ8\./
M%[[>UU2 C=I&183L.?Q\;R[<]SA>DR7/=[K8(X3'%FHWP?B\Z4D@*_U;MV]C
MAAX[RZ83%92Q3+?;:S3;5"B1*LT.PEB@2)+UE4!)"*Y?R%&E9H(7/EZDO=>I
M2V<<F/7W(\?7OCH_M$GQZ:(ZL*GT"GR?806_>MB==@'Y7KWW>O(;>$4(]A1I
MCIO9.$_, O4/>?-O+BZNY)P?Q[.8(#H.VUE>4:("FQZ\5L5[$@+MAN6>5WM+
M'^H>M'T6)"1X<?^L$O3UF 6EX)1WOBY>V4WN_XW@A+XOH/,>DJ,@WSW(W$Q>
M,]M:L0U?Z_17'?],>X3*AX5*?!B%49Y]3.:MQ;F6(CC#U![+C;B BI,1GRH<
MUUI8 93D?  FQM&T/[^B/FB\AZ_2H4I&GZC'DI8F;;5D&\G&'D8EUN:C*FR;
MD?<GVA_52F=0+VNSO*#>5'R"H?^<<N/P!9 S9@CWZ.R*0CJIRV.!;$U5U!GC
MC W%PFK\V3Z41B5]?8=&6NWBC8Z*$83',BRO=F.<"I1T:*![+^G^M[LI&J%H
M(7"'/V@NW/!Y20ADN)$QCG9L6-)PWR)2>B)PQ(YZ*+1JO\O]WHR(#D!R2D\T
M!AU\FU 6KG)+2SY3..*&,$\?%CC1DX;V7LY@;BN@C+TT+\PO33CX<?.]PR<,
MY]B[M/N("W02C/.L'Y)EW=ZJ*ZQ=[4SBK&,1-9=8NGY\>>N9ZOY+' ^+;"P;
M_+1S(3=5<AI#P7!V7KYGIQ;?-(L.A%-+;NB"0+KV?5PY#W@C;T.+4:5]+,&)
M#I-*C[C]%;=XXX%[5]0>526<S"'9H]Z5WFO3AWR\A3'L4FEJ%D_<ZW?M;IY^
M]SHC;F\1;OV !:AMA2JU82&]_6TE<7!AW7O*-6PC41S?="5VQV%E'KE=::=@
MGL\VK+(-=CF%ILP$^XEV3(+>\;FRZ^FMD'?5T,%>C&"'+J:50Y7\OO\$N%,*
MR=>\*&WA>2@J<=+PC4Z@G)FC$=(=*=(Y4QU(I6I!VAQD_7WXKK!=-Q<UL7N!
M!DEF"%K?EP40&(R\2W'1WDS J7:?13*DM*^3>];+$RW%)K&XV 3+<R&D0T7K
M>].ABGH58]I",NZ%5O[R+'&[SPKA-NMD:'=2:TGB&;=<_,%^-84V#XF+V=#L
M3B^UB>Y2&V57*U!-:=>%%+'?:=@U?KQG7Y-)E:5J=<C+Y^BH^$(_5"X9IM5@
M1Y%0WZZ7_ZO#:GU2U.7UEWF:#W\<7Q_YV5(AB0LJ4YP.ZX2OL]<&&6<(" 2F
M:W1^G:;="NFU;FNOG9XBR;AS0R  SX@@.: ""U#9.*?UW2@5FN.-WA\Q@9+/
MA+(LVKL>ED)[WN$X!R(SI*9W8;FX)OX1'6BI<S8D$P]:QO!V8P9)AA3+M0+[
MLQI$]G\;_I#6,3C5W"F U_5 ]?12#WF!CFN7ANQN7%4!06&W][2+'\F$\CP?
M"VZP=V+OTH$:=\7I36^WMWC6/OJ:4,&3?V4NBJ2R:6>.:.8E9*W=3=>JCE-U
MK0Y9[/M^$2:Y:/7SB)OR,YD#*K'U4\A7\R]STQI(:5_>NHWA''G*"$7R9832
M%^VU0ZGOPC&OB EJ+ZI!<*D^#"_B5#M:'OHAD$#8T$_/D$43_F"#2FHL;^G[
M6&3?P[1,5U1+C1'BRF.W5!#F'*M;>18/2*#,F3=\-)/#Q:BM?U_.%=4LV14+
M?+E=4AK9YO519KKB;HHV<$/[T)JOI&#C.H@NU.E<5S=(P%&O*$CUIDU:@HS;
MJ3XY_%RK[STQ?OI,7E;__&+(AG5#ZA&[#BLI/VLVG_$WY7M&L1=B*$C?U4$D
M'Z87B?_(Q658FP;@G"I'O1U@.7J_P3MU>I;JG*ZBE9C\9EQA ,RC.[TU'2FP
MT.T;Z2U&.M)Z$"%L<*@6[EKW??QH_,3#L?/E/['&B3TY0U?1.C]D83(N$R>0
M-XK+P1#J7"R@[U:4LLZ_!?I0K6(O#!G@46'H&D>?>&^"<Z<@FVE+D+GV3,H"
MQ&3@Z=2/S@#.GXF5#]>\QE5F)T+D^M[FEJ1%A);K5)V'LKF8B \3/S?UCN,\
MX96;[*KR[^34WD1%5%4R_U;ZI13F"YV*XM&9[N.00DK76^^ /;T=JTU93$E"
M.(U-<;1)$JE<D]!PR&JD59B^27''A%"+NI3-7!/Q$^Y-O$B*[&7_%@833_D4
MU1ZQWO>XTZ-Y-+4H[S3P1NQJ4KBI_R=]]U+W+PEGPETMI85I=E-U_%"X3#+Q
MR=.Z/%[67%[C#\&'%IW"T8_?PDTSK):3M#^J^@HG1\W-_X'MHYX//I5=A8<$
MT02[$$M@@?!)^]96%WA41<C#;9-&#IL^8]DMAPMK:L,J/T7.A'!O.$CS#]"D
M1L?@OFF$I]++4%2XD^'6>7..$;3CE6L2)'I3GN3#>064X@7'+5Z\-]SCO]SP
M4]/A'9&#_<9ND;=O2OUHU>8Q(H$\.+1-LG6%?R/I%Z6K/>E"?3X=UG/[3SL(
M^]^+R9^>C"P51#Z%M+&ZML,_'U,1^ETOQ):\/9J1GA3!(7%4>M.W(%O@N]'8
MFCB[P*E@L":_;]NL3G_$FR:*2O^T:K<?- 4"M7\N>R"DD@5#)<+<T03^GFPN
M)7<%24EX-\UUU6]1< 0C!O6_3O=O+^2[->.E]*Z4H;IZ%+.:&J_KBU)694\J
M9D&P#IWVBSXKP\3#0(&VJ1K>[.748Y'6RXA:@PO'IFP)&>&N6V KWOWGM*"%
MASGIM2\W5G.#>XPTJLKR5NX38*Y*5_0W.FPG*P6:']!'@QV56SFM]L-OKILC
MMMXT]A*WOC_>0&D6R\Z^RBXED8TKY^3H^-[P9DCNZ\5&LM>^[4=X"V\KHA]]
MM]R=@Y^<)%+X:>+[+*=1#-/NV]SP9JA'<TCS#;D;'<)3@H6Q1V06_RGNV3BM
M(;>Q"%E] EMQ=O-Z+_C"3_A+X2M"?^YL,II E]NM4"+4T^W>Z,>W:#]!/: _
M;(J8V+! 2J")$8GP!C7E4DBLIW)^%L\?I8)%GS%-&>\^S*TF)-]+=1ZF[?BC
M1.-9?>])]9[!//'8<(_LGAGP[F94<]#T!W/#];0;ZNNCR@66+);%GB??!X]9
ME@J37CZ\V4(3QD$5>CW^4N8Y5="^$0)3F#WD/S+P[>Q7!W$B_N [#RBUS'(0
M[55)'7\.R=%;$H\Y.[G8PIEP<<8W90XY1H*!!YJ^-D3T1\(\8VL(:)*G Z,$
M^)ME6J8S6\PIP_.>2+*WO6V-!R<&==V*ZP_8+O8OYSS_BI,P#"DLH.KQWG;O
M0N'B Y_%%3G"WR9GXG%AOQI4)LO!MY^_&LQLN6>>>[HGV&+Q6S6^J>[!.I40
M;"M:JXXPR#8'#G593V-X4*IVXV/U04, D1J^#KZBN3[\F&H(KBL<0NM[,_'^
M9M98&"3&:^&A9^7ZBP_O)L0B? 0[7S:5<,:T"U/'>?*.7,[Y?YS6@\3#J-Y&
MRW2PVN5MZ\T4Z2I\6IK\HM ?1D1O':3 A^@81C_@X)(L3=]B.G?Z@!M\4SQ"
M2A]Q<$VX?AF.\\WD]6$*D*E7O\6>:M[-P?"FER5\<DFGWE X]BG!A&,EJJ+G
M"XZ]T'=E^9,MTQ>A] .D'U-PX#@XZ7@*R])"<SS=$(^[9ZE\=6FO"GMT;ZYO
M<T)RAE:P+O?>*,C$V.?+*Y_(K.$=%::6J7;-RCU)G13VXR4C!=OG<^;J@-\*
M V)V(*;<8TY*)[4YX_@^R8,W&.EQNA#;;:NYTPK4TT>I/S+V>M^,!F8:^]2J
MF=8]/V1Y+LUMJW7^$DRGA1CMCWL)5<\P<<]A#HX:Y&&8-;YO\0T1&2<7UWZ/
M$:J4Q!M_L)AI[^>1S,'8FC38K+B;HY1@)*CGIPB)"6PP]E$89W*C0\7II2Z0
MF<EJ$VS%^AN#5V[:^/<VG5,)IL*7"-B*:CDQG_<$2WTM?N^$"\!SX"!V-9M5
MIY14&IH?G5E%.$N2CJZ7!3+EF02V^#TAR!]0J.Y)%&/4%%X[QD5YJ#?AR:>\
M@)@YMUUM^#&E->KEA6XNF3'1IZ]+=_<D57O:VN[@W'-,&V*UVF?E^(#G,O@F
MWM:PZJLYI7"YC2?4/]/B:7HTEOL-#LP+C W6G4AZ,,S1O5:0C)1?!DLC=_8&
MFI_;3TUJW2 _[K9J3*V2.8YK5*W[M!V :[+\&8O=BM5%Y=W!<%$M&TVO8$W:
ME\00EN,RG";E9;WT"RX_)%_7-N@QY?4R_,("%-+ZN;%%Y>FMM!JQ),IS FBB
M0!4^Q*^*RB4L4.@Q#GZVPP '/EQ=5%71:44_FH+7-O])3]4^,GQR.4'EX1)2
MWS/81T%Y?D'E&>'E3U_4Z*"[#F6V[?'T:MS\<P^Q>6>(8<?D<<N!@T7(TT5]
MQ(]<F2XRWF?)@ZT\A##55^$252%!FXLC$+8VG^4FKD]L;VRJZ(\8Y6T,NV]-
M@&GW(CEF(GMY5_>-4EGR[8C 5HV;U' J"T-/"B^:?!Y^7'Z+";-EMZYK-U)!
M-#J:,N37OMCKW!P"4J%9GJAH@S=F$]XBM^TS#)F-!O.KA'#VUA"(D78/$"6F
M(/MHL\$D4A1M(J(DX0O> %6Y%ZM1#KUXX:?XCU*%BUQS\2J4U\9CI.V;SX-"
M(F:04*W-,]QHMR>8?P/4;WN393/=]N>89R"IRF;OI1G?8+22>B5(N:F^,L&>
M5*<07W(YH>91X<=^IP^([=BQ]^N0@^=3;^XL<1*\)*L.$R="1:OGNIV*.JL_
M/6Q1YQ+P#./#Y:I\!W7W6U\PYR++UF5[.P%9:I*96+B$OVHJ?.Y1&;=6#_V@
M<D5E85),\BJ-^Y3' M'A*P-:[0W!2DW\^E-Q:MW2$#UWNN%*C.7#8?E?;3AM
M17SRF!$E7PND+#N+V-K<S?'OEBKP +"TEV@IW_7O-3"XR9M#J=!$$R<" 33X
M<^''GD&!=2Q :;VKPC?3J/!4(W7_J(PM%;JNWA5SY(#\L;">0RDIAN^4=P8S
M5N]W2D=J1M^H#>8H+EUZKZ\AXF@\$67Y!/6D?^&#G?.,S.P?85^N^WX]'3=P
M&:& <R>C>2=;M&Y"KFP3\TOK$]:Y2Y@BRG^@D+J>/8+RD>=RPS8N3(Q]YWL0
M7;'KB%]Y$R*QEI\\I[[C:MLA_6."9"3URU_MLV\M)H_ULU"J4D$>8^^[,?PP
M<M ^RU3'._NQ])<4CAVTB<$,B>=!OA:6_6!\N/R,($=CSZX=M?,TVGFA?BSE
M6;5SZET%$O2O#O)$<V:BY4]RL#J0P?NB=)UT:WK<%,^1>*)6"+Y]3[*OTH!L
M,?=4!U>X-Z0YB:U!'MOFL)K(Q3#5V3R?AMUPOD"!-.ZY5SM<:L-.>5GSN'8U
M8)X@/223<@,^($!ZDHR_3"37JVC2)A9#E%Q=C4RF+:H"3]ZGL;4:C' 5K>R5
M&/X*VK6%N*\=T[NMN'1F5=VVDG(QSD0W[ISBZMPO?<2&:835M$G++"-\EY^:
MV]['A,9'U>JT>SJOH<&(C 36_L<&]9R_'-X_L_Z1)VI>>BC5(CKWE$60@D87
M3 ]+\]BAU(LA_V-.F$<V%P#*B8VJB!?E]5S1?>D#GA0L7'=*F&QGC;C^DEO=
M4?9^)+YKIFQ-X/)7M0<'<\M79$=)4UU^+%,3/<^;N;]B(BGF97LSW"N+_:BQ
MN)(ZJ2)Z*Y/=TA\+P&IT.F)UD^X4QJK1I\;@R'!;!#A[4HG9U[-*K+S"[OU^
M_,#M)7G#4FE1O+V *\\/5I$?O<'D,:F\ +5.(\I8'? -PP+17D>!Q;  T''M
MBN?")0D5QM?$&>$=WYB=*.IO:2EZ,UK:C534-D;]%D.J>;\*XQN+Z=,_NG):
MV5-&*(=YQ^8C42L;(5U3KGL]1IP&$F8[A1NU/U!2O<T<;--/FUJRG%TS6X0D
M4@U1,U;06#'Q</?2?6%)4L^)"FZVO*X-&QMZ7'Y8I;ULO!<1N6&*(PVB5ALY
MQE$*,FJ/$23Q,CO:LXW%F?DJCP$?JC 7'#E@<]F.$:]&4S$F_AX\?X4%LM\;
MK)RV=;WR:J0FF=\EDP:+=LI)L'& ZW V2\RUJ;#8#8)5=^<*]F0HE\LH*[*;
M&^0-KW&*N0C-'^:VJG/G^;NN4S.ZT[S7OV>5XHEWC[[\4EV-L[?*3-ECT>RM
M"2BIEG\WIWO3O,38 %X[!,YC;)U!FSI\UI3D#=ID?*@@4P/7%[-Q[;T(HFDK
M^A'S@*<8;*P^Z"1U?_K35 .K+K.%5,][;7;%W)Y))0'?$M17\]F2+ [6Z:S[
M"@SSQCKK3E&="-D"UXJ1LA!_XS_,[WYI?9?GSUC]MI!=7*X6#-<W/'2GOO-7
MT^CY>G5GR4SAF"'$BI/6W=VSO5]$($ ,UZ24J5^A344HG$*KHY\2PTA)G]KI
MG H)?F5/'PI1[?%#>5 ])!!J,^1W^K:CL'\YLT*)V!J,NSW#"#=]<RC'X7'(
M].VB.N^ORH ;X/TV^JA*WO$]^B.- 7NQJZMO4%,L[_<,@(6S7L(GFWGNCBOA
M&G;FXQ:+T8G\&<^&,OBL&./S?(-=>ON;>4);LPWFV5.@L2AX>M 7&1EZO&U?
ME(#=Y--T:79[M:<'%H_6/C86%(3PN\DX5>P'0[TZ"#8%"N?<U>\E#@K##2F7
M]CFXI@))BQ_I2KTU8\L#EQ.0D^07%[[^<>VM%0>:<OT"Y7:V)3UX;GX+O&['
MM(N@N&<3)N'5SF^RI8XKV41I\E.1'!Z*=@F>,JXSC&L57BTB-T"[(*D0JSU#
M3M#^BA\IS\-BB:&_.%?@S).6JH*/U;LG'KDRHQ^\&+8>YN=%)XY-A<O#.JDQ
M?5]?RYXZ!]FIV3#05TN]0LS%!"Z3FS=Y:BA(;WR]>:CPJT%)8OT7XBCM.1'Z
M.W+XX.#^-W+UP$"&T?9@LZD'@L-:Q1;/68(9TA0;$$WEWB)S'(RP29&GCN'U
M&7AH8>*+1VW3X1&%[Q>Q0-.J(9<[*8;-1[@XZ9MBT[NC7)567L8?_:\>T9+L
M6^62O-3X6-Y47K;<>(;\4XT%>D]+;H\GAO/=BE^/-<GL?DYR5:[I7>4PM%[#
M8MWC68K$9[+P#"(/OKGR5TT5&E1V67<+&*<8_[30*B[RK/)PS"*U(43U ;1W
M06Y^.]TYHK^N*+6DC077F_RLYF*J \69W*_Z_&_W/GMO2?J/]KKO]O_BLZ__
MKIF27#AG+MRWQ,V<T]7G]YCBX"WC2YA-5S^5F.5#0W?_9]1(W<0@Q[9[GX58
MG\=7>TZ%.%.S)L<RC.QA 9J&*J'=JBR^K^D&3&KS5_XZ/SP_!<Z8WRD*^:,S
M>Q13:RGZU+NM/E  457E9-DX<= Y%S2?YF.=%A;$,,HBG D=7% R$_:K/'G[
MIY;K,N7!)[3F5."][F=(78\#GTXO!719/45176&%G=VB.RS-/U PE9=9!)S\
M!EZ26]TCJG+D8K>A9S_Y]-['+1>/%>[I!HUD.ST>R8C5L/+\D*_Z2 +IH(/'
M+LP27585\$7HC6\(B)=59=_UC^VTX5<Q$3<R%O:$O[H=<7M.?B_(O$KT&Z?[
M/EGQ<O_BA;)P$E(\_J"ABZ*7(;J!(]RNA6+>L34-0)4LZH$;9_B#LD/Q'AOX
M]ZL8^WN$:53!;:346U(I?O9YWSXR/OQ@EM7XPSQH<NGA8E%Z\)WSZB?]YI%,
MJ><S^T'_&WOO&1;ET^4)MR*BDI$<%9#4!"7G!I$L I*S@$H2D-S$1G*. @H2
M)"-T(Z').>=,HV2:G&EBD[I?_L_SS&RX=MYK9W9V9_<:/YS^TO=]_ZI.59U0
M=<ZI8L%ARHVO%6WK,_.55JB[*=G6R1X2*@8]-6%\,IQ&LK,+V44VAGE591;5
M[K%U;*(_Q*<B7.<>6&<W.-/*QN$";24V#"=/ZAG(J%>;/BN4"T]*GTAG%L[8
MNMNYV5XB'4)^2BH76I/9".N)3]:DSBL,J)PO+L],)PDU,JD<9,YPI_14B.FW
MK8> 5K1^EA:-":*XBTGC7T3Q4TFF)C2(M#>Q43;Q^"IJUL0OM?LKGTCJY:DO
M-S)/FML8! R(/.[65 3BL@YE1T1,(R7JP>OA%7111242L32;NM.EIRYB(G0!
M;[PR./4]Q&DY;_4%;G%:_QL#/:4:K7$H51O?@(-YQ@9??5,<%'XE;Z]WWPUJ
MRXGB7U SJJ;\4/OLC479B1D9. ;$9&SCY9JO[9@LFD:GMX!(#W:9.)+WU"T%
M13>PDVU5U_TPG=Z_M803/+P('',M/IFHK/?NW.0V#SL677G]<\^('4=H> /#
MBD%,G4B)64PGOR#L..P6*OXAY^:4;RS_3C1@-86TSXNS],E!<A*2'>6>&[=]
M+Z&5X]+(\OKC\%CJ0PE[B<X4$3^QS.?6)'*T GAXB1$[P,ZUVHDWZ!SW.F/;
M,V=.>9Y1V2W(@XE)7DF[)8;4]-/"%$3)+VO_%F/,[?1/ I,<,&\MU$M:2,A#
M/6!-7V"_[,T2J+7S=F3<CH/E418Q9M+Y;SHH:I[3ZN)G),D[-9&CA'81>=+A
M)5UE6R2$+;'+9H8[102K^SZJ4M71)<?RX00"7?JUDC'-2R;RGNK1? XETLR;
M1_KMZ\;GHB_.)(*-ZJM1F*_XMM&%W4ZTT?O6.7N?>G>O;4N &2GR+H8>D="]
M*^:+E<@RB^=O7Q[%(VKMQ!H<D;\&3Z*OO-X5L79V><3VC/TT/MX"#A^K/]RZ
M>-_(&(@4)&:-O"R.'VV"BT0TJ/Z .,@O[=[CFV'PD,R<9:R\F1,04MO7UAC&
MI@EFF4.C#A/M#$+9)1,+$V^9J@FV:,L$G5X=L=LUQ*2MRX1,[1Z]1?/=A=.S
M+S1[J)^M-\OJ";87R1]DS"^KUH)Y'ZMA 1Q,3X=5N($9:?)OT!)ZOH[ME"D)
M39M5N_&-^D1V5 J3)SQVW7K9P (3WA'/]R1W\2\P(4DA'O^&6$F<OS('_L-K
M(?^_1ER^2\HJF6 -W%2.[-R?_UC8M\7\=N6T5,]L::V3R:/[OGF]'GL8S$JP
MJ$6Z-%TL'+U<6RI$IY!!^NS#TZ6FD#JC:+/6)HYG<J[1=KQ^NCA,,"Y?U:XZ
MU[K6<3?[)R]L.QD5:8#[/27$5 9H!0:)@;&".?<!X2#?%J+SXD=[;GP5:(^6
M,]!O%TKYJ'/'>O?[9Q1K3:0(P6C>/6^H[D-!Z)GHD-1VT4%7BG?1E603/-']
M+5X/(1I!%>!XW,BG65.&V/W^. 9GD%I"?7GL"TP3I5N:N[!%LF!#*O@0)V49
MA^4[K+F+*MKW #&&E$MY'^LD-<0I1$P)]B(T-C"XD>C62K=?1'N*[78:H\-(
MP,Q2<6':O32'+5T+MG(; UA \+0\=#!I<'4 GS5BB>3GT%U@)JHSB-8CBH6R
MAT7OG7-.EABL?\GLRI\="X %U#J&+1R*SBQ?%F,!WS4GI'LGT(?36T>MR;L/
M*M/<4W1HV/-<&,E1NI&YFYGF$Z[[\PX2*UTNP_G QLF3A1UBHNG9Z\^SCV5*
M)(BA+L)3&"+4DPKU0EG"SXO?LM[4WA@CE"UG?&A'Y8,\1*X0#^]J1^L9][NJ
MQ>M[@^]\]+$ DW?&76GDEET'^6%C@LQF<>M5P'QT::9PNY3WZ(3>R-BDX*5J
M;"CEV4.CKB-%AWJ&4&"W;3?:/'?S(LJCW-107J)KNRS=62]F<G1.8<SGF4Q6
M L]G+& 9/G E@"@1K-G/J4^WM*&FN'/2DI-U$8XRQIVJ7+P+J%[&7 @A!O-X
M2P_6\)UKWU41-=7B@,9J^2(&Z$S&OS 25BE>']N-7@D-A[BBMF^/'"M10K\Q
MM>UJMTL-)4GL@CPIZBVA;TT=41X=I#AD;PR$G:ZXQ#%PXDB>/4D19.]Z==_]
MB?*?9]LF3&US'/$NQ2]SZ],+U3]Z90ZE[3WYE8*LM",*SE?(>5!! MI/'3F
M1D-OC,35B+T[J4]I FIZ>G H5)$+5Y^.L8"+/<@Q+>) E&=11T.,J\5/1PIO
MXF@8=_/48UX@ ;$U+99U^Z7",DM@IULFF>N]KDA'EW>WLPVO\K0_%O<NHV!:
M;2*(:;.8)\F'FN3FN<\'/MZ:,VW\R /?)=();V\7)Z'VP )$\\]PRP;1+";*
M/M2#+.8E$T7#/@]6)4G?3^]'P81$7G;2T1!Y/QS[J:51,_)]TC44S[5&-G D
M,/%"K^!*?(PH?6DB53;<@0@+0!/;,K; W25NA%K6SW^;;N; &70$K91.8P'U
MFK_]_9[-OG7%8XJ'Q4#P9U67P6ZM7.=*SZH;A8D?S,HO%[F-,Y_SBIHB?ZS\
M<NQHQ0+(U1"0IN:A2A\Z+( 9&HX%Y%MD(@=I32 RJ6U4]_9:5BYUH/CJOGP*
MU17Q@8*J ?+ #>G\0-_QXU+0@=Y5#(;M9CED(AKO'&5Z+=&U7C2FA.\)2?%>
MOP86R?5%-58D<,AY?Z5]A+?,\%OJA7J@"5['POG# BP K%6Y?W_V-QII[[2J
M11[61]4L5("<(S.!R"5T43W8<4E\=9$XLNAC0%]ZL"S+T?F\IA\+\"@5\AMN
M\^.IJXSPAM#U6+CA*NENGD^9$X>:I[2565>W*&7S1"G"7.*-*QGQ46P)M#.J
MB-C?Q ]8:;BD:K.7S 69[IGJHQO=Z/;)Y"#N1?!ET/:]Y?E&VEI'?+24(&=>
M8VV-'?2Y6:/ *6- 7>K+7,\AN.#3*X.Q^?<Z9JS^RBW#@R9#4&ZG32I'%D"&
MZMO$;I75*^7%$!1>V&*39Y4<O;>?5@"Q*"C=:G@QDV2+*UEO>D8H@M$]2H!8
M;O 9_2 <WI&)#S>PP.NW2UAFFL.M,$U9+,I*:S/T#*1[ 7[$&,I6:KCA+IPJ
M<JKM1%Q!/MU_O6^XG-(RC8AU$CFE++&L^KS>%_>6;SQ5A&PDL-LA$=TN'T!Y
MURV.$B<!5T"ULZ#S,J_VW%1).3KV.W28"$UO4_=I4@A8T- LQ5#'HX]2#UR>
M>AMS..T!GV"^3&0OR*/"=^,!C^E;'/CE6P$KVV3P:DOV;SVOEKX-#XI-6@:>
MKY7#? AAMJ?E<L5;73K:'4H-M^?"U^J&\3?)K+T(FS*!=\$A]\E+LW:+U@VE
MB]F#0$N/1V\,L[;[U</T50H069/0]CGN7V W!S:F39$/[^-C?0Y!Z<[S0J-O
M)C"/; YFRFQ6IZVB7*<+Q#!N6Q\[XF3BNH2S.708_;4LE!(B.D=WA<"\>V::
M=<KF[P=4<K*@/Q+^PU,%_S/0_U3V452Z>KOAJY^7^SRDL\0-]_&.2] ^.$L;
M].*_HF(4]#.W383(]P@?Q\O1DW)K/GJAZ9^E*YRWQ$"E\V70[2WT\98L"RC)
M05-EZ:WYYCSIJ&MM!P)AS<I G0!)-YETC91Z/[Q3/>H9MT<8%=]3?*SY4> X
MG;)?OLJ:V^)PV3*!7TUGHH$SUW:JV,/3ONE=%YT3!5R>"I\$GDML=VH5;<A0
M[_ZSI]-E#(S37E[K7D8C>=!]95>0'?DI*0_MHCK::P?4CHY%N8&@;*5+@R+&
MUM,7Q$^[S_PLGAE.:'XL!\J9.^(&_&:UW-E*NYT!WM2'''Q"^QA[(GL<A_:H
ML8!HUTK-C\_<U!]LB@^,*GL[K@EREDE;/ 6^1DP#)?1WETS*NKYK6V45%681
MI%NVI[ZOLQ0YQ9C'2KQ2ZE[5XQ:\].4?Y+%G(6W+='WP5ZM91/1'2H1^689J
MA XHS3A'Q0=&N1<=[PK/J%08J2J=/F^\ZZ*[D;WH,M5T?\1QSQ#I_?2M98(<
M::(N>_.8))\E1<-87N4C"R%+1)5M2$'VYD4;\\)T[E8HL!XN$=$=.?L#7=RU
M@W BI2]?0<T@&OL0=^#PF#O42A,<5UP9F=]M4C79NH9$E:F?R%N/S+4";RQ%
M)?-_3L3\U]/3&V5$\B^4>R7X*WF/*Z/83FHO39)R_ N;4W <Y/Z@<?8G^H*0
M*T;7R',WX'950]-G^_GVO5C'H;JZ_PL6PW\6^I]:] '_T:W\0_]WSA)7;2'!
MFQ_!WAO9H?4OK?\_])^$7A?,DW\N.@O&X1Z5IWCR3QL0Y"?XVZKWDO;V+#Y1
M+]+0<["C2A;0RH+J%_A_70*T6CP-CX:?U#T9 '(%QE%;441B ??6XK$ Z:<W
M_PHIA?1G'B189QY35F !S?V*5ZRI[->X)5C _N$D"*TH&'N."L6<YV!(!UDP
M/N980)/-+SU>2)MR-F3$<!B#!? P_5=O:V,!2_1CH/4NILNUV']^.;O5>?V_
M^NPH%G"?[<8;DK4#75[!U?_+EZVQ@" 7)2P@DQJRG\I-]0?E#\H?E#\H?U#^
MH/Q!^8/R!^4/RA^4/RA_4/Z@_$'Y@_('Y0_*'Y0_*']0_J#\0?F#\I\.1?=O
M*-),)-:' T6,!=9#W;=>9"5J@_X9*+?Z )/"T.&0[ 3D['GLI8&G)D^N3?M/
MQT84>UC 9"ST=7$U9*L;4:3#S$JN*:_QYR3Z/SFE4UUTYH]G8P'ZE9]H737E
M9;/^<?IXRW3_6O]BDJO> U/B:YOTFEE6GESGK[K^=V[FS>._*KG?O)][2YY<
MZS_Z"L7_'^+\JR<M_XK"_C(WG7OZWR49Q>'^O;/_)P8D]]%-HZ/^G6XIN/./
M&/]_WXPK5[-MRK17D=<68W=L1N4I[G[Z1\@2KG?SB>6V]H_=A8NRDQ\Z2N$W
M;--F"4#XV!7:S+/3OM5H&?E*X=RRURIZ CML<.P<*Y$6YZ]MR_VA?'JW'@M
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M5L$#?B7"K7"<F&(X\#."Y9T8F5 *)?/,]L0F(8*UG+6&S_R](-':*.(HN*]
MITV^H2)]SS(^X[SRQ>B;V@UMO6];X@LQKMZ0ZOGV]_;DT1L1^)9'L!\@,B,F
M EXX>S]32@W,>SF/$C\M:1#2IL9^]00+^-6D-%,ML7U[V!@%@],TCMM#+2M8
M=PVT'9@K!(&7:5A .-=9\AI^D$DYYTF!N?$)9-.X.K)!"Q2:5QDQ/_OJ[(Z_
MU'91J20Z8IL1_EWBIXZ!L[(H3KS2AY^2FLB$OPU!ET!Z^Y6=:GO&LTB#NH2N
MM;E=OH<8@V:OR5BST0[.]-?#P32,7EA M%-5A1SL2C7B4HUN=S>'V0:PF.%]
MML49L>X)*32R2?Y'1B3K%+6D9Z$MO^CHL4U^$".K#V!!Y3OJ]IJ::D>J0Q!H
MDH9BA6G^3L2QJH32!WN6ZD^W%?P!/Y[)T.>G+'<F:E#2-GY+%B'XF(?99E*9
M1@F73U.&\GZGMW@>!&BJ%<T'1[8+-[$$4'S[G, V&],H_Q9]R%0!)E-233GL
MNSW@"7J:BZLD:82T"WMM7<DP6D.0^W3%SXT^0WJBLE9CZX+[9ULW[D1@Q(8@
MCZ-*K&R9X@24HH/KP=?/I-V(,DE/I!2S&;&Q?J>DGMY#WE\=+X2)2\EW\&RL
M/ BO<SV>2J-SZ3Y'E!DK1'JP!S<QR+N!@R0U5RVE/*6XTI.+EP=UAZ2>#TF0
MVG/MR;\1B!U*"G49V8!YMUT,?2]JE_1*2IR9;9E1YGK>7 ,+\7\ #&A&O:HN
M!$>L*QT<:SA6W6CT(\N[F8Y0=/7+"1XD@IL,29/F</EV:,$EZF;FS&D:6T5+
MZGDOS<P)&OVH%'C;%\S?\=;U^ ?_5H:D\!I&PDC3+AK)G-4TS4TE=3=BO4$$
M"7:;8]C[_?+U<^)OH6@E>@0 !0J7E'43N6))'N$I4:L>S+PC+,7QT_CX 3#D
M)^I51?XVB4T3:X"@#3K&.K0_=0QE%1$3%"=K1Y7N[>Q$YN5]TXIQA%^%F\>[
M@DJ$[H+U-Y([GEO R/K)*[>\&=^FP_E!:$J*4LLLKLU6$V\*AL0)NEE/^;S%
MO&N1V$D^8&WNM%RP$1<.[.G[K#9(O9VILBXX3&67FNOG(\YY*7%;LY<> T];
M]DYW/FH;F66/^Y ;)GAE7NVM74>Q'UZY_T!HKONW7S=%C?",]L.I9L%.E^HQ
M7EBI('JML?KI2Z^N5TYZV^D'\_4\^\%4.A,T'L'<JU0X *L\ERK,$Y156&ZR
M_0/$O,0+BQ_C47L7KMGMM1N?]2B6FBGG9VV/-J9GE2EV(*Y9+8YYBMY(=1);
MP\'.T%"H);YC>[_H8N:'L9_&>W9I**IP)OF)RDOY(-$Z^]P+/2D7)(AR@XI$
MNA:W8KIG2?4Y'HT@>$U6N';IM^*<.P&(EIM*G.DA..GXUIO7)%B S>?'ISVP
MA(8S)&AV%+2]"DFR :=U&,8$E]IL?\$"*O;T%5H*!NBVT1%OW,EU&+0T(]7&
MK)HL'BC2.,5<Z3H&"4DIZHU)SQ5^8+1+)-&>">[=5FGY,/_*OF3M&\&7D2KI
MI)0E$Z<&N>S(M2B%EU%IBE5<F&(LX%%:Z<7*0E]#=6M==1B3 F9PQ-YRCCYJ
M7W#!(Z/]\#N.E%>Y8VGIXN0NS^ZN9+\-"-&?66N,2$-"W[>;A*J@&!JLI^CE
MN>4>J)\+?8?9G2$8><8$?Q% K.JP (.DWOT1#/D.,-V$HA5=W'F1$8ZT\\97
M>FV=%\7$YSB@O^)V_&,ZI&P9ROMK8=9HFDYG-9Z<\O;-LABU+N&1Z*B:RJ#&
M3#N5"ST?(O[@!K,8-D5EU$$]\V8,NZWJ5\@^)9/K\SJ:H--WK^SO!CS&?1(Z
ML'"C*X)=%X8:8L8P^QKHO/=3"(S:A(;G:SX+&<E8VY,^:A818\3CD<I>/JO7
M?8WD'D*6:O67?IFX\W--MGO=>1^Q '(0O+E",7$58H4%]+^\WIW[L1 "9S!2
M.1@WW5:X]8[\4>OJLI3WN)):>B/%>G+J6;30AM],[HQANW7'SD. ,E.>V8BD
M"?BBW;IN!9_PE#\J9]56EV%HK,Q'$<DA*85;WT\GH<X1#3A!5MGU8=@A'Z[+
MNR&)IR#0-1/.VD*WV5@0P3Y\]UUE-.X)1928AK36:S!$V]Y*(> \T3P1Q..<
MNGY:?07LC]V-9=^EH3X,I?/6U0L1(J:8LR:1_S[3$B<?9^KCTSW]5U[Q-HT;
MX0MTT.\T;OW=FX?W!\W1>IV&P6ME;CG;S[I2XJ+6;C21=CPZX;KI<57$2X@E
M:?)EIHC<PL'-Y/\U:DPX'.&V:V14.WXE00 P8H =629BY%6M8.!B]4GHKELQ
M12I-#$%5;US&.DW>F]K9424B!3NZCNG]4Z)D!S+*U/<2EO(TO5F$/X#^JJ5A
M>B30@6?ZN0XX7$]I6J_LM-JDV6L08WOSIX\95LO:;XU<WLB.R5%3*[RH*T7O
M4C,;70TY[C!T5%*+[):OK<&5.K*9>,&(T!W?JNIKVQK)7;'L5I=RU-U:O-#*
M@J9T50X)';W:XP+EPJ$+XAGHFZ/W'#06)VLUD @R6^>-@UZFI.LO.R4N9V>D
MW2?%TW[?D3S 5A&1ZI"99R\(JR;QHF(:KFTBUM_E#TL-9=Z9TO04$ ] 80&N
MDW5KCU!BU0<O:><P!+$D%N1O**5 ANWP&W%69!1Y:63W N[XU?*C"*G\W^0X
M7KLI_P2\E%S5W.F!'('3:@[PZ"XU@RT"CDR7/\D?K<1W2]X"G92#Y@QU\=/S
M*-8KT(&=\TR<+C CH_[W^GA/;R4-^PD8F7*BZ*<A02'0?'Y*YWI5F,*]894;
M,1$!'.81:J:S$^;T+C R[+Q/<[U!8SM^ (G8@T?60T5>AULV55W.*-RZX<O/
M[(@5277D[^-K!09VE2#U0M5?QV90@-NQ7L:L[;SXF/W@[G5C;E4/_S8)G3^T
M&R7:<!"4VI6A+?IRUSP=NF']TWBSL%1DK$'QQD(FF<[K2J$H#%=@]20G'%RX
MW4C&)- 3.]C]M=*Q^^5R*O>=SWJ/ES/)YL'.0$Y[85+N>F/^=1:&8BDXA&Z^
MQ0V?3M5ZYY>CT@J@UI";2F)Y/*)_M+1T7VUX!BH]7*Y6=G06"M4XR QO7GI4
MEC84UNGA,/-$[A<6$*]SQ8($#IH(*399GTX/:0KS2AM[W/2L)+L&!PDAM9NJ
M8 _9_4XY*KP@[M1.FSS<23N?5"QGB=1GT:F1L$PF[?*]45I[A3"KS@Q.\3LD
MG8ZDJ8?K81H0\=;:R2N/@FF&YULWJDC;X:T\G?_5QHU^4P&FQG8)\RUI0JN>
M+^/BL8(*MH!$"]HH1#'5#+<]]'&5G^83''<)S1O[3% /N!1+;FPKHK69^HU1
MX3N@_]9H:&%)?>G#[8O\1H]\M!?0Q_!@7YCHAH_[A3#&?B.43DRQHSU4/_?G
M@/MY<F]<L_'[^AMOKL3L(3B CVCS_>:43Y1[E__U&LQ"2K'[3+?MD,Y;,#AD
MB8YC+G8H$G=8%L:GCX)W-M6XIO.VPO9(W@V!BUR9*(RWW3W< Q[?+7/()7<Z
M3-Z]F"+-PP+:=&Y,X;Q-^"7[:<SP_!Z.@^CFH,3]"L3Q[SU>UXWW=:&]7Z?X
M&/TV!_6FX(6N#$*E; H?[VD4SR9&--JO^Z:"*NV/JJ[0FZE'-S8C%C"-!9@S
MZB5>IR?-Q1\Y#&,!/^*&"G2F8C*7XHMSC<+E/X;.OB_9H,VQ$^=IO'PDQ\'.
M%/UQJGG&[  & \$;8OGZU5GZF=H#IXX+)9\5@F';,M61<M75^H_OT+#CK(GM
MIGY0SBC0[RVT54.RO$?HETVK9V9<(=B#?70*36W/Q*4KR&T\[RUV/2649B*S
M)?-Y84^1"BH+B[2T&HPCAK1%X@YU12SR2FJ6VE[,#8:&6@3:ETWO"XL)"277
M(HL)3>>G#,L,S+\L#U:]#+Y8%BR12!\D)Y*1AJ=#M\)S;+1,ZP1VF+A*7:8_
MI0KJ9<H6HL^T_$T,6JW(^?I*LARZU_5\^)#UEW.OCI0FO[]HJJ;I(R)61V6W
MU4YK_EU*^<(6;'2?RG+'UY)6S=[!0>1E=F"X#JZO?TZ95WG;S/*:XT3<S'D^
M$KLX,$35[O?$3SS;PCU?+O#^VTQ%HQ[+.1;%6JVIZ1JF".(?JGE&?\FHU)T2
M9VG[#J=K.[OV,]KK@N"\F@GIX2K1:J,=G(+&9\8;@A+],[N2:A"[4YLSTM5U
M22]$DK,T%>K%5!-1HOXD[=/1^L R]P  -;*<1P@+H+'K.TM5@U>Z>X?)\D?%
MHT?-9X\-@4.5P[1V>HS<\#'>Q1CBI7059_5"H5*D.H6Q@2VIC?@+1K_OCX99
M5C7W55I=8-D-%[YFW;22(/L)>R@;W-3$'.<CP[:+)HK3$7<0NMGI<2^2=RF.
M^,892>>A6+O0"Y>T1#)(L8WS0!/?M/=R ,1.[U;Z""&AKY=-4EX@%E_4:\:-
M1N%@;HR]=4=YBD[T5*=>$_V$ZW&U-OA];[S*NUBI0IS*[(93$ZWN@-F%/&@A
M',<CJ9)JQNB"*7S*^&!G:K0TQ8G OI&NXE;JC5 4!PZXQI*CVSM(>NI<=9O>
M\KZ(V0*P2%I4N3F2;XE_T/6R?9%".[&<)'L(O6DAE&)]W-9/8OR-2'75:<(,
M.V_\IWJ*$?:(W7<'.7;QI3U4>U8YEG]UA?!&KWM5Q\"]-7TM*1*,I%6 G[[Y
MN34N^3IJ3N!VT,(39X9OK9Z21$E%_ZW?;6;@8OV)$\]C+(#0J NC2*;&<>ZB
M>;,459%J=_=N(27 M-.Z]]=D_<DS_Y*"%\ 85'?XWC&#.&*K-:>C1*#1XRWM
M,&UI3"E4_B0=GJN[4Q^@=.N#QHV1_K-RX:'15NHJ(MTA])HNQ&7V0M<JY$H=
M@B1DW'S-&JL5"(2']F=,=J#5,60@M,I^4_^I(V@09#M[5_S;\DD^,&-0WBEU
M/0)^9U)+812*L+O.ZML]>UTX:Y?!/Q(PMW6*&#<($#D'O%-<2M5E&);-+N/S
M4;6R6RK=S9/X_I8@,%]Y _BE\B]M)\,'A=J33=;JSQ)VW C!:BMD.*^/E??W
M+S)&;G= I>HH6$9#<1M5PA83&1SX-?N9"BJZQYOTTS5PTOI-0 1'UO]*XMQ_
M0W_M4HW;C$)*#&6BQ3FRLT;^:7.L].^;FB;U6("N-%REB/11=@17N*15%PFT
M.X:6\K)<Z8=?T-0[+.#!N +FN/DK%D"[=J6</S^XG)0J84/+)_2WLK1E:N6O
M)56[Q EAGW[(XA99P&HEBD=]5+$ UM-M3./4><2:-//FF8?79,5,RR&'7$).
M@<K6E=R=<C39VKV1RA#<6XK&*UIW8BR7W%_HH;<K+<H$U=.0=.=S?B/7OAYZ
MJ@=C?6LCIK[95+&/+#]N#VJ@S$*$Z @=+\U4%=QX&H*VH(J:KA(0BGO#-P:=
M )U/CC%3V_ YOJTH%I"!@P4\SYV FSVT\Q(<57_/ \V.Y>\!16Z_0NO>FW3#
MF>FY>8 Q)^OBBP<7'1(_9,6W!K*A<^-E,:%4MG 8'CNNFCH*I_CXN!]%&DB6
M5NW-Q3RKAWJ915AX-@A Z%5,IMD 1 41U#PQP"6SBYG670S%)GS=C)#;H62U
M_O(%'Z,B7>A8(V4BO?L#CNQXV7^OT?P'/2H5.MB_2K+WOMXZ_K$B6$I@:@">
MT4*P)@C@]O9Q#"DB@@BV'+*/=MG"(+045YV>Z^UV999%MM/R+9QB7^HXMV38
MK^S&[.)0[ '-E?N)6N,.:OE9Z?2NCM![-%-3TA@N.".["2%I[A>8*OLC1F?B
M57TK5=2XXDJZ[NSMIV9XH#YX ]\2=>7#)P.':9&;$(3*PIA_;9_=M%H^'&7P
MH52C@>=#KG\'(UYA\<5"V^Z3RDTZE6ADK682X>,W\[.(AGFZ.@@3K(815%'"
M+-6P+@HK)>^T',8PV%:]>S*V4AFSH%&]]/.NL:_M0D3#$Z+:0NA<$JIJDE2&
M[A4_WN&^VI0/@P=[V.X)E/%M@-N'O@*02*-Z*=KPXN*"P>AEPR5O5B2\_-6X
M#/7#!?1R&V+>;23D<(RW9@NOMM.+*+X05IQG-)^]2P9SVC>VGPII,"AI/U53
MU0ZWUX]]JB!F?JYG7Z#?F?]+SNK>.;/Q VKF@C"XDJ OI7=]6$=88!"+F%1Q
MW,^4KHO&;QZ4I3;O[#CZ>$?3"PY@_<9CS%."7TN>6!0_6HSIACN=IN)%'<_H
ME%=-OCEDH=.(<\XYS**)S3>8_>6C'@"<:7=Q6EU-&R^@<-'06* JX1<([%ZQ
M]>5K2:U*1]J9&!IM[-&Y;_9;27D[&9Y)4S6D=2=/_TH 571XTJ^@7B$%?=X+
M+!G-QB[!V':>H>4H9U',ZXQ)&Z:/QE<G!8W21 UTE:D U2K?<\$?Y9:$1O=/
MF[1#9L;B=JRM>1YNZ"HPY$DF73:*ZS'Z-*,-MU>7/5*.KCVS9]HPG*.!AIM>
M)6:6K)^)OY5N:EG[/9@0''[(5N3D7GVG=%__A&=7AF'5L[NC'KP'5Z.\KV"9
MH%8B$!45<>RU(FFUU"AG7%.6VJ:?X_V>)V78.$+)GD ]Q(_*.JFIFY/U-L1G
M8=FXJ=2B"0<E%+C)+QJP%-# W7$B"O/7!Z_*W,9, =Y\A+1%2[1Z!2/@C 5(
M_,DZ<.C>LF;+-6=8'VK L0#<KH*XU\';%Z5^X*_@<CZ5+\>E]D"5[IWQ7;SI
M0CNO)_F-!5)YT^_4N>8F3IEK\<T(P=4*43,V%Y7JMO=_E>.T7!42%1B4;E=-
MWTV=<HGS;&/SM-P 9J#@2%LSXM1-TJ0GOUKUWQRV986V&N9#"Q7=D&J*N_?O
M]\DQJ7='+*!>1;*5+6T*;K\.ZX#-'B\&RM!C$@_6VU-2>4H.C937E1]4/$VJ
MBS^!N4M)+[3X 5\TP UVV$'UJ?)#"T.-6BI5WCQ<B.GG^)VTW[M__I!F/[@R
M?3S&6NG#G6X)V4N]W5'7F1Y3FJUL[\:<U[ !@*CG?3S%T*"L0@\%I>1Y>63Z
M[K]29FS_IKOW=2ER_:"DCK=8O&HT[-US9UPKPPU&@7%[Q-",SJ<L63@^3AR(
M"S!RX^<XNMD51TMH^\M[XAE#*-R%!L!&;6/6"<:FIL:^V:=+Y7OBQ'FN'>_C
M1M<O%@+FM_73M$>$^+A.TOB[Z'"N+G4444R1/@(N#G6SFNIV+$%'Y)8THMLQ
M\*(BL+IN%6)MXI@.=3_S^NTK9::^[](/I^!I]1Y3;N1V8#-PS+,)C.E$IP4?
MG3)!T^.#B=)8SAFGN0TE&'KW4FRSVFHSXJ@TK.J^1_&&\.-406=+@D;MMSHI
M!UA E.G,#HM>Y$ZN_4)LFN.J#(WAH[AN9$HE%J M]V%F?#[KX"4C,$5&*\=T
MNM-^3:27^7;+V:YI:!;8>>KY&&&$SVKKD?&)A=>4H \3=*-ZO']I5]ZR^FNU
M(#]1Z&$6]^M)06**+;X/0O;/.W*=[QJ;O_++TO:Z^()AM\Y>Q.RPW?5R%2JU
M6N*QP +T0K  LXD[Q7B<!&\_H5&&39P')7Z/ J@BM'#GFI_V@.*S",\'@(XL
MQA\.GR=<=@,\!C]B!.O'>1ON?YS6KMJ_W9=S1CU-+)W$T!UZ907!^[4'!S<D
M(Q5PDADN=9-S%D<DJ:[#"_B!=PD,ZC/6_#G!*1CE7,A)+R3)P/'\22\68-I^
M/CEHUGXF,D]LPB4B^U0F]QNR0/Q)ZX'%)EWB,,G.W(Q8%I&1.EEUF]YA1;W-
MD-2S0<<KR5\^#'85^48@X\EFH@WU K"Y:_U<^3N5IOD@THAU\X/8,%=@>,KS
MB1PC93J/%';',7_Q[6(H[8QF-"_C)-_;.UEO)+LN/&!"0L,DVZEYTV!W.B-O
ML)E-TH0/%I!GO2%-6!NJDZB+V$O>0C6MS4=J-R^13AU'OUJS)\*P5J574Z_@
MQ8[Y/_6QS-^.^RWK =U29@W1T0EY>CO#ZX:!?%A +!: ?_D#HA*K<\ >!D^O
M%KG(=1X*HAY/SSF&SCFV4]6E=T4R2]J=/M%D<QF2XJ"(V@]G<GF!!90&8W0J
MEG?Y+E7;!2B,!V\=D9Q1KV !7.J4:.=M8Q-1HX8;ZUZN:>?X=IUGCO*;!)%6
MA==TTB%QP]S-4S'U2VHL2E6LPZ[]#S.6'6YAW#;K?'_\MCDPX@ H?/HHG;1F
M>F]$#MV%61'>-A)CT/1^FSA^6*J;WTI^XGA^9PX+F&+#Z/3[/'T&:>.X;0GY
M=MGHK6?DBV_\:_A!',U(X7!-*6BLX6'IANZ\0UIAK@<_V1.Y]"#W;@:OD9!>
M##-@.C\B'M+=FK+2;9J=V.')*'XPY!+7<.U9[*48N+^*F-*;VJ=< S=/,A^;
MC4]7"I42&V\Q<HZYB:;?$<[T82PH51_Z1%U75^RC.XX#4$SPBGT/J^]XQ$1D
M:T"#!2A"KN\@U,Y"'6 ^CE8EQ5D!U*?EWU8R(%W5<-7WC6,.NQK^1\][<H][
MJ7,I);LH/E\Q)?;AW?K2!*I/--D/'%!L\_)(C,[0.Q$R:V^BLR-^@ 6\-=N)
M$UZ\]")1,Y==,GMH#7W2E/A#\53X0[:2F-G8%X*)JTRT4;+$LS7?S+7ND:EL
MO<S-IGL3]I(ZCL6S\SSMNVP67LF/CI?SO'#9[BUC6+& GB+V2V2YSRLF#$72
M=^.=>_6HS=1M2<WLJL;O@^_H \3H/K-G"<5G@R%ZF,%,U2GV$&\!RIZVP#@7
M1"J.55O7PR5?B9ZNX<=>OL#/*/.HJ^<'Z$C&CXZ9#$[QB'3[)0CY1ABB[E4Q
M344O1SF1WC&4F!@M[JVF"?>UV#!9R""/B91A\-\ ?D+G8 KDF8[1H#R/DP'T
M<'LB.J+M-T^>_EIUXL#S.0$E1PLFNINVQH(NB[70]V^#I0<XNO'.)PV.I1PU
M#J*F[:\.&L>9DKJ<(GX?(+X*QV?-_'[5-Z9 I'*\_6II IF]C-S)<LIH3I(F
M@+0A(1?(A=[B=Y+/P$T2OG8#L3N[5Y+K>>(@@KG26",C?L532QJ3AO4X2-<G
M&MKJ@()$[33-@[V<56.!]_IG<0+[&C<^D#*RE'!N)K^>P&6ZIU5R@KI[$U'I
MZ,-9\MONH9FU>%@PNU@")[\"A"O:AP5F1W5ZN'T1Y&S4,A.D&5-PF$6T)TQ,
M6[/1+C0('C;!=%5\LJA2C2P.%WX.JP6L0*)=^[YK<&S<Q75IXCT8!X<,D1)@
MU";K]\.'9< W=K[<L]?]W1ZHX(S3Z6E*^A\<LR"5(;0;:: APL(FJJ06=]BE
MT\SW8=>4<->8B>&=J.B\S_3QY]H8X@/?LY 3B>Y4U]3[B;=JY^IC*O?4HO9O
M<6 !0<,=A)\RGIU/8@'A[9@GPE]WQ;& 9WH^SY:*&YG,)F]4^K1$PP?\;S&V
MPU&N=.E>;??LTRD2-%::O&GY"B^H,TE!*S)P+,"+[_K.Y*X51OES\\E.\X .
M%D"*=CL9)N!-9;W/Q95D.?Z1NJ0>0KQ]"'Y_I-)<&Z*&"@J*0O5L=P)<4A<3
M,10P?\6++*V!XVZ*S3I-N5Q#\JZ%)T[GNE2G#)72]P.5)M]%WWY!TCOS<3.V
MJXQ'D)C*P##2B,&"LK)[;ZXBKCGIUH2:9)L?<.LN8?.6Y\RXJ&'[*!)%D/$4
M\5"E-H0N[G?BD(8RO5=$]>+<L^/A, _W?:?34*7R0[=>4:'1[2;B^C0#VJY(
MSU.C]K/6C86\IP)N/"Q=9U5D,_-;PFQS771<.1?:ID_*4EZA#9/+>Q+XE7*<
MA66WYZ'&8*M.0T2_KY9.M+W([6U*6=$KH%5'!IVO7%MDKGY=T>L:JV'S"!E;
ML._S#<HW!,0<3L96H?Y,Y/!9KU/8OBK<6XI_?OXY?M<G98IA&U.Z^G)4?EZ)
M$NH+KWI?CAAYB%O2NJ%-M!_/_'4.W0"UVH+\YKYII'%!^-6C:?B*>'*FTZF)
MPL..]-@;7V(#?C?:]3*0=R[#R,KC5=)J!@T>AF(/IB=M$%^%2:H&A?J8_9 ]
ME=@U? )W8/UU8T3K7C511\RT.5LCZ/0XHP=G+U(MWA&'*!4O]@C'E->"TMVE
MBO%:+P0OB$.S?]:XV9#^2F@4@V[)*=Y"\;W?91KH&H83K-5/_%Z%#7SHIJ:W
M:+A$?F9&\G"1*2TX5;-4R2OYB"&W]8DRK4H43V6$66K. RY<\X%;LDNX/,MJ
M-HMX.TMA'USG!G4/2K^X@AZ>B_%[KCM()_U"6[5K@KU:D43O:C[O)6M=*5ZE
M%B^I$\U:]Q?QC"MLNSUSP\_XDL7MY$<0V)FPT;$Q555F%'Z/:^O^\*K>B1DQ
MND+36_/'EK \2QS_\@.7^ VN(["(X>@)3<'!:5:9T8#SJ/((4U\^_" #7F@;
M9VHW'9<@2K02P7L7PG6[RRR,3 GS& Q^Y4+]@#PC")5Z_/6.PMVC@"^HY+EQ
MQI-/R$Q\122=_JGRRISL #_19*#(C>7@:7=*<V(M7TMGXB_&<ICUH$FR_F?=
MP0!/=O\'!'*9Z V 0XS!2?>#O:07@G+7L?"W)]M3C0^F7Y;ACK*+<])\! SD
M,,T0@\ODDVO@@ZGV#+XQ"^%D\1+U#P4K1[?Z8OO\'RJ-"-5<F=8E%WO;L<Y\
MW*8!Q'>_X:QK#F3/U$O1/C@MN!%,#@E/?QE?(FX\)3ZW M/!(ML4J)OOTU:6
MO4_:?'^72@L;XA$=%8<HY000$0<^37<'AN-@+<?N;B/YZYFA)<H7U Q^&2>;
M]Y!*DU-[/WM@I#Z/H;87T?"N9@A]W$S3<<2SA<-3&$I&_D&.ORAY2*PX.BF^
MR'K-^#IEX%:CP* 7O9'/YYGH&NK.=^A8F< .0TN#@4XB#Y:8'W;)D;*H/&AA
M>:A>4-O=20LBF:NBR"+&I!!T&=B<I9^4!(TY$ZS#N_J\JXZIA00[@O7:PK-8
M*P;Y,KW%!LI3(U4/5B<SHTJ%/.()'K)-:GX[S2+Z4;,0;G8(Q )FM+& D6!W
MG6#D()$)Y$7"$(VNF#.-JNOB6@+=LRLU+(!U%._ZJ?JJ(>-M>74\ USJ12Q
MP$"NO>EQW<$@(LG7!2?AQT_2# ">V/*F"7M(Y6_7Z+O37>ZZ"8^<];ZO?8$6
M=;9W=_YVZE($)8G/8%3I+CP)KU*K$MNI[);S$=7=IRY7DFMA/@+N&2![IPQ0
MA> [X:/Z&ZWA7Y;X \WE,;$ZX2-6>.XB\)#5^Z#^!Q-:65)GJ;[_[516C)T!
M/7MJ(/6U.")Z/^BDF,'4;@Y'DY1UW35>N6=X5;,T"#YH@9DW@6@H\RS:MW%T
MW\%HWYKK:AT1O=$9H<@Y6P;\%]Y?S0V^I!?1$03,%;MI<P4S %I*',FM2=&Q
MB@F#F9;K'/-!KVD&C.27TU\C1*@HJY+'"A_K*#S/? 5D:JL:,[B2F[!?JQ4A
MRP5[$KMT?FC-!L_/_^9AF<S2'['7:^W!*;!5)T8S:8[ZR)VNURLCY)E?_^X%
M)?%_D%U\PG3P!1VT''=C_.Z'YV">4!8P'<YY7MF>A4@*>>1L3T-W]J(9?O?A
M#BE*;75'"=*E^[51\_RE+]8]L@2)IJDAI) 5^0HLP ]T?;=Z^"H,"SC=54:J
M$TG7+WT>#_KT)%J[V'WV+E=^?,YVF76U,&W2 #\.98_*>FPI^:TN T<L(%C,
MJ;ITVO/BG=V8S]-1)L)?U.Z[AWH2OA\%#!B9#BZLFX@27TZNA.744YJ/O 4
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M<%]0T=6!OV!"XU["WPXP-"?@=E)LK FGFK3U]J^]4U/[3@F?_W:PS_11&XD
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MW@#?-6W.EBNU>6WPJE/.N42"=M7BH#D2RFQD!R&Y]2"Z.$D,YPAVD> OMD
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M+=%X:IC)2Y_7JOAW9TF?^=MEH',Z$#(:G^:[3FMA-M-F(93X-@^X#R@"\:J
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MCQ%P^PXJEL&@OP=,<O+<=K?2W\T9JV)&6*34C,:BR -6[4QI:J*7E18?:7_
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MEWSC\5:&(IIEQ;TT=IRUJ1W3L+^-^Q (NS7N2'4Y:Y!K[B!X\O$EF9]75<6
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MQ)LFRA>WVE"+EJQ"?6?O04)8;(.WDX!BD"^Q>AN&7'!RM/UPPNA+E]]J=O,
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M_T35!<&;H )17.Z,R7(6/SVD"/,S+*5N<4M=WOY2'B>S3 2<H9M;J4YFTLY
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MI']HY(QDFF*\)N2/Z1D5YW9?KAYSX#;_%)FZ*%:"37 Y%K;6+O#,_M%('KB
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M,UF\94K"#QO,&-:0[M?> X3R2=,#H1_8<ZGKIIUZ_"X"Z"Q_]&N=5$7WF(=
M"3@J&3>4W6?/@2!$M5#!,AKZMTK*T*D;U*L?IU2V)%NTX/O:FC/Y:$CW/';C
M'A#&&/;7)X_,R3:7>,3Y("KS0DY)NF< K>_USK/UF2>,8PDAP>7V!#C3M!5O
MO4@5O3ZCZ6"H'/3_YOWIBZ!5%=4\WS>XF<\*BG[\[\>GHL$'\CIJEPX,=FE4
MV@I\P.#"%<8@^5[0W 'TA?17T! !P<HVS)O)KN!C3<_>/8#DKY"&JEI]6_*\
MW^!K&<4@2$G;!+<7*=N-\(9?TE_BW/-B!?&P!.F$5=-8#QJ&U%^1Y[$\#RY&
M'?RDZ U(Y<"MXK.PMO;B=\^<E0)33$>H//C<"T$FJ(.JSI*G.?.@E(?*^$\^
M(6K.R %=WY:+)QU$'CONQ#:!1EN)GK4R)?WVC?F9"8WD"9Z<;&_;!K20;*.^
MZV'/=(:&;:@<<>8JRI4=2FTWT5>M1?/T67F8T:,"I1AH_P,W<YQ&B">2Z()!
M$0B$$7HF#:/ONME6&PJ\05HKT'[X_?G)RR<GY YK0J!P(Z_-?9/YQ1&[X?E(
MV5RM==,!!VE5W@^S F'IJ\'I3TO3+\K;3OR^GFBM9B[\0+5Y2P%3%&],DMFL
M"(D ,FR3C>UV!7]-RK;:>%?0@3Q3]?KN6EOKV*TM6HR>%3==_'\U[ !L;G_1
MDEHQ;]I=V[O^D,(D'VU;8'OIXL$ =;-VA(H=/!<X4OCY:T)"H,0W6-B8[K\Z
M]]&%FEL-=Q#%NJ&$[#>VJDW[E[) 9@5_*8B SKBCEW$6)*;L<M#1@_ZL)+<
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MLYAHKO<.D3X9'I<G#AH!/8A@EA"Z:A&GL,LJ\F#I;GA9P:I%48L7O#_G@K"
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M[/F.G50MZQS_9X26TC!TG?W(G_#6[H?)7/0>X1"70!^+3CC!ROI^M",2D39
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M,[7>.7/H;-V9(5\9\E;8-DDA7,.RPGSP6.ZDKVH3HD!OT!A8T$)WP,$,AJ3
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M/I:QG3Q[;=,"HC):,+A]U=;8W"Q"R<Y.K]SE_*KT@VF.VO+L .7@T\66_GN
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M1PQD!9<N[G%M9* Y[BR6<SWXE:3+!V)?C9CP!G:M_S#NI]+8E#S5DK$N !
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MY=E8QFFC(A>@D#ZP@D=Z=$7$IJ3I!LGEE7YD8SD'XO!74+)U>VD>$-NB@Z<
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MEY7PIC[NE0XI(2,!PC?J<)"-!;Y<T0)]G-?S,*#TAJ*YS9;4Q/=.32&Z'#F
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M-S,9-DLNR<=2T7S:'++OZJ?XKMN;K/2(RY!>YI38"=P5Q7BE_NHCOB^,(0.
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M4F9BT^Q/1$W\3BI/YXU7"F5D'W!R_]7K%_H&2P+[QWDI03^Y2,SOYG(>9'Z
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MP<I2_7P23_\Y?^-'1H/7>U/SQG)(F6BD\%6*KS"0\X/8#9%^X?-F*#L- M9
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MS(6) >R9DEAH2 $_\Q&\/^FEF'G"51F'/25/-I'V)O/[W>Q/]]JVS04(-UI
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M]\_$;:S_N,L#1Z32_%5\N-'H#/-)(9.A3F>#5=T"/+*XQ;TOE>N > ?]TLO
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MJS3=HFB/285,0Q(YK3B#6BF&4?,#VC\<N2S-Y'9DGD$TQSV H3J8G*4LSV\
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M08S(? /Y'ES\D'RV@]/@&[DO5A"*0-UDV<OR5\]/.N0/B!?H/%"SRBU-, '
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M?+D_KH7J\DLZ5Q#;DAZ,+U"[NBI^AW<\Y /#H4TV#'[":^?[^$!@8Z*^3"G
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MW\,"(JI?'SDWF.L&MK<^^@H,]#:T1(=^*-:<;M L%GI%,-2"-)2P2&*G Z4
M//8YCZW%ZG7E^[$8N+LG7'_CHHFUF&["#2CHEG6P1^.#T3T@M( &)DC^@!M
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M>UDQ2JXH"KC6]\.;04A%/^N<U5$^QE"#SH*,8?D:(JH>2,2NK!IT:IN4(SM
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M%C@S;P$< 3JW@&I79 J$Z(%E5!:K]10SURGY 94L4?0I!*&*WK4%/*\6%7W
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M)E)?N&I'G#,PJ.'0P&C6?-%@:YKZ/AFFI#4L-_B1N2-?*.)940H!B?:$W_"
M!R4M5<Q63;!& (G*3Q'"9MWNH9DVND/<D5N HA.GZL7RASLY 42X(GSO0WHZ
M>6?SKR4RH.+Q\^ G'NPEO\&R3=X8W9$Q2VT-KR8<6!HT'+6@CF52>"[')#*T
M:4FB(GF?YNG*^9Z;N62X#*,[J*7AWG[=NP"AU?=G3.K5U6!.4(>9XY+LY5<A
MU3Z)AXZ"E'8JY18.!I2]Y@8:X/45@&B@,B@,'CNMO4E,.(J%%]6BUW'G5]D7
M&&=MF7GO*LM"RLD2)^%/9C9@6J636^_;/>_59!]LN!)%*@XU?58'4 IW3#N2
MZ40$$8#JQ#LK]M6_!4#,I5%MQ-NF_ARPCL&6LMTF5S,5VB6UCN2@4??=I_"(
M<"XXNT0I3O^;-!LBC6"W7[JN1C]1[!4AZM,VCZZE/N.>3?#-"!C3#G)BDW/+
M9?))&\)N.AMRXR3V<^0IAIXS6[.V/$3204=!EK6FX 3**<)<- G8G0G*C,\L
ML5^D2J6\\FT<=R7M'R4+5%FHW\^&58=5(L5MOE1NK8RX\0^5&RKH#496=6W.
MN%QMK8TT T.[3H30Q=QB7X#Z<9$B.QGS0_X"PT?K783:&W$BIL;;\;;O-,+E
MY;?WM7/BTS_+Z%2M4L\9//!*HZ.N] ;E?0FCQZQXH%+)TA$OM.'[OBDL6%DE
MK>I)H/>B4D#)SD53[8"7^&<+56%J#SK(3 N/#$[9[E+H+,++T)2[R&G\/J;\
ME=7S<:H>J@?[B@:+XL1-W_,V'CPD[W=MQ4FI]H#Z.0M(ZVD\:C]1;PTVLSG[
M4OG=L$^.*_MINH!*/\E-\B)QASPULMRRG_%.RJ4!;6."SP7=P8L,>MI<H6!?
ME;(/$<9P0-;< P%ZJ^  =:_'M9E0#>*#M7#/E+P-.WWFN^2P=P7P;&32^'W4
MMUN ^KZORL:S,L1; <X1U<,%?B?!N]04AN8POXG*C4R@>OP>>^*R\[;5&]?X
M;'2>%4Y?""L"73%^=/)P%SB6"3VA9\J05K)J#-ET(3)M3Y%*_*[ )&=*7\L4
M655L 8M<<"_G3OS1XV,?7:O9@8%U"Z@TFMP 4D]B-&;WUZ91.S'S3 !Y!2DE
MD31023AGI&!1I(J(Q!!6D9*[1TR>/:D]+=57_C7B^B0VK]<>XBH]7B9Q PU0
M1TE+![ S+0OSSAO7 98B#\;Y[?2JE@I'%$^VTA2VCFS-V&EK++JHWN.;VH]8
M\"7UXVR]ZHPHO4<7I7(L21#RF.[1&@4BP#Q"OKEU_KR/E1/H&0A8*[1X2]QS
M< NHO>'5N 4 P"$F$;;5U14C.0?/L0%^B$JP+YNW#/X209-._3:S.L9R_.K9
MD=9'8%\.50^M/ZX(NL!_+![8=6(X>9V]:0X).XMR%R)>=IA5_2SS:+1D_4>2
M<7[O(M;@VG*7/61X&2*$Y\$^9'V_]Y ^@*SA[$,0WZ>AK()7K0;;_5Q1OC1^
M6R0BS697Z]!<.%?PFOX<V]S9:%>MX[V>U%K&\[B =282D$0<97DU^P^AHVX\
M>]DH:!J#90CPA]XLNDS(/A>O1!>-C(9,Y^-=R<^GZK=GW$U!- SF>6:4%N'5
M&M2)7(K=KW@#:,V5&V5N 1M>5Y7/4&W96XY=@1\">E]423PZ-<)"S'\7ZC%9
MC:D8EHVO)C,:EK@,+1VFF>#3[O.G:)X6KWQ\91I9H%',7Q;XT[_^2%T9.-#U
M"W-W)6#T*TJYUI^YX-!AHQ=2JQ%8Y<WG.NZ)$H.-H;AJ&IJ"H0]-:$)#F]E)
M(8ZU96#;-2,8TOO5]*]\W4:E Q57](:[_4P>GC18D<42FTN#S;S[ZUD[3XZ9
M$:)H[^)8/WQO=W.9E0NOZ;6^*T)CD'(J!N1"EK=<LI3[X0?Q2%,[WX8J4IK^
MLYIP<WO:EIKIE<[7&2GU4V D9<TJHDZI*5.R_SC<[)S>L,B0#HJF3HY2%[EV
M[U[X4-2G;#,W<V7W)N+5@E 4V^$!.[1=E\L!<6]QIV78X$S:=3/?!QJVR13;
MF ,^&4PBV5:E;@&YZ<37&UV]%3MR>.FCQE*=E?XNU7C?95-7,WN'')8[WJ7V
MX[C#PT/86TYD?F+)BB:DGRWUPX'A3DB-XDC.EXFYW^E#RM(U7#OB@J?31)8U
M?=Y-:AIF@O>NM>9DN!Y-OPJ:X>D*^"$(D+L%%*JC".'NC=DOD_I+G(2;G&<S
M.S/Y\F?;F8J-P)Y:;*,$2<1K0"^Y^CL_Q9SN#Z32RE8TII^!L)3QN76[D64:
MQ 1[PN#.U4N]A1=9>\*7> 2&, J.KF 9C8+P$%4X_H!#=C([=L*505>$#)-$
M1JE<:9EEP^$U8>XUQE-H;5)QP+ ENII:">#([TN[!81]A JL>5E-[IJF=-)D
M$=.M[!>!QT25:I0Q5J0"PF@MPSEKX1:EY6HR+H30#6O #_=]57ZW5-1=JJ7Z
MI>SP<PBOG>\P]6MN<0(+%KAD&%+!KGB_FF&\8Q3'^'[3#M_3_>ZKAJIRUW<Y
M^YCCSD3;<3ULP&2IT>ZKY,$ZIY+]J[+5CMHQQYQ H/"A)K^7>L_[!SO*H'!$
M(;I 03*=?PT0-I\"$! %U_@:;VQ"M>B_%?328!#$>V.IO@Z^1JE=HW-]PBU@
MRK&XCP*K^Z* @.S$#G4EYN!/M_AB6LC]NXI^]$^;B)' ," 7MMN5077HF9JO
M[,:.^VZAFH7$2V,,P(_M#@*R1RYDMX!A/1@*N/T1Y:2'"+&8=_'5:R6*^*GX
MIKQ5;<5M+3YBIE'<A4"[!-REN: '%8N>5J^WH6^RR,[4A1,'5PMY#"R(^2F\
MKKHX?*F +@,_S6H:/&A7V!CWN28[VC9>G$REUWRL#"!PG<W9-[$@ \)!IG@H
MXZY3<<+C0*121?>+>:3\YZ$Y7DQ<'[OHG7;9C5+W; ()B)N4QOL^7ZOXNY=Y
M&TZ:D^@JF!^H?3[8%E#YII,6YM^Q<:B N0?KS-BB!&-^2H@^:M-#EXVCMP".
M)M1WO!,*IOZ?A)4[@6=K-UJ.B(B>ULS+*.6F@CW=);-W+XA@V@!B[4(MJ-"=
MU?VZ73>Z+P8:FN_"@GY--DCO\=F[+UJ>W$T+F$77"E.@45]*AG8.*(7F-FB=
M.+?:,/T^QZ?WP1CV(UCGU%6@'M3]C+[&2U>S27*H)]</O.).!Y9Z5\:[LS**
M/CGE#MYCGG"^&GOUV-+A_0&+!21/I?F]%Y4@&+F:HC*:>3?B.$ZNRS[MT\W:
M[FMM_JR6X3;8G9#=K9_RFWDW& FU*Z*9]Y='JG,D]<L4T6MD8K.,22_*<L<6
M]$H]&52_E'F'[8.'^M,YL^_Y;W&G;+DH=C^LN@68-@5O*[9'_^")&7;I6,:*
MWN@DW^FE U4^518T;R^).LAG#6PL+N -59)_J!O=#>^M0TCKZF,WI4CY*;F+
MT\-4W+#?C^3FNX;C=;#K3B*(5&U@SID_21[W4P0>N$Z /L'O/?'GWMD+I0'\
M@M\", ;4.[$7SLJCE$,J*ROS:^6>!;N>06.((Q875EGK%P3%Q9M31#_&A*3L
MSH1J/^Z*#/A1L2/.L!2.F'R5\$G9]9>XNW=VF+-0NUTQ*,J5; !TF<]\Y%+(
MOGJ_)6GH#3C0K)\E3CVMQHN1> .=AP;M!@H_(/1%[*R2O:SW>(M2<Q&-?KP+
M&N;^PO>>M '0=/1I\IIC^FO:QDR!Y)$M'BJ\Y=7FF  <1+:&HDLA..IE _:!
M&GDBWL_'UB ]6>D^[U YP<:.N89(NY98$C9J A6YX#*$$*FO!AS3+*#2^F1[
M#U0 6PS)5NM*U9MS(3Q$9@]Z$Q>*]LOA)]X"GIN;JG=(2*Y;=:*Y*!\#4>6[
M(J-OOY8JWG-TRH]UDV;-]_D^R;H7*>;@]-&$\J,ZQ8Z*+*\MC+.ES.RQ^(V3
M<Z6UU:H>IBBDI!)""59J^"ZRM#3AT9CX-82.M!N@1R=E#]Q<%;K$.RGE^Q#R
M%$X8$2[TLG4>F@@CG)K P"#'&-IQ1)?,SE75[<*OW-ZQ)#J0"%NO!F4D;_G?
M>PXD.2\:DM8^J]:LTE: %0XF0<T5]1.A/&PM3+S<CRPR WA)/B; ^;&\<FW0
MVUM55[_EB< >&RJS .WO6K:(\CY11+"?E*HS6Z3)^-:#-T\W#J.7Y@5HT<2J
MM5X9?_;)=+@LKC)WLQ'\*\7R>M_!)-6CAV>CAA4(9[2KG,?(*T!&J =L$%X]
MFYJP@G3.7'8O/A:G 0PL[&S+2FN%]0#27:6-Z?/SX+E/%<YWV<Z*^JNBLP1N
M;@']'9S2SK;/<4:NW Q0S,NW %O'5KO(ER/4A?H?(SR^H(G 0G4XDMR]4EW+
M4+==LC7D%C"J..7'YV8YP[8H!HK!6Y(9D-8@HFBC-62H?^CUL=T83C9^/T/C
M3NC0=!3@%F 2 GWBEDUA'WPWA:!J+CD"?V518ST;;W@#[$PX/F*VHMFWK0,&
M6-,O0*+:19V@IAC80S:UF=/J4J5%?/9N73 (>)8>$2X"7&':> H3#+QZ6ERB
M>?7!\*WZMP_*WI*/)BGPP1J#PCT7-G Q?V6)F]DVIF3W+$K8G 5=+3AT7.RD
M\=<KYXJ X0+QE@X+GXWC7[PFE]?YOQ9S#46+P+8^3%1[4J,KRM/F@90/B'Y>
M307^K-"7'"Q]BT?2="(^XZMT"TC@O=R](918[O4B09PC'SN_?%#_2B:'Z$@!
M*;U0'77VSN,[YJ9VN'[43WKID""EOMS^?<L3M8I;P'>FB49Q[!3ML+*:[8!O
M']:][=);/#8DVV!FWG0KW,EHYDXDFNX2+B-;X9 R:[RW%&O8Z$252N]8X'2^
M_Q1*'*'W&$58?Z*ZR1)XOOG[6Z\HH7JP-=NA@-!P?(?CBW59.XVVCTA@Y3V-
M=Z;HZ)='AIE.(^^Y4GYN;6PJ\>O<D[/N7M?; [+5!9*ZD,@^)D ][T'^KJT8
M^%"=$:<F9_A;[=8;I4@U%SOZ^T-W@U^P"-[]\N7L2H?@)XHYW-2%>)P+Z9,O
M]#$KLWSZT-AD@E(Q6;A*>#=Z?+Y=UJG2WEJK[0<VX.'>'0:EMV\0D@.-;^A,
MM?_X0M7XJ3RRA%2>6!H:G[.PYOG0='QH:KXKS,IY_NDCD7,D**#/GRA&H:'%
M]M.DS]L"-5$?M'_+,&V ((0W=9/-\2ZREX2!L?[NRU-D<]N='!AH>H47,2&E
M&I!6@I0W8(K*8DC<QA02"OZ.9[*#--PPA9 XFCB-29(^:8PU3N[A:&$0UD5T
M:<R<VSNY7V?T-W8!Z+R.$VZX=P@=W9L.8HK-1!/J1EYOSU+T^/)P3^W9 IMM
M?_E_%%M>NXLH/!M^V0'G%4]G80<H,!-E\J!%"\2:O-JOTE36*QGJO)N?XR%+
M&\U=ROWOO6..Y]DQOKK^=6\@_[02!<??FCZ2CEXZTJ9;MNG,/JG)B^:)E)[^
MOWO-B-#]HU,K@-S/_C_[A,K/AFK2E:_@)K495J63HQ/S20NDX3.EX(V_]G/[
M/:C^9^=CFM$*&F%&2_]ACHH./G=^QU]4U=5ZGQP7>7 W!T_7S"785[%DWZOU
M@]=GM@HR)ZT2*BR(^D&)][^RDBGL+Q\S%-@<=[Y6F'[94I.@9Y#&PA_4W'->
M%3UBF#5"8Q8\EO,)GY]J+NOOAXD,YIP[!XI6O@/HAJ,^$9L1+&8CO(S@39'%
M\2B>U[.:(N]'])V7B)UYOAK*<D8K3>!Z;Z:;R/\6Y"9A0>&C3;4*"M\U=L;%
M-GUD.=CJ^#=0*@-$>XK-M6CZ$WH/BE<PE=Q6 8M"#;< HIAQA?DM$9&?^MS=
M%^1&1&71TK:U8C9PS-55!@L-KT:N&WIE7/G-:B83P')>[+12('=>V1Z5\N33
MYI;G!-.YKQG/,!RCMWQ%JU?V+>ZGZG_@U90\O#=E9?-<&UTAZBX>GE/-L1L^
MT*J5R#$C\I/[<)AC=F"?%RW_%SS-M*HCSWG\V2;S94HOV!\_/J"9E+VZR,62
M=N0^-*N./Q\]Q%,+AO8JJ3%:Q1ICN4Y6WL69*(N._CZ6,BW-]/$#F:/)'WX(
MRDF44'Q/;04M_^IP<>74E? ZXYETO'>B=Y)!"=ITY8?/]J.A*"8$1 ^.Z<BE
MD\STY5.>DWPS4QCEO<S*WUY+ 8%F/M[4@'7F^SGV.#.'MI*U]%SIRQ'/"S9
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ME@<<G!C:[Y!Q+SJ6;&(6EEU^;I?R&_NBC(#:XJU@R5-R5SWK]OYYT5&@X1K
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MX:4IM3];%YSP(MLFG:(^X:8 BQ_IO^,O'N6S[A,CS=4.Z;]D<E9:56S^UEH
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MZ!.G^^_:".#7Y5=KZ])#KO\JC;O-T;W; ?AK&7.*(57)GXE_FV]==$Y:\!'
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M19N'Q1I?:_/+BA:/Z:5L1/G:AG8./\&.DJ_X3BQT\/$2U!'ZJ7:HX;)03K5
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MM1^*ZK):Y3Z([CSW#.4I)EO;AAL!L $"#3E-'YO\O[C/[+_UG\S_R5OO3O3
M2UI72,IEY-S&Q"'RI(-R4F71/*6,*1319=M-$(M&YU3A .+;G5X?3E,/M9U0
M_DF6>:'0C4,0(V33,\$(->;"$*D>JHD:+DWZ&9=Z.D$BVPPR8E9GN=1XE1A&
M?*?ZZ71_]E+OXI+;I.=0!LG^?,+%J96MHX+N0XFOCV!]Y,^AR8.##\]CDK-W
MHS*\G;!.F1RZ#7R=.M*J;0P18<$A;ES_5F4[>2(^OW8YA]T#;@GD$?)?5P>[
M)U<?X'6U.6W8W9@BEPVCVI:C=S.;[W>EHBN,F')F3^6..VK*[?WKQ69C:]R$
M=\SHUW>1,1"+[*.TO(E?&S/S^;V_UBP)P-=1;\M7(:F$QIG:YO4,3W020W'8
M5+ME(5AK-DC6;6E]T. JDB)HS-=A4DGS%"&DA$#-ZD8("I_:8SVP89**DX/:
M;5V*)+ESY0W>!3_0)T\X2;V7>D1>Z8"M*B$(_,][L]:S?&#"?SOQ\9:8FWI4
MO26&L# N]5YY&7P,4(5R8-U4/F\7KQ#_RI(-\5\'!7@NP!BHP=]CJI) 9U<8
M8NW?(KB&@(G/[HG3H>P3Q,+$9RJ=%=Z%VB*3<=V T&?X$&T>5EX"/IHTJJ9^
M[0/K._BX7SB/JK;5X)V9OT.XAXVWU/JKNZI#Y=,'F)\?;TP23 %1WDY>73SG
M=8JY^%U/Z,RCL,?ZN+-:=ZZ>^I8@7[>4I;M5F$]A2QYK)"1/+?10T]0Z:OU4
MN:JSE,NKS,5N%+:%O5(O>E>(2B")L%O!$]NM;2MN^.N*JA65Q5R_L+7<S-^W
M\!2+)Y-?IB94DT4=A\M<:4&ME^#NX+KZ&@SH1;+2&_WMO5[?CTR$+ 8K$Z_D
MN*+WL*Y;H:-T57ET <U\^@:EGRY1NUL5DOM]\^J6 MHO$!'IP_FXSK*W:?#E
MCNP5GXF1K2OG3_SM=18R_Y7F4NMX(;UW>*7^&)!@V,5[L-AP(,4<N5&.*$57
M4)S0UMC._,;CIH0WT.94^F-)37=V G@Q.7/O 3QB/DLA7*,9E?"<,F4XZ0WE
M1W;FB2U*O/\LMVCH[_,;O\':LX? BP\NOFR]([[W6+<5@HL@EAA&CBF6E-!2
MR5\< $>&_B/,]UH(5IS=(DY(K_W9N'6E_F7A>%QV&822'84@\GZKJSW4S5YZ
M]+QOTC$^><"465?U"IKCH;?),+EY>"$DT?#0;\G?F%(>%2/%PMIA)RA\;?AR
M3_]\Y'L-OR6-T7X;NA)H=?O(87%H%#O6DK?N.(/EFF&.TFD405P# JWVN4UG
MLYN7-N3W2LL0+;60#OQ$V6)B']TG73QAP=;>E3D5Q%(-P<Z;0W.0$;*B4NRB
M_)5[]BU)Z60N3:DG@!,M)U-^7_+KRHUU&RZ7O0O;RGTV%3LGSI5)C#O+N#0E
M]%+M7RAM8*)T;)1)-5T;"E=6$1P_YG_YU\S=:\[QH <F*R"@;)F[Q9YY8X8I
M1NMC@%X+G1U:PT1;K/TEN .N/<6!M>9*TD??V3+O,03[R4Q,2HEWR'E$\=MN
M C8JH)P<X\\J.!U)?#)X1[I,WDVM5=ZQP4UIWA%I1:F(/@80^0>CLI?V9QI=
M[L*Z;/S*,-=M9+P)^"@0:F==SNQ0-W57S*BW?NH[*%J_B@1DLX3']&C!H[U"
MNNSX#%_^YM%I&&5&V5 77-<49O[FJY??EZY\Z!<*.EHWJB:[\BV=V-B\7K=F
M_='4HU+X0;D[;IJ+T3;B3H[LS]BMG4*[*6T? \ZO2'TE.F8-!M^Z$X<P&V$,
M+X;4152[*7D9VQVY(CB712B)SHNX_DUOL>:C^A7KWRQG0V+'85<B_#9D3R[A
M3Z:03F%J$\\IZW&6A-R 2+&\'6P\K?0N1-IZ=2LD<G $\EX_#L>W!@GEH*#I
MXI=L"PC,WE!CL.CD)H^G0W-_\]:I/8OC&/ ZPJ0*<PA.VC7[#.M;'1JK864+
M;8?,Z#:!D__R,#^(&6&F)J@;1Z4"]H$54[79QP"-\=\,](/H)#A]93K'CT'B
M0B'&8S52!1Z58+["8'74R,YAIM'J;')RJ/F35JV^/Q3'!P^&ZBQGUYL%Q.UD
M,+4EG@A.)_D.)FAZTB>IDE$<]D.S57J1&,W5'YI+.2NVISG)W-<G76KW,"Z5
MF <R,F&6PCL=>I1>4MJPT1BY[&5V*2#IPSX^AUD)O+P/\((+0Q#M_/><ZDSJ
MAW@#_GXJ,*S4MYXQ?B'!)80 I]'7BK\FMW4!"^C*D6Y#2Y8C3B-YL0MJ;1Z@
MV]#\T1II(2<C); G"[>&C0=X!6+.).DLC"'P,LVQ?NQFP?#( LQ $*%"H&2_
M'F[[Z?=A,J!$+:-E(JZ1':3_NX1_E0(OT?2[VIW+E);)9D<V/SRTW0<?LI\(
MY=_?';Z66V(<=,6PLJ9>#-22OK)M>$9=&D=UN5V7=<?P=7(GXOROKYE,,'E3
M)G[4!=RQA<P9@4$JXH(BWV-^438B9.[PL0TZU34_W>J_T@TRUE]Q1GI4_82_
M:^6&S,^\C-&MP8KXP?M ( @R/U@U2F"D<;1B<20_=N%"WFSH6<4)4R.BXR>J
M9'@I:E^\WHJ?L"F_:2ARRN)/$!OW[#&@?0F,&5%*F(KR.LG(;UB5JBOU;N:D
MU%.F,SV?X>V=HW1E<O*58AVY$A 4DD(P7D6C0"-C460Z[QD1*R9ORZ2MW[T,
M4+1%+7]'_A=WKXDOBX9SGA_JNGO=X!$X?L2;]3:[*Y<E#^HYB2FUA<S77AH,
M5LS\@0NIL+49KWAX3M1QJ[Q-]G*;D/BAK.C)8;>I[*4FY]_$RL;BK-:G4O7P
MY:6P7_/M>1_H:U\I&Y$R:BJQ V<220\.NS\OI*,+"SPMI=]3@:]F1S>B<IT"
M9./V AS5=0? ]MI7LD)G+EQIJ$TZ-#"K;VBXH6DH+B@W:^BCU"P8A/CC&/!4
M<<!#7/ZMGR.+\HKU-I-5[XAE #A"R_9>[Q+ R-I-(;TMN@7H2 *N"ZE:9!'.
M?C2X6M<-['NHAG=GBJ+@TANZ0 'M=>F06]2ZQOQW#]VQ*E&:V^:D#J$3Y5MX
M/UJ:(_'LJN&_KC!_6P[W$@+CXG+;2 2Y5!?6]SDB^EBDY3'@Q4K*;M#>OA2/
MG_SG\_7:/(!R^PX[MNCVN MK'KMHCZ/NU,]@T]\_%HJ<3=NQ9VM%3JXF2'S0
MV%(M<IA2/RHIKHGXN]9C@CRUH%.4E=;28?@[=SJ:^" 7BHE"[F;?74>TH@4"
M_>DWL&_4SCF63@FL!=CU'2IOY=ZC4VV?,\EU+P@8;?JNCNP;IS]GEJCP\;)\
M"[V[?,I<K+BPK;!%^&,-4X#BX>*8,&(:2^?<!:"GC0R6[13XID^OW>*/,:VM
MEE@/7<\Q)FI8!?U29P5L1=H_K-96)S]Y]S2V7$_M61+MR3:EN9^GNR*DX.JP
M>S)Z9892'O.[)4<US$K#C/91K +U+^4^+R!CLQ G3%WL@21T8_S6DQ')$3<Q
MY3BD8^3_:?:9_C@,XHT,HS>$>U9CC?W\$9N7([&L^QB@F]3.X_XT2_9?9G'9
M_+>05P[X'-W55X'57(&-ZU>J6XN?J3]#<Y%MPC%G')IJ85'N-? %Q#3KVJJ1
M\>="><=; YP"H/YB-IJ'4_,"Z/0)*O"U3+!F5;>T&MCSIAA3QZ6_YA*8;?+,
M!+$Q\7NNY1BY8GTDO$KAHL)^^NK&-AO(=$@GS9,=EGS?1"6671[BPZSY$I92
MYF9*_Q3\P%\H3&TB_/?;X9T#3T='_\WH?<KW1%*FQ\OR"/HX!LQZVMO?CNO0
M^-WZSDS-^F:JL,5TDRJ#:\CTOF#VFV VE]*I$ PA0*;B&+#4Z%0Q<K[ D;)^
M>L2?OZ_(LTC-$ .2CS_+M!2<S&ZE;1+#I0/@!9C?]7L_ ^F&>801W\-\U3N,
MM475&.Y1<8)]&#>4MY/S,2 4T!YQ@-?.HSW&:0\55%<_+E/A#+!.]))/G_X]
MV4!6FDNP:O[/%TX<I?&6B76K4!X3FB>'G>)80F%_?O>5G_O/9AF6Y8N_"YD?
M,6NM?FUM'>_='5*(Z \P0F@9,7L-S/?P8V.\4TWS@\V^3'AY/O,[!2\@V+CG
M)*U&R:@S+//37:S[29!T<$1\!K&D5V"]V<$XLZ):X.RP&OX)LS"Q]JS+($J\
M\]K3I?T)R\P)SP-S87%*5"9)]-NCLO]E6<4P_$RU]KA(5TQT,?6U=5L]&&?_
M\]%#D;X&[6$8CQ&C_V+%N-_+\7AYBV6FP(8E$7-B5OHR2B;'Q[^'!ODXAJO&
MHW+S:)?Q.M3+JW[5L <\*0X3B4;*RN6U3--R2Y'MS,&6'6I$;#0__ _C_I?U
M$Y+X])EUYHK@WW>X^7_,4>S_C?B?.>[^_[-@(N3Z[WU^@&IM3O,4SO^]MU)7
M;JK0U25T8^[?L<GOG_C/B__[5M _[JN[J*&V"TSOLVWBAQ)D0ZZ/F+ $H[9S
M?]KK^W("9F1#I)C/,[4!=YD/_DG\)_&?Q'\2_TG<SA&+'UG]]VO_/_$?'2S'
MX_\%4$L#!!0    ( .*#6%))V436TO4! !^T @ 6    9S!V<V1A:C,S;FYL
M,# P,# V+FIP9^R\!U14S;<G>LB2!<E10<E!<DXB24(#2HZ"DEI$DD1ID)P%
M!!0DYQPDYYR4'"73" H(=!,;:+JGO^\?[WMWW?G?F3=SWYOG8?U8ZU35KEU[
M5]4.I\\I] )Z';CY2%5#%<#"P@*L,7\ >@E0!F[@XQ/@X]T@(" @)+Q!1$)%
M2D),3$)/>8N<BIF!E869@8GI]ET!SMML?.Q,3%P2W'SWA41%15DYI>0DA64%
M1$2%_^@$BY"0D(28A(Z4E$[X#M,=X?_TA>X"*&[@B=[X@(/%!F!38.%08*'[
M %8 P,+#^O,"_GIA8>/@XN$3W" D(L8TJ+\)8&/AX&#CXN#AX>)B:M]@Z@%<
M"CS*.T)*^+?TGA*PN5()!R7DW&!_4---K3\)NRMBX_:6D(B&EHZ>X1X')Q<W
MCZB8N(2DE+3R0Q55-76-1X^?&!@:&9N8VCY[;F?OX.CD[N'YVLO;QS<X)#0L
M/"(R*C'I?7)*ZH>/:;EY^06%1<4EI;6?Z^H;&IN:6WIZ^_H'!H>&1Z:F9V;G
MYA>^+6Y -[]O;?_XN;,+/SH^.3T[1UQ<_B$7%H"#];?KWY6+ B,7-BXN#B[!
M'W)A87O]T8 "%^^.$#ZEDA[!4]=;;,)!-Z@>).34=!.RB^C#J&W<)HEH[HIN
MW(/_(=J?DOUK@KW]'Y+L[X+]0ZY%@ 0'"S-Y.!2  G"^RY4;2/0;O_&_!'FB
M@)ZJ0S9V%-<?& 6H,'= ;I)HW1_%F%M]NY2_MM)(,P6X<J/^@3Q1.TS5*/W?
MB/^YDS0N(#=*:P)[4N6/:A$53-'?\$?_45S_%X@HXE%]Q'"I^[-)VM\IM:8F
ML%2H_N1#!>C]I3.--,#TC[%SBVABJ/3^H"SX.\]_$4EBD:[0?<HYKS#PSZF'
MDK?3@.7<G(:6L".\3 )R1C<ZKY+B?[VS?T;,)&8\=C&84=/G_FW4?\4_U/Q7
M_"D<AZ/[7Z7X$VG_5L=_XH_>J'3_JH?\48#_SZ9V?ZNBS_WG&<H?Y?\G9?]-
M)TF8N:+YDZG('_J/F?K;[?]^D,13[!$\F-SNI" DL3W(//U!X?^TX]/+<&5'
M@E)>AE\H-LA0EM=)I?*&84[!H@-EP:]J]H]DLETB,Q.X*6B CEZ 6HR90]-[
M^*I?7>PG<:620OB283V;>M_SKM,J641!J8,$ X.RTX2&]S,\+=OL'PI3=;*T
M>/V=/>E!K^@U^6)R.EL4^X'G:O"X(WO/<!5AY[WJ6_%#,YVPAE-9R%"[X/65
MT_<V+&B&1*]$ZGBQXE1Y%UY/<,RMS$[30X4-,,(6Y?\,#72"%9GCPST_BE4P
M"Q8UBG_US<,6NIB7JD)J3]>5A=77158>4*V'X,;,H+C@3*[>%/6\U$=S&_>#
MZ=@YJ;\@.2?VJZR;9@4V30H$NUT_Z>+M*T"_.[NQSYQ\XS>(HXY*0.Y-OJBR
MGN&GW%Y4A#<-W9[CC))E?PYEELH^FN(.7TXPHBO?DY.VPO$6.);@<*>D_+BO
M1>BO 2?6A"%'G;^>L\=&CHM][8?[;IB+S47SO8) ; UI>[79!"D0;_?T9R#^
M-C_ [HF0:X-?J:;R69X.<U.F?;;L= N2V41I!)$GAQ1+%RGZ6X$7[TZI1[P;
MH;8(L(DX6__SGH-E$!JP;'K#H>'/#Q?[M6YS1R3B[,=;<C10F0[G4:CS7F$?
M7%.A"CP=)T!D^#\N2._D>MA=_82A'Y[5I[?AK,*W66\6QIN4--4\'MJX]BVM
M )4DU$W<K'2)8SX8T0MN.:OP_6HJXQ]T 0V4<^]9%72AP,QE0@,%7>2%TE[4
M9O@ ;^/'3<R4[4M>8"G,5?@+HH$$FJO=M;GFK+#%AM2"W<O@77<U!G'L0_/+
M"8('6;0'MN\81RG5GQ[T&]NT$S^<KQ#;OV_YK6'KH+W[I))Q4)X7UC\?]K*B
MPI+^X-Z#FE]:SI)[4T4(4.'R-^^7/D4;=C9Z[DO,#MBKD7"\4Q<:C=ST^T'$
MY/=9FJ@R!1$1J[2SMI^O&$;*A8TSD_N]>5&/"@:OQI&Q:G!/340:-;,)0-5U
M9G'+*-QT^DY[2(RZL*(<J=OB8!_!%-* )H9OMB\&_\C7B!4V;I6J,LNHTGF/
M1N_]RL)IL;^E.UQU G[>#WBAQ."MWCHRAF9Z$EF9A#LQD%BW8;B?7@(.1Q [
M]\\'0OBYB%%4D>:EQ$F1MQ]4+?QDA6AJ##JZ:)Q'U,?V*0V8G K@=&*(JP#;
M<X3S:8A&A8Y(?$F:JT<Z;Q;!WC? *[*S1D_E>.1N06F"*IQJC!<7A;7O7&@H
M];MA]IG"=\X"--"FD'&;CSRZ)4Z"&=NBZ-.O%S8M$!*D\K2_,E>CM?,!I&G9
MKH674<9HREEYJ4\I2.2(7,E2"H[=(TCFW3-VT.V?_8N0N/^^W'2]+2+5Q!GG
M8;JN<4BAPH:8NU;3E66ZLX)7S*T+(QDX)^IA:V?OY13.N^A-TI.]%F;2?&"3
MBY!:KK/_3#/40DTC<95#P;N$X+2X@\J)P:(R2-CR"[:ZW5U"8(P[@'O7EWHL
MF,HP'C=5%?1^0 HG9AIG @TTWD[M/2PSA:KWV2F*_)0V^E0T(--L,<=,-?+D
MN/K6M=-YL'-E10>MY77^_=7*R>!OK^?)UQ6H'#L8.MN3]$)&:F%-NJ[C[;>E
MUQ!FOEG7Q%-H8*VAZ@$,5<51DZ?V1A9_N7I8=9,UPS48VAE&.+CP[#L:&!>K
M<*%"Q$G*$EV&IKTWF7<BL:4OQ&5  WTK,H\R*IS9P*W)FS<(60N>+_B;QRR7
M^Q:F\^=*J/*H/$: LI<L34=+5P8^:XT'FMM3+WD7]8A;LDTSK(W$<7>^53&W
M"11GF\ENGAJ]+BM/>,&7SU*_S0IKJESU80]7%7YO0]8%.A);=+!D2>H-H&NJ
M\4OYA&?3O#_XZ(@5%Y&J UNM+]8N?C"5WVR I=0]?)I-UHBB62U" P]..L][
MC2P*O1O\UHB6]VX9UPG>X!RQ5@7CH&@ZPQ1^#("NSNH[2W9I%JL"*ZLJV(\V
M4BB?6!,INM;XV[9ER>M$/!NT",SZ[K22V@\_JX_6GV;YQACS3ND:++A^95K2
M=J41XNL3 C&MASN>A-6$_]K&\6R-%V16( )VD9J;]E-\_ (G5QSM<>NWCDHD
M=W;,/W72'5KCC$\LRIX(W!C?LP#U>EL@&9T$\DB#CESHH<U9L;K]S"GO;6-O
M"7*\+F9.":0.$' 2H*H,NO-XF=WHC1<4K"VA'*[7^93\0U #2_-) 6REOAFV
MFJE%D?0][A'1D4($[=&>I62XQK)*FTY-*+,4&CB=(%!SA?LLNE]GY6O*LB/.
MDLQ,"?K:)0PSG"OU*EX2#LRO&ZGD_90.2"U2P16O>=-%EXR;=JP0=<G<D7:V
M6/ >3)QRT>"J1:X&U^GPE\N5STX@K%:EE0./0Q'];X0/HI4=:6>I8Q6,9K[/
M!E#>G4J<PB[5..S.V[#,*3#]25GQIW?##;2GPN)O',#^7+HK_20%GG0>E6"9
M7.1$<YD18_1ZC(4;7ZF*!U%6XM!H:DYA4B=L?H@&4FRSH2V=H6?G-"C20'->
M[*\FRJ]-%5\7%CLMOO<U_"CWO6F),J7[T&AO%*,B-& _F3.]Z;)J+G^#H![0
MK44,O72!OM66TN=\TWKD?0V>M4FV"[W[./GYD-CZXEI(.@BFFE6BVMF.*QO.
M=&54XB\_VUG?QO_RUS?OL(%L$@5JI'92K^^7!6*\]X)P>S1090$*E7V8>6]2
M_]J6HD;R.4%.%1M\O[@=$9,R.F5$;$'>\Z6WR,K)5&LT-+(1<,"QZD<#E)T;
M]'/RW<QI8P_>?@4IFUK2P\N\@WN-%FOJ*1CMGE:S-.G.;F;>23B]MC*9O>_?
M9 P$%%$O(<710*)+):23$Q5-!43"XPY,Z.],:H6"9+ 4AF;3K:*_FY?[QKT_
M&_)>5B(X+7<)T7[1,I!WEG234?+XQBE+?0W\Z<GKR>F1^XSM:YRI,:CW78>%
M\]GR+$F&]7TUI2XX<[7^U)L<\&>W'LWUL/)M J>5+CT]3V&5QZ-CXLS-)\4=
MQ&A@,'3M:FU3G=P0R1L+;XQ=Z^%_23,!VOY1LF.1X7T^4-7Y]$04:W'/4L"9
MLWL2W+,@]:KHR[C6)R-6V@'BBR0/TULMEZ4UK 4F\%1DPA4DW^KR9G$',R*Z
M]](E3)_TP3;N)Z&[TI@@@P=HS??7FA&3TR'6$)5B,V'$&[G?;P7G[*.=\%<F
M2^&;4^*0=P-#M.:1"J46/M+^,,W[]#V#P<BRD0XV-#"L]/DR?D>19?JL:6K(
M0JO[UDLH2,D<OPQN.;?Z.EBK-A$^LYZLK[:CA]29?5X+JRBH$W@R!DC*U1BA
MF+S=QJ9[WUEJ$,GU];K:T?<#AI,=O*:6RQ4-!4YG;E)=RS>H?^H-U:K6LF.7
M"Y.ZH@1@U$41(2#\)<?WWUM([%KD:$%)FE,5O[8^?9T46-F?F2"0VX0P"88$
MC)4!F2;-BR E R0MG-#?P(>_O*%G]:%Y,<&A$4%97>9]1&Y#V;$R23JP'S2,
MJF>"HX$>>KB0; ?_RH!\".3T)TXGW#[N4%:FI"*?X4GJ(R.960V4P6CG +CI
M^]&:ZB(:6)$B.!KU[5(7T'LN-+ 1>#L9OTUYH"87J=5HH$*\309 /S"K)L%E
M=&<\N?BME%/N)0<*Z#657;KTJ77"(6?TM0;T[%_'BS8MZL0G^+AZZ+J79FY7
M4<+0 #)Y#@V\*<;Y5F]A.JU:"RX;IF:W>CS7=G8(/;/C+=S17QXH.G3FO#!D
M[7=6]5NC-',DO$-!FH=3J%$%@OT(?R&:P;+*59$G8,NX4*G!$2BU3PZ-RR@>
M:YBO;O_TRS4,EVBW?L7VBO-ANIX*98A%EWVP)01NU=OP;J=FMZ&&[_$ &A#2
MBXER#JOBJ(!E[HW:3"FV$LI=<V.UKJ]%)'CG[N\7!#EOX?"(S+604X&+>A?Y
M4J$4W,KG&E49'D;M4YG\=FNOHKBQ:UA_++9#!AC:I.=[7[>%!I'A*_YR5626
M"&E[N'IOBN8BFX+2M<Y(R9RU)_Z"ZO'UYC5OV[\0TRNK .QOID^J/OD;H 'V
M>X?7'F(G[O^V0'2"97,=#5S0\*&!Y8K+;A@$&2T..3 \Y<!2N?>?S"$24Z*
M+:0CM &6F<$\M109W;&2/T_/VG_]X.$*R]N#HI8R"B.4"":6=T$#%I">2N];
M3R:M8?5U7B)+?-EN3"33V&'I<#?ZEW.DFB"_!X/ .Y77IN<1MS1@RRUM7!PJ
MNB,B\W<AL3X*_3(K FA OTY;Y(M/39@0V45EHT64<0"%L-8-5R)[!3U%>CU,
MYI+AI9(C&KT;U?<D&#I7"$)&3T/62(T#<. #L1LK%!6"^VD:FBE#NM[#E2WD
M498,F1Z1+ZS<J_6NZ@\5&1G68IY-R7*"R]-EVT;R^Y:=AW;,WUO1"6YKPQU
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MV]@L)VNR3U:LK" :N'$6F[O6)\23K:'./"!DV;D1C1!;(S.QJ&6O462\S<0
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M?\"8E?+P*I$L>P*_,L,';S]&I)NM11CGW9NRKP%"3KKM[14A+RNX7[PC<Z*
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M&;M]Y4.]SM+IB#1B[%W%MM  !>1[]K=KM9,JMRI1N$O@J;-+O^%E1ME2!/N
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MH9 CA0&?&\<0! TZU'%V6]4#^QR(Z%4X!XJB.5LYCRFW&V=RZRZ? W0Q*>>
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M\<L+>Q_]=EKA-P^RR1Y6.8;]P@T;&:;XD6@)G._?/RNW23#7A_%D&=2)EJ^
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M_^?Y*&_&_*%F&>LCNAZ+(*^9(O)E-TV\2:V>L^ZX<V#_GCC5K<RTEZHT2A*
M:N70'==O<,][B'4-UJ0O%LGL=<'G )&AKYWJOQ<GGENQ5U@=R?.E2@*'/DK\
MSMUV&7Z<^.XP+;F0Y]J3DH.73W<YIPW:<\F*T$\8NRWZ-+W]PG=Z]P_AW4*D
M;*\TX7TL82.>;/W_A;94;;KN!6;:^BI%*:LP!,L0WEMI(0+&F.0"8C0GF:?Q
MY31%J1T]I\QVW5<H-X^(Z__YK^7^B_ZDJY"4.JE&)$.=.&9MVO'AT3G 6)EI
M3?EN.3UXA,G?)ZK;T943769#N,*,8Z?<_[_X0.2(8HL9$/84+"%7>+?]YZJL
MN,;C1U[9D(MBG<"*S]+RS"(OU7O_\,:XM(MEV?&, ,&W(U9,L>%@E+G4ID7+
M; G>UF"E7A?_8,*M4U*9<-KYGGL__\,YH#R@RK[!B&!;Z FV8<;)2,_7-K];
M";O!E<>$<B&O_/=B&J*RN1D_BHU'4^P:ZD0GP7,M6&Q<.20 /<^E&>ZUC&.5
MM>N$->U3)^V-73FI-UTDQA=X/7IOBD7;J07E O$'0:&9MZ"R$U3_9O&_\/W"
M$"FMNUOL<,+>&DOLXITS4^R1M+RF'(D&]6YJ8I)("".^Z+;6)XYRR@Y 0.Z]
MRYEY>TK&PW!]@\8D&V>RE<8G.D99P&/^$?JK,&+QKX#*RC_.>0*G%1"".T\>
MTM144Y">T.Q"W.P*4VZU]F8+YU9'$BYQB.0O)=E5.CQZF;/-#NBD_^]<ZS!>
M6A',&U&Z=S,0]0IJPYF#PF)7#<GNRP3,*>)")9SW8SRX2\,VL=<$9(/!=-4)
M/P?P4 'K%:&,85W5/IL1(BLXZ>EQ/P)$'=5.$A6+"KD*KQ[R "</?/MU+@\]
MVI"GC;\_^3Q IX\7D)'@XYD59)]T:YU>K?&D_[5Z)0M?#(^84/[9RP=JT=7J
MN%/D@#LQ3?PG.A?D:/+' GJK(RH=:O^+X:H[Z!'Q7]J7K]\G7,$'AV)R,8RG
M'>.B%?7-Q99ER4XM%?$IL**5N7JLNT^<&,M';N"?F;S[-L:I+VF<\N)N9-UZ
M\U$\II;IT"<V E[-(5RX-X6W7B=&O"_HT'WJFVPQZZY FHKOPL+-8SZI+8&_
MHIU\T[4/N_^)L*J'G:O,'B%.PQH0"7M=4]7UD&YLR?L^3EF-7\=34ZQ]=<DR
M#LMWT7:GN8B/TM<L6K),G\_HW@Y\HSPI*2,B#RA(2"U+4IA%/'-Y8^P70;@M
M6#R$ &6/)[T=_H2Z+.0^[?&TQIJU.$%Z7&$15R&I*V7?&XEW)(HN<_&@)OX_
M]MXZ+NIOZQ<?1$"1$ 1I4$")H5-R$*4%I!L41&+H[L&@AA(0D,ZA0Z1;:4&D
MNZ1SZ(:9N8-^U>]SS_?>Y_SN/<]YSOV]SA^?%\QG[[7V6N\5>^U/[ ]E9^C1
M,[6P*KZKZ4R7U)G$!''1,ES,*2'=Q(E\@81I3Y4N$[UQ8,885*-]J-RPUJ@&
MQ02&Y&/3IO9BKA0)]VC71;4?"3O*(<,B-J\9. JG=G&IK"D"Q*'&'>%'!GHK
MCDH]CA+7I*3O!H7=?,C4RV]\G&\H3!!]^%K#XAH6(#EN2X)J4$-,8!T>[W4C
M1O7KBP2<>CWX!<& =  ^/<L^&\NG5WBYEVF_]6+FY)R/[D+<ZIR78:Q=5-MA
MA?M"J3A]BHP84;YB8(86UZ6!YI'*F_W%"=3/<G'NI>+' W&:R ;6Q"E+:ZJM
M^VL60VW0:*N4]:4UR^9YC^+:F3Y]\_'LE01!>L8>PV>J$89B,68=%>1\OC>!
M.=K>W&RF%4$W7+,V+73Z[.M?(BYT"NDFM\YZ.+5:]3P/?*.^(<J13X8@(I)P
M5H)LI4BYN7)DO-@O\^T7K$^,P.0AYZ)-OG "!7M7'@51<Z6-@U3\4V#/.:=K
MT=I >TZ/)^5X#&-[1'_MMT_^]R_3OJ8$.)-\7&U\?C"%F-Q3X@.4H7U"N^==
MHK.(WSV>#YMX5PZP?6F^HW@Y4#G5QK(BVXV-;[6(!^,AXR6/>$"ME/N6/Z<S
MW '.N5 ;:NW5_,Z?%[H5KSU/)Y*W_,,;"@JJ5:\<X/#-"' G=C1R&GH\OOQ6
MC73(7^,%;6J_^XZ9[;NX_4GF2_(LF;X\LG,)RU*5KN_>'4Q)$*L\TM*BT,03
MN]^-MQ8<8XHY.>=+)\5MH&]*SH5F5]"9P?9))I</L,823 ^:=+9-Z[YW\?TP
MF:7V6MMWM?6"CA<<B('$I-$E(]@1,%GD'CH4+\9)>X67?TDL5/#+HV\U"R[=
MZ("3_M#6?HT^:L/Q8C_OC+VYJ<KN1Z<V%-DNJ3@J*NX[V..FZ)^DM\1/+K;[
M_F=MTXH/>+9^!#$=H+.=B5I0.9@KM'CCG:+D+_K$[S("S*O*XEXXKA,F2<?=
MGB6LN?V?"Y97>?J:TCIA2I^87DD[;,@RS_*F'"2[!WP+RU02[061_9O ">W-
M6]8['3R9KGE'X_59B=NP9KB%GB6AFOZ,+\>SL+9EN<0Y,(L\7"RV7$)BAS!<
M(-FZ;"<*B0*<M )<;RU@KO$JR&)S_\<'=['XWW)]HL 91B]03 S-;^[)WWT1
M/_VT+V,NGQV9#>M0/:03GW2*$6\,+/)_4R1-R-#ORSIFZ5+SVM"T+J\YC:95
MK_N9H9O'M O/1*F>OC.QS*>\E''*K+>2,P\.$WR2G4PB#OZH5H$*B]UUG=,9
M5=^+55XI@-F:QU!R6$3]0H-N=5-\-4D^'YC1BD+[&9$^J 6L46_ ,Q9V.<JZ
MXYQ5&6?-47OJ\^R4!/*4Z%TB"D") D0\(BB:4*^H;:@N#=KC+VEYU1^E93"N
M\1$%>#+".YMR0BNJ^/T[PKAKY1@)5U& ]3BDNF\'Y(9%C6)TND&G1O)M7YS4
M+*GY4 (=#:SA_G; ^U:'N\SE^(Y2<GW/)(NN,/3&;_#373$_TE2]51I*9<':
MF7&K]_+XV[Z$*?%9<IX;OC)>P\-VO(8F:5/R,=<L@#$"E4\Q;TS$[P^#:AEI
MTWV9+<;A8;EL);I?:&7#:+Q9O1^H5@[<NF$@,-IU&6=R&_BY#%;3]RRV16 B
M_K9#WR33F:CC:?QZ'=B5],B/W>;)D[[/]D27(77,F&6:!-#F##RH\P,P"D#[
M'@48X4=J<%H"6"B:<I_?PAB,ARZM4<GJZB32<^H/XYR:!3Z;=Z[W%8- E9'E
M  7G/'U+7BI%-J_JEJA#.OG> :<<MAO O<[)LM#!H02%>U:IVD\E\L18O1X#
ML-C_YLG3N%1<+8]R6/2@P)Y<A5S8=8^AM5E1(Q2 02D8#2XHK6C-]^;_M-S
MY@E0+> A)"]0O*1\5Z]0K,K<:)%VJ%:;+,U*5,K:Q4WOQ:+0$0TH">!$HHH9
MK_L/>X0]([_C:3\GHZ&.L96/1H<71Q#!"_X^0!=;MOW6X(BMXY6JRIB;*ROJ
M2/JZ >G!Y]NT:?;9EH]!H\\<^N0S;N$"U@["*2Q.V5?+JJ N=CSR=Z4T>D5E
MTJ:GIB!F'_N^D-0EQ%+D<IR;S:;A)#\/,V/PT\#*3]XNN['6<'NPG+'<G-TL
M,)V8>_T1KHR*,O&:%CZD\)J(^82E-/E+"&N*XC!9\_A!?0'E^X8/5=95DW*J
M/N5)F;HKFI310^&!UAJ,T_(*]-M2EA+)-#4[6/5%P;!6\6&\/1,,^^/'F.>F
M[/L-7 /PC2+:N]'<;SPPXP-:?&@:MY<2$"6VN3V,)=>?X;7CQ#<6AWA)]<M0
M,RE_K?"YC:Z4HCV1:RC BJ0O[[G47+75.6?69Y(7'+8J/,O'#CR*3Q*N856>
M*9_?$6K M!>9N#QP_@#VV?$;'/?$>"^C,E2TI5UC0C6SX9*W(!QD]EHA_$!$
M>N/T,8[R-V\7 [-'$69V>Q(3%.T0CU78<^VXMZ:^W[0XOYF^7OW0@YU<8=\Q
MPQH^1SHHJRW="F##P1SLQ^QH'0?K=H^O4Q94F-)9F5^]5+.%J[-V4S"2N5&O
M6\C?Q&'LJ3:OP;&C9GWU*\-R/6"F%<X!G6Y 4TX,DHO+/*I;()ELF<TM"U.3
M1DUSIR@C>\*@[O&-L[;+V_=6-?D-0*K;BJT-:=;>C(?%M^14I9D*[YL4-:>[
MH9?.GJE-5PF&[<2WE,I=6T\1C8'#$]+]5ZLCY322!NVP  IS/<2?^0]BXFQ=
MV!FJ)'8?*4M $,X1KJ19$3@33C/$[I7<NRJ);X:8H/N!9=V>2G6-%8(W+]V!
M&L7>>H*AND;L1G\-Q-/9#TP(.(M@#5F>]A7</-=M_G0MKS5<J*T/>?!,QTU!
M=:BL!PX,57*N>6LK0?[-0Z/01"9R>?:TW=K\EBGBFY^(^JE@&%^^+:%T+/&)
MUO6[ T34D<P8*@>!HC006E@$F[RD+"&CIL-J88&76)B[C2D^+J]=^]+"T-MA
M?G;;)H_"[@7+-T].;G%<)15'!R7CL/+IPLR77FPCW_W[M"\X<CCN3)I$2-K<
MH[%(IA[)'A"GZO'JY^U>XDDS278 FZ'3Y>YM6=!H[.D(=X9%_YK1M;NR&!;$
MQK,R7C<D*#U<_9S9P7(&JLMJ2399!BMY[9=J4M"Y%"QEO&V9P4G15(V\K5V#
M$[J?;X3_@'2P#9A@WL3WT$&6)E^M27<85G2G=6@03-.P-7E>Q?@8Y[Z';$D5
MPTL&VT5#K=E"0?4=DEB[SYYLFA&=[G@.BAZPHW,W?<B( %)CR?#*#G]R%/MB
M^1EYAH6<SI43\TN+I9;BUW?$*E+8!R9UIJ@Y]B)9Z8CK$3TMY/MG"K%!-@P:
MC+2O (.QE5US,^2C*( 94*P\MZLKC!7<%QZLV=S/C0*D]EX6O].7N3WCOT>Z
MT<\7R](EU/%M";93WSVH>S=R>/=#1ZL';7GV#A IU0%97P05/G<;0=ZGY#SK
MDB M3R%8$Q!F "OF?AF1;7B*$28>S9&2L>;#VM>6X9XC=\,:,<Y U%^C?!,=
M>1&N*( ^!,;Y"@584'Z%:):@\,$:XHAO?OQR4_KM6 E&N"J@VQ$%&&>9LY:<
M/< WU]%K6U2]8WSU/%_O$U%<YL[E)[O]/.$MN!_[X$Y ?,FUKA;-M#O$Q)&R
M=402E)0^'QIH1^"%[ <J$%.'"=E)N0?'@PW<D:=&U-IC8Y-\TFZ'"[1)+.\Y
M XJ\'EB#TRU4)K&L>^X!+N?KKJ  P6F9*$ M@OD2OD?341.E:*3NM#+G.(W*
M@K'2IQY^I8E'E34O3 =$)>$Y1&_"%BZ!RW?\4\=]WC%ZWG:VZ0Z223TH(E.K
MV-8?QO<TM>O5GP=2ZU,CF#$'^<++\7F(/-2_DN&I+U J&LZ!K5F7W,B< E_G
MG /I/A9Z("D#IS<YM.%3([:6$X.+D?C"%O2!\FN9K\56,18IS<:<&WD,'NC'
M3&^7--V\A;OI)82 9:W&@L;)KCKB292I8G\&;NF_$R<<3D,7$WK76ID<P@B\
M\R"7FT7G-2HJ(W78<$G],K<>X=JO$;FEKWF&*NO=?)P1'49J3"#FEB^L68IX
M-2<"OL)_'V+BX+(0*4_75NI$94LXVF.??0SM,ZG2N:K#:'BEI]!R#%T\*,^!
MP=8WY,.<U:HW 1_E ?5/1H\SW""K89"DYY;"/>>,E(AN6%L>&UOAA(W@=7TD
M*>Q9;0/3-&<!:%Z;Q12V:LA<']!RT[>5=Q/Z7!\*2#F3!N'-3#0D%2 JKE(#
M6[03S=;UD)PC6SBC3G!^J*(;MKX+:2C:':Z4#++#RZP%@)_C_.5SFO;6M;Q,
MK<63<E9U6^QB_"<QZ(NW>S'LOW5KM@UQ6CFS)._8?2EHQ]<0=<R>G'+SZ$<>
M)(OXL8:3BYH-5SK3!0I;>3SVO.JUW@Y@E'CF?U0P0]*=8W!,3)5T'Y#84?1)
M*S65(+:)4J*_S'R'MVN9M7I2KITT.Z_+\68"[_C=DZ:D5X-#(+RU&(^84-M#
MG>$'U)9%.-N)ZN+<M74?MJ>^#-^N^R9<_%C, J.S?38XN$NZ;I@_UG_V@TL0
M%]E!OB'F8)&>2MW LYJS1X]3(B4=]0]>&Y*E*.IU*ZA5Q:R$U$E5]V3Q:OE0
MRUEYR7BQ]V6$A*17ZJM=HA*Q5M#9\<\V)=V(D& \"3198?4,UMNZXA;92M\0
M8\ZAAU?4,K1U!=*Q50AI1&"!VF=V:?H@ZZG(,@R3-LKRC9K0F(#L#I.8A><R
M-!(%29 FK7'I%X[VUCD*@ILH@#=5R>T C_*YT<5^+YFL]2:!R"EUMBHZ5VC)
M'(32PM60JNIEIQK?7GLH5'SE*!4_'(".Y*2GR$7K-55ETM<]E@E+N"Z<N07*
MW\]GHP!5K#/0S:*-<S%G_ABO1;409Q+?A?3M[NFT:]-@RMK[+(RO=;AN9FY+
MP^QIJUTSZY?'TT),J1.';R8F4]8,^$T7YBD=><71LWF<FO +^IJ6H0"OFY8W
M2LKLHD\PG>G?$3^,C\F?IWF@_!(^][I"_Z4#3OG=#'#>L9I^96EI?:1Z/966
M.Q-.=:$R'EH<%" / 6F"[62?A]'2H#5M+ 0\=PN6;-R&O]5M$4[<XJF:I@@C
ML&P/<P96]O'IO:.)U)&U8EE3 H+G!,^AUNA*CNQTA'^>0I<.S\WC(5:<RQL0
M*Z"1Z96S7('X]&EFTWG1.;:(3+EN/W_U@2W.3#LZO]'=7.MH'X&^1XKWM84N
MN1<>AK[;Y=Y[7NHE\M0>YW6Y0M=K[O+>YQKB[U)Q5L+ZSH5JG>YH8W\B55(4
M*S<*2%_2"\*4S-QN3_8<JB=' 5HKZT[YY;(AG[FK4( BLY->+-"58UN(__,:
MA3C7+J+'M6$XD%4]'ZS!S%BI^.G%S_%]T(KYK]B0I@*W:T@IL/VZOFLP!X<H
M;]'TM<>:8M*B>!!/*&!Z^W44F)9Q\, L(@2W[5ZLJ G_9!>RL&14D^[5?@G,
MS6&8F)N!XP0T+09V4#ZPWD\EO-M;MHX"$*V-AY;.*) 6J)KAML</[W!D< 3@
MQP38>AE;B)]ONE_*/'9' 6Z+F31N63:VX LQ#%L= (,=Q5)/3/7-+OGR%K$7
M%+ WC)G.61^9"Y)RM'#O%]8&X01[$=M,/Y?Q4X('8 3.E=HL;K-Y0))LP7@#
M[T^,<7E3'AB0AK 0OBB2URE,KS-]#9[@PWCQS9J;C<^"/RM9>2K?*R&,-;1\
MTO!.I%ZWEL$9O<WMVWC2.+,&A*\+%;=\-]G?[MUZ A)>$A4B](='ZM%='\_4
MBB@Y63"\DHH/(5A7A+DET]QVONUM:M]B'2E?F<VO>'N0/YQF;5S7X#-IJ;B^
MORC&JI;3T[0IMP_,9=:L M!+U%,F5,J5I)S^C0NP=8C1J@0Q>$3U^(%T@')E
MC<F=YOFO;Q9R"EQ*WBO8EF5#'=VPMQI&>V#67K(#R6X%6Z)1?%P-SQ[SMCXO
M:,!$=N\A>\B2*A&:GVKY,$HRCE]:&WTZ6I+!%\55KQ*SGW[OQ9ZV)LXPH*N0
M)&T.'PJ4TA3JMEXE:D5G1)\,44J'L79ZFCR1D(-\"#YZ/M5% 2H"3N(!G[?K
MAY"A<V>AEY9FLWVE#2C"9-O1OI,N/2AJ/0<<Q9J86#TLK"1*-#N?@[5M!8>)
M6;^#L!;/(J0YK[HEJ)4.'DF1-ON'J=[;0O)AY,)6*6<"SB4CI$0F5S]XPS>4
MQKN&G4L+CZ'>P@:/M'7TMML9R4!^5H(A3$.B"K;9*[6F%3U;B\"(<,LE&S8G
M.+"-##)QF "W(5A9!+YAQM@U;)[-?V?#U^T(CRA]P<C6@@(('X@(M79GJH5%
M,EONB<S/\E>]Q&=2@AZZ/FW*:1K)TI%9')-,N/04IU/$4Q63L$UWLD8@O&;2
M!ZEY)274L:*!8'"QQ$"J7,=OCV-;D";U5+.R!5_8LYOB;J4JW&:V,UP>VM5>
M([QBN=NI.7L#FUC<:@#SQJ>:PJE\<*S@YM?#><=+;C26H8G;QU'>AX7%B'>E
MU]\ B<I\2%" JVSQ"^(,N+!G5?H8JXF#M%3AS41Z_#&UYF\,6UIXY3,B)*AH
MJ4:H%'<H5^G&Z4_[5<XJ+T=F#\3GYF3!(/.K!=8<TZ2F)X%,+Z"U:?@WMUHZ
MXP7>^I.[@R.Y, YSV1H7<GJ0R_NI>'!;^<9MK^'*P_'7_1FR-Z5<F J=:-EW
MV,9]HLPK-AEBX#);A-LOA0?$[Z#3V4W"TXW&KZ5>9MER]NFK6B]O\''EQ5W'
MVX$"T@ZO85C9:+4RP7UM<#R?I,@/E.U8'_2\Y&0*">)D;Y!<G_08XH_]"!EK
M-!?8<4^##&Y0!9UJAD5QE6TG#2&RH!$9M+>1IZ=H@? YAGLTRG1F6GC:<]Y_
M'78 6.[;XF5EW(PIL51E_,#2U)$M$F U MAQ ZH/($<8$-!U'">+9INB5[/Y
M!A4)CLM\H3:,+7=.(R1HNDE4_CF/3$0$ J)ZG6$%<,O9POWJ.)\=U8R=5%QA
M-N-YU89&T<AI7;JG>O,PLY7AEUWR_IQS;4OBF7L(L.1_?L-37I<9L\?K@9T7
MRUPC_ FH;W..]9L3!V_XLI[AU8'NAIB1_E?+TT+1I:,N2(UJ"&QT[7V@;6%&
M,I<#:;M'"8D<"9C:DI3DJ<0*%D#T?W4K!SM>@N$R@<7@8VRQF0!X5@J<ZV9E
M=3MQFQV$,J=RO"CRRN!M02Z"J!8AS$DM&473RT]">K'T:.0O7F$KC]-W!>RR
M+IH8N7F,+]:M4!3:R-#+AH&$"_CQM>3MXE_3F;]">C8)T:ET \S<YI'B^[:G
MQR@ [L5KER,";];B/>"#[.+.MQR^.4)'U6#@?)),*3MCZZZH2/^R;0%X.PWW
M(T+0L;>/LZ*G?CVK>F>G?'([.3)Z>I+CS()DGQ42K572SX<0UC$M+0\C>[<D
M^8HJ;R(D@U!%EO#NR\/I+L,!P\UGT'O)$@9? 2?QM8H*[93XY8FA-S,N[Y+>
M5F6Z'/78(IFFOYS(J<8O1*U.C=J6AK?GH)#9BVYVY8X.?;]UWTC:I7?4_A&F
MS-N#IV\[-):KB'V]A5  RGU9/>=X.O5NM>&T^VF3]#D:&AT I]S]@26+]S<W
M7_%A=!VSC@.[<9'3IOC4L00%A#[1'> 4RUX])-%))7_I9#M[6<" 70<".%RP
MP6Y%%-F/%411>;V^6\H[<_4T+G!ZO%TH<%-R?C->0J<"!0B7A4P:+6HXLVO.
M*(;J:GX);Y(6+CG,B_=_SSZI8[%S<N0%".[#R84-.!G=-7'W0@',ZWQ<B9H\
M<0'%UED&EE'7"O5>XW#KA;U:WS*XE/?]_7+5%PI_?7?0 <F\PSA-5U-R1VNC
M5'Q,/[S60$JC?@#.3XY']H:Q+V7V:2O 3K@AWZ3HN%9.4=BYBJABZ9D0YBO#
M<)T:EQ<P"R7=MC9R\@-FH-+?NO+G':SB<:?<*Q1N$(]W!]3#Y=R^3S1\;VU+
M ;0&;&ZN-5%$EU9[#-4LGXMF=7K6\S4\Y+GYZ/OFG0=[!EC_L!U;;N=PL-^J
M#6RW)Y8-R'FJR9R*=\^+(?73O7AVGJEG.$)CW59L8$JXQ*6PILQT7][B?0,1
M=8#AN!07C6"A>+-L2?\\BZDU-:[GK5;#=%_F[LS1'D^:A8J.$2+$YRL+ZI45
M N-^^>-331^:4 !W<CO+;A(,0Z#VK0H]\PP-/S++5&H,G>RF>"H#M*'?4P1]
M1=0M5>2D8M.SF9-* )PN)2E( 4QGCB'R0]3\\!!>P7QV[0\#;/LKY[4B3G[>
M),9%*A*TCFEC,J[SUI; =Y??U'SSI\"!N<3[!&2MZISA)SXV*VIM-;\RR/TD
M]<;@"Z6LR[P3K8Y$8>9#O0>7-:V+_?;U@.%E>A;;,LP@-W8K%0G\<8%Y:LU'
M2+(^&QN? 8$43,7$36"WE8HL;K^.7I>YM2$I%]'+=_,D'643]ZQ\6JFO5+0\
M:<,ASW_[&$O$0.!K6^^XGEZFYL)U%6D<,0LVOBYVGHF-89=5/)VOK>2D+E!
M>_5V6["K\V'<_C&M[1;I4CE]T.T01G-2K50:5GGF2_47%Q4(D'H0UF]U-S)U
M+86]-[0.<UG=VR_=C]^7Y)4MR4,,8:XP7RJ,23#+EEK4F<AD6<D@:>NW,E(Q
MN _/$+3DNL,0H;62BAL[[IR5#?#?O1S/]>EE54>WC'/&J&$[M:M 24<$=>K3
M_N(^"=)-*_@FG'+8+7KVJ;_D/?I@L(BGB'/ERSMAI.17,EZ@_0!7T\,@)GFW
M'E;SL+]BF96[:H ?GTQI2/W:A.QRN^)ZHJ8?"89TL^S[_EY8:)D=RQJ1_<-Q
MQ9"CG1D%:RH#F299&?IB%0FBS\3R?HR/.SU>37^XT>1!XDKKL?K^JF/2A'MA
M#3-&7AH):PA&[V-I-[A2NB]W41UG^G3/LOYJKQS3$71/5_/P_;@D_4O^4!PI
M%6@R%- ]R"<FJ-$^43"70"/(8:F S]JN$-SUH2*,5.RM,7HP$C7Y#^&/P0>5
M]YV:\>\*T<><*90.SNT6L\_'B9$_+^J3H*CQ\<NR<!?0M'^07'NS6.Z';-)7
MZ-&NS?UMNR$8['SXSFF%V*;VY9ZNX,W>*;VR&VT?'C;C9=I9>K"\2,E:.?6)
M#(L1*/E8Y/ )FU?+X'*@QL=;(=<M]E4QK[LI2)+=_6;Q73NA;KU7,@/P8L5)
M@1)8,QZ9RE>@)!2089VI/3;5Y8Q59M_#TE43IAO<?;<-:0ZKJ9![%KA($3"5
M/_CX,L]$JZ@TBXFF))=Z&)"'\-I*19/*S:1+5Z5',#R@8^F^0)VQ3T\M8X;[
MV!YGXT+OD8HPF][VO77Q'!=Y0),'4<W9_8$G>Z6U+E\=->?[RHYM?49H"L#B
MW'6<_&E2 )7*?BOK8L9:_W&^JJBM*NIXO22.SMTUJH1@ITAS A,7ZN)^-$RD
MMDYG!M*C$U--I0^57-YW%#',X;\/HZ$E-VFQ$+CTHM?>\)6B^1!R]U58' G&
MFV2J?L8D3B/EUY/7KSK4+94M5$+-*7$D^B)>9MI)*4IQ,;=FCC8;#UM8!=M,
MF6"^DK305!FE(JF\;]6,+6JOE9.)10H=D1XPVMB^['_G:POIQ[J>^90;XZ(N
MD7=3GCMLS%.(1Z\^N\3EGJG=)[Z6A\!F!@"8/ZXPBX90.J/]KT>^9" S LX>
M>??M8F>(33Y/,_7.NT6)-8]7JGT2Y._=]*0JT0M[7:>K HYH!'+9B+HQ']!C
M4N&1PJ'Q4$"NZ5-P]OT%7<GW;00N.1_SCDZQ8_.NVUJEOPOSB^7/E@*HE0Q8
M\XU>%D#'L$EZ:BL//GW;^*G>:&&&0IS/N:_#D \48)+> 2/'5ALDTJ';AIH;
MS\/IQMZ[5W^%?\]D5VC'*=C'I^:QZ06B&5ZRBM"(#RB^^ESJ]S18:#R#U 8*
M2.4+QLB%F"/B0>71$TOSB2HY%C<I,WT,X 6.S,CC_/W'6-?PZ9L50MI-P=3
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MPKE9=+">,KOE/$B4G87KG*D[YG)"TPS^I'&O_A6, .!)\9BUJHMRT?Y^U2-
M=A9J47K29?&AE.$'X7#O5UC9@ERY2&D)&RCG=9ZJUR6L54F7'G=".BP6'OM]
MN3YYA!0C:R7AI(GA<N"J%*FJ0XO"[\*H+[L JD#R3)T)G,?3&.P9BSEE'#K3
M J93)M)-F"YA$=BZ]QCB[M\@QU37_$LNC,#;?=QM3Y7/\,GP\?(2;,Q9>\/O
M5*,N#9;W/ZX[LW60C5 -G7?ZY]'(::XF403IUS$TXJ1V\Q9@KP+,,*8QTM;2
MG<YW? 577=KGXH5(SGXY<,VT\^(5/)+\7/71,WIL\A@<K)?KI$'$6L\[(4_+
M6VM;<UXCTM 0Z+<6Z_+:?1:ZY.?<09F^"^J*A?G1](]LF_N4Y9DX'W#["FR\
M[/BRQ<4[\8W:!='Q?82[F]!0]0?F!P)D%0^\"I\5)OTK$=N=V5OVY-TRW2+]
M5'?JE0(]2E'ER4ZP'&B'-T@.[%VN&"@D!5>\__XJ/ZMBTSBCHWO#58U)0D7[
M_IT.!HIG.5QYSOVBM&=U<C(%8.A&(K<DOZ2GKZ<TB_7TLO.4HN+H.5FKH77>
MA/#]';$"G#2AOOF6Z/F"V8I/H89.ISE'^PS7AQR0VEVYC46YRS6C# [S4."E
M[,1-\.H=&2HQ_/A[$<XI4D]^?D0"D0+$I8[LQ9J% F:CW]634N%F,W:])9%-
MN$_)\*XMWMS'"T6>SUSVJT[:V2=0(S<>[%4/-..F,XU&STBB&*'DX\66/F 6
MY^=4GT"A8MW8U2$L]:2D+(NWCAMX[/D?W_ZK#JWY:YEPXF]KA@#GT_QH#OQ_
MRE^[=U+@>U.(] UX28K4_6YXS$RZQ4X<5JSNM?U;N'^8+"K0(["J9+E;K N$
MW[3Q8Y4"4]PF>+C9LPF.()#D>4:0D.J]SF)!I5-:N;F/H!,BMOQZ1DR8W"4(
M(<NUGQ2(S'\Q'5* 62VMMGPZS1SQ_:.2L#:5&2QP"C$-/Q2<(!TY:/HY*;A=
MK'RXX_(T6[%'/57O?)3)M")M0KAA]</OY-297 @Q2A]%'H[L]XU5W? ,U@+6
MCJ^#<^J<"5ERS@V#)R^,&_ZG;WK#+-KM#^4OX)W'-Q3UB<N1?6-V<5JQ3M;(
M2 U:2Z/(KI)>F+;Q!J:11[X/T]<!X">;R9:AF8:'47F(D!'XS[8=O"V1R=1C
M#42$K%7L*AWXZV=^GX5ID<E*N(!,9V<;9RT:,S72WY-]X(E(NP5& 6C+5TRS
MZ05$&#_IL[OIJ@HZX5KLCN[*WP?BD*TQS-P(W@**;P%G4VRG<K'!#G<YI5@S
MG/$E9=U%IL'YWF[LM"3WW"W,KQ-6&2[<;@'!=ZJ#%EJ87/NL6 %P.9<1(N.I
M@^3V5CV;-2M\UX";"-S^ZE5!9_%+=];+T^'R.R'7F+ Y5P^_8&;F^12N%,OO
M;U=QC%*?QR=U'[Q79[-SDDJE).,!D%K?(::;\L\:- <X%IUU6N3F7S+G=!;G
M.M$VWED$\#$$/KX.6SG(C(CTI;4ER')>"O>^'(AICA,SQ./-9? C:I6G,S=J
M_5(WR?QB+]]$ES8D&)S6CB8L*=O2=VHB8>?H2A9S*P)FRU$XNF?V\Z5=D*VO
M<HT&ZN)ZE!,_*^T(#=6NA,H!M8!*EZ_8P*02# LBO:A'YP5F]4E;=-[Y"D]T
MBSS'0V0H$&1?+=EBI.6(YHHFTTY)+S<'XKEJQZNF#288F_7J!\W^7/*Z^V_!
M _JTJ]$ 3JZ84AYFP1%.Y7=E-M$;B J^QV8;.V*C/:VI0*>K_BHI)+R*I$.M
MW:308H=P^<+X2W'VSF(6*\^/K29()/>)1EKX6&R>[%%\:H4%5?X/,)!)9Z=C
ME<&/RQIQ"ZANL=H6NSX#<G)X"Z?>/Y/QB3[DVW&C#!BZ&Z6QZ[A5(I/V_2:+
M?E^V&97&;82*T10//.9I4U,0X]60?\2I6*R,_=U@;XN!)EH47)Q9)M\7TYZP
M,5([1[>M*[]W:YPNZ=JV\494SBM]=EVX!2!ALQT7!.ICO"Y+'ORKLVT!56;G
M'LF\X;M/?2A^>VHCQ'LDR2RB8_T3)Q=F>3H"^#>=6[.ZHMA^;##P;X*5,ZM]
M'6@OIE.E.8W(5*4H.;/WN2/TQY1\*,/^LS$:2BQ.X<$%/I*K&6F?V"[J+G1Q
MB7^._"9TANQ/RHH@FA. B$G0S/R/+EE;K% #/[$;Q8"<RY.B%3HWW;%]YD0H
M2;!$Q+"1FI4\I4N5GZ5)M#@?XZ50/ ;SWHU(]4H#3T0H#%\\D?@1\\GJ:QC$
M#'E,9]\UASKE$]D^[GKN(E(=6&+>>3"KH6+LU/5R=^O-@=SW$)$69E*GY3D5
M0XQ/$N)K2#3*+#WT9$!C091'4G#E%_9 F06N^+:Y$TJ>WHK[(H5>HL5%$#O-
MS(,:L=:.3NG3>Y4;F[-"5R[##NGN:%V-0RR,XC+D^WFL:M6V-#<'GR4_88F?
M-W*+"/1QQCI_WRM7Y,NJ@$W\P:]*JAG1=A#>RG-=2203V\L;*:F+F^]3>C73
M<@O@"_C]<5AJI?'I>4SA;X;F>)]&U-IO6\^3TB IA]*MV:/M>C2<.)XI$GVA
M>\^BLNE=D&**4]'S&]#ADH*!\T5$S'$F1'2Y0("^\IV4\RS1>1,)9%K@*LPG
MW7AL8:Y%L-36_2T!O_C^ \=^7['3A:FE61A#L5QXL[N%FQ7W(A%:R$2S:V;X
MC>(,L*  5_>[@KX0\@/A?\9]SIEU,O L7_R;H)QZLR9[Y;=([.@>.*NX>/=,
M@YHRT$Z#BX_=O^9JO)YM%MK/U$VCNH%7D*R]:Y+-:$*CV/2BMMVJASWOF;!U
M?F07,ITK,<IWM=G1@8.@637W9]V.\6(B= [\*"UBW6KJ <I":2D;45 $V@(2
M+OU8KI%,%:]2-BP8\ J"XB/;$;5 F;?11Y8[58\O_AQ-J7>=N@*Y -\]&=_Q
MG(S<+F?"C7GM>!G74'M-B\XVW_6)RBDPZA: *KE[JC7OO%0ON;IT\"_=^H"*
M3C)S):[N69XM@K?5M6J='G''[ 0 /SD;@^;)B_8_M7P^<ZXJ-G&>:!#E8#^V
M^EIQ*H#8\[P%.$\92?@3F0^1#:",Z5G?OW/WIU_:DQNZBO-"1]P7^V#:B!7]
MK8*^&P^6WVQ,IT1JF!E&^?<)6)U=9&-"JVHKF[6IIF8JXP?S&J8@.]:H(XQD
M:Z#[0I/ _[JRWNG1@/*=?,L?\YZ</%: L#^ ,_ '$,O3B.BBZG)FY6;IU:]+
M7)>$VK@^4/>TK_BOF5-"H1D"EC)MZ.*AP!6=ATU#I8/UR%>O1V+)<@D/HW^U
MZ)1K,82GG7;X1!7V3(,&$&-7IMY@VM4N5D68_ ]YNB&>USZSL,9<,+^)\U',
M1S9Q$_<AWY=KME["@(:"?^/XZ07X+J.H^--&&3<=M'G/JAT$K^KLD<NU6BYA
MVMX-LH.99["?)'['W?"X-6 "F*14.X]B /;>:XD 34@K8)%/ZOMBG3=!J7GB
MFSU=>S7YUM\=X;SRU"3RV->PD/NW*4[_%F!S/G"3>0M8,L38/@8F_$GW(B&7
M6PD[$*J D;LBNKC%VZ!U6)33QGS.F:&W2+_IE38B:=L6^2HQ.63N*&&\(<NU
MUPP11V-(LB/GZSYDK2NTF6E:6L63Y&?JY2I(H.)OST:3'H6K^"+[GEIRY^O?
M"SH+(T5>4V$@/2B-8($8KD=<7%=LSX.4?8L;1, 'QJ5F+%\H#R?INC8M=-Z;
MI7 O+#^:RY/_7Q".\A>4=-\@WL"_!UEN [?EJ5M+\Z,5_]&M_HQ_#[MSO)LD
MRD2R%C_^&:BW'V)CB364 ,]?1C4*/)';B_8HKU+"VN0XUL7\IR];_P_ ^N2G
M=S?V3UNT2;T8GR=;XCWW*RVSF=AG1?0[R"Q9-P5>5_HMG5J%T>M?E3$C ">Q
M)/^J7\H;^_ZVGN9TB')39<!Z@H&QD,FRDY:8?L%4NK':Y1=E^X3<F4UWRIW5
M;VXM&V50=770KL1?2Z[E%JC3B_=@LG&W6-I=&0+3PMS[N77A/S 52?+C0Y4Y
M01R._PT*80][:Q%U146:U<*52:[W6W40OHANO^X7VQD"NJJ/"=\MAF"M2ITF
MO'I#WT:H3)HJ/K*N.>8%5:"^!;QHUTHGR9MYA_#9/E,93YP4%,Q>)<7HN9)5
M$O5-%A.$[^98%#=3X&T:A7"J,$X#:BS\Y%YDQ=4.V4BY?L???0I;\OO!F\OO
MY'.D\7H5:XW9!4LR(OK^*U958K)GGW%0%I#EYG;B3BM.5)KQ^-SO05_5&8E5
MF>V*T>/+3 ),!5]FZ4,.^_YAF?+ZD$[>*';&=QOU>L>YA,Y:!EWT[-E:]';U
M\&^=50ML1]+3>2@?KF+4*(AC)*UAI SFU@.2SC0PJ?Z^8$I;-W86 EW -3(W
MU8A>Q9;E7Z4CP!3YCSJ_E &540^5 NZD 8J=FD.QR&1N@>:CU8LU5QJW@&:5
M /;6;W4=T2".2,[6]<\4R!&WUZ&KKKF3Q_!D:A>I@D0&(F$KN<S+<:&L]VB0
M^S,O:Q*16X#R#J[S[+!.J^AS$]T*_'=FYZ7:E08Q4S0=S;.F#TAC.'$-/CBK
M]W5E>,W;=O0>0L773'0%/[\S6:Z6OMDY3B)3#ZK(D"+14],P#W_RGPWM*A2&
MZV*#21W55,?4MIZM"E=&KX)+[8Z9A2_8,;$1];'KC%$ZI?*<^A@_XV4X)G6Q
M!>8Z'Y/'4XXEZ)?C:"F18E"&"SQQIXZ0><$GPDJJBZ%E9TSY\OXQ4Y82 'A)
M]T7B4ECB9(;S)8 2"_/NE<I:[R__;-#^S>DB1#+ISIR08(S6QT]D)AZM>:<#
MP CAYW#\3YIW')7?E'44U!!D/L*P'>PP[.1N.QVNI>\NR[< X%AF=5&&/U_1
MH55?+#VH:FZNJ,7*,!@\E+(1E<,M'"WI;Z,6./?1P(]/*UMK8U!QGH,6V993
M/(OZ\-MX;/=$9L@LOU6$SS=M(XM6A'T@6V 2Q)[_"?$A17],WH3,=8=GWT2K
M Q?/ P-ET$ORO-E&26_S'L<DW#)/=EBL]6VT.DCIOPEYX1J<-DY70\<=)[X8
M\C$]MZ9B:A5LR")61=?EJG^V@;%C<BT1;U.WUIJ '-,?";\#2W<"\(+W/LE&
M'-RLS-?OJZ_W[28/^9R8ZL(U+A] S>QLS>$8GY;O6T=TDEOH H2M,NGZ:9&M
M7?PCQ&IC%D*38NH_X5G6VQUV\"'U6>-Z95FS<D$!@ZTVUASSA$LYY7";7P<3
M9,Q8Z%P"!EH<'?S$^[I8!+E>E>^10:96A4J<J#HH)ALVB;8<%HB>M390#E?I
MU>"XY$L!Z21PP?BH:()K?.,]Z4=.H5V;IQ<)T0A*;YYGJN_Y&=*$98@FH %,
ML>Q87[I?4^AI+.N00 >?M'5ZS-AAA8DL*G$.D?25<'8R?2#Y]]#6,7E\OW$E
MSJU*(FLAPUVO3"F.M8Q98AJYQ8>C4UM"W0#,M*2TOVY>PDPK*)YS]NE9W&+<
MA*AO,)W[%BB)?;I$;CQY<<#UI;"O<&<J5(KR('S<W*IW3Y(/ 6;F*K5C?*>5
MQI(A$RMY7#GI+XRJD]5D.0CF&OR53?[FM-K!//4%JA&JH:D"U/WN02#9RMZO
M9DX+%3XACV8O_P</^/J?\)3M*CWY1ZV)1^9_FZO@KG]SF6G^(?O_]"KU'>!H
M]/U*Q53Z*J,EBYSB6?UZV5M6MEDI6T7DM$O_*WOL\##1;+#N]%#SBI-7RQ^6
MM])\&5/L:"O00X392F1HF*Z=P?8*UPR8M&"BX\8!C&LZ<#?[V#2DD<9]YN$L
M;.>KN]TBMW*HH5@J_M/.HHGA7 W>_OL<M"),]'"@K%;M-;6X_,\SD5$B#!!D
MQ*&\B'.^GEXP#<=H*N,6\+?H9#BD0ZOH%C#2@52Y8C2&'/W8O 6\QQNY"90!
M#UE6#^Q\81@<@OR]UJ*R\_Q9*0/6PJUQCLN25J.[DH1_2NI/ME 10,L<J=58
MI3DGOQOM.*FG87UR=G2Z$84W/'$U[%ILK<B-,*SYC$7707LY353BQ[1B3;W;
M!=Z4G%9S6N9Z^(JVV6:)%*5>L? XMNAMS/7<Y*(QOB"ADF1!-%DX?R3AV(0(
MJP]SCY.E?/[?CX,S=,/7%ZSMB1VXDV_1?[\ZPJ8GB?<'\8L _B$!'IY\E[&Y
MKH@I7;R,:,"SW%CZE)F5>-8Y:D[\#3P!G?P0ZN]4/E_PB70#)ZS?L@.)GR>^
M&R:3+_L/\BYV7%=9F1V3@S<W-NBP] HL>-3EXS//Y1^WR0G.(D&NI;E\S0GH
M:3GXB >:U0XF\$"FVN9P2FQ)MMM66ZT(9QL[_;!1.%-R@KC.0$:LS-8C(O"3
MX+X*'^+?&R=<,8DN'4UM4WMVB51_9@7-45O.U3$<S>A=-UO= F3"[BSP#F:7
MNR=0POESE_:-"J,C:RFR(=/JHNO&OPH83+:HN!&4B0[3*WX]+84L$__QWT -
M3Q@>_B;OT;!WL)HTG,QZ8Q[UN8*]EA]\=G-'T,+9 4"[0F<LO5J2;,K74QN+
MSYM/[\_Y%G/!#R:?+0Y6,"P^[A,9"8.RZH\')K_WMN-C=E9%&K)W,DY)!9I
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ME GUU%J_&_L<F7[OT[;>!3KFE\>QJDM76)>(B?GP_$OCQ__:L_#IKPT,CEA
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M!3D]2*+I:Y?>./0J2#2)86>[M$9VM)9NM=U $Q^CW&S+0FJB>[WZ[8I A.5
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M%4*C-:Z VB@YS,5N0#M$==>?QH) T,BU< 91&;#R+< DP>+<WQM"O4M$A1U
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M9PP&;7'";PIOI1M:X1BTEB:1D\SY=C=-9VSOR+/(,4 !+R:"K"H4JA2+MM/
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M6COLN\HXO$VYU%ZWR7T#=34S"74 %&.W!)\,:"WF][&-=?0>:VQP)'Q6^<"
M^MC39405RB2 7^GAA5OF%RU:3J:/!@_B&C)';F0VWI$&,_0DFCSCUM,Y%K2S
MDT%!L]ZY,LY;B!8=,BP1Q0#Q);D#M1IKL;U?&\4ONL95\!WD:Q#C('6<>->'
MK(V 74VLCAR]KT#4N^Y@.DN_Y_:WS>VS6$;\Z>IBYY.#OGHH3O<)W._2/LEI
M3-P)4VDU,\2Z8]44JG8@@X),W=@9U70_]UNIQES/7EZ5Q  #BR2O^0P2^:M.
MDJNE$CK@![PE%%\!!XZG<YX\XRT%H/4$Z@%S<V+]</)O-%\]D;8U@\$64:5]
M MZH4$!N/&E#K&&@S3'>;E0, IO=(K Q ,:]9FNN#,]8<Y#D&XE!_:(P^1C
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M-_CYN,+6R_;@\W?!5/Q;J.XXJBBE61-&B$YW$+B<P#FC*<(TER_ON6GD^83
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M="(QS(\7ENO$OF36NR,"$'_P9HI!1ZZ.&H=&(Q2PO5G])GVR8[?1)K>M*FX
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MFU6+)]?1T.937Y3R""%#9&/6![54_3K1G:[?&]W!$;N'I<<#YBFZ%59)09-
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MN:ZQ+.EY9=3)(0]=Y$;R[V?E&<<@+)S"TW],JZ\3F6WV"4GR?5HI(B=_D/,
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M2T7BRP738X6;U[R&TL#>_H\]CQR6:8RUQ\7.( Q=#!DH325J<1<4R\6W?D6
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M>42M;2J]>;Z],#^VJO,!6/0IQ"D6*H<2;CWMNYQ12\,[@P6.;Y15084.E+H
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M#HM(PZFU)YD7;12JV.<=-C2W3&E?*E(,T>N$]HMG1H9OWYJ\004(;5TM,Z!
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MY50G68K1482>^VJS67>BG7>K+F.B/J4=;!SVP&-CX1*<OLO"W#GO3J7P<11
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MY;VA-NI=UC>@W:[A+\E=8,LT]5;R=.))C,<'L$2_$,K6]WJB\\IR"Y$ZK2!
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M:L^QBNZJYPP#NGJV6_J$PWU9I>IR"3/ O=D("F P\F)<4;:,$X=*MS:Q9%P
M$]5ZR"B3O)_'0)!S&!@,A&(8]TQXL3.B27;5;Y)"K%0BOU>>K$[GTUZOT5%$
MWX%.($G+.3?Q1:VS#<*46W3WHY0AQ+SM8A4O^/N3FGB]9$ZX#)O [#W;-C!5
M8K;QV% 7B#6%-G8_/25Z,Z2MX(P8W*8=AUU\,?;&LPNCV@X[+:JJ\F1/F4"C
M;PH<M3G,*(<@!?=7SV,N/ _H!/#CW[WMQ>2:'$DZ\" G-_-\W?-U_*0J>O%<
M@5=WU#B87S'EY&02C3G,ZR!>V\([K*JK\+'%Q,_YWZON)K0!AT,NT\R5AR4+
M'A=>E/C"A<@*H/JO=P_9L6PPA/_F6Y9GDYYQH_;/VV#$!5#%]"H" MF&YR1#
M&*928F[E<]'P]=IA+.,(CLQ\-L)#<VD5(4(!O'NE1 '(%#*PSS!*<ODIV6YK
MX]-/R=!LKK74T(\A&I9]_<8ML?'&$4/E7*74-QB"] I]M<_=/!^82):I-X3]
MDH(S  "< SBVM<]='Z>2$, XO>V1$C\^0\(2&+BG5,!_YHM:/&)K*#&H+UW_
MH@U61-@T26;T30YR]FDY)LX3/(YM.!9C4G!3(FZH0I@T?*+1!N/1=FKL6)$T
MX@<#_'N4G[QJE09+[U<V]%UG4I%LJL4J?IV322IZEHC:#"M$27-,P#E/()]S
MK!G3/&KP8FIXHXGC*J:>S#GJC2,X;+ XTL'XO!1X,AN=JHH &_CIR >3ZRS=
MI:B4,, !3P"5?20M5>G-D6&&40;6E4@<A_.UT8]<%93BB"3Q&*8PRF7:O$>
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M)Z.G0,^]Z2W&23,8A9\RZ7&!Q.SH5../L?5G8XLR0M]Z=S(MO5UUR(^"-.;
M."8+]3R#'K)=WY-&'4T.3(E6TT24L:@G4IP(O>\L&&99+ASE8J#V^HHV6,BQ
MHIF?XLN!=%Z80B[/:3U8,Y 4GM_@2J1NEQ*B15-N9VQ39F"F5L>P>ZAU2-!]
M)O2,[H"?+J:R1'57?S@%/C3$HP/?HBV/.4B;%L\S'^GZ^[7M&WJJWOS0:V$E
M4W*4[I9!F&4:O7*A6F(%37$*[(,PR:GGIF/_,5?/0FG5P$N#>(G[H;EL'M'2
MIT#PW<LGYZ[_W&W@ ]_A>8U#:+ //:4YRJ]EQ\ZBW7O^F.M\X\(UL<4S';\.
M1P=>\K<\(Y0]HE7E!TK>3/?^TT#&]1(FC)*")O+W#5_U*E=D.!W"^&:EM]"4
M01;;%U._;R+PBQSE@IO.2OZH+$S]0.LO&<%(7J:0E7Q&!/$G(MO?#6FDC#'8
MA4:MLTNB[66_OAY(5NB:VK\7RSLX\ !'=F)2G:V))4DPLN#SC242N0_UA!2(
M[F^98RN%R*).7I,%;]M]H?Q+\:[7?7^0NVW;N+7%AF%J21]TO"DPH_QBY!$+
M N[78XXI RE=T92O,6(EG(D%5;24U$ZM2^R\JZL-"I?^^H@SU%>@,9G;Q0<:
M+(6F-&7<.@6^2S< *M+@8DYQX^C<4K7S[C[FK)*;1V.,\'U? OSC4Z#C3-,B
M% <S6H,VIP#'O-QZT5=,9W  U3K; .$[(;[OA'2ZKQ["&&>EY_\X>K9_Q!,T
M=/8$(QI-F,0,HT'V<?[+LPT-?AZ-WC=P@G8?-V(XSM91EGZR!(<F;&7\/GBF
MY%+2@U,@^4S^;3OV^1@_4/1FNNL_')>;-'B/Z2&V_#,FS2,5>;WQ?S!:,4'L
MWQ[,-)!GP"9M^7W?HSYH#PB*"1Y/-T/IU]LYJ[U#-'%AY=:$?W+B[#]\VVR0
M4DX_^[C '^G715R'O9";"GH)"&HJ[X,4RQZ/&*:H7M9YWD(X)2:S7#U4QB >
MUX55X_L$[DO0T_^MK[5=G!F'0.)P4)E4C7?QPD#\V,O;&23S24)T*24M1G<B
M!G/7>=JOZA2/ GCXS,=<B-Q\4*1D(TTU!^+-69ACY+OA^U_#G#)Z -.GMX?^
M1!69/Z&*ZW^"*M7_#:K\'GS#^VOM\Q('NJ6A<]P/G6.[&=76.$MS3X&KM8V'
M4YAZJM^(D_#;&>G0/FEZ5^?<&^R#UO(=+['Y)0X-)K[#']]W^ MM:MS$0IP"
M;I@. 9P@38F_J^WZ<0;>C8>(*B,^KNSKZG4C#ENVR:JY=OX]F+.YTBDKC#/@
M[[IABJGC,TF@S>:T9NZPD152P@\NN1"J^?>&'/;,4,@H'8?X1XRV5NT()_8W
M4T_ZC0::^@O61)P+1=XT+8X35:=\H,8KE@PQ#XA>+X:N!YG^MHYH)$9/J= ]
MNY,'Z_J,PPH_#<"T_$^P7O_+ $G_'M8;LD/1^G2;J\X6ZT_&H#\.*Q]?W;/8
MOE*%P2!#B"*C3M,IP$GB[2E>]D?ZR49?],TX)#(]@T!$5G3!Y"F0B"]=F^[?
M2)*G2M^O__RRA(Q$2>/^#8:)9G7"B8]$O4G&^*:!XF5Z)8SDQ2-MD(+6:M'R
M$*B[-!2\.!/-QW?C>G]UZ)^BY/OF.FPGN-9G3#C2/B,STU0@"O.SW%&3:[=
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MWGRBSI@][W(9%2"YMJ\!CS&(B""+GAAI>=A9!#;Y<E*NFB"OI& H43QLDA\
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M7*#CS9(6S+%7GN[%NJWH*6#EI^9JV]_>[:C65[L^%HR,9DB=_18BJUUF((M
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M!&B*2>/7KP=P&"TY&^TC44,:C4E3?<ZAABP!?F\U^[G+1,JHEF(Z_"3!K:>
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MTP5;;_YRC?E)$#-&,O\E1? _"2.(6HUQU;CRTF\XIUGW[4K,9V<]K^\ LW>
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M/HTY/_FON:C:NL1'Z^#0-IPY>&WI3PA=4KZEBTQ^2-E('X'7AM07'_<LD@]
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M)37LR6=?%Q".YJ2CM![$G[<Y*@\>X$(4QB?[)0\_J_%W5.J]O7O+GN5"M>C
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M",1E%M+P^N%"'T'TBHXGT_>\PS)@E5>5?M*V#I+R5F.-C=0!\$M8CG:[8;V
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M.-(FCC<09#<%5O^O1<(8K1;JVN2JQ7G^!7M-EZNIO :-KI15<\1)*3E2.BA
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MZPR^]&\IF\=% O<HL#XXK4Q\Z*J",+KPLD"/T,8^R<'D:]KQ9YW:&3W& 7>
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MV(7/_6,_M/L?YP&E +ARXO\V0']U&-85:R]KYM?%VSA>?@'\^?<Y(<PS-G
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M08;:++JE)QTH&PWOWZN[Y^:GP<-0JCXC"S?*->JM,2/ [/X97K'.#U)E'-J
MP0TF\]57VPJ^6XLUG/;S<PJ=5Z'M!Y^:)%/,1<R07%:G309M!9O0@YL;(FI>
MV$$ AN2+XF@AI?UM.;N!!22S2QYH(!U;'8<PWD-<!\_+/8!LA/"#TZ9DU%3
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M6-G8.00$A83OBHC*WI.35U!4NO](4TM;1U=/W\S<XJGE,RMK%U<W=P]/+^_
MET'!(:]"P^+B7R<D)KUYFYR9E9WS(3<O_V-I67E%955U36US2VM;>T=GUY?!
MH>&1T;'QB<GYA<6EY975M?4-V/[!X='Q"?ST[+M>EP#,2__Q^9MZ$:+UPL#"
MPL3"^:[7)0R/[PR$6-CT=RX32:OCF#K=9.![<858)C:CI F7D5]CC^2)\\!5
M4B:!>6;8=]7^I-E_3;& _Y%F?U7L/_6:!/ Q+Z&-ATD(@("3#;;,YU?_-Q([
M^S,@,XSM)_TW*2<[YSW6#__ [/5GAJ?K]//:,@[9UR<D"EM2D91*DV]P!J&
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M2#L&G<"@\.3/8_5T!7"?E?KG DR+O1'++MJ"(%*;X[/IA8Z"Z9=1\\VYR8Z
MV8NPP]DK-CCM_C=K*X<)S=_R$]>8))1]08=@63M[ILQ#A1@X6*H.QI)M:SO#
M_%K>_.O+%R^B';PWP/,:-BC@8*8#B11& 3<?^0J7V8$62);C*U<"*,Q8Q_ S
MBWUEAL7E[!:"HQ_4-D3-=LE6DM&[]'H_LIOYG%GD_A3\9]=;^$L'AJ.I\W4]
M:B9VE#BO#"._E=VHQT]STH%6BINA -!9^@7"&KHWJL0,.^1[\'50P-F>>SCU
M0Z2M2L*6.3RZF3(]6#S>F]%S>=Z8X?[J4.QHV:$?AY^#5HA:I?G-!XH:JYC/
MU0XA[WV5LO7A@<KI*DE6;]J-)1TUCT$/PF"SF/K=%C"BWDG32L5L-]-#[>R<
M#%52"\YHG VA&>9 &:];PH_\1O'=7?L,M7=_&22M))F_]5DN.CG9<;;PR>?0
M7+^:FI61)TZS8&1_T%9KU]!;X,'%RT-!JR%-+K"S[:3//A'_JRGW:1=!D[<^
M>5$<*1!#%1Z7<;6$LZM#7,<#IJ8W7%[7(&'+FUMYO5CWWK++4)$3+?6P@QLO
ME171S+2RTZT:*4IM+J?DF^[52UD^) B%>644@"_ Z;UW)VGG](': 4:5*?P1
M1 7+N?#8P$@6OW/ZRIDVM)W@Z S</Z:^B%=71Q>2Z<.>$^RF*%-_+YB",^UU
M\9:D5GXS^)<"/MT+SL )G>_75Y0<XYU^W&'YX*@CAQ])%(U>2_H-T L_-%*?
M]EIC'10>E-/G(U[6LW+#6+[K/#@M^[QXE+]>:=YF%Z_'@>2@N4<TT80]=,Y[
MZ6JTS%YO_@)%I6[3:ZS+"=5:??G%LPO[%&YVM'=&8C\C='64\I10P!6"ED,#
M+9/R"'DJ:J^7SN#[AKTMRSJ6)-_=W+@#X:MGB:P5ANLP%ZYYG%V;KX2^S +C
M$=2V#%,VD$7ZRET;[+LH<)XR<.^(29!L]=917NBC1IMK;UB[Q^$6U%!H(?"*
MS]SYT+#QICZMAY%_]-ZFWFAYIQN>%[<&NS0'DS,!#FW:2(_5J%V>M?9Q:$H/
MPP>I]?B(L7XBZ\0TVB2%0=Q0W]WI-*=R;/'%;Q'^ O>UQ^FI=GR/W.R/DS2F
M%"4]4[+\I-OLX0Y-M=%A]&D&%-PCIH^+5DJH8[>NV?EJ#/@W08H.[_L65'0U
MSUVF-H.UV\1^&G63X*;AXBWF3NA%&]S9;WUC-*!48W@+],NIINA/M#E'9%FR
MF'X4B0):QXSVNC6APX<^I[S%*]6NCB39SJV.-KT5#B0VL(TJ=982[[S2&\0/
M'+'OVQ;(<4;T?P\OD98V(MQC779%*W?H!C\5VZ6-[BA[W*JW*]]>3SZ*?LE4
M$7EP,\[0?$QL/I6(VV:!Y'.-RO&>XN#=/O \@H]]>JNM.[,D/0LA-N86KNX<
MV^% <?[!_=:G(_++D+Z]+),PEEBFBIB\WC:7^,.%JD9&SR^;*K4JC$KI71S/
M>Y@L\7-+HU7O&"8&+4X[J(TPQ*V<V>11!'3&BSR^[!UQ*&"LIEY!O.6BXYY$
M*GP-^ZL:\4='K> KQ=%R>]>+BM<9-<H3QV64@>(E8;H@=S0:Y:\JN#%F#2NB
M><FU/7I![@KP6'V3Z_8,Y7OX+E^GS)2H2U# "XT5]VHV'CLU@F0*[A5/"YDX
M^LDOWH%&V)" (T[HM9YB!>;JBE"*"66:<4S6"!UEF$(+V++>R'E$(5ZDM4DG
MR_M\-?U+I:O:*6/2[-$N+S)0[9W4PY%OL VVS+S.7R>&G/V2A.#. 1<48%R$
M C*XO2Z\<9IY3REYP)LCT$/F'.ZPD%8? 10 VV4]SSW5^4J6#CL5/E]I3$]'
M2BRA5WH4P'$:<( $L:  W^'/@_G8Q.K:3XC5Y8!_ &&*7M#-]Y8463VT)AW2
MY^+'T!2+\61RZ:A +R-!2A 4T.=#=PZ?1:@X5S8RCA86Q<V,:=8%$\^;*2EB
M[D&>[A5=3(^U)-2GK>C9^^:K)6\G=G)'65,]&^3@.JC;#::<#GH]YMSSU"S4
MX[:.+9):A]4T=WK#0\G.$E.%_U"K(-XSRZ@Z*..=3KWG-].$'"9"XXR]$[6*
M 5]ZGC)Q4]88?H'("9P'WD]3)_5#F69"N-)Q*U:DVFT$64M<8L^T::%S#68M
M!2M&]R $= VOEJ4/<S=H16#8VUOQ'W*<,$H6[F9S9-;6@5[5NNT&90\=+:79
MA&A'1MBT\-P5Z3,N]^F4& K?6PWFK5=S$A!2NRK 05$_>LOE\'(M"*Z9C (0
M)R7?0QMZ@HW,OA0#5[JI/ _:'Z-[D-P'RWTE>*Y&MG%;WUJX1"H*@\GYMOI^
MU&NA7=,<$JI2SKZ@F5OEE58A$ZN3_*6LS-$KG!&)PL':47(<:^ZE::WN$!.X
MZ<?-VI=5X?G*XL<?WV>7F:>>4IN?NQ?3+3 ]E%TT&*FZITE/_I+:G@/WXIF:
MP1TE3B/J(JMG9Z09Q=/A/N1XZ0OV85G#R;U:7$U27:P8#8V=LG.0$(:-N\U&
MY?138+$<QMR#3-7F"'LGZ%Z^X#<7)XMTM3O0YII4CQ;1])#<_=V,YIM!":I:
MC<&YDH*PFT84**"B^,5TW>.8[3.SP=H&AXYD>>@\H84/_@KB@RHQ]G71&RZ#
MX751 \]6ZL7F(M5:1S6,])3L\ZG3] YT U,PQ^GT5XOI;7S>/O9UB/Q")&I.
MK5."N(5.[NT/D(W1R("*Y;,/2?Z3%8O<V=D4WP*K+K)DO .C0I-<0=C6^LAW
M@D>%B9O$>M^8GA#0!;D4!XM04%$\"C3NV5N9L7' F2T<*+TSW8+O+KB8!((=
M\9ZOGO:G9<:5RD-"?'GSX,E>#"6:>.3=7?3-T=)'Z)7!\I6OL-]\05MEPQ7E
MXF7/+@Z_,N/<N6K&O=SG.2,[9E3+)A+'Z?70%OC<D/\M?=D%T&7IPHD"X=>-
MUI8!-RZVHC]KK P7J[G"@JC>L.T:#8.O"JX_42+UX>(+IHBM0Y*TM"%K_"MV
M:$4;&C[MF=_451/@]]^R?Q7CU)$C<D>:)8KU%P6&X)=-[\L9[XWP?.!7;WZY
MNVSH0SG57R^WD%]1H+O8T)A2_ES OC6 OV_="-H&Y8([=W:W-OI+T=:I/JN3
M75855HC4L;#8&S)H'&* 1BEKA>DBVK1=ZLC[<A[#/1[8F9B4E1J+=UU6HG[L
M<L$YLS1:>'CAWRV#(4#4W.9O:\<(\$@T@1*(W(D9W?(/PC$*M8+)W; >7GI"
M(LUTB!EOY-!J1U,.(>YC*/ B,VG0;K^L]E R13NZ.966ZL+99^*Y0\G'4D[\
MR(Z[(/4PC\&%Y9-"S2$DN<W):('8%>X35Z4WP6=[[+6Y+2H^*N4^J9^^<>"7
M-K=^HNF[I9T>[6M3P/J*9:BPV+P\;*1RA94^93$?-/AN#@6\.K#J$_?>[NGY
MBL]/9>83?!8_^&&K0/Y8Q.$Z_,EYZYB+@5Z]$A-[0_V@ D5'CFLZVH%1P.DN
M.@<$4Z& T$*:1ZW8XG)>X/<]$A$Z.-F6II(U'5#!"5_>,4$C-9/:L/.'U361
M=N'8B3*?:5J2[1K:2$BW+'Z5<I7,HVM+X5=+_:/*3F[43V7:>K_Y.1F@ $)?
M=)F$Y$W^4YU$2'0CME,**\HJ'1_"XU!OP]SV;5>@Q_;4PS:^,\?#)BC+A_!7
MW<;_V?0@TC]GWR/PD#S/X*E6I/%;-Q\::$R(+8_,:LIAL5P%A)R!OS$C/T@]
M[D%DF\#X9%A_5K:G_Z[^J&J2[0#7W*?N$KS]58F&@KQ?Q6 M^),VA ->33>?
MHI)$[Y !B+"BR+JE59DDZ.C;':_'VZ&==#G7ZD*9N]TM^O9R6V_([.-4O,[K
MO.>2>.9D:)OHTN)MQQ+1<=LOHFA\E60#C']D!WXXS*.-M D/UXH66V&:+[V+
M=:X#@MU$5WM! 74$/>=%LSFX=1.1;?IK7V$X+]S4KHUS+R\E]E X/I=O34G/
M.RY(=FB1L-$<LMM]G_Q53A3GX8[SI:.%NO1PT#ZG @HPP4-$>JE 0RNFGC$&
MS&K51S%1:0B\?I[5?_6F^TTE_MQ?Z??$,QZ=+ 7-!1BL<T\_?5*P?(?UED<G
MR3H2KWS$MKQ]U%>VP+"TE%0WYW5"I)^!Q&:?N,?"T(*1DMESDM(J)KFT0I\*
MIND.MC;&I/+*N.,=JF?RY@G-/'Y*;:Z38RT]EC)#YM!J&R_Z:"I$+E/4Q))V
M>G,J]8Q-J34?IY=VF'N*HRXLNG.E@87[?G?;PTW*)QRB,K[Q=:D=-$Y;X(3K
MVJ;D+!62WF'\ OF4L37C;'T-'B:_<LYBGN-)%3&-M(EW)S'W=3Q4I3?U/WE6
MM;(L"(KVK&-_OO75SSJU*[+24OI7==J7,03.1[B+ZKG;4F4/Z5QU9)<(*,@[
MNM5/9E=U+WJ2J]BBZEV?W"S5X[E5\;%PX\VSQBR<6)^\;]_D8MR5Z!D%[]@E
M,)-DE!1Z$F@-"#AL&[RU2[Y4]=+98&5]\I/ MM"N5IVR 1NEU;O,(A]0*^B4
ME16)+E_N//05'[([=+C<5;BMD^PY\_3N$L?J<E]N=WI[$#</==BQ"!-<!<)W
MF7\BG_$NC^<%)Z_!WN6:C"FJT"=*\^I)GKB/ V=O:7HG156<;ZZS1&M45T6&
M3E'S:%Z:"MN5I(1_/# X5TW(%ZDVCZCM1,35-.&,%8&\K@[8=R18>;M.-N8Z
MF-IW,J=6YKN\2)Y$^U8%^+H^]\AL/!/3-O=-(N)SF$%XMEPFPJ2L(@2#\6XL
MB3Q&,-:<'^>HH(&-A.JH"L?ZB_,'=B][<3'SZ=YD+^>K!UBE"Z^/\FUX1S9$
M,-^K(KK27S)W4S^-<2\!!02+IU?67UNU='C=>GCV0D<@E6-1#AZ>._ZMF%:L
MM8GFRG03R8BO*0IXXS&2/ZM![#?J942LKBGU]_9M_@CIJ._M(A52Q390P-FE
M8N/:Z!#POOCZK ZZDKK&6J+^[>QJ&%NAZON_>:*NLY$/_,-!.6^'=K73*^LF
M1VUHR2%\168E/:!7Z/PS$R.,[?W?HNOAGZ'[HE8_;$;N4"Z+4SE=RPVW9:U.
M8 AEQD[M!6B/^A'JPX45-/='MHKGJ[5D<$-;S/;SP80?J]BG/)$+!B88"N(\
M&KI++Q)"GEQITZI6!K_RQ]8S:Y[YS#_DI ?T@@BC>S_"3PP&(;YXQS9&,I-6
M57+GU4O8U8SB.B1S=$0$!)L?61]S\T@JN4SUG[N,?I@D7H*8E<,3J.3F4OF$
ML42)M7%*\'3\*05LYD(I3=^\<%ZD41 IG V=''V;MW9;S@+LX'0KB?E)S!U,
MVN&TRZ.NW2!,0P/#V:DV?JXWD4N7HERBV"I?N'WEK@I#TNKUEAFL?Q#1R>*&
M,!X5TE$@9.V<I\NW186".]-3HZ_=.NPPW38D(3',Z^F:[*A"<# B;XQ2K&X3
M7'"VV<OSK. $UJ, T6TDE>?',=GZY-Z++]+..K8O$26Q:5##H^/BQL4FR1NC
M.SG0J*/H-Q["L:+;=#F<$TGVSR+ANKY0G&E^Q\RG(I+OY#R/3GMS7!5D^6-/
MDX^OF9GLH2.?.#M/P@?5*B)Q.Z)L9XS/L9%?%3[8M.,RQ:DJK:3XQ$L0*7SR
MI4$!,3PYZ$"*B0*D(;SHQ6;IR3!T<\/DXLI8AB_'R.&VF!)4>6K3YZE7DSK7
M"R4JO\W>BGPB.X^'B4+7HUT8.=D[;Y4T9=@WFUQE&Y CD3>5(WYXZ>\01G2]
M9,41<Q7"NP4YA]3:'S]OV331, !W%()V");5^:T5@GR5T4E=^^+%@*&?.]V/
M9\LJ^1/GY8@?,?VJ%+KLX]%B<LJZC0*,+) )"\XHH A\$NF]VG)AHURZ)VLP
M;4W:W[.BZ%O#=/7;X4)]E.Q;W< F5EA>U'+WO$*5IU&2%ORQ';?JNEQY#"%R
MAH N#T*80,F>)D1N_B1W@_/3'F\D0?"JCT_#MBE[%QX"Y[SE$%'P:5A #; 1
M!MGY:7!ZQ%@DB@49IFL0>/,^%=[E)A <$N?]N"GJ.U9)BO1U;&S7 @DYI6&[
MS5Y9]/15R9-C2'"MY/CB'4!MKKU2MW!!UJ*/<VS\@DGCR\"V+ 7^1P(-Q=W1
M&DC064Y1]"O>W&&>A>=*]O*GACPK7 3^AT*36'%Q8G8>'<?)=&&@TN(MEQM7
MC>>$I>2]S<Y&0T)WCM3G44 5W%G1G,HCMLQ]26(XZ@A=[A$Z<$/J39TDLF%]
MN%&W:86^72=+L\F%.RVRT9?'*XX4FT7=';O=Q?G8K#8.C*_A-+C,;C1^0!6Z
M4EL=YQ-*J91M6R>L82VZ[FN7NS[J/:62_6U*Q5)23YL"TU:B'4?:<$0O_-MQ
M'Q&XB]WD;)7NX",*P($N70*C7<KDG"U/$&V(=_,?)^7R#"3:6VDU.O'<#O,D
M238I[=]E&G?X^#G8;[O4:.MAQ E%>>6MV8$]#_PLD;*U(1>^7>C*EO*(+O!+
M5_:&_><@J]<!/G/40SSBW'-4!?G%3&.73PWKGFS?B7-9U["1Y.FOYWU/PRGU
M+/?UAQ$V#[8^;28WT*)*7<%5SH3IM\AKCBB 5-!#'EM759H&Z62$$X:D9PT^
MRLJM?'L<P*@SN[*]N1TVUT@Q.SGN6;3:4!-UI:<L<K\:2(&XS-3Y^3S84WM5
MP5LUL^D4&H;5ZJ%X&6=>:0?WO):"=1$??(B% CH7OV>.!,&#7HV@,*D[#1:V
MWN:4WP\-$<#]T/-J%I&BME<(PA>*S_15<;JV9:;Z2K&DCRD0BQAYHEI^6/FB
M:*0WMYV6'GS=\_Q!=9?0OO[+MQZ/;QC5($1'BV9#%M/;]4&O"C6)?4^7=?+8
M'%N1,M5T8=Z1B3G%$UT6;M>:N2L'!^X^OK[805*S-]4N-& %^6#M\?#SK=,,
M+ZIG'&H/TG)9$LHIXQK>]B$TT?.K ;H9AP+H]6BQT1=CW\/];/\(6@'ARBHD
MNU41#V,:B%L>/GY[38*3OZGJQJ1GG4K:@F884Q+7CB/0M*O5WX-0,(.%(T&N
MLR=T9SI4<[NGU*[I9V=JJT:@-A75#HVZH<DO.U3/\^;K<Z]%I25\\=3V+*K7
M^J F$$ZMY!B4VHL1T=](V+T@EAX!VCQ$ 5DZ#@6;-O.[.&WY@M TQBCZY9UV
MEQ=C,(@$//>CKO4C/2K.3GN,P+HOCN.( H?VVID$CSWXY-0&Z> WNY 3*S;N
M)HJ%#Y.,RA.E20B>*] U+-#NWO?'2XE[;AV32":];]L3JX9=++,/@N\6:U0A
M;KI@YT:X3NQ8*&8HX5JZ?Z9CW]6R861FF9A Z-ZR01L5N(SVO1?<#KX/+V\V
MX3'1U4N+2NK$5N$D+_ES;+B+)B"31X4=OV%%MI"G"%U7,-0."438?3!\EO_>
MYC-6QVL(ZS?S+=SM:/UW5LX[Q0/+%14>\Q)/NQ^$/TSL0?8P.'S+$E. YGAS
M25+ _:YM?$,!ULWS!AZO3Q0?GIO1<%(MX$1NNRG+#1Q^HIQ0Y%..JEXCF_QX
M$;I<.BQ)M+8M"1'*9[@=-7U??GRNA)QQ7[!L8?>JYSL#F.@&:>9PDZW.UGEV
MT^?5V*,>I2P;2MZ@>JPNT@Q;ATF6I[K9U]LU;M^E"_*:AW6$AK*>/UFR_,20
M6+2F-1@9;0BK#.6IF!MDD1H;A16^9U_TI!.>CQA[,5;DB=,>ZF;G9;5P34DY
M37V'&M A9Q1<-6:LJ"H?VUDL3Z/8[DZ*S!!Y2'#+GX:]0P4W-;E6@G>>%?'\
MB/>D8U]PN78,$0P!;1;H9/K>_KZ8R$.CCL]FIB?:1^*DLO?\;'HKK(B,C+<7
M'W\9)"*GO9)A3P17WP!= 2TVGU_ M/QIO[7110F^(H\\((CQGHNS2L=S\Q-3
M*:DWF!KGGGCS6/F6(=*MK;B")7YA=7B;:;KTB7/N+L0IW>G^6(U2=FP6C*'=
M1XW"J)MCGL>)R7+X,<'*->=8^:&OL;>ZQ;#5=VPF5QKWDJ)M&0RZ@X+=Z&62
M<&])!DK(\<TV-U[;ZYDT[O$Z;Z6*M6=]-%1-3MV?8\ZC7)?HJ[^>B^ 3JN(A
M>EH11J(MGG3)&6?)AK6EWI>F=O5]/ J0*3;H0/)%M\:WV5E4Z\EX6%3/S%0C
M-EUD1@[7_$D,)Y3][),>,+6R2)$O5R\DE-,,H8M'C(U1).M>ZPS-,+E724>)
MU%VNM%DU$^]^2L-)X19N_6:G SG\]W3J545>UX,*#9_IEPL?;\G2GX:<)%4+
M;B6?A)4;*3=YK-#(S_:D#52VFE_:5WC@UG,-2__97C);9OF=_^L=E$."ER;[
M H8H8*P O*9L##9^L1>.E ]//SMRN,"U4GZ2 :/M ?WJ("0D=Q4%1'N!ID%?
M&A^CDY;H+NBLX&V!C])RQ%IO@HC5I;#_$>23% A>2H1<.+T[K?"T\R$+$FS@
MF)IOGE3+,U!P6OHJ7A5SN8L[BL/<2LVEPV;J,!LY"=<8'<WE&5WA;7-*AEW=
M1N N.LT?VU M].5V.M_MBCB+-KN7&!!8=C>P::5*  7@VE!^B'$3HW*0)*2/
MMJ9NE!?S%UQ+FL1Y+JA<V6"GS4:IJL=0(T=Q1JBT8$*Q3DD:[ HFN!_)KO)Q
M+^4CYJQDN8L[9ZS]5^C+JSHZPPG!Y/?>!T[%&Y'FPRB'E&'BDUJCZ>?5*8R&
M.'T/KSM%@_67&DDWW+W]\_.4P1[X&(ICUSB#OCF[C-;L4AE*>RW2W/?QTM U
MEM+J7Q+^(DJI73?L.QH5\@E>O*L?(D/62+N?>M4^QK;;CG&7VY.XM$N\CZO8
M6.')UXY\UGR(*GI!Y_3Q41@4-'@9QKQ"P>S+(Y;?MVB8%%GH.J7BM3RXRU!=
M6?TUO<YQ"G?CNL1:5/)5^XU5"3RL-"$)3 RPZ#&4BO48VN):4R$2*6-H>1%#
M !][-9;C2=>A_4GWVDT#D:KVSB7[%^!:O_PNB;;+E>*C573-HE_6/FUTV:Q,
MW@^6&MC74G 6T\E  <W\>_!9O]QS;6J'V:6+?"&_.U$)J8M0:GWEW-2;]V*\
M9)<3[YU7'](.NY@\7E9VL9S'081[I!\=@@])/NJ8D&95UJ<1;!G-:$:\/:B=
M6P2YQ\^[EWVPFL0>UJDZ/MX7['I<VDD<6^[2XQ6<O<E2X+DFRZFZ1-@?V1ZG
MXQWYI4OW))H 'NNK-G_>75%Q+C1B,05U]Y1LKG^D-&2B#1,78G^QHA:@N$C1
MXS%+X!8IU-&<],EHUJ"%DW0R3I$XC< Z8V_2B*5/$SKL -F>BU6*$HS]_ VW
M5][_-3>/\*[N=KU-AK5^<>#U^*R6J^WDI-PL_>_QL=M%-L\TTPC[=[?$^<[D
M*Z@U>!0!R;V'QQ AF'"T8*BXK+O MJIBD?H7>7K3BN=(WO;T>1"M=?X"I\6(
M&SMS><P66/"S9A_LYO;]WI85PXX[!>M]V?" A;9.%@JGF+MM/FG0!>R]V>"B
MW>2I;4QKGIXI[Q=;-GW^+$()7GD3&]ID>VJ<!#Q:45+CF#&>9\EC,&3%!V,X
M'SFWP_;*&R\OQ24L6-3P3"71X*K6//3F)#SW0:(!L8%/==,UJHAMB>CJ=6/9
MQ? &>SNWN5$CY99F+'*5AE<?TTA@^$CJT2>UD9U!41/Q9;PHP*#(&R<:_*E>
M.4?:P_*C;M&6+@>E%,5K]"1:C; $!9&6W?0=N 57R"(\+C*6,TV?OJ<X'^(L
M^?+)AQ$$ZT)!'R6-\Z5G6,[13*=OQ' P&<=(K(U\[N]U/)?[\#9OJF*_%:-0
M Z<U)%'<?=/8#=TG-!2ZQN]V&KV7P3*^2USH'=)Z078NVV)B)_?UV-+?90 4
M?GJU"2[&<#J9;5D\WK<QDC$'(9O8\,9N2W\E>.7K_*NG-8["^6LXD/MS CVF
M]?0+79;E<6)YC,Z1GQ"E](>@T;B&PFL%^;B+.9R+=H\8*=XQSK[0%##"? C#
M_AJC>X_)<\C'?!&C0>=A?!.M0#!G=]UPY5M_C0<!PF?41\2;1FI-C5<^Q1Z>
M9]<D/HB>[J29ZB<2O>HQV.PT#)N:HBH2W=YVH/=\JE8?=5O. WP%M&2.CIF0
M1]\?USCIM^<*E7S\9M*KY/5.POMZRWYQV;Q]AF6N9\"&P52>W:+-DXP<Q_>I
M+5'6J:=*47&WX%DH@+&MX\(I&IU,%M!]/^QD[W!V E[A"&FUZ;9! >1JW[-[
MPC!T=H^/BSF,3O+P=XL$OC^Z&DNZ(TT6T^(;06P9M9+0,'!1U@BS;"7>ZRT[
MOCSDW^^;$P]^5U7L\_A,YTX^0BOZX>!.87OT\BE,P >QM<A(<5[1OSGI$% O
ME^]7>V(8H?Q)X=5.##[^N<^H"8(>!1"@@#4Q%! ?BB3A&.4^H)YMWCVEN85.
M*!U0P/OD0SHB^#'!]<T[XSVYIWE2W&S^@>MA<^(WG7+7C<6_C:EW6)+':NM1
M/X[,I1Z29)K5-X%'6I15AWFV/K:/#"08?*=CGOLLK:A@9O8;W&4;21.'T4.[
M1\,?&]T?MB<M?J+?K.*\=2#^&5V=N!CUM3B0MWTHL])/_:RLTQ7T#9'G$^"#
MV6/I.3FF'-[:/[ON41G7)![6&U,M1L7(=# ;+S,D%;^BE IM@YR2H-&%!"'E
M:\ A:;BB$5T%&^SA=WN?1$0?A0R?:Y^T2E@J#I<;/.,^PK/JFXPI[6!CXA4I
MCCQRP&^,O4BG+;-RP(U^O&]/3$([##'7BO>X2_?*7R@*7=0+O9FHC%C0DY[O
M>W\,N0O1E;P!]V^-AYBG0=?1>+T#ST-P)S>2=8?<7J52VHU=M@FRN%)]=Y&\
M[[Y5]H/,F<)M7[J,GBPX:_<+#!/#]L&;=9%+OKF@!]J\ 0C.!17,5J(9XZ*Z
M%N<K;Q-M8^-37D3K%RWN4H;KVA:)@_*"+$[3E*TN47EC%]/[NBQ8/)Z=(N,.
M3"&Z;:574B/'GP,ORQ)LA%S/"VL7"[JZ'85YZ3F(WM@';32ZARB@$93J<[FJ
M8&V&?>^6DAN>M#^#CF:<U$M%''&Z]GI_#-(%!L7/CY5 ^MF'+#[3M%.P1\A[
MZ>>>T6=C(3HEODIC @4HX,HIJ7=0^?[IFKO"+;,HGZNP2<9/FE5W=D WT*Z;
M0G=NAF@3:QF@:+PI'Z8(,G\-.[+N@8W6Y!A[7IDRL"8=4CN'3&>_K\*R#%MI
MI(-/2N!.J0X[V^:(Z+0_L$.2"+ES5WQU-+^AR(A%><C[4K&CU<.A4]W6BV[W
M.N>'I*:9JV/V*_4!Y]A1)P9>8]9IB,<+J1=E\R88SP;;<GJ3A/%5,:H]GJ*
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M7N6E4L@K27Z(*:+X<$XC+T=!<G#]G=]"Y),M_?63LXB#&$6Y&EO86'X1!*Z
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M&FHWUDM5EL,3^LS&!SABPLL>9[ 4HWWE8=THEVT42ZJLF9B"?ER?1CD49^N
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M+/0>)XIG972:WN?QB#RF>EBV+!XR7YEKD>U9R5EP_K+JN?Q<W6'7H^^*X**
M(/":L,UI^A[D\EYTB$*8X/CAD+/=":/07ETMAO=3B&?+YZJ9F['F7EC']HYQ
M+P)3/&@*BHONJN:\&U[,U7 ,&NP/[-#OJ7HE;N#D\22[>4H=EYSW^65P<T/W
M9WW#6H7 +;L/(NXF N?VJ^@8D-2"!\8SF>72&6VU?N9R(^&$*5TZZ@HR88<Q
MK(60*2Y@S2$D<NK=!C>QNF&N[C]P:OW326-0HQ_CGRW$WR)MHUE$B  *R$[O
MU,YY:H0".EW44("[VA*G:(.$\HNDC_H*/@MUBD^QVI\P11N:C_9<O"9:+VTV
M,ZJ[?G<]*N&="PI@3,B]<'+8--"A@VW_Z:&UQ%W6;9[:=\/O#,,N\$WP]3,^
MG3^HB?-@UIM*N_29+D?TC*X4'M#NZ=CHM)\-^.WP7W"87 -WTH,WT1G;FGR2
M%GKBI;U% 6AACA\I)W#<J8IQ$=8VX6LLLCF&WAB75[W9[;QXWL+99FT\WN1B
MR<1W:U+!M/-C%6B?#QW8QNK3>VSNFQRI'!:)D#5.O'M7_@"$/_X1/=NMDHB4
M[["ZX*>XDS CU"=M$OE;Z_0U.N%K\J"S(\L6%+"/58E6_?TH>(DY!]V1/%(F
M\Z%Z9M'2L^QEO=FOP8M(^7.'LSGPVZ*5\]QU7=%*+K=W$O(R]\0>J#JEUO02
MK%AOMU>9D=2X52M1T7%D8>B>/WKY6N3U6[[P)%X.SF?I^U=K44#QX'<="^#&
M[;-;@T:OO_8PYK-^PJE0GC_A>U96QZXQJ'@_;?;.0LX>%!%@@*P#'>0%:*10
M;5D)+>)"!!0@V=K!HQ<WB9B^U%";TPYO/_+;GDY+H[/56%Y>C+M\]\*JD0L-
MGKG)T32X2$Q+KRBG?-C4:($N40XO3G/Q+B(OO8-Y2"JDB6SLD;:8(D/0$\77
M;.28).'V!3GP"'T9<FGGH./5(-.4Q?TBK-'#DU>@R4P*&KSG<@]+>XN*4,"S
MCWQ3S4&,9@C+E/1<01>G)([<!A2 <2M98W7JB,]7;LZG(-769H9JY'K\Q^JV
M;MN9) Z<2TF,_2YI 64W6TUNB$L0#\$#9:J&MV5A/,GCYM(C82[IO17@^2?C
MXYO.Z\:WRI,47BMJ4^3:MO MBKU\ _AQM)?!<)I']56^MNB5U=B]Y+KQH%3\
MY1[PT-E9Q2VE/:&RPG2![FI7_GI9X7&908TV3=10C-^5'<XN<2Q_5O0Z0F-Z
M$7H1>9'^R<O8.Q5^LE('Q5@?2_9H>3MZ-K95IFK/<X]I/VSI$T[_W&$A-)B6
M:^\HI.6"9W+78&@NE?%25N*\5@AF'LMSNF?^/!?%O!5@4[]TQP,A]EZQQ96"
M&4E^%& +OZ=4MV7YD-9?<@<!24J'DSH9S.ZE>#Y"!DOPHK$90EA7A1WVP941
M#"V*#;3^VBM?%LBP*&XL*TK<B96BD;.T$=(PL=HEODNT1,P:<</%L#T0AM'$
MG?$)QMULE=RJON!:>S%80FVO,>M)[49"$"ZN]F&CUED/#FXMB51?>H2A=_=-
M'>; \U6'_.W1#^H:VF81*48#J?//NV%UK5>^/@A\$-*S6H#<:9"LG_V<O 7:
MB[76UI^NTX4G+F7=+Z5+= PC)D<! "Z%1(^WG$!AX;7I;VR984_^40\3)"U@
MJXAH_8X+7[HESG5.@E,<??0\8T;*E/**D\UWG]?8[Y2_\[),J!*/3"E!;+H1
MFD6J7R:1 KRO3N9HW<T9;TY@Q14Z2S.%E2&EDBTO?(61@0I-H--+&^"C?>C9
M%8C4B*N*L&'8W0I.Q1T-H6]AIW.#ZZ(L[S)EF?3MLMT'.J?>/JHYRIJ$6'32
M=IT;.^>&EY^,B+/FZ[4[#LIUS$DC$^;2<&#$_J0POAG#]G926>(WU'E,+F<Z
M@]GFCR/&6(M\1?:.*T#IW&72['9?]ZA))2^L!@K(<RELV_1?YS"S[421=8 )
M;>NE,RO?92F(!9^NQ";9C]#(@R@A>R9(V:K9HTZP_N$%J$G_<JH9<[:HKQR+
M&H]&"XOTKG8Y]-JS2:X^GG>Y;7:,$?PL7B2JA<34#"_S57I4'XQ"DI$,Z,B,
M @K0<*'#8S]IX^M"JMG+< _U^KB=@_L!-J&JQO*]NH='A6O##STL1K,W.!EE
M?YG %'B^DPUI%25I>_G>WNV4ZKQH?#1;G>E&MGJ>[H#,QZC/KKFC'F6U LNJ
M0I9?*P]LC#%@%':1V%_-"S@)$N7Z-JYY"(.H*+:S#?QN==PQ9"R?>BZY2#V6
M;ZTOE%K0LFQ-ZF3(XA)"$HL"KJ*G'?00J_("W%YK]$Q-KTC50MYQD$"V^;"!
M4Q,V]FJ)D44IW?5@NS."%@5<6!]'DX^W?$"(5I>^D&G#E]:\'E!K)W:_9+"H
ME92TI.G&6AZ'\A25G?S MOV\7H93L/R:M:5)LM*AW%!&-]ET&MY>$E+A%7@S
M'JTA2T.?[N#V42K'0OLRR6+"E=-@1Q^ZSR,JPLW>I+'N/(4"XW:KP//UE#FD
M8(6Z-D2\)E8SWUDA(9UG0YL,20#COV=@T5;^+BM637T<R= 8M)?^RA3&$X2]
M98]?)_.UNIW:;7%(4+)@/I7*X"W+<#G<GDFZ0J^IDX0G(6,]F<E9X<-$AVT<
M]:<'^]8;HUH,Q14L"62JJE.4 NIR+JG_SX^!_RN1LI*R%.X_6XB_12J3.8$W
M^$3I[KL1ZUY^TU_MG.6XYM0C1ENN+O?<.O-]<Y[Z&C8VR2MF:<:,#C1/(0:)
M1E-89$M&&WE.YILK'S_>?@^(75)4UPWX@DN#2\,^K/Z8$I8=7C%\^Y!14.,:
M2_ND=ARGN;9]+D5!N6:U7%VY($NYK!:A]-7WF.-724C(KF8HO"?>X"BD+PQ;
MO)X18BQO=3_@ME0;-W$A-MG %NV<ZFBG.0U,!\UIS?90[))J9ES$HUI99P?G
MAI&@G$,+GJ+,5$5&HEOVU\RMTG#W1J,=#\:?C0[<1P%>E8DGN\FSF7DR=EB/
M7T3?S[V(_0#N%QU"(GCA6I-L&$G'\NCL26I3[7P/.J^]&';73'=![IXQ1MYG
MNB#1," C_UGRTQ(\N3S=)L>(VQZY=\^.\@32\=>2B9](\*M450)+)(8Q_KG)
MHYG/1?I(/24[VH2LF;@=_'!G[3S("&Y&A4AT5%BOWYXUL-+NW]#!=7)_1:H4
MZTC]8HSVR/MO_SKR3_I_2^Q6[,\N_3,%B+):K K-26C.C(BS20>337E%E!BH
M<02>Q.!3.H1[B.HU5;],?%P4.%JYS<5=]%AW,?0RT#4U6KTJ6I8W?XU(U(S2
M,>#UD6TK"GC9R'L*0V?%C7*\"&88N"]H[&*?,V,?O=BEV9RJ+Z%7,/&Q_=PM
M]+)WMV8-!? NN,SN);6A $DRDY/.+"01'+K:O(D\)>D_)03W"2+R_J/E]Q:W
M70:0)JVKT'G><*0O#W0W5N'O#Y$UH8-\O)J%@(;V@9M-R!!P(_ L0S1<>0$%
MI.-!SI=T9/^#L3,<Z0595BB%()KZ%$[!-]/^K,3>GY2@^T_ABD/^PAE+AC@P
M^1)M87(:F!:]CV250!?AOB8'\VXHP#<,]%?AC C^PLC >[H"3:#] CW D:!;
M1JCZ_%5+XO\4K9;N+VSW3 YZP!P2">"5Z]Z@;GC*R5]U9/M1,%?)/S.*OX*N
M)B,U?3A0P%?J0W 23&3W/Y54_U&R-=\_LWK]&=AC=-;Q1N2G"7Z:X-_0!*#?
M,\'MQS"[K-Z2'OQ^3(3&=<[W"GJ$1N1\GSH9RMPBA28WU=X(*-=H)CP6N9SO
M>7]%R74T2C86[[5)S@,.S2 MU0]5'(XO\\\5K<PR,L,XRY=_LPA:$5=;3&5M
MP3:KYI7HIN6>7R[9[",9Z*,/FU'"T929C8%PPCU,K1:X?0Q'W=A(%US3;9^8
MI+#9IH4,46O'A%E5E?*G9">K"T#G[2? _7AHCX#:( 7 S=.E*. ]*=K<_F,(
M&^@Y317B'&T"WZLF)5/@OGJ3D\]9R31!W9*KZ&K@+[Q%?^)]A@*"ZBS0R0*W
M ?(" A\#'XLYG)Z$(^'$?E%32#^TX1NQJ8?/<;C.4W 0W%.\9Y>L9T^VP>W1
M<(-*DT.,$>CN) J(]$ !9I5H'_&$[KY0&-^&KL[PGL^I]ZA]<NZK^0S^.>#/
M 7\.^'/ ?YD!H?_9A:!DTR^B8L&OFNK\6M:XO\K:OT5=MN/L3=":2F90)Q3%
M7%+-1<)8 Y"=F9V-61A;P0QD2D+DPK4KJZ*H.I_2B?((7U>[N]FO8S?_;J*"
M#G^]J@J+(K=*P5DLCBW%[$O.C9<Y/=V,^F%LA3TR?^=Q.#Z($%Z@LM>6F^I'
MS_/YU#%W!IR+ HQK+L,K<T*CI8:ONC.+(-W>%MU+[FMKP5XXC9F2KF%DY8S=
M-GIS20H <*0XGSU2(=<L^K*%3A\J^R[P3E# R0X:7TMDT#D*.#\Q(B$Q[J*X
M,$W917"7H0"9"Q1P<9Z%))U  1G^* !Y,28G1]N%,TK1B\9K"G3(.XL"9FM!
M\W;I9V2[*&!WVE53?2O&[W]->P"*7GY=P7_]"K[P7LO+FKAUUB(R^U=4%U$
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M?.4W/EP!1^37G8:U1Z406CL-UED*:S3*X,4@>J<(!)+FR9]UEPY./!#908!
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M4L.]+D'EFG%7T(>8@>:;-94<Q:\?5NEVG_<[[PJ0#!ZJS]6=6_4BPP12A7B
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MKCKXL*E2A#:,;SS=8)&F[C\A'C>C::):_'ZG8F@M75RI39^5CBZ48)"D8_$
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M5&K479]=>IM<\)@(YSP"59[Y1/]40#BIR.#Y;3GLM7#C1X?:J==S>#0!'D:
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M=TL_/I7:G4_AM;A0':;P*FO%@KB+3DYQ:%UX\C:?0B/D]O#3#\A3MFS50X<
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M]7_! S,V4)=ANZ-Y3<@I#%@YN*G7<'*LQ<4!&BPHN<3"Q 289^HM@V=8>O'
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M[JF09MO3N%&W$.S>=)) *FR2^*!A_-ZM?)FV+EF0U&A<FS?%9!-[H?X,7_E
M9D]GYAE,[7P7&;BD5 ]+1A7""<6,575-QXHUK9N\Y/9P3O$=%&I6C!^RO2GT
MF.-XMLN[U%)NGBM)2L_96BWA<\:=C_ON0';^N,B6TA5;M6R,1C?5L'X\IZ*#
M;3#YQM)8]'QS>$;]6T[KK+>H[\%JJ+N!"CIMM";2XJ9G#%SM#:.6*+JJ5HW9
M[SY/9$^[YR\M+>I*KR(<GL.:XDX<8KS$UCBL//MCJ$2-YQMUZN:G/VFH//=L
MQ QUS_K_NS(JOH=_>HF'MGZM+@:8_NL=2N&_+&'VPT+3/Q8")"D9)IOB5!'Z
M)68Z7Z9;WSI%5/2*^J]6)D42#>FE($\ZW>=(KZQ4(,'PA5#3@R:34DG;%VFO
MYSONF:R^Z0CULIQP;.89DQGC.+I@^:(!N_W8,&U_7].2^8N.^F!EII*I:9Y\
M[MR#RXE^?>7SE59,3J?>='XJEVG37>-O7Q8D^,_>]HQZ(KSJ.-1O^8W_\BZ'
M1\?I]+,2X_ ]<O]XV=M$6BDW8(\-"*L;N3SN'1]_3S$9Z/>CZ1E\N#M^6E+C
M(UKZ>9X0'AZ"WP*"FI0UP+[*,AIAD4=?>T$HJV21#NI  ^A<'^V9>5(4Z<KE
M#!U2VMI?>XQA8PXSM-#R$0EZCT7;@ W)\5SXC7J7R\S2V8/#!STAH49R)RNB
M=ITZPTUWO'(\%:"BLGR1-/(7CL'\!(=7!8Z182ZDO<\'@E9Z]?MD9#'810R^
MH1BP#95*N,%>P#]5&_8!V2Z _?"2?5Q4)%,VS=6Y6SXTGWRXR,1WQ0[K>OF^
M7D $K$_>D+RDM<BR5KBHYGO7P#W* \E-X21XM\61,.# O(EH10RX3)A>C'A]
MT%M4S>HY\VE/RR]*[C8^??R.3H+AVVH1I1!- [:$)P19PQ77-<XJO,H-0J0!
M;C+EL!F]$4]9@>9%=@0'4P-XBSPZK!SD+7S)K='$"CO5@I! VE561(Z:QU>N
M<RR]CR:5HI/QS@UU6F\6" :$V_))WO%AC3.?HEPD[Z8JP5X:>FOK*9B_HU-3
MNBJ>#A%R,DMT'C>N*WDCLMR,&PQ0K-[0,?0Y%B-9=DXOT1ZB,:<.+D\A_^!+
M%R[7)=3]\!R:B7&.-'/' @5"7C7%]JI%S?+@TK?IP5,1AJ%<O51O=LLV"'#_
M:,!9B<0U1.7"N9K/XT'F:J!0S_-9ATWVX<TT(,-8$_8*$ ^QO8<&=$ UF)^T
M).LL<>+,DS XWQ ^7J\1!2Y:RW:D\$&=0NKOF'%U,=S\QK".G<(^PI(&%$#D
MPY97NK$5ZLIB'Y;LIAHWUF!_=$CR6&\,(Y&/D!DN.IJ":4Q?#[EM;(=%A;24
M"08L(:D6=^:P,(!^8#7RT[%EJ0!'("/7 !1U7@2\AF#O\L:%IO1-'W39$HBN
M38F !*\=8]&"NIH-/AS<W)*@EX6?*M2.-_'G%)1;/]&WJO)7XB'_;+ME$+2D
M0"^&U3YM$T=D70/S/VM8/8"H6D:/H"@5L-\O3QSONJ]H"Q2WC++&725)VL@?
M?%@J_5>QSN\H ?9C[;EP'@(ET3F._!D.'^U 8H>$H6YCNHYA^_\(%2D-@JP6
MFH./>\%'# 8Q>N3-60NSGK)CMNE5,;O&85A]A0?YLQZ3ZM'F-$MS6?M3^Y9#
M+32S=PTM:YX]2=VUYAP%!SXLE2QA-H2M%UN6)$,Z*KBFZ>SLK@4& B#'@:0Y
M*5'?A14YG@+S9R ZF82EQG;Y"KF=]F%.Q'NN;:M G95L.#BDI-A[P'8I?G=/
MS_IP043M?(6L$$/Z<%L"*N<-&P;R]:),HDMX>ZG.Q]1IDS,(H][9"MA/R_A[
M%;FF?BDV+Y[=:A=IIWPDCI)W6G5$51M^.:<[B>"HFIY,]RC<7"MG>L5F+%ZW
MWK"/8PZ-U=D/8JJO=<VL:P22\"P^_&H/%M[BQ[O)+X)35*+VZ;5J$;8>=:]J
M$]?XM%8@=8JT(7!FJV::#R_K';F-(*O2\JGX<:X!9 F\:X@GEV]^[E^TFZ,;
M$$LUR2/YN7>C%?"R*@NN6&AM0I_KE)7E[M&0+P[9)R7O>KH"+V;@BVV@' Q-
MFDL>; BVLJGX$L5ZIG<#)*58'/[F3[BF"(@!ECVM7!=?D9VVD]BAD%7#N,LU
MU,N,W/8!,P@1?>=?K.D7A/\2>9?>/O]-W/0G2QM1B'H<S!0E@_L>CY?>AS#'
M1Y0:>L&E#.\\13)">;)D-'&_NRXFW1 +N.XDO-"Q*ZA6[KO1?M"Q7AD:E[C&
M'C[K-,BNI G;#Q"U=;E?0QT*GL:-=_'WPW?\2HB*Z;8TN#F)O)O[O**)"U\T
MWEA$&P)\VMQO;3QBW<3%F;\D;\W^Y5/4$]W;;7=H"2F2W*D/4]^GD(]Y\C.E
M\*U&/E[ZNN\UQQVQ81"WJ&"QH@?[(BAH1>WT,G2^;A%4;+> <1#4'"0'/M%Y
M>LHF9S\[#,/T)!' ;6&"F+4O+C?,,_!7GTD,F" FKAF2./(9-A0"J([F+8<]
M&3#M*!:#8O7(FTZ[*^Z#2?C<]):(C%XJ&36-Z929,[I/;1G0+0'/V(Q1+4R8
MT7<QE)K_A?W-GE(@S)4#+LN0I*>0VILO^YIX#H@((QY860M"[7SZ>'F3;$8!
M5MA1C/<^=HV18<V8]2%_%_('1 L"7HQ OE?OJLV,X-QS=MUX6\V>2H@8M 4.
M<%ZXQ*1W7[R R>XHP;N1,>R@TSNHU_D2U+:A;F$XW[P[RZ>NNA6V/,1DDFN,
M6@7WCVUS!@1V <]N;*(!^ZT'.J/5"-LE;>L[D?TS\_ROT8 G>]*OD2_0@ \V
M$:@+-.!>5BU"@71R1/XR__;\V_+*'-G).,D9_?!,&9A@X%'84Y&=*ZQU(2(.
M HL\W&/P4E&X8YD>\NF!4^\]\IOJ3[#W6 T6PMF'/9D7/\*:USK;Y_E0CD8/
M-"DWQ*LU]<9$.5;P.JQ/-B%5F7U^)&&?PQ_(NLMM"U1Q[S?A+0U8RIA["MD1
MU1D0-2W$1*27%+;I&!1GFOEVJ[O.9=C.53S173M:M0L^3#9>JBE,^PP]]]I,
M-J+I52D/''ZUWL@5T'*W">I8^&D_J9>CD.VLR%Z/]AB9W^PKLNU"JC(?["?Q
M6]]T=E9VVK5?^[%$:MD4^?YT01*Y4_H??V\5?_G;!\7\6+/Y<^#,HC?G3F$6
M@LU2:\Y[(H_(YCT-@=^$S\G*88G24L,< M0=9T \;M.TUO26\[;]E/K.S#@:
M\'00#@W>S474OC8-UDT&/Q;M)C4)B@/SI#39:<^+P2]KBO/,SB=C<F=GYK<J
MSA)S0GU60J^^>4AY:8:U2:>D6CO*]S7DHJ(=SY%S3>8)5G2GG0N8RI/*DJ"I
M%,(>%/U&:_G^UUY*HRGX:(EKXO- +82Z5]Y,"Z+D/MU$.71-J&CA70K=:#K"
M*]< CT5G>1>O?R\]2.3]_A'IE;'-^0<CU;N$UH9*]3S3GXM&X8=,(]&14\M-
M?AV8]C&$T!&.S?9P<SP1_%#<G,8='7"_CG)WM('KRA;,W)#24S]'EW-&^BVM
M-%+(.@N.2"A=3)1W1GQ;UIJ>OQMD@9LOZ2\2_8$%JZH: @0%4^23Z$%L0_AY
M64&-!RUZ+\Z/\IL4X'@=*<1U\EZJL* IT[X@ES+Z+,*8OAFY->]AZME/%PG"
MM:O$^9[LY55P^M9E,-'"C"Q_Q]Q+T .;@X^Q/6U(,!M@FZ.%P_7IWC3K4G-D
M4Z]G.BC6Q6^O6>*T)%=]LHA/@4U!7KE.BT/Y52-]_29VOGC,:BN%J)BQ>8D9
M=79RD_*34QJFJ0>O5JU79E('\SV5QM=3N\_%H^UR]2W<O9H+]&G87[@\D1,:
MY.WN8\&JJ40,+'Z=^5*CNV5L^A#(=X_42VY+WZ!VF0[<<4Z;,' 4=L*(*]_5
M&(0O08E5JF(@6XJH$+.5J!NC64HI2%QF)SF[YF8=$5.G!WMC'G<J>( :A&HT
MQ&1/- \4RM)XI>-6>A_=DF#((03C O;X0:'TP#'&(*:6*"E&R]L'QEP^,A(/
M-]VV]+D"D?+9KBD=NPGJHP.W'AHAGWC=W-4RP((YQV0A> 9OU 2[-+PU29"[
M17S198? "E[Q)GGT<@)IGCW]DD5Z/)^:,,2WKS4&X'2^T!F!8T:=E>"T]CW,
MCJCC/0,GZ>FU\)716E'^Y3E09ZRU4Y8^CCHAW<V.W!Q9"W@84+<>\8*K"@VX
MA=#>5QMJO)!\?N<P1?Z6))*]$78C?;'8V&"<GPO8,[)-XG,X4_<-*L3V<&A)
MXH<VQ<](M1MF5#]C:[F+!GBB 3I'PH=#V&A KSJ<XF+C?$P7)R7['[%(^D^P
M*]<WD*ZS$*@ 2GU] =M[KQD-,,1!)C0S_14JAP9\^YO1JO]8^T?$6OXU<VTI
MQPPO!H>HN@1H49@QZFGGQN4;\."O <N_,**A^\KM!_U]Y1E1_=T H/L:R2 \
MK$^@*U#*5^)K9$"]B1#V-X=+RX*ZVN#M>7FW85%55DVI8;_)BDQ8K#^QO_QU
M=;JK/8O R<JD5PN1U4)=K L.)FIL_BH^-P!'V5GJ-X.#'Y"^\&*UE+KU&W J
M^K\$IQA_P*F_?=;9<WWRQZ]>X):U8=?E8AB2;!Y"_HL!Y>3&.%(LWNA#E(J,
M(L[@:'.G9C.]"-P]A#V1J28044D5I@05L_S&4K#.\*$+UO*NA6XX;:PCSN2K
MB'OY3H3%FC@3 J(*91Q3\*__^!CD+6)*B5+?_*C:4LM:?-\$83^IRT6HI:O8
M:!)\JZ@EH![R7APW]<M=]DO1B)K'C524*_87]%.])0?!G 3Z6G"$4\1[C1/C
M9_KB&K@M6I\^=_J@ 1[9M@CLMK@&_K6NW$(K09Z(2,E>JM6D\^-2R8R0J PW
M<#B2M]B"_OZ%EW]^).D=C5/ \]RX9;$C&2"'$;#-D49IW7(B+[>?-B$)]%:4
M0."M:$)XUE*IGK7Z\P]IQQOU6]HH=MAZ/F3E0N'1_%1SQ7VCU$U%RS&6;+N#
M0JU%\7N;.N&UQCG=1C8F9O%?W\[<AOB;2+O!R5FB^*LB+%A4#NC]X*5JG:1,
MA((N#[F !JZ3^C;7)HI'[H?O<_M&3JT<=[YRC?M\WASW/E$7MC<R%%^N2*7;
M2G<XM&&0+TU!J'_?=?=X/P(I;7L9SYD"DT'RWM3& MI[:-HMVN()!O#ERJ5Z
M3;0!!8!XX3[>7I8%&0%MTLP8&,Y*^@^2@OK9!7]=O&E[ZP'K%OAX!X3R93>H
M$/T+2:C-'V?T_;1CVG0G;N/9\#Z7!JN)6<9]XGOWOYQ\IK-\% PX0 /\SJ^M
MR+1..B6^%@[(?*,C71^"SYWR1M83:E?L:M^A/6++!PUX&+M._KZ7UH+*GCNR
M6V<JPT<4W%Y:6-JA1(RP.6B_&*P,E[09PKDR['NUE/8 !VDYC*)LXR_M\"*F
M>9\5H.;OQQBL'K=ADP;5E0:XU098[65@!O2O\1PY\F[6&41](Q^*WB0#I?2F
MQCF;J.")F@U>]*B3^7.6);G;[W>O!R=M4'XNM<YB*;)7HW7LP3#VBO(Z,'VU
M93S'ZPN&+3/?EX'&H.BP.5ZME_JF2[8AU9J!4HFJ(TYRG@A43W8"#T[[2HV@
M2^GK4HZ6N&6N@":I KF<K;(=':_9+BW/7N>SV]$'Q]BM6Q*T@F&>"@6(RB_T
M=+'6U%X"G3:XGVL!0705C15BV)0KS<X+MQP5#!6@CJ749BIR=G:6E,'+9%1S
ME!L )Z'>/"M'0TK7H2X=@])E+W$.SJ&G1O<?9&(?TH2>BOL)E>J>I %!+8CF
M@OFM QUS;^*)I7$30TZA5^]V941-<VW=A^').8U.L*=F3BRK#1-SQCQ9<G71
MZU@C7N4&2422/<K $M;Q*\E+1V9(P>S,?$W=)W[L^+><"=G[4=1;T^_H[\&C
M^9M.!OC'<W 80_,8R]NH:*$E(Q+T'"8KNY".$3VS>4[8VDFUJ&IR'+>N;PGX
MOK<Z^*V5375KD L]N]_C.-DQZ?+ WA@!7J']B/9F_TC=?1:PBOS8V[_8_/&S
M"7'+X9TA41"FV];\8KB?NJ-@Q?0WY\>Q>5>4R+C\'?V3C0]M<FPY;\(4UY'L
MT57#+7<LR<W=P.^)AP9$)F^$$OL<T>+6PY^\7NF0.$*-*JVSC]P"I &?!M3'
M3U!=L)EWLE<.0);PX0N7!.60A=8?RAP!KONH@*G6_07,Z-_,$RR6)'W<D!PW
M&\&+!KSC[88<"72B =X_J6E0K;2>T[S\P_'*%D=]+"=VP.+Q[RVK;JG(.RDB
M:$!Z#=?%Z1^D4&X-T6%ZZQF*2PSWV=',49&M?.]EDVMRRM"/!OSUTJ%_*EUJ
MQTF$JY[>% VX:1J.:8K6(:C+GS1=?E&;B:V/*M^70;KYW[QZ#L$(*5$7-$#*
MRO!T_P_Z)K^H3NFSC C36^=SBE_W9#%L\Q=/ ?YY;=Q-2#T>!DYN.QO:BP[]
M\AE4_J(ZA6,LF=^^B-<^K[B(7(?\XBDB?ED9@WAI^L$[_QV7'O]?NG3A_PN7
M+OP_XU+(O[)'5QNR:R.0S%8-$2?M%@(C EL9-P$ =WB2%_MP$W>IU+(8X8+*
M^VL\P!2QSQ]MGY:7L+7X>Q;QY&!?<X=9^B,$N_SSN8S</P,1-[.B0XM"HM7-
MZJL+3+,QX#+]-W?+_.\[N \>06K\#)%UJ!<5J2?USOY!O5BE3IHOS\W;1W<;
M#8D1FHIPZ=1(U^Q7RI[UFOO,H_62L.!Q? +(<X#C%7\GU2\L[+S!+1337^-Y
MJLDL461TM9?XU+F71RQH@+^L->;KN9&/!GCA0G=4OCM</M+OJU(O1:@Y+QP]
ML$@]'<[\V?WGXQ[8X_=F"Z5U?ID2O*0R QEN*X L/(HHEBWS^G\D#^ V\9YZ
M1C&D/;,&TV;\U-" %G\0+&^W=?/%!'@_778R<\I0.<Z^^#=\)EY-WW:,X\(V
MHM&ZI*+[I[(1:AH_2H1@2MRQ_$,UJOM=V[?H!\7$[\O9B;Y]Q+KJT.D,_JFH
M<31@/UU'![M#G_WQ>,L"XZ&A8JM=R0/G5$/WH.7G&C)598J\ZU;;CGG3'/1=
M@M=X=+N*@"])U?M82GB'_ZD*-K\I ;4JS@3IB? Z @TVG&\@;7.^%B"DE*O?
MNCP;6</.Q^:;7)3ZXW3;T4_3;09NBPMT6RIFRE/;E<4QG1GORV_?Y@F_ HIQ
M_&-TA\!"*4)Y.#P@>*-U21C6?7G#NO5'%/M/410S/Z(H[G<[I&?4[R,4F[A_
MZ.780I&8E_-NIP-T1%5S"6D/N3[X6XG;-Z2D'1;^HZP?FE_0 / FK_4YYA63
MXR43D U!VIV6(L[Q9[Q_!-W_% PR4/LC&(33D4]3[!<)0#_+Z47]\(C>Z<\3
M_"PC:=_?K^#7%,+4["D_=T+$S[U3IK=I5N+Q<R^ _\,[&6W_36_^<<XGY8]S
M/G/U<#0@(*TV2FWB;DR,/<.S/5LCK06".ZEJD\>IQ HVPYU.S'L!KD-"J(\<
M[]R=_A9434*J8GKW4GPT8$H._*GTL6$#^R"*%=(-#8!\9TSMU\PHG2-C=_[C
ML7]Y7WZ]CZ[?IW&-4L)!Z.QK!7^SH0?<#$LT$ST?QI:2=D4#?+P%:D.:5.@C
MO')TIXKR///)7W:F,N"%>D'8OGLSN$XT$2R5YW=:TXT/\'25-27R$-J['J41
MM@0?1 2"*$J:'):QQTQ'[U2IOV\Y^E2^,O76H/27@)UL/96HA6E;'&?B=E7E
M<.>Y/*7]Q91Q=#?@7#-#>Q J('!8\=W<6)-]*S))^=K1WSD+I#+9NHKC@0;H
M&9YI8L-L41+NJ9<000P!;?K3#Z SZD44 69@ CY' TK7,8.[1B6$^J>CU]S5
M255T:/_+1Z\=6!PE_G4)S#\'+F@RPVDZ7>CQ81\3.HN;'/HJ&8T8&8&)6_HF
M;G'=J6=,&)0%[3?LGY3)M5[RTE%PZ1#VSK]O21O';?OJ^0<A_E(#CF6Q1Z?R
ME\F.%X5X^<4V9$97M?0* 8:1D8ICGO=6(%2;1#N"*-:FT1)Z6IWI&6Y<"5JJ
MFPQ1'H>=  \Q*1?&2.TA1O86M;!XBHLOA!BNU XDM6@XB<O[9LE3!'6W[JTY
MI$#XAKY*04*SAK&)8"O=@O0\E:WR%W=,\K04UI1N6OFX;9TYZ&=5W%<1#7U3
MD!W$OQ)"!)/M]E>3T0<;2E79K@P\O-\-']K0U^R<LZNR!<P5,5YF'/L7>>CB
M9U?V(/.NY@9X>I6XECZ!W\C.-2L8GC9Q7#1,C*/J2U5<2+;11Y3L2,%P=\[7
MDX8-[NOF5(?ZE9^M"!5=R1A8''KK,CDLHKL@G=O+%_7X"Q&K@1;HLR;#<J+N
MKL,B>5"!0J$^SFT_SVVMVFE[N\.DPU!E[#)771U;(M?7W1JN[S@<_9%E#N%/
M4#'E!B*+=+AH@ Q"WZL(#;"9'ZP55BLF:"S'LU(3ZG. 1E@,PH"!HOK+: "A
M><, &A!2NIL1!+<E551*IK17^F3/XQ"Y@,F]?L2 UZ, $;$L&&I318>E&OUL
MA&^L8OWD[N/P%=\;(ALU[@[J3A"$O#C)@O9"3;- =:;>8%E_[;NX:^%S;QZ*
M#F/7:0JN1%!(+K82RA4HX,2?WEQY#VKJSEW2/3DETI_IML,*#);&#Q6^Y0'%
M@;NTN\RSP3XI<%^+JQD-4N6Q:R),\SA*PZ<\5@I)6 7F3^M\,U>^NR?/JJZ?
ML]_6UN754SR$A92NGSQ.3"5$^"D(OZ['OGM_[94RSQLO]]2G&WP+85'F>/?B
M@I%B7J9V-E?1@,P<F-U.TA5]&S^/Q2$*1!2(R-Q%3J#8]D;_C3N1BJ[LPRD*
M !=2S037@H6N%B:XO%F"PZS9.37+(?\U %\8E$5R**V;;N<#7"9Y&1)0\6V'
M/.5!TX01L7\*7NT@Z?&9G% :4 73_85 E@A@5=,)CYCJ&&5QN1?KCY&\6A"@
M+=(M7Z\#LLQ<8\UY,/N56)92X_VJ-396DB^$;:5%0$LI'V'Y%(YKH4DT,^NF
M53&TUV8RN-<,P9VH;FA$&,.^;(]N0]V+SGW\.1CJ+LJ$GOM3,:^A 5<DZ#ND
M76-:_41U"[?L+6I18BE#&HD\>"RY7YXJ23^T$??1* UP"M/MGB;,7TJ\?.HE
MJ#=FHL*_ENNT0=E&]\9!@B["U],@A:>LM3EXJHV@>67FMO'A V4A<!#_&-37
MDQ(6L[:7FK<0<<NPX^JLDL5D>3ENOQJ0MW1^XZBD=(FP$2)BZ0V:Y"QA'N>[
MB-(<>ME_]V&7W,X P-V?;"TA)QVR# H]<1=/=7$B"X@CO#@*5@W^<M L?*QS
M+ PX2"7W? +GC%_9:N).VWRPS</(RM*?J+5ZU:MQ' R+1VI@X-EU\#YFN MS
M0+' [Y7Z0\QHDI\>X 5EZ++$F338V*@Y#U4[&<*:FS#L1R+9 >,-;#2 3().
MT+<Z@G2[U]%3/IV ]4/I1ZR !:@8<+2A;^6Y-OB6Z/4\I72:KSAKVG?\UV\P
MRP$684JT$^!W!K?KH:*D05[L<FXFO+I/#L0WO.I$PMWVSY6QO:3=9$)*++P9
M$(7%\[ISLW+99C7K#ZW3C-=FRY^WT1)\3AU6EU?"0^QT.<P:[C1@&%-@IBRK
MK:WU051\S_TK6.)'5[ZK=T^[MJRO+/^(6IV>YK:U?E7+_H#9CMD6,\Z_U00N
MA>D:PER^%$)PMG4J=\B%WS/-N[V:W9;H95Q=2:<L5N!%*4IA@&_9,\B%HH^8
M:O!!*<!B.FSCRP+Y].R"GH+M]:\W,Z(>J=]8&::/ 771Z:J,.:7BW0L[[JQ0
M$ G2H,(-!''I.:4!M3.:#KLJ$-TJS64CHB+X-34.7>+0_!=&DBNX[@&TJ5V8
MKIT4(=M)3S"J6&VT4OSHQ.,E7?%>EL@3.M=9AZ,TH Y<\[T1K#:0\SCD?8K6
M(M;JLU=1;X0O$C(MESEDU6!L.^XV*4PML6*PZ;VE<'?3+0,O^-7ME2[P-:MC
MN M'R3!C+"7J>[=SOV"-6T'#C;!\,]#-TN,ZI!2$-:7?33GVS@N1;C:';C3
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MZE=ZQ%X7+2P:'3,.ZIM]!/<!OG0KE2@0+HDT*IZ2,\[7O3=0>;DY^TKYFKQ
MY#+='>V$Z8.N)2P PL3HJ)1T@F]& 6\E)8+"SRCHGB/(PI>,ADCNSA =X?S$
MN *,2R:L9ZQ:[-$D^07\K+$265@(2^T8 B*$4O2%L3WB+J D-:=;P[2.:804
M6JUPYM 69@MOJG+HZLA]QTX-\Q=6HHD?02HIU5U(15A _%(R$TXUG?N.%M3T
MX\VLR/)JD35[UY5B]Z$0;U*S%N8)2'647)'3#:S^!*P(7KJ>/;LNKX*8UC8@
M;HAVU.FNBPL)BT:*G/<K(6S6;NQ0Y1O 3D5OH*LCIIW6HD*R$=DXB8LU_C'&
MU%^M1HF^.0LHN#-5+X8Q&,!V4P(]3B+*IZ\16443')2,1$<\'?4B;+>^9E;9
MSE1^\)A)2&@VS3@!<*@ 7ESH2%92\%.N]LBMC;_V'@VPW":P].09\R3*M:!N
M\B9*<'OU*,A^5*Y9$:?-T*8ZE>MSV*V'X6.JX[<KP=XDG"[>8H7-L"%_QU*<
M+4NC; GC][25W%^%CIF; 6]:KR9#EL@G--_,719R=[EM5B<N7[Q'T2'5:^&2
M)$R)^3,-<[M"Q,\*G"-R\?3% V&E2K"%X/#J'(/9KB*MZD8!M=@=O>XN#LU'
M<('$G$T!P5L&%@[S]^THD[AKOP+Z97-X6+ T%^?>U6JXYP:7 J)6-.J= UX+
MV=U\B*N4=K?Y49Z9^RL=@4"3W$?O0VQQTV\^P.EFA@OQITO0"WS/OY!7U/:-
M*)/M??B]>@<-,/=#_3A\SRMXN4D!\[J]V:&O)HY)/#F3R8#1XB/^E+0O*UJ7
MI%S!*/?M5@0&24T-8^?<C^Q-#B\.KQ,JO3[.+PGK7M8,JJGBEB[0JAXH9\ -
MQ[+2\X@TR%\" C;G<3QR1A-VPX95F*?O+9PZA+[A'A]%M'[680Z+G7!R2KJ,
M#[GC?Q*=Y+2XD0UP@!!6;7FRPVKV-2-I=FNY%?*^DH0:M4=A#^^"DNU15"/(
MYW"2IU[NA]T4PE::G,[:,\3JI':^@OB.I5;DRA#3R[?#8K4QJQ]MI)BX_1":
M\?(P+BF*DA.7T\G)BJA7;QD75X^PR]((@<]&J^A(5EH#CR[)W4H8_5-W'7HN
MWD5]FHIB;QZ#K*[REUY<PY"6JAW;)PB%)6N@QEBU"*4-\5Z'G2S/1C\S U>W
M*"WN7&![@B,]5QU<V&UA6O 6GLM79.(-87RG167L>,35;7;#T!:.JN1W#@I\
M43(TH7G&0]ML7&&:-6.NF>W.Y<\B^!PJGQ38JQ'7#4%O-'*1(^^/-*D7$&BO
MU56/^^!M/$)< ZKL*&LCZ6 35=QG 7NZ_A^?C56U\CY "GLHWP"%.15#GL/W
M$A>;F=6%GZE.<_3'F4UY.GP0=G?<UUN(0!(8I2%>;ZC"F8-MJPO[K2HUK;/U
M3KL49?FWYGD0EAFNG>EU]<2Z"Q*-Q.OD'63?:<:!VY;T'8L1 2OXYTEQ[N_Z
M0^-CE6(D*7LH%\/3AK$%P> *)"4:D"*%!LA20P^)T #3?(&'5CKXBVA #7M#
M-<P[VG+I.JPN:&U,0R#T?G%]F9S04!YS\/H1U[N&UV$F>5,T%[U%MB\/0IF>
M6>FWU9TN^XCVG5 E+G(%<D8QNQ;S@\7M,T5ND?=>2GN<Q)>8G]=$$^9:O@F8
M-OL2K.4CP2!Z,<$AV'8ND[ADO%3EOS[VM.)C?"TQSA#SCM[CA:N.8!&3DO0\
MJ=?=/)+K&V"I:1_N)EP_0T3GLNTM;3F:*8F*1W2$CQ.#.H 7JU!)& CUF :#
MOI60L8T0(,)4'M;U(>%UG,W=MYKX[I6I&F(#O.THBK$FANR6Y!RW!5.W!(?U
MEI7Z\I3Y\2L=%N #>V'PI2\(XX&"A/U 42"<IM,])T5UN\.@4G+CF?+=<C$<
MJK-P;L3+9D);7/-*U_:%3N &Q*S-QGH,>& EM,T-C=:B9T.HIR%25:U50D\2
M0@#XD_M5W'13+F*MN(##Q$^BTK#<+^YTV;GO%]3&2M:T%(H":>SM/M0ST!\?
M$;RAIT"H9+IZJ.EKF.>VCI/LR8F\XK)ZNZ-_^?M%!FN&0%:SYS ]KW!P-MP6
M^?%KZ_F&BF:M+XKJD*H4WA[,4M+1_[-YIC](3/_:]C4C[813I!]H&YQL/OFZ
M&8.HNL\C-K0U4#2"[1!J\=S6S=;?U#G=4*KXUUG__B>8Z,9R'-++U135+H?L
M=&>['#%P@LNCQ)MXT0 C1M3+9B+OS7S=2G,T@) A+R,X\]:O[I'QZ)JG@9"[
MZNS+AJ]9)[P!Q,2]H=W(=N13QD[%N)9@=<R;? XAH"]]SR."]_+.R]L$W6*\
MRD@^A!&SCV+6V#:10?.4<F@D*6OH1KZ8P[EFYH@$O>XBUSLH/3Y<NJN<J9AL
M]&E1QKUW^51#G@F]</#G)]5B[OJR4A,!\:0+O.W&' %BSA]DL*L],(QXV052
MB30[H= QJ&74G/Q>(<_13H55)G0-($F[4E\$#(_]/L\#*ZX>P]&:N?M4XK/#
M^HLDCT-#:2C5\G[ M&9H=2*!(FI]C[7HXWU+/);G 7.#DOL2]%X0&&#!(*CJ
MTFNWZMO5\NI(O,@DXBO7\)VZ:36SI)?"!-N]KS>-\?5\,]+2BC6.-=Y6<.).
M"^8+=53'Y=U5,9C./OXX64%,K,;R]+@M#1B+(O<$U\('8TJ U5_-/6Q>DA^F
M+[G<&)2U^[QOD+L(\75&T4 I-";YKQ3HM4O6GN$6/-BS5U1ZIJF^" E,,/6)
M.G:<2<QOF51N3>FSJWW8!3@N:?$1;5W6; ^)H+>8/"W;+M<NXKYYTG3OL'?#
M5\SB] LHX! !E1CEZZEFV=55$N(<(0<>^&]%AL=LJBEC@[-=[8[VKP&!U7V-
M(9I^@WAO#Z_R1G35 P/0 #P;<9"%)O30(G*^:)BR71;GD1!VO="60:HTP!.Z
M; D&N.9V"H)>3N0,\QL+D51M/A:Z%G#40;+ /X"4'$'R9RFD3YM1)U@\_]"U
MMV9";&-5(D37 #?864[U\Z:$*V:>;)%[",TP:52_$!WU2/(;&HU?2O5%4< F
MLVHW.;E>AP9$[#Z[*;4-P#I.(]R7]YG><BXCB:8U<M#8[/SM>1'97^=6>\<8
M1F8(^0,A4\(0LFM_)&1$VJUA=,IH@$M<@1A;,$LQH?)O[!G[?4]K_+F:1MQH
M"\C54G;24*-J[(-!)2\.37+6<?>Z9=Y_O;G_7C/_HNR=K0?/.3%N3)96=:U%
M/359N'3(VYEI@^"?A4(12]*DFD;K?^*K5#JY[QTOZ:7ENYU>4]$H)PRB >\.
M'V%&_S'(0J8^30=I(!>UX$4?@9UP/S>0WGR302*'OP>7>QS*83X1D)\YW-[N
MK^0L-P^=G1]K4L_>K@VQM&0,T+CF,_+A(57A='BA:;;DAGX_D0=AUN5U;5U7
ME5K&)\7;I%AZ-M&V:  .Z/W>?JE:%7F)<3"/*SYXT");.%+.YMN#;!GK 7UI
MBL (OC"$^!O%@3*HE+G;]>,*/=T>>D&J:]34@Q/#F;I?U$*)RC04 ],5,O7U
MK9()LHJT7P+6Q%A++:ET=#)>E1WZO6FP;%6),^ =V>7,KHG5]NSY5'B%2C0X
M!$72#$3]4.'T#E.#'>H0V!I>R+TC<3HX^W1LJS/;&"U]P1<B\NWLU2T9S81>
MM7R60P<&-Y5TJCQ[P5K5M>3=YLN*6=TG] )[;)UV+0#Y2&MG7908?FH#_24:
M\$S31'<D,8DTOC<H*U_=3NF'/-+SI#]_/[P&F)9@?"E[6"S<#VU=Q> L%>0.
MVT*'J0P)8N18# WX[2.S#86]/OPKS7?_[MNS,/2?C)(11>-R1]V)C#':!YML
ML[RAR:*O+29 $OOV)"A$E-=V.9GJ>XYU%%8#*^"B6 \PVG+/S"[;WW]Z=D;F
M07BZ(G;NP("4#>>)<.;-B9PX_H0]]V-:S0^FR[5G6OD.<%UDD5ISQO?N8\/]
MTJ;C;?8>%T\--("=C*:%'1(3'&&^"E)'G5\,&60T!;ITVAZ4JS3^2)AWDB+Y
M[Q3_3O$7*9Y!LYXT@?.>;.#6[,F=M)4P+"ZG(F2/L=MP3T/[GFP+!/?3@Q!O
ME]4$= 80U96,MDN21K,$K9/-O-*C'(YB; 3B(U<[B5=F4Y\_:DKNYJ=62Q:9
M:^GR_Q&_]5NQ<_^5^*TS?DO04D\?A%KL43!+4=A_TJ3^!]OO*(V!\V=V,M["
M@09$Q;M@/+#-=@(S[! WYD<]5)$FFW)[^R<WZ2E6HP'WL##LHL02.> \,;@M
M?*\3&LSA1,J^]CCM@9@K4]D7Z3Y6SHW7A';O9N)>.ZIW(X0-&50FK$Q4*\[6
M]4!2^OX.#4.!IG7CSU7'.*6;IRBMCBS4,QE7'A[14[^IRA^8^;19*#ZC7=TX
MOE$6%*)P\ZM==_.+2D3#FG1Z +MWU\;M/9#B1'':)O=FS4#LH<T]H5BI\00R
M.44Y:?/Q>X^2602%](_*!\P;"&HJ2W:LWQRPAF]@F7>K0MK3H:+\Y.^-6Q][
M?%6VNZ]*XG^ZW)!,\32A0V7"]&.^;GYMCI@0&D ]6><KDNCBJTY $\IS'MSW
MT(3-O5@Q:,4$MV\0/G; ON4PK;<UHO#JUJ..VRQ=;&L..DQQD+1>%UP4JG]M
M64+F.QIPO#4 *9P6U:1@FKT_RN85!^:Y.C74;$T=SOWTR49^X$;>&=W(R(@T
M6?V7/V^5BR^%]'"C,L\FDU];+AS@0_)03C&V2Y69.$BS\Q0TX&]MRTP6[_F]
M _;_;J&T_TWV"Z&J!1?]/PI5)?)Y6Q'+7AZSGT&C$++JU3!PD%,RLS;3!'-<
M?[ Y]G49NS,_72DMOE +$3D!]UTR'U'KI8PKU)TUP/IL#&Z$=D".*&N0 Z:]
MG%U)\#U;%2TP+ %AB_(C7XC/1)$8$F!>^LN90SY[^3*'[OIFZ1=H0+OE4NLY
MOJ[WZPB$@B>&%TB&V/:/]'*V#=&O'Y/Y87J"4@SKV>2V/DL +_'#%BYO<+3R
MRC(V8HMZ)(YK )%,+30_]/MJU\U^5CQMU'?:?Y?^[])__]+-__+G3ZU_F)6+
M_MFLW,*/6;D2FF7FX*I=#X7:$3[SSK7^PZOSRCW*/$*GZ\T4'><>6P:@LK)(
M/[$F/!JBX0_L<DSY6?W+XP4"86Q_-\]#8'B>_@^>5_C7>=Y_WL//('TMBO&U
MC#KC[6VE;'OAYKGP3-OK_3<D"QA#UK[PUBNZ$XV1?5-CM[PZ.%;$PF2#Y[^*
MXH_1L;'H3>9CETELU(EX5Q_ RPRLLCE?2? BU<@W<ZAU^:%_=.L'=-?X\W2?
MCM.?QPAU-"!@,)09GKGM@?IMH=$6QXO;?X_\T3_*?E-RYG^3%7DY=% KO4_'
MR=<I"DWS__!F*U5JNH8E)U$GG2]EXSH:@!O8OG XN(_Z<<C]<3YD21FA>Q$'
M.?UQ6:R_1N8]Z=5SHOS]#026Y\EQ^;7UXL</DYDH,J!_:ST&H$%^[&^<5Y&?
M'JKS8'%^"$:HB9.CUA8N?]SV8R?BC^QG&]& 5C3@TF*?)?/?]_W[OG_?]SO=
MIPIZ9T#QYRM-#VGZ2:^.;U+E@YL&-X>;1%$F,3FO=^_G.D2DEP3$!L?.5IMD
M1?U8D?G0_FN<# \>]4G\WJQ;*B?BK=[IT-. 9O8N ZP:N%*<'6FK26O$VP=Z
M>_3O-%-3 U!\U_P39O,V/5'5FT;E=KGT&FZ4LRWJ&T/DZAE%F!&Z#EZ+/*[%
M/, 1Y#_^/AX[/O<*!W]W;Q[1":[$/.5*U\+AY *F,QKYQ07F+K\+^E)'C5_/
MZLC+._4%JKMPCBRO$ PK$;5& \0PMG\)^L6%8>X4N'S[5-J";0C)'D$#&=*%
M8+HTV9__#=TZ ?Y#:M32JE0&,9[8"QY73T5HT@N@ 2DU:, I*N+G%ZG0I7]>
MC;R\Z?PN[F+N*2KV&C>_  =-72=K_GDND_L!+11SV4A!U.T&8K[[5'>D4F1O
M;^S,D,7H69E@DUH']FTH9GQ,>7]D34F4OK5X4O/3\/[AC5B^Y5>QX7\/\;^P
M%[$"<X'/:_=?'&4[^GB177.IJ13OV7OI?*1Y;?R(*:7M349&[/9-[O4!6K>M
M>I]<V?L.G)MS^EYJJRK]I2\:Z,T*7"8CY\3JW1)X:?:4B\.Z1XO)U6\37Q'%
M3ZDRU'\L'!R6&_1*:_HQX8*3/'["(1I MF" B.B*1>&4C5.W@RH3"[<R0$VO
M**^0IMQP,<VU<*D;>KPK[3:[@'VD61G.4DVGBH-!:[%;]BXD^RG@IYM(UES+
M<Y.LR>GU7/K,P,O^&8&6A9-&[X]7AD<,2$R6'.&YG:54.H86[N]N?>L)(YX9
MJ')  [9+,E&D/Q1S).=LT8"KL@AE[%P5O=9W2"+S):PWUK;[)4U[K1;1SN(Q
M0_/;"=WAGE).6684N[GFPAYN+K7E/J_B>]K"')*,F9.<TX!/,II:T("E];<Y
M4]W&MR=RS*]P>%?6NZ(!G."G?L\F^0VQ+*:]LE$93F#\A;* ^0-[K!G0$J$K
M'2\TA4UMS)EL M-*2'U\>5@M GYO):__<5,3C+LZVN<1J]I..?T(VQ-_DMD7
MJ0D,$Q4DK+Y>%#O2M^<K1$DLD.1$BGE]_W/S_?]2BP]_TYQ+1&0KHI7'N2:U
M/^ETO^G\0"Q(FX**F3HI,>UPB<3;E?GV[7&JV<O,1OR$C:+HI.>\*9O-X$ K
M>N([H1TLE-I$[^^F9LS+V>'7G'(6V]FL"^&>GA8+.H7AB5Q7YI$K>=D[3^-E
MK.ZWH:WUJ4YT1115I3@<92>Q2Y&>+A"7&:2[>S_@D4,0DZ@W50&Q5Z+<N/6K
ML1R-8$TB.>+>.GM7,:_M]9!<'7DCLO&\2@6VM7FEQ+.C@H2U:O_JN8@XW/O[
MPL:VE%1TA4(+<<F,01YZ(Q-R%][Q0]JZF*:9)RHM6B:>,NRKUZ]V92]+;;H6
M^8YOZ'Q[X9Q 1*VM=133=X@EH@$2_/8*AUR/4E5J=&AOB;J05"HYY[HD]+LR
MEV _TQ1;7B"P6-&O@6L&&(!VY<U"56?D3VTR'Y[)[0X[1.IWFD00F8-G(C(2
M>Z#*CPF-K'PEMT)A$-QY;A4-Z:S8;LI64LZJKY^LD/)+83+M^CY#=L1N9>G[
MOO4/2U9D)QTO/11"E,=L5)>G56),4(^=L*<FOA'="XI2TPP+H-)Z1;1OX++X
MZ3L'ZJYK 1W=8:Z_?S*)N,XS^7U<88A+MO(@KSR<;YX:T;9B?F>DE!\L_%BU
MIJ[/N'ZHQ+(,#? O=$,#'LG4GG$HPX#(6%L0&M!,<5RJN2M!B:63J H3FRSB
M8"Z++V9R"K"R#<VS,CT8>(&D#86T-U36O:3V"#*)U7[ \UT_7&E#OW.BR<4Y
M6O<I+^U(E0WV&QD"M]:. 6E1+@^OQ>0GW5:3E:(US[Y+Q#);=T2/AWU6QLZY
M1?6$X?9QZ4/X9:B*J^ 7N.CUY7 B!QR&-=F-W V#R.FFS"YW5&[>[(+KH]/O
MSK<,>]>FM^^%/-Y*31!D$#',??%0=/QASAA90_+I.]N<<>2];$,]T(*250G2
MY6Y-07-8E8#& UW=/*V7$GG8SW#+-1[\SP]ZOZM=I6ET:JQ,^?;)/T$@-'+\
M*K?6/"&LN-9/5(@\S-R.#]:UMRQG5[<GM-MI9:"')T\3$I7]CKOJ'2&"JDCI
MFFL!F KQFNXUNW.M'-VPS%3/M-VTCS#;_V" T+]4M-+?,L*)GBUA*V&_;9&O
MC$&.G8Q2 08*3A/X L,S<=PR^4U[UIE4_!^W#N4$A^-E=JFL,Q3>$'%6XYCX
MNZ<I-[9D:51T4#^ZJZ9"28F+39G/4J <3"U'.;)I/_VDJP^E96Q[]EH&)AZ?
M$T'0_LQ>[$N48GC)*X>H-PX11KJ.JB<J%&QL<]H<_2>C<;<_=_I@E<BPVEAU
M?OG#Y=KG;CU?<+%V1F$,80][,ASD>P0AL8H]( _>XVT0*73F[@ND!/$LHJA*
M@H/34RS$R2SH-3_,"TU.S]8\M1$IWVITMJR$H0$!1POX6PLOQXQ8Z7?[^SOC
M(_*9HW6.E+$3MU-Q[K3 Z=.+=5T#5<M2SD[[:DJ>PWH8^"F0;.RIYW0_-*7?
M M& 3LV<$0G:TG=(&B[_];K(XSE9U4--&INU^Q1;418;09YTF8@2ECC56B8M
M1:,4 =:[H->T*].U>6E 01!>M:359&:W3H]/S1LW3].<RV_%4]X@,SN$S<KC
M!*&2%_4O#WI%B_9>@;LHD_SVV LS?$0/.X@1<1W42&^J\94XU3%*4/DVPW7?
M\%'3NI7)9L+_^8;ZNW<$>%_M7$S$*KE5^*RI&&IDV"G:#$@#V[RI Z5]M_:,
MP^:^A*?+S3H,:\S-?:ZJ3%E[RXYO?0>KY88E3=L\2RT\(O#E),=+UXS(N:MU
M&VL/TPC._P4:V+]&+V#^0OB#>'7D,H>J@D#O8RS>_AF2T$.MC@[W8J0<_V3&
M5P;\[^S)K<5&PL7RL6S?@Y1T&9UIH!<=AYGN:("KMU,/I)W&!0,Y>-$ 3Q \
M$W5KIO4<)_5B$0T(DZTI1+X['"J'[AON P?#=BZ7SJ!WT(";U@N7UX8N89"N
M"(24#1JPR039]T/Q>5BT]M&.?7>Z^/LRIY\N/<#FNZ#S/D;!D)OSK?.@9'L0
M+& .#1A^A@8L8"-_K"P([*-\35$(\,J/JJ0/B'<;-D.:P/^GO2N/:BI9^A<5
M41Q%$$2014= )"HJ(EL@(D)81$"$N+#(N(!&167?C# /4$1 $!!0 K)O065'
M)&R"@!#"%EDT)@'#3F*(A!!NON W.#/OO$^=-T_]WIGYH\[I<V[?KJKNOM6_
MJMO5K:F6/QU,M0GF;"Q!3:V!35=S 4D8:>43+I 4QP4JA5CX\6PNH.AB]N62
M/_^JDONW;/\CDF^8H;X<G9ZO:3#/8C3B=^W]]EWM(OL!\3\HRM?KQ+_.\ ?_
M+?F_G+@N)H\( 4+[5FJ6-A;:'H?[3^05+9K5.;-OQS+96Z[>>U++TQ.CKBV>
M<L/I(0X6W"D[E=L4.C&&G[_R=O _<=_N]Z+5=GUSC^O)?>Y$385P=Y704&MQ
M?U]%J#C)R=7"_6)%EC2G/4&EE)INZGKGSUVE]I\D$R.3O<N_HP "*F0LL]Q^
MSC=\V%9Q]D$9=BT*T\X%1@=0QL/B2;E;N(#(?CCYI_GM+G_Z"KI/$+\/*4&B
M>B)X!@%[@V71RV6G^KG 1EO^28XG#B2!5C@6!(1BL*-EX+ZR#(Y37#,%;J$O
MBC!*^MZQCR_9O!F=QPHVI3&32CLO+C$^* ;?2M1]75K":DZ!/#31"C;W/$^!
MI5U!KTZ_8-(P>6'GR1^$5V8EJA 9N3@EV,Q;;+2;1:V/X6MJ5%C+R4#TYFVM
M#%!\SVTNH,.S+43[^0-.7<[*,BBPN?ES63%"3>&@5_X< QXMRV&8S;XM9L?&
M/0,?*@]HX5@VO7 ."\<%_#X<MAK8DHK"A7*!Z?ES=TMA\[S0TRTRAU&,%MAD
MO$[:6]G11:!>Q3]5#/]M*SD_OTOA HE(GI'##\*Y +0#G$D9L7/XROS.?N1'
M^,;\OK5^WX8?\E/]V8^:GV1#%5J4N35U+BM\O$(1QUT&#7>BDR?M]!9>$M.S
M6.GD4%FL<YA6>OHTY>E^VKU'Y6=8YT=4LY5\B\NFBL0L#T1/[$[02-5*-!2^
MRXY,BB^Q@9=^T\COI\ZZ_Q;D8K>5"]BFHPC/P>CVL("R?)ZE[8!],+1PW2.6
MH-QU^S4\5Z)DZR<3+ZI\?2A8R6,<$^=5K*M3X;NS=5?5#8;Y/,R_FG\7ZI>K
M1^("X:M'IH4K(GJ:I3"W*2Z V8&VI4^Y0$BE,FL_/'/4.AVIJG%**31UU9/B
M*_S>X;7VU\U9T_!(Q(T+DV_4$\4T9%YH5U9&4V646,P4Y%7Q3M<GI@J@!N:-
MDUY+P;F)=;B5EKX";:JVFPV[BRCG3,S$8YTO4I"&S3'2/E+D:]KDD)EW0DL]
M^^HDT\ 4,DK$-$E"ZJZ#6H+:Y?I%]_CZ:*J6)$1(T5-ELI:G'?70!>-N,D)/
M+C)NAY51?RJC]YJV#HW% -?>DSUCR<-;Z8@7&CQSQ@ )KS%@!031R5PREYZ;
M:\T>/O^R(>&RRC+<A,JT2UC1#7J4?==4^(U'*W78(ZI'4B""!YK^$:&U. 1@
M:YJ^/GY^]J4ZFR! &V)-CFNB.0I*^^TW]VB$3I^?(];F79%93/.X-08U6YM'
MAHQF;4LKBH2']C\2-JH7BU5G#C_3FX6-> <E9[)N.3MC+NZ_:EV]^\6LU]4X
MZ/QA@?:*++U#]#-EE/5S*TR[,9LB&2_TY!A:R]H<W?NI M+/CM%WTNUKG->]
M;)S#NJ'6;(CV[8GKNA,I<41-X@UC*DDH2S%?CI5/%V'LI07%ER-3$>Q4I3'O
MN[=CY<(;0@8+<8#G"*[6G!5/?+;FZ<N;XY +<A,C)R&)NA3UW7Q3\F*,R2H_
MY*&N"LNLA+[1N+8:&[D"E6Q.;9)"9<!GMR0+3F/I%-AL\(RU0 "6TC0*/D$/
M0*Y.@] S7. 2%U"JHB$X7K8H@@LGT,6,A5=!26IZ*SXH-_U<N_\?2$B 'LNY
MDX!E4P^/4$.Q ZD?$CDS[##B;W2T-'D G?>=E9M)?7&VD]91+A#AXP=GY$FV
M=J,&9(@6G!$ES@^C55R@0J^3+?OI9!6[C=/5?RE(J4K&,7L=_Q=2#D'BZ8[L
M<16P$CZ%N>,J%@@C&P;2=SP(@5RI^=0H5EZ@ZU>HH0K=T<XNHBYZ\IW&].?)
MT4%F2V2*IJ*O>,!65<"\R$.^9ELM[Q\4/RK\C[KM<+.8:[MYWA --[>BUQY<
M! ?%U*Y?3&V'0K)L>Y12BXLCH7L5:Z(/P66B\RQP/R!V&"VAY]XV3+-==VH'
M=#4\#? M>_-4II:\WNZ<S';ZX:'W839]Q@-OH:=N1U6-5DUEZDAAXM%26]<8
MO7K/'Z^[_">C#0;]A,>--)5J$9O"MZT#*GO&<R[M8PZ'&W<6L! D6ZTZ\]$8
MZ\B^UWJW$@^GF3NXS^$;-N4!7I@"+K#9\B3S)A?8;RU0/SFCU,T%)O3F(*\P
MT,7)-JQVV%HC4:I5./\1XWV7GL";I[)?_\@Z3<**(L_FG+O4K]K+#Z0^@S=W
MA "CCCQC?Q;6#VNJ6/_>A3<'T3>PX[$,[^EB\Z$F[QW5&&1-XJ*V"@G5@7*H
M2XKM.,.WT80J4:_2D94DM(2ER@7D>3#R52EH4(QUFIP1'-X,WD6_1785"@7)
M2-*Z*]WR--<'/MWH[WCOX4PYW1IZE#:]EY[:UIRKKU4!*8*6&5\&30%/:OVX
MPAD:(=#-K?'&>4K)"0&]$G=3=W?L6N@F\=KKR1<,_1YK0X\GF&:\V+IZ<P<Q
MW[B#E89I("D+'.OE @[PG+/OR+V&:1'70G*JH3*>8H/>JI,U=WVU=7)40_'G
M J7YHQJI0-WJ90(2,E-\R/=NU#IV^)R/[%O(L"1-N:?#(.[XX:Y4@_TU=7&R
M/M"!JU:3A9^%XW;_TL@YO^8"#:'$"=G!(S*"O'Z%Y+,G4!$8'A:35'"FP,W^
M:[R--^ N+A 9]2$-Y+[-1T,XVE7#$6APM)_DF]>$LN#HBVYGYFG6."N,C/\8
M)=';,VR.JC%[P 7:]BD3.$HMK5$.7LH)EY%2X:$73R\A;+R0UJ,6)E^TAWYW
M4>0:9VE(HDO6VICXQ'3)H+6YZSW*$3[2?HEY#ID:)B9WHJ\UKHA/)(^L,'P1
M*Y)[;JG122ORPX<=(D:DDK!MF2:BYJOX7;SU[])57ST#DUKD=C86*S+JMY0U
M[0FWUH=J2\9F)IC;>[7IY@\C5+::OZYK?27P8Z&)XJ&Z6TF.JK?\2/=WC?2G
MNC^JW2!A'7I!(\4@!"0:Q*S@V6/_@#UCD1KI&;O'Y3;K":EG'8HB'IZ6TU'
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MUZ";OO\]V^J>"*9GD[]P<+(@7XZKQ5_M?\_?]%](O$G#Q^WY'U!+ P04
M" #B@UA2%+52],:' 0"'Z0$ %@   &<P=G-D86HS,VYN;# P,# P."YJ<&?L
MO 547$VW-MA8(%A" @0G0*,-!'<GN+N[T[A+H D:&H< @>#N[AK<K7%/<'>"
MP_!^]]/[WW_FWOEE9M:\I]>S5M>I.KO./J=Z[_U4[>JGN:>?@-?2XE+B #@X
M.(#A\P?PM @0!:"\>('\ @D%&1GYY4L45'1L#'0T-'3\-V]?81,3D)(0$Q 1
MO0<R4K\GIZ<@(J+AI*5G8F9C8R.EYN;G8N%C9&5C^4,(W,N7+]'1T/$P,/!8
MR(C(6/[+Q],/ !8* C?*( (<.0 >"PX!"^ZI&T * , AP?WE /SU@(-'0$1Z
M@8SR$A7MN4'M:P \' ("/"("$A(BXG.MSW,] !$+Z0T9L_"+MTI&R.2.V"R?
M8S)1*$0J.W"4)TZ K,9._B]1<=_AX1-04E'3T-*QL7-P<G'SB'X4$Y>0E))6
M4553U]#4TC8Q-3.WL+2R=G9Q=7/W\/0*" P*#OD2"HV-^QJ?D/@M*3DK.R<W
M+[^@L*BJNJ:VKKZAL:FSJ[NGMZ]_8! V.34],SLWO_!K;7UC<VM[9W?O].S\
MXO+WU?7-[1]ZP0$0X/YV_(=Z83WK!8^(B("(_(=></#N?S3 0D0B8W[Q1E@)
MV<CQ+3G+9Q1LD9C,RHZ7%*S*)SC&3A.HN$"V7Y2G?ZCV%\W^<XKY_]_2[.^*
M_4.O!0 Z MSSRT/  @@"KFYILOQ0_\2?^!-_XD_\B3_Q)_[$_U*\28B% K1I
MCL4 V$K_$:22GVO_![NAI4MJ-0%E"8U4_(P1>F=91'6V3DKYG?G*1MFG[EB0
M/51I?PM!Z-U.D8%-XJ-/VC=[NWHCFU#2RW%4P'A6 </!QJ]#?(4,F\F(C;FU
MZ= #5J%W5G0ABQ^\YTCO;FE7_W)-&)Q;0C6DQL(JF>9@?EY<7A?5H[EI;,QT
MD%\TX"^2P7^5W+'6)Y#>B@V7*::D,]]_4ZI)*C2?<^>R%%A'OUYIHXAT^X=D
MWKG7_)\ZY.],V\\/+N"<$@K8-V=\9<B[IAJP=\HI68KD;(R7K^1/+.$/L96$
MD/[$_TNAJC*P^7$L_! 19C?X4T;,N:M[ L^)W(26"X6V?7$V]+PU .7!4?<)
MH)V_%&7U-CNK4-.::;6GC:)_K[6'4VDJ>W(=:3KI^U$!,=@ 3*(/WM%@J1VZ
MT.!]:/:\>@)4KPX]@!7DI[*FR.G]BC^LJ$RI=K8 #P+ST@()\G]'I;Z:.ZT6
MY+?*<V,\;HVTCLPN1,.W'<\[9J][H!OIZ8NQ/K<=G5Z&2N72\OK7#NR"TP2
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M>%C$2IK)Q4GX=U4BMP)TEVB6:*UH /W9Y%!M@"R4A28W _&YD #]H_"W&AK
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M!*[8@.6:AMPL/S(=RUCW),67I,><I3)0;1I 4>)?V ^[7=$SC>N;;I]Z'FV
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MF+;54MS2<9SBWM64CU+U8F,>V67S\K7.G<FVM<X9>-]_P#/+[;Z&%AH\%Y+
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MKS,5N$-I^PP(3'VP)?]W[['_])[_GY5<C-C_,.P_KVM%5Q%/CA]NG@$;,L\
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MSP!WX ^-,:YTQ-(>_9^1)5=BWOPT(,%U0KI2PSVG^1/,JPM<T3 V6JC[A@Y
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MNN>?32BN'A$RV?<E]W>-S=X*QJB+$C",P25*_!(9-S'7L*+A%?N:Y"3$5O?
MFR#\Z70!5G.*\?@3P8*3X@F?OW)(X52X\$;3 TO!"]Y'*#*]=?GW01RF/SJY
M!(=9*B;<7U/^,=2&;AV;]?:M,OKR"NKE*)>^UBCOZ<!YT!9HE<VS=<#;09?\
M1'Z9W;?4GDD2]<U(=J0=64U>42SD7P&5DR]@:2:E_(H1%TEEJ5+93>C4*'36
M;3CD,]U''5+;5T\#:U_[LKJI(-_X;67N\M':Y6*E)E8V-/7 RJR1I;0*M5J
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M8LNFH7$0TG-/L,;%:'G-/@,@V:X:@SF4\-P&OI$O_+'5LNRX%<I.#06/1.!
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MRD#OKXM?Y7:<BL*N SO=!'BKK4%UJ/Y,4(?3_E ;WS9T."BZHABI!4- DGV
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M-G*B??#<Y9 G[2F0<*QE":B+-M2PQU1NR;AGPU]I9]W<@)C:&J5)?[]E?\F
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MLIT&:%8H$Z6\=J&.+?,A#,<KE1!BN4J^\*9^@MFF1LIZ@!B<U;U 9(>R*Z_
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MTIS1]+A$)TNB3YS!\=5)!WV4:K61_F5+BNS_G3S'!3_S!2/'K0_GXMY%KYI
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M1@7:)30Z"3V#+M5+7-;[@NS0N9/?AN#PE9R3J+LSJX10P)>?70]:,(Y9UD=
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M]%L #LD[%EF!!TL+75,"HH7#2]3OU77<=I5F=IQTM8@2O2R^ULL9]@B5P71
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M1K8I\Q=VRZCR&*221T#]0=SM!NU/4 S4L2'_+OS$KX&AJ.(1H-0J+9:P]3\
M^/_?*'283#@(JT($U12$BYK?N8<2WR&UVJV!ND$[4;B6+Z#NG@<]7ZBCXX>,
M]9GDT6<'C[HANB_Q23N;YE28&#+LHHV:(5AFER&]"7SFT>;XI&?=QQO,!TE0
M W5B8]S!^*',T)8-KQE>.IY!^H?XO,7Y3_O/<^'B6 LJ5*K-[[GM@,4R4B_5
M-%58+@:<'SX<1^8L0YUN&:1#^;1!]DW/R(0088$<D^S<K#]Z% L*X>J^IH\
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ML_.=3@+;W% &ZZ3N:'QH=&BT4YKU<2Q,V5%?$9<*WBNQ0ZZ[<"QBR\05FZ(
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M=1U>0]!NG 9B7A<FQST["G ]<W,BK)%AR-JJO207TG.:FB$>HML--]IR>7V
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MYNSLT-8Q<2P#.E5S@@8%3;88I+Q=WPO!N_Z'SQ>E4;K6M0X+$8W&DF^(>>[
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MM--LQ-1'/1\+&!]QL2P0=+4G\ W"!7\X&Y2TVSK"#QIVB@[8+)_VBUAC!EM
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M\X'Y)]CA9E&&1/K$S?%'AG46Y#J=;VY748_*'6^4_<Z5:/<-WF$,\-S/)#5
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MY#@/OG;XL40=@*J#OT93Y:N[-;%8..GUAF)P0ZF+0).B1BX;1W[\HM3 8?1
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M(H,8;46/4N=ZAL]0*%3#C>)=M.M]HI^H!L*B%F_.\*(,+GEHC7E2!/=]&F@
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M8KX02R80DKCM!/)P'S7JMW"EP!&BW+) ^6?"Y"KRT^:>A&.:8WR:.T(;&34
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MS^ 62NO.>8THN!2Z"GZ"Z7AY'=!1^QRU<KCA09FV7I&DT66A9'!S"ZA7[H#
M+MTCEYY\BBICVU7OQ,9,UQVJRO%_Q*T1>Z0QMB']J#YFSRP&;^/(@ Z^\A0O
MZ!8@)(&*W0)>M(7G0U+G)E]5^TR7C'D7NA>;:H)HNW&Q.S]*4V-ZGI3/6NND
M<IAT].]>'^V((T,?,ST9%K<*%#IJ(Q]TEEC)S"E*4YFVB<HTN6X/I-B*"%-
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MKMK)][:C!_]2CE]RCK^7 RQG<0NP_]7*T_]2D+_&K/A+YM;?ROS_G^;_K<R
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M,FXO!Y$+??I4_X4,]$BD[QR^HLH7)<Y]/-^.WI.)42>'X1/*5-_<_UV)R'D
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MS_LPZ.AHFM_4:&N/1O7@K8X/^- -.682@$C8.[0)>S!&4% 67?_XBE>("_%
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M92#G\2$SGV-/\Q4 ]J+%U*2(/F@H'ZGZC:YT9OOK8:'J<-FS(=$0)SW/@,M
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MMDTY*OMBV-&(52!\,"S^<2$5'.L59()/,:*L(&I+[*L@/^*(PBJ.'0/K*G#
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M*V2/)Z[(_ZFH$(#>7;77 .+66%MM_4R86EPI5 'J=0JCU(R'*2;4A,YW::[
MY]&"K!$O6IRG1I_8.7L?=R)5JC)N#P<1-['+ME'S]EYO7;U-7Y:5VXY#0;,G
M!6]=$.LDM!9=J6]]^P'S:U[QYW.TN9EE<];E57K?TT6T$EGA$A*B.D,Z;8RO
M/^L]CPLJ071=E::GE*U\6BJ@B7A+; R$KAT"&M *5[!,'1?YL-SC#E IO&+D
M &1=6[FUO"6\X2=$=-T=G_[SS%X^"N'C+1Y[MBNBXWJ[N*Y;MA 19] ; _>7
MWC)KH"A//US$YASF)$%\L-=9Y\;'V<K$9'L%L,H$R7_]%B4PC>T(O[&"<^2%
M,^?=X,%JZ.$4%,/<KKP/XU30&Y[RS\@2MA5N]1=3[NYE;I9R;%",DRCKMJ%?
MO.AE#K<KBJOEN.)M*DB39E5^O(@1#/6BV@#5F&AJ @6^^X797WHE%_A/R$]>
M%3G($"S(!L7Y,K4V^*@]I#F7(]&8H^P^F=JS)<RW,+Q!K;-0=/TN#UW#R!F;
M>2-9X3L^34=(;:4OJK8EE$7K(TB[YU#GJ320DI%+P07N@\W[DKFU4_V4I*HM
MA+'Z"ABHZSPCW55G*&FO/TLWJBY6WX9I<"4"UD\\N8V];+ZHC*Y[#WJ+O@(J
M=*>K>F45P*#F<NIB::724U'5]E9I0O&F**Q@EJ_7A1JK#&MES@@(ZMA,\.46
M>976!4Y.S>P,E SROG_KTP+_U>'>?KJ#BUNCI<4E,6D4JZ-=X7+V\)Q!1S8_
M?_^1Z7''6ZI)*>Z&JSKI2$WE_'SQRE.'F%=IIH+M>"CG<N]K&;*/F"<_JO$=
MJY+K54%U2[3,7%P@'&^-%@K&1N6ACBC;]*J$48I8] 30/L9\_I9U>:ACW33D
MP5KLX_PK #AC/_ *4/O V95]A8JS)T "N>[%$K<JSF3!<KKO[.W4U;AJRI?<
M4B?7&^SY&!%8E49$4E@?T*_8VW]A>(S>E](T=86_CX)K0D@^X23X;#F_ZSK1
M1SB/:&H8&1^2*"@K6$Y=6E/MR)_^@<*UE9<WT8E^U$XM+<:<.J=%+L[Z_&_]
M))7?[DS+F&*L&%7O)39PU3+<?SX=CQ^[=\72D]!51[=8D_^!41[2)N;BB<#)
MF3IC4UA.&2_*3_>!+J9JCBQIT8C,J3KST,Q9;NV_K4X4\<VML$#PL,H>25NG
M]SZ?LY.N]NN;E!V7."@JLJKXW1INY*L<+3%(:V&12EA,51')<-><-X*LYA(Q
M2\HR-:?U6P^PI.C]'GR%CGY4?:R!FI%->/;'D#""^0\:X35<N+=TI/ID);V1
MT(N1N)YU:O7E2U,%_"9:/AE5;K86+UM##:Y"9KP0UT<O[L(6Z%FSO/P\IG^X
M]),)*6C@$]P$M4ZUCM'M]JKBHZU"7\&U(%W*@6\GBD%NND'ZE-),3GHNO!%P
MX@TT?=HAK73).I@71!H-:2T5A<YDY3WGF.*O (8/?/LS:0M9BV;+LO$8$2.R
M/W_859(%Z=]E6&C2&=56!RZSJZA-4B,QT;J=RVJUE1^X7J:O3=&M2MV-1%]M
MU; 5FV0<W1S)EE/U6?X)V'Y064F@L:*K7%>F\%))WDQPGC*,D55?6\PL+EO6
M&B(4'E*("^_DD+L_V$AG<0R\9$I,F%PMPGOW#9XT) <\$T_T-,W-NP$[5#CR
MG+\I76QU9@C5,:P5_8GH]CA3I,_J3FZ IG25([U8]$9&5#"@"?WJMORC!#<\
MC'.%=Y\7 <%NYTJ9LFBI\!_R3UT>]@OSY4VSMQ9/F3:Z9)L<#;RI-RI53?2_
MH G1O.+WL70*TC(M7#D0[L?=YB0\3-E?$O1F=RX+Z@B-E;H,>!<(71V+7#(5
M<>?EV]H]FI0ZVQU_7\@B/HIGXQS;UQLN/G%OM]-I1^HG"?]H5U0*>XR8F^ZS
MAQG E"%,,T7ZM3!Q\P(%H?]3)OX]X>/ ><>[R'*W?3^/CQGXM53J?"O-@/6U
MQ$5W51).U,#"<Z7TIX@4'%II2?+B_+R<MIDBVL#L8N1WK9M.P)=/TW6T-)L1
M6U01HBAEW#CI*ISP@R?#X97GEH;>W3+H3Y#8J]P7+#/O_="7>+$_/7^ZI35?
M(/R\<X(GI>?W-V[W]UO5%Q[E7O >YIO+[4/L5L*.B-%S4@%X>[6'?T0HL/!V
M%<MX_+Y7DM1+SA;M\H\/BC&#%9# SDN8_ ]("27K1+21&L%TM1+E4@X*HHZ$
M;Y3W^_]LKY%XVF,V#F.%A%95:24.0/:;<'76;*Y7(2OO-3KD68G[Y'1_V=[/
M$>S7N>=N=H8 _YPCVC@X#9YQ+0]\OG[7GE;04!'+-]J= 3:[;:&!0Y@H9W W
M_:_7Y^?UP*-N4+&R99'8%NCY+H8*'6'O+KK5H(5(0)O"KP#$+WTR(FHFK,N:
MM:[?]WFY[YGO":Z1RX'4C)OUNAGJ>.^@'K-N*VGNS"T_3A=TBNG33Y]R\7-<
MO3@NK]" =PNT)WC3:/A+*]@8FY-':&^<Q TE5.VBCVCKPUC%<0]W39U.Y-Z5
M+] !3:7FL%-E?I93-)+OQB8(7)O@]<H/X'$C9 L_(,6 "2VQ)*C[_BIA+/_U
MCR]\D3 F&#<"#6IH0I49XUE&O0 ):>/[S%= .7 \WOS&,<!P&?N'N$:[J&Y=
M?$PSR3CG[*]4T62YLR5U3SF<6,HVVT#3<"$E7]OU5I')9SHT*RK-4+KX@Y,E
M(<_2G(1/SP7VLUD=0XHS$J[;DKG*RM;"Y^"EAFD]/Y0-WH@=I:NF=0:.=6[L
MTA(]O^4*H J=K.S"Y'PZ7KX]]YNOIWHV"3TC.B.)]T;$B@$HS,Z4DBO-Z?3+
M,6H:Z,?^_&@1,*:P6.F$,*^*DAVW0Q(85T4L8^^T'*I1C. QJ&;,763:EK'S
M='[Y"G!P* >2R"2W?95P#EX9;VU@2E_7<<9<B09:56!8G-,-<OSVZ9TW;<>9
M.VE?5TJ>L]8:,"!B&HX29;35"E/%^K62:]<Y7] Q>W96'K/^$2=I<Y&D\]EB
MS\5<5R3;X+U&.IM=7A$Q'DN&OU++/&.J@WX@(774L+Q^:J';,HY_SM:)#:(]
M7:@HMG(<7N[_*V8C,87XR3(4J%M,]H_QEV5+0@?HR,IMP3JM$\Q&E&^.(,]'
MZTA^4OJDDPJ9.%9P:96U4NU."4]A L:0!Y)S=<$_J-)=.,MK1B++&$&M@9A7
M/9V-7@%2GK"S5_]XC92&=Q(^UD.SB2>P/N= T'G4T?,E-=78+3Z\JK:JL0&&
ME);]^W8%'-W0U07[*R!<%2N*L>PTI(NO1)_KC964+AQ6?S+[.Y'/YP]N:E.G
M$&Q5>>PHJ)AVSD+(:XB0AT;S X +*?VH*=4P^$%BT?T*0459*(B&X4JC#C"F
MQ-RE56J)X6I1)6)B-"8SZ](,/N&/C>XJ!]AYF+F>N_*H  XZEZT#;O(8\^J5
M>U78J$V$'94W=_2W9K^_@ZAB'Q-&JD^3[A ['I![:;>9-RD&A2(76QF\[1)S
MP[S"G_?@O3ZE="EK9B>VO.D8RVTCI!HVRJDDSUWX?,64Q>QAE,K+BDJ1BSI@
MPY[F');6T,)S9F$[SWF/-5Y]K2_BIF;CMJZ@$GTYNA?2BW@QD19VL[6M,G!M
M/NWF3_!>L&OXS'I.78WT2H(OC%B\P,7+^7S3J8"UCJI]Z8K8PH$)A=RG>_'9
MN;LLX_ $#(+O1NCG[JJBIIL%@Z!$ %I)YS;P_(HZ8Y50!7,XG7F]93M1-<YU
MI^' ;@(?>0E_'6\A1ED3V1]3EDN'N?454*FM;:IA?M$&O/V 0=,B"E.+)EQ.
M^\#'9DQ@SCI:3CVL"GX[B486C'TBH.-RS1[(ER/"AV"ZR)HA9E?%:'S2'@P8
M##%*P4T<^0154JM>FC[4X^94$:],&R /((85I2Q3M%.%7_;A2M>53'F4;JF%
M3C:DQ7,:,WXBG!U1LR#@CH1;EN/T<CO;QGL%^+S4KT[@B4<Q_@"KH6O\04<:
M=(@,5>7826*H$-'G@=_>?;97;L \F:U34/P'B8>($-%Y1+WN22;\QG@LO5*-
M92C_X@UI( A]DS&!WH/RIB \!M2,S,P_ZSES3S!Z]_^P]I91<6[+NG"3$" $
M20CNP:&#NT,([@X--*Z-$]PAN$OC[DYP#P1WM^#N[LXE:^]]OG/V_<:X=X]U
M?]08S=M-RWQK5CU5]53-'C="9'J1.<<1AG@/)X!;_2-D] +R,<\D3N6S[?1)
MB<'=BEZZH#W].&$B2TWB&F?2<H=+:+^809T#K#LUTL )>97PZG&-^"=G>@KG
MA73-PV? ;TA^F><O&L5?23KZ,9L&Z9TS@O\ Y27++Z!<<VC[(127_M'V"3JQ
MZ/G/:UW+_[HV$'*C6EB#&G3'K-&I?0;3^ RPNYMLI,2ES7^TU=Z4=PHAFF77
M/O($Q;^@]TCRORZ*>Q)M\-_:GQ-8%6LL@H=,L3W92/U[U\I5@5G/@-ZQ@F?
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M"D;L'1J_RYO?Z7\^;/CE].M*A=C#IW'N7-M7U8H_@.YP_FA^\-43)^NN$N^
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M+)550#F5>O$^3#:B"LF5^$'U]TH9,!)P<%2EZ^@17+FB%"_J*A_Y\N\(+R8
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ML3G)!-P?M391"&57I2Z.2K6\ $@ ^/&_IE#!$G_P8:)AMH#A^87SYY#DN&!
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M>^U5Q*1VA_BK]N1\3]S9M0BM#BNR6BP[_1/VAYY6EG6#H^Y /H)G@.E(YC,
M8A9OQ3NT;OG%B<8W5#]?3G9="[,X:S=I@YS^4'7P"6<B0''_6'%.@SPWAVW,
MNY(,@:-'4%'!:JEQ+"(Q.R)"\E3U^TAJCE:81)>X/FQ )+=QZZ;&'5&G!=>3
M</6D?/7],'I.AA]E*V_ =#4T44:0=%>IAA=/8CI[OD ]FU^>!KDTO:,4S:;P
M0?A<(^E+M@:!N6T/"X3,LBR4"4=&,%\U/B]@31:Q/EWPI\67P0^-<XKG.NXN
MJ+D6)MH?S*UR)7EE*"?*9<9JY;Y4\*7Y[FN>M_<OC$YY:J$DJ,B*FSA<*))&
MD8?R6)8%1/;;(O,U2/M$OZ"*8*M+-,]&2/3X11^]\4+'^\*-M,O9J#3J@F!?
M,RKYG3<V:PPVY0I,<;USJ::"+(UA)O*KC!AO$+H7;,"0TIV/N^R9L5AU#K>:
M*&G=+5P)IV3%01_4['_AE )UUU78#E2(/M#0[1=H/ -ZFCV/@J,CK1DE-7(-
M['YD!4OHL(FJK9L2^<FII>N"A58-K+ >Y)IFL!,_'\S>,J%P$47J[R;M>U!
MUD5/FG^(]!RR>S9&Z-X&%-[91'3'KZ;Y/H:LBN5$ >J;.LN<A_F_OW<-G=!
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MD7I:<S5*[M]:=S.YG &__/?33.*\T(('HU?7IAQ\SQ@V/#",^@9]1/2G6FD
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M+VG)W$R(QI)]P0$@4E<??626\.>P.=NGJ$7=UB9[<]J)>"D^X,>*J18UX'B
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M8AI7;ZH-VX])BQ[NJQ]T\0=.WU$LJ+@=WRBFPVR9XF&#8N%Z4>+]D&>(O7O
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ME1[-$\YW1?<ROG*Z^/J=U03Q9(WX<'2$>JA!%2LD8MJY7(Q BE; TQ+I> _
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MO6B&82R$""/]JD_2B_@2[IB:TYG87WI$;LN;4<5(T:IX^JQZ!/.5TI,Y0%.
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M^%8G!Y^V'WW-%^J<@7K0:=3*VMUUYF.$]/&6X@2?=-D>29@;8UD_$4^AQ7S
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M2L?4UZX&(7C).D>NB%'GJ(*/1E!]R)2\710JZ/D^XKD3&^0H+/@2>!%D\W/
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M0ZL;TH_Y#[\21E&;7/R$\O#QQNF&Y49]5&K18Z:EWE1<,<E3!L-3K.<O\S$
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MZ'*7HK\GF5T0/!8+TC%E-09HVT4+_?TP9N+_,?!8Y[V],@9 /^M!Y^@8_7^
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M'K84+]0G]801SWM,.,>;W[E<T6NFW$F:'S#3%8.QH#^\E[X(_P;7;<( A*!
MH87G:1/R(?WHNV[QY^$=R(K5AF;^%0K;M.RVYMB7=:Y2V:XC:Z2 >X)>/(H:
MP50#W9[=GH:^:4B9=HTB3MU;WCRA_FZ5G"Z-<(@0WI7F[^*W(XV:N*MK]E[
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M].\Q+5].RZ\W"?20[C+0XL$"U:*]V+GU:^!&R9LU7T0[O,,RG&UD6XB?J)]
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M_S/+]LGSP?@4Y<^]1WC8*"@^>K/7)XP)T""+\;H%(.[8'^AOF[^7T!J^-K>
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M'(+3]A48M\UP)JHZ"*A/K%=7Q84D<AMF'X_RS,_B9]8)*VN64&1;!6+ ?;<
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M+<K=QH-@"P0CMY\LYGZ*Q#NHH1?0V8>YP'P1C3MZWE?;RNM3HK<Q#ZC$N=#
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M8#:B*T)ZSW"'2:(2I;:@7$<5^. A, D54]-29E=29GMNY ;5XF?E&L9[3 =
M+>'\42O&C,X6Y../"4>*1^N7B%-F(L<Z@*3-ZBO%HP6.<C7?V?G)H*8D?BYQ
M<MQG GAHO;F.RWO;5)/-OWBJ#ER^N,8BH19F:+$<^\O$':J$>;M4;88F8T$
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M\*$;QS2,O:[!RF%L=*1AF>AJ'!?>U9\ "6D4UN:R]#$M*ZH?0#0#KSPV5X;
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MA>>Z #" 1Y;$E\$]37)7\3)8NN@@Y7N$(C07?^4DPXLG%#?8DLT !Z?_\@'
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M@Q0P!SO2:JA8/MX13TS'*$$J21F$*%^BI'3HXVJ=K&1WB#*3$]6X "P\'0Q
MU&#W.W5+D[6^0O5\)=HU(_9>#0* HP1IG!%!U!SE\<I=ZZ;0#C&!I-MOVBI6
MQ-(AK'C3M_[%<]]NMM=R1$#BTGE<9F^]G/U7S+T*@9_]&M(4.8$[/V@G\+PX
M_2J<>5=YA5.:TLW/0N=98G.?PB4CD@Z(M@W^E7()_R%XLDABYM9BWJ"2QNUT
MO_HQ;FU4'FN/%7OH&=G] NWGZ1I$K9]\0_,DTAFE7ND<^I9&2IH0M\Y+8,>%
M,R@QO/8A;''U[E= ::](&Y:Y7@"@402?9*#&^]SI>+GG42Q)? GV9ES?DG/A
M@NAL-RI' @C]-"W6FG,'BJELV'F0*<5AU&O!>)+%$YOW(\E8<\[WD\'1=/KA
MIY\B='H%$>_\C%]X9'&,HHQ0V?U:GWXWL6^ >#(P<C$S79*R)U%\]Z4XCH^K
MBINM'S[T#JH$"17HCD/^J/A?P/;OA:>+U:M&!1+#&^FO)J"ARH" X(6.YJV?
MC:YV"'9'F]<#06E]^,TV/#</[)1,^0(0HHU#5NA::C"9\E@L^W-KSO>F70 Z
M\ILNK4^MU?&EOY'(BBFM:EOGI3L_D5L"5BO+52%W^$M'?P?(_>4=-[O_\H[1
M"\#-N"U"^"AX(8T@ND6C>SA]WKDI$LBB_4?#+B&\^B\-")Q<![*502T_]9R/
M+>U=N%"S]IJE)>V=KLDR)K4L_8[Q$CX'B!\,+]6*](F%%4U:ZZQ=+W[@"WN%
MJ)%#Z5I<4G@SN;,]<$\+,,ZC&Q'WU>;G#77-;TG:'2PT<,QP#G-6^*P"Y_VK
MMN[!(*2QAO*KI_V>JQFKF/#PKQ)R-/X49UV@<DNQTI2>:[^6!._4AH34Q?Y=
MOS</C##=B/"5>$$(]?N5@=&5/\8>N/F71I$-V3L+Z@9]%04N.@4"$,#&?(M1
M'-BR<A9:IO<_A?%O OU?A:%_>AB"/DUDZ?WHN'"+_V!.D>F'CW]7BL2KL[0A
M*9]+<T7GKW?<M>7&N'GCJN"MKP$V.V[ .J2N*5Q334VS1;?0?6*)1;E&NH!
M2SL$7O[K3*C\W0R6CYH%^[9YRA:I5*_\[7S]\=2E[VC&_V]"DVVV:@A63[;N
M_T.::P3%RY[^,;2V/X;I]-<?HIL3>J?;KJA#;IDX29FB[J1,DKK)[Q 3I.,[
M/F'CTOS&[.;&B?3TN*8$?H^BN4[ZGWUD^<F>UVE10+H162X<G]1,,*O6N!G3
MQX$*>ZFDX"_*@><T4?XMOZT8?+;LOD!D^/H90HRSB.M"=_&&\_YDWQ$AI*.:
MG_C7+/J5+"RHPK<)S%E;CW.O)%PJFP!P-_2J4RM;IL9DD&S\>8G](\_!I&O7
M\4G.]JCHMW:8DB@Q*SY1GD:S0%@VF^!2Q$8H3WU^Z%.KF";1W1AILM*-+!!I
MTZ?'RM:A[M\/\5R06YAS1 [F:$%Y0E</_'#I'?$[<7N\<V5^J+0&"MFQ;26/
MK<W,^ESN> 1\67U_O\^50LK&KHDU5I9J$J^$AI(#-T8*VE_OV#_!]:@OG1@7
MZ\JS!&+=.AE+XN"\)$GIU'V2L^SO!NO#$,TNCV[P>F>;/*3W7[K9.5_U5TU$
M#^$;WQ&UNKEY5^PS8T ^=^@G&P1IQP7@U@(N\'O*AB2<.\TU#<3C2O\:G%>U
M&0? #%,$\2">R#YDFOE0P/BPI2MMI@I_R$G,JF0IWCU\?9/ ':%AR4WSKEW
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M$V,UK+!6L4OCHN0 4_D? [:=V%!MCZ3)<5P@.CDR2&6EZ%O^EUD)] V"T06
M$M%\?5E-1UJKJB1//T6>\C_B0O_D=2[^X3Q>'N H[^&VD,;3'N);Y7ZD=4ZC
M:H63']T_E?6I\QOXBQ4MDH/Z-_*C1F9[IU5_],@QE@8QH-G R[3BLEL$T8-'
M)(](B[RD.2A]I57BU ?9+XV)DK3R!4"^K$WT L#8UUS3\*7!.; T00]F**,<
M+!JV =3$BG=FD@7YQ-SQ?I*KD8SJ!?5\8U 4C]VP;3S80AILF3X*:/&S(COD
MB0E2.KJ]W"Y$W:^M*,,36;6$<OGZ$VWW ?(Z83$8?&X8>7?R&>BDGN.+(7]5
M=)VN6LJX2-T6-/M/C\7\=\#>F5@M33M5QL)<-(]5<CB\,)A<RO3,W.'X]?<4
MW]>RNJSSVT N1TQ@-\NCQJ2M'D9\I!+X,V5+W*D].VLZX)7_$6ODLP&1J ]6
MD-NFCP6)#WY4:H=3X1I]?N%WZR\ ';*EBS?4J-9(Z5D:NT'1T00ZG'9GF-F,
MEEJ)?HI,S[WV(]%?I88G!@!2^<=$$W^[H0=P!;U9E&^OD.NMQWZRO1_K]Y3U
M!5(#>&]12L.- 6^(O0O[_(S/:#!\AF>O5.6>G!E@1X0R/H062WYJ:CZK[>:^
M=CU3]^V3X$;1V2/80]P4:N8Q7D1:Q>6F4NDO]:2ON>UN'P"4:\!X5/S1!%ZP
M>+YY-\"EP-[-:%KX=.1:G>B'!QE_W$P4V=RWBF7AA&>L+K3/L[A,UUT J)N@
MAU1^G"-[3W,IDA6P.[%H3==]]7&;#+5*"@[/T/NGS/N6,OYR'>0/15AC0SC&
M"CPWG'K8!B<6LX[_;1_\74:;Z'KZ&O!O0X"  [-_@K) _RE$;2+(?OK5-\3:
MQO8PT-M0Z>O*CSL;>!#N8[Y%N^0!-2D^.J5R/"N__KT=QH79C;'!;'=W89ZS
M&%N60R(J [>W/QD?I<YH0OF4N7])2,"N83/BKT6B26N^+:R\N27^">)E(?&A
MH4X"JI]B&.DC+>K<G*'=Q7\[.UEJ6PDV-[-',%R?OXG-Q5*+MHR];59(2TJ0
M<>[B*</Y#[0*UG:27!7S!.&+JPO,G)Q^'PJ_@-W"C+UGMZ<-I@S(?Z>'+ VZ
M_F<S\O\*C'Q;2@8_KQMGW#UFM<OR[^?X-=2Y92:B0TJ,2K[J!&'!($I*%IPO
M ,X9&^Z9)#=/+ .6D?0A-W!YL:^6(L(]Y=P7\(:!CV"OIS/2?&R^!KA(VQ)?
M /QDMCHY,+!NUBOPF@W)V(DW[Y=SW^Q< $*AV7NY9!< 3"%<_P*@U'<!:"._
M '0;JRQ"H[+6HJ2560K :*]2^=+^EWMQ:VP)RVD6A(_85?,;B.'N+(XC?0J&
M40:/"P"1-++$/["GB32.7;]H4U"#_5:,R78:X41ZA/1O7>,KC%BW\&?*:#E:
M<[G3R08[.<7);4,T: B*IHP&WZ["*Q=LI#F9V141FJ[3U' 1%Y-J6XR0&F,K
M0W&6GXD7?O:>']758?:FS:V(-JCZ0ZROU .[;$+25Z8))6AH7*98%H?LO=8Q
M[V%!X,K.NS);4HCJE9;P'5U4,IGKM]HLC,GWF'?/A/:((I?F0]FPR3%+&%@4
MOZCI[<986>5[OPY@=+A@+%D'Z%DF:"&&_U$VL,73LKO1C1?<5#*.YYD6X560
M?H7ZL5-'SN(LFOY!M B-[R1E8">NU+P 7(>$71JM;*LS=*@T>P?K;;Q,<9 6
M]FZUEW2Y/5A8Y-8#CB\<A_?*UY<]'O# YEZE /D7AV_DXXVP4D"'BB8P9,'>
M\=4#(:&0#6G&HW<  %'HXRMDZ\60'O_*U3U[_RGK3(9?7>[.P\D1(6S4JEAT
MLL*1_A^35#@JSW*Y$*[;=U&>LM)=SH+V!8#6Q/=4J[D0;SERQP+14\8^\\/:
M@THS B*9=>3T3W\.\0_@NO-P*[?CT6!^;Y!!_-MWW%]V*"V0>49T\;5&R(,;
M%042:=':Q]'J0Q4!N:-3F0@##X%L7V-94!GO6BH"Q1D9]R.!GFJ36V.+*4=R
MH[(JWV%9?S1*>-=PJW>2M9B3\4O3I/!L$.T2/5Z)J/YC4'/#>WLH7,;Y"RQ;
M)-%HZ?G$:_BWU_<HV2?\:+=:67"))9M(,F?WJ&E?"<O>^VTLD^LC75P\&EYH
MX3<0;R?)]];^!!4W93:1.D00YL_6*O\5('T2R9I)=(1,DP!5[%UR=X.X4(M]
M#T]GATBI9O G>!7:EJ4;>=\P496BG9(=&4,6)3J"T_#,Q;5P/%?5>HD15"L5
MO<G5OYO3:I' 0L-,->PAS]"TD%27'.,L&A6]N#[/U:KK)2TG<0$(.ZC<C83>
MJ',C<\9N9>5T/6YG"!GXE/).!9BS]6N[DK=B:6^[$ATEB!?,U3TUF/C[CL8]
MSB7^US^*^P?!S-]E15Y<5%B'YR;I_O)$^_B]SZ!_2[",B)HT/TT< _UMA1V>
M#KC^XM8Y(\$XCC1K<N;QNG#"T8,&08.Z516D^]$K^NZ1S^<49CE,M7I/8MS[
M/2GSRD*Z_1+.,\!G1\XJVAA$$9@YM1*>TDZ=X><1=HI\D-#$JBFM3,L*4N\M
MPC'U^(&VD;_X[B<&??!:O;42\WVU^10+C;3:$QB^ %A0[M/^GH)I4W(^MH1"
MUVA>J= L:9I>]ML<8O)G+^;_31!EHMFI<2#\H-O1AR[>)FIA.,AXH)4!VQL3
M=,?/AR6QT*(UAR?S3&2DOG^^]RIR I2SYYCETGT0-_#NN47DICR,RVWZCKP1
M^YG8!2 B^= :[T"<<P&(W$4/G]+TGN]SXHQU%UGCS"X <7AMEH^E#@_Z29];
M/Z9L!T"6[GUN/,_#RTIN()<V(_#.X/8+P-W:8?HMCXT,7V./YG*!@-LDBW>0
MLA/_<2&%_VOW XEHBLFK4+;3\=)<*LHIMA[I][UG^67.ND1Y<Q6.R7-B5Y*=
MQ@O9J"+&BHI>+^GVJ!W)>HWM' 8SHDJJDTR6;:>UWVNSQE0:8]OB'C"DHMZ!
M:MG ZL>/P@$W;'1(+>+V=F.S(-D>;K25%5AI;*NE<9V'0>%&SZ;*!$KXIO_T
MYIU\Z$<$CM00CI"6YG.SW7^X;^IGS7S+V-""M9,!G=P1'10GUM_]%43!XV3%
MA ,Q9'%.Y-\J(9UNRA/)S;:/CN_41-LS>H!D8]9+J][@=CO#JL]+Z)!9T_&Z
M-5G(;<%9=L7G?FMQ=1(M'W]*RY@$Z3HOF^4W(K&]T07O>Z;?FX>U;YE1;TW;
MB%F]2=V[?TVX382K^Y TJI()R&_%KAZWVH:2P:QZG!>Q(K,F"'/CRC$MXBG!
MGQ)VAVFXNG_W/A%UP%^^T6'4 HGGA#!?4L#8]Q;!3JM0= Z3069_;6N<FEP3
MI4BZ:FM!QEVXX<JUS+P:Y4?^1>5/._X)\FS_(UQ?B^+Y &18,GW@49<2I4 ;
M>\F75"*;UQG!YSBS4<2CYOHQOI7JY(%FU;Y8L34O7WH8A1M3D,,M#U1FC_^E
M* (O (D T"P!@$GO"K& L(S'R!VT^\/$,*;:UX->P3&%;&JOW"N.IJ0[(V=5
M-DRAF"R\HS2X0V1)Y@)0,X-W]D,EAXFNXPU]T+NT971[$<ME<@(<+U-E/[T.
ME4GZO_9(_1\%\5M<>M6L8Y:%+^(K_7*#Q!/)[5V@(/ G5O@95&]LJ>F;XJZK
MYW>?F7FX$WS 6%RVF36@L_7G9NMN]T063W/,@XS'Q=Y)NK&T6L24H*BBN&G'
M@E35?#_5'HNPCF107.-A]8Y*ZFZF>[G@)IV'J9H]\\ZW/6;X2XRF43G5KSDU
MQX=C\MM7[6\MNI/?/"?1GYHYSCA)W^C^E:O8Z[#.58M.H!'4KST0J>,JW?"H
MO0!(:O/TS\\#O>JE[3YJ[Q7NX0>C[3R:F75+-3*W;Y5T/WGW(K5KY7]P]]Y1
M3;[1FNB'"*B4B/2.@((@H/0>$.G2>XT*2I,.$FI0!)1>!!2D*+T$I+< TD%Z
M1WH2>I&$&B"$R^^<L]:<F7OGG#MKS9V9=?_8?R1YO^][]]Y?]GZ>_3:>)[=^
MRH4^*U!C&>3O84YY*V5,G.A@N4&SZA$XQWX)+"_8:-MW_+1ZYL7'8G668$WI
MU7)K[-4H7OHZ#87FDFC<$^<?Y:\S3NE.P$)=^P%^Y_+EV?HJ=/92_P=DP/^N
M&-"$:"Q3Y:<T++%MT3C:D$X)P^?>C,R)"O@S VB\+K95><0'MC-GQDZP"TIL
M5* #39.)+V[+7,2^^ZY5LG7'[^UH_L$6=(BLJ%P8QX$4%,<+7S3YNK!U[0Z4
M$O=*NERQUVFC2\"!S7@E5'-$\-.27-@"F4?WTK8B719ZJMQ'+M7"+<(N2?L#
M ?OQH>(E '67*M?!@..\6UDW\U&]7\I>HISMI>T46M"+Y5#[CEIFR?"'AS-P
M].-23H45IC?[7J?3<3@G4LSP+K5OOED"6_*(YZCP,[^ B.U!(.#H/\L[__\8
M*OD/A-C<^',)1>@$\_J>'$WVXM#KE"[BI$33Z&D5%:W(E+7/VT8%I3RC&?;?
M-VOI!]U<')E5U0:R?4K[ F\B-PL.+'45=7FHPALU'TBI;+Y$?X+3SR9-#ZRQ
M_%)@<U2^!.RSB7$!)O,6UI_ILU[%SHJ',OZ)Y5^EG>"J?9)YO_3P<_KIMWX<
MJ&/,RB^_C4QZ5L;D<PO;V.M*^KA7U"'>5MYPS0=\*MZL%<:KSH.;:YZAR+V(
M#^F$;A#8.U/@^0:S>>4Y4V54+V%-"B[#9X2J5<[D1^P.2A#L'_"&R,D5<4?1
M;?X:UCR(BTC@ALY*_5$R5N/D<#K>;)UH/<]'&"*G\7%:A)7D81-JP[ X-Z%.
MXZ(/G5Y]3=QS/5?!N:QJ_7]W:OM/I4(.DJ=1!E4S&N?BU/ B4AF&NXPJLA-A
MZE Z7Y&4[# J:-) 9=JL"?\N"^MZ+7!<;.$S'JB'FR8M<*%A$_E5(B"",;[)
M#;8XEO=%+H4A-'R/X;J:L>;GC15/@IO4!QT=;)C'Y,0=CZWO_Y:%]O7U/ S.
MW7>X)A_0)2,<+OBL,6-'S\6Z77Y)FKU_"N&&3+3"#:.F\M"D:EKJOGY^9)3)
MLP!8QWD4#\%TJ&,S&YR+G R?R7V@_I(4LGS'3SY@VC!G8XJ9*H,M//U-O&6W
ME#%;4-^6-@#YS]+*_ZNAE?CX[!1.HHDTP()?N$;I$I#/N01:PGAGLR^!S'_6
M*#Q)'K6JW-%649QV)QG^EG4R4BXW@=<M<9Z=2',-Y5>B>/8TE3(ZX.CDL#!#
MA=;[!2:I=*%:Z^VPQC\+[5.YNUI8/]ID&)#/)%?QJ'MZX.)6K7LB$"K.\,W'
MBV1F,YA>765-<<.W_@P08G[WXX3 T;\QC?P<_Z4?'$ZAA "U2R#HUMC&RDKJ
M2Z<'GQYZ!O68G#$'B;R96K.$1FAJO_).0<2XI>?R+&>*XDL,$&IHXZB-3,X1
MA+53*9RB7?KW";">U1%YK"UQ),XF,G4LW.!QZS>IORN /LJ^/N$C(,\_^'>O
M[,X-FI*&7\6^[+RCN]Z%-=)[.5H/U&\^D)/P-_T:Z-":;C)Q"";]4^CHQGNG
M5]D3V G.7L?DXO[DM^4'BHP=;C"\>62M?.?=!ET8X%^6#'><7:BH'R_+J?_(
MEA=_*/[=A@'S%HF71U-J=7C:*7O=;JBC@'VP+Y@6WR*(3$UW+-),^(BX8]J[
M%?QKI6B!<UWZ#=/9K&.?VAR*5#_N?I/UV.K&NLA#;:I5ER/!)P)^YKYA7GWL
M-0=+'8/WM451^6$/2[LMMR4;W6$?*E[$C36"(J<DSE*[(2#SA9XUR_YK F4>
M\79.P!$$9]9"<PED3]9='%E:N%;E;V']&H-V&/AE3EUO<NC/-D!P1C8WKQKP
M7WE^^A)@/@C2U8I#UG5=L,O?4HWMT.= 5%.943WRR@IV(-ZX553D]-9?)=UZ
M2>>G8@')7':)SSJ8I74E;1$VK4)0#9&5Y^Z4,4%42GSUH^N-8SEF18L70*3P
MK)FZ%+CVH>[78/NI-P8^\E&9H4?EL"D?OL,@Y@/]=';K:FUN^Q92AVM1N/X.
M[%;KG[BB=F&Y-H;D3%_V]Z5.!)XQ,1K&B;V7M2)!"^OPP+I7CAZ7P,V>\!K+
MG\]F4W+8VBOD]7H!@O$FF&47U82%A D66(\,>K&ZMA1#KNN1Y<+:NS!9%Z3P
MUKWBD7$YP^_;5-P_)W;SXP]5XEW!85Z7 *803Q-W>JW\X@*&+1?'E2PO\/[*
M^B-S$B$Y,W^1JSJ:^R&"D5<NZXT>&0*R1=]H_2W5M^JA!'9_:('D^27P7^Z^
MWL)CK1&$L4']U?_$6QVK>O:-QAP&(C!#=4TQJE^#@O(>UMUI+]U;>]37,Q4B
M3Z.-M0DKZ5N=V4H9Z_7GO.I+A,6?0>A2+(%Z,X69I[$U+">M1[_*D)-:<PE!
M7,<;N=U"C\MWHX<*D3<A+LH8'CW347BM)XW>5F2KH351J$%E,'146:H4+]TK
M65#H52ZZ&S=!!68&9GX@Y@QPT\@8L)[$1IWDHQ*7@"\Y%[.9^+2_WBY.'9!Q
MVPFQN>3,1:4.X:O,'2+&5R;;!;Z# "/-M6L&=CVN6(#"3Z'U2^"6?1B!%PKK
MD@3;AIL+NNDNU#98EP9G%!)7_RC:LDC.3'@A>'31KN3"V*^^0.*'A[ @'M_/
MY13P3LFKC9J*/H6@S_3(\O7-TB2CQ,"W%^9G-RW>6PV^(?JJK_L;I*/>AA<0
MZ+P$[LC)(QU;^GT\7R.Z@P>OI< PV53M:7\KOML_+R;5X 5,,QVRF (E2[;(
M7SVJ'U_SI",9L_4 :_;@UE'.SAR@MGSE0C')<76>/TS/+13PL8\5V>'RN\TU
MZ=;]_/!&H8/[T)XR)T%)H\JIARG[[3Z9"Y^()C#J96H=P3R8J5;,)>!LD]>5
MD9&K#PDLDV#+">W6U9E4B$.!2*$!;0E+FW7.5&%KG\VO2;,,V_S9563+H+/H
M/ILSK @_'M(71&RP2[(QLH=7+77)B$ _>9.V0';5M%'S C1UTU(]VXHL8J8"
MJ*R/S* /$:DPKY;=<(-93O,Y_/F46X3"0ZAOI^2/?N]:R6?N"=9"8Y> S@31
MXO^J^@[KTA;'Q;C- \PV02WO$O#4/&[X;X# H"7ZW=]5R-_Z+.6YC1^1FW*<
M_Y)RDKC%JJ_NP*L)6#P0D7?()OF7;RN/W*@=96C:&Y-1EDQ#,R?$!QR_3-+B
M?]U6(OM."U0;VB5PQ>0FO"^.3M35[*W"FGR"O? )<H:QIM1F?\T#D,#V;(B$
M0ZD\1]<95:OGU)E-'MU H22=GB<92L SY)8 N0$V+N(P1NF-<(W4B\8W+[D3
M_39'C#,@G18Z88Z44P4!; A1MHHFXG"I83<G8.)'@S#.O(7J*L3MME[L+R$M
MTG0C#P7=T3H3N^MO+D9FW'H/KERCKV=CW?;"7GQAXCT?E\&^]$:Q3!J0&=EQ
ME:*SMT\HW?*V]*T&0N\94;_#1<Y?08SVB4!;Y 6OGB7YK@ZCZY?HIYZZ\C*W
M6@NWZ9EU,MWVRDS(]8@.&%F]%!D*R[0(]&ZAK1NR;I= 8!W.N(2##0<Q^*;L
M6#HG]P%-$GG%KH"-C7RQCQ5,Y)0A]@J3_1R?@D$F_#[]@;&@WTM(1;97=(,S
MN(/VL\\$[;*:-\,;&I#UR(W)T,)7G$4;2LLCUT;_6Y^J!PE(ZF!)4TNLK2QF
M%GG&+1^;)RC]CO<8!!Q'GQWD' 26/Y8;L'^-_.:/JBK 4B4[ERKG#OI_@DF>
MU:M+NVTJ,O]7Q30#41*#SF6B1%VGX:JIPVT<;^;4YJOPA<C?6U1$;'Y[.#W2
M&+JD'&BJ&I8LS;L$5Q;X@_C#,-/95 U :V*2CI+G-4,T5(_O&?CM5JQSA7X>
MACO]VYQ$K[.XF$#)/.N@M!/3VEBWOZY#8/Z9JI::"<&I *V/ZY\B0"S7^*YU
MT=D<$\9UZIRC^C\NAZD)<@,"W#K8\@AQYR2W5R5S6I(GOBZ\FYG51*TJQ GJ
MZL2\T7K71LW37%OSMDX8Z,^"=GSOS&54%MNOBM];K"B869HSM[;*-660WM>O
M7\ =[BHR;/QGLSWR-;B46=1WZ&CMDF81LB:XO<+A8BT7Y."-!246NCL5TFZ_
MKI&M*[)OJD!!>"%=5M@(''^5%1IA1'@5+/B3G#9]5K$#S*[6[K7(01N0,!LB
M;_,_I_I1.DRM[.&!W,:Y*+-$O/OP0N>F%*IZ(W?R]X<&N[P9C!M.%?'B*GJ?
MM)Z<7UVGAN>V>70)9 4LG5]]G"Z'_CK,(1YK()2PK]==-%N><I^P4P2*HO"L
M<XMH0N,E<+0MTJ$]Y>IZ/[SOOB@W-5=NN@Y,YDS4X;",VP8C:N5$6>0P?7]H
M9[\-:@(.LY<3KU$S89'W1#CQE-=F?5T[L6#XM N?U?KR-Y%3X>6!!WZK)?G'
M]DEMR]MTRGY%'5&672;\]@CH/4*E6+W"F3E;(GN_HD*V!#'N/>?"WRVK931'
M:WLMG]'5WO>'4*W/3M%^3XI!4$K$)UB[.!IT>M)\";0N_7,$*Q,V G^^> 5>
M]@C- =UD>8SLR763MO,HPB(<GW >)XOSS=U^RS =5]PCP\WUX0#B/J1[!;P=
M?OVH^V!DG+""\@!1ZT\DU@S9HDA#.3[BZ8K,ZN\A<KB>>S4$O\!76,6U<5"S
MM%X??/%V@'<L(U'WT4&L[N98L][^XVV(""XSH#R"70I+%Q.2_&,2V<ES^'"G
M=&D@,H>X&@<CPL9U7GAU5>TZ!TB>B]?+[4M1@(G.)B^!N'GH_7%"*XJ@;6W:
M :$J#T=0OW!0V\M5$LN-9AOL(]O\9BJ /2<\30>?734^%0>>0RM%D<V6;<'"
M*@IF3\-7XOYBW^&W?^ J/'T*1N0$7#@%B^9+GN449W-?/_=TVHOR%BT/9*7?
M9#]%UIA_)RX[8C6EPT1:#C-">YW]XSUGC2,MPMW0;^K -I^)BOQ<:UNKV3^Y
MAO#WY.\"5%(+9EF,O"UUN+KO_?F_>!&6WH^?ZBZZ/?XI\/VJYROHZO(S#/A<
M_#5>C8S D!H.V_X,.WM<2/P,5X)"7\MIOY$;3;KX+>"H2$X L]?)G!7%A;6/
M_IOP]\<:B\,E$()FC0V-TSS:XB,2&")(POK$$)= 610^QE_0;[I[Z?1^*NQH
M%):0#9*=<GDUKL &9>BJC3K?E>:F4-RZP3B\:EW7%62_2[@U7KV@H'?@G)CK
M(>+]"NU[4%1M?1L:L2R?\K7[U'OUAN[KN;9R!9SEO;U(/"1W;J'HG","?EPH
MG\5+B4,?9I/;2(__& OFPM&WT\VQDOY1O 1JOTVE]H@WP&B@UF\6[FS,<X;-
MVPGLG6H<#SUHI0.O_(2J$9K:+H$<_N%NMU.V0(Y+ )( V_@-5)6J8=/5QU:;
MM2%:".HR-%US96J/U^_(53Q;C@W>: +9BI7\:/OEC_3KGXK&DZ&^5D2GIJ.<
ME*UA4.'.(*IUY"40#9>S_WY7RSSW$M",?!QV_:B7+0X"!WQ;&;C4@^FW$E2_
MZW,9Z\D -TJ6R&$KWZZ,>-0&BR\5_F@Q6?XQF +B]%:'^0'2!(W3456;,(&$
M!//B#-4P)NDO HH>^MYNIQN)C: EVII-Y]_TO==[BUMZ$+KW*RKT!7+0]7AS
MX.WC9X.(0\;5UF>&"&>LCO =QR0HK%UBVM37-ZM1E/^%HD+$5%-YQ")57(?"
MC2AUQ-,4C:I[8X_F\[X :O)JM$34N(;EY^Z!2FX]Y\($NK9 !XG,NXV8R#:A
M<ZVY/"6N$Y,W=P0F+@$D*>:[M +K%:;!T(';$6C4$4+B*KR\?U[WB2M,_,;[
M'T+78M#9V2#EU'9FMM;P^^,TVC7[)@NI]^GZ9/W7V0*FTP)IZX/ '<&",7:V
M;!F=F7J\LNX%>0'R>WBH%6SZ/L$8W7I]ES!MBV:Q[4GWWSQ]ST?\$0.*\184
MV=.?/!J\<PD83;CF/ZS,)>?/YOE&D4FIBVYEV,B\Z\RR2]8QFY]58JE3RGLN
M%4V[EU%0KCM5BV<KZ\(TF4S(R5[A%_K!?&$W;QK/L+[NH(_B%66!>BX0HZHQ
M!.5+H8)$_;4AS+7T@'>*="WWM@RA/];;9NEM&&O40#(TL?4]!^);:FVSY Z0
M/X+YED%?>JJNW<W,\)I6.&K#6X_X<%0X$'C&T0>NAQ%+7-V(>(\A^8JSR7?8
MCH[6&1O_O ZGN^X/CP.O(G5[B/25M9C=QP(=4?TD+OV "MF<1TF5VK(P,;1<
M?]+'VLS)(J.-;&>LD[7G<$M >-EX<' O,M#8RSU/Z-[3UY0S*5*E8+(E7$!'
MB_!4#K8Y1%)75LS0JI--<4C- @A%F<8@P"AG6<A.,^G6T!I3!WE!G5D'J'#;
M.K6KR=FOA=$A-5&)QBHYA"GR&HY/1'2J 1*I(%V!O9]*$OXN_W=:4/7WU?K'
M+A!%LCK-'0*?LN!TVR"7V>W>GUW7X^J^48;HD2GY%/PQP[,EPP4YZT0=*ZK#
M^=KW9-5XV;2]LD#>ZG@5#+.UX) <^I%AK-*@HR6N0!/+T,[2ZWUZTN]8T$/;
MJWKK)S&>?_K758"0^ ;K=P1G $8X410-[_O7XWOS:AZY%3&3]7RA?]?WQ9,P
M^5.ZMW']$&S-A%J?WS.3@1Y9_[\<"72_\1H!>R30:4LMSK6E3OJ51*F..JL@
M49MQS$''-K+U^HP9X_$SPX&LA6'#LUL )HX"UZ]>B\VL*(.&JK=,NMI]+N62
M>AI%3R5#8ZK B1ON(#P8HSD7Z/#/2(%?C\18!24;,G)+\WN-YSD[U%V]Y\5R
M+L5FVRDB+4G^!#O)F^S+#7N6[/=QY6[0GYN$&]4,:=%C? <41 FJ:AP6P&$K
MF=.=K4SJ<:$U4W,;$@H.Z=[EI*P\5V-Y/JL8H;G==RI],<^^FP(2TJBR_^_+
MGNJ.CHE>+$33M)3L;F@W#JT7OO?3\^D.:#Z]XN;D4+)QR]UFL)#(KSO.O:GJ
ME1"OM,6O2UWZ"26+Y3S%KPVOFR>O&!4]T+F(&ZW$D]R"OJ(M'Z@Y4'B'R?ID
MBV7_<O^7QLAN@NC(M#)$QB%M")Y37>D8%O$%<$MR1]6V(F6P]B?#%[BRPI>I
M0H6G\R9*8*>+SZG"Z?+M#1S,N%]0SX6[(61-GP.S#_6WG(=A2.E_:P\SGZBA
M--FQ<KH77?_K-SJ2_Z4;AS>"7NF>N<R@U*FH-L(719\^>.Y*Y163PY'LS_M>
MSG5V4\)TS@2KJD1,U .'-EN-[;F)G:\T5/1FR+SPLCK<UA1IDA]X:Q@!5RE4
M43FT'[6(P<N\^C#M5<O]R9<9"X>@)*H"O+NG]-T ,'\A$WXKM@05=WLK1=O%
M?^"%7"U7EU>R#Y;*0DTYBK_OA8:T:776HK=:#SLG)ZA.DF,G<AO/AJ5:VSJ3
MI30K\<MZZ!E"IA".:(0[.NR5F)<^3Q&]__B([AO_H(:3/^- %;E!="J_C?T8
M*N5''44M-N*\3=7)XBANR*)*;ALM&=%:BR"7[]3L7NOZ@-W=\N@&6XS@C%%$
M* [ \:#"]N'-%8WZE42$/;:L96M!"'Z_#M;$10?^6$Z#TY?&9'52^K95IMZN
M#M?RXG4O(#X8<J">Q5M/7P(_$21^JY)G*DMG<L_957?V%9*C"J !!.KA$/]D
M1%0MROFF?3IWQD#KA=, UD]!'->?B_-Y*Y_RI27PHL-3\L$)JIFAYS<-<A&1
M$_+P'@#[I0T$'F%65S"MG^3D2\N"!PL;J@,S)=E%KP#.K;.,%3.DHWF(BD'G
MN>F0Q.S#M*Q?/$UU')LR07T9C#YZ$BG@^/(G4_@W$<NE%@BR-],I[8OBO&L/
M@Y4)8D1H&UY0F7,BKNS)[_M3*6-B\K<*6>-^-W.@>RF7XZ@>;+CFD!$N:FQQ
M2RK,H [(]3\_V1U;S7F>2[_\XQIT"H?%^5T"'U@Z\E0M=S7>70)O9D-DFLF1
MJ1_* L$%ND))+!KWJEW7Y37TDZS 79#KCBWDU158R8@HL_DN]PH1[JPL:>D+
ML$5S[O8E0&>H6JEE34I69W;[:0]K&2E(5],NDQP[W<FF,XFWY)'P=VGZN\^-
MC$-&<\ !_Y.(HYOB$) 9Y'>3#8HD(74^<@ 7=@GP'$"N@#H3[)#&FJ2:VF).
MS>U66*SXK6)9(JM+H%/XE#>3\]]^5^20#Y1*U"7')77,_B+;F4UB,>U#>Z /
MYP6V_.ZI?W<T0])IT>P(K#.*F8L+A^C;6):?Z61YVC\!?Z#,BUL1&*E98B[
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M_IZ/^SS/ G.#&0L#>>FF.SDB*Z$].YY*N7\*4M_8+3=1$?6,2Y=MM_O3)Y=
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MF>>Z=?7)"MLR=I$!5U@F%;,D_UG0Y_8U:4U\?YRR(NMTE_5U7.@O28Q:_2#
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M@#Y-R-4F/M<@ VWW2*QAI6L+9X.X7":OP@YR70ZLNT)E X,?![T.4^5=U_2
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MD:F><%-\]E/68 ?8^Y"3[EH'P#@B48'E4J.^I*$FS_1ET22\:70%Z3*T</F
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M;!%*&C+*D"ZV%;?OTO'V<1K3)SU'KHVL6) X<:=0$<V&I; DVT'IC.#SN5[
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M^#4I9%CC9*BXFDYT!S 98.LCB\5Y;$] .ZUU!\#Y':K4CH-=;24XLIE8.*A
M"$<JUVV\G:@JUZ*2S]714>UM+=R1]OA]%4&D-I9?PW=,&?D0@YI+W>+V94WY
M^'H-G)F]24[$"JX%_- _5+M2U)\N*.LC[2AVDJ;K-TS&<@?X]'W@UEU>94ZV
M3DRC[";?X-^<ZY-%1MG_3/7;%"QDCGR"'UF$T]K715<;JJN5HZIW%.@YG7K]
ML?-D+Z8SFJ&T>T$>C'G9G/CL,B[#O@*MX7GF5&BCXUXI*]+3UV+P_>[<[XC;
M"9C:UM,K%: 5I']7>Y]6Y65"-P_$":2_[FR6.V"C9#TVZ:7;U85T,J4(=M P
M*QC,2PU14UK*KLUXXD$Y N*:,(/+4<*Y'_9FL O"%'C$\>"LF0$[4 MQ#N!B
M!_\@$+#'FCPMYN[KG.M_Q$(5HO:&,[N0)A5MXMSDQPB)Z4[>D9&:S.9%!GN/
MNAE<URM&L?8QC_A;".3-F"U9MT>&5$%.-B\ :98<[?E$B0/ :3'(YR^QXR3^
M."NYUIQL*\[S<8F8(*<0U[F&%/K(]JZB>% V[UA_DQQP&8S3:JR29T&5]-RB
MX&:FPV:)9Q>NNN?YQ(_\P3<?X!>S $P.)B  J:X^@B8-5/WOQ@-MT:8U$9Z.
M2R61W^WT >WF"3=L0S4.X+Q0+P=;'E[[!MHKP%IC<D<+P848\4)>Q9I7M_O,
M\5OT]ZK8(H42;J?,G?0VV(J_@&IIMN)L*DUV49^:V5KO +"DGNK+,J/Q\P$1
MSEF;@Q6Y;+5PEF[+18#]$L:);]EJTI&1^B3DX@.Z!;OR\E!#$4O& ]B?\5BE
MD_II'.14-+Z8HU^FFJ,V$YMC_ 94X,+Q5(N?T9@\%@;8OGF5M2>HU33AF9!]
MN<X>]&6=0O.R5$/GVLCQ9\IT_6,49]IX2G]JU#CLO)X%/?HD)"#CI"]A32^_
ML3GY^-L=8"RNZQ8CI'-,UNW11(+;R>^^N)_3)M( C^J(D_8M$6V*WUZZ<>KN
MCTVEVK=W8>?V %(JU@E5;!J_>]G^XLT=H PJ%N]*W/.'":!X;P(LW9L 00"@
MFO1?P 1$JF*9->17Y^8J67]=Z@BT&FY9Q9IT=*@INRJ>V LN+FS+A8 [>P)&
M/*><\G*+!8I'PR_BR++FFH*3'C4.X<,$MI!RO1OFX"U']Q)]=QA%ZG>F\I52
MJQ'K"R'%3:RE#[Z"Z*^9R2P"@]SE';L.WB2,=%*\5VAHOL2&;%^DX^\>?G 0
M%,>H[668JK>441U ^DOL0SRI8I+?G(GANEM2:7'.[<@%D&+0NNS#:]94\"!0
M3^%$+N&@ ( Y:>E/4OH:@PKZK(M68D7(^#.=\?<H#F2-U*YV3LIXM& 5S)*<
MVBA7X@-?LO,5$682EJFZ WP'28,W8PEW3\US_+'!2JFE<?+]F/D93N3DE+NY
MM _)X%I,!P_EJ8YA/*NHLP&[C87&1IWB[1,#L5O/@1\PL57,\3O =DG+U]*<
MER*/+4KM/E!W_;:M.:.LN:&M][LY3SP#^K7CY6__MF[)=9&$B:1X84_M^W%M
M4].=3 A"VD]XPZFJ4R:IK%[_PIM'U/=N2?>M@_>(]+H$ ]A  $<T(+B14Q-I
MJ7#.Z%RR*<%3E/9!G=5(CUK^47"A'6T"R".F1Q(X9L27C_2I&II3.0W'O004
M">%VGV)%_"ZSK*##;=T&<V=^R.;+3RK45':0)<B[+OK9V1W>MJ81^/#00.R&
MF83"0V?8EXW_!MM\L_3'QF*D@[(H1B5Z:.YO5AGPNQ#M4JR<,C,GJ4[\%\=,
MRW3RFI_(=B&>V+",\O&;Y-B#E;BX.%WTUQI^'@".:DSVQX)G$%'J$Z1@;DR:
MF\LV /=K?4KW!0G!K,&!WI2W@8U'OO!+.UV*3$H-9#HI9&Y&&O_70$';,-A(
M[R2^.34?U<DMQ'T)YHQ;^:5W* @*_1#-$Q[-UN+U[=T4WJR1'KG120KT>F<Y
MIFBZF;<J84QN?8GJ2T!;H=\J>D4/CZ+6<2,QU [*6,@>%"__(/FRFCMDP@-9
MIR)Y^H:/[R#QN<R[68R-J98;9G)??H(?VL\#5C^#A5QCH51RU@YZV*VN;X=3
MF174+JLY:R;J+NK":$+5O"6OPL=('[:2B?6CCAJM/C A0TE]OCVDU!&B":FY
M]M_]E3R S50Q5U/:^!3ZJ"26O9)$BU$]K-C<5*&BC55F&V13K 2L>)8@6?0K
MZIN5E<&IL,[)ZX1#^GCCSD!II\MJ4>\*D"WN<4VNS?X21<@;&$GH8ECU0_H\
MSERD(%L/;C[%%U0JM"Q<]$TL9U=;&WW&.!C*P1C=QQY.]I"&2WC\(I7A%Z^X
M:A7.,V88(G^&8I916><=R:YNC:AI'E>'H*"U'OE$^JRC'ED.-]DK]-KS8IU;
MVF=/==GM:"WDE@,]2B[&>?)$1H<V?3+>(8QVH%;$<=E<9[V+/6^F0B<$4NP3
M.:RH&13[#LFQ8[3I\59BX'K'A#D_FQ#?;&AA=&< %3!618:L"3A+9JC=VK9W
M5[' W<,&I6@EEP3KYY8_E-Y[2KK*7N+\L8<$@(:Z ["UW6O>6+%K.=_99A4&
MTOFXJ/[JD #V:K_2.'# '>#A'L%3/_-$OQ>E!UI]DWLFTL:IATZY][>LJYS;
M]<.7^,OG[,O2<U_=/A&B^7'(Q.!.. #M'#-'Z1R'/YNPF^@>]5:BBC_\EOB(
M@3$BGHR9N.G>R!A*_SU]$^$$9PZAG[ K-8F?U6;PE[:[ [1CF]X!1'(*0U 5
M*+]"UGV'&E%P1>S2:_%56/3C1Q_<O;J>0D>^)2HQ)%H'RH.SW5:\Y! Y,<^C
M*PL9P'&KRX^DBKJ$AHX:*"QZ/&E06Y3:>+.O$(%^A-G[N^X(YNAL"D>_>%.C
M/0W]I0&V81;M=[+?I"U55F?63Q^\!0F$AQ]UF1I!?L=>OA7GUV[M+<G;T]-H
M>$0)BMT\<"$GN%]6%=]M%:LBMY^C6E;YQW_3? >'9;A#EC4KB 89BHE&M.^E
M2H+1V9S"'/5THE1@RT13=M.07Z<OK8&RW.T X^<B@3;ZRO/?,E9Z.WD>.6SY
M*15@OTXXHZ=P10G3[-OW<;K:)"W63;#',NL?NTQ$?9U&,RF%,MT/!+_?6H7U
MF>EN=G Q;#' 1D; >>-EGQ()>T=C>AGA XTUO\ +Y>$W)>+\!7+\?5C9<(?X
MP4E<,/1[:7Z!Q%J3J./\VYML9IBC>U[;P=(&UTP^-NSL87XLU3S!$BEOL1/]
M/"_MS:<-V/P^^TJ"FO)/GBGG1;-YS8!<_]3B:?HDD](YRV>.>NW*Y_M='MU)
MB$5HM#SE0S*]4FB]605?LN^T0F:8SXK79(G,M,!FO)CG,L-T$(?I#J3!<BI/
M.RB[K4=DW[!>0\F FG=EE5.;X]XN2:(?E8??FU'2_R'KA.P_%_+@NM$<I D"
MRTI*X>D^9*CIMTJ\EG8 #P>NQT(ALDL>IG$&8F%^&^J3+?MC*K\QIC^Y<[^@
MJOZ4+VG/?F7/L^0O&@5$K8G*=AG]V&NYFKX#0*(8ULINSHU^[=\!$.+4\W#(
MR@TF35BL5]FU/"FP]7NYG^#QWW4_T:-:[@"Q\7E^T\CT_@;<]>,[P$8N-/WB
MD/E[:?N?1D]8B6IZ3&6)&6G^8<[QI94V3,F B*40Q-/W0IB/HU&")(V1Z;V8
MUUC#XK,.DGK>O+>IL[UM?6L9IR*3U5\(;^:+AQX31UEFYU[O431\7H$3AO<
MIIZ&TX$H@:LR03+UJ5^SXNSG&ZIY])NV(PYL;'/\BPE#,*:&% 2KJET8,(]Y
M"K)1IA9+3%53!MDA]-)D;><(T$#! 8*Q[LM-3*D2[[B.E!8#RZ((#E/,.Z6A
M5K1]0Q?$/N374F\TJ$3\)A=;37&-YIE$X6Z+N;\@EXB3GB?V9][I<9M5N#01
MVZ%0B*=SQ9/P7REE1#C#,3SAM].GF)6)T.=:1W*EV6V0BZU,!W#30IXDE@0]
M2EBJ /IDWB?AX/!,)[!87_MCD:Y%?><9EEF(+='$M&^\\5QD[G*"7EJ%:E@O
M^<I\J&8_EL(TB2]]1RQFYLT^UD!G.PUA7T$?A8?CHURGL?)(<MLK7A>U?5YM
MLSC$[-Y.]V3H_%4E2+D<FF]FF3JB!H,H2.$^S((!RBXI?(YNU8\<@OGW58*7
M0!8WM=%L/W'AL?'1/Y)'(BU,T[AC63Z(2.3"@,%<E);$LN*LYVK&#3.L5%*%
MVH"/$^JC;UZKSDO;-KP3]T\+S,V"L3^ZHB.)#KTY)?_QM?M LR3S2R$9=D%N
M5@2VJX82YR!N? #6>$R/9YJ>A3E D;Q9\+TF$ED2,LC< %(RM>-78Y2;H?Q@
MR>)<S$\&YR=6M'<OGE![3STF#]E4.=@W8NG:R&MWE&$]-+==17^=P[S8NZLQ
M-FJ\%8.1$-VOV4=>8=00,Q9S2!NK%9.MOGNE+*AYKO:>TWR!2_5W+ W2X_;M
MF5@3# XS3I:0V$J(#7C2 <5X/$QI6;(H1V5IR9+A9BVCVB]!AHV0QBSAZV\G
M;7_@:,_F.Z&.U_#6?TYR/#3<\CT5!>6D+E*/+)=;WC8W2EW:8DS-I+#/A;ZF
M&C;'12E'+&NBO@:#L"O:[/4G>OJ@]H)J/_-3HS#(J8*0[6\S5-<S$>00]B3+
MG-A*,^MZZG3A;IT:]>UF$',G.?!1;N7</,%+YSE0?@9,&2<1]^RC\G:BKKOO
M&7>HS?!"[Z#@"P(#O_<*A];>(PN>T_DVV<2QF42HK7C#_/1=3ZW!YC 'NJI'
M ORJ'2BG5PEN?,/U[N%>$5Y\_%T>=X#/2!N(3JP'J?P#0MGRDKTQ!4$J4G:G
M>)WAB>+,:]A/0,)H%M PYZ=FI?O2[P_V!5\Q O0/<YL&.\.K5X[04SPU,9Y\
M(U"UMZ*QXHW9_:W\:8]O=,G"%U3;G#JV0>]?AU55*FSC1_7M<T&RUF?BP3F]
M!7TY[06^%6Y[2VS\2NZ:)6RX[YPKO8 /@<4=@ %1<XHZB MZ+UZ;)Q9Q'"P>
MP0/?5---QA7("'Q,8&DX)Y,^>^UUX+9$?2HRE5_@0504U.T(*L<&KU5/\T#>
M, 7U\Q^!$&/"FM:KSR]=DY*CF^.;V*:U8S;7*W=E]">F0GP4WPK*AMI<Z&Z$
M @LETKPF!M8H9.!;HDZ  1W)6-0PTTA!*GQB.JNN]L;4>$]^0=0:36/9/:N_
M6V[T[,S?_8!E6]H'@C@T]>)-*K4T(ML]K2+XNIX/U',?:C?_(/ &?V/L,F9N
M_6>NE=&772=IQ_7N*2SC6IN<B]($ 1*YR8F3#GIXK-=3]0@%/\+RVW-MF=RR
M>6@-5QN?X^\>RV]QW9<@.M42<1$+)]AB/#Y8M[B+2HNXWZ_=Z4-Z[:2O'Y%N
MAW&B'Y?.#JM33^UF$(**4JD?E!S53:*N)__J&Y_K1?%/[3JL8NMQ^OCY"7)+
M:!P;,7WI:+&TL9Y[:?_>#23O(,[?4D^,$&)HR6%.[19Y[D3K[AGF;*,&SRW8
M4]U-B'#@<XU24.+1"-% $76-\POD^UC+,M9YU#\K&%2=<'G+.R&3+,9C_"[)
MIV3^K12PDJA:DBO*DS- (VZ67%/3BA[I:WX2 V]-[+I4,Z(P>Q1ODS.RD; >
MQ#HLEYV34W(HJULSCAB#RL]MX\'@:[<@J^?U3K_*&PKJGU4EOENR&#1]]=E&
M1TEO/)TC$J2\Y%P;P"3UO;8W:X=)64W' @XK<W.ARJT:IFO/Z"LINU9@_V8O
M>$2O/<>RI6@?(2!OP. *&YP )_L(T$-#?Z^V=EF @E4[FIX1?8IMH)%^OBK-
M+?T/AD?1F3M/A6^?3:R%XO5>CK$5[,EKZ ^WAU$T";7U/=H@P,\<[E_':J!2
MOG ^Y-RZ&*EO(Y+3=&L=]'A[O?].T.*,X)KF7E'ZBWC"OK^X-IPR.L=.OOUU
M!]A7NP/@S0W<^I_Y+?O]M@1<S$'6A8G7KX4_@-NEWU]N/<%AGQWRPSW8^2]4
MGS!6"W0AK3&."R^_YRO>&1NF*%.]:QJ5ZCKY^)0O @#XGD6AO=)BDD(XX]%4
M%B::Y"4Z\;>E:V:5QGJ/F<JJE!0=%6E"6$*X4SY.L3PIY%4P!Z]5<!IAUXPI
M?+()&7DYINCANQ'V49LE+RNVDA+:S;6I1^VTIH(#@4*@M0$IS0X?(3\)@IPO
MQQ&E[\.XRQ?C]@WTRWL$K6.D7F0"-Z0C'A2T1_IKLJDI;SUM'P__$<N%\GLT
MNS<O/"(AX2_M,&<78C,<:E8%9[8 >N? SOOM$@)J,"FB/'>"9!]%&+#4.'UI
M/#&+(TX9PZ M(GSD@>2+,] G1:Q!*42 KF4.<*8TDM ?VJ3@"-/5AD?DNB]H
MM3F0%[SKGPO)]/MSF;_!9WR#/ECE0%437P?+2&P1=2N#Y.T0J=4E.V\O!ST2
M0QN5P4&1+-D6GZP=W5Q*/4%)V4FZ[XTE2 6*\TFU&[8F%(GPOF<O_MZUC(SG
M4<F=5]AF[\4ISBJW'.I1=Y,<E08&_W/DXC\+)BDGW 7Q4^KPAV P\!%?ZNC@
MSA*I ?>1[K>&JW"TR/ADAQ4[[BUYDFVTF91W#=9J:GW/,D<I#2P&DGB^CC:R
MU;\?9GAC9-_--5:@[TXZX/H]+)#XZU\N5)SMGJI0)--5A/],>6_X\&TI1IB]
M*]HX<6+)M;H5_Z=HK*2D2'$JT.@N;J  ,)5TIM:,>*(N65C=@JG:)TZF=^F3
MIEE#"\E.36(-E*.$;@*?TJ5$OI&NL!O61VH='I,6WR-(J"*UG/E5/84HN8H;
M^>M7&$YX0L\6 U;<X16]?,JK09:.:9U5 ZR]I>^ZG(>7I0N/VG/NO2M;O^J]
MQR.9\L^NC" H!>\\HNX1+<.0QZ3A3U2PP>#!B6EE!)]C<< YHM>;M=#Z1Z9J
M?T=A<?UP<%E^;5!&J.LGM+H>_L)+]8KB[A$G6=JW<8/,8_4"W@Q%)$SO#--0
MN->*6MM<+]"G<L>2&AV0Y(ND!@+GB)D;Q:+N@J(>RW TF-P-<U$5IS' O*Y,
MKKHB6,AB-,N@S=X=P:J1GMD1T:TJ;Y'C(9I9L+!'%,I)>H0.RS<8#O4&.W@4
M,"8X<+:_7"S&OU;47I"-;?*Q9%9P$[2_[J<>M YGJV(Z^ [)P5]ND.J"WOM[
MS,5W@&',FWW(>L>S])D*R1C6KY0UO-D*KE3Z'_ 0&OPKWX %S-@%Q5."N9OA
M*I3XDN5;R.EV^%=DW,O2-1DLJ\R3HR".ZN27=4&OHT:>:I%KU*4Q4$C%9?.3
M<C(%KIJ%I[^D#->L3JPAJ4F'!D4EPW><T_&-.,LK]25)&*TWKHKO5W/I(6H<
MW*FX$6@/[?[R.8TO*"WUL><O_8D7B)NP8":<8?K8#DA+A7^'=2>GTUC#,.%.
MWJ\WK%:$/S("69O)1N'=K;D+BELDPPCH0?YPW<#%''7/R@]*SLR292.,9_CV
M^0PH6;>B)8,NPC<]UGZN#2V$%DK>T2BD8ATEH4B1B)-D[%;_),>:0:^."V&N
MB L;Z1Y)5+WC[IJ/ELG30(6 \+4*0RAC2G\/-U&LS_YTYOB*(CB\LPXO,KY=
M:37L<BK9&B!I1'O9Q3J6%K1:@7SQPK5;Z1+AY8,K:Z\\(0"!V[BII0T?'*DD
MR BZEG9TPH'3":Z[4,(CC3/7XOK@^&V+" PUYA0-],CK_(/\A>%]I V-BZU'
ME=$""C87ZQWMR'8C2C])7_,VV[1"!NU!/8ZWD/,M9>3,ZV9WZ_0\JYQQWEY$
M"7WHNL&JQ]KGL?@KW)DYRI9'%\);VYV"*9>#&$/S%*72YGA)\0R %+K^Z4(K
MP3=NGM85TH0_/GDWNI4:>'-YENL6ABHR;/XX5'#.]>G/C,SL.YG9+D/IS8\^
MJ67>^(7*? 9S>1^A22A.'3]V'2()/[3Q'2#T_F0[Z/QRMK6B@(M3_+Q(,]?G
M6Y&IQ?<7CMMI!,26!ZU.T[]0.]6<WV>E&;,?#\2R+G_X>.OQ8E/C,3\B\QG5
M[/8[4'MN'8-Q;DXNXK'J/Z +T4K#Z($N^"4O)8K\9N;<;GY(W0&\<9ND 6JW
MW>,MV_TTOU;4^6+RBN(N6=S)?@66C3/= 33O $=PP.;-JS41D,;4B_-?>&+/
M]:1"*4@7I^KKO]L%+W\7=8_[?7HSZ#GX=X7?GU/ ^CYW@)LO")[;IIQ;K9E_
MZRW+PR L@)S<>^VG<-_I^J>,-HZ2\^/<M^^??E3)\G\IMDHP6E-%(<T4J6SE
M?VJ;_#@5X:%=?A!F08M[,3<\<3YS;)/B(?=A/NB=H)9&;-Z/F&'U3]8+VOD$
MJT:$BW@QCQ96(-VI!)9'SH/OAK5TK.3=/O$+D'9Y- T'73SBG%O;6J'/T!@-
M&-0ZN?I,(14K\Y3LU>6@H/-\SM:0)]A<"9)Y()!5:T5 C5H\4*601$\Q!\\A
MDTU>1(:E:$,7]O,A/#J2 ]Q2%/(,F-)DC!/:B>5&DL]K8@P(R+!JJ8RZC[GU
M=1'5//'X2A*K?L1=.;,4T#57BDK<*<-)I[?;/P]$\EEWZW*+IMSDO:!4G<8'
M,5+X)Y9=UJ[,+LX<]P^B'<;Z1_X^]]_D!OXC0/^+3N( JJ*[C@;L*F?Y$SV(
M>Y J#7@%K 4B59\1V3P?_>-H;;(TZ3TCB(#)T E5='M6U[%1<9P >7_6^V_W
M-J8^+H0%C4L&DP,(^)I]?]^#=^$$]SQ#>\G2];=#IKSO$F" -VI_8^H_&/-@
MW:LA@D!U=)[(;BE1ONG]NB>^HA-S+W)[3Q-_X]U;2]Y@+^)OIWIZ\L*=[&J%
M9LPC.CQW )SCH);M2X)^?WZ5:UU1[CM YOU<.P[.J^GT(^.^O_OAK^]<5^0-
MR]<JWAQW +%R7\V0GF:2.T#ZC!@;8/V6:'Y/UFCJQ06> ,=@&SXZ*S5J'Q61
M[1XB/Y4F/9X?*1-U;'.HQ_NG-/B_ [2>_W/]0]"_6__P=X %^^O#8K&<\]SS
M]$XHF7<+-ZN-.]FR3C%\+N1@&"H-Q:V$5=*KJB]L.-OASNU('Y4QRI-Y: O;
M($1 G4^LGKTB.:6;IZ%H(&\[+;:LBL-L?''IT/?A6%\[U:L >E97Q4ES[4]6
M^EE5BW[3YXU'_*OW40I3PN"\IHC.BMFR%,UHS92M0G<AQ9JP-X,3.-L\-,T"
M^_KEIR3-W[*YJ3VM][5>H*ADJ-3,XC=TL2AL[<78UCK5-"%Q D7]J0)L"2(1
M3TW%"P!J([@N[]W]-'U4%!0+=0888P8U3L4^,XUFA6:*_QJ&Z/?);-NAPDV&
MG+_HI,Y>7V[I%:Q[.:"^HL..O8_/C82PCXZZ6 853=3+<&&G>,4%"%IHGG%!
MDWQNH/L1O>X[X]Z.0-"@M\3:;EDVO%>J4F2F;U_#W:GKV(I26[UUJ&Z.3-K\
M,-N+E-V:2EEJS*(HT<WL$9]BKKI"WDI>+=$IUMFMSQ0R7IIJL&B-3G%-A VV
MU<A3MK!/]VT$J#;:0+[+%J=D0"YI:;D#8<E*,OF7>!\3!P#XU\#?E_LC:O\<
M"OQ;QRS!'Y>5)0,S*Q8&@/RUD_#?7B0%6IJ3]3,%E[3L;4E&G#,0M]-\HB:C
M4NNY>3CMY69?71VG+[88@4?3:M8H#;8C<S_3J$^42S^X5!60IEWGSW@\<$N,
M'5Q_X.W7:/GB6G,)N!BQ_"KOUB_5\94O]ZGV1V :]<0SEYM.=A[T??6:CA82
M/)I#L<,ZI1$CGH$%W]H, L63X8^\+7CRO'#/<NZ !F;PV'3ZS8M3\!(J;QA:
M4+T_(#O3>7$'$-;)^+O!T[]F%D%_SBS^;7']A^UP;FG\G">/93VWG&T>*'(8
M'JVYKUML"!CR&$AD%2KEOE>$V:GG[)M;X:FPJ['1]@EA.NK\O KAY"3+_20W
MT[T"*K_WF'X.*4)]-SYBU?9<NSQUJMX)2,,"*5BFM'PV5W\U2E^=OQ8A;&%C
MGG\4?DY:#!%%Y.QY^C0E9$@I?"3S')RZ>4:=F"<R-J2;6"TX.?S8G6]NJQ\T
MGT1:Y=V/35H:*A-5-3+(^LHL,H\#6R$BX75-N&FTE2;F+-+4E@NV)FSGY9 O
M:T-<@B!?IZ1&H59!LR]X^7/2E,;,,>(&'>N%R[=DRC?#Z]0T.N<PD7#K,3W(
M1WL5"EFP6#!2CL-Y)P<^*]U&P[<ZJ!MFH O>Y>V@Y@L_ND"D!$S#^L:JFCYK
MLIZ=/3PMB0$:XY:W$4<OD8Y]WIJ4 9DZ_HP:JD+U?3"@WYCG/PO\8&_QQ2MK
M3X;# !&F77T"::\0AQ4(X588JF2[YZM6MTBP1[!QS6D53Q**CQ93<[.9@)DR
M@2"9K/',YQ:E((/3E'K;K*D*\8>&.6FH5R'>!IQE7I=0.KQN":!3\0S)\\?Z
M3<K-X1.ON'^05'[#<J6S]L'T^'4C4?^X52\<_?4VZ9$6Y#3_E#I"=6&AQPI=
M"80IO6?%(#FM7)C3M!&*S'/$1CD9TI]:/ZMW3ACI7JGHELO2D-=/6F,@=:**
MNMP,.?+SQ4Z^$ME[>R&D:T<^R8BE10D['2U2,)PHQ]#[/3<W[BT%-*2-_2DW
M XH,K(QP'I(SPU71F&0IQ;U:0Y-WG9]/S6[0:D+O)MR#Q\[)/Z0(P7!%$+^M
M,2WB+[+5+S@H*"AE^LZQD4@VDUMQ3KS]W5NBCO ER;Z_>SYKP9$!9"3_E.IP
M\8!$S2.N5HN9# R$(W+4.XB^9>:2J7B>11AU111#]_&CK>FJ:K4,%/6(5/('
M<9],G08)-4PIUPLP1<$\J1M4#9;:3 F2A3ZI:.AC^#VQE:! M%'MIC&<"@N6
M)E(Z=/=W;FPXZ!QF6\&%;42U1W>XC22H\N=T6\/(%I6BU*ICAP\5:5\&I$YN
MS87 X#Z$0J1K#*!@4U4]]Z2U40IEBV;U'-N"R[TM.QJ*M#B[TK>+;\J[!*O*
M&=%4HMY6Q3]__^4=3;,/J,_90.67F 9L-;JR*+[U:E!0Q$R.Y">OJO9&2MQ<
M_CYNMQ77V,%%A)A.U408'E2*>(]U="\A=A%5J8!?/&GUS1N$D,[6__:]^&7,
MRY<L89V*=F4J!;(X=-=XFL7%].M1RJQ5XVL3B+P&*\UH,HV"8I<-;5^FA'G=
MA)M.TKX;\,[<XVKX8,W7)]EE2QA:XT4Y=B%=,J7!31(>'H\B&E2$,"4FID76
M[(#R60N,7!VUY4-6,5/"1@[%;\'9G44E$L]#)\/=<&=Z->KW/!7WIARD,<JX
M/WU=)2@LSJP*%"3_#OIM=N]/<B\2U^CQK:==3%CX\KZJ&9V3?SQ)BTD[%F%1
M\XYUW835,17%P6P)F3GZ[Y;N7(W:<B=I11)M))5^.\_K7GR4*U[)-18UBX[U
ML:H\)4;6I%%.V&08C W8[H3M*42#NIQ!+T*7J,:[XH,B9R2&<./$*=()U?Q6
MC2T8 P9@%^UBHW)W -.?.L-SU6&G#+H3B+*C QZ1NF_O61%E-3>0V9J#L'#3
M>V]@_!KZ_7J[$R:Z$^UP#;\H^MX25/^X)6]?,/>RQMHD=AN#1F/0,_>_V!WX
M1_"'R_" (LRB--,B3WQG42*+E"&0"0;&A;T$'*J/2B^UV2@S]]1[7W%)L7/Q
M' JOU<Z;396,O\<3?)%!?+"!/F&6O)E_);MIH'E*6;%IN:6>[^;4:VT^10$A
M["R=-G8DKP9[+1.3KO/(] IYZ.MH//[(Z,L4I[[4K,?Y8*VF/YB4]NFQLLOD
MN-S7<:BM!_9\H]2^P\]Q<A^/[SAU OM332']*D<P8>3MSDW!S_Z:]E?2S?G,
MJSX/9L\+S!N1-- %>?;&<6]SOMP'K>S"K4V7.H8 ]$@6MOP"K+IUQMQ!DR(U
MA=Z3@6-4TL 2*/3AK>C%GNBS\BHE;@ID *%Z8SGQD+?4I]^EBS'\<X[B""H>
MP_&,D\* TGBSI_'S:4ZPW<*'0[AJD*\R*::OG$K/Z&JUP[EK&? QS6GP[UWS
MV9Z^[4WBUFLCPX]O)CYX53M&C8;PE[VIG+!Q(6T<T$V0II(3 >%.4%(7S#IJ
M+F(B@E#Q+3$8"C%7JB""SGIPE<49J4WB-W00RJ,4'HA&"6OK K_+5^".8MWH
MD7*QX4=4I?.(FM,HS(\[.QL1?XNR^@SXX<A?>C9@=!0I4B@9ODTY91FN-D@)
MI#_ZH+0ZR.FZ<!D3=[M3:'TN(MIMQ+>T^/2W.((<9*@9&:^ L]2A*Y6I389A
M_%&7N4-0_EWWD'!<W'?83%:<_)%F)IEM)$\7.16J.39K: )K271MRC SVZYY
M3,W&SW4TB@<]<M%J%!9,&3Z*=&E=RQQ32AEKEU3>$KPVDL<6,XVZ_4$<M79(
MS30F.VLCL[+<BIH9>T(1R*.Y@C"5-UE9?Q_)K#I"YX>;C6CF).9IW<I CKP3
M?>IF970>D;,1:=74NAO),O=@G5+S%Y-74B/E"Z?^&X&<7I>O&)>(S:\SJ0,]
M4AJS.X%R+MJQ(PF2WHU1FX9)%;)TTFC ]\;X%X677#.#QK3Q4?PG,O%;B_H4
M#79?F#&GFZ65K#)EO'6<B/2VELG(*)T, PN>'14 &W0$6H<18&FF=]D? V&R
MZ5!1RL_7L:M,U<\7'^O8KS446_%S$%D_+2(09[,'"*##(;5MLJ:6F@PJ[^*/
MXLT+5A9:8Y^.T]>5 =T=^Q\1RK,? M_DF%J>&<0SL)@$<K-\ <(*98A4I+Y=
M^-!U?\SYBE"!OPUI/[N>-,*;T9==XP]KW2OJ88Q,T2DZ4'\IOA8MX[_!,CR6
M.:KS9M.=]*R0\^,NE-7*M)$E"P;X[P1K2W_17DW+;+W6Y%'[VD.X4G,M69=[
M"37O*7-D&?E<]\_E-_XIQK4$49TCV @K0_919R!'@9$T&?J1+9E8D,=2YJFY
MZN2VE1'.+O<"=:"9NI]"#4V[#_>R4FWCQ-'F!&=C95=2L_[8#5D@_P$84U.5
MT!&;"DL)8.7^8*!KP,G%9PT:>N;_/6MX\0;43,7*:O&O8C#9198)<-%TIL.#
M+'Y3R@I>-$_8V4SS2W='Q4R<LU'YGJ^CT2VI;J[37(9ZL@[H(3")>&,G." -
M%GBT:</!5&NOT)T;B2VLDR[6K81)]65^Z8.RV$3-M2IVCIH^2=2ISNLIU%OD
M+_>CUV.4CT9C?H.,N@SYQH6?FSQ;,N5==C%5[SG/>)R0T+BWO(X5XN! ";)S
M)QM">UDM%N])_M)9&[U@$.#X:OG?D\D;_RH;\;^T8P.(_!??]FFC6M_5J!YU
M5EVJ3CNYAM["PN?%]W-Z'[L=#)3XI/'#'_8RQ.SKX/2_D/P '%TI!;@"G)\W
MJ;1NC2)MIG;Z.V_/'(;!'>ZP[C4125W?=N-/-:0:'W6$P266"=IC4J869@:S
MC*S\93*5EU]*(RU$==,0T@[4C-,H19 >*YT446]2C-RN[BW-J6VN2W&'G?W>
MSC;&N]H$:F7AWL5)G8J=<S5I8PL.X)>ZC >Q]WS+S1D$ NIRLO[JR3U(N'?I
M6+W^</7DI<G^B*/D8#C512[)4DG&@H;.:9Y8NHDR/1ET'B02>A22[WDN/_TM
M8)Q_(<>LL5J)VH#;*ZRE^G5);O6AL;+2!RV4623^^]QG)-4B.O;"H_#OI,*R
M[@DGW5>.MKH?N>X 9@W0&RT3SD2V#F>,6R/*,[@#@D1+V$8@NW"0N-_=5%][
M%&*U'ZVKPA0%MKLEHF*X]<74$;:VKGB".G(&:GDI]MK93+E3<K^29*.2U4*-
MK>MRYCPD7?&:-(!LE3HH;.XI+4P17K?(F^%=!O1U&2_NC[T((];>P3-.Y>E1
M"%%C(%LS(78>.G9KPBS^=AY%V&>WAI-V=!A1]P[+@WJRJLP];\R'8ZQ_W[JI
M8BJVF$(_*#QOW2LU0V!7VDF4:LKDMD.>LU2S,NIKE9/&':#=)(?@ASNQ_GY=
M5J?DM/4.2Y$K>41SKMWV//_[(9YCI0D710-.XM@]<5C/@Z*]:?!VU(M7DH?$
M031AR"1&S6?HC"MFU9,?:8T="6C'U%5,9'+,3RK./TU)'W\^/Q1=Z1!NY3_4
MK0^!E7#R[@>AZA[8I+_@31FCU]KM44Q5MAAT\B6?5#MG3-C;U)WX$&H"+RR^
MKN\ZWQV;6@DMEXS9ERH$EBIVMLDF595BBQ  40/N&KK!-G28@R,\K&T+"U-=
MMQ4?\CL-/2;=>\DVQC64]&NG/D:!!_%_C4VG6?BROIX\2CO:;$P4HQ7!=*N^
MXC*0K&Q?C0F6 &:#.8(4&MFL^\[D=75NZ<;/9QN+0R6;>6 ?\D.1\[.=+X?P
MJ+_\F#S0*,8X=#).4;<M]>N$ESA8C%-XY>K**N7#UY'+0 4X(EG%A2Z( 8]6
MA&<I2TO3("GBC3X=B&?":2X1W!I%Q-03;F)1^KEJ!AAHSV/0^4I5)9U-T]ME
MSDF+K- :JH"\__^"+%B5<6Y.EC\)C$?F7TNE_^L-)@+OY+,L-E1[._ ))$'!
M4[?$._"$7?:.67T7G=!R'H-CR\&F:><F@4N#I0XBZF_M_L)I9QVWHB>3R(HY
M0S\+2#P(5<=_ZY)Z<@?HCG:7/=3VG$2.R+/GA@'Y*:>K2PM-F9(-.":4'H0G
MXK\$!4]Z*ZV(O#N87:)P<W38LND1@P .D'9/=NO/GRN);C[O4<V/@635W@$>
MNLLJC-C:OG!.NII?" AZ% TJ_W-TLW%@[5.$1^&.)P_7$_T%WY/'ZU&G94IE
M+Z\36LQ/7X2\R%D#UG:\,NG->)S_]J0[T6D5>B#]A2V+"!D$^!A95Y+^Z2I6
MWUU8FH'HT@/"-)Q1FJ_1%+PLF;:[H4;>KB>P<JH?TLX"$</I8Z54M#^J.V)!
M'\$-5G^(0=U=?B,EFIRU,_VL<FX^ N;ZD?R[E>O]8/2/"RQ_R@21,2JQ0 'G
ME'< !4#ZZI3_N/ 20TN0=-<XT<,YK,EAXM!U!&2*X/,4AQ>%O)T5]6'FJ_>G
MABASZP17U?D,-%/Q# (3_:OY&Q&/M21VINKPO8=UB_07U+,9^"(T:S3!%Z#K
M0\-62$,*@R+6B,H$[!R=$4I]Z:*)+A3:^J#Q#K"&"$Y_]FGN?3!+:8+T]UD@
MR#SM:VF48I6-:5M"]5SPR;@XQE=^$19TSJTULELF:#"9VJG=<]=R\+Q.LNZU
M[8#$=5Q^F-2+8;OG;G4B3?MC+&@6_Y6JF]4B ]<S*,M@9O"IM-E[VO=N7:;7
M*K+)\I7QG,12#1L^H)R<(@U+OF=L3?U7]CU,R(!1O4T1:0^9SWS7*" ^&@_:
MS^G2^F-MC85W=52@]D<?ROJ\0,%1#N^I-Z;.+5FZ\LSY%[-+S335OXD#WL=I
M^E6?'\[[3I/XO,)-5JVQ*B8SD9D;JL5JW+]](J(BMH\]#09FDGDK=Z3D5,MF
M\%7E%_35A_NU!BG:%$ ,"3FVY1_NH94)W0$^$6DR),G^OM!K)CF9/(KQ81SO
MY8OO1BM.%80:R"DXVFFZXK<]J7H"('M>^0*U3UIB2RU4,%#$M_#*VT'G>,4J
M&2=3*MB9C6#5$.JRTJ2 YY%GCJE*PB B7IC]4/[7-Z<X/8;"D^'/:[5C5T:+
M,L\QMIDI=21L"B&&7&^9Y4E=-?X(MCA>O0W:K*%34WZL MGWYEGU.@2IGVW%
M;:!7[$.T<I5?54U\5E9Q0IGAYG[UQW;2[PD5EB:N3E%*G3"SF6D50"Q*8M>7
M)P"M>3C1RM@G;SA\\O220[]RFY=:LDAR>U86R>=F+@RL\<N&A \XT<P)-R=M
M\Q[C[INJC]\!_+B3OJP$.NA3N.NI&K OQ0J7-U2D39IV-%,V3YB\>JELHNH0
M[3GU/5M)>L\L'X1XG-A%35<W#K9X5QWC7?TY5N1'2?RIS?(-P_<&Y:P=I2"J
MR].W2W1CMLA#:?HT)U"]+;Z*K14_]*PZ93K[-Z2YXP)!)Y-.7\>=4A>E6SE]
M0-U.QM00+B#1P"ZX#F^P*YQ=[*O$^^1ZC@\:1#02%^I#>MAJ<=?MR0ZLK#IN
MB5K&75[7)DA4>*Y<E$+'\N*@\&['O<B-:"SY5FK4L'N84?"T8CR"T_27.#^
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MM9#=QQFXWJ*+.V ZKW.<]IA[)@_Z'$L5/B;?H6 @%Q1E7LE4^ZAA%Z^^NLA
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M_;%IYM>9]]]*M'_:,L$_=9D,K=GKYF711>(S)$,W"&H,^L/6U:TD78N[<R2
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M@5\%ZQU[D:8HZ)*MU<$F%%\$;-@AJ BTT%_U-NU]_JX7VBJ"!>TSHPF'(()
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M5J,R?.7#<F\>-I29$_')^QI&A]IR8AIUA,)%1;5E.L^\TR7O4SL5VY9TH\C
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M__0K;;_;)1_9H"D<$)6OYG#M]G1 /X85-.L\Y>([8BJ0*76(I38*Z.HW/!H
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M,VH(.WXN-Q5M8(<'7A;JX)"P6F-*5O2'^WMEL38SC*;^L<N+7STED')5<2C
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M+\?UNJA#'LF'CMUOFJ)V(WLJ0A>?;"]5;G++Y*S.VD9%G%BWACJGXN6C!..
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MH-/ XTC1QBRLO3AJ:*,QV1Y!XJ)(:T&FRP_@\/ZG>CD9#50!ZM4JUO?VPB_
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MY1?1_+/BUIC^;&(O5_K[N"5FN/2[187G8TZF'7?P>'#1\V:3E6]XQ^'>.?>
M-F14Q>K^VU^N9"^,>BEM+NKYZ>^6^E9U6NM^@21.EMNJO<IWJ>8/MWC2=^T1
M6%6&ZUFN(A-#@F]UV:\AE^WFJ^:G"&KQHFP-UT>9B[$)2RRO.!:0M=ON 5$D
M4=?;:T-E*AJ<">^B050Q,AD@5RAPW/]$OZ-Y*[8?([>QU]QF\2 #?.SCR<:C
MKI*""/QA_-.*IH^C'NR1WUJ#7\&,?T+C0-F5\P3A2E/L.QF-H7?IC>C2^$KS
MR&F?T_Y%%IH7ERE=\CI8<,CX(KJK9![LH: V\8AXRTOQX<9@V]1S&!@O=P-]
M"3B4+##VSY$VSB&0HI5OURZW'P^_KR<' YH>62&F3-#-LO PE.5#RUR$7I%@
M596G"-!\$#PY4+U5NP?$R/GN[U'<80(+:R=JFE_V0*%/I:C.S<312K5Y$R\=
MW-V>YA5'NS9MFCEG8=.=,%=;^5#-U,B;2X49,'Q[E-G"T7PV");79S@_\.VI
MBV'0"%.L%R<H1 -.%$Q_/Z2/= ?GQ.K -ZH>:7^S[AN:'V8N0+L=U&".J#'W
M^X8-!KAC=ZTA[>JU^S$?0O0VY>DD%C[LH2IUP HG(%+EP5ZFZQ7?3ZRYFJ0/
M46"?'&(%,P3G2A=U]766P*UE.-T8Y[(S #$$5=:$MQ$?AJW1@'')GR5NQB];
MK1 C)T4I01;3XE5!BFIB M08IBIRXP7(BL>GBW*4,[4A;T%8N<[FKQT"Z@&(
MUUJW/G@35#%FBE2#ADH23R$2MZ6&JJJO2OQRLQ[Y\?N2LH4:[2'DD5HWRRP^
MT3FK;DYOW"AXV88I2JI?38JCE%*!ZMZR;";:0!\UU-RBZ61J8Z?U=:E_AZ$C
MSFK@UNJ1S=F=$%P^LO0>\/:A0T_$MJ+B82SHLVP8EN&$!1E&,*@VE!=X\V=A
MBTVSOCN^!_1XO]]3E[''6P8RL^X@^"$*SV8&.RD6VV30017T;=E89VTS"<]P
M^##7(J5<M9N4,HL2^!(_C&EGQR#T*MO;8I:A([<\4!;VH@  !B!:;?+_"5_Y
M5[%_@!Q\_Y=VZHW>_\44\H^4(?_+V]^,G_]DE'>9_<.<H-Y!\2<\;^8_:HB\
MX,<%[#&"\^>;M"E-@29ETS8=LX$/5%:<!3?^UQ)KRJ_%UE\T4%7N%PVT_L5U
MWP#T&(H*,X1 >KII-#:<.@] A876HK]\5_U-9;_W8R%29-1BB"3\6>K^&NG"
MTM)0:3[OEAKV=9=@9C[  P\W(/_/LY'\NZO]WJ[V\BOV'WU1C?^-RMK;24_P
M5<]K4<LOLOOA6GV,+\'9#?VIQ&V"9IH2^4S#[WKS+@3$KA2-X5[W@).'KENK
MGME[>?2"@\8J(YS+,.F'>=+M3>&6K'.SL&]_DX_F'/&\RP_,^-TUTT\!/2F!
M#?9LPS\CE;2%H3F@*94L$<CVH:3IM;8,2H0EVKO-4K.=F(>YT7SA'C#>Y*.Q
M8XQ-?XPY4W!-.GY+]P!71'VO[@'W +TF0]ZS@Q]R'[3M#A=&V7Z89_ZZHA9U
M")7XYVP-YT>->V/Q20UEEGP$510&XSU"^V"N]1_UGJ9"G2Z8E59;DD'J,0.0
M5+R!VU_J#G,8]O6%V(@6G85V%P6.\7[&<T2M#.ORG&[AJ@MS^R9?28T:Y:<V
MU^6]KO;UC9.&=I1!"_J;IH3J[>3M?+L&*Y L./:$LZT>MW=*9'QT$&9_"F"I
M'P8LGC@?_Y[Y_$IK)GJ,V4YWB7#PA4#6$WMLW:NPWJ:Q)N6P6B%^L-V(0S]N
M)@,A7F&NC<=V,(Q%N5N[J::IBB75('\Y /OYNS8U=_C1OFX;PO%%1F795:)\
MT!?.-782"K) XRI_"FS0N.'D"[=8(;#P<G'T5OSZ1Z+SGU:/"@//*9Y?98H3
M9YW4%=LS1]ZH\&J\^PQ/F .QZ<_:L9:?VUJ5)24R ]+5K1(^L/NT0%&[H_"N
M?.6/WZL8 _&UIO)B[>0L-*FW12)L0(P_:X]P]@5G5*,J!' D&,3V.<(S=\3)
M\)M+C:WIB%C.!^U9!N]V/]\.B#A$6C?)A#FGF]]^87UD<,XNUQUPGG>"/K>\
MU)F3:I4P^%R9?Z7B[;E!I(>61>I7($-MD0OXU?H1CVRCG%R'>O@'!L1RDU=Q
M<XA9Y8S06\MRWZ[)X^U0%LOI\Y_;MKU7? !?B90+F]-V\GO H,DQ]LVT+T\6
MYCCNGL?LY>>#6YY<0^]/P^BQP'8V!XD^WE-V][QC2'6Q!(QD''U_3M7(<*FK
MJOM#:0"SI7#%X$ZHHO0==WG(#[!SFP&!*]S 2: KD7!#M&66A1%I!LZSYP'.
M.QFU!9J2M022\#OJ1Q5E84O><(N=#?HR;M)> 1\ X,&2XIO5KD4$1'R.,E_W
MIAV!"\A4'"Z H0/@C%OS%[ZL/XV>,^S].\72_<M:\J]TYPJ3OWG\1O]W=4WM
MMO'#>,7U]U37@'U-;8OGA\W=,4;M.0]B>;]U3Y5-BA.I@9QD4Z!CB_)H&8^%
MO=.Q',@%3<"\F3:7T:O<&'8OU&(&5R3V4#<95W 17O7+5$R3NU75RA*[K;TT
MN#W8LZZR2GF_&&?#J2<]9TL0:RXP-@:Z=@1*AP*VHKJCT(B\IK,6DUB:Q?B,
MQYKX66"U@2;^/)$\A!BY (T9%12+XJS=IO&DNVP;^H5+Q^\</W$TW]]29%M?
MQJSH[>Z3GJ3EAI!NG/&#%QD0& -7PPJ-][12 D?S'%<6+0<2JK^<S5$D6*F*
MX_(HDG?KUN-?!Y88O,;Z"IZ_D^%NLHAYEZN?ZBT*%0*%#*(OWRGS>/PW=.\?
MKU?]5S'&C&)?\N0" Z,A=-FGC8\@OP1!\E]N<;QL/S*+8_XF"!*0-WYV=:8]
M/1["S'* DI@UD!AQN:D,\6::$&:!D?CB@CRFM>K7+8R3/_AH'3)FA.#5&"%\
M9''8O(L*=[ZI#3XV8+AR -8?_BR/FO+C\[*%^5Y)"8O.#6*G<S6$XGXW.(>(
MM"AO4#PF,=3N&;99E.H)C27L'[5#W_/VO9YU@RG]%)9:%W)OWR2]3&X85_!O
M]@73]WUM/RZ%G$S(D3,@*O<9L31/BU6?WQ'CI:K,*+U@N=1P>.@"? HG8I];
MQ,KG=XW8;H1DBF(IFSY]H"!]0=XJ)IAOWZ8<UJ1G\*0C18^P>MH5RS>?K7?M
MYY,K"GC7QL,$FH6M?O2_Y?@0F4RVI0.Z8/)'A-MXX/<#X#SK;4RM)RYS(<*<
M;5338-NWAN+NBH\W*SOWQ_,!GJ/__3I6<ON,V$U! P7*5;#\-+,]RQ'K)\ZP
M1BRHUKCQ+XB&%W@/0$_\^-#E<>\!;?JW#/> 3\/B#\@SU'>-!8Z+T"SUSK?+
M/,MW0DKL*/$>@"&VSCDA]HTJ\W+8-Q!@-ZEC?)QL17&.HWRSU=X5=:50@WV-
M5GAWNK8N3E*C17!+IX=ZAZ0._VE_G M_SH((]W]Y#_"JOU)!.?CW=?\YU_W3
M64S?^/C+-XKSI[^=I#&F>-%F#?=]06726 2+K 7&!VS1&H1O\?\"4/GO!KDE
M]::#P+DK.ESOG_>INPIJ7BNHH$8MMD>=4V /KH>)89%D4QR^F$$*J[94['F>
M.=7$P*T([*3 S)IN$<%8M8G><"Q&XA #1:R4MO429F'1][:1S]RJ?QT&G5+.
MOC-KT!3A*S_>U&8KU@>-]U?H?"-N#U9*+D#'.Z)WUSC"\&"=DKUCFOM5!"/@
M)#.8YX5H$O@;!_H1=V>-/GY_6LL3RUL@'0M;3YO B46J.XR%XH9)?BIU+)3@
M@Y&<0R>RW%=2AXS9/9U<7$#"MN^?,H<"6,OP7XO,01Q5\290B!EN#6SFV(Q[
MMCE[_:M*Q^,W#RV\Z^^NC8]S__0#&./?1___<!3[CSN*;<^7F&36[(%/%#QS
M +YOZO_?]\!_(J$N2%GWH0$9:YX@MR4[Y;2(V4X?OOX61\KD$-D> 7!SUDZZ
M*X5=WOZT:K\\?R##W.TV5ZT/+%6/[>Y.[%81X.&-MTWQ9[LH_MW@WPW^W>#?
M#?[=X-\-_C4:T"^VL?F.)X;= WRQ[P'/Q<FSI8'#\-D33[A7C?'-E>]52GW^
MLI>*8'[%#)@[H8H3F[__!3-!FZC1 ZZO4</Z'U:6^;?]?QDMX#]73Z3^;.,_
M;_4?]Z9 +BMDV$/R57:R1@$)P]SJ$JCYIL ,NHKCN]Y/!/G=:XJ;W;5R/RLS
MK!#M?EL+>LGUA_"6WVO)6<@Y<=P6?OA_TYJ3PJ\,W'^+#/'E'^O3JUG\#?+'
M__B_OS72^I?4-K&Q_/G*BO[@^[HI/ O[7;U%S;4E[F_;S(]-MZ\OB]6:*TOS
M9G"'%W)%+P96;)*483HF$0/U:S4?)V:;H0VIAOIF#583!3YZ"5S*I8-Z1_EC
M45%Z7 9W=X%;M;FCF#='$IFIA$5V%_(APFP_\FEIORF]/(LN6C'D*ABXR#_2
MX=BM=]0K"_&EM# X19;+71LY&S5W=N(V[KU;5Y15RH@HK*R5EY.V"0_,&^7[
M+79;DAS]X4$TIH*-ON]#7;MX0^F\2#>VP89&/\O>R_<UY]%CB.QIQ'$[IU1Y
M*Y*?AP_E;K\5+6A,_5BBHP?>-_P9VLZ5C9COC']*.UOC^/5I-S55(-.GW=/2
M9=T"C< %G6<(E(C0QE3W17E3[B9/.2*:FN8.Z@M(7C<1A8,OXZ"@X5"N?C_C
M8]<Q:8'.?*;E$L>(6A[;!3VT(>^I7+SM>\"?0N:<V$1>YH/TZ#Z=.T YV4EY
MZ/G1,R"<*+2GT8H',-[HT(=6(JWLM/@M)]2$B^=._^:Q5.-,8-JESZO#4TJ#
MYAL$(Y /=S2G%QX,@*J^27%<KLG3<RLQ!WE_8%MC^/(> +,N%DL@(OUN]-WW
M#4 9XU9^ND4Q=\VFW-JA<&%AP[F>O]ME#.V\UTRLCS^Q3U%"F*-4KC#7]D96
MM2;JR!0BL@OG.BZ:\L%9MEI\K037<*=\4IWFJ-RJ6'"UUHT/1PZD;0ZLD]AJ
MK1NIYA4]7%9!=<K;JTN!)MD7Z<IMZX\UQY^7UFYG(NUP@<BJFZV:XJQ$@DFU
M\S%^W[N^+JQ^0GIEJ<V+V.U1>P\8(!FK_5SEE,$597.X&SX4JOL90S#V S+
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M%')61@!$'*<!TSS]2:[)2<;6N08'"#[K.SQ+&HY2I"5:KY]@%X&95)VL"YZ
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M%W)>T&P&'ZI.F?!$5RE\#M#!6V'D>B/- 3EIOBCC_)'_2#09PEBA^W SH'[
M#!T]BC7N02S0UM=G&BLO4QO\S+J/'QU]0BZOA@ZP5F-[]LE-?J#Y>Z9EYK2E
MXKJ\O,_B"^R&U?<K.,"FZI:E3,C#[D!QX  YDO+J'[-!=OC=!HQ,I)_YLD0,
M;_N(O$.^P\C5^B87I@&IST?GD/$XHSU0F'AW%A(R[]XAWCD\LZCH<WQ%67T\
M@9B%9&MHB#"\TYEZZZ57@WZHI*1?LX;F;,N*OK21'<$K+)5_";G0LGF8:,J#
MS9-JG^Y4+Y=;"4";@E60F_>FO!$Z]*L9/[:G&%(!CH,4=*T8*V>E<E)T')9D
MW?!4Y4WWYU"MK8OUG6Q]W?1VUAU@IG[OL2'+6D#]FD,9^&Q#<,U3WI&XYC?*
M8$HWF6LI0;P+[@YW<(#UA',XS>473[PB=]F+>- SI<+">\7 P94BE2_= AEK
M7]UJ1>^OIPVL5/\D$?*.XB"O=KBY&7"G86Q9S^ 9@6J=/PYP-077#@U>5'(Z
M'[]A]'#E5*T%ZYK+WM=9M6 64N,Z>))1F%M#^VZ&L&1ND(!R]:5FP42I-F>D
MF *GO,5Z!]B3)GEX<*$C9P%T&$63D2D43.9@C_FIQQ.\4:ZKCH\PT857S."
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M&0\D-(FT$S;O]!["!7% J"G*^>0N8^LY.A#;((/4QV9=1"K <8 ?VX5 D,2
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MR/Z"F>](9.V;10AOA6W/V! A.N]?[<^''VN,9#QBR 9)8]UQ -L%.PZ C^*
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M\WE#39_JON,4W!3L3+@.P<Q(,1MT\ZD%)7W9:5Q9.X1KQ;6U, Z5[J[&?I.
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MOF;(=XO//X?_XXM!CL1[/D?99$9"!B?PUP<Q="<C7RZV^NL;GW]2J*BBDY+
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MST(!G66->Z2KVEBW9U<3_>MN;2?/=%ZD^#,T"0)2_&GO\ @$Q ; @$J;XH^
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M>=4"YZRBN.?1F*#^..YH/M7WRP*<"'"BZU>.7/O/=@M=W;<+[*3CQ<RKD@Z
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MF!)&U'A'\WI(9NMPCU0CVL#NU[HAE5K@ =%+PM:4Q+'E6:%2YH[U7^N26E7
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M/?=>@G3%\01MPJ2/-".2D>Q#S.OJ*T=V==>V0$22;.HQ2T87N1EIWSX9V%#
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M SXLY6E?-G--LUF?2*T2A)Q+F&''&KSU#QI*/'S2IGH5^"D#^,2W/'3?8/"
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M+[5KV/7(Q2TL>CMP>5O]"O<KN."BVMJ@^)I1AJV73&6Z./"$--)-%KN:^=1
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MGTQ7"/OG"XDW_Y)EA'AM>\=>12@SKC3*U]$RC;K:@5) @(%(SI33P]4(G(^
M\G?]6Q%?\(7:*5]MG*M[*S+I O0G)ZT7NBSQ/GI_*#.ZIB@V*Y3LEOE.D)<+
M]Z;8P%SJ^[DW30ONM](#$1/D>A9!V19[B'UO*;4Z]B.3C(RB;R#*+";V/"Z
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M.PB0 ^!S3QKYV-8G)Z=YSD+SS#FP@*,$09'9(QH$2I47@@O3Z5-O/KJ2*!J
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MY[[\PC*[_V/0Z%.DZAIVQ)1871<%&;HC:TGI'0WQNO8WWB)J _XF0%%=E=1
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M<4F]#3OYZ*+C)HZMEW]D=/(RK 3](S,9=2\]]:C!A:IVX E0P>+YL/WT(.F
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MG-U5/=+C-;)-@49NN$CXPZDF1Q!=^'C!/VK1!0.HZ,HK<<HLF5%Q^&3FS/J
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M7M;->Q<78@[:S]"+55)ZM8JTP?M68 <U.G@4 :].K(B\BG3WDXUJWB^F^UR
M!NV+_S<R"Q0)U(9"M<?4^[&QWG=,>X+^&II+F>@;1 6AG,G?ZE)TTED:LO#2
M!U=<<.7[L<0!*<J!*0*M*(OE)LEH;\Y%=FX :_6-GW(/WUE*=_0D.)Y^>UD(
M@P%602U5=#7J& /)N3> R>GWB<\$O%&WUF\%JZ2T",810\MZZPC&WI*NZL!
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MQ/@V\ET<198S))H9Y)5+VIP_+UC@;L'O_G2_34UO,,P^F5-&VUKG']R#OM#
M@7,V!/-*W[?C/"NKNE#0.A]HGL#=1V':7O%#=G9 QKZX$IJG'3&M*Y=]!U<4
MQ"FXLLV_ 6QPQ"D2&Y@GC1>B$YJF>ZUH/7&)!"UIG9WZ>;*V9]^^#X699=-6
M#Z.ZSZ-8&GP'X TXCQ(]$RF'B6VM,.RFRF++D,JRM.*%G0A!!<Y&8P-^@S>
MU*W34FCCX0T@2)ES6NW^#0 R&>]XA'XNKUNS?:L:^\%=.N[T$]O:JEE=#]]Z
MVHH^UB?\$_AG2/E?%\\M?$G'"%C7"\&WUYD%OZNZHJ8 73R6O % 'VMY+TI]
MHAK*;H7O/O]_VOO.J*BV+=U"0$1RSH4*"DH0D)P122(Y2A3).4.1DZ"2@X*
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M/]7^7ZG)H/F/[S[L!G"+P;-3+_KSR0V 9<=A>\W+:[ZJ?%Q41^NW!6B+ V\
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MR)=PWRH -FBDND0!WP$ C-9;=6 <4/QR9^+YNQKB+I+J!BMRN73)/=>%>CV
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M3,W%5$)?!3XQ6_I>2,W"P%8_4IE\Q'A7RMRFC&_.V6S]/O"5.S,^A P\L[W
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MUIMU\5RM\*UP7]Y##D6X.@-#BV48*C*:.6D?.>\!)(::@]!NH=\>@ 5D:RM
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M>M8A.P-I UY.'Z)+R6U8RM/K@]%4)Q%8O'9[/^#&_^JN ME@VGZN="KM%G+
MAS"; E[@0)I^ 0U<!%MC $?XC7^!B.W7LL,R<SS%W=WTZQ8,(/ B P,8I#W_
M 31C\]B;H#S"&6H-N?V;EE]-')$_MLTX+#U@DE[_X=<-OT(A P$5>_\)[T]X
M_R?"LP$N^JW_0<=-E5\(*OX7P6TI*MB.9&?>2WN+J#E])7Q.?0?F4^H=;2[A
MVT6#HTMSH5O61> .&:Z(UG'X@'3,*5EWA[N"8N]QWZMY>'7Y/!+?!.M55 V'
M6Z#YC-8*Z^_UWIID#BBGUT^CJ6Y^P7)7UW2^80->=-IH.KI:A\425X[N[P"S
ML&]1U"5'RGLVH7BE1=%OW,&GPUBW<S5"#>OK3.8OCLK!5A9-D1'_4J_@<4YW
MZ=LAAV"$L9?CQ:5=K.O+PDJ=\6_36_\R(TF!UJZ7/.4J!@"O/II'7I[]@5OQ
M)\(722%H!2;]K)FC$.X^#. GR!$_$SZ7I$2%RI2HUFQ0@+ SM,)&P.M4[EC'
MR</T,^$3-^XS:E^+>.=A#H@H=D5T96-7!.\>&FD(_)GR]C;HX!ZR@W<M4]/4
M\=>L_4QY<@*R;'X<8C*@E%X__S-KOZ9<5F+6W?:GS/XODYD0* $KLZ6?95;^
M!S+++=)H14N6[$O/5 ZV\-2_JWL=&=QWU/%BR[!V?1QLX^UYY]'"]LZ><05G
M?TS-\X+>D\B5U<:@6!XG,+SD!0:PU@G^KHEE^N8 VL<*BR;0ZGNH7XW<6?AP
MR!(6I<4D!C 0BHTQ!C/0-WE24(@!+!0BWH"M&."G'8XBOI\J@3]U3E^7^9/&
MGS3^SZ3QJ9"8J5,DH6)O4H_FEH5 5O<R4M-%;"GWVZ32^H:=I,$H!E J](W/
M;^!.<T2<4G>_9+(=-C@/+,L!#XIL87W+\](\ZMV!!UD0J9]K@8LO-K [,W'M
M#Y/W]ZV064L;,O7$6IZ5.M;=V$-_\6.3(TWK=*X_K!UG9^-4^GK(X0#"2,+]
M M>AZ8?3N=F?A'4ZTQ"LTR%QU*A9=P$E_QB# ?QU$!.\TF4/B3\+GE>][^WE
M.R"77G_X\Z"?\>!.C^QZ,5"NI6#'8 !_&:2(XDF21+^I,CL='F2<2W$>7/\]
M#_-_9>'UR=%Y<K"\Y]K?Q_QPGE8:?^.&H"IGYDB">^#G01%_YR95NN'?*(*F
M?RR!E'\F@;U_GP#4_YD P/\) ?SOL@:@OH[WJBM#GN$1DMXCJ%2PYA(,K63-
MRLQ*+4X/X0#\DX*[#'S/=*!9L8<\MUW)ST-$8@!WZ$PQ $AED>%O#F7^/47"
M\9)')9@ $46W; (7)Y3R+J8!(V?!1$AOX^&">L?%FU7S[QR6;LC=>JQR0X".
ML1[:Y;J- 5R6<JMTQVV3".C66L0 AN@/*"/@:/$+SAPK%V(31LL"&Q M;Z%S
MC@F K>I56'BL0N-[1-V"&U2H)7\#WG4RK<MFVJG4!<QA:W3;&VX(H=15FEE*
M]-37E*<LP9&G>/QO+X9H&F@.?+S)[JML]:<O:_>GW2&N,F.1\ISRR@9ADH);
MTYY'&  -PN!Y*$%EW8>P34+M\.IC@@2XFK=\]:"P38'#/17Z?)(ET\Y"'Y;]
MYD%7L^W"!^XWJ1[A>:Y8?MQ'PKFA4KZ+S_:O1YY\T!^<:Q9E<7]VU&?IWR[%
MX*?L<_?KZ)B^,\_0PJA6:2F_HE9!#AY9J!9HM%!WX!Y'>L@3"DUYP+^[&(Y
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M@'CP#-WNRS%WMK]@)!$_G>P%2O"1@!\@XCO=])QE6>-"IM<X9#9?*PU4ON3
MC9M8>)KOIS-U?E,##_%<?TITZ&Y(<<O%("0:I9S9F^81C@$\BG<X]U1)RHG0
M1-(">K( )8!+RNL$7G49&Z*&NQ#[; ,.NP_!5[Z$$RS9;6A<0]V%0P,+;FX]
M#N'.SQV5JJ*BGGKK'$NPBW;!.>2;<.1/*<7F<GY]]V6UY"Y=V23V=?"[C9!W
M)<$&9SM&]A/GB\'QH6#O+'-$U6)78+U:ADS6LQ,C<9'R7D]"''JRL0BGO03
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M72ZV!08#GNT\PP!>MZ'L(O;YWA\S46Z"IVB_/!S9(?PT8MU\DGK-ZVCO#?A
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M:*KHY"P\LR=T0!79;Q#F-;./C3,['W[T0]\ZY&,!HFL/O+?HPF1V=HH>9WY
M7G JA;8HYTXO"NT($?NQJ7ZP4U9X*<>-DS*>/E8^:W$;FA!S@^-YBQOS@;=K
M454;FL]NNM=$<MM;ELY]K_^>-+\>"NLN;V, %Y5F6_+E5&-Y/1]BGAYQH[";
M[D?=K@LWM/^7):8K)IM3]?&1Q@_>]63864D1N;=A,UIC,-1QG2OG?;UFWD;"
M3%SE /5[7:69SU(A7D;:::]\#:7.J9$I 1"A7JK:N*6;.IT/UH3[]69/0RK4
M%(8*BQ@%Z5RG/@F_UV3I;3\P._6^[+4:B062#H;>1%<LNVXE**)"WF/W B/D
MV/V-WD9.+T9-1ZDX*-D 65OG= R2]OA#Y@<3>)N]1>]=HS<,W=A=/>2 Z\@,
MQ];4-[12@)^/A(-_"'SADH[$Q[=+T)G[#BN7%H94=-NSOOO(=)J_3F"X)_7,
MQ^7BFAP=991EB=(1 U@E7GG0LA2Z!U%IU%\580^HB[MP,@X.JR!W+:2FG'Z*
M:Z,]XEZHUSW9MCEZ9S:QCT+3(%GLCWZ.UXZ<$@5I!VE_]-VH*%F<I56SU-2A
M)E.04U+:V7@P6OLR9CE&0P$^AD(F?Z" <E:<:8$;PH^7YZ2&[8522&NGE(AZ
M1,O!,^P57IT-!48(*SF[ ,8'KR,5ZI_"WFR+0?#K:^.0!T9Y$^51_,_9*J4W
M^Q2(2/1DY2FTQ']W?O "?K/&*M?#;ZZ#_DY'@85H6 3K==A4L7!*X$&OTYW.
M%*],<:NGGYR3JZDIFPV[\@QE+_)LRSJ(*@?*V>X3C B/6:>05=AYOWM2=]69
M\);X8HVT\]SG\:\*R@K6*Z[2@IHC[&2VI*KD@=1SSET.MF'>36%W>2 H'D_6
MH:C!]F>A1\QO3,F4>@I%":V] ]=0T2Q83WR,3??E/3RW3!<],0#6;TW;C$W(
M*Q 2:9NR1XIR10CW3 S VB-*?.)>^(3GYRX\)%-_702U1^[Z5-$7.^+F" '\
M&CR7T,B!PQR4V+"1.GPOB=61'LK3$-LIQD"RQ(4N6>AC,6X\?[;^.6N*:B4:
M%QO)067+F6$::CVF,B/:^O"\VG=1@S@"]O3%0'0]]!-"HNU<L?W$R:=.LSV4
M^BFI>(=WJ9%"W(,QY8-V/_UO:]0='AV?9"CVX>_+Z#E%^@[VSTO]3E=DA3/V
M.!D#83L.]N3W->UBHA;KLUS1UP51^1WI(7:]L2'WGB;H-=.LO(?8[Q>]1=\>
MU#$LMK&0>2$G)<JT:"IH(Y2@7DA1VCKWK+[&>CH@<BI 2OZL/CQ8';X6*O1-
M:EJ2!L9*]GHK7$'B>?&Q+[OV\)KV5UE6+;4XDVU"1^T6B!$\/G2^O4I0]H3I
MEOG]Z:K= 4>553\><!?Z,]9>4LY"+KDLY1VRN:008[-@70WD.OACD</AHEN6
MLZ^3Q+QA8)S>RRLO0A.1(&7X/%H>N]45!9\1P1S1+![^Q ]6J9>K)ND+/GP*
MOJ^4.G9PP&N1W+3 O4>R80^6GJV/S+\\]:5L8!3$;G(= E.S-!J9ZCE>O%>&
M?\NRI;O(*_*;%K3>34A(6O&<V["B0?)$GMF*R),[6=Z;)/1H!2K%<:!(ZJGY
ML,3YU!?\"!H,JO0@T30Q:_W@R+MJ+1OTH$NR;.! J*]X1VAA0 H!S@Z3Z[@G
MN$OH<*T&UU_A'C'6K5.X/@M6"WX4!O7IJWW8=4M1[BQD&AX1'.Y?&U \Q9X8
MH[&;RNZX;M<K997/8-8>?R,_.$API?T^F@RM=EGUU&5G+/&"0E,)]KMG )!R
M:EAW9Y)SX:2QS+V*_/F6,^F3:58M1WI ^3\Z)_A;.2/YZ91NT^_OQW=_>,!'
MS(/[N&+XN-=HNE>XWI]J9K!* 9L#VFU\X;OAP=25 (J4-)3@XOM\N6OW^].(
MNF0);U!/S&."<;V7'E=;(OMR]9,D1E;:ZK7V7O@*:*R84NU++A'N)V=^G.*6
MSS&Z0<IT9@VN!^>,5]-RX(+:!#(9N8:?1?JGFS[\WI6*TZGF#>PB=GPT6L]I
M21F[+=A=91Z2<>G^U-B"RV."5-2MLA&SCHS'8VQ5JM[",_F"3_: +A%IE%"4
M_7YL15]12K8-*/2[?A]KL7*G.)VZY%H"',EQ"7H2BP&@T#,8P/PX-F5#7EUD
M#]MAAWN4CNV9AQB!^-D_H6HMQ<6WO@D?)E'@3'C4! <UWC*>L_8*0JF>?,H)
M#?"?YV=,M*+<GKN!:$O;&H\TW+K,P_>.:!/&7W/,&+!E)C1TG\E(Y/V".%_C
MS- &&TRRZFP+51;2M:_8D7(=\7S<SEXXH[;AT=<VHD7*NAM>9$?"A\04.-FN
MG!5,9-EI;K#O<2LF ^:'1,@^*>W%M4J=:.WR9]S^!0L!9O18RD_ ]AZJ:#^A
M@6_<R?MSA8N?ZPD+Y6UDDAUHQ]Y:W*LKVS&[APV&O/A:/IRK279&""]O7'L^
M&;0F1M,-D4A_+5T%:RS)V4SP"ZD$.:EK&:A>F:!_BLTA_]$#;*#7/BRB'U#*
ME[._74Y@@-Y@/L\_EGI>DV]DX\B[6/G&797[K>RF<C.DH)Y@416,AS!YPE?K
MKLGS/=#IT%(,)1@"*%LBME2'BP;2ZI#)TY.=N0TFA\X&2<#$(+$5)NI;!J-K
M3?4?OTE]-XC(245Q?T7$PT3WS=XQF+.<RXR%W,?IW]-#>:#RWT- Q(I1HMYE
M406[V]C SY7FMS_=D+QO=V8I)=!]HB*J<")\Y/[6QWV1!_RP<CA'U5L<S]MP
M6+[UFM-'#:8BN]5-;MIRW8?&=WH&\K;K@0L,;'"S*?FL#BG/6QW-K'Z7\P=D
M.'W4RL?N,CT<>FX5-DUUX\WK9E=37PP@UF.6,O%>9;Q04H^KD9ZLF:I=XZWA
M.P@;GE*SYA$Z:N@3I\1%#TB"=2'7D"ZM[_O0,S7PU8F67$14Y]QZ:H5 @+@;
MT26KY,:Q/2;2>OL<&[^K4=/*H]H[KW*#R*]>TKEF==3GLRC/%:.S_&6=+"E:
M/F6';N\,58T!-!6BA3=3\%'/XZBJO!SR_;1H0#YL>NQK>]].*)=U=-5#K>B(
M!&QFCN9#\W(&ENCLC1[5*B=X[/,K$MCQ7D+'#B'H8'>^&AAM--Z>B:"-/7\N
M0(W3N2 ^,%PO$Q(<_,'_PSJHW!:D.!;O)G,%ZI-?EY;]2&FF8#A0ZORIC@0D
MK/[.XE4Y6@W'>L5/BY6 ^"[9R*XUL[M#!KX:]>7<TYX,)*%2!IXPXJ?S)J_?
M!3S5#']7LV&Z I]NIU5+\;]K7CW*'*Y+GR^&!^J+T1OC4'#2--3_-&HS@YP_
MMVI]&^4@M*11JOUT7(IS181]Q#E@TF[Y*S=37M&*M^/MN>R>J:1OCR@%Z"VS
M5-,DY(LF)8MU#&193PJ0W"7Y^31F1BD/4$90E[J]X!&CJ7E9H6SK=P]?:N!7
M\P70!F8G+>5_=N1E":2=!]0]L7H)$4TO#KM,+6;V:E:U9ZW8QVGLA3!PV['$
M1%YF0-2MLU^PLMXOA%M%YR+14SFF)JDUA*.0\/?/B>7<%HKB8K[S:0%G9A!_
M(-!'W'7)UVM>H^K]),V;SR,(\IIOL"Q?^3#!EF1J0L9NGD++5G^_?71F0C/B
MV4(UBC/U[F$^\8,=7(UJ2ZMTV'2RW3M$V%)&H:VB1A77BYV4(.VD/JQGXC>.
MV>BE,8N29#%0U@R<6^,KW**2V,T3/AYYE@GD.M&<(!I(#T%6/Q!:RF"(7/E6
MN8LU"'W_G_UV@W:S*=^@O5!)CJD<0T'[0N6PGL::*4C>V:)XJ%TNZM%PDJ(Z
M2''PAK7IU>J:<YV/&SN"(@=S;N+(YV52!K!90=61[.*1+ .'DS-;EO.\+N,C
M%L;8)1U0RK4T9W8M!V6Z>KVXD&+W/F_' .$PB?EFD4$U]QLJ+!\IGP..A;']
M'/@(Z!]1&%6$VNBZS Y)#^SQ/9L,J.D7A[PJ'CMRO(Y0$+LU>ML2CX#FB7[)
M6E4-!#\]@_*-?B!UU=.0+*/)V:R:5VLZ#76U<8N[SXBYXYG%.Y4+YR][A)NP
MM,<=S,STV&>>L6I-$DA=;PRJL>6V6;3I_Y(]1);'NNNUUCZ2;3LEY*Y71:KJ
MZC K%[J]AURJF<=#G)7C&=&-VMR=K&8^9/2^X Y,KUF,E]4\$727[R5CEW%-
M.Q(T\3!JC[,P>%J6+ (\&/)G@N('C?KP+7X1]E@I#V)^*951?WCT#9)L7:2Q
M[9 \-%U2-8X\V'1%B^[G[3^,G&XCB;?#C7MTL2HM:#1/>$RG>N486&&L>//D
MD<,+JT+/6,II;1QU'>FW+@I$]3%GDT<!FXU,D;WU)X^Z\B25A>9W^*YC  -&
M3-_LUFBY@\]O /O[T#47(U\1 3P%<^SN9=;?C?"EZBWSCHKT0K@G,E0G1QXW
M=K%F>3HSCECE;VS!6^P3=OG$;%9$'-8D-2B7$P0+O,8R:HCRF5F3_7.'C,OO
M\:=G1R/"V V^05@F9>[8CE,EW[ NW%V*TI"^/O8BT=FXJG5ZVH[AU<;N<Z68
M5L!=I[EJ%2Z;E?U 0LW&%8F=4>W*KG24?E-%8\,([;A+#.LK_ GG<'G/,0J0
M.M7UXJ,QH=UG6CX'JU@CJ;WR.ZNIR=JHDFC,((XM>'&@- $KWK5-632=AD^W
M!BB--)7O1@;.]L +^$O  \)M$1T%TMS'WG2/,S=5NI2S;$YD* >UR"K%TM6&
M@:<1SJ961;;#F\B8Z#K^4'J%'(2\BXP(-/0P262VY?WUIRPU1T4"C6R9,UEN
M"I*D7TXT)R__2(!^^VPRSHR'1CNM2>&GTNKW3Z)?&X>^)RQZ<P0A[A5-')JB
M8A<_!"*/EX]TG1F.]F=*-&.T2];1+/LFA4D9D_JE]=^);B21@A*C#-X[*(NS
M186HS:RU6]PQ!%FE(P30X_-MBVS)0H[\X5<MJFGNQYV-WL-99F:<2? /H:ME
M>"27:'FS4EIK^O%(N1H>ZZOV58Z#7CK?U2XQB$#4KN<=J\/,Y>C3,%GYZ_)Z
M'2KIRM:1=8N^>D;2K\A9,[O8NU<F%A4+74S%O+EG1<33JL,RW]=RTHAWO*30
M[$M5I+RC-N(ULU$OO-0U-#AMG*'JH-$;GH<!C!?-[Q@R5C@VS!&2)OJLV6!#
MG@,NSCPJ13H.Q3B5]>/Y\G7#NW0P.X]!I@7)" 24> E,7EG"/KE 9Z]9*C@6
M4>CL\GCE96%8K-)!AP'#Z1O'PD*7;^,VD=2]'ZEAQ46?]XX^TSGW.?1M.IF*
MRA/I\29+MQ+=E'XW9XT!' Y/'T%$]E4?H)FKK8D^=1M3;@SJ"5.(&_<W\DTK
MQHT3'3/P:95I7,M4<Z(&WPD:GCF%\*9'N0FV+3'<G#(*?(&PU$9_'[>(7.:^
MBBKU#I\OM-1407Y^X$"NI5AB:C=^\^35=UZR'DY)W2 USVN'0H??N$N>N[%&
M:PZIU7U9<M*"V!UA%U]DSQ\]TJ[JZ,@SUBI+Y!C93^FKYC7^(;LE=1WFH?M,
MZU!Y2Y^1<%"J'#U2$QIL?IXZ&UQHY:.PK_P>6+*=0S>-EB%*U@&[3QP5WB[P
MUI?@"I7.K+*Z!>,C2R&UW1Z2O(CBB[LC+3T ,UZAT&;3>N6.A>#_JY_18Y6N
M$=*TK-O\>.<!7A5R1#?+-J_^^5;%1^+L2S+JDO[@O$(E%\<K4[-7J]-+#&*K
M\ _+ LZ@@9J/-O0_< MY@<-]'.VDW]::?N%T<RXUH,J6##DDXLA\II7QI4XZ
M?$^OV#'X^8S)P^?G1$5],VO62_5?U*NH#&/K[RIT?G1D?7.PEC+\=>B1<][W
MD6UOT#L?1?,LA*E2 9]V/]F[M(E7LK@1@Z!PW]+UQ(MLQ_/M40K-ETD@-G<S
M$BG%$V)U(Z.M;-)'3;R'D4U;1WW*^YQW'8KLCZ^*#X/,2TT*K@,V+NS>I'\(
MKO!)+#B*(/*1#Q^?HR/69\@[*&Q>PYT!![IIRR^&V8KMLI]3I 6MW%W4 +Z#
M7$[_$$\OI])G?/H!0NKAW5:YJ&=-OB)Y@^F+V$[DA5UWO<:2,DHYEW!9EM[)
MOX1Y&]A9PI&:$)LX5LO8 ,< =$HJX,,=TJ.:39_\])Y($FU<STJ-CN;YS Z9
MA:18IZ]TD0Y71*2"RX5(SK:>G?%X/"_MGNH8^G#Y6C#UAHYUIKQ*_>8XT78C
M_=;C#</1CS,W;M>HI7TPUPE_!>:"6:?VWW!R5ZSUB.@0$?$B'JV$EM#Y?[$@
M>N7N!KGVG'<E0NL55HNUL2:*N5BG\KMX]++OK6P,H)MW!%V=<T!YZ/OS+47_
M=SZM60I-V:E_Y04,G^"?7[=R!?[]1:Q___LJOQ3*290HW!C-NT]Q6^FJS4<Q
MNQS6W*[35Y(I&_<9/\ UFOLN@5O5P/16?<:&+-=B&:;W^X%$5?M?.K=L;'W$
M+79Y[P!F)!(O&_O.YRU G9?FR3;05^!MR@?M+=?TBM/#C>B?N#1OVJW8;6TE
MJ2#M>FL,#58LMK\[0Y$@TYL1@JO>U&-)L2%'FO)>P1S_H;?B+OLW."] _8F/
MU_<9%IBLWI0XO/5=19\.ON)^"W<,=$ 90.0M'3)ZM!C=V7&TFY;NBT%R^!S*
M]P@\K,WUN+T]6A7>I=X4.SK>,_Z4$(;>I2LS=#K7L$Q!1"RE9=KDJ%6UU-9H
MD0"=?,&T^^3?6 \TO.KR;9VW:!-/H7<?196(]=]G#)C* PT^N?>!1)D7XNS?
M -("81U%7>B_\L#-?[]PR\D/\PHWZ-'1/1'M]K0<4LS+381=J5%]*I8]&SF"
MDH"7C%=H^LJL5%0\:8MHG U>G&O0Z)"86I]RZ/;_G$5'YCSHM50P.6WH8=:V
M003KJ8R(HKBT?+U)V]2DP/:5[51HO,9':E1^2BWW4LE$U;O<E9$TJ&EZF]:*
M&3E'&=6=3\O1WX1B-$T]EZ1=_Q-O'?]29N"=[Z8ZTW$=]&^?);Z!3I7RV&?6
MUX;/,5^M W!#A>JNN!#3F;.<VIHJ=@K8IH=OWV2:ZOV\'8)F@]Z&CP>-,,OQ
MBLC12&N,#(+>&L\HNSO?:>^K5:9SIIW IJ)F[1)U,P"M6?R)F.2Y)FU]72M?
MV\3^WB?I(1SW_B/,_..#'O5_]: GZK7,PU^]]-T [ *2^!CD(6#Z#:5#O&R5
MR2O)XA1%U%['1=YH2G!8T[II+0J*LL:-3*_=0^BB13" -*^M0[/]C#];_VS]
MC[=^&=GF=55[0,>ME&"0_>3KU\R40E_+11+B#30^_&NK2GL+7KRS$FS/,C'E
MOG,(3(;,1[P&?JY:8/=8"+2V''*S:[<+ LTMU C)Z*"-2ZX5"<SL=7(4ZVM?
M5]38#4T.!F;IL/1Q$ZEW[\^_\^-/Z4AFCHW3<D%0%]9:XC+FS-40;6( BP:(
M7O1K*F "!A#&!"] /<, [E]-Z0-W-ECK9%$?9#M5L.U9QJ37-B'T_ 0Q@-3+
M ZM-,$44-Y & QB\M(;E*/]D]/Q#[(FX"G<!!A!H!0,B <9H.[10"I::U=^H
M1=AK5+]J[.*4=P7_7!V/IDP)Q0#6<9S/((BAG;S3ZZ")Y?4BR*^J,0"B@4[P
M$:#FA\BPDP5S;[^* 8%^5?VKF;UM?=M^ 93_J^JF/P#$_D> FG["8^ F+O$;
M.N#6LOV4"P O6!B;64A7R"SVG--G48YA -CZ^+_5 [&"'?B;8!FG4EZNQ/\0
MX\#/8E3^'W$69Q*N%?(7S0W\K+E?L]9;TJ-I8O:SGC)^)VLL;_\3&47\:BE4
MYLR(F_WC%9(QK;U+7_JO*NW_OU5D _Z=TGS#U7\K:[[?L191\FTT[N1@5H.A
MGJP\JMLMG?D;^X8)\$<_\%^Z01XB#.##NVTZ]I:FY7%S=FY,5H'=RQB =\ T
M<E2#[#+=C%,.V[&D6; ?24 K(P,HF57U+-KW^]MPZ;)U[@$_9H_"BAW=0OML
MME;<0, 307=@?X-@E]96L/+-!(8OWP]7GKEV]30@D0<_/N=W>1]X@;.&9<?V
MH$,U:;SPCI]_>XU1%,>:MZ8)%8HYF1VK(RD,X"_+QA^1@GY]B!6T\.Z%,PEJ
M??%$>]NY'"2/ 5SA>X^5'0GP%V4R-_X\RJ0- Y @>2;3)2GO8O9W$EC#N+H$
M1N(._!#W\0SP,/5/8G\2^W^*6,I/__O^L"?IF'-Z9+[@Y<>JY*\)O$[Y@I,I
M:&]^/IFNCC&=X=T^?;@-C"S2;F$$U*,GS]6K+%GOM02'&4<DU;E(5PMO^-V*
M0_/P1ZN]_B:(RG"0T=PR9;2+T 6ZJFV,;K4-+ZN_4J2!J8%WJA1:Y^26'_KY
MN#PO4JD8"!*N9/U"J"RMKOC#Z5UIK,"ZR3,P/UKX<$=D0*#<3O=+M((\)>3G
M)JP0^ K!@S)F(RB;5V5\YJ"S1R'<9F@R7SOTFP.TY0]/_=;,$,N_3U,.8JBG
M;4(7K7T[!/JKVE_1>U5\0@F.Z4['5BQ2C3>M,_%M_'V2[^ P^@+I0+,5 8Y"
M,$+^&((DZ#V+P.Y/?YTO!:;(3?*/,'S"[J_B^MY$33U/-;$U\ ];9D<D\4>_
M[+I_F6T5V!FNQ]@*.?A,H=>$NHV$7N"NH+I^!JFQGQ$;7)R/ROY?B>*/4")_
M?"?Y+[,=,OTSE'\LJ4__!.7%CT^Z_ETF_QCC",IZQ7R;"P/@C)2WP\8?_X7\
M'Z+\\3GHOXODGV#<^"-EKOX=)/)_(*9_*X#?2JGSO]9[3BI"X<1>[7J:[?YT
MSG=WIH:=#OJ"7/.O*LKZ4W#U@!-K_(R7&=]C_-8M8QF;PLQ]E/855M$=99%!
M(^B/BG+H@29+D]4JGI7D#YS#.PE&B?9AI"0QR:C]#H^9.=)]^?8]H:EG;=UK
M=]O#-=8,[SSU5F?L2<C!<R[7.T7=,F7!\O%H_B][;*!'!/J-H!_6)=#/]9N$
MTG)[HTDA9-@(@LWQEVCJ0;TB%O+GIA]A(^YD;TF O".XE7()B,3K^TO@<@7T
M#NN(R$6QCNB^M[C;/>O"O5\- BX2[3-=7'K^([(AL>+M)*9L^-4@Q5\!PME>
MF6A)KVKZ:1!6\MSMX"/"+]A0)54ZL8Y:Z!\P05 6;XD?,O?SF(R?&7I]\FK[
MR9#1_$]#?F)GD/%/$?Q?(X+&R!'P,I4-!F"L?48$'_@;' S@!YY353R/\G/K
M&?.X.]=(+$.L3&EY16LLXD(X)/[I%Y6B*<K_0\>\%(\O:888<N!P6J>_)N+D
M2+W\[_ZH6F96^NL;H5I#]PE#^%7E ?\?>^\=U]2VMHM.!$%I4>DHH(*"%%%Z
M#XB @-(4D")142D1$*2W( @(TIL*0J@"0D"4WCLH(IU(AX!20DFH 4)R)VNO
MXEI[K77V^;Z]S^^[]YX_8ID9<XZ14=[W>=[QC'>>%< DA )7]<%?1<E\]Q__
M!*N_J'[..I6JA1TLS/0?O/R[AK2(, ,OF6__\4H&V-<'[OY3P?_@Y;CBN&(@
MSJ!7CR(42GO.F@)*"Z4%V_T_Z2^P#VT$@*Q_05AV#BQ(F0S?NSM[HZKT@[5K
M_=?M-MM8[C.D#12G!C%,KFRW:3MQ(I6>WOW%[F"Q97/=> EJ1X"2\J<2['C1
M+13<-Q2H;PM!U,#5%;3WL*83Z7X7+F)@*Z8]D<?(@.=@V=S_O?OGNQ/+*]"+
M_9KR9MM>?O(:BO#T\.>7\SVC#N>/(4@J=3A)TMWB.V1 GV<WW8]O?S'F,]CN
M&CR_7EK<-WRR-XU/9@NU4U]'!J(+=<E @=5VW[-7C K&>UBMBYBZ%5-C36VU
MQC;)2!:P\MXP]\+=P?C>GO][Y3][);T2V;R9\-Y<:[#6'%[Q3LSQEN$#+!E8
MI0!]5X%ZHF=@B'/2*U&)/'C(,[$KKQ[2TU:9I/"0@:B#R+W'*$%=1U1@>DQ"
M%$=ERT!+2>7QN[66,OKECC?:B'R7[TF6W!PD P,J9.!60@G3LFAO<:6^Z5'X
M!PCWZ8W2C/T_4 OG'F]#XAK:GM78Y>S_D><9*DL,^+\7_LL7ZFKLS/KUNV9.
M9$N*;'ZP4JP<+98_$R7Z27R\4JL13[.S!R551<Z;E6->+_;>X6H!Q^Z#@""*
M^%[EP:I&>!-[>YZA]@UP=+V1P6NIK[R%WX;GR0E1,AYJS[8TW@@J%JF;'H9N
MJ6FK"$J;O;HYL'<G@[,N7S)/C7)F3:PH;Z=)71)Q$VX42AG[^5-K(9:!'2R!
M,A5@U!47 LM)[#^BQ#I55N%SOBWI74\X;)!S(-WO_P^W]HN/VKHVF%YG[?V*
M*<6*FY"!2'<R@$U-?=7Z:4NBRJ"7T3\A0&__C%/-#(HA\SW_N&%[/B%SX$'(
M/57600Z.O,I(8L L&7C4DXUH>PI=[GXP\.UN =@ Z_VJ;7N4M_]?VC'_YV\U
M^3X@,BUVY>ZPXD'XY99T(\4KU&]MR0!^<L,6L@&R@4J!0WGRQWK4F%G_%97$
M;1N>U0L+$RN0[W#?=Q*1V^PN#EO!:Y)U?YY:\K_YX0"Y.3$ ,0DGME@WD=+!
MA6@%!RTU QEX4KC&D@'9 9G&&#/%F?WBMV%DH!V=30;0XD2L[SM1,C #[P.G
MW"N2,^:L _CS@O[M&3N30/+?3KU%JN#LW8<#RM)U&^U]9B&+_,%@Y116($?!
MZGQ0@)*!DW30G5E39\6&P^,O:O@]+=:#[L.1"ZF@O\DS#=EBFS?QG-W)@6+?
M#J;[M.P8U@4>*V,-%<@1^%=.&?SO?!KQD)_,(8A7S#*R[K@'[_DB05=%!G)0
M/;T%,-HS]HW[U0HFY)(![F.^/%\*!D2NDQ3XB-!DJJZI^\\=")O/]WH,^HTF
M\$L@X,E*A=_^(?'NO^5C]* $K!N_?U;'U.45"M%6C=CHUE/3#4Q43<W*Y#HH
M<C"0V37=3] 6N@I![C5I[XM]E'BV;"1YMFFZ2%-9(#GD@>P6']U\?D-?#2S[
M[YV/S)(( LZSQ.&GJ6@X0 :F&Q8&ZOXQ"X]NAIRS.6<M_*\,1'TO=.;.0-TX
MS^?!O1\7U']$M2$&]N@V-1FH1V^']@3O748LAWY!@Q/T.!F@A'T74N?YAQ$X
MH+5?_D>L"K;MAS4UWWQU(CWT'/V_>U(*28.51#&L[#E)9IE4@NO=SP&!C7Y3
MQO15%P+6?J"+5#&8_, =7%ZLB(TOQ7->_E]UUFOFY7NW,L6%S,F (<V>BVF?
M;KE2_*L"Q-L 4B7*EG\4EF5&T!=RM$X/]??_-PM]Z$6/D('"?<M2M\%2+F?$
M\PR!GB<#&Q,[H6-<@M]PZ4:+ OO5YMHB\5/\4\2%)8,!Z'2C;M-V]U42Z\U2
MT!-:@_.%143-#ISI/6#7"YK2<.VW\LZ_,^Q@DH@F>K6!J_N@S>!O:TJ%18G5
M!G2]4<[,Q:"Y'PX%<G/V5Q!BB^'\?KIA F(LLQ]<0M#=H!?[<AAOT/-J#(OH
M_XO.X7_GH_>[Y<.RORT:29-G1 86>,F LY[&,!_(A>G^E0E^X0<W=/-'!OSW
M0WE.@,(Z,V?Y_)WB,H_E,U?25!+<9 [XG<F'L+D7M#5R"BU()[V<?>@H:NQ@
M>P<_&ZC2MDD"K24"380WU4JYQXR8HH7O])6P+^=;!KA^13KEOY*=GV!//>0"
M#:L5'2BA]CE7^_'("57Z2SJ*.BJ2EI<(0YAK@K@WQ?X[4B<O.!^:$_\"4")1
M;CP'BFO.>0L.QVD?MW7@Y5N*,F'CI_QZ1"B9L/O&)J'/!ETZSPG[LLC?P'$?
MN!V]T0EX&86@3-P#- ,,^KX=4Q&;X5$=Y7GDCN+$1?K[BO8Y)_/K%0V4R"S5
MQTD(R?L!;3)=-9[%OK*XZH*<Q(TG#V0HNRP0IL"<]9N\O)S[)_/H_>5[NP_T
M:"::_NTB_?3/!D-(?G_=.A 9$"]1[(A^#=)<ZN&?UO,!,D!2KX&2*I"S9AM/
M$&2 UP+L-_.NM>RCXKZA IE__5*!F%# ]&_'>N7?YH@?[GOAY'FO7H[XGZV&
M339H-1[\ZI9MMFAZ442!^/(%@?34U']SR(Z2KAF*72<#.RM[:O81\8$8GHT=
MQ)X;*;V,1JO"6R"^BO5_Y8<C?^>'';_^:<+[N&+T[6=?QICO==.<FX[DMAFG
M[:O^^"QQ5>=4Z?4.+Z3M&C4!C<E]J0T)YCU:J,>R_798,DQ)@8#VW4G?>_-E
M;#2][%*.KQIOWW"54%?H!S/"".DH2D@5GC/YZHXH\ZM/DT[ "4MH%L!-1VAS
M*+0-R8)+6>I41V&D9N\HODAQ0@ANG.H+L!#'=S6Q'IW#$8(.&0DU)]]URHN\
M(*6C6W!Q!YWASG.]?%"!*7.!3>WJFC+'IS#ZF<AY92X&L.4@&CAK#2[0K'_-
M,'^0+"1L19(J:?OR.^$DQ6EP#/W]!;V%>T'(<'(.=,OR^R<2KNOOVS0RL,QY
M2YJD@B,#59I_-'^ID<6FX C]+]QXC!]KZ"Q1=UJ$I]&HUC[;B57=P(#EV\2<
MHE"3@AJ^"=8_-MW;(['[X.IM[U[*A>.AP,[E=Q:9$)3 R;" 1,(R[ 3AC6.(
MY)Y*6]IKO,[SMA2AIQ0\SR2!#(+W6BBPRQBZ/=V$X"J!:UXV_5;M%O4H;?HX
MA\=,2E5YH5.WMT86(:%MR?-6[S7VUDG(YZ>;O$6I#*;GQ+7_9\.78]4O,&PM
M6[A!U-G8+-,F!7SD^,=3,@;J[@U8BQ(8*\%?XT6S9]*5EJ0E WKD5CC@8C4-
M":,[)GE,?.XYB06KQ-]O[P+UVV+;$F,M3QPS^>H8^YW"@N[.Y,0QVX3G;G?2
M+4;-RL9B9$*N$]!5[C%?IG4)!Q6S^NV8\2.ISG?\(2\%*+\/@\V0=-8]AE4Z
M\>I;K\.W$C=VN]0CB ,7]1:&!S,*QB7'L]W.?%X:0/*T&](* *G'&%5DE_8/
MSV>03A'R#'%=?L5T-6*(LS:AZDM^3@KOO?:$.H5)XH32X?DS"=_.ZWM<O))*
M3:PH5"8@TQ8J)YJZ&!NRONJZ"=M'S-/:"RID?"QD'*B6S[>V@&T6)#VV^C[;
ML195L.C2 OA(XE8P7&41PID:S\P6+M!WTL[:<+WRJ7I\J\5[ L=M%=FR=26;
MCH_=P?<Q[,K?^GUJ(Q# G9P@<)*!BZ870&0/&@J3X3^R*$!SO_A--I!+2>YC
ME\]D0&XBGP[$B9S[5ND[(EDF)&E=7^W47P%H]O%SZ$E<5[#]AN:01EQP!STC
M1]?8"<_$;2\C?&%HM;%3P_)RIIZVL-2"KPH9H.!H&ZQ!3SL08\T*=PC/R<"E
M@N.;OB&,N6^OWG XLM15J@9X1$P<(P-N1L3,S"$,;'EA(BY^\W96*B2LU/W%
M;F79MS/'%;3WQLQ68VH[T_V4Q'\N$Y?DK?GSU4RP[.8O9;U_+ONYDQ*KS,.Q
MB!?=<G'XI"7U\_<^26J ]_T/S75C W7G!'ZMSXZ9 I_0]7,S\J0\MT*]Y>7&
MU%QRS*0><>I]59J0] FQ0.!#/XUCZ]F<.MBM B <Z]"9;BHR0%_]J%:L.W*8
MBSKKH:.<@**\]'37MUN=[OR+(.PZQ>5%JE E#M<L__GBZ-QWKI1>H)<*MS&R
MWQ^_XQ,[,S:HYDVF)G"$@ ^@,7/)_B$(*<<]^71%>SRV1M135:RD:T,/@39$
M7=Y]OIY?\WCO!L_& /R:$F9/<*(QQ"PB/520]B^7)5PNE^(E_?I'K$DEJ<9R
MJH;;3E<O3H-*%6\YI)$KN=KUS/<D?'B\2!*S('U!H^ZB!G/@I8@Q 4KL6Z%0
M@C%J DZB+*[IO[]F3UEMAO](^TA\P0=;\GN['!5%K=DBXM[5!CNVL*/2N[ZG
MM*QM;<\R$YTN?S/^)$7T2$H<Q>+;3TV"]0&CG*;; 5-;S6/:*H/ID==K$F=U
M7CYU%(_]MANVCH5=:Y)P.Z*A<)53EEGNW?*A=HE_L/Z_FI\6I\@ ;)^X(!:$
MG)WS?\3LE7*&'5.745_UU5@.'OP%FP\,9[U%M#W]*0A(%"[Z#9J'CI 4TT%
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M%V6.2^+MM5=M;^9NUQJHRX=]]U/HPD2VP DNEAD$UWE4PEB=SV..[5=UE8K
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MS'ST^M2#J+ES-C0JVBK[NJV#US1(*FMDH-S&>6*;IHFT=!9<M"=!I#,J4>E
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M3^;@"XB@%/G(5L[3F=^,#<KT^-4F>=0I2SV(>?Z$+%R*I=O9BJDYZ?SP2LR
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M8X*\!(2O:^B9]^_TD5#W0#$D>9X=1'$6[.CV/<66EI"]#N.7.U%Y*5]^7&5
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M5_\U_K<9 RZ-_0VG?K/ST6)VQ+W?Q3YU[C:LN'URO'V#5DK^EI+#K,RWLH$
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M/ #^KP+8LC\';2VL:I@,,V6]>>1X$Y2H^;] J^* /V9Q7ZOGPK\+D]HD"AM
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MG(D-]E:5S[MZUC5=;"X$(CO_1N8NL!<FM&1T9.(GB[.E9M9:QGKVO%HC#S5
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MY[OXY4NP.,T6Z:#):1NG'6(I66^$>;/GP7)^Z&Y7%W,676J_WSFURZGFD'H
M90)C7JS-EWV4T,;4YF\30KD";7#G[F<V$)Z:T>M^5(URO/PZ-Z.):0T7;L#=
MHK6>(JBLK,SYLUFT_$?\%\=)/<@B=Q#E18/'&YT5L!1M,\&T=R5EM,\<D9#[
M1_.=(:^1Q99CD"SGGT=#1=X2T>@Y#I#WRAFG68!'JO%_XHYV?D3NQ?80MTBO
M[3;*U\YY^*,QO04.-X)=GOKEZPV0KLF9K9L3BG;5LH?=L1T&3X*T7DV>)F^
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M8HK$/OGU+]\A\4IQW#2,0QD04@X7/CB+/3:<,]AZW4\ZR5S],/81+41N=S[
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M*C;5XG-:K@KLTJQG2G6M242@_F&ZIBSLZ9J%F0&R?/;I.671*K;2;W3&P\@
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MMNA=":OSCD9UY0?*8$\J=#C)UK;#[IN01ME[P.@>N*;2]+P'>HW$?KD$&->
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M-))VBZT;TIO1_;'*Z%,89[?NQ/>IU!V23<B\&N+>>F8[P#7]@4QTRP$M%LN
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MZ^UD2Q_<^5;Z2:+HZ7&FJ<,2^>=Z;\\L@O ?^],8TEB[ [T31Z5Q]:6MK4G
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MG@6D=E*HP9(>J@S.U9L7YJ)Y0K[OW^1P%&>#YKY_*9<WP M"_4!WH47]<%N
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M-VV-1-,8_\(_[1C_STGL,WTH@0-]5&$8CUX4(!-M6$?D%H Q\.'3S>YYU_/
M;LP8B0/D^ C"'EM_!FCN%M^A0$I!A8.+%ON_E:#]7WNCJUDY6K+'X<B^LZ[W
MK,HA+K-?=:SVKKGBJ7F0'=&-?VZV;A7A#,H6#NX6T[WV_]-'N/]/!LJ-G :
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ME^*T["=#!7=77]\*T_2E%YVD X#XL V;3"S<QUYF$GAL'%7)1#JJ%G*B6%*
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M"]AXT9A"[?'_S0IG89\&),*II8>_7;'I,V772U>SHG9('++=^9]OX..GH).
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M[6--M^^AH@MI.+P.2PD?HJ<AI!(S>D0ZIKBW(GLWHFE;)E59RN^@>G:CS#D
M;5(\JO(V;J;VM\4.JB*K!,G[<$BJ<>*<V@%]#'Q\&<DPFKJ9/*-EPO'U*4F!
M\,U-IJE&/0I3]YO]J$Z/,WKS1="=\(?/O&J),%N7!88(X->:!S5WC7=6$EY^
M>X4?UG#D:3M8P[,-"C3/'6J^-ZFS4.R(5\6N)F1$*N?4)%$4%J =T:/=-D$G
M/^LR,\?FX9LS-=9"@& M_Y37+45-:S,<Q-0<G0?!0=PKZJ?ZP,^J.-;*R:I*
M:34?G&86!!]JQ,26?Q;<X'P]6S2U\3$M+!B=FF) <[>9Q'8*,Q<JE"1?*O'
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MK"278*Q#OX2Q[K/T2,G\D:5(J<>45*Z7H*NZN[.0#\X)L-E "35_U1(_P<P
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M&F9>6OKU6\(JU-V.H"FU*:5&M1'OV5+B:VKNE02"'SJ*[K!)R(CFF!?+DC2
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MBUCAE])(CAO<7-]D85&;D@\;Z7Y1%6!!$1%+$>OR4%RE-#3$)KYDS+$QQ5Y
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M8*5Q">2*2>7406I6<;C@*[;(NI?TV5C!NS$[4YU^E15V_%TQ&WI@#G%H6.$
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M]R%%MT^!D6#-75,&DKP>&^6827-QH^)=L0J# NF1^V!/VP3 D.T9SL&BS'&
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M:>$GK8G3G?3[F_'__Y"NA<&1WB[YQF;F+_QV?*_IQY*!/I\#ZHO@O(C3I^<
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M."P! .*O 0 6    9S!V<V1A:C,S;FYL,# P,#$U+FIP9^R\95A;V]8V'*A
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MZGBV+3W+B +HM'9Y6\&2F(+#<])*6"9O4F7G,A1D[/%>D3.^Q;K%*=I_FCJ
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MJ7LYS_Z<2.[V6!>GW1ZS3,%SU*NL.@>(?&+RG7;45[\\HL7Z9J\W^31;@/C
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M*CH%$6[1>\8*YO[]R'(L#FNMHKH_I%3K?Y$4_R:ENO\AI1K %6AE#R1(G-I
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MA<_07"]G7!)5+5UM@I-+KW["E! AL[8WCL"!J1MWDM803K6RC+8 "-U%-PI
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M6\%%K#CR IU4="6&:HB]\GT#']:+L5-A9O!#6G'$:_2E?<=[!E&PW#=N0KZ
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MDC1C-,J&O[>N$,#.;S#9@8?3N32$L*L?]#)5=YUNIB'H1?N" G1DG!!X %>
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M_D3K=15EY53(]HA&[U"3*+94Q2%[VN9QMR4.5SO+"V \^S#"8Q"Y@M1X6G
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M%"&C;Y0=)Y:BWX4YO4765S9_?:N5T4LE=0TM-^)[5><*6RV 9Z_EU;#4Q!Z
M<Z2V6!N^DT4TE.91^%RC1 J/VSBP] B#D=;IIO'D4PQ@0I(_E_K.FLP'W/J^
MQH]3![D@RYM]_KW/N)E3Y3@A1)A"Q\O4E*!R<88)$687*?3L4&AO*K.YH?4X
M:W%1FQO:57NSA"^8297[(:.1O9 #-LDL1G5@8^A5(].8&L(SZH"OH)"B,;2$
M?#Q]2RNP>-<R> 9CU@F#GI>>K*\T&^/?\-381SO2I>^!9&(I]V=BD[7)2\-+
M&]31A<3R-8+A.#I3M]SK/,=I952#.%L#)@<]MD+%<]U&?'P<V4R9IED07]]_
M>M'-/R-KX=Z2YS:MAH;7>C$T= 3)G^75_X#2I%E)SM#U969(2(I1.#)0,XWA
M^,R3;G0HE?E$-$_28V<:8C8]0>1UH]QY[[GZ &@MN)\H?P"DUWL=9>II%[E3
MUE2,'9;&J#6RH']8,2E%F6I(#VQ%5B  .VEH"(1U66"T!R$+B2+=FCO(8^AM
MN@]=5!Q%+H,6A/ORP^9'Y<V^EU)U+&,>W+(7>32^O=JT:'+L<RZ=7JJ(!FZ#
M6FHH)#F%SW:C0B2YTN@S4-2\:K6O[A72TDPNG>P4S>:^NJK'V7DPZ);W:#]9
MP4:1N0JNL=!U4(5IO^^963[H.9WXN+X3S@2R3SFG5/DE7)SS&<\)QUL@J3!7
MO[L([#A=WM@H1_BEL&_8YFK<P5<JQ%G:5/M*W7&J6U\V7" WPNWW&\HTQL74
M3C8&Q<Q;EZ4)(JQ:P3\XH&T?EFT%B0-)M)>:W(;]^+QKXAOL2 ?ZF#G3I^KB
MZ"5G*W'G-=Z?EXL1/7GAP6#^PQ/?.48M1K'E>*EH#<PL/\JZ?W:@5\1$U-T]
M4]]4'"*)JQKZCXSC_KL@<YH>EGZBD/-H<KZUI;IRNPSW#%_1C7E-__0:*DWO
M"D[KE5VQNL*V3[]>$4DL55FG"')@PP(GJ<Y9=(J/Z7"T+J\![$O+OB^?4.^(
MG'_WXM2AZ_V4RBN.DMDLTJ?6L32NK'TITV@H\L)=QX*;HO8NH%^+2$D>K:#'
M;B_-[*@KXJ79'&^(H)")B>-HMX#GN32,;*9,=G348/2+&B[C72H?Q2'DA"+T
M"1:YLU'P"IL^G$P5%'N!(_?NHN J3*&@C 'NMR:G(0N;BC$RL1_5_B%L3X8E
M<Z[YC5#1+U*4>XT"9U,:GIK=58*601*89P-)4FJN8;3LNWQRXWT-.7D A'N=
MT/].*-O<,4W@'+*--7>NI]]"\!\ YPM>,DGZ76)L7_<%,1X E.IQ#P =D<)2
MB77'3)HZ?XM]19.#JJ#^LQZ2:PW]W_*I3K]>O9.S$R'B<IIH?E7W)B>".]97
M4I5HKUW$N\B_)2_+"Z%M!>,UE]<SS2XJM:B1MW%DCW&SCXY")]N+^3T]G-HP
MDV4[RR8:91?RN+D)^=NA7U)3(\^>? R=E/O@U56Y17'Z<^)TH=,<34ZP$-=\
M<F$%M:R@LC7&^D=[;,][JI8/3B23Y!3'7DI5Y3#\HFDG]N\Y'PF^F,3H]=-!
M[/FR6>=R2W$-U\3T$%:P4+3@;;H3KYO3G..IZEU8_"9N-"37K;Y&;J=1Q"B-
ME5KF.7N"L<$(R&[K/KH.!L\5U V(@"R!X&FJ[@< X;CRN(%3==T3P=1&XDNQ
M$8UT=]J&,59W%J+R.@C:URL3A,JNZZ2SEYKJGN=-Q!+F_]BU)7\OI'^5);:1
M3L3A&YY65'\YSWC^%S_JGPB:QT<C2J.D@,F;B9P?/@!^--^L6-V&-";<>=:=
M@,XH7GKU-?Q>%-'T & \/?)I.V'=U3^_7NXWUWP 8$3>4U7!:@YZ4E=);HJU
MT.VD$M7)BON:^=>PR.#C\OC$%KT)Q-A5NBF'0[;\!S,:1;?O'@!1!"H/@%*O
MJ8I6C*[@%3035834A0JR>P.UI]ER3:@R)TS.\19.'<OHL8.>PX52RUQ7_?S<
MXW#\ZW7E8W__R8D 8$XHOL'"6H4PVP.@+T2$Z,K?U)TKBOJ8-K7"[_,;3"P)
MB!R;B?6-.B4\M6C)]/YETFZ/,>3C]Z<48:9_:L4XV<GA=;0+)?*W2^ZA6Z-Z
MB @RD*0>B\H[(ZW%W&2U$QGND8O/A_A2(N)PG.QNC[2WQ\)2DRO$@W@^\4@'
MHWY7B/$43LD+5[@+KD[\*FSZ?:/^*G /<G*$;4X<WP8C-E_DZ-IE,EZ1BLIT
M>&67QE3X /#W@>%*5]V_-)X/-=BW]0HS_[&.&Y5Z.-MP;*[GEDKN0;S:YF7X
M2U0HP-7381LT?.O#YK7G]RCOJZ-.@=;"U:,@]J5=5[>='0]:,NK@*)<SE*56
MO\D987_G75MT=+%;1L:><3D'1NQFA=1[<N>EWO:YL-N$*."KV$@>#_/:B58!
M<,\/L4]&#"D1"5Z(E<)H,R!]LZ2,QKKPCP)61+W<^V&KBV2QA>,'Q]*7C+L_
M4%VS/N9,!2;<DM81S(5GENGH2DUK,,N^:Y%RFZZ$'/.MZ3^_-9&5X];4EI'Z
MC.(3HW>1SXAAI.]VR9HV129)5E B]T_W/?X+>%**L[:4Z%+L3"FK30@"A\+*
MU?:\S9MRJ(2DP-VS"W*ZA&E8M?'#'0)&S=O*FJL(L1?\W+WN!J-EYR%D1%]8
MEHPAVU7^9$^9QD77<U\#S@'CRF8Z[1;,ZN-*66,'5#8!FHHOMQTAZZVT< %]
MW.U16:-J?9!((I&0II?3];2#[#O#M4.?XF)RJCSW]S"I1-,DR=[ K?A#[I?9
M7[]8L_>7N VCP4MONAL]JPKGFV/D5Q?HUVC(4/;T1:]>Q"]\EEMJDC*3RT@3
MA:JIUKZSU7>D=J?TV]%S@P4"6R9OV='Q7W"-/?=AS*[#VX[]BC1A7!G:8&0[
MUU@1O'(#_G)+DS<_Y$\33LJ1UDM;<_@J?'/IO9%B/V7<1S<_Y75<QYRE.C1R
MNB(X6I<PUE2ZQG%)GF9J\!N3Z8K"+'A3F;;DAJZSV:]#G%^.FO-$94;<!+,9
MU#%/#!\ ]4SZY@Y'E"XL%6O1X'M>>(AUF_EB_HZ1#\.E;5L$?QDH4);8*D!#
MSB=-#)T<%,]OX /ZD2F%"Q "Y!;&2?5D&_1Z8IL2I\64[=KI@YKIUW\Q"YR7
MZ=;[L%IL!*BAA^>^I\R90Q%%6965L;-U>M;SHS?$%,13MQ(1A$/34E*YPZO0
MKQ3)N=22*2\JG!66S?_*4S4K>#C9&O)[JD],[!]9X?WOP8>EIMJM) _. 7U.
M3_X,%.4Q5- _W0?[C:'ISRYG3-O9RD/'' 5D0TQ!<+$<?;  V:W&"!?K])<?
MA Z$I-/92:* ;7;57-,9.7.[--A@SN42U@3+03;'AQU_I:4J8?R=2Y"^SX&%
M%:5IGKI[L<--3Y,R!W\. ,&;?O/217QN80"&'YETZ.^07SMB]('IY<ATJ&GC
M<O ]47.29$\<RZ^\37;"D3K/!KRC.)).TD V8G:*)46S3)4X+>CS6$MG-@B+
MH/;Z('<-PY<EM/=!)Q8VISQNU]-VEDFE8<>^3&YN+E[5GL._*.E_:8;7;'_"
M91W)0)A!Y0DU0,*3AXZIS^ RNRQW6*$-9YG&Z.J+CR[IO)=]2NIS;Z<7 @%T
MLYC\GNR*5587W%H;#F!U:*%$:WHV>\2BPX$,;4'5OCD"^+?XK#?C'Y!0G5.C
M>]9,OA0%H ,83EM5_0>@PZFWU&G,Q_X'"[5SS-%77>?DYQ.#ZU;D R_?<V%$
M4S1VD7H)G!^$W(U>*=5X-8HPCJG%IL[1B,]S#@ABK4!!ZUT<SOE=%B$](M0Z
M-GI%]+DEN71TA380L?^_>/'_./P^ZD%,5A09+\:N5!(]#->F.9HM8RVK;L(!
MK3 2VMI7=4H,F,^K0B;Z#+C,Q<-8K&_T[NKR=H, /K55HSQUZ"M\70^Q_B!/
MB%E?\@#81^.<X!=N"M.I+@_HUQ1_AC%-QX5@4B/&LO&BM9]&[8O)T_RB!)!%
MR_QA'/"+P:LU;X(;J?%[-ZBF%&9F["\%":VVXXA9+X>VHVR0:0BI&>0-[D=%
MQ%$YZVY"MB4J2">'.4^O93MC.!#1F[?0G+%3-7[7BU83W2)TLX93%$V2UG3P
MS\<I_+V+FF^&>0E)S$"6Y\MU@M>*2 7_D*-'&/YX1K I CUW8H%9-$B&$H)$
M94"=%J<P/,5:KWE;;1E(V VP@CP'8+MB5L^T:TZP#P 0\@4"I51& S  ZO>C
MU0^ M#WY\),EDUG2HL%MQO0+Y(1+[?MK;N[:. LP6R)VZDSOH\ =L^.=,P _
M5L7."]G5#O<_M:AI^;QV_;CFC76 ]F%]&)1HJ$$DA2X49OP ^*CEB"FR(@6=
MG65),7H1_?S0%'&2AHR)>/,!H%1;;WPCO"VVON3-4U#BYN'*:Q1NFDIM$)ZB
M7B[X6R:#?X,O_?D_J"7W?P6B0T<0\0&&*^H.4U46"!UUWY9\H7K:'J5/0VN7
M;>8R:L98H$&O>44ND[RIQP\-&[\V1\5N^6@PX'ZT9I<5?1&BJ2ZW1K-\MV^G
M_%(^R_N/B>'/\7]I'X%=D@47L)C]:CU*VLR!!F"RR^::#)H44QK  D&?UB)]
M:0SMF:Q2E -C=*QI=GI( CZ$DB$Q]%%!'-A?&H@6O4&1(7\7C/8666DB">"!
MVQ5%+;K='GM&F?Z/B;\(CMR7YND1Q63?,YC^'5+\?1Q+R6XVL[40F#*)/\'>
MDM 5 E#_6*1YAA=E4_KJ+4MDWR*R>66@<HXAL2\:/4L_>P^"D!Q 93RG+=[8
M+0[M)2E;KIF2K.ASGY3+;-SJ?RO!/^;K<7 ?/P+X0#\Y+8T66AT9)"4__@Q9
M=B^PUKO95+>%L::TRHH'7V&QK07\,DJ-M;K)//,TC^1F8,J;I9@)O?")FTI1
M;EC^3.;)9<(6/[?9HV7],+;YSS]%Z7\L<C*0"TP:($M"8^5*\T*[H#(G$[RU
MHA^8",.X")&7=4FQ:;I9L1%-27-UTN]?&EK\1*&-IX_&?4[LK[2C/(+X&0+Z
MKZE.@:7%V"85:2J&G"3 ;MC<+9<]>C$T,KSX #3%^_ED00:WS""I6I3JB3(C
M(SJCMU !PH0*41QNU0O H1P?:>CO$W[^1KW-<PG9M!@>5,C[HGM3<:KX]TP4
M,SS_/@AXFM%4?\/=)%M=N]21JX[)D?-REZ%; O%9GU !4MI+?;-#D/AG/Q''
M6JA%]-A+7)?>%GD $@!!$H 8_U]]X/>YV48JOF* \>T,3&==O1W;*)M$2KHC
M5_7!F@4-FZ-@'[)N(#60$<\!'0LJ86Z$\<V+WL"F?Q  RHI4>F2W_P'^_O\T
M:"7E94QE2&+'QS7:@!Q(Q,/;$\4^C42)HM=P)-MSHO.3KN5U/]KNSW^#5J#6
MU2Z;U9K6X='5EP2Q'G(UJ*.55.LBN6J(00+6IIB^7<@TX")0"O3Y_':MY/,D
MB3N)L]#I25%S"W>!1OBXA[%GN B92:#!T<.PR;S-+_4BW."__OV4/$\'#RIS
M\ZQT;SA/7?\F'6?  . :%YHE8%A\/@S$F"O: 54NE,4Q("J*"  F35 ;#+R9
M,$_NM:\\^XTQL98^:5N&4.)^BI3"D  ;8&1%89_O*H  LF@*%?-!E_&'=GOJ
M.^RR?SU9T3*89CRS1 ]!(_1F"T=6''<@,HF#;H66A S9@+[E!4WP6V>P[]J(
M8N;F(/X=V>'_A_\3'\;&74>0,1149.F/<[CR,TKEP7HN'Z+9F>7L$UQQG;")
M\$W4A2*XXW@"W0@6%=?O8D3QFWEY:.+)NRPI0#M,X>.W T(RM-$\%#SC<)AN
MV%_OE Z&-#D*6X$\)(/=E[)-<@'O&<!_I<'/X:H.S 78W5,G!&5NB3A/(591
M/57QY7^BGE8^IK/[X06!ZI440^1V7977P!N_VG4(8&:LYI/M$Y47-&18E\4Z
MZC1U@6,<9<PEFK;B,+]S: Z)!BEL3Q3SG^JQ_G\&&4"V2_'.M3NLT\D)ET.V
M@ZD6S8-Q^[4WHRV&\W3WP@.@X]/J JGGZ37D DT??AYRUZY!#V*(SG7Z+/6Q
M2"L<0$1;,&L.LLRVH<9WJI!CUFFD,BR;*M%_ /0)K]\W\)YPK[6A/!=^.WUB
M%]1VX4J%UMWZ_9>)P<)C $-4\-@0IY0I@FF>("2D88:>#)@3;OJ+*&PRL"*K
M/9,&-S&O.80XWA$5Q=84X6<[;A4I/1'=6.',;BUQ>N(%4_W62;+Y_I<#X3/=
M0=Q&B]&PR0J<,^&>YJ85%VKGP)0'0$[9B5D-&0G-@#9YRV/D%R8H^RHL52+-
M.\V,FW$C5MD$B3:+P)IS'SO32M2TZB4W;F(V%SIH.%E[W*)LJL=\1GFG(BBQ
MU2 MSE!7U'"&5FZ1/<V\J]E0X99-EA1GC.WN:?57_M2@6&C%H7VU7Z[D10'O
M/D?>X;=!D\_]!3E#DO1< .71_U/=)6P$'P.XT\9>;/0J]A54WTZ5RLG7'#.+
MTC:$?"Q$?8-&SGOW[\+T[^LI-IFV'@ (SLDJQ_YW+?O)/5$NKX$(-]"Z0O)U
M$:@YJ@[L2^!;SEU41A+9>C8H54-=E"%$<J$D_Q6D$Y8..7"GR^QWLXF/JJR0
M$JA2-V-IPEV,&R0Z/V"<@GW9;/-AU?2F--Z8W*%]GP4VM [*IHD09?KU5C9Y
M[XAT9ED?18O5,JK'@Q?UVDU]/!R:.?B9AITH:X84,Q$/*J,3AD-T^D6SJJUF
M@O+4@A7;]#2LSY:1=O+L;"(@93H*K=/W-<NIW;!,QS&;WW+[M<ILO[OE[$+M
M09/H+8>YWT35 P #QY+#<\/KFC53C&<?4XZ\SJ-H9L<'XWQ"?76(P,V VR@O
MC)*CRMO;L$+P<W/RN@OE/+"]]ZBMH$QJHCIVZI:7-I4Z@G@8?VS;A53I1[1"
M_?A$FXF'A=>SI#'[),%U6U)(A4Z"CSOQ/>9X7HWYJ=.F\,$\S_HY]Y3)5!Z0
M+F.\$1_B;YEA,D<CON0],5$BA CY,&&K(_D2$8AG-T[[]:NL)+<FAV_."S>(
M#DRT.RN30)%@YO&WB85VDM]T0/0YPU  "Q[JHNAPA9'R4N)F[B ^6I3.0B<8
M:=B&LAO7@'G?&;'A@+?WGGS2P6I_7G;D\LD*NO6RS"]/7C/E>6=C-+XA_#6%
M;Q%6#P!=4V>FU<W@_!V0[E6@9X:WC*4 ]O(JJ( &TUB:<[-2Z&E\='SE7[4^
MV: GVL#5%Z%O4/AO, 8%M]VG/":;A0S)&H[[Z+]75ORU";O8:L4G8%R;:"4\
MN_[OA7\E%6$7+9OA)UFTI;M91TK6LU[R$9T5JVU1D-@*(K6WW^AX]1=EDH.I
M&=XRI=[E'M3<-2Z ?L:(+Y)ABA7CG1YU4A LP:T4:\>XU6?SE^BC\2/7+5U?
M>.QM(W_<)GK_*M1O3TTYV:\\F]60U5P PTVFH?4&E_<8:/_\*8U5,N27)S5\
MUITSUR-^UGU0?!LW3/H++.E$W[_-] '@GVEJ6>=20FV,,I%9[(^_LM%O)P.D
MD%[4G9\5'U_X6?&N16L(D.N[21*$[VRH1?DI<M>9LKS99+5!4"VC/Z_7Z4+]
M,U9BG=-.E/(V\8OCK0 ->0(,?@AG(I8=Y,>/)2/=A39PR<[T)8?VG)X$U^C=
MF52_/I1YKB?=JD#:@&4#Z/":A)+EE,>#J4\8)]K=JPQ182GF 2!>Z*[S'GZP
M"HL)@]F !-03& 2O=2[0B@?<2!S3=@TA-#<_MP"JD<-D7;+,K&4DZ,4,*Y"M
M6_"J$<SRZYS77-KL:9PU!^?AV\ETU.V(U64L;7"TSEUN)B''P7QZ1V7EKP:G
MB?FL)$W&7T$ UW&JA@#U>=*BWIFQ*K3H46 2Y^]18?Y-[8(KB&0DS4QGA  ?
M(BY*1 =P*LAN")":BV;BS>"B)J#-BH$^ZH^*EF]H-( ,F"=MAY[_Q3:;0M04
M44+U7$A]0+K*O.GFJR_>/:W0'>-J&0X\R]+A*,B5-R#-BG5,_-LK)SM?A3(Q
M#7G!L0J.N*B=1JS0:@5L66J0Q70BI8-*>ZFW?:F)V+%P\.I\;N/XP6WA5S="
MO\O6FG''7";]1>*6&GP(?2'A?[3DT+$H8<X_+_F+)1LK]C.QGD=-*W88=%Z7
M(']UG'H>J3OVA8V"[ZJ7ZCPO;O%;<B4O]/!UHX^)KV0T'9&&2J29SG2"._&T
MWA:P?O20<VNV05%VBVI&HV \Q<7HH_SN+Z8[4*>LFOE>/;338YS*@$NN>.?B
M8E1GT E;@D>PSGBU:AQOW>M%*46WUTO[ \0ER3<=*WWB6^!=.]WA4$_R_."S
M.^&EI:N2L#3$52<&10$#JG37.CDFG33CB[<.'W>)Y,6(GJ@4I26;VM]QS(WF
MG!(33J*MDY0+3&9]1X\9JV1=+RA83^*7,K#^[O!J_%0J@^4WKP&J56T52 7[
M=KW/^G.!V)(+H83D*Z.?=#P0O<&F_Z&(_E;\/N 6)?C6I$%;!'M;@_6YYDP%
M4IO,3."Z>@SIR\SQLN=J2-Y>'97W;/1>!,XNFHAHD6+7D'-970HYG@H< P0:
ME-LJO+$%%RI[PYA-1\'KK76I&):<BC"!?0)QA/;UB%R[MB?Y!,(<4YN*HM$8
MWRF<RCZUCIZ-?K*6# 4$S<-1<ET(VC,(>D$G!=]?6HNLV$OVSO[HDQ,VLLN$
MMY28$>LTTE<T16/QK##MBSC;Z<49RLY\_PDT#@.*^+M(]RR?)SW?9]6@.RU3
M&T_4EZME%'M*TXXR5Q5]B<,BXI*F#2/0GB@1],J<F].31<>^@T\<+S)5P187
MNQ-\N)F*P4D,8XAJTP5\98+PM.^W,L?P)]@"-_:EEVMLMS&I&O<MPR?%E9?
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MF:_7B8+*?6ON?5R)MNIA4V*-"VFZG[L:K[<#4SJF<W#BQP@6TE31HNLO&@\
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MBCG?$,+C;=9<LGJFVZ6GT\-5O!_Z'="7XV.)8 G5,.Z4FJ0\K(%KG;PU&S9
MF)6;3B5M":SIN'Z=^J#X,7?J-&B%;8CSY3X&)M8A[Y@;U@MOUD9B%Z",:XU-
M!(53G[*>OE="8!.,LC-/^GJD^8G9,F"W^4+*\DV4BN^#FK+X'2<@?X;;2O/9
M$MQ!V_)>H'-GR/A-_=S\!#2@Q19WE6^?C$/%8MC^[DNRCUN:^W+')5X=&[7
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MLQ>JE"6)\O[F,1Z-['<Y8 O+B+9F3MBW"Y?#PMZC5;U[0Y)%@9.48'<.L>]
M!G98:;;U<XI!(=Y7^82X@%8AB-8NGMIOGV#@WP/D0LU'S;7XR31(>>GIKYE%
MK8_BY*RK/%7SQUI:R,WGG4$.*1Q8:^P1VH8%"&SIT'OCXL/*LMV=TSI9KZ(!
M789'?R,NPB2ZUTF3?KG\$/NPBBY08HCMD0-A!49G.T,U'K;%_ D0Z(Q#06N/
MU9"SH4O]X3!96J7J_=1USO:#NQ6",%8R7B$(SFIHUWW[,,ZH!7FV2DZ]AUTR
M3Y2LC@MQ6%'/8^=V(#M';$+R<[B?S-3Y;[T-,Z5*+;(CUZ15K\0*%LAO'JXC
M(>E/*"Y_<9Y2]-A>_G;H*^S*KF<[>H[S;$1EM5_V\LZ%+^=L+3=$M$5B)X7D
M"8B<XV5H][+7XHY1=$-:=Z*I;)XLG$$6F[N<XLJT'Z@KI]:<L" Y0FC 9ZO@
M<"@O-*>R)K$S)HK=L>Q\+,W<PVC-9>P)/^LR?LZP 3!)!]P^/+>3NJ*KJ9&O
M'L59F/0FM+0Q+HZ$W+^IA[OJ_N)-L2/YEI.Q5QOX=*HUN9AO+6TQP1U25WTK
M6"MCON\4I_.0\/G]LR$-+,;-*)K^[$CP_0DX5+?R2%Q"%R]4?&$6SU%G+A"\
M:'#E1J"I_6.R"V'($S_QV1QU^H\AOM1-)F%W)IX99ES6O[2QKRK99$T8\9)V
M]W2852NB>'J1IN"LL5<^YG?7#M:[>R]C%R;RL(#(L$. I[@_>%U.923TBMI(
M7K9R!8U9]1BZF+HPFCC@"(>S:+8Q*WGH6WMM#11;:<"LP.2WR(+@/11149X\
MSEP 7;5,#'^V-*5@YOJ^FD+3UXP>2KI7NV(^C6[@*51,G^[,^IOC[X]+_0\>
M4"<[B=V8[]I,\7UVD;]8SS0P'[/@9-W50CUS4AB=4,20X3 ,=BDO:>ETS[,2
M,QZR%G4 .392[Z$!G&B :2&(BF9PAZ?S\SM-F84[^V\*D-0H\6PTP*4RCY$%
MWX:/&U(N:>:8,7KX@;? [!:P-SB\4)A:0N<NWZ 6Z%XS"V)4'>N@Z*"(+VJ^
MH.%)E,U. %7*46FN^>[ZH/;<Y)=32&-I"JEI<9:*FE$W6WSFYWSA=GL1732
M9LI;]11RD' ()KGKYMRXV7W1ZM[JM(0&8'*U7$C+?J_XZ.R*3S0]@.#>2-TM
MLB5JS7?OY$V+ZE1?? 1E(-.[K2$S7I#705.+(]QF'ZT)6Q!<U7%,2)(D:X.5
M0:K6%$7@81(INIZOY&79@A<+G!ES"U!X:$!X.T*7(2-]'*3!9F]%9$++2H,&
ML*S 60F:83R*3[K#+3PU%:,+"]L[F7IT(Y'U9\MSKV_?W0Y:8OXJM@QS$U>&
M5UL8)I6V93P*L5R/6 UQPOU<'%\15F]GKYZH-> 4](8-VW' :(6A.KHZSX%I
M8WH$^OJ SS'!][$/%\O;&P=Q[Y :8\$,-4&;5V)W)Q%U&>.P=3A)N #BRII]
MHD@M\KB95_#:(D5_LE&XQM!12UWE_?>$VI(G(_)I*ZE6(^(K98=;8K/6JAH0
MYOCXC]TV&Y"-OB >'>^V*Y?D')8QT^@X/\1C9F6#R]UJD]\742]/ML]:9&.S
M<9:^ZN%E-_7VRY.FNW8 *-D1Z,2A;?U95"^.DX]0R,7&:T'6 &K%F/81@[QG
M0\N>$/ABEE':T,5K5XL[DOP[4M/,C.&6;-@NU7N/5<7X.>D6UC3?$O2;89:#
MW,Q0$A5H0-A^$<O@>T-&PA>,#(.FJ:'@17IK-$"G(:\H# =?1/@1Q;T'U$5&
MR W4<Y>YH^ZSA*G=#!9SR<1MJ"R4# VH?;$:MO>ZA2_+A[)AT*1-R0,"FJK.
MF.#9YSHC:'7%:A5Z^.:N6=B9F285W4BA,]V'UU"^%7%VUO08J<UJ,5-5B-8!
MI6G,E3F541]]!;,LP'ES&-(**A,P9%!O<NI<A( 7D-$KKWQ5M>)%+'V<U2':
MCASCY1MFX0'1)64XH $0WJNV8C7>L\9T&HX#:2\+P+7BEE%0^X2&^5IWPS%Z
MU_,O7EW>!;BUQ646YSPG3XH$'9-Y?-A3SSFWEI[N1_B#+:,:K;25/Z5D&H^Q
M^?D^7=.5]@4OH)1.+$&#[YGEHYU6F!5T8/.=5-3X'7LE&K>J:"N)]&6&;>E&
MMI2WC4VX ,]$+6U)T8".9H[SH(L"<<DK*QW)N70B1)#"N5Q6&>;*3Y.50MAS
M*OA27A;&SR3GK.DXC<5QOZ6/G\:-%V4MV)O3%D>2'$+Y@@EIUACZ@5$K):L)
M;/,@#P+M;C\6]C:RC9W75%3]\<[Q"<:G#VWC:/,*8;B6THK#PY%>U6(:9- #
MX##MT&$U.\F#>!\=.UG>=G7%Z&G:LI#O"P('8H&,\Y=J.C-W!/0Y6T^*/1*6
MUGJWZ((W';[),HY&ULD17B81*LI%+L<T09B*@IO^^J7M3-=086\F0[,('YHX
MQ@JLLHX8AAA^I%7V5WZGT^[GU,?0/RO3()+$+OT0J#X+IS"QM5#I-O9P<W-H
MFQ\<5!DCZ_^M9T3_78">L"P: ^?;;4>;W0ZNT">2[F(9YJ/\@U,-ZC:X0I"C
M]06X179 "(>1?KP/L-U>MXI\.JIT(FG\DZ/4ZKRGLJRD9T[2CZ1)OK^FY<C8
MR'<I_@C/9SGF88X/FP6XJ#]??7E 48Z@<EK63>>)JJV.K=<AA?KEL(F0;G?-
MMG[.5F4HN9N2ATI>4<^2]HMT5Q3I&,,(E3G[)S) UW>7P@=3M$;S9:_$I*/L
M+D#XH^N>@O I=VR!!9JL5)7:ZBK9I4]E'T^T,2'ZZM&FTWQ&QYU9CE5[.1=O
MI2^=]3=TQ%)S%7)T'^^F)$L;*=6,[.P8[D/-.*@<@W'+I<J:$=/,52\38MRS
MOH5I##D+E(N*]S[G-[HKBN/NW'[A+8\Z13FS96<X&]5N'A#.G)3,%D2^#N+L
M9&2(I;Z[VE/_3J521+TWX^O</G[55;B@/YKG!D-).'AC[1?6"F\DWB;;RN(L
MO8L/6%1E9S>MC>X6CG.<'@JYS;*=\TPH:&(_#BZ,!M#>2+UT0@74*%& V^'4
M.T"2Z_O:BE$OIHQ58WA%EW/<?=)LS+@P^N\QI5"I%.8[45C2XZIF[&;7$MXY
MOI/=%+7/*8)GV3]\P6SKLSP_^C1X>J]_#',0IK4AY/^)U=9I'<^H[Z!PW= T
MIT]V/'=4!UXJY"E^/?\)*.\$X%ANJ7_?<M0EP?78N6*4W@6A^'R,PQYFZ2K[
M1;N2=<L?I9XD:Q0IVZ<S&$J<N=2COLFOQ:QU:^OB+K>1BZC^F:K9KG+"_&N?
M@9!-[0/>KHEUUUCL;FO.8,[.KUB\(!2^J#8*_ !U2HU0?LQKHMR%9Y]?;%\6
MXIEZDY0M,VZ+;)(;8N8KOH"R/0'1*-VSC$R3KGF3:1"2D5!@X>UHL'0EN1**
M\!L6FR#%Q.#93$\9*:!DPWUPA\?.Y8&6#^E8:W2J2;718LFI["8H*<6"W=0B
MVWN0LYL\M,*),(]))D9C:%DZ UD=<R%,RWR=6,?G#7R^J#MO5L'B^#6CZ7NC
M)9I\E:9^IS?#ON6*KHX9NX7DWBU1TB[ 'MI;I'MA>P65>K<<V:W-'MQ>G2D(
MOZO^)=-7&#(8V")4!#>DA=ME#&->K+,,%/2N*(02!+)EAFZ/DGH)IT?'6N4O
M1BJI> *Y$7GU0_."9FW\D:";.Z]JZQW&N.$I,PTL)D6+QRJGX3+*ET\+$7Z1
M[Z%')ETUUMK&-FY#*(F@*W<9=YJPPM(ZL]2Z.6O]S7^.M+-=#J:KQNPIP%1*
M'K4<TYV@?^'/!MY(1P.$#G%<GPNUQWSDLX+QADI#)"-PR12?%8DC98YL3R]L
MSQ?!_H8?FH>3AA']@\DRN9-2.Q</VU$^H)O[$X=LZL_%EH.W;\;]3$UJ[#8Y
M\,2>E.<[ZY)":AMZ(Y3]BG:5-1YT)'QB=$->.:S+][M2\KT+\/4Q.Y?#6+Z3
M7IZ-,1(.-DVENT@=J4*&]/'75VLU]HJ%3*21&OH:!0JHM55@^?NX^M O4R^&
MG.1?&]<X.W0YZ _U WG3/B6VWO]TD^:QB]\:I*L:7EWK</!M6W;;[2(O7$<>
M)-1]AS#"X\F6EL0=7I)OVQ/LA3:%H7'MXOL$%3\^L^'1A@ T8%$[[G(45=ZL
MIZ\SUP%S9(Z(-C!V(F*K+_*VQ@@@ZVIS8WVG^OAQ,CUNKN67%0<6\3G;(GJL
M2*4B>E=Z\_&5^DI183DT($)C#E6%MZ2#FYC+%Y_']K7SU=R3(T+IHG5.[3M.
MU8;W=-/LA-1Q<QCK[ >:!0Z8K7I6-(XK)0:WV0[1 'S-/*#*>,?#_?+W(G@<
MR7YV(C"]H^YGSJ*E@0% *2P1\@$QAI&N&/X0/U0'&H#=8U@P-)C87ZF15$^?
M-]R=O4;.$,>B5!X_EI3ZZ9*5M3$17+8\_J1*X,RT^F-.K,L,3_#*2*BEMOQ&
M(@F'-;,4;2X1Z(ZXZ9"K5:HUE?%62<$"WBFI"1I@#XYY-0!>Y+5  W1O:-34
MI.P;\3;'A0<30(Q5X/B%)15CJC%B,0/DBCSN5,=<CHI>[?H+T KP+L>:CK46
M?-AFY]@[7Y6AKS9<(+^L>'A&R.L+]A?5F $Z\;T]ZO/FTS'[^;E3#&T?ZJZJ
MIS(/_7R%R"L=\_5FFDJ4!)WTWKY3U0I*ENFT@KP??C.@& MAS6WYFU<ISB8:
MGP6D$=6$P=W%?/.!MM_K^(UM/6E">IK,<HEZ/N;G#5F-!@MF&17Z$E:^HPDV
M5#/ CGPGZ77@*JI6^,/A_/70XG?XAR>Z>?7V)]B+C/W;<3DU+'!X-K<9H(5N
MEUNE6GKR=WRQRX'0YK8:F_;08UY$E<?"QFKQB'<63Q]+H:")H7DZ9+KCOYC]
MN'D59US[V9I2^ U"Y9<_;]]0DE#Y\XV_C"(R,20)5?^X_O#CEN];OX(=*_>O
M5/P%E!A:GL25//6+%1DKU-*F+RJT^_Q5LM6!"GO(E8S#6"^5Q1AH/0D7<=9S
MWR^*6$7D3?+_6$XAR/VM)X_^W8 9AXT>H#9L%8EJTW:EX-K;]"3?]_Q -;HL
M0W&O8UP09@3%:TLP@"!LC5YA[B(I+T$-&-JQ7K"\[H\YSM\<HI4E/<V2KDR*
MY,?.7?8?5SCK7-E*^O?_>,14=65)DE^9TB.#WI;]UX\@[%=&IFQW999!;Y5_
MB2HR]B\>_</8_X/I7U3)6V/.Z+1?-XAU:2?"<9Z],W0]JFXS]Y8B 6U#D>&'
M@LWO$UE,@G+MACD362'!&JL"DHWMCM,CT&&5L=Z*J>H->A.#GQ]^_AW^FZSR
MQWIFOD= *G&69;_\0.V9^B1S]E -@6P!=R0:\)Y\#.79*7WQ<+3A8%)NPX+5
MMG!DVVS3<'P1#4#<+$<#4O:5T8!;O+"+D\B:+J:S'CW$[Y6_5_Y*I1IXUU_;
MO=9KPGXC89.9BSLX>. HH:YYO+FD"]R$ T(#1!<S4/= ^J<[],[1RO]1U8D&
M_%[W>]U?J8,&*I4$*97+T*S675K.L+U8[[4<-)%*>K/]/BL=\JTX_3?/T?9O
M"QA,Z?"&>=RZ>5%,=>G2N@DSKHN,;M6R$S*:\C3)T50Z5YK,4UH7#W\R6&I@
MBQ(AN%\>#7C$B+SJ(.Z0M%(?WD<#.F111*MH@-&\2*@M].D9%H]IO0\:X!\T
M'W9VZVID2W<U7!1'O$%FH'S%3V^+-X5M>DF'>SM@]0MF\!Z<7#S6O\(I_2LX
M"<%7&/TVPL7>]5RUW?!S#$C->B8TX',8ZKG2;L8Y]?U%:IUWA[CF/5Z7?X:A
MJ75/^O(Z>!\?[$\]C@Q[>+:(]]E1"K2R\PL,*&(.B/@J+1H0'G7!A&IO<<<:
M>^B-F<"M+_X+!+LE7E<4/J.^>)^*D#X6H^T0J\9<I1A(.#W_!8(_9[UDC^K9
M40?UT^7@L;ZY7^#X!>^781_V\7X7W_^#XI->XHAO8!2+^:[_9\TK_67S-W]7
M\O].)?\NOE\37_K?]]ZOX-M$46W,/AH[8J:KJ^,PN[?H;LE/_56#=W]RV+!/
M6+/JC1&_L8<S&X]J09_0\_\'YH_^?8&9"0 %M4V2;_A0)SRICN6LPQ4>DY7Y
MRA5#ZRM(Y)2]UB/KQ&"_K"&FZ6P^$]%&IGCK,!-:.8\;X 2^+[.7/<[.M?'N
MG4Z(=QO5EP)9!6<1N0C[J.<#DD35OWE>\5_;)9;.$\GRL)OS*]$AHV\9_0#/
M+:.IC\8/%D4/]-1W=YZCQL9&7ZLZUS7T3N@$'Q/M8*>I,5'@QAP(]C+L'\L<
MVCEM5G]*3Y:=C85SPW_KL?R_.S!SRDL"'*COE6$6(CVD T3'^-  (0/CB&EP
MJMRNN.59VK!0C&&XU"U8JI=S&M@0&6H<<FWJFWP+X"MFOS?K7&<)GTW0*94/
M5^JD-+<D(7 @Q>V_,X7B?P>\$AK0Y7_'0[W5=Z^%3F%T]]Z^+Q=>R=DH[WJ^
MVO3<<P0)\VNJDN\X6.<DS0/N'ROFP2DO@^]OZ9KP$K+X8P+N8CM[\6J%9D[/
MJ4Z^=S?Z,4OMV_2;=R;__G"=I@KVX8SD..7M4%M\RMPR*67M&$BY![_GCM1W
M(D-?')!41A8O;S\D0B4D+-:#@IS5L752V+S^477EU(=N&XG0].*-;:9A=8,L
MJIP@@:K:&X3*6N'_V(8&76I?GD1=LY;;%B[^Z2R*&(4%ZFJ?5]C]I=@5.U:8
M8,;UNY6^95-^MJXTDDQDDWU^/>JU2-=TRTFK."W*S@/ Z5,#M;%4BLFHD>R(
MVF:9?2U6?8DAE8568@_OP24JYY#V!6TTX-Z%J.%G':VB:),7$%?C,=6V9^IJ
M9Z7T<CKP=@(IT* 3#* -2KE5":]@$#Y6F6 ,:!3QB5F)<XG2G)&UMO.GD_"]
ME2-!HEB69%1S>S :WRJ0!_C92W2W(A&V%G>@+Z6+"&<)]_"JAIIV*_K:DD)3
MUE_>7,J@'2=0*0EW2 )'^W1.B"VS$6W%I=S>C4UYI6O]H4I80HQ;;0ZQ$N#\
MPK2XCF714)WB?FJ.UM+K.L:BY! ]8NFP >T4AMW6E0#;]_S4/$K?''!#=,T"
MO.BSUL7N5 V;?4A\+_VH=)5;EY=S.$-!;8:;:2#**R=Q0)?$SRG16K^54W.&
MW=#@%'"&"12Q^%X-%W4P>R<_(3XC/G,V=+;$JZ[B&?@ECH.S8T##:5QE0:4B
MX%FT^[4(W<H6\3MKDS?J"B:D7G4H;EOFOTG#+LD^>:,V%11G]#:]THL3 >K#
MGSU]Y1L.FXL.):ZCX<!"2CP-9L]C4: %]YFUB3_6$ AN2B9S8-./<%J5LSRG
MXI7T)!I[Y\4!_3JXQIWY& .;QBOXW"]*#UAH$9)IJ3)1EO=(XB1\&78GU-^U
MJ^Q-GF2S2@@A-FO9WUR+_#7 $L$MWT8#<,NH-XMN,$38BZ !@F? **2PE#>H
MY8E$)6?:]$H_L']/JD0J]^T-Y;<WO+8=/TY&BMZE%"_KY)27E=<7\_BM'?K_
M%;CVRD-EX"F5]Y[$LW.7H,L,;%.0C3;E4+U/S'SY$6_+_6EM.->/\WS1P;ZL
M*W@$%CCIH#&^]Y3O*A^)-L+2.TOX%:-.J5RXDE.YN*Y4?X;Y]A\Q%-8O2!,T
M@-8*O$V^ /K#;Z>KW_/?Q&<601(+TKH+' !+JD=C"6>S\X3!Z="Q7C>B+,0,
MN?YU-X^U'3I0@,A[?WD? )!U#T]_I P-(.R\D35=TD*C6JY4;NG%OX<+*]!5
ML 6SRF,SJ'U! [1V&14K1]02=7(\HD4SY!T#=R\;:_8N@Q>).%QRKAM1C"GO
M>:+$-L$SO!IG70^H@V(_8NC"',+*I?@B/=1A07-[)T:H-6B,F)>Z('N;1KD@
M@W/][1IYCL"*2JYK*DSQO:(8#"5P$X2;ET)V=GDF(GNB*A?%B>)U?(H&1+X$
M;XSJ7R94S6$@!W6I$$[G;1QFK(:R*$P448]BLI[[2!;\=686E3J9LY#X^P&X
MEA0T%/O+-XSK3L*@P"'P8CKLTJ?A@'>;6,@ZZU-===E7DD\1;]>2C""[E_PH
M.18T8&P##>#6-LSW?*V>ZJ2@N9^;D8=L^E:9H'&;NC8J[43K8(M?O7;(]DU5
M9?Q(1&G(-/DA1_#]3OKEF!*R$HKX2>Y0C2H<#LFZX9WYBH#;7)L8;S(Q=-U(
ME-9CDVOB-9:/:ZAJ%VK51T6P*]U4Z>3H<5:%1\ WP)W\<#0 Z@!>Y35KCY.0
MV7U2IJ'$)7G_QA'E>J5OPV*B'GA,4/R0?/_HK"&.<R!'/#F4%=%^$>:"!AP/
M70T4>3=J0D:3\V84/L\8];B= &90,8OZN.*+GI7B1S_5Y^P1HQ9>[A62N/1J
MR/3?W]G2%4A@AS)+VAH).2YF@;EIE7=[Q@(N@"#"?*V9E9O,3Q$!'MZ@(F0=
M&D 5*ZZJ/8E;DN.V(B-9];3R2?'CP/SB;?$^CR9DPT_5.^2?-/)4"6X-Z^TS
M-[(XV$\D>-R-<'-$)%C>D[KS263YA X8 3^I?S1*9/JI; S_QHTP0,)1'UZF
M&"W2LL:)RW 4C[[NV34X!*1]>4?U=,$-^M KCS7\UIHN*96>1](<27RR=89U
MZ&PS8NRC%=UK:]OYX(7/C$3=;AG-<6<WNAZ<:DBG+G>-*2# Q&X%JJ-;C]RU
MY-^LTUUV4+-[VVOX<$0<=U.!WU\9K1.K1@"S:G+Y)G,3;O+ LIJRI.?*O7\L
M)+1RTY?R=M2K+ ><>E;*2!NP"HT0"0A^R: R,_;(:;K$VB1G/'[?^1%:W)W2
M/74 /<L(H/,EA-"IA4@1J1E@J ";@?GK/3U'HC5VK\*85 8DC35_ZQ#W_Q($
M9KDWM(IB;FG<SI>@,@D,? C&\7BVIFZ[F=[P)6'4Y&XDL\JM'MO PM5A52GG
MASG$87&K192>+Z.D1VT>3QL9);ET%*Z?>SBJ^D:NNWU19&^4)-1X[__WGJ5U
MHL(9+2JC=+:U\?O4%/&>C+=O4$/=0JJ0@GXXM[-U^JA@CL)-^%45]XS%@3PS
MZ>.!/%19QKQX8%DWGRZK4H0QZMXKIHM&&%TZ?"EZ:(!OT_8H_L%HPO$.Z;,B
M/9N'BO1V&4F8D^4B[O-!'/A*5L<@E@_O<.J>HLK;E77U57*VB"3[^R;KM5U%
M2>3WVN+-OJMFR$1Y9W2X[1-:=_8UU+GW=PAB$:J\R0\@)M1)\H X4PPJI:W.
M$B##+A,-CH5R(S5'[ E@CT5#09&E(P_]6C-4[69EJBWLA+Y'H7C#9)4I<)BJ
M!2[3:@9=E-*V"+P4=D<:57DS]XVR5X<7CG+ID(F(<_/XS4+C@Y+],#:@^ ?>
MA<-/4/6H@>U-BZ.\1!^Z/;:5C[;7QQAO)='@!NF*!WI99*_IW4N53V;@[H!B
MJ),N&HW"SR)K\@TL%+$?T)D6R(H9?=X-+;5.=TM@>[XHZ.^Z^+!SD7HO#VX+
MTT(&:FG72H8_5&@0 (QQ2VHU/=,XKK,V])3N[K(T%UH:?9?7[FXU(V"RV3Q8
MHT2!K.]N&74)LJ7X2.=59<"9:HE8S1*A%U17K_FL;M+=W3^WVPZQ%>%V7Y8X
M:$(#?&C<>%<EVGV(1HV4<R>MP\,^U5S#.!L+&]1PWC]3-^DIW6<G6B*R"80I
M[5$_&]Q*$&7HB"<T]'GZ.:S('5H-T]LX236O]5K8AAFP<D'<O&ZPX,5;M@H-
M)A0K2Q)-O_E'!AE$FZEW>,2_6(3E=E/1)5U44S?K:7^V<+ \ZZG+!"7O'!@-
MUH>5E(6V=;&:J[%(I4G=9&WLM>>#9-8DCPL!O5HA6DRP1-%?Y.GX'?X%4R8_
M<@1TUS\VURZ:'T$HOMJ,?G=*/0I/J$\><4*6*W#-]YK<,'E^4UIB?*RG)OE]
MC5Z.O0G3HWD'^ EE@]R952)!#Y;L=A@WB>+@LJ0<4WI=\X??GB/+Y:B<SOSU
MBF-E7RT@X!P7#<B2E,V5[#RD4+5IS[E@[/?5DB_H2N5YGRD]3J6TS#KDKSYD
ME3Y4AF2C>85/=Z?="[?<IIZ:X/5H_O)9R@R3@^0/J_S:_ULS]G\-?MIYU.HN
MWNJ-"9(L:'J+5\UQ*-Y59UKJO,7+JTLS/_!5N'^!-@V:1&\FE1_)583KIGF:
M "GQ-C_F']*6N64^G=<#A%4&J4"NG&/1ZQ^W?J3]=O=6J+S"T,O9S7G:&0>,
MQT"1ACHBQQ(M1E4LR=_SE5S3DK[3ZDV;OE:RIJ50EVF \P%C(0]&(-#B(#%1
M-#'Q/J>'W=3\JC\^P,IE^\TOX/@_"H^R,C_CDK2(XQ0Y;ZGOU _ODF"R0#B/
M"E.1JA5SAP2)J%.B=4*@#N<(@DJ=ENQ5#J-+& <:X"]L?378$6S8B9"^8)ZR
M/;O=@P9XA>W"E-,+SJ4)+IK.ZL3:X\!-R15HP.>DN9..G];"%*? _8H_G4[P
M""$$F\^#/XG!E$J6YG9SK!M6&?DO]W^L)/ZQ56J$7H8D]:1 ZC)>P="FN^O/
MF\E $6Y57EY?1@/JI9' W 'IXU#&4[_UPW,JW:N&7*90OH[@.=J?5O[^1">*
M:)U'^3+C(\K@=]K^7Z0M&PUH2@D$7[S/FD*MPE2S;77/'7O^\]VP_WP7\HM6
M_=G^%S+[.VW_:MK2_A[:Z*DG2?_0K!V* FD/^FP)\CR.2XXV8&6:KX4P02W+
MS31TAEQ-BWU]OQ!#F J[_L>3 /\.?^.B,E9A;?Z@3!VQ%(2-NNQ+J*,":RVF
M"X\Y+'D9F3._2N^6F7)O58:V:Q4L9'O!EDH$[OM&?;*!!L!T-]@*1P9Z]SBE
M!YR O:F[%5[J:(#X$_ <#%5'_<O21(S?QA.QH/1ZIRN3*IV'G9[ZH2[!1ZN_
M+*%Z"JE?OSO4)3K(^45#TK\L'5L;G'W#2U^%)8LCK) %*!\#-*!!_]+CSTJE
M(*Q1 V\22:\U-.".6:O^P0'6Y1D:L#'P9\7+1$VQ4LS5&M85):2V& L:D/I)
M?&<,#= +^[/BYF3CT2=JR0%](7#3Q![PXJ+Q:GC=<';X9R734;S"KV?LD-,A
M%'$?I&%E&>_\" T8R_AEZ9ROV-L4Z[\67/F_C^"&^-@OQT_K0"O@O^MU;*T_
M2! -^%V$O]O>KPLN_R<;:?\O;40-V'?O0G7/N:7SKNN]TNJO5, KH=;-28+:
M!HLF+YMUN*XML@M"/9 6 \B01^I*1E(0.=:D?JW?NFO^/PX$A/X.3SQ4<S_C
MI?BPNH'/:5M2+3^Z3,WX+J3.[UQLO-O2?WGQ=!>YA^6_32/9TR+Q+6B,MMRK
M]]GU/-*'\_6!&-J3JDN>&;TPW-=70S2]=V__U;/W*BJ#Z=PUZ;ZO0P&$R9%5
ME#M-87A@D%O85B34H RC3[QUZA38;V!@ .3^S@9P S>-CFY^2GFV+(_:@Z;4
M&Y%H3P[;IJT-!#Z63(>P?AK^K:=;?@<(P/#55[_^(U@2BL'-:=6'(5)SR+IH
M@/T3K=^TT3XLHR (&85 0-TL@2&.]C9WTMK%Y38:1X^=@:9&6A0#8O:$*C$L
MK=JY CPQAWDS5.97)O+U7TD\:P72"'%0B$P07%08/:Z*^"AZ#M::CY$O5B>C
M^XY])HYH" P(1'QZ^3'H8]L)G>,A]*ZWK9EBMXOM<XI!82(  +"FF)D%2Q:]
ME_[;'R#Y]X<_Y&]^.?#TCB0]V><;5^6R7^UDHL<D(\A(KV4:^"EF?L:+1STT
MQ_F,3'<;D0G0GY7R#G$8.21IM<5! T!(N]FFM],32TB*F)V+@I799-#:$][+
M+%%7Z40MBB]7_6WMR^?_JOUN69E9ZV[IWYT;< ^IM^8(GW]A6'UTN9CJ[\T
MN7\M%X#Q]H9=*O:%\&48(JLV!E %;PFD33]&.<^.]1B!/+5"IV@',W UWUYA
M@7(;_(7$$@!_U7$S<\O_;-HN/H,'4*9B&ON;.[K_+< )5RI*Q3-W7*?!X RB
M?F1EQDAIJ8NE)C0:8IM+^E[*I/>K8UA;,8H!W!'AB09@_$BO:#R.S!]K%L=[
M3!>^7>6V1VBPKR",O=P0!'>T1L0_*@_ *Y^3FWZ.^T2TAU]WSW_[':);5^Y
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MCJ]FRZ4?J;]0XV9I+Q>L_32]"!0=O9O)VC9:R9L$BQKD#JMS2K_CLBX?;II
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MCQ!G^]M'\T;&-=^1RR(LYWH2[@BCCI-:8NG3U\\=JA,M7]2?P\HE>;Y+%A8
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M.F^;LKQG6]0V6K>-OSW<NNWV31";L=L>G60^_8Y\NE=6?7(-2)*9Z=RP_>L
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M7 QY1OU+?AMWE9N(NKO:&NP%1J?!",G+Z9.NS(WYS;G&SF+:^;ML2TO3]9<
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M*VI*JDH $1$1\(SP!^!_ (\!\LN7R2Z3DI.1D5%0D%-2,]!04U%1LUR]1L?
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M]4=W;3-9OJY\:"#&0-*_6VP%D*%%;B/CKH6D@$,( 3SIM#& UHI"E0=PU7H
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MLUR1'3)(\$]"!1BSY4<D!UCKZQ1G2,4<B99=+E6X%_JN!TI5_W/&62_PX3"
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M;4YZ/Z$:BWBIU-TW^J;%@,1N0^.+F%J*PZT;^$3_IPW#",5'G,OEX4WS>GF
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M.X$[K1/DD))#(G<[ 789/@5=HF5&$DGBE65EJ5!=:,VN9Q<N[ ))^4>JWUW
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M5>POH*4DP4C-3#5^!U#[MB=E_L;4HG=5Z.[]5*-75T/F:E$'9Z@NNZ%UV3C
MQDF+"=2 E[S/.\6Z&H^(K\:_$7%*N(5I;#=R-Q:OC\';E;I519?&R?:^OUKH
M9O'4CN.[0Y)5W48MOKZCJ),G.A;GC]@20,M<\J),.,'M<T]R^\@BBYS:HOO=
ME@N^@JO!SK7.7])Q^=;4 J#U7 ++.X@3[S+!HK[Q!FBH1Y2E<SS_D<DZ(1<W
M3P=6N<E2/].TA T[PW:.)"MZ^!SW;L-#=L-N]&A#XC#52_]R)DH+;&#]@)AP
M9-7Q<3#=NMH3%B*.[\I_KYWRZV$-2^N]631XT->11\=ACDI":8EV%!!KV4=.
MM>'")XDS<"O?)_F# [?G)9/%6&XU@/D;G+88+JTQ/QSN)E#61WY*D9JX^'-%
M'=,ZH:^SKF.LSYP>;@&^-Q4D<F).B)KB(V7319Z'A>)[9EXL/06N#[G=4 3R
MHP!FZ2B 7$F@90AWH-.FO45J4$\"XF4E"D#JE:VH!<>/*JZKR]ED2'L?1TF*
M+>Q;C,@N=B1#"L)^77W5F2 6[QB.P\(ZQ^M*Q3WJ .%:;^[64A:$FUA'H(=,
MU7;A+@WB]Q_YZE$5I2W&BTIRY,/'.^:#G\^>G$#]/B:OA+^CX 3N<_!LZJ7-
MY6ZHF@2,^=%GF-4E<T^)^>3AJ?:-,B#^0BH^55$GL@6B6;Z8&.PF,?N9-^(\
MMI,LYOI3>A0"#%"9>868K;)0MA,S5JJI^_B6H"NR"H'YOJL>$0T]RLI2+@CU
MI$MCS,=&L.3_E:%  <@Y-]KF)3B(:T-3S*NT \HMDV[G\X#)<^3W5&4]M37I
M-%D1IEY]WPU>P875NKKG.SB8BXNFB\CVSQKLE>171*5"VT$$\DQ(JIF":)R?
M5U/L%;')*CFLZ!.!^"@ DYC&[98P,GRV&F:-5"Z.>O#.0@$4*.T^"SC5PHH<
MTGVF9#_!?W69QC2$JEJ+WG/$P'SC($A:8^7-3E_EME7J*A=P.=79<"EUJ ;&
M9\%[7<5['M +W.O'L^YRK(EV*6A[R!-HV979)V0,E:RH$EICFNOBLN^B[_IS
MZN*28_XR_V&*E=Y5LG[0U4E,/9]G6%):,W[4IUYIZX6(W(\/_I.89G#*-;8N
MVJ.W[YXJ.IZVTCRG-LA=.203LJ@?>$&4.,70 UIU?5ZC\F\VPIBK_C<;_9DE
MP%"E]GK26H,/M#+3V7SJ3W/\XME (E]9QG-6Q,;6TF=!).7!7!,M^K3$EQD*
MZW.F#Z(?6<KO*\&(E"<.T@0=@A6+5AS1NTJV"V]:2'M98"(5F9@#.'^CFC@V
M_WF%@ YT(:TYVP.=QW7E?*W*02AS> !$8PR,1 $T B1I?WY<-7UI01V6<S_Y
M;!QC35)N"](I..4:8*B5C\?_(TW3'4%DICCP(+5TUR.6D2/P,0)]:-LCZM-V
M,'6PX"_$L/Q\A_B6/-PWRJ6H@^ASL\^^,&G/L.PR(%@P9BN!#%$X8$[2&1(H
M[%F\P(#1]G6/Q>.4'*=G3R0/)]?QZ_)5H#7!JQR^5IHN1XWGP$J+/X$\UDZE
M@=*=F?BLPKE4B<Q,'BB ;[?Q"FPHU!L%"%,N?K,P_S([/#Y*E&3"GNZE-QV:
MPU@^L%2U#050')45V1\5 ;C_O,[#Z,MAGNMBV;]=A!5?I9$G6;=Z8&GG[*&#
MVYECA=<;^#@/R>6=]E@9$:G)''+]M$QPBYA[X_1)$ZG<S6VMM SE<ZFH>(T#
M;=GB]83XDS(JY8C<!:/ AZB/0?PRE""R5_$:4>GYJ3151>Z38:;!79YW(D8I
M$P2@_:73KM>+*^L(TJNU*2R6C-I&1M,4A %CM?UM:C? 16#_V,YIEN#T\RON
M-]P:="J _"V35DN$:(%Q_H"OO/9;2;1Q_^;(*I?C0,%2D^6!<O)FN<]ODF68
MD-X_':4(6^"8?29F/*-G-87A$E;R.X;46W!J?8QTN.-6?Z:-OU1WP<KK8N=0
M)IPT0K2^#8(#,. BCK$O4R&ZTMQ1Z"7Y*?<(WP9,650BR,FG8VMS0(II1E!2
M<4!L,6<-IRHF0%FD;R\L(6^XTU_RR7]*=5D85+C@*!,$61)5VE?:UCMD11^_
M="*_YX<^:XW',),RA*?14#94NU7_U6WLJ-CP[CTP2YT<=*>(MS'0F2$P#Z@P
M5-W,=G3ZZ3+F,'T66(NLFGUMK9U]J=!+H3.?<YGK7L+YYYE1\5/>#ZHV-M3G
MFKU023$_0L&DL-H>W);=QK9IT4SW%<=0$CGJ1%&IAD.GK\]5N'>/^6-GR;WM
MJ4?KDG"3@BX]I[Y5+?HKD[(NKFSJVJ08RN_ Y8^%])76/QJ\X"SZ]$8#S"4W
MJ--!&F U/5O+5%H9Q#')R4D_705M"OF45*89D%NM:J?&KC^;,D@Y3%D0^XR<
M^):U7/C_Z.VAEZJ@!D>?F#U5,EQ/J@\71<@QZ7,4(  % #D&=-_@&*, ;>NC
M5;.*5D:Y#U]!>\AK)/+/?RO,19"\?02+NHE[%& -!5A?DOX?Q<F"S__?-ND4
MY=Z@ (]:N+LQ3VRZ'"V[Z.V'SL[8$:9<K].DNH"Y3JUZ%"#AKKO@4:-W:H_*
MRA-KDX^HO_)$CD "RL>]^$%EH&LUS]5]P'];(/SG[AN3A ;=75\;]E[^H]#]
MIT3Y]/\FV2%)0@W09]HLY%U[00YC&\5T9%RGO+.6FO+@*E8Q\T=W=T<I1MC1
MC5A<H:.^RJ=F3?SO/'>J*,!\Y=6:!.QB:Z_+Q(>:)'>'H>T]>B]%1?W!5P/Z
MZ&JK3_X[CC=YUPJ!=18X_$SPTBA&"K'.\BN#IW/.70+IFK0641=C,?,L;IG]
MSDY_<SQ-8/;&9NVND4/$4OF.9PI)L0S/:/N)_ZHY0TC+KNTX2H#:T%VXH#2!
M*4[[( I@0)BPVG\4LM;6\T95_EW)]B7W&RWC9\1:VIK_=,]OX.FI"0^FQ3C^
M^@(9C G]_A _ZHIW$:$P/8:3@69GN9)BDMF5DUF2XFFS0<!I@WM[]> TWF!!
MO(:@7-A?6@VO2JHE/6>EE]+0\#\(]2S:HCGUU'4DT2VN=;.HC5R&_HZ04$%7
M5PX,P-6C(U\S38C6#Q6GX$&.4W;X'/HG8SC0(U?FD/0'E.._LR2$(B:^8N>N
MECVUR?5?@G?%E/56+P)3E,/'!9MO%SZ/6"Z#]S6^.J@:.%&?>,JW[$.8)\"-
M1^T.7#LPR66%HX9RU^>/$&H/H\DIMMR,>SNM6?=U48Y_J [R3T+P"JQ@UJP8
MGZ8?4ZY4.I8A!'L.]ZV0K/Y/1T1 &T@#"G#@<<K(F(:9)_C][_/%HD:!4.VT
MOYY$F_%$?<WQF+^:/:S/2,80<D8S#3>-'%G2>!/E8US]F"UQ;=8(?[HS)X/-
MW5;:# DD56?S5XYR%C^,S?B6+;H(Q:=+N?V='R^4[03G$L1O0J8+B&92CHRE
MP8[SK;F+8>ISK^!Z?[](J-I26\"^K)F,$T7%6R;K(O5\H>\]Z)[O1XLPZ#!@
MH7O__NVI*ASGG4"T:K(,=/QMJ ,\=Z4FS NX&+1 ))2NK^UGVGSJ9?XU(I8A
M4<2"\!,YYE<6II 52#)MCLWT%3MA)XZ1K9='QW'.[EXDZ;\7KXO4>(D PU,I
M"MO>E%\QI=Q7=M8JJ#&L4BA9/@G%U_0!;W>@6?O:@:"DK<W)K[AV]\?*J:+&
M?U8Q\GA\G(K;01<>FM,TNY>!;?,K4(J:1M$6@@\EW A!?23E<84[(5^V2DD2
MH#%4K?=!F^W?JHN!EHDWR>S)1*4Z)FN\H2:YSP\U>ZF4.7IZ_TF:7>$QE],]
M.Z*%?)T[&^\QC53Z@P+48" 5DB>02BN@R]WUN2KCA56>/NN/+MMDTE:V9^#L
MQ=XMXL>ZFC[@\7A'Z+8QWXV)^O'Y$#ND!@5P(WST#&?:\_TQ(A]@9K&U>?@B
MW'LTZDK(M(FGADC^Y$*J>2X4(-# 9,/)[T2"JJ37G6B074&.,9;@G'+/1/W1
M\40T-.?:IA^W@^9.Q(/WJE72#G5=KJD23C?S0_!J_;M?7JKN"R@+BDXZZ\9N
MC:&C2^+?");7./DCVPLG2L<VQ@;.#=#.U*>/KAW-?)9U8:6Q3'",7'M79U==
MK@&M\E$XDE&TQ/S^7?M<M?%$_Y+W2(<S1B+N3> #AUO,5RTPB)_#&)Z:>4.C
M$5+0%=;W]<<A[P@N?$=(B5>&AL/G'"E1@@)\FJ%\:UZ2[BI(9M"^(-%7&#L;
M\\/X]P<TIO(>")OX3'?&,HF]X88$VB--/;M#MH_?1ZC"<I9>Y:VN.%L(0K)5
MK;\#>*6-4WI)R7RZGG8TMS1]9<MT4(J;"?7 $*FDPSV&5 6*NI.L$,J^:O?!
M8=C80L\\J&0>$Y<J%13ILC?S>F,\M*816QL9K?1&(-RZ$O )I#*%J"04CD@;
MC1MA/Y'Z#I:U]$4!<#Z*3]2K7EFBXPL[+'^GO72#JF6/7T?BZB<J"^189=="
M-+04I?_2__V#GW[M.3D!'[Y/407=;I&=D4S;"WTR0;S]S;JEI]B@3X]7!-$X
MKZ(C7UA=#91J;@I=,V(A>(?K6-0D0P%MB^,63NCW<1<C27(A4$GZ*8Y)0I1^
M.G5N^U:ZHSMI()"W/L1-</&==:"O^,NM@O/A T4PHRZB<',>)])N^_;B4?K@
M';L>E\R_F.WX<9-NDN*?U.+YL^Q>U=)/>D #?V70A:.7*(4)7!1Q,#/W_=&S
MI'1K3$ZD7'.H=Y<KZJ  R>-V*( IT<V\-?0,,^S2^3NH8.2^,AY>G8U,@1Y)
M$YF82/XB*#/2PES%.0PZ?.$TV-S%.WG*V:#&YU&,E:DSC5X1+S:U[;F=O(@I
MS?#=?'<H[M%F(=U'0QK;CAH15^ZRFR*[\C>['L=!MR"5X!1;;[J^H?H /]*]
M8VV>5(/=$<Q8O>ZHJV92<\+&R/_"W%L'Q15]Z:)-2" !$@*!X!(<&@GND$#P
MX)I&@S<:W#U8XYX0W*WQQB6X6V,)[BZ-=Z"!2^[,F_N;>3-3<^^\6_7^6%6G
MJL_N?;:M_7U[+]DB"M$<59U]["2?USIPG:0DAO+!431>8A)CVX%+!X L*=("
MKJ*)_>3MTFT)KWH6%8\T!.L"#%CO <\ZH\4?65W"3-PXND?P]X0]2)<$R$6R
ME:;%^=4U1.3,2MV]>M&[4VUK4US/LG3#<DFHT5 -(QH4TQ6E'^39A.<5TC/#
M6+/:QBNHT]'?A*7A[8YXI"<M#" ,;%[3Y[D/G#^0FGVMZ/SU^4P\';E"2Y#9
MD)X\G^POQJ&+0]UKMR!4)AI?D# NUP?6OO)9D1-Y\:;@PH5BWU.W4./C@,/L
MH(XFPR32BN^/FHU<C 5YA_3G)*U/( N= =Z_)!LH?F4HRN3L9S @8"F74LNA
M1Q7>,?',QJ.+K2%?G#Y=?TB%;O<(6T>IO<(YE=QBU9_@_LFK4DBWS7!>0Z,>
MH0H!+<C!@+]\&:VTW^ZJ[<7/WQT)C-\#2JGBH+86AK.P=):U7OO'BVL:U)QT
MAZ(QBX<*:Q3B:HC9B'O *MVD+>7>G-D]0#;*0VQ['F*VW?TC'?2[#"5>,#H[
MRI?<Z]WNFPG5[AEBRCL_ CJ>,0M[0ZXCB6;:,?+JIJCC27),]:MQR#W\9RU6
M2F6AWHS&<4QHN0ON^QG65-V7H-;9+KZZ)NG&*1V&BRA'N25<Y7QG7Y(061%!
M,X*B 9I>=" .GLY4TJ[W2''GM)@,8]Y[BHJ>$9# 2QHR36-,1]>$Z\F#>\!&
MM>$#ZH#< PY@YH.]NV(L5MI1]M1U7AJ:B<5S2D3^8#8;NY2UUL/5^EA=WM2B
M%/"<\E"OI:UX0Q+1?''**C)%!5E8JK<0>V@#$NAZX4_YW TT&FY6_OLV^8YK
M N-Y1T=_.9%>S90(\[K,"6'2CX7?2E^5PKBT!>AN-$@+(RM0AOC@-HKJ!AF+
M)]MCSR[6(<42ZE:JGCJT AT" U:>+K 6U[J)CI<T KW3F/#\DB;;EKI4EY97
M'R=EP]!E%W6F2]:]TB.,<B#,./^9M?O9,;[R;>%: ]O!K$WRMS.SNZ0\(2UA
MO^[F7M!7;2J.N2\3K^_>Z/+*;I3=KF3Y2^/RJ'[L%C92E>(?UM_D?]Y55(#^
MU]8>R'</T*VIPH%2>\A\,%"R5H YN;E6*D#!,UK@)H>W'D\WUD5WN>7!?,YM
MV)/LGXE Z7,$\0>H$K_FN:8Y*_9IU1WF:4PKK?\7%)>\4H8GQ[7M7JM@!NW[
MG5*T/^QMH7?F19JW]G>2]?> "\0]8'@:Z\^PS(G9GF]HP#W -31+NQC%<P^(
M)7CX>;$]MH*U0AT)O@=0,S^LHV:_-_J?W'K'.,3OL(1!3#FM"1O_<M@>(/7H
M/^4$I#O5;[15!CT#N9BK) F =<3QO*)Q[ZCRY:0 $I=UIV)_J,._.9N_4_PH
M0/X7YWXU59MXAR=C^_@C2,!$6E0^Z_&4OTE6#QL!&GD=0CF&CWBC[VJ*:EM)
M%LX[3\K"=)#[*%T*P+DNIY(75EY8@P.AA0@DV*B6<.1$8OD0H&&#=(6/O=P_
MW0-:5%ZI10L\2H8 W@%VQ.6?8A:-L!$ 7+, 0C@/U3)@ZJD&I*VG@IC0WG*G
MX4*92<@GI ",]?DR;+"6;A(CB.2\)_K#ASW7T- ORM9P!ABI%^7XO_3W#)!&
M.WPH!>AUSP)@HO^-IQ^0MN)C^9,B!&R9]9B:,O<\_V&</Z+!<[TLZ8U.)<DJ
M=SZAT>3G^+]"'W>0QG *^%MX3S 7_6_CI=AJ7\6:!0H^W6U%*RPILR(D8(GV
MQT%3RO$7&>H!V4<X<Q",K(GCFI_"S3#61J(]<;ZT*K]S+\/>'Z- ?:BSI;;L
M4Z@T%AL_>Q-9O>&\.%LO?SG(]"@DJJ @)A<$/DF#MBA0'NOAF$,5[!]O<W61
M?[N[#D+M/32Y*)ST,(J0P%4U0.&A$TX>O@X]:,H\ 9WXY\,C5HB"KH>A=_*)
ML&?U(RLK)C0 P @';5?A/XCXJOZ)\ &D=8U'3A9EX=A:="6#6G.E)\H<+^1>
M&A67F[7PKNG$=A$>V$#$M(_/R^\@C]<RMG_X5.C5C=3.?3P=;O$(RRL6:X0^
MY^B0/F@]JM49>],?]3>(A!N/>D/N$PK(9;+K)=_^DUH%<NMQ-IT<B-3_5G#*
M?Q"2>K_3U[![@$M[TJ>2V7]YUF'%5&-9DWP-L?@6U$IIY7F7> #,/E<7F;JX
M93K3GCW/Z6RBDI+9JH!26EU/&#71Y>2>::6,@%B))'<*/(KW95(S:G7</D3,
MI*N6%HN0^KX_EG6C_B?JB,2]*)V6'KL3/[H'K%#-5&A4CS]TF']VL7P_!.*0
M 4L"I>9LXK4BK-G]_S'P)J9DK+55KSI; ]L4N1:;S>YNW135L=.[".?_"^'T
M"<ECI9@Q9.-.)AV#U%3?/<?" *APPE-(R.$3[W2^@N9+CW5HG]^NY/*RL1'H
MR=%)7;I[CW$/*CYPZ#GN/Y.+^%)S>V6B3T?82+)80V1P5/U*HUZ)+ZJP?$2?
M4I5"AP5&IS\L&MS.!ZWQ^&<O4Q\%LV46NK] WL^_*_%ASN"@8581]!^NA-?+
M$%@JNZBP@)@(8_\&6N6$?$3[297T\-:W8\C;YVP,'EGH@.C$VK^K;93Y"W>:
MZC^Y\58_< @I/@&:,&.!B??[L'?%3%E:$@Z3,';,? *5MS]''63?T3Y^]/Q!
ME^#K=KUZ12[[]8(E2U/1JE=10::Q-D2=H+J L ^1.IZ3:BL,&9P1:1)UZO6E
MK-?%;GU3H2^-;SG53KFA51$L(EXZM$;B+5=.&+TYGO>E>%5CUD/*9G_Q$Y"8
MY772?,-7#&+JEYY!JO2U>'P[JU%DTQI8R9$S1.:'[#FW4A1%.0&A)&.>']W^
M9NV(S [0 @3]@D0+NW\6C*;[^# %WQ5;YJQ5_J_XLO^Q#,S48BO:O4P!E$4,
MRK9PS1)!+:]C0JDAARZ,R4]B@>Q+0:+[\!*R4DN[PZ5GZ[ADD80TZ=UP:_6$
M0+,,@CCBMY_3(/%5L$/L.[S"P.M>\#"&GFQH;&!M=DM]!J_[EC0.U]O.8G(7
MYH:J&K;?L=] U-]6N.+E4'ML@@P?$@Z9PR/BE9SBY@F]BM93F>-\ Z0^L--P
M$[?TX..N,J96%%E] 4^$I+".7*EZIKY+,$VIK_RM*U+=0$P"R%"&E[F3*>#I
MB.7R&+8W.&K^*#(\2\U??0#%?*7"5JDMBK!1XX!H .5:<YY4U".:8$UB@&NQ
MS7[A"\VB/::<N*)_JW+4^!?%Y4%_]SQ_$:I_=<%;\8^;G_:HL7@$A_JY".Y-
MK>BC5N750I1_X3V@_! 5[&'FF=FE_ =-^1Z@/_\':V^HC<_#XQZ 4)V;D"(\
MR*3^KZ:;0"/L&7X=6SO[2@;'>GK#*,N7H9*HKXW$*\Z.U\OO;9JC.^I:RS &
M12\.H>PQGS:I@6?;SN+5')Z)4V:F.XK1(MH[%[F5,EXW0K K6/]\3&@)=>42
M,E7!K,J;&'B91*<5&1FJ'BM3;BVVWBTD!<W55R@&A<F<A&O$C)_I\7<J%-N)
M$34-T0I&#F=_#U]/P\TJ)UOE#[3QUK;W$"LW2X4O=O8 8DN2!0=6;E2X%W@J
M\,&D2]+I?C@'0B7U(W]<RKG79"#F\ M#W$^_]E0_U!@0-DNY]*O6D[4W3\UR
M5K@;#/ULQVOA=LDY#L0>0-5'> AVD&Q<"A:BM!!U\6T,B-OQ.AI]-01TXHQL
MFXJCG4)9'G!NCP<"+]$A)@)@8U7SR6IVT","HTARNU&@[Z+:W"#]F5L?N9%'
MI*>_4,+U;)*W N(N?74LF.OW;BRQ$3]>H]IF(ZMP:LT)HW9+-8(OM."W8+2B
M\F ]%T:'*LPO4QYPB!OE+5"_;"($J_PAT'LG+I94\>0V?RI$V*N(WH4$2!X0
M1ME N#WCA]'"<1M.KOWZ5'1?)KGA3(=BPZ77H:/<>N7V:Y-A],4-R>)B5EB6
MA2"]I#_N)@1PR2:I605?X3;4EWJ$EM:_8K$C/*W(T4/*4"W_R^JM_._>D5\F
MYYBI)]:'ZN]/9+HIY%"&Q;<_E*N2LD)F.4)9'#(3'>"ER )Q /C28<_@Y71/
M6Z'-:A)AOIC1^0 !VCEASV)KGK'"][7@9S_!Y$QC4S-:N6N'F/)I[SV*.\@+
MHYJK968I@".^]%:.UIE/:Z/DINA2U"3?H%=1S_2&(R+>__@0J&CWS [&K.X\
MR7.<EMGK+THZ<[IT_21CQG(KO$G$YFG9H7J/$$/DO/T%,8WW2L%!Y75 ?P4_
M4F+6T[=J31'-[(SMX#N(T&Y8CFI<^\WJ^NJS"ZB>^\[P S"T-*[@%B#SPDU)
M&\<<!_E6%.Y5/6.U?].@QGU3_SC@2%AS[HSJ&9)#>=);IVDVQ,5=*8[5KZ7V
M$S;G.GJ%P)C(;*'*F_@A<L[:^*8<I@%S ?23<E]E"J0Y,-?FNK7]VPL!0:I,
M^8KU8UP#9(JD E!?6I@8-3[97(66T-!?_H"%.ZFP>70)8E0:OLJJ/U+]<J"S
M7DZ0"KCP\FKV:GA\>2;#*I/;VQ&ZQ9)W?9E@:T_?W115!!$C:9D6$$OWG/WN
M39PNU1Y6>V-=UUA9]PW;0L1,UN[=U<]RZ]7MKV4MNA76JGM1=,FNCB&O]S8U
M?X=OK$]200%>YDEK/F0@QU3?;)Q1<7\^LE.1F;2KE_,?X&,L4J07%D8 E*)[
M3*0(<Z'[JYXETJE:WO@G&?NF<<^(@VK+/1C;/+4*NV^:H4[=GE1?5^/6(/LV
MDXDB28R8IQU9%K9.:[?8*E53MF4P68-5MHW.T([1R?$K%# )2>OFY)9C_=S)
M@;7'/@Q#ABV@UF%$H<R;&K$A]*0+7*5HZT- '^_R/9P.9YVD3WRF&(4A'=-U
MW2F^K'O /VN9A?NII'I/ZVU+./UFDXA"DQ18@Y RSR) J[331?D%?_@=OZ$.
M3S5]16R,(U[8@O\+<1$5VAD;E-GJ_DV7M7W)?$L7TLU$7,)S9LNZYXX6)33>
M(KP:5&I9*0J=KH7,M\S81/LHPRN0]3U7X]Y4\&.1TY2Y1,[0.'?JMW_"^B3A
M_L+-[:1(U\$=7>527=:\=;1J<4Y=K:NWBQ(UNH/QO8L4Q&_%PRIPX+7+7RMW
MXQCR2_*G=TF2C2=Q,G]J+@?/+;P6XV]#+/WPG9T3@9C"G#)3T!FAZ*)^JM,V
MSC_\Q.[V@.ZW^OYCDS-%N[ZLX[#O'[5($_'[Q8-<GUVCS[24=':(,7M_F"93
M2]6".Q\G WUZWA_.+XM,+U-X\\#/*9[ VI_GS;C5?:0CHS=IL,@H\!<-2%=5
M:'ZBPB4G\*CQ)I/"W1SNQZ!OL.QWP];@:]RXC/SF_0[YV7RF?M_X"KO.0R<N
MMA S;I).2^0."VF2LQL7I;:%SI&,/ES//O^#/(U9= =]FHT#:G\XXR6WGLJP
M<U))>UYD/N,\[UZ0K'MC)JOT&S>U_<VY",)]UT 58;5&?*'\4D=G@6?.<1"T
M$.]0^RJ0>Y*F6H1W!8G2/GG5'>%]RI?R9)TD6PXKU%%I87V>!^T 9 $Y%S4V
M>1Z=_[@:_0K=*#-+U!I]+3.L7$1\9;=@\A@?>YV&);+\,._,WSH0&;/Z7/AG
M^^_4[5!5* /$!J^E3IEX'SESU>M#,[C=@;?/U:UXKHB?]R,&K>D$[B_4BK4W
MJX>@><]0%/B)[6F&SA;9VJBOR2YRICWDX W\'%M7V.NJ'4+_QL[@W2$CW4;<
M3(,B8^>U4@2B1K6]JIYSP0 <LUT5%WT =&6$!,G-TB&.?P)M)=[<=*!%*6>#
ML8*0YO["(Y*]I!@I7ZB;I]G6$T]J^62OU_,-@[0GRT'T(7=STHGFO)\TDJ]Q
MS@P^KXP%I_+EK_YR$7\IR;9XNV7F"M:Q?7PR?NVD=Q@30M393N[L14SO5FMA
MX2]L8<GTFRH=X 5;O(!^Q?!J#EN)]".()/"%I10BN]Y-LS]OS2A\''\/<*Y[
M=FT!]>"/XO7AZ*;"C_Y>L1<R]J%*N?',6&:==I/"*<.J,-S6E[@O9\1A=43]
MX+H,W?L)J9I.]$(T$_JR6:H #=@\CC9*^M/""MJ1-?L]X$'W?W^DZ%8\3R,P
M&$=M$Z,:/=WQW-,>#X4YQ5&NM#LSL1;7WC*(H6B*XD?:YNVW$06IS^8F[V[\
M^:P.!,1%?^NXRI(I!Z>.II>]WP9?.>@Q^D3%B^7"^-5GSA<I:>EO-]X"N$._
M/*/L*JY@0AQ%M^$@IYRC1'_;L!]^[*3I7G$*&(-7BT@QQ-X#7KL\15DQWHT
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MOUI+6AR!7@4_:>VN#'>AKG[LV!RB'10-ZT!N:TT=W-'I*3RY@,^#1+A$Y(
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M?N.^)J7*6S>7D;=DQO(6@WV..UM2*8PJ3O"$8E0C(J2-;7@K%YDY#  $ J/
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M+2OSJ%](P+<ZF1BGZA*>8++.CYGYB!8J!1^,+M."T?!#U0FC>0E*P9>=^&T
MUUL "?A4\U57U5#^[UZ'T'K(9^*(H^25/;/9Z%:BREYD3,(CS"L=U4.[O_!W
M#H0;P7T"LSMJ.9A7YBB['K6-B54A>[%/8/KV5;9; )^FD/%8J_F:)=T2)K2[
M_A8 KFME&?J PQL\1[8G/[P=R +Y_FJ*9Q5=_RF<XPL/B/B[.E-8!,Q/7[
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MV02CG4 1#+C43*%@9PLT7O2Y68F&O3_G/.?!GBPQ)@JI^0J8;9RM_&S&P%-
MPK#/#1I>@2FHZV#TEV-8?PF7KEJ2/1+AR'RW7GD'PPO:,T^<F37KK5X_5)<B
M>[5W!CN*7"9IG9T9-1C_<WSFA_O-[2.--[/%%YQY1P$EV>_NE(,P>N7.4(\=
M"S_4JP2\D?ALI^1+0[/TA)X$\CFHE69^IGCSE\8V&Y:7MP"[R1/X]S50Q!DS
M*<1@'_'<OVFDNUUH;IT29PGT>==";AJ,5?)S6(41\-E&$+EZUY&OZ,1GQ_F>
M0>+B4];)(@(Y.Y+?C&],U^W5\T8&CY9L58_<>]G^[!;0Y2T:YNR*M*O54$XF
M('Y%UK)HU0*.6CE6W;\+S;',/YWP>V[HT+> >(]UGQ(%QF;%'PMSL>$;QZ8K
M5+\A*]WS60@4<N%-;0.O5V)/140L%:[<8'"F9;BU42MW01DQ6<UKJ##5)C.)
M/G\OD&+]ZO@6L-UI <M;^.F0LW,^$:M!56>_/A8&F,5?S29R; 8FG"UI':Z\
MATVJ6OE?[[<K =YC3&\TVAONX.48NJVA@XFXT<)5NP7 72=V)<%WH(M6W[*8
M]%!#<)N6G#-SR_&I<G(R39>68IP,VS&((J<=1\,^\?SE_K+$*>T'H(BT#<QU
M14 YAY(:GE1'TX%%\'I=&)8$1I#R\$D2U=+U03%SG#N3* IQL!7E?'9$;*'$
MU/(A1PVW@32TF#E[I@E,/N\O/RLMX>NO(5,8G^E,\>:U6B@WSN?&48EG0:Q3
M!,RU7VC$A_JSK_Z:TC%V]"J-[?=ENN?R9G^1SE$1O_CK!.I<9HKHD7MP(-Q2
M_:GQ4PI;P S>@5QPA2;''I(Z>-69]>KQF9]XIZG/4[R#4[:[24WD"PK%.LGU
M,$KUT&&;C9]TIMP,SUD1?A;OET[/K[@%_.QU@"K= L:5Z['T^9AN'30W)**G
M]J<3C9F2;4')Z1^H)8RC<,W<!!I[3G?J]7<2B>N1MG/5"I4$;+>S!P4R[/DP
M\F)N >UA[O/4$<ZM.BBO[C>-WP>6R.O<H)X_5F\0,Y@5K:9I+'79G''15=3:
M?,RN&W<*%&]7,J++SYSD^_YE+"$\5)P^:!M8"'!#=:*!G9]5P/<X\NWHL+ER
M$"H5%U^0*VJES^OF16US QVDNK7NW99BMC=^[F@E/L*=#AIYP[HC:7>NOTR3
M?HP4.5YO)?2ZHN@7&?<71<7GY]P"['>;NRO/XPM^_*3ST!9*Z$^69[RF_*_5
M]B"D:X'F<4%'U:CD)*.[>!P;W"[S./]DHPMG O^DMBU"9^*8@$('_<U+DH'R
M>MM\19F4.JKO#"H'GL3+.([H376L+Z!SB'W_Z: D4O#ZZK#\3+P8E*KB< L@
MN(CUU A0W 3O+S#PZ+Q>< NPQYV<GNXS""6S3J=[_2K<T^PR \2]UD%HA@$;
M-%W)7-5_7?W0\/F0Y7*SB8Q&P16Y0K[2;?L'I%J_3&L:+H%WPRJ,L_<Z2% 5
M=^:S9,VAX?T !3@'B9F3)1%;,R#"%,S;*2%AQ@=E /&ODK@Y\0JNOYZB=QS!
MU; ?]MUPP^^XX[Z^Q\V-@U7O=DDX,Q\[Y[T>+5JS4"AT$I.4Z\)+&A\$RJS+
M,S#IL1W+<2W)$>?2?? V;+C0J+A/LI4FJ[NB-86S[?R,0ZP9[FN#3.?\]!FO
M1&TGG.K/+8"<8J &-672,_JL(I;/@HF(+%6\S(38 B?5K.:)W/PMP(F\7&4S
M8.D'.ML1<#8IK+Y@HH_GQ?-BZ)G<HB<X=P125$H:*M?C#(&$.*P'&_OG4QQL
MV8\X04BL@;1F\&"V8_M@ =8W[K^DF,W&\,O'_P<+G+&NA5SE,\K+\-D;F?Q+
M_:F'_Z6MRO\W-4KMYP X!7+Y#PKTK0R8ZDV1X84KLC0#C*K+AT&<M"?UP_PB
MC:DB?Q$PT '&$!)UGR[S;@%<Z4U0P&Z_/JJP(1TX[QP5\K$;W_<6<-GK20D
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M^$A[=X]:GXY&T[(3\V.>.O#C]D29C((BL3<,]P%P7T/GT=YR<68W!Q#8Q91
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M*M:B;NJ:/7LS*C,HN*I^X,_7'+;S&G=R@-2;_=SFC!-P[@:F)9)83:Z'WKZ
M5HU)Y-TN =5O_]>3O"PH*1[M9T0?VRVF^R0)J;@T$D70E+O3_N=^!-YH#<TX
MUBN2PM[]V.]+K'I7U4>]]AA0OY?L\W0-R)J?WR?Z$(E?:WOIO1CCHOE;0!>W
MR.3K.)[#P>&AY"#57G=9$AW\7J*2=7H="R6 %WVII'!ZAN[,4[II\(/EV-,$
M2L@0$-5JSR>F\7&=F]"3]1(D T9;#2SV,AZF>3HP9!^/7^+LQ9_U0!+T3F[^
M&W-O'15W\_4)=H(F! C!G2!!&@GN$"!X<'<($*21X.[!&@L0(#3NVC@T3O
MP1IH"$[C[F[#\]OWG7??V3EG9\[L[.X?=4Z?^ZVN4W7K4U=*[F488ENH79!V
M=%F_QN0RTCQ[7N]K4E$44>=:WW T?-^ZM9P?@R%]($"HUBTAPURV5/G9,C+-
MV<G'5326-*\Q]%UD=]\JRZ\C:=5I-XW<;743+'F'AM<BQ>%_G)UT [ W6@)>
M2%/.<WT\$HS4EF:1 WC?@Z"FI'(T>%O27P=9\&NGZ)JY7(K\-\,\I33K'^:;
M$TZE,V\4RV)RCK.8B [/*E6.B:-='P&O,*%_'$6'GJW/]0CVGU6 5H)+VJ:Y
MLI';U?&':E<. N>.D;.ME_&1^@O<1(<K@BA%\!:@\V">O74LB[):L/S.,&8[
M8U<*Y[N\/!/=7CI[_$_?GMWHJ$"O@I=DQG%*UE-7?M'(='_WV<@]=DA%+UAI
MF?DBC>0:[''.=^GU6FY,WESNL_S<:V&!>H,2"&3JRE#D@4)C"H1^'*2UA\OC
M]N0W9S+4C3L6A?Y&MS!)4G%*=Z_8<WYV7HZ+KM^+\8VG]Z-:.ZK[:@EM\\L^
M&"-O+M3<5F0>EM@VR"\DD^7%D>9B0Y!@3I[J[&3L4F[CKG:G.0%5G^5$,0@V
M1PEVGMI)VKC9O$O:YWYH"S^UG< 5=.'U#_.,D!F8*YGKSMG^JE#3:_Y2Z(2$
M@[;UY)B\WU@\425!XS[%])F%,O]] !5P<E3A9"E<K;XRIG[7JU//2^2\TRX.
MGD$JK.#H&JK/<@S^6SN6-U97#/WVP@P0_<K<5,0/E-APY/<0N:K9,3Y8F/K^
M_LZ@V1]CL640RG9?T#9H,.Q$X=PX#]Y#EVT D4Q".E++2[JE@H[3.4>/L;J=
M/H&/JTT'O:F2_C[A5C1O]4'B*&")M]-7NL9/L4^(,%V#AX/)[0USIW'Z)%E*
M=X;[[* \E+<E<DTBGC0IR+' S;D(L\*'HG58025YS5AP8J]5'*GT;E-:&GP@
M_\)SU:&Q3^!RHPW+Z)BA,ISGY\$A"K? ,UJ3UOUM0]SN-CJ%R4K_.2\7)[XR
M.Z_@E?9M2LP#4/Y54,X.65);S 8D6*_<D@LS5LPALT.!A:FI+WUQ059I0%(C
M3CW15^U$<L!M95\2R_D#5_/W;*I[8%-5>XA:-?C@;W<WRX&&\9/RPL)W*ZD^
M?A>\BQ43$_$; Q:P;1RRT@"?DX()B:$E+RT4T^]OQH^*NNA-%^96#CGVP$-E
M&:V D+:R&(386_WMF[3M"VUBH>CC1T YT:JPDKO6IHMG5K<_^=1!+MQUH**2
MP7DB[:ONP:BHWSU0B%/=43%%7YE9;Z;6\IA]T4B!7/B>Y>#7X-=*H65J>'.&
MHV'MF.MT6\OGUU]+A:K/*AF/K2(.>:_V%I4(]U9BUP$0K;>GVV>/@)=;=TYD
M2YX=W7SX!WPGM8Z2G@Y)K<72 S:.5^AXE?29, 85,+">(4MBDK;>_,]>D355
M4Z^K&.FQ/2PR>1VZ[)E U+=)MP'UB0+:E!M/K41WZ9#S'8.7Q4@Z"8#E'Y3-
M]?@V!58A41KIY.!:F922%P6,/A#BI3?0O$GZ^HFZEF'9P95%-'J4;7CA>/O;
M.5O]4AN8.S&9+QPW<91D0>_]57?W(G5CYNB'\0/VR,\C8\R.:4LBT_S0W13O
MS4@>Q=2SAAHU#[(RH:0OU^'H#3&8 P;)BQZ<25[22Y 'V?RK,KUJN.6$]D7/
M GE4:"QW_ GGH;IG2J_[(BE?ATW0FOR<PSJ-_>4],.LJY4E!45$] BK/'MP,
MD!#61.N(;I9I%LR+\A)X=!,'8J.VC.ETKB"*^T[UXQ*K/E$.6VXF(Z9D_"Z\
M>9C8I!9QYC8)G8FH\D#?R7<C9)M*Q[-.-*"7H]7%Q(+%)OWRY6[@]R><8NV)
M1A&;$MQ&I+ )=@X =6VUZ'C2VH9?^+_K.Q68.%.\G7F]K/3F3=$9M /;LVNT
M)]AZ%:SH\]/_[LW]BB%12CGHX7G$MH<^9V.]-L=&7WZ"6%[<2', YLX#*:(^
MLM+.'KNB>/D:W+,6>^=:5J+ PM8GY$&;H2>HU^9#8>M9OW(5R0Z]3_%\!+18
M/XQ@C"YE%?A\5-GH2K '-DET[D-.HSY*'2>;:IK_=N#< \%[91AZ3_ZZ<KS*
M;ZJX^9E)?TPA1EX+WK FT_)Z;J;[RJJ#=WCX6(QM!*'/=K[0[+>=)P5;JN?H
MU3P5$;>G<FK_VG03;V0<532G9YW<,-83+,[L 1#X+,N36]('^9$TL[:CD =V
M_RA&>4R9%<GS"*C7?\.7+L2O)9847^'Y,*$P.9(!LG0J-F(:*F@<F1TX@M;8
M=+RI;R%W:9C_Q7#2K]13,KJK;NP9WFU,-LV.GE6DZ%&BT#.\]KS?W6OWGJ7M
MAU^>O&&*NB'XH"?Y$8"_3%PM4;Q-W(#U]I=7"LI)K]I597G-=F0A6_F<$5Q%
MQ&^$^P1!'"VBXH'$(I':2IB5HMB^W?X>-BJ">SK;G!69)X81&D%ZNKIY"M42
MZ')R$(],3"\@I1_@$2?L=5L1[F^".[PA)[?_4Q/](@SGPUU9X5@]N<$HCO[.
MZQXV>V/1%9)HFLTV<UMPWDH2 D!:;;?LHR/NY<96U*DH$PE.CE2-W](-T5/
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M8!]E>!M?X,L7 (MT+27E<YY],5 1#:HQ]_S%/>A'?3WB? MMN/=6 C4D8O6
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M)'WBHP;<VX'7JJI.TUF%0%JJN<0\\,6NRC\IKS'TGR/'U?IY-)Z;Q^OBX."
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M<,1&]"/@#<6D0(MQ[REP=KU4(:;BK2P3G,F42T*T-+0CHBZJI:$^1 V6X";
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M_<Z"L(H7RTG8^J6]6/WTN&[IA&+R#;G0>X>+R=^(.U'+"FCSPF'/FQ<$S =
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M'(4&5V*%Z3"% PG@EAC;1@00G%2^"DAY<NGT0$S-@2!EFY.^FW./PH#TG)2
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MIN]+M9%BR4Z:@.I3^ACG9JKS+?!QC=O8[UV2VV.6"5'=>\#+OLN;X-^1""S
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M7(:T;?H!DH%L^D1Q!?< V&'9PY^QZ1/B_,_2)%F>WXYUWEB)I7O.9D^#KV(
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ML(^K6<CY"*"-5B5?>OGH_8]!ADR-]L#R4ZE>_L75EO4J:]2EZ+<^35."PZA
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M&>+[OS*Y[>6>,$XK)4XH+;<&)0I0!?/.93#^U-S0M!145=%C%4G\=WQ4:5'
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M?1?K @F2D];/T"<;4EF-7:?+Z:-Z93>^+COUPW%?0&$YC,+\M(*A2XN$5KG
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M^Q5>=1?)2P^$W#%Z.MF+0BX?65%9QVT@3PV50HMLRGY"EC+AO&P3R0B#Q_>
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MU5P"[15X1&K!,F[BC+&KT]0/T7:X<M%D>E_864%Y%[5N2&*4+ ERU++<)2P
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M/3G0V_<QL53#:,GZ>#O237\% )]4 6\OZ8C B.;=' F?NES-"14*A$'.+I7
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M-F58VP?68&;]2;6"R7'8Z4G1X%^02YC@_6"04KH6\7+B#NP=8#ZB1_F+UK*
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M&^,FME&GU=!T#H+9YU1F0QUE$(C4X.+STR#+$]<1/";7@:OAU/I.B8>^^9&
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M?' \Z[J:KS9A#5(G(I>%(;/"K&-Y=L"P:&SVA-$HL8S1G_,W$HEJ:2837&B
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MX(@LCJB7:6[5HHM$T+XN:MP8PHRFR/@[?8N\P</+*1/7@."$Y?)?Y_[GZ]>
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M^LU=\,(%_Q(!6U>E$V]$2?:SL4'^&#6\5]KIS!U-[C%E"UL5O??K\9[ ?MG
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MJ?W7M4H2;(_F:DHE3RRFWK$+>WXW47R?+C)TYY($QNZY-CSJIF +ORMIVLC
MNC@2^D!C4>-Q4%BP2(#M*G3_BZ[:='A6V5+ IV<M!UC [LH@_&.+K+1$=J_=
M^*99Y0GWYS-O&74]Q'A(WF2!__6SE5WZFI9!C[6BJKBNIK3_!C3/Y.AD\&T5
M5^\R^R]7=I>8R$P\?5@V9'H\!AZ7Y=TSU-V3- QU=)[JXY]NVX2GLQ(]Z;2:
M+K U]\'M0-H[GX,HGJ5]X+5IN/+P_]KZ)YO,6@ 8?(K;F&-L9*/"/F.8CA::
MVT0*ASI[M*J.'/\"?3H.N]IUCR$_K7 ;-OT&5XYTKLDPL#\4^3HQ;,__883,
M9GQM%/#7_/*^+@4G7DY=M# 2E\93*T\P::JE'=[WM1@5;M" +(0*!&NHU-0/
M$I7NQ6M\08-3&J9JR2C0EG,U'C/<]=6^XAK:\4129"]/Y)@7K<IW_-+CF>+R
MP&X[%RET"N1_].=L+(R"R<I]ZF/;F+KA3!P^(=W>AO?,3!ZGJO\&R3CT]PCZ
M.1K"Q5)+%3D2!J5X.4T)65<PN<$R^K6!$L)SO=#RW@62,B[Y%@R30V_O"/4G
M$=C]?&W68:DZ  T>E19$='7N>RS::C4W?=-Y8"MDN< :^"AJ"RITT,;JLXM9
M-I@SU)@\/7]4)BS99VWS5,9O?7WBR2\!T5AQ?0-'6<S2MO#2PP$6EF1S#AZ.
M=)R9) NJU7@R.PO:&G/O+HL''Z2^&9*>(Y?8"2U09NMI/U&1JZ;#6" L31]-
M,H=8EH;8)[)_:,1+/L,"9UJ$!8JKZO?]VZL42HUE^EPW!'9-02_G,GQR?<@Z
MT_K"F[LOQ]'J)/XYW@WZ"=^NLWTK*CR0A&%M]RTX1U;-7\POG@^%<QHRLKCQ
MD,/,?:(5JQJO1.=*;?&PP,F8:K+I,5>-_NR$Y$,;Z0]D)@AG0A_G3F:VB;QO
MNG,,5R9: =/2<#J6ZXQ%<"L*DNV H:B>H=!I-XT5H>!L7&X(9=((?,B#6]LR
M(W"Z';"W4%R^RF1A2 1ZHEXYL^^I\K*.YI-9'RFQ NOK/U'(NQ(";6P^(3HS
M >I017L;YT=A2],'Q+2LWMW,RF>%/A]@+Q&D145[S%2PW!3J=([S2+<JH'4,
M9T>.^7R$7.T1$3#(7?MV 97TO+GI2K"MW$;P1A7Y?ZD"EA%@/N=DVFWRI%ND
M[C)P/V):C6[+WFSM> M1!D,0?A1UI("$>0:+RKW/L7(I.83,,T&2 7^M'36C
M3(JJF=.CN_,F#B<"L 2A.<]#0LV^V@JZJ26E6.^G.GI^$_C@:_#+J;J;=6FY
M8')XU>:1XWXZ:E3?^&&7*FU)+X5[PYR!%2-Z@@4^.DH_6HUNWD&;EJI=%SHQ
M/#)3K7K8&L$=<X8N;4;8ACBC)58'*SP.5,Q0?D8#6C:D[F- ?TXVT7DFVVS6
M6F!?W,5QAJA^1#V'(TOS^ GT63W,XUMS7TW]3#E7HP4]1[(:65>+@LED$0PC
ML;@SL:1JQPF2KKP^R'VHPJ+=:^]S!6^-#Y.6G#^/=G>_._M5YZ ]=1@GZ2CI
M9NFD#3<CF2-?NZZ;[\YIJ5T/VNJ#$D3'QR[[(V7I.J_C7=C:&^H4'X-T7,3O
M^=WRK3!9AGN'.HH4T&-*,9D#)%7J'ME]/]=O!6[CSKU.XX](,;(V9G^=;".!
MI_NV\</M)56;Y\_IWK[MP%UJ\8:+KOU$#1M/.$+3CC341XFK#P=T@^4OZ4=;
MIVR1H#YS9<64\U5^L46.DCA??1F0"7!!+/AL7"=\K*HI;%-@+4"#UG:7KQ86
MX>'/G^#H66+<*;'#F,17OZ[N"XLZ*)>E\1';M]-I\38\QE-@MWUU:/BC#RS^
M$D$8PC5-;6[5@] L?M&<:5G7?_P(<R1"<AYJXTF23\7.&G=F<:%=-?WZY*@B
MIR[ZZ3)_*,M7*!_*MDRM -6LC4A/2]NE3M@XX#(DO8W+G7"@)Q++[!P5)# +
M]8S^.JU>]:63JNDA+GO]639I]&IXE%.9AR/UD?S,.6<O*G:CWJ431A@#RS6J
M5GWMS)XQ,LEKM:M"M=).CB;)I)34FP]<'RT:]<E>4'$COU:N>PKUG6Y?IP-C
M 3/=/T1 M?'%_&9JX4.:R]CR2AF\J=#Q+5T'7D^N#)>4E]%N \_?K06#AVK:
M0R_]%F1@L:*:XEK)T8\'77((&[*52XTMYQW$5OWYOU0\D.&(["8;T=N >2UV
M>Q>"N] B*6UTJ%;2Y!P'1^]"S=L#]\.U>D[7XOB<&4QV_:!]:H%\?<?^'@TU
MS[_T_>RQ_F'U1^L)+ ]V&@E5_VR2D;>(&T(T4M#.EVK0 F9B/CX0.PHC3,#U
MX.!E:TGM@Q#5'+!T4SCXZ8^.>,]%;XJ4<S_&&1QO=>*L]AE?&6WMO9Y!#@DR
MZTS4$5,N!@>V:<O1LY!(JP:NFM_?/='.L+"2(,H+SF,"RMM)[=/JLF2SYS-K
MKW.37EK@_XKG?-(%^QI C2AOF8@-6#(7F#NN$GC0G_(+S^W1D<DR,=1:+9YV
M7"2>K3.0'QC1 #A6M-BGA6NEF!Z3"U[_IIY,"IYJT+Z<+H<>"#NFK,YM\N8X
M-W,X$67UM5AV,S-#HB3K\BKV4G6_X7TI:"'Z:<"X=GRK*NB!CZPS_N(OV>1
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MV*77[O?2J;E\Z>??]BU_K424VSSY9:SE-U-*\:G,FZ4+G0ETJY3V%=6P(UN
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M)QRA2AJ3L%M5TL)KCBR]HRXBA5];@HG_5![LI4/XRM>&KR2D\2O8S+I&YMP
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M0;K98K4BDLJRX)?_PFC!ER'BH-GEVM585JBU$7G1@SKUR6?#2U_H^XAH=F_
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MA()+1#WCDF])>I!@,Q%ET<5N^F&2NV%<JLT<I2A"OHAPT?^*Q2>S#56)Q4U
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M-<KR1+2JNY5_:],>.LXXKAJD<OLD]QO"AA\RZ5W7AU'2V>B:V^UX(;LL.Q>
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M*+;N;="M^) 4BL&9WRZ0R\O-20'XB .C.>"=)_-M7V$ #89R?W;^<*=P<3J
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MJ<@OA#?I^^']KOM[/P.2^ROL_%.!PONV0 G\5FM^__,"\G.:\_\"M!^6D"]
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MV=C,R$"QV$7*&7O JU7)OD!_LK[3+B_'H4JQVU.@H<26^2QDMC) />'%+<'
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MWHM[:V56]:K63S!E/@,1GJ562'SN<JI73/M Q/!V&O+.#!H <D8#TB%WEM&
M#0T,8P=5H"P?W2C=(LDM>+M,'>GB=29*<!Q"(]XZ0<(MEBU.CH4\3PHOBHZX
MNVH18#)EU6S%)-QN.(\4SO-4$($[%ADH.Y 2<\T!):[(EZX:DD:5 X^KSHV]
MUKKES !3<VVJ]6CV)^US%$VH'0"_D:HDB4W?"RD%79<#4[D\)K(:3K&_'VYV
M&I&$4E231[VHW 3E\2YT(LA7V[4;65^KN%^-SL^/HY>4#3+E(9.TKE0/,D_6
M3T4ER+;YIWCT->0XFW+TE?BR0SFL/8X>5:'PT:V,1)Y/97OC&E[<W*-CD>!'
M2FFF2M*>CN3[0.)/[W;;V:&$^WVEW$W4:ASW%AZ#KR$EJJA3L>P"^Z6[337B
MVJ&DU'2BJK&46J\><IQ*[Z8IHXK6+T<\SQCO88\]=8\BLN>8K+Q)'7B<)K'0
MV9'G%051L+8I/[2;I8G,NMXAVH^N)IJ%ZX:';F43OZX!6^W S=L=X758TMSY
MMM02#0C]_=,[N3N>0EZ35DD#=6["XSEU6>/U[FSO92_MO0%V'* !CL#A.C1
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M>CH!@L<4M+/;18YA^^,[*19/GV G4.39G/&.5N\O]6=!'.LU>>8GK\EGSE'
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M# -P94:\.9/%J+63_11+D2LS)I!2J^]\2RL.QFO[_?T:6&&"2B(:6*-AAI<
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M BR-F>_5SRSR39\TF6*HD7UUZ[+I!3V+*)-<Q!(9]U+B!RR*,8L/3R;F5C7
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M'F\-)P\#;73U[:?S.;B<65K00?%!#H-MSKSDP"-E2;.=",;B4CL6PT=/SLQ
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M+5[58XF5F2D/5,4+S0F7-#A[TCDLED]LL-7) :;].OQ?,&" /I[5G6/-N$-
MI7XVH/M5BJOMQY"*^K5Z_81L4\$YHCOGO!?"ZHAMFJK-OGOA[A]3>-^)?BUK
M:#VC20))^!O[BS&+E%NI\]"/G)[")J][B,S9 P9O3'H?"[=:JF(5DJ^V.N:J
MHW:?R;<F]'W4' '5*%)@C+)0<4+&)EFTMPYP)%&-.BZYD'VBBV-S6Z Y3301
M\D4&N$;Y.IFM3.3)R5AL4(^78/Q_P++U+Z1_53%2C"XC4:LBK+3K2+7)V<:T
M1):TCSJ\[:-TNP7T H\N"=*IO<U5?="HFIU"K_NQGIS[I[E>''GXG$99]2 7
MJ"OJ>6+J"=&.K%K0W+IFX\&[QB$BV"RCH&&H"I,W75R6D.6<X'&,<BT]>RJ5
M0Q%!(L/CDD]D&K[F<0H^TC( SFQ2T.[% * S[E4$V2!T]9IY"-)\MAT^XK.>
M;Z1U'P/4AKLE'AN1D_+Y-!)%B8N^?W8R_$IV:)$1##!+"_==7XE8M&"_L*L_
M4 V%<X6B&;<++4M90 %^GR3=$A*'O80B.*SY**PV(R@'0 DJ.SWF'^JQP4\3
MRTSLZFT/1[U%$[>RT51+K@(HX1K9U0 R#VF9(B/*<Z&B<87L<'0F\U.4+0FB
MT]?/(_363+(0^AG6[EKBRHNC05V:3DO:Q5##BF=&-ZT_J.'/U'E \)HFU9B:
M:/(B-D !A1')&"#2%P/8$F. 5!;LJ?&9]J<9Y=26"U*&H*OAB%9P8I@[+;^W
MXU(D9=QLU'YX9S =^PI2:H,! SA V!!A8UCZZ-Y!+>\%E^>]Y7B $^0\2IPK
MH);@_';],NPT/^.6C>!(3WS>6?NYU2Q&2JD:^N##D2+4*2,1RO>W/MX)"NO,
M;1.Z9<M4&+RY&$8]5VVD6V""O40,-VYZH%' N2!E@&,3#K?5P89YT"-56T>N
M7]^V.N1-2@VM3ZF.\^1!OIG92N5F[@H.^(1V]$E!FFLC"AH6* PCTL-Y!Z_>
MP&Y8%J/# .1/2R$T8(CT$!]81]JW$O!K=<ELG3ZQE$#2GV?E4$EWDZER](/%
MO"7S@6J=J9-LIJG3L.G^HV#Z0K:CI(9YK>,8MKJ* 0QYL;I1E^#7 V'YE]$>
M*N21=].5Y?*#3^"YWILBZ?,$+5.%EF6((=[1G#2H-W]QE-@PCYV# 4::, "#
M=E@KD53S^@/0=F\\\&F_<8P-.=*V3):VMGR1I]N^RUY3EZR60']6L$LVY"J/
M9L\9EOM.$<<?FBUR&G W^K0Z_](S>@0%P3YDOL^,=N7?2<(/F\VH<LQ#W9A*
MZG2VR,?=[KK (_K*1><5O+=%H")X:-6)N-F:-WT^HB8LWUD7ZQRDZ1J80%YH
M;HMT12 FW3QMM-/%A:W]O)E:,2\63)?4DW;)$P2?=_5[F4&IKY<NW7-0!A=\
MF  B6#UQ^Q[93$=: E:[#,R3'CRVVN[:[>1D,FT0LM=,L6B[6Z@,SWSZ$9[9
MS"EA3%%=Y9T6[FK;B,K";ET?UJ5!W3XG%*RR,;.=$!C5_E$[L=7:7T/7K_2%
MI;B,J@3>:PGFF_M'[-'(AUA(G\S%PW;2M41J+PSPE#1P_7ALR2!&@CYM_GJ%
MCCI1+BZ(+_5)6H)3PG2Z32)-&5<9\BT[W\V[%RGW'M^'I%MX]GZL'\G!'U<]
M&#8.0=.!<S41KSZN:;C5$G=MW>@A]5C"EI)$VL_4U)S3+3-WLV8,)A=S!?74
M,;])P!JHI>5K77AEL^V"6&>JUJ,Y& DQ;SB]FT]\Q_*N%F,;T^0E+@5V\QD,
M$,+%6%G99VWDHCRKCZ6_?_?DW'$O\+=I!-=S(@,Y)#K%;3C['!MQ<#ZI.LYM
M^E;?#YQ)KR]2)5<XQ<-]<[I=--^E/L(/&4:W>7#F.F0S55?*_1XVFA2=GOAI
M0?1Y$H$@\FRAC$%MO\%C_?87=/+W'-&.&V7;\HT#D%D^"X>KY1!N7=F?6WBJ
MU].#$/)FHKOKS.@GYC(E[K<PP*6]5 R@,P!9NNPEH@"/B;/, P],M2%D;W%T
M4V"':>PO(OEF]I1.Y>78CG0+J;X;YN<?CI])O,]Q)5*2M=0^P3R]%ADT9_[X
M<55# AE#Z@D\0 DQ[9^/8H=E<UAD\DA6&@JWNZN^UM%^YP(G4B\XRT,M=E88
M2?KQN,:_7SRW+K6^3^SWM-XP>IQQI!R\>M]'&BF?I38>+(%7WXIBP6[V) =#
M[B/(H9ZMV6TZ!!SEUT+-/Q2@+X!OKAN<([XS.HOJB=YN]W^@'J4TGAP8,CR(
MSBQ@3Z\K008,]U1(9ST/^.3=PX)-U<8\X.Y(0D94XJ)J%K"*$K]4'X58-D+:
MN_?NAU1.[L+J7>!DV1DFGNRA'E;OTYJ!LZ*V=7<+DVL]>)U!^&5G4^C;X*=U
MTP%W# !O;AZ#! HI<)11?)@9O4\"J_-11C+,U@3QDUW2=$%LE:\WB\ILZSX!
M;0EQ'=GS[1Q_^CR["Q\!%G+0Q*-$4[:LR'-KH?[U(%>4TJ#E)L-A";V-2-DV
MJ+4O&X&[:H1S+C'? QN.*@&#9#A'.G4_BM$*_^S<)&$WP%F:P<1)+U[J&A\3
MZ25BECB[".7KI8HK,S\[,.;2:2I/?\4\ QD%'VP^ #W5.7A#Q3K;SE2_ZR:\
MOE[GFQ:KJL1A*\G3/9F[T!LH>L$(X8$\'DE,/Y)L\EV]N)N$[S-#NMM9WU#"
MT3;!HG>M46@(1+=+<$VMI/A!!)45PP0&.,BM0DK,?!"ZF5SV<2RZIAJ(%FT2
MA C,HIG Q*U4&"#8J+:T*%+3J2GUREWL!!.L!%JDQ\SA.EV/G+@:H<Z]%_%"
M.T?F ^ZT\&E)>%OJ46:F5FUW9RGQ(.B5RY54N*;FX([4$%Z34$2R4X#3B4)W
MNN.PD%!?33I1R$ALJ,#=TR3,@KT$_=/*JE3>OS]:44^I7XQFJGA&'G\UBK+0
M82E!9656['((J'&*KB^#>'2YGS$U-9H2%.+P3-'F%]2W_Q[E>SC31@>/\!0]
M##Q'9#[O<5NVEQ8\]<",7\Z%FQ![E+C50P)V1+7:0D=;.6AY1:*F^ZI6,$*+
MW]N34'K6^D)&IJ,;;7M,VJ6<.9QAKQNWX**MR0"QIO?H6?-HA+.W(P2'%R_;
MXI+%NH%%*/OJV_EZ>O!5<.\=3;[H1W$T/'>;;^PFG==]ZLDH,.TC41KR(NBJ
MOI4+0Y9H/IC@%6U#&)TZ!1O3)X[VHFF=;?C^;'WR3-UMF.J0?L+9OMQ+R31[
MPN8Q0R+8NCIF_/SBRKYW!DJ\/R;PV!^/I)^)7 *K4!L:#5MZ*M.</>VJZH-Z
M@$BCNSJ<)"=J6U9QZF$BC+G.81K>N_]I42T(M %"%&0>I_M3O'5TZU?*SH9,
M9-GE!G,"IJC+??/][KA^!JQ\/0;TH:-SGT:\5LX4(G!G*0SEED]Z\NTNQN02
MA@#*;0!V.KC[F /79810?-;[2V<&/]5<I]D]Z,/)?C,[R= 1C &,-1=-%HW+
M3&X96YO56,[>;3^\E![B="=W"<A4./&XUFWO"0:(L)?% (6%1\]&BE6)$: W
MU\#3]TI+_98YNXE=?./L$\Z@2[$Z/7L;MK#>0U:K/W_YG_^<]LTR79P5%=O@
MV@C:!HT.I.U,((HP<W)<SB'VM OVD]Q@/56SASSADK=HH, GS5F=DM/><P$:
MGUJX*[E+;C8^:-=8]N1')C2K5!87%U5*H\+5/U SO(3X.B1P(SGBZS.O)*=I
M<=9T.//>N]%;9KB4>.**"OIF6="0R;,GB@(5<V*TUF\F^4HA0/Z[C@^+-7)1
M1Q,$<+[Y1&)W#WN8AX:LH N5L,CIL1R"*8:JPE1'//K.V:J=%^07K+Q:J?5]
M.UK!S9Z]!S[%1L,7&5\F3B8BDDZ[\\F?0KJ>&G+45AJ6N^6G+!LVB0%V5T<N
MCI2&D9G&#E<KSSOC=!KJ/:4QL-61PP#GCR 8X!88LOGA>)"Y*4*#$DY\0Z1=
M.A)HNUAP^GV; ,07 (OZ;> \1=,WC22RC6L]"T_,)EU.I'+73)\&>T[+%]>&
MSGZT6>S2L\'!  450L[PT.F6D?6LT?N<!<_=9T(I#D:8,MU/#^FL4RL.,5S(
MGN=BA )C2+PT6>M473.K2O51#HB?/6J%\\&<\E0<3)KWP\Y\*$O&Z)H\O3/?
MJH9(E'F*J<WRG@D112SV5&48+8KM-<*P?=PRC:PB[=$+2KS=I',Z5Q#E?O6X
M5:^L'X5/B"DSJ)Z,E!10#76G'5@<<G>(9?'O]-5.8TCJH(<(3(3-7'^]??*%
M4H 8@4Y#AOF($/5,G>B; ].*LE,+D-W(A#P3[(5)JRGY\^Y2SWO.$.JX-,")
M/J EZWQ@JB&E;@W^"X*R'>GQZP_/O/=F:. KF=OT4TG@-JR&*EJ[IE(CF@E<
MM[L@7M4E$SF39H1GL.9#[XL* %$S=%$<\?D;65V'65%=.%]2P!)N,[S"+P_%
MF2J5^2$X9ZO'M7@W_^U/#4[L_"V@+:[?BIT<,Y6,?;GJ,I4QH\!PT+U@!9RW
M#01>HH06W@#ZJ!K-MSE]H9; %!:";\UV2G,TUN$^#N.!*M-LH8]J/"@PZ;VN
M$E0BI&OMC/WT5%VHE\@=>$6 (^@D^)5LK$2H7%2+*YU+(00QG&F=BV(9LLY7
MXWV@N8&SJC9U$WF[GGD84FIAE5IF#*H]94=Q\#Z?:W8JUWC&0ZK9F2K-KMVF
M,K <%+6;1,"$E,@97:;C.I0X:K$1_WAU^F+C.[>A8UA,-!;O<L>N8M_ QW,Q
M.4HLQ !+W 1'AZ)S4JAK1QC XS'7X>=B%7!9#.$3Y+1NW5=UU3+4BT!KG;<2
M*=L4R+LVCB+9*KBVD)\TF5B(5#'V$SFKMDR.F%SA%S4WZ3 4NUI5> MQ.=BQ
M$&]B6:&Z=2&C]3'/*<#](SQ,Y74_2NN*]8;2&2?"NO$3=8-*R.19;9%W"U1I
MUZ[2,%J<Y5M(A/>.S*'U+V" Z1(T+_(X5!W6S;U[/S<^?0;2YB6TK5A=A6@/
MI3('CY8-35^:NZ$U\K[Z\DO>?*J!%D@719/M&OMSN'6S'$/3'7F*:Y,187R'
M'NP52:=^]F1#1LU)I7>-V(R#.0F9EIP+<?;6YY_<9 K.J4CFQ=IN:(4$$*]J
MI,4K![=:Z#TN]-GO.!YVWYHY8KR2F[_BM+"-O&A$(5]89]()/Z<8HQJQ&R K
M2"0=O(M:;H#W5F" '0I_]-%Q^"'0ZZ_53%XMX:72WE'%]V%2](;5SK4T4&R6
M@HCD,D1>)E^*.C6ZJZOQ >D";UM\XYHV8J\K)=#QPB876C?7X.<D<O72+(WF
M5%;[<YS/CDU5$>IP'>XPTG1 9.CEY=T&N[L,A2?Z.5TS:[BPON![-H31E"*T
M.7X%I]'#I)O!4H:+01AR\*'P(5S4*\^=TJCK[+:5 0909T4_PQK%?_;/3Q?_
MY<3[TLY-A=8_R.&5O$:B3&GBNRH?$:/^<%&J=N0+F/=L(J[\)9'QN/;8"YM1
M&&#XG=%QVI2,FA7/T0H9<:Z*FZR>R\JT/.5Q?U'Q_1KO<Z'5PZS\.5 K Y;Z
M=1T1>%NR'>=Z69#JLY>GMG'XYLC/.B*D8 9[7/:73,O7FG'!8_CL28BP-^\$
MY?LN-_33F13D1WF>\Y@1S1>\J)TPE$=Q(I-^GV1EF\LG@2U1&[X].G73//?Z
MF-HN^_C!2,9>6MOS89N GG;<5,;X-Q!JL-U-2FK5,I4'3\X_R43(+8X*<6=-
M$(<4\8OZ@D'-A?Y.4]?+ZAKJJN*9B,)K"/)YO>OD'>ANP,>O8JN5,L)QXMF=
M6)5,AN^.\EQ]6[3!WCF')$YM6X&AY]?ICV;1I"M.UW,-#?%>$ZDPX9Y=;;T<
M*W:O1()$B>)SD:ALWM5AP6E0516A[\<=XR2$I6A6_:H^+%,>XM BCKOQ^)3[
MZMQT0'5F<%(\'MN426E6542CZ-5]D6<#E2^*=T0B\D?-8R!F@P5$8/N0MW;7
M5#M;71(;-S\1^A\YBG:_;PCR9(UM3J#8RF?\X.S@=)%6;,.DO/S<DH- ;*C0
MS;3>^2FSX?Z.&VP&E*1N,@C\Z/S+ZP('U%X":S9W"YG@HDVRPJJ28<J(\Y'O
M;.WX3W+NWT*7Q4)FWIDW)MPHK8)O3?0^7CL'G&WLI8>]"B_HM1XNJY'#D7=;
M76 _$7X.Z^7# ZM,\URU5C=CMJZ3/FQOS:@/S^SFX\O*9FV5M/J==&!4C73G
M&C:"[P<Y$IR9[KA]]FP%WJ>YK?1'Y6Z6)(IW'_U9<SB2IS[_^'UIS_V[LE[O
MZ\7CSWLQ@X_=@.)S$&JE^)J?6G\A-.C5OT(Z_Q7;^5\Z4WPL(O:?$5F^$AC4
MNNK_WI/>Y$ $XI17!7H0OZ=9&2L/+^V_7:-"_3@'Q^*\*A2,I/#D,XV4WI=-
MICQ0K5[A]DB5J0JPK[^,O97C<59;G@AY[D*LRK"QE;9,\)&]SJP'5><C@:MO
M7U^0 .N^80];VR0S.S"8YBBP(\$ KVV/S,?Y:I9VCHBV5E1P(UK4HL0G&(IA
M#=BC[; Z(WI/+0>4G-M'L'SC<RI+?;6&]HU.@!]F/LEZUW9TMIY32Y[<:P-6
M$3@?^3CG!"LS)>6RCOC,)$[[R &WCU3TFB5I().7TB*B$(Q0#=PI/*^6WE;8
MS7.]?\MJH6!)XY5?<;JX6\;:(:\/>^GC5VM/WW^8500WMS40.%;FN]_9M#>_
MB+WXAF+WI&J]:?Q3JHQ7I]9+3D,-\#-'1V)1KM<3X= Q_P][B4(6Z+VKYME(
MC=>%7KS]7$IQH/M#P@7G[$MZ27I%1#\M)>[WI4?+-JUDGLP^44NV/6L<LE ;
MK[8;=^(:46JOU;/P7E=UTMZWC4=X K4CLPT^M>*S-:MQCB&W"A@B;)(Z-$&O
M7+4O\RH.[8Q[:#1ILJ=SGD_%+VM!;MX>Y)7W&PNF\DA3H \F>&;G0KO:A]"R
M;@5]8CY(//3Y!#6W%0Z6]Y[>NH0!QA^@WMDV@ K&#XUE [8BDBT\+]5P>3=\
M_9>=+BCON1F5\@)!3&/VC7U261C3FFKIL.<E\.OW!GT7KZL09JDA2@T@C3F+
M?FBFU3%00&J_NS:^<Y$B0P'N8O#!XSK=-[D6]42#ODFZ[)U:E@>JS]Q=9!]E
M+7-=4'12\PFMG ,-Q\3BA=F'#*N]'_JH9D"XK',.(7DQQ5U^P%%-LBTNO)BV
M9PW"ME<'=!YYZR\0)'9JH97G1&DT(8$.+".;&[I'N+Z54^U5X]*+&LU<^WW\
M"VQFF>G9<FS=Q!V^US[A5BE]TS[L_]+_YPAK%@-0[W1:\LFQMUQ('J?VC?"W
MH,$ ,KL-!"N*YE2G7JT9\'3A1GVR5P 7W@YJ\015#Z8!<1?6F$N<"HAG.3^B
M8T8\R8:2(PS+[![;W6!/U,CO*S?B#T&=+5BF8Q>Y#&^*-69*X)OQF0Z3Z7S/
M5<^ ''[O$.<P7.[=\X%"[X3PZM(]6UFH5B/,#GT*_DR$$+ZFPNKW_-5 O4"9
M7<)U:ZHPBC$\4B,!Z\X%RS:1?=%TUPQ6[MN/])\CC'UA"&O?GD0[IW=%/-QH
M\E87_..:[1S![%9GYKCIM'GI>2>Z) _V)2U%;XFF]MXBI'PK!KB $K=V@[&$
ME+V4$B3 IO/"W<^EON%PR&+)V<>HR**L.(I;#-6@KF32^[P<S.]S/"?M<K\U
MN%$F?UIW3+W%,.$.EH+SO.H#:2@P(T)DLG\ >NK9E35>2NSR=,WZ7OPHHOWI
M+,+3FRDH/#(LGKE=7%N$I55PA=W$_5.Z-DH2SLB9WISQHLOP1O#+"R+1YK?A
MHH'NQK#*W092!O&3=WC:Y+7L +KH3;6T5IJFCY14'(IL]$U9C:0SGI?UYPB"
M]\JO?XJDOHX5L,2]3;4'(C?'2P;;;2 ($\1\]94IF<)D8/5$2"58&WL^1"F,
MO*);71Q?V33_@K"\0LA)VTOX4("4B8E3^O]^\<G%&Z18U?1S'<_F^EE.M))J
MKDNA/18P0#W+H2(&2'1IV(0")1(JO]V(#$$6IZP/85X<_<KU?[T.*P-]VG^!
M1B:=XU6V_NMUZF]\3KS[/5/U?\94]S<&),J0_\G@5Z-B]?SM<<4?$NKO,*G_
M"TRQWR74\+^GZG^*ZO>J_FEB_3"J?]I_P[^"Z6]($W^$J>IO-_*_0_755--^
M5%.)/\<HC?_H<?1?KZ/^)/5]NZ/^VRK]$8O^1C]+_]OCQ7^VGGZ@\\-^U/._
M%]-WZ>D/^\[X7V+ZX7#V<X+LCV:.?RW4K['R[V?:QIK"2%#+,KD*]?\56M3]
M38N_Q_:_Q*KOT-B_R!^_,\VX5%4*PY-N [Z GD,.!C 3W=[D/T)(C86A#M]A
M '>%4_%L%5]O%#\O?!#9ADR38!E!\W^[\<C" +VUT_NM@'I*[M'7&^8?9O';
M#<C\+VC$R$QRIO]M9']C:_8WMK])+/WW'$J^F<.T^0\ :_B- <L_53KTCSB0
M"I1_//E$." )YS]@=/9?^B_]EWXQ*1G%5&U2K0PLU1,UU'MY[MWH:5XR.2'W
MH(V*+(P5NJ_HQXJC/!EUH)B.;+X]S$2H;G:U\^)239&<>_L,!L#3<1=',$9H
M314Q4C)%!#+#,\'M32,-!$(2N)I3Q1T$- $MH+;"9Z'ZJ];)Z060-_%I\>U/
M=PX_0(:E*28WM4_=^M-F#?Y7DC0*IJ&\ -K/;IPWH($"CB0//1U<WD3<. ZG
M7HPIJ=O'@3(A\/->/QN;:0>?'5Y@A26KN]^G&RI*!41"PWJ"T*Z91SNL;YH]
MAG&63+"&'E!)R-?.@.RE%R4P@# Q^B#I+$L6:JEA,04R_3#W4G%3==2:"=;.
M _7W4MV-'G)\AE*B[-D'-'TGGRG*<9!O7A#)\**5D&22G-66[QM<PC+)*,DY
M6L!>E5-7#"4=.L(#I"5HL].?A*H1Y ,"T& YRIF[50>#VV+G)'C+3TLW[O+V
M\QK,W$T[P!8C4I2.U_C)"X_B>PC51[UR>*2/\X5ZILZ ]YLA3N3J-E2T8B=A
MS+?A:(\%6P::>^HH?^0@Z/D\!G L47HGY(3@+;F;3;6E'G;"BRFEI*%B)_'@
MC.:7,Y[6UUEVAC@_'Y\B1L7[D%M+W*8F.5I;WO%F>HS!$P;&@JR@]\_A+"<T
MV/D/(=(8("GD^"-85;4')HLJ]N8/;R3A4;$&LMU-CFC&[O.1_P5'>;*R8)ED
M&57Y33K+L;75Y]DJZP^7?M U<.Z[YHI#@I4LP7N5@7[>== P_H9";4%6:K8^
M]-@F>L,T!@VC_M*(%'Q5[PR]SX0"=M9_P*JQ+XLSV%NNJ\2'^KB8N[_AG.*A
M#;-V?5^ /7=J:+@>J+D:R1^>)Y7).PQS PFKF^WKX"/N;,X>-MQ@(%$]%SZW
M+)UE[ES/A6 D C_9?'O^]C721HD#56/X-=E!KMV:]@;H3:- J6>A6+3;1VPC
M[=H,TD4UQ0D]+"F5L381"EB-;03;^5S9KTJ%NYICRF-T0*\KBFWVEBG.-->9
MJ[Y$D5=75<$9+\U$9GW49\0 !*1+[U_P:I[Z,Z<:_Y&4':E'2]=%W*I><MA>
M-&(NTRCD1([#L#*0JH<B_"TC_J:4BR:KJ"7L9L="<K-JOQ)'9]J=I<B[,EEV
M .D.01,7"2VD*?#\%EEUF2!-5"=M"'CDJ=!9Y@ AACPS3W4N7"-\D6W 3C1:
M RD,(TP&MZA/<*M9-3A(NO+?.NC#&;2#Y.JOF<_3RJL.9R"8/I;5[;XQJG:0
MP(?4VK"O+K9'CBX]'.FX@ $Z;V. RN.0U;>$;2>/ZR[AQW7C3=8Z]LV3@^ZB
M".J6!/+W,8(?%F)(+63/MXP,10!Z80Q(J:W"4\C=E%N6+H^RFZE2[^)*>P_M
MB:8#;BI1>9JK\8P:(:E&K*D3]1,.A3%"M_+,N6!=A^9NJ\$O_!Y*V*_J=,(%
MCC;<R1TMUN0_S#?VZMFC26'QSP()6JCC&/6R*IX6"U<EX8W ,UM,'F^[OQ++
MHGY]=ED!:0UC#JCES[^D/='%<;'IW?FTE_B[F_D(@J;R/9D!L[UVL_-9X43@
MPGAW_1Q-I$\;>6P,MR745"H&6!6C:T PRR'X ^8'K6L%8@FLX*>M&5_:QV^M
MVS6W>=)4A'HHR7:!YRT#NEL,=@LS4$S6G(6^O!U&&$"MZ#P&$-@.&SN'EGC'
MA:[' 'OB8G3*R:/(WA:;KNNQ3.M-=\:U4HE]=%[ !Z40*KYYVCI@[RM*[^GU
MXZ3;P-D-QM.?@)6&W4E(1,$<C&]P#$R@''FMK#82*XD %\$<*B0^)TK,EQ#!
MVX3C421.* 1-XVN@0!*H!UI?K@I!ZM.TA,-*Z\]J,D[=4#4\V4[(L%-0L^=5
M+O_:M.*BITUW%2H+^WTM?X%$(=AUY&$P@LWJT9+;R!/4+610KKGGI2B9_H5(
M=O#\UC-)EXC<?*1L5D?#^5T)3G12AZIPO:*._@S%*0S0$B3/O]"]MCA-TX==
ML"%D.E/SPOQ%5<%Z]W.#J7:\=5TQY+4V6[#_&PPP-CA+=U($O$^[^@*Y;$@S
MA0^U2W7@>9(Y6&8+.6><8'T2'/_V6F]T'40&Z$*0A[E+S'$1EL6$\'9:]:A0
MI#!S",L9:>LB!QNK7TINN3W70C7>9-+(0]%7EI<CUDXO1SNS*G..(G3\$0NP
MCJ7K$3'B#H9O 1?LAITD_,W&*;:PU@1J/Y3>/1'UAW3![.WHRRB)]QNU4M>#
MTN_#WYQS,>X2JE&)7<, 3FBC;#.UM8MJ!#U5\H$">-.^M39CR<K@R\_E"/=Q
MDI/.\'%RM7M2#<+>;QA7AY+3;TZ!=]ZY8H F>6IM<*YT_+DMJI71X$KTQ54=
MZSF"(%MD6)./]).65@9?(L'K4G31(R@2^&Y/1(J.V0C%B8\B$J!)$#H':$>6
M( @4Y0Q+A>EF4^X6,1D(%0LW:,QNP! -_I9Z[S<,ZOPHS[ R$(>ZD-Z_;"D+
MDS02K%C!>WF <Z,PV9-E3(JKN>L]&S<1JXZ 0]*9>C)D/TH]F6>RB+^\A2-Q
MG4!WH&;E4_.,Q& KK"N G_:UF)THH:Y4WT^-5NJ?CTB)L%82W?FR#D^I1$@*
M UP:3L< .J^_;#K@&G3(K7-K.9<Q5K2=$?UDPP)_=[JA$4*>$UEH=9>R,3;?
MUI-R. 6. 8+UAA8EP3-Q@<HKKB,5#>N$*;Z"O.-/W/!&T<^P8*LN,%$ ^?3V
MUCM+VW-V<3<NU?L@5"HPP%F<QL-W\M0ZYF)J^.UU8(+ LA?3 9Y7S7/=)*>Y
MST1D=6)G\FV@Z?O3^T2PM4VW(?G0/IP](06<7A$2>%LR;%WS4.#-D%QI1<\H
MC:JY+9RK=1@NE-77\?9:F<%-OK?(<ZW3<#^PSZ'\&MJY0]7*=KCNRO9>X*OU
M5Y:EZ>IG9N->GP)L17 0,16S(-)F0]X!BGLIK$EV-CRVNG=0$E'OD+;9,OC\
MC=1AKI^Z&JL?@'O;LVU=',^+UA.++ #%/3:B; ?\, $.77P^EI&-/  7^*3:
M-$4UY*Z9$R(H[[@-75RTP%W9Y?+QY.E?UUC75X\^?=>W\Y&*)S8&Z$ E[KYK
MB/:X]V7]+LQ+1!5IC^!2AD]5D25F3T@S!=6W2Q.PF*^ T]3UU0E]V,\_$1SI
M@)#F/1[T9-#)PR54;_'";]G6E0/C+F^Z$Z;+7^SBJYY'DV -]/_DL<!#>YF+
M?M)JLXJRH*:T#&FJMR$T4$HUO>-R!:<3?1WA5#:G2R&=J=Y+7W&-(L7W[)LW
M;7(2,"X_3V:X4TQ\[0 >5'*.FB:Y,)T>SNQGZ7BRP4>Z OJ1VB9"ZF8A'W)N
M+HAD0+<YIH"IZMF"%LU3ND0-H PNU4Y>O?NJ+3JKPS!^]+0TQ7P$6L(61(8R
MS#-#LT6)%[OHEP76%@5&U.4F'R7LG M0VE>+X2GJ."%Y=W5$=* N?O7V@''L
M^C4UL:WL"9K"FTD$,7R]?F@F>'D@616O%X->>9M@K$C9*@B[UM2C\,.$:75P
MF[JE%W<-G<R!*A9"%.:Q46W%2Z&GQGDIUOSJRFC!]@R_O^7.T16/>]K-?*V-
M;^Z.TOI,>0G'_P><(O^%7@M)I=R"<1(MWJL\C"RXMF2N$T73A],5.XV/,IXY
M>MB;+B68LVBQ]VE9VG(&1 UN5E9WO%M 0D?E%@QG7^%)VGV3Q((-8"&5[8G?
M&H*MQ7V:QT@+7@"?'FD1KYCK0-F<6?[L>O3W)'GQ8=18O0JRK)#6O*WBS&OB
M4X4;X<;!H1GU@8B"4@<NW*FIK&[H4WK:SL(7:#H3 AB$6C-]1YY1L+9SWV?[
M_$X2GBZ>NWHE?-H?-J W>!$\(OA\<8$948 O)]%0?C^5R$5NX5-.[N@BWVXL
MBAT#X.JCQ<HQP M(B ND31?;], JPC)KF8S]C-0'MO:HEW,D6"MHLF']$7=F
M8PCQ:2Z"[FM]H7CN%>2H9UR' 8E'^'52,RIE]'Z'DB]O )2/)X2K0.DN5U+V
MR3S9:ZJAS-.DX]4?Y15:^G ^'!=E66%'_:C<YGK1%46R08>9QL[NIZ[Z8:M:
ML\@NV+!_U]T^]\J3DO9J,1HX4"&/ HX1PMZ+$?4N:5JGCD%@@!,64Z STUI7
MFWJ9NQ(M,$ (.*'&PEK(TL,JWX=ID(6Y7,Y#>W8=EP ?[(3'@QT-%2)#(]HO
MUVO7^3U $.E_%!$9@SP]+B$=08VTDG=4+#4N4&#O$R!'E&=UG\1[AGC0+B3;
M[E4QT.=@^784/O1!?SYBQP;"%D4"O%?(R4D"3@.?O]ZUE!P5Y*I[Y($!UD)T
M6G5$#\48&OQYBW(TR:62>N'Q@/':(0:@IU5%UQ1N\8VYWPO,0$)R?"DO<<RH
M4L*Q*'EI%7BBNU>'W*AV+67:A*7D*DN>&5Z^G>$E8H^D99&G)F6."9C[4@Y%
M0TIV1DNVR?7#WM8.P[HTD)9S!"(W=*_>W)K('EN5;"A8G28L>^%XO;OG=,=<
MR/W3;GTX:>Z72YV0QGGU-Z*Z%3& .^YV@S\19T7+"[E%4)WAXDB$K@18L#DP
M"7Q[7-:0&NJY/Y%0MCT=[,Z7@^1JW70[?U^/V*5()C6T:L%+V'PN>!7TY(Y!
M<!<+]J<1?CCN2'?%^[2(6R%>P8L-,C/NBG.<UNT9/3V:^H>I6VEFGD;+\?L@
M?[H++V[!Q<<F/#=6$+(B @6W6@&;J2M(<;NQH=AZVJJG+L&ZG=LGHD4F1B["
M$D^L'EP//,HNG/3S>,,07 ^#]+#&^R"C&G6NFC*ZQ0G%G0WN:(T>*6,.=-<L
M1-VIK2@[9+=XL-5,]-)XJ ]''XY_6;W,/.7L0PE*U&K@\,8&RAA!O%9!7-Y9
M\)3E["S6#5C=_FS#TX99<GB*YOW4]0>H;="R#O5<&*X9FAAA$/_T0H?>MONH
MD7+'<2AQ@V& IU1\_D^-:HJ-97--:MN,'ODU=N;)/W$]&M>=,HGL&!#GX- _
M.<_:C@$TBLNFH0?[ ;Q<:V&O _:](@58)W;'W(GAEE,O1ZC>H3@)(Z[?+KCZ
M^5@,Y4P,D(*2TL8 5R9O>6. ^G<>I @10WG_:F_F34D U0K& *VZ9W26$E@]
M'K_%,5=_?I>27) : XRH4^VWR+FU4M%0<12A<DNY)003L6GZ3O<V9E&B]#F\
M;,)I#NW8EP6V>GU$CG7>;SAD_9C5T4'R_:,GN6A;G<R?NVG/"!R&ELB71=<9
M' ^HY$R'C0-(T^![*0'I<?EI '[:.B\6XEA_O"\L[=O)#CQF+I_-,+2@<QM)
M04DCK^'[9US/3J:DHZB*N3SOO<(>A_1(6AG& (06&2_DJD.97@4Z!7K1NL'J
M"RHKH"M3=R^+(3K2U>B."P9=I/"<(!Z!6MC](4[Z#]<>6=W]]&RDTOVAWO3Y
MW1BE,U<-"'5P$.2S4ZFSTR0URT[.Q!IOV^X&W]6T=K?5\3'--:O>?Z.M*E=7
M7$WE6XI%(B07AV-AVRL#;$-\#LA>P0@HSPG+3,CC/&O7=T7H'(HV@7#DJ%D&
MB82"#:5A]<;]^>Z:23H>)?=>-U0D4DR5S[_TO%0QCY!O60Y/CGW8?!ZT T&W
M>7$+:680X"#'8"-R54QZX;Q6^1U[A<EED[>U'\SX3'6+NG F<>[B@ 9J19MU
M\83D8"&F='MCX!1C/-[!8!KG5=W;X%Z9ZPWGK7F[;L2A:FP" GCN"V=A-XM\
MJ9\:=KLQ -M!C#09RX=YO9Q4QB@HLD&J%&'E[7IE9YP:R8Q-/3R1N,!NMJF&
MC,J[;6ELJ3CGB?N)R1X)\V)#R0WI#Z,OZ4B;C0]V$V;KV/M #\(:][@RP?RR
MY>&/!DYU"%<6DB#-X6Y*L<K^JB.PK:3 BKS[=CT>JTM%)[R 1EH6+).?GMVR
M5O9YU)?)G0DONC $QCT\'VDK1F>,T(<]]:2NL&26TQM[&N2G!WD?ABB\#"=H
M/I)OKZX8WYRZ94#M4"*J*O*DZIVQ'(*N.%=K>L(T]AWC %FG=V7G@4J(7RH"
M6[9,4_-B]IL3.W?*C\/TK22"?(<ZGD')P<?%)<%2)V5]3Q19U3,@'T\K45G$
M0ZG](!R9R86"2,$<</FA5E68;N1N$B$J!5P>C+Y=A0&@QR8F*^>J[2SE)ST;
M5U$4;!A1_PQK>4H0+N6W*<2<I17$\BCZL:F*X<PB92$%DC5G<A2\)<CR*GY*
M[^WJN)=+#GD]*V*A+*W G]<YY *U&L?Q,!%9J(#D@P]OWHXNJ],0O3([0BCI
MFK7+B[7.6_IGGA?Q=,:H=L6:3F=%]$(*?"^$Q$ZS!3)@)%RU2$(O3 6=\Z0'
MCZ,OY%^F+K9B=@&9W#MB[XV=*T]Y2^DN?!$G&==T5%6X![H-.N6N4(>X7\G!
M/$#W02:JUD?GE;CX+0D2I;]L@(E7PXH4PRXP[W971QC1,K0XQ4L^C]"JZ<B^
M9NS;V<I;@)>0+"%QTD\3/,\0JP"1^>AN.;<N^B8&.HC>6[C/X.L:3U1)ZT$Z
MVP"OJI7,X@(U6W!4;XQ.BE052L.-0]:$##..4H;6XB##MUVS4[JE,QQY51.0
M76WQL4_=)1X/-H6E3M 6TM,D%VP,KPC6F&Q<M.GO2'X6"@LZGP!E2?LSWZ6=
M?*#9;)>@A6#,/AI1:-[-2AK,R]?UJ'M5RQEL%4J?N4-J!@78;N;/5H5U)5!\
M%$==2?:?-Y-A.9$G8!E2LEE14A%X8!7*].  5]_D0)/;:-#B0V#GY5.,Z&@G
M*)#"J\WB,&C1?E2D"\_EUA0_L>[',D<7D/2P5.&$'B$TR^'5C:Z%%^<>7+:O
MZ=1:7(5620#8H5],XI:ML:53LI4E+.Y6!Q&]GJA  A1X,M4SUJ]NF0_S59L/
MZ+L"83M6W8GTA3C]K,M=77>-=/?ZJ/RZ;@_L#$\:ZY_D//IX*[&GU"3I9.LM
M1WUS-_)81VN2SJ4E@NU<$H73VIG^O&Z4YV/&'$NMCV8I.O*%E/K%2+EX:VAO
M79\<$^>O26)\>%V#+#;S^JKL.?"+PRZ*WD4-7@4L*-3-Y$HJ=^]YNV0T)<G5
M(S,-%NS+7.>7PN46VC,T_'>W?,U.*BOD)&'U804_R$HZDU'NMW"-!L$8X)J;
M=:DD"=X3:"GZBBS.XK5C;PR[!A002SH/ 'OI/SG&L9XYJ3?0+W;^0AO^'1."
M M8=13$\DW[TEL\NR1.6QD8)X #7@P0+%$&.VI(_7(CM#$*[9!YML>XH8"N3
M@@&L=9F'5]\ 4 T6K(1[NMN=HIL14M$4RU0$2#P1*' /2_97S(5=./.&,CW%
MBV'K,09(D#ZN&Z&ZE[D^S2?N=V3VB^&I]=]7)@$]^H(K[#:K2=(9LIX/FG;C
M3=1#]._DO 2..^_//.R&IC>,;Q,I)<3DXMFP>F(]V"T>5G]F*9W7[973/%E5
M;92?58T4!BB(0ZPLI\(G7Q4QGC4ZB0:AJ]?K09KY%=ZE:8I>CQX<*#LP9R^(
MTA;&6*I*#W0!6%,?A -!L]I^B7,$V*9[U\N5M-3)[S9%?<3N'2$-FMOT'<L,
MJE6+A:TPEC8EGWSU-BG1VK5/]*3[58?9TQ_NC-LN^ M[V,;S%I5539D^,"7O
MRY]Z7EZ0B9Q5/&)7JK>%:V^DSH "Y6<_&!J71<KY2L]%A$LMZTKZA.-=AM[3
M8.?7&+9TX.31OKT>\(0[YE)E U);A_BX:[8PP#1OGF!"B(0!$M)R781Q4 4#
MR#_N*VYD5"D#7!);5L-(>X7+HV>7I@U6#S\\=$"YJ8::>UZH@B<&EIIL7G%?
M?1%()"T<>G!0@SU02SU'<9SG,,#M@^.2-CD^Z[6&<,\@6BCI6%GFJ-R>6GGX
M6P@1>'A</6'OFBFA5F/C(N A;-YO*3KWEN!@H>%MNC#KY6O4:I8@^?XK1)MK
M_>,<=RSU@.5E'7:X-BW*/EO.((_W*$^X&G%D#FEKP$7=*M35F9;(BPD9?:W)
M&U)!]WQ97?>LNQ2S_^ZR$%/6A_;SK1U$ #\9;8C2:$)F.DJZSZ]NIFOTA%4\
M'X_4:CC[2R0G3)I/E$ DUDXZH;4\& ,X5^P6RKTZ&7XWS>:ACPX>/.)=8LOD
MXTYIPG+P@5'DJ+7]]%(*-/+)G_WNXK_TIQ(!(Q)A,H!\/#S/*O*PD7C-'DTZ
MZBY0K=EPPM3*_\93KGFV]I!2$/(NBMTM,]@E.$Y\@]T'R91?/3H)MMO\6%D2
M'DZ0F;FLW)>0#B%VEQAQYT)0<EC+7 GON?D!Q;C[SC4,Q2B@NV<]'C)_&^_%
MOA4MFW^0.VDZN*FWLR%L/T#4F>WH8Z& Z(FSUHSF)1ZQHO;&UCTA'%0OA^,W
MYPJ#U[/4V^32E#:Y1D^!8.Q+LTW>ZUJ+3U'D:<C;?<V9K8=MH-KHZC*'9R].
M0JG*HTWS3;?4IMKKS]XP+)!%DQ(\%5UL/ X)RE.*,G/%L2E+*B*@(DU:$:XK
MIVZ>BQ]*)5',:JHEGP.AP@[(WXON7-/9U9*'HFG'P;E:KX<6:L$Z0\&7,L3U
M%H?C)^ZMKG]UZUK_5M$+? WG45)^/1MBU>(\& #GL;!GV1HW<S2N)/[M+%"T
M_10'7"4:=BC/K!"T#_TB8IKWF@GH@JF^//^TI?_:H;/5Y%@MM>0S<,F<\5YH
M0IZEDM+'QCE@M^"9^YG%#H&UA9%C16  G3KBIOIS ^X,QO/+"$^$US0[05Q.
MZ>T2HZ.N@'P#IQNX:9'F;] 7+M8AP_)TO9\!V\?ZEF]9=S<1.5?KJ'<Y[IYB
M\#Y?&-RXV3H-;#(]<>4*ER9$V&D/7<KIO>%J2:+XWQU._W^GI[8Z;O8SYUY8
M@YIAPI=FZ25%EPD)]ZL6ZO"CH,ZD3X&Y>"VE_G\^M2Y]7(1A]Z(T9\RGR<"1
M;S5STZGDBB?TL&/X)C7'VRVM:0A9U/I.*=/ZRK7^>?(YY2Q,=O:^G!O+4Q0C
MK>_& -N32X?7,$"O\Q';.Q(LS;5>#" \O9/ZU]^YO JGK$M$4?N0@;#/OUQ+
M) "5O[3_2Y.IO/ZO?#" C,C7BW]L]C\Y00;^Z,DCEN\ ]NWL_E"DG\+<]4<$
M@OSEPZ)^&,:W"/"-W1W[]4\D_S:K_QW\RO]X<.I;N/^AT7V7Z;C^<I/[';NI
MGV]S/Z,G_\_4^,U=]Z_\X5\YUS_7(_KK _(_H/X?-?-_VSV^0\"?[I!3W^.U
MO\Y\_ZZK5?_Z!.LOR1;?(M;OC9S5\^OSQ?\!@>?;.^7O?>$71;%O=-%OC$VZ
M?_V;XJ^N&+[)_G_H,S,5E,6811;^'_;>.ZJIK6L7WX" =%%Z%U!01$1I(A 0
M:2+2>U,1:0(B+4 @($VZ@(" %.E*B2B]=Q"D-Z4GH4I+J %"<N/1<]Y3WGO'
M[QOWW.]\8_S>/^8@66.3M>8SYWSF7&NOO7;:/W?LR'_D[Q*]<HW;LVK#>0TU
M3UZTU;Y* 6J5(*LEV"?C(NX4O /K8U(,<#7SSRHE%\>#Y:3LJ=Z>@SWG4P[N
MHWY7);3+:%:4FKU,>9'=Y_E&,3+]/ U'1+7JQD7[_ZP[_4?^]U(WCGPXU#ZG
MQB0#7Z#\LM,,NUT"[9#CBFG#L5</&\&GK.G>Y%6>^8+& _XI=S.\SN>ZNE _
M[>4:-6^5(A?OQ]H/%I5E, L9\[8OW>(<5&%=2LFVIHN48U^-IW(P)N%^B0V.
M;7^ J7"$:M=J&%I$#:D';)'I2'$%HHNE8P<.;\ E\@XS_-?N1!HCN(P%)O'
MN/FH5U(3YJL,96Z-6$Y,EV'>F//3L>9?S__ZGR Z9_S55J+M'$@ZI+^!/5OV
M:R+HJ_END!=Z9-*ZZF':X;Y".NDMGE576R:-<AY&CMODV%=,C"61O7G4GIGL
M>4$<_;IE22L.@<I6VW:*10^+;T")96Z-,S%+7QJR?B/W\%YZ9^6*/%>?*I#>
M]*@.L82T"7:\O%#Q<MHYK%N"5U:AW5LLX]OL\; ENYF)\'Z40+G'6>N&A_P>
M/0A_60S$%14K->T&6@\K295'[X=BE5MNL,]O:ZI.P1LOSK'/G4\]5R7Z[9I0
M0E>?-$Y_P4( -9./P@-MHNU++UJ7PO603S+I2HR?O16H%%_R;&23$;GO*Y[3
ML?HYF- U_T.#3G^(,DX ]9CYPPL;2AW%;_*PY-U4ZUIT[T+M:2;U#]5<B_ZR
MR]_' /)>AD[RF3.'XLZ"?=KB#B0DWYV7Y8M_!J6<ZV_2N*K^9/#;&:$/\S8L
M.'WD1'GP4B#$\%S6YUMC'YZ5Y,.\@4.'=M"I,LN39NUD>8_H+FY8"E,@JC<Q
M%NFG<;NSQP=BQRI->U!ZMR@AW=KJ.($C*6X1O_)%T!DY#F.PR.V/->75<08I
MSI=".DGL0$/^LM=PS!E!C?6>>,!/PPELA;@;BIA6*-H9OIZ@ZS7+JAV.=@[)
MH+U49Y<W8S9MIG9&@4>>N4')^U'RG.P->'LYKI9F)$[,8^W*\0TM<A6$YG,3
M\N",[L::S[/;?:#DT!%]82I$98C[:GGYLX6LA&B&.[6N!^/^8$_U:DPP\C[C
MU!KUVL/8[0$;/  SQ/%BSN!..1P9"U_FG'L%*=*\J&*Y),^M2W:"F%9ATVSS
M.<3U#=AJ842$016ZD+(UFV"%(6_[L,I-F[BS$;<X(1'E/_]1L'^7$3Z&8QN7
ML41"+^+8"]K;BDS43ODS^/H6D$R4X8'(&8;&:B.EME(F*9J+CMQIGHG[5Z8G
M<_:VBF*KNFM>!UK*8)4PQG9P#0KQ&^QY]R(91[N65LQ%FFD\/%![^:0]'SMM
MJ9]KWH\D^!-[FY_8($28Q?'VBGZ_:N<E*&7S4(,HV%"OSO1A51R3E?]0R>#A
M>-"LICMR\_EYO@N3+D]T9';T^[ESG;#*&!ONP,?"L+42+M6>Q[[348"O$,=;
M,7OT>^O[+Q3FQN0:$;U\K5H'*0D3MS1O]7^&4B)PU. X#<.6IR9WU[:-.1[N
M7O2&\EEH(WQ!EFC-Z'G3"(<W'./$4CW*'N^6#K3(WRN@82VN4UYR;BOQ47U!
ME!MKXD(:.J-.CY?4LEQ>=+E:L")F RN\18+Y1QQ+7D_)I[Z6N^)KBZ$I,HNZ
M>Z01^W5.=%/+^T(FG<UXG48NQFE\G2VANRU_XZU,Y8 AGQTZOR7)4YT\3<PG
MFJ0KB*ZOSAG!]-$%T<BMYL 1^DDMB+X$3"X%*G%P[8!2\*%F@X;U*JN]SD=>
M2-:\JV(/''*-;;!/NE55)%B'=>B/S+.EUQG.:8:=JZZL&73BM]D*3:87R-S$
MMOOH_ZWU R/I])#QA(;K98];P9-<_H_RB_I/0;OJ"PBT6I9Q2)%)RXJ3PFAP
MOD@M>LMWK);#S8'EUYRIP0.-Y^N86U-DO/<C[@];/PT3*Z*BZZA/QA&M*)TT
M/6CNY 2U^-^@H4-8AI0?C%&9SL65-AG[Z3ADCI5'.%*I5HUL]/BFDTY-*M\5
MFL<#3& _*"DFK2ANR4=9,1O&M;M>DY<K48@Z[U/]R<YDP$F@\3:0@6/._S4B
M!3%+<%Z7FF7?^^((*!U$V!DQ2P^UF>H:[%Q([-Y%U!LLS9U/FK\>@K.&/#%E
MP>D1+5MPH],C$/IX(,P1<6,_\O45K)"ZX:CCCOE5QYNKGO&4&X[9YQON#O'7
MH<:C>9^-N3:P)T2^E+G2!<N1@2QJAAINM";ZGY%G :'J9<X=KS8>;=FK^DEB
M;AM2+9J5^)3=HB008BB.*;"]X2R;;ULQ&X/ TUW8G1$<T62$B@.-PN>FAY=>
M-6?2&0_6*>4Y[.$\TCPY>J:$'H:/PF++:$QU4 (1HYS)U%</GG:FLSQJ*/U0
M&WW8S5X0K:-/W:@HS_3W[])-Y6,,>^7JKP'<PX1VF(B$G)+(]2A8RKFW$ ,W
MF\[HB*&8,7M^:ZL]/FKH/"DX]#D;LFV6?K&B-CGV8;5HU&S+-7.;-N[@&N=@
MK%A-5-IP\JG@>VV0V=O _I%ZE8CC$&)"/U& U4#WA0/(''TY"=[C#-*I44UZ
M+Q"_P[B802QN6IC&N]5G8Q/.1$KEL6KA@[Z+6]7#!,CF#%T)8U$.[PSH-P%V
MOS1(@.^:Q@CUI7EU+$8&F,^DOC/^MA?A;B6M<88Z1#$%M7D*PC^T,WL":M\*
MQ@.VJJUQJJT^N@W$]H:6$X85U&L#C%-$RS2 S\(_>'?_#^(Z<ZUN5 P/4)M/
MKQ!I3*E7*UX&EX2D+)?DLA#GW N<\9=S1U5V.+PJOZ 9SO@H(+1GH;,[8ZS:
MF1.<AO5!@'N#:Y_+T[>R<&2TU+>:8*[#BRUV-Q*O"T_W&5OQ4 ZA^ELUZ3 /
M[KLX.EE7K?/7Q>X4UO EI'"1#]X-A+-3D;&X13(?CJNH1>J,3)41 I_G'W\_
MTJ^":HSA.L>]/$$MW'_XJ71R^'"\8MKL7''1QZXF?GNC>$L^</C64H>%1%7<
M*)OQY4>3E-%(&2WR/*PDRC=JO'5:8?-<V*,1K7<;]RC]I4#%7N-!XF%UG,B"
M')JMG :].I3>:^ZALFR,"[(@FX+#4# PJPC#W5?=> IL:8R:CZTH).D8>EUX
MYG5&,> ;%"_<_BJ95A\Y13=BV/7^=T_AK2Z+!*?SL^&!9]E1DY),[QY =:>X
MQQI\C$^#N,6BF_7=B=5D0PZ!(V+N77H\4"/4WFA[TNJ(*U5N<#'T(EVY=S@&
M=C/ZJ_&N^CWB2"QN=,Z2!6+I@#!_,#-Y-_YS984.%6UDA_^-&/\/U\"6NLI]
MH[$>. T+T9*I5!"[Q13IE%7-(^#889DN<$(LQ3  \E6O*.E6EP)G:><VC'0D
M6ZV!9ZJ3IUL<?H(+*48T*]G9JVKZ'#',H\-LRY^!+J&D$K;IE#MO%W1:7?RS
M?VWP@9[A\"DP>2O7G<=NJ4]O!Z:55^8O3W@DICXN@@=!W_NS 4X1]\3JF?J^
MGS#]#">[V@.U%3E@%FL\/,0#7VE\F(0Z_]  "/RR9YQ&]Y<]XU\A6@\:Z<HU
MZI'-)9)[OGC@!6TA'C ?/V#;Q'K>.\QXMGO#ML/\S0TE .S<U$[>4:1IJ[E3
M4HL\C%DKED+&\D%OS_F=^O;>3NYZQ+K.R3A]0>,J &VNV>GXM ^]=LG11LU$
MMN^(UN6U%2&=*Z#H>\ 6:+KI,Z_];M8K?U._<=+B&[([C$]'_0694'\#Y4I_
M'H9AJD_":ZO,/V-C#AH D\3DHYE\/;7BU=['9I<&5Y3JQES! \& $OH&@@33
M<B!6?]UTS44MN&E1><4B8 Y*-06V@J?GBW>_K*X-SA&:5I8Z%DK"W(?/TGS)
M\>ZH+)A(C?_\Y./QK.NFQ2>)['R'"=G=BC1WAJ5/UKS77KO(<TM A+1F3[EA
M]QXH^8AT+) WY:1GZ7?..[35<3YIX,"$.NRU+A2=>34O4&F_ZQPU<1S9P/JL
M>V;Q^L-$^2_*_22$+"S/ROWQB+O<W@Y[3@\/2.]?,)@X=[4KML!"_0J'80R6
M>)@_0F-$G%GGM(&>XFKDTD%X+Z86S698%=]Z:)9++Y6N)!._(L_8((2]K6'^
M<, MZPZ1?Z(^CI=.8=UTE@PKX)J]/#[1._(XSJS-0/Q^WV"?0R3&!EY/B7 I
M=#@,.OGN:S2YG]%AROX1C8/RB-[7E?T7MV_>X[?)S*1++"M20W-*NJ8IQ.!D
M');[P\+9X7O9Z8,QBT)+YC<%4/MM7G(#$L]A=T*/A[X?@E^+\ S;^2K']6G>
MO)W/G#=(_W%\NBU)+X[LNB6;%">U<,9GPZ'1[?$F#0DU]\E>1;NMK)A'FT^A
MAZ,[PG]OQ9.*H#M@+N<^W(O' PKBN<8-/'@@UD>;4&W;@7;.R'/SK'BG]<4B
M&!L^:FRW"S&R]'F/>X(Z^AE57H*SPTJG3^+<^\'$8O&(<RFJX=\>/0YAY5R=
MDN/'RGX8+[-S>ER<'7[(.)5N$E [&0Z@?05:9\YB8DI\:Q[7=.&!NE=(2J%)
MB$U.>Q:$MW'X#7\.TZ3KJ@7[')1I%GRM38BC"#'5\.F-5=-B_2:"9HTMIF7]
M[L;7UE;AA@6^>@ R#D_3-!K:U00IT3I5Q&Y=1H:OBM19HRD=5*(-:J-8[C\/
MY?#3FPU,\DCTN[8M8ATN59?'&I_K2RKY''*5S^K<>IC6=7*[3+H4&5*77"7D
M28'QB;O\)\X<8_=A67(\TFJH?6UPEV@9SUO.=L@L,B)*>K7#\.GRG&]:QL*7
M*Q1[,,^1-N1<XF77Q>,73OT6=7XOB18:3X#FP9:'B] $WVOA!SYST[OEH9%C
MIF^'6+ ?)*\WP3)%L([P(RK#% V=J6#6E@JU3+HTG'!'+.1FS9=,&SNI7=@;
M&6!=X)E8A5,>(TY_6^6Y2 XZ)MHZ992U85#B2V>%P[<,NI79K](T"6%' VT,
MQR[R;"__[B6TL28=M3E:NU%=W=GC9/>%8SQPH8)0-6X+M%.(M2+MN&^)[$41
M;'=A&%INM;IO(9S>0CK.AIJ(?+S-3'*@U\"1?E*.M_UR?LPE<XEC7+7X!H@1
MMN.)XNP^J-C8((]C>.:Z+D\/8<U0DF/9<D/B7M#:T(R++S6RS2HYTU_X<,F=
M1U1B)@-7DSHGW><^N7CGX.9EWVL357C@E%Q_F"0=-.[9&JLDU%,,F+ZYV7$5
M["<%L]A9R834QB]TCC-^LR3.&TP<0PA2L,6[\O@A)VI!]/8F]*@3:\.F+&Q?
MGH_0CW.X6 BAP'=P($7G6!9J4Z[7 ^0C_^R*I7%2RE[J?5^:A/:A<VV=%*PR
M*<!P5J'9K.G7]L6IS[%GD:ZO*=_B 0JF&$* "CD?803?FXUD%4S:'_K.-YC7
MSU]M-'\WEU+_2UE%]DM%6V!3$S+&=VDK1Q44UD?Z2"!\Y\*YK7B]"I'75I\9
M2'M3+HK%/I1?;GZY=5*&C3_Y;.0GH7>"K.>B20$UI0<QC,L:DB_%3<T/.F2:
M33Y=[ I WNOV/O7T^S$=UCVPE??V;_/4W<(\D$+L[N)Y-(#P/UQ(<FQ&N:VK
M&*#:1T,2NRO/T%1;15)N.X=F4(J#Z, ILNIZ5S[<HI /BJ_=@MFW"P/GGN"!
M,Q!6D4BQ$\^&'TRWP6-3\VZ,NRH!7B*MW,28P!:VJ*YZL,F86_/)MKF]=;-'
M;U&&;97>Q=.?G1T_&">/7W)]YKIBJ3PHSRU.%X"[X,3FX-NXF8$J^=C22/*@
MK#IZU:3J],L;06H#QPX3MIDG=4Z$?%$\?4+)_%WF$Z'F#;]3F!!+9O6WH95;
M;$N]W*)]UW9@?EG^K*<3PAAV*4GEP@4!F!RF>.Y8I4-:*:'D]6#8V8S/SE=B
M.X9 Q=XT#$1+C91UG 48D'I]Y<@=Z\67TFO\*%)O$MZNR,BK)YL9O@F2M$#L
M4!9;C@;JQV2W*(281,]$Y4]\* ,]2YG>R.5(^=S# 40MN5Q2\F4.%Y5G,9Q0
M;(9?*"L6>NPD_%EKR9^"<:X?!6J_JMHW9!+7%K^=@8+EEBH!D'X\0"G9SCU;
M@0<:8C"&.=B+J/-OYU9$4K5M8UYG7F[1S/7V92!"0D\UG/I4;"_R;GF(5^/L
MYU@N(KGRSB\09K3P+N+RFXN=)Z4N]1D%K%O>?A .M _NL$! \)&A-;(3MD\T
M/79A% T8843MY$J)A?J#H>L/U F=YP@2V!D$5\9D'^TU[G]_R_VZ'RM68JSN
M H*I883M#'UDP9>[T 0?1@:B!3QP6HZ9CJ'W.#N_IAU"QG(%OMJ;B;F&*$P-
M"H$/WB<OO,Y#9W_X*!Q8Q++"U2U/VH;==_*L/LB!^"+-S_W-#P/H[9K:U TY
MK6=W'-Q_:';X0LDLRU^&KP5*47[,WCYVF-8S^<KJ16DK!S+#?E^'",G!YLY
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M""?L.YR1VC]!(<"H,H$D_.IBD8OR#_/"?C4O3O]!Y.]_[H=M$9&4?^C5%'=
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MS)F8/D[TO3ES?3M&. <8BWMO34VKP$KFSZG$F.2"$.8=VUS[^(T)W?_ZL1T
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MCH%H;<0P"7,-,6+!,\:LUE@F4:G1LN2OF>LQPX\6#@T1JVQHB*>4^Q9=Y%M
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MH_!3A\V]B,6A2I7/J"A?B+OB8L2J(U],LI9PH"C?1\G=$[$O'R?K$^C6"4&
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MJ+<;0VJ*&W+F>A7G8NYE1? (>U$&*%A@.@*%%"2+3<SM5KY-FE6)1H5]73N
M%J_,;M[D)0$H44)A$'[IG6FG:ZZQQL7R_,-QBF$"IK;8AZAU(VWG.R0><$50
M-"[H-AY;8#&AL(\@C:[VU<5=W^V;OSQ]V8M7SSORRX^T__1$&A[:WQ;I=/05
MLGT_G7:RW0*DH#3#4 /W844GG-KC26_"?$0%LK<F--!](2Q>%E#]Z%<S5H O
M)*HY:!.KV7$D(' WF 0TSUPLYWI(IK&BS#8+<I,A^,T+J1I^V9+0>^\0X<D;
MA_QF3@*0#9RV>PT<U=6EY5$3RQ-B/P8C;"@R2N3G2C*8XU#+R3J3IW)=I"AE
M%FP@??6F[373N4BTZ7[)93T3YAMFFZU1_!1]2F17--UO**K.C55"PP@G$:+N
M-L3M))3];S<K%G@<CGKQF'F]P.:GC5^C%<8<:^GT49(8"QH"11&B^:&#>Z%=
MF>H)<%U/UG/X$N<=Y7-'R8!,D&+#'=A#'+*98<6;DT7N84;",M5A3)2FY+*;
M58""_EQO0GWF%&SI("K%^61YUSVV#K+C/GP4)3U"8,-DH&;,)G_L(7";&QSY
MX!E>NEX_&S7 M_H^_NW%_8>2>MG6W)9+^U]F:0D7<+1E^9?:WQ<[4:Y^?B#[
M")63WP;HO1]VV'Y[59[CQE<:K0H-M(64.5Z\56?^8TEPC,M]Z8>MKUG;O<=&
M#/1./'E^/H+N.2.-/].EX\X(=@]7JSY244QU.URG//;[C8]3W:P+9W/K;X<!
MFZCG)E(YF3]J7GG'OTGHV[IRY_RR"'QX_;YVH=WYZ(>\=[/!-Y/#@'UDZRS(
M5Q4MY(=R\WSHX^XWT,UBR*1^C<:SNX.]SLF/9FWP5MD31NB7DRISFU<,#=49
MR939_+D&,P<D.'2DSDDUO^8;&4TY&E)4DSL6YC_6-'/1 GR4OR1-#JIBV1(1
MK4*8'%B9NGW\ /=2OWMC_-,!G1%_.BB)H(_M;N5F'^,^O!&LY= :A/%LV/0Q
M\EM54L(]"^O;G%E_H!\ATHQTM3#0OWYU6X^?(@1O-X?$JVZK,\S-WE9Y%14X
M@)#KQ@_FVGM7A0@YN$UJ.1IW)QJW.P_5RS/J427Z,@\XN9E3;QQ>']+VRDY<
MKUYD95J2CM5B>C-T(R?;>/Q=U"(G=>EQ"R46X_7;V1O*W'V4D)X;@A&JY^1L
MHHCQEW+#<=3-)Y^/#NL'7QB\\Q[RUL]2#? ,:>YV8FW#N$Q,6(1;"!Y[O@M4
MEGMG;?MOGR2@TQ%3H>A9.*DFJ+7-A#FX4>:K@8^_-)_ _NAUA]7B<PUP7VU:
MF%S38-U9GZM2W,H\9CYO$";M^"LYX9!3?L6)>XEWF:U7^B Y@+?6@PC@GD:N
M#H\NO=\^DW_122]0AY#1H3;REH]\Z(7+MSTJQ4=+W=).X,LZY!Y[YV84=9++
M?>==P$W6 SY#GY%=U8^].8<;*K;Z0R3]?#Z1@',9 Q7RG9<K/:@_E?)093#-
M^AK@>CN"W7X42WQOVQFCGIWF;BP&O"]4O^"4^ S*L-2E+1)CI5N%-[LU!G-?
MQIT,L_=.J!44[Y)^QUE*]#60DPY5T, >M@W:3JRU3-WK:3)\'=<T1Z?,C>][
M)];#Z),,UV&G*0]+/WB/DL9WY$^9X*4$PJ_,7.S+%GO#R0D]C6ZDQ9=A:%\G
M2LO5)>PZ1\9LWE[UT:,:L+NJM<>K?L Y$K_U> @?ATX++RIVE#S-5_$J2IJK
MJ/'F@=B,>W55U(/#DHR0>64&: S!*U:S3OZ!M<>M+F].;V@)-)IPW(7$.'80
M:\%+RIS'?0;Q;'>)+;-WTMCBRZF.NO1;\VG%IK5X<(&)\M X?+-3+")(H I2
M#,=K8/*")5"GERJEH6*"V+:*3RI-G7N%!R'M_6=5'Z_9;O9+*1E.1J3U!<A"
M@F'71B5FF1J#*Y(>O&+FK^V[&;-3C$#&:G&'YJYZ7'<4;>K )G]OX+:K088K
M7=#&:*6+3F8E"FIPB9QT0Y23M8?FI&DCCX<7:0/^(!C<6Z@D4_(CS]: 5(\-
M&\&^ZJ4O%<:";/RM23<T0=-*UJ5(!1SDYL^";\I8XN8L>Y]ZI2>ZG>E]G5M1
M&I>O606..?0R,G=2+AP9DWI;A)]B6(D=_TZ7R1,F'QZ8DA_5"4+5>^:%2JQ$
M^F"^?7^5J'LJ>=[VOK<;RAIOB)[%:Q!X6&V@R:[?1?5CME$BNOO7^DF A>J!
M'F6++W4CA0"JL_9HEEA_W]XC50QOX76V?Y(W]7,5G_-5OY>H[,)DW$P:<];<
MFCJ;GHAQ.,A*-OUT'0_&6,$PO25?M46D-3PU<J9NLN/.%![<(>5_J8QJ]:G0
M![3&K62G3P(=4C7Q,9"K4EB0XY>O!(.A1'VLY$9WX@NO\)WC$3VP\OA:QLAC
MR]IG56I7J?17[;]X534YF"W#SIS3_!H[N O.6"(4#MG^&LLL*;J4))>\2U"Y
MXY-+E7>G"/O.K$NC%?[G;*M,^%[<@E;V.RG$TG?-)V]?Y0>R]WY.N+KCL] Z
M3_5Q"V-&)F9;RM?1 S30&D]'-@>"K"7-Y[L&+RCUQT<K?L,YDFA?G\66755B
M"D(5U@CSP4&;DQ/#R@MM)4:,/!>F)J-DO@?(G#WSR5^X8K#XFJ_\.\;GZTPQ
M6<+J0^KP/"RR.27<SQ;NSUMS:#[QMBOI,]5('"P0[7.ZO)%F:10*G,YX=N?3
M#GFELS)KZB7L%V3H]M-AE/X"Q#W@FVZ%EX+%V3HX>C%6Z(P1"5![M&_P$9SC
M\Y:1;'Z& Z_M?3"QPLU7?VCP>3)>S)1O*GFMS@M=BZ3W--_NEKH1'5->!9"9
MFS.2]7B"6O:4V+ 5#4D>/X;:C6-#HK0D(W'B35"B2%CGX^Q0FK,),YK$^!^,
M5@&R.'2A3_^IMDQ[S0_G7ZBW>C\;@<8?9TWO<8@0ITO<G%]$X1<^G_R,<LL,
M4*!=F6NH]Z??W;BCA9K>T_HN^@ELLA.IK5I=B]7^\;ESL9P;IC4O4Q(;!J ;
M./'7]YI-SO9&+L34Q7Z\KX<;9HJ?:PR92 RI<\I?D19K'C +IF9\L_EU&W4[
M,T!\)T56DHM]O>\B13?;G323>25VSZN'30F)W0A>W441R_=Q >)$R1^>N37!
MU_,R6--!+&,*+%GX#I/$N]C*DFA[S:\QC#&!*VL&DI#@Y ^V>T]G^,92/8LS
M'D5!1"J-:>6^U$/1_:$$"$9VQ^GTE/!7X]B@ESP3[V8]G3 6X72/*^P2.*[[
M/Q;M^*;,#@;FKE@7=)&-/YP ?8,-FNT%$H0<T(JT F?\33<T2<",D\F/7\5Q
M_E5!T=4@[T0"7B@)-;KV<C2*FE]K.=N(1977-T[)DH"&2!6<OJ:#Q:>QF/3N
MUA.!6%EB?!(6JL^22F-J-5M7Z9+M[9H,+"HIT93$@@@[Q\/_'8LS-TH]3;4-
M6<&/(DC ?&9=RWQQT1[%S<T+L;>T^[[P<<%'ZF38?"5S!<A93=5/'2>HRMP"
MN/-D.(0.3\'79"3FO34.?),AU@'[&HR4=,((O>UI9)98LGZN$>'0?356( ]?
M.E>(.F=7>1"5G()R4/>(*E+,IQ@J?AZN60E*O-_Q#78)-VFU["VO@917;"A?
MX\#L9F4M%5@7V@Y7]/#<OY]MPUUG9!B5B &%SHB%Z#=6^O@I,=-(%P#\LI_Z
M38!E):$%@MAPM]]:S.(FTRA!.-0:C\B-!WMI09**0!&[+M+/+SR?X8NS?A<0
MR$?!-.0K%8G&,K^.Y>$Y(6O$RA.GS.V*ZP&M]9[;Z]]AJL>L(-E:\FQ;6LY<
MB)@$2=]7?")Z! ?/.^2TM9=E28ATGJ>*?7=;EFFE1FY>[0.-[+D2E0,]JC!3
M"\(]:;K]TBDOG^#5@B636<Y;><WLEFE'CB0@9:7-YS)5.J&PLT%N4L<9/7GI
M.5]T:-1U83]^\HY (H>GJ3[6(^6I>RY/OX3\V\.X.#-PJVX(3].>R(K<K4>F
MY^?J'HLQI'V#?9F3F8%0V)U:-DR@.:=^:F&TH2!/Y=W2\%>S\[;?KF>S ]_\
M.3RS='', 8T/@^6]T&0/0ST71S]>0\X3>9.-24 >\@<<.3SWA<CN>]UVB"VU
M<Y;**I8-A(=:XCYIY>-=M9)'K_ :O9*ASHZF3BTGJY]K/('WV&N6<V]K3Z*)
MK5,N8UIIXPMK8/;TV%-_NR9$/XJ1%/QPON,F6N):V$1?>):I77?&3<P):@Z[
M[W$F^#C,+/UXPUOKK&[@M<,CX_%*?@K=.<<JS[W$"85AB>A6L21%N=&+B$Y_
MQ,$!>*BV_T4#Y4?LEU=5$P&33UVH.H\&B3I>:2]+G+9UPZ63RYGI>RZFN02$
M4.4 ?M)F'<@*?K=^RF6Q+O33&WH/=OC"MBSPYG(K3U*YXQ0;5(VAG?-.H341
M>F8FG0Y6'-%Z[YZM'-O)4@/9>,WX,K1'Y(-2FU+C(M-2@^ D"3A5F=68%VN+
MK0IQJ!/-:,HSW7KOVWLT/U/:P+\,S\4SXS=:NFI9EFTIPH[2JDC (_NTJ2V&
MK?W""7@/\?224!Y>9*JZQ;R!^#;8F; R_)M'AW\HVBY?L?WMEY_\QCA5\LMH
M-D:5-\SPV1Z*$;N1@EW!Z+0GNL;D+0L=YBJ2*9" G<*IJY&[R+QEL3:AZ2*7
M3KJIB)9X";*'Z. GN9HQGQ8<V?("& $ <"-_!5!2.5ZQ);]<%30E?R.B)8N)
MK4!$-,R$GSP[^6%$;XVVYKWZF]2I,E9!'FWLF0?\;5IJ@)AF5KQ')WOUMF6R
MX8W(ZYE!=P;(CGOUB[&G'I[OI)?EDA:V5P8 L@"YNX/*)S5X16^)\MK/>5@F
M'V<*]IF908;46>D48>Z,>B?$3%4$'&-9IT,\].Q@,RS**'JQJ(!\F0+;=.I9
MRW(2D&:,V'BF:ZKM)JO)H[]\COIX['[+0,CF\>J]-<PCQ2Z*Y-2?E\-Q*+L(
M98"Q9'>S[Z0W7\S?9<T;5#X-$\+1?T>P>0YU-(^RV5K>WZ.1@U9XO&,^4$J#
M^UQ:D"K-:4WS5Y:5 -;$=4-N#J=_J.*P"B)_MEU8?O^W/RSG_Q\86-B]X&0!
MPH"$L/ U$1+0KZ(Q84D"4I\'7,K,_'F_S<"=W=>(Q?3TT[;Y#<,@PC:C7RYX
M_\?/KPK7REM(@.))L%T(T9OZW_S_YO]_@U_K^/D&?G+[?];Z_9O_W_S_ROS_
M OY%Q/_KJ///\:?9A1QB BYG9AQ39YGX+P2K?$X_^9<F_/F$EZ']"8WQQSFG
MQH(:"5 8V\SZ'$[T0GV[>T>9;I\.T2])R-^\>%P!^+[!*[T3")M?B!HQ+(0M
MBZ[LS ">WQ/O_)Z[X#A_)KQL7$PF&GC]POWN)C\YY.*U_>^-\=PW++9Z$5>/
MDU3DYW\Y,<3^7ZC(WS$?ZTOM]\2<_Z0>_]_)5.K_2R25M?VC7A5L\R>:%/:[
M,BS^X\4T=CW_JYC?5S5K%???_OI3UO)[=2C\4BW#2XQDX)C_HL3_N]$=*OS7
M5_^*^=L$'Z7^ZUOA_ZB%_Y9F^!_ZOE_JK]X0_WBW^6<1\]]=[9]-@_\M./Y%
M!O4S\O3X_\%6M/]DY/G'N?%_#S/_*9S_/BK]K:[T%WCD[U7Q)QWI=X(+?B]&
MZ.]8F[\B3/_=?.1W&OFE?K]OHS\B.?5W@A+^0Y N0!8@\N]9S7_C_W7$9E6?
M7= JDZ]\8]5@.U*^\3*R8(KU=LZW)-JIF\[(O@"E-YD-<C4X4)@@BK>\>F0C
MUG,2?N'U KBOBJ<4'RZA?5$J]W/+^5!=GJUT4,&A?LC-[[Y4W!DL+Q['Z6\I
MC3)N;-&:%JR8"]L"O4Q]G@L6D!>29'E>:?"OAXV"Z++4+]]G3Z-Q9OX7$@_A
M:XTVHF^\UC7[&<G6RN_>?13 I7;9MA<08GSU*( Y[-;0 )G:93OQ_R_..R-G
M6[>L",U)-8BD,G)]9KPT#P$I--Q=KFP[0!0QS<^R[=0_6C$WOSPH3-\+=*K)
MN/AUC'Z<) %![.UOT;IK7QT-Y-(]POF>4!T,4 W'Z' .AEYT=[.,[G(Y>ZFM
M1ZJ4S2:>)\+]D0P3.NV$PCV$5-;E<%<!;=K>P759@;# >:G:(O,5Q%?FTJE+
M;U1CPYXL+O-3C">VP[CMZC+>3;(L[;4YJ%W58>]D"%%GH\D[/];SE 2<WGD+
M:6Z<1+G4QBMTA/.=A^IC(6W2P\L,/ZKT%4I/3+-9OVV8S0%\ZG_SB>V_!H_^
M,8NQ;]W1UO &]CDZ9C?ONNL>[), ZH.\&R0@F@MYY&SQS4( ?TB\>;N !%A
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M?I_K/*]XD+Q- B+]688=?.6=$#9VG/1JYU7?6Y\G 0?Y%*,2.H\F84/W1QS
M;F(E&A5FU37!HRS)7DP\*K&MVR@PGJI06RG.+[<V-OJ]&W=2'R+>]3A>N(.8
M/ /;H7*4:8N=]E&,&JPR!\E %8H '^D(-1G3.)=R*?J\C5G"8AQLWEI^RMBT
MAP1X:WZ)4M1$13FY%48RM.;=KNEX>Z(+A82!=E EZ3&9V#J7O!G36\@F6XI
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M78N2JV!L_^CK1:.X31*P CV+8T W$B[HF9JI/1D[UZ4IJ*&J#+ZYM-=98#L
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MI;=1HEBC\ADJW#N=_!MHZ\NRB9S/DL?QQ?.%NJRPB:8\*BDLQ19=9.LOJ<.
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M3A@0/#'!H>WV_-07'I4@0TXR_3MJ@-<N"INH.NJ^M.,3>IFA]WQ,@,(#:X)
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M>[11K^V$:J)3 K2O/URR; &<7WM3<_NLQ8&5OT24+'[558IFE*^K!GR!/Z^
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M!Z]K $.#A85^B-?=O;H;I%J5DC!&7$R/U)XJ0IF!3IH:>A9D0%8RGK7/A+=
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M"#.GI*R$D R_L(C07R$8^/CXA/<(:8B(:(18&5B%_@\?J!Z % ]DAU,'PG@
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MX0=,ATY7U-Q@T)AP>#R.A@C:%..07H_/F&K+!C%9$P-M*G?39F:KE9IWN-7
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M[!.9-[5'_,;.PL=*:E:"8KR*J0X,) IO,#>74%\H%TFGACF+57JXLOAE?Z;
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MUICH=+?$FWPD:G7?6>Q*-S+AP5>U$GK*7PUHA^SH/F'>L;2 +2-5JZWN]E#
M9!FH:::#K<C)%^P)=B$SW ='S$*V*P<ND(U'E-O7B;=I4=UK:,L?_O0P%QA
M R"*-A2P8(A\U?YYTI@(;H!4L4-;N_)V '!%)W$57F8T@,VLE9\ZKY0U&[I^
M+UZ';X/UB>Z<! _M"G_?=9A/G(GNNCM?F<HGB.(?NRP=#,L_F,35VW3#.'!W
MHJ9.5W^91;E2K&V*<*HT=S:EB'XSL+1Z&<%9MG?+FS$7Y%H!KA));"C^\.G8
MA@UR43D9Q)VOLG''ZEKX\F1=N.7$$12.R':[["9U@CG0SR;N& =A5&B4' H[
M4L<IL][]$*5.1 ';;M,AW1OZB#/-#.WV)CA1\L9DXN-JP"M$'AUDJD>PLBYZ
M]%H_NU[(CY?[Q1HD&B-\KCR^2*>^OIY;CT"#="ZS.YVS?.*N_W]0&&D]%<#_
M=( 7-^-I8W>\!MA?<N@EY,YPTD_9-,QXDF_[!4;:?=ZXLZRE]L:8WS^.]Q2F
M6OI EKZ^L"O]F5JZ8)R[ B,9?C1\*ASF>1*^_;)".FM'QL.Y;>%]2: JV1^(
M!(_G!ZEY&IAO=*,8?OGAV+8O0<"";ZF3[L'2*Y,24U%SQM5]4 ;"M4K%-Y\O
MR;UAF:S8<YC1TZ+AL5[Z3PQ+_XI;V9:(NUHH;X,K&T/:F,(:/;QXTU_X,/"5
MC!B)*5"XV5X,9XZK^L77[?>A94U-= G1)L_[-0/-''Q8N+MH8=ZUD;,C.CE>
MZP'*II8/9HKF1*2SN:+(-%MH\PF9(RJ8OR:5,UJ$OXD.1"-_G00!,L6F:7<3
MXI7SFIM>ND?75&&,<;\(8_J3.R6K:AG\I*Q(/W(TV;W0W8@^X0();]P5.DL5
MG[1+G;%9"QMV!*, M@AT];,@1P%*-5>*TQFJ4S\;=,59_D2=@$']2,KV>=$C
M^L476.Y"Z1-U8X#74N)M: T*./J! L[)+5UA$VHSC;R\0YT-,3XO)/A;!P)<
M9XGDLF7;\C(W;)GU!<W7W]Z*>V^,FGVL>6'R[29B"=CG$VFGQQZHKM+=NXF-
M^1G"83GJ[^M48'K&7IV,!L;/Y DV4WI]4_RF&@.;5=^&;**IB*VI'WB(:GZ8
MD*YBB"Z.)_(G00]<+G*33_#GW(769VG5K\H1PY3'-M/U'6I%-<V%.K8>K0L[
MG'7'"CB9(5EYD6QMRCFPLXD@8Q ,!MIT-6"3%ZQIZ U@/$DL&+7Q.?PQ_IUI
ML2*$ E:]%EUE:?'L<%B8K"6? $(*Y4AY9F$Z_;A9K)_*CF&S^9:Q"@6\]O-9
MV\@6*EM$ 7I#Y]79RX8==5FK/;P/*'=;=; 1#KJPU8%M3\UJ,/<(E^R-+J[X
MIOP?[OF\\(!/*6I,DR<4S4]S&P>=U\@[NN!Q=/5243:#:@&+</G(\4[[<L8^
MY4<.7*,*]*_+>:Q#[63C_7%J77%RX&)S(E^ATI^]+?MSU7;,[FVLTRMU/0G(
M%SPGU'G0>"O\TWNZ9KRP[.EKMT2.1&>@'Y'CRDYMZE-6 ?'I$3S?;1\CT8\T
MF'8]>?#R3>A]$F7]PP"[KFK;RV8N.C&::V,@B*CV@)K0RT*]BOUNVA$T)<"_
M4=>8[+_RX,%V,GCTEO:U]P3#&IA5Y\>6/4_P\-;YF(4;-B+#.,G :!8%N$M5
MY#:N.B[QE42^:FJ*#F<T:Q7!Z+U%EU>S$A30!2GV-=+E& _'$@+T-H$P$TL1
MV,!"%-/DLE B1[VOL8[=/;/%OGL,J;K$7*"A&DLW?.>LW&P!J@R]IN_GVW0'
M2 J&_04U9#;S-J_58 B9%9EI>=3[UF=Q@3,=I!NCB<1.]8KNA^.G[3O' X"W
MX7>_4YU@Y3YQ?)I1EA5LK_/A^^IQ<4)5CU4 ]V[""\?=*>V4%G(E#V@NN.T1
M,"S+.]$(B6PHOK%R]+5?4Y7DS;UX<2NY959V&]VH4)>+C]L(Z,%S)O\&JE>[
M$/M],9I:"4Y:I.&R7[T\YU=?-$#T80A)HXZ0H05OP!Q\A-?$UY+:@WF-^^F"
MLDJB/1VH0-_>8SJ"/B' =.(1S].P3F15?&+IRK\ID'RI8L9S;-@WE5IZ]KQ%
M\@^X(!^SKD//UNU6WAN@Y1#"K7:9H7E-(TL$^ _U\;V2.'XX_9J&?:H9R#H/
M"A72=N]B080("! A,^1_U&@,@SZ+?I(1WM)(^99AQ$NMI$RX&2I+Q3OJOY-,
M4Z*6+'C&)9-8[>^3XI4E/T#?V")-9L_B,!M'<"(CN!%U*XL5.>Y4FLUD4U>Q
MQ@VSZ^J.C<H;;E?\_4WZSA%41DAP@LLVW]$P-,-?NEDM-K@:]BVA/?1XW-D;
MMA?_*O;703ER/RC_9(^R>2,/5)/FY59;(BX>F3/4"'A=<3>H9P:SL*$ QEIY
MA/98(PJXV;I>*#3OMVM,9YV;++M5>;.&!QM;B&1M,\LP$OK"Y@IXRCVT0JC*
M>+A5Y/<+H8&W)B0R\]9P*]-;E;:I^2;SP,(W+D@B2*78G]25G'N$7"VL0RQ(
MNAB/G;7$)OU!J.1IK-5OW+JAVPOYZ79M]M>3KFI5+"%IT5MYQ.:(A-XU>GM#
MQY6Z582QBC7(S.D2)L]'ART?#OC[1A33R??SC@:&?5$?PKJ:$#UB>2=LGA<C
M0TG<LGF(+Q,[<%,CO2 G([UES?QCL/2F*W-"(I\@5S3CQFS(-#BG>WSJ [$\
MR#*MDM")FFU:V!P%A-^2,\4*=K:GKEA^V9EP/JAU'1M+_1+V[E AGYAD0^W6
MSQ(=%_+5 :RB.^FY(+AJEJT9D<ZPFB2KB:>IF!P]_#UUG8;<EPFZ+X^*(Q^$
M"G7X\DU$!1FX%BPFM0GFZM >977D,L&W'<O:>@CR 9GQ=XTRDAM:H\QD%LYM
M884=GQY*&[O& '!&LV?S'9*U+PX#BC8=_ '^ZA3+,2?W#".]\4C>!SC,4556
MU @_1*2&&/S#0X-4SL87L/D\[Y+])%.++TYL--_RB<G544!RLR?R" 4(6I9)
M&5/:;$BWNS&,5;6SOIT+!<Z&*9<24C%VK4C1V$6V" 5T(RD/'D.&H) 3DAWS
MC%@9 >\:9Q_Q^T+8;^M_B"X\*695D354R"<10<0[7_M46E<KB!V[,T8NW/*4
M=/IT/8(;)5J3V[,;^@[9Q,_M,W%.09J]7KCBR/2-D"\N2/Y,Q#9W%)]9LQ+J
MJ&HGQY7()]Z5F.>:%Z$Q!# .+*TW3_]P!3C\.:_5QVRQHD+(Z\U[1[G]<C!9
M$PS5R"?>]BH>\Y^X9<L5 R&50<AKRAD_&YWY1]9)WN!NJ#1#+=I=1?0T%)A>
MP$F0JIT"=Q=([P,89*@#<I*X8PZ)Z>#VK0;[&'^0>A_^]J6VCV"Y^I3.2VS
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M;UA2G<R4F[SQ.[;TMROYUB9P.5!V=U<]2C7D/5R=1WHH>)BT+ZX><AN:9Z/
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MA=:4^[DQ]HGG*Y[/M/A(=*"9LQN4VH89S45>%ID3= +Y-B^IW.(IT*8[)+)
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MHT(GS#??O#1/G4<*.[H<F1G+JZK>P6C_-BZ\;X>0(* OC1/&E>.V+J.DO$F
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M<T^[1=:"5'Y>E=&F?A> ]4O +P&_!/P2\)\1,/E' GI _[? F-]&*+$FQUL
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MCYJDM5O&S#D=>?@8@P<))J71^:S9<?O5< FR^(74VD\UO[7EBL4].S*$K.1
MME3JEJL^<JWS0?MQ/H.B2UNE)5 IYQP#_3&.^PE;(6[1$1^I#E_WEJ_6IX*>
MN5IL]JFS:'A]>!3\[7[#2+S!S2;MF#?D.(I5K'PDZYX]1B!_-1\P#Q\IX#&S
MI.>)(U[!"7^F'!>FZB(8] G^XC\31^TOCI.FG@^'0O<RJV(/>+.9FF$.+C\^
M@ Q# "!F'BD+)(N<?@;?=22XZM\@4.*? #T^H.IO+O3O#?02O >BP<L.&5X0
M *1PSNK)*5<21)1KNLGY(AT<N L>,KT%^$RP.KJR]X7(YK I%>9,2<@V1?4K
M=1 2ZH"GSQS3$-;V'K4(3[7LK@+-/8;XWN#[%=MH+A?2;WH)(.=KM7)K"6ZS
MF85#!8?%\*'VT>.&)H5/P1C2LU]*BWI;-=]RV!'GV7W_YI?0@HG[Z36M:)$
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M;P&#2S<NHTOD-NGG5_X#99?"^4Y^,+R9,QP5J84M V*$'>('NP6(Q'P?58H
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M>OX>NH,C63-<HDFD;M<U,-L-569E.:_K,=CZR)%Z-[?PBW]K]9 OA_\>0B<
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MYT-V=5L7< 3H'1$*!\EV\.\JBDIC!%'O S2 K*0XA]'/C^3#I^_]U[)N7)"
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M3 YM\K6::X:NM$Q-A=S<2E\.W4(*_ =&TU.!4\X[P$G5/6_8Z6FV]]5XW#W
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MGEE --T'[.5C.]K5E^CR^W"KS:B8 :L$$(&B<M^M7H?D$8;7)*P9\R5@NU/
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M[OF'XR]. 04; IOW"6?).TIJ?R:#_[NFOS7+[:3-NH!O>Y; _RN'G,UFC(/
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M>L2"0^NOL=CP5I)SE&Q,##2NH09W3,U4"[3T-+%7V?M.@1(NU49A0KV-II&
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MZM,C#R(X'?X/4$L! A0#%     @ XH-84DPY";<2G 0 D"Q! !4
M     ( !     &%D<'0M,3!K7S(P,C Q,C,Q+FAT;5!+ 0(4 Q0    ( .*#
M6%*2#*W+T!H  "8] 0 1              "  46<! !A9'!T+3(P,C Q,C,Q
M+GAS9%!+ 0(4 Q0    ( .*#6%(Y?<D4\!$  (,; 0 5              "
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M_04 861P="UE>#$P,3)?,C$X+FAT;5!+ 0(4 Q0    ( .*#6%)!U0:G-4@
M +G- 0 3              "  38/!@!A9'!T+65X,3 Q-E\S-# N:'1M4$L!
M A0#%     @ XH-84@H^90O120  -P8" !,              ( !G%<& &%D
M<'0M97@Q,#$W7S,S.2YH=&U02P$"% ,4    " #B@UA2'AKM05("   ,"
M$@              @ &>H08 861P="UE>#(Q,5\Q-S4N:'1M4$L! A0#%
M  @ XH-84O4D,>\K!   AQ<  !(              ( !(*0& &%D<'0M97@R
M,S%?,CDW+FAT;5!+ 0(4 Q0    ( .*#6%)H,W=4O@D  &=K   2
M      "  7NH!@!A9'!T+65X,S$Q7S$W."YH=&U02P$"% ,4    " #B@UA2
M)RGR-JX)  "X<   $@              @ %IL@8 861P="UE>#,Q,E\Q-SDN
M:'1M4$L! A0#%     @ XH-84CM*6[E@!@  !B\  !(              ( !
M1[P& &%D<'0M97@S,C%?,3<V+FAT;5!+ 0(4 Q0    ( .*#6%)76>0LC 8
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M,'9S9&%J,S-N;FPP,# P,#4N:G!G4$L! A0#%     @ XH-84DG91-;2]0$
M'[0" !8              ( !<^L- &<P=G-D86HS,VYN;# P,# P-BYJ<&=0
M2P$"% ,4    " #B@UA2!H"$OV'9  "9< $ %@              @ %YX0\
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M+FIP9U!+ 0(4 Q0    ( .*#6%(:T]XX)X4! +6" @ 6              "
M 936&P!G,'9S9&%J,S-N;FPP,# P,3<N:G!G4$L! A0#%     @ XH-84E/>
M>LPWZ0  %V0! !8              ( ![UL= &<P=G-D86HS,VYN;# P,# Q
;."YJ<&=02P4&     "$ (0"9"   6D4>

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
